PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Vargas, JLC; Belforte, N; Di Polo, A				Vargas, Jorge L. Cueva; Belforte, Nicolas; Di Polo, Adriana			The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling	NEUROBIOLOGY OF DISEASE			English	Article						Gliosis; Neurodegeneration; cAMP Phosphodiesterase inhibitor; Optic nerve; Ocular hypertension	CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; MIGRATION INHIBITORY FACTOR; SOLUBLE ADENYLYL-CYCLASE; TRAUMATIC BRAIN-INJURY; DBA/2J MOUSE MODEL; SPINAL-CORD-INJURY; OPTIC-NERVE HEAD; INTRAOCULAR-PRESSURE; NEURODEGENERATIVE DISEASES; MICROGLIAL ACTIVATION	Glaucoma is a neurodegenerative disease and the leading cause of irreversible blindness worldwide. Vision deficits in glaucoma result from the selective loss of retinal ganglion cells (RGC). Glial cell-mediated neuroinflammation has been proposed to contribute to disease pathophysiology, but whether this response is harmful or beneficial for RGC survival is not well understood. To test this, we characterized the role of ibudilast, a clinically approved cAMP phosphodiesterase (PDE) inhibitor with preferential affinity for PDE type 4 (PDE4). Here, we demonstrate that intraocular administration of ibudilast dampened macroglia and microglia reactivity in the retina and optic nerve hence decreasing production of proinflammatory cytokines in a rat model of ocular hypertension. Importantly, ibudilast promoted robust RGC soma survival, prevented axonal degeneration, and improved anterograde axonal transport in glaucomatous eyes without altering intraocular pressure. Intriguingly, ocular hypertension triggered upregulation of PDE4 subtype A in Muller glia, and ibudilast stimulated CAMP accumulation in these cells. Co-administration of ibudilast with Rp-cAMPS, a cell-permeable and non-hydrolysable cAMP analog that inhibits protein kinase A (PICA), completely blocked ibudilast-induced neuroprotection. Collectively, these data demonstrate that ibudilast, a safe and well-tolerated glial cell modulator, attenuates gliosis, decreases levels of proinflammatory mediators, and enhances neuronal viability in glaucoma through activation of the cAMP/PICA pathway. This study provides insight into PDE4 signaling as a potential target to counter the harmful effects associated with chronic gliosis and neuroinflammation in glaucoma. (C) 2016 Elsevier Inc. All rights reserved.	Univ Montreal, Dept Neurosci, Montreal, PQ H2X 0A9, Canada; Univ Montreal, Ctr Rech Univ Montreal CRCHUM, Montreal, PQ H2X 0A9, Canada		Di Polo, A (corresponding author), Univ Montreal, Dept Neurosci, CRCHUM, 900 Rue St Denis,Room R09-720, Montreal, PQ H2X 0A9, Canada.	adriana.di.polo@umontreal.ca		Belforte, Nicolas/0000-0001-5857-8006; Cueva-Vargas, Jorge Luis/0000-0002-8332-9404	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [CIHR-VIH-105439]; Groupe de recherche sur le systeme nerveux central at the Universite de Montreal; Fonds de recherche Quebec-Sante (FRQS)	We thank Dr. Timothy Kennedy (McGill University) for helpful comments on the manuscript. This work was supported by a grant from the Canadian Institutes of Health Research (CIHR-VIH-105439). N.B. is the recipient of a H. H. Jasper Postdoctoral Research Fellowship in Neurosciences from the Groupe de recherche sur le systeme nerveux central at the Universite de Montreal, and a Postdoctoral Fellowship from the Fonds de recherche Quebec-Sante (FRQS) A.D.P. is a Chercheur National of FRQS.	Abbott CJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114546; Ahlers KE, 2015, GLIA, V63, P1694, DOI 10.1002/glia.22835; Ahmed F, 2004, INVEST OPHTH VIS SCI, V45, P1247, DOI 10.1167/iovs.03-1123; Ajami B, 2007, NAT NEUROSCI, V10, P1538, DOI 10.1038/nn2014; Almasieh M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.23; Almasieh M, 2013, INVEST OPHTH VIS SCI, V54, P3171, DOI 10.1167/iovs.12-11481; Angelucci A, 1996, J NEUROSCI METH, V65, P101, DOI 10.1016/0165-0270(95)00155-7; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269; Bacher M, 2010, MOL MED, V16, P116, DOI 10.2119/molmed.2009.00123; BAUSHER LP, 1995, EXP EYE RES, V60, P43, DOI 10.1016/S0014-4835(05)80082-X; BODE DC, 1993, J PHARMACOL EXP THER, V267, P1286; Bosco A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043602; Bosco A, 2011, J COMP NEUROL, V519, P599, DOI 10.1002/cne.22516; Cen LP, 2015, NEUROSCIENCE, V311, P56, DOI 10.1016/j.neuroscience.2015.09.067; CHARBONNEAU H, 1986, P NATL ACAD SCI USA, V83, P9308, DOI 10.1073/pnas.83.24.9308; Chidlow G, 2012, NEUROBIOL DIS, V48, P568, DOI 10.1016/j.nbd.2012.07.026; Chong RS, 2015, CURR OPIN OPHTHALMOL, V26, P73, DOI 10.1097/ICU.0000000000000125; Corredor RG, 2012, J NEUROSCI, V32, P7734, DOI 10.1523/JNEUROSCI.5288-11.2012; Crish SD, 2010, P NATL ACAD SCI USA, V107, P5196, DOI 10.1073/pnas.0913141107; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Dal Piaz V, 2000, EUR J MED CHEM, V35, P463, DOI 10.1016/S0223-5234(00)00179-3; Dengler-Crish CM, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00290; DOSTMANN WRG, 1995, FEBS LETT, V375, P231, DOI 10.1016/0014-5793(95)01201-O; Ebneter A, 2010, INVEST OPHTH VIS SCI, V51, P6448, DOI 10.1167/iovs.10-5284; Firth SI, 2005, CELL CALCIUM, V37, P425, DOI 10.1016/j.ceca.2005.01.010; Fujino H, 2009, ACTA NEUROPATHOL, V117, P75, DOI 10.1007/s00401-008-0440-9; Galindo-Romero C, 2013, INVEST OPHTH VIS SCI, V54, P974, DOI 10.1167/iovs.12-11207; Gerlo S, 2011, CELL MOL LIFE SCI, V68, P3823, DOI 10.1007/s00018-011-0757-8; Gibson LCD, 2006, EUR J PHARMACOL, V538, P39, DOI 10.1016/j.ejphar.2006.02.053; Goldberg JL, 2002, NEURON, V33, P689, DOI 10.1016/S0896-6273(02)00602-5; Gramlich OW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057557; Hernandez MR, 2008, PROG BRAIN RES, V173, P353, DOI 10.1016/S0079-6123(08)01125-4; Houslay MD, 2005, DRUG DISCOV TODAY, V10, P1503, DOI 10.1016/S1359-6446(05)03622-6; Houslay MD, 2010, TRENDS BIOCHEM SCI, V35, P91, DOI 10.1016/j.tibs.2009.09.007; Howell G.R., 2014, COLD SPRING HARB PER, V4; Howell GR, 2012, J CLIN INVEST, V122, P1246, DOI 10.1172/JCI61135; Howell GR, 2011, J CLIN INVEST, V121, P1429, DOI 10.1172/JCI44646; Huang Z, 2006, LIFE SCI, V78, P2663, DOI 10.1016/j.lfs.2005.10.026; Imai Y, 2002, GLIA, V40, P164, DOI 10.1002/glia.10149; Inacio AR, 2011, J CEREBR BLOOD F MET, V31, P1093, DOI 10.1038/jcbfm.2010.194; Inman DM, 2007, GLIA, V55, P942, DOI 10.1002/glia.20516; Inoue N, 2008, ARZNEIMITTELFORSCH, V58, P277, DOI 10.1055/s-0031-1296507; Iona S, 1998, MOL PHARMACOL, V53, P23, DOI 10.1124/mol.53.1.23; Johnson EC, 2009, J GLAUCOMA, V18, P341, DOI 10.1097/IJG.0b013e31818c6ef6; Kuehn MH, 2008, EXP EYE RES, V87, P89, DOI 10.1016/j.exer.2008.04.012; Lebrun-Julien F, 2010, P NATL ACAD SCI USA, V107, P3817, DOI 10.1073/pnas.0909276107; Lebrun-Julien F, 2009, J NEUROSCI, V29, P5536, DOI 10.1523/JNEUROSCI.0831-09.2009; Lebrun-Julien F, 2009, MOL CELL NEUROSCI, V40, P410, DOI 10.1016/j.mcn.2008.12.005; Lee YS, 2014, J OCUL PHARMACOL TH, V30, P138, DOI 10.1089/jop.2013.0199; Leibinger M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.126; Li YM, 2003, J NEUROSCI, V23, P7830; Mali RS, 2011, EXP EYE RES, V92, P528, DOI 10.1016/j.exer.2011.03.017; Matsuda A, 1997, J NEUROIMMUNOL, V77, P85, DOI 10.1016/S0165-5728(97)00061-1; Mehats C, 2002, TRENDS ENDOCRIN MET, V13, P29, DOI 10.1016/S1043-2760(01)00523-9; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Millecamps S, 2013, NAT REV NEUROSCI, V14, P161, DOI 10.1038/nrn3380; Mizuno T, 2004, NEUROPHARMACOLOGY, V46, P404, DOI 10.1016/j.neuropharm.2003.09.009; Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184; Morrison JC, 2015, EXP EYE RES, V141, P23, DOI 10.1016/j.exer.2015.05.012; Mouton P. R., 2002, PRINCIPLES PRACTICES; Nadal-Nicolas FM, 2009, INVEST OPHTH VIS SCI, V50, P3860, DOI 10.1167/iovs.08-3267; Nakazawa T, 2006, J NEUROSCI, V26, P12633, DOI 10.1523/JNEUROSCI.2801-06.2006; NATHANSON JA, 1980, P NATL ACAD SCI-BIOL, V77, P7420, DOI 10.1073/pnas.77.12.7420; Noguchi M, 2009, BIOL PHARM BULL, V32, P1924, DOI 10.1248/bpb.32.1924; Park YH, 2015, EXP EYE RES, V132, P136, DOI 10.1016/j.exer.2015.01.026; Paterniti I, 2014, CURR MED CHEM, V21, P2830, DOI 10.2174/0929867321666140217102428; Pearce W, 2015, CURR OPIN OPHTHALMOL, V26, P233, DOI 10.1097/ICU.0000000000000143; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; PENFOLD PL, 1991, VISUAL NEUROSCI, V7, P383, DOI 10.1017/S0952523800004879; Popp J, 2009, J PSYCHIATR RES, V43, P749, DOI 10.1016/j.jpsychires.2008.10.006; Poulsen Jeppe N, 2014, Int J Physiol Pathophysiol Pharmacol, V6, P1; Prinz M, 2011, GLIA, V59, P177, DOI 10.1002/glia.21104; Reichenbach A, 2013, GLIA, V61, P651, DOI 10.1002/glia.22477; Ren LZ, 2010, ADV EXP MED BIOL, V703, P95, DOI 10.1007/978-1-4419-5635-4_7; Rodgers KM, 2014, J NEUROTRAUM, V31, P487, DOI [10.1089/NEU.2013.3090, 10.1089/neu.2013.3090]; Rojas B, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-133; Rolan P, 2009, EXPERT OPIN PHARMACO, V10, P2897, DOI 10.1517/14656560903426189; Ruzafa N, 2015, Arch Soc Esp Oftalmol, V90, P522, DOI 10.1016/j.oftal.2015.03.009; Sachs BD, 2007, BIOCHEM SOC T, V35, P1273, DOI 10.1042/BST0351273; Sanchez RN, 2003, INVEST OPHTH VIS SCI, V44, P4006, DOI 10.1167/iovs.03-0040; Sanchez-Guajardo V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008784; Schaal SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043634; Schwartz M, 2008, PROG BRAIN RES, V173, P375, DOI 10.1016/S0079-6123(08)01126-6; Schwartz Michal, 2009, J Ocul Biol Dis Infor, V2, P73; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830; Stellwagen D, 1999, NEURON, V24, P673, DOI 10.1016/S0896-6273(00)81121-6; Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036; Stewart MW, 2015, DIABETES METAB SYNDR, V8, P473, DOI 10.2147/DMSO.S72792; Sun D, 2013, GLIA, V61, P1218, DOI 10.1002/glia.22507; Suzumura A, 1999, BRAIN RES, V837, P203, DOI 10.1016/S0006-8993(99)01666-2; Tezel G, 2004, BRAIN RES, V996, P202, DOI 10.1016/j.brainres.2003.10.029; Tezel G, 2013, CURR OPIN PHARMACOL, V13, P23, DOI 10.1016/j.coph.2012.09.013; Tezel G, 2012, INVEST OPHTH VIS SCI, V53, P4220, DOI 10.1167/iovs.11-9101; Tezel G, 2010, INVEST OPHTH VIS SCI, V51, P5071, DOI 10.1167/iovs.10-5289; Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013; Travaglione S, 2002, TOXICOL IN VITRO, V16, P405, DOI 10.1016/S0887-2333(02)00028-0; Vargas JLC, 2015, J NEUROSCI, V35, P12088, DOI 10.1523/JNEUROSCI.1273-15.2015; Vecino E, 2016, PROG RETIN EYE RES, V51, P1, DOI 10.1016/j.preteyeres.2015.06.003; Wang L, 2002, INVEST OPHTH VIS SCI, V43, P1088; Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014; Watanabe M, 2003, NEUROSCIENCE, V116, P733, DOI 10.1016/S0306-4522(02)00562-6; Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0; Whitaker CM, 2009, NEUROSCIENCE, V163, P1277, DOI 10.1016/j.neuroscience.2009.07.045; Wilson GN, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0399-0; Wohl SG, 2010, INVEST OPHTH VIS SCI, V51, P2686, DOI 10.1167/iovs.09-4537; Yang XJ, 2011, INVEST OPHTH VIS SCI, V52, P8442, DOI 10.1167/iovs.11-8152; Yoshioka A, 1998, J NEUROCHEM, V70, P2416; Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104; Zhou Y, 2005, MOL THER, V12, P402, DOI 10.1016/j.ymthe.2005.04.004; Zhu J, 2001, CNS DRUG REV, V7, P387	113	25	26	0	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	SEP	2016	93						156	171		10.1016/j.nbd.2016.05.002			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DQ8IE	WOS:000379452600016	27163643				2022-02-06	
J	Zhang, MK; Cui, ZW; Cui, H; Cao, Y; Wang, Y; Zhong, CL				Zhang, Mingkun; Cui, Zhenwen; Cui, Hua; Cao, Yang; Wang, Yong; Zhong, Chunlong			Astaxanthin alleviates cerebral edema by modulating NKCC1 and AQP4 expression after traumatic brain injury in mice	BMC NEUROSCIENCE			English	Article						Astaxanthin; Traumatic brain injury; Aquaporin-4; Na+-K+-2Cl(-) co-transporter-1; Cerebral edema	EXPERIMENTAL SUBARACHNOID HEMORRHAGE; FLUID PERCUSSION INJURY; CULTURED ASTROCYTES; OXIDATIVE STRESS; VASOGENIC EDEMA; RATS; AQUAPORIN-4; COTRANSPORTER-1; MANAGEMENT; APOPTOSIS	Background: Astaxanthin is a carotenoid pigment that possesses potent antioxidative, anti-inflammatory, antitumor, and immunomodulatory activities. Previous studies have demonstrated that astaxanthin displays potential neuroprotective properties for the treatment of central nervous system diseases, such as ischemic brain injury and subarachnoid hemorrhage. This study explored whether astaxanthin is neuroprotective and ameliorates neurological deficits following traumatic brain injury (TBI). Results: Our results showed that, following CCI, treatment with astaxanthin compared to vehicle ameliorated neurologic dysfunctions after day 3 and alleviated cerebral edema and Evans blue extravasation at 24 h (p < 0.05). Astaxanthin treatment decreased AQP4 and NKCC1 mRNA levels in a dose-dependent manner at 24 h. AQP4 and NKCC1 protein expressions in the peri-contusional cortex were significantly reduced by astaxanthin at 24 h (p < 0.05). Furthermore, we also found that bumetanide (BU), an inhibitor of NKCC1, inhibited trauma-induced AQP4 upregulation (p < 0.05). Conclusions: Our data suggest that astaxanthin reduces TBI-related injury in brain tissue by ameliorating AQP4/NKCC1-mediated cerebral edema and that NKCC1 contributes to the upregulation of AQP4 after TBI.	[Zhang, Mingkun; Cui, Hua; Cao, Yang; Wang, Yong; Zhong, Chunlong] Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, 160 Pujian Rd, Shanghai 200127, Peoples R China; [Cui, Zhenwen] Qingdao Univ, Affiliated Hosp, Dept Neurosurg, Qingdao 266005, Peoples R China		Wang, Y; Zhong, CL (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Dept Neurosurg, 160 Pujian Rd, Shanghai 200127, Peoples R China.	wangyong68@163.com; drchunlongzhong@126.com			basic research program of project 973 by the Ministry of Science and Technology of China [2011CB013304]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571184, 81070990, 30670719, 30500525]; Shanghai Science and Technology CommissionShanghai Science & Technology CommitteeScience & Technology Commission of Shanghai Municipality (STCSM) [15140902100, 10QH1401700, 09140901300]; Shanghai Municipal Education CommissionShanghai Municipal Education Commission (SHMEC) [09SG20]	This research was supported by a basic research program of project 973 by the Ministry of Science and Technology of China (2011CB013304), and by Grants from the National Natural Science Foundation of China (Nos. 81571184, 81070990, 30670719, 30500525), the Shanghai Science and Technology Commission (Nos. 15140902100, 10QH1401700, 09140901300) and the Shanghai Municipal Education Commission (No. 09SG20).	Ambati RR, 2014, MAR DRUGS, V12, P128, DOI 10.3390/md12010128; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Cabrera S, 2012, Q REV BIOL, V87, P89; Cao F, 2016, J NEUROTRAUM, V33, P175, DOI 10.1089/neu.2015.3887; Cao Y, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0251-1; Chan KC, 2009, J FOOD SCI, V74, pH225, DOI 10.1111/j.1750-3841.2009.01274.x; Doelken M, 2007, DIAGN INTERV RADIOL, V13, P125; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Eghwrudjakpor PO, 2010, LIBYAN J MED, V5, DOI [10.4176/091104, 10.3402/ljm.v5i0.4620]; Fassett RG, 2009, FUTUR CARDIOL, V5, P333, DOI 10.2217/FCA.09.19; Gao Y, 2015, J NEUROCHEM, V134, P340, DOI 10.1111/jnc.13123; Guerin M, 2003, TRENDS BIOTECHNOL, V21, P210, DOI 10.1016/S0167-7799(03)00078-7; Gunnarson E, 2008, GLIA, V56, P587, DOI 10.1002/glia.20627; Hui H, 2016, NEUROCHEM INT, V94, P23, DOI 10.1016/j.neuint.2016.02.002; Jayakumar AR, 2011, J NEUROCHEM, V117, P437, DOI 10.1111/j.1471-4159.2011.07211.x; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Khan SK, 2010, THROMB RES, V126, P299, DOI 10.1016/j.thromres.2010.07.003; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Liu XB, 2009, FORUM NUTR, V61, P129, DOI 10.1159/000212745; Lopez-Rodriguez AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128782; Lu KT, 2008, CRIT CARE MED, V36, P917, DOI 10.1097/CCM.0B013E31816590C4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Pasantes-Morales H, 2010, NEUROSCIENCE, V168, P871, DOI 10.1016/j.neuroscience.2009.11.074; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Stewart JS, 2008, FOOD CHEM TOXICOL, V46, P3030, DOI 10.1016/j.fct.2008.05.038; Tollner K, 2015, EUR J PHARMACOL, V746, P167, DOI 10.1016/j.ejphar.2014.11.019; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wu Q, 2014, MAR DRUGS, V12, P6125, DOI 10.3390/md12126125; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Zhang XS, 2014, J SURG RES, V192, P206, DOI 10.1016/j.jss.2014.05.029; Zhang XS, 2014, J NEUROSURG, V121, P42, DOI 10.3171/2014.2.JNS13730; Zheng D, 2014, NEUROPHARMACOLOGY, V84, P13, DOI 10.1016/j.neuropharm.2014.04.013; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	36	25	27	6	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	AUG 31	2016	17								60	10.1186/s12868-016-0295-2			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DW0PD	WOS:000383341900002	27581370	Green Published, gold			2022-02-06	
J	Bao, HJ; Yang, XF; Huang, YX; Qiu, HY; Huang, GP; Xiao, H; Kuai, JX				Bao, Haijun; Yang, Xiaofang; Huang, Yuxiu; Qiu, Haiyang; Huang, Genping; Xiao, Hua; Kuai, Jinxia			The neuroprotective effect of apelin-13 in a mouse model of intracerebral hemorrhage	NEUROSCIENCE LETTERS			English	Article						Apoptosis; Apelin-13; Intracerebral hemorrhage	ISCHEMIC REPERFUSION INJURY; FOCAL CEREBRAL-ISCHEMIA; BRAIN-BARRIER DAMAGE; TRANSIENT MODEL; RECEPTOR; EDEMA; APJ; INHIBITION; POLOXAMER-188; INFLAMMATION	Adipocytokine apelin-13 is a peptide which could reportedly protect the brain against ischemic reperfusion injury and traumatic brain injury (TBI). Whether apelin-13 has any roles to play in intracerebral hemorrhage (ICH) has not been clarified. We aimed to investigate the roles of apelin-13 in ICH and effects on ICH-induced apoptosis. Firstly, CD-1 mice were subjected to infusion of Type IV collagenase (to induce ICH) or saline (for shams) into the left striatum. ICH animals received intracerebroventricular administration of vehicle, apelin-13 (50 mu g dissolved in 5 mu l saline) immediately after ICH. The motor function and the cerebral water content (CWC) as well as blood brain barrier (BBB) disruption were measured, coupled with determination of ICH-induced neural cell death by Terminal-deoxynucleoitidyl Transferase Mediated Nick End Labeling (TUNEL). The apoptosis-associated proteins caspase-3 and Bcl-2 as well as the brain edema-associated proteins aquaporin-4 (AQP4) and MMP-9 were all assessed with western blotting. The results showed that apelin-13 decreased CWC and reduced Evans blue leakage into injured hemispheres, with the motor function significantly improved. Additionally, apelin-13 also acutely decreased the number of ICH-induced TUNEL-positive (TUNEL+) cells at 48 h after ICH. The expressions of AQP4, MMP-9, caspse-3 and Bcl-2 were all downregulated by apelin-13 at 24 h and 4811 after ICH. All these results revealed that apelin-13 attenuated brain edema and reduced cellular death by suppressing apoptosis after ICH in mice. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Bao, Haijun; Yang, Xiaofang; Huang, Yuxiu; Qiu, Haiyang; Huang, Genping; Xiao, Hua] Xuzhou Med Univ, Dept Pathol, Xuzhou, Peoples R China; [Kuai, Jinxia] Xuzhou Med Univ, Dept Forens Med, 209 Tongshan Rd, Xuzhou, Peoples R China		Kuai, JX (corresponding author), Xuzhou Med Univ, Dept Forens Med, 209 Tongshan Rd, Xuzhou, Peoples R China.	55752663@qq.com			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81302612]; Student Innovation Training Program of Jiangsu Province [201510313010Z]	The study was supported by the National Science Foundation of China (No. 81302612) and Student Innovation Training Program of Jiangsu Province (No. 201510313010Z).	Aboutaleb N, 2014, INT J PEPT RES THER, V20, P127, DOI 10.1007/s10989-013-9374-8; Bao HJ, 2015, NEUROCHEM RES, V40, P89, DOI 10.1007/s11064-014-1469-x; Bao HJ, 2012, NEUROCHEM RES, V37, P2856, DOI 10.1007/s11064-012-0880-4; Busch R, 2015, CELL SIGNAL, V27, P1286, DOI 10.1016/j.cellsig.2015.03.011; Chang JJ, 2014, J STROKE CEREBROVASC, V23, P2498, DOI 10.1016/j.jstrokecerebrovasdis.2014.07.005; Choe W, 2000, J NEUROVIROL, V6, pS61; Hosoya M, 2000, J BIOL CHEM, V275, P21061, DOI 10.1074/jbc.M908417199; Hwang BY, 2011, CEREBROVASC DIS, V31, P211, DOI 10.1159/000321870; Jiao H, 2013, EXP THER MED, V5, P797, DOI 10.3892/etm.2013.902; Khaksari M, 2012, J MOL NEUROSCI, V48, P201, DOI 10.1007/s12031-012-9808-3; Krafft PR, 2012, STROKE, V43, P844, DOI 10.1161/STROKEAHA.111.639989; Li M, 2015, MEDICINE, V94; Nicchia GP, 2004, NEUROSCIENCE, V129, P935, DOI 10.1016/j.neuroscience.2004.07.055; O'Carroll AM, 2013, J ENDOCRINOL, V219, pR13, DOI 10.1530/JOE-13-0227; ODOWD BF, 1993, GENE, V136, P355, DOI 10.1016/0378-1119(93)90495-O; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Sandal S, 2015, NEUROSCI LETT, V602, P133, DOI 10.1016/j.neulet.2015.06.059; Sawane M, 2011, AM J PATHOL, V179, P2691, DOI 10.1016/j.ajpath.2011.08.024; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Wang J, 2005, BRAIN, V128, P1622, DOI 10.1093/brain/awh489; Wang T, 2015, J MOL NEUROSCI, V55, P240, DOI 10.1007/s12031-014-0313-8; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xin Q, 2015, PEPTIDES, V63, P55, DOI 10.1016/j.peptides.2014.09.016; Yamashiro S, 2015, NEUROL MED-CHIR, V55, P819, DOI 10.2176/nmc.oa.2014-0136; Zhang MY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087241	27	25	27	1	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 15	2016	628						219	224		10.1016/j.neulet.2016.06.046			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DT6JP	WOS:000381590800036	27343409	Bronze			2022-02-06	
J	Ibanez, I; Diez-Guerra, FJ; Gimenez, C; Zafra, F				Ibanez, Ignacio; Javier Diez-Guerra, F.; Gimenez, Cecilio; Zafra, Francisco			Activity dependent internalization of the glutamate transporter GLT-1 mediated by beta-arrestin 1 and ubiquitination	NEUROPHARMACOLOGY			English	Article						Intracellular trafficking; Endocytosis; Glutamate; Ubiquitination; Transport	SYNAPTIC-TRANSMISSION; MICE LACKING; ENDOCYTOSIS; PHOSPHORYLATION; UBIQUITYLATION; DEGRADATION; ASTROCYTES; ISCHEMIA; EPILEPSY; CORTEX	GLT-1 is the main glutamate transporter in the brain and undergoes trafficking processes that control its concentration on the cell surface thereby shaping glutamatergic neurotransmission. We have investigated how the traffic of GLT-1 is regulated by transporter activity. We report that internalization of GLT-1 from the cell surface is accelerated by transportable substrates like glutamate or aspartate, as well as by the transportable inhibitor L-trans-2,4-PDC, but not by the non-substrate inhibitor WAY 213613 in primary mixed cultures and in transiently transfected HEK293 cells. Analysis of the mechanism of endocytosis in HEK293 cells revealed that glutamate promoted the association with the transporter of the adaptor protein beta-arrestin and the ubiquitin ligase Nedd4-2. The addition of glutamate is accompanied by an increase in the transporter ubiquitination, and the internalization is suppressed by an ubiquitination inhibitor (PYR41), and in a mutant defective in C-terminal lysines. The glutamate triggered endocytosis was also suppressed by siRNA for beta-arrestin. This regulatory mechanism might be relevant in controlling the amount of transporter on the cell surface in conditions such as ischemia or traumatic brain injury, where extracellular concentrations of glutamate are persistently elevated. (C) 2016 Elsevier Ltd. All rights reserved.	[Ibanez, Ignacio; Javier Diez-Guerra, F.; Gimenez, Cecilio; Zafra, Francisco] Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, Fac Ciencias, Consejo Super Invest Cient, C Nicolas Cabrera 1, E-28049 Madrid, Spain; [Ibanez, Ignacio; Gimenez, Cecilio; Zafra, Francisco] Ctr Invest Biomed Red Enfermedades Raras, Barcelona, Spain; [Ibanez, Ignacio; Gimenez, Cecilio; Zafra, Francisco] Inst Salud Carlos III, IdiPAZ, Madrid, Spain		Zafra, F (corresponding author), Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, C Nicolas Cabrera 1, E-28049 Madrid, Spain.	fzafra@cbm.csic.es	Diez-Guerra, Fco. Javier/K-9063-2014; Gimenez, Cecilio/K-8027-2014; Zafra, Francisco/A-6121-2008	Diez-Guerra, Fco. Javier/0000-0003-1707-4519; Gimenez, Cecilio/0000-0001-6726-8405; Zafra, Francisco/0000-0003-3801-3109	Spanish MINECOSpanish Government [SAF2011-29961, SAF2014-55686-R]; Fundacion Ramon Areces	We would like to thank E. Nunez for expert technical help. This work was supported by grants from the Spanish MINECO (SAF2011-29961 and SAF2014-55686-R), and by an institutional grant from the "Fundacion Ramon Areces". The group is member of the Network for Rare Disease Research (CIBERER).	Abe K, 2001, J NEUROCHEM, V76, P217, DOI 10.1046/j.1471-4159.2001.00062.x; Becuwe M, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/242764; Benediktsson AM, 2012, GLIA, V60, P175, DOI 10.1002/glia.21249; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; Cremona ML, 2011, NAT NEUROSCI, V14, P469, DOI 10.1038/nn.2781; Fontana A. C., 2015, J NEUROTRAUMA; Garcia-Tardon N, 2012, J BIOL CHEM, V287, P19177, DOI 10.1074/jbc.M112.355909; Ghaddar K, 2014, MOL CELL BIOL, V34, P4447, DOI 10.1128/MCB.00699-14; Gonzalez MI, 2004, CURR OPIN PHARMACOL, V4, P30, DOI 10.1016/j.coph.2003.09.004; Gonzalez-Gonzalez IM, 2008, GLIA, V56, P963, DOI 10.1002/glia.20670; Gurevich V. V., 2014, CURR PROTOC PHARM, V67; Jimenez E, 2011, J BIOL CHEM, V286, P10712, DOI 10.1074/jbc.M110.167056; Kendall RT, 2014, J BIOL CHEM, V289, P26155, DOI 10.1074/jbc.M114.595728; Kommaddi RP, 2013, PROG MOL BIOL TRANSL, V118, P175, DOI 10.1016/B978-0-12-394440-5.00007-3; Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006; Leon S, 2009, EXP CELL RES, V315, P1574, DOI 10.1016/j.yexcr.2008.11.014; Lopez-Colome AM, 2012, ASN NEURO, V4, P331, DOI 10.1042/AN20120022; Mitani A, 2003, J NEUROSCI, V23, P7176, DOI 10.1523/JNEUROSCI.23-18-07176.2003; Munir M, 2000, NEUROCHEM INT, V37, P147, DOI 10.1016/S0197-0186(00)00018-8; Murphy-Royal C, 2015, NAT NEUROSCI, V18, P219, DOI 10.1038/nn.3901; Nishizawa Y, 2001, LIFE SCI, V69, P369, DOI 10.1016/S0024-3205(01)01142-0; Otis TS, 2004, NEUROCHEM INT, V45, P537, DOI 10.1016/j.neuint.2003.11.007; Petr GT, 2015, J NEUROSCI, V35, P5187, DOI 10.1523/JNEUROSCI.4255-14.2015; Polo S, 2008, CELL, V135, P590, DOI 10.1016/j.cell.2008.10.032; Puca L, 2013, J CELL SCI, V126, P4457, DOI 10.1242/jcs.130500; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Robinson MB, 2006, HANDB EXP PHARM, V175, P251; Sattler R, 2006, HANDB EXP PHARM, V175, P277; Saunders C, 2000, P NATL ACAD SCI USA, V97, P6850, DOI 10.1073/pnas.110035297; Shea FF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050557; Sheldon AL, 2008, NEUROCHEM INT, V53, P296, DOI 10.1016/j.neuint.2008.07.010; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tzingounis AV, 2007, NAT REV NEUROSCI, V8, P935, DOI 10.1038/nrn2274; Underhill SM, 2015, J NEUROSCI, V35, P5260, DOI 10.1523/JNEUROSCI.4365-14.2015	35	25	25	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	AUG	2016	107						376	386		10.1016/j.neuropharm.2016.03.042			11	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	DQ1HZ	WOS:000378953400035	27044663				2022-02-06	
J	Di Battista, AP; Rhind, SG; Richards, D; Churchill, N; Baker, AJ; Hutchison, MG				Di Battista, Alex P.; Rhind, Shawn G.; Richards, Doug; Churchill, Nathan; Baker, Andrew J.; Hutchison, Michael G.			Altered Blood Biomarker Profiles in Athletes with a History of Repetitive Head Impacts	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; INCLUSION-BODY MYOSITIS; COATED-PLATELET LEVELS; NECROSIS-FACTOR-ALPHA; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; BASE-LINE; TAU; PLASMA	The long-term health effects of concussion and sub-concussive impacts in sport are unknown. Growing evidence suggests both inflammation and neurodegeneration are pivotal to secondary injury processes and the etiology of neurodegenerative diseases. In the present study we characterized circulating brain injury and inflammatory mediators in healthy male and female athletes according to concussion history and collision sport participation. Eighty-seven university level athletes (male, n = 60; female, n = 27) were recruited before the start of the competitive season. Athletes were healthy at the time of the study (no medications, illness, concussion or musculoskeletal injuries). Dependent variables included 29 inflammatory and 10 neurological injury analytes assessed in the peripheral blood by immunoassay. Biomarkers were statistically evaluated using partial least squares multivariate analysis to identify possible relationships to self-reported previous concussion history, number of previous concussions and collision sport participation in male and female athletes. Multiple concussions were associated with increases in peripheral MCP-1 in females, and MCP-4 in males. Collision sport participation was associated with increases in tau levels in males. These results are consistent with previous experimental and clinical findings that suggest ongoing inflammatory and cerebral injury processes after repetitive mild head trauma. However, further validation is needed to correlate systemic biomarkers to repetitive brain impacts, as opposed to the extracranial effects common to an athletic population such as exercise and muscle damage.	[Di Battista, Alex P.; Baker, Andrew J.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Di Battista, Alex P.; Rhind, Shawn G.] Def Res & Dev Canada, Toronto Res Ctr, Toronto, ON, Canada; [Rhind, Shawn G.; Richards, Doug; Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Churchill, Nathan; Hutchison, Michael G.] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Crit Care Anesthesia & Surg, Toronto, ON, Canada; [Baker, Andrew J.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON, Canada		Hutchison, MG (corresponding author), Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada.; Hutchison, MG (corresponding author), St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada.	michael.hutchison@utoronto.ca		Rhind, Shawn/0000-0003-2300-0620; Di Battista, Alex/0000-0002-3325-6833	CIMVHR	The work was supported by CIMVHR Task 7.	Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Anthony DC, 2014, EXP NEUROL, V258, P105, DOI 10.1016/j.expneurol.2014.03.013; Avila J, 2014, J ALZHEIMERS DIS, V40, pS7, DOI 10.3233/JAD-131832; Baker JG, 2015, CLIN PEDIAT PHILA; Ballabio D, 2013, PLS DA ANAL METHODS, DOI [10.1002/elps.201500352, DOI 10.1002/ELPS.201500352]; Balu R, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0484-2; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; Bouman A, 2005, HUM REPROD UPDATE, V11, P411, DOI 10.1093/humupd/dmi008; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Breland UM, 2010, CARDIOVASC RES, V86, P265, DOI 10.1093/cvr/cvq044; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Bulut M, 2006, ADV THER, V23, P12, DOI 10.1007/BF02850342; Buonora JE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00068; Cahill L, 2006, NAT REV NEUROSCI, V7, P477, DOI 10.1038/nrn1909; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Comper P, 2010, BRAIN INJURY, V24, P1257, DOI 10.3109/02699052.2010.506854; Debad J, 2016, KEYST S AX CELLL BIO; Deyhle MR, 2016, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00424; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Erlanger DM, 2015, BRAIN INJURY, V29, P171, DOI 10.3109/02699052.2014.965211; Fakhran S, 2013, RADIOLOGY, V269, P249, DOI 10.1148/radiol.13122343; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gosselin N, 2010, PHYSICIAN SPORTSMED, V38, P27, DOI 10.3810/psm.2010.10.1805; Armitage EG, 2015, ELECTROPHORESIS, V36, P3050, DOI 10.1002/elps.201500352; Gu YJ, 1996, J NEUROCHEM, V67, P1235; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jaerve A, 2012, CELL TISSUE RES, V349, P229, DOI 10.1007/s00441-012-1427-3; Jaerve A, 2011, EXP NEUROL, V231, P284, DOI 10.1016/j.expneurol.2011.07.002; Jin SJ, 2009, TOHOKU J EXP MED, V217, P87, DOI 10.1620/tjem.217.87; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kumar RG, 2015, J HEAD TRAUMA REHAB, V30, P369, DOI 10.1097/HTR.0000000000000067; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Maurage CA, 2004, NEUROPATH APPL NEURO, V30, P624, DOI 10.1111/j.1365-2990.2004.00577.x; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Meehan WP, 2016, J NEUROTRAUM, V33, P254, DOI 10.1089/neu.2015.3930; Mendez MF, 2015, J ALZHEIMERS DIS, V47, P985, DOI 10.3233/JAD-143207; Muccigrosso MM, 2016, BRAIN BEHAV IMMUN, V54, P95, DOI 10.1016/j.bbi.2016.01.009; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nogalska A, 2011, NEUROSCI LETT, V503, P229, DOI 10.1016/j.neulet.2011.08.042; Olivera A, 2015, JAMA NEUROL, V72, P1109, DOI 10.1001/jamaneurol.2015.1383; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Peake JM, 2005, EUR J APPL PHYSIOL, V95, P514, DOI 10.1007/s00421-005-0035-2; Perry HV, 2014, MICROGLIAL PRIMING N, V10, P217; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Prodan CI, 2016, J NEUROTRAUM, V33, P818, DOI 10.1089/neu.2014.3846; Prodan CI, 2014, J HEAD TRAUMA REHAB, V29, P522, DOI 10.1097/HTR.0000000000000010; Ramien C., 2016, NEUROSCI BIOBEHAV RE; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Su SH, 2014, BRAIN BEHAV IMMUN, V38, P111, DOI 10.1016/j.bbi.2014.01.009; Takeuchi H, 2006, J BIOL CHEM, V281, P21362, DOI 10.1074/jbc.M600504200; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; Webster KM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0457-7; Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1; Yawata I, 2008, LIFE SCI, V82, P1111, DOI 10.1016/j.lfs.2008.03.010; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zetterberg H, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt163; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	82	25	25	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2016	11	7							e0159929	10.1371/journal.pone.0159929			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DT5IH	WOS:000381515600065	27458972	Green Published, gold			2022-02-06	
J	Marfia, G; Navone, SE; Hadi, LA; Paroni, M; Berno, V; Beretta, M; Gualtierotti, R; Ingegnoli, F; Levi, V; Miozzo, M; Geginat, J; Fassina, L; Rampini, P; Tremolada, C; Riboni, L; Campanella, R				Marfia, Giovanni; Navone, Stefania Elena; Hadi, Loubna Abdel; Paroni, Moira; Berno, Valeria; Beretta, Matteo; Gualtierotti, Roberta; Ingegnoli, Francesca; Levi, Vincenzo; Miozzo, Monica; Geginat, Jens; Fassina, Lorenzo; Rampini, Paolo; Tremolada, Carlo; Riboni, Laura; Campanella, Rolando			The Adipose Mesenchymal Stem Cell Secretome Inhibits Inflammatory Responses of Microglia: Evidence for an Involvement of Sphingosine-1-Phosphate Signalling	STEM CELLS AND DEVELOPMENT			English	Article							TRAUMATIC BRAIN-INJURY; SPHINGOSINE KINASE 1; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; REGENERATIVE MEDICINE; NONENZYMATIC METHOD; FINGOLIMOD FTY720; STROMAL CELLS; NITRIC-OXIDE; TISSUE	Central nervous system (CNS) inflammation is primarily driven by microglial cells which secrete proinflammatory cytokines and undergo proliferation upon activation, as it occurs in neurodegenerative diseases. Uncontrolled or prolonged CNS inflammation is potentially harmful and can result in cellular damage. Recently, many studies have focused on human adipose tissue as an attractive source of cytokines with immunosuppressive properties that potentially modulate inflammation. Our study aimed to evaluate if different methods of human tissue collection could affect adipose mesenchymal stem cell (ADSC)-derived cytokine secretion and investigate the effects of ADSC secretome in modulating microglia activation and the possible implication of sphingosine-1-phosphate (S1P) in these effects. Our results demonstrate that the conditioned medium (CM) of ADSCs isolated by two different processing methods (lipoaspirate and Lipogems) significantly inhibited the lipopolysaccharide (LPS)-induced effects on microglia activation, including microglial expression of CD68, cytokine secretion, proliferation, and migration. Pulse studies with radiolabeled sphingosine demonstrated that LPS treatment of resting microglia induced a significant increase of both cellular and extracellular S1P. Moreover, and of relevance, FTY720, a functional antagonist of S1P receptor, inhibited the multiple LPS-induced proinflammatory effects on microglia, and S1P suppressed the anti-inflammatory effect of ADSC-CM. This suggests that LPS-mediated microglial activation is countered by ADSC-CM through the modulation of sphingosine kinase/S1P signalling.	[Marfia, Giovanni; Navone, Stefania Elena; Beretta, Matteo; Levi, Vincenzo; Rampini, Paolo; Campanella, Rolando] Univ Milan, Lab Expt Neurosurg & Cell Therapy, Neurosurg Unit, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Via Francesco Sforza 35, I-20122 Milan, Italy; [Hadi, Loubna Abdel; Riboni, Laura] Univ Milan, LITA Segrate, Dept Med Biotechnol & Translat Med, Milan, Italy; [Paroni, Moira; Berno, Valeria; Geginat, Jens] Ist Nazl Genet Mol Romeo & Enrica Invernizzi, Milan, Italy; [Gualtierotti, Roberta; Ingegnoli, Francesca] Ist Gaetano Pini, Div Rheumatol, Milan, Italy; [Miozzo, Monica] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Pathol, Milan, Italy; [Fassina, Lorenzo] Univ Pavia, Dept Hlth Sci & Ind & Informat Engn, Pavia, Italy; [Tremolada, Carlo] Ist Image, Milan, Italy		Marfia, G (corresponding author), Univ Milan, Lab Expt Neurosurg & Cell Therapy, Neurosurg Unit, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Via Francesco Sforza 35, I-20122 Milan, Italy.	giovanni.marfia@unimi.it	Levi, Vincenzo/AAB-9294-2019; Geginat, Jens/AAA-5818-2019; navone, stefania/Y-4779-2019; Ingegnoli, Francesca/B-6226-2017; Marfia, Giovanni/AAB-8702-2020; Paroni, Moira/K-6470-2016; Gualtierotti, Roberta/V-5991-2019; navone, stefania e/K-7264-2016; Marfia, Giovanni/N-4650-2014; Gualtierotti, Roberta/Q-8425-2016; Campanella, Rolando/AAB-8998-2019; Riboni, Laura/R-4281-2017; Berno, Valeria/AAN-3997-2020; tremolada, Carlo f m/AAN-8027-2020; Campanella, Rolando/T-9814-2017; Fassina, Lorenzo/K-9283-2015; Miozzo, Monica Rosa/AAC-6401-2022	Levi, Vincenzo/0000-0003-2713-6357; Geginat, Jens/0000-0003-4813-0384; navone, stefania/0000-0002-0097-9146; Ingegnoli, Francesca/0000-0002-6727-1273; Marfia, Giovanni/0000-0002-5849-7000; Paroni, Moira/0000-0001-8199-3128; Gualtierotti, Roberta/0000-0001-6465-7624; navone, stefania e/0000-0002-0097-9146; Marfia, Giovanni/0000-0002-5849-7000; Gualtierotti, Roberta/0000-0001-6465-7624; Riboni, Laura/0000-0002-4149-8226; Berno, Valeria/0000-0001-5848-494X; tremolada, Carlo f m/0000-0003-1331-5995; Campanella, Rolando/0000-0001-8382-1776; Fassina, Lorenzo/0000-0002-5587-4632; Miozzo, Monica Rosa/0000-0002-6523-4575; Abdel Hadi, loubna/0000-0002-5271-0798	IRCCS Foundation Ca' Granda Ospedale Policlinico Milan and Universita degli Studi di Milano, Italy	This work was supported by IRCCS Foundation Ca' Granda Ospedale Policlinico Milan and Universita degli Studi di Milano, Italy. The authors thank Dr. Clara Di Vito for performing ELISAs, Dr. Letizia Venturini for assessing immunofluorescent analyses, and Prof. Giovanni Ricevuti for critical reviewing of the article.	Anelli V, 2005, J NEUROCHEM, V92, P1204, DOI 10.1111/j.1471-4159.2004.02955.x; Anthony DC, 2010, MULT SCLER S10, V16, pS283; AOKI M, 2016, MEDIAT INFLAMM, V2016, DOI DOI 10.1155/2016/8606878; Bianchi F, 2013, CELL TRANSPLANT, V22, P2063, DOI 10.3727/096368912X657855; Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248; Buehrer Benjamin M, 2013, Methods Mol Biol, V1001, P1, DOI 10.1007/978-1-62703-363-3_1; Carelli S, 2015, CELL TRANSPLANT, V24, P1233, DOI 10.3727/096368914X681603; Chan TM, 2014, CELL TRANSPLANT, V23, P541, DOI 10.3727/096368914X678409; Choi JW, 2011, P NATL ACAD SCI USA, V108, P751, DOI 10.1073/pnas.1014154108; Czech B, 2009, BIOCHEM BIOPH RES CO, V389, P251, DOI 10.1016/j.bbrc.2009.08.142; Dossena M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112746; Elahi KC, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5646384; Fain JN, 2006, VITAM HORM, V74, P443, DOI 10.1016/S0083-6729(06)74018-3; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Franquesa M, 2015, STEM CELLS, V33, P880, DOI 10.1002/stem.1881; Giori A., 2015, CELLR4, V3, pe1544; Giri RK, 2003, J IMMUNOL, V170, P5281, DOI 10.4049/jimmunol.170.10.5281; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Gutierrez-Fernandez M, 2015, EXPERT OPIN BIOL TH, V15, P873, DOI 10.1517/14712598.2015.1040386; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; Jackson SJ, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-76; Jiang LX, 2010, STEM CELLS DEV, V19, P221, DOI 10.1089/scd.2009.0170; Jose S, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0149-8; Kapur SK, 2013, BIOCHIMIE, V95, P2222, DOI 10.1016/j.biochi.2013.06.001; Kimura A, 2007, STEM CELLS, V25, P115, DOI 10.1634/stemcells.2006-0223; Kitatani K, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/7602526; Kolar MK, 2014, STEM CELLS DEV, V23, P1659, DOI 10.1089/scd.2013.0416; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Lin HY, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-13; Liu Y, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-135; Marfia G, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0457-5; Marfia G, 2015, STEM CELLS DEV, V24, P320, DOI 10.1089/scd.2014.0282; Marfia G, 2014, GLIA, V62, P1968, DOI 10.1002/glia.22718; Masgutov RF, 2015, CLIN EXP MED, V6, P1; McGeer EG, 2007, CNS DRUGS, V21, P789, DOI 10.2165/00023210-200721100-00001; McIntosh KR, 2013, EXPERT REV CLIN IMMU, V9, P175, DOI [10.1586/eci.12.96, 10.1586/ECI.12.96]; Mehling M, 2011, NEUROLOGY, V76, pS20, DOI 10.1212/WNL.0b013e31820db341; Montelatici E, 2015, BIOCHEM CELL BIOL, V93, P74, DOI 10.1139/bcb-2014-0094; Morganti-Kossmann MC, 2002, CURR OPIN CRIT CARE, V2, P101; Navone SE, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt396; Nayak D, 2010, NEUROSCIENCE, V166, P132, DOI 10.1016/j.neuroscience.2009.12.020; Neubrand VE, 2014, GLIA, V62, P1932, DOI 10.1002/glia.22714; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Ooi YY, 2015, NEUROIMMUNOMODULAT, V22, P233, DOI 10.1159/000365483; Qin JB, 2012, INT J NANOMED, V7, P5191, DOI 10.2147/IJN.S35647; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Riazi Ali M., 2009, V482, P55, DOI 10.1007/978-1-59745-060-7_5; Riboni L, 2000, METHOD ENZYMOL, V311, P656; Riboni L, 2001, J BIOL CHEM, V276, P12797, DOI 10.1074/jbc.M011570200; Safford KA, 2005, CURR DRUG TARGETS, V6, P57, DOI 10.2174/1389450053345028; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; Schilling T, 2002, NEUROSCIENCE, V109, P827, DOI 10.1016/S0306-4522(01)00534-6; Shah FS, 2013, CYTOTHERAPY, V15, P979, DOI 10.1016/j.jcyt.2013.04.001; Soliven B, 2011, NEUROLOGY, V76, pS9, DOI 10.1212/WNL.0b013e31820d9507; Streit WJ, 2000, J NEUROSCI RES, V61, P10, DOI 10.1002/1097-4547(20000701)61:1<10::AID-JNR2>3.0.CO;2-E; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tham CS, 2003, INT J DEV NEUROSCI, V21, P431, DOI 10.1016/j.ijdevneu.2003.09.003; Tremolada C, 2015, EUR J MUSC DIS, V3, P2; Wei X, 2009, STEM CELLS, V27, P478, DOI 10.1634/stemcells.2008-0333; Wei Y, 2011, ANN NEUROL, V69, P119, DOI 10.1002/ana.22186; Yan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084116; Yeh DC, 2015, CELL TRANSPLANT, V24, P487, DOI 10.3727/096368915X686940; Yoshimura K, 2006, J CELL PHYSIOL, V208, P64, DOI 10.1002/jcp.20636; Zhang ZY, 2007, J CELL MOL MED, V11, P307, DOI 10.1111/j.1582-4934.2007.00019.x; Zhi L, 2006, J CELL PHYSL, V208, P109; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	68	25	26	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	JUL 15	2016	25	14					1095	1107		10.1089/scd.2015.0268			13	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	DR0QD	WOS:000379611100006	27217090	Green Submitted			2022-02-06	
J	Dong, H; Ma, YF; Ren, ZX; Xu, B; Zhang, YH; Chen, J; Yang, B				Dong, Hui; Ma, Yunfu; Ren, Zengxi; Xu, Bin; Zhang, Yunhe; Chen, Jing; Yang, Bo			Sigma-1 Receptor Modulates Neuroinflammation After Traumatic Brain Injury	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; Sigma-1 receptor; Nitrosative stress; Oxidative stress	MACROPHAGE SUBSETS; SPINAL-CORD; MICROGLIA; MICE; ACTIVATION; NEUROTOXICITY; INFLAMMATION; SURVIVAL; TISSUE; RAT	Traumatic brain injury (TBI) remains a significant clinical problem and contributes to one-third of all injury-related deaths. Activated microglia-mediated inflammatory response is a distinct characteristic underlying pathophysiology of TBI. Here, we evaluated the effect and possible mechanisms of the selective Sigma-1 receptor agonist 2-(4-morpholinethyl)-1-phenylcyclohexanecarboxylate (PRE-084) in mice TBI model. A single intraperitoneal injection 10 mu g/g PRE-084, given 15 min after TBI significantly reduced lesion volume, lessened brain edema, attenuated modified neurological severity score, increased the latency time in wire hang test, and accelerated body weight recovery. Moreover, immunohistochemical analysis with Iba1 staining showed that PRE-084 lessened microglia activation. Meanwhile, PRE-084 reduced nitrosative and oxidative stress to proteins. Thus, Sigma-1 receptors play a major role in inflammatory response after TBI and may serve as useful target for TBI treatment in the future.	[Dong, Hui; Yang, Bo] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Zhengzhou 450052, Henan, Peoples R China; [Dong, Hui; Ma, Yunfu; Zhang, Yunhe; Chen, Jing] Zhengzhou Univ, Affiliated Hosp 3, Dept Pediat Neurosurg, Zhengzhou 450052, Henan, Peoples R China; [Ren, Zengxi] Pingdingshan Second Peoples Hosp, Dept Neurosurg, Pingdingshan 467000, Henan, Peoples R China; [Xu, Bin] Shanxi Dayi Hosp, Dept Neurosurg, Taiyuan 030000, Shanxi, Peoples R China		Yang, B (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, Zhengzhou 450052, Henan, Peoples R China.	dr_yangbo@126.com			Chinese Academy of SciencesChinese Academy of Sciences [XDA01030300]; 211 Project-phase III of Zhengzhou University-the basic and clinical research of stem cells; Excellent Youth Foundation of Henan Scientific Committee [114100510005]; Henan Province; Bureau of Science and Technology Development Project from Henan Province [200902310250]	This study was supported by Strategic Priority Research Program of the Chinese Academy of Sciences (XDA01030300), 211 Project-phase III of Zhengzhou University-the basic and clinical research of stem cells, Excellent Youth Foundation of Henan Scientific Committee (114100510005), Young Excellent Teachers in University Funded Projects of Henan Province, and Bureau of Science and Technology Development Project from Henan Province (200902310250).	Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Chen ZZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092133; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Girgis H, 2013, BRAIN RES, V1491, P78, DOI 10.1016/j.brainres.2012.10.049; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Hinson HE, 2015, J TRAUMA ACUTE CARE, V78, P184, DOI 10.1097/TA.0000000000000468; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kimura Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075760; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mancuso R, 2012, NEUROTHERAPEUTICS, V9, P814, DOI 10.1007/s13311-012-0140-y; Maurice T, 2009, PHARMACOL THERAPEUT, V124, P195, DOI 10.1016/j.pharmthera.2009.07.001; Opara J A, 2014, J Med Life, V7, P124; Pabba M, 2014, J NEUROSCI, V34, P11325, DOI 10.1523/JNEUROSCI.0458-14.2014; Peviani M, 2014, NEUROBIOL DIS, V62, P218, DOI 10.1016/j.nbd.2013.10.010; Raivich G, 2005, TRENDS NEUROSCI, V28, P571, DOI 10.1016/j.tins.2005.09.001; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Salter MW, 2014, CELL, V158, P15, DOI 10.1016/j.cell.2014.06.008; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Xie CC, 2015, BRAIN RES, V1602, P1, DOI 10.1016/j.brainres.2014.03.021; Yang Y, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-108; Yuan YM, 2015, BRAIN BEHAV IMMUN, V48, P287, DOI 10.1016/j.bbi.2015.04.008; Zhao J, 2014, INVEST OPHTH VIS SCI, V55, P3375, DOI 10.1167/iovs.13-12823; Zhao S, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-67	37	25	26	0	9	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JUL	2016	36	5					639	645		10.1007/s10571-015-0244-0			7	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	DN9LP	WOS:000377401400001	26228028				2022-02-06	
J	Chelly, J; Deye, N; Guichard, JP; Vodovar, D; Vong, L; Jochmans, S; Thieulot-Rolin, N; Sy, O; Serbource-Goguel, J; Vinsonneau, C; Megarbane, B; Vivien, B; Tazarourte, K; Monchi, M				Chelly, Jonathan; Deye, Nicolas; Guichard, Jean-Pierre; Vodovar, Dominique; Ly Vong; Jochmans, Sebastien; Thieulot-Rolin, Nathalie; Sy, Oumar; Serbource-Goguel, Jean; Vinsonneau, Christophe; Megarbane, Bruno; Vivien, Benoit; Tazarourte, Karim; Monchi, Merhan			The optic nerve sheath diameter as a useful tool for early prediction of outcome after cardiac arrest: A prospective pilot study	RESUSCITATION			English	Article						Cardiac arrest; Neuroprognostication; Optic nerve sheath diameter; Outcome; Ultrasonography	CEREBRAL-BLOOD-FLOW; EUROPEAN RESUSCITATION COUNCIL; TRAUMATIC BRAIN-INJURY; THERAPEUTIC HYPOTHERMIA; CARDIOPULMONARY-RESUSCITATION; INTRACRANIAL-PRESSURE; COMPUTED-TOMOGRAPHY; HOSPITAL ADMISSION; COMATOSE SURVIVORS; OHCA SCORE	Introduction: Optic nerve sheath diameter (ONSD) measurement could detect increased intracranial pressure, and might predict outcome in post-cardiac arrest (CA) patients. We assessed the ability of bedside ONSD ultrasonographic measurement performed within day 1 after CA occurrence to predict in-hospital survival in patients treated with therapeutic hypothermia (TH). Methods: In two French ICUs, a prospective study included all consecutive patients with CA without traumatic or neurological etiology, successfully resuscitated and TH-treated. ONSD measurements were performed on day 1, 2, and 3 (ONSD1, 2, 3 respectively) after return of spontaneous circulation. All records were registered according to Utstein style. Results: ONSD1, 2, 3 were assessed in 36, 21, and 14 patients respectively. 19/36 patients (53%) were discharged alive from hospital, including 14/36 (39%) with favorable neurological outcome (Cerebral Performance Category [CPC] score 1-2). Survivors and non-survivors were similar regarding age, sex, cardiovascular risk factors, location and etiology of CA, simplified acute physiology score II, occurrence of post-CA shock, and clinical parameters collected during ONSD measurements. Median ONSD1 was significantly larger in non-survivors versus survivors (7.2 mm [interquartile: 6.8-7.4] versus 6.5 mm [interquartile: 6.0-6.8]; p = 0.008). After adjustment on predictive factors, ONSD1 was significantly associated with in-hospital mortality (OR 6.3; 95% CI [1.05-40] per mm of ONSD1 above 5.5 mm; p = 0.03), and CPC score (OR for 1 point increase in CPC score: 3.2; 95% CI [1.2-9.4] per mm of ONSD1 above 5.5 mm; p = 0.03). ONSD1 was significantly correlated with brain edema assessed by the cerebrum gray matter attenuation to white matter attenuation ratio, measured by the brain computed tomography scan performed on admission in 20 patients (Spearman rho = -0.5, p = 0.04). Conclusions: ONSD seems a promising tool to early assess outcome in post-CA patients treated with TH. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Chelly, Jonathan; Ly Vong; Jochmans, Sebastien; Thieulot-Rolin, Nathalie; Sy, Oumar; Serbource-Goguel, Jean; Vinsonneau, Christophe; Monchi, Merhan] Hop Marc Jacquet, Intens Care Unit, 1 Rue Freteau de Peny, F-77000 Melun, France; [Deye, Nicolas; Vodovar, Dominique; Megarbane, Bruno] Grp Hosp Lariboisiere St Louis Fernand Widal, AP HP, Med & Toxicol Intens Care Unit, 2 Rue Ambroise Pare, F-75545 Paris, France; [Deye, Nicolas] Grp Hosp Lariboisiere St Louis Fernand Widal, AP HP, INSERM U942, 2 Rue Ambroise Pare, F-75545 Paris, France; [Guichard, Jean-Pierre] Grp Hosp Lariboisiere St Louis Fernand Widal, AP HP, Dept Radiol, 2 Rue Ambroise Pare, F-75545 Paris, France; [Vivien, Benoit] Hop Necker Enfants Malad, AP HP, SAMU 75, 149 Rue Sevres, F-75015 Paris, France; [Tazarourte, Karim] Hop Marc Jacquet, SAMU 77, 1 Rue Freteau de Peny, F-77000 Melun, France		Chelly, J (corresponding author), Hop Marc Jacquet, Intens Care Unit, 1 Rue Freteau de Peny, F-77000 Melun, France.	jonathan.chelly@ch-melun.fr	jochmans, sebastien/Y-3897-2019	jochmans, sebastien/0000-0002-7111-4107; tazarourte, karim/0000-0002-3376-1258; Chelly, Jonathan/0000-0002-8198-1239; Vodovar, Dominique/0000-0002-8196-5511; Megarbane, Bruno/0000-0002-2522-2764			Adrie C, 2006, EUR HEART J, V27, P2840, DOI 10.1093/eurheartj/ehl335; Alvarez-Fernandez JA, 2009, RESUSCITATION, V80, P1321, DOI 10.1016/j.resuscitation.2009.07.011; Bauerle J, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-187; Bauerle J, 2012, J NEUROIMAGING, V22, P42, DOI 10.1111/j.1552-6569.2010.00546.x; Bisschops LLA, 2012, CRIT CARE MED, V40, P2362, DOI 10.1097/CCM.0b013e318255d983; Chelly J, 2012, RESUSCITATION, V83, P1444, DOI 10.1016/j.resuscitation.2012.08.321; Crepeau AZ, 2014, RESUSCITATION, V85, P785, DOI 10.1016/j.resuscitation.2014.01.019; Deakin CD, 2010, RESUSCITATION, V81, pE93, DOI 10.1016/j.resuscitation.2010.08.027; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; GUEUGNIAUD PY, 1991, INTENS CARE MED, V17, P392, DOI 10.1007/BF01720676; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hassen GW, 2014, J EMERGENCY MED, P450; Hunziker S, 2011, CRIT CARE MED, V39, P1670, DOI 10.1097/CCM.0b013e318218a05b; Iida K, 1997, CRIT CARE MED, V25, P971, DOI 10.1097/00003246-199706000-00013; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; JENNETT B, 1975, LANCET, V1, P480; Kamps MJA, 2013, INTENS CARE MED, V39, P1671, DOI 10.1007/s00134-013-3004-y; Kim YH, 2014, ACAD EMERG MED, V21, P1121, DOI 10.1111/acem.12477; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Legrand M, 2013, CRIT CARE, V17, DOI 10.1186/cc13133; Lemiale V, 2008, RESUSCITATION, V76, P17, DOI 10.1016/j.resuscitation.2007.06.028; Lovrencic-Huzjana A., 2012, PERSPECT MED, V1, P414; Metter RB, 2011, RESUSCITATION, V82, P1180, DOI 10.1016/j.resuscitation.2011.04.001; Nordmark J, 2009, ACTA ANAESTH SCAND, V53, P289, DOI 10.1111/j.1399-6576.2008.01885.x; Oddo M, 2014, CRIT CARE MED, V42, P1340, DOI 10.1097/CCM.0000000000000211; Sandroni C, 2014, RESUSCITATION, V85, P1779, DOI 10.1016/j.resuscitation.2014.08.011; Sandroni C, 2013, RESUSCITATION, V84, P1324, DOI 10.1016/j.resuscitation.2013.06.020; Sekhon MS, 2014, NEUROCRIT CARE, V21, P245, DOI 10.1007/s12028-014-0003-y; Sekhon MS, 2014, INTENS CARE MED, V40, P1267, DOI 10.1007/s00134-014-3392-7; Sunde K, 2007, EUR HEART J, V28, P773, DOI 10.1093/eurheartj/ehl536; Sundgreen C, 2001, STROKE, V32, P128, DOI 10.1161/01.STR.32.1.128; Topcuoglu MA, 2015, J NEUROIMAGING, V25, P906, DOI 10.1111/jon.12233; Ueda T, 2015, J NEUROIMAGING; Voicu S, 2014, CRIT CARE MED, V42, P1849, DOI 10.1097/CCM.0000000000000339; Wessels T, 2006, ULTRASOUND MED BIOL, V32, P1845, DOI 10.1016/j.ultrasmedbio.2006.06.023; Zellner T, 2013, RESUSCITATION, V84, P1382, DOI 10.1016/j.resuscitation.2013.03.021	38	25	29	1	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JUN	2016	103						7	13		10.1016/j.resuscitation.2016.03.006			7	Critical Care Medicine; Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine	DL8NL	WOS:000375898600014	26995663				2022-02-06	
J	Flygt, J; Gumucio, A; Ingelsson, M; Skoglund, K; Holm, J; Alafuzoff, I; Marklund, N				Flygt, Johanna; Gumucio, Astrid; Ingelsson, Martin; Skoglund, Karin; Holm, Jonatan; Alafuzoff, Irina; Marklund, Niklas			Human Traumatic Brain Injury Results in Oligodendrocyte Death and Increases the Number of Oligodendrocyte Progenitor Cells	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Apoptosis; Human; Immunohistochemistry; Oligodendrocyte; Oligodendrocyte progenitor cells; Traumatic brain injury	DIFFUSE AXONAL INJURY; CENTRAL-NERVOUS-SYSTEM; RAT SPINAL-CORD; MULTIPLE-SCLEROSIS LESIONS; SITU DNA FRAGMENTATION; FACTOR-ALPHA-RECEPTOR; FATAL HEAD-INJURY; WHITE-MATTER; ADULT CNS; INCREASED EXPRESSION	Oligodendrocyte (OL) death may contribute to white matter pathology, a common cause of network dysfunction and persistent cognitive problems in patients with traumatic brain injury (TBI). Oligodendrocyte progenitor cells (OPCs) persist throughout the adult CNS and may replace dead OLs. OL death and OPCs were analyzed by immunohistochemistry of human brain tissue samples, surgically removed due to life-threatening contusions and/or focal brain swelling at 60.6 +/- 75 hours (range 4-192 hours) postinjury in 10 severe TBI patients (age 51.7 +/- 18.5 years). Control brain tissue was obtained postmortem from 5 age-matched patients without CNS disorders. TUNEL and CC1 co-labeling was used to analyze apoptotic OLs, which were increased in injured brain tissue (p < 0.05), without correlation with time from injury until surgery. The OPC markers Olig2, A2B5, NG2, and PDGFR-alpha were used. In contrast to the number of single-labeled Olig2, A2B5, NG2, and PDGFR-alpha-positive cells, numbers of Olig2 and A2B5 co-labeled cells were increased in TBI samples (p < 0.05); this was inversely correlated with time from injury to surgery (r = -0.8, p < 0.05). These results indicate that severe focal human TBI results in OL death and increases in OPCs postinjury, which may influence white matter function following TBI.	[Flygt, Johanna; Skoglund, Karin; Holm, Jonatan; Marklund, Niklas] Uppsala Univ, Dept Neurosci, Neurosurg, Uppsala, Sweden; [Gumucio, Astrid; Ingelsson, Martin] Uppsala Univ, Dept Publ Hlth & Caring Sci, Geriatr, Uppsala, Sweden; [Alafuzoff, Irina] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden		Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, Ing 85,2 Tr, SE-75185 Uppsala, Sweden.	Niklas.Marklund@neuro.uu.se		Marklund, Niklas/0000-0002-9797-5626			Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Baracskay KL, 2007, GLIA, V55, P1001, DOI 10.1002/glia.20519; Baumann N, 2001, PHYSIOL REV, V81, P871, DOI 10.1152/physrev.2001.81.2.871; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; Boulanger JJ, 2014, NEUROSCIENCE, V269, P343, DOI 10.1016/j.neuroscience.2014.03.063; Bradl M, 2010, ACTA NEUROPATHOL, V119, P37, DOI 10.1007/s00401-009-0601-5; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Carroll WM, 1998, BRAIN, V121, P293, DOI 10.1093/brain/121.2.293; Chari DM, 2007, INT REV NEUROBIOL, V79, P589, DOI 10.1016/S0074-7742(07)79026-8; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Clarke LE, 2012, J NEUROSCI, V32, P8173, DOI 10.1523/JNEUROSCI.0928-12.2012; Cole TB, 2004, JAMA-J AM MED ASSOC, V291, P2531, DOI 10.1001/jama.291.21.2531; Conti AC, 1998, J NEUROSCI, V18, P5663; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Cudrici C, 2006, J REHABIL RES DEV, V43, P123, DOI 10.1682/JRRD.2004.08.0111; Cui QL, 2013, AM J PATHOL, V183, P516, DOI 10.1016/j.ajpath.2013.04.016; Czepiel M, 2015, GLIA, V63, P513, DOI 10.1002/glia.22769; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.3.CO;2-E; Dent KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121541; Dewar D, 2003, J CEREBR BLOOD F MET, V23, P263, DOI 10.1097/01.WCB.0000053472.41007.F9; Di Bello IC, 1999, J NEUROCYTOL, V28, P365, DOI 10.1023/A:1007069815302; Dore-Duffy P, 2006, J CEREBR BLOOD F MET, V26, P613, DOI 10.1038/sj.jcbfm.9600272; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Fancy SPJ, 2004, MOL CELL NEUROSCI, V27, P247, DOI 10.1016/j.mcn.2004.06.015; Fancy SPJ, 2011, ANNU REV NEUROSCI, V34, P21, DOI 10.1146/annurev-neuro-061010-113629; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; Geha S, 2010, BRAIN PATHOL, V20, P399, DOI 10.1111/j.1750-3639.2009.00295.x; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Horner PJ, 2000, J NEUROSCI, V20, P2218; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; Jadasz JJ, 2012, CELL TISSUE RES, V349, P331, DOI 10.1007/s00441-012-1331-x; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnstone JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080975; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Lojewski X, 2014, STEM CELL TRANSL MED, V3, P458, DOI 10.5966/sctm.2013-0117; Lotocki G, 2011, THER HYPOTHERMIA TEM, V1, DOI 10.1089/ther.2010.0011; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; LUDWIN SK, 1978, LAB INVEST, V39, P597; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maeda Y, 2001, ANN NEUROL, V49, P776, DOI 10.1002/ana.1015; MAJOCHA RE, 1989, J NEUROCHEM, V53, P953, DOI 10.1111/j.1471-4159.1989.tb11798.x; Maki T, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00275; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Merrill JE, 1999, NEUROPATH APPL NEURO, V25, P435; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Miller BA, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-28; Moransard M, 2011, BRAIN, V134, P1315, DOI 10.1093/brain/awr070; Morelli PI, 2006, ATHEROSCLEROSIS, V184, P39, DOI 10.1016/j.atherosclerosis.2005.03.026; Oliver-De La Cruz J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099253; Oumesmar BN, 1997, J NEUROSCI, V17, P125, DOI 10.1523/JNEUROSCI.17-01-00125.1997; Piaton G, 2010, J NEUROCHEM, V114, P1243, DOI 10.1111/j.1471-4159.2010.06831.x; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rhee W, 2009, GLIA, V57, P510, DOI 10.1002/glia.20780; Sahinkaya FR, 2014, EXP NEUROL, V255, P113, DOI 10.1016/j.expneurol.2014.02.025; Sanchez I, 1996, J NEUROSCI, V16, P5095; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shaw K, 2001, CLIN NEUROPATHOL, V20, P106; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Simpson JE, 2007, NEUROPATH APPL NEURO, V33, P410, DOI 10.1111/j.1365-2990.2007.00828.x; Skoglund K, 2012, CRIT CARE MED, V40, P216, DOI 10.1097/CCM.0b013e31822d7dbd; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Sun F, 2010, GLIA, V58, P1304, DOI 10.1002/glia.21009; Takahashi C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.335; Trotter J, 2010, BRAIN RES REV, V63, P72, DOI 10.1016/j.brainresrev.2009.12.006; Uschkureit T, 2000, J NEUROSCI, V20, P5225, DOI 10.1523/JNEUROSCI.20-14-05225.2000; VIGNAIS L, 1995, NEUROREPORT, V6, P1993, DOI 10.1097/00001756-199510010-00010; Wegner M, 2001, MICROSC RES TECHNIQ, V52, P746, DOI 10.1002/jemt.1059; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Wilson HC, 2006, J NEUROIMMUNOL, V176, P162, DOI 10.1016/j.jneuroim.2006.04.014; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Windrem MS, 2004, NAT MED, V10, P93, DOI 10.1038/nm974; Yeung MSY, 2014, CELL, V159, P766, DOI 10.1016/j.cell.2014.10.011; Young KM, 2013, NEURON, V77, P873, DOI 10.1016/j.neuron.2013.01.006	99	25	26	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUN	2016	75	6					503	515		10.1093/jnen/nlw025			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	DO3FC	WOS:000377665000003	27105664	Bronze			2022-02-06	
J	Papadimitriou, KI; Wang, C; Rogers, ML; Gowers, SAN; Leong, CL; Boutelle, MG; Drakakis, EM				Papadimitriou, Konstantinos I.; Wang, Chu; Rogers, Michelle L.; Gowers, Sally A. N.; Leong, Chi L.; Boutelle, Martyn G.; Drakakis, Emmanuel M.			High-Performance Bioinstrumentation for Real-Time Neuroelectrochemical Traumatic Brain Injury Monitoring	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						analog-to-digital conversion; bioinstrumentation; biosensors; microdialysis; microfluidics; traumatic brain injury	SPREADING DEPOLARIZATIONS; ONLINE MICRODIALYSIS; ISCHEMIA; DEPRESSION; STROKE	Traumatic brain injury (TBI) has been identified as an important cause of death and severe disability in all age groups and particularly in children and young adults. Central to TBIs devastation is a delayed secondary injury that occurs in 30-40% of TBI patients each year, while they are in the hospital Intensive Care Unit (ICU). Secondary injuries reduce survival rate after TBI and usually occur within 7 days post-injury. State-of-art monitoring of secondary brain injuries benefits from the acquisition of high-quality and time-aligned electrical data i.e., ElectroCorticoGraphy (ECoG) recorded by means of strip electrodes placed on the brains surface, and neurochemical data obtained via rapid sampling microdialysis and microfluidics-based biosensors measuring brain tissue levels of glucose, lactate and potassium. This article progresses the field of multi-modal monitoring of the injured human brain by presenting the design and realization of a new, compact, medical-grade amperometry, potentiometry and ECoG recording bioinstrumentation. Our combined TBI instrument enables the high-precision, real-time neuroelectrochemical monitoring of TBI patients, who have undergone craniotomy neurosurgery and are treated sedated in the ICU. Electrical and neurochemical test measurements are presented, confirming the high-performance of the reported TBI bioinstrumentation.	[Papadimitriou, Konstantinos I.; Wang, Chu; Rogers, Michelle L.; Gowers, Sally A. N.; Leong, Chi L.; Boutelle, Martyn G.; Drakakis, Emmanuel M.] Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London, England; [Papadimitriou, Konstantinos I.; Drakakis, Emmanuel M.] Bioinspired VLSI Circuits & Syst Grp, London, England; [Wang, Chu; Rogers, Michelle L.; Gowers, Sally A. N.; Leong, Chi L.; Boutelle, Martyn G.] Biomed Sensors Grp, London, England		Boutelle, MG; Drakakis, EM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Bioengn, London, England.; Drakakis, EM (corresponding author), Bioinspired VLSI Circuits & Syst Grp, London, England.; Boutelle, MG (corresponding author), Biomed Sensors Grp, London, England.	m.boutelle@imperial.ac.uk; e.drakakis@imperial.ac.uk		Rogers, Michelle/0000-0002-1434-2322; Gowers, Sally/0000-0002-2407-2266; Papadimitriou, Konstantinos I./0000-0002-0995-4834; Leong, Chi Leng/0000-0002-2654-1345	Wellcome Trust / UK Department of Health Healthcare Innovation Challenge Fund [HICF-0510-080]	We thank the Wellcome Trust / UK Department of Health Healthcare Innovation Challenge Fund (HICF-0510-080) for finding. The authors would also like to thank Dr. Toby Jeffcote for sharing his expertise on ECoG measurements in TBI and Professor Antony Strong for kindly providing us with the artificial ECoG/SD signal.	[Anonymous], 2010, LANCET NEUROL, V9, P331, DOI 10.1016/S1474-4422(10)70069-7; Asano E, 2005, EPILEPSIA, V46, P1086, DOI 10.1111/j.1528-1167.2005.05205.x; Bhatia R, 2006, NEUROSURGERY, V58, P313, DOI 10.1227/01.NEU.0000208963.42378.83; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Faul M, 2010, TRAUMATIC BRAIN INJU; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; Glaros KN, 2013, IEEE T BIOMED CIRC S, V7, P363, DOI 10.1109/TBCAS.2012.2200677; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2009, J NEUROPHYSIOL, V102, P2563, DOI 10.1152/jn.00345.2009; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Jeffcote T, 2014, NEUROCRIT CARE, V20, P21, DOI 10.1007/s12028-013-9938-7; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao AAP, 1944, J NEUROPHYSIOL, V7, P391, DOI 10.1152/jn.1944.7.6.391; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Liu M. M, 2006, DEMYSTIFYING SWITCHE, V1; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Oliveira-Ferreira AI, 2010, J CEREBR BLOOD F MET, V30, P1504, DOI 10.1038/jcbfm.2010.40; Park J., 2003, PRACTICAL DATA ACQUI; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; Rogers ML, 2013, ANAL BIOANAL CHEM, V405, P3881, DOI 10.1007/s00216-013-6770-z; Rogers M, 2011, PHYS CHEM CHEM PHYS, V13, P5298, DOI 10.1039/c0cp02810j; Rogers ML, 2013, ACS CHEM NEUROSCI, V4, P799, DOI 10.1021/cn400047x; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2005, CRIT CARE MED, V33, P2147, DOI 10.1097/01.CCM.0000179029.95415.51; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Whitfield PC, 2009, HEAD INJURY: A MULTIDISCIPLINARY APPROACH, P1, DOI 10.1017/CBO9780511576515; Woitzik J, 2012, J CEREBR BLOOD F MET, V32, P203, DOI 10.1038/jcbfm.2011.169; Yue XC, 2008, IEEE T BIOMED CIRC S, V2, P66, DOI 10.1109/TBCAS.2008.925639	35	25	25	0	20	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAY 19	2016	10								212	10.3389/fnhum.2016.00212			15	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	DM0TV	WOS:000376059600001	27242477	Green Published, gold			2022-02-06	
J	Skogan, AH; Egeland, J; Zeiner, P; Overgaard, KR; Oerbeck, B; Reichborn-Kjennerud, T; Aase, H				Skogan, Annette Holth; Egeland, Jens; Zeiner, Pal; Overgaard, Kristin Romvig; Oerbeck, Beate; Reichborn-Kjennerud, Ted; Aase, Heidi			Factor structure of the Behavior Rating Inventory of Executive Functions (BRIEF-P) at age three years	CHILD NEUROPSYCHOLOGY			English	Article						Executive function; BRIEF-P; Preschool; Factor analysis; Development	CONFIRMATORY FACTOR-ANALYSIS; AUTISM SPECTRUM DISORDERS; LATENT VARIABLE APPROACH; TRAUMATIC BRAIN-INJURY; PRESCHOOL-CHILDREN; INDIVIDUAL-DIFFERENCES; CRITERION VALIDITY; YOUNG-CHILDREN; FOLLOW-UP; DIMENSIONS	The preschool period is an important developmental period for the emergence of cognitive self-regulatory skills or executive functions (EF). To date, evidence regarding the structure of EF in preschool children has supported both unitary and multicomponent models. The aim of the present study was to test the factor structure of early EF as measured by the Behavior Rating Inventory of Executive Function-Preschool version (BRIEF-P). BRIEF-P consists of five subscales and three broader indexes, hypothesized to tap into different subcomponents of EF. Parent ratings of EF from a nonreferred sample of children recruited from the Norwegian Mother and Child Cohort Study (N=1134; age range 37-47months) were subjected to confirmatory factor analyses (CFA). Three theoretically derived models were assessed; the second-order three-factor model originally proposed by the BRIEF-P authors, a true first-order one-factor model and a second-order one-factor model. CFA fit statistics supported the original three-factor solution. However, the difference in fit was marginal between this model and the second-order one-factor model. A follow-up exploratory factor analysis (EFA) supported the existence of several factors underlying EF in early preschool years, with a considerable overlap with the five BRIEF-P subscales. Our results suggest that some differentiation in EF has taken place at age 3 years, which is reflected in behavior ratings. The internal consistency of the BRIEF-P five clinical subscales is supported. Subscale interrelations may, however, differ at this age from those observed in the preschool group as a whole.	[Skogan, Annette Holth; Zeiner, Pal; Overgaard, Kristin Romvig; Oerbeck, Beate] Oslo Univ Hosp, Div Mental Hlth & Addict, Pb 4959 Nydalen, N-0424 Oslo, Norway; [Egeland, Jens] Univ Oslo, Inst Psychol, Oslo, Norway; [Egeland, Jens] Vestfold Hosp Trust, Div Mental Hlth & Addict, Tonsberg, Norway; [Reichborn-Kjennerud, Ted; Aase, Heidi] Norwegian Inst Publ Hlth, Div Mental Hlth, Oslo, Norway; [Reichborn-Kjennerud, Ted] Univ Oslo, Inst Clin Med, Oslo, Norway		Skogan, AH (corresponding author), Oslo Univ Hosp, Div Mental Hlth & Addict, Pb 4959 Nydalen, N-0424 Oslo, Norway.	annette.holth.skogan@ous-hf.no			Norwegian South Eastern Health Region [2010081]; Norwegian Ministry of Health; Norwegian Health Directorate; South Eastern Health Region; G & PJ Sorensen Fund for Scientific Research; Norwegian Resource Centre for ADHD, Tourette's syndrome and Narcolepsy; Ministry of Education and Research; NIH/NIEHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [N0-ES75558]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 UO1 NS047537-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS047537] Funding Source: NIH RePORTER	The study was supported by a grant from the Norwegian South Eastern Health Region, grant no. 2010081. The study "Preschool ADHD: Early characteristics, developmental trajectories, risk and protective factors in a prospective birth cohort (The ADHD study)" from which the present data were drawn, was supported by funds and grants from the Norwegian Ministry of Health, The Norwegian Health Directorate, The South Eastern Health Region, G & PJ Sorensen Fund for Scientific Research, and from The Norwegian Resource Centre for ADHD, Tourette's syndrome and Narcolepsy. MoBa is supported by the Norwegian Ministry of Health and the Ministry of Education and Research, NIH/NIEHS (Contract no. N0-ES75558) and NIH/NINDS (Grant no. 1 UO1 NS047537-01).	Achenbach T M, 2000, Pediatr Rev, V21, P265, DOI 10.1542/pir.21-8-265; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Best JR, 2010, CHILD DEV, V81, P1641, DOI 10.1111/j.1467-8624.2010.01499.x; Bonillo A, 2012, CHILD NEUROPSYCHOL, V18, P347, DOI 10.1080/09297049.2011.613808; Byrne B.M., 2012, STRUCTURAL EQUATION; Byrne BM, 2005, J PERS ASSESS, V85, P17, DOI 10.1207/s15327752jpa8501_02; Carlson SA, 2005, DEV NEUROPSYCHOL, V28, P595, DOI 10.1207/s15326942dn2802_3; Carlson SM, 2001, CHILD DEV, V72, P1032, DOI 10.1111/1467-8624.00333; Delis DC, 2003, J INT NEUROPSYCH SOC, V9, P936, DOI 10.1017/S1355617703960139; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Duku E, 2014, CHILD NEUROPSYCHOL, V20, P358, DOI 10.1080/09297049.2013.796919; Egeland J, 2010, CHILD NEUROPSYCHOL, V16, P326, DOI 10.1080/09297041003601462; Egger H. L., 2004, HDB INFANT TODDLER M, P223; Egger HL, 2006, J CHILD PSYCHOL PSYC, V47, P313, DOI 10.1111/j.1469-7610.2006.01618.x; Espy KA, 1999, BRAIN COGNITION, V41, P178, DOI 10.1006/brcg.1999.1117; Espy KA, 2001, CLIN NEUROPSYCHOL, V15, P46, DOI 10.1076/clin.15.1.46.1908; Espy KA, 2011, J CHILD PSYCHOL PSYC, V52, P33, DOI 10.1111/j.1469-7610.2010.02265.x; Ezpeleta L, 2015, J ATTEN DISORD, V19, P476, DOI 10.1177/1087054712466439; Ezpeleta L, 2012, J CHILD PSYCHOL PSYC, V53, P1128, DOI 10.1111/j.1469-7610.2012.02545.x; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; Field A., 2017, DISCOVERING STAT USI, V5th; Garon N, 2008, PSYCHOL BULL, V134, P31, DOI 10.1037/0033-2909.134.1.31; Gioia G., 2002, J INT NEUROPSYCH SOC, V8, P143; Gioia G. A., 2003, BEHAV RATING INVENTO; Gioia G.A., 2002, BEHAV RATING INVENTO; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Greene N, 2011, EPIDEMIOLOGY, V22, P815, DOI 10.1097/EDE.0b013e31822939fd; Hill AL, 2006, DEV PSYCHOL, V42, P913, DOI 10.1037/0012-1649.42.5.913; Hongwanishkul D, 2005, DEV NEUROPSYCHOL, V28, P617, DOI 10.1207/s15326942dn2802_4; Hovik KT, 2017, J ATTEN DISORD, V21, P811, DOI 10.1177/1087054714550336; Hughes C, 2010, DEV NEUROPSYCHOL, V35, P20, DOI 10.1080/87565640903325691; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Isquith PK, 2004, DEV NEUROPSYCHOL, V26, P403, DOI 10.1207/s15326942dn2601_3; Lamm C, 2010, DEV NEUROPSYCHOL, V35, P156, DOI 10.1080/87565640903526512; Lee K, 2013, CHILD DEV, V84, P1933, DOI 10.1111/cdev.12096; Lehto JE, 2003, BRIT J DEV PSYCHOL, V21, P59, DOI 10.1348/026151003321164627; Magnus P, 2006, INT J EPIDEMIOL, V35, P1146, DOI 10.1093/ije/dyl170; Mahone EM, 2007, CLIN NEUROPSYCHOL, V21, P569, DOI 10.1080/13854040600762724; Marsh HW, 2004, STRUCT EQU MODELING, V11, P320, DOI 10.1207/s15328007sem1103_2; Miller MR, 2012, J COGN DEV, V13, P395, DOI 10.1080/15248372.2011.585478; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nicholas J., 2006, BRIEF P NORWEGIAN MA; Nilsen RM, 2013, PAEDIATR PERINAT EP, V27, P553, DOI 10.1111/ppe.12077; Nilsen RM, 2009, PAEDIATR PERINAT EP, V23, P597, DOI 10.1111/j.1365-3016.2009.01062.x; Overgaard KR, 2016, J ATTEN DISORD, V20, P573, DOI 10.1177/1087054712463063; Pauli-Pott U, 2011, CLIN PSYCHOL REV, V31, P626, DOI 10.1016/j.cpr.2011.02.005; Posner MI, 2012, DEV PSYCHOL, V48, P827, DOI 10.1037/a0025530; Rubia K, 2013, EUR CHILD ADOLES PSY, V22, P719, DOI 10.1007/s00787-012-0291-8; Teunisse JP, 2012, J CLIN EXP NEUROPSYC, V34, P714, DOI 10.1080/13803395.2012.670209; Tsujimoto S, 2008, NEUROSCIENTIST, V14, P345, DOI 10.1177/1073858408316002; van der Ven SHG, 2013, BRIT J DEV PSYCHOL, V31, P70, DOI 10.1111/j.2044-835X.2012.02079.x; Wasserman T, 2013, APPL NEUROPSYCH-CHIL, V2, P88, DOI 10.1080/21622965.2013.748394; Watkins M. W, 2002, MONTE CARLO PCA PARA; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; Wichstrom L, 2012, J CHILD PSYCHOL PSYC, V53, P695, DOI 10.1111/j.1469-7610.2011.02514.x; Wiebe SA, 2011, J EXP CHILD PSYCHOL, V108, P436, DOI 10.1016/j.jecp.2010.08.008; Willoughby MT, 2010, PSYCHOL ASSESSMENT, V22, P306, DOI 10.1037/a0018708; Zelazo PD, 2003, MONOGR SOC RES CHILD, V68, P1, DOI 10.1111/j.0037-976X.2003.00261.x	62	25	28	1	43	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0929-7049	1744-4136		CHILD NEUROPSYCHOL	Child Neuropsychol.	MAY 18	2016	22	4					472	492		10.1080/09297049.2014.992401			21	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	DD3UN	WOS:000369848600006	25573465	Green Published			2022-02-06	
J	Tom, SE; Wickwire, EM; Park, YJ; Albrecht, JS				Tom, Sarah E.; Wickwire, Emerson M.; Park, Yujin; Albrecht, Jennifer S.			Nonbenzodiazepine Sedative Hypnotics and Risk of Fall-Related Injury	SLEEP			English	Article						hip fracture; nonbenzodiazepine sedative hypnotics (NBSH); traumatic brain injury	RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; CASE-CROSSOVER DESIGN; HIP-FRACTURES; OLDER-ADULTS; SLEEP DISTURBANCES; PRIMARY INSOMNIA; ZOLPIDEM; PHARMACOTHERAPY; MEDICATION	Study Objectives: The objective of this study was to test the hypothesis that use of zolpidem, eszopiclone, and zaleplon would be associated with increased risk of traumatic brain injury (TBI) and hip fracture. Methods: We conducted a case-crossover study on a 5% random sample of Medicare beneficiaries age 65 y or older hospitalized with either TBI (n = 15,031) or hip fracture (n = 37,833) during 2007-2009. Use of zolpidem, eszopiclone, or zaleplon during the 30-day period prior to injury hospitalization was compared to use during four control periods at 3, 6, 9, and 12 mo prior to injury. The primary outcome was hospitalization for TBI or hip fracture. Results: Zolpidem use during the month prior to injury was associated with increased risk of TBI (odds ratio [OR] 1.87; 95% confidence interval [CI] 1.56, 2.25); however, eszopiclone use during the same period was not associated with increased risk (OR 0.67; 95% CI 0.40, 1.13). Zolpidem use during the month prior to injury was associated with increased risk of hip fracture (OR 1.59; 95% CI 1.41, 1.79); however, eszopiclone use during the same period was not associated with increased risk (OR 1.12; 95% CI 0.83, 1.50). Analysis of zaleplon use in the month prior to injury was limited by low drug utilization but was not associated with increased risk of TBI (OR 0.85; 95% CI 0.21, 3.34) or hip fracture (OR 0.92; 95% CI 0.40, 2.13) in this study. Conclusions: For the treatment of insomnia in older adults, eszopiclone may present a safer alternative to zolpidem, in terms of fall-related injuries.	[Tom, Sarah E.; Park, Yujin] Univ Maryland, Sch Pharm, Pharmaceut Hlth Serv Res Dept, 10 S Pine St,MSTF 334C, Baltimore, MD 21201 USA; [Wickwire, Emerson M.] Univ Maryland, Sch Med, Dept Psychiat, 10 S Pine St,MSTF 334C, Baltimore, MD 21201 USA; [Wickwire, Emerson M.] Univ Maryland, Sch Med, Dept Med, 10 S Pine St,MSTF 334C, Baltimore, MD 21201 USA; [Albrecht, Jennifer S.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, 10 S Pine St,MSTF 334C, Baltimore, MD 21201 USA		Albrecht, JS (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, 10 S Pine St,MSTF 334C, Baltimore, MD 21201 USA.	jalbrecht@epi.umaryland.edu		Albrecht, Jennifer/0000-0003-4838-2274	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12HD43489-14]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD043489] Funding Source: NIH RePORTER	This was not an industry supported study. Dr. Albrecht was supported by NIH grant K12HD43489-14 (Tracey, PI). Dr. Wickwire has moderated non-commercial scientific discussion for Merck and is an equity shareholder in WellTap. The other authors have indicated no financial conflicts of interest.	Ancoli-Israel S, 2009, SLEEP MED, V10, pS7, DOI 10.1016/j.sleep.2009.07.004; Avidan AY, 2005, J AM GERIATR SOC, V53, P955, DOI 10.1111/j.1532-5415.2005.53304.x; Berry SD, 2013, JAMA INTERN MED, V173, P754, DOI 10.1001/jamainternmed.2013.3795; Blackwell T, 2006, J GERONTOL A-BIOL, V61, P405, DOI 10.1093/gerona/61.4.405; Blackwell T, 2014, SLEEP, V37, P655, DOI 10.5665/sleep.3562; Botteman MF, 2007, CNS DRUGS, V21, P319, DOI 10.2165/00023210-200721040-00005; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; Centers for Medicare & Medicaid Services, CHRON COND DAT WAR; Chung SD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067459; Daley M, 2009, SLEEP MED, V10, P427, DOI 10.1016/j.sleep.2008.04.005; Darcourt G, 1999, J PSYCHOPHARMACOL, V13, P81, DOI 10.1177/026988119901300109; Diem Susan J, 2014, J Gerontol Geriatr Res, V3, P158; Faul M, 2010, TRAUMATIC BRAIN INJU; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Finkle WD, 2011, J AM GERIATR SOC, V59, P1883, DOI 10.1111/j.1532-5415.2011.03591.x; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Ford ES, 2014, SLEEP, V37, P1283, DOI 10.5665/sleep.3914; Fortier-Brochu E, 2012, SLEEP MED REV, V16, P83, DOI 10.1016/j.smrv.2011.03.008; Frey DJ, 2011, J AM GERIATR SOC, V59, P73, DOI 10.1111/j.1532-5415.2010.03229.x; Ganguli M, 1996, J AM GERIATR SOC, V44, P778, DOI 10.1111/j.1532-5415.1996.tb03733.x; Jacobs GD, 2004, ARCH INTERN MED, V164, P1888, DOI 10.1001/archinte.164.17.1888; Kang Dong-Yoon, 2012, J Prev Med Public Health, V45, P219, DOI 10.3961/jpmph.2012.45.4.219; Lai MM, 2014, MAYO CLIN PROC, V89, P589, DOI 10.1016/j.mayocp.2014.01.021; Leger D, 2014, J SLEEP RES, V23, P143, DOI 10.1111/jsr.12104; Lin FY, 2014, SLEEP, V37, P673, DOI 10.5665/sleep.3566; Maclure M, 2000, ANNU REV PUBL HEALTH, V21, P193, DOI 10.1146/annurev.publhealth.21.1.193; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Marr A., 2004, CENTRAL NERVOUS SYST; Morin CM, 2009, JAMA-J AM MED ASSOC, V301, P2005, DOI 10.1001/jama.2009.682; Morin CM, 1999, JAMA-J AM MED ASSOC, V281, P991, DOI 10.1001/jama.281.11.991; Mullington JM, 2009, PROG CARDIOVASC DIS, V51, P294, DOI 10.1016/j.pcad.2008.10.003; SALVA P, 1995, CLIN PHARMACOKINET, V29, P142, DOI 10.2165/00003088-199529030-00002; Sauvanet JP, 1988, IMIDAZOPYRIDINES SLE; Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487; Sivertsen B, 2006, JAMA-J AM MED ASSOC, V295, P2851, DOI 10.1001/jama.295.24.2851; Stone KL, 2008, ARCH INTERN MED, V168, P1768, DOI 10.1001/archinte.168.16.1768; Stone KL, 2014, J AM GERIATR SOC, V62, P299, DOI 10.1111/jgs.12649; Tariq SH, 2008, CLIN GERIATR MED, V24, P93, DOI 10.1016/j.cger.2007.08.009; Thurman DJ., 1995, GUIDELINES SURVEILLA; Wang PS, 2001, J AM GERIATR SOC, V49, P1685, DOI 10.1111/j.1532-5415.2001.49280.x; Zint K, 2010, PHARMACOEPIDEM DR S, V19, P1248, DOI 10.1002/pds.2031	41	25	27	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA		1550-9109		SLEEP	Sleep	MAY 1	2016	39	5					1009	1014	PII sp-00414-15	10.5665/sleep.5742			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	DK8PE	WOS:000375188400007	26943470	Green Published, Bronze			2022-02-06	
J	Lee, S; Mattingly, A; Lin, A; Sacramento, J; Mannent, L; Castel, MN; Canolle, B; Delbary-Gossart, S; Ferzaz, B; Morganti, JM; Rosi, S; Ferguson, AR; Manley, GT; Bresnahan, JC; Beattie, MS				Lee, Sangmi; Mattingly, Aaron; Lin, Amity; Sacramento, Jeffrey; Mannent, Leda; Castel, Marie-Noelle; Canolle, Benoit; Delbary-Gossart, Sandrine; Ferzaz, Badia; Morganti, Josh M.; Rosi, Susanna; Ferguson, Adam R.; Manley, Geoffrey T.; Bresnahan, Jacqueline C.; Beattie, Michael S.			A novel antagonist of p75NTR reduces peripheral expansion and CNS trafficking of pro-inflammatory monocytes and spares function after traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Traumatic brain injury (TBI); p75 neurotrophin receptor (p75NTR); Inflammatory responses; Pro-inflammatory monocytes; Neuroprotection; Therapeutic target	NF-KAPPA-B; NERVE GROWTH-FACTOR; NEUROTROPHIN RECEPTOR; BONE-MARROW; MICROGLIAL ACTIVATION; HIPPOCAMPAL-NEURONS; OUTCOME PREDICTION; DENDRITIC CELLS; TNF-ALPHA; RECOVERY	Background: Traumatic brain injury (TBI) results in long-term neurological deficits, which may be mediated in part by pro-inflammatory responses in both the injured brain and the circulation. Inflammation may be involved in the subsequent development of neurodegenerative diseases and post-injury seizures. The p75 neurotrophin receptor (p75NTR) has multiple biological functions, affecting cell survival, apoptotic cell death, axonal growth, and degeneration in pathological conditions. We recently found that EVT901, a novel piperazine derivative that inhibits p75NTR oligomerization, is neuroprotective, reduces microglial activation, and improves outcomes in two models of TBI in rats. Since TBI elicits both CNS and peripheral inflammation, we used a mouse model of TBI to examine whether EVT901 would affect peripheral immune responses and trafficking to the injured brain. Methods: Cortical contusion injury (CCI)-TBI of the sensory/motor cortex was induced in C57Bl/6 wild-type mice and CCR2+/RFP heterozygote transgenic mice, followed by treatment with EVT901, a selective antagonist of p75NTR, or vehicle by i.p. injection at 4 h after injury and then daily for 7 days. Brain and blood were collected at 1 and 6 weeks after injury. Flow cytometry and histological analysis were used to determine peripheral immune responses and trafficking of peripheral immune cells into the lesion site at 1 and 6 weeks after TBI. A battery of behavioral tests administered over 6 weeks was used to evaluate neurological outcome, and stereological estimation of brain tissue volume at 6 weeks was used to assess tissue damage. Finally, multivariate principal components analysis (PCA) was used to evaluate the relationships between inflammatory events, EVT901 treatment, and neurological outcomes. Results: EVT901 is neuroprotective in mouse CCI-TBI and dramatically reduced the early trafficking of CCR2+ and pro-inflammatory monocytes into the lesion site. EVT901 reduced the number of CD45(high)CD11b+ and CD45(high)F4/80 + cells in the injured brain at 6 weeks. TBI produced a significant increase in peripheral pro-inflammatory monocytes (Ly6C(int-high) pro-inflammatory monocytes), and this peripheral effect was also blocked by EVT901 treatment. Further, we found that blocking p75NTR with EVT901 reduces the expansion of pro-inflammatory monocytes, and their response to LPS in vitro, supporting the idea that there is a peripheral EVT901 effect that blunts inflammation. Further, 1 week of EVT901 blocks the expansion of pro-inflammatory monocytes in the circulation after TBI, reduces the number of multiple subsets of pro-inflammatory monocytes that enter the injury site at 1 and 6 weeks post-injury, and is neuroprotective, as it was in the rat. Conclusions: Together, these findings suggest that p75NTR signaling participates in the production of the peripheral pro-inflammatory response to CNS injury and implicates p75NTR as a part of the pro-inflammatory cascade. Thus, the neuroprotective effects of p75NTR antagonists might be due to a combination of central and peripheral effects, and p75NTR may play a role in the production of peripheral inflammation in addition to its many other biological roles. Thus, p75NTR may be a therapeutic target in human TBI.	[Lee, Sangmi; Lin, Amity; Sacramento, Jeffrey; Morganti, Josh M.; Rosi, Susanna; Ferguson, Adam R.; Manley, Geoffrey T.; Bresnahan, Jacqueline C.; Beattie, Michael S.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurol Surg, Box 08991001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94143 USA; [Mattingly, Aaron; Rosi, Susanna; Ferguson, Adam R.; Beattie, Michael S.] Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA; [Mannent, Leda; Castel, Marie-Noelle; Canolle, Benoit; Ferzaz, Badia] Sanofi Rech, Early Candidate, 195 Route Espagne, Chilly Mazarin, France; [Delbary-Gossart, Sandrine] Evotec, 195 Route Espagne, F-31036 Toulouse, France		Beattie, MS (corresponding author), Univ Calif San Francisco, Brain & Spinal Injury Ctr, Dept Neurol Surg, Box 08991001 Potrero Ave,Bldg 1,Rm 101, San Francisco, CA 94143 USA.; Beattie, MS (corresponding author), Univ Calif San Francisco, Biomed Sci Grad Program, San Francisco, CA 94143 USA.	michael.beattie@ucsf.edu	Beattie, Michael S/A-8953-2009; Morganti, Josh/AAL-9727-2020	Morganti, Josh/0000-0002-4183-0049; Ferguson, Adam/0000-0001-7102-1608	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038079]; UCSF/BASIC pilot funds; Sanofi R and D; UCSF; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087458, R01NS038079, R01NS067092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG042016] Funding Source: NIH RePORTER	We would like to thank Dr. Jenny Haefeli and Pavan Upadhyayula for the PCA syndromic plots and software development and Dr. Xiaokui Ma for the technical support in the tissue sectioning. Thanks to Dr. Noah Saederup and Dr. Israel F. Charo at Gladstone Institute, UCSF, for providing the CCR2<SUP>+/RFP</SUP> Tg mice [ 50] to Dr. Rosi who provided them for the current experiment. This work was supported by NIH NS038079, with the statistical support from NS067092, UCSF/BASIC pilot funds, and a sponsored research agreement (SRA) between Sanofi R and D and UCSF.	Alabanza LM, 2013, J IMMUNOL, V191, P3764, DOI 10.4049/jimmunol.1202556; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Beattie MS, 2010, EUR J NEUROSCI, V32, P290, DOI 10.1111/j.1460-9568.2010.07343.x; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bouet V, 2009, NAT PROTOC, V4, P1560, DOI 10.1038/nprot.2009.125; Bramlett HM, 2015, J NEUROTRAUM, V32, P1834, DOI 10.1089/neu.2014.3352; Cardona AE, 2006, NAT PROTOC, V1, P1947, DOI 10.1038/nprot.2006.327; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen CY, 2013, DEV NEUROSCI-BASEL, V35, P474, DOI 10.1159/000355874; Chen QY, 2013, J IMMUNOL, V190, P1048, DOI 10.4049/jimmunol.1202455; Choi S, 2014, NEUROSCIENCE, V257, P11, DOI 10.1016/j.neuroscience.2013.10.058; Choi S, 2009, ASN NEURO, V1, DOI 10.1042/AN20090009; Croft M, 2013, NAT REV DRUG DISCOV, V12, P147, DOI 10.1038/nrd3930; Delbary-Gossart S, 2016, BRAIN; Fleming SM, 2013, JOVE-J VIS EXP, DOI 10.3791/50303; Flores-Torales E, 2010, FOLIA HISTOCHEM CYTO, V48, P682, DOI 10.2478/v10042-010-0063-6; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; Gao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096741; Gardiner E, 2012, MOL PSYCHIATR, V17, P827, DOI 10.1038/mp.2011.78; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gola H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-40; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Han JH, 2005, NAT IMMUNOL, V6, P1198, DOI 10.1038/ni1274; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; Ho L, 2012, J ALZHEIMERS DIS, V31, P301, DOI 10.3233/JAD-2012-120598; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Ibanez CF, 2012, TRENDS NEUROSCI, V35, P431, DOI 10.1016/j.tins.2012.03.007; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Inoue T, 2013, EXP NEUROL, V248, P136, DOI 10.1016/j.expneurol.2013.06.006; Irvine K -A., 2010, J VIS EXP; Irvine KA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00116; Jiang YM, 2008, MOL IMMUNOL, V45, P1557, DOI 10.1016/j.molimm.2007.10.008; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kharatishvili I, 2010, CURR OPIN NEUROL, V23, P183, DOI 10.1097/WCO.0b013e32833749e4; Kuci S, 2010, HAEMATOL-HEMATOL J, V95, P651, DOI 10.3324/haematol.2009.015065; Lee SM, 2011, J NEUROTRAUM, V28, P1893, DOI 10.1089/neu.2011.1860; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liesz A, 2015, J NEUROSCI, V35, P583, DOI 10.1523/JNEUROSCI.2439-14.2015; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Longo FM, 2013, NAT REV DRUG DISCOV, V12, P507, DOI 10.1038/nrd4024; Meeker R, 2014, J NEUROIMMUNE PHARM, V9, P615, DOI 10.1007/s11481-014-9566-9; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nassenstein C, 2006, EXP TOXICOL PATHOL, V57, P55, DOI 10.1016/j.etp.2006.02.008; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Patanella AK, 2010, J NEUROSCI RES, V88, P1106, DOI 10.1002/jnr.22276; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Perry VH, 2010, ACTA NEUROPATHOL, V120, P277, DOI 10.1007/s00401-010-0722-x; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Poulsen KL, 2014, J PHARMACOL EXP THER, V350, P164, DOI 10.1124/jpet.114.214189; Qu CF, 2004, J EXP MED, V200, P1231, DOI 10.1084/jem.20032152; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rogers ML, 2010, J NEUROIMMUNOL, V226, P93, DOI 10.1016/j.jneuroim.2010.05.040; Roux PP, 1999, J NEUROSCI, V19, P6887, DOI 10.1523/JNEUROSCI.19-16-06887.1999; Saederup N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013693; Saiwai H, 2013, J NEUROCHEM, V125, P74, DOI 10.1111/jnc.12135; Schachtrup C, 2015, NAT NEUROSCI, V18, P1077, DOI 10.1038/nn.4054; Schor NF, 2005, PROG NEUROBIOL, V77, P201, DOI 10.1016/j.pneurobio.2005.10.006; Schwab JM, 2014, EXP NEUROL, V258, P121, DOI 10.1016/j.expneurol.2014.04.023; Schwulst SJ, 2013, J TRAUMA ACUTE CARE, V75, P780, DOI 10.1097/TA.0b013e318299616a; Sebastiani A, 2015, J NEUROTRAUM, V32, P1599, DOI 10.1089/neu.2014.3751; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Shames BD, 1999, J SURG RES, V83, P69, DOI 10.1006/jsre.1998.5564; Sharif O, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-1; Shen WY, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-137; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Shi J, 2013, STEM CELLS, V31, P2561, DOI 10.1002/stem.1516; Skeldal S, 2011, BIOESSAYS, V33, P614, DOI 10.1002/bies.201100036; Srinivasan B, 2004, J BIOL CHEM, V279, P41839, DOI 10.1074/jbc.M402872200; Staniszewska I, 2008, J CELL SCI, V121, P504, DOI 10.1242/jcs.000232; Szaflarski JP, 2014, NEUROPSYCH DIS TREAT, V10, P1469, DOI 10.2147/NDT.S50421; Takatsuru Y, 2009, BRAIN RES, V1294, P45, DOI 10.1016/j.brainres.2009.07.092; Tep C, 2013, J NEUROSCI, V33, P397, DOI 10.1523/JNEUROSCI.0399-12.2013; Terry RL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-270; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; Ultsch MH, 1999, J MOL BIOL, V290, P149, DOI 10.1006/jmbi.1999.2816; Underwood CK, 2008, INT J BIOCHEM CELL B, V40, P1664, DOI 10.1016/j.biocel.2007.06.010; Verbeke S, 2013, FEBS LETT, V587, P2591, DOI 10.1016/j.febslet.2013.06.039; Volosin M, 2008, J NEUROSCI, V28, P9870, DOI 10.1523/JNEUROSCI.2841-08.2008; Wensink AC, 2015, J IMMUNOL, V194, P491, DOI 10.4049/jimmunol.1401214; YAN Q, 1988, J NEUROSCI, V8, P3481; Yang Y, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-108; Yuan FR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090463; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhang HQ, 2011, J NEUROSCI, V31, P15894, DOI 10.1523/JNEUROSCI.3943-11.2011	99	25	25	0	4	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	APR 22	2016	13								88	10.1186/s12974-016-0544-4			21	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	DJ9KB	WOS:000374531300001	27102880	Green Published, gold			2022-02-06	
J	Tzekov, R; Dawson, C; Orlando, M; Mouzon, B; Reed, J; Evans, J; Crynen, G; Mullan, M; Crawford, F				Tzekov, Radouil; Dawson, Clint; Orlando, Megan; Mouzon, Benoit; Reed, Jon; Evans, James; Crynen, Gogce; Mullan, Michael; Crawford, Fiona			Sub-Chronic Neuropathological and Biochemical Changes in Mouse Visual System after Repetitive Mild Traumatic Brain Injury	PLOS ONE			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; MICROTUBULE-ASSOCIATED PROTEINS; RETINAL GANGLION-CELLS; HEAT-SHOCK PROTEINS; OPTIC-NERVE LESION; AXONAL-TRANSPORT; BASIC-PROTEIN; ALTERED EXPRESSION; APOLIPOPROTEIN-E; CATHEPSIN-D	Repetitive mild traumatic brain injury (r-mTBI) results in neuropathological and biochemical consequences in the human visual system. Using a recently developed mouse model of r-mTBI, with control mice receiving repetitive anesthesia alone (r-sham) we assessed the effects on the retina and optic nerve using histology, immunohistochemistry, proteomic and lipidomic analyses at 3 weeks post injury. Retina tissue was used to determine retinal ganglion cell (RGC) number, while optic nerve tissue was examined for cellularity, myelin content, protein and lipid changes. Increased cellularity and areas of demyelination were clearly detectable in optic nerves in r-mTBI, but not in r-sham. These changes were accompanied by a similar to 25% decrease in the total number of Brn3a-positive RGCs. Proteomic analysis of the optic nerves demonstrated various changes consistent with a negative effect of r-mTBI on major cellular processes like depolymerization of microtubules, disassembly of filaments and loss of neurons, manifested by decrease of several proteins, including neurofilaments (NEFH, NEFM, NEFL), tubulin (TUBB2A, TUBA4A), microtubule-associated proteins (MAP1A, MAP1B), collagen (COL6A1, COL6A3) and increased expression of other proteins, including heat shock proteins (HSP90B1, HSPB1), APOE and cathepsin D. Lipidomic analysis showed quantitative changes in a number of phospholipid species, including a significant increase in the total amount of lysophosphatidylcholine (LPC), including the molecular species 16:0, a known demyelinating agent. The overall amount of some ether phospholipids, like ether LPC, ether phosphatidylcholine and ether lysophosphatidylethanolamine were also increased, while the majority of individual molecular species of ester phospholipids, like phosphatidylcholine and phosphatidylethanolamine, were decreased. Results from the biochemical analysis correlate well with changes detected by histological and immunohistochemical methods and indicate the involvement of several important molecular pathways. This will allow future identification of therapeutic targets for improving the visual consequences of r-mTBI.	[Tzekov, Radouil; Dawson, Clint; Orlando, Megan; Mouzon, Benoit; Reed, Jon; Evans, James; Crynen, Gogce; Mullan, Michael; Crawford, Fiona] Roskamp Inst, Sarasota, FL USA; [Tzekov, Radouil] Univ S Florida, Dept Ophthalmol, Tampa, FL USA; [Tzekov, Radouil; Mouzon, Benoit; Evans, James; Crawford, Fiona] James A Haley Vet Adm, Tampa, FL USA		Tzekov, R (corresponding author), Roskamp Inst, Sarasota, FL USA.; Tzekov, R (corresponding author), Univ S Florida, Dept Ophthalmol, Tampa, FL USA.; Tzekov, R (corresponding author), James A Haley Vet Adm, Tampa, FL USA.	rtzekov@roskampinstitute.net	Dawson, Clint/AAH-3213-2021	Dawson, Clint/0000-0001-7273-0684; Tzekov, Radouil/0000-0002-3662-9818	Department of DefenseUnited States Department of Defense [W81XWH-10-1-0759]; Roskamp Foundation	This work was supported by Department of Defense award W81XWH-10-1-0759 (to Fiona Crawford), and the Roskamp Foundation.	Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; ADAMCZEWSKAGONCERZEWICZ Z, 1981, J NEUROCHEM, V36, P1378, DOI 10.1111/j.1471-4159.1981.tb00575.x; Agudo-Barriuso M, 2011, MYSTERY GLAUCOMA, P91; Aquino DA, 1997, J NEUROPATH EXP NEUR, V56, P664; Atkins Edward J, 2008, Rev Neurol Dis, V5, P73; Beaulieu JM, 1999, BIOCHEM CELL BIOL, V77, P41, DOI 10.1139/bcb-77-1-41; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bilyk J R, 1994, Semin Ophthalmol, V9, P200, DOI 10.3109/08820539409060016; Blondeau N, 2002, J CEREBR BLOOD F MET, V22, P821, DOI 10.1097/00004647-200207000-00007; Bocquet A, 2009, J NEUROSCI, V29, P11043, DOI 10.1523/JNEUROSCI.1924-09.2009; CAMMER W, 1986, BRAIN RES, V364, P91, DOI 10.1016/0006-8993(86)90990-X; Carroll W M, 1983, Clin Exp Neurol, V19, P17; Chen H, 2014, SURV OPHTHALMOL, V59, P64, DOI 10.1016/j.survophthal.2013.02.005; Chidlow G, 2005, MOL VIS, V11, P387; Chidlow G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114838; Cho Y, 2015, J BIOL CHEM, V290, P22759, DOI 10.1074/jbc.M115.638445; Conde C, 2009, NAT REV NEUROSCI, V10, P319, DOI 10.1038/nrn2631; Cwiklinska H, 2003, INT IMMUNOL, V15, P241, DOI 10.1093/intimm/dxg022; DAS SK, 1978, LIPIDS, V13, P679, DOI 10.1007/BF02533745; de Monasterio-Schrader P, 2012, CELL MOL LIFE SCI, V69, P2879, DOI 10.1007/s00018-012-0958-9; Dieterich DC, 2002, EUR J NEUROSCI, V15, P1433, DOI 10.1046/j.1460-9568.2002.01977.x; Faul M, 2010, TRAUMATIC BRAIN INJU; Galindo-Romero C, 2011, EXP EYE RES, V92, P377, DOI 10.1016/j.exer.2011.02.008; GOTO K, 1990, NEUROSCI LETT, V117, P269, DOI 10.1016/0304-3940(90)90675-Y; Greenwald BD, 2012, BRAIN INJURY, V26, P1338, DOI 10.3109/02699052.2012.706356; Grzelczyk A, 2013, BIOCHIMIE, V95, P667, DOI 10.1016/j.biochi.2012.10.009; Gupta R, 2005, J ORTHOP RES, V23, P1232, DOI 10.1016/j.orthres.2004.12.010; Hensley K, 2011, MOL NEUROBIOL, V43, P180, DOI 10.1007/s12035-011-8166-4; HERRMANN H, 1985, J BIOL CHEM, V260, P5797; Hsieh CC, 2000, ATHEROSCLEROSIS, V151, P481, DOI 10.1016/S0021-9150(00)00453-6; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; Ikeno Y, 2009, J NEUROSCI RES, V87, P190, DOI 10.1002/jnr.21821; Jacobs SM, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0389-5; Joachim SC, 2011, INVEST OPHTH VIS SCI, V52, P3468, DOI 10.1167/iovs.10-5763; Johnson EC, 2007, INVEST OPHTH VIS SCI, V48, P3161, DOI 10.1167/iovs.06-1282; Kim H, 2011, FEBS LETT, V585, P18, DOI 10.1016/j.febslet.2010.11.033; Kubo T, 2002, J NEUROCHEM, V82, P1129, DOI 10.1046/j.1471-4159.2002.01060.x; Kuhlmann T, 2002, J NEUROSCI RES, V67, P185, DOI 10.1002/jnr.10104; Lachapelle F, 2005, BRAIN PATHOL, V15, P198; Lavi S, 2007, CIRCULATION, V115, P2715, DOI 10.1161/CIRCULATIONAHA.106.671420; Levkovitch-Verbin H, 2000, INVEST OPHTH VIS SCI, V41, P4169; Li Y, 2011, J CELL BIOCHEM, V112, P1930, DOI 10.1002/jcb.23113; Lin PC, 2011, J BIOL CHEM, V286, P41466, DOI 10.1074/jbc.M111.283580; LIU KM, 1985, CELL TISSUE RES, V242, P245; Martin A, 2003, J NEUROSCI, V23, P5416; Maxwell WL, 2013, BRAIN SCI, V3, P1374, DOI 10.3390/brainsci3031374; MCKERRACHER L, 1990, J NEUROSCI, V10, P2834; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nagai J, 2011, J NEUROCHEM, V118, P256, DOI 10.1111/j.1471-4159.2011.07297.x; Nguyen JV, 2011, P NATL ACAD SCI USA, V108, P1176, DOI 10.1073/pnas.1013965108; NIXON RA, 1984, J NEUROCHEM, V43, P507, DOI 10.1111/j.1471-4159.1984.tb00928.x; NIXON RA, 1990, J CELL BIOL, V110, P437, DOI 10.1083/jcb.110.2.437; Padilla ND, 2003, IMMUNOLOGY, V109, P564, DOI 10.1046/j.1365-2567.2003.01681.x; Pasvogel AE, 2010, BIOL RES NURS, V11, P325, DOI 10.1177/1099800409346056; Petratos S, 2012, BRAIN, V135, P1794, DOI 10.1093/brain/aws100; Prilloff S, 2012, INVEST OPHTH VIS SCI, V53, P1460, DOI 10.1167/iovs.11-8306; Raasakka A, 2014, NEUROSCI BULL, V30, P956, DOI 10.1007/s12264-013-1437-5; Rodemer C, 2003, HUM MOL GENET, V12, P1881, DOI 10.1093/hmg/ddg191; Rosenberger TA, 2002, J LIPID RES, V43, P59; Saab S, 2014, BIOCHIMIE, V107, P58, DOI 10.1016/j.biochi.2014.07.023; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Salinas-Navarro M, 2009, VISION RES, V49, P637, DOI 10.1016/j.visres.2009.01.010; Saunders LL, 2009, ARCH PHYS MED REHAB, V90, P1853, DOI 10.1016/j.apmr.2009.05.020; Schilling T, 2009, J CELL PHYSIOL, V221, P325, DOI 10.1002/jcp.21857; SCHMIDTKASTNER R, 1994, RESTOR NEUROL NEUROS, V6, P145, DOI 10.3233/RNN-1994-6208; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; SCHOENFELD TA, 1989, J NEUROSCI, V9, P1712; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Sherafat MA, 2011, NEUROCHEM RES, V36, P1887, DOI 10.1007/s11064-011-0510-6; SNYDER DS, 1985, J NEUROCYTOL, V14, P579, DOI 10.1007/BF01200799; STOLL G, 1989, GLIA, V2, P170, DOI 10.1002/glia.440020306; Surgucheva I, 2002, J NEUROSCI RES, V68, P97, DOI 10.1002/jnr.10198; Surguchov A, 2001, J NEUROSCI RES, V65, P68, DOI 10.1002/jnr.1129; Takahashi M, 2002, ATHEROSCLEROSIS, V161, P387, DOI 10.1016/S0021-9150(01)00674-8; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Teigler A, 2009, HUM MOL GENET, V18, P1897, DOI 10.1093/hmg/ddp110; Thukkani AK, 2003, CIRCULATION, V108, P3128, DOI 10.1161/01.CIR.0000104564.01539.6A; Tytell M, 2005, INT J HYPERTHER, V21, P445, DOI 10.1080/02656730500041921; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wender M, 1981, Acta Neuropathol Suppl, V7, P36; Wong EV, 2003, J NEUROSCI, V23, P3112; Xu K, 2013, SCIENCE, V339, P452, DOI 10.1126/science.1232251; You YY, 2011, INVEST OPHTH VIS SCI, V52, P6911, DOI 10.1167/iovs.11-7434; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Yuan AD, 2006, J NEUROSCI, V26, P10006, DOI 10.1523/JNEUROSCI.2580-06.2006; Zhao J, 2016, METHOD ENZYMOL, V568, P477, DOI 10.1016/bs.mie.2015.09.012; Zhou ZG, 2011, LIPIDS, V46, P879, DOI 10.1007/s11745-011-3575-8; Zhu XD, 2007, AM J RESP CELL MOL, V36, P585, DOI 10.1165/rcmb.2006-0391OC	92	25	25	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 18	2016	11	4							e0153608	10.1371/journal.pone.0153608			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DJ9IK	WOS:000374527000029	27088355	Green Published, gold, Green Submitted			2022-02-06	
J	Wood, JN; French, B; Fromkin, J; Fakeye, O; Scribano, PV; Letson, MM; Makoroff, KL; Feldman, KW; Fabio, A; Berger, R				Wood, Joanne N.; French, Benjamin; Fromkin, Janet; Fakeye, Oludolapo; Scribano, Philip V.; Letson, Megan M.; Makoroff, Kathi L.; Feldman, Kenneth W.; Fabio, Anthony; Berger, Rachel			Association of Pediatric Abusive Head Trauma Rates With Macroeconomic Indicators	ACADEMIC PEDIATRICS			English	Article						child abuse; economic recession; traumatic brain injury	CHILD MALTREATMENT; BRAIN-INJURY; RECESSION; INFANTS; IMPACT	OBJECTIVE: We aimed to examine abusive head trauma (AHT) incidence before, during and after the recession of 2007-2009 in 3 US regions and assess the association of economic measures with AHT incidence. METHODS: Data for children <5 years old diagnosed with AHT between January 1, 2004, and December 31, 2012, in 3 regions were linked to county-level economic data using an ecologic time series analysis. Associations between county level AHT rates and recession period as well as employment growth, mortgage delinquency, and foreclosure rates were examined using zero-inflated Poisson regression models. RESULTS: During the 9-year period, 712 children were diagnosed with AHT. The mean rate of AHT per 100,000 child years increased from 9.8 before the recession to 15.6 during the recession before decreasing to 12.8 after the recession. The AHT rates after the recession were higher than the rates before the recession (incidence rate ratio 1.31, P =.004) but lower than rates during the recession (incidence rate ratio 0.78, P =.005). There was no association between the AHT rate and employment growth, mortgage delinquency rates, or foreclosure rates. CONCLUSIONS: In the period after the recession, AHT rate was lower than during the recession period yet higher than the level before the recession, suggesting a lingering effect of the economic stress of the recession on maltreatment risk.	[Wood, Joanne N.; Scribano, Philip V.] Childrens Hosp Philadelphia, Div Gen Pediat, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Fakeye, Oludolapo] Childrens Hosp Philadelphia, PolicyLab, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Scribano, Philip V.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [French, Benjamin] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Fromkin, Janet; Berger, Rachel] UPMC, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA USA; [Letson, Megan M.] Nationwide Childrens Hosp, Columbus, OH USA; [Letson, Megan M.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Makoroff, Kathi L.] Mayerson Ctr Safe & Healthy Children, Cincinnati, OH USA; [Makoroff, Kathi L.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Feldman, Kenneth W.] Seattle Childrens Hosp, Div Gen Pediat, Seattle, WA USA; [Feldman, Kenneth W.] Seattle Childrens Hosp, Childrens Protect Program, Seattle, WA USA; [Feldman, Kenneth W.] Univ Washington, Sch Med, Seattle, WA USA; [Fabio, Anthony] Epidemiol Data Coordinating Ctr, Dept Epidemiol, Baltimore, MD USA; [Fabio, Anthony] Epidemiol Data Coordinating Ctr, Grad Sch Publ Hlth, Baltimore, MD USA; [Berger, Rachel] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA		Wood, JN (corresponding author), Childrens Hosp Philadelphia, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA.	woodjo@email.chop.edu		Letson, Megan/0000-0001-6689-7015; Fabio, Anthony/0000-0002-6808-4939; Feldman, Kenneth/0000-0002-9020-5223	Casey Family Programs; Matty Eapen Foundation; CoreLogic Solutions LLC.	This study was funded in part by a grant from Casey Family Programs, and the related parent study was funded by a grant from the Matty Eapen Foundation. Access to mortgage delinquency and foreclosure data for the study was provided through a grant from CoreLogic Solutions LLC. Sponsors had no role in study design, collection, analysis, and interpretation of data, the writing of the report, and the decision to submit for publication. We thank Lori Vavul-Roediger, MD (Dayton Children's Hospital), and Yolanda Duralde (Mary Bridge Hospital) for obtaining data about children with AHT evaluated at hospitals other than the study hospitals.	Aboa-Eboule C, 2013, J NEUROL, V260, P605, DOI 10.1007/s00415-012-6686-0; [Anonymous], 2011, STAT NAT HOUS; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Berger LM, 2005, SOC SERV REV, V79, P237, DOI 10.1086/428957; Berger RP, 2015, INJURY PREV, V21, pE133, DOI 10.1136/injuryprev-2013-040924; Berger RP, 2011, PEDIATRICS, V128, P637, DOI 10.1542/peds.2010-2185; Brooks-Gunn J, 2013, CHILD ABUSE NEGLECT, V37, P721, DOI 10.1016/j.chiabu.2013.08.004; Cancian M., 2010, EFFECT FAMILY INCOME; Child Welfare Information Gateway, 2014, DIFF RESP REP CHILD; COULTON CJ, 1995, CHILD DEV, V66, P1262, DOI 10.2307/1131646; Curtis T, 2000, CHILD ABUSE NEGLECT, V24, P1151, DOI 10.1016/S0145-2134(00)00176-9; Drake B, 1996, CHILD ABUSE NEGLECT, V20, P1003, DOI 10.1016/0145-2134(96)00091-9; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Eckenrode J, 2014, PEDIATRICS, V133, P454, DOI 10.1542/peds.2013-1707; Federal Interagency Forum on Child and Family Statistics, 2011, AM CHILDR KEY NAT IN; Finkelhor D, 2009, UPDATED TRENDS CHILD; Finkelhor D, 2012, HAVE SEXUAL ABUSE PH; Freisthler B, 2006, CHILD MALTREATMENT, V11, P263, DOI 10.1177/1077559506289524; Frioux S, 2014, MATERN CHILD HLTH J, V18, P2202, DOI 10.1007/s10995-014-1469-0; Hooft A, 2013, J PEDIATR-US, V162, P80, DOI 10.1016/j.jpeds.2012.06.037; Huang MI, 2011, J NEUROSURG-PEDIATR, V8, P171, DOI 10.3171/2011.5.PEDS1139; Kan J, 2008, SOURCES FORECLOSURE; Keenan HT, 2004, AM J PREV MED, V26, P189, DOI 10.1016/j.amepre.2003.10.023; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KOTCH JB, 1995, CHILD ABUSE NEGLECT, V19, P1115, DOI 10.1016/0145-2134(95)00072-G; LAMBERT D, 1992, TECHNOMETRICS, V34, P1, DOI 10.2307/1269547; Lovell P, 2008, IMPACT MORTGAGE CRIS; Millett L, 2011, CHILD YOUTH SERV REV, V33, P1280, DOI 10.1016/j.childyouth.2011.03.001; National Bureau of Economic Research, 2014, US BUS CYCL EXP CONT; Rajmil L, 2014, INT J ENV RES PUB HE, V11, P6528, DOI 10.3390/ijerph110606528; Sermons MW, 2011, STATE HOMELESSNESS A; Shanahan ME, 2013, PEDIATRICS, V132, pE1546, DOI 10.1542/peds.2013-2049; U.S. Census Bureau, 2010, 2010 CENS DAT; U. S. Census Bureau Population Division, INT EST RES POP 5 YE; United States Census Bureau, 2010, AN EST RES POP COUNT; United States Census Bureau, 2011, 2009 2011 AM COMM SU; Wood JN, 2012, PEDIATRICS, V130, pE358, DOI 10.1542/peds.2011-3755; Xiang J, 2013, BRAIN INJURY, V27, P1555, DOI 10.3109/02699052.2013.831126	38	25	25	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1876-2859	1876-2867		ACAD PEDIATR	Acad. Pediatr.	APR	2016	16	3					224	232		10.1016/j.acap.2015.05.008			9	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	DI3RZ	WOS:000373417500003	26183000				2022-02-06	
J	Zhao, S; Gao, X; Dong, WR; Chen, JH				Zhao, Shu; Gao, Xiang; Dong, Weiren; Chen, Jinhui			The Role of 7,8-Dihydroxyflavone in Preventing Dendrite Degeneration in Cortex After Moderate Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; Dendrite; Degeneration; Brain-derived neurotrophic factor; 7,8-Dihydroxyflavone	SYNAPTIC PLASTICITY; MOUSE MODEL; NEUROTROPHIC FACTOR; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; MEMORY DEFICITS; TRKB AGONIST; CELLS; BDNF; RAT	Our previous research showed that traumatic brain injury (TBI) induced by controlled cortical impact (CCI) not only causes massive cell death, but also results in extensive dendrite degeneration in those spared neurons in the cortex. Cell death and dendrite degeneration in the cortex may contribute to persistent cognitive, sensory, and motor dysfunction. There is still no approach available to prevent cells from death and dendrites from degeneration following TBI. When we treated the animals with a small molecule, 7,8-dihydroxyflavone (DHF) that mimics the function of brain-derived neurotrophic factor (BDNF) through provoking TrkB activation reduced dendrite swellings in the cortex. DHF treatment also prevented dendritic spine loss after TBI. Functional analysis showed that DHF improved rotarod performance on the third day after surgery. These results suggest that although DHF treatment did not significantly reduced neuron death, it prevented dendrites from degenerating and protected dendritic spines against TBI insult. Consequently, DHF can partially improve the behavior outcomes after TBI.	[Zhao, Shu; Dong, Weiren] Southern Med Univ, Dept Histol & Embryol, Guangzhou, Guangdong, Peoples R China; [Gao, Xiang; Chen, Jinhui] Indiana Univ, Spinal Cord & Brain Injury Res Grp, 950 W Walnut St, Indianapolis, IN 46202 USA; [Gao, Xiang; Chen, Jinhui] Indiana Univ, Stark Neurosci Res Inst, 950 W Walnut St, Indianapolis, IN 46202 USA; [Gao, Xiang; Chen, Jinhui] Indiana Univ, Dept Neurosurg, 950 W Walnut St, Indianapolis, IN 46202 USA; [Chen, Jinhui] Indiana Univ, Sch Med, 950 W Walnut St, Indianapolis, IN 46202 USA; [Dong, Weiren] 1838 North Guangzhou Blvd, Guangzhou 510515, Guangdong, Peoples R China		Chen, JH (corresponding author), Indiana Univ, Sch Med, 950 W Walnut St, Indianapolis, IN 46202 USA.; Dong, WR (corresponding author), 1838 North Guangzhou Blvd, Guangzhou 510515, Guangdong, Peoples R China.	wrdong@163.com; chen204@iupui.edu			Indiana Spinal Cord & Brain Injury Research Grants; Ralph W. and Grace M. Showalter Research Award; Indiana University Biological Research Grant; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RR025761, 1R21NS072631-01A]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001108] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025761] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075733, R21NS072631] Funding Source: NIH RePORTER	This work was supported through funding from the Indiana Spinal Cord & Brain Injury Research Grants, the Ralph W. and Grace M. Showalter Research Award, Indiana University Biological Research Grant, and NIH grants RR025761 and 1R21NS072631-01A.	Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Andero R, 2012, GENES BRAIN BEHAV, V11, P503, DOI 10.1111/j.1601-183X.2012.00801.x; Andero R, 2012, HIPPOCAMPUS, V22, P399, DOI 10.1002/hipo.20906; Andero R, 2011, AM J PSYCHIAT, V168, P163, DOI 10.1176/appi.ajp.2010.10030326; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Campbell JN, 2012, J NEUROTRAUM, V29, P201, DOI 10.1089/neu.2011.1761; Chen J, 2009, J NEUROTRAUM, DOI [10.1089/neu.2008-0744, DOI 10.1089/NEU.2008-0744]; Chen J, 2011, NEUROSCI LETT, V499, P181, DOI 10.1016/j.neulet.2011.05.054; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; Devi L, 2012, NEUROPSYCHOPHARMACOL, V37, P434, DOI 10.1038/npp.2011.191; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Gao X, 2008, J NEUROTRAUM, V25, P985, DOI 10.1089/neu.2008.0460; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2007, J NEUROSCI, V27, P14317, DOI 10.1523/JNEUROSCI.3206-07.2007; Gao X, 2013, EXP NEUROL, V239, P38, DOI 10.1016/j.expneurol.2012.09.012; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gao X, 2009, EXP NEUROL, V219, P516, DOI 10.1016/j.expneurol.2009.07.007; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Harborne JB, 2000, PHYTOCHEMISTRY, V55, P481, DOI 10.1016/S0031-9422(00)00235-1; Harris KM, 1999, CURR OPIN NEUROBIOL, V9, P343, DOI 10.1016/S0959-4388(99)80050-6; Jang SW, 2010, P NATL ACAD SCI USA, V107, P2687, DOI 10.1073/pnas.0913572107; Johnson RA, 2012, J APPL PHYSIOL, V112, P704, DOI 10.1152/japplphysiol.01361.2011; Kishino A, 1997, EXP NEUROL, V144, P273, DOI 10.1006/exnr.1996.6367; Liu X, 2010, J MED CHEM, V53, P8274, DOI 10.1021/jm101206p; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Park HY, 2012, ONCOL REP, V28, P353, DOI 10.3892/or.2012.1773; Park HY, 2012, INT J MOL MED, V29, P1146, DOI 10.3892/ijmm.2012.935; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Risher WC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022351; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; SHOLL DA, 1956, PROG NEUROBIOL, V2, P324; Sorra KE, 2000, HIPPOCAMPUS, V10, P501, DOI 10.1002/1098-1063(2000)10:5<501::AID-HIPO1>3.0.CO;2-T; Spencer JPE, 2008, P NUTR SOC, V67, P238, DOI 10.1017/S0029665108007088; Srivastava DP, 2013, NEUROSCIENCE, V239, P17, DOI 10.1016/j.neuroscience.2012.12.004; UYLINGS HBM, 1986, J NEUROSCI METH, V18, P127, DOI 10.1016/0165-0270(86)90116-0; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Zeng Y, 2012, J ALZHEIMERS DIS, V31, P765, DOI 10.3233/JAD-2012-120886; Zeng Y, 2012, J NEUROCHEM, V122, P800, DOI 10.1111/j.1471-4159.2012.07830.x; Zhang R, 2009, BIOL PHARM BULL, V32, P166, DOI 10.1248/bpb.32.166; Zhang ZT, 2014, NEUROPSYCHOPHARMACOL, V39, P638, DOI 10.1038/npp.2013.243; Zoladz JA, 2010, J PHYSIOL PHARMACOL, V61, P533	48	25	25	1	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	APR	2016	53	3					1884	1895		10.1007/s12035-015-9128-z			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG7KQ	WOS:000372263600044	25801526	Green Accepted			2022-02-06	
J	Toth, A; Kovacs, N; Tamas, V; Kornyei, B; Nagy, M; Horvath, A; Rostas, T; Bogner, P; Janszky, J; Doczi, T; Buki, A; Schwarcz, A				Toth, Arnold; Kovacs, Noemi; Tamas, Viktoria; Kornyei, Balint; Nagy, Mate; Horvath, Andrea; Rostas, Tamas; Bogner, Peter; Janszky, Jozsef; Doczi, Tamas; Buki, Andras; Schwarcz, Attila			Microbleeds may expand acutely after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Susceptibility weighted imaging; Traumatic brain injury; Diffuse axonal injury; Microbleed; Microhemorrhage; Magnetic resonance imaging	CEREBRAL MICROBLEEDS; AXONAL INJURY; INTRACEREBRAL HEMORRHAGE; ECHO MRI; LESIONS; PREDICTION; CHILDREN; CT	Background and purpose: Susceptibility weighted imaging (SWI) is a very sensitive tool for the detection of microbleeds in traumatic brain injury (TBI). The number and extent of such traumatic microbleeds (TMBs) have been shown to correlate with the severity of the injury and the clinical outcome. However, the acute dynamics of TMBs have not been revealed so far. Since TBI is known to constitute dynamic pathological processes, we hypothesized that TMBs are not constant in their appearance, but may progress acutely after injury. Materials and methods: We present here five closed moderate/severe (Glasgow coma scale <= 13) TBI patients who underwent SWI very early (average = 23.4 h), and once again a week (average = 185.8 h) after the injury. The TMBs were mapped at both time points by a conventional radiological approach and their numbers and volumes were measured with manual tracing tools by two observers. TMB counts and extents were compared between time points. Results: TMBs were detected in four patients, three of them displaying an apparent TMB change. In these patients, TMB confluence and apparent growth were detected in the corpus callosum, coronal radiation or subcortical white matter, while unchanged TMBs were also present. These changes caused a decrease in the TMB count associated with an increase in the overall TMB volume over time. Conclusion: We have found a compelling evidence that diffuse axonal injury-related microbleed development is not limited strictly to the moment of injury: the TMBs might expand in the acute phase of TBI. The timing of SWI acquisition may be relevant for optimizing the prognostic utility of this imaging biomarker. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Toth, Arnold; Kovacs, Noemi; Tamas, Viktoria; Kornyei, Balint; Nagy, Mate; Horvath, Andrea; Bogner, Peter; Doczi, Tamas; Buki, Andras; Schwarcz, Attila] Pecs Med Sch, Dept Neurosurg, Ret U 2, H-7623 Pecs, Hungary; [Horvath, Andrea; Doczi, Tamas] Diagnost Ctr Pecs, Ret U 2, H-7623 Pecs, Hungary; [Rostas, Tamas; Bogner, Peter] Pecs Med Sch, Dept Radiol, Ifjusag Str 13, H-7623 Pecs, Hungary; [Janszky, Jozsef] Pecs Med Sch, Dept Neurol, Ret U 2, H-7623 Pecs, Hungary; [Janszky, Jozsef; Doczi, Tamas; Buki, Andras; Schwarcz, Attila] MTA PTE Clin Neurosci MR Res Grp, Pecs, Hungary		Toth, A (corresponding author), Dept Neurosurg, Ret U 2 Pecs, H-7623 Pecs, Hungary.	prsarn@gmail.com; noemi.kovacs5@gmail.com; tamas.viktoria@pte.hu; kornyei.balint@windowslive.com; nagy.mate@pte.hu; andrhorvath@gmail.com; rostas.tamas@pte.hu; peter.bogner@gmail.com; jozseEjanszky@gmail.com; doczi.tamas@pte.hu; 2saturn@pte.hu; schwarcz.attila@pte.hu	Kornyei, Balint/AAK-7548-2020		Hungarian Brain Research Program Grant [KTIA_13_NAP-A-II/8, KTIA_13_NAP-A-II/9, SROP-4.2.2.A-11/1/KONV-2012-0017]; Hungarian Scientific Research Fund Grant [OTKA/109132]	This study was funded by Hungarian Brain Research Program Grant No. KTIA_13_NAP-A-II/8, Grant No. KTIA_13_NAP-A-II/9, SROP-4.2.2.A-11/1/KONV-2012-0017 and Hungarian Scientific Research Fund Grant No. OTKA/109132.	Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beauchamp MH, 2013, CORTEX, V49, P591, DOI 10.1016/j.cortex.2012.08.015; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Belayev L, 2007, BRAIN RES, V1157, P146, DOI 10.1016/j.brainres.2007.04.077; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cheng AL, 2013, STROKE, V44, P2782, DOI 10.1161/STROKEAHA.113.002267; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Di Ieva A., 2015, J NEUROSURG, P1; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Gregg NM, 2015, JAMA NEUROL, V72, P1021, DOI 10.1001/jamaneurol.2015.1359; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Iwamura A, 2012, NEURORADIOLOGY, V54, P335, DOI 10.1007/s00234-011-0892-9; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Knight RA, 2008, STROKE, V39, P2596, DOI 10.1161/STROKEAHA.107.506683; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Liu WH, 2012, STROKE, V43, P2916, DOI 10.1161/STROKEAHA.112.658369; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Parizel PM, 2001, EUR RADIOL, V11, P1770, DOI 10.1007/s003300000800; Poels MMF, 2010, STROKE, V41, pS103, DOI 10.1161/STROKEAHA.110.595181; Ryan N.P., 2014, HUM BRAIN MAPP; Schaible E.V., 2013, ANTICOAGULATION PATI; Schoonjans F, 1995, COMPUT METH PROG BIO, V48, P257, DOI 10.1016/0169-2607(95)01703-8; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	33	25	26	0	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 23	2016	617						207	212		10.1016/j.neulet.2016.02.028			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DI5LB	WOS:000373539400035	26912192				2022-02-06	
J	Wang, HC; Lin, YJ; Shih, FY; Chang, HW; Su, YJ; Cheng, BC; Su, CM; Tsai, NW; Chang, YT; Kwan, AL; Lu, CH				Wang, Hung-Chen; Lin, Yu-Jun; Shih, Fu-Yuan; Chang, Hsueh-Wen; Su, Yu-Jih; Cheng, Ben-Chung; Su, Chih-Min; Tsai, Nai-Wen; Chang, Ya-Ting; Kwan, Aij-Lie; Lu, Cheng-Hsien			The Role of Serial Oxidative Stress Levels in Acute Traumatic Brain Injury and as Predictors of Outcome	WORLD NEUROSURGERY			English	Article						Glutathione; Outcome; Oxidative stress; Traumatic brain injury	ENTRAPPED SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; HEAD-INJURY; IN-VIVO; RATS; INFLAMMATION; MECHANISMS; ISCHEMIA; CHILDREN; MODERATE	BACKGROUND: Oxidative stress is thought to participate in the pathobiology of secondary brain injury after acute traumatic brain injury (TBI). This study posits that oxidative stress levels in acute TBI are predictive of outcome. METHODS: Two hundred and twenty-nine blood samples from 88 patients admitted within 24 hours after TBI were obtained on admission and on days 4 and 7. Serial plasma oxidative level and antioxidant were examined in 88 patients with acute TBI and 27 control individuals. RESULTS: Compared with controls, patients with TBI had significantly increased serum glutathione (GSH) levels on presentation and significantly decreased erythrocyte superoxide dismutase levels. Outcome was assessed on discharge using the Glasgow Outcome Scale. Serum GSH and erythrocyte superoxide dismutase levels were significantly higher in the good outcome group than in the poor outcome group on day 1 (P = 0.008 and P = 0.026, respectively). In the logistic regression analysis, only motor deficits and GSH levels on presentation were independently associated with outcome. A GSH cutoff value of 1.106 mu mol/L on presentation was associated with good outcome in patients with acute TBI. CONCLUSIONS: Quantifying biomarkers of oxidative stress and antioxidant status of serum correlate with trauma severity and may be used to predict outcomes after TBI. Higher serum GSH levels on admission are associated with better outcome.	[Wang, Hung-Chen; Lin, Yu-Jun; Shih, Fu-Yuan] Kaohsiung Chang Gung Mem Hosp, Dept Neurosurg, Kaohsiung, Taiwan; [Chang, Hsueh-Wen; Su, Yu-Jih; Cheng, Ben-Chung] Kaohsiung Chang Gung Mem Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Su, Chih-Min] Kaohsiung Chang Gung Mem Hosp, Dept Emergency Med, Kaohsiung, Taiwan; [Tsai, Nai-Wen; Chang, Ya-Ting; Lu, Cheng-Hsien] Kaohsiung Chang Gung Mem Hosp, Dept Neurol, Kaohsiung, Taiwan; Chang Gung Univ, Coll Med, Kaohsiung, Taiwan; [Lin, Yu-Jun; Chang, Hsueh-Wen; Cheng, Ben-Chung; Chang, Ya-Ting; Lu, Cheng-Hsien] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 80424, Taiwan; [Kwan, Aij-Lie] Kaohsiung Med Univ, Dept Neurosurg, Coll Med, Kaohsiung, Taiwan; [Lu, Cheng-Hsien] Xiamen Chang Gung Mem Hosp, Dept Neurol, Xiamen, Fujian, Taiwan		Lu, CH (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Neurol, Kaohsiung, Taiwan.; Lu, CH (corresponding author), Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 80424, Taiwan.; Lu, CH (corresponding author), Xiamen Chang Gung Mem Hosp, Dept Neurol, Xiamen, Fujian, Taiwan.	chlu99@ms44.url.com.tw		Su, Yu-Jih/0000-0002-7274-3458; WANG, HUNG-CHEN/0000-0003-3962-1958			Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Awasthi D, 1997, SURG NEUROL, V47, P581; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HERBERT V, 1994, STEM CELLS, V12, P289, DOI 10.1002/stem.5530120305; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; Johnston SC, 1998, NEUROLOGY, V51, P411, DOI 10.1212/WNL.51.2.411; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; KONTOS CD, 1992, AM J PHYSIOL, V263, pH1234, DOI 10.1152/ajpheart.1992.263.4.H1234; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Ma Anlun, 2008, Cardiovascular & Hematological Agents in Medicinal Chemistry, V6, P20; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; OYESIKU NM, 1993, NEUROSURGERY, V32, P518; Oyesiku NM, 1993, NEUROSURGERY, V32, P525; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Zimmermann M, 2011, METHODS MOL BIOL, V740, P57, DOI 10.1007/978-1-61779-108-6_8	28	25	25	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAR	2016	87						463	470		10.1016/j.wneu.2015.10.010			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DI3HR	WOS:000373390200060	26481337				2022-02-06	
J	Wing, R; Amanullah, S; Jacobs, E; Clark, MA; Merritt, C				Wing, Robyn; Amanullah, Siraj; Jacobs, Elizabeth; Clark, Melissa A.; Merritt, Chris			Heads Up: Communication Is Key in School Nurses' Preparedness for Facilitating "Return to Learn" Following Concussion	CLINICAL PEDIATRICS			English	Article						concussion; head injury; mild traumatic brain injury; school nurses; return to learn; return to school; pediatrics	COGNITIVE REST; SPORT; RECOMMENDATIONS; STATEMENT; RECOVERY	Background. Recent literature advocates for a school academic team, including school nurses, to support concussed students' return to the classroom. This study aimed to assess the current understanding and practices of a sample of school nurses regarding the concept of return to learn in concussed students. Methods. Cross-sectional survey of New England school nurses. Results. The greatest barrier to the school nurses' functioning within the academic rehabilitation team for students with concussion was inadequate communication with the provider that diagnosed the concussion (73%). Of the 151 school nurses surveyed, 19% felt that they did not have the training necessary for this role. Other barriers included inadequate concussion training (38%) and inadequate time necessary to care for a student with concussion (30%). Conclusions. By identifying specific gaps in knowledge and challenges at the school level, these results inform interdisciplinary medical teams about the importance of educating and facilitating effective return to learn academic plans.	[Wing, Robyn; Amanullah, Siraj; Jacobs, Elizabeth; Clark, Melissa A.; Merritt, Chris] Brown Univ, Providence, RI 02912 USA; [Wing, Robyn; Amanullah, Siraj; Jacobs, Elizabeth; Merritt, Chris] Rhode Isl Hosp, Hasbro Childrens Hosp, Providence, RI 02903 USA		Wing, R (corresponding author), Hasbro Childrens Hosp, 593 Eddy St,Claverick 2, Providence, RI 02903 USA.	robyn_wing@brown.edu	Meijer, Anna/K-5118-2016		University Emergency Medicine Foundation of Providence, RI	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding was provided through a seed grant from the University Emergency Medicine Foundation of Providence, RI.	Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bergren Martha Dewey, 2012, NASN Sch Nurse, V27, P36; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grady MF, 2012, PEDIATR ANN, V41, P377, DOI 10.3928/00904481-20120827-12; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McAvoy K., REAP BENEFITS GOOD C; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Ohio Department of Health, 2008, 2008 SCH NURS SURV F; Piebes SK, 2009, J SCH NURS, V25, P270, DOI 10.1177/1059840509339782; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Wang LY, 2014, JAMA PEDIATR, V168, P642, DOI 10.1001/jamapediatrics.2013.5441	27	25	26	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	MAR	2016	55	3					228	235		10.1177/0009922815592879			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	DE1VN	WOS:000370414700004	26130394				2022-02-06	
J	Schober, ME; Requena, DF; Abdullah, OM; Casper, TC; Beachy, J; Malleske, D; Pauly, JR				Schober, Michelle E.; Requena, Daniela F.; Abdullah, Osama M.; Casper, T. Charles; Beachy, Joanna; Malleske, Daniel; Pauly, James R.			Dietary Docosahexaenoic Acid Improves Cognitive Function, Tissue Sparing, and Magnetic Resonance Imaging Indices of Edema and White Matter Injury in the Immature Rat after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; DTI; Morris water maze; pediatric	CONTROLLED CORTICAL IMPACT; MORRIS WATER MAZE; IN-VIVO; AXON DIAMETER; DIFFUSION; EXPRESSION; SUPPLEMENTATION; MODEL; TERM; VULNERABILITY	Traumatic brain injury (TBI) is the leading cause of acquired neurologic disability in children. Specific therapies to treat acute TBI are lacking. Cognitive impairment from TBI may be blunted by decreasing inflammation and oxidative damage after injury. Docosahexaenoic acid (DHA) decreases cognitive impairment, oxidative stress, and white matter injury in adult rats after TBI. Effects of DHA on cognitive outcome, oxidative stress, and white matter injury in the developing rat after experimental TBI are unknown. We hypothesized that DHA would decrease early inflammatory markers and oxidative stress, and improve cognitive, imaging and histologic outcomes in rat pups after controlled cortical impact (CCI). CCI or sham surgery was delivered to 17 d old male rat pups exposed to DHA or standard diet for the duration of the experiments. DHA was introduced into the dam diet the day before CCI to allow timely DHA delivery to the pre-weanling pups. Inflammatory cytokines and nitrates/nitrites were measured in the injured brains at post-injury Day (PID) 1 and PID2. Morris water maze (MWM) testing was performed at PID41-PID47. T2-weighted and diffusion tensor imaging studies were obtained at PID12 and PID28. Tissue sparing was calculated histologically at PID3 and PID50. DHA did not adversely affect rat survival or weight gain. DHA acutely decreased oxidative stress and increased anti-inflammatory interleukin 10 in CCI brains. DHA improved MWM performance and lesion volume late after injury. At PID12, DHA decreased T2-imaging measures of cerebral edema and decreased radial diffusivity, an index of white matter injury. DHA improved short- and long-term neurologic outcomes after CCI in the rat pup. Given its favorable safety profile, DHA is a promising candidate therapy for pediatric TBI. Further studies are needed to explore neuroprotective mechanisms of DHA after developmental TBI.	[Schober, Michelle E.; Requena, Daniela F.; Casper, T. Charles] Univ Utah, Dept Pediat, Div Crit Care, Salt Lake City, UT 84158 USA; [Abdullah, Osama M.] Univ Utah, Dept Bioengn, Salt Lake City, UT 84158 USA; [Beachy, Joanna; Malleske, Daniel] Univ Utah, Dept Pediat, Div Neonatol, Salt Lake City, UT 84158 USA; [Pauly, James R.] Univ Kentucky, Coll Pharm, Lexington, KY USA; [Pauly, James R.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA		Schober, ME (corresponding author), Univ Utah, Sch Med, POB 581289, Salt Lake City, UT 84158 USA.	michelle.schober@hsc.utah.edu					Abdullah L, 2014, FASEB J, V28, P5311, DOI 10.1096/fj.14-258228; Adelson PD, 2013, CHILD NERV SYST, V29, P43, DOI 10.1007/s00381-012-1932-4; Adelson PD, 1998, ACT NEUR S, V71, P104; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Alexander DC, 2010, NEUROIMAGE, V52, P1374, DOI 10.1016/j.neuroimage.2010.05.043; Anderson V, 2006, AM J PHYS MED REHAB, V85, P767, DOI 10.1097/01.phm.0000233176.08480.22; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Barazany D, 2009, BRAIN, V132, P1210, DOI 10.1093/brain/awp042; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Begum G, 2013, TRANSL STROKE RES, V4, P635, DOI 10.1007/s12975-013-0282-1; Bendszus M, 2002, J NEUROSURG, V97, P1419, DOI 10.3171/jns.2002.97.6.1419; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Bockhorst KH, 2008, J NEUROSCI RES, V86, P1520, DOI 10.1002/jnr.21607; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Card JP, 2005, J NEUROTRAUM, V22, P989, DOI 10.1089/neu.2005.22.989; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Chang CY, 2013, J NUTR BIOCHEM, V24, P2127, DOI 10.1016/j.jnutbio.2013.08.004; Chang PKY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0244-5; Colombo J, 2013, AM J CLIN NUTR, V98, P403, DOI 10.3945/ajcn.112.040766; Corser-Jensen CE, 2014, EXP NEUROL, V256, P7, DOI 10.1016/j.expneurol.2014.03.008; Di Pietro V, 2014, FREE RADICAL BIO MED, V69, P258, DOI 10.1016/j.freeradbiomed.2014.01.032; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fleith M, 2005, CRIT REV FOOD SCI, V45, P205, DOI 10.1080/10408690590956378; Guseva MV, 2008, J NEUROTRAUM, V25, P975, DOI 10.1089/neu.2008.0516; Huang Z, 2012, NEUROSCI LETT, V526, P138, DOI 10.1016/j.neulet.2012.08.018; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Innis SM, 2008, BRAIN RES, V1237, P35, DOI 10.1016/j.brainres.2008.08.078; JONES BJ, 1968, J PHARM PHARMACOL, V20, P302, DOI 10.1111/j.2042-7158.1968.tb09743.x; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.0.CO;2-Q; Kinnavane L, 2015, BEHAV BRAIN RES, V285, P67, DOI 10.1016/j.bbr.2014.07.049; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Krafft PR, 2012, INT J STROKE, V7, P398, DOI 10.1111/j.1747-4949.2012.00838.x; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar RG, 2015, BRAIN BEHAV IMMUN, V45, P253, DOI 10.1016/j.bbi.2014.12.021; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lauritzen L, 2002, LIPIDS, V37, P237, DOI 10.1007/s11745-002-0886-2; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lewis M, 2013, AM J EMERG MED, V31, DOI 10.1016/j.ajem.2012.05.014; Lien EL, 2009, PROSTAG LEUKOTR ESS, V81, P125, DOI 10.1016/j.plefa.2009.05.004; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mao HJ, 2010, J NEUROTRAUM, V27, P877, DOI 10.1089/neu.2008.0616; Massaro AN, 2015, DEV MED CHILD NEUROL, V57, P441, DOI 10.1111/dmcn.12646; Mayer D, 2007, NEUROIMAGE, V35, P1077, DOI 10.1016/j.neuroimage.2007.01.006; McQuillen PS, 2004, PEDIATR NEUROL, V30, P227, DOI 10.1016/j.pediatrneurol.2003.10.001; Meola D., 2013, J ALZHEIMER DIS PA S, P10; Miller SL, 2012, NEUROENDOCRINOLOGY, V96, P13, DOI 10.1159/000336378; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Paterniti I, 2014, J NEUROINFLAMM, V11, DOI [10.1186/1742-2094-11-6, 10.1186/s12974-014-0136-0]; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Potts Mathew B, 2006, NeuroRx, V3, P143; R Core Team, 2012, R LANG ENV STAT COMP; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Reger ML, 2009, DEV PSYCHOBIOL, V51, P672, DOI 10.1002/dev.20402; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; Russell KL, 2014, PROSTAG LEUKOTR ESS, V90, P5, DOI 10.1016/j.plefa.2013.11.003; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schober ME, 2014, J NEUROTRAUM, V31, pA65; Schober ME, 2014, J NEUROTRAUM, V31, P358, DOI 10.1089/neu.2013.2922; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; Schober ME, 2012, METAB BRAIN DIS, V27, P167, DOI 10.1007/s11011-012-9309-7; Schwarzmaier SM, 2015, J NEUROTRAUM, V32, P990, DOI 10.1089/neu.2014.3775; Schwarzmaier SM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00358; Semple BD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103386; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Shimazawa M, 2009, BRAIN RES, V1251, P269, DOI 10.1016/j.brainres.2008.11.031; Stonehouse W, 2014, NUTRIENTS, V6, P2730, DOI 10.3390/nu6072730; Tajuddin N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101223; Tuor UI, 2014, NEUROIMAGE-CLIN, V6, P32, DOI 10.1016/j.nicl.2014.08.003; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wainwright PE, 1999, J NUTR, V129, P1079, DOI 10.1093/jn/129.5.1079; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2014, NEUROREHAB NEURAL RE, V28, P75, DOI 10.1177/1545968313498650; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	88	25	25	1	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2016	33	4					390	402		10.1089/neu.2015.3945			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	DD2NH	WOS:000369758800008	26247583	Green Published			2022-02-06	
J	Arnould, A; Dromer, E; Rochat, L; Van der Linden, M; Azouvi, P				Arnould, A.; Dromer, E.; Rochat, L.; Van der Linden, M.; Azouvi, P.			Neurobehavioral and self-awareness changes after traumatic brain injury: Towards new multidimensional approaches	ANNALS OF PHYSICAL AND REHABILITATION MEDICINE			English	Article						Apathy; Impulsivity; Anosognosia; Traumatic brain injury; Multidimensional approach	APATHY; IMPULSIVITY; MODERATE; ANOSOGNOSIA; PERSONALITY; CAREGIVERS; MODEL; HEMIPLEGIA; INVENTORY; SEVERITY	Neurobehavioral and self-awareness changes are frequently observed following traumatic brain injury (TBI). These disturbances have been related to negative consequences on functional outcomes, caregiver distress and social reintegration, representing therefore a challenge for clinical research. Some studies have recently been conducted to specifically explore apathetic and impulsive manifestations, as well as self-awareness impairments in patients with TBI. These findings underlined the heterogeneity of clinical manifestations for each behavioral disturbance and the diversity of psychological processes involved. In this context, new multidimensional approaches taking into account the various processes at play have been proposed to better understand and apprehend the complexity and dynamic nature of these problematic behaviors. In addition, the involvement of social and environmental factors as well as premorbid personality traits have increasingly been addressed. These new multidimensional frameworks have the potential to ensure targeted and effective rehabilitation by allowing a better identification and therefore consideration of the various mechanisms involved in the onset of problematic behaviors. In this context, the main objective of this position paper was to demonstrate the interest of multidimensional approaches in the understanding and rehabilitation of problematic behaviors in patients with TBI. (C) 2015 Elsevier Masson SAS. All rights reserved.	[Arnould, A.; Dromer, E.; Azouvi, P.] Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, 104 Blvd Raymond Poincare, F-92380 Garches, France; [Arnould, A.; Rochat, L.; Van der Linden, M.] Univ Geneva, Unite Psychopathol & Neuropsychol Cognit, Geneva, Switzerland; [Arnould, A.; Dromer, E.; Azouvi, P.] Univ Versailles St Quentin En Yvelines, HANDIReSP, EA 4047, F-78000 Versailles, France; [Rochat, L.; Van der Linden, M.] Univ Geneva, Swiss Ctr Affect Sci, Geneva, Switzerland; [Van der Linden, M.] Univ Liege, Unite Psychopathol Cognit, Liege, Belgium		Arnould, A (corresponding author), Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, 104 Blvd Raymond Poincare, F-92380 Garches, France.; Arnould, A (corresponding author), Univ Geneva, Unite Psychopathol & Neuropsychol Cognit, Geneva, Switzerland.; Arnould, A (corresponding author), Univ Versailles St Quentin En Yvelines, HANDIReSP, EA 4047, F-78000 Versailles, France.	annabelle.arnould@rpc.aphp.fr		Rochat, Lucien/0000-0002-9992-2720			Arnould A, 2015, BRAIN INJURY, P1; Arnould A, 2013, NEUROPSYCHOL REV, V23, P210, DOI 10.1007/s11065-013-9236-3; Bechara A, 2005, CURR OPIN NEUROL, V18, P734, DOI 10.1097/01.wco.0000194141.56429.3c; Billieux J., 2008, TRAITE PSYCHOPATHOLO, V1, P137; Bivona U, 2014, J HEAD TRAUMA REHAB, V29, P157, DOI 10.1097/HTR.0b013e3182864f0b; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Coben R.A., 1995, ARCH CLIN NEUROPSYCH, V10, P310; Coben RA, 1995, ARCH CLIN NEUROPSYCH, V10, P309; Crosson B, 1989, J HEAD TRAUMA REHAB, V4, P91; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; Desmurget M, 2009, SCIENCE, V324, P811, DOI 10.1126/science.1169896; Ennis N, 2013, NEUROPSYCHOL REHABIL, V23, P1, DOI 10.1080/09602011.2012.712871; Esposito F, 2014, AGING MENT HEALTH, V18, P521, DOI 10.1080/13607863.2013.856865; Esposito F, 2014, ARCH GERONTOL GERIAT, V58, P43, DOI 10.1016/j.archger.2013.09.002; Esposito F, 2012, DEMENT GER COGN D EX, V2, P456, DOI 10.1159/000345037; Esposito F, 2010, ALZ DIS ASSOC DIS, V24, P131, DOI 10.1097/WAD.0b013e3181c9c168; FEINBERG TE, 1990, NEUROLOGY, V40, P1391, DOI 10.1212/WNL.40.9.1391; Fleming JM, 1996, BRAIN INJURY, V10, P1; Gay P, 2008, ACTA PSYCHOL, V129, P332, DOI 10.1016/j.actpsy.2008.08.010; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; GOLD M, 1994, NEUROLOGY, V44, P1804, DOI 10.1212/WNL.44.10.1804; Gray J.M, 1994, CLIN REHABIL, V8, P188, DOI [10.1177/026921559400800302, DOI 10.1177/026921559400800302, DOI 10.1080/09602010902949207]; Ham TE, 2014, BRAIN, V137, P586, DOI 10.1093/brain/awt350; Jumisko E, 2007, J FAM NURS, V13, P353, DOI 10.1177/1074840707303842; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Karnath HO, 2005, J NEUROSCI, V25, P7134, DOI 10.1523/JNEUROSCI.1590-05.2005; Kelly G, 2008, BRAIN INJURY, V22, P457, DOI 10.1080/02699050802060647; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Lane-Brown AT, 2009, BRAIN INJURY, V23, P999, DOI 10.3109/02699050903379347; LEVINE DN, 1990, BRAIN COGNITION, V13, P233, DOI 10.1016/0278-2626(90)90052-P; Malec JF, 2004, REHABIL PSYCHOL, V49, P55, DOI 10.1037/0090-5550.49.1.55; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McAllister TW, 2007, BRAIN INJURY MED, P815; Meulemans T, 2000, TRAITE NEUROPSYCHOLO, V1, P301; Miller J, 2003, PERS INDIV DIFFER, V34, P1403, DOI 10.1016/S0191-8869(02)00122-8; Mulin E, 2011, INT J GERIATR PSYCH, V26, P158, DOI 10.1002/gps.2508; Robert PH, 2002, INT J GERIATR PSYCH, V17, P1099, DOI 10.1002/gps.755; Rochat L, 2013, J INT NEUROPSYCH SOC, V19, P890, DOI 10.1017/S1355617713000672; Rochat L, 2011, PSYCHOPATHOLOGY, V44, P158, DOI 10.1159/000322454; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; Rush BK, 2006, REHABIL PSYCHOL, V51, P257, DOI 10.1037/0090-5550.51.3.257; Sela-Kaufman M, 2013, J CLIN EXP NEUROPSYC, V35, P584, DOI 10.1080/13803395.2013.799123; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sinha N, 2013, J NEUROPSYCHOL, V7, P255, DOI 10.1111/jnp.12013; Sockeel P, 2006, J NEUROL NEUROSUR PS, V77, P579, DOI 10.1136/jnnp.2005.075929; Spikman JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065581; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Vocat R, 2010, BRAIN, V133, P3578, DOI 10.1093/brain/awq297; Vuilleumier P, 2004, CORTEX, V40, P9, DOI 10.1016/S0010-9452(08)70918-3; Vuilleumier P, 2000, BEHAVIOR AND MOOD DISORDERS IN FOCAL BRAIN LESIONS, P465; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7; Wilson BA, 1993, BEHAV ASSESSMENT DYS; Zasler Nathan D, 2013, Handb Clin Neurol, V110, P377, DOI 10.1016/B978-0-444-52901-5.00032-0; Zermatten A, 2005, J NERV MENT DIS, V193, P647, DOI 10.1097/01.nmd.0000180777.41295.65	60	25	27	0	8	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	1877-0657	1877-0665		ANN PHYS REHABIL MED	Ann. Phys. Rehabil. Med.	FEB	2016	59	1			SI		18	22		10.1016/j.rehab.2015.09.002			5	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	FO5JF	WOS:000416890700004	26585583	Green Submitted, Bronze			2022-02-06	
J	Despins, EH; Turkstra, LS; Struchen, MA; Clark, AN				Despins, Emily H.; Turkstra, Lyn S.; Struchen, Margaret A.; Clark, Allison N.			Sex-Based Differences in Perceived Pragmatic Communication Ability of Adults With Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Communication; Rehabilitation; Sex factors; Social behavior	CLOSED-HEAD-INJURY; FACIAL EXPRESSION; EMOTION RECOGNITION; GENDER-DIFFERENCES; DISCOURSE; MIND; CONVERSATION; COMPETENCE; PERCEPTION; CHILDREN	Objective: To identify sex-based differences in self-reported and close other reported perceptions of communication behaviors in adults with traumatic brain injury (TBI). Design: Between-groups comparison of questionnaire data from men and women with TBI and their close others. Setting: University academic department. Participants: Adults with medically documented TBI (n=160) and adults without TBI (n=81; control group) (N=241). Interventions: Not applicable. Main Outcome Measure: La Trobe Communication Questionnaire, a standardized measure of communication problems in everyday life. Results: Participants with TBI endorsed more communication problems than controls (P<.001). There were no significant differences in self-ratings (P=.20) or in the ratings of close others (P=.09) in communication behaviors of men with TBI compared with women with TBI. There was no difference between the self-ratings of women with TBI and their close others (P=.59). However, men with TBI significantly underreported communication problems compared with reports of close others (P<.001). Conclusions: Women with TBI might be more accurate than men with TBI in recognizing their own pragmatic communication problems. (C) 2016 by the American Congress of Rehabilitation Medicine	[Despins, Emily H.; Turkstra, Lyn S.] Univ Wisconsin, Dept Commun Sci & Disorders, 1975 Willow Dr, Madison, WI 53706 USA; [Struchen, Margaret A.; Clark, Allison N.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Struchen, Margaret A.; Clark, Allison N.] Texas Inst Rehabil Res Mem Hermann, Brain Injury Res Ctr, Houston, TX USA		Turkstra, LS (corresponding author), Univ Wisconsin, Dept Commun Sci & Disorders, 1975 Willow Dr, Madison, WI 53706 USA.	lsturkstra@wisc.edu	Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921	National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [111330010152, H133B031117, H133A070043]; Walker Foundation	Supported in part by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant nos. 111330010152, Assessment of Pragmatic communication Abilities after Traumatic Brain Injury; H133B031117, Rehabilitation Research and Training Center on Community Integration of Persons with Traumatic Brain Injury; H133A070043, Texas Traumatic Brain Injury Model System at Texas Institute of Rehabilitation Research Memorial Hermann) and the Walker Foundation.	Auster CJ, 2000, SEX ROLES, V43, P499, DOI 10.1023/A:1007119516728; Bach LJ, 2006, BRAIN COGNITION, V60, P196; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; BEM SL, 1981, PSYCHOL REV, V88, P354, DOI 10.1037/0033-295X.88.4.354; BEM SL, 1985, NEBR SYM MOTIV, V32, P179; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bosacki S, 1999, SOC DEV, V8, P237, DOI 10.1111/1467-9507.00093; Bracy C., 2005, BRAIN IMPAIR, V6, P1, DOI DOI 10.1375/brim.6.1.1.65476; Centers for Disease Control and Prevention, 2014, TRAUM BRAIN INJ US F; CLARK MS, 1988, ANNU REV PSYCHOL, V39, P609, DOI 10.1146/annurev.psych.39.1.609; Coelho C., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Douglas J., 2011, BRAIN IMPAIR, V11, P171; Douglas JM, 2007, APHASIOLOGY, V21, P1181, DOI 10.1080/02687030600980950; Douglas JM, 2000, APHASIOLOGY, V14, P251, DOI 10.1080/026870300401469; Duffy, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Friedland D, 1998, BRAIN INJURY, V12, P1, DOI 10.1080/026990598122818; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; HALL JA, 1978, PSYCHOL BULL, V85, P845, DOI 10.1037/0033-2909.85.4.845; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; Jennett B., 1986, MED N AM, V36, P5210; Johnson JE, 2012, BRAIN INJURY, V26, P1118, DOI 10.3109/02699052.2012.666370; Jones CA, 2011, BRAIN INJURY, V25, P844, DOI 10.3109/02699052.2011.585507; Kessels RPC, 2014, J NEUROPSYCHOL, V8, P75, DOI 10.1111/jnp.12009; Krach S, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-9; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; McClure EB, 2000, PSYCHOL BULL, V126, P424, DOI 10.1037/0033-2909.126.3.424; McGann W, 1997, BRAIN INJURY, V11, P621, DOI 10.1080/026990597123179; MCNEILLBROWN D, 1997, INT PERSPECTIVES TRA, P247; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Muller F, 2010, CORTEX, V46, P1088, DOI 10.1016/j.cortex.2009.08.014; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Russell TA, 2012, COG EMOT, V21, P1554; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Schrijnemaekers AC, 2014, J HEAD TRAUMA REHAB, V29, pE9, DOI 10.1097/01.HTR.0000438117.63852.b4; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; SNOW P, 2000, BRAIN IMPAIR, V1, P57; Struchen MA, 2011, J HEAD TRAUMA REHAB, V26, P4, DOI 10.1097/HTR.0b013e3182048e98; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Tannen D., 1994, GENDER DISCOURSE; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Turkstra LS, 2000, APHASIOLOGY, V14, P349, DOI 10.1080/026870300401405; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Watts AJ, 2006, APHASIOLOGY, V20, P707, DOI 10.1080/02687030500489953; Willard VW, 2009, PSYCHO-ONCOLOGY, V18, P893, DOI 10.1002/pon.1502; Yamasue H, 2009, PSYCHIAT CLIN NEUROS, V63, P129, DOI 10.1111/j.1440-1819.2009.01944.x	55	25	26	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2016	97	2		1			S26	S32		10.1016/j.apmr.2014.06.023			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	DC4RI	WOS:000369207600004	25662398	Bronze			2022-02-06	
J	Misic, B; Dunkley, BT; Sedge, PA; Da Costa, L; Fatima, Z; Berman, MG; Doesburg, SM; McIntosh, AR; Grodecki, R; Jetly, R; Pang, EW; Taylor, MJ				Misic, Bratislav; Dunkley, Benjamin T.; Sedge, Paul A.; Da Costa, Leodante; Fatima, Zainab; Berman, Marc G.; Doesburg, Sam M.; McIntosh, Anthony R.; Grodecki, Richard; Jetly, Rakesh; Pang, Elizabeth W.; Taylor, Margot J.			Post-Traumatic Stress Constrains the Dynamic Repertoire of Neural Activity	JOURNAL OF NEUROSCIENCE			English	Article						connectivity; dynamics; MEG; network; PTSD; TBI	BRAIN SIGNAL VARIABILITY; MULTISCALE ENTROPY ANALYSIS; PSYCHOPHYSIOLOGICAL ASSESSMENT; FUNCTIONAL CONNECTIVITY; SPATIAL NAVIGATION; NEUROIMAGING DATA; HUMAN HIPPOCAMPAL; MASS MODEL; DISORDER; MEG	Post-traumatic stress disorder (PTSD) is an anxiety disorder arising from exposure to a traumatic event. Although primarily defined in terms of behavioral symptoms, the global neurophysiological effects of traumatic stress are increasingly recognized as a critical facet of the human PTSD phenotype. Here we use magnetoencephalographic recordings to investigate two aspects of information processing: inter-regional communication (measured by functional connectivity) and the dynamic range of neural activity (measured in terms of local signal variability). We find that both measures differentiate soldiers diagnosed with PTSD from soldiers without PTSD, from healthy civilians, and from civilians with mild traumatic brain injury, which is commonly comorbid with PTSD. Specifically, soldiers with PTSD display inter-regional hypersynchrony at high frequencies (80-150 Hz), as well as a concomitant decrease in signal variability. The two patterns are spatially correlated and most pronounced in a left temporal subnetwork, including the hippocampus and amygdala. We hypothesize that the observed hypersynchrony may effectively constrain the expression of local dynamics, resulting in less variable activity and a reduced dynamic repertoire. Thus, the re-experiencing phenomena and affective sequelae in combat-related PTSD may result from functional networks becoming "stuck" in configurations reflecting memories, emotions, and thoughts originating from the traumatizing experience.	[Misic, Bratislav; Taylor, Margot J.] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN 47405 USA; [Dunkley, Benjamin T.; Doesburg, Sam M.; Pang, Elizabeth W.] Hosp Sick Children, Dept Diagnost Imaging, Toronto, ON M5G 1X8, Canada; [Sedge, Paul A.] Canadian Forces Hlth Serv, Directorate Mental Hlth, Ottawa, ON K1K 0T2, Canada; [Da Costa, Leodante] Sunnybrook Med Ctr, Div Neurosurg, Toronto, ON M4N 3M5, Canada; [Fatima, Zainab; McIntosh, Anthony R.] Baycrest Ctr Geriatr Care, Res Inst, Toronto, ON M6A 2E1, Canada; [Berman, Marc G.] Univ Chicago, Dept Psychol, Chicago, IL 60637 USA; [Grodecki, Richard] Canadian Forces Environm Med Estab, Toronto, ON M3K 2C9, Canada; [Jetly, Rakesh] Def Res & Dev Canada, Toronto, ON N3K 2C9, Canada		Misic, B (corresponding author), Indiana Univ, Dept Psychol & Brain Sci, 1101 E 10th St, Bloomington, IN 47405 USA.	bmisic@indiana.edu		Dunkley, Ben/0000-0001-6173-1171; McIntosh, Anthony/0000-0002-1784-5662	Defense Research and Development Canada [SW7719-135182/001/TOR]; Canadian Forces Health Services; James S. McDonnell Foundation grant; Natural Sciences and Engineering Research Council of Canada postdoctoral fellowshipNatural Sciences and Engineering Research Council of Canada (NSERC)	This work was supported by Defense Research and Development Canada (contract SW7719-135182/001/TOR) and the Canadian Forces Health Services to M.J.T. and E.W.P. and a James S. McDonnell Foundation grant to A.R.M., B.M. was supported by an Natural Sciences and Engineering Research Council of Canada postdoctoral fellowship.	American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Attal Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059856; Balderston NL, 2013, JOVE-J VIS EXP, DOI 10.3791/50212; Bardouille T, 2008, NEUROIMAGE, V42, P323, DOI 10.1016/j.neuroimage.2008.04.176; Berman MG, 2014, NEUROIMAGE, V103, P267, DOI 10.1016/j.neuroimage.2014.09.027; Bish JP, 2004, NEUROSCI LETT, V362, P48, DOI 10.1016/j.neulet.2004.02.032; Boersma M, 2013, BRAIN CONNECT, V3, P41, DOI 10.1089/brain.2012.0127; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Brookes MJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120991; Brown VM, 2014, NEUROPSYCHOPHARMACOL, V39, P351, DOI 10.1038/npp.2013.197; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Catarino A, 2011, CLIN NEUROPHYSIOL, V122, P2375, DOI 10.1016/j.clinph.2011.05.004; Cornwell BR, 2008, J NEUROSCI, V28, P5983, DOI 10.1523/JNEUROSCI.5001-07.2008; Cornwell BR, 2007, NEUROIMAGE, V37, P282, DOI 10.1016/j.neuroimage.2007.04.055; Cornwell BR, 2010, AM J PSYCHIAT, V167, P836, DOI 10.1176/appi.ajp.2009.09050614; Cornwell BR, 2008, BRAIN RES, V1244, P103, DOI 10.1016/j.brainres.2008.09.068; Costa M, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.021906; Costa M, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.068102; David O, 2003, NEUROIMAGE, V20, P1743, DOI 10.1016/j.neuroimage.2003.07.015; Deco G, 2013, TRENDS NEUROSCI, V36, P268, DOI 10.1016/j.tins.2013.03.001; Deco G, 2009, P NATL ACAD SCI USA, V106, P10302, DOI 10.1073/pnas.0901831106; Dimitriadis SI, 2013, NEUROIMAGE, V83, P307, DOI 10.1016/j.neuroimage.2013.06.036; Dunkley BT, 2014, NEUROIMAGE-CLIN, V5, P377, DOI 10.1016/j.nicl.2014.07.017; Efron B., 1986, STAT SCI, V1, P54, DOI 10.1214/ss/1177013815; Engdahl B, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/6/066005; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Felmingham K, 2010, J ABNORM PSYCHOL, V119, P241, DOI 10.1037/a0017551; Friston KJ, 1995, HUM BRAIN MAPP, V3, P56, DOI 10.1002/hbm.460030106; Garber BG, 2012, CAN J PSYCHIAT, V57, P736, DOI 10.1177/070674371205701205; Garrett DD, 2015, P NATL ACAD SCI USA, V112, P7593, DOI 10.1073/pnas.1504090112; Garrett DD, 2014, CEREB CORTEX, V24, P2931, DOI 10.1093/cercor/bht150; Garrett DD, 2013, NEUROSCI BIOBEHAV R, V37, P610, DOI 10.1016/j.neubiorev.2013.02.015; Garrett DD, 2011, J NEUROSCI, V31, P4496, DOI 10.1523/JNEUROSCI.5641-10.2011; Garrett DD, 2010, J NEUROSCI, V30, P4914, DOI 10.1523/JNEUROSCI.5166-09.2010; Georgopoulos AP, 2010, J NEURAL ENG, V7, DOI 10.1088/1741-2560/7/1/016011; Hamada Y, 2004, HIPPOCAMPUS, V14, P426, DOI 10.1002/hipo.10196; Heisz JJ, 2012, NEUROIMAGE, V63, P1384, DOI 10.1016/j.neuroimage.2012.08.018; Hung YW, 2012, NEUROIMAGE, V60, P545, DOI 10.1016/j.neuroimage.2011.12.003; Ibrahim GM, 2014, BRAIN, V137, P2690, DOI 10.1093/brain/awu214; James LM, 2013, JAMA PSYCHIAT, V70, P410, DOI 10.1001/jamapsychiatry.2013.878; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Keane TM, 1998, J CONSULT CLIN PSYCH, V66, P914, DOI 10.1037/0022-006X.66.6.914; Kirsch Peter, 2003, Neural Plasticity, V10, P291, DOI 10.1155/NP.2003.291; Kitayama N, 2006, J AFFECT DISORDERS, V90, P171, DOI 10.1016/j.jad.2005.11.006; Kitayama N, 2005, J AFFECT DISORDERS, V88, P79, DOI 10.1016/j.jad.2005.05.014; Kolassa IT, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-56; Lau TM, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-47; Luo Q, 2007, NEUROIMAGE, V34, P839, DOI 10.1016/j.neuroimage.2006.09.023; McCabe C, 2011, NEUROIMAGE, V57, P1317, DOI 10.1016/j.neuroimage.2011.05.051; McIntosh AR, 2014, CEREB CORTEX, V24, P1806, DOI 10.1093/cercor/bht030; McIntosh AR, 2013, ANNU REV PSYCHOL, V64, P499, DOI 10.1146/annurev-psych-113011-143804; McIntosh AR, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000106; McIntosh AR, 2004, NEUROIMAGE, V23, pS250, DOI 10.1016/j.neuroimage.2004.07.020; Mills T, 2012, BRAIN TOPOGR, V25, P248, DOI 10.1007/s10548-012-0217-2; Misic B, 2015, CEREB CORTEX, V25, P2815, DOI 10.1093/cercor/bhu082; Misic B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111007; Misic B, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00090; Misic B, 2010, J NEUROPHYSIOL, V104, P2667, DOI 10.1152/jn.00648.2010; Mizuno T, 2010, CLIN NEUROPHYSIOL, V121, P1438, DOI 10.1016/j.clinph.2010.03.025; Muthukumaraswamy SD, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00138; Oizumi M, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003588; Orr SP, 2000, J AFFECT DISORDERS, V61, P225, DOI 10.1016/S0165-0327(00)00340-2; PITMAN RK, 1987, ARCH GEN PSYCHIAT, V44, P970; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Pole N, 2007, PSYCHOL BULL, V133, P725, DOI 10.1037/0033-2909.133.5.725; Quraan MA, 2011, HUM BRAIN MAPP, V32, P812, DOI 10.1002/hbm.21068; Quraan MA, 2010, NEUROIMAGE, V49, P2387, DOI 10.1016/j.neuroimage.2009.10.012; Rabinak Christine A, 2011, Front Psychiatry, V2, P62, DOI 10.3389/fpsyt.2011.00062; Raja Beharelle A, 2012, NEUROIMAGE, V60, P1528, DOI 10.1016/j.neuroimage.2012.01.037; Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039; Schaefer A, 2014, CURR BIOL, V24, P2314, DOI 10.1016/j.cub.2014.08.024; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; Small M, 2004, PHYSICA D, V194, P283, DOI 10.1016/j.physd.2004.03.006; Tagliazucchi E, 2014, HUM BRAIN MAPP, V35, P5442, DOI 10.1002/hbm.22562; Takahashi T, 2010, NEUROIMAGE, V51, P173, DOI 10.1016/j.neuroimage.2010.02.009; Tononi G, 2012, ARCH ITAL BIOL, V150, P56, DOI 10.4449/aib.v149i5.1388; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Vakorin VA, 2011, J NEUROSCI, V31, P6405, DOI 10.1523/JNEUROSCI.3153-10.2011; Vinck M, 2011, NEUROIMAGE, V55, P1548, DOI 10.1016/j.neuroimage.2011.01.055; Yang AC, 2013, NEUROBIOL AGING, V34, P428, DOI 10.1016/j.neurobiolaging.2012.05.004; Ye AX, 2014, HUM BRAIN MAPP, V35, P6049, DOI 10.1002/hbm.22604; Zavaglia M, 2008, IEEE T BIO-MED ENG, V55, P69, DOI 10.1109/TBME.2007.897814; Zhou Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046833	85	25	25	1	17	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 13	2016	36	2					419	431		10.1523/JNEUROSCI.1506-15.2016			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DB2PX	WOS:000368352600016	26758834	Green Published, Bronze			2022-02-06	
J	Yu, M; Zhang, Y; Chen, XY; Zhang, T				Yu, Mei; Zhang, Yuan; Chen, Xiaoyu; Zhang, Tao			Antidepressant-like effects and possible mechanisms of amantadine on cognitive and synaptic deficits in a rat model of chronic stress	STRESS-THE INTERNATIONAL JOURNAL ON THE BIOLOGY OF STRESS			English	Article						Amantadine; chronic stress; cognition; synaptic plasticity; NR2B; PSD-95	CHRONIC MILD STRESS; LONG-TERM POTENTIATION; TRAUMATIC BRAIN-INJURY; NMDA RECEPTOR; GLUTAMATE RELEASE; DENTATE GYRUS; WATER MAZE; DEPRESSION; PLASTICITY; HIPPOCAMPUS	The aim of this study was to examine whether amantadine (AMA), as a low-affinity noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, is able to improve cognitive deficits caused by chronic stress in rats. Male Wistar rats were divided into four groups: control, control + AMA, stress and stress + AMA groups. The chronic stress model combined chronic unpredictable stress (CUS) with isolated feeding. Animals were exposed to CUS continued for 21 days. AMA (25 mg/kg) was administrated p.o. for 20 days from the 4th day of CUS to the 23rd. Weight and sucrose consumption were measured during model establishing period. Spatial memory was evaluated using the Morris water maze (MWM) test. Following MWM testing, both long-term potentiation (LTP) and depotentiation were recorded in the hippocampal CA1 region. NR2B and postsynaptic density protein 95 (PSD-95) proteins were measured by Western-blot analysis. AMA increased weight and sucrose consumption of stressed rats. Spatial memory and reversal learning in stressed rats were impaired relative to controls, whereas AMA significantly attenuated cognitive impairment. AMA also mitigated the chronic stress-induced impairment of hippocampal synaptic plasticity, in which both the LTP and depotentiation were significantly inhibited in stressed rats. Moreover, AMA enhanced the expression of hippocampal NR2B and PSD-95 in stressed rats. The data suggest that AMA may be an effective therapeutic agent for depression-like symptoms and associated cognitive disturbances.	[Zhang, Tao] Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China; [Zhang, Tao] Nankai Univ, Minist Educ, Key Lab Bioact Mat, Tianjin 300071, Peoples R China		Zhang, T (corresponding author), Nankai Univ, Coll Life Sci, Tianjin 300071, Peoples R China.; Zhang, T (corresponding author), Nankai Univ, Minist Educ, Key Lab Bioact Mat, Tianjin 300071, Peoples R China.	zhangtao@nankai.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [31171053, 11232005]; Funds for National Basic Science Personnel Training [J1103503]; 111 ProjectMinistry of Education, China - 111 Project [B08011]	This work was supported by grants from the National Natural Science Foundation of China (31171053, 11232005), Funds for National Basic Science Personnel Training (J1103503) and 111 Project (B08011). The authors have no conflict of interest to declare.	Airaksinen E, 2004, PSYCHOL MED, V34, P83, DOI 10.1017/S0033291703008559; Alfarez DN, 2003, EUR J NEUROSCI, V17, P1928, DOI 10.1046/j.1460-9568.2003.02622.x; An L, 2013, ALCOHOL CLIN EXP RES, V37, P763, DOI 10.1111/acer.12040; An L, 2013, NEUROBIOL LEARN MEM, V100, P18, DOI 10.1016/j.nlm.2012.12.003; BALDESSARINI RJ, 1972, BIOCHEM PHARMACOL, V21, P77, DOI 10.1016/0006-2952(72)90252-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Casarotto PC, 2007, EUR NEUROPSYCHOPHARM, V17, P735, DOI 10.1016/j.euroneuro.2007.03.001; Cera N, 2014, NEUROPSYCH DIS TREAT, V10, P1093, DOI 10.2147/NDT.S54423; Collingridge GL, 2013, NEUROPHARMACOLOGY, V64, P13, DOI 10.1016/j.neuropharm.2012.06.051; Conrad CD, 2010, PROG NEURO-PSYCHOPH, V34, P742, DOI 10.1016/j.pnpbp.2009.11.003; Cousins SL, 2012, J BIOL CHEM, V287, P13465, DOI 10.1074/jbc.M111.292862; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Ehrlich I, 2007, P NATL ACAD SCI USA, V104, P4176, DOI 10.1073/pnas.0609307104; Fox CJ, 2006, HIPPOCAMPUS, V16, P907, DOI 10.1002/hipo.20230; Henningsen K, 2009, BEHAV BRAIN RES, V198, P136, DOI 10.1016/j.bbr.2008.10.039; Hosenbocus S, 2013, J CAN ACAD CHILD ADO, V22, P55; Huber TJ, 1999, PHARMACOPSYCHIATRY, V32, P47, DOI 10.1055/s-2007-979191; Jun D, 2010, J ECT, V26, P126, DOI 10.1097/YCT.0b013e3181a9947a; Kaefer V, 2010, J APPL TOXICOL, V30, P745, DOI 10.1002/jat.1550; Kim JJ, 2002, NAT REV NEUROSCI, V3, P453, DOI 10.1038/nrn849; Li B, 2003, J NEUROSCI, V23, P11244; Lou JS, 2010, PHARM BIOL, V48, P1328, DOI 10.3109/13880201003789440; Marsden WN, 2013, PROG NEURO-PSYCHOPH, V43, P168, DOI 10.1016/j.pnpbp.2012.12.012; McEwen BS, 2001, HUM PSYCHOPHARM CLIN, V16, pS7, DOI 10.1002/hup.266; Mizoguchi K, 2000, J NEUROSCI, V20, P1568; MORYL E, 1993, PHARMACOL TOXICOL, V72, P394, DOI 10.1111/j.1600-0773.1993.tb01351.x; Neves G, 2008, NAT REV NEUROSCI, V9, P65, DOI 10.1038/nrn2303; Nishikawa N, 2009, PARKINSONISM RELAT D, V15, P351, DOI 10.1016/j.parkreldis.2008.08.005; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Qi YJ, 2013, CEREB CORTEX, V23, P932, DOI 10.1093/cercor/bhs086; Quan MN, 2011, NEUROSCIENCE, V182, P88, DOI 10.1016/j.neuroscience.2011.03.026; Quan MN, 2011, BRAIN RES BULL, V85, P109, DOI 10.1016/j.brainresbull.2011.03.002; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Richter-Levin G, 1998, LEARN MEMORY, V4, P445, DOI 10.1101/lm.4.6.445; RICHTER-LEVIN G, 1995, BEHAV BRAIN RES, V66, P37, DOI 10.1016/0166-4328(94)00121-U; Rogoz Z, 2007, PHARMACOL REP, V59, P778; Rogoz Z, 2008, PHARMACOL REP, V60, P817; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Stryjer R, 2003, INT CLIN PSYCHOPHARM, V18, P93, DOI 10.1097/00004850-200303000-00005; Szakacs Reka, 2012, Neuropsychopharmacol Hung, V14, P29; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Willner P, 2005, NEUROPSYCHOBIOLOGY, V52, P90, DOI 10.1159/000087097; Willner P, 1997, PSYCHOPHARMACOLOGY, V134, P319, DOI 10.1007/s002130050456; Xu P, 2012, PLOS ONE, V7; Zarate Carlos A, 2002, Psychopharmacol Bull, V36, P35	46	25	26	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1025-3890	1607-8888		STRESS	Stress	JAN 2	2016	19	1					104	113		10.3109/10253890.2015.1108302			10	Behavioral Sciences; Endocrinology & Metabolism; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Endocrinology & Metabolism; Neurosciences & Neurology	DB7JS	WOS:000368691800013	26466744				2022-02-06	
J	Ahdidan, J; Raji, CA; Deyoe, EA; Mathis, J; Noe, KO; Rimestad, J; Kjeldsen, TK; Mosegaard, J; Becker, JT; Lopez, O				Ahdidan, Jamila; Raji, Cyrus A.; DeYoe, Edgar A.; Mathis, Jedidiah; Noe, Karsten O.; Rimestad, Jens; Kjeldsen, Thomas K.; Mosegaard, Jesper; Becker, James T.; Lopez, Oscar			Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Hippocampus; magnetic resonance imaging; quantification	TEMPORAL-LOBE EPILEPSY; ADNI HARMONIZED PROTOCOL; VOXEL-BASED MORPHOMETRY; ALZHEIMERS-DISEASE; MAGNETIC-RESONANCE; ENTORHINAL CORTEX; BRAIN ATROPHY; MANUAL SEGMENTATION; PHYSICAL-ACTIVITY; SUBFIELD VOLUMES	Background: Multiple neurological disorders including Alzheimer's disease (AD), mesial temporal sclerosis, and mild traumatic brain injury manifest with volume loss on brain MRI. Subtle volume loss is particularly seen early in AD. While prior research has demonstrated the value of this additional information from quantitative neuroimaging, very few applications have been approved for clinical use. Here we describe a US FDA cleared software program, Neuroreader (TM), for assessment of clinical hippocampal volume on brain MRI. Objective: To present the validation of hippocampal volumetrics on a clinical software program. Method: Subjects were drawn (n = 99) from the Alzheimer Disease Neuroimaging Initiative study. Volumetric brain MR imaging was acquired in both 1.5 T (n = 59) and 3.0 T (n = 40) scanners in participants with manual hippocampal segmentation. Fully automated hippocampal segmentation and measurement was done using a multiple atlas approach. The Dice Similarity Coefficient (DSC) measured the level of spatial overlap between Neuroreader (TM) and gold standard manual segmentation from 0 to 1 with 0 denoting no overlap and 1 representing complete agreement. DSC comparisons between 1.5 T and 3.0 T scanners were done using standard independent samples T-tests. Results: In the bilateral hippocampus, mean DSC was 0.87 with a range of 0.78-0.91 (right hippocampus) and 0.76-0.91 (left hippocampus). Automated segmentation agreement with manual segmentation was essentially equivalent at 1.5 T (DSC = 0.879) versus 3.0 T (DSC = 0.872). Conclusion: This work provides a description and validation of a software program that can be applied in measuring hippocampal volume, a biomarker that is frequently abnormal in AD and other neurological disorders.	[Ahdidan, Jamila] Brainreader, Horsens, Denmark; [Raji, Cyrus A.] UCLA Med Ctr, Los Angeles, CA USA; [DeYoe, Edgar A.; Mathis, Jedidiah] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA; [Noe, Karsten O.; Rimestad, Jens; Kjeldsen, Thomas K.; Mosegaard, Jesper] Alexandra Inst, Aarhus, Denmark; [Becker, James T.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA; [Becker, James T.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [Becker, James T.; Lopez, Oscar] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA		Raji, CA (corresponding author), UCLA Med Ctr, Dept Radiol, Los Angeles, CA 90095 USA.	cyrusraji@gmail.com			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG005133] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER		Abdallah CG, 2015, J PSYCHOPHARMACOL, V29, P591, DOI 10.1177/0269881114544776; Ahdidan J, 2011, ACTA PSYCHIAT SCAND, V123, P211, DOI 10.1111/j.1600-0447.2010.01644.x; Alzheimer's Association, HEALTHC PROF FREQ AS; Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003; Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Barnes J, 2009, NEUROBIOL AGING, V30, P1711, DOI 10.1016/j.neurobiolaging.2008.01.010; Benedict RHB, 2009, J NEUROL NEUROSUR PS, V80, P201, DOI 10.1136/jnnp.2008.148403; Boccardi M, 2015, ALZHEIMERS DEMENT, V11, P175, DOI 10.1016/j.jalz.2014.12.002; Boccardi M, 2015, ALZHEIMERS DEMENT, V11, P184, DOI 10.1016/j.jalz.2013.03.001; Boccardi M, 2014, J NEUROIMAGING, V24, P509, DOI 10.1111/jon.12065; Boccardi M, 2011, J ALZHEIMERS DIS, V26, P61, DOI 10.3233/JAD-2011-0004; Bocchetta M, 2015, ALZHEIMERS DEMENT, V11, P151, DOI 10.1016/j.jalz.2013.12.019; Boyle CP, 2015, NEUROBIOL AGING, V36, pS194, DOI 10.1016/j.neurobiolaging.2014.05.036; Brewer JB, 2009, BEHAV NEUROL, V21, P21, DOI [10.1155/2009/616581, 10.3233/BEN-2009-0226]; Carmichael OT, 2005, NEUROIMAGE, V27, P979, DOI 10.1016/j.neuroimage.2005.05.005; Cherbuin N, 2009, DEMENT GERIATR COGN, V28, P47, DOI 10.1159/000229025; Cohen J., 2013, STAT POWER ANAL BEHA; de Lanerolle NC, 2005, EPILEPSY BEHAV, V7, P190, DOI 10.1016/j.yebeh.2005.06.003; Desikan RS, 2013, AM J NEURORADIOL, V34, P2075, DOI 10.3174/ajnr.A3644; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; Duchesne S, 2015, ALZHEIMERS DEMENT, V11, P161, DOI 10.1016/j.jalz.2015.01.002; Erickson KI, 2010, NEUROLOGY, V75, P1415, DOI 10.1212/WNL.0b013e3181f88359; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Ezekiel F, 2004, ALZ DIS ASSOC DIS, V18, P196; Farid N, 2012, RADIOLOGY, V264, P542, DOI 10.1148/radiol.12112638; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fotuhi M, 2012, NAT REV NEUROL, V8, P189, DOI 10.1038/nrneurol.2012.27; Frisoni GB, 2015, ALZHEIMERS DEMENT, V11, P111, DOI 10.1016/j.jalz.2014.05.1756; Goodkind M, 2015, JAMA PSYCHIAT, V72, P305, DOI 10.1001/jamapsychiatry.2014.2206; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Haukvik UK, 2015, BIOL PSYCHIAT, V77, P581, DOI 10.1016/j.biopsych.2014.06.020; Hirata Y, 2005, NEUROSCI LETT, V382, P269, DOI 10.1016/j.neulet.2005.03.038; Hoef LWV, 2013, EPILEPSY RES, V106, P155, DOI 10.1016/j.eplepsyres.2013.05.008; Hughes S, 2013, MEDSCAPE; Ishiwata A, 2014, DEMENT GERIATR COGN, V38, P170, DOI 10.1159/000358510; Jack CR, 2008, J MAGN RESON IMAGING, V27, P685, DOI 10.1002/jmri.21049; Jack CR, 2010, ALZHEIMERS DEMENT, V6, P212, DOI 10.1016/j.jalz.2010.03.004; Jack CR, 2011, ALZHEIMERS DEMENT, V7; KESSLAK JP, 1991, NEUROLOGY, V41, P51, DOI 10.1212/WNL.41.1.51; Killiany RJ, 2002, NEUROLOGY, V58, P1188, DOI 10.1212/WNL.58.8.1188; Kirson N, 2013, ALZHEIMERS DEMENT, V9, pP845; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; Lehmann M, 2010, NEUROIMAGE, V49, P2264, DOI 10.1016/j.neuroimage.2009.10.056; Modat M, 2010, COMPUT METH PROG BIO, V98, P278, DOI 10.1016/j.cmpb.2009.09.002; Moran NF, 2001, BRAIN, V124, P167, DOI 10.1093/brain/124.1.167; Mueller SG, 2009, EPILEPSIA, V50, P1474, DOI 10.1111/j.1528-1167.2009.02010.x; Mulder ER, 2014, NEUROIMAGE, V92, P169, DOI 10.1016/j.neuroimage.2014.01.058; Nenadic I, 2015, SCHIZOPHR RES, V161, P169, DOI 10.1016/j.schres.2014.10.041; Ochs AL, 2015, J NEUROIMAGING, V25, P721, DOI 10.1111/jon.12229; OLTON DS, 1979, BEHAV BRAIN SCI, V2, P313, DOI 10.1017/S0140525X00062713; Ourselin S, 2001, IMAGE VISION COMPUT, V19, P25, DOI 10.1016/S0262-8856(00)00052-4; Pennanen C, 2004, NEUROBIOL AGING, V25, P303, DOI 10.1016/S0197-4580(03)00084-8; Perez-Miralles FC, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000132; Raji CA, 2015, AM J NEURORADIOL, V36, P1803, DOI 10.3174/ajnr.A4409; Raji CA, 2014, AM J PREV MED, V47, P444, DOI 10.1016/j.amepre.2014.05.037; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; Ramani A, 2006, RADIOLOGY, V241, P26, DOI 10.1148/radiol.2411050628; Redlich R, 2014, JAMA PSYCHIAT, V71, P1222, DOI 10.1001/jamapsychiatry.2014.1100; Ringman JM, 2010, J NEUROL, V257, P839, DOI 10.1007/s00415-009-5436-4; Rodrigue KM, 2004, J NEUROSCI, V24, P956, DOI 10.1523/JNEUROSCI.4166-03.2004; Sanchez-Benavides G, 2010, PSYCHIAT RES-NEUROIM, V181, P219, DOI 10.1016/j.pscychresns.2009.10.011; Shen Q, 2011, THESIS; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Tellez-Zenteno Jose F, 2012, Epilepsy Res Treat, V2012, P630853, DOI 10.1155/2012/630853; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; Varma VR, 2015, HIPPOCAMPUS, V25, P605, DOI 10.1002/hipo.22397; Varon D, 2015, INT J GERIATR PSYCH, V30, P192, DOI 10.1002/gps.4126; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; Wignall EL, 2004, BIOL PSYCHIAT, V56, P832, DOI 10.1016/j.biopsych.2004.09.015; Winston GP, 2013, EPILEPSIA, V54, P2166, DOI 10.1111/epi.12408; Wisse LEM, 2015, J AFFECT DISORDERS, V175, P1, DOI 10.1016/j.jad.2014.12.052; Xu Y, 2000, NEUROLOGY, V54, P1760, DOI 10.1212/WNL.54.9.1760; Zou KH, 2004, ACAD RADIOL, V11, P178, DOI 10.1016/S1076-6332(03)00671-8	76	25	26	0	9	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	49	3					723	732		10.3233/JAD-150559			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CZ4WS	WOS:000367104100012	26484924	Green Accepted, Green Submitted, Bronze, Green Published			2022-02-06	
J	Cacabelos, R; Torrellas, C; Fernandez-Novoa, L; Aliev, G				Cacabelos, Ramon; Torrellas, Clara; Fernandez-Novoa, Lucia; Aliev, Gjumrakch			Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection	CURRENT PHARMACEUTICAL DESIGN			English	Article						Neuroimmune system; CNS disorders; Alzheimer's disease; genomics; histamine; immune markers	CENTRAL-NERVOUS-SYSTEM; INTERLEUKIN-10 GENE PROMOTER; TNF-ALPHA GENE; ALZHEIMERS-DISEASE; MICROGLIAL ACTIVATION; IMMUNE-SYSTEM; T-CELLS; THERAPEUTIC STRATEGIES; INFLAMMATORY RESPONSES; INCREASED EXPRESSION	The neuroimmune system represents a dense network of biochemical signals associated with neurotransmitters, neuropeptides, neurohormones, cytokines, chemokines, and growth factors synthesized in neurons, glial cells and immune cells, to maintain systemic homeostasis. Endogenous and/or exogenous, noxious stimuli in any tissue are captured by sensor cells to inform the brain; likewise, signals originating at the central nervous system (CNS) level are transmitted to peripheral immune effectors which react to central stimuli. This multidirectional information system makes it possible for the CNS to respond to peripheral damage and for alterations in brain function to be reflected in peripheral immune changes. Different CNS disorders, such as anxiety, depression, psychosis, stroke, Alzheimer's disease, Parkinson's disease, attention-deficit hyperactivity disorder, migraine, epilepsy, vascular dementia, mental retardation, cerebrovascular encephalopathy, multiple sclerosis, brain tumors, cranial nerve neuropathies, mental retardation and post-traumatic brain injury exhibit changes in CD3, CD4, CD7, HLA-DR, CD25, CD28, and CD56 immune markers. Histamine is an important pleiotropic factor in neuroimmune regulation. This biogenic amine shows age-and sex-dependent changes in the CNS, and is significantly altered, together with interleukin-1 beta and TNF-alpha, in Alzheimer's disease and other neurodegenerative disorders in which neuroinflammation appears to be an aggravating phenotype. Therapeutic intervention to halt progression of deleterious neuroinflammatory reactions in CNS disorders is a major challenge for molecular pharmacology in the future.	[Cacabelos, Ramon; Torrellas, Clara] Camilo Jose Cela Univ, Madrid, Spain; [Cacabelos, Ramon; Torrellas, Clara] Inst Med Sci & Genom Med, EuroEspes Biomed Res Ctr, Bergondo 15165, Coruna, Spain; [Cacabelos, Ramon; Fernandez-Novoa, Lucia] EuroEspes Biotechnol, Corunna, Spain; [Aliev, Gjumrakch] Univ Atlanta, Sch Hlth Sci & Healthcare Adm, Atlanta, GA USA; [Aliev, Gjumrakch] Russian Acad Sci, Inst Physiol Act Cpds, Chernogolovka 142432, Russia; [Aliev, Gjumrakch] GALLY Int Biomed Res Consulting LLC, San Antonio, TX 78229 USA		Cacabelos, R (corresponding author), Inst Med Sci & Genom Med, EuroEspes Biomed Res Ctr, Bergondo 15165, Coruna, Spain.	rcacabelos@euroespes.com	Aliev, Gjumrakch/K-7302-2017; Aliev, Gjumrakch/AAE-7734-2020	Aliev, Gjumrakch/0000-0001-7373-3182			Achour SB, 2010, NEUROCHEM INT, V57, P440, DOI 10.1016/j.neuint.2010.02.013; Ager RR, 2010, J NEUROCHEM, V113, P389, DOI 10.1111/j.1471-4159.2010.06595.x; Alvarez XA, 1996, MOL CHEM NEUROPATHOL, V29, P237, DOI 10.1007/BF02815005; Alvarez XA, 1997, CNS DRUG REV, V3, P181; Alvarez XA, 1992, ANN PSYCHIAT, V3, P329; Anders S, 2015, BRAIN RES, V1617, P93, DOI 10.1016/j.brainres.2015.02.043; Anderson CNG, 2006, J PHYSIOL-LONDON, V575, P367, DOI 10.1113/jphysiol.2006.113795; Arion D, 2007, BIOL PSYCHIAT, V62, P711, DOI 10.1016/j.biopsych.2006.12.021; Bajetto A, 2001, FRONT NEUROENDOCRIN, V22, P147, DOI 10.1006/frne.2001.0214; Banks WA, 2010, NEUROBIOL DIS, V37, P26, DOI 10.1016/j.nbd.2009.07.031; Banks WA, 2009, IMMUNOL ALLERGY CLIN, V29, P223, DOI 10.1016/j.iac.2009.02.001; Baronio D, 2014, ANN GEN PSYCHIATR, V13, DOI 10.1186/s12991-014-0034-y; Bechmann I, 2005, NEUROMOL MED, V7, P217, DOI 10.1385/NMM:7:3:217; Behrens MM, 2008, J NEUROSCI, V28, P13957, DOI 10.1523/JNEUROSCI.4457-08.2008; Bennett M, 2009, AUST NZ J PSYCHIAT, V43, P711, DOI 10.1080/00048670903001943; Bernstein HG, 2009, EXPERT REV NEUROTHER, V9, P1059, DOI 10.1586/ERN.09.59; Bilbo SD, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.014.2009; Bitanihirwe BKY, 2010, INT J NEUROPSYCHOPH, V13, P981, DOI 10.1017/S1461145710000192; Boksa P, 2010, BRAIN BEHAV IMMUN, V24, P881, DOI 10.1016/j.bbi.2010.03.005; Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007; Bradshaw NJ, 2008, BIOCHEM BIOPH RES CO, V377, P1091, DOI 10.1016/j.bbrc.2008.10.120; Bresee C, 2009, INT J NEUROPSYCHOPH, V12, P861, DOI 10.1017/S1461145709000315; Brietzke E, 2009, J AFFECT DISORDERS, V116, P214, DOI 10.1016/j.jad.2008.12.001; Brown AS, 2010, AM J PSYCHIAT, V167, P261, DOI 10.1176/appi.ajp.2009.09030361; Brynskikh A, 2008, BRAIN BEHAV IMMUN, V22, P861, DOI 10.1016/j.bbi.2007.12.008; CACABELOS R, 1989, METHOD FIND EXP CLIN, V11, P353; CACABELOS R, 1987, TOHOKU J EXP MED, V151, P429, DOI 10.1620/tjem.151.429; CACABELOS R, 1987, NEUROENDOCRINOLOGY, V45, P368, DOI 10.1159/000124761; CACABELOS R, 1985, BIOGENIC AMINES, V3, P9; Cacabelos R, 2005, EXPERT OPIN PHARMACO, V6, P1967, DOI 10.1517/14656566.6.12.1967; Cacabelos R, 2003, NEUROL RES, V25, P567, DOI 10.1179/016164103101202002; Cacabelos R, 2003, PHARMACOGENOMICS, V4, P597, DOI 10.1517/phgs.4.5.597.23795; CACABELOS R, 1993, AGENTS ACTIONS, V38, pC260, DOI 10.1007/BF01996479; CACABELOS R, 1993, ANN NY ACAD SCI, V695, P321, DOI 10.1111/j.1749-6632.1993.tb23076.x; CACABELOS R, 1994, METHOD FIND EXP CLIN, V16, P141; CACABELOS R, 1991, METHOD FIND EXP CLIN, V13, P703; CACABELOS R, 1990, METHOD FIND EXP CLIN, V12, P341; Cacabelos R, 1986, B JPN NEUROCHEM SOC, V25, P271; Cacabelos R, 2013, DRUG DES, V2, P2; Cacabelos R, 2011, GEN T EUROESPES J IN, V3, P6; Cacabelos R, 1992, ANN PSYCHIAT, V3, P147; Cacabelos R, 2006, DRUGS FUTURE SB, V31, P5, DOI DOI 10.2217/1745509X.1.2.303; CACABELOS R, 1992, ANN PSYCHIAT, V3, P233; Cacabelos R, 2013, OPEN J PSYCHIAT, V3, P46, DOI DOI 10.4236/0JPSYCH.2013.31008; Cacabelos R., 1990, HISTAMINERGIC NEURON, P241; Cacabelos R, 2005, AGING HLTH, V1, P303; Cacabelos R, 2014, J EXPT CLIN MED, V6, P75, DOI [10.1016/j.jecm.2014.03.010, DOI 10.1016/J.JECM.2014.03.010]; Cacabelos R, 2009, HDB NEUROPSYCHIATRIC, V4, P3; Cacabelos Ramon, 2005, Methods Find Exp Clin Pharmacol, V27 Suppl A, P1; Cacabelos R, 2014, METHODS MOL BIOL, V1175, P323, DOI 10.1007/978-1-4939-0956-8_13; Cacabelos R, 2014, EXPERT OPIN DRUG DIS, V9, P1059, DOI 10.1517/17460441.2014.930124; Cacabelos R, 2011, CNS NEUROSCI THER, V17, P541, DOI 10.1111/j.1755-5949.2010.00187.x; Cacabelos R, 2009, EXPERT REV MOL DIAGN, V9, P567, DOI [10.1586/erm.09.42, 10.1586/ERM.09.42]; Calingasan NY, 2002, NEUROBIOL AGING, V23, P31, DOI 10.1016/S0197-4580(01)00246-9; Carrera I, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/709145; Carter CJ, 2009, SCHIZOPHRENIA BULL, V35, P1163, DOI 10.1093/schbul/sbn054; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; Cerri AP, 2009, ARCH GERONTOL GERIAT, V49, P29, DOI 10.1016/j.archger.2009.09.009; Chakrabarty P, 2010, FASEB J, V24, P548, DOI 10.1096/fj.09-141754; Chakraborty S, 2010, J NEUROSCI RES, V88, P1615, DOI 10.1002/jnr.22343; Chandley MJ, 2009, SCHIZOPHR RES, V109, P98, DOI 10.1016/j.schres.2009.01.023; Chang RCC, 2009, CELL MOL IMMUNOL, V6, P317, DOI 10.1038/cmi.2009.42; Chen YX, 2016, CURR TOP MED CHEM, V16, P485, DOI 10.2174/1568026615666150813142423; Chittiprol S, 2009, INT IMMUNOPHARMACOL, V9, P1215, DOI 10.1016/j.intimp.2009.07.002; Christian LM, 2009, BRAIN BEHAV IMMUN, V23, P750, DOI 10.1016/j.bbi.2009.02.012; Chrousos GP, 2009, ANN NY ACAD SCI, V1179, P153, DOI 10.1111/j.1749-6632.2009.04988.x; Chu TT, 2009, J HUM GENET, V54, P665, DOI 10.1038/jhg.2009.93; Chubb JE, 2008, MOL PSYCHIATR, V13, P36, DOI 10.1038/sj.mp.4002106; Cimino PJ, 2009, AM J PATHOL, V175, P1622, DOI 10.2353/ajpath.2009.090443; Clerici M, 2009, CNS SPECTRUMS, V14, P419, DOI 10.1017/S1092852900020393; Coogan AN, 2008, BRAIN RES, V1232, P104, DOI 10.1016/j.brainres.2008.07.087; Cotman CW., 1987, NEUROIMMUNE ENDOCRIN; Cox D, 2015, J NERV MENT DIS, V203, P393, DOI 10.1097/NMD.0000000000000289; Crepel A, 2010, CLIN GENET, V77, P389, DOI 10.1111/j.1399-0004.2009.01318.x; Cui K, 2009, SCHIZOPHR RES, V113, P288, DOI 10.1016/j.schres.2009.05.003; Czerski PM, 2008, NEUROPSYCHOBIOLOGY, V57, P88, DOI 10.1159/000135642; Da Mesquita S, 2015, BRAIN BEHAV IMMUN, V49, P280, DOI 10.1016/j.bbi.2015.06.008; Davenport CM, 2010, J NEUROCHEM, V112, P552, DOI 10.1111/j.1471-4159.2009.06485.x; Dean B, 2009, AUST NZ J PSYCHIAT, V43, P13, DOI 10.1080/00048670802534416; Debnath M, 2015, J NEUROIMMUNE PHARM, V10, P610, DOI 10.1007/s11481-015-9626-9; Deneka A, 2015, GENE, V570, P25, DOI 10.1016/j.gene.2015.06.062; Dhabhar FS, 2009, J PSYCHIATR RES, V43, P962, DOI 10.1016/j.jpsychires.2009.05.010; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Ding Ying, 2015, Mol Neuropsychiatry, V1, P1; Dorban G, 2010, HISTOCHEM CELL BIOL, V133, P493, DOI 10.1007/s00418-010-0687-9; Drerup CM, 2009, DEVELOPMENT, V136, P2623, DOI 10.1242/dev.030577; Eikelenboom P, 2006, J NEURAL TRANSM, V113, P1685, DOI 10.1007/s00702-006-0575-6; Enomoto A, 2009, NEURON, V63, P774, DOI 10.1016/j.neuron.2009.08.015; Fang F, 2010, FASEB J, V24, P1043, DOI 10.1096/fj.09-139634; Fatemi SH, 2009, SCHIZOPHRENIA BULL, V35, P528, DOI 10.1093/schbul/sbn187; Feleder C, 2010, BIOL PSYCHIAT, V67, P386, DOI 10.1016/j.biopsych.2009.09.028; Fernandes BS, 2016, MOL PSYCHIATR, V21, P554, DOI 10.1038/mp.2015.87; Fernandez-Novoa L, 2001, BEHAV BRAIN RES, V124, P213, DOI 10.1016/S0166-4328(01)00215-7; FERNANDEZNOVOA L, 1995, INFLAMM RES, V44, P55, DOI 10.1007/BF01630488; FERNANDEZNOVOA L, 1994, METHOD FIND EXP CLIN, V16, P279; FERNANDEZNOVOA L, 1993, METHOD FIND EXP CLIN, V15, P735; Ferreira AC, 2015, PROG NEUROBIOL, V131, P120, DOI 10.1016/j.pneurobio.2015.06.005; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Frezza D, 2009, INT J IMMUNOPATH PH, V22, P115, DOI 10.1177/039463200902200113; Gabbay V, 2009, J CHILD ADOL PSYCHOP, V19, P423, DOI 10.1089/cap.2008.0140; Glanzer JG, 2007, J NEUROCHEM, V102, P627, DOI 10.1111/j.1471-4159.2007.04568.x; Gos T, 2014, BRAIN BEHAV IMMUN, V41, P59, DOI 10.1016/j.bbi.2014.05.012; Griffiths M, 2007, INT REV NEUROBIOL, V82, P29, DOI 10.1016/S0074-7742(07)82002-2; Grippo AJ, 2009, STRESS, V12, P1, DOI 10.1080/10253890802046281; Grove RA, 2014, CURR ALZHEIMER RES, V11, P47, DOI 10.2174/1567205010666131212110148; Guilloux JP, 2015, NEUROPSYCHOPHARMACOL, V40, P701, DOI 10.1038/npp.2014.226; Haig GM, 2014, J ALZHEIMERS DIS, V42, P959, DOI 10.3233/JAD-140291; Halacheva K, 2009, PSYCHIAT RES, V169, P51, DOI 10.1016/j.psychres.2008.05.011; Hanson DR, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-7; Hein AM, 2010, BRAIN BEHAV IMMUN, V24, P243, DOI 10.1016/j.bbi.2009.10.002; Heinisch S, 2009, NEUROSCIENCE, V164, P1210, DOI 10.1016/j.neuroscience.2009.08.075; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Herberth M, 2010, MOL PSYCHIATR, V15, P364, DOI 10.1038/mp.2008.120; Hope S, 2009, BIPOLAR DISORD, V11, P726, DOI 10.1111/j.1399-5618.2009.00757.x; Hoppe JB, 2010, J PINEAL RES, V48, P230, DOI 10.1111/j.1600-079X.2010.00747.x; Hosoi Toru, 2002, Current Drug Targets - Inflammation and Allergy, V1, P257, DOI 10.2174/1568010023344599; Howes OD, 2009, SCHIZOPHRENIA BULL, V35, P549, DOI 10.1093/schbul/sbp006; Hu F, 2009, BRAIN BEHAV IMMUN, V23, P455, DOI 10.1016/j.bbi.2009.01.001; Hu RD, 2015, ACS CHEM NEUROSCI, V6, P1759, DOI 10.1021/acschemneuro.5b00192; Husband AJ, 1992, BEHAV IMMUNITY; Ibi D, 2010, BEHAV BRAIN RES, V206, P32, DOI 10.1016/j.bbr.2009.08.027; Ito HT, 2010, BRAIN BEHAV IMMUN, V24, P930, DOI 10.1016/j.bbi.2010.03.004; Kanerva K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006858; Kim JY, 2009, NEURON, V63, P761, DOI 10.1016/j.neuron.2009.08.008; Kim YK, 2016, PROG NEURO-PSYCHOPH, V64, P277, DOI 10.1016/j.pnpbp.2015.06.008; Kinney DK, 2010, MED HYPOTHESES, V74, P555, DOI 10.1016/j.mehy.2009.09.040; Kiyota T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006197; Koido K, 2010, J PSYCHIATR RES, V44, P275, DOI 10.1016/j.jpsychires.2009.09.001; Kornhuber J, 2009, EUR ARCH PSY CLIN N, V259, P199, DOI 10.1007/s00406-009-0061-x; Kraft R, 2015, CHANNELS, V9, P244, DOI 10.1080/19336950.2015.1071747; Kudrna JJ, 2015, HUM VACC IMMUNOTHER, V11, P1921, DOI 10.1080/21645515.2015.1065364; Lang UE, 2007, CELL PHYSIOL BIOCHEM, V20, P687, DOI 10.1159/000110430; Laske C, 2008, PSYCHIAT RES, V158, P83, DOI 10.1016/j.psychres.2006.04.023; Levite M, 2016, ACTA PHYSIOL, V216, P42, DOI 10.1111/apha.12476; Leza JC, 2015, NEUROSCI BIOBEHAV R, V55, P612, DOI 10.1016/j.neubiorev.2015.05.014; Liao P, 2010, PFLUG ARCH EUR J PHY, V460, P353, DOI 10.1007/s00424-009-0753-0; Licinio J, 2007, EXP PHYSIOL, V92, P807, DOI 10.1113/expphysiol.2007.038471; Lindqvist D, 2009, BIOL PSYCHIAT, V66, P287, DOI 10.1016/j.biopsych.2009.01.030; Loftis JM, 2010, NEUROBIOL DIS, V37, P519, DOI 10.1016/j.nbd.2009.11.015; Lombardi VRM, 1998, J NEUROSCI RES, V54, P539, DOI 10.1002/(SICI)1097-4547(19981115)54:4<539::AID-JNR11>3.3.CO;2-H; Lombardi VRM, 2004, METHOD FIND EXP CLIN, V26, P523, DOI 10.1358/mf.2004.26.7.863735; Lombardi VRM, 1998, METHOD FIND EXP CLIN, V20, P377, DOI 10.1358/mf.1998.20.5.485697; MacLean AG, 2012, WORLD J VIROL, V4, P42; Maletic V, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00098; Maneiro E, 1997, METHOD FIND EXP CLIN, V19, P5; Manenschijn L, 2009, ANN NY ACAD SCI, V1179, P179, DOI 10.1111/j.1749-6632.2009.05013.x; Matsumoto A, 2015, ANESTH ANALG, V120, P895, DOI 10.1213/ANE.0000000000000606; Matsunaga M, 2009, BRAIN BEHAV IMMUN, V23, P931, DOI 10.1016/j.bbi.2009.03.007; Matsuzaki S, 2007, NEUROCHEM INT, V51, P165, DOI 10.1016/j.neuint.2007.06.018; Mayilyan KR, 2008, DRUG NEWS PERSPECT, V21, P200, DOI 10.1358/dnp.2008.21.4.1213349; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; McGeer PL, 2002, J NEUROVIROL, V8, P529, DOI 10.1080/13550280290100969; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; Mehlhorn G, 2000, INT J DEV NEUROSCI, V18, P423, DOI 10.1016/S0736-5748(00)00012-5; Meyer U, 2009, PSYCHOPHARMACOLOGY, V206, P587, DOI 10.1007/s00213-009-1504-9; Milior G, 2015, BRAIN BEHAV IMMUN; Millar JK, 2007, J PHYSIOL-LONDON, V584, P401, DOI 10.1113/jphysiol.2007.140210; Miller AH, 2010, BRAIN BEHAV IMMUN, V24, P1, DOI 10.1016/j.bbi.2009.09.009; Miller AH, 2009, BRAIN BEHAV IMMUN, V23, P149, DOI 10.1016/j.bbi.2008.08.006; Muller N, 2010, CURR OPIN INVEST DR, V11, P31; Mundo E, 2005, AM J MED GENET B, V132B, P1, DOI 10.1002/ajmg.b.30100; Na KS, 2007, NEUROPSYCHOBIOLOGY, V56, P55, DOI 10.1159/000111535; Naegelen I, 2015, J LEUKOCYTE BIOL, V97, P557, DOI 10.1189/jlb.3A0514-254RR; Nakata K, 2009, P NATL ACAD SCI USA, V106, P15873, DOI 10.1073/pnas.0903413106; Nautiyal KM, 2008, P NATL ACAD SCI USA, V105, P18053, DOI 10.1073/pnas.0809479105; O'Connor JC, 2009, J NEUROSCI, V29, P4200, DOI 10.1523/JNEUROSCI.5032-08.2009; Ohi K, 2015, SCHIZOPHRENIA BULL, V41, P909, DOI 10.1093/schbul/sbu171; Ovaskainen Y, 2009, PSYCHIAT RES, V167, P73, DOI 10.1016/j.psychres.2007.12.004; Ozbey U, 2008, PSYCHIAT CLIN NEUROS, V62, P307, DOI 10.1111/j.1440-1819.2008.01798.x; Ozbey U, 2009, WORLD J BIOL PSYCHIA, V10, P461, DOI 10.1080/15622970802626580; Pace TWW, 2009, ANN NY ACAD SCI, V1179, P86, DOI 10.1111/j.1749-6632.2009.04984.x; Park KM, 2010, CELL SIGNAL, V22, P519, DOI 10.1016/j.cellsig.2009.11.006; Passos GF, 2009, AM J PATHOL, V175, P1586, DOI 10.2353/ajpath.2009.081113; Peng YP, 2005, NEUROSCI LETT, V374, P192, DOI 10.1016/j.neulet.2004.10.069; Piehl F, 2009, NEUROSCIENCE, V158, P1143, DOI 10.1016/j.neuroscience.2008.08.031; Postal M, 2015, AUTOIMMUN REV, V14, P30, DOI 10.1016/j.autrev.2014.09.001; Potvin S, 2008, BIOL PSYCHIAT, V63, P801, DOI 10.1016/j.biopsych.2007.09.024; Qiu LQ, 2015, J LEUKOCYTE BIOL, V97, P723, DOI 10.1189/jlb.3A0214-106R; Rapaport MH, 2010, NEUROPSYCHOPHARMACOL, V35, P428, DOI 10.1038/npp.2009.145; Rasmussen HB, 2006, AM J PSYCHIAT, V163, P507, DOI 10.1176/appi.ajp.163.3.507; Rettori V, 2009, ANN NY ACAD SCI, V1153, P35, DOI 10.1111/j.1749-6632.2008.03968.x; Ribeiro-Santos R, 2014, CURR NEUROPHARMACOL, V12, P273, DOI 10.2174/1570159X1203140511160832; Ross R, 1991, CYTOKINE INTERACTION; Rossi D, 2009, BRAIN RES BULL, V80, P224, DOI 10.1016/j.brainresbull.2009.07.012; Saetre P, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-46; Savage JC, 2015, J NEUROSCI, V35, P6532, DOI 10.1523/JNEUROSCI.4586-14.2015; Schafer DP, 2010, BIOCHEM SOC T, V38, P476, DOI 10.1042/BST0380476; Schmitt Andrea, 2005, Neuropsychiatr Dis Treat, V1, P171, DOI 10.2147/nedt.1.2.171.61048; Schosser A, 2007, AM J MED GENET B, V144B, P347, DOI 10.1002/ajmg.b.30416; Schumacher J, 2009, HUM MOL GENET, V18, P2719, DOI 10.1093/hmg/ddp204; Schwarz MJ, 2006, EUR ARCH PSY CLIN N, V256, P72, DOI 10.1007/s00406-005-0603-9; Severance EG, 2015, BRAIN BEHAV IMMUN, V44, P148, DOI 10.1016/j.bbi.2014.09.009; Shan L, 2015, TRENDS NEUROSCI, V38, P167, DOI 10.1016/j.tins.2014.12.008; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Singh B, 2009, CYTOKINE, V47, P1, DOI 10.1016/j.cyto.2009.05.005; Skaper SD, 2010, FASEB J, V24, P337, DOI 10.1096/fj.09-138883; Song J, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00061; Spector NH, 1989, NEUROIMMUNE NETWORKS; Sperner-Unterweger B, 2015, CURR OPIN PSYCHIATR, V28, P201, DOI 10.1097/YCO.0000000000000153; Sriskantharajah S, 2010, SCIENCE, V327, P1093, DOI 10.1126/science.1187271; Stefansson H, 2009, NATURE, V460, P744, DOI 10.1038/nature08186; Stone JL, 2008, NATURE, V455, P237, DOI 10.1038/nature07239; Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5; Stringer S, 2014, SCHIZOPHR RES, V159, P347, DOI 10.1016/j.schres.2014.09.004; Su SY, 2009, CIRC-CARDIOVASC GENE, V2, P614, DOI 10.1161/CIRCGENETICS.109.870386; Sugino H, 2009, PROG NEURO-PSYCHOPH, V33, P303, DOI 10.1016/j.pnpbp.2008.12.006; Sun SL, 2009, BRAIN RES, V1268, P13, DOI 10.1016/j.brainres.2009.02.071; Takahashi T, 2009, PSYCHIAT RES-NEUROIM, V172, P128, DOI 10.1016/j.pscychresns.2009.01.005; Takata K, 2007, EUR J NEUROSCI, V26, P2458, DOI 10.1111/j.1460-9568.2007.05852.x; Takenouchi T, 2010, ARCH IMMUNOL THER EX, V58, P91, DOI 10.1007/s00005-010-0069-y; Tan MG, 2010, J NEUROSCI RES, V88, P1157, DOI 10.1002/jnr.22290; Teixeira AL, 2008, PROG NEURO-PSYCHOPH, V32, P710, DOI 10.1016/j.pnpbp.2007.11.019; Theze J, 1999, CYTOKINE NETWORK IMM; Tiligada E, 2009, EXPERT OPIN INV DRUG, V18, P1519, DOI 10.1517/14728220903188438; Toben C, 2015, J NEUROIMMUNE PHARM, V10, P595, DOI 10.1007/s11481-015-9620-2; Tomasik J, 2014, SCHIZOPHR RES; Tomppo L, 2009, BIOL PSYCHIAT, V65, P1055, DOI 10.1016/j.biopsych.2009.01.014; Torres KCL, 2009, PROG NEURO-PSYCHOPH, V33, P229, DOI 10.1016/j.pnpbp.2008.11.011; Torres KCL, 2009, PROG NEURO-PSYCHOPH, V33, P214, DOI 10.1016/j.pnpbp.2008.10.020; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Verma S, 2006, BRAIN BEHAV IMMUN, V20, P449, DOI 10.1016/j.bbi.2005.10.005; Vojdani A, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1093/ecam/nep064; Walker DG, 2009, EXP NEUROL, V215, P5, DOI 10.1016/j.expneurol.2008.09.003; Watanabe T., 1991, HISTAMINERGIC NEUROS; Wei JY, 2015, PSYCHIAT RES, V228, P695, DOI 10.1016/j.psychres.2015.06.002; Xie LK, 2015, BRAIN RES, V1623, P63, DOI 10.1016/j.brainres.2015.03.026; Xu J, 2015, J CLIN INVEST, V125, P1579, DOI 10.1172/JCI76468; Xu X, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r234; Yang JH, 2015, FREE RADICAL BIO MED, V78, P156, DOI 10.1016/j.freeradbiomed.2014.11.002; Yin Y, 2015, ARTERIOSCL THROM VAS, V35, P804, DOI 10.1161/ATVBAHA.115.305282; Yu L, 2004, SCHIZOPHR RES, V71, P179, DOI 10.1016/j.schres.2004.01.001; Zai G, 2006, PSYCHOPHARMACOLOGY, V188, P171, DOI 10.1007/s00213-006-0482-4; Zhan Y, 2014, EUR PSYCHIAT, V29, P307, DOI 10.1016/j.eurpsy.2014.03.004; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; Zhang XY, 2009, PSYCHOPHARMACOLOGY, V204, P177, DOI 10.1007/s00213-008-1447-6; Zhu J, 2009, EXP CLIN PSYCHOPHARM, V17, P198, DOI 10.1037/a0016033; [No title captured]	237	25	27	0	22	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1381-6128	1873-4286		CURR PHARM DESIGN	Curr. Pharm. Design		2016	22	7					819	848		10.2174/1381612822666151209150954			30	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	DG4VQ	WOS:000372071600007	26648474				2022-02-06	
J	Krause-Titz, UR; Warneke, N; Freitag-Wolf, S; Barth, H; Mehdorn, HM				Krause-Titz, U. R.; Warneke, N.; Freitag-Wolf, S.; Barth, H.; Mehdorn, H. M.			Factors influencing the outcome (GOS) in reconstructive cranioplasty	NEUROSURGICAL REVIEW			English	Article						Cranioplasty; Complications; Glasgow Outcome Scale; Hydrocephalus; Seizures; Decompressive craniectomy	CEREBRAL-ARTERY INFARCTION; DECOMPRESSIVE CRANIECTOMY; BRAIN-INJURY; BLOOD-FLOW; HEMICRANIECTOMY; RISK; HYDROCEPHALUS; MULTICENTER; EPILEPSY; SEIZURES	After performing a decompressive craniectomy, a cranioplastic surgery is usually warranted. The complications of this reconstructive procedure may differ from the initial operation. The authors of this study report on their experience to define patient-specific and procedural risk factors for possible complications following cranioplasty influencing the outcome (Glasgow Outcome Scale (GOS)), mobility, shunt dependency, and seizures. A retrospective analysis of 263 patients of all ages and both sexes who had undergone cranioplasty after craniectomy for traumatic brain injury (including chronic subdural hematoma), subarachnoidal hemorrhage (including intracerebral hemorrhage), ischemic stroke, and tumor surgery in one single center in 12 years from January 2000 to March 2012 has been carried out. A multiple logistic regression analysis was performed to identify potential risk factors (age, gender, used cranioplasty material, initial diagnosis, clipped or coil-embolized subarachnoidal hemorrhage (SAH) patients, time interval, complications especially hydrocephalus and seizures, mobility) upon the prognosis described as a dichotomized Glasgow Outcome Scale. Two hundred forty-eight patients met the study criteria. The overall complication rate after cranioplastic surgery was 18.5 % (46 patients). Complications included: surgical site infection, epidural hematoma, hydrocephalus with or without former SAH, and new-onset seizures. Logistic regression analysis identified significant correlation between a low GOS (2 or 3) and postoperative seizures (OR 2.37, CI 1.35-4.18, p < 0.05), shunt-depending hydrocephalus (OR 5.83, CI 3.06-11.11, p < 0.05), and age between 51 and 70 years (OR 2.4, 95 % CI 1.09-5.29, p = 0.029). However, gender, time interval between craniectomy and cranioplasty, initial diagnosis, and used cranioplasty material had no significant influence on post-cranioplasty complications as surgical site infections, hematoma, wound healing disturbance, seizures, or hydrocephalus. Evaluation of treatment modality in aneurysmal SAH clip vs. coil showed no significant relation to postoperative complications either. Complications after cranioplastic surgery are a common problem, as prognostic factors could identify a shunt-depending hydrocephalus and epilepsia to develop a major deficit after cranioplastic surgery (GOS 2 or 3). We detected a significant extra risk of people between the age of 51 and 70 years to end up in GOS level 2 or 3.	[Krause-Titz, U. R.; Barth, H.; Mehdorn, H. M.] UKSH, Dept Neurosurg, D-24105 Kiel, Germany; [Warneke, N.] Univ Hosp Munster, Dept Neurosurg, D-48149 Munster, Germany; [Freitag-Wolf, S.] UKSH, Inst Med Informat & Stat, D-24105 Kiel, Germany		Krause-Titz, UR (corresponding author), UKSH, Dept Neurosurg, Campus Kiel,Arnold Heller Str 3,Haus 41, D-24105 Kiel, Germany.	ricklef@web.de					Al-Tamimi YZ, 2012, BRIT J NEUROSURG, V26, P510, DOI 10.3109/02688697.2011.633640; Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Butzkueven H, 2000, NEUROLOGY, V55, P1315, DOI 10.1212/WNL.55.9.1315; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chiang HY, 2011, J NEUROSURG, V114, P1746, DOI 10.3171/2011.1.JNS10782; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Dunisch P, 2013, J NEUROSURG, V118, P1141, DOI 10.3171/2013.1.JNS12860; ERCULEI F, 1963, J NEUROSURG, V20, P1085, DOI 10.3171/jns.1963.20.12.1085; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; GRANTHAM EG, 1948, J NEUROSURG, V5, P19, DOI 10.3171/jns.1948.5.1.0019; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Hettige S, 2012, ACTA NEUROCHIR, V154, P1725, DOI 10.1007/s00701-012-1429-7; Hill CS, 2012, BRIT J NEUROSURG, V26, P832, DOI 10.3109/02688697.2012.692839; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; JENNETT B, 1975, LANCET, V1, P480; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Kim BJ, 2012, J KOREAN NEUROSURG S, V52, P541, DOI 10.3340/jkns.2012.52.6.541; Kolakowsky-Hayner SA, 2013, BRAIN INJURY, V27, P578, DOI 10.3109/02699052.2013.765595; KONIG F, 1890, ZENTRALBL CHIR, V17, P497; Kreider GN, 1920, J AMER MED ASSOC, V74, P1024, DOI 10.1001/jama.1920.26210150001013; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; MARIE P, 1916, SOC CHIR PARIS B MEM, V42, P1608; Nievas MNCY, 2006, NEUROL RES, V28, P139, DOI 10.1179/016164106X98008; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Rahme R, 2012, J NEUROSURG, V117, P749, DOI 10.3171/2012.6.JNS111140; Rahme R, 2010, NEUROSURGERY, V67, P675, DOI 10.1227/01.NEU.0000383142.10103.0B; Rankin J, 1957, SCOTT MED J, V5; Sanan A, 1997, NEUROSURGERY, V40, P588, DOI 10.1097/00006123-199703000-00033; Schuss P, 2012, J NEUROTRAUM, V29, P1090, DOI 10.1089/neu.2011.2176; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Thesleff T, 2011, NEUROSURGERY, V68, P1535, DOI 10.1227/NEU.0b013e31820ee24e; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Walcott BP, 2013, J NEUROSURG, V118, P757, DOI 10.3171/2013.1.JNS121626; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wiggins A, 2013, NEUROSURGERY, V72, P248, DOI 10.1227/NEU.0b013e31827b98f3; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053; Woolf JI, 1945, INT ABSTR SURG, V81, P1; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547; Yoshida K, 1996, J NEUROL NEUROSUR PS, V61, P166, DOI 10.1136/jnnp.61.2.166	45	25	29	0	20	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	JAN	2016	39	1					133	139		10.1007/s10143-015-0678-3			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	DA5AL	WOS:000367814400028	26621678				2022-02-06	
J	Majdan, M; Brazinova, A; Mauritz, W				Majdan, Marek; Brazinova, Alexandra; Mauritz, Walter			Epidemiology of traumatic spinal cord injuries in Austria 2002-2012	EUROPEAN SPINE JOURNAL			English	Article						Traumatic spinal cord injury; Spinal cord injury; Epidemiology; Incidence; Mortality	GLOBAL INCIDENCE; BRAIN-INJURY	The aim of this study was to analyse the epidemiological patterns (mortality, incidence of non-fatal cases and overall incidence), of traumatic spinal cord injuries (TSCI) in 2002-2012 in Austria. TSCI-related deaths and hospital admissions in Austria 2002-2012 were obtained from Statistics Austria and analysed. Mortality rates, as well as non-fatal and overall incidence rates were calculated and compared across the age spectrum and by sex. Additionally, the main causes and demographic characteristics of victims were analysed. The crude overall incidence rate of TSCI was 16.96, CI 95 % 16.95-16.97 and the standardized incidence rate was 13.98, CI 95 % 13.97-13.99 per million (annual average rate). An annual increase in fatality rates was observed occurring mostly in the age group > 65 years (Kendall's Tau = 0.1). Falls (mortality rate 19.58, CI 95 % 19.57-19.59) and injuries at home (incidence rate 56.57, CI 95 % 56.56-56.58) were the principal causes of fatal and non-fatal TSCI, respectively. Injuries to the neck region were the most common. All indicators were the highest for the age group > 65 years: non-fatal incidence rate 23.55, CI 95 % 23.54-23.56; mortality rate 21.4, CI 95 % 21.39-21.41; and overall incidence rate 47.9, CI 95 % 47.89-47.91. A clear male dominance was observed (incidence rate ratio 1.9, CI 95 % 1.4-2.7). The population > 65 years has been at the highest risk of TSCI in Austria for the analysed period and therefore preventive activities should be focused on this group. The increasing overall incidence of TSCI was driven by the increasing mortality rates that were highest in the age group > 65 years. We advocate harmonization of epidemiological reporting especially regarding aetiology of TSCI in order to better inform policy makers and prevention.	[Majdan, Marek; Brazinova, Alexandra] Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Univ Namestie 1, Trnava 91701, Slovakia; [Majdan, Marek; Brazinova, Alexandra; Mauritz, Walter] INRO, Moelkergasse 4-3, A-1080 Vienna, Austria		Majdan, M (corresponding author), Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Univ Namestie 1, Trnava 91701, Slovakia.; Majdan, M (corresponding author), INRO, Moelkergasse 4-3, A-1080 Vienna, Austria.	mmajdan@igeh.org; abrazinova@igeh.org; walter.mauritz@igeh.org	Brazinova, Alexandra/C-4265-2016; Majdan, Marek/K-5017-2012	Brazinova, Alexandra/0000-0003-0625-256X; Majdan, Marek/0000-0001-8037-742X			Ackery A, 2004, J NEUROTRAUM, V21, P1355, DOI 10.1089/neu.2004.21.1355; Ahmad O. B., 2001, GPE DISCUSSION PAPER, V31; Aragon TJ, 2012, EP EP TOOLS R PACK V; Fitzharris M, 2014, SPINAL CORD, V52, P117, DOI 10.1038/sc.2013.135; Furlan JC, 2013, CAN J NEUROL SCI, V40, P456, DOI 10.1017/S0317167100014530; Hagen EM, 2009, SPINAL CORD, V47, P367, DOI 10.1038/sc.2008.118; Hagen EM, 2010, J NEUROL NEUROSUR PS, V81, P368, DOI 10.1136/jnnp.2009.178798; Jazayeri SB, 2015, EUR SPINE J, V24, P905, DOI 10.1007/s00586-014-3424-6; Knutsdottir S, 2012, SPINAL CORD, V50, P123, DOI 10.1038/sc.2011.105; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; Lee BB, 2014, SPINAL CORD, V52, P110, DOI 10.1038/sc.2012.158; Mauritz W, 2014, WIEN KLIN WOCHENSCHR, V126, P278, DOI 10.1007/s00508-014-0521-9; Mauritz W, 2014, WIEN KLIN WOCHENSCHR, V126, P42, DOI 10.1007/s00508-013-0456-6; McDonald JW, 2002, LANCET, V359, P417, DOI 10.1016/S0140-6736(02)07603-1; McKinley WO, 1999, ARCH PHYS MED REHAB, V80, P1402, DOI 10.1016/S0003-9993(99)90251-4; McLeod AI, 2011, KEND KEND RANK CORR; Pickett GE, 2006, SPINE, V31, P799, DOI 10.1097/01.brs.0000207258.80129.03; Polinder S, 2007, B WORLD HEALTH ORGAN, V85, P27, DOI 10.2471/BLT.06.030973; R Development Core Team, 2012, R LANG ENV STAT COMP; Rahimi-Movaghar V, 2013, NEUROEPIDEMIOLOGY, V41, P65, DOI 10.1159/000350710; van den Berg MEL, 2010, NEUROEPIDEMIOLOGY, V34, P184, DOI 10.1159/000279335; Van Den Berg M, 2011, J NEUROTRAUM, V28, P469, DOI 10.1089/neu.2010.1608; van den Berg MEL, 2010, J NEUROTRAUM, V27, P1517, DOI 10.1089/neu.2009.1138; WHO, 2013, INTERNATIONAL PERSPECTIVES ON SPINAL CORD INJURY, P1; WHO, 1992, INT STAT CLASS DIS R	25	25	27	1	12	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0940-6719	1432-0932		EUR SPINE J	Eur. Spine J.	JAN	2016	25	1					62	73		10.1007/s00586-015-3985-z			12	Clinical Neurology; Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Orthopedics	DB6FI	WOS:000368608900006	25957283				2022-02-06	
S	Marklund, N		Kobeissy, F; Dixon, CE; Hayes, RL; Mondello, S		Marklund, Niklas			Rodent Models of Traumatic Brain Injury: Methods and Challenges	INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS	Methods in Molecular Biology		English	Article; Book Chapter						Traumatic brain injury; Controlled cortical impact (CCI); Fluid percussion injury (FPI); Rats; Mice; Neurodegeneration; Outcome	CONTROLLED CORTICAL IMPACT; FLUID PERCUSSION INJURY; POSTTRAUMATIC EPILEPSY; AXONAL INJURY; PRESSURE; MODERATE; MOUSE; EPIDEMIOLOGY; CRANIOTOMY; POSITION	Traumatic brain injury (TBI) has been named the most complex disease in the most complex organ of the body. It is the most common cause of death and disability in the Western world in people <40 years old and survivors commonly suffer from persisting cognitive deficits, impaired motor function, depression and personality changes. TBI may vary in severity from uniformly fatal to mild injuries with rapidly resolving symptoms and without doubt, it is a markedly heterogeneous disease. Its different subtypes differs in their pathophysiology, treatment options and long-term consequences and to date, there are no pharmacological treatments with proven clinical benefit available to TBI patients. To enable development of novel treatment options for TBI, clinically relevant animal models are needed. Due to their availability and low costs, numerous rodent models have been developed which have substantially contributed to our current understanding of the pathophysiology of TBI. The most common animal models used in laboratories worldwide are likely the controlled cortical impact (CCI) model, the central and lateral fluid percussion injury (FPI) models, and weight drop/impact acceleration (I/A) models. Each of these models has inherent advantages and disadvantages; these need to be thoroughly considered when selecting the rodent TBI model according to the hypothesis and design of the study. Since TBI is not one disease, refined animal models must take into account the clinical features and complexity of human TBI. To enhance the possibility of establishing preclinical efficacy of a novel treatment, the preclinical use of several different experimental models is encouraged as well as varying the species, gender, and age of the animal. In this chapter, the methods, limitations, and challenges of the CCI and FPI models of TBI used in rodents are described.	[Marklund, Niklas] Uppsala Univ, Dept Neurosci, Div Neurosci, Uppsala, Sweden		Marklund, N (corresponding author), Uppsala Univ, Dept Neurosci, Div Neurosci, Uppsala, Sweden.			Marklund, Niklas/0000-0002-9797-5626			Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Armstead WM, 1997, P SOC EXP BIOL MED, V214, P210; Axelson HW, 2013, RESTOR NEUROL NEUROS, V31, P73, DOI 10.3233/RNN-2012-120242; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Bondi CO, 2015, NEUROSCI BIOBEHAV R, V58, P123, DOI 10.1016/j.neubiorev.2014.12.004; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Clausen F, 2005, ACTA NEUROCHIR, V147, P775, DOI 10.1007/s00701-005-0550-2; Clausen F, 2014, BRAIN RES, V1588, P37, DOI 10.1016/j.brainres.2014.08.043; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ekmark-Lewen S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-44; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feng JF, 2012, J NEUROTRAUM, V29, P1167, DOI 10.1089/neu.2011.1867; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hanell A, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00252; Hanell A, 2012, J NEUROTRAUM, V29, P2660, DOI 10.1089/neu.2012.2376; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Kilkenny C, 2010, J PHARMACOL PHARMACO, V1, P94, DOI 10.4103/0976-500X.72351; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Plantman S, 2012, J NEUROTRAUM, V29, P1219, DOI 10.1089/neu.2011.2182; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schutz C, 2006, CRIT CARE MED, V34, P492, DOI 10.1097/01.CCM.0000198326.32049.7F; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Todd MM, 1996, J NEUROSURG ANESTH, V8, P296, DOI 10.1097/00008506-199610000-00007; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	51	25	26	1	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA	1064-3745	1940-6029	978-1-4939-3816-2; 978-1-4939-3814-8	METHODS MOL BIOL	Methods Mol. Biol.		2016	1462						29	46		10.1007/978-1-4939-3816-2_3	10.1007/978-1-4939-3816-2		18	Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences	Book Citation Index – Science (BKCI-S)	Biochemistry & Molecular Biology; Neurosciences & Neurology	BH1UG	WOS:000398551500005	27604711				2022-02-06	
J	Winter, L; Moriarty, HJ; Robinson, K; Piersol, CV; Vause-Earland, T; Newhart, B; Iacovone, DB; Hodgson, N; Gitlin, LN				Winter, Laraine; Moriarty, Helene J.; Robinson, Keith; Piersol, Catherine V.; Vause-Earland, Tracey; Newhart, Brian; Iacovone, Delores Blazer; Hodgson, Nancy; Gitlin, Laura N.			Efficacy and acceptability of a home-based, family-inclusive intervention for veterans with TBI: A randomized controlled trial	BRAIN INJURY			English	Article						Community reintegration; family; in-home service; rehabilitation; traumatic brain injury; veterans	TRAUMATIC BRAIN-INJURY; COGNITIVE REHABILITATION; COMMUNITY REINTEGRATION; SERVICE MEMBERS; CAREGIVER; MILITARY; OUTCOMES; NEUROREHABILITATION; INTEGRATION; DEMENTIA	Objective: Traumatic brain injury (TBI) often undermines community re-integration, impairs functioning and produces other symptoms. This study tested an innovative programme for veterans with TBI, the Veterans' In-home Programme (VIP), delivered in veterans' homes, involving a family member and targeting the environment (social and physical) to promote community re-integration, mitigate difficulty with the most troubling TBI symptoms and facilitate daily functioning. Setting: Interviews and intervention sessions were conducted in homes or by telephone. Participants: Eighty-one veterans with TBI at a VA polytrauma programme and a key family member. Design: This was a 2-group randomized controlled trial. Control-group participants received usual-care enhanced by two attention-control telephone calls. Follow-up interviews occurred up to 4 months after baseline interview. Main measures: VIP's efficacy was evaluated using measures of community re-integration, target outcomes reflecting veterans' self-identified problems and self-rated functional competence. Results: At follow-up, VIP participants had significantly higher community re-integration scores and less difficulty managing targeted outcomes, compared to controls. Self-rated functional competence did not differ between groups. In addition, VIP's acceptability was high. Conclusion: A home-based, family-inclusive service for veterans with TBI shows promise for improving meaningful outcomes and warrants further research and clinical application.	[Winter, Laraine] Philadelphia Res & Educ Fdn, Philadelphia, PA 19104 USA; [Winter, Laraine; Moriarty, Helene J.] Dept Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA 19104 USA; [Moriarty, Helene J.] Villanova Univ, Coll Nursing, Villanova, PA 19085 USA; [Robinson, Keith; Newhart, Brian; Iacovone, Delores Blazer] Dept Vet Affairs Med Ctr, Med Rehabil Serv, Philadelphia, PA 19104 USA; [Robinson, Keith] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Piersol, Catherine V.; Vause-Earland, Tracey] Thomas Jefferson Univ, Sch Hlth Profess, Philadelphia, PA 19107 USA; [Hodgson, Nancy; Gitlin, Laura N.] Johns Hopkins Univ, Sch Nursing, Ctr Innovat Care Aging, Baltimore, MD USA		Winter, L (corresponding author), Philadelphia Res & Educ Fdn, Philadelphia VA Med Ctr, Univ & Woodland Ave, Philadelphia, PA 19104 USA.	laraine.winter@gmail.com		Piersol, Catherine/0000-0003-4992-8988	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21 HD068857] Funding Source: Medline		ANDRESEN EM, 1994, AM J PREV MED, V10, P77, DOI 10.1016/S0749-3797(18)30622-6; Asher I. E., 2007, OCCUPATIONAL THERAPY; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; BATTLE CC, 1966, AM J PSYCHOTHER, V20, P184, DOI 10.1176/appi.psychotherapy.1966.20.1.184; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P290, DOI 10.1097/HTR.0000000000000070; Berg IJ, 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI DOI 10.1080/09602019108401384; Blais AR, 2009, MIL PSYCHOL, V21, P365, DOI 10.1080/08995600902914727; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Bovend'Eerdt TJ, 2010, ARCH PHYS MED REHAB, V91, P939, DOI 10.1016/j.apmr.2010.03.008; Brown M, 2004, J HEAD TRAUMA REHAB, V46, P469; Centers for Disease Control and Prevention, 2014, TRAUMATIC BRAIN INJU; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KA, 2009, ARCH PHYS MED REHAB, V90, pS52, DOI 10.1016/j.apmr.2009.05.019; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Cifu DX, 2010, AM J PHYS MED REHAB, V89, P688, DOI 10.1097/PHM.0b013e3181e722ad; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Cooper DB, 2015, BRAIN IMAGING BEHAV, V9, P403, DOI 10.1007/s11682-015-9440-2; Davis T, 2015, ARCH DIS CHILDHOOD-E, V100, P97, DOI 10.1136/archdischild-2014-306797; Defense and Veterans Brain Injury Center, 2014, DOD WORLDW NUMB TBI; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Florian V, 1989, INT DISABILITY STUDI, V13, P150; Gitlin LN, 2008, AM J GERIAT PSYCHIAT, V16, P229, DOI 10.1097/JGP.0b013e318160da72; Gitlin LN, 2006, J AM GERIATR SOC, V54, P809, DOI 10.1111/j.1532-5415.2006.00703.x; Gitlin LN, 2010, JAMA-J AM MED ASSOC, V304, P983, DOI 10.1001/jama.2010.1253; Gitlin LN, 2010, J AM GERIATR SOC, V58, P1465, DOI 10.1111/j.1532-5415.2010.02971.x; Gitlin LN, 2003, GERONTOLOGIST, V43, P532, DOI 10.1093/geront/43.4.532; Glynn SM, 2013, CLIN CHILD FAM PSYCH, V16, P410, DOI 10.1007/s10567-013-0153-z; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Josman N, 1999, Can J Occup Ther, V66, P33; Kaschel R, 2002, NEUROPSYCHOL REHABIL, V12, P127, DOI 10.1080/09602010143000211; Kazis LE., 2000, MED OUTCOMES TRUST M, V5, P1; Kim EC, 2007, J NEUROPSYCHIATRY CL, V19; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; LAWTON MP, 1983, GERONTOLOGIST, V23, P349, DOI 10.1093/geront/23.4.349; Lawton MP., 1973, PSYCHOL ADULT DEV AG, P619, DOI [DOI 10.1037/10044-020, 10.1037/10044-020]; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Lewin, 1935, DYNAMIC THEORY PERS; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Marshall S, 2015, BRAIN INJURY, V29, P688, DOI 10.3109/02699052.2015.1004755; McCulloch KL, 2015, J HEAD TRAUMA REHAB, V30, P56, DOI 10.1097/HTR.0000000000000104; MILDERS MV, 1995, NEUROPSYCHOL REHABIL, V5, P223, DOI 10.1080/09602019508401468; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Oddy M, 2003, NEUROPSYCHOL REHABIL, V13, P259, DOI 10.1080/09602010244000345; Pace GM, 1999, BRAIN INJURY, V13, P535; Park HY, 2015, OCCUP THER INT, V22, P104, DOI 10.1002/oti.1389; Pollard D, 2005, ALLENS COGNITIVE LEV; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Prigatano GP, 1986, NEUROSPYCHOLOGICAL R; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Resnik L, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-145; Resnik L, 2011, J REHABIL RES DEV, V48, P89, DOI 10.1682/JRRD.2010.04.0070; Resnik L, 2009, J REHABIL RES DEV, V46, P469, DOI 10.1682/JRRD.2008.07.0082; Roitman DM, 1996, PHYS OCCUPATIONAL TH, V14, P43; Salter K, 2008, BRAIN INJURY, V22, P820, DOI 10.1080/02699050802425428; Sander AM, 2010, J HEAD TRAUMA REHAB, V25, P121, DOI 10.1097/HTR.0b013e3181cd1635; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2011, J TRAUMA STRESS, V24, P660, DOI 10.1002/jts.20706; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Stejskal TM, 2012, NEUROREHABILITATION, V31, P75, DOI 10.3233/NRE-2012-0776; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Vanderploeg RD, 2008, ARCH PHYS MED REHAB, V89, P2227, DOI 10.1016/j.apmr.2008.06.015; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Williamson GM, 1998, HEALTH PSYCHOL, V17, P152, DOI 10.1037/0278-6133.17.2.152; Wisniewski SR, 2003, PSYCHOL AGING, V18, P375, DOI 10.1037/0882-7974.18.3.375; Zasler ND, 2003, NEUROPSYCHOL REHABIL, V13, P31, DOI 10.1080/09602010	69	25	25	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2016	30	4					373	387		10.3109/02699052.2016.1144080			15	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DK1BF	WOS:000374646200002	26983578				2022-02-06	
J	Tian, J; Dai, HM; Deng, YY; Zhang, J; Li, Y; Zhou, J; Zhao, MY; Zhao, MW; Zhang, C; Zhang, YX; Wang, PP; Bing, GY; Zhao, LL				Tian, Jing; Dai, Hongmei; Deng, Yuanying; Zhang, Jie; Li, Ying; Zhou, Jun; Zhao, Mingyi; Zhao, Mengwen; Zhang, Chen; Zhang, Yuxi; Wang, Peipei; Bing, Guoying; Zhao, Lingling			The effect of HMGB1 on sub-toxic chlorpyrifos exposure-induced neuroinflammation in amygdala of neonatal rats	TOXICOLOGY			English	Article						Chlorpyrifos; Inflammatory; High-mobility group box 1; Nuclear factor kappa B; Interleukin-6; Tumor necrosis factor-alpha	TRAUMATIC BRAIN-INJURY; PRENATAL EXPOSURE; PESTICIDE; INFLAMMATION; PATHWAY; TARGET	Chlorpyrifos (CPF), one of organophosphorus pesticides (OPs), is associated with developmental neurotoxicity. Inflammatory response is closely related with CPF-induced neurotoxicity. The present study aimed at exploring whether sub-toxic CPF exposure on neonatal rats results in neuroinflammation that mediated by HMGB1/TLR4/NF-kappa B signaling pathway in the amygdala. The neonatal rats were subcutaneously injected with 5 mg/kg CPF for 4 consecutive days (postnatal day 11-14) with or without HMGB1 inhibitor, glycyrrhizin. We assessed the levels of pro-inflammatory cytokines at 12, 24, and 72 h after CPF exposure. The role of HMGB1 on neuroinflammation in sub-toxic exposure during brain development was studied. CPF-treated neonatal rats exhibited a significant increase in the expression of pro-inflammatory cytokines, such as IL-6, TNF-alpha and HMGB1, and a significant increase in the activation of NF-kappa B in the amygdala after CPF exposure. Inhibited HMGB1 reduced the release of IL-6 and TNF-alpha, and inhibited activation of NF-kappa B. Our findings indicate that CPF exposure on developmental brain might induce the activation of neuroinflammation mediated by HMGB1/TLR4/NF-kappa B pathway in the amygdala. (C) 2015 The Authors. Published by Elsevier Ireland Ltd.	[Tian, Jing; Dai, Hongmei; Deng, Yuanying; Li, Ying; Zhou, Jun; Zhao, Mingyi; Zhao, Mengwen; Zhang, Chen; Wang, Peipei; Zhao, Lingling] Cent S Univ, Xiangya Hosp 3, Dept Pediat, Changsha 410013, Hunan, Peoples R China; [Zhang, Jie] Cent S Univ, Xiangya Hosp 2, Dept Neurol, Changsha 410013, Hunan, Peoples R China; [Zhang, Yuxi] Nanjing Med Univ, Nanjing Childrens Hosp, Dept Cardiol Surg, Nanjing, Jiangsu, Peoples R China; [Bing, Guoying] Univ Kentucky, Sch Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Zhao, LL (corresponding author), Cent S Univ, Xiangya Hosp 3, Dept Pediat, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	llzhao2011@qq.com		Bing, Guoying/0000-0003-0609-8152	Key Subjects of Hunan Province [2012]	This research received specific grant from Key Subjects of Hunan Province (2012).	Ahmed A, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22945; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Bouchard MF, 2011, ENVIRON HEALTH PERSP, V119, P1189, DOI 10.1289/ehp.1003185; Chang ZL, 2010, INFLAMM RES, V59, P791, DOI 10.1007/s00011-010-0208-2; Crews FT, 2013, BIOL PSYCHIAT, V73, P602, DOI 10.1016/j.biopsych.2012.09.030; Dai HM, 2015, TOXICOLOGY, V334, P72, DOI 10.1016/j.tox.2015.06.003; Day HEW, 2005, EUR J NEUROSCI, V21, P441, DOI 10.1111/j.1460-9568.2005.03865.x; Gong G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089450; Holloway-Erickson CM, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00017; Jung HS, 2014, KOREAN J ANESTHESIOL, V66, P136, DOI 10.4097/kjae.2014.66.2.136; Juranek J, 2012, BRAIN IMAGING BEHAV, V6, P36, DOI 10.1007/s11682-011-9140-5; Kang S, 2007, FASEB J, V21, pA484; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110; Marks AR, 2010, ENVIRON HEALTH PERSP, V118, P1768, DOI 10.1289/ehp.1002056; Meyer U, 2011, PHARMACOL THERAPEUT, V132, P96, DOI 10.1016/j.pharmthera.2011.06.003; Montgomery SL, 2012, J NEUROIMMUNE PHARM, V7, P42, DOI 10.1007/s11481-011-9287-2; Mullins RJ, 2015, NEUROTOXICOLOGY, V48, P9, DOI 10.1016/j.neuro.2015.02.002; Paxinos C.Wa.G., 2007, RAT BRAIN STEREOTAXI; Rauh V, 2011, ENVIRON HEALTH PERSP, V119, P1196, DOI 10.1289/ehp.1003160; Roya TS, 2004, DEV BRAIN RES, V148, P197, DOI 10.1016/j.devbrainres.2003.12.004; Shelton JF, 2014, ENVIRON HEALTH PERSP, V122, P1103, DOI 10.1289/ehp.1307044; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Teng SX, 2015, BRAIN BEHAV IMMUN, V45, P145, DOI 10.1016/j.bbi.2014.11.006; Trendelenburg G, 2008, J CEREBR BLOOD F MET, V28, P867, DOI 10.1038/sj.jcbfm.9600609; Venerosi A, 2010, PSYCHOPHARMACOLOGY, V208, P99, DOI 10.1007/s00213-009-1713-2; Zhang JC, 2014, BRAIN RES, V1582, P176, DOI 10.1016/j.brainres.2014.07.002; Zhang J, 2015, TOXICOLOGY, V336, P17, DOI 10.1016/j.tox.2015.07.014; Zhang Jie, 2011, Zhongguo Dang Dai Er Ke Za Zhi, V13, P989	29	25	25	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-483X			TOXICOLOGY	Toxicology	DEC 2	2015	338						95	103		10.1016/j.tox.2015.10.010			9	Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Toxicology	CZ2VF	WOS:000366962000011	26524701	hybrid			2022-02-06	
J	Locher, RJ; Lunnemann, T; Garbe, A; Schaser, KD; Schmidt-Bleek, K; Duda, G; Tsitsilonis, S				Locher, R. J.; Luennemann, T.; Garbe, A.; Schaser, K-D.; Schmidt-Bleek, K.; Duda, G.; Tsitsilonis, S.			Traumatic brain injury and bone healing: radiographic and biomechanical analyses of bone formation and stability in a combined murine trauma model	JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS			English	Article						Traumatic Brain Injury; Fracture Healing; Polytrauma; microCT	CONTROLLED CORTICAL IMPACT; HEAD-INJURY; FEMORAL FRACTURES; ENERGY-METABOLISM; CALLUS FORMATION; RAT MODEL; UNION; MASS	Introduction: The combination of traumatic brain injury (TBI) and long-bone fractures has previously been reported to lead to exuberant callus formation. The aim of this experimental study was to radiographically and biomechanically study the effect of TBI on bone healing in a mouse model. Materials and methods: 138 female C57/Black6N mice were assigned to four groups (fracture (Fx) / TBI / combined trauma (Fx/TBI) / controls). Femoral osteotomy and TBI served as variables: osteotomies were stabilized with external fixators, TBI was induced with controlled cortical impact injury. During an observation period of four weeks, in vivo micro-CT scans of femora were performed on a weekly basis. Biomechanical testing of femora was performed ex vivo. Results: The combined-trauma group showed increased bone volume, higher mineral density, and a higher rate of gap bridging compared to the fracture group. The combined-trauma group showed increased torsional strength at four weeks. Discussion: TBI results in an increased formation of callus and mineral density compared to normal bone healing in mice. This fact combined with a tendency towards accelerated gap bridging leads to increased torsional strength. The present study underscores the empirical clinical evidence that TBI stimulates bone healing. Identification of underlying pathways could lead to new strategies for bone-stimulating approaches in fracture care.	[Locher, R. J.; Luennemann, T.; Garbe, A.; Schaser, K-D.; Tsitsilonis, S.] Charite, Ctr Musculoskeletal Surg, D-13353 Berlin, Germany; [Schmidt-Bleek, K.; Duda, G.] Charite, Julius Wolff Inst, D-13353 Berlin, Germany; [Schmidt-Bleek, K.; Duda, G.; Tsitsilonis, S.] Charite, Berlin Brandenburg Ctr Regenerat Therapies, D-13353 Berlin, Germany		Locher, RJ (corresponding author), Charite, Ctr Musculoskeletal Surg, Augustenburger Pl 1, D-13353 Berlin, Germany.	ricarda.locher@charite.de	Schmidt-Bleek, Katharina/O-9816-2015; Duda, Georg N/H-2085-2016	Duda, Georg N/0000-0001-7605-3908; Seemann, Ricarda/0000-0001-5752-070X	German Research Society (DFG)German Research Foundation (DFG) [TS 303/1-1]	The authors have no conflict of interest. This study was funded by the German Research Society (DFG, project TS 303/1-1).	Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; CALANDRIELLO B, 1964, Bull Hosp Joint Dis, V25, P170; Cheung KMC, 2003, J ORTHOP RES, V21, P685, DOI 10.1016/S0736-0266(03)00026-3; Council N. R, 2011, GUID CAR US LAB AN; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Einhorn TA, 2005, J ORTHOP TRAUMA, V19, pS4, DOI 10.1097/00005131-200511101-00002; Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003; Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P219; Giannoudis PV, 2006, INJURY, V37, pS18, DOI 10.1016/j.injury.2006.08.020; Histing T, 2011, BONE, V49, P591, DOI 10.1016/j.bone.2011.07.007; Karsenty G, 2012, ANNU REV PHYSIOL, V74, P87, DOI 10.1146/annurev-physiol-020911-153233; Katsnelson A, 2010, NATURE, V466, P914, DOI 10.1038/466914a; Kooistra BW, 2010, J ORTHOP TRAUMA, V24, pS81, DOI 10.1097/BOT.0b013e3181ca3fd1; Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Mehta M, 2010, BONE, V47, P219, DOI 10.1016/j.bone.2010.05.029; Morley J, 2005, INJURY, V36, P363, DOI 10.1016/j.injury.2004.08.028; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521, DOI 10.1302/0301-620X.69B4.3611150; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Tsitsilonis S, 2015, INJURY, V46, P661, DOI 10.1016/j.injury.2015.01.044; Wang L, 2011, CHIN J TRAUMATOL, V14, P7, DOI 10.3760/cma.j.issn.1008-1275.2011.01.002; Wei YZ, 2008, J PHARM PHARMACOL, V60, P1667, DOI 10.1211/jpp/60.12.0013; Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051	28	25	27	0	8	JMNI	NAFPLION	7 SPILIADOU SQ, NAFPLION, 21 100, GREECE	1108-7161			J MUSCULOSKEL NEURON	J. Musculoskelet. Neuronal Interact.	DEC	2015	15	4					309	315					7	Neurosciences; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Physiology	DB1CF	WOS:000368244900002	26636276				2022-02-06	
J	Morgan, CD; Zuckerman, SL; King, LE; Beaird, SE; Sills, AK; Solomon, GS				Morgan, Clinton D.; Zuckerman, Scott L.; King, Lauren E.; Beaird, Susan E.; Sills, Allen K.; Solomon, Gary S.			Post-concussion syndrome (PCS) in a youth population: defining the diagnostic value and cost-utility of brain imaging	CHILDS NERVOUS SYSTEM			English	Article						Brain injury; Concussion; Magnetic resonance imaging (MRI); Computed tomography (CT) neuroimaging; Mild traumatic brain injury; Decision making; Post-concussion syndrome; Sports	HIGH-SCHOOL; RECOVERY; SYMPTOMS; INJURY	Purpose Approximately 90% of concussions are transient, with symptoms resolving within 10-14 days. However, a minority of patients remain symptomatic several months post-injury, a condition known as post-concussion syndrome (PCS). The treatment of these patients can be challenging. The goal of our study was to assess the utility and cost-effectiveness of neurologic imaging two or more weeks post-injury in a cohort of youth with PCS. We conducted a retrospective study of 52 pediatric patients with persistent post-concussion symptoms after 3 months. We collected demographics and neuroimaging results obtained greater than 2 weeks post-concussion. Neuroimaging ordered in the first 2 weeks post-concussion was excluded, except to determine the rate of re-imaging. Descriptive statistics and corresponding cost data were collected. Of 52 patients with PCS, 23/52 (44 %) had neuroimaging at least 2 weeks after the initial injury, for a total of 32 diagnostic studies. In summary, 1/19 MRIs (5.3 %), 1/8 CTs (13 %), and 0/5 x-rays (0 %) yielded significant positive findings, none of which altered clinical management. Chronic phase neuroimaging estimated costs from these 52 pediatric patients totaled $129,025. We estimate the cost to identify a single positive finding was $21,000 for head CT and $104,500 for brain MRI. In this cohort of pediatric PCS patients, brain imaging in the chronic phase (defined as more than 2 weeks after concussion) was pursued in almost half the study sample, had low diagnostic yield, and had poor cost-effectiveness. Based on these results, outpatient management of pediatric patients with long-term post-concussive symptoms should rarely include repeat neuroimaging beyond the acute phase.	[Morgan, Clinton D.; Zuckerman, Scott L.; Sills, Allen K.; Solomon, Gary S.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Vanderbilt Sports Concuss Ctr, Nashville, TN 37212 USA; [King, Lauren E.; Beaird, Susan E.] Vanderbilt Univ, Sch Med, Div Pediat Neurol, Nashville, TN 37212 USA		Zuckerman, SL (corresponding author), Vanderbilt Univ, Sch Med, Dept Neurol Surg, Vanderbilt Sports Concuss Ctr, Med Ctr North T-4224, Nashville, TN 37212 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019	Morgan, Clinton/0000-0002-7511-0488	Rawlings	Support for this study came from an unrestricted educational grant from Rawlings. Dr. Solomon is a consultant for ImPACT, Nashville Predators, and Tennessee Titans. Otherwise, the study authors have no conflicts of interest or financial interests to report.	American Psychiatric A. American Psychiatric Association Task Force on D.-I, 2000, DIAGN STAT MAN MENT; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Forbes JA, 2013, PEDIATR NEUROSURG, V49, P43, DOI 10.1159/000355121; Gonzalez PG, 2011, PM&R, V3, pS413, DOI 10.1016/j.pmrj.2011.08.536; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Packard RC, 2000, HEADACHE, V40, P736, DOI 10.1046/j.1526-4610.2000.00128.x; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Parsch CS, 1997, NEUROSURGERY, V40, P483, DOI 10.1097/00006123-199703000-00010; Peterlin BL, 2008, HEADACHE, V48, P517, DOI 10.1111/j.1526-4610.2008.00917.x; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Reddy CC, 2013, J HEAD TRAUMA REHAB, V28, P260, DOI 10.1097/HTR.0b013e318257fbc6; Riley Debra, 2014, Nurse Pract, V39, P50, DOI 10.1097/01.NPR.0000446871.69156.a3; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Sener RN, 1997, COMPUT MED IMAG GRAP, V21, P341; Solomon Gary S, 2013, J Surg Orthop Adv, V22, P193; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Zamosky L., 2013, HEALTHCARE INSURANCE, P75; Zuckerman SL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12279; Zuckerman SL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12257	30	25	25	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	DEC	2015	31	12					2305	2309		10.1007/s00381-015-2916-y			5	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	CW6AM	WOS:000365079000015	26419243				2022-02-06	
J	Alali, AS; Gomez, D; Sathya, C; Burd, RS; Mainprize, TG; Moulton, R; Falcone, RA; de Mestral, C; Nathens, A				Alali, Aziz S.; Gomez, David; Sathya, Chethan; Burd, Randall S.; Mainprize, Todd G.; Moulton, Richard; Falcone, Richard A., Jr.; de Mestral, Charles; Nathens, Avery			Intracranial pressure monitoring among children with severe traumatic brain injury	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						head injury; intracranial pressure; multilevel analysis; propensity score; traumatic brain injury; trauma	BRIEF CONCEPTUAL TUTORIAL; SOCIAL EPIDEMIOLOGY; MULTILEVEL ANALYSIS; OUTCOMES; IMPACT; RISK	OBJECT Well-designed studies linking intracranial pressure (ICP) monitoring with improved outcomes among children with severe traumatic brain injury (TBI) are lacking. The main objective of this study was to examine the relationship between ICP monitoring in children and in-hospital mortality following severe TBI. METHODS An observational study was conducted using data derived from 153 adult or mixed (adult and pediatric) trauma centers participating in the American College of Surgeons (ACS) Trauma Quality Improvement Program (TQIP) and 29 pediatric trauma centers participating in the pediatric pilot TQIP between 2010 and 2012. Random-intercept multilevel modeling was used to examine the association between ICP monitoring and in-hospital mortality among children with severe TBI <= 16 years of age after adjusting for important confounders. This association was evaluated at the patient level and at the hospital level. In a sensitivity analysis, this association was reexamined in a propensity-matched cohort. RESULTS A total of 1705 children with severe TBI were included in the study cohort. The overall in-hospital mortality was 14.3% of patients (n = 243), whereas the mortality of the 273 patients (16%) who underwent invasive ICP monitoring was 11% (n = 30). After adjusting for patient-and hospital-level characteristics, ICP monitoring was associated with lower in-hospital mortality (adjusted OR 0.50; 95% CI 0.30-0.85; p = 0.01). It is possible that patients who were managed with ICP monitoring were selected because of an anticipated favorable or unfavorable outcome. To further address this potential selection bias, the analysis was repeated with the hospital-specific rate of ICP monitoring use as the exposure. The adjusted OR for death of children treated at high ICP use hospitals was 0.49 compared with those treated at low ICP use hospitals (95% CI 0.31-0.78; p = 0.003). Variations in ICP monitoring use accounted for 15.9% of the interhospital variation in mortality among children with severe TBI. Similar results were obtained after analyzing the data using propensity score matching methods. CONCLUSIONS In this observational study, ICP monitoring use was associated with lower hospital mortality at both the patient and hospital levels. However, the contribution of variable ICP monitoring rates to interhospital variation in pediatric TBI mortality was modest.	[Alali, Aziz S.; Gomez, David; Sathya, Chethan; de Mestral, Charles; Nathens, Avery] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada; [Alali, Aziz S.; Moulton, Richard] Univ Ottawa, Div Neurosurg, Ottawa, ON K1N 6N5, Canada; [Alali, Aziz S.; Gomez, David; Sathya, Chethan; de Mestral, Charles; Nathens, Avery] Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada; [Sathya, Chethan; Nathens, Avery] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON M5S 1A1, Canada; [Burd, Randall S.] Childrens Natl Med Ctr, Div Trauma & Burn Surg, Washington, DC 20010 USA; [Mainprize, Todd G.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Div Neurosurg, Toronto, ON M5S 1A1, Canada; [Falcone, Richard A., Jr.] Cincinnati Childrens Hosp Med Ctr, Div Pediat Surg, Cincinnati, OH 45229 USA; [Nathens, Avery] Sunnybrook Hlth Sci Ctr, Dept Surg, Toronto, ON M4N 3M5, Canada		Alali, AS (corresponding author), Sunnybrook Res Inst, 2075 Bayview Ave,Rm D-574, Toronto, ON M4N 3M5, Canada.	aziz.alali@mail.utoronto.ca		Gomez, David/0000-0002-0926-2547	Canada Research Chair Program in Systems of Trauma Care	This work was supported in part by funds from a Canada Research Chair Program in Systems of Trauma Care (to Dr. Nathens). No competing financial interests exist.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS28; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Austin PC, 2007, J THORAC CARDIOV SUR, V134, P1128, DOI 10.1016/j.jtcvs.2007.07.021; Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; BARZILAY Z, 1988, INTENS CARE MED, V14, P417, DOI 10.1007/BF00262899; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Chesnut RM, 2008, J TRAUMA, V65, P500, DOI 10.1097/TA.0b013e31818020b3; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Citerio G, 2008, INTENS CARE MED, V34, P1173, DOI 10.1007/s00134-008-1080-1; *COMM INJ SCAL, 1998, ABBR INJ SCAL 1998 R; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dean NP, 2007, J NEUROSURG, V107, P387, DOI 10.3171/PED-07/11/387; Hemmila MR, 2010, J TRAUMA, V68, P253, DOI 10.1097/TA.0b013e3181cfc8e6; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Kleinman ME, 2010, CIRCULATION, V122, pS876, DOI 10.1161/CIRCULATIONAHA.110.971101; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kozar RA, 2014, J TRAUMA ACUTE CARE, V76, P634, DOI 10.1097/TA.0000000000000130; Langlois J. A., 2000, TRAUMATIC BRAIN INJU; Larsen K, 2005, AM J EPIDEMIOL, V161, P81, DOI 10.1093/aje/kwi017; Maas AI, 2008, J TRAUMA, V65, P966, DOI 10.1097/TA.0b013e318184ee7b; Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960; Merlo J, 2005, J EPIDEMIOL COMMUN H, V59, P729, DOI 10.1136/jech.2004.023929; Merlo J, 2006, J EPIDEMIOL COMMUN H, V60, P290, DOI 10.1136/jech.2004.029454; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; O'Brien RM, 2007, QUAL QUANT, V41, P673, DOI 10.1007/s11135-006-9018-6; Oyetunji TA, 2011, J SURG RES, V165, pE37, DOI 10.1016/j.jss.2010.09.025; Parsons LS, 2001, SAS US GROUP INT 26; Pfenninger J, 2002, SWISS MED WKLY, V132, P116; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Shafi S, 2009, J AM COLL SURGEONS, V209, P521, DOI 10.1016/j.jamcollsurg.2009.07.001; Shahlaie K, 2011, YOUMANS WINN NEUROLO, P3362; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Wijeysundera DN, 2012, ANESTHESIOLOGY, V116, P25, DOI 10.1097/ALN.0b013e31823cfc03	40	25	25	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	NOV	2015	16	5					523	532		10.3171/2015.3.PEDS14507			10	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	CU3QK	WOS:000363439700010	26273741	Bronze			2022-02-06	
J	Donders, J; Oh, YI; Gable, J				Donders, Jacobus; Oh, Ye In; Gable, Jessica			Self- and Informant Ratings of Executive Functioning After Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						executive functioning; mild traumatic brain injury; outcomes; risk factors	CARD SORTING TEST; COGNITIVE RESERVE; DIAGNOSIS THREAT; HEAD-INJURY; SYMPTOMS; VALIDITY; INDIVIDUALS; PERFORMANCE; CHILDREN; ADULTS	Objective: To determine correlates of self-and informant reports on a standardized rating of executive functioning in persons with mild traumatic brain injury. Setting: Outpatient clinic at a rehabilitation hospital. Participants: One hundred referred persons whomet criteria formild traumatic brain injury (ie, time to follow commands < 30 minutes, posttraumatic amnesia < 24 hours, and Glasgow Coma Scale score > 12). Design: Retrospective case series review. Main Measures: Participants and informants completed the Behavior Rating Inventory of Executive FunctionAdult Version (BRIEF-A) during outpatient neuropsychological evaluations within 30 to 360 days postinjury. Results: Participant and informant BRIEF-A ratings were strongly correlated, but participants rated themselves as worse than informants did. Regression analysis revealed that higher levels of education and presence of intracranial neuroimaging findings were associated with better BRIEF-A ratings whereas worse BRIEF-A ratings were associated with longer time since injury and prior psychiatric treatment. BRIEF-A ratings were not correlated with laboratory measures of executive functioning. Conclusions: Subjective perceptions of executive dysfunction during the first year after mild TBI are driven primarily by premorbid factors and do not reflect acquired cerebral impairment.	[Donders, Jacobus] Mary Free Bed Rehabil Hosp, Grand Rapids, MI 49503 USA; [Oh, Ye In] Calvin Coll, Grand Rapids, MI 49506 USA; [Gable, Jessica] Hope Coll, Holland, MI 49423 USA		Donders, J (corresponding author), Mary Free Bed Rehabil Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jacobus.donders@maryfreebed.com					Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Anderson PJ, 2010, STUD NEUROPSYCHOL NE, P3; Banos J, 2010, PRINCIPLES PRACTICE, P329; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Culbertson W C, 2005, TOWER LONDON DREXEL; Deepika A, 2013, J HEAD TRAUMA REHAB, V28, P442, DOI 10.1097/HTR.0b013e31825e19e5; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Demery JA, 2010, CLIN NEUROPSYCHOL, V24, P1292, DOI 10.1080/13854046.2010.528452; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Fox J., 1991, REGRESSION DIAGNOSTI; Garcia-Molina A, 2012, BRAIN INJURY, V26, P864, DOI 10.3109/02699052.2012.655362; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Halari R, 2006, SCHIZOPHRENIA BULL, V32, P751, DOI 10.1093/schbul/sbl002; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Krishnan M, 2012, CLIN NEUROPSYCHOL, V26, P951, DOI 10.1080/13854046.2012.708166; Lahr Denise, 2007, Cogn Neuropsychiatry, V12, P25, DOI 10.1080/13546800600714791; Larrabee GJ, 2013, BEHAV SCI LAW, V31, P686, DOI 10.1002/bsl.2087; Levi Y, 2013, J INT NEUROPSYCH SOC, V19, P664, DOI 10.1017/S1355617713000192; Lovstad M, 2012, BRAIN INJURY, V26, P1586, DOI 10.3109/02699052.2012.698787; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Merrick EE, 2003, CLIN NEUROPSYCHOL, V17, P153, DOI 10.1076/clin.17.2.153.16512; Millis SR, 2003, CHILD NEUROPSYCHOL, V9, P221, DOI 10.1076/chin.9.3.221.16455; Murphy KR, 2004, STAT POWER ANAL; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P132, DOI 10.1080/13803390902858874; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Roth R, BEHAV RATING INVENTO; Sakamoto M, 2013, J NEUROVIROL, V19, P442, DOI 10.1007/s13365-013-0196-4; Sesma HW, 2010, PEDIATRICS, V121, pS1686; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Solsnes AE, 2014, J INT NEUROPSYCH SOC, V20, P506, DOI 10.1017/S1355617714000332; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Trontel HG, 2013, J CLIN EXP NEUROPSYC, V35, P960, DOI 10.1080/13803395.2013.844770; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Wilson KR, 2011, REHABIL PSYCHOL, V56, P100, DOI 10.1037/a0023446	44	25	25	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2015	30	6					E30	E39		10.1097/HTR.0000000000000120			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DD0JN	WOS:000369606300004	25699624				2022-02-06	
J	Teixeira, SN; Osaku, EF; Costa, CRLD; Toccolini, BF; Costa, NL; Candia, MF; Leite, MA; Jorge, AC; Duarte, PAD				Teixeira, Sandy Nogueira; Osaku, Erica Fernanda; Lima de Macedo Costa, Claudia Rejane; Toccolini, Beatriz Fernandes; Costa, Nicolle Lamberti; Candia, Maria Fernanda; Leite, Marcela Aparecida; Jorge, Amaury Cezar; Delfino Duarte, Pericles Almeida			Comparison of Proportional Assist Ventilation Plus, T-Tube Ventilation, and Pressure Support Ventilation as Spontaneous Breathing Trials for Extubation: A Randomized Study	RESPIRATORY CARE			English	Article						intensive care units; ventilator weaning; airway extubation; respiration; artificial; respiratory insufficiency; protocols; mortality	MECHANICAL VENTILATION; PREDICTORS; OUTCOMES	BACKGROUND: Failure to wean can prolong ICU stay, increase complications associated with mechanical ventilation, and increase morbidity and mortality. The spontaneous breathing trial (SBT) is one method used to assess weaning. The aim of this study was to assess proportional assist ventilation plus (PAV+) as an SBT by comparing its applicability, safety, and efficacy with T-tube and pressure support ventilation (PSV). METHODS: A randomized study was performed involving 160 adult subjects who remained on mechanical ventilation for > 24 h. Subjects were randomly assigned to the PAV+, PSV, or T-tube group. When subjects were ready to perform the SBT, subjects in the PAV+ group were ventilated in PAV+ mode (receiving support of up to 40%), the pressure support was reduced to 7 cm H2O in the PSV group, and subjects in the T-tube group were connected to one T-piece with supplemental oxygen. Subjects were observed for signs of intolerance, whereupon the trial was interrupted. When the trial succeeded, the subjects were extubated and assessed until discharge. RESULTS: The subjects were predominantly male (66.5%), and the leading cause of admission was traumatic brain injury. The groups were similar with respect to baseline characteristics, and no significant difference was observed among the groups regarding extubation success or failure. Analysis of the specificity and sensitivity revealed good sensitivity for all groups; however, the PAV+ group had higher specificity (66.6%) and higher sensitivity (97.6%), with prediction of similar to 92.1% of the success and failure events. CONCLUSIONS: No significant differences in the groups was observed regarding the rate of extubation failure, duration of mechanical ventilation, and ICU and hospital stay, indicating that PAV+ is an alternative for use as an SBT.	[Teixeira, Sandy Nogueira; Osaku, Erica Fernanda; Lima de Macedo Costa, Claudia Rejane; Toccolini, Beatriz Fernandes; Costa, Nicolle Lamberti; Candia, Maria Fernanda; Leite, Marcela Aparecida; Jorge, Amaury Cezar; Delfino Duarte, Pericles Almeida] Western Parana State Univ Hosp, Intens Care Unit, BR-85806470 Cascavel, Parana, Brazil; [Jorge, Amaury Cezar] Western Parana State Univ Hosp, Dept Med, BR-85806470 Cascavel, Parana, Brazil		Teixeira, SN (corresponding author), Western Parana State Univ Hosp, Ave Tancredo Neves 3224, BR-85806470 Cascavel, Parana, Brazil.	sandy.fisio@hotmail.com		Osaku, Erica/0000-0001-7642-8394			Aguirre-Bermeo H, 2014, MED INTENSIVA, V38, P363, DOI 10.1016/j.medin.2013.08.003; Ambrosino N, 2012, EUR RESPIR J, V39, P487, DOI 10.1183/09031936.00094411; Artime CA, 2014, RESP CARE, V59, P991, DOI 10.4187/respcare.02926; Blackwood B, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006904.pub2; Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Bosma K, 2007, CRIT CARE MED, V35, P1048, DOI 10.1097/01.CCM.0000260055.64235.7C; Bosma K, 2013, CHEST, V144, DOI 10.1378/chest.1704978; Caruso P, 1999, CHEST, V115, P1096, DOI 10.1378/chest.115.4.1096; Cordioli RL, 2013, CURR OPIN CRIT CARE, V19, P31, DOI 10.1097/MCC.0b013e32835c517d; Costa R, 2011, INTENS CARE MED, V37, P1494, DOI 10.1007/s00134-011-2297-y; Deab SAE, 2014, RESP CARE, V59, P301, DOI 10.4187/respcare.03037; Dries DJ, 2004, J TRAUMA, V56, P943, DOI 10.1097/01.TA.0000124462.61495.45; Ely EW, 2000, CHEST, V15, P522; Epstein SK, 1997, CHEST, V112, P186, DOI 10.1378/chest.112.1.186; Eskandar N, 2007, CRIT CARE CLIN, V23, P263, DOI 10.1016/j.ccc.2006.12.002; Esteban A, 1997, AM J RESP CRIT CARE, V156, P459, DOI 10.1164/ajrccm.156.2.9610109; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Gil B, 2003, CLIN PULM MED, V10, P226; Hannan LM, 2013, RESPIROLOGY, V18, P154, DOI 10.1111/j.1440-1843.2012.02266.x; Kacmarek RM, 2011, RESP CARE, V56, P140, DOI 10.4187/respcare.01021; Khamiees M, 2001, CHEST, V120, P1262, DOI 10.1378/chest.120.4.1262; Krishnan JA, 2004, AM J RESP CRIT CARE, V169, P673, DOI 10.1164/rccm.200306-761OC; Lellouche F, 2006, AM J RESP CRIT CARE, V174, P894, DOI 10.1164/rccm.200511-1780OC; Lone NI, 2011, CRIT CARE, V15, DOI 10.1186/cc10117; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; Macnaughton PD, 2007, ANAEST INTENS CARE M, V8, P489, DOI 10.1016/j.mpaic.2007.08.021; Moore FA, 2004, J TRAUMA, V56, P951; Namen AM, 2001, AM J RESP CRIT CARE, V163, P658, DOI 10.1164/ajrccm.163.3.2003060; Nemer SN, 2011, J BRAS PNEUMOL, V37, P669, DOI 10.1590/S1806-37132011000500016; Thille AW, 2013, CURR OPIN CRIT CARE, V19, P57, DOI 10.1097/MCC.0b013e32835c5095; Tobin MJ, 2004, AM J RESP CRIT CARE, V169, P661, DOI 10.1164/rccm.2401006; Vitacca M, 2003, Monaldi Arch Chest Dis, V59, P342; Xirouchaki N, 2008, INTENS CARE MED, V34, P2026, DOI 10.1007/s00134-008-1209-2	33	25	25	0	5	DAEDALUS ENTERPRISES INC	IRVING	9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA	0020-1324	1943-3654		RESP CARE	Respir. Care	NOV	2015	60	11					1527	1535		10.4187/respcare.03915			9	Critical Care Medicine; Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Respiratory System	CV6FH	WOS:000364365600002	26152472	Bronze			2022-02-06	
J	Ya, JC; Zheng, KB; Zhang, X				Ya, Junchao; Zheng, Kebin; Zhang, Xiang			Rosiglitazone exerts neuroprotective effects via the suppression of neuronal autophagy and apoptosis in the cortex following traumatic brain injury	MOLECULAR MEDICINE REPORTS			English	Article						rosiglitazone; neuroprotection; traumatic brain injury; inflammatory; autophagy; apoptosis; rats	GAMMA AGONIST ROSIGLITAZONE; CONTROLLED CORTICAL IMPACT; SECONDARY INJURY; CELL-DEATH; RAT MODEL; MECHANISMS; MICE; PPAR; PROTECTS; DISEASE	Traumatic brain injury (TBI) is one of the leading causes of mortality and morbidity in adults and children worldwide. Recent studies have demonstrated that both apoptosis and autophagy participate in TBI-induced neuronal cell death and functional loss. The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist rosiglitazone (RSG) is a well-known anti-inflammatory, which carries out its effects via the activation of PPAR-gamma. Previous studies have suggested that RSG may exert neuroprotective effects in animal models of both chronic and acute brain injury; however, whether RSG is involved in autophagic neuronal death following TBI remains to be elucidated. The present study aimed to determine whether RSG carries out its neuroprotective properties via the attenuation of neuronal apoptosis and autophagy, following TBI in a rat model. Furthermore, the role of RSG was investigated with regards to the modulation of inflammation and glutamate excitotoxicity, and the impact of RSG on functional recovery following TBI was determined The rats were subjected to controlled cortical impact injury, prior to being randomly divided into three groups: A sham-operated group, a TBI group, and an RSG treatment group. The RSG treatment group was intraperitoneally treated with 2 mg/kg RSG immediately after TBI. The results of the present study demonstrated that RSG treatment following TBI significantly reduced neuronal apoptosis and autophagy, and increased functional recovery. These effects were correlated with a decrease in the protein expression levels of tumor necrosis factor alpha and interleukin-6. However, no significant changes were observed in the protein expression levels of glutamate transporter-1 in the brain cortex. The results of the present study provide in vivo evidence that RSG may exert neuroprotective effects via the inhibition of neuronal apoptosis and autophagy following experimental TBI in rats, and the mechanism underlying these effects may be associated with the anti-inflammatory action of RSG. The present study offers a novel insight into the potential use of RSG as a neuroprotective agent for the treatment of cerebral injuries.	[Ya, Junchao; Zhang, Xiang] Cent Hosp Cangzhou, Dept Neurosurg, Cangzhou 061000, Hebei, Peoples R China; [Zheng, Kebin] Hebei Univ, Affiliated Hosp, Dept Neurosurg, Baoding 071000, Hebei, Peoples R China		Ya, JC (corresponding author), Cent Hosp Cangzhou, Dept Neurosurg, Cangzhou 061000, Hebei, Peoples R China.	junchaoyao24k@163.com			Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2013201283]	The present study was supported by a grant from the Natural Science Foundation of Hebei Province (grant no. H2013201283)	Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78; Chaturvedi RK, 2008, J NEUROCHEM, V106, P506, DOI 10.1111/j.1471-4159.2008.05388.x; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Cui CM, 2014, NEUROL SCI, V35, P695, DOI 10.1007/s10072-013-1585-4; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Liu Y, 2014, MOL MED REP, V9, P333, DOI 10.3892/mmr.2013.1803; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Mohanty P, 2004, J CLIN ENDOCR METAB, V89, P2728, DOI 10.1210/jc.2003-032103; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Rao VLR, 1998, J NEUROCHEM, V70, P2020; RINK A, 1995, AM J PATHOL, V147, P1575; Risner ME, 2006, PHARMACOGENOMICS J, V6, P246, DOI 10.1038/sj.tpj.6500369; Schutz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Xu M, 2011, ACTA PHARMACOL SIN, V32, P1089, DOI 10.1038/aps.2011.50; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang Q, 2010, NEUROL RES, V32, P852, DOI 10.1179/016164110X12556180206112	28	25	27	0	9	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	NOV	2015	12	5	A				6591	6597		10.3892/mmr.2015.4292			7	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	CW3JP	WOS:000364888900025	26351751	Green Published, Green Submitted, hybrid			2022-02-06	
J	Giatti, S; Garcia-Segura, LM; Melcangi, RC				Giatti, Silvia; Miguel Garcia-Segura, Luis; Melcangi, Roberto Cosimo			New steps forward in the neuroactive steroid field	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						Synthesis; Metabolism; Levels; Sex difference; Protection; Detrimental effects	ACUTE REGULATORY PROTEIN; PERIPHERAL NERVOUS-SYSTEM; NEURAL ANDROGEN RECEPTOR; TRAUMATIC BRAIN-INJURY; SEX-DIMORPHIC CHANGES; GENDER-DIFFERENCES; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; MULTIPLE-SCLEROSIS; BENZODIAZEPINE-RECEPTOR	Evidence accumulated in recent years suggests that the systemic treatment with neuroactive steroids, or the pharmacological modulation of its production by brain cells, represent therapeutic options to promote neuroprotection. However, new findings, which are reviewed in this paper, suggest that the factors to be considered for the design of possible therapies based on neuroactive steroids are more complex than previously thought. Thus, although as recently reported, the nervous system regulates neuroactive steroid synthesis and metabolism in adaptation to modifications in peripheral steroidogenesis, the neuroactive steroid levels in the brain do not fully reflect its levels in plasma. Even, in some cases, neuroactive steroid level modifications occurring in the nervous tissues, under physiological and pathological conditions, are in the opposite direction than in the periphery. This suggests that the systemic treatment with these molecules may have unexpected outcomes on neural steroid levels. In addition, the multiple metabolic pathways and signaling mechanisms of neuroactive steroids, which may change from one brain region to another, together with the existence of regional and sex differences in its neural levels are additional sources of complexity that should be clarified. This complexity in the levels and actions of these molecules may explain why in some cases these molecules have detrimental rather than beneficial actions for the nervous system. This article is part of a Special Issue entitled 'Steroid Perspectives'. (C) 2015 Elsevier Ltd. All rights reserved.	[Giatti, Silvia; Melcangi, Roberto Cosimo] Univ Milan, Dept Pharmacol & Biomol Sci, I-20133 Milan, Italy; [Miguel Garcia-Segura, Luis] CSIC, Inst Cajal, E-28002 Madrid, Spain		Melcangi, RC (corresponding author), Univ Milan, Ctr Excellence Neurodegenerat Dis, Sect Biomed & Endocrinol, Dept Pharmacol & Biomol Sci, Via Balzaretti 9, I-20133 Milan, Italy.	roberto.melcangi@unimi.it	Melcangi, Roberto Cosimo/AAA-6534-2022; Garcia-Segura, Luis M/U-3711-2017; Giatti, Silvia/G-9334-2016	Garcia-Segura, Luis M/0000-0002-2450-2916; Giatti, Silvia/0000-0001-7741-826X; MELCANGI, COSIMO ROBERTO/0000-0003-0861-8967	Fondazione CariploFondazione Cariplo [2012-0547]; Ministerio de Economia y Competitividad, Spain [BFU2011-30217-C03-01]	We acknowledge financial support from the Fondazione Cariplo to R.C.M. (Grant number 2012-0547) and the Ministerio de Economia y Competitividad, Spain to L.M.G.S. (BFU2011-30217-C03-01).	Aaberg ML, 2008, J DIABETES COMPLICAT, V22, P83, DOI 10.1016/j.jdiacomp.2007.06.009; Aguirre C, 2010, J NEUROCHEM, V115, P1277, DOI 10.1111/j.1471-4159.2010.07038.x; Aguirre CC, 2009, EUR J NEUROSCI, V29, P447, DOI 10.1111/j.1460-9568.2008.06591.x; Almey A, 2014, ENDOCRINOLOGY, V155, P4422, DOI 10.1210/en.2014-1463; Andersen K, 1999, NEUROLOGY, V53, P1992, DOI 10.1212/WNL.53.9.1992; Arevalo MA, 2011, J MOL ENDOCRINOL, V46, pR1, DOI 10.1677/JME-10-0122; Backstrom T, 2014, PROG NEUROBIOL, V113, P88, DOI 10.1016/j.pneurobio.2013.07.005; Barros LA, 2015, NEUROSCI BIOBEHAV R, V49, P193, DOI 10.1016/j.neubiorev.2014.11.015; Basit Abdul, 2004, J Coll Physicians Surg Pak, V14, P79; Bauman ML, 2005, INT J DEV NEUROSCI, V23, P183, DOI 10.1016/j.ijdevneu.2004.09.006; Belelli D, 2005, NAT REV NEUROSCI, V6, P565, DOI 10.1038/nrn1703; Bengtsson SK, 2013, CURR ALZHEIMER RES, V10, P38; Biamonte F, 2009, NEUROBIOL DIS, V36, P103, DOI 10.1016/j.nbd.2009.07.001; Booya F, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-24; Brinton RD, 2013, NAT REV ENDOCRINOL, V9, P241, DOI 10.1038/nrendo.2013.31; Brinton Roberta Diaz, 2006, Current Alzheimer Research, V3, P185; Brunton J.A., 2013, PROG NEUROBIOL; Buletko AB, 2012, NEUROTOXICOL TERATOL, V34, P336, DOI 10.1016/j.ntt.2012.03.003; Bychowski ME, 2012, HORM BEHAV, V61, P598, DOI 10.1016/j.yhbeh.2012.02.009; Carroll JC, 2008, NEUROSCI LETT, V445, P229, DOI 10.1016/j.neulet.2008.09.010; Caruso A, 2004, J NEUROCHEM, V88, P1179, DOI 10.1046/j.1471-4159.2004.02284.x; Caruso D, 2010, J NEUROENDOCRINOL, V22, P1137, DOI 10.1111/j.1365-2826.2010.02064.x; Caruso D, 2008, NEUROCHEM INT, V52, P560, DOI 10.1016/j.neuint.2007.06.004; Caruso D, 2008, J MOL NEUROSCI, V34, P249, DOI 10.1007/s12031-007-9029-3; Caruso D, 2015, J STEROID BIOCHEM, V146, P74, DOI 10.1016/j.jsbmb.2014.03.012; Caruso D, 2014, J NEUROCHEM, V130, P591, DOI 10.1111/jnc.12745; Caruso D, 2013, PSYCHONEUROENDOCRINO, V38, P2278, DOI 10.1016/j.psyneuen.2013.04.016; Caruso D, 2013, NEUROBIOL AGING, V34, P1080, DOI 10.1016/j.neurobiolaging.2012.10.007; Caruso D, 2010, J NEUROCHEM, V114, P921, DOI 10.1111/j.1471-4159.2010.06825.x; Cermenati G, 2010, J NEUROSCI, V30, P11896, DOI 10.1523/JNEUROSCI.1898-10.2010; Chen C, 2014, ENDOCRINOLOGY, V155, P2976, DOI 10.1210/en.2013-1844; Cheng J, 2007, J CEREBR BLOOD F MET, V27, P1553, DOI 10.1038/sj.jcbfm.9600457; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Coirini H, 2002, NEUROSCIENCE, V113, P883, DOI 10.1016/S0306-4522(02)00224-5; Confavreux C, 2003, BRAIN, V126, P770, DOI 10.1093/brain/awg081; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; Cummins CL, 2006, BIOCHEM SOC T, V34, P1110, DOI 10.1042/BST0341110; Darbra S, 2014, PROG NEUROBIOL, V113, P95, DOI 10.1016/j.pneurobio.2013.07.007; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; de Michele F, 2003, NEUROL SCI, V24, P172, DOI 10.1007/s10072-003-0115-1; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fombonne E, 1999, PSYCHOL MED, V29, P769, DOI 10.1017/S0033291799008508; Fombonne E, 2003, J AUTISM DEV DISORD, V33, P365, DOI 10.1023/A:1025054610557; Fratiglioni L, 1997, NEUROLOGY, V48, P132, DOI 10.1212/WNL.48.1.132; Garcia-Segura LM, 2009, FRONT NEUROENDOCRIN, V30, pV, DOI 10.1016/j.yfrne.2009.04.006; Gemignani F, 2006, MOVEMENT DISORD, V21, P1254, DOI 10.1002/mds.20928; Giatti S, 2009, NEUROSCIENCE, V164, P520, DOI 10.1016/j.neuroscience.2009.08.005; Giatti S, 2013, J NEUROIMMUNE PHARM, V8, P238, DOI 10.1007/s11481-012-9385-9; Giatti S, 2012, J MOL ENDOCRINOL, V49, pR125, DOI 10.1530/JME-12-0127; Giatti S, 2010, NEUROCHEM INT, V56, P118, DOI 10.1016/j.neuint.2009.09.009; Gonzales RJ, 2013, PFLUG ARCH EUR J PHY, V465, P627, DOI 10.1007/s00424-013-1267-3; Handa RJ, 2008, HORM BEHAV, V53, P741, DOI 10.1016/j.yhbeh.2007.09.012; Hirst JJ, 2014, J STEROID BIOCHEM, V139, P144, DOI 10.1016/j.jsbmb.2013.04.002; Hoffman GE, 2001, EXP NEUROL, V171, P272, DOI 10.1006/exnr.2001.7783; Hojo Y, 2009, ENDOCRINOLOGY, V150, P5106, DOI 10.1210/en.2009-0305; Holmes S, 2013, ENDOCRINOLOGY, V154, P4281, DOI 10.1210/en.2013-1242; Irwin RW, 2014, PROG NEUROBIOL, V113, P40, DOI 10.1016/j.pneurobio.2013.08.004; JO D-H, 1989, Steroids, V54, P287, DOI 10.1016/0039-128X(89)90003-2; Kaye W, 2008, PHYSIOL BEHAV, V94, P121, DOI 10.1016/j.physbeh.2007.11.037; Khasnavis S, 2013, J BIOL CHEM, V288, P20843, DOI 10.1074/jbc.M112.443556; Kim HJ, 2003, MOL BRAIN RES, V115, P39, DOI 10.1016/S0169-328X(03)00177-3; Kipp M, 2009, FRONT NEUROENDOCRIN, V30, P188, DOI 10.1016/j.yfrne.2009.04.004; Kiziltan ME, 2007, J NEUROL SCI, V258, P75, DOI 10.1016/j.jns.2007.02.028; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Lacapere JJ, 2003, STEROIDS, V68, P569, DOI 10.1016/S0039-128X(03)00101-6; Lambert Jeremy J, 2009, Psychoneuroendocrinology, V34 Suppl 1, pS48, DOI 10.1016/j.psyneuen.2009.08.009; Lambert JJ, 2003, PROG NEUROBIOL, V71, P67, DOI 10.1016/j.pneurobio.2003.09.001; Lavaque E, 2006, NEUROSCIENCE, V138, P741, DOI 10.1016/j.neuroscience.2005.05.060; Lavaque E, 2006, J NEUROBIOL, V66, P308, DOI 10.1002/neu.20221; Lewis C, 2008, NEUROSCI LETT, V448, P130, DOI 10.1016/j.neulet.2008.10.011; Lu SF, 2003, J NEUROBIOL, V57, P163, DOI 10.1002/neu.10260; Luchetti S, 2011, NEUROSCIENCE, V191, P6, DOI 10.1016/j.neuroscience.2011.04.010; Luchetti S, 2014, J NEUROPATH EXP NEUR, V73, P123, DOI 10.1097/NEN.0000000000000037; Luchetti S, 2011, NEUROBIOL AGING, V32, P1964, DOI 10.1016/j.neurobiolaging.2009.12.014; Luchetti S, 2010, BRAIN PATHOL, V20, P945, DOI 10.1111/j.1750-3639.2010.00396.x; Madigan JE, 2012, EQUINE VET J, V44, P109, DOI 10.1111/j.2042-3306.2011.00504.x; Maninger N, 2009, FRONT NEUROENDOCRIN, V30, P65, DOI 10.1016/j.yfrne.2008.11.002; Marcus SM, 2008, COMPR PSYCHIAT, V49, P238, DOI 10.1016/j.comppsych.2007.06.012; Marx CE, 2011, NEUROSCIENCE, V191, P78, DOI 10.1016/j.neuroscience.2011.06.076; Marx CE, 2006, BIOL PSYCHIAT, V60, P1287, DOI 10.1016/j.biopsych.2006.06.017; Marx CE, 2009, NEUROPSYCHOPHARMACOL, V34, P1885, DOI 10.1038/npp.2009.26; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Meffre D, 2007, J STEROID BIOCHEM, V104, P293, DOI 10.1016/j.jsbmb.2007.03.003; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Melcangi RC, 2013, J NEUROENDOCRINOL, V25, P957, DOI 10.1111/jne.12110; Melcangi RC, 2014, PROG NEUROBIOL, V113, P56, DOI 10.1016/j.pneurobio.2013.07.006; Melcangi RC, 2014, PROG NEUROBIOL, V113, P1, DOI 10.1016/j.pneurobio.2013.09.005; Melcangi RC, 2013, J SEX MED, V10, P2598, DOI 10.1111/jsm.12269; Melcangi Roberto Cosimo, 2011, Front Endocrinol (Lausanne), V2, P104, DOI 10.3389/fendo.2011.00104; Melcangi RC, 2012, J MOL NEUROSCI, V46, P177, DOI 10.1007/s12031-011-9570-y; Melcangi RC, 2010, HORM BEHAV, V57, P2, DOI 10.1016/j.yhbeh.2009.06.001; Mensah-Nyagan AG, 2008, NEUROCHEM INT, V52, P554, DOI 10.1016/j.neuint.2007.06.010; Mitro N, 2012, NEUROCHEM INT, V60, P616, DOI 10.1016/j.neuint.2012.02.025; Mo QX, 2006, J STEROID BIOCHEM, V99, P50, DOI 10.1016/j.jsbmb.2005.11.011; Mo QX, 2009, J STEROID BIOCHEM, V114, P135, DOI 10.1016/j.jsbmb.2009.01.015; Mo QM, 2004, MOL BRAIN RES, V126, P165, DOI 10.1016/j.molbrainres.2004.05.001; Morohaku K, 2014, ENDOCRINOLOGY, V155, P89, DOI 10.1210/en.2013-1556; Murray HE, 2003, NEUROSCIENCE, V116, P213, DOI 10.1016/S0306-4522(02)00578-X; Nag S, 2014, NEUROSCIENCE, V267, P122, DOI 10.1016/j.neuroscience.2014.02.040; Nakano T, 2010, BRAIN RES, V1357, P124, DOI 10.1016/j.brainres.2010.08.013; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Noonan CW, 2002, NEUROLOGY, V58, P136, DOI 10.1212/WNL.58.1.136; Noorbakhsh F, 2011, BRAIN, V134, P2703, DOI 10.1093/brain/awr200; Gomes FGN, 2014, PSYCHONEUROENDOCRINO, V50, P106, DOI 10.1016/j.psyneuen.2014.08.009; Orlando R, 2007, BRAIN RES, V1165, P21, DOI 10.1016/j.brainres.2007.06.047; Orton SM, 2006, LANCET NEUROL, V5, P932, DOI 10.1016/S1474-4422(06)70581-6; Padua L, 2006, NEUROL SCI, V27, P417, DOI 10.1007/s10072-006-0722-8; Palmen SJMC, 2004, BRAIN, V127, P2572, DOI 10.1093/brain/awh287; Panzica GC, 2012, J NEUROENDOCRINOL, V24, P1, DOI 10.1111/j.1365-2826.2011.02265.x; Papadopoulos V, 1997, J BIOL CHEM, V272, P32129, DOI 10.1074/jbc.272.51.32129; Parodi S, 2011, FRONT NEUROENDOCRIN, V32, P416, DOI 10.1016/j.yfrne.2011.06.003; Patte-Mensah C, 2014, PROG NEUROBIOL, V113, P70, DOI 10.1016/j.pneurobio.2013.07.004; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Pediaditakis I, 2015, ENDOCRINOLOGY, V156, P16, DOI 10.1210/en.2014-1596; Pesaresi M, 2010, HORM BEHAV, V57, P46, DOI 10.1016/j.yhbeh.2009.04.008; PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/pnas.88.10.4553; Qin Y., 2015, J STEROID BIOCH MOL; Roglio I, 2008, NEUROSCIENCE, V155, P673, DOI 10.1016/j.neuroscience.2008.06.034; Romeo E, 1998, AM J PSYCHIAT, V155, P910, DOI 10.1176/ajp.155.7.910; Rosario ER, 2006, BRAIN RES, V1099, P206, DOI 10.1016/j.brainres.2006.03.127; Rosario ER, 2011, NEUROBIOL AGING, V32, P604, DOI 10.1016/j.neurobiolaging.2009.04.008; Rose KA, 1997, P NATL ACAD SCI USA, V94, P4925, DOI 10.1073/pnas.94.10.4925; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Safarinejad MR, 2008, J NEUROENDOCRINOL, V20, P1368, DOI 10.1111/j.1365-2826.2008.01791.x; Schule C, 2014, PROG NEUROBIOL, V113, P79, DOI 10.1016/j.pneurobio.2013.09.003; Schumacher M, 2014, PROG NEUROBIOL, V113, P6, DOI 10.1016/j.pneurobio.2013.09.004; Schwendimann RN, 2007, INT REV NEUROBIOL, V79, P377, DOI 10.1016/S0074-7742(07)79017-7; Simonds VA, 2003, J AFFECT DISORDERS, V77, P197, DOI 10.1016/S0165-0327(02)00113-1; Smith CC, 2014, MOL PHARMACOL, V86, P390, DOI 10.1124/mol.114.094128; Tsuji M, 2012, EXP NEUROL, V233, P214, DOI 10.1016/j.expneurol.2011.10.004; Tsutsui K, 2012, CEREBELLUM, V11, P414, DOI 10.1007/s12311-011-0341-7; Uzunova V, 1998, P NATL ACAD SCI USA, V95, P3239, DOI 10.1073/pnas.95.6.3239; VOLKMAR FR, 1993, J AUTISM DEV DISORD, V23, P579, DOI 10.1007/BF01046103; Wei T, 1997, BRAIN, V120, P1067, DOI 10.1093/brain/120.6.1067; Weill-Engerer S, 2002, J CLIN ENDOCR METAB, V87, P5138, DOI 10.1210/jc.2002-020878; Wicher G, 2015, J STEROID BIOCHEM, V145, P21, DOI 10.1016/j.jsbmb.2014.09.022; Yang SH, 2002, J APPL PHYSIOL, V92, P195, DOI 10.1152/jappl.2002.92.1.195; Yang SY, 2014, J STEROID BIOCHEM, V143, P460, DOI 10.1016/j.jsbmb.2014.07.001; Yao J, 2011, BRAIN RES, V1379, P2, DOI 10.1016/j.brainres.2010.11.090; Yue X, 2005, P NATL ACAD SCI USA, V102, P19198, DOI 10.1073/pnas.0505203102; Zorumski CF, 2013, NEUROSCI BIOBEHAV R, V37, P109, DOI 10.1016/j.neubiorev.2012.10.005	141	25	25	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	SEP	2015	153				SI		127	134		10.1016/j.jsbmb.2015.03.002			8	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	CS9AY	WOS:000362382700015	25797031				2022-02-06	
J	Rocchi, L; Niccolini, F; Politis, M				Rocchi, Lorenzo; Niccolini, Flavia; Politis, Marios			Recent imaging advances in neurology	JOURNAL OF NEUROLOGY			English	Article						Magnetic resonance imaging; Positron emission tomography; Movement disorders; Dementia; Epilepsy; Traumatic brain injury; Multiple sclerosis	POSITRON-EMISSION-TOMOGRAPHY; TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; MILD COGNITIVE IMPAIRMENT; AMYLOID-BETA DEPOSITION; SEROTONIN 1A RECEPTORS; RESTING STATE NETWORKS; IN-VIVO DETECTION; FLORBETAPIR F 18; PARKINSONS-DISEASE	Over the recent years, the application of neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) has considerably advanced the understanding of complex neurological disorders. PET is a powerful molecular imaging tool, which investigates the distribution and binding of radiochemicals attached to biologically relevant molecules; as such, this technique is able to give information on biochemistry and metabolism of the brain in health and disease. MRI uses high intensity magnetic fields and radiofrequency pulses to provide structural and functional information on tissues and organs in intact or diseased individuals, including the evaluation of white matter integrity, grey matter thickness and brain perfusion. The aim of this article is to review the most recent advances in neuroimaging research in common neurological disorders such as movement disorders, dementia, epilepsy, traumatic brain injury and multiple sclerosis, and to evaluate their contribution in the diagnosis and management of patients.	[Rocchi, Lorenzo; Niccolini, Flavia; Politis, Marios] Kings Coll London, Dept Basic & Clin Neurosci, Inst Psychiat Psychol & Neurosci IoPPN, Neurodegenerat Imaging Grp, London SE5 8AF, England		Politis, M (corresponding author), Kings Coll London, Dept Basic & Clin Neurosci, Inst Psychiat Psychol & Neurosci IoPPN, Neurodegenerat Imaging Grp, London SE5 8AF, England.	marios.politis@imperial.ac.uk	Rocchi, Lorenzo/K-7983-2016	Rocchi, Lorenzo/0000-0003-3979-156X	Parkinson&apos;s UKParkinson&apos;s UK [G-1303] Funding Source: Medline; Parkinson&quot;s UKParkinson&apos;s UK [G-1303] Funding Source: researchfish		Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abela E, 2014, CLIN NEURORADIOL, V24, P5, DOI 10.1007/s00062-014-0284-8; Adlard PA, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00327; Agosta F, 2014, HUM BRAIN MAPP, V35, P1921, DOI 10.1002/hbm.22302; Baudrexel S, 2014, MOVEMENT DISORD, V29, P380, DOI 10.1002/mds.25749; Beach TG, 2014, J NEUROPATH EXP NEUR, V73, P948, DOI 10.1097/NEN.0000000000000114; Benzinger TLS, 2013, P NATL ACAD SCI USA, V110, pE4502, DOI 10.1073/pnas.1317918110; Berg D, 2008, LANCET NEUROL, V7, P1044, DOI 10.1016/S1474-4422(08)70239-4; Bertholdo D, 2013, NEUROIMAG CLIN N AM, V23, P359, DOI 10.1016/j.nic.2012.10.002; Binnewijzend MAA, 2014, EUR RADIOL, V24, P2326, DOI 10.1007/s00330-014-3172-3; Bohnen NI, 2014, MOVEMENT DISORD, V29, P1118, DOI 10.1002/mds.25929; Bohnen NI, 2013, NEUROLOGY, V81, P1611, DOI 10.1212/WNL.0b013e3182a9f558; Bohnen NI, 2013, MOVEMENT DISORD, V28, P1492, DOI 10.1002/mds.25534; Bouwmans AEP, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002613; Bunzeck N, 2013, PARKINSONISM RELAT D, V19, P1136, DOI 10.1016/j.parkreldis.2013.08.011; Butler T, 2013, J NEUROIMAGING, V23, P129, DOI 10.1111/j.1552-6569.2010.00572.x; Cataldi M, 2013, EPILEPSIA, V54, P2048, DOI 10.1111/epi.12400; Chen S, 2014, EUR J RADIOL, V83, P564, DOI 10.1016/j.ejrad.2013.11.024; Chen SH, 2012, NEUROIMAGE, V60, P299, DOI 10.1016/j.neuroimage.2011.11.092; Cherubini A, 2014, MOVEMENT DISORD, V29, P266, DOI 10.1002/mds.25737; Chhatwal JP, 2012, J ALZHEIMERS DIS, V31, pS155, DOI 10.3233/JAD-2012-120730; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Cho H, 2013, J ALZHEIMERS DIS, V35, P813, DOI 10.3233/JAD-121927; Choi IY, 2011, MULT SCLER J, V17, P289, DOI 10.1177/1352458510384010; Chugani HT, 2013, NEUROLOGY, V81, P674, DOI 10.1212/WNL.0b013e3182a08f3f; Colasanti A, 2014, J NUCL MED, V55, P1112, DOI 10.2967/jnumed.113.135129; Deng BM, 2013, AM J ALZHEIMERS DIS, V28, P154, DOI 10.1177/1533317512470207; Deoni SCL, 2008, J MAGN RESON IMAGING, V27, P1421, DOI 10.1002/jmri.21079; Deoni SCL, 2007, J MAGN RESON IMAGING, V25, P570, DOI 10.1002/jmri.20836; Di Paola M, 2014, HUM BRAIN MAPP, V35, P3143, DOI 10.1002/hbm.22391; Dominguez JF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074131; Doraiswamy PM, 2014, MOL PSYCHIATR, V19, P1044, DOI 10.1038/mp.2014.9; Dukart J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018111; Edison P, 2013, NEUROPSYCHOPHARMACOL, V38, P938, DOI 10.1038/npp.2012.255; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Fan Z, 2015, ALZHEIMERS DEMENT, V11, P608, DOI 10.1016/j.jalz.2014.06.016; Filippi M, 2013, MULT SCLER J, V19, P418, DOI 10.1177/1352458512457842; Fleisher AS, 2012, LANCET NEUROL, V11, P1057, DOI 10.1016/S1474-4422(12)70227-2; Fling BW, 2013, BRAIN, V136, P2405, DOI 10.1093/brain/awt172; Fozouni N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076343; Gaenslen A, 2008, LANCET NEUROL, V7, P417, DOI 10.1016/S1474-4422(08)70067-X; Georgiou-Karistianis N, 2013, BRAIN COGNITION, V83, P80, DOI 10.1016/j.bandc.2013.07.004; Giannetti P, 2015, BRAIN, V138, P110, DOI 10.1093/brain/awu331; Giannetti P, 2014, NEUROBIOL DIS, V65, P203, DOI 10.1016/j.nbd.2014.01.018; Gomperts SN, 2013, NEUROLOGY, V80, P85, DOI 10.1212/WNL.0b013e31827b1a07; Hanganu A, 2014, BRAIN, V137, P1120, DOI 10.1093/brain/awu036; Hara K, 2014, PARKINSONISM RELAT D, V20, P157, DOI 10.1016/j.parkreldis.2013.10.007; Hardy J, 2006, ALZHEIMER'S DISEASE: A CENTURY OF SCIENTIFIC AND CLINICAL RESEARCH, P151; Harrison DM, 2013, J NEUROL, V260, P397, DOI 10.1007/s00415-012-6638-8; Hatashita S, 2014, EUR J NUCL MED MOL I, V41, P290, DOI 10.1007/s00259-013-2564-y; Hellwig S, 2012, NEUROLOGY, V79, P1314, DOI 10.1212/WNL.0b013e31826c1b0a; Herz DM, 2014, ANN NEUROL, V75, P829, DOI 10.1002/ana.24138; Hong JY, 2014, PARKINSONISM RELAT D, V20, P999, DOI 10.1016/j.parkreldis.2014.06.011; Hong JY, 2014, NEUROLOGY, V82, P1597, DOI 10.1212/WNL.0000000000000385; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Hsiao IT, 2014, JAMA NEUROL, V71, P758, DOI 10.1001/jamaneurol.2014.290; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Iraji A, 2015, J NEUROTRAUM, V32, P1031, DOI 10.1089/neu.2014.3610; Jack CR, 2014, NEUROLOGY, V82, P1605, DOI 10.1212/WNL.0000000000000386; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Josephs KA, 2008, ANN NEUROL, V64, P4, DOI 10.1002/ana.21426; Kandiah N, 2014, PARKINSONISM RELAT D, V20, P1203, DOI 10.1016/j.parkreldis.2014.08.024; Kawai N, 2013, BRAIN INJURY, V27, P1026, DOI 10.3109/02699052.2013.794963; Kearney H, 2014, MULT SCLER J, V20, P72, DOI 10.1177/1352458513492245; Kiferle L, 2011, EUR J NEUROL, V18, P226, DOI 10.1111/j.1468-1331.2010.03154.x; Kitzler HH, 2012, NEUROIMAGE, V59, P2670, DOI 10.1016/j.neuroimage.2011.08.052; Klawiter Eric C, 2013, Continuum (Minneap Minn), V19, P1058, DOI 10.1212/01.CON.0000433283.00221.37; Kung HF, 2010, J MED CHEM, V53, P933, DOI 10.1021/jm901039z; Lenfeldt N, 2013, J NEUROL, V260, P2823, DOI 10.1007/s00415-013-7080-2; Lim YY, 2014, BRAIN, V137, P221, DOI 10.1093/brain/awt286; Lin SC, 2014, J NUCL MED, V55, P73, DOI 10.2967/jnumed.113.121897; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Lipp A, 2013, NEUROIMAGE-CLIN, V3, P381, DOI 10.1016/j.nicl.2013.09.006; Liu P, 2014, NEUROSCI LETT, V582, P99, DOI 10.1016/j.neulet.2014.08.053; Llufriu S, 2014, JAMA NEUROL, V71, P840, DOI 10.1001/jamaneurol.2014.895; Loane C, 2013, NEUROLOGY, V80, P1850, DOI 10.1212/WNL.0b013e318292a31d; Loane C, 2011, AM J TRANSL RES, V3, P323; Londono AC, 2014, NEUROL-NEUROIMMUNOL, V1, DOI 10.1212/NXI.0000000000000045; Luo J, 2014, MULT SCLER J, V20, P349, DOI 10.1177/1352458513495935; Mak E, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt248; Malkki H, 2014, NAT REV NEUROL, V10, P243, DOI [10.1038/nrneurol.2014.63, 10.1038/nrneurol.2014.209, 10.1038/nrneurol.2013.267, 10.1038/nrneurol.2014.61, 10.1038/nrneurol.2014.21, 10.1038/nrneurol.2013.250, 10.1038/nrneurol.2014.142, 10.1038/nrneurol.2014.168]; Martinez A, 2013, NEUROLOGY, V80, P1465, DOI 10.1212/WNL.0b013e31828cf809; Maruyama M, 2013, NEURON, V79, P1094, DOI 10.1016/j.neuron.2013.07.037; Matsuura K, 2013, EUR NEUROL, V70, P70, DOI 10.1159/000350291; Mattsson N, 2014, BRAIN, V137, P1550, DOI 10.1093/brain/awu043; McConathy J, 2015, BIOL PSYCHIAT, V77, P685, DOI 10.1016/j.biopsych.2014.08.024; McKeith IG, 2006, J ALZHEIMERS DIS, V9, P417, DOI 10.1212/wnl.47.5.1113; Mishra AK, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0086852, 10.1371/journal.pone.0095280]; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Morales DA, 2013, PSYCHIAT RES-NEUROIM, V213, P92, DOI 10.1016/j.pscychresns.2012.06.001; Moshe SL, 2015, LANCET, V385, P884, DOI 10.1016/S0140-6736(14)60456-6; Muller MLTM, 2013, MOVEMENT DISORD, V28, P296, DOI 10.1002/mds.25213; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Niccolini F, 2014, EUR J NEUROL, V21, P694, DOI 10.1111/ene.12362; Niccolini F, 2014, J NEUROL, V261, P2251, DOI 10.1007/s00415-014-7302-2; Niccolini F, 2014, WORLD J RADIOL, V6, P301, DOI 10.4329/wjr.v6.i6.301; Niethammer M, 2013, NEUROIMAGE, V78, P204, DOI 10.1016/j.neuroimage.2013.03.070; O'Sullivan SS, 2011, BRAIN, V134, P969, DOI 10.1093/brain/awr003; Ogisu K, 2013, NEURORADIOLOGY, V55, P719, DOI 10.1007/s00234-013-1171-8; Oh U, 2011, J NEUROIMMUNE PHARM, V6, P354, DOI 10.1007/s11481-010-9243-6; Ohtsuka C, 2014, PARKINSONISM RELAT D, V20, P755, DOI 10.1016/j.parkreldis.2014.04.005; Okamura N, 2014, BRAIN, V137, P1762, DOI 10.1093/brain/awu064; Ong KT, 2015, J NEUROL NEUROSUR PS, V86, P431, DOI 10.1136/jnnp-2014-308094; Pagonabarraga J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054980; Pereira JB, 2014, NEUROLOGY, V82, P2017, DOI [10.1212/WNL.0000000000000483, 10.1212/01.wnl.0000457455.74798.9a]; Petrou M, 2012, NEUROLOGY, V79, P1161, DOI 10.1212/WNL.0b013e3182698d4a; Politis M, 2010, NEUROLOGY, V75, P1920, DOI 10.1212/WNL.0b013e3181feb2ab; Politis M, 2014, NAT REV NEUROL, V10, P708, DOI 10.1038/nrneurol.2014.205; Politis M, 2014, J CLIN INVEST, V124, P1340, DOI 10.1172/JCI71640; Politis M, 2013, BRAIN, V136, P400, DOI 10.1093/brain/aws326; Politis M, 2012, J NEUROL, V259, P1769, DOI 10.1007/s00415-012-6428-3; Politis M, 2012, NEUROLOGY, V79, P523, DOI 10.1212/WNL.0b013e3182635645; Politis M, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00096; Politis M, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003391; Politis M, 2011, THESCIENTIFICWORLDJO, V11, P1726, DOI 10.1100/2011/172893; Politis M, 2011, MOVEMENT DISORD, V26, P1997, DOI 10.1002/mds.23743; Politis M, 2011, NEUROBIOL DIS, V43, P609, DOI 10.1016/j.nbd.2011.05.009; Politis M, 2011, HUM BRAIN MAPP, V32, P258, DOI 10.1002/hbm.21008; Politis M, 2010, NEUROBIOL DIS, V40, P216, DOI 10.1016/j.nbd.2010.05.028; Politis M, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000976; Polotis M, 2015, BEHAV BRAIN RES, V277, P136, DOI 10.1016/j.bbr.2014.07.037; Poudel GR, 2014, J PSYCHIATR NEUROSCI, V39, P87, DOI 10.1503/jpn.120226; Prestia A, 2013, NEUROLOGY, V80, P1048, DOI 10.1212/WNL.0b013e3182872830; Prodoehl J, 2013, MOVEMENT DISORD, V28, P1816, DOI 10.1002/mds.25491; Putcha D, 2011, J NEUROSCI, V31, P17680, DOI 10.1523/JNEUROSCI.4740-11.2011; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ratchford JN, 2012, J NEUROL, V259, P1199, DOI 10.1007/s00415-011-6337-x; Rissanen E, 2014, J NUCL MED, V55, P939, DOI 10.2967/jnumed.113.131698; Rovira A, 2013, NEUROIMAG CLIN N AM, V23, P459, DOI 10.1016/j.nic.2013.03.005; Salvatore C, 2014, J NEUROSCI METH, V222, P230, DOI 10.1016/j.jneumeth.2013.11.016; Sanchez-Castaneda C, 2015, HUM BRAIN MAPP, V36, P50, DOI 10.1002/hbm.22612; Sanzaro E, 2014, J ULTRAS MED, V33, P1635, DOI 10.7863/ultra.33.9.1635; Sbardella E, 2013, MULT SCLER INT, V2013, DOI 10.1155/2013/671730; Scherfler C, 2013, BRAIN, V136, P3028, DOI 10.1093/brain/awt234; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sheline YI, 2013, BIOL PSYCHIAT, V74, P340, DOI 10.1016/j.biopsych.2012.11.028; Shine JM, 2013, BRAIN, V136, P3671, DOI 10.1093/brain/awt272; Siderowf A, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-79; Stankoff B, 2011, ANN NEUROL, V69, P673, DOI 10.1002/ana.22320; Stocchetti N, 2014, LANCET NEUROL, V13, P14, DOI 10.1016/S1474-4422(13)70280-1; Storti SF, 2014, NEUROIMAGE, V102, P49, DOI 10.1016/j.neuroimage.2013.06.028; Stromillo ML, 2013, NEUROLOGY, V80, P2090, DOI 10.1212/WNL.0b013e318295d707; Tabrizi SJ, 2013, LANCET NEUROL, V12, P637, DOI 10.1016/S1474-4422(13)70088-7; Takano A, 2013, EJNMMI RES, V3, DOI 10.1186/2191-219X-3-30; Tang CC, 2013, J CLIN INVEST, V123, P4076, DOI 10.1172/JCI69411; Teipel S, 2014, NEUROBIOL AGING, V35, P482, DOI 10.1016/j.neurobiolaging.2013.09.029; Temel S, 2013, NEURORADIOL J, V26, P3; Teune LK, 2014, NEUROIMAGE-CLIN, V5, P240, DOI 10.1016/j.nicl.2014.06.007; Theodore WH, 2012, J NUCL MED, V53, P1375, DOI 10.2967/jnumed.112.103093; Theodore WH, 2012, EPILEPSIA, V53, P129, DOI 10.1111/j.1528-1167.2011.03309.x; Tiwari VN, 2012, J CHILD NEUROL, V27, P598, DOI 10.1177/0883073811422751; Toledo JB, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-26; Ulla M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057904; Unschuld PG, 2012, NEUROSCI LETT, V514, P204, DOI 10.1016/j.neulet.2012.02.095; Villemagne VL, 2011, J NUCL MED, V52, P1210, DOI 10.2967/jnumed.111.089730; Vivash L, 2013, J NUCL MED, V54, P1270, DOI 10.2967/jnumed.112.107359; Winter Y, 2011, PARKINSONISM RELAT D, V17, P265, DOI 10.1016/j.parkreldis.2011.01.003; Wintermark P, 2013, J CHILD NEUROL, V28, P1474, DOI 10.1177/0883073813488666; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zarei M, 2013, J NEUROL NEUROSUR PS, V84, P875, DOI 10.1136/jnnp-2012-304126; Ziegler E, 2014, NEUROIMAGE, V99, P498, DOI 10.1016/j.neuroimage.2014.06.033	162	25	25	1	25	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	SEP	2015	262	9					2182	2194		10.1007/s00415-015-7711-x			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CT7ZV	WOS:000363035400023	25808503				2022-02-06	
J	Sanchez-Vallejo, V; Benlloch-Navarro, S; Lopez-Pedrajas, R; Romero, FJ; Miranda, M				Sanchez-Vallejo, V.; Benlloch-Navarro, S.; Lopez-Pedrajas, R.; Romero, F. J.; Miranda, M.			Neuroprotective actions of progesterone in an in vivo model of retinitis pigmentosa	PHARMACOLOGICAL RESEARCH			English	Article						Progesterone; Retinitis pigmentosa; Gliosis; Glutamate; Glutathione	TRAUMATIC BRAIN-INJURY; CONE CELL-DEATH; CILIARY NEUROTROPHIC FACTOR; OXIDATIVE STRESS; RETINAL-DEGENERATION; INDUCED APOPTOSIS; GENE-EXPRESSION; MOUSE MODEL; PROTECTS; PHOTORECEPTORS	Progesterone has been shown to have neuroprotective effects in experimental acute brain injury models, but little is known about the effects of steroid sex hormones in models of retinitis pigmentosa (RP). The aim of this study was to asses whether progesterone had a protective effect in one animal model of RP (the rd1 mice), and whether its action was due at least in part, to its ability to reduce free radical damage or to increase antioxidant defences. Rd1 and wild type (wt) mice received an oral administration of 100 mg/kg body/weight of progesterone on alternate days starting at postnatal day 7 (PN7) and were sacrificed at different postnatal days. Our results show that progesterone decreases cell death, as the number of TUNEL-positive cells were decreased in the ONL of the retina from treated rd1 mice. At PN15, treatment with progesterone increased values of ERG b-wave amplitude (p < 0,5) when compared with untreated mice. Progesterone also decreased the observed gliosis in RP, though this effect was transient. Treatment with progesterone significantly reduced retinal glutamate concentrations at PN15 and PN17. To clarify the mechanism by which progesterone is able to decrease retinal glutamate concentration, we examined expression levels of glutamine synthase (GS). Our results showed a significant increase in GS in rd1 treated retinas at PN13. Treatment with progesterone, significantly increase not only GSH but also oxidized glutathione retinal concentrations, probably because progesterone is able to partially increase glutamate cysteine ligase c subunit (GCLC) at PN15 and PN17 (p < 0,05). In summary, our results demonstrate that oral administration of progesterone appears to act on multiple levels to delay photoreceptor death in this model of RP. (C) 2015 Elsevier Ltd. All rights reserved.	[Sanchez-Vallejo, V.; Benlloch-Navarro, S.; Lopez-Pedrajas, R.; Miranda, M.] Univ CEU Cardenal Herrera, Dept Ciencias Biomed, Inst Ciencias Biomed, Valencia 46113, Spain; [Romero, F. J.] Univ Catolica Valencia San Vicente Martir, Fac Med, Valencia, Spain		Miranda, M (corresponding author), Univ CEU Cardenal Herrera, Dept Ciencias Biomed, Inst Ciencias Biomed, Avda Seminario S-N, Valencia 46113, Spain.	mmiranda@uch.ceu.es	Lopez-Pedrajas, Rosa/L-2734-2014; Miranda, Maria/ABG-5343-2020; Miranda, Maria/L-3471-2014; Benlloch-Navarro, Soledad/K-8255-2014	Lopez-Pedrajas, Rosa/0000-0003-4845-6544; Miranda, Maria/0000-0002-3738-367X; Miranda, Maria/0000-0002-3738-367X; Benlloch-Navarro, Soledad/0000-0001-5748-0082; Romero, Francisco J/0000-0001-8701-5907	Ministerio de Ciencia e InnovacionInstituto de Salud Carlos IIISpanish GovernmentEuropean Commission [SAF 2010-21317]; Fundacion Mutua Madrilena, Proyecto de Investigacion Preconsolidado CEU-UCH [PRCEU-UCH 16/12]; Consolidacion de Indicadores CEU-UCH	This work was partially supported by grants from Ministerio de Ciencia e Innovacion (SAF 2010-21317) to FJR, and Fundacion Mutua Madrilena, Proyecto de Investigacion Preconsolidado CEU-UCH (PRCEU-UCH 16/12) and Consolidacion de Indicadores CEU-UCH 2014-2015 to MM.	Aggarwal R, 2008, J PHARM PHARMACOL, V60, P731, DOI 10.1211/jpp.60.6.0008; Arroba AI, 2014, ADV EXP MED BIOL, V801, P373, DOI 10.1007/978-1-4614-3209-8_47; Bok D, 2002, EXP EYE RES, V74, P719, DOI 10.1006/exer.2002.1176; Cayouette M, 1998, J NEUROSCI, V18, P9282; Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418; Corrochano S, 2008, INVEST OPHTH VIS SCI, V49, P4188, DOI 10.1167/iovs.08-2182; Crupi R, 2013, PHARMACOL RES, V70, P80, DOI 10.1016/j.phrs.2012.12.009; Dalkara D, 2014, CR BIOL, V337, P185, DOI 10.1016/j.crvi.2014.01.002; Delyfer MN, 2005, MOL VIS, V11, P688; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Doonan F, 2011, J NEUROCHEM, V118, P915, DOI 10.1111/j.1471-4159.2011.07354.x; FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554; Fletcher EL, 1996, J COMP NEUROL, V376, P343; Fletcher EL, 2000, MICROSC RES TECHNIQ, V50, P89, DOI 10.1002/1097-0029(20000715)50:2<89::AID-JEMT1>3.0.CO;2-9; Ghosh F, 2012, CURR EYE RES, V37, P704, DOI 10.3109/02713683.2012.663856; Gorovits R, 1997, P NATL ACAD SCI USA, V94, P7024, DOI 10.1073/pnas.94.13.7024; Gouix E, 2014, PHARMACOL RES, V87, P8, DOI 10.1016/j.phrs.2014.06.002; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gu LM, 2014, INVEST OPHTH VIS SCI, V55, P8208, DOI 10.1167/iovs.14-14435; Guarneri P, 2003, ANN NY ACAD SCI, V1007, P117, DOI 10.1196/annals.1286.012; Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; He YX, 2015, CURR STEM CELL RES T, V10, P258, DOI 10.2174/1574888X09666141027103552; HERRMANN H, 1945, J BIOL CHEM, V158, P33; Hoang YD, 2009, BIOL REPROD, V81, P636, DOI 10.1095/biolreprod.109.078378; Hwang JY, 2009, CELL CALCIUM, V45, P233, DOI 10.1016/j.ceca.2008.10.006; Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144; Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949; Kaldi I, 2004, EUR J OPHTHALMOL, V14, P306, DOI 10.5301/EJO.2008.1363; Kalloniatis M, 1999, PROG RETIN EYE RES, V18, P811, DOI 10.1016/S1350-9462(98)00036-6; Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004; Kaur P, 2007, J NEUROSCI RES, V85, P2441, DOI 10.1002/jnr.21370; Kennan A, 2005, TRENDS GENET, V21, P103, DOI 10.1016/j.tig.2004.12.001; Kern TS, 2014, DIABETES METAB J, V38, P163, DOI 10.4093/dmj.2014.38.3.163; Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152; Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103; Kumar DM, 2005, FREE RADICAL BIO MED, V38, P1152, DOI 10.1016/j.freeradbiomed.2004.12.007; Lei BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103969; Li C, 2006, GLIA, V53, P392, DOI 10.1002/glia.20291; Liu M, 2010, MINERVA ENDOCRINOL, V35, P127; Liu S, 2013, NEURAL REGEN RES, V8, P2800, DOI 10.3969/j.issn.1673-5374.2013.30.002; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu Na, 2008, Nan Fang Yi Ke Da Xue Xue Bao, V28, P2026; Mancini M, 2014, PHARMACOL RES, V87, P80, DOI 10.1016/j.phrs.2014.06.010; Martin KR, 2015, CURR OPIN OPHTHALMOL, P26; Meyer M, 2010, CELL MOL NEUROBIOL, V30, P123, DOI 10.1007/s10571-009-9437-8; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; Miranda M, 2010, FREE RADICAL BIO MED, V48, P216, DOI 10.1016/j.freeradbiomed.2009.10.042; Miyamoto N, 1999, J IMMUNOL, V163, P374; Nakazawa T, 2006, BRAIN RES, V1093, P141, DOI 10.1016/j.brainres.2006.03.084; Nilsen J, 2002, NEUROREPORT, V13, P825, DOI 10.1097/00001756-200205070-00018; Nixon E, 2012, INVEST OPHTH VIS SCI, V53, P4739, DOI 10.1167/iovs.12-9517; Ola MS, 2011, NEUROCHEM INT, V59, P656, DOI 10.1016/j.neuint.2011.06.010; OSTEEN WK, 1977, EXP EYE RES, V25, P361, DOI 10.1016/0014-4835(77)90103-8; Paquet-Durand F, 2006, J NEUROCHEM, V96, P802, DOI 10.1111/j.1471-4159.2005.03628.x; Paquet-Durand F, 2009, J NEUROCHEM, V108, P796, DOI 10.1111/j.1471-4159.2008.05822.x; PERRY TL, 1982, NEUROSCI LETT, V33, P305, DOI 10.1016/0304-3940(82)90390-1; Petersen SL, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00164; POW DV, 1995, NEUROSCI LETT, V193, P25, DOI 10.1016/0304-3940(95)11657-I; Pulido JE, 2007, EXP DIABETES RES, DOI 10.1155/2007/36150; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Rex TS, 2004, MOL THER, V10, P855, DOI 10.1016/j.ymthe.2004.07.027; Robertson CL, 2015, J BIOENERG BIOMEMBR, V47, P43, DOI 10.1007/s10863-014-9585-5; Roesch Karin, 2012, Mol Vis, V18, P1197; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221; Sanvicens N, 2006, J NEUROCHEM, V98, P1432, DOI 10.1111/j.1471-4159.2006.03977.x; Sanz MM, 2007, NEUROSCIENCE, V145, P1120, DOI 10.1016/j.neuroscience.2006.12.034; Schutte M, 1998, NEUROSCI LETT, V246, P53, DOI 10.1016/S0304-3940(98)00229-8; Shen JK, 2005, J CELL PHYSIOL, V203, P457, DOI 10.1002/jcp.20346; Singh M, 2013, HORM BEHAV, V63, P284, DOI 10.1016/j.yhbeh.2012.06.003; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Sotic E., 1992, NEUROSCI LETT, V142, P128; Stein DG, 2008, BRAIN RES REV, V57, P386, DOI 10.1016/j.brainresrev.2007.06.012; ULSHAFER RJ, 1990, BRAIN RES, V531, P350, DOI 10.1016/0006-8993(90)90800-Q; Usui S, 2009, MOL THER, V17, P778, DOI 10.1038/mt.2009.47; Verdier L, 2002, AM J PHYSIOL-ENDOC M, V282, pE215, DOI 10.1152/ajpendo.00117.2001; Wang YQ, 2015, GRAEF ARCH CLIN EXP, V253, P17, DOI 10.1007/s00417-014-2657-8; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xu FF, 2014, BRAIN INJURY, V28, P1594, DOI 10.3109/02699052.2014.943289; Yang HP, 2005, MOL CELL BIOL, V25, P5933, DOI 10.1128/MCB.25.14.5933-5946.2005; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yu DY, 2000, INVEST OPHTH VIS SCI, V41, P3999	84	25	25	0	5	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-6618			PHARMACOL RES	Pharmacol. Res.	SEP	2015	99						276	288		10.1016/j.phrs.2015.06.019			13	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	CR8DA	WOS:000361580100030	26158501				2022-02-06	
J	Slowik, A; Beyer, C				Slowik, Alexander; Beyer, Cordian			Inflammasomes are neuroprotective targets for sex steroids	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						Microglia; Astroglia; Estrogen; Progesterone; Neuroinflammation; Inflammasome	ESTROGEN-REGULATED MICRORNAS; TRAUMATIC BRAIN-INJURY; INNATE IMMUNE-RESPONSE; NLRP3 INFLAMMASOME; MOLECULAR PLATFORM; CEREBRAL-CORTEX; ACUTE STROKE; CELL-DEATH; PROGESTERONE; ACTIVATION	Neuroinflammation in the central nervous system is triggered by toxic stimuli or degenerative events, orchestrates the interplay of brain-intrinsic immune cells and neighboring neural cells, and sequentially allows leukocyte extravasation from the periphery into the brain parenchyma. During the inflammatory cascade, immune-competent cells become activated and secrete a plethora of cytokines and chemokines which form a local inflammatory signaling network important for warding off harmful stimuli to the host but are likewise necessary to preserve damaged brain tissue. Inflammatory responses are initiated by extra-and intra-cellular pathogen and danger-associated receptors. These signals are processed by multiprotein complexes termed inflammasomes which trigger the production of biologically active interleukins-1 and 18 after the cleavage of caspase-1. Estrogens and progesterone are neuroprotective and anti-inflammatory in diverse disease models of the brain in particular under acute inflammatory conditions such as stroke and traumatic brain injury. Both steroids are able to attenuate proinflammatory cytokine activity. Recent literature and our own studies provide convincing evidence that the anti-inflammatory potency of these steroids result from a complex interaction with the inflammasome activation and their up-stream regulatory network of miRNAs in brain-intrinsic innate immune cells. This article examines steroid-inflammasome interactions in the brain during brain injury and illuminates the importance of regulation initial upstream events during neuroinflammation. This article is part of a Special Issue entitled 'Steroid Perspectives'. (C) 2015 Elsevier Ltd. All rights reserved.	[Slowik, Alexander; Beyer, Cordian] Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, D-52074 Aachen, Germany		Beyer, C (corresponding author), Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, D-52074 Aachen, Germany.	cbeyer@ukaachen.de		Dr. Slowik, Alexander/0000-0001-9907-2263	Medical Faculty of the RWTH Aachen	We would like to acknowledge Leoni Lammerding and Adib Zendedel for their scientific contributions to this topic in our lab. This work was supported by a START grant (AS) from the Medical Faculty of the RWTH Aachen.	Abais J.M., 2014, ANTIOXID REDOX SIGNA; Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Alcocer-Gomez E, 2014, BRAIN BEHAV IMMUN, V36, P111, DOI 10.1016/j.bbi.2013.10.017; Arevalo MA, 2013, HORM BEHAV, V63, P216, DOI 10.1016/j.yhbeh.2012.02.021; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bauernfeind F, 2012, J IMMUNOL, V189, P4175, DOI 10.4049/jimmunol.1201516; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Bordet R, 2000, J CEREBR BLOOD F MET, V20, P1190, DOI 10.1097/00004647-200008000-00004; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; Busillo JM, 2011, J BIOL CHEM, V286, P38703, DOI 10.1074/jbc.M111.275370; Chakraborty S, 2010, J NEUROSCI RES, V88, P1615, DOI 10.1002/jnr.22343; Cochrane DR, 2012, MOL CELL ENDOCRINOL, V357, P50, DOI 10.1016/j.mce.2011.09.022; Codolo G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055375; Cunningham M, 2011, CLIN REV ALLERG IMMU, V40, P66, DOI 10.1007/s12016-010-8203-5; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Dai R, 2011, TRANSL RES, V157, P163, DOI 10.1016/j.trsl.2011.01.007; Dai RJ, 2008, BLOOD, V112, P4591, DOI 10.1182/blood-2008-04-152488; Dang J, 2011, BRAIN BEHAV IMMUN, V25, P715, DOI 10.1016/j.bbi.2011.01.013; De Bosscher K, 2010, BRAIN BEHAV IMMUN, V24, P1035, DOI 10.1016/j.bbi.2010.06.010; De Nicola AF, 2013, J NEUROENDOCRINOL, V25, P1095, DOI 10.1111/jne.12043; Duffy BA, 2014, NEUROBIOL DIS, V63, P229, DOI 10.1016/j.nbd.2013.12.001; Elkabes S, 2014, EXP NEUROL, V259, P28, DOI 10.1016/j.expneurol.2014.01.008; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326; Fann DYW, 2014, EXP NEUROL, V257, P114, DOI 10.1016/j.expneurol.2014.04.017; Fann DYW, 2013, AGEING RES REV, V12, P941, DOI 10.1016/j.arr.2013.09.004; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Finger JN, 2012, J BIOL CHEM, V287, P25030, DOI 10.1074/jbc.M112.378323; Finlay-Schultz J, 2014, ONCOGENE, P0; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Frohman EM, 2006, NEW ENGL J MED, V354, P942, DOI 10.1056/NEJMra052130; Giannoni E, 2011, INFECT IMMUN, V79, P2690, DOI 10.1128/IAI.00076-11; Gotte M, 2010, Minerva Ginecol, V62, P559; Grimm A, 2014, BBA-MOL BASIS DIS, V1842, P2427, DOI 10.1016/j.bbadis.2014.09.013; Habib P, 2015, J STEROID BIOCHEM, V146, P3, DOI 10.1016/j.jsbmb.2014.02.018; Habib P, 2014, NEUROENDOCRINOLOGY, V99, P156, DOI 10.1159/000362279; Habib P, 2013, J STEROID BIOCHEM, V138, P195, DOI 10.1016/j.jsbmb.2013.06.003; Han SJ, 2014, HUM REPROD UPDATE, V20, P467, DOI 10.1093/humupd/dmu002; Hanamsagar R, 2011, J NEUROCHEM, V119, P736, DOI 10.1111/j.1471-4159.2011.07481.x; Haneklaus M, 2013, CURR OPIN IMMUNOL, V25, P40, DOI 10.1016/j.coi.2012.12.004; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Hirsch Etienne C, 2012, Parkinsonism Relat Disord, V18 Suppl 1, pS210, DOI 10.1016/S1353-8020(11)70065-7; Hoffmann S., 2014, J MOL NEUROSCI; Horvath GL, 2011, IMMUNOL REV, V243, P119, DOI 10.1111/j.1600-065X.2011.01050.x; Hsu LC, 2008, P NATL ACAD SCI USA, V105, P7803, DOI 10.1073/pnas.0802726105; Hughes GC, 2012, AUTOIMMUN REV, V11, pA502, DOI 10.1016/j.autrev.2011.12.003; Iliopoulos D, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005053; Jamilloux Y, 2013, GLIA, V61, P539, DOI 10.1002/glia.22454; Jia SJ, 2014, DISCOV MED, V18, P237; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Kangas R, 2014, MECH AGEING DEV, V143, P1, DOI 10.1016/j.mad.2014.11.001; Kipp M, 2012, J NEUROENDOCRINOL, V24, P62, DOI 10.1111/j.1365-2826.2011.02163.x; Kodahl AR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101950; KOEHLER PJ, 1995, ANTI-CANCER DRUG, V6, P19, DOI 10.1097/00001813-199502000-00002; Kofoed EM, 2011, NATURE, V477, P592, DOI 10.1038/nature10394; Kovats S, 2012, HORM BEHAV, V62, P254, DOI 10.1016/j.yhbeh.2012.04.011; Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452; Lippai D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070945; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Martin BN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5977; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Miao EA, 2011, IMMUNOL REV, V243, P206, DOI 10.1111/j.1600-065X.2011.01044.x; Rubio-Perez JM, 2012, SCI WORLD J, DOI 10.1100/2012/756357; Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499; Moller T, 2010, J NEURAL TRANSM, V117, P1001, DOI 10.1007/s00702-010-0430-7; Momeni M, 2013, IRAN J IMMUNOL, V10, P103, DOI IJIv10i2A5; Munding C, 2006, CELL DEATH DIFFER, V13, P1938, DOI 10.1038/sj.cdd.4401896; Munoz-Cruz S, 2011, CURR TOP MED CHEM, V11, P1714; Nalbandian G, 2005, IMMUNOL RES, V31, P91, DOI 10.1385/IR:31:2:091; Nallamshetty S, 2013, FREE RADICAL BIO MED, V64, P20, DOI 10.1016/j.freeradbiomed.2013.05.022; Nishi Y, 2013, KIDNEY INT, V83, P662, DOI 10.1038/ki.2012.475; Ownby RL, 2010, CURR PSYCHIAT REP, V12, P39, DOI 10.1007/s11920-009-0082-1; Panchanathan R, 2011, MOL IMMUNOL, V49, P273, DOI 10.1016/j.molimm.2011.08.022; Peng H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030344; Pimplikar SW, 2014, J CLIN IMMUNOL, V34, pS64, DOI 10.1007/s10875-014-0032-5; Rao P, 2013, FRONT MOL NEUROSCI, V6, DOI 10.3389/fnmol.2013.00039; Rathinam VAK, 2010, NAT IMMUNOL, V11, P395, DOI 10.1038/ni.1864; Rege Shraddha D, 2013, ISRN Neurol, V2013, P375852, DOI 10.1155/2013/375852; Ritzel RM, 2013, HORM BEHAV, V63, P238, DOI 10.1016/j.yhbeh.2012.04.007; Savage CD, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00288; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schroder K, 2012, IMMUNOBIOLOGY, V217, P1325, DOI 10.1016/j.imbio.2012.07.020; Selvamani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032662; Shi L, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-93; Shichita T, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00319; Siegel C, 2011, P NATL ACAD SCI USA, V108, P11662, DOI 10.1073/pnas.1102635108; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Skaper SD, 2014, CNS NEUROL DISORD-DR, V13, P1654; Spence RD, 2013, J NEUROSCI, V33, P10924, DOI 10.1523/JNEUROSCI.0886-13.2013; Stutz A, 2009, J CLIN INVEST, V119, P3502, DOI 10.1172/JCI40599; Su L, 2009, IMMUNOL LETT, V125, P151, DOI 10.1016/j.imlet.2009.07.003; Sun YX, 2012, IMMUNOL LETT, V146, P25, DOI 10.1016/j.imlet.2012.04.007; Tan MS, 2013, MOL NEUROBIOL, V48, P875, DOI 10.1007/s12035-013-8475-x; Toms D, 2015, MOL CELL ENDOCRINOL, V399, P95, DOI 10.1016/j.mce.2014.07.022; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Trendelenburg G, 2014, J CEREBR BLOOD F MET, V34, P1857, DOI 10.1038/jcbfm.2014.159; Ulbrich C, 2012, J STEROID BIOCHEM, V131, P10, DOI 10.1016/j.jsbmb.2012.01.007; Unlu S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038899; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Verway M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003407; Walker AK, 2014, PHARMACOL REV, V66, P80, DOI 10.1124/pr.113.008144; Williams KC, 2012, MOL ENDOCRINOL, V26, P1857, DOI 10.1210/me.2012-1199; Xie YL, 2014, CLIN TRANSL ONCOL, V16, P898, DOI 10.1007/s12094-014-1166-x; Yao X, 2014, AM J PHYSIOL-HEART C, V306, pH882, DOI 10.1152/ajpheart.00475.2013; Yin Y, 2009, INT J IMMUNOPATH PH, V22, P311, DOI 10.1177/039463200902200208; Yuan DZ, 2015, REPROD SCI, V22, P223, DOI 10.1177/1933719114537714; Zendedel A, 2015, J NEUROIMMUNOL, V278, P200, DOI 10.1016/j.jneuroim.2014.11.007; Zhang N, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/370530; Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072985; Zhao Y, 2011, NATURE, V477, P596, DOI 10.1038/nature10510; Zhu Y, 2013, J HUAZHONG U SCI-MED, V33, P730, DOI [10.1007/s11596-013-1188-6, 10.3724/SP.J.1087.2013.00730]	115	25	25	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	SEP	2015	153				SI		135	143		10.1016/j.jsbmb.2015.02.013			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	CS9AY	WOS:000362382700016	25747343				2022-02-06	
J	Jiang, L; Zhong, J; Dou, X; Cheng, C; Huang, Z; Sun, X				Jiang, L.; Zhong, J.; Dou, X.; Cheng, C.; Huang, Z.; Sun, X.			EFFECTS OF APOE ON INTRACELLULAR CALCIUM LEVELS AND APOPTOSIS OF NEURONS AFTER MECHANICAL INJURY	NEUROSCIENCE			English	Article						TBI; intracellular calcium level; APOE polymorphism; neuron; mechanical injury	TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E PROTECTS; THERAPEUTIC STRATEGIES; ALZHEIMERS-DISEASE; EEG ALTERATIONS; E-GENOTYPE; E4; RESPONSES; PATHOPHYSIOLOGY; ASSOCIATION	Objective: The current study aimed to explore the effects of apolipoprotein e (ApoE) on intracellular calcium ([Ca2+](i)) and apoptosis of neurons after mechanical injury in vitro. Methods: A neuron mechanical injury model was established after primary neurons obtained from APOE knockout and wild-type (WT) mice, and four experimental groups were generated: Group-ApoE4, Group-ApoE3, Group-ApoE(-) and Group-WT. Recombinant ApoE4 and ApoE3 were added to Group-ApoE4 and Group-ApoE3 respectively, and Group-ApoE(-) and Group-WT were control groups. Intracellular calcium was labeled by fluo-3/AM and examined using laser scanning confocal microscope and flow cytometry, and the apoptosis of neurons was also evaluated. Results: The intracellular calcium levels and apoptosis rates of mice neurons were significantly higher in Group-ApoE4 than in Group-ApoE3 and Group-WT after mechanical injury. However, without mechanical injury on neurons, no significant differences in intracellular calcium levels and apoptosis rates were found among all four experimental groups. The effects of ApoE4 on intracellular calcium levels and apoptosis rates of injured neurons were partly decreased by EGTA treatment. Conclusion: Compared with ApoE3-treatment and WT neurons, ApoE4 caused higher intracellular calcium levels and apoptosis rates of neurons after mechanical injury. This suggested APOE polymorphisms may affect neuron apoptosis after mechanical injury through different influences on intracellular calcium levels. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved.	[Jiang, L.; Zhong, J.; Cheng, C.; Huang, Z.; Sun, X.] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China; [Dou, X.] Chongqing Med Univ, Chongqing 400016, Peoples R China		Sun, X (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, 1 Youyi Rd, Chongqing 400016, Peoples R China.	sunxch1445@qq.com		sun, xiao chuan/0000-0001-6992-332X; Jiang, Li/0000-0002-2407-3672; Huang, Zhijian/0000-0002-8241-0761	National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30973087, 81371378]	The authors declare that they have no conflict of interest. The study was supported by National Science Foundation of China (approval number: 30973087 and 81371378).	Aono M, 2002, NEUROBIOL DIS, V11, P214, DOI 10.1006/nbdi.2002.0541; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Chang SJ, 2005, P NATL ACAD SCI USA, V102, P18694, DOI 10.1073/pnas.0508254102; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Grammas P, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-26; Halliday MR, 2013, JAMA NEUROL, V70, P1198, DOI 10.1001/jamaneurol.2013.3841; Hiekkanen H, 2009, BRAIN INJURY, V23, P396, DOI 10.1080/02699050902926259; Houlden H, 2006, J NEUROL NEUROSUR PS, V77, P1106, DOI 10.1136/jnnp.2006.095513; Huang YD, 2012, CELL, V148, P1204, DOI 10.1016/j.cell.2012.02.040; Jiang L, 2011, NEUROSCI LETT, V505, P160, DOI 10.1016/j.neulet.2011.10.011; Jiang Y, 2007, J NEUROTRAUM, V24, P1802, DOI 10.1089/neu.2007.0299; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Johnson JE, 2007, MOL VIS, V13, P887; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kumaria A, 2008, BRIT J NEUROSURG, V22, P200, DOI 10.1080/02688690701772413; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Paul J, 2007, J EXP MED, V204, P1999, DOI 10.1084/jem.20070304; Ponomareva NV, 2008, NEUROBIOL AGING, V29, P819, DOI 10.1016/j.neurobiolaging.2006.12.019; Qiu Z, 2003, NEUROSCIENCE, V122, P291, DOI 10.1016/j.neuroscience.2003.08.017; Rice DS, 1998, DEVELOPMENT, V125, P3719; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Veinbergs I, 2002, J NEUROSCI RES, V67, P379, DOI 10.1002/jnr.10138; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; YASUDA T, 1993, PEDIATR NEUROSURG, V19, P21, DOI 10.1159/000120695; Zhong ZH, 2009, J CLIN INVEST, V119, P3437, DOI 10.1172/JCI38476; Zhou S, 2013, FEBS LETT, V587, P254, DOI 10.1016/j.febslet.2012.12.003; Zlokovic BV, 2013, JAMA NEUROL, V70, P440, DOI 10.1001/jamaneurol.2013.2152	34	25	28	2	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	AUG 20	2015	301						375	383		10.1016/j.neuroscience.2015.06.005			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CM7MO	WOS:000357877800033	26073697				2022-02-06	
J	Greenham, M; Hearps, S; Gomes, A; Rinehart, N; Gonzalez, L; Gordon, A; Mackay, M; Lo, W; Yeates, K; Anderson, V				Greenham, Mardee; Hearps, Stephen; Gomes, Alison; Rinehart, Nicole; Gonzalez, Linda; Gordon, Anne; Mackay, Mark; Lo, Warren; Yeates, Keith; Anderson, Vicki			Environmental Contributions to Social and Mental Health Outcomes Following Pediatric Stroke	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; PROBLEM-SOLVING INTERVENTION; ARTERIAL ISCHEMIC-STROKE; FRIENDSHIP QUALITY; CHILDHOOD; PREDICTORS; COMPETENCE; CHILDREN; RECOVERY	Mental health and social outcomes following acquired brain injury (ABI) in children are often considered to be due to brain insult, but other factors, such as environment, may also play a role. We assessed mental health and social function in children with chronic illness, with and without stroke (a form of ABI), and typically developing (TD) controls to examine environmental influences on these outcomes. We recruited 36 children diagnosed with stroke, 15 with chronic asthma, and 43 TD controls. Children and parents completed questionnaires rating child mental health and social function and distal and proximal environment. TD children had significantly less internalizing and social problems than stroke and asthma groups, and engaged in more social activities than children with stroke. Poorer parent mental health predicted more internalizing and social problems and lower social participation. Family dysfunction was associated with internalizing problems. Lower parent education contributed to children's social function. Children with chronic illness are at elevated risk of poorer mental health and social function. Addition of brain insult leads to poorer social participation. Quality of home environment contributes to children's outcomes, suggesting that supporting parent and family function provides an opportunity to optimize child mental health and social outcomes.	[Greenham, Mardee; Hearps, Stephen; Gomes, Alison; Rinehart, Nicole; Mackay, Mark; Anderson, Vicki] Murdoch Childrens Res Inst, Clin Sci, Melbourne, Vic 3052, Australia; [Greenham, Mardee; Anderson, Vicki] Univ Melbourne, Sch Psychol Sci, Melbourne, Vic, Australia; [Gomes, Alison; Gonzalez, Linda] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Rinehart, Nicole] Deakin Univ, Sch Psychol, Melbourne, Vic, Australia; [Gordon, Anne] Evelina London Childrens Hosp, Paediat Neurol, London, England; [Gordon, Anne] Kings Coll London, Inst Psychol Psychiat & Neurosci, London, England; [Mackay, Mark] Royal Childrens Hosp, Dept Neurol, Melbourne, Vic, Australia; [Mackay, Mark] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Lo, Warren; Yeates, Keith] Nationwide Childrens Hosp, Neurosci Ctr, Columbus, OH USA		Greenham, M (corresponding author), Murdoch Childrens Res Inst, 50 Flemington Rd, Parkville, Vic 3052, Australia.	mardee.greenham@mcri.edu.au	Greenham, Mardee/AAR-1711-2020; Yeates, Keith/AAJ-4223-2020; Hearps, Stephen/L-6853-2016; Lo, Warren/E-3531-2011	Rinehart, Nicole/0000-0001-6109-3958; Yeates, Keith/0000-0001-7680-2892; Hearps, Stephen/0000-0003-2984-1172	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Research Institute, Nationwide Children's HospitalOhio State University [231308]; Murdoch Childrens Research Institute; Victorian Governmental Operational Infrastructure Scheme	This study was supported by grants from the Australian National Health and Medical Research Council (Anderson), the Research Institute, Nationwide Children's Hospital (# 231308), Murdoch Childrens Research Institute, and Victorian Governmental Operational Infrastructure Scheme.	Achenbach TM, 1991, MANUAL CHILD BEHAV C; ANDERSON V, 2001, DEV NEUROPSYCHOLOGY; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson V, 2014, SOC NEUROSCI-UK, V9, P471, DOI 10.1080/17470919.2014.932308; Anderson-Parente JK., 1990, COGN REHABIL, V8, P22; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bedell G, 2009, DEV NEUROREHABIL, V12, P342, DOI 10.3109/17518420903087277; BRESLAU N, 1990, ARCH GEN PSYCHIAT, V47, P15; De Schryver ELLM, 2000, DEV MED CHILD NEUROL, V42, P313, DOI 10.1017/S0012162200000554; deVeber GA, 2000, J CHILD NEUROL, V15, P316, DOI 10.1177/088307380001500508; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Evans GW, 2004, AM PSYCHOL, V59, P77, DOI 10.1037/0003-066X.59.2.77; Everts R, 2008, CHILD NEUROPSYCHOL, V14, P323, DOI 10.1080/09297040701792383; Friefeld S, 2004, CNS SPECTRUMS, V9, P465; Gaertner AE, 2010, J CHILD FAM STUD, V19, P101, DOI 10.1007/s10826-009-9289-3; Galvin J, 2010, AUST OCCUP THER J, V57, P152, DOI 10.1111/j.1440-1630.2010.00853.x; Gerring JP, 2012, J NEUROTRAUM, V29, P621, DOI 10.1089/neu.2011.2234; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Gordon AL, 2002, J CHILD NEUROL, V17, P429, DOI 10.1177/088307380201700606; Greenham M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00022; Hajek CA, 2014, J CHILD NEUROL, V29, P887, DOI 10.1177/0883073813491828; Hartel C, 2004, EUR J NEUROL, V11, P431, DOI 10.1111/j.1468-1331.2004.00861.x; Hurvitz Edward, 2004, Top Stroke Rehabil, V11, P51; Jackson C, 2007, OCCUP MED-OXFORD, V57, P79, DOI 10.1093/occmed/kql169; Kolb B, 2007, DEV PSYCHOBIOL, V49, P107, DOI 10.1002/dev.20199; Langley AK, 2004, J CHILD ADOL PSYCHOP, V14, P105, DOI 10.1089/104454604773840544; Leventer RJ, 1999, NEUROLOGY, V53, P715, DOI 10.1212/WNL.53.4.715; Lo W, 2014, INT J STROKE, V9, P1037, DOI 10.1111/ijs.12222; Long B, 2011, J CHILD NEUROL, V26, P279, DOI 10.1177/0883073810380049; Max JE, 2002, J AM ACAD CHILD PSY, V41, P555, DOI 10.1097/00004583-200205000-00013; McLoyd VC, 1998, AM PSYCHOL, V53, P185, DOI 10.1037/0003-066X.53.2.185; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Merrel KW, 1998, SOCIAL SKILLS CHILDR; Nassau JH, 1997, J PEDIATR PSYCHOL, V22, P771, DOI 10.1093/jpepsy/22.6.771; Neuner B, 2011, ANN NEUROL, V70, P70, DOI 10.1002/ana.22381; O'Keeffe F, 2012, BRAIN INJURY, V26, P1072, DOI 10.3109/02699052.2012.661117; PARKER JG, 1993, DEV PSYCHOL, V29, P611, DOI 10.1037/0012-1649.29.4.611; Repetti RL, 2002, PSYCHOL BULL, V128, P330, DOI 10.1037/0033-2909.128.2.330; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Steinlin M, 2004, EUR J PEDIATR, V163, P245, DOI 10.1007/s00431-003-1357-x; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Terrell-Deutsch B., 1999, LONELINESS CHILDHOOD, P11, DOI 10.1017/cbo9780511551888.002; Trauner DA, 1996, ASSESSMENT, V3, P265, DOI [DOI 10.1177/1073191196003003007, 10.1177/1073191196003003007]; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179; Wade SL, 2009, J PEDIATR PSYCHOL, V34, P517, DOI 10.1093/jpepsy/jsn081; Wade SL, 2005, REHABIL PSYCHOL, V50, P337, DOI 10.1037/0090-5550.50.4.337; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wechsler D., 1999, WASI WECHSLER ABBREV; Woods D, 2015, SOCIAL CARE NEURODIS, V5, P70, DOI [DOI 10.1108/SCN-01-2014-0001, 10.1108/SCN-01-2014-0001]; Woods D., 2014, SOCIAL CARE NEURODIS, V5, P51, DOI [10.1108/SCN-01-2013-0002, DOI 10.1108/SCN-01-2013-0002]; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; [No title captured]	56	25	25	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.	AUG 18	2015	40	6					348	362		10.1080/87565641.2015.1095191			15	Psychology, Developmental; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	CU1YW	WOS:000363319300002	26491988				2022-02-06	
J	Merritt, VC; Meyer, JE; Arnett, PA				Merritt, Victoria C.; Meyer, Jessica E.; Arnett, Peter A.			A novel approach to classifying postconcussion symptoms: The application of a new framework to the Post-Concussion Symptom Scale	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Sports-related concussion; Postconcussion symptoms; Collegiate athletes	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; NEUROCOGNITIVE PERFORMANCE; HIGH-SCHOOL; SEX-DIFFERENCES; RECOVERY; RETURN; PLAY; STABILITY; SEVERITY	Introduction: Self-report measures such as the Post-Concussion Symptom Scale (PCSS) are frequently used during baseline and postconcussion testing to evaluate athletes' symptom profiles. However, the common approach of evaluating the total symptom score and/or symptom clusters may not allow for a complete understanding of the nature of athletes' symptom reporting patterns. The primary objective of this study was to apply three global indices of distress variables, derived from the Symptom Checklist-90-Revised (SCL-90-R) framework, to the PCSS at baseline and postconcussion. We aimed to evaluate the utility of these symptom indices in relation to four PCSS symptom clusters and the total PCSS symptom score. Method: Participants included college athletes evaluated at baseline (N = 846) and postconcussion (N = 86). Athletes underwent neuropsychological testing at both time points, including completion of the PCSS and a paper/pencil and computerized test battery. Eight symptom indices were derived from the PCSS, and a postconcussion neurocognitive composite score was calculated. Results: Results showed that there were significant mean increases from baseline to postconcussion on four of the eight symptom indices evaluated. Furthermore, a significant proportion of athletes showed no change from baseline to postconcussion when evaluating the total symptom score, but showed at least a one standard deviation increase in symptom reporting from baseline to postconcussion when evaluating at least one other symptom index (i.e., a global index of distress or symptom cluster). Finally, the three global indices of distress variables, two of the four symptom clusters, and the total symptom score significantly predicted a postconcussion neurocognitive composite score, such that greater postconcussion symptoms were associated with lower postconcussion neurocognitive performance. Conclusions: These findings suggest that, in addition to evaluating the postconcussion total symptom score, there may be value in examining more specific symptom indices such as the global indices of distress variables and symptom clusters.	[Merritt, Victoria C.; Meyer, Jessica E.; Arnett, Peter A.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA		Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA.	vca106@psu.edu		Merritt, Victoria/0000-0001-5683-4168	Penn State Sports Medicine	The authors have no conflicts of interest to report. No formal grant funding was obtained for this project; however, we would like to thank Penn State Sports Medicine and Wayne Sebastianelli for their ongoing support of our concussion program.	[Anonymous], 2010, IBM SPSS STAT WIND V; Barth JT, 1989, MILD HEAD INJURY SPO; Benedict, 2001, HOPKINS VERBAL LEARN; Benedict R., 1997, BRIEF VISUOSPATIAL M; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cegalis J.A., 1994, VIGIL W CONTINUOUS P; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Derogatis L. R., 1994, SCL 90 R ADM SCORING, VThird; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Dougan BK, 2014, J INT NEUROPSYCH SOC, V20, P81, DOI 10.1017/S1355617713001288; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; ImPACT Applications Inc., 2012, IMPACT TEST TECHN MA; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell M, 2000, IMPACT IMMEDIATE POS; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Merritt VC, 2014, J CLIN EXP NEUROPSYC, V36, P1098, DOI 10.1080/13803395.2014.983463; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Pardini D., 2004, BR J SPORTS MED, V38, P661; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Smith A., 1991, SYMBOL DIGIT MODALIT; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird	51	25	25	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG 9	2015	37	7					764	775		10.1080/13803395.2015.1060950			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	CQ1ZS	WOS:000360399700008	26241079				2022-02-06	
J	Kroshus, E; Baugh, CM; Hawrilenko, MJ; Daneshvar, DH				Kroshus, Emily; Baugh, Christine M.; Hawrilenko, Matthew J.; Daneshvar, Daniel H.			Determinants of Coach Communication About Concussion Safety in US Collegiate Sport	ANNALS OF BEHAVIORAL MEDICINE			English	Article						Concussion; Sport; Communication; Coach; Gender	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; YOUTH SPORTS; SOCIAL SUPPORT; ICE HOCKEY; CDC HEADS; PAIN; SOCIALIZATION; KNOWLEDGE; RISK	Communication between coaches and athletes about concussion safety can reinforce or undermine a sport culture in which concussion under-reporting is often endemic. This study tested a model in which self-reported coach communication about concussion safety was predicted by factors including concussion knowledge, attitudes and beliefs, sex of the coach, and sex of the team coached. Participants were 997 coaches of contact and collision sports teams competing in National Collegiate Athletic Association Division I, II, or III. Concussion attitudes and beliefs were the strongest predictors of communication, and the small effect of knowledge on communication was transmitted nearly entirely through its effect on attitudes and beliefs. Much of the variability in communication was attributable to the sex of the coach and the sex of the team coached. These results serve as a starting point for the design of coach-targeted interventions that encourage communication about health and safety with athletes.	[Kroshus, Emily] Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA 02116 USA; [Kroshus, Emily] Natl Collegiate Athlet Assoc, Sport Sci Inst, Indianapolis, IN USA; [Kroshus, Emily; Baugh, Christine M.] Harvard Univ, Edmond J Safra Ctr Eth, Cambridge, MA 02138 USA; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Baugh, Christine M.] Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Hawrilenko, Matthew J.] Clark Univ, Dept Clin Psychol, Worcester, MA 01610 USA; [Daneshvar, Daniel H.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Daneshvar, Daniel H.] Sports Legacy Inst, Waltham, MA USA		Kroshus, E (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Social & Behav Sci, 221 Columbus Ave, Boston, MA 02116 USA.	emk329@mail.harvard.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338; Daneshvar, Daniel/0000-0003-3691-9513			Adams A, 2010, J LANG SOC PSYCHOL, V29, P278, DOI 10.1177/0261927X10368833; Ajzen I, 2011, BASIC APPL SOC PSYCH, V33, P101, DOI 10.1080/01973533.2011.568834; Anderson E, 2009, ROUTL RES GEND SOC, P1; Anderson E, 2008, SEX ROLES, V58, P104, DOI 10.1007/s11199-007-9337-7; Anderson E, 2011, J HOMOSEXUAL, V58, P565, DOI 10.1080/00918369.2011.563652; Anderson E, 2010, J GENDER STUD, V19, P249, DOI 10.1080/09589236.2010.494341; [Anonymous], 2013 14 NCAA SPORTS; Atkinson Michael, 2010, SEXUAL SPORTS RHETOR, P15; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bianco T, 2001, RES Q EXERCISE SPORT, V72, P376, DOI 10.1080/02701367.2001.10608974; Blumer H., 1969, SYMB INTERACT; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Cleveland JN, 2000, WOMEN MEN ORG SEX GE; Covassin T, 2013, AM J SPORT MED, V41, P2885, DOI 10.1177/0363546513499230; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; CURRY TJ, 1993, SYMB INTERACT, V16, P273, DOI 10.1525/si.1993.16.3.273; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Deschamps J. C., 1982, SOCIAL IDENTITY INTE, P85; Donnelly P., 2000, HDB SPORTS STUDIES, P77, DOI DOI 10.4135/9781848608382.N5; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.10.FOCUS10222; Eckner JT, 2014, BRIT J SPORT MED, V48, P112, DOI 10.1136/bjsports-2012-091579; ELY RJ, 1995, ACAD MANAGE J, V38, P589, DOI 10.2307/256740; Fenton LT, 2010, RES Q EXERCISE SPORT, V81, P212; Fisher A. Craig, 1993, Journal of Athletic Training, V28, P48; Fogel C., 2011, CANADA SOCIAL SCI, V7, P1; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Hammond LE, 2014, QUAL RES SPORT EXERC, V6, P161, DOI 10.1080/2159676X.2013.796488; Hinyard LJ, 2007, HEALTH EDUC BEHAV, V34, P777, DOI 10.1177/1090198106291963; Kauer K., 2006, WOMEN SPORT PHYS ACT, V15, P42, DOI DOI 10.1123/WSPAJ.15.1.42; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Koester MC, 2000, J ATHL TRAINING, V35, P466; Kroshus E, J ATHL TRAI IN PRESS; Kroshus E, 2015, ANN BEHAV MED, V49, P95, DOI 10.1007/s12160-014-9636-5; Kroshus E, 2014, EAT DISORD, V22, P193, DOI 10.1080/10640266.2013.874827; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lapchick R, 2010 RACIAL GENDER R; LaVoi N., 2013, DECLINE WOMEN COACHE; Liston K, 2006, SPORT SOC, V9, P388, DOI 10.1080/17430430600673407; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Malcom NL, 2006, J CONTEMP ETHNOGR, V35, P495, DOI 10.1177/0891241605283571; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Merriam S.B., 2001, NEW DIRECTIONS ADULT, V2001, P3, DOI 10.1002/ace.3; MEZIROW J, 1981, ADULT ED, V32, P3, DOI 10.1177/074171368103200101; Miller JL, 1996, SEX ROLES, V35, P111, DOI 10.1007/BF01548178; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; NIXON HL, 1994, SOCIOL SPORT J, V11, P79, DOI 10.1123/ssj.11.1.79; Partridge B, 2014, J BIOETHIC INQ, V11, P65, DOI 10.1007/s11673-013-9491-2; Pike E. C. J., 2005, International Review for the Sociology of Sport, V40, P201, DOI 10.1177/1012690205057199; Podlog L, 2007, PSYCHOL SPORT EXERC, V8, P535, DOI 10.1016/j.psychsport.2006.07.008; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Raftery AE, 1995, SOCIOL METHODOL, V25, P111, DOI 10.2307/271063; Roderick M, 2006, SOCIOL HEALTH ILL, V28, P76, DOI 10.1111/j.1467-9566.2005.00483.x; Rudman LA, 2008, RES ORGAN BEHAV, V28, P61, DOI 10.1016/j.riob.2008.04.003; Safai P, 2003, SOCIOL SPORT J, V20, P127, DOI 10.1123/ssj.20.2.127; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Sherman Roberta Trattner, 2005, Eat Disord, V13, P447; Smith PM, 2006, FAM CONSUM SCI RES J, V34, P276, DOI 10.1177/1077727X05283598; Sundgot-Borgen J, 2010, SCAND J MED SCI SPOR, V20, P112, DOI 10.1111/j.1600-0838.2010.01190.x; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tomlinson A., 1997, Journal of Sport and Social Issues, V21, P134, DOI 10.1177/019372397021002003; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Voracek M, 2010, SCAND J MED SCI SPOR, V20, P853, DOI 10.1111/j.1600-0838.2009.01031.x; Waldron JJ, 2005, QUEST, V57, P315, DOI 10.1080/00336297.2005.10491860; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Wiese-Bjornstal DM, 2010, SCAND J MED SCI SPOR, V20, P103, DOI 10.1111/j.1600-0838.2010.01195.x; Yang JZ, 2010, J ATHL TRAINING, V45, P372, DOI 10.4085/1062-6050-45.4.372	75	25	26	3	25	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0883-6612	1532-4796		ANN BEHAV MED	Ann. Behav. Med.	AUG	2015	49	4					532	541		10.1007/s12160-014-9683-y			10	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	CM4ZJ	WOS:000357695400005	25712480				2022-02-06	
J	Nudi, ET; Jacqmain, J; Dubbs, K; Geeck, K; Salois, G; Searles, MA; Smith, JS				Nudi, Evan T.; Jacqmain, Justin; Dubbs, Kelsey; Geeck, Katalin; Salois, Garrick; Searles, Madeleine A.; Smith, Jeffrey S.			Combining Enriched Environment, Progesterone, and Embryonic Neural Stem Cell Therapy Improves Recovery after Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						enriched environment; eNSC; progesterone; TBI	CONTROLLED CORTICAL IMPACT; RANDOMIZED CLINICAL-TRIAL; SEVERE HEAD-INJURY; CONTUSION INJURY; FUNCTIONAL RECOVERY; COGNITIVE DEFICITS; FEMALE RATS; SUBVENTRICULAR ZONE; PREFRONTAL CORTEX; TRANSPLANTATION	Millions of persons every year are affected by traumatic brain injury (TBI), and currently no therapies have shown efficacy in improving outcomes clinically. Recent research has suggested that enriched environments (EE), embryonic neural stem cells (eNSC), and progesterone (PROG) improve functional outcomes after TBI, and further, several investigators have suggested that a polytherapuetic approach may have greater efficacy than a single therapy. The purpose of the current study was to determine if varying combinations of post-injury EE, progesterone therapy, or eNSC transplantation would improve functional outcomes over just a single therapy. A controlled cortical impact was performed in rats to create a lesion in the medial frontal cortex. The rats were then placed in either EE or standard environments and administered 10mg/kg progesterone or vehicle injections 4h post-injury and every 12h for 72h after the initial injection. Seven days after the surgery, rats were transplanted with either eNSCs or media. Rats were then tested on the open field test, Barnes maze, Morris water maze, and Rotor-Rod tasks. Improved functional outcomes were shown on a majority of the behavioral tasks in animals that received a combination of therapies. This effect was especially prominent with therapies that were combined with EE. Immunohistochemistry showed that the transplanted eNSCs survived, migrated, and displayed neural phenotypes. These data suggest that a poly-therapeutic approach after TBI improves functional recovery to a greater magnitude. Moreover, when polytherapies are combined with EE, the effects on recovery are enhanced, leading to greater recovery of function.	[Nudi, Evan T.; Jacqmain, Justin; Dubbs, Kelsey; Geeck, Katalin; Salois, Garrick; Searles, Madeleine A.; Smith, Jeffrey S.] Saginaw Valley State Univ, Brain Res Lab, University Ctr, MI 48710 USA		Smith, JS (corresponding author), Saginaw Valley State Univ, Crystal M Lange Coll Hlth & Human Serv, Dept Hlth Sci, 7400 Bay Rd, University Ctr, MI 48710 USA.	jsmith12@svsu.edu		Smith, Jeffrey/0000-0001-5499-4475	Dow Student Research and Creativity Institute; Field Neuroscience Institute	This study was funded, in part, by a Dow Student Research and Creativity Institute grant, awarded to E.T.N. and a Field Neuroscience Institute research contract, awarded to J.S.S. The authors would like to thank Jennica Young, Ivy Hiatt, Tim Pionk, and Kimberly Meerschaert for their help with animal care and assistance throughout the course of the study.	Adekoya N., 2002, SURVEILLANCE TRAUMAT; Angelucci F, 2009, CEREBELLUM, V8, P499, DOI 10.1007/s12311-009-0129-1; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Galani R, 1997, NEUROBIOL LEARN MEM, V67, P43, DOI 10.1006/nlme.1996.3745; Gleave JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072039; Gold EM, 2013, REGEN MED, V8, P483, DOI 10.2217/rme.13.41; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hicks AU, 2007, NEUROSCIENCE, V146, P31, DOI 10.1016/j.neuroscience.2007.01.020; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Jones TA, 2012, J NEUROTRAUM, V29, P1455, DOI 10.1089/neu.2011.2207; Ke MT, 2013, NAT NEUROSCI, V16, P1154, DOI 10.1038/nn.3447; Kesner RP, 2011, NEUROBIOL LEARN MEM, V96, P417, DOI 10.1016/j.nlm.2011.07.002; Kline AE, 2012, J NEUROTRAUM, V29, P1960, DOI 10.1089/neu.2012.2385; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; Komitova M, 2005, STROKE, V36, P1278, DOI 10.1161/01.STR.0000166197.94147.59; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; LABBE R, 1983, SCIENCE, V221, P470, DOI 10.1126/science.6683427; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Maegele M, 2005, EUR J NEUROSCI, V21, P2406, DOI 10.1111/j.1460-9568.2005.04070.x; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; National Institute of Neurological Disorders and Stroke, 2014, TRAUM BRAIN INJ RES; Nudi E. T., 2013, J NEUROTRAUM, V30; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Peruzzaro ST, 2013, RESTOR NEUROL NEUROS, V31, P431, DOI 10.3233/RNN-120299; Peterson TC, 2012, J NEUROTRAUM, V29, P2823, DOI 10.1089/neu.2012.2471; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Ramic M, 2006, BRAIN RES, V1111, P176, DOI 10.1016/j.brainres.2006.06.063; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Riess P, 2007, J NEUROTRAUM, V24, P216, DOI 10.1089/neu.2006.0141; Risedal A, 2002, BRAIN RES BULL, V58, P315, DOI 10.1016/S0361-9230(02)00796-7; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shaw CL, 2013, BEHAV BRAIN RES, V236, P94, DOI 10.1016/j.bbr.2012.08.024; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820	76	25	26	1	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2015	32	14					1117	1129		10.1089/neu.2014.3618			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CV0TB	WOS:000363965000011	25268854				2022-02-06	
J	Glaviano, NR; Benson, S; Goodkin, HP; Broshek, DK; Saliba, S				Glaviano, Neal R.; Benson, Shari; Goodkin, Howard P.; Broshek, Donna K.; Saliba, Susan			Baseline SCAT2 Assessment of Healthy Youth Student-Athletes: Preliminary Evidence for the Use of the Child-SCAT3 in Children Younger Than 13 Years	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						neurocognitive testing; neuropsychological testing; SCAT3; Child-SCAT3	HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; CONCUSSION ASSESSMENT; SPORT CONCUSSION; INTERNATIONAL-CONFERENCE; STANDARDIZED ASSESSMENT; CONSENSUS STATEMENT; POSTURAL STABILITY; SEX-DIFFERENCES; NORMATIVE DATA	Objective:To compare baseline scores of middle and high school students on the Sport Concussion Assessment Tool 2 (SCAT2) by sex and age.Design:Cross-sectional study.Setting:Single private school athletic program.Participants:Three hundred sixty-one middle and high school student-athletes.Intervention:Preseason SCAT2 was administered to student-athletes before athletic participation.Main Outcome Measures:Total SCAT2 score, symptoms, symptom severity, Glasgow coma scale, modified Balance Error Scoring System (BESS), coordination, and Standardized Assessment of Concussion (SAC) with subsections: Orientation, Immediate Memory, Concentration, and Delayed Recall.Results:No differences were found in total SCAT2 scores between sex (P = 0.463) or age (P = 0.21). Differences were found in subcomponents of the SCAT2. Twelve year olds had significantly lower concentration scores (3.3 1.2) than 15 and 18 year olds (3.9 1.0 and 4.2 +/- 1.0, respectively). The 12 year olds also had the lowest percentage of correct responses for the SAC's concentration 5-digit (46%), 6-digit (21%), and months' backward (67%) tasks. Females presented with more symptoms (20.0 +/- 2.2 vs 20.6 +/- 2.1 P = 0.007) better immediate memory (14.6 +/- 0.9 vs 14.3 +/- 1.0, P = 0.022) and better BESS scores (27.2 +/- 2.3 vs 26.6 +/- 2.6, P = 0.043) than their male counterparts.Conclusions:Normative values for total SCAT2 and subscale scores show differences in concentration between ages, whereas symptoms, BESS, and immediate memory differed between sexes. We also found that 12 year olds have increased difficultly with the advanced concentration tasks, which lends support to the development of a separate instrument, such as the Child-SCAT3. The presence of developmental differences in the younger age groups suggests the need for annual baseline testing.Clinical Relevance:Subtle differences between age and sex have been identified in many components of the SCAT2 assessment. These differences may support the current evolution of concussion assessment tools to provide the most appropriate test. Baseline testing should be used when available, and clinicians should be aware of potential differences when using normalized values.	[Glaviano, Neal R.] Univ Virginia, Dept Kinesiol, Exercise & Sport Injury Lab, Charlottesville, VA USA; [Benson, Shari] St Annes Belfield Sch, Charlottesville, VA USA; [Goodkin, Howard P.] Univ Virginia, Dept Neurol, Charlottesville, VA 22903 USA; [Broshek, Donna K.] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22903 USA; [Saliba, Susan] Univ Virginia, Curry Sch Educ, Dept Human Serv Kinesiol Program Area, Charlottesville, VA 22903 USA		Glaviano, NR (corresponding author), Univ Virginia, Exercise & Sport Injury Lab, Mem Gymnasium, POB 400267, Charlottesville, VA 22903 USA.	ng2w@virginia.edu	Glaviano, Neal/AAW-1648-2020; Broshek, Donna/ABA-4208-2021	Glaviano, Neal/0000-0003-4515-8015; Broshek, Donna/0000-0002-7175-7815; Goodkin, Howard/0000-0003-0528-4949; Saliba, Susan/0000-0001-7179-8310			[Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Capitani E, 1997, NEUROPSYCHOL REHABIL, V7, P295, DOI 10.1080/713755543; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Choe MC, 2012, CURR OPIN PEDIATR, V24, P689, DOI 10.1097/MOP.0b013e32835a1a44; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Faul M, 2010, TRAUMATIC BRAIN INJU; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hopkins WG, 2009, MED SCI SPORT EXER, V41, P3, DOI 10.1249/MSS.0b013e31818cb278; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Kendall PC, 1999, J CONSULT CLIN PSYCH, V67, P285, DOI 10.1037/0022-006X.67.3.285; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee AJY, 2007, J APPL BIOMECH, V23, P173, DOI 10.1123/jab.23.3.173; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832	39	25	25	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2015	25	4					373	379		10.1097/JSM.0000000000000154			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	CM2EK	WOS:000357492400011	25318531				2022-02-06	
J	Sayer, NA; Orazem, RJ; Noorbaloochi, S; Gravely, A; Frazier, P; Carlson, KF; Schnurr, PP; Oleson, H				Sayer, Nina A.; Orazem, Robert J.; Noorbaloochi, Siamak; Gravely, Amy; Frazier, Patricia; Carlson, Kathleen F.; Schnurr, Paula P.; Oleson, Heather			Iraq and Afghanistan War Veterans with Reintegration Problems: Differences by Veterans Affairs Healthcare User Status	ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH			English	Article						Veterans; Healthcare service needs; Mental health; Posttraumatic stress disorder; Traumatic brain injury; Department of Veterans Affairs Healthcare	TRAUMATIC BRAIN-INJURY; BINGE DRINKING; DEPLOYMENT; MILITARY; SERVICES; FREEDOM; RISK	We studied 1,292 Iraq and Afghanistan War veterans who participated in a clinical trial of expressive writing to estimate the prevalence of perceived reintegration difficulty and compare Veterans Affairs (VA) healthcare users to nonusers in terms of demographic and clinical characteristics. About half of participants perceived reintegration difficulty. VA users and nonusers differed in age and military background. Levels of mental and physical problems were higher in VA users. In multivariate analysis, military service variables and probable traumatic brain injury independently predicted VA use. Findings demonstrate the importance of research comparing VA users to nonusers to understand veteran healthcare needs.	[Sayer, Nina A.; Orazem, Robert J.; Noorbaloochi, Siamak; Gravely, Amy; Oleson, Heather] Minneapolis VA Healthcare Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA; [Sayer, Nina A.; Noorbaloochi, Siamak] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Sayer, Nina A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Frazier, Patricia] Univ Minnesota, Dept Psychol, Minneapolis, MN 55455 USA; [Carlson, Kathleen F.] Portland VA Med Ctr, Ctr Improve Vet Involvement Care, Portland, OR USA; [Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA; [Schnurr, Paula P.] Natl Ctr PTSD, White River Jct, VT USA; [Schnurr, Paula P.] Geisel Sch Med Dartmouth, Hanover, NH USA		Sayer, NA (corresponding author), Minneapolis VA Healthcare Syst, Ctr Chron Dis Outcomes Res, One Vet Dr, Minneapolis, MN 55417 USA.	nina.sayer@va.gov	Sayer, Nina/E-3249-2016; Noorbaloochi, Siamak/ABB-5817-2020		Department of Veterans Affairs (VA)US Department of Veterans Affairs; Health Services Research and Development (HSRD) Service [DHI-07-150]; Department of Defense (DoD)United States Department of Defense [08-2-0045]	This research was supported by the Department of Veterans Affairs (VA), Health Services Research and Development (HSR&D) Service (Grant No. DHI-07-150) and the Department of Defense (DoD) (Grant No. 08-2-0045). The sponsors were not involved in any aspect of the study's design and conduct; data collection, management, analysis, or interpretation of data; or in the preparation, review or approval of the manuscript. The findings and conclusions presented in this manuscript are those of the authors and do not necessarily represent the views of the VA, HSR&D, or DoD.	Agha Z, 2000, ARCH INTERN MED, V160, P3252, DOI 10.1001/archinte.160.21.3252; Baikie KA, 2012, J AFFECT DISORDERS, V136, P310, DOI 10.1016/j.jad.2011.11.032; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Derogatis L.R., 2000, BRIEF SYMPTOM INVENT; Derogatis L.R., 1993, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dillman DA., 2000, MAIL INTERNET SURVEY; Foa E. B., 1995, POSTTRAUMATIC STRESS; Frazier P, 2003, CONT T VOC, P251; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hynes DM, 2007, MED CARE, V45, P214, DOI 10.1097/01.mlr.0000244657.90074.b7; Jaycox, 2008, INVISIBLE WOUNDS WAR; King D. W., 2003, MANUAL DEPLOYMENT RI; Koepsell TD, 2009, PREV MED, V48, P267, DOI 10.1016/j.ypmed.2009.01.008; Kovac SH, 2002, SUICIDE LIFE-THREAT, V32, P428, DOI 10.1521/suli.32.4.428.22335; Kroenke K, 2009, J AFFECT DISORDERS, V114, P163, DOI 10.1016/j.jad.2008.06.026; Littman Alyson J, 2012, Prev Chronic Dis, V9, pE99; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Naimi TS, 2003, JAMA-J AM MED ASSOC, V289, P70, DOI 10.1001/jama.289.1.70; Nelson KM, 2007, PUBLIC HEALTH REP, V122, P93, DOI 10.1177/003335490712200113; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Pennebaker JW., 1982, PSYCHOL PHYS SYMPTOM; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Sayer NA, 2014, SOC ISS POLICY REV, V8, P33, DOI 10.1111/sipr.12001; Sayer NA, 2011, J TRAUMA STRESS, V24, P660, DOI 10.1002/jts.20706; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seal KH, 2010, J TRAUMA STRESS, V23, P5, DOI 10.1002/jts.20493; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; U. S. Department of Veterans Affairs, 2010, NAT CTR VET AN STAT; U.S. Department of Veterans Affairs Epidemiology Program, 2014, AN VA HLTH CAR UT OP; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Weathers FW, 1995, PTSD CHECKLIST MILIT; WECHSLER H, 1995, AM J PUBLIC HEALTH, V85, P982, DOI 10.2105/AJPH.85.7.982	39	25	25	0	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0894-587X	1573-3289		ADM POLICY MENT HLTH	Adm. Policy. Ment. Health	JUL	2015	42	4					493	503		10.1007/s10488-014-0564-2			11	Health Policy & Services; Public, Environmental & Occupational Health	Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health	CJ7EC	WOS:000355656100012	24913102	Green Published, hybrid			2022-02-06	
J	Sweeney, TE; Salles, A; Harris, OA; Spain, DA; Staudenmayer, KL				Sweeney, Timothy E.; Salles, Arghavan; Harris, Odette A.; Spain, David A.; Staudenmayer, Kristan L.			Prediction of neurosurgical intervention after mild traumatic brain injury using the national trauma data bank	WORLD JOURNAL OF EMERGENCY SURGERY			English	Article						Traumatic brain injury; National trauma data bank; Neurosurgery	INTRACRANIAL HEMORRHAGE; ADULT PATIENTS; ADMISSION	Introduction: Patients with mild traumatic brain injury (TBI) as defined by an admission Glasgow Coma Score (GCS) of 14-15 often do not require neurosurgical interventions, but which patients will go on to require neurosurgical care has been difficult to predict. We hypothesized that injury patterns would be associated with need for eventual neurosurgical intervention in mild TBI. Methods: The National Trauma Databank (2007-2012) was queried for patients with blunt injury and a diagnosis of TBI with an emergency department GCS of 14-15. Patients were stratified by age and injury type. Multiple logistic regression for neurosurgical intervention was run with patient demographics, physiologic variables, and injury diagnoses as dependent variables. Results: The study included 50,496 patients, with an overall 8.8 % rate of neurosurgical intervention. Neurosurgical intervention rates varied markedly according to injury type, and were only correlated with age for patients with epidural and subdural hemorrhage. In multiple logistic regression, TBI diagnoses were predictive of need for neurosurgical interventions; moreover, after controlling for injury type and severity score, age was not significantly associated with requiring neurosurgical intervention. Conclusions: We found that in mild TBI, injury pattern is associated with eventual need for neurosurgical intervention. Patients with cerebral contusion or subarachnoid hemorrhage are much less likely to require neurosurgical intervention, and the effects of age are not significant after controlling for other patient factors. Prospective studies should validate this finding so that treatment guidelines can be updated to better allocate ICU resources.	[Sweeney, Timothy E.; Salles, Arghavan; Spain, David A.; Staudenmayer, Kristan L.] Stanford Univ, Med Ctr, Dept Surg, Stanford, CA 94305 USA; [Harris, Odette A.] Stanford Univ, Med Ctr, Dept Neurosurg, Stanford, CA 94305 USA		Sweeney, TE (corresponding author), Stanford Univ, Med Ctr, Dept Surg, 300 Pasteur Dr, Stanford, CA 94305 USA.	tes17@stanford.edu; kristans@stanford.edu		Sweeney, Timothy/0000-0002-3596-1093	NLM training grantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [2T15LM007033]; Stanford Department of Surgery	TES was supported by NLM training grant 2T15LM007033 and the Stanford Department of Surgery. We would like to thank Jay Bhattacharya and Eran BenDavid for helpful comments, and Lakshika Tennakoon for data preparation. The NTDB remains the full and exclusive copyrighted property of the American College of Surgeons. The American College of Surgeons is not responsible for any claims arising from works based on the original Data, Text, Tables, or Figures.	Bee TK, 2009, J TRAUMA, V66, P1015, DOI 10.1097/TA.0b013e31819adbc8; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Faul M, 2010, TRAUMATIC BRAIN INJU; Hukkelhoven CWPM, 2005, INTENS CARE MED, V31, P799, DOI 10.1007/s00134-005-2628-y; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Nishijima DK, 2014, ANN EMERG MED, V63, P448, DOI 10.1016/j.annemergmed.2013.11.003; Nishijima DK, 2013, ANN EMERG MED, V61, P509, DOI 10.1016/j.annemergmed.2012.08.024; Nishijima DK, 2012, INJURY, V43, P1827, DOI 10.1016/j.injury.2011.07.020; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Ratcliff JJ, 2014, AM J EMERG MED, V32, P844, DOI 10.1016/j.ajem.2014.04.003; Seddighi AS, 2013, BRAIN INJURY, V27, P1666, DOI 10.3109/02699052.2013.830333; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tong WS, 2011, NEURORADIOLOGY, V53, P305, DOI 10.1007/s00234-010-0659-8; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092	18	25	26	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1749-7922			WORLD J EMERG SURG	World J. Emerg. Surg.	JUN 6	2015	10								23	10.1186/s13017-015-0017-6			7	Emergency Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Surgery	CK4UR	WOS:000356219300001	26060506	Green Published, gold			2022-02-06	
J	Czerniak, SM; Sikoglu, EM; Navarro, AAL; McCafferty, J; Eisenstock, J; Stevenson, JH; King, JA; Moore, CM				Czerniak, Suzanne M.; Sikoglu, Elif M.; Navarro, Ana A. Liso; McCafferty, Joseph; Eisenstock, Jordan; Stevenson, J. Herbert; King, Jean A.; Moore, Constance M.			A resting state functional magnetic resonance imaging study of concussion in collegiate athletes	BRAIN IMAGING AND BEHAVIOR			English	Article						Concussion; fMRI; Resting state; Functional connectivity; Neurocognition	DORSOLATERAL PREFRONTAL CORTEX; ANTERIOR CINGULATE CORTEX; DEFAULT NETWORK; HIGH-SCHOOL; BRAIN; CONNECTIVITY; IMPACT; INTERFERENCE; METAANALYSIS; INJURY	Sports-related concussions are currently diagnosed through multi-domain assessment by a medical professional and may utilize neurocognitive testing as an aid. However, these tests have only been able to detect differences in the days to week post-concussion. Here, we investigate a measure of brain function, namely resting state functional connectivity, which may detect residual brain differences in the weeks to months after concussion. Twenty-one student athletes (9 concussed within 6 months of enrollment; 12 non-concussed; between ages 18 and 22 years) were recruited for this study. All participants completed the Wisconsin Card Sorting Task and the Color-Word Interference Test. Neuroimaging data, specifically resting state functional Magnetic Resonance Imaging data, were acquired to examine resting state functional connectivity. Two sample t-tests were used to compare the neurocognitive scores and resting state functional connectivity patterns among concussed and non-concussed participants. Correlations between neurocognitive scores and resting state functional connectivity measures were also determined across all subjects. There were no significant differences in neurocognitive performance between concussed and non-concussed groups. Concussed subjects had significantly increased connections between areas of the brain that underlie executive function. Across all subjects, better neurocognitive performance corresponded to stronger brain connectivity. Even at rest, brains of concussed athletes may have to 'work harder' than their healthy peers to achieve similar neurocognitive results. Resting state brain connectivity may be able to detect prolonged brain differences in concussed athletes in a more quantitative manner than neurocognitive test scores.	[Czerniak, Suzanne M.; Sikoglu, Elif M.; Navarro, Ana A. Liso; McCafferty, Joseph; King, Jean A.; Moore, Constance M.] Univ Massachusetts, Sch Med, Dept Psychiat, Ctr Comparat NeuroImaging, Worcester, MA 01604 USA; [Sikoglu, Elif M.; Navarro, Ana A. Liso; Eisenstock, Jordan; King, Jean A.; Moore, Constance M.] Univ Massachusetts, Mem Med Sch, Dept Psychiat, Worcester, MA 01605 USA; [Navarro, Ana A. Liso] Univ Geneva, Sch Med, Dept Psychiat, Off Med Pedag, CH-1211 Geneva 8, Switzerland; [Eisenstock, Jordan] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA; [Stevenson, J. Herbert] Univ Massachusetts, Mem Med Sch, Dept Sports Med, Worcester, MA 01605 USA; [King, Jean A.; Moore, Constance M.] Univ Massachusetts, Sch Med, Dept Radiol, Worcester, MA USA		Czerniak, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Psychiat, Ctr Comparat NeuroImaging, 303 Belmont St, Worcester, MA 01604 USA.	suzanne.czerniak@umassmed.edu; muazzez.sikoglu@umassmed.edu; aliso@bluewin.ch; jpm059@bucknell.edu; jordan.eisenstock@umassmemorial.org; john.stevenson@umassmemorial.org; jean.king@umassmed.edu; Constance.Moore@umassmed.edu			National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH073998]; University of Massachusetts Medical School; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBGEP3-134252]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM107000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073998] Funding Source: NIH RePORTER	National Institute of Mental Health to CMM (MH073998), and start-up funds to CMM from the University of Massachusetts Medical School. Swiss National Science Foundation (PBGEP3-134252) to AAL.	Allen EA, 2011, FRONT SYST NEUROSCI, V5, DOI 10.3389/fnsys.2011.00002; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Buchsbaum BR, 2005, HUM BRAIN MAPP, V25, P35, DOI 10.1002/hbm.20128; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Chai XQJ, 2011, NEUROPSYCHOPHARMACOL, V36, P2009, DOI 10.1038/npp.2011.88; Conklin SM, 2007, NEUROSCI LETT, V421, P209, DOI 10.1016/j.neulet.2007.04.086; Cullen KR, 2009, NEUROSCI LETT, V460, P227, DOI 10.1016/j.neulet.2009.05.022; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Delis DC., 2001, DELIS KAPLAN EXECUTI; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Friston Karl J., 1994, Human Brain Mapping, V2, P56, DOI 10.1002/hbm.460020107; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hayama HR, 2009, NEUROPSYCHOLOGIA, V47, P2409, DOI 10.1016/j.neuropsychologia.2009.04.010; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kelly AMC, 2009, CEREB CORTEX, V19, P640, DOI 10.1093/cercor/bhn117; Laird AR, 2005, HUM BRAIN MAPP, V25, P6, DOI 10.1002/hbm.20129; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leung HC, 2000, CEREB CORTEX, V10, P552, DOI 10.1093/cercor/10.6.552; Lie CH, 2006, NEUROIMAGE, V30, P1038, DOI 10.1016/j.neuroimage.2005.10.031; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Mahaffey Bran L, 2012, Mo Med, V109, P445; Margulies DS, 2007, NEUROIMAGE, V37, P579, DOI 10.1016/j.neuroimage.2007.05.019; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Monchi O, 2001, J NEUROSCI, V21, P7733, DOI 10.1523/JNEUROSCI.21-19-07733.2001; Qin SZ, 2009, BIOL PSYCHIAT, V66, P25, DOI 10.1016/j.biopsych.2009.03.006; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Silton RL, 2010, NEUROIMAGE, V50, P1292, DOI 10.1016/j.neuroimage.2009.12.061; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Song XW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025031; Staudinger MR, 2011, CEREB CORTEX, V21, P2578, DOI 10.1093/cercor/bhr041; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tsushima WT, 2013, APPL NEUROPSYCH-CHIL, V2, P13, DOI 10.1080/09084282.2011.643967	47	25	25	2	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	JUN	2015	9	2					323	332		10.1007/s11682-014-9312-1			10	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CI7TB	WOS:000354966600017	25112544	Green Accepted			2022-02-06	
J	Ravindra, VM; Riva-Cambrin, J; Sivakumar, W; Metzger, RR; Bollo, RJ				Ravindra, Vijay M.; Riva-Cambrin, Jay; Sivakumar, Walavan; Metzger, Ryan R.; Bollo, Robert J.			Risk factors for traumatic blunt cerebrovascular injury diagnosed by computed tomography angiography in the pediatric population: a retrospective cohort study	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						cerebrovascular injury; computed tomography angiography; pediatrics; traumatic brain injury; trauma; technique	CLINICAL-PREDICTION RULES; RADIATION-EXPOSURE; BRAIN-INJURY; CHILDREN; CT	OBJECT Computed tomography angiography (CTA) is frequently used to examine patients for blunt cerebrovascular injury (BCVI) after cranial trauma, but the pediatric population at risk for BCVI is poorly defined. Although CTA is effective for BCVI screening in adults, the increased lifetime risk for malignant tumors associated with this screening modality warrants efforts to reduce its use in children. The authors' objective was to evaluate the incidence of BCVI diagnosed by CTA in a pediatric patient cohort and to create a prediction model to identify children at high risk for BCVI. METHODS Demographic, clinical, and radiographic data were collected retrospectively for pediatric patients who underwent CTA during examination for traumatic cranial injury from 2003 through 2013. The primary outcome was injury to the carotid or vertebral artery diagnosed by CTA. RESULTS The authors identified 234 patients (mean age 8.3 years, range 0.04-17 years, 150 [64%] boys) who underwent CTA screening for BCVI. Of these, 24 (10.3%) had a focal neurological deficit, and 153 (65.4%) had intracranial hemorrhage on a head CTA. Thirty-seven BCVls were observed in 36 patients (15.4%), and 16 patients (6.8%) died. Multivariate regression analysis identified fracture through the carotid canal, petrous temporal bone fracture, Glasgow Coma Scale (GCS) score of < 8, focal neurological deficit, and stroke on initial CT scan as independent risk factors for BCVI. A prediction model for identifying children at high risk for BCVI was created. A score of <= 2 yielded a 7.9% probability of BCVI and a score of >= 3 a risk of 39.3% for BCVI. CONCLUSIONS For cranial trauma in children, fracture of the petrous temporal bone or through the carotid canal, focal neurological deficit, stroke, and a GCS score of < 8 are independent risk factors for BCVI.	[Ravindra, Vijay M.; Riva-Cambrin, Jay; Sivakumar, Walavan; Bollo, Robert J.] Univ Utah, Sch Med, Dept Neurosurg, Div Pediat Neurosurg, Salt Lake City, UT USA; [Metzger, Ryan R.] Univ Utah, Sch Med, Dept Surg, Salt Lake City, UT USA; [Metzger, Ryan R.] Primary Childrens Med Ctr, Div Pediat Surg, Salt Lake City, UT 84113 USA		Bollo, RJ (corresponding author), Primary Childrens Med Ctr, Div Pediat Neurosurg, 100 N Mario Capecchi Dr,Ste 1475, Salt Lake City, UT 84113 USA.	robert.bollo@hsc.utah.edu					Azarakhsh N, 2013, J TRAUMA ACUTE CARE, V75, P1006, DOI 10.1097/TA.0b013e31829d3526; Biffl WL, 2006, J TRAUMA, V60, P745, DOI 10.1097/01.ta.0000204034.94034.c4; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Biffl WL, 1999, AM J SURG, V178, P517, DOI 10.1016/S0002-9610(99)00245-7; Bok APL, 1996, J TRAUMA, V40, P968, DOI 10.1097/00005373-199606000-00017; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Carrillo EH, 1999, J TRAUMA, V46, P1120, DOI 10.1097/00005373-199906000-00030; Chamoun RB, 2008, J NEUROS-PEDIATR, V2, P101, DOI 10.3171/PED/2008/2/8/101; Donnelly LF, 2005, AM J ROENTGENOL, V184, P655, DOI 10.2214/ajr.184.2.01840655; Eastman AL, 2006, J TRAUMA, V60, P925, DOI 10.1097/01.ta.0000197479.28714.62; Jones TS, 2012, AM J SURG, V204, P7, DOI 10.1016/j.amjsurg.2011.07.015; Kaye D, 2011, J TRAUMA, V70, P1051, DOI 10.1097/TA.0b013e318211857d; Kopelman TR, 2011, J TRAUMA, V71, P559, DOI 10.1097/TA.0b013e318226eadd; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; Lew SM, 1999, PEDIATR NEUROSURG, V30, P239, DOI 10.1159/000028804; Liesemer K, 2014, PEDIATR CRIT CARE ME, V15, P554, DOI 10.1097/PCC.0000000000000150; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Redberg R F, 2014, NY TIMES; Sarkar K, 2014, J NEUROSURG-PEDIATR, V13, P307, DOI 10.3171/2013.12.PEDS13223; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Slovis TL, 2003, PEDIATRICS, V112, P971, DOI 10.1542/peds.112.4.971; Tu JV, 1997, J CLIN EPIDEMIOL, V50, P743, DOI 10.1016/S0895-4356(97)89028-2; Wang AC, 2012, J TRAUMA ACUTE CARE, V72, P1599, DOI 10.1097/TA.0b013e318246ead4; WEINSTEIN MC, 1980, CLIN DECISION ANAL, P84	29	25	26	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUN	2015	15	6					599	606		10.3171/2014.11.PEDS14397			8	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	CI8OL	WOS:000355031500008	25745952	Bronze			2022-02-06	
J	Shatillo, A; Salo, RA; Giniatullin, R; Grohn, OH				Shatillo, Artem; Salo, Raimo A.; Giniatullin, Rashid; Groehn, Olli H.			Involvement of NMDA receptor subtypes in cortical spreading depression in rats assessed by fMRI	NEUROPHARMACOLOGY			English	Article						Spreading depression; BOLD; fMRI; Glutamate; NMDA receptors	METHYL-D-ASPARTATE; CEREBRAL-BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; NEUROLOGICAL DISORDERS; DIZOCILPINE MK-801; MIGRAINE HEADACHE; GLUTAMATE RELEASE; FUNCTIONAL MRI; IFENPRODIL; ANTAGONIST	Cortical spreading depression (CSD) is a phenomenon implicated in migraine with aura and associated with other neurological disorders (e.g. stroke, brain trauma). Current evidence points to the essential role of NMDA receptors in CSD mechanisms. However, the roles of multiple subunits of NMDA receptors expressed in neurons, glia and blood vessels in vivo, are little explored. Using BOLD fMRI of urethane anesthetized rats as an integrative CSD readout, we tested the involvement of different NMDA receptor subtypes in CSD induction and propagation. Rats were treated with a non-selective NMDA blocker (MK-801), NR2B antagonist (ifenprodil) or a NR2A selective antagonist (TCN-201). CSD was induced during fMRI scanning by application of KCl onto the cerebral cortex and fMRI data were collected by 9.41 MRI. The non-specific NMDA antagonist MK-801 coinpletely blocked CSD, which was not observed in the NR2A group where TCN-201 did not alter the CSD features. Unexpectedly, the NR2B specific antagonist ifenprodil largely promoted the initial negative phase of the BOLD CSD response, likely due to altered neurovascular coupling. Our data suggest key roles and differential involvement of NMDA receptor subtypes in CSD generation and propagation, highlighting an important role for the NR2B subtype. (C) 2015 Elsevier Ltd. All rights reserved.	[Shatillo, Artem; Salo, Raimo A.; Giniatullin, Rashid; Groehn, Olli H.] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Kuopio 70700, Finland; [Giniatullin, Rashid] Kazan Fed Univ, Neurobiol Lab, Kazan 420008, Republic Of Tat, Russia		Shatillo, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Neulaniementie 2, Kuopio 70700, Finland.	artem.shatillo@uef.fi; raimo.salo@uef.fi; rashid.giniatullin@uef.fi; olli.grohn@uef.fi	Giniatullin, Rashid/Y-9687-2018	Salo, Raimo/0000-0003-3610-236X	Academy of FinlandAcademy of FinlandEuropean Commission [252511]; University of Eastern Finland; UEF-Brain strategic funding; Center for International Mobility (CIMO) [TM-09-6241]; program of competitive growth of Kazan Federal UniversityMinistry of Education and Science, Russian FederationProject 5-100, Ministry of Education and Science, Russian Federation	This work was supported by the Academy of Finland (252511), University of Eastern Finland and UEF-Brain strategic funding and Center for International Mobility (CIMO) TM-09-6241 fund. RG was partially supported by the program of competitive growth of Kazan Federal University.	ARAI Y, 1991, NEUROPHARMACOLOGY, V30, P809, DOI 10.1016/0028-3908(91)90190-M; Autio JA, 2014, J CEREBR BLOOD F MET, V34, P768, DOI 10.1038/jcbfm.2014.16; Ayata C, 2013, STROKE, V44, pS87, DOI 10.1161/STROKEAHA.112.680264; Bandettini Peter A, 1800, Neuroimage, V61, pA3, DOI 10.1016/j.neuroimage.2012.01.130; Brennan KC, 2007, J NEUROPHYSIOL, V97, P4143, DOI 10.1152/jn.00028.2007; Brittain MK, 2012, NEUROPHARMACOLOGY, V63, P974, DOI 10.1016/j.neuropharm.2012.07.012; Busija DW, 2007, BRAIN RES REV, V56, P89, DOI 10.1016/j.brainresrev.2007.05.011; Chang JC, 2010, BRAIN, V133, P996, DOI 10.1093/brain/awp338; Charles AC, 2013, NAT REV NEUROL, V9, P637, DOI 10.1038/nrneurol.2013.192; Comon P, 1994, SIGNAL PROCESS, V36, P287; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dzamba D, 2013, CURR NEUROPHARMACOL, V11, P250, DOI 10.2174/1570159X11311030002; Eikermann-Haerter K, 2008, CURR OPIN NEUROL, V21, P294, DOI 10.1097/WCO.0b013e3282fc25de; Faria LC, 2004, J NEUROPHYSIOL, V92, P2610, DOI 10.1152/jn.00466.2004; GARDNERMEDWIN AR, 1994, J CEREBR BLOOD F MET, V14, P7, DOI 10.1038/jcbfm.1994.2; GRAFSTEIN B, 1956, J NEUROPHYSIOL, V19, P154, DOI 10.1152/jn.1956.19.2.154; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Iijima T, 1998, NEUROSCI RES, V32, P201, DOI 10.1016/S0168-0102(98)00090-X; Kudo C., 2008, EXP NEUROL; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao A., 1945, J NERV MENT DIS, V102, P512; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359; LeMaistre JL, 2012, J CEREBR BLOOD F MET, V32, P537, DOI 10.1038/jcbfm.2011.161; Loftis JM, 2003, PHARMACOL THERAPEUT, V97, P55, DOI 10.1016/S0163-7258(02)00302-9; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Ma JY, 1996, AM J PHYSIOL-HEART C, V270, pH1085, DOI 10.1152/ajpheart.1996.270.3.H1085; MCCOOL BA, 1995, NEUROPHARMACOLOGY, V34, P621, DOI 10.1016/0028-3908(95)00030-A; MCLACHLAN RS, 1992, CAN J NEUROL SCI, V19, P487, DOI 10.1017/S0317167100041688; Menniti FS, 2000, NEUROPHARMACOLOGY, V39, P1147, DOI 10.1016/S0028-3908(99)00211-7; MILNER PM, 1958, ELECTROEN CLIN NEURO, V10, P705, DOI 10.1016/0013-4694(58)90073-7; Monaghan DT, 2012, NEUROCHEM INT, V61, P581, DOI 10.1016/j.neuint.2012.01.004; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; NEHLS DG, 1990, BRAIN RES, V511, P271, DOI 10.1016/0006-8993(90)90172-8; OBRENOVITCH TP, 1995, J NEUROPHYSIOL, V73, P2107, DOI 10.1152/jn.1995.73.5.2107; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406; Paoletti P, 2007, CURR OPIN PHARMACOL, V7, P39, DOI 10.1016/j.coph.2006.08.011; Peeters M, 2007, J PHARMACOL EXP THER, V321, P564, DOI 10.1124/jpet.106.117101; Pietrobon D, 2013, ANNU REV PHYSIOL, V75, P365, DOI 10.1146/annurev-physiol-030212-183717; Roberts TJ, 2008, NEUROSCI LETT, V444, P42, DOI 10.1016/j.neulet.2008.07.090; ROD MR, 1989, CAN J NEUROL SCI, V16, P340, DOI 10.1017/S031716710002919X; Sanz-Clemente A, 2013, NEUROSCIENTIST, V19, P62, DOI 10.1177/1073858411435129; Sharp CD, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-28; Shatillo A, 2013, NEUROSCIENCE, V253, P341, DOI 10.1016/j.neuroscience.2013.09.002; Shmuel A, 2006, NAT NEUROSCI, V9, P569, DOI 10.1038/nn1675; Smith JM, 2006, BIOL REV, V81, P457, DOI 10.1017/S1464793106007081; Somjen GG, 2001, PHYSIOL REV, V81, P1065, DOI 10.1152/physrev.2001.81.3.1065; Sonn J, 2000, BRAIN RES, V882, P212, DOI 10.1016/S0006-8993(00)02827-4; Sukhotinsky I, 2008, J CEREBR BLOOD F MET, V28, P1369, DOI 10.1038/jcbfm.2008.35; Toda N, 2009, CAN J PHYSIOL PHARM, V87, P581, DOI [10.1139/Y09-048, 10.1139/y09-048]; Verkhratsky A, 2007, NEUROSCIENTIST, V13, P28, DOI 10.1177/1073858406294270; Wang MY, 2012, BRIT J PHARMACOL, V165, P235, DOI 10.1111/j.1476-5381.2011.01553.x; WOODS RP, 1994, NEW ENGL J MED, V331, P1689, DOI 10.1056/NEJM199412223312505; YOUNG AR, 1981, J CEREBR BLOOD F MET, V1, P117, DOI 10.1038/jcbfm.1981.12; Zhou N, 2013, J CEREBR BLOOD F MET, V33, P1582, DOI 10.1038/jcbfm.2013.113	60	25	25	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	JUN	2015	93						164	170		10.1016/j.neuropharm.2015.01.028			7	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	CH0RK	WOS:000353729900016	25688928				2022-02-06	
J	Boutis, K; Weerdenburg, K; Koo, E; Schneeweiss, S; Zemek, R				Boutis, Kathy; Weerdenburg, Kirstin; Koo, Ellen; Schneeweiss, Suzan; Zemek, Roger			The Diagnosis of Concussion in a Pediatric Emergency Department	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; CHILDREN; MANAGEMENT; SYMPTOMS; KNOWLEDGE; PHYSICIANS; STATEMENT; SPECTRUM	Objectives To compare the proportion of children diagnosed with a concussion by pediatric emergency physicians vs the proportion who met criteria for this injury as recommended by Zurich Fourth International Conference on Concussion consensus statement and to determine clinical variables associated with a physician diagnosis of a concussion. Study design This was a prospective, cross-sectional study conducted at a tertiary care pediatric emergency department. We enrolled children ages 5 through 17 who presented with a head injury and collected data on demographics, mechanism of injury, head injury-related symptoms/signs, physician diagnosis, and discharge advice. Results We identified 495 children whose mean age was 10.1 years (SD 3.4 years); 308 (62.2%) were male. Emergency physicians diagnosed concussion in 200 (40.4%; 95% CI 36.1, 44.7) children, and 443 (89.5%; 95% CI 86.8, 92.2) met criteria for concussion in accordance with the Zurich consensus statement (P < .0001). Age >= 10 years (OR 1.8), presentation >= 1 day after injury (OR 2.4), injury from collision sports (OR 5.6), and symptoms of headache (OR 2.2) or amnesia (OR 3.4) were the variables significantly associated with an emergency physician's diagnosis of concussion. Conclusions Pediatric emergency physicians diagnosed concussion less often relative to international consensus-based guidelines and used a limited number of variables to make this diagnosis compared with current recommendations. Thus, pediatric emergency physicians may be missing cases of concussion and the corresponding opportunity to provide critical advice for cognitive and physical management.	[Boutis, Kathy; Weerdenburg, Kirstin; Koo, Ellen; Schneeweiss, Suzan] Hosp Sick Children, Div Emergency Med, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Boutis, Kathy; Weerdenburg, Kirstin; Koo, Ellen; Schneeweiss, Suzan] Univ Toronto, Toronto, ON, Canada; [Zemek, Roger] Childrens Hosp Eastern Ontario, Dept Pediat, Div Emergency Med, Ottawa, ON K1H 8L1, Canada; [Zemek, Roger] Univ Ottawa, Ottawa, ON, Canada		Boutis, K (corresponding author), Hosp Sick Children, Div Emergency Med, Dept Pediat, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	kathy.boutis@sickkids.ca	Schneeweiss, Sebastian/C-2125-2013; Zemek, Roger/H-1039-2018; Meijer, Anna/K-5118-2016	Schneeweiss, Sebastian/0000-0003-2575-467X; 	Hospital for Sick Children, via the Pediatric Research Academic Initiative at SickKids Emergency (PRAISE); Canadian Hospitals Injury Reporting and Prevention Program	Funded by the Hospital for Sick Children, via the Pediatric Research Academic Initiative at SickKids Emergency (PRAISE), and the Canadian Hospitals Injury Reporting and Prevention Program. The authors declare no conflicts of interest.	[Anonymous], 2013, BR J SPORTS MED, V47, P259; Aubry M, 2002, BRIT J SPORT MED, V36, P6; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Buchanan K, 2011, ANN EMERG MED, V58, pS185, DOI 10.1016/j.annemergmed.2011.06.048; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; Craton N, 2014, CLIN J SPORT MED, V24, P93; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Davis GA, 2014, BRIT J SPORT MED, V48, P98, DOI 10.1136/bjsports-2012-092132; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V12, P547, DOI 10.1007/s11910-012-0299-y; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Kinnaman KA, 2014, PEDIATR EMERG CARE, V30, P458, DOI 10.1097/PEC.0000000000000161; Kirkwood MW, 2014, PEDIATRICS, V133, P643, DOI 10.1542/peds.2013-3195; Lebrun CM, 2013, BRIT J SPORT MED, V47, P54, DOI 10.1136/bjsports-2012-091480; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Parachute Canada, 2014, RET PLAY GUID; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Purcell LK, 2014, PAED CHILD HEALT-CAN, V19, P153, DOI 10.1093/pch/19.3.153; Sarsfield MJ, 2013, PEDIATR EMERG CARE, V29, P884, DOI 10.1097/PEC.0b013e31829ec0d9; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Stewart TC, 2014, J TRAUMA ACUTE CARE, V76, P736, DOI 10.1097/TA.0b013e3182aafdf5; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Upchurch C, 2014, CLIN J SPORT MED; Zemek R, 2014, GUIDELINES DIAGNOSIN; Zemek R, 2014, CJEM IN PRESS; Zemek R, 2013, ACAD EMERG MED, V20, P1041, DOI 10.1111/acem.12220; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	39	25	26	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	MAY	2015	166	5					1214	U436		10.1016/j.jpeds.2015.02.013			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	CG6DW	WOS:000353387100025	25919731				2022-02-06	
J	Malik, M; Rangel-Barajas, C; Sumien, N; Su, C; Singh, M; Chen, ZL; Huang, RQ; Meunier, J; Maurice, T; Mach, RH; Luedtke, RR				Malik, Maninder; Rangel-Barajas, Claudia; Sumien, Nathalie; Su, Chang; Singh, Meharvan; Chen, Zhenglan; Huang, Ren-Qi; Meunier, Johann; Maurice, Tangui; Mach, Robert H.; Luedtke, Robert R.			The effects of sigma (sigma 1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice	BRITISH JOURNAL OF PHARMACOLOGY			English	Article							EXTRACELLULAR ACETYLCHOLINE LEVEL; D-ASPARTATE RECEPTOR; NMDA RECEPTORS; NEUROTROPHIC FACTOR; ALZHEIMERS-DISEASE; CONCISE GUIDE; IN-VIVO; CHOLINERGIC HYPOTHESIS; NEURONAL PLASTICITY; LEARNING IMPAIRMENT	Background and PurposeCognitive deficits in patients with Alzheimer's disease, Parkinson's disease, traumatic brain injury and stroke often involve alterations in cholinergic signalling. Currently available therapeutic drugs provide only symptomatic relief. Therefore, novel therapeutic strategies are needed to retard and/or arrest the progressive loss of memory. Experimental ApproachScopolamine-induced memory impairment provides a rapid and reversible phenotypic screening paradigm for cognition enhancement drug discovery. Male C57BL/6J mice given scopolamine (1mgkg(-1)) were used to evaluate the ability of LS-1-137, a novel sigma (sigma 1) receptor-selective agonist, to improve the cognitive deficits associated with muscarinic antagonist administration. Key ResultsLS-1-137 is a high-affinity (K-i = 3.2nM) sigma 1 receptor agonist that is 80-fold selective for sigma 1, compared with sigma 2 receptors. LS-1-137 binds with low affinity at D2-like (D2, D3 and D4) dopamine and muscarinic receptors. LS-1-137 was found to partially reverse the learning deficits associated with scopolamine administration using a water maze test and an active avoidance task. LS-1-137 treatment was also found to trigger the release of brain-derived neurotrophic factor from rat astrocytes. Conclusions and ImplicationsThe sigma 1 receptor-selective compound LS-1-137 may represent a novel candidate cognitive enhancer for the treatment of muscarinic receptor-dependent cognitive deficits.	[Malik, Maninder; Rangel-Barajas, Claudia; Sumien, Nathalie; Su, Chang; Singh, Meharvan; Chen, Zhenglan; Huang, Ren-Qi; Luedtke, Robert R.] Univ North Texas Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA; [Meunier, Johann; Maurice, Tangui] AMYLGEN, Montferrier Surlez, France; [Meunier, Johann; Maurice, Tangui] INSERM, U710, F-75654 Paris 13, France; [Maurice, Tangui] Univ Montpellier, F-34059 Montpellier, France; [Mach, Robert H.] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA		Luedtke, RR (corresponding author), Univ North Texas Hlth Sci Ctr, Dept Pharmacol & Neurosci, 3500 Camp Bowie, Ft Worth, TX 76107 USA.	robert.luedtke@unthsc.edu	Maurice, Tangui/AAP-2499-2020	Maurice, Tangui/0000-0002-4074-6793; Singh, Meharvan/0000-0002-8072-1769; Mach, Robert/0000-0002-7645-2869	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG027956] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01 AG027956] Funding Source: Medline		Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1607, DOI 10.1111/bph.12447; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1582, DOI 10.1111/bph.12446; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1449, DOI 10.1111/bph.12444; Antonini V, 2011, J ALZHEIMERS DIS, V24, P569, DOI 10.3233/JAD-2011-101794; Antonini V, 2009, J NEUROCHEM, V109, P744, DOI 10.1111/j.1471-4159.2009.06000.x; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; Craig LA, 2011, NEUROSCI BIOBEHAV R, V35, P1397, DOI 10.1016/j.neubiorev.2011.03.001; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Dumas JA, 2011, PHARMACOL BIOCHEM BE, V99, P254, DOI 10.1016/j.pbb.2011.02.022; Ebert U, 1998, EUR J CLIN INVEST, V28, P944; ENNACEUR A, 1992, PSYCHOPHARMACOLOGY, V109, P321, DOI 10.1007/BF02245880; Espallergues J, 2007, BRIT J PHARMACOL, V152, P267, DOI 10.1038/sj.bjp.0707386; FLOOD JF, 1986, BEHAV NEURAL BIOL, V45, P169, DOI 10.1016/S0163-1047(86)90750-8; Fontanilla D, 2009, SCIENCE, V323, P934, DOI 10.1126/science.1166127; Francardo V, 2014, BRAIN, V137, P1998, DOI 10.1093/brain/awu107; Francis PT, 1999, J NEUROL NEUROSUR PS, V66, P137, DOI 10.1136/jnnp.66.2.137; Fujimoto M, 2012, SYNAPSE, V66, P630, DOI 10.1002/syn.21549; Hashimoto K, 2013, PROG NEUROBIOL, V100, P15, DOI 10.1016/j.pneurobio.2012.09.001; Hayashi T., 2005, Current Neuropharmacology, V3, P267, DOI 10.2174/157015905774322516; Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036; Hayashi T, 2011, EXPERT OPIN THER TAR, V15, P557, DOI 10.1517/14728222.2011.560837; Huang RQ, 2010, NEUROPHARMACOLOGY, V58, P1246, DOI 10.1016/j.neuropharm.2010.03.006; Huang RQ, 1999, J NEUROPHYSIOL, V82, P1233, DOI 10.1152/jn.1999.82.3.1233; Huang YS, 2001, J MED CHEM, V44, P4404, DOI 10.1021/jm010384j; Huang YS, 1998, J MED CHEM, V41, P2361, DOI 10.1021/jm980032l; HULME EC, 1978, MOL PHARMACOL, V14, P737; Hunt DL, 2012, CURR OPIN NEUROBIOL, V22, P496, DOI 10.1016/j.conb.2012.01.007; Institute for Laboratory Animal Resources, 1996, GUIDE CARE USE LAB A; Ishikawa M, 2010, J RECEPT LIGAND CH R, V3, P25; Ito K, 2013, J CARDIOVASC PHARM, V62, P222, DOI 10.1097/FJC.0b013e3182970b15; JUNIEN JL, 1991, EUR J PHARMACOL, V200, P343, DOI 10.1016/0014-2999(91)90593-F; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/jphysiol.2010.192278]; KIRK CJ, 1994, J PHARMACOL EXP THER, V271, P1080; Kitaichi K, 2000, J CHEM NEUROANAT, V20, P375, DOI 10.1016/S0891-0618(00)00106-X; Klinkenberg I, 2010, NEUROSCI BIOBEHAV R, V34, P1307, DOI 10.1016/j.neubiorev.2010.04.001; Kourrich S, 2012, TRENDS NEUROSCI, V35, P762, DOI 10.1016/j.tins.2012.09.007; Kume T, 2002, EUR J PHARMACOL, V455, P91, DOI 10.1016/S0014-2999(02)02582-7; LINDEFORS N, 1992, EXP BRAIN RES, V88, P78, DOI 10.1007/BF02259130; Liu YT, 2007, J NEUROSCI, V27, P2846, DOI 10.1523/JNEUROSCI.0116-07.2007; Luedtke RR, 2012, BRAIN RES, V1441, P17, DOI 10.1016/j.brainres.2011.12.047; LUTHIN GR, 1984, J PHARMACOL EXP THER, V228, P648; Martina M, 2007, J PHYSIOL-LONDON, V578, P143, DOI 10.1113/jphysiol.2006.116178; Massey PV, 2004, J NEUROSCI, V24, P7821, DOI 10.1523/JNEUROSCI.1697-04.2004; MATSUNO K, 1993, J PHARMACOL EXP THER, V265, P851; MATSUNO K, 1995, BRAIN RES, V690, P200, DOI 10.1016/0006-8993(95)00618-Z; MATSUNO K, 1992, BRAIN RES, V575, P315, DOI 10.1016/0006-8993(92)90096-R; MATSUNO K, 1994, EUR J PHARMACOL, V261, P43, DOI 10.1016/0014-2999(94)90298-4; Mattson Mark P, 2004, NeuroRx, V1, P111, DOI 10.1007/BF03206571; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; Maurice T, 2006, J PHARMACOL EXP THER, V317, P606, DOI 10.1124/jpet.105.097394; MAURICE T, 1994, PHARMACOL BIOCHEM BE, V49, P859, DOI 10.1016/0091-3057(94)90235-6; Maurice T, 1998, NEUROSCIENCE, V83, P413, DOI 10.1016/S0306-4522(97)00405-3; Maurice T, 2002, DRUG NEWS PERSPECT, V15, P617, DOI 10.1358/dnp.2002.15.10.740241; Maurice T, 2001, BRAIN RES, V898, P113, DOI 10.1016/S0006-8993(01)02152-7; Maurice T, 1996, BRAIN RES, V733, P219, DOI 10.1016/0006-8993(96)00565-3; Maurice T, 2009, PHARMACOL THERAPEUT, V124, P195, DOI 10.1016/j.pharmthera.2009.07.001; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; Meunier J, 2006, BRIT J PHARMACOL, V149, P998, DOI 10.1038/sj.bjp.0706927; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Niitsu T, 2012, CURR PHARM DESIGN, V18, P875, DOI 10.2174/138161212799436476; Nishikawa H, 2000, EUR J PHARMACOL, V404, P41, DOI 10.1016/S0014-2999(00)00595-1; OLTON DS, 1968, PHYSIOL BEHAV, V3, P719, DOI 10.1016/0031-9384(68)90142-X; Ortega-Roldan JL, 2013, J BIOL CHEM, V288, P21448, DOI 10.1074/jbc.M113.450379; Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143; Peviani M, 2014, NEUROBIOL DIS, V62, P218, DOI 10.1016/j.nbd.2013.10.010; Ring RM, 2013, J PSYCHOPHARMACOL, V27, P930, DOI 10.1177/0269881113497614; Ruscher K, 2011, BRAIN, V134, P732, DOI 10.1093/brain/awq367; Scarpini E, 2003, LANCET NEUROL, V2, P539, DOI 10.1016/S1474-4422(03)00502-7; Senda T, 1997, PHYSIOL BEHAV, V61, P257, DOI 10.1016/S0031-9384(96)00447-7; Seth P, 1998, J NEUROCHEM, V70, P922; Shetty RA, 2013, AGE, V35, P1821, DOI 10.1007/s11357-012-9484-9; Su C, 2012, ENDOCRINOLOGY, V153, P4389, DOI 10.1210/en.2011-2177; Su TP, 2003, CURR MED CHEM, V10, P2073, DOI 10.2174/0929867033456783; Tarawneh R, 2010, CLIN GERIATR MED, V26, P125, DOI 10.1016/j.cger.2009.12.003; Tchedre KT, 2008, INVEST OPHTH VIS SCI, V49, P4993, DOI 10.1167/iovs.08-1867; Tovar KR, 2002, NEURON, V34, P253; Tsai Shang-Yi, 2009, Central Nervous System Agents in Medicinal Chemistry, V9, P184; Urani A, 1998, BRAIN RES, V799, P64, DOI 10.1016/S0006-8993(98)00469-7; van Waarde A, 2011, BEHAV BRAIN RES, V221, P543, DOI 10.1016/j.bbr.2009.12.043; Villard V, 2011, J PSYCHOPHARMACOL, V25, P1101, DOI 10.1177/0269881110379286; VILNER BJ, 1995, CANCER RES, V55, P408; Yagasaki Y, 2006, J BIOL CHEM, V281, P12941, DOI 10.1074/jbc.M508157200; Yamada K, 2002, LIFE SCI, V70, P735, DOI 10.1016/S0024-3205(01)01461-8; Yamada K, 2004, DRUG NEWS PERSPECT, V17, P435, DOI 10.1358/dnp.2004.17.7.863702	88	25	25	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	MAY	2015	172	10					2519	2531		10.1111/bph.13076			13	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	CG6EQ	WOS:000353389600009	25573298	Green Published, Bronze			2022-02-06	
J	Major, BP; Rogers, MA; Pearce, AJ				Major, Brendan P.; Rogers, Mark A.; Pearce, Alan J.			Using transcranial magnetic stimulation to quantify electrophysiological changes following concussive brain injury: A systematic review	CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY			English	Article						concussion; evoked potential; mild traumatic brain injury; systematic review; transcranial magnetic stimulation	SPORT-RELATED CONCUSSION; HUMAN MOTOR CORTEX; CHRONIC TRAUMATIC ENCEPHALOPATHY; IMPAIRED CORTICAL INHIBITION; SILENT PERIOD; HEAD-INJURY; LONG-TERM; INTRACORTICAL INHIBITION; FOOTBALL CODES; EXCITABILITY	Mild traumatic brain injury (mTBI) and sports concussion are a growing public health concern, with increasing demands for more rigorous methods to quantify changes in the brain post-injury. Electrophysiology, and in particular, transcranial magnetic stimulation (TMS), have been demonstrated to provide prognostic value in a range of neurological conditions; however, no review has quantified the efficacy of TMS in mTBI/concussion. In the present study, we present a systematic review and critical evaluation of the scientific literature from 1990 to 2014 that has used TMS to investigate corticomotor excitability responses at short-term (<12months), medium-term (1-5years), and long-term (>5years) post-mTBI/concussion. Thirteen studies met the selection criteria, with six studies presenting short-term changes, five studies presenting medium-term changes, and two studies presenting long-term changes. Irrespective of time post-concussion, change in intracortical inhibition was the most reported observation. Other findings included increased stimulation threshold, and slowed neurological conduction time. Although currently limited, the data suggest that TMS has prognostic value in detecting neurophysiological changes post-mTBI/concussion.	[Major, Brendan P.; Rogers, Mark A.; Pearce, Alan J.] Deakin Univ, Sch Psychol, Melbourne, Vic, Australia		Pearce, AJ (corresponding author), Deakin Univ, Sch Psychol, 221 Burwood Highway, Burwood, Vic 3125, Australia.	alan.pearce@deakin.edu.au	Pearce, Alan J/W-1195-2018	Pearce, Alan J/0000-0002-9264-9880; Major, Brendan/0000-0003-0991-5656; Rogers, Mark/0000-0002-6808-9545			Alwis DS, 2013, CLIN EXP PHARMACOL P, V40, P473, DOI 10.1111/1440-1681.12100; Assocation AMO, 2011, MAN CONC AUSTR FOOTB; Bajbouj M, 2006, BIOL PSYCHIAT, V59, P395, DOI 10.1016/j.biopsych.2005.07.036; Benwell NM, 2007, EXP BRAIN RES, V179, P255, DOI 10.1007/s00221-006-0790-2; Birbaumer N, 2008, CURR OPIN NEUROL, V21, P634, DOI 10.1097/WCO.0b013e328315ee2d; BRASILNETO JP, 1995, ACTA NEUROL SCAND, V92, P383; Chen R, 2000, MUSCLE NERVE, pS26; Chen R, 2008, CLIN NEUROPHYSIOL, V119, P504, DOI 10.1016/j.clinph.2007.10.014; Chipchase L, 2012, CLIN NEUROPHYSIOL, V123, P1698, DOI 10.1016/j.clinph.2012.05.003; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Corp DT, 2014, NEUROSCI BIOBEHAV R, V43, P74, DOI 10.1016/j.neubiorev.2014.03.017; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Darling SR, 2014, CLIN J SPORT MED, V24, P128, DOI 10.1097/JSM.0000000000000026; Daskalakis ZJ, 2002, ARCH GEN PSYCHIAT, V59, P347, DOI 10.1001/archpsyc.59.4.347; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dimou S, 2014, J NEUROTRAUM, V31, P413, DOI 10.1089/neu.2013.3050; Eldaief Mark C, 2013, Neurol Clin Pract, V3, P519; Gilbert F, 2012, MED J AUSTRALIA, V196, P561, DOI 10.5694/mja11.11218; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; INGHILLERI M, 1993, J PHYSIOL-LONDON, V466, P521; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Killane I, 2013, ENG MED BIOL SOC EMB; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Kutcher JS, 2013, BRIT J SPORT MED, V47, P299, DOI 10.1136/bjsports-2013-092257; Livingston SC, 2012, J CLIN NEUROPHYSIOL, V29, P23, DOI 10.1097/WNP.0b013e318246ae46; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McDonnell MN, 2007, EXP BRAIN RES, V180, P181, DOI 10.1007/s00221-006-0849-0; McGinley M, 2010, EXP GERONTOL, V45, P671, DOI 10.1016/j.exger.2010.04.005; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Miller NR, 2014, BRAIN INJURY, P1; Moher D, 2009, PHYS THER, V89, P873, DOI 10.1093/ptj/89.9.873; Muller-Dahlhaus JFM, 2008, J PHYSIOL-LONDON, V586, P495, DOI 10.1113/jphysiol.2007.142059; Partridge B, 2014, NEUROETHICS-NETH, V7, P63, DOI 10.1007/s12152-013-9182-z; Pearce A. J., 2011, CLIN EXERCISE REHABI, P68; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Pearce AJ, 2012, J SCI MED SPORT, V15, P164, DOI 10.1016/j.jsams.2011.09.001; Philpott AL, 2013, NEUROSCI BIOBEHAV R, V37, P1420, DOI 10.1016/j.neubiorev.2013.05.009; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Siebner HR, 1998, MUSCLE NERVE, V21, P1209, DOI 10.1002/(SICI)1097-4598(199809)21:9<1209::AID-MUS15>3.0.CO;2-M; SLAVIN RE, 1995, J CLIN EPIDEMIOL, V48, P9, DOI 10.1016/0895-4356(94)00097-A; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Tallus J, 2013, J NEUROTRAUM, V30, P1270, DOI 10.1089/neu.2012.2760; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Vucic S, 2013, J NEUROL NEUROSUR PS, V84, P1161, DOI 10.1136/jnnp-2012-304019; W.H. Organization, 2006, NEUR DIS PUBL HLTH C; Werhahn KJ, 1999, J PHYSIOL-LONDON, V517, P591, DOI 10.1111/j.1469-7793.1999.0591t.x; WILSON SA, 1993, J NEUROL SCI, V114, P216, DOI 10.1016/0022-510X(93)90301-E; Wolters A., 2008, OXFORD HDB TRANSCRAN, P91; Ziemann U, 1998, NEUROLOGY, V51, P1320, DOI 10.1212/WNL.51.5.1320; Ziemann U, 1996, ANN NEUROL, V40, P367, DOI 10.1002/ana.410400306; Ziemann U., 2008, OXFORD HDB TRANSCRAN, P135	69	25	26	0	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1440-1681			CLIN EXP PHARMACOL P	Clin. Exp. Pharmacol. Physiol.	APR	2015	42	4					394	405		10.1111/1440-1681.12363			12	Pharmacology & Pharmacy; Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy; Physiology	CE4WY	WOS:000351832200011	25603731				2022-02-06	
J	Solga, AC; Pong, WW; Walker, J; Wylie, T; Magrini, V; Apicelli, AJ; Griffith, M; Griffith, OL; Kohsaka, S; Wu, GF; Brody, DL; Mardis, ER; Gutmann, DH				Solga, Anne C.; Pong, Winnie W.; Walker, Jason; Wylie, Todd; Magrini, Vincent; Apicelli, Anthony J.; Griffith, Malachi; Griffith, Obi L.; Kohsaka, Shinichi; Wu, Gregory F.; Brody, David L.; Mardis, Elaine R.; Gutmann, David H.			RNA-Sequencing Reveals Oligodendrocyte and Neuronal Transcripts in Microglia Relevant to Central Nervous System Disease	GLIA			English	Article						laser-capture microdissection; fluorescence-activated cell sorting; macrophage	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRANSLATIONAL PROFILING APPROACH; CONTROLLED CORTICAL IMPACT; AMYLOID-BETA-PROTEIN; PERITONEAL-MACROPHAGES; ALVEOLAR MACROPHAGES; ACTIVATION; EXPRESSION; SUBPOPULATIONS; FRACTIONATION	Expression profiling of distinct central nervous system (CNS) cell populations has been employed to facilitate disease classification and to provide insights into the molecular basis of brain pathology. One important cell type implicated in a wide variety of CNS disease states is the resident brain macrophage (microglia). In these studies, microglia are often isolated from dissociated brain tissue by flow sorting procedures [fluorescence-activated cell sorting (FACS)] or from postnatal glial cultures by mechanic isolation. Given the highly dynamic and state-dependent functions of these cells, the use of FACS or short-term culture methods may not accurately capture the biology of brain microglia. In the current study, we performed RNA-sequencing using Cx3cr1(+/GFP) labeled microglia isolated from the brainstem of 6-week-old mice to compare the transcriptomes of FACS-sorted versus laser capture microdissection (LCM). While both isolation techniques resulted in a large number of shared (common) transcripts, we identified transcripts unique to FACS-isolated and LCM-captured microglia. In particular, approximate to 50% of these LCM-isolated microglial transcripts represented genes typically associated with neurons and glia. While these transcripts clearly localized to microglia using complementary methods, they were not translated into protein. Following the induction of murine experimental autoimmune encephalomyelitis, increased oligodendrocyte and neuronal transcripts were detected in microglia, while only the myelin basic protein oligodendrocyte transcript was increased in microglia after traumatic brain injury. Collectively, these findings have implications for the design and interpretation of microglia transcriptome-based investigations. GLIA 2015;63:531-548	[Solga, Anne C.; Pong, Winnie W.; Apicelli, Anthony J.; Wu, Gregory F.; Brody, David L.; Gutmann, David H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Walker, Jason; Wylie, Todd; Magrini, Vincent; Griffith, Malachi; Griffith, Obi L.; Mardis, Elaine R.] Washington Univ, Sch Med, Genome Inst, St Louis, MO USA; [Kohsaka, Shinichi] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neurochem, Kodaira, Tokyo 1870031, Japan		Gutmann, DH (corresponding author), Dept Neurol, Box 8111,660 South Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu	Griffith, Malachi/P-1285-2014; Apicelli, Anthony/AAB-8879-2021; Mardis, Elaine/W-2202-2019; Magrini, Vincent/AAT-5830-2020; Griffith, Obi/P-1286-2014	Griffith, Malachi/0000-0002-6388-446X; Apicelli, Anthony/0000-0001-6791-8113; Magrini, Vincent/0000-0002-2019-4872; Pong, Winnie/0000-0001-8254-3305; Griffith, Obi/0000-0002-0843-4271; Gutmann, David/0000-0002-3127-5045	NCI Cancer Center Support GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA91842]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC4 NS072916]; W.M. Keck FoundationW.M. Keck Foundation; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA091842] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC4NS072916] Funding Source: NIH RePORTER	Grant sponsor: NCI Cancer Center Support Grant (to The Siteman Cancer Center); Grant number: #P30 CA91842; Grant sponsor: National Institutes of Health; Grant number: RC4 NS072916 (to DHG); Grant sponsor: W.M. Keck Foundation (to WWP).	Boddeke EWGH, 1999, EUR J PHARMACOL, V374, P309, DOI 10.1016/S0014-2999(99)00307-6; Cabanski CR, 2014, J MOL DIAGN, V16, P440, DOI 10.1016/j.jmoldx.2014.03.004; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Casha S, 2012, BRAIN, V135, P1224, DOI 10.1093/brain/aws072; CHANDLER DB, 1986, J LEUKOCYTE BIOL, V39, P371, DOI 10.1002/jlb.39.4.371; Davalos D, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2230; DAVIS JB, 1992, BIOCHEM BIOPH RES CO, V189, P1096, DOI 10.1016/0006-291X(92)92317-Q; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Doyle JP, 2008, CELL, V135, P749, DOI 10.1016/j.cell.2008.10.029; Fitzner D, 2011, J CELL SCI, V124, P447, DOI 10.1242/jcs.074088; Gitik M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-24; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Graeber MB, 2002, GLIA, V40, P252, DOI 10.1002/glia.10147; HASSAN NF, 1991, J LEUKOCYTE BIOL, V50, P86, DOI 10.1002/jlb.50.1.86; Heiman M, 2008, CELL, V135, P738, DOI 10.1016/j.cell.2008.10.028; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hirasawa T, 2005, J NEUROSCI RES, V81, P357, DOI 10.1002/jnr.20480; Hurley SD, 1999, GLIA, V25, P304, DOI 10.1002/(SICI)1098-1136(19990201)25:3<304::AID-GLIA10>3.0.CO;2-W; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Izzo A, 2008, BIOL CHEM, V389, P333, DOI 10.1515/BC.2008.037; Jack C, 2005, J NEUROSCI RES, V81, P363, DOI 10.1002/jnr.20482; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kaindl AM, 2012, ANN NEUROL, V72, P536, DOI 10.1002/ana.23626; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Khodosevich K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001151; Klein RS, 2004, J CELL BIOCHEM, V92, P213, DOI 10.1002/jcb.20052; Lemarchant S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-133; Lewis CA, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/803701; Liang KJ, 2009, INVEST OPHTH VIS SCI, V50, P4444, DOI 10.1167/iovs.08-3357; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; MATSUMOTO Y, 1992, J NEUROIMMUNOL, V37, P23, DOI 10.1016/0165-5728(92)90152-B; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Miranda KC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096094; MORIMURA T, 1990, ACTA NEUROPATHOL, V80, P287, DOI 10.1007/BF00294647; OHMANN HB, 1986, J LEUKOCYTE BIOL, V39, P167, DOI 10.1002/jlb.39.2.167; Ohtaki Hirokazu, 2013, Acta Neurochir Suppl, V118, P49, DOI 10.1007/978-3-7091-1434-6_8; ONEILL SJ, 1984, INFECT IMMUN, V46, P282, DOI 10.1128/IAI.46.1.282-284.1984; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934; Parkhurst CN, 2010, CURR OPIN NEUROBIOL, V20, P595, DOI 10.1016/j.conb.2010.07.002; PENFOLD PL, 1991, VISUAL NEUROSCI, V7, P383, DOI 10.1017/S0952523800004879; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; Petersohn D, 1996, EUR J BIOCHEM, V239, P827, DOI 10.1111/j.1432-1033.1996.0827u.x; PLASMAN N, 1993, RES IMMUNOL, V144, P151, DOI 10.1016/0923-2494(93)80070-F; Pong WW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077571; Pong WW, 2013, ANN NEUROL, V73, P303, DOI 10.1002/ana.23813; Racke M.K., 2001, CURR PROTOC NEUROSCI; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; RASMUSSEN SE, 1983, ACTA PATH MICRO IM C, V91, P299; RINNER WA, 1995, GLIA, V14, P257, DOI 10.1002/glia.440140403; Roberts A, 2011, BIOINFORMATICS, V27, P2325, DOI 10.1093/bioinformatics/btr355; Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r22; Roggendorf W, 1996, ACTA NEUROPATHOL, V92, P288, DOI 10.1007/s004010050520; Sanz E, 2009, P NATL ACAD SCI USA, V106, P13939, DOI 10.1073/pnas.0907143106; Sasaki A, 1997, ACTA NEUROPATHOL, V94, P316, DOI 10.1007/s004010050713; Simmons GW, 2011, J NEUROPATH EXP NEUR, V70, P51, DOI 10.1097/NEN.0b013e3182032d37; Szabo M, 2013, NEUROSCIENCE, V241, P280, DOI 10.1016/j.neuroscience.2013.03.033; Tariq MA, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr547; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Veillette A, 2007, IMMUNITY, V27, P698, DOI 10.1016/j.immuni.2007.11.005; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Waller R, 2012, J NEUROSCI METH, V208, P108, DOI 10.1016/j.jneumeth.2012.04.014; Wang LH, 1996, J NEUROSCI, V16, P6197; Windak R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073294	67	25	25	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	APR	2015	63	4					531	548		10.1002/glia.22754			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB9SX	WOS:000349973900002	25258010	Green Accepted			2022-02-06	
J	Buonora, JE; Yarnell, AM; Lazarus, RC; Mousseau, M; Latour, LL; Rizoli, SB; Baker, AJ; Rhind, SG; Diaz-Arrastia, R; Mueller, GP				Buonora, John E.; Yarnell, Angela M.; Lazarus, Rachel C.; Mousseau, Michael; Latour, Lawrence L.; Rizoli, Sandro B.; Baker, Andrew J.; Rhind, Shawn G.; Diaz-Arrastia, Ramon; Mueller, Gregory P.			Multivariate analysis of traumatic brain injury: development of an assessment score	FRONTIERS IN NEUROLOGY			English	Article						biomarkers; assessment score; human; mild traumatic brain injury; multivariate analysis	NEURON-SPECIFIC ENOLASE; C-TERMINAL HYDROLASE; CREATINE-KINASE-BB; MILD HEAD-INJURY; SERUM-LEVELS; CEREBROSPINAL-FLUID; NEUROTROPHIC FACTOR; OXIDATIVE STRESS; SYSTEMS BIOLOGY; ICE HOCKEY	Important challenges for the diagnosis and monitoring of mild traumatic brain injury (mTBI) include the development of plasma biomarkers for assessing neurologic injury, monitoring pathogenesis, and predicting vulnerability for the development of untoward neurologic outcomes. While several biomarker proteins have shown promise in this regard, used individually, these candidates lack adequate sensitivity and/or specificity for making a definitive diagnosis or identifying those at risk of subsequent pathology. The objective for this study was to evaluate a panel of six recognized and novel biomarker candidates for the assessment of TB I in adult patients. The biomarkers studied were selected on the basis of their relative brain-specificities and potentials to reflect distinct features of TBI mechanisms including (1) neuronal damage assessed by neuron-specific enolase (NSE) and brain derived neurotrophic factor (BDNF); (2) oxidative stress assessed by peroxiredoxin 6 (PRDX6); (3) glial damage and gliosis assessed by glial fibrillary acidic protein and S100 calcium binding protein beta (S100b); (4) immune activation assessed by monocyte chemoattractant protein 1/chemokine (C-C motif) ligand 2 (MCP1/CCL2); and (5) disruption of the intercellular adhesion apparatus assessed by intercellular adhesion protein-5 (ICAM-5). The combined fold-changes in plasma levels of PRDX6, S100b, MCP1, NSE, and BDNF resulted in the formulation of a TBI assessment score that identified mTBI with a receiver operating characteristic (ROC) area under the curve of 0.97, when compared to healthy controls. This research demonstrates that a profile of biomarker responses can be used to formulate a diagnostic score that is sensitive for the detection of mTBI. Ideally, this multivariate assessment strategy will be refined with additional biomarkers that can effectively assess the spectrum of TBI and identify those at particular risk for developing neuropathologies as consequence of a mTBI event.	[Buonora, John E.; Lazarus, Rachel C.; Mousseau, Michael; Mueller, Gregory P.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Buonora, John E.] US Army, Grad Program Anesthesia Nursing, Acad Hlth Sci, Ft Sam Houston, TX USA; [Yarnell, Angela M.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci Res, Behav Biol Branch, Silver Spring, MD USA; [Latour, Lawrence L.] NINDS, Stroke Branch, Bethesda, MD 20892 USA; [Latour, Lawrence L.; Rhind, Shawn G.] Toronto Res Ctr, Def Res & Dev Canada, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Anesthesia, Keenan Res Ctr,Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Surg, Keenan Res Ctr,Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Rizoli, Sandro B.; Baker, Andrew J.] Univ Toronto, St Michaels Hosp, Dept Crit Care Med, Keenan Res Ctr,Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, Cara Phelan Ctr Trauma Res, Brain Injury Lab, Keenan Res Ctr,Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA		Mueller, GP (corresponding author), Uniformed Serv Univ Hlth Sci USU, Dept Anat Physiol & Genet, Room C2117,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	gregory.mueller@usuhs.edu	Latour, Larry/AAH-5663-2021	Latour, Larry/0000-0001-6160-5263; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Rhind, Shawn/0000-0003-2300-0620	Defense Medical Research and Development; Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; TriService Nursing Research Program Grant [HT9404-12-1-TS13]; Department of National Defense of Canada (DND) through the Technology Investment Fund (TIF) program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003120] Funding Source: NIH RePORTER	Principle source of funding was provided by a grant from the Defense Medical Research and Development, the Center for Neuroscience and Regenerative Medicine and the TriService Nursing Research Program Grant # HT9404-12-1-TS13. The authors also gratefully acknowledge the support of the Department of National Defense of Canada (DND) through the Technology Investment Fund (TIF) program. We also would like to acknowledge Mr. James Freedy for his contribution to the development of the single and multiplex assay platforms; Ms. Maria Shiu and Mr. Alex Di Battista for their technical assistance with sample collection and processing. The opinions expressed here are those of the author(s), and are not necessarily representative of those of the Uniformed Services University of the Health Sciences (USUHS), the United States Army and/or the Department of Defense, USA.	Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Bazarian JJ, 2006, RESTOR NEUROL NEUROS, V24, P163; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Blyth BJ, 2010, EMERG MED CLIN N AM, V28, P571, DOI 10.1016/j.emc.2010.03.003; Bruce J, 2014, CLIN NEUROPSYCHOL, V28, P14, DOI 10.1080/13854046.2013.866272; Carr ME, 2009, MIL MED, V174, P622, DOI 10.7205/MILMED-D-02-4708; Chase Alex, 2014, Nat Rev Neurol, V10, P240, DOI 10.1038/nrneurol.2014.65; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chhunchha B, 2013, AM J PHYSIOL-CELL PH, V304, pC636, DOI 10.1152/ajpcell.00345.2012; Cirillo C, 2011, WORLD J GASTROENTERO, V17, P1261, DOI 10.3748/wjg.v17.i10.1261; Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010; Cook GA, 2014, MIL MED, V179, P1083, DOI 10.7205/MILMED-D-13-00435; DAY INM, 1984, CLIN CHIM ACTA, V136, P219, DOI 10.1016/0009-8981(84)90295-X; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Di Battista AP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00044; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; El-Maraghi S, 2013, EGYPT J CRIT CARE ME, V1, P25, DOI 10.1016/j.ejccm.2012.12.002; Fatma N, 2009, FREE RADICAL RES, V43, P783, DOI 10.1080/10715760903062887; Feala JD, 2013, J NEUROTRAUM, V30, P1101, DOI 10.1089/neu.2012.2631; Fujimura H, 2002, THROMB HAEMOSTASIS, V87, P728; Goemaere J, 2012, J COMP NEUROL, V520, P258, DOI 10.1002/cne.22689; Graham MR, 2011, INT J IMMUNOPATH PH, V24, P119, DOI 10.1177/039463201102400114; Guingab-Cagmat JD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00061; Guo H, 2000, ANN NEUROL, V48, P590, DOI 10.1002/1531-8249(200010)48:4<590::AID-ANA5>3.3.CO;2-Z; Guzel A, 2008, NEUROSURG REV, V31, P439, DOI 10.1007/s10143-008-0148-2; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; KATZ RT, 1992, AM FAM PHYSICIAN, V46, P1491; KENT C, 1992, DEV BRAIN RES, V68, P241, DOI 10.1016/0165-3806(92)90066-6; Kim RY, 2014, J NEUROIMMUNOL, V274, P53, DOI 10.1016/j.jneuroim.2014.06.009; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Manevich Y, 2014, FREE RADICAL BIO MED, V72, P210, DOI 10.1016/j.freeradbiomed.2014.04.002; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newman TA, 2013, HUM REPROD, V28, P2502, DOI 10.1093/humrep/det274; Ning L, 2013, J CELL SCI, V126, P77, DOI 10.1242/jcs.106674; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Ploughman M, 2009, STROKE, V40, P1490, DOI 10.1161/STROKEAHA.108.531806; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Sedaghat F, 2008, HIPPOKRATIA, V12, P198; Selenica MLB, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-86; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Tait RJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-171; Tator CH, 2002, INJURY PREV, V8, pIV33, DOI 10.1136/ip.8.suppl_4.iv33; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xu Y, 2014, EXP ANIM TOKYO, V63, P247, DOI 10.1538/expanim.63.247; Yang HP, 2012, COMP FUNCT GENOM, DOI 10.1155/2012/368938; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	67	25	26	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	MAR 30	2015	6								68	10.3389/fneur.2015.00068			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CU8EV	WOS:000363775100001	25870583	Green Published, gold			2022-02-06	
J	Moreno, E; Fernandez-Marrero, Y; Meyer, P; Rhiner, C				Moreno, Eduardo; Fernandez-Marrero, Yuniel; Meyer, Patricia; Rhiner, Christa			Brain Regeneration in Drosophila Involves Comparison of Neuronal Fitness	CURRENT BIOLOGY			English	Article							ADULT MIDGUT REGENERATION; CELL COMPETITION; IMAGINAL DISCS; PATHWAY; STEM; MECHANISMS; MYC; PROLIFERATION; APOPTOSIS; WINGLESS	Darwinian-like cell selection has been studied during development and cancer [1-11]. Cell selection is often mediated by direct intercellular comparison of cell fitness, using "fitness fingerprints" [12-14]. In Drosophila, cells compare their fitness via several iso-forms of the transmembrane protein Flower [12, 13]. Here, we studied the role of intercellular fitness comparisons during regeneration. Regeneration-competent organisms are traditionally injured by amputation [15, 16], whereas in clinically relevant injuries such as local ischemia or traumatic injury, damaged tissue remains within the organ [17-19]. We reasoned that "Darwinian" interactions between old and newly formed tissues may be important in the elimination of damaged cells. We used a model of adult brain regeneration in Drosophila in which mechanical puncture activates regenerative neurogenesis based on damage-responsive stem cells [20]. We found that apoptosis after brain injury occurs in damage-exposed tissue located adjacent to zones of de novo neurogenesis. Injury-affected neurons start to express isoforms of the Flower cell fitness indicator protein not found on intact neurons. We show that this change in the neuronal fitness fingerprint is required to recognize and eliminate such neurons. Moreover, apoptosis is inhibited if all neurons express "low-fitness" markers, showing that the availability of new and healthy cells drives tissue replacement. In summary, we found that elimination of impaired tissue during brain regeneration requires comparison of neuronal fitness and that tissue replacement after brain damage is coordinated by injury-modulated fitness fingerprints. Intercellular fitness comparisons between old and newly formed tissues could be a general mechanism of regenerative tissue replacement.	[Moreno, Eduardo; Fernandez-Marrero, Yuniel; Meyer, Patricia; Rhiner, Christa] Univ Bern, Inst Cell Biol IZB, CH-3012 Bern, Switzerland		Rhiner, C (corresponding author), Univ Bern, Inst Cell Biol IZB, CH-3012 Bern, Switzerland.	christa.rhiner@izb.unibe.ch		Rhiner, Christa/0000-0001-7577-8042; moreno, eduardo/0000-0001-5040-452X; Fernandez-Marrero, Yuniel/0000-0003-4102-6955	University of Bern; European Research CouncilEuropean Research Council (ERC)European Commission; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Josef Steiner Cancer Research Foundation	We thank Dr. Alain Hauser for help with statistical analysis; H. Bellen, B. Thompson, K. Basler, I. Hariharan, and the Bloomington stock center for providing flies; and the Hybridoma Bank for antibodies. Research in this paper was supported by the University of Bern (C.R.) and grants of the European Research Council, the Swiss National Science Foundation, and the Josef Steiner Cancer Research Foundation to E.M.	Alvarado AS, 2006, NAT REV GENET, V7, P873, DOI 10.1038/nrg1923; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Bach EA, 2007, GENE EXPR PATTERNS, V7, P323, DOI 10.1016/j.modgep.2006.08.003; Bergantinos C, 2010, DEVELOPMENT, V137, P1169, DOI 10.1242/dev.045559; Bondar T, 2010, CELL STEM CELL, V6, P309, DOI 10.1016/j.stem.2010.03.002; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Chatterjee N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034063; Classen AK, 2009, NAT GENET, V41, P1150, DOI 10.1038/ng.445; Claveria C, 2013, NATURE, V500, P39, DOI 10.1038/nature12389; Cordero JB, 2012, EMBO J, V31, P3901, DOI 10.1038/emboj.2012.248; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; Fernandez-Hernandez I, 2013, CELL REP, V3, P1857, DOI 10.1016/j.celrep.2013.05.034; Freeman MR, 2014, CURR OPIN NEUROBIOL, V27, P224, DOI 10.1016/j.conb.2014.05.001; Grusche FA, 2011, DEV BIOL, V350, P255, DOI 10.1016/j.ydbio.2010.11.020; HOLM S, 1979, SCAND J STAT, V6, P65; Karpowicz P, 2010, DEVELOPMENT, V137, P4135, DOI 10.1242/dev.060483; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Martins VC, 2014, NATURE, V509, P465, DOI 10.1038/nature13317; Merino MM, 2015, CELL, V160, P461, DOI 10.1016/j.cell.2014.12.017; Merino MM, 2013, CURR BIOL, V23, P1300, DOI 10.1016/j.cub.2013.05.053; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Moreno E, 2004, CELL, V117, P117, DOI 10.1016/S0092-8674(04)00262-4; Moreno E, 2002, NATURE, V416, P755, DOI 10.1038/416755a; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; Oertel M, 2006, GASTROENTEROLOGY, V130, P507, DOI 10.1053/j.gastro.2005.10.049; Petrova E, 2012, DIS MODEL MECH, V5, P553, DOI 10.1242/dmm.008623; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rhiner C, 2010, DEV CELL, V18, P985, DOI 10.1016/j.devcel.2010.05.010; ROBINOW S, 1988, DEV BIOL, V126, P294, DOI 10.1016/0012-1606(88)90139-X; Sancho M, 2013, DEV CELL, V26, P19, DOI 10.1016/j.devcel.2013.06.012; Shaw RL, 2010, DEVELOPMENT, V137, P4147, DOI 10.1242/dev.052506; Smith-Bolton RK, 2009, DEV CELL, V16, P797, DOI 10.1016/j.devcel.2009.04.015; Tamori Y, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000422; Tanaka EM, 2011, DEV CELL, V21, P172, DOI 10.1016/j.devcel.2011.06.016; Thompson BJ, 2006, CELL, V126, P767, DOI 10.1016/j.cell.2006.07.013; Tornini VA, 2014, DEV CELL, V29, P139, DOI 10.1016/j.devcel.2014.04.007; Vermeulen L, 2013, SCIENCE, V342, P995, DOI 10.1126/science.1243148; Vincent JP, 2013, NAT REV MOL CELL BIO, V14, P581, DOI 10.1038/nrm3639; Yao CK, 2009, CELL, V138, P947, DOI 10.1016/j.cell.2009.06.033	39	25	25	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0960-9822	1879-0445		CURR BIOL	Curr. Biol.	MAR 30	2015	25	7					955	963		10.1016/j.cub.2015.02.014			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	CE8KL	WOS:000352091100034	25754635	Green Published, hybrid			2022-02-06	
J	Leonard, AV; Thornton, E; Vink, R				Leonard, Anna V.; Thornton, Emma; Vink, Robert			The Relative Contribution of Edema and Hemorrhage to Raised Intrathecal Pressure after Traumatic Spinal Cord Injury	JOURNAL OF NEUROTRAUMA			English	Article						hemorrhage; spinal cord injury; edema; intrathecal pressure	BLOOD-FLOW; BARRIER PERMEABILITY; VASCULAR MECHANISMS; COMPRESSION INJURY; BRAIN-INJURY; RAT; ISCHEMIA; BALLOON; PATHOPHYSIOLOGY; REPAIR	Raised intrathecal pressure (ITP) after traumatic spinal cord injury (SCI) is a critically important aspect of injury development that may result in significantly greater tissue damage and worsened functional outcome. Raised ITP is caused by the accumulation of blood and/or water (edema), and while their occurrence after traumatic SCI has been well established, the relative contribution of both processes to the development of ITP after SCI has not yet been determined. Accordingly, the current study investigates the temporal profile of raised ITP after traumatic SCI in relation to both hemorrhage and edema development. A closed balloon compression injury was induced at T10 in New Zealand White rabbits. Animals were thereafter assessed for spinal water content (edema), ITP, lesion and hemorrhage volume, and albumin immunoreactivity from 5 h to 1 week post-SCI. Early increases in ITP at 5 h post-injury were associated with significant increases in blood volume. ITP, however, was maximal at 3 days post-SCI, at which time there was an associated significant increase in edema that persisted for 1 week. We conclude that raised ITP after traumatic SCI is initially driven by volumetric increases in hemorrhage, while edema becomes the primary driver of ITP at 3 days post-injury.	[Leonard, Anna V.; Thornton, Emma] Univ Adelaide, Sch Med Sci, Adelaide Ctr Neurosci Res, Adelaide, SA 5005, Australia; [Vink, Robert] Univ S Australia, Div Hlth Sci, Adelaide, SA 5001, Australia		Leonard, AV (corresponding author), Univ Adelaide, Sch Med Sci, Level 4 Med Sch South,Frome Rd, Adelaide, SA 5005, Australia.	anna.leonard@adelaide.edu.au	Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	Neil Sacshe Foundation Fellowship; Neurosurgical Research Foundation (Australia)	Funded, in part, by a Neil Sacshe Foundation Fellowship to AVL, and by the Neurosurgical Research Foundation (Australia).	Ates O, 2007, J CLIN NEUROSCI, V14, P658, DOI 10.1016/j.jocn.2006.03.023; Batchelor PE, 2011, J NEUROTRAUM, V28, P809, DOI 10.1089/neu.2010.1622; Bilgen M, 2002, MAGN RESON IMAGING, V20, P337, DOI 10.1016/S0730-725X(02)00504-0; Cohen DM, 2009, NMR BIOMED, V22, P332, DOI 10.1002/nbm.1343; Demediuk P, 1990, Adv Neurol, V52, P225; Goldsmith HS, 2009, J AM COLL SURGEONS, V208, P289, DOI 10.1016/j.jamcollsurg.2008.10.021; GOODMAN JH, 1976, J NEUROSURG, V44, P418, DOI 10.3171/jns.1976.44.4.0418; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Helps SC, 2012, APPL IMMUNOHISTO M M, V20, P82, DOI 10.1097/PAI.0b013e31821fc8cd; Horn EM, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E12; JACOBS TP, 1992, STROKE, V23, P367, DOI 10.1161/01.STR.23.3.367; Jaeger CB, 1997, EXP NEUROL, V144, P381, DOI 10.1006/exnr.1996.6405; Kwon BK, 2009, J NEUROSURG-SPINE, V10, P181, DOI 10.3171/2008.10.SPINE08217; Leonard AV, 2013, J NEUROTRAUM, V30, P1812, DOI 10.1089/neu.2013.2993; LEVI L, 1993, NEUROSURGERY, V33, P1007, DOI 10.1097/00006123-199312000-00008; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; MARTIN D, 1992, J NEUROSCI RES, V32, P539, DOI 10.1002/jnr.490320409; NEMECEK S, 1977, ACTA NEUROCHIR, V37, P7, DOI 10.1007/BF01401922; Nesic O, 2006, NEUROSCIENCE, V143, P779, DOI 10.1016/j.neuroscience.2006.08.079; Padayachy LC, 2010, CHILD NERV SYST, V26, P441, DOI 10.1007/s00381-009-1034-0; Popovich PG, 2012, EXP NEUROL, V233, P615, DOI 10.1016/j.expneurol.2010.11.016; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; SENTER HJ, 1979, J NEUROSURG, V50, P198, DOI 10.3171/jns.1979.50.2.0198; SHARMA HS, 1993, NEUROSCIENCE, V57, P443, DOI 10.1016/0306-4522(93)90076-R; Sharma HS, 2005, CURR PHARM DESIGN, V11, P1353, DOI 10.2174/1381612053507837; SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; SYPERT GW, 1990, CLIN NEUR, V36, P186; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Vale FL, 1997, J NEUROSURG, V87, P239, DOI 10.3171/jns.1997.87.2.0239; Vanicky I, 2001, J NEUROTRAUM, V18, P1399, DOI 10.1089/08977150152725687; Vink R, 2003, ACT NEUR S, V86, P257; WANG R, 1993, SURG NEUROL, V39, P348, DOI 10.1016/0090-3019(93)90198-A; Whetstone WD, 2003, J NEUROSCI RES, V74, P227, DOI 10.1002/jnr.10759; WINKLER T, 1994, NEUROSCI RES, V21, P91, DOI 10.1016/0168-0102(94)90072-8; YOUNG W, 1982, J NEUROSURG, V56, P706, DOI 10.3171/jns.1982.56.5.0706	38	25	27	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2015	32	6					397	402		10.1089/neu.2014.3543			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CC9DQ	WOS:000350668400004	25111333				2022-02-06	
J	Rodger, J; Sherrard, RM				Rodger, Jennifer; Sherrard, Rachel M.			Optimising repetitive transcranial magnetic stimulation for neural circuit repair following traumatic brain injury	NEURAL REGENERATION RESEARCH			English	Article									[Rodger, Jennifer] Univ Western Australia, Sch Anim Biol, Expt & Regenerat Neurosci, Perth, WA 6009, Australia; [Sherrard, Rachel M.] Univ Paris 06, Sorbonne Univ, Paris, France; [Sherrard, Rachel M.] CNRS, Inst Biol Paris Seine B2A, UMR Biol Adaptat & Ageing 8256, Paris, France		Rodger, J (corresponding author), Univ Western Australia, Sch Anim Biol, Expt & Regenerat Neurosci, Perth, WA 6009, Australia.	jennifer.rodger@uwa.edu.au	Rodger, Jennifer/H-5735-2014; LUO, JINGJING/AAZ-6697-2021; Sherrard, Rachel M/D-5446-2013; Sherrard, Rachel/Y-1355-2019	Rodger, Jennifer/0000-0003-3413-4229; LUO, JINGJING/0000-0002-3222-1276; Sherrard, Rachel/0000-0002-6595-3545			Deng ZD, 2013, BRAIN STIMUL, V6, P1, DOI 10.1016/j.brs.2012.02.005; Di Lazzaro V, 2013, BRAIN STIMUL, V6, P469, DOI 10.1016/j.brs.2013.01.004; Ellaway PH, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00042; Grehl S, 2015, BRAIN STIMUL, V8, P114, DOI 10.1016/j.brs.2014.09.012; Henrich-Noack Petra, 2013, Neurosci Lett, V543, P1, DOI 10.1016/j.neulet.2013.03.013; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Makowiecki K, 2014, J NEUROSCI, V34, P10780, DOI 10.1523/JNEUROSCI.0723-14.2014; Mix A, 2015, DEV NEUROBIOL, V75, P1, DOI 10.1002/dneu.22205; Pell GS, 2011, PROG NEUROBIOL, V93, P59, DOI 10.1016/j.pneurobio.2010.10.003; Rodger J, 2012, FASEB J, V26, P1593, DOI 10.1096/fj.11-194878; Vlachos A, 2012, J NEUROSCI, V32, P17514, DOI 10.1523/JNEUROSCI.0409-12.2012; Wiltschko R., 1995, MAGNETIC ORIENTATION	12	25	25	0	11	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	1673-5374	1876-7958		NEURAL REGEN RES	Neural Regen. Res.	MAR	2015	10	3					357	359		10.4103/1673-5374.153676			3	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	CH0VH	WOS:000353740000007	25878575	Green Submitted, Green Published, gold			2022-02-06	
J	Pechmann, A; Anastasopoulos, C; Korinthenberg, R; van Velthoven-Wurster, V; Kirschner, J				Pechmann, Astrid; Anastasopoulos, Constantin; Korinthenberg, Rudolf; van Velthoven-Wurster, Vera; Kirschner, Janbernd			Decompressive Craniectomy after Severe Traumatic Brain Injury in Children: Complications and Outcome	NEUROPEDIATRICS			English	Article						traumatic brain injury; decompressive craniectomy; children; complications; outcome	INTRACRANIAL HYPERTENSION; CLINICAL ARTICLE; RISK-FACTORS; PEDIATRIC-PATIENTS; SUBDURAL HYGROMA; ADULTS; CRANIOPLASTY; MANAGEMENT; SEIZURES; INFANTS	Decompressive craniectomy (DC) is a controversially discussed neurosurgical procedure to reduce elevated intracranial pressure after severe traumatic brain injury (TBI). In contrast to adults, several studies could show a benefit for the pediatric population, but still DC is considered as an emergency procedure only. The aim of our study was to identify secondary complications and long-term sequelae of the procedure. All children presenting to the University Medical Center Freiburg between 2005 and 2013 who underwent DC after severe TBI were retrospectively reviewed with respect to complications and outcome. Twelve children were included with a mean Glasgow Coma Scale of 4.5 +/- 1.7. The most frequent complications after TBI and DC were formation of hygroma (83%), aseptic bone resorption of the reimplanted bone flap (50%), post-traumatic hydrocephalus (42%), secondary infection or dysfunction of ventriculoperitoneal shunt (25%) or cranioplasty (33%), and epilepsy (33%). Because of these complications, 75% of patients required further surgery in addition to cranioplasty with up to eight interventions. At follow-up, mean Glasgow Outcome Scale was 3.3 +/- 1.2. Within our patient population, we demonstrated high incidence of complications after DC, leading to further surgical procedures and longer hospitalization. These potential complications have to be considered in any decision about DC as an emergency procedure.	[Pechmann, Astrid; Anastasopoulos, Constantin; Korinthenberg, Rudolf; Kirschner, Janbernd] Univ Med Ctr Freiburg, Div Neuropediat & Muscle Disorders, D-79106 Freiburg, Germany; [van Velthoven-Wurster, Vera] Univ Med Ctr Freiburg, Dept Neurosurg, Freiburg, Germany		Kirschner, J (corresponding author), Univ Med Ctr Freiburg, Div Neuropediat & Muscle Disorders, Mathildenstr 1, D-79106 Freiburg, Germany.	Janbernd.Kirschner@uniklinik-freiburg.de	Korinthenberg, Rudolf/A-9796-2009; Kirschner, Janbernd/Q-1493-2019; Kirschner, Janbernd/H-7418-2016	Kirschner, Janbernd/0000-0003-1618-7386; Kirschner, Janbernd/0000-0003-1618-7386; Korinthenberg, Rudolf/0000-0002-4638-3460			Aarabi B, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0947; Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Bowers CA, 2013, J NEUROSURG-PEDIATR, V11, P526, DOI 10.3171/2013.1.PEDS12483; Cambra FJ, 2010, AN PEDIATR, V73, P12, DOI 10.1016/j.anpedi.2010.02.011; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Giza CC, 2007, CURR OPIN CRIT CARE, V13, P143, DOI 10.1097/MCC.0b013e32808255dc; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; Honeybul S, 2012, J NEUROTRAUM, V29, P1872, DOI 10.1089/neu.2012.2356; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; JENNETT B, 1975, LANCET, V1, P480; Jeon SW, 2011, J KOREAN NEUROSURG S, V49, P355, DOI 10.3340/jkns.2011.49.6.355; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Liu YG, 2009, INJURY, V40, P968, DOI 10.1016/j.injury.2009.01.006; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Martin KD, 2014, ACTA NEUROCHIR, V156, P813, DOI 10.1007/s00701-014-2021-0; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Suarez EP, 2011, J TRAUMA, V71, P133, DOI 10.1097/TA.0b013e318211071f; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Shi SS, 2011, CHIN J TRAUMATOL, V14, P343, DOI 10.3760/cma.j.issn.1008-1275.2011.06.004; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410	33	25	30	0	10	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0174-304X	1439-1899		NEUROPEDIATRICS	Neuropediatrics	FEB	2015	46	1					5	12		10.1055/s-0034-1393707			8	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	AZ3OK	WOS:000348136600003	25343328				2022-02-06	
J	Stasolla, F; Caffo, AO; Damiani, R; Perilli, V; Di Leone, A; Albano, V				Stasolla, Fabrizio; Caffo, Alessandro O.; Damiani, Rita; Perilli, Viviana; Di Leone, Antonia; Albano, Vincenza			Assistive technology-based programs to promote communication and leisure activities by three children emerged from a minimal conscious state	COGNITIVE PROCESSING			English	Article						Assistive technology; Traumatic brain injury; Post-coma; Minimal conscious state; Quality of life; Social validation	AUTISM SPECTRUM DISORDERS; TRAUMATIC BRAIN-INJURY; SCANNING KEYBOARD EMULATOR; MICROSWITCH-BASED PROGRAMS; QUALITY-OF-LIFE; MOTOR DISABILITIES; MULTIPLE DISABILITIES; ALZHEIMERS-DISEASE; 2 BOYS; ENGAGEMENT	This study proposed the use of assistive technology (AT) to promote communication and leisure opportunities by three children with traumatic brain injury (TBI). Furthermore, it assessed the effects of such technology on the indices of positive participation and provided a social validation procedure. Three children emerged from a minimal conscious state and presenting extensive motor disabilities were involved. The intervention program allowed the participants to request and to choice preferred items independently and to perform literacy through a keyboard emulator. A multiple probe design across behaviors with post-intervention check was employed. Outcome measures were correct requests, understandable words, intervals with positive participation, and scores of social validation assessment. Request and choice behaviors and literacy improved significantly during intervention phases. During post-intervention check, all participants consolidated their performance. Moreover, indices of positive participation increased during intervention phases. Scores of social validation assessment showed that the combination of both behaviors was preferable to the same considered separately. AT program showed to be suitable for promoting constructive engagement and literacy behaviors by children with TBI. Future research is needed to generalize this data to a larger sample and to develop new technology for people with different levels of disabilities due to TBI.	[Stasolla, Fabrizio] Lega Filo dOro Res Ctr, Molfetta, Italy; [Caffo, Alessandro O.; Damiani, Rita; Di Leone, Antonia; Albano, Vincenza] Univ Bari, Dept Educ Sci, Bari, Italy; [Perilli, Viviana] Lega Filo dOro Res Ctr, Lesmo, Italy		Stasolla, F (corresponding author), Lega Filo dOro Res Ctr, Molfetta, Italy.	f.stasolla@psico.uniba.it	Stasolla, Fabrizio/I-5418-2019	Stasolla, Fabrizio/0000-0003-1626-9664; Caffo, Alessandro O./0000-0003-3973-8152			Anderson V, 2012, J HEAD TRAUMA REHAB, V27, P199, DOI 10.1097/HTR.0b013e31821a9d2b; Caffo AO, 2014, RES DEV DISABIL, V35, P572, DOI 10.1016/j.ridd.2013.12.003; Chiapparino C, 2011, LIFE SPAN DISABIL, V14, P45; CRAWFORD MR, 1993, J DEV PHYS DISABIL, V5, P349; FELCE D, 1995, RES DEV DISABIL, V16, P51, DOI 10.1016/0891-4222(94)00028-8; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Hagen C, 1998, LEVELS COGNITIVE FUN; Kramer ME, 2013, J HEAD TRAUMA REHAB, V28, P361, DOI 10.1097/HTR.0b013e31824da031; Lancioni GE, 2007, PERCEPT MOTOR SKILL, V105, P47, DOI 10.2466/PMS.105.1.47-54; Lancioni GE, 2006, J INTELL DISABIL RES, V50, P739, DOI 10.1111/j.1365-2788.2006.00839.x; Lancioni GE, 2014, AUT CHILD PSYCHO, P1, DOI 10.1007/978-1-4899-8029-8; Lancioni G, 2010, DEV NEUROREHABIL, V13, P248, DOI 10.3109/17518423.2010.485596; Lancioni GE, 2007, J DEV PHYS DISABIL, V19, P593, DOI 10.1007/s10882-007-9073-5; Lancioni Giulio E, 2005, Cogn Process, V6, P177, DOI 10.1007/s10339-005-0003-0; Lancioni GE, 2013, RES DEV DISABIL, V34, P2959, DOI 10.1016/j.ridd.2013.06.006; Lancioni GE, 2013, J DEV PHYS DISABIL, V25, P273, DOI 10.1007/s10882-012-9301-5; Lancioni GE, 2012, RES DEV DISABIL, V33, P1605, DOI 10.1016/j.ridd.2012.03.028; Lancioni GE, 2010, RES DEV DISABIL, V31, P1121, DOI 10.1016/j.ridd.2010.06.019; Lancioni GE, 2009, RES DEV DISABIL, V30, P203, DOI 10.1016/j.ridd.2008.03.001; Lancioni GE, 2006, J DEV PHYS DISABIL, V18, P383, DOI 10.1007/s10882-006-9024-6; Lidstrom H, 2012, DISABIL REHABIL-ASSI, V7, P287, DOI 10.3109/17483107.2011.635332; Ratliffe KT, 2012, INFORM TECHNOL DEV, V18, P209, DOI 10.1080/02681102.2011.643207; Sasse N, 2013, J HEAD TRAUMA REHAB, V28, P464, DOI 10.1097/HTR.0b013e318263977d; Stasolla F, 2014, NEUROREHABILITATION, V35, P253, DOI 10.3233/NRE-141112; Stasolla F, 2014, RES AUTISM SPECT DIS, V8, P1071, DOI 10.1016/j.rasd.2014.05.016; Stasolla F, 2014, RES AUTISM SPECT DIS, V8, P472, DOI 10.1016/j.rasd.2014.01.007; Stasolla F, 2014, RES AUTISM SPECT DIS, V8, P376, DOI 10.1016/j.rasd.2013.12.020; Stasolla F, 2013, RES AUTISM SPECT DIS, V7, P1265, DOI 10.1016/j.rasd.2013.07.010; Stasolla F, 2013, RES DEV DISABIL, V34, P2694, DOI 10.1016/j.ridd.2013.05.029	29	25	25	0	12	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1612-4782	1612-4790		COGN PROCESS	Cogn. Process.	FEB	2015	16	1					69	78		10.1007/s10339-014-0625-1			10	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	AZ3GS	WOS:000348116100007	25077461				2022-02-06	
J	de Koning, ME; Spikman, JM; Coers, A; Schonherr, MC; van der Naalt, J				de Koning, Myrthe E.; Spikman, Jacoba M.; Coers, Annemieke; Schonherr, Marleen C.; van der Naalt, Joukje			Pathways of care the first year after moderate and severe traumatic brain injury-Discharge destinations and outpatient follow-up	BRAIN INJURY			English	Article						Discharge destinations; outcome; outpatient visit; post-acute care; rehabilitation; return to work; traumatic brain injury	INPATIENT REHABILITATION; OUTCOMES; ADULTS; NEEDS; TRANSITION; HEALTH; RETURN; HOME	Primary objective: To determine the pathways of care within the first year after traumatic brain injury (TBI) and to explore whether provided care is related to residual impairments. Research design: Retrospective study of 343 patients with moderate and severe TBI admitted to a Level-1 trauma centre. Methods and procedures: Discharge destinations from hospital to home and frequency of outpatient visits were determined. Outcome was defined 1 year after injury by the Extended Glasgow Outcome Scale and Return to Work. Results: Most (94%) patients had returned home 1-year after injury despite cognitive (76%), behavioural (67%) and physical (55%) impairments. One in four patients was severely disabled and 32% had resumed work on a previous level. Two-thirds of all patients went home as secondary discharge destination and 50% needed inpatient rehabilitation. Almost half of patients needed outpatient care, mostly for behavioural and cognitive impairments. One in 10 patients consulted a psychiatrist, with 55% unfavourable outcome. Of those patients initially discharged to home without follow-up, eventually 10% needed outpatient rehabilitation. Conclusions: One-year after injury most patients had returned home with residual impairments and frequent medical consultations. This finding warrants further investigation to define appropriate aftercare by various medical specialists aimed at long-term community integration.	[de Koning, Myrthe E.; Coers, Annemieke; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Neuropsychol, Groningen, Netherlands; [Schonherr, Marleen C.] Univ Groningen, Univ Med Ctr Groningen, Dept Rehabil Med, Groningen, Netherlands		van der Naalt, J (corresponding author), Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	j.van.der.naalt@umcg.nl		van der Naalt, Joukje/0000-0001-9873-2418; Spikman, Jacoba/0000-0002-6477-0763			Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, P125; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; de Guise E, 2006, J HEAD TRAUMA REHAB, V21, P527, DOI 10.1097/00001199-200611000-00007; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Esselman PC, 2004, ARCH PHYS MED REHAB, V85, P1445, DOI 10.1016/j.apmr.2003.10.018; Fleming J, 2013, J HEAD TRAUMA REHABI; Foster M, 2004, SOC SCI MED, V59, P1867, DOI 10.1016/j.socscimed.2004.02.017; Fraas M, 2007, BRAIN INJURY, V21, P1267, DOI 10.1080/02699050701721794; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Huebner RA, 2003, AM J OCCUP THER, V57, P177, DOI 10.5014/ajot.57.2.177; Jourdan C, 2013, NEUROREHAB NEURAL RE, V27, P35, DOI 10.1177/1545968312440744; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kim H, 2006, CAN J NEUROL SCI, V33, P48, DOI 10.1017/S0317167100004686; Koponen S, 2011, BRAIN INJURY, V25, P1029, DOI 10.3109/02699052.2011.607783; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Malec JF, 2009, BRAIN INJURY, V23, P22, DOI 10.1080/02699050802590320; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Nalder E, 2012, J HEAD TRAUMA REHAB, V27, P143, DOI 10.1097/HTR.0b013e3182168fb1; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Rusconi S, 2003, DISABIL REHABIL, V25, P1281, DOI 10.1080/09638280310001608582; Schootman M, 1999, BRAIN INJURY, V13, P995; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner BJ, 2008, DISABIL REHABIL, V30, P1153, DOI 10.1080/09638280701532854; Turner BJ, 2011, DISABIL REHABIL, V33, P818, DOI 10.3109/09638288.2010.513422; Van Baalen B, 2008, BRAIN INJURY, V22, P25, DOI 10.1080/02699050701810662; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Willemse-Van Son AHP, 2009, J REHABIL MED, V41, P521, DOI 10.2340/16501977-0377; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	38	25	25	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	4					423	429		10.3109/02699052.2014.982188			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	CF8JE	WOS:000352803300002	25437043				2022-02-06	
J	Franke, LM; Czarnota, JN; Ketchum, JM; Walker, WC				Franke, Laura M.; Czarnota, Jenna N.; Ketchum, Jessica M.; Walker, William C.			Factor Analysis of Persistent Postconcussive Symptoms Within a Military Sample With Blast Exposure	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast; factor analysis; postconcussive syndrome; Rivermead Postconcussion Questionnaire; traumatic brain injury	TRAUMATIC BRAIN-INJURY; POST-CONCUSSION SYNDROME; HEAD-INJURY; QUESTIONNAIRE; ASSOCIATION; PREVALENCE; COMPLAINTS; MECHANISM; CRITERIA; FIT	Objective: To determine the factor structure of persistent postconcussive syndrome symptoms in a blast-exposed military sample and validate factors against objective and symptom measures. Setting: Veterans Affairs medical center and military bases. Participants: One hundred eighty-one service members and veterans with at least 1 significant exposure to blast during deployment within the 2 years prior to study enrollment. Design: Confirmatory and exploratory factor analyses of the Rivermead Postconcussion Questionnaire. Main Measures: Rivermead Postconcussion Questionnaire, PTSD (posttraumatic stress disorder) Symptom Checklist-Civilian, Center for Epidemiological Studies Depression scale, Sensory Organization Test, Paced Auditory Serial Addition Test, California Verbal Learning Test, and Delis-Kaplan Executive Function System subtests. Results: The 3-factor structure of persistent postconcussive syndrome was not confirmed. A 4-factor structure was extracted, and factors were interpreted as reflecting emotional, cognitive, visual, and vestibular functions. All factors were associated with scores on psychological symptom inventories; visual and vestibular factors were also associated with balance performance. There was no significant association between the cognitive factor and neuropsychological performance or between a history of mild traumatic brain injury and factor scores. Conclusion: Persistent postconcussive symptoms observed months after blast exposure seem to be related to 4 distinct forms of distress, but not to mild traumatic brain injury per se, with vestibular and visual factors possibly related to injury of sensory organs by blast.	[Franke, Laura M.; Walker, William C.] Def & Vet Brain Injury Ctr, Richmond, VA 23249 USA; [Franke, Laura M.; Walker, William C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Richmond, VA USA; [Czarnota, Jenna N.; Ketchum, Jessica M.] Virginia Commonwealth Univ, Dept Biostat, Sch Med, Richmond, VA USA; [Franke, Laura M.; Walker, William C.] Adv Mil Med Inc, Henry M Jackson Fdn, Bethesda, MD USA		Franke, LM (corresponding author), Def & Vet Brain Injury Ctr, 1201 Broad Rock Blvd 151, Richmond, VA 23249 USA.	Laura.Manning3@va.gov	Ketchum, Jessica/AAE-8200-2020	Ketchum, Jessica/0000-0002-5566-3691	Congressionally Directed Medical Research Projects (CDMRP) [W91ZSQ8118N620]; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs [W91YTZ-12-C-0132]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32ES007334]; NIEHS, T32 Training Grant: Integration of Mixtures, Toxicology, Toxicogenomics and Statistics [T32ES007334]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32ES007334] Funding Source: NIH RePORTER	This work was funded by the Congressionally Directed Medical Research Projects (CDMRP) Award # W91ZSQ8118N620 and in part by the Defense and Veterans Brain Injury Center (DVBIC) through contract # W91YTZ-12-C-0132 to the Henry M. Jackson Foundation.; The project was supported by National Institutes of Health T32ES007334. Jenna Czarnota is supported by NIEHS, T32 Training Grant: Integration of Mixtures, Toxicology, Toxicogenomics and Statistics (T32ES007334).	[Anonymous], 2008, DOD VA COMM DEF TBI; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.88.3.588; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Brown M.W., 1993, SOCIOL METHOD RES, P136; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Cernich AN, 2012, J HEAD TRAUMA REHAB, V27, P253, DOI 10.1097/HTR.0b013e3182585cd5; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 2001, DELIS KAPLAN EXECUTI; Ehrlinger J, 2003, J PERS SOC PSYCHOL, V84, P5, DOI 10.1037/0022-3514.84.1.5; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Gorsuch R.L., 1983, FACTOR ANAL; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; HUSAINI BA, 1980, J COMMUNITY PSYCHOL, V0008, P00020, DOI [DOI 10.1002/1520-6629(198001, DOI 10.1002/1520-6629(198001)8:1&LT;20::AID-JCOP2290080105&GT;3.0.CO;2-Y]; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; LIPOWSKI ZJ, 1988, AM J PSYCHIAT, V145, P1358; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; TANELIAN T, 2008, INVISIBLE WOUNDS MEN; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Walker WC, 2013, J HEAD TRAUMA REHAB, V28, P68, DOI 10.1097/HTR.0b013e318255dfd0; Weathers F.W., 1993, ANN CONV INT SOC TRA; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; ZANE RS, 1991, OTOLARYNG HEAD NECK, V104, P137, DOI 10.1177/019459989110400129	48	25	25	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					E34	E46		10.1097/HTR.0000000000000042			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400005	24695267	Green Accepted			2022-02-06	
J	Goodus, MT; Guzman, AM; Calderon, F; Jiang, YH; Levison, SW				Goodus, Matthew T.; Guzman, Alanna M.; Calderon, Frances; Jiang, Yuhui; Levison, Steven W.			Neural Stem Cells in the Immature, but Not the Mature, Subventricular Zone Respond Robustly to Traumatic Brain Injury	DEVELOPMENTAL NEUROSCIENCE			English	Article						Subventricular zone; Neurogenesis; Stem cells; Progenitor; Cell proliferation	LEUKEMIA INHIBITORY FACTOR; CONTROLLED CORTICAL IMPACT; HYPOXIC-ISCHEMIC INJURY; RAT-BRAIN; PERINATAL HYPOXIA/ISCHEMIA; CELLULAR PROLIFERATION; REACTIVE ASTROCYTES; CEREBRAL-CORTEX; MOUSE-BRAIN; ADULT RATS	Pediatric traumatic brain injury is a significant problem that affects many children each year. Progress is being made in developing neuroprotective strategies to combat these injuries. However, investigators are a long way from therapies to fully preserve injured neurons and glia. To restore neurological function, regenerative strategies will be required. Given the importance of stem cells in repairing damaged tissues and the known persistence of neural precursors in the subventricular zone (SVZ), we evaluated regenerative responses of the SVZ to a focal brain lesion. As tissues repair more slowly with aging, injury responses of male Sprague Dawley rats at 6, 11, 17, and 60 days of age and C57BI/6 mice at 14 days of age were compared. In the injured immature animals, cell proliferation in the dorsolateral SVZ more than doubled by 48 h. By contrast, the proliferative response was almost undetectable in the adult brain. Three approaches were used to assess the relative numbers of bona fide neural stem cells, as follows: the neurosphere assay (on rats injured at postnatal day 11, P11), flow cytometry using a novel 4-marker panel (on mice injured at P14) and staining for stem/progenitor cell markers in the niche (on rats injured at P17). Precursors from the injured immature SVZ formed almost twice as many spheres as precursors from uninjured age-matched brains. Furthermore, spheres formed from the injured brain were larger, indicating that the neural precursors that formed these spheres divided more rapidly. Flow cytometry revealed a 2-fold increase in the percentage of stem cells, a 4-fold increase in multipotential progenitor-3 cells and a 2.5-fold increase in glial-restricted progenitor-2/multipotential-3 cells. Analogously, there was a 2-fold increase in the mitotic index of nestin+/Mash1-immunoreactive cells within the immediately subependymal region. As the early postnatal SVZ is predominantly generating glial cells, an expansion of precursors might not necessarily lead to the production of many new neurons. On the contrary, many BrdU+/doublecortin+ cells were observed streaming out of the SVZ into the neocortex 2 weeks after injuries to P11 rats. However, very few new mature neurons were seen adjacent to the lesion 28 days after injury. Altogether, these data indicate that immature SVZ cells mount a more robust proliferative response to a focal brain injury than adult cells, which includes an expansion of stem cells, primitive progenitors and neuroblasts. Nonetheless, this regenerative response does not result in significant neuronal replacement, indicating that new strategies need to be implemented to retain the regenerated neurons and glia that are being produced. (C) 2014 S. Karger AG, Basel	[Goodus, Matthew T.; Guzman, Alanna M.; Calderon, Frances; Jiang, Yuhui; Levison, Steven W.] Rutgers State Univ, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA; [Goodus, Matthew T.; Guzman, Alanna M.; Calderon, Frances; Jiang, Yuhui; Levison, Steven W.] Rutgers State Univ, New Jersey Med Sch, Grad Sch Biomed Sci, Newark, NJ 07103 USA		Levison, SW (corresponding author), Rutgers State Univ, New Jersey Med Sch, Dept Neurol & Neurosci, Lab Regenerat Neurobiol, 205 South Orange Ave, Newark, NJ 07103 USA.	steve.levison@rutgers.edu	Levison, Steven W./Q-6903-2019; Goodus, Matthew T/O-4986-2016	Levison, Steven W./0000-0002-1264-7309; Goodus, Matthew T/0000-0001-5022-8562	New Jersey Commission on Brain Injury Research [09-3207-BIR-E-2]	This research was supported by grant 09-3207-BIR-E-2 from the New Jersey Commission on Brain Injury Research awarded to S.W.L.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Aguirre A, 2005, J NEUROSCI, V25, P11092, DOI 10.1523/JNEUROSCI.2981-05.2005; Alagappan D, 2013, ASN NEURO, V5, DOI 10.1042/AN20120032; Alagappan D, 2009, ASN NEURO, V1, DOI 10.1042/AN20090002; Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009; Banner LR, 1997, EXP NEUROL, V147, P1, DOI 10.1006/exnr.1997.6536; Bessis A, 2007, GLIA, V55, P233, DOI 10.1002/glia.20459; Brazel CY, 2005, NEUROSCIENCE, V131, P55, DOI 10.1016/j.neuroscience.2004.10.038; Buono KD, 2011, THESIS U MED DENT NE, P1; Buono KD, 2012, DEV NEUROSCI-BASEL, V34, P449, DOI 10.1159/000345155; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Clancy B, 2007, NEUROTOXICOLOGY, V28, P931, DOI 10.1016/j.neuro.2007.01.014; Covey MV, 2011, ANN NEUROL, V70, P616, DOI 10.1002/ana.22473; Covey MV, 2010, DEV NEUROSCI-BASEL, V32, P488, DOI 10.1159/000321607; Craig CG, 1996, J NEUROSCI, V16, P2649; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Faiz M, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-26; Felling RJ, 2006, J NEUROSCI, V26, P4359, DOI 10.1523/JNEUROSCI.1898-05.2006; Florio P, 2007, ADV CLIN CHEM, V43, P117, DOI 10.1016/S0065-2423(06)43004-3; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Goings GE, 2004, BRAIN RES, V996, P213, DOI 10.1016/j.brainres.2003.10.034; Jones KS, 2012, AM J STEM CELLS, V1, P48; Keenan HT, 2006, DEV NEUROSCI-BASEL, V28, P256, DOI 10.1159/000094152; Kennard MA, 1936, AM J PHYSIOL, V115, P138, DOI 10.1152/ajplegacy.1936.115.1.138; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kim WR, 2011, EUR J NEUROSCI, V33, P599, DOI 10.1111/j.1460-9568.2010.07557.x; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Levison SW, 1997, J NEUROSCI RES, V48, P83, DOI 10.1002/(SICI)1097-4547(19970415)48:2<83::AID-JNR1>3.0.CO;2-8; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Macas J, 2006, J NEUROSCI, V26, P13114, DOI 10.1523/JNEUROSCI.4667-06.2006; Mattson MP, 2008, ANN NY ACAD SCI, V1144, P97, DOI 10.1196/annals.1418.005; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Miller JT, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-63; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Popa-Wagner A, 2011, AGEING RES REV, V10, P71, DOI 10.1016/j.arr.2009.10.008; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Romanko MJ, 2004, J CEREBR BLOOD F MET, V24, P814, DOI 10.1097/01.WCB.0000123906.17746.00; ROMIJN HJ, 1991, EARLY HUM DEV, V26, P61, DOI 10.1016/0378-3782(91)90044-4; Rothstein RP, 2002, DEV NEUROSCI-BASEL, V24, P426, DOI 10.1159/000069052; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shi J, 2007, EUR J NEUROSCI, V25, P3499, DOI 10.1111/j.1460-9568.2007.05624.x; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Smith KS, 2007, BEHAV NEUROSCI, V121, P449, DOI 10.1037/0735-7044.121.3.449; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Szele FG, 1996, J COMP NEUROL, V368, P439, DOI 10.1002/(SICI)1096-9861(19960506)368:3<439::AID-CNE9>3.0.CO;2-6; Tanaka N, 1999, BRAIN RES, V827, P130, DOI 10.1016/S0006-8993(99)01319-0; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Xu G, 2005, DEV NEUROSCI-BASEL, V27, P228, DOI 10.1159/000085996; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	54	25	26	0	10	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2015	37	1					29	42		10.1159/000367784			14	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	CB5IK	WOS:000349660500003	25377490				2022-02-06	
J	Joseph, B; Pandit, V; Aziz, H; Kulvatunyou, N; Zangbar, B; Green, DJ; Haider, A; Tang, A; O'Keeffe, T; Gries, L; Friese, RS; Rhee, P				Joseph, Bellal; Pandit, Viraj; Aziz, Hassan; Kulvatunyou, Narong; Zangbar, Bardiya; Green, Donald J.; Haider, Ansab; Tang, Andrew; O'Keeffe, Terence; Gries, Lynn; Friese, Randall S.; Rhee, Peter			Mild traumatic brain injury defined by Glasgow Coma Scale: Is it really mild?	BRAIN INJURY			English	Article						Glasgow Coma Scale; mild brain injury; outcome trauma; traumatic brain injury	NEW-ORLEANS CRITERIA; MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; CT; PREDICTORS; RULE	Introduction: Conventionally, a Glasgow Coma Scale (GCS) score of 13-15 defines mild traumatic brain injury (mTBI). The aim of this study was to identify the factors that predict progression on repeat head computed tomography (RHCT) and neurosurgical intervention (NSI) in patients categorized as mild TBI with intracranial injury (intracranial haemorrhage and/or skull fracture). Methods: This study performed a retrospective chart review of all patients with traumatic brain injury who presented to a level 1 trauma centre. Patients with blunt TBI, an intracranial injury and admission GCS of 13-15 without anti-platelet and anti-coagulation therapy were included. The outcome measures were: progression on RHCT and need for neurosurgical intervention (craniotomy and/or craniectomy). Results: A total of 1800 patients were reviewed, of which 876 patients were included. One hundred and fifteen (13.1%) patients had progression on RHCT scan. Progression on RHCT was 8-times more likely in patients with subdural haemorrhage >= 10 mm, 5-times more likely with epidural haemorrhage >= 10 mm and 3-times more likely with base deficit >= 4. Forty-seven patients underwent a neurosurgical intervention. Patients with displaced skull fracture were 10-times more likely and patients with base deficit >4 were 21-times more likely to have a neurosurgical intervention. Conclusion: In patients with intracranial injury, a mild GCS score (GCS 13-15) in patients with an intracranial injury does not preclude progression on repeat head CT and the need for a neurosurgical intervention. Base deficit greater than four and displaced skull fracture are the greatest predictors for neurosurgical intervention in patients with mild TBI and an intracranial injury.	[Joseph, Bellal; Pandit, Viraj; Aziz, Hassan; Kulvatunyou, Narong; Zangbar, Bardiya; Green, Donald J.; Haider, Ansab; Tang, Andrew; O'Keeffe, Terence; Gries, Lynn; Friese, Randall S.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma Crit Care Emergency Surg & Burns, Tucson, AZ 85727 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care Burns & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85727 USA.	bjoseph@surgery.arizona.edu	Aziz, Hassan/ABA-5681-2021; Zangbar, Bardiya/K-7147-2014	Zangbar, Bardiya/0000-0003-1215-1693; Aziz, Hassan/0000-0003-0406-1946			Carlson AP, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.8.FOCUS10182; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Faul M, 2010, TRAUMATIC BRAIN INJU; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P965, DOI 10.1097/TA.0000000000000161; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P817, DOI 10.1097/TA.0b013e3182aafcf0; Joseph B, 2014, AM SURGEON, V80, P43; Joseph B, 2014, J SURG RES, V186, P287, DOI 10.1016/j.jss.2013.08.009; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Kisat M, 2012, J SURG RES, V173, P31, DOI 10.1016/j.jss.2011.04.059; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; Rixen D, 2001, SHOCK, V15, P83, DOI 10.1097/00024382-200115020-00001; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092	21	25	26	0	10	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	1					11	16		10.3109/02699052.2014.945959			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AW1WC	WOS:000346078000002	25111571				2022-02-06	
J	Sambasivan, K; Grilli, L; Gagnon, I				Sambasivan, Krithika; Grilli, Lisa; Gagnon, Isabelle			Balance and mobility in clinically recovered children and adolescents after a mild traumatic brain injury	JOURNAL OF PEDIATRIC REHABILITATION MEDICINE			English	Article						Balance; mobility or gait; children and adolescents; Mild Traumatic Brain Injury; concussion		PURPOSE: To compare the ability of clinical balance measures to detect differences between children recovered from a mild Traumatic Brain Injury (mTBI) and healthy controls. METHODS: A cross-sectional study, with twenty-six children with mTBI and twenty-two age-matched controls was conducted. Balance was evaluated on three scales: Bruininks-Osteresky Test-second edition; Balance Error Scoring System and Community Balance and Mobility Scale, along with gait analysis of three paradigms (self-selected paced walking, obstacle crossing and tandem walking), under single and dual-task conditions, using GAITRite (R) walkway. Independent sample t-tests (alpha = 0.05) were used to identify group differences. Dual-Task Cost (DTC) was analyzed using repeated measures ANOVA and t-tests. Discriminant analysis predicted which balance measure best identified the groups. RESULTS: Children with mTBI performed worse on all balance scales (p < 0.05). Gait parameters were significantly better for the controls. There were no group differences on the motor and cognitive DTC. The Community Balance and Mobility Scale and gait parameters including velocity at obstacle crossing and parameters for tandem walking, best discriminated the groups. CONCLUSION: Clinical balance assessments may need to include static and dynamic measures, to capture possible performance difficulties. The inclusion of these measures will enhance clinical decision making and prevent premature return to physical activities in children with mTBI.	[Sambasivan, Krithika] McGill Univ, Sch Phys & Occupat Therapy, 3654 Promenade Sir William Osler, Montreal, PQ H3G 1Y5, Canada; [Grilli, Lisa; Gagnon, Isabelle] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Montreal, PQ, Canada		Gagnon, I (corresponding author), McGill Univ, Sch Phys & Occupat Therapy, 3654 Promenade Sir William Osler, Montreal, PQ H3G 1Y5, Canada.	isabelle.gagnon8@mcgill.ca		Gagnon, Isabelle/0000-0003-2043-1644	Fonds de la recherche du Quebec-SanteFonds de la Recherche en Sante du Quebec; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); McGill University Health Center Research Institute	Programme de partenariat OPPQ/REPAR, 2012-2014. IG is supported by the Fonds de la recherche du Quebec-Sante, the Canadian Institutes of Health Research and by the McGill University Health Center Research Institute.	Alderson L, 2007, PHYS THER REV, V12, P3, DOI 10.1179/108331907X174943; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bruininks R., 2005, OSTERESKY TEST MOTOR; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Cherng RJ, 2009, GAIT POSTURE, V29, P204, DOI 10.1016/j.gaitpost.2008.08.003; Clegg H, 2009, COMMUNITY BALANCE MO; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Deitz Jean C, 2007, Phys Occup Ther Pediatr, V27, P87, DOI 10.1300/J006v27n04_06; Draganich LF, 2004, J BIOMECH, V37, P889, DOI 10.1016/j.jbiomech.2003.11.002; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Geuze Reint H., 2005, Neural Plasticity, V12, P183, DOI 10.1155/NP.2005.183; Greene BR, 2012, J APPL BIOMECHANICS, V28; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; HIRABAYASHI S, 1995, BRAIN DEV-JPN, V17, P111, DOI 10.1016/0387-7604(95)00009-Z; Horak FB, 1997, PHYS THER, V77, P517, DOI 10.1093/ptj/77.5.517; Howe JA, 2006, CLIN REHABIL, V20, P885, DOI 10.1177/0269215506072183; Iverson GL, 2008, BRAIN INJURY, V22, P147, DOI 10.1080/02699050701867407; Katz-Leurer M, 2011, NEUROREHABILITATION, V29, P45, DOI 10.3233/NRE-2011-0676; Kontos AP, 2012, AM J SPORTS MED; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lowrey CR, 2007, EXP BRAIN RES, V182, P289, DOI 10.1007/s00221-007-0986-0; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McFadyen BJ, 2001, GAIT POSTURE, V13, P7, DOI 10.1016/S0966-6362(00)00090-4; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Montero-Odasso M, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-35; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Piek JP, 1999, DEV MED CHILD NEUROL, V41, P159, DOI 10.1017/S0012162299000341; Rinehart NJ, 2006, DEV MED CHILD NEUROL, V48, P819, DOI 10.1017/S0012162206001769; SALLIS JF, 1988, AM J EPIDEMIOL, V127, P933, DOI 10.1093/oxfordjournals.aje.a114896; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Thorpe DE, 2005, ARCH PHYS MED REHAB, V86, P2342, DOI 10.1016/j.apmr.2005.07.301; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wright FV, 2010, BRAIN INJURY, V24, P1585, DOI 10.3109/02699052.2010.523045; Wright MJ, 2012, PHYS OCCUP THER PEDI, V32, P416, DOI 10.3109/01942638.2012.705418	46	25	25	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1874-5393	1875-8894		J PEDIATR REHAB MED	J. Pediatr. Rehab. Med.		2015	8	4					335	344		10.3233/PRM-150351			10	Pediatrics	Emerging Sources Citation Index (ESCI)	Pediatrics	VG7LK	WOS:000448290900007	26684073	Green Submitted			2022-02-06	
J	Singh, T; Adekoya, OA; Jayaram, B				Singh, Tanya; Adekoya, Olayiwola Adedotun; Jayaram, B.			Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study	MOLECULAR BIOSYSTEMS			English	Article							ENERGY COMPONENT ANALYSIS; PROTEIN-LIGAND COMPLEXES; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; COMPUTATIONAL PROTOCOL; RECEPTOR FLEXIBILITY; TISSUE INHIBITOR; PHYSICOCHEMICAL DESCRIPTORS; BARRIER DISRUPTION; FORCE-FIELD	Matrix metalloproteinases (MMPs) consist of a class of proteins required for normal tissue function. Their over expression is associated with many disease states and hence the interest in MMPs as drug targets. Almost all MMP inhibitors have been reported to fail in clinical trials due to lack of specificity. Zinc in the binding site of metalloproteinases performs essential biological functions and contributes to the binding affinity of inhibitors. The multiple possibilities for coordination geometry and the consequent charge on the zinc atom indicate that parameters developed are not directly transferable across different families of zinc metalloproteinases with different zinc coordination geometries, active sites and ligand architectures which makes it difficult to evaluate metal-ligand interactions. In order to assist in drug design endeavors for MMP targets, a computationally tractable pathway is presented, comprising docking of small molecule inhibitors against the target MMPs, derivation of quantum mechanical charges on the zinc ion in the active site and the amino acids coordinating with zinc including the inhibitor molecule, molecular dynamics simulations on the docked ligand-MMP complexes and evaluation of binding affinities of the ligand-MMP complexes via an accurate scoring function for zinc containing metalloprotein-ligand complexes. The above pathway was applied to study the interaction of inhibitor Batimastat with MMPs, which resulted in a high correlation between the predicted binding free energies and experiment, suggesting the potential applicability of the pathway. We then proceeded to formulate a few design principles which identify the key protein residues for generating molecules with high affinity and specificity against each of the MMPs.	[Singh, Tanya; Jayaram, B.] Indian Inst Technol, Dept Chem, New Delhi 110016, India; [Singh, Tanya; Jayaram, B.] Indian Inst Technol, Supercomp Facil Bioinformat & Computat Biol, New Delhi 110016, India; [Singh, Tanya; Jayaram, B.] Indian Inst Technol, Kusuma Sch Biol Sci, New Delhi 110016, India; [Adekoya, Olayiwola Adedotun] Univ Tromso, Dept Pharm, N-9001 Tromso, Norway		Adekoya, OA (corresponding author), Univ Tromso, Dept Pharm, N-9001 Tromso, Norway.	tanya@scfbio-iitd.res.in; olayiwola.adekoya@uit.no; bjayaram@chemistry.iitd.ac.in	Jayaram, B/G-9130-2011	Jayaram, B/0000-0002-5495-2213	Department of Biotechnology, Govt. of IndiaDepartment of Biotechnology (DBT) India; Council of Scientific & Industrial Research, Govt. of IndiaCouncil of Scientific & Industrial Research (CSIR) - India; Norwegian research councilResearch Council of NorwayEuropean Commission	This work is supported by grants from the Department of Biotechnology, Govt. of India. Tanya Singh is a recipient of Senior Research Fellowship from Council of Scientific & Industrial Research, Govt. of India. Adekoya Olayiwola acknowledges the support from Norwegian research council. The authors thank Prof. N. G. Ramesh for commenting on the synthesizability of the molecules designed.	Adcock SA, 2006, CHEM REV, V106, P1589, DOI 10.1021/cr040426m; Amantea D, 2008, NEUROSCIENCE, V152, P8, DOI 10.1016/j.neuroscience.2007.12.030; Amaro RE, 2008, J COMPUT AID MOL DES, V22, P693, DOI 10.1007/s10822-007-9159-2; Ardi VC, 2007, P NATL ACAD SCI USA, V104, P20262, DOI 10.1073/pnas.0706438104; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bertini I, 2006, ANGEW CHEM INT EDIT, V45, P7952, DOI 10.1002/anie.200603100; Berynskyy M., 2013, CURR PHYS CHEM, V3, P27; Blavier L, 1999, ANN NY ACAD SCI, V878, P108, DOI 10.1111/j.1749-6632.1999.tb07677.x; Cai QW, 2012, MOL MED REP, V5, P1438, DOI 10.3892/mmr.2012.849; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)02122-5; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Dudev T, 2009, J PHYS CHEM B, V113, P11754, DOI 10.1021/jp904249s; Durrant JD, 2010, J MOL RECOGNIT, V23, P173, DOI 10.1002/jmr.989; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elkington P, 2011, J CLIN INVEST, V121, P1827, DOI 10.1172/JCI45666; Elkins PA, 2002, ACTA CRYSTALLOGR D, V58, P1182, DOI 10.1107/S0907444902007849; Feng YQ, 2002, BBA-PROTEINS PROTEOM, V1598, P10, DOI 10.1016/S0167-4838(02)00307-2; Fingleton B, 2007, CURR PHARM DESIGN, V13, P333, DOI 10.2174/138161207779313551; Fisher JF, 2006, CANCER METAST REV, V25, P115, DOI 10.1007/s10555-006-7894-9; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Fujimoto M, 2008, J CEREBR BLOOD F MET, V28, P1674, DOI 10.1038/jcbfm.2008.59; Giangreco I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025597; Greenidge PA, 2013, J CHEM INF MODEL, V53, P201, DOI [10.1021/ci300425v, 10.1021/cI300025v]; Gupta A, 2007, PROTEIN PEPTIDE LETT, V14, P632; Horn HW, 2004, J CHEM PHYS, V120, P9665, DOI 10.1063/1.1683075; Hu JL, 2007, NAT REV DRUG DISCOV, V6, P480, DOI 10.1038/nrd2308; Hu X, 2003, J MOL GRAPH MODEL, V22, P115, DOI 10.1016/S1093-3263(03)00153-0; Jain T, 2005, FEBS LETT, V579, P6659, DOI 10.1016/j.febslet.2005.10.031; Jain T, 2007, PROTEINS, V67, P1167, DOI 10.1002/prot.21332; Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.0.CO;2-P; Jayaram B, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S17-S7; Jayaram B, 1999, J COMPUT PHYS, V151, P333, DOI 10.1006/jcph.1998.6173; Jayaram B, 2002, J COMPUT CHEM, V23, P1, DOI 10.1002/jcc.10009; Kalra P, 2001, J MED CHEM, V44, P4325, DOI 10.1021/jm010175z; Kalva S, 2014, J MOL GRAPH MODEL, V49, P25, DOI 10.1016/j.jmgm.2013.12.008; Kawasaki Y, 2008, NAT MED, V14, P331, DOI 10.1038/nm1723; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kleifeld O, 2001, J BIOL CHEM, V276, P17125, DOI 10.1074/jbc.M011604200; Kofla-Dlubacz A, 2012, DIGEST DIS SCI, V57, P706, DOI 10.1007/s10620-011-1936-z; Kokh DB, 2011, WIRES COMPUT MOL SCI, V1, P298, DOI 10.1002/wcms.29; Kumar MS, 2006, J PERIODONTOL, V77, P1803, DOI 10.1902/jop.2006.050293; Langley DR, 2007, J VIROL, V81, P3992, DOI 10.1128/JVI.02395-06; Lavery R, 2010, NUCLEIC ACIDS RES, V38, P299, DOI 10.1093/nar/gkp834; Liu H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-583; Liu LY, 2008, NEUROSCI LETT, V434, P155, DOI 10.1016/j.neulet.2007.12.052; Lovejoy B, 1999, NAT STRUCT BIOL, V6, P217; Mukherjee G, 2013, PHYS CHEM CHEM PHYS, V15, P9107, DOI 10.1039/c3cp44697b; Murphy G, 2002, ARTHRITIS RES THER, V4, DOI 10.1186/ar572; Noble LJ, 2002, J NEUROSCI, V22, P7526; Pannu R, 2007, J NEUROCHEM, V101, P182, DOI 10.1111/j.1471-4159.2006.04354.x; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Ramer R, 2008, J NATL CANCER I, V100, P59, DOI 10.1093/jnci/djm268; Rodrigues WF, 2012, BRIT J PHARMACOL, V165, P2140, DOI 10.1111/j.1476-5381.2011.01686.x; Rouffet M, 2009, ORG BIOMOL CHEM, V7, P3817, DOI 10.1039/b910543c; Rowsell S, 2002, J MOL BIOL, V319, P173, DOI 10.1016/S0022-2836(02)00262-0; Sagel SD, 2005, PEDIATR PULM, V39, P224, DOI 10.1002/ppul.20165; Shaikh SA, 2007, CURR PHARM DESIGN, V13, P3454, DOI 10.2174/138161207782794220; Shaikh SA, 2004, ARCH BIOCHEM BIOPHYS, V429, P81, DOI 10.1016/j.abb.2004.05.019; Shaikh SA, 2007, J MED CHEM, V50, P2240, DOI 10.1021/jm060542c; Shibata N, 2005, NEUROBIOL AGING, V26, P1011, DOI 10.1016/j.neurobiolaging.2004.09.004; Shubayev VI, 2000, BRAIN RES, V855, P83, DOI 10.1016/S0006-8993(99)02321-5; Singh T, 2011, J CHEM INF MODEL, V51, P2515, DOI 10.1021/ci200193z; Skiles JW, 2004, CURR MED CHEM, V11, P2911, DOI 10.2174/0929867043364018; Sommer C, 1997, NEUROSCI LETT, V237, P45, DOI 10.1016/S0304-3940(97)00813-6; Soni A, 2013, CURR PHARM DESIGN, V19, P4687, DOI 10.2174/13816128113199990379; STOTE RH, 1995, PROTEINS, V23, P12, DOI 10.1002/prot.340230104; Sunami E, 2000, Oncologist, V5, P108, DOI 10.1634/theoncologist.5-2-108; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Tu GG, 2008, CURR MED CHEM, V15, P1388, DOI 10.2174/092986708784567680; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Warner RL, 2004, EXP MOL PATHOL, V76, P189, DOI 10.1016/j.yexmp.2004.01.003; WARSHEL A, 1976, J MOL BIOL, V103, P227, DOI 10.1016/0022-2836(76)90311-9; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; Whittaker M, 1999, CHEM REV, V99, P2735, DOI 10.1021/cr9804543; Wong S, 2009, J CHEM THEORY COMPUT, V5, P422, DOI 10.1021/ct8003707; Wysocki AB, 1999, WOUND REPAIR REGEN, V7, P154, DOI 10.1046/j.1524-475X.1999.00154.x; Yang HJ, 2011, TOXICOL IN VITRO, V25, P1638, DOI 10.1016/j.tiv.2011.06.015; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807	81	25	25	3	21	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	1742-206X	1742-2051		MOL BIOSYST	Mol. Biosyst.		2015	11	4					1041	1051		10.1039/c5mb00003c			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	CE0KQ	WOS:000351493300006	25611160	Green Published, hybrid			2022-02-06	
J	Falciglia, F; Giordano, M; Aulisa, AG; Di Lazzaro, A; Guzzanti, V				Falciglia, Francesco; Giordano, Marco; Aulisa, Angelo G.; Di Lazzaro, Antonio; Guzzanti, Vincenzo			Radial Neck Fractures in Children: Results When Open Reduction Is Indicated	JOURNAL OF PEDIATRIC ORTHOPAEDICS			English	Article						radial neck fractures; children; open reduction	PERCUTANEOUS REDUCTION; FIXATION; HEAD; MANAGEMENT	Background: Radial neck fractures in children are rare, representing 5% of all elbow pediatric fractures. Most are minimally displaced or nondisplaced. Severely displaced or angulated radial neck fractures often have poor outcomes, even after open reduction, and case series reported in literature are limited. The aim of the study is to analyze the outcomes of patients with a completely displaced and angulated fracture who underwent open reduction when closed reduction failed. Methods: Between 2000 and 2009, 195 patients with radial neck fractures were treated in our institute. Twenty-four cases satisfied all the inclusion criteria and were evaluated clinically and radiologically at a mean follow-up of 7 years. At follow-up, the carrying angle in full elbow extension and the range of motion of the elbow and forearm were measured bilaterally. We recorded clinical results as good, fair, or poor according to the range of movement and the presence of pain. Radiographic evaluation documented the size of the radial head, the presence of avascular necrosis, premature physeal closure, and cubitus valgus. Results: Statistical analysis showed that fair and poor results are directly correlated with loss of pronation-supination (P = 0.001), reduction of elbow flexion-extension (P = 0.001), increase of elbow valgus angle (P = 0.002), necrosis of the radial head (P = 0.001), premature physeal closure (P = 0.01), and associated lesions (olecranon fracture with or without dislocation of the elbow) (P = 0.002). Discussion: In our cases, residual radial head deformity due to premature closure of the growth plate and avascular necrosis were correlated with a functional deficit. Associated elbow injury was coupled with a negative prognosis. In our series, about 25% of patients had fair and 20% had poor results. Outcomes were good in 55% and felt to represent a better outcome than if the fracture remained nonanatomically reduced with residual angulation and/or displacement of the radial head. This study reports the largest series of these fractures with a combination of significant angulation and displacement of the fracture requiring open reduction. We feel that open reduction is indicated when the head of the radius is completely displaced and without contact with the rim of the metaphysis.	[Falciglia, Francesco; Giordano, Marco; Aulisa, Angelo G.; Di Lazzaro, Antonio; Guzzanti, Vincenzo] Childrens Hosp Bambino Gesu, Inst Sci Res, Dept Orthopaed & Traumatol, I-00165 Rome, Italy; [Guzzanti, Vincenzo] Univ Cassino, I-03043 Cassino, FR, Italy		Falciglia, F (corresponding author), Childrens Hosp Bambino Gesu, Inst Sci Res, Dept Orthopaed & Traumatol, Pzza S Onofrio 4, I-00165 Rome, Italy.	francesco.falciglia@opbg.net	Aulisa, Angelo gabriele/AAH-9244-2019; Falciglia, Francesco/AAI-2543-2019; Giordano, Marco/AAH-9404-2019	Aulisa, Angelo gabriele/0000-0003-2917-9385; Falciglia, Francesco/0000-0002-2028-6611; Giordano, Marco/0000-0002-9646-8892; Guzzanti, Vincenzo/0000-0002-7694-8995			Al-Aubaidi Z, 2012, INJURY, V43, P301, DOI 10.1016/j.injury.2011.08.001; Cha SM, 2012, INT ORTHOP, V36, P803, DOI 10.1007/s00264-011-1387-3; Chotel F, 2004, J PEDIATR ORTHOP B, V13, P268, DOI 10.1097/01.bpb.0000111050.85604.f1; DORMANS JP, 1990, ORTHOP CLIN N AM, V21, P257; DSOUZA S, 1993, J PEDIATR ORTHOPED, V13, P232; Klitscher D, 2009, J PEDIATR ORTHOPED, V29, P698, DOI 10.1097/BPO.0b013e3181b76895; METAIZEAU JP, 1980, REV CHIR ORTHOP, V66, P47; METAIZEAU JP, 1993, J PEDIATR ORTHOPED, V13, P355, DOI 10.1097/01241398-199305000-00015; NEWMAN JH, 1977, INJURY, V9, P114, DOI 10.1016/0020-1383(77)90004-3; O'Brien P I, 1965, Clin Orthop Relat Res, V41, P51; Pring Maya E, 2012, J Pediatr Orthop, V32 Suppl 1, pS14, DOI 10.1097/BPO.0b013e31824b251d; Radomisli TE, 1998, CLIN ORTHOP RELAT R, P30; REIDY JA, 1963, J BONE JOINT SURG AM, V45, P1355, DOI 10.2106/00004623-196345070-00002; Rodriguez-Merchan EC, 1991, ORTHOPEDICS, V14, P697; SALTER RB, 1963, J BONE JOINT SURG AM, V45, P587, DOI 10.2106/00004623-196345030-00019; Schmittenbecher PP, 2005, J PEDIATR ORTHOPED, V25, P45; STEELE JA, 1992, J BONE JOINT SURG BR, V74, P760, DOI 10.1302/0301-620X.74B5.1527130; STEINBERG EL, 1988, J PEDIATR ORTHOPED, V8, P35, DOI 10.1097/01241398-198801000-00009; Tan Bryan Hsi Ming, 2011, J Orthop Surg (Hong Kong), V19, P209; Tarallo L, 2013, J ORTHOP TRAUMATOL, V14, P291, DOI 10.1007/s10195-013-0252-0; TIBONE JE, 1981, J BONE JOINT SURG AM, V63, P100, DOI 10.2106/00004623-198163010-00013; Ugutmen E, 2010, J PEDIATR ORTHOP B, V19, P289, DOI 10.1097/BPB.0b013e32833918a0; Ursei Monica, 2006, Acta Orthop Belg, V72, P131; Vocke AK, 1998, J PEDIATR ORTHOP B, V7, P217, DOI 10.1097/01202412-199807000-00007; Waters PM, 2001, J PEDIATR ORTHOPED, V21, P570, DOI 10.1097/00004694-200109000-00003; Wilkins KE, 1996, FRACTURES CHILDREN, P586; Zimmerman RM, 2013, J BONE JOINT SURG AM, V95A, P1825, DOI 10.2106/JBJS.L.01130	27	25	27	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-6798	1539-2570		J PEDIATR ORTHOPED	J. Pediatr. Orthop.	DEC	2014	34	8					756	762					7	Orthopedics; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Pediatrics	AT5TI	WOS:000345004600006	25171679	Green Published			2022-02-06	
J	Okasha, AS; Fayed, AM; Saleh, AS				Okasha, Ahmed Said; Fayed, Akram Muhammad; Saleh, Ahmad Sabry			The FOUR Score Predicts Mortality, Endotracheal Intubation and ICU Length of Stay After Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Glasgow Coma Scale; FOUR score; Glasgow outcome score; Outcome assessment; Length of stay	GLASGOW COMA SCALE; INTENSIVE-CARE-UNIT; HEAD-INJURY; UNRESPONSIVENESS SCORE; SEVERITY SCORE; FULL OUTLINE; VALIDATION; IMPACT; OUTCOMES; VERSION	The Glasgow Coma Scale (GCS) is the most widely accepted scale for assessing levels of consciousness, clinical status, as well as prognosis of traumatic brain injury (TBI) patients. The Full Outline of UnResponsiveness (FOUR) score is a new coma scale developed addressing the limitations of the GCS. The aim of this prospective cohort study was to compare the performance of the FOUR score vs. the GCS in predicting TBI outcomes. From April to July 2011, 60 consecutive adult patients with TBI admitted to the Alexandria Main University Hospital intensive care units (ICU) were enrolled in the study. GCS and FOUR score were documented on arrival to emergency room. Outcomes were in-hospital mortality, unfavorable outcome [Glasgow outcome scale extended (GOSE) 1-4], endotracheal intubation, and ICU length of stay (LOS). Fifteen (25 %) patients died and 35 (58 %) had unfavorable outcome. When predicting mortality, the FOUR score showed significantly higher area under receiver operating characteristic curve (AUC) than the GCS score (0.850 vs. 0.796, p = 0.025). The FOUR score and the GCS score were not different in predicting unfavorable outcome (AUC 0.813 vs. 0.779, p = 0.136) and endotracheal intubation (AUC 0.961 vs. 0.982, p = 0.06). Both scores were good predictors of ICU LOS (r (2) = 0.40 [FOUR score] vs. 0.41 [GCS score]). The FOUR score was superior to the GCS in predicting in-hospital mortality in TBI patients. There was no difference between both scores in predicting unfavorable outcome, endotracheal intubation, and ICU LOS.	[Okasha, Ahmed Said] Univ Alexandria, Fac Med, Dept Anesthesia & Surg Intens Care, Alexandria, Egypt; [Fayed, Akram Muhammad] Univ Alexandria, Fac Med, Dept Crit Care Med, Alexandria, Egypt; [Saleh, Ahmad Sabry] Kom el Shoqafa Chest Hosp, Intens Care Unit, Alexandria 21572, Egypt		Saleh, AS (corresponding author), Kom el Shoqafa Chest Hosp, Intens Care Unit, Khufu St, Alexandria 21572, Egypt.	sabryccm@gmail.com	Saleh, Ahmad Sabry/AAG-9732-2019	Saleh, Ahmad/0000-0001-9791-1086; Fayed, Akram/0000-0001-6991-4407			Adnet F, 1996, LANCET, V348, P123, DOI 10.1016/S0140-6736(05)64630-2; Agrawal Deepak, 2012, J Emerg Trauma Shock, V5, P217, DOI 10.4103/0974-2700.99685; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Champion HR, 1996, J TRAUMA, V40, P42, DOI 10.1097/00005373-199601000-00009; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chen BX, 2013, ACTA NEUROCHIR, V155, P2133, DOI 10.1007/s00701-013-1854-2; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Frontera JA, 2011, NEUROCRIT CARE, V14, P260, DOI 10.1007/s12028-010-9418-2; Gruenberg DA, 2006, AM J CRIT CARE, V15, P502; Hoffmann M, 2012, BRIT J SURG, V99, P122, DOI 10.1002/bjs.7707; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; Idrovo L, 2010, EUR NEUROL, V63, P364, DOI 10.1159/000292498; Kim YJ, 2011, J EMERG NURS, V37, P328, DOI 10.1016/j.jen.2010.04.017; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; Kramer AA, 2012, CRIT CARE MED, V40, P2671, DOI 10.1097/CCM.0b013e318258fd88; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Marcati E, 2012, INTERN EMERG MED, V7, P145, DOI 10.1007/s11739-011-0583-x; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Matis G, 2008, ACTA NEUROL BELG, V108, P75; McNett M, 2014, NEUROCRIT CARE, V21, P52, DOI 10.1007/s12028-013-9947-6; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Qualls M, 2010, ACAD EMERG MED, V17, P1113, DOI 10.1111/j.1553-2712.2010.00874.x; Ray P, 2010, ANESTHESIOLOGY, V112, P1023, DOI 10.1097/ALN.0b013e3181d47604; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sadaka F, 2012, NEUROCRIT CARE, V16, P95, DOI 10.1007/s12028-011-9617-5; Singh B, 2013, BRAIN INJURY, V27, P293, DOI 10.3109/02699052.2012.743182; Sitsapesan HA, 2013, WORLD NEUROSURG, V79, P568, DOI 10.1016/j.wneu.2012.09.018; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Vivien B, 2012, AM J EMERG MED, V30, P1032, DOI 10.1016/j.ajem.2011.06.022; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wisborg T, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-62; World Health Organization, 2006, NEUR DIS PUBL HLTH C, P164	40	25	26	0	13	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2014	21	3					496	504		10.1007/s12028-014-9995-6			9	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AT2TY	WOS:000344790100016	24865273				2022-02-06	
J	Anderova, M; Benesova, J; Mikesova, M; Dzamba, D; Honsa, P; Kriska, J; Butenko, O; Novosadova, V; Valihrach, L; Kubista, M; Dmytrenko, L; Cicanic, M; Vargova, L				Anderova, Miroslava; Benesova, Jana; Mikesova, Michaela; Dzamba, David; Honsa, Pavel; Kriska, Jan; Butenko, Olena; Novosadova, Vendula; Valihrach, Lukas; Kubista, Mikael; Dmytrenko, Lesia; Cicanic, Michal; Vargova, Lydia			Altered Astrocytic Swelling in the Cortex of alpha-Syntrophin-Negative GFAP/EGFP Mice	PLOS ONE			English	Article							3-DIMENSIONAL CONFOCAL MORPHOMETRY; BLOOD-BRAIN-BARRIER; DIFFUSION PARAMETERS; VOLUME REGULATION; GLIAL-CELLS; AQUAPORIN-4; EXPRESSION; K+; MORPHOLOGY; ISCHEMIA	Brain edema accompanying ischemic or traumatic brain injuries, originates from a disruption of ionic/neurotransmitter homeostasis that leads to accumulation of K+ and glutamate in the extracellular space. Their increased uptake, predominantly provided by astrocytes, is associated with water influx via aquaporin-4 (AQP4). As the removal of perivascular AQP4 via the deletion of alpha-syntrophin was shown to delay edema formation and K+ clearance, we aimed to elucidate the impact of alpha-syntrophin knockout on volume changes in individual astrocytes in situ evoked by pathological stimuli using three dimensional confocal morphometry and changes in the extracellular space volume fraction (alpha) in situ and in vivo in the mouse cortex employing the real-time iontophoretic method. RT-qPCR profiling was used to reveal possible differences in the expression of ion channels/transporters that participate in maintaining ionic/neurotransmitter homeostasis. To visualize individual astrocytes in mice lacking alpha-syntrophin we crossbred GFAP/EGFP mice, in which the astrocytes are labeled by the enhanced green fluorescent protein under the human glial fibrillary acidic protein promoter, with alpha-syntrophin knockout mice. Three-dimensional confocal morphometry revealed that alpha-syntrophin deletion results in significantly smaller astrocyte swelling when induced by severe hypoosmotic stress, oxygen glucose deprivation (OGD) or 50 mM K+. As for the mild stimuli, such as mild hypoosmotic or hyperosmotic stress or 10 mM K+, alpha-syntrophin deletion had no effect on astrocyte swelling. Similarly, evaluation of relative alpha changes showed a significantly smaller decrease in alpha-syntrophin knockout mice only during severe pathological conditions, but not during mild stimuli. In summary, the deletion of alpha-syntrophin markedly alters astrocyte swelling during severe hypoosmotic stress, OGD or high K+.	[Anderova, Miroslava; Benesova, Jana; Mikesova, Michaela; Dzamba, David; Honsa, Pavel; Kriska, Jan; Butenko, Olena] Acad Sci Czech Republ, Inst Expt Med, Dept Cellular Neurophysiol, Prague, Czech Republic; [Novosadova, Vendula; Valihrach, Lukas; Kubista, Mikael] Acad Sci Czech Republ, Gene Express Lab, Inst Biotechnol, Prague, Czech Republic; [Anderova, Miroslava; Dmytrenko, Lesia; Cicanic, Michal; Vargova, Lydia] Charles Univ Prague, Fac Med 2, Dept Neurosci, Prague, Czech Republic		Anderova, M (corresponding author), Acad Sci Czech Republ, Inst Expt Med, Dept Cellular Neurophysiol, Prague, Czech Republic.	anderova@biomed.cas.cz	Butenko, Olena/AAL-3766-2021; Novosadova, Vendula/AAJ-1449-2021; Kubista, Mikael/A-5689-2008; Anderova, Miroslava/H-2249-2014; Valihrach, Lukas/H-4368-2014; Kriska, Jan/D-4889-2019	Butenko, Olena/0000-0003-2959-559X; Kubista, Mikael/0000-0002-2940-352X; Anderova, Miroslava/0000-0002-9030-4571; Valihrach, Lukas/0000-0002-6704-4337; Kriska, Jan/0000-0001-5684-5828	Grant Agency of the Czech RepublicGrant Agency of the Czech Republic [GA CR 13-02154S, P304/12/G069]; European Regional Development FundEuropean Commission [BIOCEV CZ.1.05/1.1.00/02.0109]; Operational Programme Education for Competitiveness from the European Social Fund [CZ.1.07/2.3.00/30.0045]; state budget of the Czech Republic	This study was supported by the grants GA CR 13-02154S, and P304/12/G069 from the Grant Agency of the Czech Republic, by the project BIOCEV CZ.1.05/1.1.00/02.0109 from the European Regional Development Fund and by the Operational Programme Education for Competitiveness CZ.1.07/2.3.00/30.0045 from the European Social Fund and the state budget of the Czech Republic. The authors state that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams ME, 2000, J CELL BIOL, V150, P1385, DOI 10.1083/jcb.150.6.1385; Alvestad S, 2013, EPILEPSY RES, V105, P30, DOI 10.1016/j.eplepsyres.2013.01.006; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; Amiry-Moghaddam M, 2004, NEUROSCIENCE, V129, P999, DOI 10.1016/j.neuroscience.2004.08.049; Anderova M, 2011, J CEREBR BLOOD F MET, V31, P894, DOI 10.1038/jcbfm.2010.168; Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Benesova J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029725; Benesova J, 2009, J NEUROSCI RES, V87, P96, DOI 10.1002/jnr.21828; Binder DK, 2012, GLIA, V60, P1203, DOI 10.1002/glia.22317; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Bragg AD, 2006, GLIA, V53, P879, DOI 10.1002/glia.20347; Chvatal A, 2007, J ANAT, V210, P671, DOI 10.1111/j.1469-7580.2007.00724.x; Chvatal A, 2007, J NEUROSCI RES, V85, P260, DOI 10.1002/jnr.21113; Connors NC, 2004, J BIOL CHEM, V279, P28387, DOI 10.1074/jbc.M402604200; Dmytrenko L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068044; Florence CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051124; Fryclenlund DS, 2006, P NATL ACAD SCI USA, V103, P13532, DOI 10.1073/pnas.0605796103; HEINEMANN U, 1977, BRAIN RES, V120, P231, DOI 10.1016/0006-8993(77)90903-9; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Lindinger MI, 2011, J PHYSIOL-LONDON, V589, P2887, DOI 10.1113/jphysiol.2011.206730; Macaulay N, 2004, NEUROSCIENCE, V129, P1031, DOI 10.1016/j.neuroscience.2004.06.045; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Matthias K, 2003, J NEUROSCI, V23, P1750; McManus ML, 1998, ANESTHESIOLOGY, V88, P1586, DOI 10.1097/00000542-199806000-00023; MOODY WJ, 1974, EXP NEUROL, V42, P248, DOI 10.1016/0014-4886(74)90023-5; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; NICHOLSON C, 1981, J PHYSIOL-LONDON, V321, P225, DOI 10.1113/jphysiol.1981.sp013981; Nolte C, 2001, GLIA, V33, P72; PasantesMorales H, 1996, METAB BRAIN DIS, V11, P187, DOI 10.1007/BF02237957; Pivonkova H, 2010, NEUROCHEM INT, V57, P783, DOI 10.1016/j.neuint.2010.08.016; Potokar M, 2013, GLIA, V61, P917, DOI 10.1002/glia.22485; Ransom CB, 2000, J PHYSIOL-LONDON, V522, P427, DOI 10.1111/j.1469-7793.2000.00427.x; Ross SB, 2007, AM J PHYSIOL-CELL PH, V293, pC1181, DOI 10.1152/ajpcell.00066.2007; Rusnakova V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069734; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Song D, 2014, J NEUROSCI RES; SYKOVA E, 1992, MONITORING NEURONAL, P261; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Takano T, 2014, GLIA, V62, P78, DOI 10.1002/glia.22588; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vargova L, 2001, J NEUROSCI RES, V65, P129, DOI 10.1002/jnr.1136; Vorisek I, 1997, J CEREBR BLOOD F MET, V17, P191; Walz W, 2000, NEUROCHEM INT, V36, P291, DOI 10.1016/S0197-0186(99)00137-0; Zeynalov E, 2008, CRIT CARE MED, V36, P2634, DOI 10.1097/CCM.0b013e3181847853; Zoremba N, 2008, J CEREBR BLOOD F MET, V28, P1665, DOI 10.1038/jcbfm.2008.58	48	25	25	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 26	2014	9	11							e113444	10.1371/journal.pone.0113444			34	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CA8CZ	WOS:000349145400053	25426721	Green Submitted, Green Published, gold			2022-02-06	
J	Andelic, N; Soberg, HL; Berntsen, S; Sigurdardottir, S; Roe, C				Andelic, Nada; Soberg, Helene L.; Berntsen, Svein; Sigurdardottir, Solrun; Roe, Cecilie			Self-Perceived Health Care Needs and Delivery of Health Care Services 5 Years After Moderate-to-Severe Traumatic Brain Injury	PM&R			English	Article							DISABILITY; REHABILITATION; POPULATION; PEOPLE; NORWAY; ADULTS; COMA	Objective: To describe the self-perceived health care needs of patients with moderate-to-severe traumatic brain injury (TBI) and to assess the impact of the functional level at 1 year after injury on patients' unmet needs at the 5-year follow-up. Design: A prospective follow-up study. Setting: Clinical research. Participants: A total of 93 patients participated in the 5-year follow-up. Methods: We registered demographic and injury-related data at the time of admission and the scores for the Disability Rating Scale, Glasgow Outcome Scale-Extended, and Short Form 36 subscales for physical functioning and mental health at 1 and 5 years. The patients' self-perceived health care needs and use of health care services at 5 years were the main outcome measurements. Results: At the 5-year follow-up, 70% of patients reported at least 1 perceived need. The self-perceived health care needs were met for 39% of the patients. The patients with unmet needs (n = 29 [31%]) reported frequent needs in emotional (65%), vocational (62%), and cognitive (58%) domains. These patients were significantly more likely to present a less severe disability on the Disability Rating Scale at the 1-year follow-up (odds ratio [OR] 0.11 [95% confidence interval {CI}, 0.02-0.7]; P = .02). Worse mental health at the 1-year follow-up and a younger age (16-29 years) largely predicted unmet needs at the 5-year follow-up (OR 3.28 [95% CI, 1.1-10.04], P = .04; and OR 4.93 [95% CI, 0.16-15.2], P = .005, respectively). Conclusion: Gaps between self-perceived health care needs and health care services received at the 5-year follow-up were found. An important message to clinicians who provide health care services in the late TBI phase is that they should be aware of patients' long-term needs regarding cognitive and emotional difficulties. Of equal importance is an emphasis on long-term vocational rehabilitation services. To ensure the appropriateness of health care service delivery, health care services after TBI should be better targeted at less-severe TBI population as well.	[Andelic, Nada; Soberg, Helene L.; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Div Surg & Clin Neurosci, Oslo, Norway; [Soberg, Helene L.; Sigurdardottir, Solrun] Univ Oslo, Inst Hlth & Soc, Res Ctr Habilitat & Rehabil Models & Serv, Fac Med, Oslo, Norway; [Berntsen, Svein] Sorlandet Hosp, Dept Phys Med & Rehabil, Kristiansand, Norway; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp, Dept Res, Nesoddtangen, Norway		Andelic, N (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, Div Surg & Clin Neurosci, Oslo, Norway.	nandelic@online.no		Andelic, Nada/0000-0002-3719-4406	Institute of Health and Society, Research Centre for Habilitation and Rehabilitation Models and Services; Faculty of Medicine, University of Oslo; Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway	This study was funded by the Institute of Health and Society, Research Centre for Habilitation and Rehabilitation Models and Services, the Faculty of Medicine, University of Oslo, and the Department of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, Norway.	Allen SM, 1997, MED CARE, V35, P1132, DOI 10.1097/00005650-199711000-00005; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; Borg J, 2011, AM J PHYS MED REHAB, V90, P65, DOI 10.1097/PHM.0b013e3181fc80e7; Clemes M D, 2001, Health Mark Q, V19, P3, DOI 10.1300/J026v19n01_02; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; Fraas M, 2007, BRAIN INJURY, V21, P1267, DOI 10.1080/02699050701721794; Grasdal AL, 2011, INT J EQUITY HEALTH, V10, DOI 10.1186/1475-9276-10-25; Greenspan AI, 2000, BRAIN INJURY, V14, P417; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; Hodgkinson A, 2000, J HEAD TRAUMA REHAB, V15, P1208, DOI 10.1097/00001199-200012000-00003; Jennekens N, 2010, J CLIN NURS, V19, P1198, DOI 10.1111/j.1365-2702.2009.03114.x; Kjeldsberg M, 2013, SCAND J PRIM HEALTH, V31, P36, DOI 10.3109/02813432.2012.751697; Laursen B, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-001521; Loge JH, 1998, SCAND J SOC MED, V26, P250; McColl MA, 2010, DISABIL SOC, V25, P205, DOI 10.1080/09687590903537406; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Phillips VL, 2004, J HEAD TRAUMA REHAB, V19, P217, DOI 10.1097/00001199-200405000-00003; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Prang KH, 2012, BRAIN INJURY, V26, P1611, DOI 10.3109/02699052.2012.698790; Rappaport M, 2005, NEUROPSYCHOL REHABIL, V15, P442, DOI 10.1080/09602010443000335; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Stover M, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-375; TEASDALE G, 1974, LANCET, V2, P81; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; WARE JE, 1994, INT J MENT HEALTH, V23, P49, DOI 10.1080/00207411.1994.11449283; Willemse-van Son AHP, 2009, J REHABIL MED, V41, P59, DOI 10.2340/16501977-0294; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	32	25	25	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	NOV	2014	6	11					1013	1021		10.1016/j.pmrj.2014.05.005			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	AU4YJ	WOS:000345614000008	24844444				2022-02-06	
J	Dias, C; Silva, MJ; Pereira, E; Silva, S; Cerejo, A; Smielewski, P; Rocha, AP; Gaio, AR; Paiva, JA; Czosnyka, M				Dias, Celeste; Silva, Maria Joao; Pereira, Eduarda; Silva, Sofia; Cerejo, Antonio; Smielewski, Peter; Rocha, Ana Paula; Rita Gaio, A.; Paiva, Jose-Artur; Czosnyka, Marek			Post-Traumatic Multimodal Brain Monitoring: Response to Hypertonic Saline	JOURNAL OF NEUROTRAUMA			English	Article						Cerebral blood flow; cerebral perfusion pressure; cerebrovascular reactivity; hypertonic saline; intracranial pressure	CEREBRAL PERFUSION-PRESSURE; INTENSIVE-CARE-UNIT; INTRACRANIAL-PRESSURE; HEAD-INJURY; BLOOD-FLOW; SUBARACHNOID HEMORRHAGE; HYPERTENSION; TISSUE; OXYGENATION; MANNITOL	Emerging evidence suggests that hypertonic saline (HTS) is efficient in decreasing intracranial pressure (ICP). However there is no consensus about its interaction with brain hemodynamics and oxygenation. In this study, we investigated brain response to HTS bolus with multimodal monitoring after severe traumatic brain injury (TBI). We included 18 consecutive TBI patients during 10 days after neurocritical care unit admission. Continuous brain monitoring applied included ICP, tissue oxygenation (PtO2) and cerebral blood flow (CBF). Cerebral perfusion pressure (CPP), cerebrovascular resistance (CVR), and reactivity indices related to pressure (PRx) and flow (CBFx) were calculated. ICM + software was used to collect and analyze monitoring data. Eleven of 18 (61%) patients developed 99 episodes of intracranial hypertension (IHT) greater than 20 mm Hg that were managed with 20% HTS bolus. Analysis over time was performed with linear mixed-effects regression modelling. After HTS bolus, ICP and CPP improved over time (p < 0.001) following a quadratic model. From baseline to 120 min, ICP had a mean decrease of 6.2 mm Hg and CPP a mean increase of 3.1 mmHg. Mean increase in CBF was 7.8 mL/min/100 g (p < 0.001) and mean decrease in CVR reached 0.4 mm Hg*min*100 g/mL (p = 0.01). Both changes preceded pressures improvement. PtO2 exhibited a marginal increase and no significant models for time behaviour could be fitted. PRx and CBFx were best described by a linear decreasing model showing autoregulation recover after HTS (p = 0.01 and p = 0.04 respectively). During evaluation, CO2 remained constant and sodium level did not exhibit significant variation. In conclusion, management of IHT with 20% HTS significantly improves cerebral hemodynamics and cerebrovascular reactivity with recovery of CBF appearing before rise in CPP and decrease in ICP. In spite of cerebral hemodynamic improvement, no significant changes in brain oxygenation were identified.	[Dias, Celeste; Pereira, Eduarda; Silva, Sofia; Paiva, Jose-Artur] Univ Hosp Sao Joao, Dept Intens Care, Oporto, Portugal; [Cerejo, Antonio] Univ Hosp Sao Joao, Dept Neurosurg, Oporto, Portugal; [Silva, Maria Joao; Rocha, Ana Paula; Rita Gaio, A.] Univ Porto, Dept Math, P-4100 Oporto, Portugal; [Smielewski, Peter; Czosnyka, Marek] Addenbrookes Hosp, Dept Clin Neurosci, Cambridge, England		Dias, C (corresponding author), Univ Hosp Sao Joao, Neurocrit Care Unit, Dept Intens Care, Oporto, Portugal.	mceleste.dias@gmail.com	Dias, Celeste/AAD-8711-2019; Dias, Celeste/L-9901-2014; Rocha, Ana Paula/D-2813-2012; Cerejo, Antonio/AAT-7863-2020; Dias, Celeste/AAV-3820-2020; Paiva, Jose-Artur/AAO-9730-2021	Dias, Celeste/0000-0003-0340-9808; Rocha, Ana Paula/0000-0003-3218-7001; Cerejo, Antonio/0000-0001-9136-873X; Dias, Celeste/0000-0003-0340-9808; Paiva, Jose-Artur/0000-0003-4323-0220; Gaio, Rita/0000-0003-3906-0775; Smielewski, Peter/0000-0001-5096-3938	European Regional Development Fund through program COMPETE; Portuguese Government through FCT - Fundacao para a Ciencia e a Tecnologia [PEst-C/MAT/UI0144/2013]; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G9439390, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001237, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	Ana Rita Gaio and Ana Paula Rocha were partially funded by the European Regional Development Fund through the program COMPETE and by the Portuguese Government through the FCT - Fundacao para a Ciencia e a Tecnologia under the project PEst-C/MAT/UI0144/2013.	Aiyagari V, 2006, J CRIT CARE, V21, P163, DOI 10.1016/j.jcrc.2005.10.002; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Bourdeaux C, 2010, NEUROCRIT CARE, V13, P24, DOI 10.1007/s12028-010-9368-8; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS55; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Chesnut RM, 2013, INTENS CARE MED, V39, P771, DOI 10.1007/s00134-013-2852-9; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Diringer MN, 2013, CURR OPIN CRIT CARE, V19, P77, DOI 10.1097/MCC.0b013e32835eba30; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Hinson HE, 2013, J INTENSIVE CARE MED, V28, P3, DOI 10.1177/0885066611400688; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Latorre JGS, 2009, NEUROLOGIST, V15, P193, DOI 10.1097/NRL.0b013e31819f956a; Lazaridis C, 2013, CRIT CARE MED, V41, P1353, DOI 10.1097/CCM.0b013e31827ca4b3; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; MAZZONI MC, 1990, CIRC SHOCK, V31, P407; Mortazavi MM, 2012, J NEUROSURG, V116, P210, DOI 10.3171/2011.7.JNS102142; Muehlschlegel S, 2013, NEUROCRIT CARE, V18, P318, DOI 10.1007/s12028-013-9817-2; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Orban JC, 2007, ANN FR ANESTH, V26, P440, DOI 10.1016/j.annfar.2007.03.001; Paredes-Andrade E, 2012, NEUROCRIT CARE, V17, P204, DOI 10.1007/s12028-011-9574-z; Pinheiro J. C., 2000, MIXED EFFECTS MODELS; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; R Development Core Team, 2011, R LANG ENV STAT COMP; Rangel-Castillo L, 2008, NEUROL CLIN, V26, P521, DOI 10.1016/j.ncl.2008.02.003; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Roquilly A, 2011, CRIT CARE, V15, DOI 10.1186/cc10522; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; Scalfani M. T., 2012, J CRIT CARE, V27, pe527; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Sheth KN, 2013, NEUROCRIT CARE, V18, P26, DOI 10.1007/s12028-012-9780-3; SIGGAARDANDERSEN O, 1995, ACTA ANAESTH SCAND, V39, P137; Smielewski P, 2008, ACTA NEUROCHIR SUPPL, V102, P145, DOI 10.1007/978-3-211-85578-2_30; Stein DM, 2013, NEUROCRIT CARE, V18, P332, DOI 10.1007/s12028-013-9832-3; Strandvik GF, 2009, ANAESTHESIA, V64, P990, DOI 10.1111/j.1365-2044.2009.05986.x; Suarez Jose I, 2004, Cleve Clin J Med, V71 Suppl 1, pS9; Toung TJ, 2008, CRIT CARE MED, V36, P256, DOI 10.1097/01.CCM.0000295306.52783.1E; Tseng MY, 2007, J NEUROSURG, V107, P274, DOI 10.3171/JNS-07/08/0274; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Varsos GV, 2013, NEUROCRIT CARE, V18, P341, DOI 10.1007/s12028-013-9830-5; Wells DL, 2012, CRIT CARE, V16, DOI 10.1186/cc11678; White H, 2008, EUR J ANAESTH, V25, P104, DOI 10.1017/S0265021507003420; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WOLF MB, 1971, AM J PHYSIOL, V221, P1392, DOI 10.1152/ajplegacy.1971.221.5.1392	50	25	25	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 1	2014	31	22					1872	1880		10.1089/neu.2014.3376			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CB4ZO	WOS:000349637400006	24915462				2022-02-06	
J	Hazra, A; Macolino, C; Elliott, MB; Chin, J				Hazra, Anupam; Macolino, Christine; Elliott, Melanie B.; Chin, Jeannie			Delayed Thalamic Astrocytosis and Disrupted Sleep-Wake Patterns in a Preclinical Model of Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						sleep-wake; traumatic brain injury; thalamus; sleep fragmentation; inflammation	LESS-THAN-1 HZ OSCILLATION; CORTICAL IMPACT INJURY; FDG-PET; MILD; NEURONS; DISTURBANCES; METABOLISM; DISORDERS; MICE; NEURODEGENERATION	Traumatic brain injury (TBI) involves diffuse axonal injury and induces subtle but persistent changes in brain tissue and function and poses challenges for early detection of neurological injury. The present study uses an automated behavioral analysis system to assess alterations in rodent behavior in the subacute phase in a preclinical mouse model of TBI, controlled cortical impact (CCI) injury. In the first few weeks following CCI, mice demonstrated normal exploratory behaviors and other typical home-cage behaviors. However, beginning 4 weeks post-injury, CCI mice developed disruptions in sleep-wake patterns, including an increased number of awakenings from sleep. Such impaired sleep maintenance was accompanied by an increased latency to reach peak sleep in CCI mice. These sleep disruptions implicate involvement of the thalamocortical network, the activity of which must be tightly regulated to control sleep maintenance. After injury, there was an increase in reactive microglia in thalamic regions as well as delayed reactive astrocytosis that was evident in the thalamic reticular nucleus, which preceded the development of sleep disruptions. These data suggest that cortical injury may trigger inflammatory responses in deeper neuroanatomical structures, including the thalamic reticular nucleus. Such engagement of the thalamus may perturb the thalamocortical network that regulates sleep/awake patterns and contribute to sleep disruptions observed in this model as well as those documented in patients with TBI. (C) 2014 Wiley Periodicals, Inc.	[Hazra, Anupam; Elliott, Melanie B.; Chin, Jeannie] Thomas Jefferson Univ, Dept Neurosci, Philadelphia, PA 19107 USA; [Hazra, Anupam; Macolino, Christine; Elliott, Melanie B.; Chin, Jeannie] Thomas Jefferson Univ, Farber Inst Neurosci, Philadelphia, PA 19107 USA; [Macolino, Christine; Elliott, Melanie B.] Thomas Jefferson Univ, Dept Neurol Surg, Philadelphia, PA 19107 USA		Chin, J (corresponding author), Thomas Jefferson Univ, Dept Neurosci, 900 Walnut St,Rm 444, Philadelphia, PA 19107 USA.	jeannie.chin@jefferson.edu	Hazra, Anupam/ABD-6774-2020; Ritter, Stefanie L/D-9312-2012	Hazra, Anupam/0000-0002-3679-7950; Chin, Jeannie/0000-0001-9902-3744	Alzheimer's AssociationAlzheimer's Association; Margaret Q. Landenberger Research Foundation; DODUnited States Department of Defense [PR110389]	Contract grant sponsor: Alzheimer's Association; Contract grant sponsor: Margaret Q. Landenberger Research Foundation; Contract grant sponsor: DOD; Contract grant sponsor: PR110389 (to M.B.E.).	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Adamah-Biassi EB, 2013, BEHAV BRAIN RES, V243, P306, DOI 10.1016/j.bbr.2013.01.003; Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Anderson MP, 2005, P NATL ACAD SCI USA, V102, P1743, DOI 10.1073/pnas.0409644102; Arciniegas DB, 2008, CRIT CARE CLIN, V24, P737, DOI 10.1016/j.ccc.2008.06.001; Beenhakker MP, 2009, NEURON, V62, P612, DOI 10.1016/j.neuron.2009.05.015; Ben Achour S, 2012, NEUROCHEM RES, V37, P2464, DOI 10.1007/s11064-012-0807-0; Blethyn KL, 2006, J NEUROSCI, V26, P2474, DOI 10.1523/JNEUROSCI.3607-05.2006; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Bouilleret V, 2009, J NEUROTRAUM, V26, P1999, DOI 10.1089/neu.2009.0943; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Carter MD, 2011, AUTISM RES, V4, P57, DOI 10.1002/aur.180; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Crabtree JW, 2013, EUR J NEUROSCI, V37, P850, DOI 10.1111/ejn.12098; Cueni L, 2008, NAT NEUROSCI, V11, P683, DOI 10.1038/nn.2124; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Elliott MB, 2012, HEADACHE, V52, P966, DOI 10.1111/j.1526-4610.2012.02160.x; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Elliott MB, 2009, BRAIN RES, V1305, P183, DOI 10.1016/j.brainres.2009.09.104; Faul M, 2010, TRAUMATIC BRAIN INJU; Fujita M., 2010, NAT COMMUN, V1110, P1; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hirsch Lawrence J, 2008, Epilepsy Curr, V8, P97, DOI 10.1111/j.1535-7511.2008.00254.x; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Ito S, 2013, NEUROBIOL DIS, V49, P29, DOI 10.1016/j.nbd.2012.08.003; Jacobowitz DM, 2012, BRAIN RES, V1465, P80, DOI 10.1016/j.brainres.2012.05.008; Jhuang H, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1064; Ji RR, 2013, PAIN S1, V154; Jones EG, 2009, ANN NY ACAD SCI, V1157, P10, DOI 10.1111/j.1749-6632.2009.04534.x; Kasturi BS, 2009, J NEUROTRAUM, V26, P1315, DOI [10.1089/neu.2008.0751, 10.1089/neu.2008-0751]; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lange RT, 2013, J NEUROTRAUM, V30, P958, DOI 10.1089/neu.2012.2743; Lee J, 2004, P NATL ACAD SCI USA, V101, P18195, DOI 10.1073/pnas.0408089101; Llinas RR, 2006, J NEUROPHYSIOL, V95, P3297, DOI 10.1152/jn.00166.2006; Lull N, 2010, BRAIN INJURY, V24, P1098, DOI 10.3109/02699052.2010.494592; Martinowich K, 2011, MOL BRAIN, V4, DOI 10.1186/1756-6606-4-11; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; McMahon PJ, 2013, J NEUROTRAUM; Mochel F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018336; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Nardone R, 2011, J NEUROTRAUM, V28, P1165, DOI 10.1089/neu.2010.1748; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Onyszchuk G, 2009, NEUROSCI LETT, V452, P204, DOI 10.1016/j.neulet.2009.01.049; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Santarnecchi E, 2013, J SLEEP RES, V22, P337, DOI 10.1111/jsr.12006; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Steele AD, 2007, P NATL ACAD SCI USA, V104, P1983, DOI 10.1073/pnas.0610779104; STERIADE M, 1993, J NEUROSCI, V13, P3284; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Tang L, 2011, RADIOLOGY, V260, P831, DOI 10.1148/radiol.11110014; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; THOMAS WE, 1992, BRAIN RES REV, V17, P61; Vanderploeg RD, 2013, J HEAD TRAUMA REHAB, V28, P211, DOI 10.1097/HTR.0b013e31828b50db; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wortzel HS, 2012, CURR TREAT OPTION NE, V14, P493, DOI 10.1007/s11940-012-0193-6; Zafonte RD, 1997, AM J PHYS MED REHAB, V76, P246, DOI 10.1097/00002060-199705000-00018; Zhou Y, 2013, J MAGN RESO IN PRESS	71	25	26	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	NOV	2014	92	11					1434	1445		10.1002/jnr.23430			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AN4CJ	WOS:000340534900003	24964253				2022-02-06	
J	Mir, IN; Chalak, LF				Mir, Imran N.; Chalak, Lina F.			Serum biomarkers to evaluate the integrity of the neurovascular unit	EARLY HUMAN DEVELOPMENT			English	Article							NEURON-SPECIFIC ENOLASE; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; FIBRILLARY ACIDIC PROTEIN; TRAUMATIC BRAIN-INJURY; C-TERMINAL HYDROLASE; WHITE-MATTER INJURY; NEONATAL ENCEPHALOPATHY; CEREBROSPINAL-FLUID; PERINATAL ASPHYXIA; CARDIAC-SURGERY	Biomarkers have the potential to enable the clinicians to screen infants for brain injury, monitor progression of disease, identify injured brain regions, assess efficacy of neuroprotective therapies, and offer hope to identify the timing of the injury, thus shedding light on the potential pathophysiology and the most effective therapy. Currently, clinicians do not routinely use biomarkers to care for neonates with Neonatal Encephalopathy (NE) and brain injury due to prenatal hypoxia-asphyxia. This review will cover potential biomarkers of the neurovascular unit in the setting of NE that (i) can help assess the degree or severity of encephalopathy at birth; (ii) can help monitor progression of disease process and efficacy of neuroprotective therapy; (iii) can help assess neurodevelopmental outcome. These biomarkers will be summarized in two categories: 1) Specific biomarkers targeting the neurovascular unit such as glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), S100B, and neuron specific enolase (NSE) and 2) general inflammatory cytokines, such as interleuldn-6 (IL-6), interleukin-1b (IL-1b), and pNF-H, among others. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Mir, Imran N.; Chalak, Lina F.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA		Chalak, LF (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA.	lina.chalak@utsouthwestern.edu	Mir, Imran Nazir/K-1447-2019	Mir, Imran Nazir/0000-0002-6343-0337	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD069521] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD069521] Funding Source: NIH RePORTER		Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Bailey SL, 2006, CRIT REV IMMUNOL, V26, P149, DOI 10.1615/CritRevImmunol.v26.i2.40; Bartha AI, 2004, PEDIATR RES, V56, P960, DOI 10.1203/01.PDR.0000144819.45689.BB; Basile AM, 2001, EUR NEUROL, V45, P151, DOI 10.1159/000052114; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Celtik C, 2004, BRAIN DEV-JPN, V26, P398, DOI 10.1016/j.braindev.2003.12.007; Chalak LF, 2014, J PEDIATR-US, V164, P468, DOI 10.1016/j.jpeds.2013.10.067; Chiesa C, 2003, EUR J CLIN INVEST, V33, P352, DOI 10.1046/j.1365-2362.2003.01136.x; Dammann O, 2008, CLIN PERINATOL, V35, P643, DOI 10.1016/j.clp.2008.07.011; de Vries LS, 2010, ARCH DIS CHILD-FETAL, V95, pF220, DOI 10.1136/adc.2008.148205; Douglas-Escobar M, 2013, FRONT NEUROL, V3, DOI 10.3389/fneur.2012.00185; Douglas-Escobar M, 2010, PEDIATR RES, V68, P531, DOI 10.1203/PDR.0b013e3181f85a03; Ellison VJ, 2005, PEDIATR RES, V57, P282, DOI 10.1203/01.PDR.0000148286.53572.95; Elovitz MA, 2011, INT J DEV NEUROSCI, V29, P663, DOI 10.1016/j.ijdevneu.2011.02.011; Ennen CS, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.025; Fairchild KD, 2000, J INTERF CYTOK RES, V20, P1049, DOI 10.1089/107999000750053708; FINER NN, 1981, J PEDIATR-US, V98, P112, DOI 10.1016/S0022-3476(81)80555-0; Foster-Barber A, 2001, DEV NEUROSCI-BASEL, V23, P213, DOI 10.1159/000046146; Gazzolo D, 2004, CRIT CARE MED, V32, P131, DOI 10.1097/01.CCM.0000104116.91462.CD; Gazzolo D, 2010, J MATERN-FETAL NEO M, V23, P66, DOI 10.3109/14767058.2010.507960; Gazzolo D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004298; Gonzalez FF, 2006, ARCH DIS CHILD-FETAL, V91, pF454, DOI 10.1136/adc.2005.092445; Hagberg H, 1996, PEDIATR RES, V40, P603, DOI 10.1203/00006450-199610000-00015; HAY E, 1984, J NEUROL NEUROSUR PS, V47, P724, DOI 10.1136/jnnp.47.7.724; HELLSTROMWESTAS L, 1995, ARCH DIS CHILD-FETAL, V72, pF34, DOI 10.1136/fn.72.1.F34; Kaneko T, 2009, RESUSCITATION, V80, P790, DOI 10.1016/j.resuscitation.2009.04.003; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928; Leviton A, 1999, PEDIATR RES, V46, P566, DOI 10.1203/00006450-199911000-00013; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Liu XH, 1999, J CEREBR BLOOD F MET, V19, P1099, DOI 10.1097/00004647-199910000-00006; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Malaeb S, 2009, J CHILD NEUROL, V24, P1119, DOI 10.1177/0883073809338066; Marlow N, 2005, ARCH DIS CHILD-FETAL, V90, pF380, DOI 10.1136/adc.2004.067520; Massaro AN, 2013, PEDIATR CRIT CARE ME, V14, P310, DOI 10.1097/PCC.0b013e3182720642; McAdams RM, 2012, NEUROL RES INT, V2012, DOI 10.1155/2012/561494; PAHLMAN S, 1984, TUMOUR BIOL, V5, P127; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; PERLMAN JM, 1989, AM J DIS CHILD, V143, P617, DOI 10.1001/archpedi.1989.02150170119037; Qian J, 2009, EUR J PEDIATR, V168, P71, DOI 10.1007/s00431-008-0711-4; Ramaswamy V, 2009, PEDIATR NEUROL, V40, P215, DOI 10.1016/j.pediatrneurol.2008.09.026; Risso FM, 2013, ACTA PAEDIATR, V102, pE467, DOI 10.1111/apa.12343; ROINE RO, 1989, ARCH NEUROL-CHICAGO, V46, P753, DOI 10.1001/archneur.1989.00520430047015; Rostene W, 2011, J NEUROCHEM, V118, P680, DOI 10.1111/j.1471-4159.2011.07371.x; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Russwurm S, 2002, J INTERF CYTOK RES, V22, P215, DOI 10.1089/107999002753536185; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Savman K, 1998, PEDIATR RES, V43, P746; Schmitt B, 1998, BRAIN DEV-JPN, V20, P536, DOI 10.1016/S0387-7604(98)00046-1; Shah P, 2004, ARCH DIS CHILD-FETAL, V89, P152, DOI 10.1136/adc.2002.023093; Shalak LF, 2002, MENT RETARD DEV D R, V8, P14, DOI 10.1002/mrdd.10006; SHANKARAN S, 1991, EARLY HUM DEV, V25, P135, DOI 10.1016/0378-3782(91)90191-5; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Tayal V, 2008, EUR J PHARMACOL, V579, P1, DOI 10.1016/j.ejphar.2007.10.049; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; Thoresen M, 2010, PEDIATRICS, V126, pE131, DOI 10.1542/peds.2009-2938; Vela JM, 2002, MOL CELL NEUROSCI, V20, P489, DOI 10.1006/mcne.2002.1127; Volpe JJ, 2003, PEDIATRICS, V112, P176, DOI 10.1542/peds.112.1.176; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Yoon BH, 2003, BJOG-INT J OBSTET GY, V110, P124, DOI 10.1016/S1470-0328(03)00063-6	62	25	25	1	11	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-3782	1872-6232		EARLY HUM DEV	Early Hum. Dev.	OCT	2014	90	10					707	711		10.1016/j.earlhumdev.2014.06.010			5	Obstetrics & Gynecology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Obstetrics & Gynecology; Pediatrics	AR1YA	WOS:000343379300026	25064445				2022-02-06	
J	Tanabe, K; Matsushima-Nishiwaki, R; Kozawa, O; Iida, H				Tanabe, Kumiko; Matsushima-Nishiwaki, Rie; Kozawa, Osamu; Iida, Hiroki			Dexmedetomidine suppresses interleukin-1 beta-induced interleukin-6 synthesis in rat glial cells	INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE			English	Article						alpha(2)-adrenoceptor; dexmedetomidine; interleukin-1 beta; interleukin-6; intracellular signaling	C6 GLIOMA-CELLS; SEDATION; RELEASE; EXPRESSION; KINASE	Dexmedetomidine, an alpha(2)-adrenoceptor agonist, is used as a sedative medication for criticalyl ill patients and is known to exert neuroprotective effects by direct action on neurons and indirect action on neurons through astrocytes. Interleukin (IL)-6 plays a key role in neuroinflammation, which accompanies infection, traumatic brain injury, ischemia, neurodegenerative disorders, as both a pro-inflammatory cytokine and an anti-inflammatory cytokine. Dexmedetomidine suppresses immune function. However, the effects of dexmedetomidine on cytokine synthesis in the central nervous system (CNS) remain elusive. We previously reported that IL-1 beta stimulates IL-6 synthesis in the rat C6 glioma cell line through the phosphorylation of p38 mitogen-activated protein (MAP) kinase, stress-activated protein kinase (SAPK)/c-Jun N-terminal kinase (JNK) and I kappa B. In the present study, we investigated the effects of dexmedetomidine on the IL-1 beta-induced IL-6 synthesis in C6 cells. Dexmedetomidine inhibited the IL-1 beta-stimulated IL-6 release and mRNA expression in C6 cells. 8-Bromo-adenosine-3',5'-cyclic monophosphate, but not 8-bromo-guanosine 3',5'-cyclic monophosphate, significantly enhanced the IL-1 beta-induced IL-6 release and mRNA expression. However, dexmedetomidine failed to affect cAMP accumulation in the cells treated with IL-1 beta or forskolin, an activator of adenylyl cyclase. Yohimbine, an alpha(2)-adrenoceptor antagonist, did not reverse the suppressive effects of dexmedetomidine on the IL-1 beta-induced IL-6 release. Dexmedetomidine did not affect the IL-1 beta-induced phosphorylation of p38 MAP kinase, SAPK/JNK, I kappa B, nuclear factor (NF)-kappa B or c-Jun. Our findings strongly suggest that dexmedetomidine inhibits the IL-1 beta-induced IL-6 synthesis independently of the adenylyl cyclase-cAMP pathway through alpha(2)-adrenoceptors in C6 glioma cells. It is possible that dexmedetomidine may affect the immune system in the CNS by regulating the production of IL-6.	[Tanabe, Kumiko; Iida, Hiroki] Gifu Univ, Grad Sch Med, Dept Anesthesiol & Pain Med, Gifu 5011194, Japan; [Matsushima-Nishiwaki, Rie; Kozawa, Osamu] Gifu Univ, Grad Sch Med, Dept Pharmacol, Gifu 5011194, Japan		Tanabe, K (corresponding author), Gifu Univ, Grad Sch Med, Dept Anesthesiol & Pain Med, Yanagido 1-1, Gifu 5011194, Japan.	kumiko-t@m2.gyao.ne.jp			Ministry of Education, Science, Sports and Culture of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [23592248]	We are very grateful to Yumiko Kurokawa for her skillful technical assistance. The present study was supported in part by a Grant-in-Aid for Scientific Research (23592248) from the Ministry of Education, Science, Sports and Culture of Japan.	AANTAA R, 1995, ANN MED, V27, P439, DOI 10.3109/07853899509002452; Adcock IM, 2001, IMMUNOL CELL BIOL, V79, P376, DOI 10.1046/j.1440-1711.2001.01025.x; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Bekker A, 2013, J NEUROSURG ANESTH, V25, P16, DOI 10.1097/ANA.0b013e31826318af; Benarroch EE, 2005, MAYO CLIN PROC, V80, P1326, DOI 10.4065/80.10.1326; Chen Y, 2000, ANESTH ANALG, V91, P353, DOI 10.1097/00000539-200008000-00022; Edwards LP, 2012, CARDIOVASC THER, V30, P199, DOI 10.1111/j.1755-5922.2011.00268.x; Eser O, 2008, BRAIN RES, V1218, P250, DOI 10.1016/j.brainres.2008.04.045; Gallagher HC, 2004, NEUROTOXICOL TERATOL, V26, P73, DOI 10.1016/j.ntt.2003.07.013; Huang R, 2000, BRAIN RES, V873, P297, DOI 10.1016/S0006-8993(00)02525-7; Iirola T, 2012, BRIT J ANAESTH, V108, P460, DOI 10.1093/bja/aer441; Kang SH, 2013, ACTA ANAESTH SCAND, V57, P480, DOI 10.1111/aas.12039; Kawashima A, 2008, PROSTAG LEUKOTR ESS, V79, P59, DOI 10.1016/j.plefa.2008.07.002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambertsen KL, 2012, J CEREBR BLOOD F MET, V32, P1677, DOI 10.1038/jcbfm.2012.88; Ma DQ, 2004, BRIT MED BULL, V71, P77, DOI 10.1093/bmb/ldh036; Memis D, 2007, BRIT J ANAESTH, V98, P550, DOI 10.1093/bja/aem017; Morioka N, 2010, J PHARMACOL SCI, V113, P234, DOI 10.1254/jphs.10031FP; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; Qiao H, 2009, CRIT CARE, V13, DOI 10.1186/cc8012; Saavedra A, 2008, PROG NEUROBIOL, V86, P186, DOI 10.1016/j.pneurobio.2008.09.006; Sanders RD, 2007, CURR OPIN INVEST DR, V8, P25; Sanders Robert D, 2011, Anesthesiol Clin, V29, P687, DOI 10.1016/j.anclin.2011.09.008; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Simonds WF, 1999, TRENDS PHARMACOL SCI, V20, P66, DOI 10.1016/S0165-6147(99)01307-3; Spooren A, 2011, BRAIN RES REV, V67, P157, DOI 10.1016/j.brainresrev.2011.01.002; Talke P, 1996, ANESTHESIOLOGY, V85, P551, DOI 10.1097/00000542-199609000-00014; Tanabe K, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-68; Venn RM, 2001, BRIT J ANAESTH, V86, P650, DOI 10.1093/bja/86.5.650; Yan M, 2011, NEUROCHEM INT, V58, P549, DOI 10.1016/j.neuint.2011.01.013; Zhang FJ, 2012, J PHARM PHARMACOL, V64, P120, DOI 10.1111/j.2042-7158.2011.01382.x; Zhang Yonghua, 2005, Current Neuropharmacology, V3, P317, DOI 10.2174/157015905774322534; Zumwalt JW, 1999, ENDOCRINOLOGY, V140, P888, DOI 10.1210/en.140.2.888	33	25	28	1	15	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1107-3756	1791-244X		INT J MOL MED	Int. J. Mol. Med.	OCT	2014	34	4					1032	1038		10.3892/ijmm.2014.1863			7	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	AQ4AL	WOS:000342734500014	25069417	Bronze			2022-02-06	
J	Bachynski, KE; Goldberg, DS				Bachynski, Kathleen E.; Goldberg, Daniel S.			Youth Sports & Public Health: Framing Risks of Mild Traumatic Brain Injury in American Football and Ice Hockey	JOURNAL OF LAW MEDICINE & ETHICS			English	Article							PLAY GUIDELINES; CONCUSSION; IMPACT; RETURN	The framing of the risks of experiencing mild traumatic brain injury in American football and ice hockey has an enormous impact in defining the scope of the problem and the remedies that are prioritized. According to the prevailing risk frame, an acceptable level of safety can be maintained in these contact sports through the application of technology, rule changes, and laws. An alternative frame acknowledging that these sports carry significant risks would produce very different ethical, political, and social debates.	[Bachynski, Kathleen E.] Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, New York, NY 10027 USA; [Goldberg, Daniel S.] E Carolina Univ, Brody Sch Med, Dept Bioeth & Interdisciplinary Studies, Greenville, NC USA		Bachynski, KE (corresponding author), Columbia Univ, Dept Sociomed Sci, Mailman Sch Publ Hlth, New York, NY 10027 USA.						Anderson AJ, 2000, PEDIATRICS, V105, P657, DOI 10.1542/peds.105.3.640; [Anonymous], 2009, CLOSING GAP GENERATI; Bachynski KE, 2012, AM J PUBLIC HEALTH, V102, P2214, DOI 10.2105/AJPH.2012.300721; Bauer RM, 2012, ARCH CLIN NEUROPSYCH, V27, P362, DOI 10.1093/arclin/acs027; Belson K., 2013, NY TIMES; Breslow J. M., COMMUNICATION; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Chokshi DA, 2012, NEW ENGL J MED, V367, P295, DOI 10.1056/NEJMp1206268; Chou R, 2009, LANCET, V373, P463, DOI 10.1016/S0140-6736(09)60172-0; Crouse Karen, 2013, NY TIMES; CUTLER DM, 2001, HLTH AFF MILLWOOD, V20, P11; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Deyo RA, 2009, J AM BOARD FAM MED, V22, P62, DOI 10.3122/jabfm.2009.01.080102; Dixon J. L., 1989, SAFETY ICE HOCKEY, P207; Donaldson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069122; Echlin PS, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12286; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Fainaru-Wada M, 2013, LEAGUE DENIAL N F L; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; GEERTZ C, 1972, DAEDALUS, P1; Goldberg DS, 2013, J LEGAL MED, V34, P157, DOI 10.1080/01947648.2013.800792; Goldberg DS, 2008, HEC FORUM, V20, P337, DOI 10.1007/s10730-008-9079-0; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; HODGSON VR, 1975, MED SCI SPORT EXER, V7, P225; Hofmann B, 2002, INT J TECHNOL ASSESS, V18, P675; Hulse William F., 1981, SPORTS INJURIES UNTH, P378; Johnson LSM, 2012, J SCHOOL HEALTH, V82, P180, DOI 10.1111/j.1746-1561.2011.00684.x; Jonas MF, 2011, PUBLIC HEALTH ETH-UK, V4, P129, DOI 10.1093/phe/phr023; Kreck C., 2014, COMMUNICATION; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Markowitz J. S., 2013, PIGSKIN CROSSROADS E, P50; Maske M., 2007, WASHINGTON POST; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGrew CA, 2011, CURR SPORT MED REP, V10, P394, DOI 10.1249/JSR.0b013e318237c2a5; McGUIRE A, 2009, EC NEW HLTH TECHNOLO, P3; Molcho M, 2011, INJURY PREV, V17, P147, DOI 10.1136/ip.2010.030023; Munthe C., 2012, PRICE PRECAUTION ETH; National Operating Committee for Standards on Athletic Equipment, FAQS; NEWHOUSE JP, 1992, J ECON PERSPECT, V6, P3, DOI 10.1257/jep.6.3.3; Noble David F., 1997, RELIG TECHNOLOGY DIV; Partridge B., 2013, NEUROETHICS, DOI 10.1007/s12152-013-9182-z; Pop Warner Little Scholars Inc., FOOTB SAF; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Rothman DJ, 1997, BEGINNINGS COUNT TEC; Ryan Allan J., 1968, NAT C PROT EQ SPORTS, P12; Schankman S., 2013, ESPN            0501; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Schwarz A, 2010, NY TIMES; Schwarz Alan, 2007, NY TIMES; Smith M. D., POLAMALU SAYS PLAYER; Smith M. D., STEELRES R CLARK IM; Starfield B, 2008, J EPIDEMIOL COMMUN H, V62, P580, DOI 10.1136/jech.2007.071027; Thompson H., 2009, US HOCKEY MAGAZI SEP; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; Van Dellen T. R., 1950, CHICAGO TRIBUNE; Walter K. D., 2013, AAP NEWS, V34, P17, DOI DOI 10.1542/AAPNEWS.20133410-17	62	25	25	0	27	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1105	1748-720X		J LAW MED ETHICS	J. Law Med. Ethics	FAL	2014	42	3			SI		323	333		10.1111/jlme.12149			11	Ethics; Law; Medical Ethics; Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine	AQ4ED	WOS:000342745000007	25264090				2022-02-06	
J	Hosseini, B; Flora, DB; Banwell, BL; Till, C				Hosseini, Banafsheh; Flora, David B.; Banwell, Brenda L.; Till, Christine			Age of Onset as a Moderator of Cognitive Decline in Pediatric-Onset Multiple Sclerosis	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Pediatric multiple sclerosis; Longitudinal analysis; Processing speed; Working memory; Cognitive reserve; Age of onset	INFORMATION-PROCESSING SPEED; TRAUMATIC BRAIN-INJURY; PSYCHOSOCIAL FEATURES; WORKING-MEMORY; JUVENILE MS; CHILDREN; RESERVE; CHILDHOOD; EFFICIENCY; ADOLESCENTS	Cognitive impairment is often reported in pediatric-onset multiple sclerosis (MS). Using serial cognitive data from 35 individuals with pediatric-onset MS, this study examined how age at disease-onset and proxies of cognitive reserve may impact cognitive maturation over the course of childhood and adolescence. Neuropsychological evaluations were conducted at baseline and up to four more assessments. Of the 35 participants, 7 completed only one assessment, 5 completed two assessments, 13 completed three assessments, 10 completed four or more assessments. Growth curve modeling was used to assess longitudinal trajectories on the Trail Making Test-Part B (TMT-B) and the Symbol Digit Modalities (SDMT; oral version) and to examine how age at disease onset, baseline Full Scale IQ, and social status may moderate rate of change on these measures. Mean number of evaluations completed per patient was 2.8. Younger age at disease onset was associated with a greater likelihood of cognitive decline on both the TMT-B (p = .001) and SDMT (p = .005). Baseline IQ and parental social status did not moderate any of the cognitive trajectories. Findings suggest that younger age at disease-onset increases the vulnerability for disrupted performance on measures of information processing, visual scanning, perceptual/motor speed, and working memory. Proxies of cognitive reserve did not protect against the progression of decline on these measures. Young patients with MS should be advised to seek follow-up cognitive evaluation to assess cognitive maturation and to screen for the potential late emergence of cognitive deficits. (JINS, 2014, 20, 796-804)	[Hosseini, Banafsheh; Flora, David B.; Till, Christine] York Univ, Dept Psychol, Toronto, ON M3J 1P3, Canada; [Banwell, Brenda L.; Till, Christine] Hosp Sick Children, Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada; [Banwell, Brenda L.] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA		Till, C (corresponding author), York Univ, Dept Psychol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	ctill@yorku.ca		Flora, David/0000-0001-7472-0914; Till, Christine/0000-0001-5030-3155	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Multiple Sclerosis Society of Canada; Scottish Rite Charitable Foundation	This study was supported in part by the Canadian Institutes of Health Research, the Multiple Sclerosis Society of Canada, and the Scottish Rite Charitable Foundation. We thank Emily Ursell, Courtney Fair-brother, Julie Coleman and Austin Sye for assistance with recruitment and testing of research participants. We also thank the children and families who generously contributed their time to this research. The authors of this study declare no conflicts of interest.	Amato MP, 2008, NEUROLOGY, V70, P1891, DOI 10.1212/01.wnl.0000312276.23177.fa; Amato MP, 2010, NEUROLOGY, V75, P1134, DOI 10.1212/WNL.0b013e3181f4d821; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Archibald CJ, 2000, J CLIN EXP NEUROPSYC, V22, P686, DOI 10.1076/1380-3395(200010)22:5;1-9;FT686; Banwell BL, 2005, NEUROLOGY, V64, P891, DOI 10.1212/01.WNL.0000152896.35341.51; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barratt W., 2006, BARRATT SIMPLI UNPUB; Benedict RHB, 2008, MULT SCLER J, V14, P940, DOI 10.1177/1352458508090923; Benedict RHB, 2010, J INT NEUROPSYCH SOC, V16, P829, DOI 10.1017/S1355617710000688; Boiko A, 2002, NEUROLOGY, V59, P1006, DOI 10.1212/WNL.59.7.1006; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; Dennis M., 2006, COGNITIVE RESERVE TH, P53; Drew MA, 2009, ARCH CLIN NEUROPSYCH, V24, P47, DOI 10.1093/arclin/acp007; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Ghezzi A, 1997, MULT SCLER, V3, P43, DOI 10.1177/135245859700300105; Hart SA, 2007, INTELLIGENCE, V35, P233, DOI 10.1016/j.intell.2006.08.004; Holland AA, 2014, CHILD NEUROPSYCHOL, V20, P71, DOI 10.1080/09297049.2012.748888; Kesler SR, 2010, BRAIN IMAGING BEHAV, V4, P256, DOI 10.1007/s11682-010-9104-1; Krupp LB, 2007, NEUROLOGY, V68, pS7, DOI 10.1212/01.wnl.0000259422.44235.a8; Leavitt VM, 2011, J CLIN EXP NEUROPSYC, V33, P580, DOI 10.1080/13803395.2010.541427; MacAllister WS, 2007, DEV NEUROPSYCHOL, V32, P625, DOI 10.1080/87565640701375872; MacAllister WS, 2005, NEUROLOGY, V64, P1422, DOI 10.1212/01.WNL.0000158474.24191.BC; Marin SE, 2013, J CHILD NEUROL, V28, P1577, DOI 10.1177/0883073812465010; Marrie RA, 2008, MULT SCLER J, V14, P1091, DOI 10.1177/1352458508092263; Portaccio E, 2009, MULT SCLER J, V15, P620, DOI 10.1177/1352458508101950; Reitan R, 1959, MANUAL ADM SCORING T; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Singer J, 2003, APPL LONGITUDINAL DA APPL LONGITUDINAL DA, DOI [10.1093/acprof:oso/ 9780195152968.003.0001, DOI 10.1093/ACPROF:OSO/9780195152968.003.0001]; Smith A., 2002, SYMBOL DIGIT MODALIT; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Sumowski JF, 2010, BRAIN, V133, P362, DOI 10.1093/brain/awp307; Sumowski JF, 2009, J INT NEUROPSYCH SOC, V15, P606, DOI 10.1017/S1355617709090912; Till C, 2012, ARCH CLIN NEUROPSYCH, V27, P495, DOI 10.1093/arclin/acs058; Till C, 2011, NEUROPSYCHOLOGY, V25, P319, DOI 10.1037/a0022051; Till C, 2013, NEUROPSYCHOLOGY, V27, P210, DOI 10.1037/a0031665; Wechsler D., 1991, WISC 3 WECHSLER INTE; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Weiss L. G., 1999, CANADIAN J SCH PSYCH, V14, P1, DOI [10.1177/082957359901400202, DOI 10.1177/082957359901400202]	42	25	26	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2014	20	8					796	804		10.1017/S1355617714000642			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	AT4ZB	WOS:000344951500003	25033163				2022-02-06	
J	Waldron-Perrine, B; Hennrick, H; Spencer, RJ; Pangilinan, PH; Bieliauskas, LA				Waldron-Perrine, Brigid; Hennrick, Heather; Spencer, Robert J.; Pangilinan, Percival H.; Bieliauskas, Linas A.			Postconcussive Symptom Report in Polytrauma: Influence of Mild Traumatic Brain Injury and Psychiatric Distress	MILITARY MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; NEUROPSYCHOLOGICAL PERFORMANCE; CHRONIC PAIN; BASE RATES; VETERANS; DEPLOYMENT; BLAST; IRAQ; AFGHANISTAN	Many studies have evaluated the influence of mild traumatic brain injury (mTBI) on neuropsychological test performance and on report of postconcussive symptoms. However, most studies that examine postconcussion syndrome (PCS) do not address the issue of "polytrauma," which is common in military mTBI. This study investigated simultaneously demographic, injury-related, and psychiatric symptom predictors of PCS report in a veteran, polytrauma sample. In prediction of overall report of PCS symptoms with demographic, traumatic brain injury, psychiatric and sleep variables, 60% of the variance was explained. Semipartial correlations revealed that post-traumatic stress disorder uniquely explained 7% of the variance, depression 2%, and sleep dissatisfaction 3%; injury and demographic characteristics accounted for no unique variance. In all 5 hierarchical multiple regressions (prediction of total Neurobehavioral Symptom Inventory score and 4 individual factor scores), the total models were significant (p < 0.001). Accurate diagnosis and treatment necessitates an integrative analysis of PCS, psychiatric, behavioral, and health symptom report in addition to neuropsychological functioning in the polytrauma population. This study demonstrated that emotional distress was uniquely predictive of total report of PCS and that no injury-related characteristics were predictive. This is of particular relevance in a Veteran population given the high rates of both mTBI and psychiatric disturbance.	[Waldron-Perrine, Brigid; Hennrick, Heather; Spencer, Robert J.; Pangilinan, Percival H.; Bieliauskas, Linas A.] VA Ann Arbor Healthcare Syst, Ann Arbor, MI 48105 USA; [Pangilinan, Percival H.] Univ Michigan Hlth Syst, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA; [Bieliauskas, Linas A.] Univ Michigan Hlth Syst, Dept Psychiat, Ann Arbor, MI 48109 USA		Waldron-Perrine, B (corresponding author), VA Ann Arbor Healthcare Syst, 2215 Fuller Dr, Ann Arbor, MI 48105 USA.						Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Corrigan JD, 2008, JAMA-J AM MED ASSOC, V300, P720, DOI 10.1001/jama.300.6.720; Demery JA, 2010, CLIN NEUROPSYCHOL, V24, P1292, DOI 10.1080/13854046.2010.528452; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Drag LL, 2012, J INT NEUROPSYCH SOC, V18, P576, DOI 10.1017/S1355617712000203; Drag LL, 2011, J CLIN PSYCHOL MED S, V18, P91, DOI 10.1007/s10880-011-9222-y; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ommaya AK, 1996, J TRAUMA, V41, P972, DOI 10.1097/00005373-199612000-00005; Reitan RM, 1992, TRAIL MAKING TEST MA; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Spencer R, 2012, NEUROPSYCHOLOGY PRAC; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Uomoto JM, 2009, REHABIL PSYCHOL, V54, P259, DOI 10.1037/a0016907; Waldron-Perrine B, 2012, MIL MED, V177, P1293, DOI 10.7205/MILMED-D-12-00169; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zachary, 2000, SHIPLEY I LIVING SCA; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	48	25	25	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	AUG	2014	179	8					856	864		10.7205/MILMED-D-13-00282			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	AN7UO	WOS:000340806700007	25102528	Bronze			2022-02-06	
J	Bryczkowski, SB; Lopreiato, MC; Yonclas, PP; Sacca, JJ; Mosenthal, AC				Bryczkowski, Sarah B.; Lopreiato, Maeve C.; Yonclas, Peter P.; Sacca, James J.; Mosenthal, Anne C.			Delirium prevention program in the surgical intensive care unit improved the outcomes of older adults	JOURNAL OF SURGICAL RESEARCH			English	Article						Delirium; Outcomes; SICU; Benzodiazepines; Mechanical ventilation; ICU; Elderly; Old; Surgery; Trauma	MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; CRITICALLY-ILL PATIENTS; RISK-FACTORS; DURATION; HALOPERIDOL; INTERVENTION; RELIABILITY; PROPHYLAXIS; PREDICTOR	Background: Hospital-acquired delirium is a known risk factor for negative outcomes in patients admitted to the surgical intensive care unit (SICU). Outcomes worsen as the duration of delirium increases. The purpose of this study was to evaluate the efficacy of a delirium prevention program and determine whether it decreased the incidence and duration of hospital-acquired delirium in older adults (age > 50 y) admitted to the SICU. Methods: A prospective pre-or post-intervention cohort study was done at an academic level I trauma center. Older adults admitted to the SICU were enrolled in a delirium prevention program. Those with traumatic brain injury, dementia, or 0 d of obtainable delirium status were excluded from analysis. The intervention consisted of multidisciplinary education, a pharmacologic protocol to limit medications associated with delirium, and a nonpharmacologic sleep enhancement protocol. Primary outcomes were incidence of delirium and delirium-free days/30. Secondary outcomes were ventilator-free days/30, SICU length of stay (LOS), daily and cumulative doses of opioids (milligram, morphine equivalents) and benzodiazepines (milligram, lorazepam equivalents), and time spent in severe pain (greater than or equal to 6 on a scale of 1 -10). Delirium was measured using the Confusion Assessment Method for the ICU. Data were analyzed using Chi-squared and Wilcoxon rank sum analysis. Results: Of 624 patients admitted to the SICU, 123 met inclusion criteria: 57 preintervention (3/12-6/12) and 66 postintervention (7/12-3/13). Cohorts were similar in age, gender, ratio of trauma patients, and Injury Severity Score. Postintervention, older adults experienced delirium at the same incidence (pre 47% versus 58%, P = 0.26), but for a significantly decreased duration as indicated by an increase in delirium-free days/30 (pre 24 versus 27, P = 0.002). After intervention, older adults with delirium had more vent-free days (pre 21 versus 25, P = 0.03), shorter SICU LOS (pre 13 [median 12] versus 7 [median 6], P 0.01) and were less likely to be treated with benzodiazepines (pre 85% versus 63%, P = 0.05) with a lower daily dose when prescribed (pre 5.7 versus 3.6 mg, P = 0.04). After intervention, all older adults spent less time in pain (pre 4.7 versus 3.1 h, P = 0.02), received less total opioids (pre 401 versus 260 mg, P= 0.01), and had shorter SICU LOS (pre 9 [median 5] versus 6 [median 4], P = 0.04). Conclusions: Although delirium prevention continues to be a challenge, this study successfully decreased the duration of delirium for older adults admitted to the SICU. Our simple, cost-effective program led to improved pain and sedation outcomes. Older adults with delirium spent less time on the ventilator and all patients spent less time in the SICU. (C) 2014 Elsevier Inc. All rights reserved.	[Bryczkowski, Sarah B.; Lopreiato, Maeve C.; Yonclas, Peter P.; Sacca, James J.; Mosenthal, Anne C.] Rutgers New Jersey Med Sch, Dept Surg, Newark, NJ 07101 USA		Mosenthal, AC (corresponding author), Rutgers New Jersey Med Sch, Dept Surg, 185 South Orange Ave,MSB G506, Newark, NJ 07101 USA.	Mosentac@NJMS.Rutgers.edu			Healthcare Foundation of New Jersey; Department of Surgery at Rutgers-New Jersey Medical School	Research made possible by the funding of the Healthcare Foundation of New Jersey and the Department of Surgery at Rutgers-New Jersey Medical School. The authors give a special thanks to Jasmine Garces-King, MSN, RN, ACNP-BC, and Patricia Walling, APN for their vital role in staff education. The authors also thank David Livingston, MD for his guidance during the writing process. Finally, the authors thank Robert Lavery for his statistical guidance.	Angles EM, 2008, AM J SURG, V196, P864, DOI 10.1016/j.amjsurg.2008.07.037; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; Fann J R, 2000, Semin Clin Neuropsychiatry, V5, P64; GANDEVIA B, 1964, Med J Aust, V2, P320; Gilmore ML, 2013, GEN HOSP PSYCHIAT, V35, P370, DOI 10.1016/j.genhosppsych.2012.12.009; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Hopkins RO, 2006, CURR OPIN CRIT CARE, V12, P388, DOI 10.1097/01.ccx.0000244115.24000.f5; Inouye SK, 2006, NEW ENGL J MED, V354, P1157, DOI 10.1056/NEJMra052321; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Jackson N, 2008, POSTGRAD MED J, V84, P121, DOI 10.1136/pgmj.2007.062117; Jones SF, 2012, CURR OPIN CRIT CARE, V18, P146, DOI 10.1097/MCC.0b013e32835132b9; Khan BA, 2012, CHEST, V142, P48, DOI 10.1378/chest.11-2100; Lat I, 2009, CRIT CARE MED, V37, P1898, DOI 10.1097/CCM.0b013e31819ffe38; Leonard, 2018, ADV PSYCH TREAT, V14, P292, DOI [DOI 10.1192/APT.BP.107.003723, 10.1192/apt.bp.107.003723]; McAvay GJ, 2006, J AM GERIATR SOC, V54, P1245, DOI 10.1111/j.1532-5415.2006.00815.x; Mistraletti G, 2008, MINERVA ANESTESIOL, V74, P329; Morandi A, 2011, CURR OPIN CRIT CARE, V17, P43, DOI 10.1097/MCC.0b013e3283427243; Morrison RS, 2003, J GERONTOL A-BIOL, V58, P76; Page VJ, 2013, LANCET RESP MED, V1, P515, DOI 10.1016/S2213-2600(13)70166-8; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC; Pisani MA, 2009, CRIT CARE MED, V37, P177, DOI 10.1097/CCM.0b013e318192fcf9; Rea RS, 2007, PHARMACOTHERAPY, V27, P588, DOI 10.1592/phco.27.4.588; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Soja SL, 2008, INTENS CARE MED, V34, P1263, DOI 10.1007/s00134-008-1031-x; Tabet N, 2005, AGE AGEING, V34, P152, DOI 10.1093/ageing/afi031; van den Boogaard M, 2013, CRIT CARE, V17, DOI 10.1186/cc11933; van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892	32	25	29	0	33	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUL	2014	190	1					280	288		10.1016/j.jss.2014.02.044			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Surgery	AK5DN	WOS:000338444700043	24666988				2022-02-06	
J	Vaughan, CG; Gerst, EH; Sady, MD; Newman, JB; Gioia, GA				Vaughan, Christopher G.; Gerst, Elyssa H.; Sady, Maegan D.; Newman, Julie B.; Gioia, Gerard A.			The Relation Between Testing Environment and Baseline Performance in Child and Adolescent Concussion Assessment	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						baseline testing; concussion testing; neurocognitive testing; computerized testing	SPORTS; SCHOOL; IMPACT	Background: Previous research has demonstrated differences in cognitive performance when baseline concussion assessment is performed in a group versus an individual setting. Accurate baseline assessment is imperative when such data are used to make clinical decisions regarding cognitive and symptom recovery after concussion. Hypothesis: The use of similar standardized test administration procedures and test conditions across group and individual settings results in no differences in cognitive performance or symptom reporting. Study Design: Cohort study; Level of evidence, 3. Methods: A total of 939 participants (aged 5-18 years), including 313 tested individually and 626 tested in a group setting, matched on age, sex, and attention-deficit/hyperactivity disorder status, were administered concussion baseline assessment using the desktop version of the Immediate Post-Concussion Assessment and Cognitive Testing and a new pediatric measure, the Multimodal Assessment of Cognition & Symptoms for Children. Cognitive performance, symptom reports, and rates of invalid performance were compared between settings. Results: No significant differences were found between individual and group testing settings for the age-based Learning and Memory Accuracy composite and Response Speed composite standard scores on the Multimodal Assessment of Cognition & Symptoms for Children. Accounting for age and sex, adolescents' performance on the Immediate Post-Concussion Assessment and Cognitive Testing revealed no differences between settings on the 4 composite raw scores (Verbal Memory, Visual Memory, Visual Motor Speed, and Reaction Time). Furthermore, symptom reporting was similar between settings on both measures. Rates of invalid performance did not differ between the 2 administration groups for either age group. There was an interaction effect for invalid performance between attention-deficit/hyperactivity disorder and setting in younger children (aged 5-12 years), with higher rates of invalid performance for children in the group setting with attention-deficit/hyperactivity disorder compared with those without, although there were no differences in the individual setting. Conclusion: In this sample, children given a baseline assessment in a group setting performed no differently than children tested individually when standardized administration procedures were used by trained test administrators. Previous evidence suggesting differences between settings may be attributable to the variability in test administration and supervision rather than the environment itself. The importance of standardized procedures and proper supervision during baseline concussion assessment is supported by these findings.	[Vaughan, Christopher G.; Gerst, Elyssa H.; Sady, Maegan D.; Newman, Julie B.; Gioia, Gerard A.] Childrens Natl Hlth Syst, Rockville, MD 20850 USA		Vaughan, CG (corresponding author), Childrens Natl Hlth Syst, Div Pediat Neuropsychol, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA.	cvaughan@childrensnational.org			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU323352-01]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5-M01-RR-020359-02, P30/HDO40677-07]; USA Hockey at Children's National Health System	One or more of the authors has declared the following potential conflict of interest or source of funding: C. G. V. is a test author of the Multimodal Assessment of Cognition & Symptoms, with royalties expected. G. A. G. is a test author of several measures, including the Multimodal Assessment of Cognition & Symptoms, with royalties expected. Research support has been provided through several grants for test and measure development for the assessment of pediatric concussion by the Centers for Disease Control and Prevention (grant U17/CCU323352-01) and the National Institutes of Health (grants 5-M01-RR-020359-02 and P30/HDO40677-07). USA Hockey has sponsored broader implementation of the concussion program (research and education, predominantly with ice hockey organizations) at Children's National Health System.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Cernich AN, 2007, ARCH CLIN NEUROPSYCH, V22, pS39, DOI 10.1016/j.acn.2006.10.004; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2013, ARCH CLIN NEUROPSYCH, V28, P476, DOI 10.1093/arclin/act024; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Lovell M, 2000, IMPACT IMMEDIATE POS; Lovell MR, IMPACT 2007 6 0 CLIN; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Podell K, 2004, STUD NEUROPSYCHOL DE, P375; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Roebuck-Spencer TM, 2013, J ATHL TRAINING, V48, P499, DOI 10.4085/1062-6050-48.3.11; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P499, DOI 10.1093/arclin/act034; Schatz P, 2013, AM J SPORT MED, V41, P321, DOI 10.1177/0363546512466038; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Vaughan C., 2009, J INT NEUROPSYCH SOC, V15, P189; Woodard JL, 2012, J CLIN SPORT PSYCH, V57, P524	20	25	25	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUL	2014	42	7					1716	1723		10.1177/0363546514531732			8	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Sport Sciences	AN6QT	WOS:000340721900031	24787043				2022-02-06	
J	Brown, EA; Kenardy, JA; Dow, BL				Brown, Erin A.; Kenardy, Justin A.; Dow, Belinda L.			PTSD Perpetuates Pain in Children With Traumatic Brain Injury	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						children; mutual maintenance; pain; perpetual avoidance; posttraumatic stress; PTSD; TBI; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; HEALTH QUESTIONNAIRE; MUTUAL MAINTENANCE; RISK-FACTORS; BURNS; ADOLESCENTS; PREVALENCE; SYMPTOMS; RELIABILITY; DISABILITY	Objective This study tested theoretical models of the relationship between pain and posttraumatic stress disorder (PTSD) in children with traumatic brain injury (TBI). Methods Participants consisted of 195 children aged 6-15 years presenting to 1 of 3 Australian hospitals following a mild-severe TBI. Children were assessed at 3, 6, and 18 months after their accident for PTSD (via the Clinician-Administered PTSD Scale for Children and Adolescents [CAPS-CA] clinical interview) as well as physical pain (via the Child Health Questionnaire, 50-item version [CHQ-PF50]). Trained clinicians administered the CAPS-CA at home visits, and the CHQ-PF50 was collected through questionnaires. Results Structural equation modeling found the data supported the mutual maintenance model and also the nested perpetual avoidance model. Conclusions Both models indicate PTSD is driving the presence of pain, and not vice versa. A fourth model stating this was proposed. Therefore, it may be useful to address PTSD symptoms in treating child pain for expediting recovery.	[Brown, Erin A.; Kenardy, Justin A.; Dow, Belinda L.] Univ Queensland, Sch Med, Ctr Natl Res Disabil & Rehabil Med CONROD, Brisbane, Qld, Australia		Brown, EA (corresponding author), Univ Queensland, Royal Brisbane & Womens Hosp, CONROD, Level 1 Edith Cavell Bldg, Herston, Qld 4029, Australia.	e.brown5@uq.edu.au	Kenardy, Justin A/H-6603-2014; Dow, Belinda/G-8402-2011; Kenardy, Justin/F-2085-2010	Kenardy, Justin A/0000-0001-9475-8450; Dow, Belinda/0000-0003-3645-9414; Brown, Erin A./0000-0001-9963-1192			Aaron J, 1999, J PEDIATR PSYCHOL, V24, P335, DOI 10.1093/jpepsy/24.4.335; Anderson V, 2012, DISABIL REHABIL, V34, P1639, DOI 10.3109/09638288.2012.656789; Australian Bureau of Statistics, 2006, YB AUSTR 2006; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; de Leeuw R, 2005, HEADACHE, V45, P1365, DOI 10.1111/j.1526-4610.2005.00269.x; De Young A. C., 2014, J TRAUMATIC ST UNPUB; De Young AC, 2014, J CHILD ADOL PSYCHOP, V24, P9, DOI 10.1089/cap.2013.0066; Dirkzwager AJE, 2007, PSYCHOSOM MED, V69, P435, DOI 10.1097/PSY.0b013e318052e20a; Dunne R. L., 2010, THESIS U QUEENSLAND; Dunne RL, 2012, CLIN J PAIN, V28, P755, DOI 10.1097/AJP.0b013e318243e16b; Iselin G, 2010, J ANXIETY DISORD, V24, P774, DOI 10.1016/j.janxdis.2010.05.011; Kenardy J, 2012, J CLIN CHILD ADOLESC, V41, P5, DOI 10.1080/15374416.2012.632348; King S, 2011, PAIN, V152, P2729, DOI 10.1016/j.pain.2011.07.016; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Kline R. B., 2012, HDB STRUCTURAL EQUAT, P111; Landgraf JM, 1996, CHILD HLTH QUESTIONN; Liedl A, 2010, PSYCHOL MED, V40, P1215, DOI 10.1017/S0033291709991310; Liedl Alexandra, 2008, Torture, V18, P69; McGrath PJ, 2008, J PAIN, V9, P771, DOI 10.1016/j.jpain.2008.04.007; Nader K., 1996, CLIN ADM PTSD SCALE; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Norman SB, 2008, PSYCHOL MED, V38, P533, DOI 10.1017/S0033291707001389; O'Donnell ML, 2013, J CLIN PSYCHIAT, V74, pE137, DOI 10.4088/JCP.12m08011; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Otis JD, 2006, PSYCHOLOGICAL KNOWLEDGE IN COURT: PTSD, PAIN, AND TBI, P242, DOI 10.1007/0-387-25610-5_14; Raat H, 2005, J EPIDEMIOL COMMUN H, V59, P75, DOI 10.1136/jech.2003.012914; Ritchie C, 2013, PAIN, V154, P2198, DOI 10.1016/j.pain.2013.07.001; Saxe G, 2001, J AM ACAD CHILD PSY, V40, P915, DOI 10.1097/00004583-200108000-00013; Saxe GN, 2005, AM J PSYCHIAT, V162, P1299; Schafer JL, 2002, PSYCHOL METHODS, V7, P147, DOI 10.1037//1082-989X.7.2.147; Scheeringa MS, 2011, DEPRESS ANXIETY, V28, P770, DOI 10.1002/da.20736; Scheeringa MS, 2006, AM J PSYCHIAT, V163, P644, DOI 10.1176/appi.ajp.163.4.644; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; Stoddard FJ, 2006, J AM ACAD CHILD PSY, V45, P87, DOI 10.1097/01.chi.0000184934.71917.3a; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Trickey D, 2012, CLIN PSYCHOL REV, V32, P122, DOI 10.1016/j.cpr.2011.12.001; Villano CL, 2007, J REHABIL RES DEV, V44, P167, DOI 10.1682/JRRD.2006.05.0052; Waters E, 2000, J PEDIATR PSYCHOL, V25, P381, DOI 10.1093/jpepsy/25.6.381	40	25	25	1	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693	1465-735X		J PEDIATR PSYCHOL	J. Pediatr. Psychol.	JUN	2014	39	5					512	520		10.1093/jpepsy/jsu014			9	Psychology, Developmental	Social Science Citation Index (SSCI)	Psychology	AI7JN	WOS:000337065100003	24727749				2022-02-06	
J	Hughes, JD; Rabinstein, AA				Hughes, Joshua D.; Rabinstein, Alejandro A.			Early Diagnosis of Paroxysmal Sympathetic Hyperactivity in the ICU	NEUROCRITICAL CARE			English	Article						Paroxysmal sympathetic hyperactivity; ICU; Diagnosis; Sympathetic storm; Dysautonomia	TRAUMATIC BRAIN-INJURY; DYSAUTONOMIA	Paroxysmal sympathetic hyperactivity (PSH) is a complication of acquired brain injury manifesting with episodic tachycardia, tachypnea, hypertension, diaphoresis, hypertonia, and posturing. No universally accepted diagnostic criteria exist and diagnosis is often delayed until the rehabilitation phase. Electronic records were screened to identify consecutive cases of PSH diagnosed in an intensive care unit (ICU) between 1/2006 and 8/2012 and assess the validity of early clinical diagnosis against formal diagnostic criteria. Data collected included patient demographics, brain injury etiology, symptoms noted by the clinician to support the diagnosis of PSH, PSH manifestations, therapeutic interventions, relevant brain imaging, and investigations to exclude alternative diagnoses. An operational set of diagnostic criteria based on previous literature was used for comparison. Fifty-three consecutive patients with PSH were identified. Mean age was 33.6 +/- A 14.5 years (range 16-67). Traumatic brain injury was the most common etiology (30 patients, 56.6 %) but causes were diverse. Mean time to diagnosis was 8.3 +/- A 11.0 days; 31 patients (59 %) were diagnosed within 7 days and 20 patients (38 %) within 3 days of admission. Tachycardia was almost uniformly present, and diaphoresis, fever, hypertension, and tachypnea were also present in most cases. Dystonia and posturing were present in less than half of patients. 89 % of clinically diagnosed cases met formal diagnostic criteria. Paroxysmal sympathetic hyperactivity can be diagnosed early in the ICU. Strict diagnostic criteria supported the clinician's diagnosis in the majority of cases. Diagnosis should not be rejected because of any particular sign's absence, especially dystonia and posturing.	[Hughes, Joshua D.] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA; [Rabinstein, Alejandro A.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA		Rabinstein, AA (corresponding author), Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA.	rabinstein.alejandro@mayo.edu		Hughes, Joshua/0000-0003-0362-302X			Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Dolce G, 2011, J NEUROTRAUM, V25, P1079; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Fernandez-Ortega JF, 2012, J NEUROTRAUM, V29, P1364, DOI 10.1089/neu.2011.2033; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Krach LE, 1997, J NEUROL REHABIL, V11, P41; Moussouttas M, 2012, NEUROCRIT CARE, V16, P381, DOI 10.1007/s12028-012-9673-5; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Perkes IE, 2011, BRAIN INJURY, V25, P925, DOI 10.3109/02699052.2011.589797; Rabinstein AA, 2004, ARCH NEUROL-CHICAGO, V61, P1625, DOI 10.1001/archneur.61.10.1625-a; Rabinstein AA, 2008, CURR TREAT OPTION N, V10, P151, DOI 10.1007/s11940-008-0016-y; Rabinstein AA, 2007, NEUROL RES, V29, P680, DOI 10.1179/016164107X240071	14	25	28	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2014	20	3					454	459		10.1007/s12028-013-9877-3			6	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AI7RH	WOS:000337092900014	23884511				2022-02-06	
J	Hubel, N; Scholl, E; Dahlem, MA				Huebel, Niklas; Schoell, Eckehard; Dahlem, Markus A.			Bistable Dynamics Underlying Excitability of Ion Homeostasis in Neuron Models	PLOS COMPUTATIONAL BIOLOGY			English	Article							CORTICAL SPREADING DEPRESSION; POTASSIUM DYNAMICS; MIGRAINE GENETICS; WAVE PATTERNS; DEPOLARIZATION; STATES; SIMULATIONS; SEIZURES; SODIUM; TISSUE	When neurons fire action potentials, dissipation of free energy is usually not directly considered, because the change in free energy is often negligible compared to the immense reservoir stored in neural transmembrane ion gradients and the long-term energy requirements are met through chemical energy, i.e., metabolism. However, these gradients can temporarily nearly vanish in neurological diseases, such as migraine and stroke, and in traumatic brain injury from concussions to severe injuries. We study biophysical neuron models based on the Hodgkin-Huxley (HH) formalism extended to include time-dependent ion concentrations inside and outside the cell and metabolic energy-driven pumps. We reveal the basic mechanism of a state of free energy-starvation (FES) with bifurcation analyses showing that ion dynamics is for a large range of pump rates bistable without contact to an ion bath. This is interpreted as a threshold reduction of a new fundamental mechanism of ionic excitability that causes a long-lasting but transient FES as observed in pathological states. We can in particular conclude that a coupling of extracellular ion concentrations to a large glial-vascular bath can take a role as an inhibitory mechanism crucial in ion homeostasis, while the Na+/K+ pumps alone are insufficient to recover from FES. Our results provide the missing link between the HH formalism and activator-inhibitor models that have been successfully used for modeling migraine phenotypes, and therefore will allow us to validate the hypothesis that migraine symptoms are explained by disturbed function in ion channel subunits, Na+/K+ pumps, and other proteins that regulate ion homeostasis.	[Huebel, Niklas; Schoell, Eckehard] Tech Univ Berlin, Dept Theoret Phys, Berlin, Germany; [Dahlem, Markus A.] Humboldt Univ, Dept Phys, D-10099 Berlin, Germany		Hubel, N (corresponding author), Tech Univ Berlin, Dept Theoret Phys, Berlin, Germany.	dahlem@physik.hu-berlin.de			Bundesministerium fur Bildung und Forschung within the Bernstein Center of Computational Neuroscience BerlinFederal Ministry of Education & Research (BMBF) [BMBF 01GQ1001B, 01GQ1109]	This work was supported by the Bundesministerium fur Bildung und Forschung (BMBF 01GQ1001B, 01GQ1109) within the Bernstein Center of Computational Neuroscience Berlin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AIHARA K, 1983, BIOPHYS J, V41, P87, DOI 10.1016/S0006-3495(83)84408-7; Arce H, 2000, CHAOS, V10, P411, DOI 10.1063/1.166508; Atwater I, 1980, HORM METAB RES S, V10, P100; Barreto E, 2011, J BIOL PHYS, V37, P361, DOI 10.1007/s10867-010-9212-6; Bazhenov M, 2004, J NEUROPHYSIOL, V92, P1116, DOI 10.1152/jn.00529.2003; BEILBY MJ, 1979, AUST J PLANT PHYSIOL, V6, P337; Boucher PA, 2012, J COMPUT NEUROSCI, P1; Cha CY, 2011, J GEN PHYSIOL, V138, P21, DOI 10.1085/jgp.201110611; Cha CY, 2009, BIOPHYS J, V97, P3086, DOI 10.1016/j.bpj.2009.08.060; Chang JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070469; Charles AC, 2013, NAT REV NEUROL, V9, P637, DOI 10.1038/nrneurol.2013.192; CHAY TR, 1983, BIOPHYS J, V42, P181, DOI 10.1016/S0006-3495(83)84384-7; Cressman JR, 2009, J COMPUT NEUROSCI, V26, P159, DOI 10.1007/s10827-008-0132-4; Dahlem MA, 2008, J THEOR BIOL, V251, P202, DOI 10.1016/j.jtbi.2007.11.019; Dahlem MA, 2004, ANN PHYS-BERLIN, V13, P442, DOI 10.1002/andp.200410087; Dahlem MA, 2013, CHAOS, V23, DOI 10.1063/1.4813815; Dahlem MA, 2013, TRANSL NEUROSCI, V4, P282, DOI 10.2478/s13380-013-0127-0; Dahlem MA, 2013, J MATH NEUROSCI, V3, DOI 10.1186/2190-8567-3-7; Dahlem MA, 2010, PHYSICA D, V239, P889, DOI 10.1016/j.physd.2009.08.009; Dahlem MA, 2008, CHAOS, V18, DOI 10.1063/1.2937120; Dahlem MA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005007; DIFRANCESCO D, 1985, PHILOS T ROY SOC B, V307, P353, DOI 10.1098/rstb.1985.0001; Doedel E.J., 2009, AUTO 07P CONTINUATIO; DOKOS S, 1993, ANN BIOMED ENG, V21, P321, DOI 10.1007/BF02368625; Dreier JP, 2013, NEUROSCIENTIST, V19, P25, DOI 10.1177/1073858412453340; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; EBIHARA L, 1980, BIOPHYS J, V32, P779, DOI 10.1016/S0006-3495(80)85016-8; Endresen LP, 2000, EUR BIOPHYS J BIOPHY, V29, P90, DOI 10.1007/s002490050254; Ermentrout B, 1998, REP PROG PHYS, V61, P353, DOI 10.1088/0034-4885/61/4/002; Ermentrout G., 2010, MATH FDN NEUROSCIENC; FITZHUGH R, 1961, BIOPHYS J, V1, P445, DOI 10.1016/S0006-3495(61)86902-6; Florence G, 2009, J THEOR BIOL, V258, P219, DOI 10.1016/j.jtbi.2009.01.032; Frohlich F, 2008, NEUROSCIENTIST, V14, P422, DOI 10.1177/1073858408317955; Frohlich F, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.031922; Hahn PJ, 2001, J COMPUT NEUROSCI, V11, P5, DOI 10.1023/A:1011250329341; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Kager H, 2000, J NEUROPHYSIOL, V84, P495, DOI 10.1152/jn.2000.84.1.495; Kuznetsov YA, 1995, ELEMENTS APPL BIFURC; May RM, 2004, SCIENCE, V303, P790, DOI 10.1126/science.1094442; Miura RM, 2007, EUR PHYS J-SPEC TOP, V147, P287, DOI 10.1140/epjst/e2007-00214-8; Muller M, 1998, BRAIN RES, V812, P1, DOI 10.1016/S0006-8993(98)00812-9; NAGUMO J, 1962, P IRE, V50, P2061, DOI 10.1109/JRPROC.1962.288235; Noble D, 2001, PHILOS T ROY SOC A, V359, P1127, DOI 10.1098/rsta.2001.0820; Postnov DE, 2012, BRAIN RES, V1434, P200, DOI 10.1016/j.brainres.2011.10.001; Postnov DE, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.031921; Rinzel J., 1989, METHODS NEURONAL MOD, P251; Schneider FM, 2009, CHAOS, V19, DOI 10.1063/1.3096411; Shapiro BE, 2001, J COMPUT NEUROSCI, V10, P99, DOI 10.1023/A:1008924227961; Silberstein SD, 2013, HEADACHE, V53, P1207, DOI 10.1111/head.12156; Silberstein SD, 2013, HEADACHE, V53, P1218, DOI 10.1111/head.12169; Somjen GG, 2008, J COMPUT NEUROSCI, V25, P349, DOI 10.1007/s10827-008-0083-9; Varghese A, 1997, J THEOR BIOL, V189, P33, DOI 10.1006/jtbi.1997.0487; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Yao W, 2011, B MATH BIOL, V73, P2773, DOI 10.1007/s11538-011-9647-3; Yu N, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002664; Zamecnik J, 2012, EUR J NEUROSCI, V36, P2017, DOI 10.1111/j.1460-9568.2012.08107.x; Zandt BJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022127	57	25	25	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA		1553-7358		PLOS COMPUT BIOL	PLoS Comput. Biol.	MAY	2014	10	5							e1003551	10.1371/journal.pcbi.1003551			15	Biochemical Research Methods; Mathematical & Computational Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Mathematical & Computational Biology	AI9VB	WOS:000337288000002	24784149	gold, Green Published, Green Submitted			2022-02-06	
J	Leunissen, I; Coxon, JP; Caeyenberghs, K; Michiels, K; Sunaert, S; Swinnen, SP				Leunissen, Inge; Coxon, James P.; Caeyenberghs, Karen; Michiels, Karla; Sunaert, Stefan; Swinnen, Stephan P.			Task switching in traumatic brain injury relates to cortico-subcortical integrity	HUMAN BRAIN MAPPING			English	Article						executive function; diffusion tensor imaging; traumatic brain injury; basal ganglia	BLUNT HEAD-INJURY; BASAL GANGLIA; COGNITIVE CONTROL; AXONAL INJURY; FOCAL LESIONS; DIFFUSION TRACTOGRAPHY; EXECUTIVE FUNCTION; FUNCTIONAL-ROLE; NEUROPSYCHOLOGY; DYSFUNCTION	Suppressing and flexibly adapting actions are a critical part of our daily behavioral repertoire. Traumatic brain injury (TBI) patients show clear impairments in this type of action control; however, the underlying mechanisms are poorly understood. Here, we tested whether white matter integrity of cortico-subcortical pathways could account for impairments in task switching, an important component of executive functioning. Twenty young adults with TBI and eighteen controls performed a switching task requiring attention to global versus local stimulus features. Diffusion weighted images were acquired and whole brain tract-based spatial statistics (TBSS) were used to explore where white matter damage was associated with switching impairment. A crossing fiber model and probabilistic tractography further identified the specific fiber populations. Relative to controls, patients with a history of TBI had a higher switch cost and were less accurate. The TBI group showed a widespread decline in fractional anisotropy (FA) throughout the TBSS skeleton. FA in the superior corona radiata showed a negative relationship with switch cost. More specifically, this involved cortico-subcortical loops with the (pre-)supplementary motor area and superior frontal gyrus. These findings provide evidence for damage to frontal-subcortical projections in TBI, which is associated with task switching impairments. Hum Brain Mapp 35:2459-2469, 2014. (c) 2013 Wiley Periodicals, Inc.	[Leunissen, Inge; Caeyenberghs, Karen; Swinnen, Stephan P.] Katholieke Univ Leuven, Movement Control & Neuroplast Res Grp, Dept Kinesiol, Grp Biomed Sci, Louvain, Belgium; [Coxon, James P.] Univ Auckland, Movement Neurosci Lab, Dept Sport & Exercise Sci, Auckland 1, New Zealand; [Michiels, Karla] Univ Hosp, Dept Phys Med & Rehabil, Louvain, Belgium; [Sunaert, Stefan] Katholieke Univ Leuven, Med Imaging Res Ctr, Grp Biomed Sci, Louvain, Belgium		Leunissen, I (corresponding author), Tervuursevest 101, B-3001 Heverlee, Belgium.	inge.leunissen@faber.kuleuven.be	Coxon, James/S-1286-2019	Coxon, James/0000-0003-2351-8489; Leunissen, Inge/0000-0002-3977-3620; Caeyenberghs, Karen/0000-0001-7009-6843	Research Program of the Research Foundation-Flanders (FWO)FWO [G.0483.10, Levenslijn G.0482.10, G.A114.11]; Interuniversity Attraction Poles program of the Belgian federal governmentBelgian Federal Science Policy Office [P7/11]; PhD fellowship of the Research Foundation-Flanders (FWO)FWO	Contract grant sponsor: Research Program of the Research Foundation-Flanders (FWO); Contract grant number: G.0483.10; Levenslijn G.0482.10; and G.A114.11; Contract grant sponsor: Interuniversity Attraction Poles program of the Belgian federal government [P7/11]; Contract grant sponsor: PhD fellowship of the Research Foundation-Flanders (FWO).	ALEXANDER GE, 1990, PROG BRAIN RES, V85, P119; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Behrens TEJ, 2007, NEUROIMAGE, V34, P144, DOI 10.1016/j.neuroimage.2006.09.018; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; Bianchi L., 1895, BRAIN, V18, P497, DOI [10.1016/s0140-6736(01)24735-7, DOI 10.1093/BRAIN/18.4.497]; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; BRANDT J, 1996, NEUROPSYCHOLOGICAL A, P312; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Caeyenberghs K, 2012, BRAIN, V135, P1293, DOI 10.1093/brain/aws048; Carrera E, 2006, NEUROLOGY, V66, P1817, DOI 10.1212/01.wnl.0000219679.95223.4c; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Forstmann BU, 2011, J NEUROSCI, V31, P17242, DOI 10.1523/JNEUROSCI.0309-11.2011; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gold BT, 2010, NEUROBIOL AGING, V31, P512, DOI 10.1016/j.neurobiolaging.2008.04.005; Graybiel AM, 2005, CURR OPIN NEUROBIOL, V15, P638, DOI 10.1016/j.conb.2005.10.006; Grieve SM, 2007, AM J NEURORADIOL, V28, P226; Hellyer PJ, 2012, ANN NEUROL; Hikosaka O, 2010, TRENDS COGN SCI, V14, P154, DOI 10.1016/j.tics.2010.01.006; HOLM S, 1979, SCAND J STAT, V6, P65; Jbabdi S, 2011, BRAIN CONNECT, V1, P169, DOI 10.1089/brain.2011.0033; Jbabdi S, 2010, NEUROIMAGE, V49, P247, DOI 10.1016/j.neuroimage.2009.08.039; Johansen-Berg H, 2005, CEREB CORTEX, V15, P31, DOI 10.1093/cercor/bhh105; Johansen-Berg H, 2010, CURR OPIN NEUROL, V23, P351, DOI 10.1097/WCO.0b013e32833b7631; Kanai R, 2011, NAT REV NEUROSCI, V12, P231, DOI 10.1038/nrn3000; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Krause M, 2012, CORTEX, V48, P97, DOI 10.1016/j.cortex.2011.03.014; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Leunissen I, 2013, HUM BRAIN MAPP, V34, P1254, DOI 10.1002/hbm.21508; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levy R, 2006, CEREB CORTEX, V16, P916, DOI 10.1093/cercor/bhj043; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lowenstein Daniel H, 2009, Ann Neurol, V66, pA7, DOI 10.1002/ana.21876; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mansfield EL, 2011, J NEUROSCI, V31, P14688, DOI 10.1523/JNEUROSCI.2390-11.2011; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; Mink JW, 1996, PROG NEUROBIOL, V50, P381, DOI 10.1016/S0301-0082(96)00042-1; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Monchi O, 2006, ANN NEUROL, V59, P257, DOI 10.1002/ana.20742; Nachev P, 2008, NAT REV NEUROSCI, V9, P856, DOI 10.1038/nrn2478; Nambu A, 2002, NEUROSCI RES, V43, P111, DOI 10.1016/S0168-0102(02)00027-5; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; Newcombe VFJ, 2011, BRAIN, V134, P759, DOI 10.1093/brain/awq388; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rushworth MFS, 2004, TRENDS COGN SCI, V8, P410, DOI 10.1016/j.tics.2004.07.009; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAYLOR AE, 1995, BRAIN COGNITION, V28, P281, DOI 10.1006/brcg.1995.1258; Tournier JD, 2011, MAGN RESON MED, V65, P1532, DOI 10.1002/mrm.22924; Van der Werf YD, 2000, NEUROPSYCHOLOGIA, V38, P613, DOI 10.1016/S0028-3932(99)00104-9; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	66	25	25	2	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	MAY	2014	35	5					2459	2469		10.1002/hbm.22341			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AE5FB	WOS:000334012100048	23913872	Green Accepted, Green Published			2022-02-06	
J	Manohar, S; Jamesdaniel, S; Salvi, R				Manohar, Senthilvelan; Jamesdaniel, Samson; Salvi, Richard			Cisplatin Inhibits Hippocampal Cell Proliferation and Alters the Expression of Apoptotic Genes	NEUROTOXICITY RESEARCH			English	Article						Cisplatin; Apoptosis; Hippocampus; Bid; Bcl2a1	KAPPA-B ACTIVATION; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; BCL-2 FAMILY-MEMBERS; HUMAN BREAST-CANCER; SUBVENTRICULAR ZONE; ADULT NEUROGENESIS; DOWN-REGULATION; DENTATE GYRUS; UP-REGULATION	The hippocampus, which is critical for memory and spatial navigation, contains a proliferating stem cell niche that is especially vulnerable to antineoplastic drugs such as cisplatin. Although the damaging effects of cisplatin have recently been recognized, the molecular mechanisms underlying its toxic effects on this vital region are largely unknown. Using a focused apoptosis gene array, we analyzed the early cisplatin-induced changes in gene expression in the hippocampus of adult Sprague-Dawley rats and compared the results to those from the inferior colliculus, a non-mitotic auditory region resistant to cisplatin-induced cell death. Two days after a 12 mg/kg dose of cisplatin, significant increases were observed in five proapoptotic genes: Bik, Bid, Bok, Trp53p2, and Card6 and a significant decrease in one antiapoptotic gene Bcl2a1. In contrast, Nol3, an antiapoptotic gene, showed a significant increase in expression. The cisplatin-induced increase in Bid mRNA and decrease in Bcl2a1 mRNA were accompanied by a corresponding increase and decrease of their respective proteins in the hippocampus. In contrast, the cisplatin-induced changes in Bcl2a1, Bid, Bik, and Bok gene expression in the inferior colliculus were strikingly different from those in the hippocampus consistent with the greater susceptibility of the hippocampus to cisplatin toxicity. Cisplatin also significantly reduced immunolabeling of the cell proliferation marker Ki67 in the subgranular zone of the hippocampus 2 days post-treatment. These results indicate that cisplatin-induced hippocampal cell death is mediated by increased expression of proapoptotic and decreased antiapoptotic genes and proteins that likely inhibit hippocampal cell proliferation.	[Manohar, Senthilvelan; Jamesdaniel, Samson; Salvi, Richard] SUNY Buffalo, Ctr Hearing & Deafness, Buffalo, NY 14214 USA		Salvi, R (corresponding author), SUNY Buffalo, Ctr Hearing & Deafness, 137 Cary Hall, Buffalo, NY 14214 USA.	smanohar@buffalo.edu; salvi@buffalo.edu	Jamesdaniel, Samson/ABA-2616-2021	Jamesdaniel, Samson/0000-0002-5269-9007	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DC011808]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC011808] Funding Source: NIH RePORTER	Research supported in part by NIH grant (R01DC011808).	Abe K, 2009, WORLD J GASTROENTERO, V15, P5228, DOI 10.3748/wjg.15.5228; Aimone JB, 2009, NEURON, V61, P187, DOI 10.1016/j.neuron.2008.11.026; Amptoulach Sousana, 2011, Chemother Res Pract, V2011, P843019, DOI 10.1155/2011/843019; Appleby PA, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001063; Bachstetter AD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010496; Barha CK, 2011, EXP NEUROL, V231, P72, DOI 10.1016/j.expneurol.2011.05.016; Bekinschtein P, 2007, NEURON, V53, P261, DOI 10.1016/j.neuron.2006.11.025; Blank T, 2002, J NEUROSCI, V22, P3788; Bolouri MR, 2004, J NEUROIMAGING, V14, P290, DOI 10.1177/1051228404265751; Bullwinkel J, 2006, J CELL PHYSIOL, V206, P624, DOI 10.1002/jcp.20494; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chang L W, 1990, J Toxicol Sci, V15 Suppl 4, P125; Chen D, 2005, CELL DEATH DIFFER, V12, P358, DOI 10.1038/sj.cdd.4401536; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng QW, 2000, ONCOGENE, V19, P4936, DOI 10.1038/sj.onc.1203861; Couillard-Despres S, 2009, MOL PSYCHIATR, V14, P856, DOI 10.1038/mp.2008.147; Dawe RJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026286; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Devarajan P, 2002, HEARING RES, V174, P45, DOI 10.1016/S0378-5955(02)00634-2; Dietrich Joerg, 2006, J Biol, V5, P22, DOI 10.1186/jbiol50; Dufner A, 2006, P NATL ACAD SCI USA, V103, P988, DOI 10.1073/pnas.0510380103; Dufner A, 2008, MOL CELL BIOL, V28, P1541, DOI 10.1128/MCB.01359-07; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Femenia T, 2012, BRAIN RES, V1476, P58, DOI 10.1016/j.brainres.2012.03.053; FuseNagase Y, 1997, CLIN ELECTROENCEPHAL, V28, P55, DOI 10.1177/155005949702800110; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Graciarena M, 2010, BRAIN BEHAV IMMUN, V24, P1301, DOI 10.1016/j.bbi.2010.06.005; GREGG RW, 1992, J CLIN ONCOL, V10, P795, DOI 10.1200/JCO.1992.10.5.795; Harter P, 2011, INT J GYNECOL CANCER, V21, P289, DOI 10.1097/IGC.0b013e31820aaafd; Hattiangady B, 2004, NEUROBIOL DIS, V17, P473, DOI 10.1016/j.nbd.2004.08.008; Henshall DC, 2001, CELL DEATH DIFFER, V8, P1169, DOI 10.1038/sj.cdd.4400921; HIGHLEY M, 1992, MED PEDIATR ONCOL, V20, P143, DOI 10.1002/mpo.2950200210; Holmgreen SP, 1999, CELL DEATH DIFFER, V6, P525, DOI 10.1038/sj.cdd.4400519; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hur J, 2006, CANCER RES, V66, P10153, DOI 10.1158/0008-5472.CAN-05-3696; Hurria A, 2006, BREAST CANCER RES TR, V98, P343, DOI 10.1007/s10549-006-9171-6; Iosif RE, 2006, J NEUROSCI, V26, P9703, DOI 10.1523/JNEUROSCI.2723-06.2006; Ishida N, 1997, NEUROSCIENCE, V81, P1183, DOI 10.1016/S0306-4522(97)00220-0; Ishikawa K, 1997, BEHAV BRAIN RES, V83, P39, DOI 10.1016/S0166-4328(97)86043-3; Jacobs S, 2010, CANCER CHEMOTH PHARM, V65, P817, DOI 10.1007/s00280-009-1085-7; James SE, 2008, NEUROTOXICOLOGY, V29, P605, DOI 10.1016/j.neuro.2008.04.008; Jamesdaniel S, 2008, J PROTEOME RES, V7, P3516, DOI 10.1021/pr8002479; Jessberger S, 2009, LEARN MEMORY, V16, P147, DOI 10.1101/lm.1172609; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Ju CX, 2008, EUR J PHARMACOL, V589, P281, DOI 10.1016/j.ejphar.2008.04.050; Jung M, 2009, TOXICOL APPL PHARM, V234, P236, DOI 10.1016/j.taap.2008.10.014; Kaasa S, 1988, Antibiot Chemother (1971), V41, P226; Kang KP, 2009, NEPHROL DIAL TRANSPL, V24, P3012, DOI 10.1093/ndt/gfp242; Kannarkat G, 2007, CURR OPIN NEUROL, V20, P719; KESNER RP, 1995, NEUROBIOL LEARN MEM, V64, P237, DOI 10.1006/nlme.1995.0006; Kim JB, 2004, BRAIN RES, V1027, P1, DOI 10.1016/j.brainres.2004.070.93; Kim JK, 2004, CANCER LETT, V212, P61, DOI 10.1016/j.canlet.2004.02.021; Kraus KS, 2010, NEUROSCIENCE, V167, P1216, DOI 10.1016/j.neuroscience.2010.02.071; Kyd RJ, 2005, CEREB CORTEX, V15, P720, DOI 10.1093/cercor/bhh173; Lane David P., 1992, Current Biology, V2, P581, DOI 10.1016/0960-9822(92)90154-3; Lee S, 2006, NEPHROL DIAL TRANSPL, V21, P2085, DOI 10.1093/ndt/gfl209; Li CY, 2008, MOL CANCER THER, V7, P1647, DOI 10.1158/1535-7163.MCT-07-2444; Li SY, 2005, AM J PHYSIOL-RENAL, V289, pF469, DOI 10.1152/ajprenal.00038.2005; Lim CS, 2005, J NEUROSCI RES, V82, P831, DOI 10.1002/jnr.20692; Liu Yanxia, 2003, Research Communications in Molecular Pathology and Pharmacology, V113, P97; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Luft T, 2008, CURR NEUROVASC RES, V5, P21; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Manohar S, 2012, NEUROSCIENCE, V202, P169, DOI 10.1016/j.neuroscience.2011.12.013; Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017; Matsuda Tomohiro, 2005, Breast Cancer, V12, P279, DOI 10.2325/jbcs.12.279; Medina-Ramirez CM, 2011, CANCER RES, V71, P7705, DOI 10.1158/0008-5472.CAN-11-2192; Mercier I, 2005, CELL DEATH DIFFER, V12, P682, DOI 10.1038/sj.cdd.4401631; Mezosi E, 2004, J CLIN ENDOCR METAB, V89, P250, DOI 10.1210/jc.2003-030697; Minami T, 1998, TOXICOLOGY, V130, P107, DOI 10.1016/S0300-483X(98)00103-6; Moita MAP, 2003, NEURON, V37, P485, DOI 10.1016/S0896-6273(03)00033-3; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morgan RJ, 2012, INVEST NEW DRUG, V30, P723, DOI 10.1007/s10637-010-9557-5; Mustafa S, 2008, EUR J NEUROSCI, V28, P323, DOI 10.1111/j.1460-9568.2008.06325.x; Naumovski L, 1996, MOL CELL BIOL, V16, P3884; Navarro-Quiroga I, 2006, J COMP NEUROL, V497, P833, DOI 10.1002/cne.21037; Niedermeyer Ernst, 2011, Am J Electroneurodiagnostic Technol, V51, P82; Ortin I, 2009, BIOORGAN MED CHEM, V17, P8040, DOI 10.1016/j.bmc.2009.10.007; Piccolini VM, 2012, EXP NEUROL, V234, P239, DOI 10.1016/j.expneurol.2011.12.044; Pietropaolo S, 2007, BEHAV PHARMACOL, V18, P533, DOI 10.1097/FBP.0b013e3282da0bf6; Prestia A, 2011, PSYCHIAT RES-NEUROIM, V192, P77, DOI 10.1016/j.pscychresns.2010.12.015; Ramesh G, 2004, KIDNEY INT, V66, pS56, DOI 10.1111/j.1523-1755.2004.09109.x; Rzeski W, 2004, ANN NEUROL, V56, P351, DOI 10.1002/ana.20185; Scoville WB, 2000, J NEUROPSYCH CLIN N, V12, P103; Sehouli J, 2012, ANN ONCOL, V23, P2259, DOI 10.1093/annonc/mdr628; Shabani M, 2012, INT J NEUROSCI, V122, P439, DOI 10.3109/00207454.2012.673515; Shih AY, 2006, J NEUROSCI, V26, P10514, DOI 10.1523/JNEUROSCI.3178-06.2006; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; So H, 2008, JARO-J ASSOC RES OTO, V9, P290, DOI 10.1007/s10162-008-0126-y; Soussain C, 2009, LANCET, V374, P1639, DOI 10.1016/S0140-6736(09)61299-X; Tanaka A, 2007, MECH AGEING DEV, V128, P303, DOI 10.1016/j.mad.2007.01.002; Troy L, 2000, PSYCHO-ONCOL, V9, P29, DOI 10.1002/(SICI)1099-1611(200001/02)9:1<29::AID-PON428>3.0.CO;2-Z; Tsuji T, 2009, TOXICOL APPL PHARM, V234, P202, DOI 10.1016/j.taap.2008.09.031; Valente T, 2009, J ALZHEIMERS DIS, V18, P849, DOI 10.3233/JAD-2009-1188; Van der Gucht E, 2006, ANAT REC PART A, V288A, P753, DOI 10.1002/ar.a.20350; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vanderwolf CH, 2001, BEHAV BRAIN RES, V127, P25, DOI 10.1016/S0166-4328(01)00354-0; Veena J, 2009, J NEUROSCI RES, V87, P831, DOI 10.1002/jnr.21907; Verstappen CCP, 2003, DRUGS, V63, P1549, DOI 10.2165/00003495-200363150-00003; Vogler M, 2012, CELL DEATH DIFFER, V19, P67, DOI 10.1038/cdd.2011.158; Wakahara K, 2005, J INFECT DIS, V191, P930, DOI 10.1086/428134; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wang Q, 2012, INT J CLIN EXP PATHO, V5, P555; Wei L, 2010, NEUROSCIENCE, V168, P288, DOI 10.1016/j.neuroscience.2010.03.015; Weiss B, 2008, NEUROTOXICOLOGY, V29, P891, DOI 10.1016/j.neuro.2008.03.009; Werner AB, 2002, J BIOL CHEM, V277, P22781, DOI 10.1074/jbc.M201469200; Whitney Kriscinda A, 2008, J Support Oncol, V6, P313; Xu Y, 2012, CANCER LETT, V314, P232, DOI 10.1016/j.canlet.2011.09.034; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yang FY, 2012, INT J NANOMED, V7, P2573, DOI 10.2147/IJN.S31675; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zhang N, 2005, CELL RES, V15, P749, DOI 10.1038/sj.cr.7290345	113	25	25	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1029-8428	1476-3524		NEUROTOX RES	Neurotox. Res.	MAY	2014	25	4					369	380		10.1007/s12640-013-9443-y			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AE7JH	WOS:000334173200005	24277158	Green Accepted			2022-02-06	
J	Rivkin, MA; Saraiya, PV; Woodrow, SI				Rivkin, Mark A.; Saraiya, Piya V.; Woodrow, Sarah I.			Sinovenous thrombosis associated with skull fracture in the setting of blunt head trauma	ACTA NEUROCHIRURGICA			English	Article						Cerebral sinus; Sinus thrombosis; Skull fracture; Head trauma	DURAL SINUS THROMBOSIS; INJURY	Emerging literature suggests that closed head injuries may be an important etiology of cerebral venous sinus thrombosis (CVST). Fractures over the dural sinuses, in particular, may predispose such patients to this secondary complication. The purpose of this study was to determine the incidence and characteristics of CVST resulting from skull fractures overlying cerebral venous sinuses at a single tertiary care center. A retrospective review of consecutive patients presenting to our institution with skull fractures from blunt head trauma between 1 January 2009 and 31 December 2011 who underwent either a computed tomography (CT) or magnetic resonance (MR) venogram. Patient demographics, associated intracranial injuries, admission Glasgow Coma Scale (GCS), presence of CVST, and post-hospital disposition were recorded. Overall, 908 patients with skull fractures presented to the institution. Of those, 63 had fractures over a sinus and a venogram satisfying inclusion criteria. Twenty-two (34.9 %) patients demonstrated a thrombus in at least one sinus. There was no statistical difference in patient demographics, presenting GCS, length of stay (LOS), or outcome between patients with or without a thrombus. Pediatric patients had significantly shorter LOS (11 vs. 4 days, p < 0.01) compared to adults. Adults had a greater incidence of total sinus occlusions while children had more non-occlusive thrombus formations; both were statistically significant (p = 0.035 and p = 0.037, respectively). This report suggests that over 10 % of skull fractures involve cerebral venous sinuses, thus emphasizing the need to rule out CVST in patients suffering blunt head trauma. We propose including a venogram as part of the initial trauma work-up for these patients. Moreover, our data suggest that pediatric patients may be predisposed to less severe injuries than their adult counterparts.	[Rivkin, Mark A.; Woodrow, Sarah I.] Cooper Univ Hosp, Dept Neurosurg, Camden, NJ 08103 USA; [Saraiya, Piya V.] Cooper Univ Hosp, Dept Radiol, Camden, NJ 08103 USA		Rivkin, MA (corresponding author), 32 Conshohocken State Rd,F-3, Bala Cynwyd, PA 19004 USA.	rivkin@comcast.net; Saraiya-Piya@CooperHealth.edu; Woodrow-Sarah@CooperHealth.edu					Almandoz JED, 2010, RADIOLOGY, V255, P570, DOI 10.1148/radiol.10091565; Bousser MG, 2007, LANCET NEUROL, V6, P162, DOI 10.1016/S1474-4422(07)70029-7; Daligic A, 2008, TURK NEUROSURG, V18, P70; Einhaupl K, 2010, EUR J NEUROL, V17, P1229, DOI 10.1111/j.1468-1331.2010.03011.x; Ferro JM, 2004, STROKE, V35, P664, DOI 10.1161/01.STR.0000117571.76197.26; Ferro JM, 2003, PRACT NEUROL, P214, DOI [10.1046/j.1474-7766.2003.04146.x, DOI 10.1046/J.1474-7766.2003.04146.X]; Filippidis A, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.8.FOCUS09167; Fujii Y, 2009, J TRAUMA, V66, P1002, DOI 10.1097/TA.0b013e31819a0277; Holzmann D, 1999, LARYNGOSCOPE, V109, P645, DOI 10.1097/00005537-199904000-00024; Meltzer H, 2000, J TRAUMA, V49, P981, DOI 10.1097/00005373-200011000-00035; MILLER JD, 1968, LANCET, V2, P991; Muthukumar N, 2005, CHILD NERV SYST, V21, P86, DOI 10.1007/s00381-004-0926-2; Nehme J, 2009, INT J PEDIATR OTORHI, V73, P629, DOI 10.1016/j.ijporl.2008.10.025; Rahman M, 2009, NEUROSURG FOCUS, V27, DOI 10.3171/2009.7.FOCUS09146; Saposnik G, 2011, STROKE, V42, P1158, DOI 10.1161/STR.0b013e31820a8364; Stam J, 2005, NEW ENGL J MED, V352, P1791, DOI 10.1056/NEJMra042354; Stiefel D, 2000, EUR J PEDIATR SURG, V10, P41, DOI 10.1055/s-2008-1072321; TAHA JM, 1993, NEUROSURGERY, V32, P541, DOI 10.1227/00006123-199304000-00008; Takahashi S, 2012, J STROKE CEREBROVASC, V21, P338, DOI 10.1016/j.jstrokecerebrovasdis.2009.12.011; Yokota H, 2006, J NEUROSURG, V104, P849, DOI 10.3171/jns.2006.104.5.849; Yuen HW, 2005, ANN ACAD MED SINGAP, V34, P639; Zhao X, 2008, J NEUROTRAUM, V25, P104, DOI 10.1089/neu.2007.0351	22	25	28	0	2	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAY	2014	156	5					999	1007		10.1007/s00701-014-2025-9			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	AF0TC	WOS:000334426000023	24573982				2022-02-06	
J	Mitchell, K; Shah, JP; Tsytsikova, LV; Campbell, AM; Affram, K; Symes, AJ				Mitchell, Kendall; Shah, Jill P.; Tsytsikova, Lyubov V.; Campbell, Ashley M.; Affram, Kwame; Symes, Aviva J.			LPS antagonism of TGF-beta signaling results in prolonged survival and activation of rat primary microglia	JOURNAL OF NEUROCHEMISTRY			English	Article						cytokines; inflammation; LPS; TLR4; microglia; smad signaling; TGF-	GROWTH-FACTOR-BETA; ALTERNATIVE ACTIVATION; INHIBITORY SMADS; SPINAL-CORD; IN-VITRO; TGF-BETA-1; BRAIN; CELLS; MACROPHAGES; NEUROTOXICITY	Accumulating evidence indicates that activated microglia contribute to the neuropathology involved in many neurodegenerative diseases and after traumatic injury to the CNS. The cytokine transforming growth factor-beta 1 (TGF-beta 1), a potent deactivator of microglia, should have the potential to reduce microglial-mediated neurodegeneration. It is therefore perplexing that high levels of TGF-beta 1 are found in conditions where microglia are chronically activated. We hypothesized that TGF-beta 1 signaling is suppressed in activated microglia. We therefore activated primary rat microglia with lipopolysaccharide (LPS) and determined the expression of proteins important to TGF-beta 1 signaling. We found that LPS treatment decreased the expression of the TGF-beta receptors, T beta R1 and T beta R2, and reduced protein levels of Smad2, a key mediator of TGF-beta signaling. LPS treatment also antagonized the ability of TGF-beta to suppress expression of pro-inflammatory cytokines and to induce microglial cell death. LPS treatment similarly inhibited the ability of the TGF-beta related cytokine, Activin-A, to down-regulate expression of pro-inflammatory cytokines and to induce microglial cell death. Together, these data suggest that microglial activators may oppose the actions of TGF-beta 1, ensuring continued microglial activation and survival that eventually may contribute to the neurodegeneration prevalent in chronic neuroinflammatory conditions.	[Mitchell, Kendall; Shah, Jill P.; Tsytsikova, Lyubov V.; Campbell, Ashley M.; Affram, Kwame; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Affram, Kwame; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Program Neurosci, Bethesda, MD 20814 USA		Symes, AJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	aviva.symes@usuhs.edu	Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939	Defense Medical Research Development Program	This study was supported by a grant from the Defense Medical Research Development Program (AJS). We are grateful to members of the Symes laboratory for their helpful comments and suggestions. The opinions and assertions contained herein are the private opinions of the authors and are not to be construed as reflecting the views of the Uniformed Services University of the Health Sciences or the US Department of Defense. The authors have no conflict of interest to declare.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Bitzer M, 2000, GENE DEV, V14, P187; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brionne TC, 2003, NEURON, V40, P1133, DOI 10.1016/S0896-6273(03)00766-9; Brodie C, 1998, J NEUROIMMUNOL, V81, P20, DOI 10.1016/S0165-5728(97)00154-9; Choi KC, 2006, NAT IMMUNOL, V7, P1057, DOI 10.1038/ni1383; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Dmitriev AE, 2011, J BONE JOINT SURG AM, V93A, P1488, DOI 10.2106/JBJS.J.00904; Dmitriev AE, 2010, SPINE J, V10, P16, DOI 10.1016/j.spinee.2009.10.003; Echeverry S, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-16; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Gordon S, 2007, EUR J IMMUNOL, V37, pS9, DOI 10.1002/eji.200737638; Heldin CH, 2012, CELL TISSUE RES, V347, P21, DOI 10.1007/s00441-011-1190-x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Herrera AJ, 2000, NEUROBIOL DIS, V7, P429, DOI 10.1006/nbdi.2000.0289; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Itoh S, 1998, J BIOL CHEM, V273, P29195, DOI 10.1074/jbc.273.44.29195; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim EY, 2011, FEBS LETT, V585, P779, DOI 10.1016/j.febslet.2011.01.044; Kim WK, 2004, J IMMUNOL, V172, P7015, DOI 10.4049/jimmunol.172.11.7015; Kofler J, 2011, TOXICOL PATHOL, V39, P103, DOI 10.1177/0192623310387619; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Lanz TV, 2010, J CLIN INVEST, V120, P2782, DOI 10.1172/JCI41709; Le YY, 2004, J IMMUNOL, V173, P962, DOI 10.4049/jimmunol.173.2.962; Lodge PA, 1996, J LEUKOCYTE BIOL, V60, P502, DOI 10.1002/jlb.60.4.502; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x; Park SH, 2005, J BIOCHEM MOL BIOL, V38, P9; Quan TH, 2005, J BIOL CHEM, V280, P8079, DOI 10.1074/jbc.M409647200; SALIMUDDIN, 1999, AM J PHYSIOL, V277, pE110; Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663; Smith GM, 1997, J NEUROSCI, V17, P9624; Spittau B, 2013, GLIA, V61, P287, DOI 10.1002/glia.22435; Stout RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/jlb.0504272; Sugama S, 2007, J NEUROIMMUNOL, V192, P31, DOI 10.1016/j.jneuroim.2007.08.016; Susarla BTS, 2011, J NEUROCHEM, V119, P868, DOI 10.1111/j.1471-4159.2011.07470.x; SUZUMURA A, 1993, J IMMUNOL, V151, P2150; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tarkowski E, 2002, NEUROBIOL AGING, V23, P237, DOI 10.1016/S0197-4580(01)00285-8; Topper JN, 1997, P NATL ACAD SCI USA, V94, P9314, DOI 10.1073/pnas.94.17.9314; Tsunobuchi H, 2004, BIOCHEM BIOPH RES CO, V316, P712, DOI 10.1016/j.bbrc.2004.02.104; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; van Rossum D, 2008, GLIA, V56, P271, DOI 10.1002/glia.20611; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Xiao BG, 1997, NEUROSCI LETT, V226, P71, DOI 10.1016/S0304-3940(97)00234-6; Zhang BX, 2009, CANCER LETT, V277, P114, DOI 10.1016/j.canlet.2008.11.035; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328; Zhou XL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-210	53	25	27	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	APR	2014	129	1					155	168		10.1111/jnc.12612			14	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AD3JT	WOS:000333135800014	24251648	Bronze			2022-02-06	
J	Chen, D; Bao, L; Lu, SQ; Xu, F				Chen, Du; Bao, Long; Lu, Shi-qi; Xu, Feng			Serum Albumin and Prealbumin Predict the Poor Outcome of Traumatic Brain Injury	PLOS ONE			English	Article							GLYCEMIC CONTROL; HYPERGLYCEMIA; RESUSCITATION; PROGNOSIS; CHILDREN	Background: Serum albumin and prealbumin are both negative acute-phase reactants, and usually at low levels in stress. We aim to determine their predictive values for poor outcome of traumatic brain injury (TBI). Methods: A total of 326 patients of TBI were enrolled and followed-up by telephone 6 months after discharge. They were divided into a favorable group (GOS: 3 to 5) and an unfavorable group (GOS: 1 to 2). Serum albumin and prealbumin were measured from vein blood within 24 h after admission. Results: Ninety one (27.9%) patients were with poor outcome (GOS: 1 to 2). The unfavorable group had lower albumin and prealbumin (P, 0.001). Albumin and prealbumin were both positively correlated with GCS (r = 0.489, P < 0.001; r = 0.222, P < 0.001, respectively) and GOS (r = 0.518, P < 0.001; r = 0.314, P < 0.001, respectively). After adjustment for confounding factors, the odds ratios of albumin and prealbumin were 0.866, 95% CI: 0.829 to 0.904 and 0.990, 95% CI: 0.985 to 0.995, respectively. In subgroup of GCS <= 8 (n = 101), the crude and adjusted odds ratios of serum albumin were both statistically significant (P = 0.027, P = 0.033, respectively), while prealbumin were not (P = 0.553, P = 0.576, respectively). The AUC of albumin for predicting poor outcome was 0.762, 95% CI: 0.712 to 0.807, which was significantly higher than that of prealbumin (0.664, 95% CI: 0.610 to 0.715). In analyses of all patients and subgroup of GCS <= 8, the AUCs of serum albumin were both significantly higher than those of prealbumin (P = 0.001, P = 0.045, respectively). Conclusions: Both serum albumin and prealbumin could predict the poor outcome of TBI, but the former is much better, especially, in patients with severe TBI.	[Chen, Du; Bao, Long; Lu, Shi-qi; Xu, Feng] Soochow Univ, Affiliated Hosp 1, Dept Emergency Med, Suzhou, Peoples R China		Xu, F (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Emergency Med, Suzhou, Peoples R China.	sdfyycd@foxmail.com	Chen, Du/AAM-8789-2021	Chen, Du/0000-0001-6990-3310			Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Bernard F, 2008, J TRAUMA, V64, P872, DOI 10.1097/TA.0b013e31803428cc; Cabassi A, 2013, INT J CARDIOL; Collins N, 2001, Adv Skin Wound Care, V14, P235, DOI 10.1097/00129334-200109000-00009; Cooper DJ, 2013, J NEUROTRAUM, V30, P512, DOI 10.1089/neu.2012.2573; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Gao C, 2011, CLIN EXP MED, V11, P49, DOI 10.1007/s10238-010-0103-8; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kawai H, 2012, WORLD J SURG, V36, P2853, DOI 10.1007/s00268-012-1766-y; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Matsushima K, 2012, J CRIT CARE, V27, P125, DOI 10.1016/j.jcrc.2011.08.012; Melo JRT, 2010, ACTA NEUROCHIR, V152, P1559, DOI 10.1007/s00701-010-0680-z; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nelson DW, 2012, J NEUROTRAUM, V29, P2613, DOI 10.1089/neu.2012.2468; ROCCA B, 1987, Annales Francaises d'Anesthesie et de Reanimation, V6, P476, DOI 10.1016/S0750-7658(87)80091-6; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Rossi JL, 2011, J NEUROSCI RES, V89, P852, DOI 10.1002/jnr.22600; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Saadat SMS, 2012, CHILD NERV SYST, V28, P1773, DOI 10.1007/s00381-012-1753-5; Sharma Deepak, 2012, Anesthesiol Clin, V30, P333, DOI 10.1016/j.anclin.2012.04.003; Shutter L, 2012, CRIT CARE MED, V40, P1995, DOI 10.1097/CCM.0b013e3182514c15; Smith RL, 2012, PEDIATR CRIT CARE ME, V13, P85, DOI 10.1097/PCC.0b013e3182192c30; Vespa P, 2012, CRIT CARE MED, V40, P1923, DOI 10.1097/CCM.0b013e31824e0fcc; Wahlstrom MR, 2009, ACTA ANAESTH SCAND, V53, P18, DOI 10.1111/j.1399-6576.2008.01798.x; Yang Tian-jun, 2013, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V25, P301, DOI 10.3760/cma.j.issn.2095-4352.2013.05.016; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	28	25	30	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2014	9	3							e93167	10.1371/journal.pone.0093167			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AE0SR	WOS:000333677000123	24671050	Green Submitted, Green Published, gold			2022-02-06	
J	Roberts, BW; Kilgannon, JH; Chansky, ME; Trzeciak, S				Roberts, Brian W.; Kilgannon, J. Hope; Chansky, Michael E.; Trzeciak, Stephen			Association between initial prescribed minute ventilation and post-resuscitation partial pressure of arterial carbon dioxide in patients with post-cardiac arrest syndrome	ANNALS OF INTENSIVE CARE			English	Article						Cardiac arrest; Heart arrest; Cardiopulmonary resuscitation; Resuscitation; Anoxic brain injury; Shock; Hypocapnia; Hypercapnia; Minute ventilation	INTERNATIONAL LIAISON COMMITTEE; EUROPEAN RESUSCITATION COUNCIL; AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY-RESUSCITATION; STROKE FOUNDATION; CEREBRAL-ISCHEMIA; BRAIN; HYPERVENTILATION; SURVIVAL; INJURY	Background: Post-cardiac arrest hypocapnia/hypercapnia have been associated with poor neurological outcome. However, the impact of arterial carbon dioxide (CO2) derangements during the immediate post-resuscitation period following cardiac arrest remains uncertain. We sought to test the correlation between prescribed minute ventilation and post-resuscitation partial pressure of CO2 (PaCO2), and to test the association between early PaCO2 and neurological outcome. Methods: We retrospectively analyzed a prospectively compiled single-center cardiac arrest registry. We included adult (age >= 18 years) patients who experienced a non-traumatic cardiac arrest and required mechanical ventilation. We analyzed initial post-resuscitation ventilator settings and initial arterial blood gas analysis (ABG) after initiation of post-resuscitation ventilator settings. We calculated prescribed minute ventilation: MV (mL/kg/min) = [[tidal volume (TV)/ideal body weight (IBW)] x respiratory rate (RR)] for each patient. We then used Pearson's correlation to test the correlations between prescribed MV and PaCO2. We also determined whether patients had normocapnia (PaCO2 between 30 and 50 mmHg) on initial ABG and tested the association between normocapnia and good neurological function (Cerebral Performance Category 1 or 2) at hospital discharge using logistic regression analyses. Results: Seventy-five patients were included. The majority of patients were in-hospital arrests (85%). Pulseless electrical activity/asystole was the initial rhythm in 75% of patients. The median (IQR) TV, RR, and MV were 7 (7 to 8) mL/kg, 14 (14 to 16) breaths/minute, and 106 (91 to 125) mL/kg/min, respectively. Hypocapnia, normocapnia, and hypercapnia were found in 15%, 62%, and 23% of patients, respectively. Good neurological function occurred in 32% of all patients, and 18%, 43%, and 12% of patients with hypocapnia, normocapnia, and hypercapnia respectively. We found prescribed MV had only a weak correlation with initial PaCO2, R = -0.40 (P < 0.001). Normocapnia was associated with good neurological function, odds ratio 4.44 (95% CI 1.33 to 14.85). Conclusions: We found initial prescribed MV had only a weak correlation with subsequent PaCO2 and that early Normocapnia was associated with good neurological outcome. These data provide rationale for future research to determine the impact of PaCO2 management during mechanical ventilation in post-cardiac arrest patients.	[Roberts, Brian W.; Kilgannon, J. Hope; Chansky, Michael E.; Trzeciak, Stephen] Rowan Univ, Cooper Med Sch, Cooper Univ Hosp, Dept Emergency Med, Camden, NJ 08103 USA; [Trzeciak, Stephen] Rowan Univ, Cooper Med Sch, Cooper Univ Hosp, Dept Med,Div Crit Care Med, Camden, NJ 08103 USA		Roberts, BW (corresponding author), Rowan Univ, Cooper Med Sch, Cooper Univ Hosp, Dept Emergency Med, One Cooper Plaza,K152, Camden, NJ 08103 USA.	roberts-brian-w@cooperhealth.edu					ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; Ausina A, 1998, ACT NEUR S, V71, P1; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Buunk G, 1997, STROKE, V28, P1569, DOI 10.1161/01.STR.28.8.1569; CRAPO RO, 1982, B EUR PHYSIOPATH RES, V18, P419; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; del Castillo J, 2012, RESUSCITATION, V83, P1456, DOI 10.1016/j.resuscitation.2012.07.019; Falkenbach P, 2009, RESUSCITATION, V80, P990, DOI 10.1016/j.resuscitation.2009.04.044; Gaul GB, 1996, RESUSCITATION, V32, P169, DOI 10.1016/0300-9572(96)00956-2; GREISEN G, 1987, ACTA PAEDIATR SCAND, V76, P401, DOI 10.1111/j.1651-2227.1987.tb10489.x; Hajbaghery MA, 2005, RESUSCITATION, V66, P317, DOI 10.1016/j.resuscitation.2005.04.004; Hodgman EI, 2012, J TRAUMA ACUTE CARE, V72, P844, DOI 10.1097/TA.0b013e31824ef9d2; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; JENNETT B, 1975, LANCET, V1, P480; KAGSTROM E, 1983, ACTA PHYSIOL SCAND, V118, P281, DOI 10.1111/j.1748-1716.1983.tb07272.x; Kilgannon JH, 2008, RESUSCITATION, V79, P410, DOI 10.1016/j.resuscitation.2008.07.019; Krep H, 2000, CRIT CARE MED, V28, P2873, DOI 10.1097/00003246-200008000-00031; Krep H, 2000, CRIT CARE MED, V28, P2866, DOI 10.1097/00003246-200008000-00030; Langhelle A, 2005, RESUSCITATION, V66, P271, DOI 10.1016/j.resuscitation.2005.06.005; Langhelle A, 2003, RESUSCITATION, V56, P247, DOI 10.1016/S0300-9572(02)00409-4; Lee CC, 2011, EMERG MED J, V28, P432, DOI 10.1136/emj.2009.087593; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Murray SB, 2006, ACAD EMERG MED, V13, P530, DOI 10.1197/j.aem.2005.11.084; Nadkarni VM, 2006, JAMA-J AM MED ASSOC, V295, P50, DOI 10.1001/jama.295.1.50; NEMOTO EM, 1975, STROKE, V6, P425, DOI 10.1161/01.STR.6.4.425; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Peberdy MA, 2003, RESUSCITATION, V58, P297, DOI 10.1016/S0300-9572(03)00215-6; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; PLUM F, 1972, ANN INTERN MED, V76, P328, DOI 10.7326/0003-4819-76-2-328; Roberts BW, 2013, CIRCULATION, V127, P2107, DOI 10.1161/CIRCULATIONAHA.112.000168; Roberts BW, 2013, CRIT CARE MED, V41, P1492, DOI 10.1097/CCM.0b013e31828a39e9; ROUT MW, 1971, BRIT MED J, V3, P7, DOI 10.1136/bmj.3.5765.7; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; Schneider AG, 2013, RESUSCITATION, V84, P927, DOI 10.1016/j.resuscitation.2013.02.014; Tok D, 2004, TOHOKU J EXP MED, V202, P265, DOI 10.1620/tjem.202.265; Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8; Trzeciak S, 2009, CRIT CARE MED, V37, P2895, DOI 10.1097/CCM.0b013e3181b01d8c; Trzeciak S, 2009, RESUSCITATION, V80, P617, DOI 10.1016/j.resuscitation.2009.03.014; VANNUCCI RC, 1995, PEDIATRICS, V95, P868; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6	45	25	28	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	2110-5820			ANN INTENSIVE CARE	Ann. Intensive Care	MAR 7	2014	4								9	10.1186/2110-5820-4-9			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AT8DR	WOS:000345164700001	24602367	gold, Green Published			2022-02-06	
J	Nhac-Vu, HT; Hours, M; Chossegros, L; Charnay, P; Tardy, H; Martin, JL; Mazaux, JM; Laumon, B				Hoang-Thy Nhac-Vu; Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Martin, Jean-Louis; Mazaux, Jean-Michel; Laumon, Bernard			Prognosis of Outcome in Adult Survivors of Road Accidents in France: One-Year Follow-Up in the ESPARR Cohort	TRAFFIC INJURY PREVENTION			English	Article						outcome prediction; road crash; homogeneous outcome groups; Injury Impairment Scale; WHOQOL-BREF; ESPARR	POSTTRAUMATIC-STRESS-DISORDER; INJURY SEVERITY SCORE; TRAFFIC ACCIDENTS; PSYCHOLOGICAL TRAUMA; IMPROVES ACCURACY; MAJOR TRAUMA; RISK-FACTORS; HEALTH; CONSEQUENCES; COMPENSATION	Objective: The consequences of road crashes are various, and few studies have dealt with the multidimensionality of outcomes. The aim of the present study was to assess the multidimensional nature of outcomes one year after a crash and to determine predictive factors that could help in adapting medical and social care to prevent such consequences to improve road crash victims' prognosis. Methods: The study population was the 886 respondents to the one-year follow-up from the ESPARR (Etude et Suivi d'une Population d'Accidentes de la Route du Rhone) cohort, aged 16years; the analysis was carried out only on the 616 subjects who fully completed a self-report questionnaire on health, social, emotional, and financial status one year after a crash. Multiple correspondence analysis and hierarchical clustering was implemented to produce homogeneous groups according to differences in outcome. Groups were compared using the World Health Organization Quality of Life Assessment (WHOQOL-BREF, a standard instrument of quality of life, assessing physical health, psychological health, social relationships, and environment) and the Injury Impairment Scale (IIS), a tool to predict road crash sequelae. Baseline predictive factors for group attribution were analyzed by weighted multinomial logistic regression models. Results: Three hundred seventeen of the 616 subjects (60.1%) were men. Mean age was 36.9years (SD = 16.5). Five victim groups were identified in terms of consequences at one year: one group (206 subjects, 33.4%) with few problems, one with essentially physical sequelae, one with problems that were essentially both physical and social, and 2 groups with a wider range of problems (one including psychological problems but fewer environmental problems; the last one reported negative physical, psychological, social, and environmental impact; notably, all had post-concussion syndrome [PCS]). There were significant differences between groups in terms of family status, injury severity, and certain types of injury (thorax, spine, lower limbs). Comparison on the WHOQOL-BREF confirmed that groups reporting more adverse outcomes had a lower quality of life. Description of the 5 groups by IIS indicators showed that IIS underestimated physical consequences one year after the crash. In addition to the known prognostic factors such as age, initial injury severity, and injury type, socioeconomic fragility and having a relative involved in the accident emerged as predictive of poor outcome at one year. Conclusions: One year after the crash, victims may still be experiencing multiple problems in terms of not only physical health but also of mental health, social life, and environment. Poor outcome may be predicted from both accident-related factors and socioeconomic fragility. Our results are useful in catching the attention of both clinicians and the public administration regarding victims at risk of suffering from important consequences after an accident. If those suffering head injuries are recognized, it would be very important to better consider and treat posttraumatic stress disorder (PTSD) or PCS. Furthermore, subjects from lower socioeconomic backgrounds, with or without lower limb injuries, have numerous difficulties after an accident, notably for returning to work. An objective would be to provide them with more specific support. Supplemental materials are available for this article. Go to the publisher's online edition of Traffic Injury Prevention to view the supplemental file.	[Hoang-Thy Nhac-Vu; Hours, Martine; Chossegros, Laetitia; Charnay, Pierrette; Tardy, Helene; Martin, Jean-Louis; Laumon, Bernard] Univ Lyon, UMRESTTE, IFSTTAR, Lyon, France; [Mazaux, Jean-Michel] Bordeaux Univ, Rehabil & Phys Med Unit, St Andre Hosp, Bordeaux, France; [Mazaux, Jean-Michel] Bordeaux Univ, Rehabil & Phys Med Unit, Pellegrin Hosp, Bordeaux, France		Hours, M (corresponding author), IFSTTAR, UMRESTTE, Case 24,25 Ave F Mitterand, F-69675 Bron, France.	martine.hours@ifsttar.fr	TARDY, HELENE/AAE-6287-2019; Martin, Jean-Louis/X-6588-2019; Nhac-Vu, Hoang-Thy/AAY-2994-2021	TARDY, HELENE/0000-0001-8351-9825; Martin, Jean-Louis/0000-0002-3426-9601; Nhac-Vu, Hoang-Thy/0000-0001-6557-621X	French Ministry of Equipment, Transport, Housing, Tourism and Sea [SU0400066]; National Agency for ResearchFrench National Research Agency (ANR) [ANR-07-TSFA-007-01]; French Ministry of Health [PHRC-N03, PHRC-N051]	We acknowledge funding from the French Ministry of Equipment, Transport, Housing, Tourism and Sea (Predit 3 Program, "New Knowledge in the Field of Road Safety," No. SU0400066); the National Agency for Research (Program Predit 4, "Safe, Reliable and Adapted Transport," No. ANR-07-TSFA-007-01); and the French Ministry of Health (PHRC 2003 Program: PHRC-N03 and PHRC 2005: PHRC-N051).	AMOROS E., 2008, B EPIDEMIOLOGIQUE HE, V19, P157; Arnold R, 2005, SOC SCI MED, V61, P2144, DOI 10.1016/j.socscimed.2005.04.025; Association for the Advancement of Automotive Medicine, 1990, ABBR INH SCAL 1990 R; Barnes Jo, 2009, Ann Adv Automot Med, V53, P195; Barnes Jo, 2006, Annu Proc Assoc Adv Automot Med, V50, P253; Chossegros L, 2011, ACCIDENT ANAL PREV, V43, P471, DOI 10.1016/j.aap.2010.10.004; CORNES P, 1992, INJURY, V23, P256, DOI 10.1016/S0020-1383(05)80011-7; Cunningham C, 2001, Ir Med J, V94, P169; Gaulle-Anthonioz GD, 1995, J OFFICIEL; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Harris IA, 2008, J ORTHOP TRAUMA, V22, P216, DOI 10.1097/BOT.0b013e31815c11dc; Nhac-Vu HT, 2012, TRAFFIC INJ PREV, V13, P239, DOI 10.1080/15389588.2011.647139; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Hours M, 2008, ACCIDENT ANAL PREV, V40, P1789, DOI 10.1016/j.aap.2008.06.017; Hours M, 2010, ACCIDENT ANAL PREV, V42, P412, DOI 10.1016/j.aap.2009.09.002; Hudek-Knezevic J, 2009, CROAT MED J, V50, P394, DOI 10.3325/cmj.2009.50.394; Jeavons S, 2000, J TRAUMA STRESS, V13, P359, DOI 10.1023/A:1007797904536; Jeavons S, 2000, BEHAV RES THER, V38, P499, DOI 10.1016/S0005-7967(99)00073-X; Koren D, 1999, AM J PSYCHIAT, V156, P367; Koren D, 2002, AM J PSYCHIAT, V159, P855, DOI 10.1176/appi.ajp.159.5.855; Laumon B, 1999, P 41 ANN M ASS ADV A, P127; Lecomte T, 1996, PRECARITE SOCIALE CU; Li L, 2001, EUR J PUBLIC HEALTH, V11, P81, DOI 10.1093/eurpub/11.1.81; Mayou R, 2003, INJURY, V34, P197, DOI 10.1016/S0020-1383(02)00285-1; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Mayou R, 2002, PSYCHOL MED, V32, P671, DOI 10.1017/S0033291702005470; Mayou R, 2002, BRIT J PSYCHIAT, V180, P441, DOI 10.1192/bjp.180.5.441; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Ottosson C, 2005, J TRAUMA, V58, P553, DOI 10.1097/01.TA.0000152634.66513.AF; Saevareid HI, 2007, AGING MENT HEALTH, V11, P658, DOI 10.1080/13607860701368513; Soderstrom CA, 1997, J TRAUMA, V43, P925; Spicer Rebecca S, 2011, Ann Adv Automot Med, V55, P365; Valent F, 2002, ACCIDENT ANAL PREV, V34, P71, DOI 10.1016/S0001-4575(00)00104-4; Vorko-Jovic A, 2006, J SAFETY RES, V37, P93, DOI 10.1016/j.jsr.2005.08.009; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967	37	25	26	0	24	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1538-9588	1538-957X		TRAFFIC INJ PREV	Traffic Inj. Prev.	FEB 17	2014	15	2					138	147		10.1080/15389588.2013.804180			10	Public, Environmental & Occupational Health; Transportation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Transportation	277IU	WOS:000328813000005	24345015	Green Submitted			2022-02-06	
J	Schober, ME; Requena, DF; Block, B; Davis, LJ; Rodesch, C; Casper, TC; Juul, SE; Kesner, RP; Lane, RH				Schober, Michelle E.; Requena, Daniela F.; Block, Benjamin; Davis, Lizeth J.; Rodesch, Christopher; Casper, T. Charles; Juul, Sandra E.; Kesner, Raymond P.; Lane, Robert H.			Erythropoietin Improved Cognitive Function and Decreased Hippocampal Caspase Activity in Rat Pups after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; controlled cortical impect; developmental; EPO; memory	RECOMBINANT ERYTHROPOIETIN; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; PROTECTS; MODEL; PHARMACOKINETICS; RECEPTOR; NEUROPROTECTION; LOCALIZATION; APOPTOSIS	Traumatic brain injury (TBI) is a leading cause of acquired neurologic disability in children. Erythropoietin (EPO), an anti-apoptotic cytokine, improved cognitive outcome in adult rats after TBI. To our knowledge, EPO has not been studied in a developmental TBI model. Hypothesis: We hypothesized that EPO would improve cognitive outcome and increase neuron fraction in the hippocampus in 17-day-old (P17) rat pups after controlled cortical impact (CCI). Methods: EPO or vehicle was given at 1, 24, and 48h after CCI and at post injury day (PID) 7. Cognitive outcome at PID14 was assessed using Novel Object Recognition (NOR). Hippocampal EPO levels, caspase activity, and mRNA levels of the apoptosis factors Bcl2, Bax, Bcl-xL, and Bad were measured during the first 14 days after injury. Neuron fraction and caspase activation in CA1, CA3, and DG were studied at PID2. Results: EPO normalized recognition memory after CCI. EPO blunted the increased hippocampal caspase activity induced by CCI at PID1, but not at PID2. EPO increased neuron fraction in CA3 at PID2. Brain levels of exogenous EPO appeared low relative to endogenous. Timing of EPO administration was associated with temporal changes in hippocampal mRNA levels of EPO and pro-apoptotic factors. Conclusion/Speculation: EPO improved recognition memory, increased regional hippocampal neuron fraction, and decreased caspase activity in P17 rats after CCI. We speculate that EPO improved cognitive outcome in rat pups after CCI as a result of improved neuronal survival via inhibition of caspase-dependent apoptosis early after injury.	[Schober, Michelle E.; Casper, T. Charles] Univ Utah, Dept Pediat, Div Crit Care, Salt Lake City, UT 84158 USA; [Requena, Daniela F.; Block, Benjamin; Davis, Lizeth J.; Lane, Robert H.] Univ Utah, Dept Pediat, Div Neonatol, Salt Lake City, UT 84158 USA; [Rodesch, Christopher] Univ Utah, Dept Pediat, Div Hlth Sci Res Core Facil, Salt Lake City, UT 84158 USA; [Kesner, Raymond P.] Univ Utah, Dept Psychol, Salt Lake City, UT 84158 USA; [Juul, Sandra E.] Univ Washington, Sch Med, Div Neonatol, Seattle, WA USA		Schober, ME (corresponding author), Univ Utah, Sch Med, Dept Pediat, Div Crit Care, POB 581289, Salt Lake City, UT 84158 USA.	michelle.schober@hsc.utah.edu			CHRCDA [NIH K12HD001410]; Divisions of Neonatology and Pediatric Critical Care Medicine, Department of Pediatrics, University of Utah, Salt Lake City, Utah; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001410] Funding Source: NIH RePORTER	Statement of Financial Support: funding for this study was provided by the CHRCDA (NIH K12HD001410) and from the Divisions of Neonatology and Pediatric Critical Care Medicine, Department of Pediatrics, University of Utah, Salt Lake City, Utah. Input on histology from Scott Rogers, PhD<SUP>1</SUP> is greatly appreciated.	Agarwal MK, 2004, CELL CYCLE, V3, P205; Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Ammar HI, 2011, AM J PHYSIOL-HEART C, V301, pH2413, DOI 10.1152/ajpheart.01096.2010; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson V, 2012, INT J DEV NEUROSCI, V30, P217, DOI 10.1016/j.ijdevneu.2011.09.008; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Broadbent NJ, 2010, LEARN MEMORY, V17, P794, DOI 10.1101/lm.1650110; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161; D'Amelio M, 2010, CELL DEATH DIFFER, V17, P1104, DOI 10.1038/cdd.2009.180; Dame C, 2001, BIOL NEONATE, V79, P228; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Dzietko M, 2004, NEUROBIOL DIS, V15, P177, DOI 10.1016/j.nbd.2003.10.006; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Gonzalez FF, 2009, DEV NEUROSCI-BASEL, V31, P403, DOI 10.1159/000232558; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hagemeyer N, 2012, MOL MED, V18, P628, DOI 10.2119/molmed.2011.00457; Juul SE, 2008, PEDIATRICS, V122, P383, DOI 10.1542/peds.2007-2711; Juul SE, 1999, PEDIATR DEVEL PATHOL, V2, P148, DOI 10.1007/s100249900103; Juul SE, 2004, BIOL NEONATE, V85, P138, DOI 10.1159/000074970; Kim SS, 2008, J KOREAN MED SCI, V23, P484, DOI 10.3346/jkms.2008.23.3.484; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li Y, 2008, ACTA NEUROCHIR SUPPL, V105, P105; Li Yun-Xia, 2008, Neurosci Bull, V24, P89, DOI 10.1007/s12264-008-0089-3; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Liao ZB, 2009, NEUROL INDIA, V57, P722, DOI 10.4103/0028-3886.59466; Lieutaud T, 2008, J NEUROTRAUM, V25, P1179, DOI 10.1089/neu.2008.0591; Liu J, 2006, GLIA, V53, P360, DOI 10.1002/glia.20289; Lowthert L, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-15; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Mandalis A, 2007, DEV NEUROPSYCHOL, V32, P683, DOI 10.1080/87565640701376045; Marvizon JCG, 2007, NEUROSCIENCE, V148, P250, DOI 10.1016/j.neuroscience.2007.05.036; McBride J, 2013, IEEE T BIO-MED ENG, V60, P90, DOI 10.1109/TBME.2012.2223698; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; Pavlica S, 2012, BRAIN RES, V1452, P18, DOI 10.1016/j.brainres.2012.02.043; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Pierce DR, 2011, BRAIN RES, V1378, P54, DOI 10.1016/j.brainres.2011.01.028; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Polster BM, 2003, CELL DEATH DIFFER, V10, P365, DOI 10.1038/sj.cdd.4401158; Ponce LL, 2012, PATHOPHYSIOLOGY, V20, P31; Rakusan K, 2001, AM J PHYSIOL-HEART C, V281, pH2425, DOI 10.1152/ajpheart.2001.281.6.H2425; Reger ML, 2009, DEV PSYCHOBIOL, V51, P672, DOI 10.1002/dev.20402; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.1289/ehp.00108s3511; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sargin D, 2009, GLIA, V57, P693, DOI 10.1002/glia.20797; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Schober ME, 2010, J NEUROTRAUM, V27, P2011, DOI 10.1089/neu.2009.1226; Scott HL, 2012, EUR J NEUROSCI, V36, P2941, DOI 10.1111/j.1460-9568.2012.08220.x; Shein NA, 2008, J NEUROTRAUM, V25, P112, DOI 10.1089/neu.2007.0358; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Sola A, 2005, PEDIATR RES, V57, p110R, DOI 10.1203/01.PDR.0000159571.50758.39; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Statler PA, 2007, PEDIATR RES, V61, P671, DOI 10.1203/pdr.0b013e31805341dc; SWIGART RH, 1965, CIRC RES, V17, P30, DOI 10.1161/01.RES.17.1.30; Tang ZH, 2013, NEUROPHARMACOLOGY, V67, P8, DOI 10.1016/j.neuropharm.2012.10.017; Vairano M, 2002, EUR J NEUROSCI, V16, P584, DOI 10.1046/j.1460-9568.2002.02125.x; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Wu YW, 2012, PEDIATRICS, V130, P683, DOI 10.1542/peds.2012-0498; Xenocostas A, 2005, EUR J CLIN PHARMACOL, V61, P189, DOI 10.1007/s00228-005-0896-7; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Yamada M, 2011, J PATHOL, V224, P101, DOI 10.1002/path.2862; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Zhang YL, 2012, EXP NEUROL, V235, P336, DOI 10.1016/j.expneurol.2012.02.015; Zhu L, 2009, BRAIN RES, V1289, P96, DOI 10.1016/j.brainres.2009.07.015	76	25	26	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2014	31	4					358	369		10.1089/neu.2013.2922			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	AA7PY	WOS:000331290600008	23972011	Green Published			2022-02-06	
J	Agrawal, RG; Owen, JA; Levin, PS; Hewetson, A; Berman, AE; Franklin, SR; Hogue, RJ; Chen, YK; Walz, C; Colvard, BD; Nguyen, J; Velasquez, O; Al-Hasan, Y; Blednov, YA; Fowler, AK; Syapin, PJ; Bergeson, SE				Agrawal, Rajiv G.; Owen, Julie A.; Levin, Patricia S.; Hewetson, Aveline; Berman, Ari E.; Franklin, Scott R.; Hogue, Ryan J.; Chen, Yukun; Walz, Chris; Colvard, Benjamin D.; Nguyen, Jonathan; Velasquez, Oscar; Al-Hasan, Yazan; Blednov, Yuri A.; Fowler, Anna-Kate; Syapin, Peter J.; Bergeson, Susan E.			Bioinformatics Analyses Reveal Age-Specific Neuroimmune Modulation as a Target for Treatment of High Ethanol Drinking	ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH			English	Article						Alcoholism; Drinking-in-Dark; FVB; NJxC57BL; 6J F1 Mouse; Medications Development; Minocycline; Bioinformatics	RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; ALCOHOL-USE DISORDERS; GENE-EXPRESSION; C57BL/6J MICE; MICROGLIAL ACTIVATION; RECEPTOR ACTIVATION; MICROARRAY ANALYSIS; IMMUNE FUNCTION; BINGE DRINKING	BackgroundUse of in silico bioinformatics analyses has led to important leads in the complex nature of alcoholism at the genomic, epigenomic, and proteomic level, but has not previously been successfully translated to the development of effective pharmacotherapies. In this study, a bioinformatics approach led to the discovery of neuroimmune pathways as an age-specific druggable target. Minocycline, a neuroimmune modulator, reduced high ethanol (EtOH) drinking in adult, but not adolescent, mice as predicted a priori. MethodsAge and sex-divergent effects in alcohol consumption were quantified in FVB/NJxC57BL/6J F1 mice given access to 20% alcohol using a 4h/d, 4-day drinking-in-dark (DID) paradigm. In silico bioinformatics pathway overrepresentation analysis for age-specific effects of alcohol in brain was performed using gene expression data collected in control and DID-treated, adolescent and adult, male mice. Minocycline (50mg/kg i.p., once daily) or saline alone was tested for an effect on EtOH intake in the F1 and C57BL/6J (B6) mice across both age and gender groups. Effects of minocycline on the pharmacokinetic properties of alcohol were evaluated by comparing the rates of EtOH elimination between the saline- and minocycline-treated F1 and B6 mice. ResultsAge and gender differences in DID consumption were identified. Only males showed a clear developmental increase difference in drinking over time. In silico analyses revealed neuroimmune-related pathways as significantly overrepresented in adult, but not in adolescent, male mice. As predicted, minocycline treatment reduced drinking in adult, but not adolescent, mice. The age effect was present for both genders, and in both the F1 and B6 mice. Minocycline had no effect on the pharmacokinetic elimination of EtOH. ConclusionsOur results are a proof of concept that bioinformatics analysis of brain gene expression can lead to the generation of new hypotheses and a positive translational outcome for individualized pharmacotherapeutic treatment of high alcohol consumption.	[Agrawal, Rajiv G.; Owen, Julie A.; Hewetson, Aveline; Franklin, Scott R.; Hogue, Ryan J.; Chen, Yukun; Al-Hasan, Yazan; Fowler, Anna-Kate; Syapin, Peter J.; Bergeson, Susan E.] Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol & Neurosci, South Plains Alcohol & Addict Res Ctr, Lubbock, TX 79430 USA; [Levin, Patricia S.; Berman, Ari E.; Walz, Chris; Colvard, Benjamin D.; Nguyen, Jonathan; Velasquez, Oscar; Blednov, Yuri A.] Univ Texas Austin, Waggoner Ctr Alcohol & Addict Res, Austin, TX 78712 USA		Bergeson, SE (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol & Neurosci, South Plains Alcohol & Addict Res Ctr, 3601 4th St,MS 6592, Lubbock, TX 79430 USA.	Susan.Bergeson@TTUHSC.edu	Colvard, Benjamin/ABA-1814-2020; Chen, Yu/Y-3292-2019		NIAAA INIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [U01AA13475, U01AA13520]; South Plains Alcohol and Addiction Research Center; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R21AA021142, U01AA013520, U01AA013475] Funding Source: NIH RePORTER	Supported by NIAAA INIA grants U01AA13475 (SEB), U01AA13520 (YAB), and the South Plains Alcohol and Addiction Research Center.	Agrawal RG, 2011, BRAIN BEHAV IMMUN, V25, pS165, DOI 10.1016/j.bbi.2011.03.002; Ai ZH, 2013, J OBSTET GYNAECOL RE, V39, P1052, DOI 10.1111/jog.12022; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Anton RF, 2006, JAMA-J AM MED ASSOC, V295, P2003, DOI 10.1001/jama.295.17.2003; BABOR TF, 1992, ARCH GEN PSYCHIAT, V49, P599; Bahrami F, 2012, MINI-REV MED CHEM, V12, P44, DOI 10.2174/138955712798868977; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bennett ME, 1999, J STUD ALCOHOL, V60, P605, DOI 10.15288/jsa.1999.60.605; Blednov YA, 2011, BRAIN BEHAV IMMUN, V25, pS92, DOI 10.1016/j.bbi.2011.01.008; Blednov YA, 2005, ALCOHOL CLIN EXP RES, V29, P1949, DOI 10.1097/01.alc.0000187605.91468.17; Blednov YA, 2005, BEHAV BRAIN RES, V165, P110, DOI 10.1016/j.bbr.2005.06.026; Blednov YA, 2012, ADDICT BIOL, V17, P108, DOI 10.1111/j.1369-1600.2010.00284.x; Brown SA, 2004, ANN NY ACAD SCI, V1021, P234, DOI 10.1196/annals.1308.028; Brown SA, 2001, RECENT DEV ALCOHOL, V15, P307; Cippitelli A, 2010, BIOL PSYCHIAT, V67, P823, DOI 10.1016/j.biopsych.2009.12.018; Corona AW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-93; Crews FT, 2012, ALCOHOL RES-CURR REV, V34, P355; Crews FT, 2009, ALCOHOL ALCOHOLISM, V44, P115, DOI 10.1093/alcalc/agn079; Daniels GM, 2002, GENES BRAIN BEHAV, V1, P35, DOI 10.1046/j.1601-1848.2001.00008.x; Davis RL, 2005, BRAIN RES REV, V49, P494, DOI 10.1016/j.brainresrev.2005.01.008; Dawes MA, 2004, ALCOHOL ALCOHOLISM, V39, P166, DOI 10.1093/alcalc/agh045; Edenberg HJ, 2005, GENES BRAIN BEHAV, V4, P20, DOI 10.1111/j.1601-183X.2004.00091.x; Fernandez-Lizarbe S, 2009, J IMMUNOL, V183, P4733, DOI 10.4049/jimmunol.0803590; Finn DA, 2007, ALCOHOL CLIN EXP RES, V31, P939, DOI 10.1111/j.1530-0277.2007.00379.x; Garrido-Mesa N, 2013, PHARMACOL RES, V67, P18, DOI 10.1016/j.phrs.2012.10.006; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Grant BF, 1997, J SUBST ABUSE, V9, P103, DOI 10.1016/S0899-3289(97)90009-2; Greenfield SF, 2010, ALCOHOL CLIN EXP RES, V34, P1803, DOI 10.1111/j.1530-0277.2010.01267.x; Guasti L, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-35; Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-15; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Huang TY, 2009, TOXICOL APPL PHARM, V237, P69, DOI 10.1016/j.taap.2009.02.026; Johnson BA, 2003, LANCET, V361, P1677, DOI 10.1016/S0140-6736(03)13370-3; Kapsimali M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r173; Kerns Robnet T., 2008, V447, P395, DOI 10.1007/978-1-59745-242-7_26; Key J, 2006, CANCER CAUSE CONTROL, V17, P759, DOI 10.1007/s10552-006-0011-0; Kielian T, 2007, AM J PATHOL, V171, P1199, DOI 10.2353/ajpath.2007.070231; Kloppenburg M, 1996, ANTIMICROB AGENTS CH, V40, P934, DOI 10.1128/AAC.40.4.934; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kranzler HR, 2001, ALCOHOL CLIN EXP RES, V25, P1335, DOI 10.1097/00000374-200109000-00014; Lewohl JM, 2000, ALCOHOL CLIN EXP RES, V24, P1873, DOI 10.1097/00000374-200012000-00018; Liu JA, 2011, P NATL ACAD SCI USA, V108, P4465, DOI 10.1073/pnas.1019020108; Medina KL, 2008, ALCOHOL CLIN EXP RES, V32, P386, DOI 10.1111/j.1530-0277.2007.00602.x; Melon LC, 2013, PHARMACOL BIOCHEM BE, V104, P177, DOI 10.1016/j.pbb.2013.01.005; Mulligan MK, 2008, GENES BRAIN BEHAV, V7, P677, DOI 10.1111/j.1601-183X.2008.00405.x; Mulligan MK, 2011, ALCOHOL CLIN EXP RES, V35, P659, DOI 10.1111/j.1530-0277.2010.01384.x; Mulligan MK, 2006, P NATL ACAD SCI USA, V103, P6368, DOI 10.1073/pnas.0510188103; Nikodemova M, 2010, J NEUROIMMUNOL, V219, P33, DOI 10.1016/j.jneuroim.2009.11.009; Orio L, 2010, NEUROTOX RES, V18, P187, DOI 10.1007/s12640-009-9120-3; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Qin HW, 2005, BLOOD, V106, P3114, DOI 10.1182/blood-2005-02-0759; R Development Core Team,, 2006, R LANG ENV STAT COMP; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Rhodes JS, 2005, PHYSIOL BEHAV, V84, P53, DOI 10.1016/j.physbeh.2004.10.007; Scheffel J, 2012, GLIA, V60, P1930, DOI 10.1002/glia.22409; Sewell KL, 1996, CELL IMMUNOL, V167, P195, DOI 10.1006/cimm.1996.0027; Soliman GM, 2010, MACROMOL BIOSCI, V10, P278, DOI 10.1002/mabi.200900259; Squeglia Lindsay M, 2012, Psychopharmacology (Berl), V220, P529, DOI 10.1007/s00213-011-2500-4; Sullivan EV, 2008, EXP NEUROL, V213, P10, DOI 10.1016/j.expneurol.2008.05.016; Tabakoff B, 2003, J NEUROSCI, V23, P4491; URBANOMARQUEZ A, 1995, JAMA-J AM MED ASSOC, V274, P149, DOI 10.1001/jama.274.2.149; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; Yang LP, 2007, MOL VIS, V13, P1083; Yoon SY, 2012, NEUROSCIENCE, V221, P214, DOI 10.1016/j.neuroscience.2012.06.024; Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771; Zhao P, 2007, J NEUROSCI, V27, P2357, DOI 10.1523/JNEUROSCI.0138-07.2007	67	25	26	0	10	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0145-6008	1530-0277		ALCOHOL CLIN EXP RES	Alcoholism (NY)	FEB	2014	38	2					428	437		10.1111/acer.12288			10	Substance Abuse	Science Citation Index Expanded (SCI-EXPANDED)	Substance Abuse	297PC	WOS:000330266400017	24125126	Green Accepted			2022-02-06	
J	Goverover, Y; Chiaravalloti, N				Goverover, Yael; Chiaravalloti, Nancy			The impact of self-awareness and depression on subjective reports of memory, quality-of-life and satisfaction with life following TBI	BRAIN INJURY			English	Article						Awareness; brain injury; community integration; outcome; rehabilitation	TRAUMATIC BRAIN-INJURY; HEALTH SURVEY; DEFICITS; ASSOCIATION; VALIDATION; SYMPTOMS; RETURN; TESTS	Objective: To determine the relationship between self-awareness and depressive symptomatology with self-reports of memory, Quality-of-Life (QoL) and satisfaction with life in individuals with traumatic brain injury (TBI). Methods: Cross-sectional survey of 30 community dwelling adults, who sustained a TBI at least 1 year prior to study enrolment. Participants completed questionnaires to assess the constructs of depression, self-awareness, QoL, satisfaction with life and memory. Results: Symptoms of depression were significantly associated with self-reports of poor memory abilities, lower QoL and lower satisfaction with life. Additionally, higher levels of self-awareness were associated with lower ratings of QoL and reduced memory abilities and better strategy use regarding memory. However, when examining the contribution of each construct individually, depressive symptomatology, and not self-awareness, was significantly associated with subjective self-reports of memory, QoL and satisfaction with life. Conclusions: This pattern of relationships illustrates that, when a person has a low level of depressive symptoms, his/her reports of QoL, memory and satisfaction with life will be more positive; however, he/she will demonstrate more difficulty with self-awareness. Thus, psychological aspects of recovery must, therefore, be taken into account when using self-reported measures in the evaluation of persons who have sustained TBI.	[Goverover, Yael] NYU, Dept Occupat Therapy, New York, NY 10012 USA; [Goverover, Yael; Chiaravalloti, Nancy] Kessler Fdn Res Ctr, W Orange, NJ USA; [Chiaravalloti, Nancy] Rutgers State Univ, Dept Phys Med & Rehabil, New Jersey Med Sch, Newark, NJ 07102 USA		Goverover, Y (corresponding author), NYU, Steinhardt Sch Culture Educ & Human Dev, Dept Occupat Therapy, 35 West 4th St,11th Floor, New York, NY 10012 USA.	yg243@nyu.edu		Chiaravalloti, Nancy/0000-0003-2943-7567	Department of EducationUS Department of Education; NIDRR [H133A070037]	The authors report no conflicts of interest. The contents of this article were developed under a grant from the Department of Education, NIDRR grant number H133A070037. However, those contents do not necessarily represent the policy of the Department of Education and you should not assume endorsement by the Federal Government. This study was presented in part at the 3rd Federal Interagency Conference on TBI in Washington DC, 13-15 June 2011.	Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chang CH, 2003, MULT SCLER J, V9, P160, DOI 10.1191/1352458503ms885oa; Corrigan J., 2000, SATISFACTION LIFE SC; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dowds MM, 2011, J HEAD TRAUMA REHAB, V26, P339, DOI 10.1097/HTR.0b013e3181f2bf1d; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Fleming J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI [https://doi.org/10.1177/030802269505800204, DOI 10.1177/030802269505800204]; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Gasquoine P., 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187, https://doi.org/10.1037/0894-4105.6.3.187]; GILEWSKI MJ, 1990, PSYCHOL AGING, V5, P482, DOI 10.1037/0882-7974.5.4.482; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Goverover Y, 2004, J CLIN EXP NEUROPSYC, V26, P737, DOI 10.1080/13803390490509321; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Kraus J. F., 1999, REHABILITATION ADULT, P3; Lewis L., 1991, AWARENESS DEFICIT BR, P223; Lundqvist A, 2010, BRAIN INJURY, V24, P823, DOI 10.3109/02699051003724986; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Nyenhuis DL, 1998, J PERS ASSESS, V70, P386, DOI 10.1207/s15327752jpa7002_14; Ownsworth T, 2006, CLIN PSYCHOL REV, V26, P783, DOI 10.1016/j.cpr.2006.05.003; Ownsworth T, 2011, J INT NEUROPSYCH SOC, V17, P112, DOI 10.1017/S1355617710001311; Prigatano GP, 2005, ACT NEUR S, V93, P39; Sandhaug M, 2012, DISABIL REHABIL, V34, P904, DOI 10.3109/09638288.2011.626484; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; ZELINSKI EM, 1990, PSYCHOL AGING, V5, P388, DOI 10.1037/0882-7974.5.3.388	43	25	25	0	21	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2014	28	2					174	180		10.3109/02699052.2013.860474			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	302XR	WOS:000330638900006	24304140				2022-02-06	
J	Li, W; Ling, HP; You, WC; Liu, HD; Sun, Q; Zhou, ML; Shen, W; Zhao, JB; Zhu, L; Hang, CH				Li, Wei; Ling, Hai-Ping; You, Wan-Chun; Liu, Huan-Dong; Sun, Qing; Zhou, Meng-Liang; Shen, Wei; Zhao, Jin-Bing; Zhu, Lin; Hang, Chun-Hua			Elevated Cerebral Cortical CD24 Levels in Patients and Mice with Traumatic Brain Injury: A Potential Negative Role in Nuclear Factor Kappa B/Inflammatory Factor Pathway	MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; CD24; Inflammatory response; Short hairpin RNA; Knockdown	CLOSED-HEAD INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PROTEIN 88 MYD88; INFLAMMATORY RESPONSE; IMMUNE-RESPONSES; T-CELLS; EXPRESSION; ACTIVATION; ADULT; MODEL	Increasing evidence indicates that sterile inflammatory response contributes to secondary brain injury following traumatic brain injury (TBI). However, the specific mechanisms remain largely unknown, as is whether CD24, known as an important regulator in the non-infectious inflammatory response, plays a role in secondary brain injury after TBI. Here, the expression of CD24 was detected in samples from patients with TBI by quantitative real-time polymerase chain reaction (PCR), western blotting, immunohistochemistry and immunofluorescence. RNA interference was used to investigate the effects of CD24 on inflammatory response in a mouse model of TBI. Nuclear factor kappa B (NF-kappa B) DNA-binding activity was measured by electrophoretic mobility shift assay, and the levels of downstream pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and Interleukin 1 beta (IL-1 beta) were detected by real-time PCR. The results indicated that both the mRNA and protein levels of CD24 were markedly elevated after TBI in humans and mice, showing a time-dependent expression. The expression of CD24 could be observed in neurons, astrocytes and microglia in both humans and mice. Meanwhile, downregulation of CD24 significantly induced an increase of NF-kappa B DNA-binding activity and mRNA levels of TNF-alpha and IL-1 beta. These findings indicated that CD24 expression could negatively regulate the NF-kappa B/inflammatory factor pathway after experimental TBI in mice, thus providing a novel target for therapeutic intervention of TBI.	[Li, Wei; You, Wan-Chun; Sun, Qing; Zhou, Meng-Liang; Zhu, Lin; Hang, Chun-Hua] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Ling, Hai-Ping; Liu, Huan-Dong; Zhou, Meng-Liang; Shen, Wei; Zhu, Lin; Hang, Chun-Hua] Southern Med Univ Guangzhou, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Jiangsu, Peoples R China; [Zhao, Jin-Bing] Nanjing Med Univ, Nanjing Brain Hosp, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China		Hang, CH (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	hang_neurosurgery@163.com	Li, Wei/ABE-4301-2021	Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Foundation, ChinaNational Natural Science Foundation of China (NSFC) [81171170, 8100053, 81271377]	We gratefully acknowledge the generous technical assistance from Dr. Gen-bao Feng. This study was supported by grants from the National Natural Science Foundation, China (no. 81171170 for C. H. Hang, no. 8100053 for M. L. Zhou, and no. 81271377 for L. Zhu).	Ahmed MAH, 2010, INFLAMM BOWEL DIS, V16, P795, DOI 10.1002/ibd.21134; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Bai XF, 2004, J EXP MED, V200, P447, DOI 10.1084/jem.20040131; Bai XF, 2000, J CLIN INVEST, V105, P1227, DOI 10.1172/JCI9012; Baumann P, 2005, CANCER RES, V65, P10783, DOI 10.1158/0008-5472.CAN-05-0619; Belvindrah R, 2002, J NEUROSCI, V22, P3594; Bianchi ME, 2009, SCIENCE, V323, P1683, DOI 10.1126/science.1172794; Bleckmann C, 2009, J PROTEOME RES, V8, P567, DOI 10.1021/pr800729r; Calaora V, 1996, NEUROSCIENCE, V73, P581, DOI 10.1016/0306-4522(96)00042-5; Cavassani KA, 2008, J EXP MED, V205, P2609, DOI 10.1084/jem.20081370; Chen GY, 2009, SCIENCE, V323, P1722, DOI 10.1126/science.1168988; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fukushima T, 2007, J BIOL CHEM, V282, P18634, DOI 10.1074/jbc.M609567200; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Graeber MB, 2011, FEBS LETT, V585, P3798, DOI 10.1016/j.febslet.2011.08.033; Hang CH, 2005, NEUROL INDIA, V53, P312, DOI 10.4103/0028-3886.16930; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Jiang W, 2011, STEM CELLS, V29, P609, DOI 10.1002/stem.608; KAY R, 1991, J IMMUNOL, V147, P1412; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; Kristiansen G, 2004, J MOL HISTOL, V35, P255; Lescot T, 2007, PRESSE MED, V36, P1117, DOI 10.1016/j.lpm.2007.01.017; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Li W, 2013, NEUROL SCI, V34, P847, DOI 10.1007/s10072-012-1131-9; Ling HP, 2013, J SURG RES, V179, pE227, DOI 10.1016/j.jss.2012.03.030; Liu YQ, 2009, J MATER RES, V24, P24, DOI 10.1557/JMR.2009.0034; Liu Y, 2007, TRENDS IMMUNOL, V28, P315, DOI 10.1016/j.it.2007.05.001; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Qiu Q, 2011, STEM CELLS DEV, V20, P2177, DOI 10.1089/scd.2010.0352; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457; Warger T, 2006, J BIOL CHEM, V281, P22545, DOI 10.1074/jbc.M502900200; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001	39	25	25	1	9	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	FEB	2014	49	1					187	198		10.1007/s12035-013-8509-4			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AA4EC	WOS:000331046800016	23881416				2022-02-06	
J	Geddes, RI; Sribnick, EA; Sayeed, I; Stein, DG				Geddes, Rastafa I.; Sribnick, Eric A.; Sayeed, Iqbal; Stein, Donald G.			Progesterone Treatment Shows Benefit in a Pediatric Model of Moderate to Severe Bilateral Brain Injury	PLOS ONE			English	Article							IMMATURE RATS; RECEPTOR KNOCKOUT; SEX-DIFFERENCES; FEMALE RATS; RECOVERY; BEHAVIOR; EDEMA; YOUNG; GABA; MICE	Purpose: Controlled cortical impact (CCI) models in adult and aged Sprague-Dawley (SD) rats have been used extensively to study medial prefrontal cortex (mPFC) injury and the effects of post-injury progesterone treatment, but the hormone's effects after traumatic brain injury (TBI) in juvenile animals have not been determined. In the present proof-of-concept study we investigated whether progesterone had neuroprotective effects in a pediatric model of moderate to severe bilateral brain injury. Methods: Twenty-eight-day old (PND 28) male Sprague Dawley rats received sham (n = 24) or CCI (n = 47) injury and were given progesterone (4, 8, or 16 mg/kg per 100 g body weight) or vehicle injections on post-injury days (PID) 1-7, subjected to behavioral testing from PID 9-27, and analyzed for lesion size at PID 28. Results: The 8 and 16 mg/kg doses of progesterone were observed to be most beneficial in reducing the effect of CCI on lesion size and behavior in PND 28 male SD rats. Conclusion: Our findings suggest that a midline CCI injury to the frontal cortex will reliably produce a moderate TBI comparable to what is seen in the adult male rat and that progesterone can ameliorate the injury-induced deficits.	[Geddes, Rastafa I.; Sribnick, Eric A.; Sayeed, Iqbal; Stein, Donald G.] Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA		Stein, DG (corresponding author), Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA.	dstei04@emory.edu	Stein, Donald/AAJ-5139-2020; Sribnick, Eric/AAH-6693-2020	Geddes, Rastafa/0000-0002-7313-761X	Allen and Company; Centers for Injury Control [R49CE001494-04]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001494] Funding Source: NIH RePORTER	This work was supported by gifts in support of research from Allen and Company and by the Centers for Injury Control Grant No. R49CE001494-04. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baykara B, 2013, BIOTECH HISTOCHEM, V88, P250, DOI 10.3109/10520295.2013.769630; Blumberg MS, 1998, DEV PSYCHOBIOL, V33, P107, DOI 10.1002/(SICI)1098-2302(199809)33:2<107::AID-DEV2>3.0.CO;2-N; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Clancy B, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.020.2009; Conti F, 2004, BRAIN RES REV, V45, P196, DOI 10.1016/j.brainresrev.2004.03.003; Coomber B, 2010, BRAIN RES, V1361, P124, DOI 10.1016/j.brainres.2010.09.037; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; CRUZ APM, 1994, PHARMACOL BIOCHEM BE, V49, P171, DOI 10.1016/0091-3057(94)90472-3; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Espinoza TR, 2011, J HEAD TRAUMA REHAB, V26, P497, DOI 10.1097/HTR.0b013e31823088fa; Faul M, 2010, TRAUMATIC BRAIN INJU; Frye CA, 2011, J PSYCHOPHARMACOL, V25, P421, DOI 10.1177/0269881109349836; Galanopoulou AS, 2008, EPILEPSY RES, V80, P99, DOI 10.1016/j.eplepsyres.2008.04.013; GAYTAN F, 1988, ANDROLOGIA, V20, P450; Gerrish CJ, 1998, PHYSIOL BEHAV, V64, P463, DOI 10.1016/S0031-9384(98)00077-8; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Golub MS, 2006, BIRTH DEFECTS RES B, V77, P455, DOI 10.1002/bdrb.20089; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; HOLMES GL, 1984, DEV BRAIN RES, V16, P45, DOI 10.1016/0165-3806(84)90061-0; Kasturi BS, 2009, RESTOR NEUROL NEUROS, V27, P265, DOI [10.3233/RNN-2009-0475, 10.3233/RNN-2009-0476]; Kolb B, 1996, BEHAV NEUROSCI, V110, P1271, DOI 10.1037/0735-7044.110.6.1271; Kosten TA, 2012, NEUROSCI BIOBEHAV R, V36, P1985, DOI 10.1016/j.neubiorev.2012.07.003; Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702; McCarthy MM, 2002, TRENDS NEUROSCI, V25, P307, DOI 10.1016/S0166-2236(02)02182-3; Nold C, 2013, AM J OBSTET GYNECOL, V208, pS26, DOI 10.1016/j.ajog.2012.10.216; Norwitz Errol R, 2011, Rev Obstet Gynecol, V4, P60; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Reddy DS, 2005, BRAIN RES, V1033, P96, DOI 10.1016/j.brainres.2004.11.026; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Rodgers RJ, 1997, BRAZ J MED BIOL RES, V30, P289, DOI 10.1590/S0100-879X1997000300002; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Russell KL, 2011, J NEUROSCI METH, V199, P214, DOI 10.1016/j.jneumeth.2011.05.008; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Silva-Gomez AB, 2003, BRAIN RES, V973, P285, DOI 10.1016/S0006-8993(03)02537-X; Soderpalm AHV, 2004, PSYCHONEUROENDOCRINO, V29, P339, DOI 10.1016/S0306-4530(03)00033-7; Stanley RM, 2012, PEDIATRICS, V129, pE24, DOI 10.1542/peds.2011-2074; Stein DG, 2013, HORM BEHAV, V63, P291, DOI 10.1016/j.yhbeh.2012.05.004; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tsuji M, 2012, EXP NEUROL, V233, P214, DOI 10.1016/j.expneurol.2011.10.004; Uysal N, 2013, TURK NEUROSURG, V23, P129, DOI 10.5137/1019-5149.JTN.5582-11.1; Varty GB, 2000, BIOL PSYCHIAT, V47, P864, DOI 10.1016/S0006-3223(99)00269-3; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	50	25	25	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2014	9	1							e87252	10.1371/journal.pone.0087252			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	301CJ	WOS:000330510000120	24489882	Green Submitted, Green Published, gold			2022-02-06	
J	Mayer, AR; Toulouse, T; Klimaj, S; Ling, JM; Pena, A; Bellgowan, PSF				Mayer, Andrew R.; Toulouse, Trent; Klimaj, Stefan; Ling, Josef M.; Pena, Amanda; Bellgowan, Patrick S. F.			Investigating the Properties of the Hemodynamic Response Function after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						fMRI; hemodynamic response function; sensorimotor; traumatic brain injury	CEREBRAL-BLOOD-FLOW; BOLD POSTSTIMULUS UNDERSHOOT; OXIDATIVE-METABOLISM; WORKING-MEMORY; OXYGEN-METABOLISM; FOOTBALL PLAYERS; FMRI; ACTIVATION; MRI; RECOVERY	Although several functional magnetic resonance imaging (fMRI) studies have been conducted in human models of mild traumatic brain injury (mTBI), to date no studies have explicitly examined how injury may differentially affect both the positive phase of the hemodynamic response function (HRF) as well as the post-stimulus undershoot (PSU). Animal models suggest that the acute and semi-acute stages of mTBI are associated with significant disruptions in metabolism and to the microvasculature, both of which could impact on the HRF. Therefore, fMRI data were collected on a cohort of 30 semi-acute patients with mTBI (16 males; 27.83 +/- 9.97 years old; 13.00 +/- 2.18 years of education) and 30 carefully matched healthy controls (HC; 16 males; 27.17 +/- 10.08 years old; 13.37 +/- 2.31 years of education) during a simple sensory-motor task. Patients reported increased cognitive, somatic, and emotional symptoms relative to controls, although no group differences were detected on traditional neuropsychological examination. There were also no differences between patients with mTBI and controls on fMRI data using standard analytic techniques, although mTBI exhibited a greater volume of activation during the task qualitatively. A significant GroupxTime interaction was observed in the right supramarginal gyrus, bilateral primary and secondary visual cortex, and the right parahippocampal gyrus. The interaction was the result of an earlier time-to-peak and positive magnitude shift throughout the estimated HRF in patients with mTBI relative to HC. This difference in HRF shape combined with the greater volume of activated tissue may be indicative of a potential compensatory mechanism to injury. The current study demonstrates that direct examination and modeling of HRF characteristics beyond magnitude may provide additional information about underlying neuropathology that is not available with more standard fMRI analyses.	[Mayer, Andrew R.; Toulouse, Trent; Klimaj, Stefan; Ling, Josef M.; Pena, Amanda] Lovelace Biomed & Environm Res Inst, Mind Res Network, Albuquerque, NM USA; [Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Bellgowan, Patrick S. F.] Laureate Inst Brain Res, Tulsa, OK USA; [Bellgowan, Patrick S. F.] Univ Tulsa, Fac Community Med, Tulsa, OK 74104 USA		Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org	Klimaj, Stefan/AAV-4060-2020				Ances BM, 2009, HUM BRAIN MAPP, V30, P1120, DOI 10.1002/hbm.20574; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Behzadi Y, 2005, NEUROIMAGE, V25, P1100, DOI 10.1016/j.neuroimage.2004.12.057; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bellgowan PSF, 2006, NEUROIMAGE, V29, P1244, DOI 10.1016/j.neuroimage.2005.08.042; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; BOX G. E. P., 1994, TIME SERIES ANAL FOR, V3rd; Burock MA, 1998, NEUROREPORT, V9, P3735, DOI 10.1097/00001756-199811160-00030; Buxton RB, 1998, MAGNET RESON MED, V39, P855, DOI 10.1002/mrm.1910390602; Buxton RB, 2004, NEUROIMAGE, V23, pS220, DOI 10.1016/j.neuroimage.2004.07.013; Cohen MS, 1997, NEUROIMAGE, V6, P93, DOI 10.1006/nimg.1997.0278; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Faul M, 2010, TRAUMATIC BRAIN INJU; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; Frackowiak R S, 1988, Am J Physiol Imaging, V3, P24; Giza CC, 2001, J ATHL TRAINING, V36, P228; Glover GH, 1999, NEUROIMAGE, V9, P416, DOI 10.1006/nimg.1998.0419; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Harshbarger TB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002914; Hua J, 2011, J CEREBR BLOOD F MET, V31, P1599, DOI 10.1038/jcbfm.2011.35; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Logothetis NK, 2008, NATURE, V453, P869, DOI 10.1038/nature06976; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lu HZ, 2004, J CEREBR BLOOD F MET, V24, P764, DOI 10.1097/01.WCB.0000124322.60992.5C; Mangia S, 2007, J CEREBR BLOOD F MET, V27, P1055, DOI 10.1038/sj.jcbfm.9600401; Mayer AR, 2007, J INT NEUROPSYCH SOC, V13, P839, DOI 10.1017/S1355617707071081; Mayer AR, 2012, BRAIN IMAGING BEHAV, V6, P343, DOI 10.1007/s11682-012-9178-z; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Palmer HS, 2010, J NEUROTRAUM, V27, P853, DOI 10.1089/neu.2009.1225; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Poser BA, 2011, HUM BRAIN MAPP, V32, P141, DOI 10.1002/hbm.21003; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Rasmussen IA, 2008, J NEUROTRAUM, V25, P1057, DOI 10.1089/neu.2008.0520; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schroeter ML, 2006, NEUROIMAGE, V30, P349, DOI 10.1016/j.neuroimage.2005.09.048; Shen Q, 2008, J MAGN RESON IMAGING, V27, P599, DOI 10.1002/jmri.21203; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Talairach J., 1988, COPLANAR STERIOTOXIC; van Zijl PCM, 2012, NEUROIMAGE, V62, P1092, DOI 10.1016/j.neuroimage.2012.01.029; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; [No title captured]	66	25	25	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2014	31	2					189	197		10.1089/neu.2013.3069			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	291ZE	WOS:000329870600005	23965000	Green Published			2022-02-06	
J	Shivaji, T; Lee, A; Dougall, N; McMillan, T; Stark, C				Shivaji, Tara; Lee, Andrew; Dougall, Nadine; McMillan, Thomas; Stark, Cameron			The epidemiology of hospital treated traumatic brain injury in Scotland	BMC NEUROLOGY			English	Article						Traumatic brain injury; Accidental falls; Patient admissions; Epidemiology; Scotland; Trends	HEAD-INJURY; OLDER-ADULTS; TRENDS; ENGLAND; POPULATION; ADMISSION; SUICIDE; PEOPLE; IMPACT; STAY	Background: Traumatic Brain Injury (TBI) is an important global public health problem made all the more important by the increased likelihood of disability following a hospital admission for TBI. Understanding those groups most at risk will help inform interventions designed to prevent causes of TBI, such as falls prevention measures. This study identifies the rate of hospitalisation episodes of TBI in Scotland, explores causes of TBI admissions, and trends in hospitalisation episodes by age and gender over a twelve year period using routinely collected hospital data. Methods: A retrospective analysis of routine hospital episode data identified records relating to TBI for the twelve years between 1998 and 2009. Descriptive and joinpoint regression analysis were used, average annual percentage changes (AAPC) and annual percentage change (APC) in rates were calculated. Results: Between 1998 and 2009 there were 208,195 recorded episodes of continuous hospital care in Scotland as a result of TBI. Almost half (47%) of all TBIs were the result of falls, with marked peaks observed in the very young and the oldest groups. The AAPC of hospitalization episode rates over the study period for boys and girls aged 0-14 were -4.9% (95% CI -3.5 to-6.3) and -4.7% (95% CI -2.6 to -6.8) respectively. This reduction was not observed in older age groups. In women aged 65 and over there was an APC of 3.9% (95% CI 1.2 to 6.6) between 2004 and 2009. Conclusions: Hospitalisation for TBI is relatively common in Scotland. The rise in the age-adjusted rate of hospitalisation episodes observed in older people indicates that reduction of TBI should be a public health priority in countries with an ageing population. Public health interventions such as falls prevention measures are well advised and evaluations of such interventions should consider including TBI hospitalisation as an alternative or supplementary outcome measure to fractured neck of femur. Further research is needed to advance understanding of the associations of risk factors with increased incidence of TBI hospital episodes in the elderly population.	[Shivaji, Tara; Stark, Cameron] NHS Highland, Dept Publ Hlth, Inverness IV2 3BW, Scotland; [Lee, Andrew] NHS Natl Serv Scotland, Informat Serv Div, Edinburgh EH12 9EB, Midlothian, Scotland; [Dougall, Nadine] Univ Stirling, Sch Nursing Midwifery & Hlth, NMAHP Res Unit, Stirling FK9 4NF, Scotland; [McMillan, Thomas] Univ Glasgow, Gartnavel Royal Hosp, Coll Med Vet & Life Sci, Inst Hlth & Wellbeing, Glasgow G12 0XH, Lanark, Scotland; [Stark, Cameron] Univ Aberdeen, Ctr Hlth Sci, Ctr Rural Hlth, Inverness IV2 3JH, Scotland		Dougall, N (corresponding author), Univ Stirling, Sch Nursing Midwifery & Hlth, NMAHP Res Unit, Unit 13 Sc House, Stirling FK9 4NF, Scotland.	nadine.dougall@stir.ac.uk	Stark, Cameron R/D-5874-2017; Dougall, Nadine J/O-8145-2015	Stark, Cameron R/0000-0003-1255-7415; Dougall, Nadine J/0000-0003-3462-6960	Chief Scientist Office [NMAHP1] Funding Source: Medline		Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Bajaj A, 2010, WIEN KLIN WOCHENSCHR, V122, P346, DOI 10.1007/s00508-010-1394-1; Bellner J, 2003, J NEUROL NEUROSUR PS, V74, P351, DOI 10.1136/jnnp.74.3.351; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P272; Dunn L, 2003, J NEUROL NEUROSUR PS, V74, P1060, DOI 10.1136/jnnp.74.8.1060; Faul M, 2010, TRAUMATIC BRAIN INJU; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Kannus P, 2007, INJURY, V38, P81, DOI 10.1016/j.injury.2006.08.027; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kempton A, 2000, HEALTH PROMOT INT, V15, P27, DOI 10.1093/heapro/15.1.27; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.3.CO;2-Q; Langlios JA, 2006, TRAUMATIC BRAIN INJU; Leon DA, 2003, UNDERSTANDING HLTH S; Lopez-Campos JL, 2013, INT J TUBERC LUNG D, V17, P131, DOI 10.5588/ijtld.12.0419; Marr A, 2002, CENTRAL NERVOUS SYST; Mauritz W, 2008, EUR J PUBLIC HEALTH, V18, P575, DOI 10.1093/eurpub/ckn079; McClure R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004441.pub2; McMillan TM, 2011, J NEUROL NEUROSUR PS, V82, P931, DOI 10.1136/jnnp.2010.222232; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nichols M, 2013, EUR HEART J, V34, P3017, DOI 10.1093/eurheartj/eht159; OECD, 2010, HLTH GLANC EUR 2010, DOI [DOI 10.1787/HEALTH_GLANCE-2010-EN, 10.1787/health_glance-2010-en]; Ponsky TA, 2005, J TRAUMA, V59, P1292, DOI 10.1097/01.ta.0000197439.19171.25; Saxena S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007484; Scottish Intercollegiate Guidelines Network, 2009, EARL MAN PAT HEAD IN; Shravat BP, 2006, EMERG MED J, V23, P109, DOI 10.1136/emj.2004.022327; Stark C, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-80; Stavrinides V, 2010, ONLINE J CLIN AUDITS, V2; Stephenson S, 2005, ACCIDENT ANAL PREV, V37, P825, DOI 10.1016/j.aap.2005.03.024; Swann IJ, 2001, EMERG MED J, V18, P352, DOI 10.1136/emj.18.5.352; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tennant A, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-21; Thomas K, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-314; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P1631; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	41	25	26	0	18	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	JAN 6	2014	14								2	10.1186/1471-2377-14-2			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	294QV	WOS:000330062800001	24386897	Green Published, gold			2022-02-06	
J	Baker, DA; Connery, AK; Kirk, JW; Kirkwood, MW				Baker, David A.; Connery, Amy K.; Kirk, John W.; Kirkwood, Michael W.			Embedded Performance Validity Indicators Within the California Verbal Learning Test, Children's Version	CLINICAL NEUROPSYCHOLOGIST			English	Article						California Verbal Learning Test; Children's Version (CVLT-C); Embedded validity indicators; Performance validity testing; Noncredible effort; Suboptimal performance; Postconcussion; Mild Traumatic Brain Injury	DISABILITY CONSULTATIVE EXAM; TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY; DIGIT SPAN; NEUROPSYCHOLOGICAL EVALUATION; SUBOPTIMAL EFFORT; INCOMPLETE EFFORT; TEST-II; TOMM; ADOLESCENTS	To date, few studies have examined the use of embedded performance validity indicators in pediatric populations. The present study examined the utility of variables within the California Verbal Learning Test, Children's Version (CVLT-C) in detecting noncredible effort among a pediatric mild traumatic brain injury sample. The sample consisted of 411 clinically referred patients aged 8-16 years. A total of 13% of the participants failed both the Medical Symptom Validity Test and at least one other performance validity measure. No demographic or injury-related variables differentiated the noncredible and adequate effort groups. The noncredible group performed significantly worse than the adequate effort group across a majority of CVLT-C variables. Logistic regression analysis revealed that the Recognition Discriminability (RD) score was the most robust in predicting noncredible effort. Among this relatively high-functioning sample, an RD cutoff z-score of -0.5 resulted in sensitivity of 55% and specificity of 91%. A more conservative RD cutoff z-score of -1.0 resulted in sensitivity of 41% and specificity of 97%. These findings are comparable to the classification statistics found for many embedded indicators in the adult literature. Although only moderately sensitive, the RD score on the CVLT-C appears to have good utility in identifying noncredible effort in a relatively high-functioning pediatric mTBI population.	Univ Colorado Denver, Sch Med, Dept Phys Med & Rehabil, Aurora, CO USA; Childrens Hosp Colorado, Aurora, CO 80045 USA		Baker, DA (corresponding author), Childrens Hosp Colorado, Concuss Program, 13123 E 16th Ave,285, Aurora, CO 80045 USA.	david.baker@childrenscolorado.org					Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Belsley D.A., 2004, REGRESSION DIAGNOSTI; Belsley DA., 1980, REGRESSION DIAGNOSTI, DOI 10.1002/0471725153; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Boone K. B., 2008, CLIN NEUROPSYCHOL, V23, P729; Boone K.B., 2007, ASSESSMENT FEIGNED C; Brooks BL, 2012, ARCH CLIN NEUROPSYCH, V27, P858, DOI 10.1093/arclin/acs087; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Courtney JC, 2003, CHILD NEUROPSYCHOL, V9, P109, DOI 10.1076/chin.9.2.109.14507; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Delis D.C., 2000, CALIFORNIA VERBAL LE; Delis DC., 1994, CALIFORNIA VERBAL LE; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; Donders J, 2011, CLIN NEUROPSYCHOL, V25, P173, DOI 10.1080/13854046.2010.536781; Flaro L., 2009, NEUROPSYCHOLOGY MALI, P369; Green CM, 2011, CLIN NEUROPSYCHOL, V25, P585; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2005, MANUAL WORD MEMORY T; Green P, 2004, GREENS MED SYMPTOM V; Henry G. K., 2005, FORENSIC NEUROPSYCHO, P205; Kirk JW, 2011, CHILD NEUROPSYCHOL, V17, P242, DOI 10.1080/09297049.2010.533166; Kirkwood M. W., 2013, CHILD NEUROPSYCOLOGY, DOI 10.1080/09297049.2012.759553; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; Kirkwood MW, 2012, PSYCHOL ASSESSMENT, V24, P36, DOI 10.1037/a0024628; Kirkwood MW, 2011, ARCH CLIN NEUROPSYCH, V26, P377, DOI 10.1093/arclin/acr040; Kirkwood MW, 2010, CHILD NEUROPSYCHOL, V16, P604, DOI 10.1080/09297049.2010.495059; Kirkwood MW, 2010, CLIN NEUROPSYCHOL, V24, P860, DOI 10.1080/13854040903527287; Lange RT, 2010, J CLIN EXP NEUROPSYC, V32, P961, DOI 10.1080/13803391003645657; Larrabee G.J., 2007, ASSESSMENT MALINGERE; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; Loughan AR, 2012, ARCH CLIN NEUROPSYCH, V27, P716, DOI 10.1093/arclin/acs072; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; MacAllister WS, 2009, CHILD NEUROPSYCHOL, V15, P521, DOI 10.1080/09297040902748226; McCaffrey R. J., 2009, NEUROPSYCHOLOGY MALI, P377; McKinzey RK, 2003, BRIT J CLIN PSYCHOL, V42, P95, DOI 10.1348/014466503762842048; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Slick DJ, 2000, J CLIN EXP NEUROPSYC, V22, P569, DOI 10.1076/1380-3395(200010)22:5;1-9;FT569; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Welsh AJ, 2012, ARCH CLIN NEUROPSYCH, V27, P735, DOI 10.1093/arclin/acs063; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	48	25	25	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN 2	2014	28	1					116	127		10.1080/13854046.2013.858184			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AA0AF	WOS:000330756800008	24229006				2022-02-06	
J	Cottingham, ME; Victor, TL; Boone, KB; Ziegler, EA; Zeller, M				Cottingham, Maria Easter; Victor, Tara L.; Boone, Kyle B.; Ziegler, Elizabeth A.; Zeller, Michelle			Apparent Effect of Type of Compensation Seeking (Disability Versus Litigation) on Performance Validity Test Scores may be due to Other Factors	CLINICAL NEUROPSYCHOLOGIST			English	Article						Compensation; Performance validity; Neuropsychology; Disability; mTBI	SOCIAL-SECURITY DISABILITY; TRAUMATIC BRAIN-INJURY; WORD RECOGNITION TEST; MILD HEAD TRAUMA; SUSPECT EFFORT; RESPONSE BIAS; SYMPTOM EXAGGERATION; CONSULTATIVE EXAM; CROSS-VALIDATION; BASE RATES	Neuropsychologists use performance validity tests (PVTs; Larrabee, 2012) to ensure that results of testing are reflective of the test taker's true neurocognitive ability, and their use is recommended in all compensation-seeking settings. However, whether the type of compensation context (e.g., personal injury litigation versus disability seeking) impacts the nature and extent of neurocognitive symptom feigning has not been adequately investigated. PVT performance was compared in an archival data set of noncredible individuals in either a personal injury litigation (n = 163) or a disability-seeking context (n = 201). Individuals were deemed noncredible based on meeting Slick, Sherman, and Iverson's (1999) criteria including failure on at least two PVTs and a lack of congruency between their low cognitive scores and normal function in activities of daily living (ADLs). In general, disability seekers tended to perform in a less sophisticated manner than did litigants (i.e., they failed more indicators and did so more extensively). Upon further investigation, these differences were in part accounted for by type of diagnoses feigned; those seeking compensation for mental health diagnoses were more likely to feign or exaggerate a wide variety of cognitive deficits, whereas those with claimed medical diagnoses (i.e., traumatic brain injury) were more targeted in their attempts to feign and/or exaggerate neurocognitive compromise.	[Cottingham, Maria Easter] Olive View UCLA Med Ctr, Dept Psychiat, Sylmar, CA 91342 USA; [Victor, Tara L.] Calif State Univ, Dept Psychol, Carson, CA USA; [Boone, Kyle B.] Alliant Int Univ, Calif Sch Forens Studies, Los Angeles, CA USA; [Ziegler, Elizabeth A.] Spokane Vet Adm Med Ctr, Dept Mental Behav Hlth, Spokane, WA USA; [Zeller, Michelle] Greater Los Angeles Vet Healthcare Syst, Dept Psychol, Los Angeles, CA USA		Cottingham, ME (corresponding author), TBI Clin, 11050 Mt Belvedere Blvd,Bldg 25, Ft Drum, NY 13601 USA.	mecottingham@gmail.com	Victor, Tara/K-6581-2019				Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Bell-Sprinkel TL, 2013, CLIN NEUROPSYCHOL, V27, P516, DOI 10.1080/13854046.2012.744853; Bianchini KJ, 2006, CLIN NEUROPSYCHOL, V20, P831, DOI 10.1080/13854040600875203; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Boone K. B., 2002, DOT COUNTING TEST MA; Boone KB, 2005, ARCH CLIN NEUROPSYCH, V20, P301, DOI 10.1016/j.acn.2004.08.001; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Buddin R., 2012, IS MILITARY COMPENSA; Buddin R, 2005, ANAL MILITARY DISABI; Chafetz M. D, 2013, MILD TRAUMATIC BRAIN; Chafetz MD, 2008, CLIN NEUROPSYCHOL, V22, P529, DOI 10.1080/13854040701346104; Chafetz MD, 2007, ARCH CLIN NEUROPSYCH, V22, P1, DOI 10.1016/j.acn.2006.10.003; Chafetz MD, 2011, ARCH CLIN NEUROPSYCH, V26, P306, DOI 10.1093/arclin/acr030; Chafetz MD, 2010, CLIN NEUROPSYCHOL, V24, P1045, DOI 10.1080/13854046.2010.481637; Dean AC, 2008, CLIN NEUROPSYCHOL, V22, P705, DOI 10.1080/13854040701440493; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Denning J., 2012, ANN M AM AC CLIN NEU; Freeman T, 2008, PSYCHIAT RES, V158, P374, DOI 10.1016/j.psychres.2007.04.002; Green P, 2013, MILD TRAUMATIC BRAIN; Green P., 2003, MANUAL WORD MEMORY T; Green P, 2004, GREENS MED SYMPTOM V; Greiffenstein M., 2008, TXB CLIN NEUROPSYCHO, P905; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Kaufmann PM, 2009, CLIN NEUROPSYCHOL, V23, P1130, DOI 10.1080/13854040903107809; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Langton Lynn, 2005, CIVIL BENCH JURY TRI; Larrabee GJ, 2012, J INT NEUROPSYCH SOC, V18, P625, DOI 10.1017/S1355617712000240; McNally RJ, 2013, J ANXIETY DISORD, V27, P520, DOI 10.1016/j.janxdis.2013.07.002; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Morton III D. A, 2010, NOLOS GUIDE SOCIAL S; Nakagawa S, 2004, BEHAV ECOL, V15, P1044, DOI 10.1093/beheco/arh107; Nitch S, 2006, CLIN NEUROPSYCHOL, V20, P873, DOI 10.1080/13854040590967603; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Roberson CJ, 2013, CLIN NEUROPSYCHOL, V27, P495, DOI 10.1080/13854046.2012.737027; Sherman DS, 2002, CLIN NEUROPSYCHOL, V16, P242, DOI 10.1076/clin.16.3.242.13860; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Smith K., CLIN NEUROP IN PRESS; *SOC SEC ADV BOARD, 2003, SOC SEC DEF DIS; Social Security Administration, 2013, NUMB PEOPL US SEEK R; Solomon RE, 2010, CLIN NEUROPSYCHOL, V24, P1243, DOI 10.1080/13854046.2010.514864; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Victor TL., 2007, ASSESSMENT FEIGNED C, P310, DOI [DOI 10.1076/JCEN.25.7.979.16481, 10.1076/jcen.25.7.979.16481]	51	25	26	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2014	28	6					1030	1047		10.1080/13854046.2014.951397			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	AP4MR	WOS:000342051600010	25157537				2022-02-06	
J	Kraus, JF; Hsu, P; Schafer, K; Afifi, AA				Kraus, Jess F.; Hsu, Paul; Schafer, Kathryn; Afifi, A. A.			Sustained outcomes following mild traumatic brain injury: Results of a five-emergency department longitudinal study	BRAIN INJURY			English	Article						Cohort study; comparison cohort; emergency department; inverse probability weighting; outcomes; persistent symptoms; post-concussion; Rivermead Post-Concussion Symptoms Questionnaire	MINOR HEAD-INJURY; POST-CONCUSSION SYMPTOMS; EMERGENCY-DEPARTMENT; POSTCONCUSSIVE SYNDROME; EARLY PREDICTORS; QUESTIONNAIRE; RECOVERY; CONSCIOUSNESS; RELIABILITY; POPULATION	Objective: To report on the occurrence of sustained outcomes including post-concussion symptoms, health services used and indicators of social disruption following a mild traumatic brain injury (MTBI). Research design: A dual cohort comparing MTBI Emergency Department (ED) patients and a comparison group of non-head injured ED patients. Methods and procedures: The outcomes measures employed were the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) and indicators of health services used and social disruption all recorded at the ED and at 3 and 6 months post-ED discharge. 'Sustained' meant a positive response to these measures at 3 and 6 months. Main outcomes and results: Reasonable follow-up success was achieved at 3 and 6 months and the cohorts were alike on all demographic descriptors. RPQ average score and symptom occurrence were far more frequent among MTBI patients than for the comparison cohort from 3 to 6 months. The use of health services and indicators of social disruption were also more frequent among MTBI post-discharge patients. Conclusions: These findings argue that some with an MTBI suffer real complaints and they are sustained from 3 to at least 6 months. More effort should be given toward specificity of these symptoms from those reported by members of the comparison group.	[Kraus, Jess F.] Univ Calif Los Angeles, Dept Epidemiol, San Marcos, CA 92089 USA; [Hsu, Paul] Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA USA; [Schafer, Kathryn] Scripps Mem Hosp, Trauma Serv, La Jolla, CA USA; [Afifi, A. A.] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA		Kraus, JF (corresponding author), Univ Calif Los Angeles, Dept Epidemiol, 1173 San Marino Dr 4202, San Marcos, CA 92089 USA.	jkraus3637@roadrunner.com	Schafer, Katrin/P-4728-2015	Hsu, Paul/0000-0002-6153-364X			Afifi AA, 2007, ANNU REV PUBL HEALTH, V28, P95, DOI 10.1146/annurev.publhealth.28.082206.094100; American Psychiatric Association, 1994, DIAGN STAT MAN MEN D; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABILITATION MED, V43, P4; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gravel J, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-63; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; ICD-9-CM, 1989, INT CLASS DIS 9 REV; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rienmann BL, 2002, J ATHL TRAINING, V35, P19; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; TEASDALE G, 1974, LANCET, V2, P81; World Health Organization, 1992, ICD 10 CLASSIFICATIO	52	25	25	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	10					1248	1256		10.3109/02699052.2014.916420			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AN2ZZ	WOS:000340455900003	24841806				2022-02-06	
J	Moore, RD; Broglio, SP; Hillman, CH				Moore, Robert D.; Broglio, Steven P.; Hillman, Charles H.			Sport-Related Concussion and Sensory Function in Young Adults	JOURNAL OF ATHLETIC TRAINING			English	Article						mild traumatic brain injuries; visual processing; event-related potentials; pattern-reversal visual evoked potentials	TRAUMATIC BRAIN-INJURY; VISUAL-EVOKED POTENTIALS; INTERNATIONAL-CONFERENCE; SELECTIVE ATTENTION; OPTIC NEURITIS; HISTORY; LONG; ABNORMALITIES; PERFORMANCE; STATEMENT	Context: The long-term implications of concussive injuries for brain and cognitive health represent a growing concern in the public consciousness. As such, identifying measures sensitive to the subtle yet persistent effects of concussive injuries is warranted. Objective: To investigate how concussion sustained early in life influences visual processing in young adults. We predicted that young adults with a history of concussion would show decreased sensory processing, as noted by a reduction in P1 event-related potential component amplitude. Design: Cross-sectional study. Setting: Research laboratory. Patients or Other Participants: Thirty-six adults (18 with a history of concussion, 18 controls) between the ages of 20 and 28 years completed a pattern-reversal visual evoked potential task while event-related potentials were recorded. Main Outcome Measure(s): The groups did not differ in any demographic variables (all P values > .05), yet those with a concussive history exhibited reduced P1 amplitude compared with the control participants (P =.05). Conclusions: These results suggest that concussion history has a negative effect on visual processing in young adults. Further, upper-level neurocognitive deficits associated with concussion may, in part, result from less efficient downstream sensory capture.	[Moore, Robert D.; Hillman, Charles H.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA		Broglio, SP (corresponding author), ATC, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu	Hillman, Charles/AAD-4828-2019; Meijer, Anna/K-5118-2016	Hillman, Charles/0000-0002-3722-5612	National Athletic Trainers' Association Research & Education Foundation	Funding for this project was provided by the National Athletic Trainers' Association Research & Education Foundation.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BRIGELL M, 1994, DOC OPHTHALMOL, V86, P65, DOI 10.1007/BF01224629; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2011, INT J PSYCHOPHYSIOL, V82, P16, DOI 10.1016/j.ijpsycho.2011.02.010; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Brosseau-Lachaine O, 2008, BRAIN INJURY, V22, P657, DOI 10.1080/02699050802203353; Brusa A, 2001, BRAIN, V124, P468, DOI 10.1093/brain/124.3.468; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chatrian G. E., 1985, American Journal of EEG Technology, V25, P83; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dockree PM, 2011, INT J PSYCHOPHYSIOL, V82, P53, DOI 10.1016/j.ijpsycho.2011.01.004; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Freed S, 1997, BRAIN INJURY, V11, P25, DOI 10.1080/026990597123782; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Halliday A. M., 1982, EVOKED POTENTIALS CL; Hecht S, 2005, CLIN J SPORT MED, V15, P281, DOI DOI 10.1097/01.jsm.0000172669.85640.05; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hillyard SA, 1998, PHILOS T ROY SOC B, V353, P1257, DOI 10.1098/rstb.1998.0281; HILLYARD SA, 1984, PERCEPT PSYCHOPHYS, V36, P185, DOI 10.3758/BF03202679; Hillyard SA, 1998, P NATL ACAD SCI USA, V95, P781, DOI 10.1073/pnas.95.3.781; Hugdahl K, 1995, J CLIN EXP NEUROPSYC, V17, P833, DOI 10.1080/01688639508402432; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Key APF, 2005, DEV NEUROPSYCHOL, V27, P183, DOI 10.1207/s15326942dn2702_1; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Lachapelle J, 2004, VISION RES, V44, P2835, DOI 10.1016/j.visres.2004.06.007; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mellow TB, 2011, DOC OPHTHALMOL, V122, P133, DOI 10.1007/s10633-011-9267-0; Moore RD, 2014, J ATHL TRAIN, V49; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; National Center for Injury Prevention and Control, 2002, INJ FACT BOOK 2001 2; Odom JV, 2010, DOC OPHTHALMOL, V120, P111, DOI 10.1007/s10633-009-9195-4; OKEN BS, 1987, ELECTROEN CLIN NEURO, V68, P153, DOI 10.1016/0168-5597(87)90042-6; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Sarnthein J, 2009, CLIN NEUROPHYSIOL, V120, P1835, DOI 10.1016/j.clinph.2009.08.014; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Tay SY, 2010, J NEUROTRAUM, V27, P77, DOI 10.1089/neu.2009.1074; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Trip SA, 2006, NEUROIMAGE, V31, P286, DOI 10.1016/j.neuroimage.2005.11.051; Turgeon C, 2011, EAR HEARING, V32, P667, DOI 10.1097/AUD.0b013e31821209d6	57	25	25	0	12	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JAN-FEB	2014	49	1					36	41		10.4085/1062-6050-49.1.02			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	AQ3LX	WOS:000342696500005	24377961	Green Published			2022-02-06	
J	Silverberg, ND; Luoto, TM; Ohman, J; Iverson, GL				Silverberg, Noah D.; Luoto, Teemu M.; Ohman, Juha; Iverson, Grant L.			Assessment of mild traumatic brain injury with the King-Devick Test (R) in an emergency department sample	BRAIN INJURY			English	Article						All neuropsychology/behavior; assessment of cognitive disorders/dementia; brain trauma; diagnostic test assessment; MRI	VISUAL SCREENING TOOL; SPORT CONCUSSION; SYMPTOMS	Objective: The King-Devick Test (R) (K-D) is a brief measure of cognitive processing speed and rapid gaze shifting that appears sensitive to the effects of sport-related concussion. This study evaluated its diagnostic and incremental validity in civilian patients with mild traumatic brain injury (MTBI). Methods: Participants with MTBI (n = 26) and controls with non-head injuries (n = 33) were prospectively recruited from an Emergency Department (ED). They underwent a clinical evaluation including the K-D test and the Sport Concussion Assessment Tool 2 (SCAT2). Magnetic resonance imaging (MRI) was conducted within 10 days post-injury. Results: The patients with MTBI differed from those without MTBI on components of the SCAT2, including the Symptom Scale (Cohen's d = 1.02-1.15, p<0.001) and Standardized Assessment of Concussion (d = 0.81, p = 0.004), but not the K-D test (d = 0.40, p = 0.148). In a logistic regression analysis, the K-D Test did not contribute over and above these two measures in predicting group membership (MTBI vs. control), p = 0.191. Low K-D Test scores in the MTBI group (<1 SD below controls) were not associated with poor SCAT2 performance, loss of consciousness or traumatic abnormalities on MRI, suggesting these cases may have been false positives. Conclusions: The present findings do not support the K-D Test for the assessment of civilian MTBI in an ED setting.	[Silverberg, Noah D.] Univ British Columbia, Dept Med, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Silverberg, Noah D.] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Luoto, Teemu M.; Ohman, Juha] Tampere Univ Hosp, Dept Neurosci & Rehabil, FI-33521 Tampere, Finland; [Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA		Luoto, TM (corresponding author), Tampere Univ Hosp, Dept Neurosci & Rehabil, POB 2000, FI-33521 Tampere, Finland.	teemu.luoto@pshp.fi	Luoto, Teemu/W-6468-2018	Luoto, Teemu/0000-0002-7329-3284; Iverson, Grant/0000-0001-7348-9570; Ohman, Juha/0000-0002-6592-1367	Medical Research Fund of Tampere University Hospital; Maire Taponen Foundation; Emil Aaltonen Foundation	The authors report no conflicts of interest. This study has been supported by the Medical Research Fund of Tampere University Hospital, the Maire Taponen Foundation and the Emil Aaltonen Foundation.	Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Davies EC, 2012, NEUROLOGY, V78, pE103, DOI 10.1212/WNL.0b013e318251833d; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Larrabee GJ, 2013, CLIN NEUROPSYCHOL, V27, P215, DOI 10.1080/13854046.2013.769634; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Luoto TM, 2014, J NEUROTRAUM, V31, P728, DOI 10.1089/neu.2013.3174; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Preece MHW, 2010, NEUROPSYCHOLOGY, V24, P493, DOI 10.1037/a0018903; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x	24	25	25	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	12					1590	1593		10.3109/02699052.2014.943287			4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AR6UD	WOS:000343717700010	25093537				2022-02-06	
J	Wang, KW; Wang, HK; Chen, HJ; Liliang, PC; Liang, CL; Tsai, YD; Cho, CL; Lu, K				Wang, Kuo-Wei; Wang, Hao-Kuang; Chen, Han-Jung; Liliang, Po-Chou; Liang, Cheng-Loong; Tsai, Yu-Duan; Cho, Chung-Lung; Lu, Kang			Simvastatin Combined with Antioxidant Attenuates the Cerebral Vascular Endothelial Inflammatory Response in a Rat Traumatic Brain Injury	BIOMED RESEARCH INTERNATIONAL			English	Article							L-ASCORBIC-ACID; VITAMIN-C; NITRIC-OXIDE; ATORVASTATIN; DYSFUNCTION; ISCHEMIA; STATINS; MARKERS; STRESS	Traumatic brain injury (TBI) leads to important and deleterious neuroinflammation, as evidenced by indicators such as edema, cytokine production, induction of nitric oxide synthase, and leukocyte infiltration. After TBI, cerebral vascular endothelial cells play a crucial role in the pathogenesis of inflammation. In our previous study, we proved that simvastatin could attenuate cerebral vascular endothelial inflammatory response in a rat traumatic brain injury. This purpose of this study was to determine whether simvastatin combined with an antioxidant could produce the same effect or greater and to examine affected surrogate biomarkers for the neuroinflammation after traumatic brain injury in rat. In our study, cortical contusions were induced, and the effect of acute and continuous treatment of simvastatin and vitamin C on behavior and inflammation in adult rats following experimental TBI was evaluated. The results demonstrated that simvastatin combined with an antioxidant could provide neuroprotection and it may be attributed to a dampening of cerebral vascular endothelial inflammatory response.	[Wang, Kuo-Wei; Wang, Hao-Kuang; Chen, Han-Jung; Liliang, Po-Chou; Liang, Cheng-Loong; Tsai, Yu-Duan; Lu, Kang] I Shou Univ, E Da Hosp, Dept Neurosurg, Kaohsiung 824, Taiwan; [Cho, Chung-Lung] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung, Taiwan		Lu, K (corresponding author), I Shou Univ, E Da Hosp, Dept Neurosurg, Kaohsiung 824, Taiwan.	kanglu.1002@gmail.com		Wang, Hao-Kuang/0000-0002-1928-7502	Research Program of E-DA hospital [EDAHP 101013]	This study was supported by a Research Program of E-DA hospital (EDAHP 101013).	Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Beckman JA, 2001, CIRCULATION, V103, P1618, DOI 10.1161/01.CIR.103.12.1618; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brown AA, 2001, AM J CLIN NUTR, V73, P673; Burk RF, 2006, J NUTR, V136, P1576, DOI 10.1093/jn/136.6.1576; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Duffy SJ, 2001, AM J PHYSIOL-HEART C, V280, pH528, DOI 10.1152/ajpheart.2001.280.2.H528; Engler MM, 2003, CIRCULATION, V108, P1059, DOI 10.1161/01.CIR.0000086345.09861.A0; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Greenwood J, 2007, TRENDS IMMUNOL, V28, P88, DOI 10.1016/j.it.2006.12.003; Gupta Amrita Das, 2006, J Basic Clin Physiol Pharmacol, V17, P87; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Han XG, 2011, NEUROSCI LETT, V487, P255, DOI 10.1016/j.neulet.2010.09.007; Hattiwale SH, 2013, BIOMETALS, V26, P329, DOI 10.1007/s10534-013-9617-3; Heller R, 2001, J BIOL CHEM, V276, P40, DOI 10.1074/jbc.M004392200; Huang A, 2000, J BIOL CHEM, V275, P17399, DOI 10.1074/jbc.M002248200; Jackson TS, 1998, CIRC RES, V83, P916; Jawa Randeep S, 2006, J Intensive Care Med, V21, P63, DOI 10.1177/0885066605284325; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Pirat A, 2006, ANESTH ANALG, V102, P225, DOI 10.1213/01.ane.0000189554.41095.98; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Sanchez-Moreno C, 2004, STROKE, V35, P163, DOI 10.1161/01.STR.0000105391.62306.2E; Shao HT, 2007, ANN THORAC SURG, V84, P2011, DOI 10.1016/j.athoracsur.2007.07.022; Sheu JR, 2008, YB CHINESE MED PHARM, V26, P161; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wang KW, 2014, ANN CLIN LAB SCI, V44, P145; Wannamethee SG, 2006, AM J CLIN NUTR, V83, P567, DOI 10.1093/ajcn.83.3.567	31	25	25	0	5	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2314-6133	2314-6141		BIOMED RES INT	Biomed Res. Int.		2014	2014								910260	10.1155/2014/910260			6	Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology; Research & Experimental Medicine	AJ6ZJ	WOS:000337845100001	25013810	Green Submitted, Green Published, gold			2022-02-06	
J	Du, XP; Ewert, DL; Cheng, WH; West, MB; Lu, JZ; Li, W; Floyd, RA; Kopke, RD				Du, Xiaoping; Ewert, Donald L.; Cheng, Weihua; West, Matthew B.; Lu, Jianzhong; Li, Wei; Floyd, Robert A.; Kopke, Richard D.			Effects of Antioxidant Treatment on Blast-Induced Brain Injury	PLOS ONE			English	Article							FOCAL CEREBRAL-ISCHEMIA; IMPULSE NOISE BLAST; REDUCES OXIDATIVE STRESS; N-ACETYLCYSTEINE; C-FOS; RAT-BRAIN; INDUCED NEUROTRAUMA; COCHLEAR NUCLEUS; SPIRAL GANGLION; ANIMAL-MODEL	Blast-induced traumatic brain injury has dramatically increased in combat troops in today's military operations. We previously reported that antioxidant treatment can provide protection to the peripheral auditory end organ, the cochlea. In the present study, we examined biomarker expression in the brains of rats at different time points (3 hours to 21 days) after three successive 14 psi blast overpressure exposures to evaluate antioxidant treatment effects on blast-induced brain injury. Rats in the treatment groups received a combination of antioxidants (2,4-disulfonyl alpha-phenyl tertiary butyl nitrone and N-acetylcysteine) one hour after blast exposure and then twice a day for the following two days. The biomarkers examined included an oxidative stress marker (4-hydroxy-2-nonenal, 4-HNE), an immediate early gene (c-fos), a neural injury marker (glial fibrillary acidic protein, GFAP) and two axonal injury markers [amyloid beta (A4) precursor protein, APP, and 68 kDa neurofilament, NF-68]. The results demonstrate that blast exposure induced or up-regulated the following: 4-HNE production in the dorsal hippocampus commissure and the forceps major corpus callosum near the lateral ventricle; c-fos and GFAP expression in most regions of the brain, including the retrosplenial cortex, the hippocampus, the cochlear nucleus, and the inferior colliculus; and NF-68 and APP expression in the hippocampus, the auditory cortex, and the medial geniculate nucleus (MGN). Antioxidant treatment reduced the following: 4-HNE in the hippocampus and the forceps major corpus callosum, c-fos expression in the retrosplenial cortex, GFAP expression in the dorsal cochlear nucleus (DCN), and APP and NF-68 expression in the hippocampus, auditory cortex, and MGN. This preliminary study indicates that antioxidant treatment may provide therapeutic protection to the central auditory pathway (the DCN and MGN) and the non-auditory central nervous system (hippocampus and retrosplenial cortex), suggesting that these compounds have the potential to simultaneously treat blast-induced injuries in the brain and auditory system.	[Du, Xiaoping; Ewert, Donald L.; Cheng, Weihua; West, Matthew B.; Lu, Jianzhong; Li, Wei; Kopke, Richard D.] Hough Ear Inst, Oklahoma City, OK 73112 USA; [Floyd, Robert A.; Kopke, Richard D.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; [Kopke, Richard D.] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, Oklahoma City, OK USA; [Kopke, Richard D.] Univ Oklahoma, Hlth Sci Ctr, Dept Otolaryngol, Oklahoma City, OK USA		Kopke, RD (corresponding author), Hough Ear Inst, Oklahoma City, OK 73112 USA.	rkopke@houghear.org			United States Department of Navy, Office of Naval Research [N00014-09-1-0999]	This research was supported by grant N00014-09-1-0999 from the United States Department of Navy, Office of Naval Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Abi-Hachem Ralph N, 2010, Recent Pat CNS Drug Discov, V5, P147; Ahmed F, 2012, ELECTROPHORESIS, V33, P3705, DOI 10.1002/elps.201200299; Armstrong KL, 1998, BIOCHEM BIOPH RES CO, V253, P114, DOI 10.1006/bbrc.1998.9762; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Bemeur C, 2010, METAB BRAIN DIS, V25, P241, DOI 10.1007/s11011-010-9201-2; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; BROWN MC, 1995, J COMP NEUROL, V357, P85, DOI 10.1002/cne.903570109; BROWN RFR, 1993, INT J EXP PATHOL, V74, P151; Cernak I, 2000, J NEUROTRAUM, V17, P53, DOI 10.1089/neu.2000.17.53; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 1999, BRAIN INJURY, V13, P1005; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chang EY, 2011, J MATERN-FETAL NEO M, V24, P732, DOI 10.3109/14767058.2010.528089; Chavko M, 2009, SHOCK, V32, P325, DOI 10.1097/SHK.0b013e31819c38f1; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Choi CH, 2011, FREE RADICAL RES, V45, P1162, DOI 10.3109/10715762.2011.605360; Clausen F, 2008, J NEUROTRAUM, V25, P1449, DOI 10.1089/neu.2008.0585; CORNELIUS C, 2013, ANTIOXID REDOX SIGNA; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; DELLANNA ME, 1995, EXP NEUROL, V131, P144, DOI 10.1016/0014-4886(95)90016-0; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; DRAGUNOW M, 1989, J NEUROSCI METH, V29, P261, DOI 10.1016/0165-0270(89)90150-7; Du Xiaoping, 2011, Int J Otolaryngol, V2011, P612690, DOI 10.1155/2011/612690; Du XP, 2012, HEARING RES, V283, P1, DOI 10.1016/j.heares.2011.11.013; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; EHRET G, 1991, BRAIN RES, V567, P350, DOI 10.1016/0006-8993(91)90819-H; Elsayed NM, 2003, TOXICOLOGY, V189, P63, DOI 10.1016/S0300-483X(03)00153-7; Elsayed NM, 2000, TOXICOLOGY, V155, P91, DOI 10.1016/S0300-483X(00)00281-X; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Ewert DL, 2012, HEARING RES, V285, P29, DOI 10.1016/j.heares.2012.01.013; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Floyd RA, 2008, FREE RADICAL BIO MED, V45, P1361, DOI 10.1016/j.freeradbiomed.2008.08.017; Franke LM, 2012, J REHABIL RES DEV, V49, P985, DOI 10.1682/JRRD.2011.12.0250; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Gleich O, 1995, NEUROREPORT, V7, P29, DOI 10.1097/00001756-199512000-00006; Gorbunov NV, 1997, AM J PHYSIOL-LUNG C, V272, pL320, DOI 10.1152/ajplung.1997.272.2.L320; Haase GM, 2011, AM J OTOLARYNG, V32, P55, DOI 10.1016/j.amjoto.2009.09.002; Han M, 2003, CELL MOL BIOL, V49, P1249; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Hoshino S, 2003, NEUROL MED-CHIR, V43, P165, DOI 10.2176/nmc.43.165; Idrizbegovic E, 1998, BRAIN RES, V800, P86, DOI 10.1016/S0006-8993(98)00504-6; Jatana M, 2006, PEDIATR RES, V59, P684, DOI 10.1203/01.pdr.0000215045.91122.44; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; KOCHANEK PM, 2013, J NEUROTRAUMA; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kopke RD, 2007, HEARING RES, V226, P114, DOI 10.1016/j.heares.2006.10.008; KOVESDI E, 2012, NEUROLOGIST, V3, P111, DOI DOI 10.3389/FNEUR.2012.00111; Kovesdi E, 2011, FRONT NEUROSCI-SWITZ, V5, DOI 10.3389/fnins.2011.00042; Kraus KS, 2010, NEUROSCIENCE, V167, P1216, DOI 10.1016/j.neuroscience.2010.02.071; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Lee TF, 2008, PEDIATR RES, V64, P256, DOI 10.1203/PDR.0b013e31817cfcc0; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Li DR, 2012, LEGAL MED-TOKYO, V14, P84, DOI 10.1016/j.legalmed.2011.12.007; Liu JQ, 2010, J NEUROTRAUM, V27, P1865, DOI 10.1089/neu.2010.1325; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Marshall JWB, 2001, STROKE, V32, P190, DOI 10.1161/01.STR.32.1.190; Miller JM, 2007, J NEUROSCI RES, V85, P1959, DOI 10.1002/jnr.21320; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Nakagawa A, 2008, ACTA NEUROCHIR SUPPL, V102, P421, DOI 10.1007/978-3-211-85578-2_82; Niu YL, 2011, ARCH BIOCHEM BIOPHYS, V515, P89, DOI 10.1016/j.abb.2011.07.016; Olucha F E, 1997, Acta Otorrinolaringol Esp, V48, P85; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Phillips Y Y, 1989, Ann Otol Rhinol Laryngol Suppl, V140, P17; PODE D, 1989, MIL MED, V154, P288; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; ROBERTO M, 1989, ANN OTO RHINOL LARYN, V98, P23; Saint Marie RL, 1999, J COMP NEUROL, V404, P258, DOI 10.1002/(SICI)1096-9861(19990208)404:2<258::AID-CNE9>3.0.CO;2-U; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; SATO K, 1993, ACTA OTO-LARYNGOL, P18; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; Sekiya T, 2009, EXP NEUROL, V218, P117, DOI 10.1016/j.expneurol.2009.04.014; Singh V, 2007, INDIAN J EXP BIOL, V45, P1037; SKOTAK M, 2013, J NEUROTRAUMA; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Tumer N, 2013, NEUROSCI LETT, V544, P62, DOI 10.1016/j.neulet.2013.03.042; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Valiyaveettil M, 2013, NEUROSCI LETT, V539, P1, DOI 10.1016/j.neulet.2013.01.028; Valiyaveettil M, 2012, J REHABIL RES DEV, V49, P1153, DOI 10.1682/JRRD.2011.09.0182; Valiyaveettil M, 2012, NEUROSCI LETT, V506, P141, DOI 10.1016/j.neulet.2011.10.067; VandeVord PJ, 2012, ANN BIOMED ENG, V40, P227, DOI 10.1007/s10439-011-0420-4; Wallhausser-Franke E, 2003, EXP BRAIN RES, V153, P649, DOI 10.1007/s00221-003-1614-2; Wang XY, 2007, ANN NEUROL, V61, P263, DOI 10.1002/ana.21066; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu JA, 2011, AM J OTOLARYNG, V32, P8, DOI 10.1016/j.amjoto.2009.08.012; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yi JH, 2006, J NEUROTRAUM, V23, P86, DOI 10.1089/neu.2006.23.86; Zhao ZG, 2001, BRAIN RES, V909, P46, DOI 10.1016/S0006-8993(01)02618-X	120	25	26	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2013	8	11							e80138	10.1371/journal.pone.0080138			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	247EE	WOS:000326597400113	24224042	Green Published, gold, Green Submitted			2022-02-06	
J	Anderson, MI; Simpson, GK; Morey, PJ				Anderson, Malcolm I.; Simpson, Grahame K.; Morey, Peter J.			The Impact of Neurobehavioral Impairment on Family Functioning and the Psychological Well-Being of Male Versus Female Caregivers of Relatives With Severe Traumatic Brain Injury: Multigroup Analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						caregiver gender; family functioning; neurobehavioral impairment; psychological distress; traumatic brain injury	LIFE SATISFACTION; DISTRESS; PREDICTORS; MODEL; STRESS; TBI; REHABILITATION; INDIVIDUALS; SYMPTOMS; SPOUSES	Objective: To examine the differential effect of neurobehavioral impairments (cognitive, behavioral, and social) on family functioning, family roles, and psychological distress in male versus female caregivers of relatives with severe traumatic brain injury (TBI). Design: Structural equation modeling with multigroup analysis conducted in a cross-sectional sample to test an established theoretical model. Participants: An aggregated sample of 122 caregivers (46 male, 76 female) of people with severe TBI. The sample comprised 64 spouses and 58 parents (29 parental couples) of 93 persons with TBI. Measures: Neurobehavioral Problem Checklist; Family Assessment Device; and Brief Symptom Inventory. Results: Structural equation modeling showed that the proposed model had acceptable fit indices for the combined sample. Multigroup analysis indicated that both male and female caregivers (i) responded similarly to the neurobehavioral impairments experienced by the injured relative and (ii) reported behavior having a direct effect on family functioning, which, in turn, increased psychological distress. However, the effect of disrupted family functioning was more influential on the level of distress in male caregivers than in female caregivers. Conclusion: Evidence was found for gender-specific pathways underlying the psychological distress of male versus female caregivers. Such findings can assist in tailoring family support strategies so that they cater for caregivers of both genders.	[Anderson, Malcolm I.] Avondale Coll Higher Educ, Fac Nursing & Hlth, Sydney, NSW, Australia; [Simpson, Grahame K.] Liverpool Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia; [Simpson, Grahame K.] Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [Morey, Peter J.] Avondale Coll Higher Educ, Fac Business, Cooranbong, NSW, Australia		Anderson, MI (corresponding author), Avondale Coll Higher Educ, Fac Nursing & Hlth, Sydney, NSW, Australia.	malcolm.anderson@avondale.edu.au	Simpson, Grahame K/W-1074-2019	Simpson, Grahame K/0000-0001-8156-9060; Anderson, Malcolm/0000-0003-2963-7497	Avondale College of Higher Education Foundation; Australasian Research Institute [050301]	This work was supported by the Avondale College of Higher Education Foundation and the Australasian Research Institute (grant 050301). The authors acknowledge the contributions made by the staff from the Brain Injury Rehabilitation Programmes in New South Wales in facilitating this project. The authors declare no conflicts of interest.	AKAIKE H, 1987, PSYCHOMETRIKA, V52, P317, DOI 10.1007/BF02294359; Anderson M. I., 2006, STRESS ITS IMPACT SO, P23; Anderson MI, 2009, BRAIN INJURY, V23, P931, DOI 10.3109/02699050903302336; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.88.3.588; Blake H, 2008, INT J THER REHABIL, V15, P263, DOI 10.12968/ijtr.2008.15.6.29878; Camplair PS, 1989, THESIS UMI ANN ARBOR, P153; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Chwalisz K, 1996, REHABIL PSYCHOL, V41, P91, DOI 10.1037/0090-5550.41.2.91; Derogatis L.R., 1993, BRIEF SYMPTOM INVENT; Derogatis LD, 1983, SCL 90R  ADM SCORING; ELLIOTT GR, 1982, STRESS HUMAN HLTH AN; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EPSTEIN NB, 1978, J MARRIAGE FAM COUNS, V4, P19, DOI 10.1111/j.1752-0606.1978.tb00537.x; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; FRISTAD MA, 1989, J MARITAL FAM THER, V15, P259, DOI 10.1111/j.1752-0606.1989.tb00808.x; Frosch S, 1997, BRAIN INJURY, V11, P891; Gan C, 2002, BRAIN INJURY, V16, P311, DOI 10.1080/02699050110104426; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Ho R., 2006, HDB UNIVARIATE MULTI; HOBFOLL SE, 1989, AM PSYCHOL, V44, P513, DOI 10.1037/0003-066X.44.3.513; Hoofien D, 2001, BRAIN INJURY, V15, P189; Joreskog K. G., 1993, LISREL 8 USERS REFER; Kabacoff R.I., 1990, J FAM PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Klose M, 2004, Arch Womens Ment Health, V7, P133, DOI 10.1007/s00737-004-0047-7; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kreutzer J., 1987, GEN HLTH HIST QUESTI; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEATHAM J, 1996, BRAIN INJURY, V10, P543; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Livingston LA, 2010, NEUROREHABILITATION, V27, P73, DOI 10.3233/NRE-2010-0582; MacCullum RC, 1980, PSYCHOL METHODS, V88, p[588, 130]; Munck IME., 1979, MODEL BUILDING COMP; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; SOLOMON C R, 1991, Brain Injury, V5, P253, DOI 10.3109/02699059109008096; Spielberger C.D., 1992, J FAMILY PSYCHOL, V6, P99, DOI [10.1037/0893-3200.6.2.99, DOI 10.1037/0893-3200.6.2.99]; Thompson HJ, 2009, J NEUROSCI NURS, V41, P148, DOI 10.1097/JNN.0b013e3181a23eda; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; Winstanley J, 2006, J HEAD TRAUMA REHAB, V21, P453, DOI 10.1097/00001199-200611000-00001; [No title captured]	50	25	26	1	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2013	28	6					453	463		10.1097/HTR.0b013e31825d6087			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	299AA	WOS:000330365200010	22832371				2022-02-06	
J	Franzblau, M; Gonzales-Portillo, C; Gonzales-Portillo, GS; Diamandis, T; Borlongan, MC; Tajiri, N; Borlongan, CV				Franzblau, Max; Gonzales-Portillo, Chiara; Gonzales-Portillo, Gabriel S.; Diamandis, Theo; Borlongan, Mia C.; Tajiri, Naoki; Borlongan, Cesar V.			Vascular damage: A persisting pathology common to Alzheimer's disease and traumatic brain injury	MEDICAL HYPOTHESES			English	Article							BARRIER BREAKDOWN; EXPRESSION; TARGET; PATHOPHYSIOLOGY; INFLAMMATION; HYPOTHESIS; CAVEOLIN-1; MECHANISM; GENES; MODEL	Alzheimer's disease (AD) and traumatic brain injury (TBI) are both significant clinical problems characterized by debilitating symptoms with limited available treatments. Interestingly, both neurological diseases are characterized by neurovascular damage. This impaired brain vasculature correlates with the onset of dementia, a symptom associated with hippocampal degeneration seen in both diseases. We posit that vascular damage is a major pathological link between TBI and AD, in that TBI victims are predisposed to AD symptoms due to altered brain vasculature; vice versa, the progression of AD pathology may be accelerated by TBI especially when the brain insult worsens hippocampal degeneration. Our hypothesis is supported by recent data reporting expedited AD pathology in presymptomatic transgenic AD mice subjected to TBI. If our hypothesis is correct, treatments targeted at repairing the vasculature may prove effective at treating both diseases and preventing the evolution of AD symptoms in TBI victims. (C) 2013 Elsevier Ltd. All rights reserved.	[Franzblau, Max; Gonzales-Portillo, Chiara; Gonzales-Portillo, Gabriel S.; Diamandis, Theo; Borlongan, Mia C.; Tajiri, Naoki; Borlongan, Cesar V.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33613 USA		Tajiri, N (corresponding author), 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	cborlong@health.usf.edu	Borlongan, Cesar/I-5696-2012	Borlongan, Cesar/0000-0002-2966-9782; Borlongan, Mia/0000-0003-3223-8374	Department of Neurosurgery and Brain Repair; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS071956-01]; Department of DefenseUnited States Department of Defense [W81XWH-11-1-0634]; James and Esther King Foundation for Biomedical Research Program; SanBio Inc.; KMPHC; NeuralStem Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER	This research was supported by the Department of Neurosurgery and Brain Repair funds. CVB is supported by National Institutes of Health, National Institute of Neurological Disorders and Stroke 1R01NS071956-01, Department of Defense W81XWH-11-1-0634, James and Esther King Foundation for Biomedical Research Program, SanBio Inc., KMPHC and NeuralStem Inc.	Aliev G, 2003, NEUROL RES, V25, P665, DOI 10.1179/016164103101201977; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Arendash GW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035751; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Borlongan CV, 2012, EXP NEUROL, V237, P142, DOI 10.1016/j.expneurol.2012.06.024; Borroni B, 2002, J NEUROL SCI, V203, P189, DOI 10.1016/S0022-510X(02)00289-7; Cirrito JR, 2008, NEURON, V58, P42, DOI 10.1016/j.neuron.2008.02.003; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; Davies TA, 2000, AMYLOID, V7, P153, DOI 10.3109/13506120009146830; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Duckworth JL, 2012, PATHOPHYSIOLOGY; Goeller J, 2012, J NEUROTRAUM, V29, P1970, DOI 10.1089/neu.2011.2224; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Iadecola C, 2010, STROKE, V41, pS127, DOI 10.1161/STROKEAHA.110.595488; Infante-Duarte C, 2008, J MOL MED, V86, P975, DOI 10.1007/s00109-007-0292-0; Jantaratnotai N, 2011, INT J ALZHEIMERS DIS; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Kellogg SL, 2011, SOC NEUR ABSTR, V561, P20; McKeating EG, 1998, ACT NEUR S, V71, P200; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; Miller G, 2011, SCIENCE, V333, P517, DOI 10.1126/science.333.6042.517; Mlekusch R, 2009, NEUROSCI LETT, V466, P135, DOI 10.1016/j.neulet.2009.09.043; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nag S, 2011, NEUROPATH APPL NEURO, V37, P3, DOI 10.1111/j.1365-2990.2010.01138.x; Nag S, 2009, NEUROPATH APPL NEURO, V35, P417, DOI 10.1111/j.1365-2990.2008.01009.x; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; Oby E, 2006, EPILEPSIA, V47, P1761, DOI 10.1111/j.1528-1167.2006.00817.x; Palmer JC, 2010, NEUROPATH APPL NEURO, V36, P487, DOI 10.1111/j.1365-2990.2010.01084.x; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; Skaper SD, 2007, ANN NY ACAD SCI, V1122, P23, DOI 10.1196/annals.1403.002; Stanimirovic DB, 2012, J CEREBR BLOOD F MET, V32, P1207, DOI 10.1038/jcbfm.2012.25; Tajiri N, 2011, INT C ALZH DRUG DISC, V12, P12; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; Tompkins P, 2013, J NEUROTRAUMA; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Verdile G, 2004, PHARMACOL RES, V50, P397, DOI 10.1016/j.phrs.2003.12.028; Walker DG, 2008, MICROVASC RES, V75, P411, DOI 10.1016/j.mvr.2007.10.004; WHITEHOUSE PJ, 1981, ANN NEUROL, V10, P122, DOI 10.1002/ana.410100203; Yesil Y, 2012, ARCH GERONTOL GERIAT, V55, P257, DOI 10.1016/j.archger.2011.09.016; Yeung D, 2008, ACTA NEUROPATHOL, V115, P635, DOI 10.1007/s00401-008-0364-4; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zlokovic BV, 2010, NAT MED, V16, P1370, DOI 10.1038/nm1210-1370	51	25	25	0	9	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	NOV	2013	81	5					842	845		10.1016/j.mehy.2013.09.012			4	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	257DI	WOS:000327363400023	24074832	Green Accepted			2022-02-06	
J	Rosenthal, JF; Erickson, JC				Rosenthal, Jacqueline F.; Erickson, Jay C.			Post-Traumatic Stress Disorder in US Soldiers With Post-Traumatic Headache	HEADACHE			English	Article						post-traumatic headache; post-traumatic stress disorder; concussion; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; MOTOR-VEHICLE ACCIDENTS; SERVICE MEMBERS; MIGRAINE; PREVALENCE; CONCUSSION; IRAQ; ASSOCIATION; DEPRESSION; VETERANS	ObjectiveTo determine the impact of post-traumatic stress disorder (PTSD) on headache characteristics and headache prognosis in U.S. soldiers with post-traumatic headache. BackgroundPTSD and post-concussive headache are common conditions among U.S. Army personnel returning from deployment. The impact of comorbid PTSD on the characteristics and outcomes of post-traumatic headache has not been determined in U.S. Army soldiers. MethodsA retrospective cohort study was conducted among 270 consecutive U.S. Army soldiers diagnosed with post-traumatic headache at a single Army neurology clinic. All subjects were screened for PTSD at baseline using the PTSD symptom checklist. Headache frequency and characteristics were determined for post-traumatic headache subjects with and without PTSD at baseline. Headache measures were reassessed 3 months after the baseline visit, and were compared between groups with and without PTSD. ResultsOf 270 soldiers with post-traumatic headache, 105 (39%) met screening criteria for PTSD. There was no significant difference between subjects with PTSD and those without PTSD with regard to headache frequency (17.2 vs 15.7 headache days per month; P=.15) or chronic daily headache (58.1% vs 52.1%; P=.34). Comorbid PTSD was associated with higher headache-related disability as measured by the Migraine Disability Assessment Score. Three months after the baseline neurology clinic visit, the number of subjects with at least 50% reduction in headache frequency was similar among post-traumatic headache cases with and without PTSD (25.9% vs 26.8%). ConclusionPTSD is prevalent among U.S. Army soldiers with post-traumatic headache. Comorbid PTSD is not associated with more frequent headaches or chronic daily headache in soldiers evaluated at a military neurology clinic for chronic post-traumatic headache. Comorbid PTSD does not adversely affect short-term headache outcomes, although prospective controlled trials are needed to better assess this relationship.	[Rosenthal, Jacqueline F.; Erickson, Jay C.] Madigan Army Med Ctr, Neurol Serv, Tacoma, WA 98431 USA		Rosenthal, JF (corresponding author), Martin Army Community Hosp, 7950 Martin Loop, Ft Benning, GA 31905 USA.	jacqueline.f.rosenthal.mil@mail.mil			Comprehensive National Neuroscience Program at the Uniformed Services University of Health Sciences, Bethesda, MD, USA	This study was supported by the Comprehensive National Neuroscience Program at the Uniformed Services University of Health Sciences, Bethesda, MD, USA.	Afari N, 2009, HEADACHE, V49, P1267, DOI 10.1111/j.1526-4610.2009.01517.x; [Anonymous], 2004, CEPHALALGIA, V24, p2nd, DOI DOI 10.1111/J.1468-2982.2003.00824.X; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; CHIBNALL JT, 1994, HEADACHE, V34, P357, DOI 10.1111/j.1526-4610.1994.hed3406357.x; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; HICKLING EJ, 1992, HEADACHE, V32, P147, DOI 10.1111/j.1526-4610.1992.hed3203147.x; Hickling EJ, 1992, HEADACHE Q-CURR TREA, V3, P285; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Management of Concussion/mTBI Working Group, 2009, J REHABIL RES DEV, V46, pCP1; Packard RC, 2008, CURR PAIN HEADACHE R, V12, P67, DOI 10.1007/s11916-008-0013-6; Peterlin BL, 2008, HEADACHE, V48, P517, DOI 10.1111/j.1526-4610.2008.00917.x; Peterlin BL, 2011, HEADACHE, V51, P860, DOI 10.1111/j.1526-4610.2011.01907.x; Peterlin BL, 2011, CEPHALALGIA, V31, P235, DOI 10.1177/0333102410378051; Peterlin BL, 2009, HEADACHE, V49, P541, DOI 10.1111/j.1526-4610.2009.01368.x; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Rosenthal JF, 2011, HEADACHE, V51, P3; Ruff Robert L, 2010, F1000 Med Rep, V2, P64, DOI 10.3410/M2-64; Seifert TD, 2010, CURR PAIN HEADACHE R, V14, P292, DOI 10.1007/s11916-010-0117-7; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tatrow K, 2003, HEADACHE, V43, P755, DOI 10.1046/j.1526-4610.2003.03133.x; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2012, HEADACHE, V52, P732, DOI 10.1111/j.1526-4610.2012.02112.x; Theeler BJ, 2012, CURR TREAT OPTION NE, V14, P36, DOI 10.1007/s11940-011-0157-2; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Waung MW, 2012, CURR PAIN HEADACHE R, V16, P533, DOI 10.1007/s11916-012-0294-7; Weathers F.W., 1993, ANN CONV INT SOC TRA; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604	33	25	26	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	NOV	2013	53	10					1564	1572		10.1111/head.12200			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	255PZ	WOS:000327253600005	24001181				2022-02-06	
J	Roberts, DJ; Jenne, CN; Leger, C; Kramer, AH; Gallagher, CN; Todd, S; Parney, IF; Doig, CJ; Yong, VW; Kubes, P; Zygun, DA				Roberts, Derek J.; Jenne, Craig N.; Leger, Caroline; Kramer, Andreas H.; Gallagher, Clare N.; Todd, Stephanie; Parney, Ian F.; Doig, Christopher J.; Yong, V. Wee; Kubes, Paul; Zygun, David A.			A Prospective Evaluation of the Temporal Matrix Metalloproteinase Response after Severe Traumatic Brain Injury in Humans	JOURNAL OF NEUROTRAUMA			English	Article						brain injuries; cerebrospinal fluid; craniocerebral trauma; matrix metalloproteinase; microdialysis	BARRIER DISRUPTION; BLOOD; MATRIX-METALLOPROTEINASE-9; EXPRESSION; EDEMA; INHIBITION; OVEREXPRESSION; MICRODIALYSIS; INFLAMMATION; MEDIATORS	Accumulating pre-clinical data suggests that matrix metalloproteinase (MMP) expression plays a critical role in the pathophysiology of secondary brain injury. We conducted a prospective multimodal monitoring study in order to characterize the temporal MMP response after severe traumatic brain injury (TBI) in eight critically ill humans and its relationship with outcomes. High-cutoff, cerebral microdialysis (n=8); external ventricular drainage (n=3); and arterial and jugular venous bulb catheters were used to collect microdialysate, cerebrospinal fluid, and arterial and jugular bulb blood over 6 days. Levels of MMP-8 and -9 were initially high in microdialysate and then gradually declined over time. After these MMPs decreased, a spike in the microdialysate levels of MMP-2 and -3 occurred, followed by a gradual rise in the microdialysate concentration of MMP-7. Use of generalized estimating equations suggested that MMP-8 concentration in microdialysate was associated with mortality (p=0.019) and neurological outcome at hospital discharge (p=0.013). Moreover, the mean microdialysate concentration of MMP-8 was 2.4-fold higher among those who died after severe TBI than in those who survived. Mean microdialysate levels of MMP-8 also rose with increasing intracranial pressure (ICP), whereas those of MMP-7 decreased with increasing cerebral perfusion pressure (CPP). Significant changes in the mean microdialysate concentrations of MMP-1, -2, -3, and -9 and MMP-1, -2, -3, -7, and -9 also occurred with increases in microdialysate glucose and the lactate/pyruvate ratio, respectively. These results imply that monitoring of MMPs following severe TBI in humans is feasible, and that their expression may be associated with clinical outcomes, ICP, CPP, and cerebral metabolism.	[Roberts, Derek J.] Univ Calgary, Dept Surg, Calgary, AB, Canada; [Roberts, Derek J.; Doig, Christopher J.; Zygun, David A.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Roberts, Derek J.; Jenne, Craig N.; Leger, Caroline; Kramer, Andreas H.; Todd, Stephanie; Doig, Christopher J.; Kubes, Paul] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Kramer, Andreas H.; Gallagher, Clare N.; Yong, V. Wee] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Kramer, Andreas H.; Gallagher, Clare N.; Yong, V. Wee; Kubes, Paul] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Yong, V. Wee] Univ Calgary, Dept Oncol, Calgary, AB, Canada; [Kubes, Paul] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Jenne, Craig N.; Leger, Caroline; Kubes, Paul] Univ Calgary, Calvin Phoebe & Joan Snyder Inst Chron Dis, Calgary, AB, Canada; Foothills Med Ctr, Calgary, AB, Canada; [Parney, Ian F.] Mayo Clin, Coll Med, Dept Neurol Surg, Rochester, MN USA; [Zygun, David A.] Univ Alberta, Div Crit Care Med, Edmonton, AB T6G 2B7, Canada		Zygun, DA (corresponding author), Univ Alberta, Div Crit Care Med, 8440-112 St, Edmonton, AB T6G 2B7, Canada.	zygun@ualberta.ca	Doig, Christopher/AAC-7949-2020; Roberts, Derek J./L-6229-2019	Doig, Christopher/0000-0002-8576-9139; Roberts, Derek J./0000-0001-6111-6291; Parney, Ian/0000-0002-9702-8047; Yong, V. Wee/0000-0002-2600-3563	Alberta Innovates Health Solutions; Canadian Intensive Care Foundation; Snyder Chair for Translational Research in Critical Care Medicine; Alberta Innovates - Health Solutions Clinician Fellowship Award; Clinician Investigator and Surgeon Scientist Programs at the University of Calgary	This work was supported by grants from Alberta Innovates Health Solutions (formally the Alberta Heritage Foundation for Medical Research [awarded to Dr. Zygun]), the Canadian Intensive Care Foundation (awarded to Dr. Zygun), and the Snyder Chair for Translational Research in Critical Care Medicine (awarded to Dr. Kubes). Dr. Roberts is supported by an Alberta Innovates - Health Solutions Clinician Fellowship Award and funding from the Clinician Investigator and Surgeon Scientist Programs at the University of Calgary. Dr. Jenne is funded by an Alberta Innovates Health Solutions Postdoctoral Fellowship Award.	Bar-Or A, 2003, BRAIN, V126, P2738, DOI 10.1093/brain/awg285; Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bilousova TV, 2006, J NEUROCHEM, V97, P44, DOI 10.1111/j.1471-4159.2006.03701.x; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chen JL, 2011, STROKE, V42, P445, DOI 10.1161/STROKEAHA.110.596486; duPont NC, 2005, J REPROD IMMUNOL, V66, P175, DOI 10.1016/j.jri.2005.03.005; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Falo MC, 2008, J NEUROTRAUM, V25, P769, DOI 10.1089/neu.2008.0511; Folgueras AR, 2008, J BIOL CHEM, V283, P9465, DOI 10.1074/jbc.M709522200; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gurney KJ, 2006, NEUROBIOL DIS, V23, P87, DOI 10.1016/j.nbd.2006.02.006; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hutchinson PJA, 2002, ACT NEUR S, V81, P359; JENNETT B, 1975, LANCET, V1, P480; Kawai N, 2003, J NEUROTRAUM, V20, P649, DOI 10.1089/089771503322144563; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Kumari R, 2011, J NEUROCHEM, V119, P1029, DOI 10.1111/j.1471-4159.2011.07487.x; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Nygardas PT, 2002, CLIN EXP IMMUNOL, V128, P245, DOI 10.1046/j.1365-2249.2002.01855.x; Reyes R, 2009, J NEUROSURG, V110, P1218, DOI 10.3171/2008.8.JNS08382; Roberts DJ, 2008, EXPERT OPIN DRUG MET, V4, P1245, DOI 10.1517/17425255.4.10.1245 ; ROSENBERG GA, 1992, BRAIN RES, V576, P203, DOI 10.1016/0006-8993(92)90681-X; Szklarczyk A, 2008, FASEB J, V22, P3757, DOI 10.1096/fj.07-101402; TEASDALE G, 1974, LANCET, V2, P81; Van Hove I, 2012, J NEUROCHEM, V123, P203, DOI 10.1111/j.1471-4159.2012.07900.x; Vilalta A, 2008, ACTA NEUROCHIR SUPPL, V102, P415, DOI 10.1007/978-3-211-85578-2_81; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Vittinghoff E, 2012, REGRESSION METHODS B, P261; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Zhang HQ, 2010, NEUROSCIENTIST, V16, P156, DOI 10.1177/1073858409355830	42	25	26	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2013	30	20					1717	1726		10.1089/neu.2012.2841			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	232JW	WOS:000325491000004	23725031				2022-02-06	
J	Si, DW; Wang, HT; Wang, Q; Zhang, CY; Sun, JY; Wang, ZG; Zhang, ZF; Zhang, YX				Si, Daowen; Wang, Haitao; Wang, Qian; Zhang, Chengyun; Sun, Jingyu; Wang, Zhigang; Zhang, Zuofeng; Zhang, Yuxin			Progesterone treatment improves cognitive outcome following experimental traumatic brain injury in rats	NEUROSCIENCE LETTERS			English	Article						Progesterone; Traumatic brain injury; Cognitive function; Inflammation; Apoptosis	SEX STEROID-HORMONES; HEAD-INJURY; CNS INJURY; ALLOPREGNANOLONE; NEUROPROTECTION; EXPRESSION; MODEL	Progesterone (FROG) has recently been shown to have a neuroprotective effect and improve cognitive outcome in animal models of traumatic brain injury (TBI). However, the precise mechanisms remain unclear. This study was aimed to investigate the inhibitory effects of PROG on inflammation and apoptosis in the hippocampus after TBI and its influence on the cognitive outcome. In this study, the model of TBI was established by modified Feeney's weight-dropping method. The PROG was given in a dose of 16 mg/kg by intraperitoneal injection 1 h post injury and subsequent injections subcutaneously at 6 h and 12 h after TBI. Brain samples were extracted at 24h after trauma. The expression of COX-2 and caspase-3 was measured by immunohistochemistry and western blot technique. The cognitive outcome was assessed by Morris water maze test (MWM). The results revealed that the expression of COX-2 and caspase-3 in TBI-PROG group was distinctly less than those of the TB! group (p < 0.05). In addition, the performance of Morris water maze showed that progesterone treatment exhibited shorter latencies, more platform crossings and more time swimming in the quadrant area in the TBI + PROG rats compared to the TBI rats. In conclusion, post-TBI PROG administration may attenuate inflammation and apoptosis in the hippocampus, and this may be one of the mechanisms by which PROG improves cognitive outcome following TBI. (C) 2013 Elsevier Ireland Ltd. All rights reserved.	[Si, Daowen; Wang, Haitao; Wang, Qian; Zhang, Chengyun; Zhang, Zuofeng; Zhang, Yuxin] Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Hebei Province, Peoples R China; [Sun, Jingyu] Tangshan Fengrun Peoples Hosp, Dept Osteol, Tangshan 063000, Hebei Province, Peoples R China; [Wang, Zhigang] Tangshan Fengrun Second Peoples Hosp, Dept Clin Lab, Tangshan 063000, Hebei Province, Peoples R China		Zhang, YX (corresponding author), Hebei United Univ, Sch Basic Med Sci, Tangshan 063000, Hebei Province, Peoples R China.	sidaowen@yahoo.com.cn; jpzyx@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81201048]; Natural Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei Province [H2012401009]; Tangshan Science and Technology Research and Development Program [12140209a-55]; Higher School Science Research Project of Education Department of Hebei Province, China [Z2011168]	This work was supported by National Natural Science Foundation of China (81201048); Natural Science Foundation of Hebei Province (H2012401009); Tangshan Science and Technology Research and Development Program (12140209a-55); Higher School Science Research Project of Education Department of Hebei Province (Z2011168), China.	Barha C.K., EXPT NEUROLOGY, V231; Berry C, 2011, AM J SURG, V201, P429, DOI 10.1016/j.amjsurg.2010.10.008; Cooke PS, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00108; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Garay LI, 2012, NEUROSCIENCE, V226, P40, DOI 10.1016/j.neuroscience.2012.09.032; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Ishrat T, 2010, EXP NEUROL, V226, P183, DOI 10.1016/j.expneurol.2010.08.023; Labombarda F, 2010, NEUROIMMUNOMODULAT, V17, P146, DOI 10.1159/000258709; Li ZY, 2012, J NEUROTRAUM, V29, P343, DOI 10.1089/neu.2011.1807; Luoma JI, 2012, J STEROID BIOCHEM, V131, P30, DOI 10.1016/j.jsbmb.2011.11.002; Orr PI, 2009, PHARMACOL BIOCHEM BE, V93, P177, DOI 10.1016/j.pbb.2009.05.012; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Shahrokhi N, 2012, PAK J PHARM SCI, V25, P219; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Vagnerova K, 2008, ANESTH ANALG, V107, P201, DOI 10.1213/ane.0b013e31817326a5; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wali B, 2011, RESTOR NEUROL NEUROS, V29, P61, DOI 10.3233/RNN-2011-0579; Wang YS, 2009, J NEUROL SCI, V285, P172, DOI 10.1016/j.jns.2009.06.034; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	30	25	28	1	19	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 11	2013	553						18	23		10.1016/j.neulet.2013.07.052			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	239FT	WOS:000326008700004	23954829				2022-02-06	
J	Aziz, H; Rhee, P; Pandit, V; Ibrahim-Zada, I; Kulvatunyou, N; Wynne, J; Zangbar, B; O'Keeffe, T; Tang, A; Friese, RS; Joseph, B				Aziz, Hassan; Rhee, Peter; Pandit, Viraj; Ibrahim-Zada, Irada; Kulvatunyou, Narong; Wynne, Julie; Zangbar, Bardiya; O'Keeffe, Terence; Tang, Andrew; Friese, Randall S.; Joseph, Bellal			Mild and moderate pediatric traumatic brain injury: Replace routine repeat head computed tomography with neurologic examination	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Pediatric traumatic brain injury; repeat head CT; neurological examination; progression on repeat head CT; neurosurgical intervention	CT; UTILITY; CHILDREN	BACKGROUND: Opinion is divided on the role of routine repeat head computed tomography (RHCT) for guiding clinical management in pediatric patients with blunt head trauma. We hypothesize that routine RHCT does not lead to change in management in mild and moderate traumatic brain injury (TBI). METHODS: This is a 3-year retrospective study of all patients of age 2 years to 18 years with blunt TBI admitted to our Level 1 trauma center with an abnormal head CT. Indications for RHCT (routine vs. neurologic deterioration) and their findings (progression or improvement) were recorded. Neurosurgical intervention was defined as extraventricular drain placement, craniectomy, or craniotomy. Primary outcome was a change in management after RHCT. RESULTS: A total of 291 pediatric patients were identified; of which 191 patients received an RHCT. Routine RHCT did not lead to neurosurgical intervention in the mild and moderate TBI group. In patients who received RHCT due to neurologic decline (n = 7), radiographic progression was seen on 85% of the patients (n = 6), with subsequent neurosurgical interventions in three patients. Two of these patients had a Glasgow Coma Scale (GCS) score of less than 8 at admission. CONCLUSION: Our study showed that the neurologic examination can be trusted and is reliable in pediatric blunt TBI patients in determining when an RHCT scan is necessary. We recommend that RHCT is required routinely in patients with intracranial hemorrhage with GCS score of 8 or less and in patients with GCS greater than 8 and that RHCT be performed only when there are clinical indications. Copyright (C) 2013 by Lippincott Williams & Wilkins	[Aziz, Hassan; Rhee, Peter; Pandit, Viraj; Ibrahim-Zada, Irada; Kulvatunyou, Narong; Wynne, Julie; Zangbar, Bardiya; O'Keeffe, Terence; Tang, Andrew; Friese, Randall S.; Joseph, Bellal] Univ Arizona, Dept Surg, Div Trauma, Tucson, AZ 85727 USA		Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85727 USA.	bjoseph@surgery.arizona.edu	Aziz, Hassan/ABA-5681-2021; Zangbar, Bardiya/K-7147-2014	Aziz, Hassan/0000-0003-0406-1946; Zangbar, Bardiya/0000-0003-1215-1693			Brenner DJ, AJR AM J ROENTGENOL, V176, P289; Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Figg RE, 2006, PEDIATR SURG INT, V22, P215, DOI 10.1007/s00383-005-1560-0; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Joseph B, 2013, AM SURG; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; LEVI L, 1991, BRIT J NEUROSURG, V5, P617, DOI 10.3109/02688699109002885; da Silva PSL, 2008, J TRAUMA, V65, P1293, DOI 10.1097/TA.0b013e318156866c; Mattox K, 2012, TRAUMA; Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd; Slovis TL, 2002, RADIOLOGY, V223, P5, DOI 10.1148/radiol.2231012100; Stippler M, 2012, EMERG MED J, V29, P528, DOI 10.1136/emermed-2011-200162; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89	19	25	26	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	OCT	2013	75	4					550	554		10.1097/TA.0b013e3182a53a77			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	300IK	WOS:000330457400002	24064865				2022-02-06	
J	Nalder, E; Fleming, J; Cornwell, P; Shields, C; Foster, M				Nalder, Emily; Fleming, Jennifer; Cornwell, Petrea; Shields, Cassandra; Foster, Michele			Reflections on life: Experiences of individuals with brain injury during the transition from hospital to home	BRAIN INJURY			English	Article						Community integration; life course; lived experience	POSTTRAUMATIC GROWTH; ADJUSTMENT; IDENTITY	Background: The transition from hospital to home has been described as a distinct rehabilitation phase for individuals with brain injury. As most research to date has quantitatively measured outcomes or used a sample with mixed brain injury diagnoses, less is known about the experience of transition following traumatic brain injury (TBI). Aims: This study aimed to examine the lived experiences of individuals with TBI during the first 6 months following discharge from hospital. Design: A qualitative investigation was conducted with 16 individuals with TBI using semi-structured interviews. Data analysis: Data were analysed thematically using a Framework approach. Results: Transition experiences were characterized by a desire to return to normality and a changed perspective on life, by accepting change or altering priorities. The process of transition was dynamic as individuals experienced the dominant themes in cyclical patterns. Conclusions: Research has highlighted the significant adjustment for individuals with TBI, particularly in relation to identity change, appraisal and coping. The themes of wanting normality and changing life perspective which were dominant in the current study highlight the significance of the transition phase in the process of adjustment and that transition is characterized by adapting to a new normality.	[Nalder, Emily; Fleming, Jennifer; Shields, Cassandra] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia; [Nalder, Emily; Fleming, Jennifer] Queensland Hlth, Ctr Functioning & Hlth Res, Brisbane, Qld, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Queensland Hlth, Occupat Therapy Dept, Brisbane, Qld 4102, Australia; [Cornwell, Petrea] Griffith Univ, Griffith Hlth Inst, Brisbane, Qld 4111, Australia; [Cornwell, Petrea] Queensland Hlth, Metro North Hlth Serv Dist, Brisbane, Qld, Australia; [Foster, Michele] Univ Queensland, Sch Social Work & Human Serv, Brisbane, Qld, Australia		Nalder, E (corresponding author), Baycrest Hosp, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	emily.nalder@uqconnect.edu.au	Cornwell, Petrea/AAE-5547-2019		Australian Research Council Linkage GrantAustralian Research Council [LP0776294]; Department of Communities (Disability Services); Acquired Brain Injury Outreach service	We wish to acknowledge the funding support for this project by way of an Australian Research Council Linkage Grant (LP0776294) and partner organizations Department of Communities (Disability Services) and Acquired Brain Injury Outreach service.	Byrne-Armstrong H., 2001, CRITICAL MOMENTS QUA; Carroll E, 2011, NEUROPSYCHOL REHABIL, V21, P289, DOI 10.1080/09602011.2011.555972; Chamberlain DJ, 2006, J ADV NURS, V54, P407, DOI 10.1111/j.1365-2648.2006.03840.x; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Creswell JW, 2017, DESIGNING CONDUCTING, V3rd; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Elder G.H., 2009, CRAFT LIFE COURSE RE; ELDER GH, 1975, ANNU REV SOCIOL, V1, P165, DOI 10.1146/annurev.so.01.080175.001121; FORTUNE N, 1999, DEFINITION INCIDENCE; Goodman J., 2006, COUNSELING ADULTS TR; Gracey F, 2009, NEUROPSYCHOL REHABIL, V19, P867, DOI 10.1080/09602010903027763; Hawley CA, 2008, BRAIN INJURY, V22, P427, DOI 10.1080/02699050802064607; Heller W, 2006, J REHABIL, V72, P44; Levack WMM, 2010, DISABIL REHABIL, V32, P986, DOI 10.3109/09638281003775394; MARKUS H, 1986, AM PSYCHOL, V41, P954, DOI 10.1037/0003-066X.41.9.954; McGrath JC, 2006, BRAIN INJURY, V20, P767, DOI 10.1080/02699050600664566; Muenchberger H, 2008, BRAIN INJURY, V22, P979, DOI 10.1080/02699050802530532; Nalder E, 2012, BRAIN INJURY, V26, P1381, DOI 10.3109/02699052.2012.676225; Nalder E, 2012, J HEAD TRAUMA REHAB, V27, P143, DOI 10.1097/HTR.0b013e3182168fb1; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; Padilla R, 2003, AM J OCCUP THER, V57, P413, DOI 10.5014/ajot.57.4.413; Patton M.Q., 1990, QUALITATIVE EVALUATI; Powell T, 2007, BRAIN INJURY, V21, P31, DOI 10.1080/02699050601106245; Powers L., 2006, J DISABIL POLICY STU, V17, P66, DOI DOI 10.1177/10442073060170020301; QSR International Pty Ltd, 2010, NVIVO QUAL DAT AN SO; Ritchie J., 2003, QUALITATIVE RES PRAC; Rittman M, 2007, TOP STROKE REHABIL, V14, P21, DOI 10.1310/tsr1402-21; Shotton L, 2007, BRAIN INJURY, V21, P857, DOI 10.1080/02699050701481621; Turner B, 2007, BRAIN INJURY, V21, P1119, DOI 10.1080/02699050701651678; Turner B, 2011, NEUROPSYCHOL REHABIL, V21, P64, DOI 10.1080/09602011.2010.527747; Turner BJ, 2008, DISABIL REHABIL, V30, P1153, DOI 10.1080/09638280701532854	32	25	25	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2013	27	11					1294	1303		10.3109/02699052.2013.823560			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	217YQ	WOS:000324399800009	23924357				2022-02-06	
J	Chan, V; Zagorski, B; Parsons, D; Colantonio, A				Chan, Vincy; Zagorski, Brandon; Parsons, Daria; Colantonio, Angela			Older adults with acquired brain injury: a population based study	BMC GERIATRICS			English	Article						Brain injury; Epidemiology; Outcomes	ALZHEIMERS-DISEASE; MAJOR DEPRESSION; EPIDEMIOLOGY; TRENDS; SYSTEM; TUMORS; RISK; AGE	Background: Acquired brain injury (ABI), which includes traumatic (TBI) and non-traumatic brain injury (nTBI), is a leading cause of death and disability worldwide. The objective of this study was to examine the trends, characteristics, cause of brain injury, and discharge destination of hospitalized older adults aged 65 years and older with an ABI diagnosis in a population with universal access to hospital care. The profile of characteristics of patients with TBI and nTBI causes of injury was also compared. Methods: A population based retrospective cohort study design with healthcare administrative databases was used. Data on acute care admissions were obtained from the Discharge Abstract Database and patients were identified using the International Classification of Diseases - Version 10 codes for Ontario, Canada from April 1, 2003 to March 31, 2010. Older adults were examined in three age groups -65 to 74, 75 to 84, and 85+ years. Results: From 2003/04 to 2009/10, there were 14,518 episodes of acute care associated with a TBI code and 51, 233 episodes with a nTBI code. Overall, the rate of hospitalized TBI and nTBI episodes increased with older age groups. From 2007/08 to 2009/10, the percentage of patients that stayed in acute care for 12 days or more and the percentage of patients with delayed discharge from acute care increased with age. The most common cause of TBI was falls while the most common type of nTBI was brain tumours. The percentage of patients discharged to long term care and complex continuing care increased with age and the percentage discharged home decreased with age. In-hospital mortality also increased with age. Older adults with TBI and nTBI differed significantly in demographic and clinical characteristics and discharge destination from acute care. Conclusions: This study showed an increased rate of acute care admissions for both TBI and nTBI with age. It also provided additional support for falls prevention strategies to prevent injury leading to cognitive disability with costly human and economic consequences. Implications for increased numbers of people with ABI are discussed.	[Chan, Vincy; Colantonio, Angela] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON M5G 2A2, Canada; [Chan, Vincy; Colantonio, Angela] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5G 1V7, Canada; [Zagorski, Brandon] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON M5T 3M6, Canada; [Parsons, Daria] Ontario Neurotrauma Fdn, Toronto, ON M4P 2Y3, Canada; [Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5G 1V7, Canada		Colantonio, A (corresponding author), Univ Hlth Network, Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada.	angela.colantonio@utoronto.ca	Chan, Vincy/AAA-7813-2020	Chan, Vincy/0000-0002-6884-044X; Colantonio, Angela/0000-0003-2094-4765	Ontario Neurotrauma Foundation [2010-ABI-TRAJECT-869]; Toronto Rehabilitation Institute Foundation; Ministry of Health and Long-Term Care (MOHLTC)Ministry of Health and Long-Term Care, Ontario; Saunderson Family Chair in Acquired Brain Injury Research; Canadian Institutes of Health Research Chair in Gender, Work and HealthCanadian Institutes of Health Research (CIHR) [CGW-126580]; Jane Gillett Pediatric ABI Studentship through the Ontario Neurotrauma Foundation; Canadian Institutes of Health Research and Pediatric Oncology Group of Ontario; Brain Canada-CIBC Brain Cancer Training Award from Brain Canada; CIBC	Funding for this study was obtained from the Ontario Neurotrauma Foundation (#2010-ABI-TRAJECT-869), the Toronto Rehabilitation Institute Foundation, and a grant from the Ministry of Health and Long-Term Care (MOHLTC) to the Toronto Rehabilitation Institute, University Health Network. Dr. Colantonio received support through the Saunderson Family Chair in Acquired Brain Injury Research and through a Canadian Institutes of Health Research Chair in Gender, Work and Health (#CGW-126580). Vincy Chan received support from the Jane Gillett Pediatric ABI Studentship through the Ontario Neurotrauma Foundation, the Doctoral Research Award from the Canadian Institutes of Health Research and Pediatric Oncology Group of Ontario, and a Brain Canada-CIBC Brain Cancer Training Award from Brain Canada and CIBC. We would like to thank the MOHLTC for providing us with the data and Ms. Sandra Sokoloff for her comments and assistance in the editing process of this manuscript.	Arora RS, 2010, EUR J CANCER, V46, P1607, DOI 10.1016/j.ejca.2010.02.007; Canadian Institute for Health Information, DISCH ABSTR DAT MET; Canadian Institute for Health Information, 2009, ALT LEV CAR CAN ALT LEV CAR CAN; Cancer Care Ontario, CANC FACT AG DISTR B; Cancer Care Ontario, CANC ONT OV STAT REP; Centers for Disease Control and Prevention, INJ DAT RES TOOLS FR; Chan V, 2013, CAN J AGING, V32, P278, DOI 10.1017/S0714980813000317; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen AY, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-16; Chen AY, 2011, EMERG THEMES EPIDEMI, V8, DOI 10.1186/1742-7622-8-4; Colantonio A, 2012, LHIN REPORTS; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Colantonio A, 2011, J REHABIL MED, V43, P311, DOI 10.2340/16501977-0783; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Croxford R., 2006, CANADIAN I HLTH INFO; Faul M, 2010, TRAUMATIC BRAIN INJU; Fletcher AE, 2007, BRAIN INJURY, V21, P691, DOI 10.1080/02699050701426873; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Harvey LA, 2012, INJURY, V7, P188; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Lonn S, 2004, INT J CANCER, V108, P450, DOI 10.1002/ijc.11578; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MAO Y, 1991, CAN MED ASSOC J, V145, P1583; Menzel JC, 2008, BRAIN INJURY, V22, P375, DOI 10.1080/02699050802001492; National Cancer Institute, 1975, AG ADJ SEER INC RAT; Pickett William, 2004, Chronic Dis Can, V25, P32; Raad J, 2007, ARCH PHYS MED REHAB, V94, P1426; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; *STAT CAN, POP SEX AG GROUP PRO; *STAT CAN, PROJ POP AG GROUP AC; Statistics Canada, POP YEAR PROV TERR; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; World Health Organization, 2006, TRAUM BRAIN INJ NEUR, P164	41	25	25	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2318			BMC GERIATR	BMC Geriatr.	SEP 23	2013	13								97	10.1186/1471-2318-13-97			12	Geriatrics & Gerontology; Gerontology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Geriatrics & Gerontology	228RX	WOS:000325206900001	24060144	gold, Green Published			2022-02-06	
J	Head, J; Helton, WS				Head, James; Helton, William S.			Perceptual decoupling or motor decoupling?	CONSCIOUSNESS AND COGNITION			English	Article						Motor control; Motor decoupling; Perceptual decoupling; Response inhibition; SART; Sustained attention	TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; RESPONSE-INHIBITION; VIGILANCE; MIND; TASK; LAPSES; EXPERIENCE; AWARENESS; FAILURES	The current investigation was conducted to elucidate whether errors of commission in the Sustained Attention to Response Task (SARI) are indicators of perceptual or motor decoupiing. Twenty-eight participants completed SARTs with motor and perceptual aspects of the task manipulated. The participants completed four different SART blocks whereby stimuli location uncertainty and stimuli acquisition were manipulated. In previous studies of more traditional sustained attention tasks stimuli location uncertainty reduces sustained attention performance. In the case of the SARI the motor manipulation (stimuli acquisition), but not the perceptual manipulation (stimuli location uncertainty) significantly reduced commission errors. The results suggest that the majority of SARI commission errors are likely to be indicators of motor decoupling not necessarily perceptual decoupling. (C) 2013 Elsevier Inc. All rights reserved.	[Head, James; Helton, William S.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand		Helton, WS (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	Deak.Helton@canterbury.ac.nz					ADAMS JA, 1964, J EXP PSYCHOL, V67, P127, DOI 10.1037/h0046473; Boulinguez P, 2008, J NEUROPHYSIOL, V99, P1572, DOI 10.1152/jn.01198.2007; Boulinguez P, 2009, CLIN NEUROPHYSIOL, V120, P730, DOI 10.1016/j.clinph.2009.02.167; Chan RCK, 2005, CLIN REHABIL, V19, P188, DOI 10.1191/0269215505cr838oa; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050110034325; Christoff K, 2009, P NATL ACAD SCI USA, V106, P8719, DOI 10.1073/pnas.0900234106; Chun MM, 2011, ANNU REV PSYCHOL, V62, P73, DOI 10.1146/annurev.psych.093008.100427; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Greene CM, 2009, NEUROPSYCHOLOGIA, V47, P591, DOI 10.1016/j.neuropsychologia.2008.10.003; Head J, 2012, CONSCIOUS COGN, V21, P1617, DOI 10.1016/j.concog.2012.08.009; Head J, 2012, EXP BRAIN RES, V216, P103, DOI 10.1007/s00221-011-2914-6; Helton WS, 2008, ACTA PSYCHOL, V129, P18, DOI 10.1016/j.actpsy.2008.04.002; Helton WS, 2011, EXP BRAIN RES, V212, P429, DOI 10.1007/s00221-011-2749-1; Helton WS, 2011, EXP BRAIN RES, V209, P401, DOI 10.1007/s00221-011-2563-9; Helton WS, 2011, PSYCHOL RES-PSYCH FO, V75, P384, DOI 10.1007/s00426-010-0316-1; Helton WS, 2010, CONSCIOUS COGN, V19, P77, DOI 10.1016/j.concog.2010.01.006; Helton WS, 2009, CONSCIOUS COGN, V18, P600, DOI 10.1016/j.concog.2009.06.002; Helton WS, 2009, J CLIN EXP NEUROPSYC, V31, P39, DOI 10.1080/13803390801978856; Helton WS, 2005, BRIT J PSYCHOL, V96, P249, DOI 10.1348/000712605X38369; Hong SL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011461; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2004, NEUROPSYCHOL REHABIL, V14, P89, DOI 10.1080/09602010343000110; Mrazek MD, 2011, J EXP SOC PSYCHOL, V47, P1243, DOI 10.1016/j.jesp.2011.05.011; O'Connell RG, 2006, NEUROPSYCHOL REHABIL, V16, P653, DOI 10.1080/09602010500200250; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Peebles D, 2004, PROCEEDINGS OF THE SIXTH INTERNATIONAL CONFERENCE ON COGNITIVE MODELING, P231; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Seli P., 2012, BEHAV RES METHODS; Seli P, 2012, CAN J EXP PSYCHOL, V66, P44, DOI 10.1037/a0025111; Seli P, 2012, CONSCIOUS COGN, V21, P277, DOI 10.1016/j.concog.2011.09.017; Smallwood J, 2004, CONSCIOUS COGN, V13, P657, DOI 10.1016/j.concog.2004.06.003; Smallwood J, 2007, COGNITION EMOTION, V21, P816, DOI 10.1080/02699930600911531; Smallwood J, 2007, PSYCHON B REV, V14, P527, DOI 10.3758/BF03194102; Smallwood J, 2006, PSYCHOL BULL, V132, P946, DOI 10.1037/0033-2909.132.6.946; Stevenson H, 2011, BRAIN COGNITION, V77, P215, DOI 10.1016/j.bandc.2011.08.007; Wardack C., 2012, EUROPEAN J NEUROSCIE, P1; Warm JS, 2008, HUM FACTORS, V50, P433, DOI 10.1518/001872008X312152; WARM JS, 1996, HUM FAC TRANSP, P183; Wickens C. D., 1993, WORKLOAD TRANSITION, P139	41	25	25	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8100	1090-2376		CONSCIOUS COGN	Conscious. Cogn.	SEP	2013	22	3					913	919		10.1016/j.concog.2013.06.003			7	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	235SG	WOS:000325740400025	23838467				2022-02-06	
J	Parra, MW; Zucker, L; Johnson, ES; Gullett, D; Avila, C; Wichner, ZA; Kokaram, CR				Parra, Michael W.; Zucker, Lloyd; Johnson, Eric S.; Gullett, Diane; Avila, Cristina; Wichner, Zachary A.; Kokaram, Candace R.			Dabigatran bleed risk with closed head injuries: are we prepared? Clinical article	JOURNAL OF NEUROSURGERY			English	Article						dabigatran; warfarin; closed head injury; anticoagulation reversal protocol; traumatic brain injury	TRAUMATIC INTRACRANIAL HEMORRHAGE; ATRIAL-FIBRILLATION; STROKE PREVENTION; WARFARIN REVERSAL; SINGLE-CENTER; ETEXILATE; MORTALITY; PHARMACODYNAMICS; PHARMACOKINETICS; ANTICOAGULATION	Object. The direct thrombin inhibitor dabigatran has recently been approved in the US as an alternative to warfarin. The lack of guidelines, protocols, and an established specific antidote to reverse the anticoagulation effect of dabigatran potentially increases the rates of morbidity and mortality in patients with closed head injury (CHI). Confronted with this new problem, the authors reviewed their initial clinical experience. Methods. The authors retrospectively reviewed all cases of adult patients (age >= 18 years) who sustained CHI secondary to ground-level falls and who presented to the authors' provisional regional Level I trauma center between February 2011 and May 2011. The authors divided these patients into 3 groups based on anticoagulant therapy: dabigatran, warfarin, and no anticoagulants. Results. Between February 2011 and May 2011, CHIs from ground-level falls were sustained by 5 patients while on dabigatran, by 15 patients on warfarin, and by 25 patients who were not on anticoagulants. The treatment of the patients on dabigatran at the authors' institution had great diversity. Repeat CT scans obtained during reversal showed 4 of 5 patients with new or expanded hemorrhages in the dabigatran group, whereas the warfarin group had 3 of 15 (p = 0.03). The overall mortality rate for patients sustaining CHI on dabigatran was 2(40%) of 5, whereas that of the warfarin group was 0 (0%) of 15 (p = 0.05). Conclusions. It is critical for physicians involved in the care of patients with CHI on dabigatran to be aware of an elevated mortality rate if no treatment protocol or guideline is in place. The authors will soon implement a reversal management protocol for patients with CHI on dabigatran at their institution in an attempt to improve efficacy and safety in their treatment approach.	[Parra, Michael W.; Zucker, Lloyd; Johnson, Eric S.; Gullett, Diane; Avila, Cristina; Wichner, Zachary A.; Kokaram, Candace R.] Delray Med Ctr, Provis Level Trauma Ctr 1, Delray Beach, FL USA; [Parra, Michael W.; Johnson, Eric S.; Avila, Cristina; Wichner, Zachary A.] Nova SE Univ, Coll Osteopath Med, Ft Lauderdale, FL 33314 USA		Parra, MW (corresponding author), Nova SE Univ, Sch Med, Dept Surg, Delray Med Ctr,Provis Level Trauma Ctr 1, 5352 Linton Blvd, Delray Beach, FL 33484 USA.	michaelwparra@yahoo.com					American College of Surgeons, NAT TRAUMA DAT REP 2; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Hanley JP, 2004, J CLIN PATHOL, V57, P1132, DOI 10.1136/jcp.2003.008904; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Kalina M, 2008, AM SURGEON, V74, P858; Makris M, 2001, BRIT J HAEMATOL, V114, P271, DOI 10.1046/j.1365-2141.2001.02908.x; OSLER T, 1988, AM J SURG, V156, P537, DOI 10.1016/S0002-9610(88)80548-8; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; Safaoui MN, 2009, AM J SURG, V197, P785, DOI 10.1016/j.amjsurg.2008.04.003; Sartori MT, 2009, CLIN APPL THROMB-HEM, V15, P628, DOI 10.1177/1076029609335909; Sorensen B, 2006, THROMB HAEMOSTASIS, V96, P446, DOI 10.1160/TH06-04-0205; Stangier J, 2008, CLIN PHARMACOKINET, V47, P285, DOI 10.2165/00003088-200847050-00001; Stangier J, 2010, CLIN PHARMACOKINET, V49, P259, DOI 10.2165/11318170-000000000-00000; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Testerman George M, 2009, Tenn Med, V102, P37; Tran A, 2011, CARDIOL REV, V19, P154, DOI 10.1097/CRD.0b013e3182137758; van Ryn J, 2010, THROMB HAEMOSTASIS, V103, P1116, DOI 10.1160/TH09-11-0758; VANRYN J, 2008, HAEMATOL HEMATOL S1, V93, P148; Wallentin L, 2010, LANCET, V376, P975, DOI 10.1016/S0140-6736(10)61194-4	21	25	25	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2013	119	3					760	765		10.3171/2013.3.JNS12503			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	204IJ	WOS:000323358700028	23634730	Bronze			2022-02-06	
J	Van Wie, EY; Fosgate, GT; Mankin, JM; Jeffery, ND; Kerwin, SC; Levine, GJ; Greatting, HH; Chen, AV; Barker, AK; Levine, JM				Van Wie, E. Y.; Fosgate, G. T.; Mankin, J. M.; Jeffery, N. D.; Kerwin, S. C.; Levine, G. J.; Greatting, H. H.; Chen, A. V.; Barker, A. K.; Levine, J. M.			Prospectively Recorded versus Medical Record-Derived Spinal Cord Injury Scores in Dogs with Intervertebral Disk Herniation	JOURNAL OF VETERINARY INTERNAL MEDICINE			English	Article						Gait scores; Texas spinal cord injury score; Neurotrauma; Canine; Modified Frankel score	INTERRATER RELIABILITY	Background Validated spinal cord injury (SCI) scores have been established for veterinary species but are not uniformly used in practice. Hypothesis/objectives To determine the level of agreement of SCI scores at the time of admission versus those assigned from reconstructed medical records in a population of dogs with intervertebral disk herniation (IVDH). Animals Eighty-six client-owned dogs with confirmed IVDH. Methods Retrospective study. Medical records were reviewed for history, physical examination, neurologic examination, and recorded Modified Frankel score (MFS) and Texas spinal cord injury score (TSCIS) at the time of admission. Three raters, all board-certified neurologists, assigned MFS and TSCIS based on digitized abstracted medical records to each patient. These scores were then compared to the recorded score at the time of admission. Results Actual agreement for MFS and TSCIS derived from medical records by the 3 raters compared to prospectively derived MFS and TSCIS was 77.9 and 51.2%, respectively. A kappa value of 0.572 (95% CI 0.450, 0.694; P < .001) and an ICC of 0.533 (95% CI 0.410, 0.646; P < .001) were calculated for MFS scores. A kappa value of 0.100 (95% CI 0.000, 0.222; P = .107), and an ICC of 0.503 (95% CI 0.377, 0.620; P < .001) were calculated for TSCIS scores. Conclusions and Clinical Importance Results showed that SCI scores recorded at the time of admission often do not agree with those retrospectively abstracted from medical records. Agreement was less when using the more complex TSCIS scale and therefore the MFS scale might be more appropriate for use in retrospective studies.	[Van Wie, E. Y.; Mankin, J. M.; Kerwin, S. C.; Levine, G. J.; Greatting, H. H.] Texas A&M Univ, Dept Small Anim Clin Sci, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA; [Fosgate, G. T.] Univ Pretoria, Dept Prod Anim Studies, Onderstepoort, South Africa; [Jeffery, N. D.; Barker, A. K.] Iowa State Univ, Dept Small Anim Clin Sci, Coll Vet Med, Ames, IA USA; [Levine, G. J.] Texas A&M Univ, Dept Vet Pathobiol, Coll Vet Med & Biomed Sci, College Stn, TX 77843 USA; [Chen, A. V.] Washington State Univ, Coll Vet Med & Biomed Sci, Dept Small Anim Clin Sci, Pullman, WA 99164 USA; Texas A&M Univ, College Stn, TX 77843 USA		Levine, JM (corresponding author), Texas A&M Univ, Dept Small Anim Clin Sci, 4474 TAMU, College Stn, TX 77843 USA.	jlevine@cvm.tamu.edu	Fosgate, Geoffrey T/N-8700-2014	Fosgate, Geoffrey T/0000-0002-9432-0042; Jeffery, Nick/0000-0002-9812-1788			Brisson BA, 2010, VET CLIN N AM-SMALL, V40, P829, DOI 10.1016/j.cvsm.2010.06.001; Frankel H L, 1969, Paraplegia, V7, P179; Ishida K, 2013, STROKE, V44, P803, DOI 10.1161/STROKEAHA.112.675611; Jonsson M, 2000, SPINAL CORD, V38, P675, DOI 10.1038/sj.sc.3101067; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Levine GJ, 2009, PREV VET MED, V89, P121, DOI 10.1016/j.prevetmed.2009.02.016; Levine JM, 2009, J SMALL ANIM PRACT, V50, P507, DOI 10.1111/j.1748-5827.2009.00834.x; Marino RJ, 2003, J SPINAL CORD MED S1, V26, pS50; Olby NJ, 2001, AM J VET RES, V62, P1624, DOI 10.2460/ajvr.2001.62.1624; Yavuz N, 1998, SPINAL CORD, V36, P832, DOI 10.1038/sj.sc.3100726	10	25	25	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0891-6640	1939-1676		J VET INTERN MED	J. Vet. Intern. Med.	SEP	2013	27	5					1273	1277		10.1111/jvim.12149			5	Veterinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Veterinary Sciences	217VR	WOS:000324391000040	23888873				2022-02-06	
J	Ibrahim, GM; Fallah, A; Macdonald, RL				Ibrahim, George M.; Fallah, Aria; Macdonald, R. Loch			Clinical, laboratory, and radiographic predictors of the occurrence of seizures following aneurysmal subarachnoid hemorrhage Clinical article	JOURNAL OF NEUROSURGERY			English	Article						subarachnoid hemorrhage; seizure; traumatic brain injury	ONSET SEIZURES; INTRAVENTRICULAR HEMORRHAGE; ANTICONVULSANT PROPHYLAXIS; INTRACRANIAL ANEURYSMS; CEREBRAL ANEURYSMS; COIL EMBOLIZATION; EPILEPSY; TRIAL; RISK; STROKE	Object. At present, the administration of prophylactic antiepileptic medication following aneurysmal subarachnoid hemorrhage (SAH) is controversial, and the practice is heterogeneous. Here, the authors sought to inform clinical decision making by identifying factors associated with the occurrence of seizures following aneurysm rupture. Methods. Exploratory analysis was performed on 413 patients enrolled in CONSCIOUS-1 (Clazosentan to Overcome Neurological Ischemia and Infarction Occurring after Subarachnoid Hemorrhage), a prospective randomized trial of clazosentan for the prevention of angiographic vasospasm. The association among clinical, laboratory, and radiographic covariates and the occurrence of seizures following SAH were determined. Covariates with a significance level of p < 0.20 on univariate analysis were entered into a multivariate logistic regression model. Receiver operating characteristic (ROC) curve analysis was used to define optimal predictive thresholds. Results. Of the 413 patients enrolled in the study, 57 (13.8%) had at least 1 seizure following SAH. On univariate analysis, a World Federation of Neurosurgical Societies grade of IV-V, a greater subarachnoid clot burden, and the presence of midline shift and subdural hematomas were associated with seizure activity. On multivariate analysis, only a subarachnoid clot burden (OR 2.76, 95% CI 1.39-5.49) and subdural hematoma (OR 5.67, 95% CI 1.56-20.57) were associated with seizures following SAH. Using ROC curve analysis, the optimal predictive cutoff for subarachnoid clot burden was determined to be 21 (of a possible 30) on the Hijdra scale (area under the curve 0.63). Conclusions. A greater subarachnoid clot burden and subdural hematoma are associated with the occurrence of seizures after aneurysm rupture. These findings may help to identify patients at greatest risk for seizures and guide informed decisions regarding the prescription of prophylactic anticonvulsive therapy. Clinical trial registration no.: NCT00111085 (ClinicalTrials.gov).	Univ Toronto, Labatt Family Ctr Excellence Brain Injury & Traum, Li Ka Shing Knowledge Inst, Div Neurosurg,St Michaels Hosp,Keenan Res Ctr, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Surg, Toronto, ON M5S 1A1, Canada		Macdonald, RL (corresponding author), St Michaels Hosp, 30 Bond St, Toronto, ON M5B 1W8, Canada.	MacdonaldLo@smh.ca		Fallah, Aria/0000-0002-9703-0964	Actelion Pharmaceuticals, Ltd.; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	Actelion Pharmaceuticals, Ltd., was the sponsor of the CON-SCIOUS-1 trial; the company provided the authors with the trial data set but had no role in this exploratory analysis nor in the development of the article. The data analysis and writing are the work of the authors. R. Loch Macdonald has ownership in and is the chief scientific officer for Edge Therapeutics, Inc.; is a consultant for Actelion Pharmaceuticals; and receives support from the Canadian Institutes of Health Research for non study related clinical or research effort.	Adelow C, 2011, EPILEPSIA, V52, P301, DOI 10.1111/j.1528-1167.2010.02757.x; Arboix A, 1999, CLIN NEUROL NEUROSUR, V101, P100, DOI 10.1016/S0303-8467(99)00026-8; BAKER CJ, 1995, NEUROSURGERY, V37, P863, DOI 10.1227/00006123-199511000-00003; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; BERGER AR, 1988, NEUROLOGY, V38, P1363, DOI 10.1212/WNL.38.9.1363; BRAWLEY BW, 1968, J NEUROSURG, V28, P1, DOI 10.3171/jns.1968.28.1.0001; Butzkueven H, 2000, NEUROLOGY, V55, P1315, DOI 10.1212/WNL.55.9.1315; Byrne JV, 2003, NEUROSURGERY, V52, P545, DOI 10.1227/01.NEU.0000047672.25068.4A; CABRAL RJ, 1976, J NEUROL NEUROSUR PS, V39, P1052, DOI 10.1136/jnnp.39.11.1052; Choi KS, 2009, J KOREAN NEUROSURG S, V46, P93, DOI 10.3340/jkns.2009.46.2.93; Claassen J, 2003, NEUROLOGY, V60, P208, DOI 10.1212/01.WNL.0000038906.71394.DE; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; De Reuck J, 2005, EUR NEUROL, V54, P68, DOI 10.1159/000087715; Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303; ECHLIN F, 1971, J NEUROSURG, V35, P646, DOI 10.3171/jns.1971.35.6.0646; GRAEB DA, 1982, RADIOLOGY, V143, P91, DOI 10.1148/radiology.143.1.6977795; HART RG, 1981, NEUROSURGERY, V8, P417, DOI 10.1227/00006123-198104000-00002; Hart Y, 2011, J NEUROSURG, V115, P1159, DOI 10.3171/2011.6.JNS101836; HASAN D, 1993, ANN NEUROL, V33, P286; HIJDRA A, 1990, STROKE, V21, P1156, DOI 10.1161/01.STR.21.8.1156; Hoh BL, 2011, NEUROSURGERY, V69, P644, DOI 10.1227/NEU.0b013e31821bc46d; Huff JS, 2001, NEUROLOGY, V56, P1423, DOI 10.1212/WNL.56.10.1423; Ibrahim GM, 2011, J NEUROSURG, V115, P1191, DOI 10.3171/2011.7.JNS11725; KOTILA M, 1992, EPILEPSIA, V33, P495, DOI 10.1111/j.1528-1157.1992.tb01698.x; KVAM DA, 1983, NEUROSURGERY, V12, P14, DOI 10.1227/00006123-198301000-00003; Lanzino G, 2011, NEUROCRIT CARE, V15, P247, DOI 10.1007/s12028-011-9584-x; LEROUX PD, 1992, NEUROSURGERY, V31, P678, DOI 10.1227/00006123-199210000-00010; Lin CL, 2003, J NEUROSURG, V99, P978, DOI 10.3171/jns.2003.99.6.0978; Macdonald RL, 2008, STROKE, V39, P3015, DOI 10.1161/STROKEAHA.108.519942; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; OHMAN J, 1990, NEUROSURGERY, V27, P578; Pinto AN, 1996, J NEUROL, V243, P161, DOI 10.1007/BF02444009; Rhoney DH, 2000, NEUROLOGY, V55, P258, DOI 10.1212/WNL.55.2.258; ROSE FC, 1965, BRIT MED J, V1, P18, DOI 10.1136/bmj.1.5426.18; Rosengart AJ, 2007, J NEUROSURG, V107, P253, DOI 10.3171/JNS-07/08/0253; Shah D, 2009, SEIZURE-EUR J EPILEP, V18, P676, DOI 10.1016/j.seizure.2009.09.003; SUNDARAM MBM, 1986, CAN J NEUROL SCI, V13, P229, DOI 10.1017/S0317167100036325; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; TEASDALE GM, 1988, J NEUROL NEUROSUR PS, V51, P1457, DOI 10.1136/jnnp.51.11.1457; UKKOLA V, 1990, ACTA NEUROCHIR, V106, P115, DOI 10.1007/BF01809452; Zubkov Alexander Y, 2008, Rev Neurol Dis, V5, P178	42	25	25	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2013	119	2					347	352		10.3171/2013.3.JNS122097			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	187CL	WOS:000322094400014	23581590				2022-02-06	
J	Kvandal, P; Sheppard, L; Landsverk, SA; Stefanovska, A; Kirkeboen, KA				Kvandal, Per; Sheppard, Lawrence; Landsverk, Svein A.; Stefanovska, Aneta; Kirkeboen, Knut A.			Impaired cerebrovascular reactivity after acute traumatic brain injury can be detected by wavelet phase coherence analysis of the intracranial and arterial blood pressure signals	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article; Proceedings Paper	SCAI 10th International Conference on Complexity in Acute Illness (ICCAI)	SEP, 2011	Bonn, GERMANY	Soc Complex Acute Illness (SCAI)		Brain injury; Autoregulation; Cerebrovascular reactivity; Cerebral perfusion pressure; Wavelet transform; Spectral energy; Wavelet phase coherence; Phase shift	CEREBRAL VASOMOTOR REACTIVITY; HEAD-INJURY; FLOW VELOCITY; TIME-SERIES; AUTOREGULATION; OSCILLATIONS; SKIN	The objective of the study was to evaluate the wavelet spectral energy of oscillations in the intracranial pressure (ICP) signal in patients with acute traumatic brain injury (TBI). The wavelet phase coherence and phase shift in the 0.006-2 Hz interval between the ICP and the arterial blood pressure (ABP) signals were also investigated. Patients were separated into normal or impaired cerebrovascular reactivity, based on the pressure reactivity index (PRx). Spectral energy, phase coherence and phase shift in the low frequency and cardiorespiratory intervals were compared for the two groups. Data were prospectively collected and analyzed retrospectively in 22 patients, within the first week after acute TBI. The ICP and ABP signals were continuously recorded for 40 min and the wavelet transform was used to calculate the spectral energy and phase of the signals. The average ICP wavelet energy spectrum showed distinct peaks around 1.0 (cardiac), 0.25 (respiratory) and 0.03 Hz. Patients with normal cerebrovascular reactivity (negative PRx) had 38.6 % (+/- SD 16.7 %) of the mean wavelet energy below the lower limit of the respiratory frequency band (0.14 Hz) compared to only 18.1 % (+/- SD 17.8 %) in patients with altered cerebrovascular reactivity (positive PRx) (difference: p = 0.0057). Wavelet phase coherence between the ABP and ICP signals was statistically significant (p < 0.05) in the 0.006-2 Hz interval. The phase shift between the ABP and ICP signals was around zero in the 0.14-1.0 Hz interval. Seven patients with PRx between -0.4943 and -0.1653 had a phase shift in the interval 0.07-0.14 Hz, whereas 15 patients with PRx between -0.1019 and 0.3881 had a phase shift in the interval 0.006-0.07 Hz. We conclude that the wavelet transform of the ICP signal shows spectral peaks at the cardiac, respiratory and 0.03 Hz frequencies. Normal cerebrovascular reactivity seems to be manifested as increased spectral energy in the frequency interval < 0.14 Hz. A phase shift between the ICP and ABP signals in the interval 0.07-0.14 Hz indicates normal cerebrovascular reactivity, while a phase shift in the interval 0.006-0.07 Hz indicates altered cerebrovascular reactivity.	[Kvandal, Per] Oslo Univ Hosp, Intens Care Unit, N-0407 Oslo, Norway; [Sheppard, Lawrence; Stefanovska, Aneta] Univ Lancaster, Dept Phys, Nonlinear Biomed Phys Grp, Lancaster, England; [Landsverk, Svein A.; Kirkeboen, Knut A.] Dept Anesthesiol, Ulleval, Norway; [Landsverk, Svein A.; Kirkeboen, Knut A.] Univ Oslo, Fac Med, Oslo Univ Hosp, Oslo, Norway		Kvandal, P (corresponding author), Oslo Univ Hosp, Intens Care Unit, N-0407 Oslo, Norway.	uxpekv@ous-hf.no; aneta@lancaster.ac.uk	Stefanovska, Aneta/AAH-3651-2020; Sheppard, Lawrence/P-3653-2016	Stefanovska, Aneta/0000-0001-6952-8370; 			Addison PS., 2002, ILLUSTRATED WAVELET; AUER LM, 1983, ACTA NEUROCHIR, V68, P93, DOI 10.1007/BF01406205; Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Bandrivskyy A., 2004, CARDIOVASC ENG, V4, P89, DOI [10.1023/B:CARE.0000025126.63253.43, DOI 10.1023/B:CARE.0000025126.63253.43]; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; Kvandal P, 2006, MICROVASC RES, V72, P120, DOI 10.1016/j.mvr.2006.05.006; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; Lang EW, 1999, NEUROL RES, V21, P665, DOI 10.1080/01616412.1999.11740995; Latka M, 2007, PHYSIOL MEAS, V28, P465, DOI 10.1088/0967-3334/28/5/002; Lemaire JJ, 2002, ACTA NEUROCHIR, V144, P243, DOI 10.1007/s007010200032; Lewis PM, 2008, ACTA NEUROCHIR, V150, P139, DOI 10.1007/s00701-007-1447-z; MORLET J, 1983, NATO ASI SER, V1, P233, DOI DOI 10.1007/978-3-642-82002-1_12; Schreiber T, 2000, PHYSICA D, V142, P346, DOI 10.1016/S0167-2789(00)00043-9; Sheppard LW, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.046205; Soderstrom T, 2003, AM J PHYSIOL-HEART C, V284, pH1638, DOI 10.1152/ajpheart.00826.2000; Stefanovska A, 1999, IEEE T BIO-MED ENG, V46, P1230, DOI 10.1109/10.790500; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Zunker P, 1986, NEW TRENDS CEREBRAL, P718	23	25	29	2	23	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307			J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	AUG	2013	27	4			SI		375	383		10.1007/s10877-013-9484-z			9	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Anesthesiology	175VJ	WOS:000321261400002	23748602	hybrid, Green Published, Green Accepted			2022-02-06	
J	Nishijima, DK; Shahlaie, K; Sarkar, K; Rudisill, N; Holmes, JF				Nishijima, Daniel K.; Shahlaie, Kiarash; Sarkar, Korak; Rudisill, Nancy; Holmes, James F.			Risk of unfavorable long-term outcome in older adults with traumatic intracranial hemorrhage and anticoagulant or antiplatelet use	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							HEAD-INJURY; PREINJURY WARFARIN; ELDERLY-PATIENTS; BRAIN-INJURY; MANAGEMENT; THERAPY; TRIALS; SCALES	Study objective: The objective was to compare neurological outcomes at 6 months in older patients with preinjury warfarin or clopidogrel use and mild traumatic intracranial hemorrhage with those without prior use of these medications. Methods: This was a retrospective study conducted at a Level 1 trauma center from April 2009 to July 2010. Patients older than 55 years with isolated mild head injury (Glasgow Coma Scale score 13-15 and Abbreviated Injury Score <3 in nonhead body region) were included. Demographic, clinical, and outcome data were abstracted from an existing traumatic brain injury database. The primary end point of unfavorable extended Glasgow Outcome Score at 6 months was compared between patients with and without preinjury warfarin or clopidogrel use. Results: Seventy-seven eligible patients were identified: 27 (35%) with preinjury warfarin or clopidogrel use and 50 (65%) without. Baseline characteristics (sex, Glasgow Coma Scale score, Injury Severity Score, computed tomography score, and in-hospital mortality) were similar between cohorts, although the preinjury warfarin or clopidogrel cohort was older than the control group (P < .05). Patients in the preinjury warfarin or clopidogrel cohort were more likely to have an unfavorable outcome (16/27; 59.3%; 95% confidence interval, 40.7%-77.8%) as compared with those without (18/50; 36.0%; 95% confidence interval, 22.7%-49.3%) (P = .05). Conclusion: Older adults with preinjury warfarin or clopidogrel use and mild traumatic intracranial hemorrhage may be at an increased risk for unfavorable long-term neurological outcomes compared with similar patients without preinjury use of these medications. (C) 2013 Elsevier Inc. All rights reserved.	[Nishijima, Daniel K.; Holmes, James F.] Univ Calif Davis, Sch Med, Dept Emergency Med, Sacramento, CA 95817 USA; [Shahlaie, Kiarash; Rudisill, Nancy] Univ Calif Davis, Sch Med, Dept Neurol Surg, Sacramento, CA 95817 USA; [Sarkar, Korak] Univ Calif Davis, Sch Med, Dept Neurol, Sacramento, CA 95817 USA		Nishijima, DK (corresponding author), Univ Calif Davis, Med Ctr, Sacramento, CA 95817 USA.	daniel.nishijima@ucdmc.ucdavis.edu			National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000002, KL2TR000134]; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000002, KL2TR000134] Funding Source: NIH RePORTER	DN was supported through a Mentored Clinical Research Training Program Award (grant UL1TR000002 and linked award KL2TR000134) from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. NCATS and NIH had no role in the design and conduct of the study, in the analysis or interpretation of the data, or in the preparation of the data. The views expressed in this article are solely the responsibility of the authors and do not necessarily represent the official view of NCATS or NIH. Information on NCATS is available at http://www.ncats.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp.	Boulis NM, 1999, NEUROSURGERY, V45, P1113, DOI 10.1097/00006123-199911000-00020; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Karni A, 2001, AM SURGEON, V67, P1098; Kawamata T, 1995, SURG NEUROL, V44, P438, DOI 10.1016/0090-3019(95)00249-9; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yasuda CL, 2003, ARQ NEURO-PSIQUIAT, V61, P1011, DOI 10.1590/S0004-282X2003000600023	17	25	26	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	AUG	2013	31	8					1244	1247		10.1016/j.ajem.2013.04.035			4	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	201SN	WOS:000323163400017	23759685	Green Accepted			2022-02-06	
J	Calcagnile, O; Holmen, A; Chew, M; Unden, J				Calcagnile, Olga; Holmen, Anders; Chew, Michelle; Unden, Johan			S100B levels are affected by older age but not by alcohol intoxication following mild traumatic brain injury	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article							MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; SCANDINAVIAN GUIDELINES; INITIAL MANAGEMENT; PROTEIN S100B; SERUM; S-100B; MARKER; DAMAGE; RULE	Introduction: Biomarkers of brain damage and head injury are potentially useful tools in the management of afflicted patients. Particularly S100B has received much attention and has been adapted into clinical guidelines. Alcohol intoxication and higher age (65 years and over) have been used as risk factors for serious complications following head injury. The effect of these factors on S100B levels has not been fully established in a relevant patient cohort. Methods: We prospectively included 621 adult patients with mild traumatic brain injury (TBI) and S100B sampling. Mild TBI was defined as Glasgow Come Scale 14-15 with loss of consciousness and/or amnesia, but without high-risk factors for intracranial complications. These patients would normally require CT scanning according to local and most international guidelines. S100B was sampled within 3 hours following trauma. Results: 280 patients (45%) were intoxicated by alcohol. Alcohol intoxication had no effect on S100B levels (p = 0.65) and the performance of S100B remained unchanged in these patients. 115 patients (22%) were 65 years or older with elevated S100B levels being more common in this group compared to patients under 65 (p = 0.029). Although the sensitivity of S100B was unchanged in older patients, the specificity was poorer. Conclusion: S100B can be used reliably in mild TBI patients with alcohol intoxication. The clinically utility of S100B in older patients may be limited by very poor specificity leading to only a small decrease in CT scanning.	[Calcagnile, Olga] Hallands Hosp, Dept Pediat Med, S-30185 Halmstad, Sweden; [Holmen, Anders] Hallands Hosp, Dept Res & Dev, S-30185 Halmstad, Sweden; [Chew, Michelle] Lund Univ, Hallands Hosp, Dept Anaesthesia & Intens Care, S-30185 Halmstad, Sweden; [Chew, Michelle] Lund Univ, Hallands Hosp, Inst Clin Sci Malmo, S-30185 Halmstad, Sweden; [Unden, Johan] Lund Univ, Skanes Univ Hosp, Dept Intens Care & Perioperat Med, S-20502 Malmo, Sweden; [Unden, Johan] Lund Univ, Skanes Univ Hosp, Inst Clin Sci Malmo, S-20502 Malmo, Sweden		Unden, J (corresponding author), Lund Univ, Skanes Univ Hosp, Dept Intens Care & Perioperat Med, S-20502 Malmo, Sweden.	dr.johan.unden@gmail.com					Astrand R, 2011, CLIN CHIM ACTA, V412, P2190, DOI 10.1016/j.cca.2011.08.009; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Calcagnile O, 2012, BMC EMERG MED, V12, DOI 10.1186/1471-227X-12-13; Cervellin G, 2012, CLIN BIOCHEM, V45, P408, DOI 10.1016/j.clinbiochem.2012.01.006; Foerch C, 2007, STROKE, V38, P2491, DOI 10.1161/STROKEAHA.106.480111; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P123, DOI 10.1097/HTR.0b013e31820e6840; Morton MJ, 2012, ANN EMERG MED, V60, P361, DOI 10.1016/j.annemergmed.2011.12.026; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Muller K, 2006, CLIN CHEM LAB MED, V44, P1111, DOI 10.1515/CCLM.2006.211; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Mussack T, 2000, ACT NEUR S, V76, P393; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Soreide K, 2007, WORLD J SURG, V31, P2092, DOI 10.1007/s00268-007-9226-9; Stein SC, 2000, NEW ENGL J MED, V343, P1570; Stein SC, 2005, J NEUROSURG, V102, P183; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50	22	25	25	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	JUL 6	2013	21								52	10.1186/1757-7241-21-52			6	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	178MZ	WOS:000321453400001	23830006	Green Published, gold			2022-02-06	
J	Ishaq, GM; Saidu, Y; Bilbis, LS; Muhammad, SA; Jinjir, N; Shehu, BB				Ishaq, Gaafar M.; Saidu, Yusuf; Bilbis, Lawal S.; Muhammad, Suleiman A.; Jinjir, Nasir; Shehu, Bello B.			Effects of alpha-tocopherol and ascorbic acid in the severity and management of traumatic brain injury in albino rats	JOURNAL OF NEUROSCIENCES IN RURAL PRACTICE			English	Article						Antioxidant; oxidative stress; supplementation; traumatic brain injury		Background: Traumatic brain injury (TBI) is accompanied by substantial accumulation of biomarkers of oxidative stress and depletion of antioxidants reserve which initiate chain reactions that damage brain cells. The present study investigated the role of ascorbic acid and alpha-tocopherol on the severity and management of TBI in rats. Materials and Methods: Wistar rats were subjected to closed head injury using an accelerated impact device. Rats were administered 45 mg/kg and 60 mg/kg body weight of ascorbic acid, alpha-tocopherol or a combination of the two vitamins for 2 weeks pre- and post injury. Blood and brain tissue homogenates were analyzed for vitamin C, vitamin E, malondialdehyde, superoxide dismutase, and creatine kinase activities. Results: The results indicated that TBI caused significant (P < 0.05) decreased in vitamins C and E levels in the blood and brain tissue of TBI-untreated rats. The activities of superoxide dismutase in TBI rats were markedly reduced when compared with non traumatized control and showed a tendency to increased following supplementation with vitamins C and E. Supplementation of the vitamins significantly (P < 0.05) reduced malondialdehyde in the treatment groups compared with the TBI-untreated group. Conclusion: The study indicated that pre- and post treatment with ascorbic acid and alpha-tocopherol reduced oxidative stress induced by brain injury and effectively reduced mortality rate in rats.	[Ishaq, Gaafar M.; Saidu, Yusuf; Bilbis, Lawal S.; Muhammad, Suleiman A.; Shehu, Bello B.] Usmanu Danfodiyo Univ, Dept Biochem, PMB 2346, Sokoto, Nigeria; [Jinjir, Nasir] Usmanu Danfodiyo Univ, Dept Neurosurg, PMB 2346, Sokoto, Nigeria		Saidu, Y (corresponding author), Usmanu Danfodiyo Univ, Dept Biochem, PMB 2346, Sokoto, Nigeria.	yusdab@yahoo.com	Muhammad, Suleiman/ABA-3384-2020	Muhammad, Suleiman/0000-0003-2421-3556			Anagnostopoulos D I, 1988, Br J Neurosurg, V2, P169, DOI 10.3109/02688698808992666; Awojebi OA, 1987, NIGERIAN MED PRACTI, V13, P49; Bagchi D, 1998, GEN PHARMACOL, V30, P771, DOI 10.1016/S0306-3623(97)00332-7; Baker H, 1968, CLIN VITAMINOLOGY ME, P172; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Boya P, 1999, J HEPATOL, V31, P808, DOI 10.1016/S0168-8278(99)80281-5; Chaudiere J, 1999, FOOD CHEM TOXICOL, V37, P949, DOI 10.1016/S0278-6915(99)00090-3; DZHANDZHAVA TG, 1992, VOP MED KHIM, V38, P33; FEARNSIDE MR, 1997, HEAD INJURY PATHOPHY, P3; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Graham DI, 1997, GREENFIELDS NEUROPAT, P197; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; IVink R, 1987, BIOCHEM BIOPH RES CO, V149, P594; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; Jian WN, 2009, ZHEN CI YAN JI, V34, P52; Kwiatkowska S, 1999, RESP MED, V93, P272, DOI 10.1016/S0954-6111(99)90024-0; Lamprecht W, 1974, METHOD ENZYMAT AN, P1776; Martin A, 2002, NUTR REV, V60, P308, DOI 10.1301/002966402320583433; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Natelson S., 1971, TECHNIQUES CLIN CHEM, P165; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; Rice ME, 1998, NEUROSCIENCE, V82, P1213; SIMON JA, 1992, J AM COLL NUTR, V11, P107; SINGAL PK, 1983, ADV EXP MED BIOL, V161, P391; Thornhill S, 2000, BMJ-BRIT MED J; Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001; Wang JY, 2006, CURR PHARM DESIGN, V12, P3521, DOI 10.2174/138161206778343109; Xiong Y, 2001, MITOCHONDRIAL DYSFUN, P257	31	25	25	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0976-3147	0976-3155		J NEUROSCI RURAL PRA	J. Neurosci. Rural Pract.	JUL-SEP	2013	4	3					292	297		10.4103/0976-3147.118784			6	Clinical Neurology	Emerging Sources Citation Index (ESCI)	Neurosciences & Neurology	V3W4E	WOS:000218648300012	24250162	gold, Green Published			2022-02-06	
J	Johnson, BS; Boudiab, LD; Freundl, M; Anthony, M; Gmerek, GB; Carter, J				Johnson, Barbara S.; Boudiab, Lina D.; Freundl, Margaret; Anthony, Maureen; Gmerek, Gregory B.; Carter, Jemica			Enhancing VETERAN-CENTERED CARE: A Guide for Nurses in Non-VA Settings	AMERICAN JOURNAL OF NURSING			English	Article						chronic pain; hazardous exposure; homelessness; military sexual trauma; military veteran; polytrauma; posttraumatic stress disorder; substance use disorder; suicide; traumatic brain injury; veteran	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MILITARY SEXUAL TRAUMA; MENTAL-HEALTH; CHRONIC PAIN; IRAQI FREEDOM; AUDIT-C; WAR; POLYTRAUMA; PREVALENCE	There are currently 22.5 million living U.S. military veterans, and this number is expected to increase dramatically as military personnel return from Iraq and Afghanistan. Although honorably discharged veterans may qualify for health care through the U.S. Department of Veterans Affairs (VA), only about 25% of all veterans take advantage of this benefit; a majority seek services in non-VA settings. It's imperative for nurses in all civilian care settings to understand the impact that military service has on veterans' health. This article provides an overview of veterans' unique health care issues, focusing particularly on traumatic brain injury, polytrauma, hazardous exposures, chronic pain, posttraumatic stress disorder, military sexual trauma, substance use disorders, suicide, and homelessness. Evidence-based assessment tools and treatment guidelines for these health issues are discussed. A resource table provides telephone numbers and Web sites offering tools, educational materials, and veteran services. A second table provides detailed veteran-centered health assessment and screening questions.	[Johnson, Barbara S.; Boudiab, Lina D.] Aleda E Lutz VA Med Ctr, VA Nursing Acad, Saginaw, MI USA; [Freundl, Margaret; Gmerek, Gregory B.; Carter, Jemica] John Dingell VA Med Ctr, VA Nursing Acad, Detroit, MI USA; [Anthony, Maureen] Univ Detroit, Mercy McAuley Sch Nursing, Detroit, MI USA		Johnson, BS (corresponding author), Aleda E Lutz VA Med Ctr, VA Nursing Acad, Saginaw, MI USA.	barbara.johnson19@va.gov			Department of Veterans AffairsUS Department of Veterans Affairs	This project was funded by an unrestricted educational grant in whole through federal funds from the Department of Veterans Affairs and administered through the Veterans Health Administration Office of Academic Affiliations. The opinions expressed herein do not necessarily reflect the views of the Department of Veterans Affairs or its affiliates, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.	Adkins RE, 1967, MEDICAL CARE OF VETE; American Psychiatric Association, 2000, DIAGNOSTIC AND STATI; American Psychiatric Association, 1980, DIAGNOSTIC AND STATI; Bagalman E, 2011, SUICIDE PTSD AND SUB; Belanger HG, 2005, J REHABIL RES DEV, V42, P403, DOI 10.1682/JRRD.2004.08.0095; Bradley KA, 2007, ALCOHOL CLIN EXP RES, V31, P1208, DOI 10.1111/j.1530-0277.2007.00403.x; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Chan BL, 2007, NEW ENGL J MED, V357, P2206, DOI 10.1056/NEJMc071927; Clark JD, 2002, J PAIN SYMPTOM MANAG, V23, P131, DOI 10.1016/S0885-3924(01)00396-7; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Cobb Anne M, 2008, J Trauma Nurs, V15, P192, DOI 10.1097/01.JTN.0000343326.93204.0b; Committee on the Initial Assessment of Readjustment Needs of Military Personnel Veterans and their Families Board on the Health of Select Populations Institute of Medicine of the National Academies, 2010, RETURNING HOME FROM; Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides Board on the Health of Select Populations Institute of Medicine of the National Academies, 2010, VETERANS AND AGENT O; Daniron-Rodriguez J, 2004, MIL MED, V169, P243, DOI 10.7205/MILMED.169.3.243; Defense and Veterans Brain Injury Center, 2013, DEPARTMENT OF DEFENS; Defense and Veterans Brain Injury Center, CONCUSSION MTBI SCRE; Defense Manpower Data Center Human Resources Strategic Assessment Program (HRSAP), 2012, 2012 WORKPLACE AND G; Demers A, 2011, J LOSS TRAUMA, V16, P160, DOI 10.1080/15325024.2010.519281; Denneson LM, 2011, J REHABIL RES DEV, V48, P1119, DOI 10.1682/JRRD.2010.12.0243; Department of Veterans Affairs Veterans Health Administration, 2010, VHA HANDBOOK 117204; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Galloway K. T., 2011, AM NURSE TODAY S, V6, P8; Gamache G, 2003, AM J PUBLIC HEALTH, V93, P1132, DOI 10.2105/AJPH.93.7.1132; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; Geiling J, 2012, MIL MED, V177, P1235, DOI 10.7205/MILMED-D-12-00031; Gierisch JM, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110131; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Hannah G, 2011, GETTING TO OUTCOMES; Harada ND, 2002, MED CARE, V40, P117; Haskell SG, 2012, CLIN J PAIN, V28, P163, DOI 10.1097/AJP.0b013e318223d951; HealthyPeople.gov, 2012, 2020 TOPICS AND OBJE; Hovanitz CA, 2002, APPL PSYCHOPHYS BIOF, V27, P29, DOI 10.1023/A:1014524521152; Jakupcak M, 2010, DEPRESS ANXIETY, V27, P1001, DOI 10.1002/da.20722; Kaplan MS, 2009, J TRAUMA, V67, P503, DOI 10.1097/TA.0b013e3181b36521; Kemp J, 2012, SUICIDE DATA REPORT; Kimerling R, 2008, PSYCHIAT SERV, V59, P635, DOI 10.1176/appi.ps.59.6.635; Kimerling R, 2007, AM J PUBLIC HEALTH, V97, P2160, DOI 10.2105/AJPH.2006.092999; Kulka RA, 1990, TRAUMA AND THE VIETN; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Maestas KL, 2011, REHABIL PSYCHOL, V56, P366, DOI 10.1037/a0025447; Magruder KM, 2012, AM J PUBLIC HEALTH, V102, pS118, DOI 10.2105/AJPH.2011.300451; McNamee MJ, 2006, ENCYCLOPEDIA OF NURS, P277; Miles D., 2010, AMERICAN FORCES PRES; Miller M, 2008, NEW ENGL J MED, V359, P989, DOI 10.1056/NEJMp0805923; [National Center for Veterans Analysis and Statistics United States Department of Veterans Affairs], 2013, PROFILE OF VETERANS; National Coalition for Homeless Veterans, BACKGROUND AND STATI; Neason Kathleen, 2006, RN, V69, P30; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Olszewski TM, 2005, J PSYCHOSOC NURS MEN, V43, P40; Otis JD, 2009, PAIN MED, V10, P1300, DOI 10.1111/j.1526-4637.2009.00715.x; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Petzel RA, 2010, VHA DIRECTIVE MILITA; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Probst C, 2010, J TRAUMA, V68, P706, DOI 10.1097/TA.0b013e3181a8b21c; Richardson C, 2003, C2KBR 22 CENSUS 2000; Riggs DS, 2012, MIL MED, V177, P14, DOI 10.7205/MILMED-D-12-00140; Saxon A. J., 2011, PSYCHIAT TIMES, V28, P49; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Siddharthan K, 2008, REHABIL NURS, V33, P221, DOI 10.1002/j.2048-7940.2008.tb00231.x; Skidmore WC, 2011, SOC WORK HEALTH CARE, V50, P85, DOI 10.1080/00981389.2010.522913; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100107-01, 10.3928/02793695-20100108-02]; Solomon Z, 2008, PSYCHOL MED, V38, P1427, DOI 10.1017/S0033291708002808; Spelman JF, 2012, J GEN INTERN MED, V27, P1200, DOI 10.1007/s11606-012-2061-1; Suris A, 2008, TRAUMA VIOLENCE ABUS, V9, P250, DOI 10.1177/1524838008324419; U.S. Census Bureau, 2012, VETERANS BY SELECTED, P340; U.S. Department of Defense Task Force on the Prevention of Suicide by Members of the Armed Forces, 2010, FINAL REPORT; U.S. Department of Labor Women's Bureau, 2011, TRAUMA INFORMED CARE; U.S. Department of the Army, 2012, ADRP 6 22 C1, pC1; U.S. Department of Veterans Affairs, 2012, PUBLIC HEALTH MILI T; U.S. Department of Veterans Affairs, 2013, PUBLIC HEALTH HEALTH; U.S. Department of Veterans Affairs, 2011, SUICIDE RISK ASSESSM; U.S. Department of Veterans Affairs, 2012, PUBLIC HEALTH MILITA; U.S. Department of Veterans Affairs, 2012, GERIATRICS AND EXTEN; U.S. Department of Veterans Affairs, 2012, GREAT AMERICAN SMOKE; U.S. Department of Veterans Affairs, 2012, POLYTRAUMA TBI SYSTE; U.S. Department of Veterans Affairs, 2013, PUBLIC HEALTH MILITA; U.S. Department of Veterans Affairs and U.S. Department of Defense, 2000, CLINICAL PRACTICE GU; U.S. Department of Veterans Affairs and U.S. Department of Defense, 2010, CLINICAL PRACTICE GU; U.S. Department of Veterans Affairs and U.S. Department of Defense, 2009, CLINICAL PRACTICE GU; U.S. Department of Veterans Affairs National Center for PTSD, 2007, MILITARY SEXUAL TRAU; U.S. Department of Veterans Affairs National Center for PTSD, 2007, AGING VETERANS AND P; U.S. Department of Veterans Affairs National Center for PTSD, 2007, TRAUMATIC BRAIN INJU; U.S. Department of Veterans Affairs National Center for PTSD, UNDERSTANDING PTSD; U.S. Department of Veterans Affairs National Center for PTSD, 2012, PTSD SCREENING INSTR; U.S. Department of Veterans Affairs National Center for PTSD, 2007, CHRONIC PAIN AND PTS; U.S. Department of Veterans Affairs National Center for Veterans Analysis and Statistics, 2013, VA BENEFITS AND HEAL; U.S. Department of Veterans Affairs National Center for Veterans Analysis and Statistics, 2010, VETERAN POPULATION P; U.S. Department of Veterans Affairs National Center for Veterans Analysis and Statistics, 2013, DEPARTMENT OF VETERA; U.S. Department of Veterans Affairs Office of Academic Affiliations, 2012, MILITARY HEALTH HIST; U.S. Department of Veterans Affairs Office of Patient Care Services and Office of Mental Health Services, 2012, FACT SHEET VA SUICID; U.S. Department of Veterans Affairs Office of Public and Intergovernmental Affairs, 2013, HOMELESS VETERANS AB; U.S. Department of Veterans Affairs Office of Public Health and Environmental Hazards, 2010, ANALYSIS OF VA HEALT; U.S. Department of Veterans Affairs Office of Public Health and Environmental Hazards, 2010, VHA TOBACCO USE CESS; U.S. Department of Veterans Affairs Veterans Health Administration Research and Development Cooperative Studies Program (CSP), 2010, CSP 579 HEALTH VIEWS; United States Government Accountability Office, 2008, GAO 08 276; United States Interagency Council on Homelessness, 2010, OPENING DOORS FEDERA; Uomoto JM, 2009, REHABIL PSYCHOL, V54, P259, DOI 10.1037/a0016907; Valente S, 2007, MIL MED, V172, P259, DOI 10.7205/MILMED.172.3.259; WAGNER TH, 2007, PSYCHOL SERVICES, V0004; Watts DD, 2011, J NEUROSCI NURS, V43, P122, DOI 10.1097/JNN.0b013e3182135af6; Wieland Diane M, 2011, Pa Nurse, V66, P17; Wieland DM, 2011, PA NURSE, V66, P21; Wisco BE, 2012, MIL MED, V177, P7, DOI 10.7205/MILMED-D-12-00111; World Health Organization, 2012, RABIES A NEGLECTED Z; Zeitzer MB, 2008, AAOHN J, V56, P347, DOI 10.3928/08910162-20080801-03	105	25	25	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0002-936X	1538-7488		AM J NURS	Am. J. Nurs.	JUL	2013	113	7					24	39		10.1097/01.NAJ.0000431913.50226.83			16	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	299AI	WOS:000330366200015	23764699				2022-02-06	
J	Lapitskaya, N; Gosseries, O; De Pasqua, V; Pedersen, AR; Nielsen, JF; de Noordhout, AM; Laureys, S				Lapitskaya, Natallia; Gosseries, Olivia; De Pasqua, Victor; Pedersen, Asger Roer; Nielsen, Joergen Feldbaek; de Noordhout, Alain Maertens; Laureys, Steven			Abnormal Corticospinal Excitability in Patients with Disorders of Consciousness	BRAIN STIMULATION			English	Article						Vegetative state; Unresponsive wakefulness syndrome; Minimally conscious state; Brain injury; Transcranial magnetic stimulation; Motor evoked potentials; Somatosensory evoked potentials; Short latency afferent inhibition	TRANSCRANIAL MAGNETIC STIMULATION; TRAUMATIC BRAIN-INJURY; CENTRAL CHOLINERGIC CIRCUITS; LATENCY AFFERENT INHIBITION; VIVO FUNCTIONAL-EVALUATION; MOTOR EVOKED-POTENTIALS; VEGETATIVE STATE; CORTEX; RECOVERY; STROKE	Background: Transcranial magnetic stimulation (TMS) has been frequently used to explore changes in the human motor cortex in different conditions, while the extent of motor cortex reorganization in patients in vegetative state (VS) (now known as unresponsive wakefulness syndrome, UWS) and minimally conscious (MCS) states due to severe brain damage remains largely unknown. Objective/hypothesis: It was hypothesized that cortical motor excitability would be decreased and would correlate to the level of consciousness in patients with disorders of consciousness. Methods: Corticospinal excitability was assessed in 47 patients (24 VS/UWS and 23 MCS) and 14 healthy controls. The test parameters included maximal peak-to-peak M-wave (Mm a x), F-wave persistence, peripheral and central motor conduction times, sensory (SEP) and motor evoked (MEP) potential latencies and amplitudes, resting motor threshold (RMT), stimulus/response curves, and short latency afferent inhibition (SAI). TMS measurements were correlated to the level of consciousness (assessed using the Coma Recovery Scale-Revised). Results: On average, the patient group had lower M-max, lower MEP and SEP amplitudes, higher RMTs, narrower stimulus/response curves, and reduced SAI compared to the healthy controls (P < 0.05). The SAI alterations were correlated to the level of consciousness (P < 0.05). Conclusions: The findings demonstrated the impairment of the cortical inhibitory circuits in patients with disorders of consciousness. Moreover, the significant relationship was found between cortical inhibition and clinical consciousness dysfunction. (C) 2013 Elsevier Inc. All rights reserved.	[Lapitskaya, Natallia; Pedersen, Asger Roer; Nielsen, Joergen Feldbaek] Hammel Neurorehabil & Res Ctr, Res Dept, DK-8450 Hammel, Denmark; [Lapitskaya, Natallia; Gosseries, Olivia; Laureys, Steven] Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, B-4000 Liege, Belgium; [Lapitskaya, Natallia; De Pasqua, Victor; de Noordhout, Alain Maertens; Laureys, Steven] Univ Liege, Dept Neurol, B-4000 Liege, Belgium; [De Pasqua, Victor; de Noordhout, Alain Maertens] Ctr Hosp Reg Citadelle, B-4000 Liege, Belgium		Lapitskaya, N (corresponding author), Hammel Neurorehabil & Res Ctr, Res Dept, Voldbyvej 15, DK-8450 Hammel, Denmark.	natlap@rm.dk	Laureys, Steven/A-3349-2011; Gosseries, Olivia/AAB-6469-2020; Laureys, Steven/AAN-2097-2021; Nielsen, Jorgen Feldbak/AAR-6384-2021	Gosseries, Olivia/0000-0001-9011-7496; Laureys, Steven/0000-0002-3096-3807; Nielsen, Jorgen Feldbak/0000-0001-5339-171X	European Neurological Society Fellowship; Danish Medical Research CouncilDanish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Belgian National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; European Commission (DISCOS); French Speaking Community Concerted Research Action; James McDonnell Foundation; Mind Science Foundation; University of LiegeUniversity of Liege; European Commission (Mindbridge)European Commission; European Commission (DECODER); European Commission (COST)	NL was supported by the European Neurological Society Fellowship and Danish Medical Research Council. This research was funded by the Belgian National Funds for Scientific Research (FNRS), the European Commission (DISCOS, Mindbridge, DECODER & COST), the French Speaking Community Concerted Research Action, the James McDonnell Foundation, the Mind Science Foundation and the University of Liege.	Abbruzzese G, 2002, J CLIN NEUROPHYSIOL, V19, P307, DOI 10.1097/00004691-200208000-00005; [Anonymous], 2003, Clin Med (Lond), V3, P249; Babiloni C, 2009, HUM BRAIN MAPP, V30, P1431, DOI 10.1002/hbm.20612; Bagnato S, 2012, CLIN NEUROPHYSIOL, V123, P1937, DOI 10.1016/j.clinph.2012.03.014; Bagnato S, 2011, J PERIPHER NERV SYST, V16, P315, DOI 10.1111/j.1529-8027.2011.00363.x; Bernabeu M, 2009, J NEUROTRAUM, V26, P2185, DOI 10.1089/neu.2008.0859; Boly M, 2011, SCIENCE, V332, P858, DOI 10.1126/science.1202043; Chen R, 2008, CLIN NEUROPHYSIOL, V119, P504, DOI 10.1016/j.clinph.2007.10.014; Chistyakov AV, 2001, J NEUROL NEUROSUR PS, V70, P580, DOI 10.1136/jnnp.70.5.580; Chistyakov AV, 1998, ACTA NEUROCHIR, V140, P467, DOI 10.1007/s007010050126; Chistyakov AV, 1999, CLIN NEUROPHYSIOL, V110, P1080, DOI 10.1016/S1388-2457(99)00029-2; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; Delvaux V, 2003, CLIN NEUROPHYSIOL, V114, P1217, DOI 10.1016/S1388-2457(03)00070-1; Di Lazzaro V, 2004, CLIN NEUROPHYSIOL, V115, P255, DOI 10.1016/j.clinph.2003.10.009; Di Lazzaro V, 2006, NEUROLOGY, V66, P1111, DOI 10.1212/01.wnl.0000204183.26231.23; Di Lazzaro V, 2005, J PHYSIOL-LONDON, V564, P661, DOI 10.1113/jphysiol.2004.061747; Di Lazzaro V, 2003, NEUROL RES, V25, P143, DOI 10.1179/016164103101201292; Di Lazzaro V, 2002, NEUROLOGY, V59, P392, DOI 10.1212/WNL.59.3.392; Di Lazzaro V, 2008, CLIN NEUROPHYSIOL, V119, P2494, DOI 10.1016/j.clinph.2008.08.010; Di Lazzaro V, 1999, CLIN NEUROPHYSIOL, V110, P1297, DOI 10.1016/S1388-2457(99)00060-7; Di Lazzaro V, 2012, STROKE, V43, P250, DOI 10.1161/STROKEAHA.111.631085; DOMANN R, 1993, NEUROSCI LETT, V155, P69, DOI 10.1016/0304-3940(93)90675-B; Fernandez-Espejo D, 2011, NEUROIMAGE, V54, P103, DOI 10.1016/j.neuroimage.2010.08.035; Fujiki M, 2006, NEUROSCI LETT, V405, P226, DOI 10.1016/j.neulet.2006.07.005; Giacino JT, 2004, NEUROREHABILITATION, V19, P293; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; HOMBERG V, 1991, ELECTROEN CLIN NEURO, V81, P377, DOI 10.1016/0168-5597(91)90027-U; Kloppel S, 2008, NEUROIMAGE, V40, P1782, DOI 10.1016/j.neuroimage.2008.01.019; Lapitskaya N, 2013, BRAIN STIMUL, V6, P130, DOI 10.1016/j.brs.2012.03.010; Lapitskaya N, 2009, PROG BRAIN RES, V177, P191, DOI 10.1016/S0079-6123(09)17713-0; Laureys S, 2005, TRENDS COGN SCI, V9, P556, DOI 10.1016/j.tics.2005.10.010; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Magistris MR, 1999, BRAIN, V122, P265, DOI 10.1093/brain/122.2.265; Manganelli F, 2008, CLIN NEUROPHYSIOL, V119, P351, DOI 10.1016/j.clinph.2007.10.011; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; MITTMANN T, 1994, NEUROSCIENCE, V60, P891, DOI 10.1016/0306-4522(94)90270-4; Moosavi SH, 1999, J NEUROL SCI, V164, P179, DOI 10.1016/S0022-510X(99)00065-9; Nardone R, 2008, J NEURAL TRANSM, V115, P737, DOI 10.1007/s00702-007-0003-6; Nardone R, 2011, DEMENT GERIATR COGN, V32, P18, DOI 10.1159/000330016; Nardone R, 2011, J NEURAL TRANSM, V118, P1349, DOI 10.1007/s00702-011-0650-5; Neumann-Haefelin T, 2000, J CEREBR BLOOD F MET, V20, P45, DOI 10.1097/00004647-200001000-00008; Oliviero A, 2005, CLIN NEUROPHYSIOL, V116, P2592, DOI 10.1016/j.clinph.2005.07.015; Paulus W, 2008, BRAIN STIMUL, V1, P151, DOI 10.1016/j.brs.2008.06.002; Pennisi G, 1999, STROKE, V30, P2666, DOI 10.1161/01.STR.30.12.2666; Puksa L, 2003, CLIN NEUROPHYSIOL, V114, P1079, DOI 10.1016/S1388-2457(03)00028-2; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Rossini PM, 1999, ELECTROENCEPHALOGR S, V52, P171; Samii A, 1998, MUSCLE NERVE, V21, P1445, DOI 10.1002/(SICI)1097-4598(199811)21:11<1445::AID-MUS12>3.3.CO;2-4; Schiene K, 1996, J CEREBR BLOOD F MET, V16, P906, DOI 10.1097/00004647-199609000-00014; Selden NR, 1998, BRAIN, V121, P2249, DOI 10.1093/brain/121.12.2249; Siebner HR, 2003, EXP BRAIN RES, V148, P1, DOI 10.1007/s00221-002-1234-2; Takeuchi N, 2006, BRAIN INJURY, V20, P991, DOI 10.1080/02699050600909771; Talelli P, 2006, CLIN NEUROPHYSIOL, V117, P1641, DOI 10.1016/j.clinph.2006.01.016; Taverni JP, 1998, BRAIN INJURY, V12, P77; Tokimura H, 2000, J PHYSIOL-LONDON, V523, P503, DOI 10.1111/j.1469-7793.2000.t01-1-00503.x; VALLSSOLE J, 1994, NEUROLOGY, V44, P735, DOI 10.1212/WNL.44.4.735	59	25	25	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1935-861X	1876-4754		BRAIN STIMUL	Brain Stimul.	JUL	2013	6	4					590	597		10.1016/j.brs.2013.01.002			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	189UA	WOS:000322292600018	23403267	Green Published			2022-02-06	
J	Rabinowitz, AR; Arnett, PA				Rabinowitz, Amanda R.; Arnett, Peter A.			Intraindividual Cognitive Variability Before and After Sports-Related Concussion	NEUROPSYCHOLOGY			English	Article						concussion; intraindividual variability; traumatic brain injury	PERFORMANCE; IMPACT; AGE; DEFICITS; DECLINE; SPEED	Objective: Inconsistent performance is associated with cognitive dysfunction in a number of clinical populations. However, intraindividual cognitive variability in healthy individuals is poorly understood. Inconsistency poses a challenge to clinicians when interpreting change over time. This study examined intraindividual cognitive variability within a sample of college athletes tested at baseline and postconcussion. Method: Athletes (n = 71) and control participants (n = 42) were tested with a comprehensive neuropsychological battery at baseline and postconcussion (athletes) or one month later (controls). A subset of indices with high internal consistency was used to calculate overall performance and performance variability. A k-means cluster analysis of baseline and postconcussion performance variability examined heterogeneity within the sample. Results: In the athlete sample, performance variability was significantly greater than zero, and was negatively correlated with overall performance at both time points (p < .001). Wechsler Test of Adult Reading Full Scale IQ estimate was significantly correlated with overall performance (p < .01), but not with performance variability. Cluster analysis revealed low-variability (n = 46) and high-variability (n = 25) cluster groups. Whereas the low-variability cluster group exhibited a pattern of performance similar to that of control participants, membership in the high-variability cluster group was associated with postconcussion cognitive dysfunction. Conclusion: These findings suggest that normative cognitive performance in college athletes is characterized by significant intraindividual variation across tests. Cross-test intraindividual variability may impart clinically meaningful information, as higher levels of variability were related to poorer overall performance and postconcussion cognitive dysfunction.	[Rabinowitz, Amanda R.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Arnett, Peter A.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA		Rabinowitz, AR (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 370 Stemmler Hall, Philadelphia, PA 19104 USA.	rabinowitz.a@gmail.com					Anstey KJ, 2007, NEUROPSYCHOLOGIA, V45, P1911, DOI 10.1016/j.neuropsychologia.2006.11.020; Backman L, 2006, NEUROSCI BIOBEHAV R, V30, P791, DOI 10.1016/j.neubiorev.2006.06.005; Bailey C. M., 2005, 33 ANN M INT NEUR SO; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barth JT, 1989, MILD HEAD INJURY, P257; Benedict R., 1997, BRIEF VISUOSPATIAL M; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BRITTON TC, 1991, ELECTROEN CLIN NEURO, V81, P186, DOI 10.1016/0168-5597(91)90071-5; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; BUNCE DJ, 1993, PSYCHOL AGING, V8, P26, DOI 10.1037/0882-7974.8.1.26; Cegalis J., 1991, VIGIL SOFTWARE ASSES; CONDER R, 1992, COMPUTERIZED ASSESSM; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Halpern DF, 1997, AM PSYCHOL, V52, P1091, DOI 10.1037/0003-066X.52.10.1091; Holtzer R, 2008, JAMA-J AM MED ASSOC, V300, P823, DOI 10.1001/jama.300.7.823; Hultsch D. F., 2008, HDB AGING COGNITION, P491, DOI DOI 10.4324/9780203837665.CH10; Hultsch D. F., 2004, NEW FRONTIERS COGNIT, P65, DOI DOI 10.1093/ACPROF:OSO/9780198525691.003.0004; Hultsch DF, 2000, NEUROPSYCHOLOGY, V14, P588, DOI 10.1037/0894-4105.14.4.588; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kliegel M, 2004, GERONTOLOGY, V50, P39, DOI 10.1159/000074388; Lovden M, 2007, NEUROPSYCHOLOGIA, V45, P2827, DOI 10.1016/j.neuropsychologia.2007.05.005; Lovell M, 2000, IMPACT IMMEDIATE POS; MacDonald SWS, 2009, PSYCHOL AGING, V24, P792, DOI 10.1037/a0017798; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ragan BG, 2007, ATHLET THER TODAY, V12, P2; Ram N, 2005, PSYCHOL AGING, V20, P623, DOI 10.1037/0882-7974.20.4.623; Randolph C, 2005, J ATHL TRAINING, V40, P139; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schretlen DJ, 2003, J INT NEUROPSYCH SOC, V9, P864, DOI 10.1017/S1355617703960061; Smith A., 1982, SYMBOL DIGIT MODALIT; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Stuss DT, 2003, BRAIN, V126, P2363, DOI 10.1093/brain/awg237; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Walhovd KB, 2007, NEUROPSYCHOLOGIA, V45, P2277, DOI 10.1016/j.neuropsychologia.2007.02.022; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT; West R, 2002, BRAIN COGNITION, V49, P402, DOI 10.1006/brcg.2001.1507	43	25	25	0	22	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JUL	2013	27	4					481	490		10.1037/a0033023			10	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	185SC	WOS:000321989600008	23876120				2022-02-06	
J	Siegel, BS; Davis, BE				Siegel, Benjamin S.; Davis, Beth Ellen		Comm Psychosocial Aspects Child; Family Hlth & Sect Uniformed Serv	Health and Mental Health Needs of Children in US Military Families	PEDIATRICS			English	Article						military; families; children; deployment; mental health; health maintenance	FACING WARTIME DEPLOYMENTS; CENTERED PREVENTION; YOUNG-CHILDREN; DESERT-STORM; COMBAT; ARMY; IRAQ; INTERVENTION; PEDIATRICIAN; MALTREATMENT	The wars in Afghanistan and Iraq have been challenging for US uniformed service families and their children. Almost 60% of US service members have family responsibilities. Approximately 2.3 million active duty, National Guard, and Reserve service members have been deployed since the beginning of the wars in Afghanistan and Iraq (2001 and 2003, respectively), and almost half have deployed more than once, some for up to 18 months' duration. Up to 2 million US children have been exposed to a wartime deployment of a loved one in the past 10 years. Many service members have returned from combat deployments with symptoms of posttraumatic stress disorder, depression, anxiety, substance abuse, and traumatic brain injury. The mental health and well-being of spouses, significant others, children (and their friends), and extended family members of deployed service members continues to be significantly challenged by the experiences of wartime deployment as well as by combat mortality and morbidity. The medical system of the Department of Defense provides health and mental health services for active duty service members and their families as well as activated National Guard and Reserve service members and their families. In addition to military pediatricians and civilian pediatricians employed by military treatment facilities, nonmilitary general pediatricians care for >50% of children and family members before, during, and after wartime deployments. This clinical report is for all pediatricians, both active duty and civilian, to aid in caring for children whose loved ones have been, are, or will be deployed.						Siegel, Benjamin/0000-0003-3572-2575			American Psychological Association, 2007, PSYCH NEEDS US MIL S; [Anonymous], 2009, HON OUR BAB TODDL SU; Applewhite LW, 1986, CHILD ADOLESC SOCIAL, V13, P23; Aranda MC, 2011, MIL MED, V176, P402, DOI 10.7205/MILMED-D-10-00202; Bachynski KE, 2012, INJURY PREV, V18, P405, DOI 10.1136/injuryprev-2011-040112; Barker LH, 2009, MIL MED, V174, P1033, DOI 10.7205/MILMED-D-04-1108; Beardslee W, 2011, PREV SCI, V12, P339, DOI 10.1007/s11121-011-0234-5; CHANDRA A, 2008, UNDERSTANDING IMPACT; Chandra A, 2010, PEDIATRICS, V125, P16, DOI 10.1542/peds.2009-1180; Chartrand MM, 2008, ARCH PEDIAT ADOL MED, V162, P1009, DOI 10.1001/archpedi.162.11.1009; Coleman WL, 2009, PEDIATRICS, V124, P410, DOI 10.1542/peds.2009-1061; Cozza SJ, 2005, PSYCHIAT QUART, V76, P371, DOI 10.1007/s11126-005-4973-y; Cozza SJ, 2010, J TRAUMA STRESS, V23, P112, DOI 10.1002/jts.20488; Davis BE, 2012, PEDIATRICS, V129, pS3, DOI 10.1542/peds.2010-3797c; Department of Defense, 2009, DEM PROF MIL COMM; Drummet AR, 2003, FAM RELAT, V52, P279, DOI 10.1111/j.1741-3729.2003.00279.x; Flake EM, 2009, J DEV BEHAV PEDIATR, V30, P271, DOI 10.1097/DBP.0b013e3181aac6e4; Foy Jane Meschan, 2010, Pediatrics, V125 Suppl 3, pS109, DOI 10.1542/peds.2010-0788F; Gibbs DA, 2007, JAMA-J AM MED ASSOC, V298, P528, DOI 10.1001/jama.298.5.528; Gorman GH, 2010, PEDIATRICS, V126, P1058, DOI 10.1542/peds.2009-2856; Gorman LA, 2011, PSYCHIAT SERV, V62, P28, DOI 10.1176/ps.62.1.pss6201_0028; Hagan JF, 2005, PEDIATRICS, V116, P787, DOI 10.1542/peds.2005-1498; Hill R, 1971, FAMILIES STRESS ADJU; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Howell Alison, 2011, WAR COMES HOME TOLL; Huebner AJ., 2005, ADJUSTMENTS ADOLESCE; Jensen PS, 1996, J AM ACAD CHILD PSY, V35, P433, DOI 10.1097/00004583-199604000-00009; KELLEY ML, 1994, AM J ORTHOPSYCHIAT, V64, P103, DOI 10.1037/h0079499; LAGRONE DM, 1978, AM J PSYCHIAT, V135, P1040; Lester P, 2012, AM J PUBLIC HEALTH, V102, pS48, DOI 10.2105/AJPH.2010.300088; Lester P, 2011, MIL MED, V176, P19, DOI 10.7205/MILMED-D-10-00122; Lester P, 2010, J AM ACAD CHILD PSY, V49, P310, DOI 10.1016/j.jaac.2010.01.003; Levetown M, 2008, PEDIATRICS, V121, pE1441, DOI 10.1542/peds.2008-0565; Lozano P, 2010, ARCH PEDIAT ADOL MED, V164, P561, DOI 10.1001/archpediatrics.2010.86; Mansfield AJ, 2011, ARCH PEDIAT ADOL MED, V165, P999, DOI 10.1001/archpediatrics.2011.123; Mansfield AJ, 2010, NEW ENGL J MED, V362, P101, DOI 10.1056/NEJMoa0900177; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; National Military Family Association, 2005, REP CYCL DEPL SURV A; National Scientific Council on the Developing Child, 2010, PERS FEAR ANX CAN AF; Orthner DK, 2005, SAF 5 SURVEY REPORT; PATTERSON JM, 1984, J MARRIAGE FAM, V46, P95, DOI 10.2307/351868; Pincus SH, 2001, EMOTIONAL CYCLE DEPL; RAND Corporation, 2008, INVISIBLE WOUNDS WAR; Rentz ED, 2007, AM J EPIDEMIOL, V165, P1199, DOI 10.1093/aje/kwm008; ROSEN LN, 1993, MIL MED, V158, P465, DOI 10.1093/milmed/158.7.465; Saltzman WR, 2011, CLIN CHILD FAM PSYCH, V14, P213, DOI 10.1007/s10567-011-0096-1; Smith DC, 2010, OBSTET GYNECOL, V116, P679, DOI 10.1097/AOG.0b013e3181eb6c84; Strategic Outreach to Families of All Reservists (SOFAR), SOFAR GUID HELP CHIL; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Waterhouse M, 2008, CRS C; Wessel MA, 2003, PEDIATR REV, V24, P183, DOI 10.1542/pir.24-6-183; Wolraich ML, 2000, PEDIATRICS, V105, P445; Woolston J L, 1986, Pediatr Rev, V8, P169, DOI 10.1542/pir.8-6-169	54	25	25	0	27	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUN	2013	131	6					E2002	E2015		10.1542/peds.2013-0940			14	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	197HH	WOS:000322840200040	23713100	Bronze			2022-02-06	
J	O'Sullivan, DM; Fife, GP; Pieter, W; Shin, I				O'Sullivan, David M.; Fife, Gabriel P.; Pieter, Willy; Shin, Insik			Safety performance evaluation of taekwondo headgear	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							BLOWS	Background With over 20 years of taekwondo concussion research highlighting the high incidence of injury, previous studies recommend an investigation of headgear impact attenuation performance. Objective To examine impact attenuation differences between the anterior, posterior and sides of selected taekwondo headgear brands. Design Between-groups. Setting Biomechanics laboratory. Methods Five different commercially available taekwondo headgear were selected for impact testing. A 50th percentile Hybrid II Dummy Crash Test head and neck was fitted with the selected helmet and was bolted to a 25 kg steel torso-like structure. Each headgear model was impacted eight times to the anterior, posterior and sides by a 6.75 kg bowling ball at three heights to produce 52.25, 85 and 144 J strikes. Main outcome measurements Resultant head linear acceleration. Results Two-way (HelmetxLocation) mixed analysis of variance with repeated measures on the second factor was performed to determine the differences between headgear by location of impact. There was a two-way (HelmetxLocation) interaction for acceleration (eta(2)=0.368). Conclusions Taekwondo headgear manufacturers and sport governing bodies must consider improving the design of especially anterior helmet properties.	[O'Sullivan, David M.] Chung Ang Univ, Dept Phys Educ, Anseong, South Korea; [Fife, Gabriel P.] Yonsei Univ, Dept Phys Educ, Integrat Sport Sci Lab, Seoul 120749, South Korea; [Pieter, Willy] Keimyung Univ, Dept Taekwondo, Taegu, South Korea; [Shin, Insik] Seoul Natl Univ, Dept Phys Educ, Seoul, South Korea		Fife, GP (corresponding author), Yonsei Univ, Dept Phys Educ, Integrat Sport Sci Lab, 50 Yonsei Ro, Seoul 120749, South Korea.	fifeg.yonsei@gmail.com			Yonsei University Research Fund	This study was supported by the Yonsei University Research Fund.	Aare M, 2004, INT J CRASHWORTHINES, V9, P15, DOI 10.1533/ijcr.2004.0268; [Anonymous], 2013, WORLD TAEKWONDO 0101; [Anonymous], F 2397 04 SPEC PROT; [Anonymous], 2008, WORLD TAEKW HEADQ; Chiu PH, 2007, J BIOMECH; Cohen J., 2013, STAT POWER ANAL BEHA; Cohen JE, 2010, ISR MED ASSOC J, V12, P509; Duncan J M, 1874, Br Med J, V2, P763; Fife GP, 2013, BRIT J SPORT MED, V47, P1161, DOI 10.1136/bjsports-2012-090979; Fife GP, INT SPORT M IN PRESS; Foster J. K., 1977, STAPP CAR CRASH J, V21, P975, DOI [10.4271/770938, DOI 10.4271/770938]; GURDJIAN ES, 1947, JAMA-J AM MED ASSOC, V134, P1072, DOI 10.1001/jama.1947.02880300014005; Hamel A, 2013, INT J LEGAL MED, V127, P111, DOI 10.1007/s00414-011-0627-9; Hanson O, 2011, P 3 INT S TAEKW STUD, P108; Hertzberg HE, 1969, P 13 STAPP CAR CRASH; Hopkins GW, NEW VIEW STAT; Kim SB, 1997, KOREAN J PHYS ED, V36, P348; Koh JO, 2004, CLIN J SPORT MED, V14, P72, DOI 10.1097/00042752-200403000-00004; Koh JO, 2002, J SPORT MED PHYS FIT, V42, P348; Koh JO, 2002, CROSSING BOUND INTER, V1, P79; Koh JO, 2011, P 3 INT S TAEKW STUD, P202; Leopold J., 1999, LOS ANGELES TIM 0111; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; Lieu D, 1995, THESIS U CALIFORNIA; McElhaney JH, 1962, P S HUM IMP RESP WAR; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; National Highway Traffic Safety Administration, 2013, THOR ADV CRASH TEST; National Operating Committee on Standards for Athletic Equipment (NOCSAE), 2009, 00108M10 NOCSAE DOC; O'Sullivan D, 2009, J SPORT SCI MED, V8, P13; Pieter W, 1998, J ROY SOC HEALTH, V118, P272, DOI 10.1177/146642409811800512; Pieter W, 2012, BRIT J SPORT MED, V46, P485, DOI 10.1136/bjsports-2012-091011; PINTAR FA, 1990, 34TH P STAPP CAR CRA, P55; Queck C, 2009, STRAITS TIMES S 0711; SAE (Society of Automotive Engineers), 1995, J2111 SAE; Scott MW, 1993, 930094 SAE INC; Siana J E, 1986, Br J Sports Med, V20, P165; Spittle, 1991, HYBRID 2 HYBRID 3 DU; Van Mechelen W, 1992, AETIOLOGY PREVENTION; Yoganandan N, 2004, CLIN BIOMECH, V19, P225, DOI 10.1016/j.clinbiomech.2003.12.014	41	25	25	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2013	47	7					447	451		10.1136/bjsports-2012-091416			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	124OW	WOS:000317475200010	23349318				2022-02-06	
J	Ponsford, JL; Downing, MG; Stolwyk, R				Ponsford, Jennie L.; Downing, Marina G.; Stolwyk, Rene			Factors Associated With Sexuality Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						sexual changes; sexuality; sexuality questionnaire; traumatic brain injury	PSYCHIATRIC-DISORDERS; INDIVIDUALS; DYSFUNCTION; VALIDATION	Background: Previous research has demonstrated that sexuality is compromised following traumatic brain injury (TBI). Objectives: The aim of this study was to determine the association between sexuality following TBI and demographic, injury-related, and postinjury variables (age, gender, time since injury, posttraumatic amnesia duration, independence in activities of daily activities (ADL), antidepressant use, depression, and self-esteem). Methods: Participants included 986 individuals with predominantly moderate to severe TBI, who completed the Brain Injury Questionnaire of Sexuality (BIQS), the Hospital Anxiety and Depression Scale, and the Rosenberg Self-Esteem Scale and an ADL assessment on 1 or more occasions, providing a total of 1673 assessments across 1, 2, 3, 5, 10, and 20 years postinjury. Results: Being depressed, older in age, at shorter time postinjury, and less independent in ADL significantly predicted poorer overall BIQS scores as well as the Sexual Functioning subscale score. Poorer Relationship Quality and Self-esteem scores on the BIQS were predicted by older age at injury and higher levels of depression. Lower Mood score on the BIQS was associated with shorter posttraumatic amnesia duration, younger age, and higher levels of depression. Self-esteem was associated positively with sexuality outcome. Conclusions: Therapeutic interventions for sexuality need to focus on depression where indicated and self-esteem and address specific barriers to social participation and opportunities for sexual contact in individuals who are less independent in ADL.	[Ponsford, Jennie L.; Downing, Marina G.; Stolwyk, Rene] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Ponsford, Jennie L.; Downing, Marina G.] Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie L.] Natl Trauma Res Inst, Melbourne, Vic, Australia		Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Bldg 17,Wellington Rd, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Downing, Marina/AAX-2380-2020	Downing, Marina/0000-0002-3126-6632	Transport Accident Commission, through the Institute for Safety, Compensation and Recovery Research	This project is funded by the Transport Accident Commission, through the Institute for Safety, Compensation and Recovery Research.	Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Basson R, 2007, LANCET, V369, P409, DOI 10.1016/S0140-6736(07)60197-4; Cooper-Evans S, 2008, NEUROPSYCHOL REHABIL, V18, P607, DOI 10.1080/09602010801948516; Corona G, 2009, J SEX MED, V6, P1259, DOI 10.1111/j.1743-6109.2009.01248.x; Downing MG, 2013, J HEAD TRAUMA REHAB, V28, P171, DOI 10.1097/HTR.0b013e31828b4f63; Gaudet L, 2001, SEX DISABIL, V19, P111, DOI 10.1023/A:1010673722429; Gill CJ, 2011, J HEAD TRAUMA REHAB, V26, P56, DOI 10.1097/HTR.0b013e3182048ee9; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Horn LJ, 1990, J HEAD TRAUMA REHAB, V5, P1; Howes H, 2005, BRAIN INJURY, V19, P135, DOI 10.1080/02699050410001720077; Howes HFR, 2005, BRAIN INJURY, V19, P403, DOI 10.1080/02699050400025158; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; Lindau ST, 2007, NEW ENGL J MED, V357, P762, DOI 10.1056/NEJMoa067423; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; PFEIFFER E, 1972, J AM GERIATR SOC, V20, P151, DOI 10.1111/j.1532-5415.1972.tb00789.x; Ponsford J, 2003, NEUROPSYCHOL REHABIL, V13, P275, DOI 10.1080/09602010244000363; Ponsford J, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1067; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Rosenberg M., 1965, SOC ADOLESCENT SELF; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Shoshan L, 2012, REHABIL NURS, V37, P11, DOI 10.1002/RNJ.00002; SIMPSON GK, 1999, YOU ME ED PROGRAM SE; Snaith R., 1994, HOSP ANXIETY DEPRESS; Stolwyk RJ, 2013, J HEAD TRAUMA REHAB, V28, P164, DOI 10.1097/HTR.0b013e31828197d1; Verschuren JEA, 2010, J SEX RES, V47, P153, DOI 10.1080/00224491003658227; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa	30	25	25	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2013	28	3					195	201		10.1097/HTR.0b013e31828b4f7b			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	149PS	WOS:000319334000006	23661071				2022-02-06	
J	Gao, HL; Li, C; Nabeka, H; Shimokawa, T; Saito, S; Wang, ZY; Cao, YM; Matsuda, S				Gao, H. L.; Li, C.; Nabeka, H.; Shimokawa, T.; Saito, S.; Wang, Z. Y.; Cao, Y. M.; Matsuda, S.			ATTENUATION OF MPTP/MPP+ TOXICITY IN VIVO AND IN VITRO BY AN 18-MER PEPTIDE DERIVED FROM PROSAPOSIN	NEUROSCIENCE			English	Article						prosaposin-derived 18-mer peptide; dopaminergic neurons; 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-methyl-4-phenylpyridinium ion; SH-SY5Y; Parkinson's disease	CEREBELLAR GRANULE NEURONS; INDUCED PARKINSONS-DISEASE; ACTIVATED PROTEIN-KINASE; TRAUMATIC BRAIN-INJURY; CELL-DEATH PREVENTION; C-JUN; DOPAMINERGIC-NEURONS; GLIAL-CELLS; SIGNAL-TRANSDUCTION; NEUROTROPHIC FACTOR	Parkinson's disease (PD) is a chronic progressive neurological disorder with an increasing incidence in the aging population. Neuroprotective and/or neuroregenerative strategies remain critical in the treatment of this increasingly prevalent disease. Prosaposin is a neurotrophic factor whose neurotrophic activity is attributed to a stretch of 12 amino acids located at the N-terminal region of saposin C. The present study was performed to investigate the protective effect and mechanism of action of a prosaposin-derived 18-mer peptide (PS18: LSELIINNATEELLIKGL) in Parkinson's disease models. We used 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 1-methyl-4-phenylpyridinium ion (MPP+)-induced dopaminergic neurotoxicity in C57BL/6J mice or SH-SY5Y cells and explored the protective effect and mechanisms of action of PS18 on dopaminergic neurons. Treatment with 2.0 mg/kg PS18 significantly improved behavioral deficits, enhanced the survival of tyrosine hydroxylase-positive neurons, and decreased the activity of astrocytes in the substantia nigra and striatum in MPTP-induced PD model mice. In vitro, a Cell Counting Kit-8 assay and Hoechst 33258 staining revealed that co-treatment with 300 ng/mL PS18 and 5 mM MPP+ protected against MPP+-induced nuclear morphological changes and attenuated cell death induced by MPP+. We also found that PS18-FAM entered the cells, and the retention time of PS18-FAM in the cytoplasm of MPP+-treated cells was shorter than that of untreated cells. In addition, PS18 showed protection from MPP+/MPTP-induced apoptosis in the SH-SY5Y cells and dopaminergic neurons in the PD model mice via suppression of the c-Jun N-terminal kinase/c-Jun pathway; upregulation of Bcl-2; downregulation of BAX, attenuating mitochondrial damage; and inhibition of caspase-3. These findings suggest that PS18 may provide a valuable therapeutic strategy for the treatment of progressive neurodegenerative diseases such as PD. (C) 2013 IBRO. Published by Elsevier Ltd. All rights reserved.	[Gao, H. L.; Li, C.; Nabeka, H.; Shimokawa, T.; Matsuda, S.] Ehime Univ, Grad Sch Med, Dept Anat & Embryol, Toon, Ehime 7910295, Japan; [Saito, S.] Gifu Univ, Fac Appl Biol Sci, Lab Vet Anat, Gifu, Japan; [Gao, H. L.; Wang, Z. Y.] Northeastern Univ, Coll Life & Hlth Sci, Shenyang, Peoples R China; [Li, C.; Cao, Y. M.] China Med Univ, Dept Immunol, Shenyang, Peoples R China		Nabeka, H (corresponding author), Ehime Univ, Grad Sch Med, Dept Anat & Embryol, Toon, Ehime 7910295, Japan.	nabeka@m.ehime-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [14370466, 22591637, 19659380]	This study was supported in part by Grants to SM (Nos. 14370466, 22591637, 19659380) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The English in this document has been checked by at least two professional editors, both native speakers of English. For a certificate, please see: http://www.textcheck.com/certificate/AOHNpL.	Beal M F, 1992, Curr Opin Neurobiol, V2, P657, DOI 10.1016/0959-4388(92)90035-J; Bjorklund A, 2007, TRENDS NEUROSCI, V30, P194, DOI 10.1016/j.tins.2007.03.006; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; Borsello T, 2007, CURR PHARM DESIGN, V13, P1875; Cabral ALB, 2001, MOL CELL ENDOCRINOL, V175, P67, DOI 10.1016/S0303-7207(01)00396-3; Campana WM, 1998, FASEB J, V12, P307, DOI 10.1096/fasebj.12.3.307; Cheng BH, 2007, AUTON NEUROSCI-BASIC, V134, P38, DOI 10.1016/j.autneu.2007.02.002; Choi WS, 1999, J NEUROSCI RES, V57, P86, DOI 10.1002/(SICI)1097-4547(19990701)57:1<86::AID-JNR9>3.3.CO;2-5; Chun HS, 2001, J NEUROCHEM, V76, P1010, DOI 10.1046/j.1471-4159.2001.00096.x; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Crompton M, 2000, CURR OPIN CELL BIOL, V12, P414, DOI 10.1016/S0955-0674(00)00110-1; Czlonkowska A, 1996, NEURODEGENERATION, V5, P137, DOI 10.1006/neur.1996.0020; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dodel RC, 1998, NEUROSCIENCE, V86, P701, DOI 10.1016/S0306-4522(98)00154-7; FURST W, 1988, BIOL CHEM H-S, V369, P317, DOI 10.1515/bchm3.1988.369.1.317; Gao HL, 2009, NEUROTOX RES, V16, P416, DOI 10.1007/s12640-009-9072-7; Gearan T, 2001, PARKINSONISM RELAT D, V8, P19, DOI 10.1016/S1353-8020(00)00078-X; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hartmann A, 2001, J NEUROCHEM, V76, P1785, DOI 10.1046/j.1471-4159.2001.00160.x; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213; Hiesberger T, 1998, EMBO J, V17, P4617, DOI 10.1093/emboj/17.16.4617; Himeda T, 2006, J NEURAL TRANSM, V113, P1887, DOI 10.1007/s00702-006-0482-x; HINENO T, 1991, BIOCHEM BIOPH RES CO, V176, P668, DOI 10.1016/S0006-291X(05)80236-0; Hiraiwa M, 1997, P NATL ACAD SCI USA, V94, P4778, DOI 10.1073/pnas.94.9.4778; HIRAIWA M, 1992, P NATL ACAD SCI USA, V89, P11254, DOI 10.1073/pnas.89.23.11254; HIRAIWA M, 1993, J BIOCHEM-TOKYO, V114, P901, DOI 10.1093/oxfordjournals.jbchem.a124274; Hiraiwa M, 1997, BIOCHEM BIOPH RES CO, V240, P415, DOI 10.1006/bbrc.1997.7673; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Hozumi I, 1999, NEUROSCI LETT, V267, P73, DOI 10.1016/S0304-3940(99)00325-0; Igase K, 1999, J CEREBR BLOOD F MET, V19, P298, DOI 10.1097/00004647-199903000-00008; Joel D, 2000, NEUROSCIENCE, V96, P451, DOI 10.1016/S0306-4522(99)00575-8; Junn E, 2001, J NEUROCHEM, V78, P374, DOI 10.1046/j.1471-4159.2001.00425.x; Kanthasamy AG, 2006, FREE RADICAL BIO MED, V41, P1578, DOI 10.1016/j.freeradbiomed.2006.08.016; Kim HE, 2001, BIOCHEM BIOPH RES CO, V286, P659, DOI 10.1006/bbrc.2001.5446; Kim IS, 2011, EUR J PHARMACOL, V650, P48, DOI 10.1016/j.ejphar.2010.09.063; Kohutnicka M, 1998, IMMUNOPHARMACOLOGY, V39, P167, DOI 10.1016/S0162-3109(98)00022-8; Kotani Y, 1996, J NEUROCHEM, V66, P2197; Kotani Y, 1996, J NEUROCHEM, V66, P2019; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Lee DH, 2008, BIOCHEM PHARMACOL, V75, P2345, DOI 10.1016/j.bcp.2008.03.013; Liberatore GT, 1999, NAT MED, V5, P1403; Matsuda W, 2009, J NEUROSCI, V29, P444, DOI 10.1523/JNEUROSCI.4029-08.2009; Mazumder Suparna, 2008, V414, P13; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Misasi R, 2001, FASEB J, V15, P467, DOI 10.1096/fj.00-0217com; Misasi R, 2004, EXP CELL RES, V298, P38, DOI 10.1016/j.yexcr.2004.04.011; Mizuno Y, 1998, INTERNAL MED, V37, P192, DOI 10.2169/internalmedicine.37.192; Morita F, 2001, J CEREBR BLOOD F MET, V21, P1295, DOI 10.1097/00004647-200111000-00005; Morris MA, 2001, FASEB J, V15, pA1026, DOI 10.1096/fj.00-0603fje; Newman M, 2009, J ALZHEIMERS DIS, V16, P133, DOI 10.3233/JAD-2009-0945; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; OBRIEN JS, 1995, FASEB J, V9, P681, DOI 10.1096/fasebj.9.8.7768361; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; OYARCE AM, 1991, ARCH BIOCHEM BIOPHYS, V290, P503, DOI 10.1016/0003-9861(91)90573-2; Pan J, 2007, NEUROSCI LETT, V428, P82, DOI 10.1016/j.neulet.2007.09.032; Pan J, 2010, LAB INVEST, V90, P156, DOI 10.1038/labinvest.2009.124; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Przedborski S, 2000, RESTOR NEUROL NEUROS, V16, P135; Qi XY, 1996, J BIOL CHEM, V271, P6874, DOI 10.1074/jbc.271.12.6874; Rawal N, 2007, CELL DEATH DIFFER, V14, P381, DOI 10.1038/sj.cdd.4402010; Riedout HJ, 2001, HISTOL HISTOPATHOL, V16, P895, DOI 10.14670/HH-16.895; RORMAN EG, 1989, GENOMICS, V5, P486, DOI 10.1016/0888-7543(89)90014-1; Samii A, 2004, LANCET, V363, P1783, DOI 10.1016/S0140-6736(04)16305-8; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; Saporito MS, 2000, J NEUROCHEM, V75, P1200, DOI 10.1046/j.1471-4159.2000.0751200.x; Saporito MS, 1999, J PHARMACOL EXP THER, V288, P421; Sikora J, 2007, ACTA NEUROPATHOL, V113, P163, DOI 10.1007/s00401-006-0148-7; Song B, 2011, NEUROSCI LETT, V505, P76, DOI 10.1016/j.neulet.2011.09.060; Sortwell CE, 2000, J COMP NEUROL, V426, P143; Sun YN, 2005, WORLD J GASTROENTERO, V11, P4827, DOI 10.3748/wjg.v11.i31.4827; TAKAHASHI T, 1994, J NEURAL TRANSM-GEN, V98, P107, DOI 10.1007/BF01277014; Tatton WG, 2003, ANN NEUROL, V53, pS61, DOI 10.1002/ana.10489; Taylor EM, 2000, J PHARMACOL EXP THER, V293, P403; Teismann P, 2003, MOVEMENT DISORD, V18, P121, DOI 10.1002/mds.10332; Teng XC, 2006, J NEUROCHEM, V97, P1126, DOI 10.1111/j.1471-4159.2006.03833.x; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsuboi K, 1998, DEV BRAIN RES, V110, P249, DOI 10.1016/S0165-3806(98)00109-6; UNGERSTEDT U, 1971, ACTA PHYSIOL SCAND, P49; VANELDIK LJ, 1984, P NATL ACAD SCI-BIOL, V81, P6034; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; Yamada M, 2010, BIOCHEM BIOPH RES CO, V402, P312, DOI 10.1016/j.bbrc.2010.10.023; Yokoyama H, 2011, NEUROL SCI, V32, P1, DOI 10.1007/s10072-010-0424-0	88	25	25	0	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 16	2013	236						373	393		10.1016/j.neuroscience.2013.01.007			21	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	115QT	WOS:000316827700032	23321539				2022-02-06	
J	Esquenazi, A; Lee, S; Packel, AT; Braitman, L				Esquenazi, Alberto; Lee, Stella; Packel, Andrew T.; Braitman, Leonard			A Randomized Comparative Study of Manually Assisted Versus Robotic-Assisted Body Weight Supported Treadmill Training in Persons With a Traumatic Brain Injury	PM&R			English	Article							DRIVEN GAIT ORTHOSIS; STROKE REHABILITATION; PHYSICAL-THERAPY; MUSCLE STRENGTH; BOBATH CONCEPT; WALKING SPEED; SPINAL-CORD; IMPACT; PHYSIOTHERAPY; IMPROVEMENT	Objectives: (1) To compare the effects of robotic-assisted treadmill training (RATT) and manually assisted treadmill training (MATT) in participants with traumatic brain injury (TBI) and (2) to determine the potential impact on the symmetry of temporal walking parameters, 6-minute walk test, and the mobility domain of the Stroke Impact Scale, version 3.0 (SIS). Design: Randomized prospective study. Subjects: A total of 16 participants with TBI and a baseline over ground walking self-selected velocity (SSV) of >= 0.2 m/s to 0.6 m/s randomly assigned to either the RATT or MATT group. Intervention: Gait training for 45 minutes, 3 times a week with either RATT or MATT for a total of 18 training sessions. Outcome Measures: Primary: Overground walking SSV, maximal velocity. Secondary: Spatiotemporal symmetry, 6-minute walk test, and SIS. Results: Between-group differences were not statistically significant for any measure. However, from pretraining to post-training, the average SSV increased by 49.8% for the RATT group (P = .01) and by 31% for MATT group (P = .06). The average maximal velocity increased by 14.9% for the RATT group (P = .06) and by 30.8% for the MATT group (P = .01). Less staffing and effort was needed for RATT in this study. Step-length asymmetry ratio improved during SSV by 33.1% for the RATT group (P = .01) and by 9.1% for the MATT group (P = .73). The distance walked increased by 11.7% for the robotic group (P = .21) and by 19.3% for manual group (P = .03). A statistically significant improvement in the mobility domain of the SIS was found for both groups (P <= .03). Conclusions: The results of this study demonstrate greater improvement in symmetry of gait (step length) for RATT and no significant differences between RATT and MATT with regard to improvement in gait velocity, endurance, and SIS. Our study provides evidence that participants with a chronic TBI can experience improvements in gait parameters with gait training with either MATT or RATT.	[Esquenazi, Alberto] MossRehab, Dept Phys Med & Rehabil, Gait & Mot Anal Lab, Elkins Pk, PA 19027 USA; [Lee, Stella] MossRehab, Gait & Mot Anal Lab, Elkins Pk, PA 19027 USA; [Packel, Andrew T.] MossRehab, Dept Phys Therapy, Gait & Mot Anal Lab, Elkins Pk, PA 19027 USA; [Braitman, Leonard] Albert Einstein Healthcare Network, Res & Technol Dev, Philadelphia, PA USA		Esquenazi, A (corresponding author), MossRehab, Dept Phys Med & Rehabil, Gait & Mot Anal Lab, 60 Township Line Rd, Elkins Pk, PA 19027 USA.	aesquena@einstein.edu	Packel, Andrew/AAJ-4840-2021	Packel, Andrew/0000-0002-5048-1661	MossRehab Research Fund; Department of Defense, CDC	Disclosure related to this publication: grant, MossRehab Research Fund; Disclosure outside this publication: grants, Department of Defense, CDC	Adolph KE, 2003, CHILD DEV, V74, P475, DOI 10.1111/1467-8624.7402011; Bohannon RW, 2007, J REHABIL MED, V39, P14, DOI 10.2340/16501977-0018; Brunham Sandra, 1992, Physiotherapy Theory and Practice, V8, P215, DOI 10.3109/09593989209108105; Carr J. H., 1998, NEUROLOGICAL REHABIL; Chen G, 2005, GAIT POSTURE, V22, P57, DOI 10.1016/j.gaitpost.2004.06.008; Cherng RJ, 2007, AM J PHYS MED REHAB, V86, P548, DOI 10.1097/PHM.0b013e31806dc302; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Colombo G, 2000, J REHABIL RES DEV, V37, P693; Colombo G, 2001, SPINAL CORD, V39, P252, DOI 10.1038/sj.sc.3101154; Combs Stephanie A., 2011, Physiotherapy Theory and Practice, V27, P223, DOI 10.3109/09593985.2010.485628; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; da Cunha IT, 2002, ARCH PHYS MED REHAB, V83, P1258, DOI 10.1053/apmr.2002.34267; DeJong G, 2005, ARCH PHYS MED REHAB, V86, pS1, DOI 10.1016/j.apmr.2005.09.003; DICKSTEIN R, 1986, PHYS THER, V66, P1233, DOI 10.1093/ptj/66.8.1233; Dobkin B, 2006, NEUROLOGY, V66, P484, DOI 10.1212/01.wnl.0000202600.72018.39; Dromerick Alexander W, 2006, NeuroRx, V3, P428, DOI 10.1016/j.nurx.2006.07.004; Duncan PW, 2011, NEW ENGL J MED, V364, P2026, DOI 10.1056/NEJMoa1010790; Duncan PW, 2003, NEUROLOGY, V60, P291, DOI 10.1212/01.WNL.0000041493.65665.D6; Elovic E, 1996, MED REHABILITATION T; Esquenazi A, 2011, PHYS MED REHABILITAT, P99; Fait PE, 2011, PERCEPT MOTOR SKILL, V112, P29, DOI 10.2466/05.10.23.25.PMS.112.1.29-43; Flansbjer UB, 2006, ARCH PHYS MED REHAB, V87, P974, DOI 10.1016/j.apmr.2006.03.008; Freivogel S, 2008, BRAIN INJURY, V22, P625, DOI 10.1080/02699050801941771; Hafsteinsdottir TB, 2005, J NEUROL NEUROSUR PS, V76, P788, DOI 10.1136/jnnp.2004.042267; Harris-Love ML, 2001, NEUROREHAB NEURAL RE, V15, P105, DOI 10.1177/154596830101500204; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; Hesse S, 2001, ARCH PHYS MED REHAB, V82, P1547, DOI 10.1053/apmr.2001.26607; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; Hornby TG, 2008, STROKE, V39, P1786, DOI 10.1161/STROKEAHA.107.504779; Husemann B, 2007, STROKE, V38, P349, DOI 10.1161/01.STR.0000254607.48765.cb; International Classification of Functioning Disability and Health, WHO MEMB STAT 54 WOR; Jezernik S, 2003, SPINAL CORD, V41, P657, DOI 10.1038/sj.sc.3101518; KARNI A, 1995, NATURE, V377, P155; Kollen BJ, 2009, STROKE, V40, pE89, DOI 10.1161/STROKEAHA.108.533828; KOTTKE FJ, 1978, ARCH PHYS MED REHAB, V59, P567; Kwakkel G, 2006, DISABIL REHABIL, V28, P823, DOI 10.1080/09638280500534861; Lai SM, 2003, STROKE, V34, P488, DOI 10.1161/01.STR.0000054162.94998.C0; Lamontagne A, 2004, STROKE, V35, P2543, DOI 10.1161/01.STR.0000144685.88760.d7; Laufer Y, 2001, J REHABIL RES DEV, V38, P69; Lennon S, 2006, DISABIL REHABIL, V28, P873, DOI 10.1080/09638280500535132; Lin KC, 2010, NEUROREHAB NEURAL RE, V24, P486, DOI 10.1177/1545968309356295; Lin PY, 2006, ARCH PHYS MED REHAB, V87, P562, DOI 10.1016/j.apmr.2005.12.042; Macko R F, 2005, Top Stroke Rehabil, V12, P45; Mayr A, 2007, NEUROREHAB NEURAL RE, V21, P307, DOI 10.1177/1545968307300697; McCain KJ, 2008, ARCH PHYS MED REHAB, V89, P684, DOI 10.1016/j.apmr.2007.09.050; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; Moseley AM, 2004, J HEAD TRAUMA REHAB, V19, P341, DOI 10.1097/00001199-200407000-00008; Partridge C, 1996, Physiother Res Int, V1, P205, DOI 10.1002/pri.59; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; Patterson SL, 2008, J REHABIL RES DEV, V45, P221, DOI 10.1682/JRRD.2007.02.0024; Perry J, 2010, GAIT ANALYSIS: NORMAL AND PATHOLOGICAL FUNCTION, SECOND EDITION, P1; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Pohl M, 2002, STROKE, V33, P553, DOI 10.1161/hs0202.102365; RICHARDS CL, 1993, ARCH PHYS MED REHAB, V74, P612, DOI 10.1016/0003-9993(93)90159-8; Sacco K, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00146; Schwartz I, 2009, PM&R, V1, P516, DOI 10.1016/j.pmrj.2009.03.009; Smith GV, 1999, STROKE, V30, P2112, DOI 10.1161/01.STR.30.10.2112; Smith PS, 2008, CLIN REHABIL, V22, P997, DOI 10.1177/0269215508088988; Sullivan KJ, 2002, ARCH PHYS MED REHAB, V83, P683, DOI 10.1053/apmr.2002.32488; Taylor A, 1980, P INT C REH ENG TOR; Torres-Oviedo G, 2011, PROG BRAIN RES, V191, P65, DOI 10.1016/B978-0-444-53752-2.00013-8; Tucker JA, 2008, REHABIL PSYCHOL, V53, P279, DOI 10.1037/a0012963; Tyrell CM, 2011, PHYS THER, V91, P392, DOI 10.2522/ptj.20090425; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Wada Y, 2010, AM J PHYS MED REHAB, V89, P683, DOI 10.1097/PHM.0b013e3181e29d27; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Westlake KP, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-18; Williams G, 2009, ARCH PHYS MED REHAB, V90, P587, DOI 10.1016/j.apmr.2008.10.013; Wirz M, 2005, ARCH PHYS MED REHAB, V86, P672, DOI 10.1016/j.apmr.2004.08.004	70	25	25	1	35	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	APR	2013	5	4					280	290		10.1016/j.pmrj.2012.10.009			11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	137VI	WOS:000318465900003	23200117				2022-02-06	
J	Tang, ZH; Sun, XC; Huo, G; Xie, YF; Shi, QH; Chen, S; Wang, XS; Liao, ZB				Tang, Zhaohua; Sun, Xiaochuan; Huo, Gang; Xie, Yanfeng; Shi, Quanhong; Chen, Song; Wang, Xiaoshu; Liao, Zhengbu			Protective effects of erythropoietin on astrocytic swelling after oxygen-glucose deprivation and reoxygenation: Mediation through AQP4 expression and MAPK pathway	NEUROPHARMACOLOGY			English	Article						Erythropoietin; Neuroprotection; Brain edema; Astrocyte; Aquaporin4; MAPK	RECOMBINANT-HUMAN-ERYTHROPOIETIN; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CULTURED ASTROCYTES; SUBARACHNOID HEMORRHAGE; GLIAL-CELLS; AQUAPORIN-4; PHOSPHORYLATION; KINASE; INHIBITION	Recent in vivo studies have shown that erythropoietin (EPO) offers strong protection against brain edema. However, the intracellular and molecular mechanisms behind this beneficial effect have not been specified. The aim of this study was to determine whether human erythropoietin (rhEPO) reduces the astrocytic swelling created by oxygen-glucose deprivation followed by reoxygenation (OGD/Reox) in vitro and whether this effect can be mediated through the modulation of aquaporin4 (AQP4) expression in the plasma membrane (PM) and phosphorylation of the mitogen-activated protein kinase pathway (MAPK) pathway. Our results showed that OGD/Reox produced increase in cell volume, morphological swelling, and mitochondrial swelling. These changes were associated with the up-regulation of AQP4 in PM and the over-activation of MAPK. Silencing AQP4 expression using small interfering ribonucleic acid for AQP4 was found to block astrocytic swelling. Inhibition of the over-activation of MAPK mitigated the PM AQP4 overabundance and cellular swelling. As expected, treatment with rhEPO significantly reduced the OGD/Reox-induced increase in cell volume, morphological swelling, and mitochondrial swelling as well as the up-regulation of AQP4 in PM. In addition, cultures treated with the neutralizing anti-EPO antibody worsened the PM AQP4 abundance and cellular swelling, abolishing the protective effects mediated by rhEPO treatment. Furthermore, the over-activation of these MAPK after OGD/Reox was attenuated by rhEPO treatment significantly. In conclusion, our data strongly suggest that rhEPO can protect astrocytes from swelling caused by ischemia and reperfusion-like injury. This neuroprotective capacity is partially mediated by diminishing the MAPK-activity-dependent overabundance of AQP4 in PM. (c) 2012 Elsevier Ltd. All rights reserved.	[Tang, Zhaohua; Sun, Xiaochuan; Huo, Gang; Xie, Yanfeng; Shi, Quanhong; Wang, Xiaoshu; Liao, Zhengbu] Chongqing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Chongqing 400016, Peoples R China; [Chen, Song] Chongqing Med Univ, Lab Med Mol Biol, Chongqing 400016, Peoples R China		Liao, ZB (corresponding author), Chongqing Med Univ, Dept Neurosurg, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China.	liaozhengbu@hotmail.com	liao, ZB/ABF-8804-2021	liao, ZB/0000-0003-4591-9689; sun, xiao chuan/0000-0001-6992-332X	National Natural Science Funds of ChinaNational Natural Science Foundation of China (NSFC) [30801182]	This research was supported by the National Natural Science Funds of China (30801182). We would like to thank Xinggang Zhi for his technical assistance.	Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.0.CO;2-P; Bouzat P, 2011, CRIT CARE MED, V39, P2099, DOI 10.1097/CCM.0b013e31821cb7b2; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; Eid T, 2004, J NEUROPATH EXP NEUR, V63, P73, DOI 10.1093/jnen/63.1.73; Giovannini MG, 2001, J NEUROSCI, V21, P7053, DOI 10.1523/JNEUROSCI.21-18-07053.2001; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; He ZH, 2012, STROKE, V43, P484, DOI 10.1161/STROKEAHA.111.626432; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; Kadohira I, 2008, BIOCHEM BIOPH RES CO, V377, P463, DOI 10.1016/j.bbrc.2008.09.155; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655, DOI 10.1152/ajpcell.1995.269.3.C655; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nielsen S, 1997, J NEUROSCI, V17, P171; Panickar KS, 2009, EXP NEUROL, V216, P420, DOI 10.1016/j.expneurol.2008.12.024; Qiao HM, 2012, BRAIN RES, V1448, P71, DOI 10.1016/j.brainres.2012.02.003; Rabie T, 2008, PHYSIOLOGY, V23, P263, DOI 10.1152/physiol.00016.2008; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Rao KVR, 2010, GLIA, V58, P1490, DOI 10.1002/glia.21023; Su KH, 2011, J CELL PHYSIOL, V226, P3330, DOI 10.1002/jcp.22678; Talving P, 2010, ANN SURG, V251, P1, DOI 10.1097/SLA.0b013e3181b844fa; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Wang XY, 2004, J NEUROCHEM, V91, P900, DOI 10.1111/j.1471-4159.2004.02769.x; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Yang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033596; Yip HK, 2011, CRIT CARE, V15, DOI 10.1186/cc10002; Zechariah A, 2010, STROKE, V41, P1008, DOI 10.1161/STROKEAHA.109.574418; Zelenina M, 2010, NEUROCHEM INT, V57, P468, DOI 10.1016/j.neuint.2010.03.022; Zhang J, 2010, CYTOKINE, V52, P252, DOI 10.1016/j.cyto.2010.08.011; Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367	36	25	36	3	27	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908			NEUROPHARMACOLOGY	Neuropharmacology	APR	2013	67						8	15		10.1016/j.neuropharm.2012.10.017			8	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	097ME	WOS:000315477400002	23142737				2022-02-06	
J	Li, J; Zhao, L; He, X; Zeng, YJ; Dai, SS				Li, Jun; Zhao, Li; He, Xie; Zeng, Yi-Jun; Dai, Shuang-Shuang			Sinomenine Protects against Lipopolysaccharide-Induced Acute Lung Injury in Mice via Adenosine A(2A) Receptor Signaling	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; ISCHEMIA-REPERFUSION INJURY; NF-KAPPA-B; ALKALOID SINOMENINE; CYTOKINE EXPRESSION; MAST-CELLS; IN-VIVO; ACTIVATION; INFLAMMATION; NEUTROPHILS	Sinomenine (SIN) is a bioactive alkaloid extracted from the Chinese medicinal plant Sinomenium acutum, which is widely used in the clinical treatment of rheumatoid arthritis (RA). However, its role in acute lung injury (ALI) is unclear. In this study, we investigate the role of SIN in lipopolysaccharide (LPS)-induced ALI in mice. After ALI, lung water content and histological signs of pulmonary injury were attenuated, whereas the PaO2/FIO2 (P/F) ratios were elevated significantly in the mice pretreated with SIN. Additionally, SIN markedly inhibited inflammatory cytokine TNF-alpha and IL-1 beta expression levels as well as neutrophil infiltration in the lung tissues of the mice. Microarray analysis and real-time PCR showed that SIN treatment upregulated adenosine A(2A) receptor (A(2A)R) expression, and the protective effect of SIN was abolished in A(2A)R knockout mice. Further investigation in isolated mouse neutrophils confirmed the upregulation of A(2A)R by SIN and showed that A(2A)R-cAMP-PKA signaling was involved in the anti-inflammatory effect of SIN. Taken together, these findings demonstrate an A(2A)R-associated anti-inflammatory effect and the protective role of SIN in ALI, which suggests a potential novel approach to treat ALI.	[Li, Jun] Third Mil Med Univ, Southwest Hosp, Dept Cardiothorac Surg, Chongqing, Peoples R China; [Zhao, Li; He, Xie; Zeng, Yi-Jun; Dai, Shuang-Shuang] Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing, Peoples R China		Dai, SS (corresponding author), Third Mil Med Univ, Dept Biochem & Mol Biol, Chongqing, Peoples R China.	tmmubiodss@yahoo.com.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81172817]; Natural Science Foundation of Chongqing, ChinaNatural Science Foundation of Chongqing [CSTC2009BB5317]	This work is supported by National Natural Science Foundation of China (81172817), Natural Science Foundation of Chongqing, China (CSTC2009BB5317). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, pL1137, DOI 10.1152/ajplung.2000.279.6.L1137; Allen-Gipson DS, 2006, AM J PHYSIOL-LUNG C, V290, pL849, DOI 10.1152/ajplung.00373.2005; Belperio JA, 2002, J CLIN INVEST, V110, P1703, DOI 10.1172/JCI200215849; Bonneau O, 2006, AM J PHYSIOL-LUNG C, V290, pL1036, DOI 10.1152/ajplung.00422.2005; Bshesh K, 2002, J LEUKOCYTE BIOL, V72, P1027; Candinas D, 1996, TRANSPLANTATION, V62, P1855, DOI 10.1097/00007890-199612270-00030; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Cheng Y, 2009, INT IMMUNOPHARMACOL, V9, P894, DOI 10.1016/j.intimp.2009.03.014; Dai SS, 2010, J NEUROCHEM, V113, P1536, DOI 10.1111/j.1471-4159.2010.06716.x; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; Eckle T, 2008, J CLIN INVEST, V118, P3301, DOI 10.1172/JCI34203; Eckle T, 2009, PHYSIOLOGY, V24, P298, DOI 10.1152/physiol.00022.2009; Ellman PI, 2008, J SURG RES, V149, P3, DOI 10.1016/j.jss.2007.08.008; Ernens I, 2006, CIRC RES, V99, P590, DOI 10.1161/01.RES.0000241428.82502.d4; Folkesson HG, 2012, AM J PHYSIOL-LUNG C, V303, pL259, DOI 10.1152/ajplung.00395.2011; Gazoni LM, 2008, J THORAC CARDIOV SUR, V135, P156, DOI 10.1016/j.jtcvs.2007.08.041; Graham DB, 2007, J CLIN INVEST, V117, P3445, DOI 10.1172/JCI32729; Hasko G, 2008, J LEUKOCYTE BIOL, V83, P447, DOI 10.1189/jlb.0607359; Heyn J, 2012, SHOCK, V37, P156, DOI 10.1097/SHK.0b013e31823f16bc; HOJO H, 1985, J IMMUNOPHARMACOL, V7, P33, DOI 10.3109/08923978509026467; Huang J, 2007, J ETHNOPHARMACOL, V114, P180, DOI 10.1016/j.jep.2007.07.036; Kim HM, 2000, J ETHNOPHARMACOL, V70, P135, DOI 10.1016/S0378-8741(99)00160-9; Kok T. W., 2005, Angiogenesis, V8, P3, DOI 10.1007/s10456-005-2892-z; KONDO Y, 1994, BIOCHEM PHARMACOL, V48, P1050, DOI 10.1016/0006-2952(94)90378-6; Li W, 2008, NEUROSCIENCE, V151, P1198, DOI 10.1016/j.neuroscience.2007.11.020; Lin MC, 1997, J CLIN INVEST, V99, P737, DOI 10.1172/JCI119219; LIU L, 1994, ARZNEIMITTEL-FORSCH, V44-2, P1223; LIU L, 1994, INT J IMMUNOPHARMACO, V16, P685, DOI 10.1016/0192-0561(94)90142-2; Liu LA, 1996, INT J IMMUNOPHARMACO, V18, P529, DOI 10.1016/S0192-0561(96)00025-2; Lukashev D, 2004, J IMMUNOL, V173, P21, DOI 10.4049/jimmunol.173.1.21; Malcolm KC, 2003, AM J PHYSIOL-LUNG C, V284, pL663, DOI 10.1152/ajplung.00094.2002; Mark W, 2003, TRANSPLANTATION, V75, P940, DOI 10.1097/01.TP.0000056610.22062.03; Martin TR, 2002, J CLIN INVEST, V110, P1603, DOI 10.1172/JCI200217302; Murphree LJ, 2005, BIOCHEM J, V391, P575, DOI 10.1042/BJ20050888; Nadeem A, 2007, AM J PHYSIOL-LUNG C, V292, pL1335, DOI 10.1152/ajplung.00416.2006; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Reece TB, 2005, J THORAC CARDIOV SUR, V129, P1137, DOI 10.1016/j.jtcvs.2004.11.042; Reutershan J, 2007, J IMMUNOL, V179, P1254, DOI 10.4049/jimmunol.179.2.1254; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Sharma AK, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-58; Spicuzza L, 2006, EUR J PHARMACOL, V533, P77, DOI 10.1016/j.ejphar.2005.12.056; Thiel M, 2005, PLOS BIOL, V3, P1088, DOI 10.1371/journal.pbio.0030174; Vieregge B, 1999, PLANTA MED, V65, P80, DOI 10.1055/s-2006-960446; Wang QX, 2011, INT IMMUNOPHARMACOL, V11, P373, DOI 10.1016/j.intimp.2010.11.018; Wang Y, 2005, J ETHNOPHARMACOL, V98, P37, DOI 10.1016/j.jep.2004.12.022; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Wu RQ, 2006, CRIT CARE MED, V34, P1273, DOI 10.1097/01.CCM.0000208437.93725.18; YAMASAKI H, 1976, ACTA MED OKAYAMA, V30, P1; Zhao Y, 2007, INT IMMUNOPHARMACOL, V7, P637, DOI 10.1016/j.intimp.2007.01.007; Zhong H, 2003, J IMMUNOL, V171, P338, DOI 10.4049/jimmunol.171.1.338	50	25	33	1	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2013	8	3							e59257	10.1371/journal.pone.0059257			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	109ZC	WOS:000316409800076	23555007	Green Published, Green Submitted, gold			2022-02-06	
J	Figley, SA; Chen, YH; Maeda, A; Conroy, L; McMullen, JD; Silver, JI; Stapleton, S; Vitkin, A; Lindsay, P; Burrell, K; Zadeh, G; Fehlings, MG; DaCosta, RS				Figley, Sarah A.; Chen, Yonghong; Maeda, Azusa; Conroy, Leigh; McMullen, Jesse D.; Silver, Jason I.; Stapleton, Shawn; Vitkin, Alex; Lindsay, Patricia; Burrell, Kelly; Zadeh, Gelareh; Fehlings, Michael G.; DaCosta, Ralph S.			A Spinal Cord Window Chamber Model for In Vivo Longitudinal Multimodal Optical and Acoustic Imaging in a Murine Model	PLOS ONE			English	Article							MULTIPLE-SCLEROSIS; NERVOUS-SYSTEM; INJURY; TOMOGRAPHY; MICROSCOPY; REGENERATION; INFLAMMATION; PATHOLOGY; PROTEIN; BRAIN	In vivo and direct imaging of the murine spinal cord and its vasculature using multimodal (optical and acoustic) imaging techniques could significantly advance preclinical studies of the spinal cord. Such intrinsically high resolution and complementary imaging technologies could provide a powerful means of quantitatively monitoring changes in anatomy, structure, physiology and function of the living cord over time after traumatic injury, onset of disease, or therapeutic intervention. However, longitudinal in vivo imaging of the intact spinal cord in rodent models has been challenging, requiring repeated surgeries to expose the cord for imaging or sacrifice of animals at various time points for ex vivo tissue analysis. To address these limitations, we have developed an implantable spinal cord window chamber (SCWC) device and procedures in mice for repeated multimodal intravital microscopic imaging of the cord and its vasculature in situ. We present methodology for using our SCWC to achieve spatially co-registered optical-acoustic imaging performed serially for up to four weeks, without damaging the cord or induction of locomotor deficits in implanted animals. To demonstrate the feasibility, we used the SCWC model to study the response of the normal spinal cord vasculature to ionizing radiation over time using white light and fluorescence microscopy combined with optical coherence tomography (OCT) in vivo. In vivo power Doppler ultrasound and photoacoustics were used to directly visualize the cord and vascular structures and to measure hemoglobin oxygen saturation through the complete spinal cord, respectively. The model was also used for intravital imaging of spinal micrometastases resulting from primary brain tumor using fluorescence and bioluminescence imaging. Our SCWC model overcomes previous in vivo imaging challenges, and our data provide evidence of the broader utility of hybridized optical-acoustic imaging methods for obtaining multiparametric and rich imaging data sets, including over extended periods, for preclinical in vivo spinal cord research.	[Figley, Sarah A.; Fehlings, Michael G.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Figley, Sarah A.; Burrell, Kelly; Zadeh, Gelareh; Fehlings, Michael G.] Univ Hlth Network, Toronto Western Res Inst, Krembil Neurosci Program, Toronto, ON, Canada; [Chen, Yonghong; McMullen, Jesse D.; Silver, Jason I.; Vitkin, Alex; DaCosta, Ralph S.] Princess Margaret Hosp, Ontario Canc Inst, Univ Hlth Network, Toronto, ON M4X 1K9, Canada; [Maeda, Azusa; Conroy, Leigh; Stapleton, Shawn; Vitkin, Alex; DaCosta, Ralph S.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Vitkin, Alex; Lindsay, Patricia; DaCosta, Ralph S.] Princess Margaret Hosp, Dept Radiat Oncol, Univ Hlth Network, Toronto, ON M4X 1K9, Canada		DaCosta, RS (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Univ Hlth Network, Toronto, ON M4X 1K9, Canada.	rdacosta@uhnres.utoronto.ca	Vitkin, Alex/I-8166-2012; Vitkin, Alex/C-8123-2016	Vitkin, Alex/0000-0001-5495-8888; Conroy, Leigh/0000-0003-0055-3660; Fehlings, Michael/0000-0002-5722-6364	Cancer Care Ontario; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [93578]; Ontario Ministry of Health and Long Term careMinistry of Health and Long-Term Care, Ontario	This research was funded in part by Cancer Care Ontario (DaCosta holds a CCO Research Chair in Cancer Imaging; https://www.cancercare.on.ca/), the Canadian Institutes of Health Research (awarded to Dr. DaCosta, reference number 93578; http://www.cihr-irsc.gc.ca/e/193.html) and the Ontario Ministry of Health and Long Term Care (http://www.health.gov.on.ca/en/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson CR, 2009, SPINAL CORD: A CHRISTOPHER AND DANA REEVE FOUNDATION TEXT AND ATLAS, P115; Bhavna Y, 2009, CURR BIOL, V19, P930; Bilgen M., 2006, NEUROANATOMY, V5, P12; BRAUN IF, 1983, RADIOLOGY, V147, P459, DOI 10.1148/radiology.147.2.6340159; Byrnes KR, 2010, J MAGN RESON IMAGING, V32, P836, DOI 10.1002/jmri.22323; Cadotte DW, 2012, BIOMED OPT EXPRESS, V3, P911, DOI 10.1364/BOE.3.000911; Clarkson R, 2011, MED PHYS, V38, P845, DOI 10.1118/1.3533947; Davalos D, 2008, J NEUROSCI METH, V169, P1, DOI 10.1016/j.jneumeth.2007.11.011; Dibaj P, 2010, GLIA, V58, P1133, DOI 10.1002/glia.20993; DOMMISSE GF, 1974, J BONE JOINT SURG BR, VB 56, P225, DOI 10.1302/0301-620X.56B2.225; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Dray C, 2009, P NATL ACAD SCI USA, V106, P9459, DOI 10.1073/pnas.0900222106; Farrar MJ, 2012, NATURE METHODS ADV; Fehlings MG, 2011, NEUROTHERAPEUTICS, V8, P704, DOI 10.1007/s13311-011-0076-7; Fenrich KK, 2012, J PHYSIOL-LONDON, V590, P3665, DOI 10.1113/jphysiol.2012.230532; HORNSEY S, 1990, INT J RADIAT ONCOL, V18, P1437, DOI 10.1016/0360-3016(90)90319-F; Hsu W, 2012, NEUROSURGERY, DOI [10.1227/NEU.1220-b1013e3182532e3182571, DOI 10.1227/NEU.1220-B1013E3182532E3182571]; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Johannssen HC, 2010, J PHYSIOL-LONDON, V588, P3397, DOI 10.1113/jphysiol.2010.191833; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kim JV, 2010, J IMMUNOL METHODS, V352, P89, DOI 10.1016/j.jim.2009.09.007; Kirkpatrick JP, 2010, INT J RADIAT ONCOL, V76, pS42, DOI 10.1016/j.ijrobp.2009.04.095; Lassmann H, 2005, BRAIN PATHOL, V15, P217; Liu TW, 2011, BIOCONJUGATE CHEM, V22, P1021, DOI 10.1021/bc200169x; Madi S, 2001, AM J NEURORADIOL, V22, P1768; MARCUS ML, 1977, CIRC RES, V41, P128, DOI 10.1161/01.RES.41.1.128; MCAFEE PC, 1986, SPINE, V11, P295, DOI 10.1097/00007632-198605000-00001; Misgeld T, 2006, NAT REV NEUROSCI, V7, P449, DOI 10.1038/nrn1905; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; NIX W, 1976, STROKE, V7, P560, DOI 10.1161/01.STR.7.6.560; Ntziachristos V, 2010, NAT METHODS, V7, P603, DOI [10.1038/NMETH.1483, 10.1038/nmeth.1483]; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; POWERS BE, 1992, INT J RADIAT ONCOL, V23, P539, DOI 10.1016/0360-3016(92)90009-7; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Sahgal A, 2011, J NEUROSURG-SPINE, V14, P151, DOI 10.3171/2010.9.SPINE091005; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Shtoyerman E, 2000, J NEUROSCI, V20, P8111; SIEGAL T, 1995, INT J RADIAT ONCOL, V31, P57, DOI 10.1016/0360-3016(94)E0305-4; Sinescu Crina, 2010, J Med Life, V3, P254; Stroman PW, 2005, CLIN MED RES, V3, P146, DOI 10.3121/cmr.3.3.146; Tench CR, 2005, J NEUROIMAGING, V15, p94S, DOI 10.1177/1051228405283292; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; VANDERKOGEL AJ, 1993, RADIOTHER ONCOL, V29, P105, DOI 10.1016/0167-8140(93)90234-Y; Wang XD, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2192804; Xu MH, 2006, REV SCI INSTRUM, V77, DOI 10.1063/1.2195024; Yu WR, 2011, ACTA NEUROPATHOL, V122, P747, DOI 10.1007/s00401-011-0882-3	46	25	26	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2013	8	3							e58081	10.1371/journal.pone.0058081			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	109YM	WOS:000316407400015	23516432	Green Published, gold, Green Submitted			2022-02-06	
J	Maruta, J; Heaton, KJ; Kryskow, EM; Maule, AL; Ghajar, J				Maruta, Jun; Heaton, Kristin J.; Kryskow, Elisabeth M.; Maule, Alexis L.; Ghajar, Jamshid			Dynamic visuomotor synchronization: Quantification of predictive timing	BEHAVIOR RESEARCH METHODS			English	Article						Attention; Smooth pursuit; Test-retest reliability; Concussion; Traumatic brain injury	PURSUIT EYE-MOVEMENTS; TRAUMATIC BRAIN-INJURY; SMOOTH-PURSUIT; PARKINSONS-DISEASE; COGNITIVE CONTROL; CEREBRAL CONTROL; TARGET MOTIONS; ATTENTION; TRACKING; DEFICITS	When a moving target is tracked visually, spatial and temporal predictions are used to circumvent the neural delay required for the visuomotor processing. In particular, the internally generated predictions must be synchronized with the external stimulus during continuous tracking. We examined the utility of a circular visual-tracking paradigm for assessment of predictive timing, using normal human subjects. Disruptions of gaze-target synchronization were associated with anticipatory saccades that caused the gaze to be temporarily ahead of the target along the circular trajectory. These anticipatory saccades indicated preserved spatial prediction but suggested impaired predictive timing. We quantified gaze-target synchronization with several indices, whose distributions across subjects were such that instances of extremely poor performance were identifiable outside the margin of error determined by test-retest measures. Because predictive timing is an important element of attention functioning, the visual-tracking paradigm and dynamic synchronization indices described here may be useful for attention assessment.	[Maruta, Jun; Ghajar, Jamshid] Brain Trauma Fdn, New York, NY 10007 USA; [Heaton, Kristin J.; Kryskow, Elisabeth M.; Maule, Alexis L.] USA, Environm Med Res Inst, Natick, MA 01760 USA; [Heaton, Kristin J.; Maule, Alexis L.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA		Maruta, J (corresponding author), Brain Trauma Fdn, 7 World Trade Ctr,34th Floor,250 Greenwich St, New York, NY 10007 USA.	jmaruta@braintrauma.org	Maruta, Jun/I-3790-2019; Heaton, Kristin J/E-3660-2013	Maruta, Jun/0000-0002-5054-6605; 			Angelaki DE, 2003, J NEUROSCI, V23, P2971; BAHILL AT, 1983, VISION RES, V23, P1573; Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; BARTKO JJ, 1966, PSYCHOL REP, V19, P3, DOI 10.2466/pr0.1966.19.1.3; BARTKO JJ, 1991, SCHIZOPHRENIA BULL, V17, P483, DOI 10.1093/schbul/17.3.483; Baumann O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007110; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Blekher T, 1997, INVEST OPHTH VIS SCI, V38, P1768; Boeder P, 1962, Br J Ophthalmol, V46, P397, DOI 10.1136/bjo.46.7.397; BRONSTEIN AM, 1985, BRAIN, V108, P925, DOI 10.1093/brain/108.4.925; Chen Y, 2002, PROG BRAIN RES, V140, P255; COLLEWIJN H, 1984, J PHYSIOL-LONDON, V351, P217, DOI 10.1113/jphysiol.1984.sp015242; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Diefendorf AR, 1908, BRAIN, V31, P451, DOI 10.1093/brain/31.3.451; Ettinger U, 2008, CEREB CORTEX, V18, P1148, DOI 10.1093/cercor/bhm147; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gronqvist H, 2006, VISION RES, V46, P1754, DOI 10.1016/j.visres.2005.11.007; Heide W, 1996, BRAIN, V119, P1951, DOI 10.1093/brain/119.6.1951; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; HOLZMAN PS, 1976, ARCH GEN PSYCHIAT, V33, P1415; Hwang K, 2010, J NEUROSCI, V30, P15535, DOI 10.1523/JNEUROSCI.2825-10.2010; IACONO WG, 1979, ARCH GEN PSYCHIAT, V36, P1361; KEATING EG, 1991, EXP BRAIN RES, V86, P311; Khan AZ, 2010, J VISION, V10, DOI 10.1167/10.13.7; Kowler E, 2011, VISION RES, V51, P1457, DOI 10.1016/j.visres.2010.12.014; Krauzlis RJ, 2005, NEUROSCIENTIST, V11, P124, DOI 10.1177/1073858404271196; Lekwuwa GU, 1996, BRAIN, V119, P473, DOI 10.1093/brain/119.2.473; Lekwuwa GU, 1996, BRAIN, V119, P491, DOI 10.1093/brain/119.2.491; LIPTON RB, 1980, PSYCHIAT RES, V3, P193, DOI 10.1016/0165-1781(80)90036-0; Lisberger SG, 2010, NEURON, V66, P477, DOI 10.1016/j.neuron.2010.03.027; Lovejoy LP, 2009, VISION RES, V49, P1275, DOI 10.1016/j.visres.2009.01.011; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; MORROW MJ, 1995, ANN NEUROL, V37, P443, DOI 10.1002/ana.410370406; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Orban de Xivry J. J., 2009, ENCY NEUROSCIENCE, P421; Osborne LC, 2005, NATURE, V437, P412, DOI 10.1038/nature03961; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RASHBASS C, 1961, J PHYSIOL-LONDON, V159, P326, DOI 10.1113/jphysiol.1961.sp006811; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; ROTHENBERG SJ, 1981, PSYCHOPHARMACOLOGY, V74, P237, DOI 10.1007/BF00427101; Rottach KG, 1996, VISION RES, V36, P2189, DOI 10.1016/0042-6989(95)00302-9; SHAGASS C, 1976, ARCH GEN PSYCHIAT, V33, P121; SIMPSON JI, 1981, ANN NY ACAD SCI, V374, P20, DOI 10.1111/j.1749-6632.1981.tb30856.x; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; UMEDA Y, 1975, ORL J OTO-RHINO-LARY, V37, P290, DOI 10.1159/000275237; Van Donkelaar P, 2002, PROG BRAIN RES, V140, P267; VANDERSTEEN J, 1983, VISION RES, V23, P1655, DOI 10.1016/0042-6989(83)90180-3; VANGELDER P, 1995, VISION RES, V35, P667, DOI 10.1016/0042-6989(94)00161-E; Wang P, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00085; WESTHEIMER G, 1954, AMA ARCH OPHTHALMOL, V52, P710; WHITE OB, 1983, BRAIN, V106, P571, DOI 10.1093/brain/106.3.571	55	25	25	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1554-351X			BEHAV RES METHODS	Behav. Res. Methods	MAR	2013	45	1					289	300		10.3758/s13428-012-0248-3			12	Psychology, Mathematical; Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	156DK	WOS:000319800900027	22956395	Green Published			2022-02-06	
J	Nakagawa, H; Ueno, M; Itokazu, T; Yamashita, T				Nakagawa, H.; Ueno, M.; Itokazu, T.; Yamashita, T.			Bilateral movement training promotes axonal remodeling of the corticospinal tract and recovery of motor function following traumatic brain injury in mice	CELL DEATH & DISEASE			English	Article						traumatic brain injury; rehabilitative training; functional recovery; corticospinal tract	SPINAL-CORD; STRUCTURAL PLASTICITY; CORTICAL PLASTICITY; PYRAMIDAL TRACT; STAIRCASE TEST; RAT FORELIMB; ADULT RATS; STROKE; TASK; SYSTEM	Traumatic brain injury (TBI) results in severe motor function impairment, and subsequent recovery is often incomplete. Rehabilitative training is considered to promote restoration of the injured neural network, thus facilitating functional recovery. However, no studies have assessed the effect of such trainings in the context of neural rewiring. Here, we investigated the effects of two types of rehabilitative training on corticospinal tract (CST) plasticity and motor recovery in mice. We injured the unilateral motor cortex with contusion, which induced hemiparesis on the contralesional side. After the injury, mice performed either a single pellet-reaching task (simple repetitive training) or a rotarod task (bilateral movement training). Multiple behavioral tests were then used to assess forelimb motor function recovery: staircase, ladder walk, capellini handling, single pellet, and rotarod tests. The TBI+rotarod group performed most forelimb motor tasks (staircase, ladder walk, and capellini handling tests) better than the TBI-only group did. In contrast, the TBI+reaching group did not perform better except in the single pellet test. After the injury, the contralateral CST, labeled by biotinylated dextran amine, formed sprouting fibers into the denervated side of the cervical spinal cord. The number of these fibers was significantly higher in the TBI+rotarod group, whereas it did not increase in the TBI+reaching group. These results indicate that bilateral movement training effectively promotes axonal rewiring and motor function recovery, whereas the effect of simple repetitive training is limited. Cell Death and Disease (2013) 4, e534; doi:10.1038/cddis.2013.62; published online 7 March 2013	[Nakagawa, H.; Ueno, M.; Itokazu, T.; Yamashita, T.] Osaka Univ, Dept Mol Neurosci, Grad Sch Med, Suita, Osaka 5650871, Japan; [Nakagawa, H.; Ueno, M.; Itokazu, T.; Yamashita, T.] Japan Sci & Technol Agcy JST, CREST, Chiyoda Ku, Tokyo, Japan; [Itokazu, T.] Kyoto Univ, Dept Neurol, Grad Sch Med, Sakyo Ku, Kyoto, Japan		Yamashita, T (corresponding author), Osaka Univ, Dept Mol Neurosci, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yamashita@molneu.med.osaka-u.ac.jp	Ueno, Masaki/J-1216-2019	Itokazu, Takahide/0000-0003-2977-7190; Ueno, Masaki/0000-0003-1484-9921; Yamashita, Toshihide/0000-0003-4559-7018	Core Research for Evolutional Science and Technology (CREST) from Japan Science and Technology Agency (JST)Japan Science & Technology Agency (JST)Core Research for Evolutional Science and Technology (CREST)	We thank Dr. J Patrick Card (University of Pittsburgh) and Lynn W Enquist (Princeton University) for their kind gift of PRV. This work was supported by Core Research for Evolutional Science and Technology (CREST) from Japan Science and Technology Agency (JST).	Allred RP, 2008, J NEUROSCI METH, V170, P229, DOI 10.1016/j.jneumeth.2008.01.015; Baird AL, 2001, BRAIN RES BULL, V54, P243, DOI 10.1016/S0361-9230(00)00457-3; CALLISTER RJ, 1987, J COMP NEUROL, V255, P369, DOI 10.1002/cne.902550305; Cauraugh JH, 2005, PROG NEUROBIOL, V75, P309, DOI 10.1016/j.pneurobio.2005.04.001; Conner JM, 2005, NEURON, V46, P173, DOI 10.1016/j.neuron.2005.03.003; Ding Y, 2004, NEUROSCIENCE, V123, P667, DOI 10.1016/j.neuroscience.2003.08.031; Dobkin BH, 2009, CURR OPIN NEUROL, V22, P563, DOI 10.1097/WCO.0b013e3283314b11; Flavell SW, 2008, ANNU REV NEUROSCI, V31, P563, DOI 10.1146/annurev.neuro.31.060407.125631; French B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006073.pub2; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Girgis J, 2007, BRAIN, V130, P2993, DOI 10.1093/brain/awm245; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Jones TA, 1999, J NEUROSCI, V19, P10153; Kiehn O, 1998, ANN NY ACAD SCI, V860, P110, DOI 10.1111/j.1749-6632.1998.tb09043.x; Kjaerulff O, 1996, J NEUROSCI, V16, P5777; Krajacic A, 2010, BEHAV BRAIN RES, V214, P323, DOI 10.1016/j.bbr.2010.05.053; Krajacic A, 2009, EUR J NEUROSCI, V29, P641, DOI 10.1111/j.1460-9568.2008.06600.x; Lee HJ, 2007, STEM CELLS, V25, P1204, DOI 10.1634/stemcells.2006-0409; LEMON RN, 1993, EXP PHYSIOL, V78, P263, DOI 10.1113/expphysiol.1993.sp003686; Liu ZW, 2008, STROKE, V39, P2571, DOI 10.1161/STROKEAHA.107.511659; Luft AR, 2004, JAMA-J AM MED ASSOC, V292, P1853, DOI 10.1001/jama.292.15.1853; Maier IC, 2008, J NEUROSCI, V28, P9386, DOI 10.1523/JNEUROSCI.1697-08.2008; Martinowich K, 2007, NAT NEUROSCI, V10, P1089, DOI 10.1038/nn1971; McKenna JE, 2000, J COMP NEUROL, V419, P286, DOI 10.1002/(SICI)1096-9861(20000410)419:3<286::AID-CNE2>3.0.CO;2-3; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Miklyaeva EI, 1996, BEHAV NEUROSCI, V110, P117; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; NAKAYAMA H, 1994, ARCH PHYS MED REHAB, V75, P852, DOI 10.1016/0003-9993(94)90108-2; Omoto S, 2010, J NEUROSCI, V30, P13045, DOI 10.1523/JNEUROSCI.3228-10.2010; Ploughman M, 2007, EUR J NEUROSCI, V25, P3453, DOI 10.1111/j.1460-9568.2007.05591.x; Quinlan KA, 2007, J NEUROSCI, V27, P6521, DOI 10.1523/JNEUROSCI.1618-07.2007; Ramanathan D, 2006, P NATL ACAD SCI USA, V103, P11370, DOI 10.1073/pnas.0601065103; Smith JM, 2007, BRAIN, V130, P915, DOI 10.1093/brain/awl393; Starkey ML, 2011, EXP NEUROL, V232, P81, DOI 10.1016/j.expneurol.2011.08.006; Starkey ML, 2012, BRAIN, V135, P3265, DOI 10.1093/brain/aws270; Stinear CM, 2008, BRAIN, V131, P1381, DOI 10.1093/brain/awn051; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tabuse M, 2010, J CLIN NEUROSCI, V17, P1412, DOI 10.1016/j.jocn.2010.01.056; Tennant Kelly A, 2010, J Vis Exp, DOI 10.3791/2076; Ueno M, 2012, BRAIN, V135, P1253, DOI 10.1093/brain/aws053; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; Wang L, 2011, P NATL ACAD SCI USA, V108, P2545, DOI 10.1073/pnas.1014335108; WHISHAW IQ, 1993, BEHAV BRAIN RES, V56, P59, DOI 10.1016/0166-4328(93)90022-I; Whishaw IQ, 1996, BEHAV BRAIN RES, V77, P135, DOI 10.1016/0166-4328(95)00209-X; Whishaw IQ, 1998, BEHAV BRAIN RES, V93, P167, DOI 10.1016/S0166-4328(97)00152-6; Whitall J, 2000, STROKE, V31, P2390, DOI 10.1161/01.STR.31.10.2390; Will B, 2004, PROG NEUROBIOL, V72, P167, DOI 10.1016/j.pneurobio.2004.03.001; Woldag H, 2003, CLIN REHABIL, V17, P723, DOI 10.1191/0269215503cr669oa; Wolpaw JR, 1997, TRENDS NEUROSCI, V20, P588, DOI 10.1016/S0166-2236(97)01133-8; Xu TH, 2009, NATURE, V462, P915, DOI 10.1038/nature08389; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	51	25	25	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	MAR	2013	4								e534	10.1038/cddis.2013.62			9	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	116FR	WOS:000316868700013	23470541	Green Published, gold			2022-02-06	
J	Rozzelle, CJ; Aarabi, B; Dhall, SS; Gelb, DE; Hurlbert, RJ; Ryken, TC; Theodore, N; Walters, BC; Hadley, MN				Rozzelle, Curtis J.; Aarabi, Bizhan; Dhall, Sanjay S.; Gelb, Daniel E.; Hurlbert, R. John; Ryken, Timothy C.; Theodore, Nicholas; Walters, Beverly C.; Hadley, Mark N.			Spinal Cord Injury Without Radiographic Abnormality (SCIWORA)	NEUROSURGERY			English	Article						Pediatric patient population; SCIWORA; Spinal immobilization	RESONANCE-IMAGING CORRELATION; CHILDREN; CONCUSSION; YOUNG		[Rozzelle, Curtis J.] Univ Alabama Birmingham, Childrens Hosp Alabama, Div Neurol Surg, Birmingham, AL USA; [Aarabi, Bizhan] Univ Maryland, Dept Neurosurg, Baltimore, MD 21201 USA; [Gelb, Daniel E.] Univ Maryland, Dept Orthopaed, Baltimore, MD 21201 USA; [Dhall, Sanjay S.] Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA; [Hurlbert, R. John] Univ Calgary, Dept Clin Neurosci, Univ Calgary Spine Program, Fac Med, Calgary, AB, Canada; [Ryken, Timothy C.] Univ Iowa, Iowa Spine & Brain Inst, Waterloo, ON, Canada; [Theodore, Nicholas] Barrow Neurol Inst, Div Neurol Surg, Phoenix, AZ 85013 USA; [Walters, Beverly C.; Hadley, Mark N.] Univ Alabama Birmingham, Div Neurol Surg, Birmingham, AL USA; [Walters, Beverly C.] Inova Hlth Syst, Dept Neurosci, Falls Church, VA USA		Hadley, MN (corresponding author), UAB Div Neurol Surg, 510 20th St S,FOT 1030, Birmingham, AL 35294 USA.	mhadley@uabmc.edu	Walters, Beverly/R-8411-2019	Walters, Beverly/0000-0002-5244-4282; Theodore, Nicholas/0000-0001-5355-2683			[Anonymous], 2002, NEUROSURGERY S, V50, pS100; Bosch PP, 2002, SPINE, V27, P2788, DOI 10.1097/00007632-200212150-00009; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRUCE DA, 1989, PEDIATR NEUROSCI, V15, P216, DOI 10.1159/000120471; Dare AO, 2002, J NEUROSURG, V97, P33, DOI 10.3171/spi.2002.97.1.0033; DAVIS PC, 1993, AM J NEURORADIOL, V14, P607; DELBIGIO MR, 1989, SPINE, V14, P37, DOI 10.1097/00007632-198901000-00007; DICKMAN CA, 1991, J SPINAL DISORD, V4, P296, DOI 10.1097/00002517-199109000-00006; Eleraky MA, 2000, J NEUROSURG, V92, P12, DOI 10.3171/spi.2000.92.1.0012; GRABB PA, 1994, NEUROSURGERY, V35, P406, DOI 10.1227/00006123-199409000-00007; HADLEY MN, 1988, J NEUROSURG, V68, P18, DOI 10.3171/jns.1988.68.1.0018; HAMILTON MG, 1992, J NEUROSURG, V77, P700, DOI 10.3171/jns.1992.77.5.0700; Liao CC, 2005, J NEUROSURG, V103, P17, DOI 10.3171/ped.2005.103.1.0017; OSENBACH RK, 1989, PEDIATR NEUROSCI, V15, P168, DOI 10.1159/000120464; OSENBACH RK, 1992, NEUROSURGERY, V30, P385, DOI 10.1227/00006123-199203000-00012; Pang D, 2004, NEUROSURGERY, V55, P1325, DOI 10.1227/01.NEU.0000143030.85589.E6; PANG D, 1989, J TRAUMA, V29, P654, DOI 10.1097/00005373-198905000-00021; PANG D, 1982, J NEUROSURG, V57, P114, DOI 10.3171/jns.1982.57.1.0114; POLLACK IF, 1988, J NEUROSURG, V69, P177, DOI 10.3171/jns.1988.69.2.0177; Pollina J, 1999, PEDIATR NEUROSURG, V30, P263, DOI 10.1159/000028808; Ramon S, 1997, SPINAL CORD, V35, P664, DOI 10.1038/sj.sc.3100490; RATHBONE D, 1992, J PEDIATR ORTHOPED, V12, P616; ROSSITCH E, 1992, PEDIATR NEUROSURG, V18, P149; RUGE JR, 1988, J NEUROSURG, V68, P25, DOI 10.3171/jns.1988.68.1.0025; Torg JS, 1996, J BONE JOINT SURG AM, V78A, P1308, DOI 10.2106/00004623-199609000-00003; Torg JS, 1997, J NEUROSURG, V87, P843, DOI 10.3171/jns.1997.87.6.0843; Turgut M, 1996, Eur Spine J, V5, P148, DOI 10.1007/BF00395505	27	25	31	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAR	2013	72			2			227	233		10.1227/NEU.0b013e3182770ebc			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	103TP	WOS:000315942300022	23417193				2022-02-06	
J	Elliott, JT; Milej, D; Gerega, A; Weigl, W; Diop, M; Morrison, LB; Lee, TY; Liebert, A; Lawrence, KS				Elliott, Jonathan T.; Milej, Daniel; Gerega, Anna; Weigl, Wojciech; Diop, Mamadou; Morrison, Laura B.; Lee, Ting-Yim; Liebert, Adam; Lawrence, Keith St.			Variance of time-of-flight distribution is sensitive to cerebral blood flow as demonstrated by ICG bolus-tracking measurements in adult pigs	BIOMEDICAL OPTICS EXPRESS			English	Article							NEAR-INFRARED SPECTROSCOPY; INDOCYANINE GREEN; NONINVASIVE MEASUREMENT; TRANSIT TIME; PHOTONS; MOMENTS; VOLUME; BRAIN; MEDIA; MODEL	Variance of time-of-flight distributions have been shown to be more sensitive to cerebral blood flow (CBF) during dynamic-contrast enhanced monitoring of neurotrauma patients than attenuation. What is unknown is the degree to which variance is affected by changes in extracerebral blood flow. Furthermore, the importance of acquiring the arterial input function (AIF) on quantitative analysis of the data is not yet clear. This animal study confirms that variance is both sensitive and specific to changes occurring in the brain when measurements are acquired on the surface of the scalp. Furthermore, when the variance data along with the measured AIF is analyzed using a nonparametric deconvolution method, the recovered change in CBF is in good agreement with CT perfusion values. (c) 2013 Optical Society of America	[Elliott, Jonathan T.; Lee, Ting-Yim; Lawrence, Keith St.] Univ Western Ontario, Dept Med Biophys, London, ON N6A 3K7, Canada; [Elliott, Jonathan T.; Diop, Mamadou; Morrison, Laura B.; Lee, Ting-Yim; Lawrence, Keith St.] St Josephs Hosp, Lawson Hlth Res Inst, Imaging Div, London, ON N6A 4V2, Canada; [Milej, Daniel; Gerega, Anna; Liebert, Adam] Polish Acad Sci, Nalecz Inst Biocybernet & Biomed Engn, PL-02109 Warsaw, Poland; [Weigl, Wojciech] Med Univ Warsaw, Dept Anesthesiol & Intens Care, PL-02005 Warsaw, Poland		Elliott, JT (corresponding author), Univ Western Ontario, Dept Med Biophys, 1151 Richmond St, London, ON N6A 3K7, Canada.	jellio@uwo.ca	St. Lawrence, Keith/B-5726-2015; Lee, Ting-Yim/M-1721-2013; Milej, Daniel/B-6729-2014; Weigl, Wojciech/B-4294-2015; Liebert, Adam/D-7654-2011; Diop, Mamadou/B-6487-2015; Gerega, Anna/AAR-1496-2021	Milej, Daniel/0000-0003-3173-0834; Weigl, Wojciech/0000-0001-5184-6602; Gerega, Anna/0000-0002-9809-6041; Liebert, Adam/0000-0003-1643-7568; St Lawrence, Keith/0000-0001-8022-8205	European Community's Seventh Framework Programme (FP7) [201076]; Canadian Health Institutes of Research; Heart and Stroke Foundation of CanadaHeart & Stroke Foundation of Canada	This research project was supported by funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under Grant agreement No. 201076, the Canadian Health Institutes of Research, and the Heart and Stroke Foundation of Canada. The authors gratefully acknowledge Jennifer Hadway who provided consultation regarding the animal experiments.	Brown DW, 2002, PEDIATR RES, V51, P564, DOI 10.1203/00006450-200205000-00004; Cenic A, 1999, AM J NEURORADIOL, V20, P63; Diop M, 2012, OPT LETT, V37, P2358, DOI 10.1364/OL.37.002358; Diop M, 2010, PROC SPIE, V7555, DOI 10.1117/12.842521; Diop M, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3488626; Elliott JK, 2010, TLS-TIMES LIT SUPPL, P15; Elliott JT, 2012, OPT LETT, V37, P2571, DOI 10.1364/OL.37.002571; Elliott JT, 2011, PROC SPIE, V7896, DOI 10.1117/12.875361; Fantini S, 1999, PHYS MED BIOL, V44, P1543, DOI 10.1088/0031-9155/44/6/308; FRIBERG L, 1986, SCAND J CLIN LAB INV, V46, P375, DOI 10.3109/00365518609083685; Gora F, 2002, J NEUROSURG ANESTH, V14, P218, DOI 10.1097/00008506-200207000-00008; GRUBB RL, 1977, J NEUROSURG, V46, P446, DOI 10.3171/jns.1977.46.4.0446; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; Jaynes ET, 2003, PROBABILITY THEORY L; Jelzow A, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.5.057003; Kacprzak M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2743964; Kuebler WM, 1998, J CEREBR BLOOD F MET, V18, P445, DOI 10.1097/00004647-199804000-00013; LANDSMAN MLJ, 1976, J APPL PHYSIOL, V40, P575, DOI 10.1152/jappl.1976.40.4.575; Liebert A, 2006, NEUROIMAGE, V31, P600, DOI 10.1016/j.neuroimage.2005.12.046; Liebert A, 2005, NEUROIMAGE, V24, P426, DOI 10.1016/j.neuroimage.2004.08.046; Liebert A, 2004, APPL OPTICS, V43, P3037, DOI 10.1364/AO.43.003037; Liebert A, 2003, APPL OPTICS, V42, P5785, DOI 10.1364/AO.42.005785; Liebert A., 2012, BIOMEDICAL OPTICS; MEIER P, 1954, J APPL PHYSIOL, V6, P731, DOI 10.1152/jappl.1954.6.12.731; Steinbrink J, 2001, PHYS MED BIOL, V46, P879, DOI 10.1088/0031-9155/46/3/320; Steinkellner O, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3505009; Terborg C, 2003, CEREBROVASC DIS, V16, P36, DOI 10.1159/000070113; THOMPSON HK, 1964, CIRC RES, V14, P502, DOI 10.1161/01.RES.14.6.502; US Food and Drug Administration, 2012, APPR DRUG PROD THER; ZACCANTI G, 1995, P SOC PHOTO-OPT INS, V2359, P755	30	25	25	0	10	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	2156-7085			BIOMED OPT EXPRESS	Biomed. Opt. Express	FEB 1	2013	4	2					206	218		10.1364/BOE.4.000206			13	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	088AQ	WOS:000314806600003	23413183	Green Submitted, Green Published, gold			2022-02-06	
J	Tong, J; Liu, WM; Wang, XW; Han, XD; Hyrien, O; Samadani, U; Smith, DH; Huang, JH				Tong, Jing; Liu, Weimin; Wang, Xiaowei; Han, Xiaodi; Hyrien, Ollivier; Samadani, Uzma; Smith, Douglas H.; Huang, Jason H.			Inhibition of Nogo-66 Receptor 1 Enhances Recovery of Cognitive Function after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; locomotor function; Nogo receptors; recovery	MYELIN-ASSOCIATED GLYCOPROTEIN; SPINAL-CORD-INJURY; CONTROLLED CORTICAL IMPACT; MONOCLONAL-ANTIBODY IN-1; PROMOTES AXONAL REGENERATION; NEURITE GROWTH-INHIBITORS; GENE-EXPRESSION; OBJECT RECOGNITION; VOLUNTARY EXERCISE; NERVOUS-SYSTEM	Central nervous system (CNS) axons recover poorly following injury because of the expression of myelin-derived inhibitors of axonal outgrowth such as Nogo, myelin-associated glycoprotein (MAG), and oligodendrocyte-myelin glycoprotein (OMgp), all of which bind to the Nogo-66 receptor 1 (NgR1). Herein we examine the role of NgR1 in the recovery of motor and cognitive function after traumatic brain injury (TBI) using a controlled cortical impact (CCI) model in NgR1 knockout (KO) and wild-type (WT) mice. Four weeks post-injury, scores on the Novel Object Recognition test were significantly increased in NgR1 KO mice compared with WT mice (p < 0.05), but motor behavior test scores did not differ significantly between the two groups. Nissl staining showed that NgR1 KO mice had less brain injury volume 2 weeks after CCI (p < 0.05). Histological analysis revealed more doublecortin (DCX+) cells (p < 0.01) and more Ki-67+ cells in the contralateral dentate gyrus (DG) (p < 0.05) 2 weeks after CCI in NgR1 KO mice than in WT. Furthermore, DCX+ cells still retained their longer processes in KO mice (p < 0.01) 4 weeks following trauma. The number of bromodeoxyuridine (BrdU) + cells did not differ between the two groups at 4 weeks post-trauma, but KO mice had higher numbers of cells that co-stained with NeuN, a marker of mature neurons. Increased transcription of growth-associated protein (GAP)-43 in both the injured and contralateral sides of the hippocampus (both p < 0.05) was detected in NgR1 KO mice relative to WT. These data suggest that NgR1 negatively influences plasticity and cognitive recovery after TBI.	[Tong, Jing; Liu, Weimin; Wang, Xiaowei; Han, Xiaodi; Huang, Jason H.] Univ Rochester, Dept Neurosurg, Med Ctr, Rochester, NY 14642 USA; [Hyrien, Ollivier] Univ Rochester, Dept Biostat & Computat Biol, Med Ctr, Rochester, NY 14642 USA; [Tong, Jing; Liu, Weimin; Wang, Xiaowei; Huang, Jason H.] Univ Rochester, Ctr Neural Dev & Dis, Rochester, NY 14642 USA; [Tong, Jing] Hebei Med Univ, Dept Neurosurg, Affiliated Hosp 4, Shijiazhuang, Hebei, Peoples R China; [Han, Xiaodi] Beijing Tiantan Puhua Hosp, Beijing, Peoples R China; [Samadani, Uzma] NYU, Dept Neurosurg, New York, NY 10016 USA; [Smith, Douglas H.] Univ Penn, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA		Huang, JH (corresponding author), Univ Rochester, Dept Neurosurg, 601 Elmwood Ave,Box 670, Rochester, NY 14642 USA.	Jason_huang@urmc.rochester.edu	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168	University of Rochester institutional grant;  [NIH-R01-NS-067435]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024160] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS067435] Funding Source: NIH RePORTER	The authors thank Dr. Roman J. Giger for providing NgR1 KO mice, and Mr. Jiankai Yang, and Drs. Xiaolin Chen and Patricia Smith for help with data collection and analysis. This work was supported, in part, by a University of Rochester institutional grant (JHH), and by NIH-R01-NS-067435 (JHH).	Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bareyre FM, 2002, J NEUROSCI, V22, P7097; Bevins RA, 2006, NAT PROTOC, V1, P1306, DOI 10.1038/nprot.2006.205; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bomze HM, 2001, NAT NEUROSCI, V4, P38, DOI 10.1038/82881; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Bruns J. Jr., 2003, EPILEPSIA, V10, P2, DOI DOI 10.1046/J.1528-1157.44.S10.3.X; Cafferty WBJ, 2006, J NEUROSCI, V26, P12242, DOI 10.1523/JNEUROSCI.3827-06.2006; Cao Y, 2008, NEUROREHAB NEURAL RE, V22, P262, DOI 10.1177/1545968307308550; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chivatakarn O, 2007, J NEUROSCI, V27, P7117, DOI 10.1523/JNEUROSCI.1541-07.2007; Chytrova G, 2008, EUR J NEUROSCI, V27, P1, DOI 10.1111/j.1460-9568.2007.05982.x; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Dimou L, 2006, J NEUROSCI, V26, P5591, DOI 10.1523/JNEUROSCI.1103-06.2006; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faul M, 2010, TRAUMATIC BRAIN INJU; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.3.CO;2-L; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Frey D, 2000, J CELL BIOL, V149, P1443, DOI 10.1083/jcb.149.7.1443; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hanell A, 2010, J NEUROTRAUM, V27, P1297, DOI 10.1089/neu.2009.1255; Harvey PA, 2009, J NEUROSCI, V29, P6285, DOI 10.1523/JNEUROSCI.5885-08.2009; Karlen A, 2009, P NATL ACAD SCI USA, V106, P20476, DOI 10.1073/pnas.0905390106; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Lee HJ, 2008, J NEUROSCI, V28, P2753, DOI 10.1523/JNEUROSCI.5586-07.2008; Lee JK, 2004, J NEUROSCI, V24, P6209, DOI 10.1523/JNEUROSCI.1643-04.2004; Li SX, 2003, J NEUROSCI, V23, P4219; Li SX, 2005, MOL CELL NEUROSCI, V29, P26, DOI 10.1016/j.mcn.2004.12.008; Li SX, 2004, J NEUROSCI, V24, P10511, DOI 10.1523/JNEUROSCI.2828-04.2004; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loncarevic-Vasiljkovic N, 2009, EXP NEUROL, V220, P198, DOI 10.1016/j.expneurol.2009.08.024; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; McGee AW, 2005, SCIENCE, V309, P2222, DOI 10.1126/science.1114362; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Miyake K, 2002, BRAIN RES, V935, P24, DOI 10.1016/S0006-8993(02)02420-4; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Ng CEL, 2002, J NEUROSCI RES, V67, P559, DOI 10.1002/jnr.10134; Onose G, 2009, SPINAL CORD, V47, P716, DOI 10.1038/sc.2009.52; Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144; Petrinovic MM, 2010, DEVELOPMENT, V137, P2539, DOI 10.1242/dev.048371; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; SAVIO T, 1990, P NATL ACAD SCI USA, V87, P4130, DOI 10.1073/pnas.87.11.4130; Schlager GW, 2011, EXP NEUROL, V230, P67, DOI 10.1016/j.expneurol.2010.11.021; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; Searle S. R., 2006, VARIANCE COMPONENTS; Seymour AB, 2005, J CEREBR BLOOD F MET, V25, P1366, DOI 10.1038/sj.jcbfm.9600134; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Taglialatela G, 2009, BEHAV BRAIN RES, V200, P95, DOI 10.1016/j.bbr.2008.12.034; Tanic N, 2007, J MOL NEUROSCI, V32, P38, DOI 10.1007/s12031-007-0006-7; Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Venkatesh K, 2007, J CELL BIOL, V177, P393, DOI 10.1083/jcb.200702102; Walker CT, 2010, BRAIN RES, V1347, P125, DOI 10.1016/j.brainres.2010.05.075; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Winking H, 2004, CYTOGENET GENOME RES, V105, P251, DOI 10.1159/000078196; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Yu PP, 2008, NEUROBIOL DIS, V32, P535, DOI 10.1016/j.nbd.2008.09.012	79	25	30	0	16	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2013	30	4					247	258		10.1089/neu.2012.2493			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	093CM	WOS:000315169300002	22967270	Green Published			2022-02-06	
J	Lei, C; Lin, S; Zhang, C; Tao, W; Dong, W; Hao, Z; Liu, M; Wu, B				Lei, C.; Lin, S.; Zhang, C.; Tao, W.; Dong, W.; Hao, Z.; Liu, M.; Wu, B.			ACTIVATION OF CEREBRAL RECOVERY BY MATRIX METALLOPROTEINASE-9 AFTER INTRACEREBRAL HEMORRHAGE	NEUROSCIENCE			English	Article						intracerebral hemorrhage; matrix metalloproteinase-9; neurogenesis; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; MATRIX-METALLOPROTEINASE EXPRESSION; NEURAL PROGENITOR CELLS; SUBVENTRICULAR ZONE; FOCAL ISCHEMIA; BRAIN-INJURY; ANGIOGENESIS; NEUROGENESIS; INHIBITION; PROTEASES	Cerebral ischemia, traumatic brain injury, intracerebral hemorrhage and other brain insults trigger neurogenesis in the subventricular zone and hippocampal subgranular zone, and newly formed blood vessels promote the migration of these new neuronal cells to damaged brain regions. The molecular steps involved in brain injury-induced angiogenesis and neurogenesis are unclear. Here we used a rat model of collagenase-induced intracerebral hemorrhage (ICH) to examine whether matrix metalloproteinase-9 (MMP-9), a zinc endopeptidase that regulates growth factor levels during recovery from brain injury, is involved in neurogenesis and angiogenesis following ICH. Induction of ICH led to significant increases in the levels of MMP-9, vascular endothelial growth factor (VEGF), and nerve growth factor (NGF), as well as in the numbers of 5-bromo-2-deoxyuridine (BrdU)- and doublecortin (DCX)-positive cells, in the ipsilateral brain. Intracerebroventricular injection of MMP-9 siRNA reduced these ICH-induced increases. These findings suggest that MMP-9 may promote angiogenesis and neurogenesis during recovery from ICH. (C) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Lei, C.; Lin, S.; Zhang, C.; Tao, W.; Dong, W.; Hao, Z.; Liu, M.; Wu, B.] Sichuan Univ, Stroke Clin Res Unit, Dept Neurol, W China Hosp, Chengdu 610041, Sichuan Provinc, Peoples R China; [Liu, M.; Wu, B.] Sichuan Univ, Key Lab Human Dis Biotherapy State, Chengdu 610041, Peoples R China; [Liu, M.; Wu, B.] Sichuan Univ, Minist Educ, Chengdu 610041, Peoples R China		Liu, M (corresponding author), Sichuan Univ, Stroke Clin Res Unit, Dept Neurol, W China Hosp, 37 Guo Xue Xiang, Chengdu 610041, Sichuan Provinc, Peoples R China.	leichunyan328@163.com; wumu8413@163.com; zhangcanfei2003@163.com; annietao-tao@gmail.com; toto.topig@hotmail.com; zhilong1983@126.com; wyplmh@hotmail.com; dragonwbtxf@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30900472]; Department of Science and Technology of Sichuan Province [2012FZ0006]; Ph.D. Programs Foundation of the Ministry of Education of ChinaMinistry of Education, China [20110181110026]	This research was supported by the National Natural Science Foundation of China (30900472), the Science and Technology Support Program of the Department of Science and Technology of Sichuan Province (2012FZ0006), and the Ph.D. Programs Foundation of the Ministry of Education of China (20110181110026).	Aleksandrova NP, 2010, EUR J MED RES, V15, P3; Barkho BZ, 2008, STEM CELLS, V26, P3139, DOI 10.1634/stemcells.2008-0519; Bausch D, 2011, ANGIOGENESIS, V14, P235, DOI 10.1007/s10456-011-9207-3; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chopp M, 2007, STROKE, V38, P827, DOI 10.1161/01.STR.0000250235.80253.e9; del Zoppo GJ, 2010, ANN NY ACAD SCI, V1207, P46, DOI 10.1111/j.1749-6632.2010.05760.x; Ergul A, 2012, STROKE, V43, P2270, DOI 10.1161/STROKEAHA.111.642710; Font MA, 2010, CURR CARDIOL REV, V6, P238, DOI 10.2174/157340310791658802; Fu LB, 2011, NEUROSCI LETT, V491, P174, DOI 10.1016/j.neulet.2011.01.030; Fukuda S, 2004, STROKE, V35, P998, DOI 10.1161/01.STR.0000119383.76447.05; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Hao Q, 2011, STROKE, V42, P453, DOI 10.1161/STROKEAHA.110.596452; Hu Q, 2009, EXP NEUROL, V216, P35, DOI 10.1016/j.expneurol.2008.11.007; Jayanth P, 2010, CELL SIGNAL, V22, P1193, DOI 10.1016/j.cellsig.2010.03.011; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Krum JM, 2008, EXP NEUROL, V212, P108, DOI 10.1016/j.expneurol.2008.03.019; Lee CHZ, 2007, STROKE, V38, P2563, DOI 10.1161/STROKEAHA.106.481515; Lee SR, 2006, J NEUROSCI, V26, P3491, DOI 10.1523/JNEUROSCI.4085-05.2006; Montaner J, 2001, STROKE, V32, P1759, DOI 10.1161/01.STR.32.8.1759; Nagy V, 2006, J NEUROSCI, V26, P1923, DOI 10.1523/JNEUROSCI.4359-05.2006; Nico B, 2009, NEUROSCIENCE, V161, P1057, DOI 10.1016/j.neuroscience.2009.04.028; Okauchi M, 2009, STROKE, V40, P1858, DOI 10.1161/STROKEAHA.108.535765; Park KP, 2009, STROKE, V40, P2836, DOI 10.1161/STROKEAHA.109.554824; Pratheeshkumar P, 2011, J ENVIRON PATHOL TOX, V30, P139, DOI 10.1615/JEnvironPatholToxicolOncol.v30.i2.50; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosell A, 2008, CURR OPIN PHARMACOL, V8, P82, DOI 10.1016/j.coph.2007.12.001; Shen JF, 2008, J CEREBR BLOOD F MET, V28, P1460, DOI 10.1038/jcbfm.2008.37; Shimotake J, 2010, STROKE, V41, P343, DOI 10.1161/STROKEAHA.109.564229; Shubayev VI, 2004, J NEUROSCI RES, V77, P229, DOI 10.1002/jnr.20160; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Tang T, 2007, BRAIN RES, V1175, P134, DOI 10.1016/j.brainres.2007.08.028; Tete S, 2012, CLIN ORAL IMPLAN RES, V23, P1254, DOI 10.1111/j.1600-0501.2011.02300.x; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wang L, 2006, J NEUROSCI, V26, P5996, DOI 10.1523/JNEUROSCI.5380-05.2006; Xue MZ, 2008, NEUROL RES, V30, P775, DOI 10.1179/174313208X341102; Yagi K, 2009, STROKE, V40, P626, DOI 10.1161/STROKEAHA.108.520262; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhao BQ, 2007, STROKE, V38, P748, DOI 10.1161/01.STR.0000253500.32979.d1; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	40	25	27	1	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JAN 29	2013	230						86	93		10.1016/j.neuroscience.2012.11.008			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	082JH	WOS:000314387600010	23201258				2022-02-06	
J	Foley, LM; O'Meara, AMI; Wisniewski, SR; Hitchens, TK; Melick, JA; Ho, C; Jenkins, LW; Kochanek, PM				Foley, Lesley M.; O'Meara, Alia M. Iqbal; Wisniewski, Stephen R.; Hitchens, T. Kevin; Melick, John A.; Ho, Chien; Jenkins, Larry W.; Kochanek, Patrick M.			MRI assessment of cerebral blood flow after experimental traumatic brain injury combined with hemorrhagic shock in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						ASL-MRI; hemorrhagic shock; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SECONDARY INSULTS; RAT-BRAIN; RESUSCITATION; HYPOTENSION; PERFUSION; MODEL; ISCHEMIA; DAMAGE; TIME	Secondary insults such as hypotension or hemorrhagic shock (HS) can greatly worsen outcome after traumatic brain injury (TBI). We recently developed a mouse combined injury model of TBI and HS using a controlled cortical impact (CCI) model and showed that 90 minutes of HS can exacerbate neuronal death in hippocampus beneath the contusion. This combined injury model has three clinically relevant phases, a shock, pre hospital, and definitive care phases. Mice were randomly assigned to four groups, shams as well as a CCI only, an HS only, and a CCI HS groups. The CCI and HS reduced cerebral blood flow (CBF) in multiple regions of interest (ROIs) in the hemisphere ipsilateral and contralateral to injury. Hemorrhagic shock to a level of similar to 30 mm Hg exacerbated the CCI-induced CBF reductions in multiple ROIs ipsilateral to injury (hemisphere and thalamus) and in the hemisphere contralateral to injury (hemisphere, thalamus, hippocannpus, and cortex, all P<0.05 versus CCI only, HS only or both). An important effect of HS duration was also seen after CCI with maximal CBF reduction seen at 90 minutes (P<0.0001 group-time effect in ipsilateral hippocampus). Given that neuronal death in hippocampus is exacerbated by 90 minutes of HS in this model, our data suggest an important role for exacerbation of posttraumatic ischemia in mediating the secondary injury in CCI plus HS. In conclusion, the serial, non invasive assessment of CBF using ASL-MRI (magnetic resonance imaging with arterial spin labeling) is feasible in mice even in the complex setting of combined CCI HS. The impact of resuscitation therapies and various mutant mouse strains on CBF and other outcomes merits investigation in this model. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 129-136; doi:10.1038/jcbfm.2012.145; published online 17 October 2012	[O'Meara, Alia M. Iqbal; Melick, John A.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Sch Med, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA; [Hitchens, T. Kevin; Ho, Chien] Carnegie Mellon Univ, Mellon Inst, Pittsburgh NMR Ctr Biomed Res, Dept Biol Sci, Pittsburgh, PA 15213 USA; [Jenkins, Larry W.] Univ Pittsburgh, Dept Neurol Surg, Safar Ctr Resuscitat Res, Sch Med, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Sch Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Ho, Chien/O-6112-2016	Kochanek, Patrick M/0000-0002-2627-913X; Ho, Chien/0000-0002-4094-9232; , Alia Marie/0000-0003-3158-7943; Wisniewski, Stephen/0000-0002-3877-9860	DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-10-C2124]; NS [30318];  [W81XWH-09-2-0187];  [W81XWH-06-1-0247];  [P41EB-001977]	This study was supported by W81XWH-09-2-0187 (PMK), W81XWH-06-1-0247 (PMK), DARPA N66001-10-C2124 (PMK); NS 30318 (PMK), and P41EB-001977 (CH). The views, opinions, and/or findings contained in this article/presentation are those of the author/presenter and should not be interpreted as representing the official views or policies, either expressed or implied, of the Defense Advanced Research Projects Agency or the Department of Defense. Approved for Public Release, Distribution Unlimited.	Atkins JL, 2011, P ATACCC FORT LAUD F; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Carrillo P, 1998, J TRAUMA, V45, P239, DOI 10.1097/00005373-199808000-00007; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Crookes BA, 2004, J TRAUMA, V57, P547, DOI 10.1097/01.TA.0000135162.85859.4C; CRUMRINE RC, 1991, J CEREBR BLOOD F MET, V11, P272, DOI 10.1038/jcbfm.1991.59; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276, DOI 10.1152/ajpheart.1992.263.4.H1276; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Foley LM, 2008, J NEUROTRAUM, V25, P299, DOI 10.1089/neu.2007.0471; Foley LM, 2005, MAGN RESON MED, V54, P798, DOI 10.1002/mrm.20621; Garner J, 2010, ANN SURG, V251, P1131, DOI 10.1097/SLA.0b013e3181e00fcb; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Lacombe P, 2005, STROKE, V36, P1053, DOI 10.1161/01.STR.0000163080.82766.eb; Lammie GA, 1999, J NEUROTRAUM, V16, P603, DOI 10.1089/neu.1999.16.603; Lee EJ, 1999, J NEUROL SCI, V164, P117, DOI 10.1016/S0022-510X(99)00068-4; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Manole MD, 2009, J CEREBR BLOOD F MET, V29, P197, DOI 10.1038/jcbfm.2008.112; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Pierce ET., 1971, ATLAS MOUSE BRAIN SP; Robertson CS, 2012, J NEUROTRAUM, V29, P1156, DOI 10.1089/neu.2011.1827; Schutz C, 2006, CRIT CARE MED, V34, P492, DOI 10.1097/01.CCM.0000198326.32049.7F; Sell SL, 2008, ANESTHESIOLOGY, V108, P873, DOI 10.1097/ALN.0b013e31816c8a15; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; SINGH NC, 1992, J CEREBR BLOOD F MET, V12, P802, DOI 10.1038/jcbfm.1992.111; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stern S, 2009, SHOCK, V31, P64, DOI 10.1097/SHK.0b013e3181778dc3; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Trabold R, 2006, BRAIN RES, V1071, P237, DOI 10.1016/j.brainres.2005.11.095; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; YUAN XQ, 1992, SURG GYNECOL OBSTET, V174, P305; ZHANG WG, 1995, MAGNET RESON MED, V33, P370, DOI 10.1002/mrm.1910330310; ZHANG WG, 1993, MAGNET RESON MED, V29, P416, DOI 10.1002/mrm.1910290323	51	25	28	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2013	33	1					129	136		10.1038/jcbfm.2012.145			8	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	066MJ	WOS:000313224600017	23072750	Green Published, Bronze			2022-02-06	
J	Wang, T; Van, KC; Gavitt, BJ; Grayson, JK; Lu, YC; Lyeth, BG; Pichakron, KO				Wang, Tao; Van, Ken C.; Gavitt, Brian J.; Grayson, J. Kevin; Lu, Yi-Cheng; Lyeth, Bruce G.; Pichakron, Kullada O.			Effect of fish oil supplementation in a rat model of multiple mild traumatic brain injuries	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Mild traumatic brain injury; omega-3 fatty acids; dietary supplementation; hippocampus; morris water maze	POLYUNSATURATED FATTY-ACIDS; FLUID-PERCUSSION MODEL; DIETARY SUPPLEMENTATION; DOCOSAHEXAENOIC ACID; HEAD TRAUMA; US SOLDIERS; HIPPOCAMPUS; IMPAIRMENT; CONCUSSION; COGNITION	Purpose: Repetitive mild traumatic brain injury (TBI) is a major military and sports health concern. The purpose of this study was to determine if a diet rich in omega-3 fatty acids would reduce cognitive deficits and neuronal cell death in a novel fluid percussion rat model of repetitive mild TBIs. Methods: Thirty-two Sprague-Dawley rats were assigned to either an experimental rat chow enhanced with 6% fish oil (source of omega-3 fatty acids) or a control rat chow. Both rat chows contained equivalent quantities of calories, oil, and nutrients. After four weeks, both groups received mild repetitive bilateral fluid percussion TBIs on two sequential days. Pre-injury diets were resumed, and the animals were monitored for two weeks. On post-injury days 10-14, Morris Water Maze testing was performed to assess spatial learning and cognitive function. Animals were euthanized at 14 days post-injury to obtain specimens for neurohistopathology. Results: There was no difference in pre-injury weight gain between groups. Post-injury, animals on the fish oil diet lost less weight and recovered their weight significantly faster. By 14 days, the fish oil diet group performed significantly better in the Morris Water Maze. Neurohistopathology identified a non-significant trend toward a higher density of hippocampal neurons in the fish oil diet group. Conclusions: Pre-injury dietary supplementation with fish oil improves recovery of body weight and provides a small improvement in cognitive performance in a rat model of multiple mild TBIs.	[Wang, Tao] 306th Hosp PLA, Dept Neurosurg, Beijing, Peoples R China; [Wang, Tao; Van, Ken C.; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; [Gavitt, Brian J.; Pichakron, Kullada O.] David Grant Med Ctr, Dept Surg, Travis AFB, CA USA; [Gavitt, Brian J.; Pichakron, Kullada O.] Univ Calif Davis, Dept Surg, Sacramento, CA 95817 USA; [Gavitt, Brian J.; Grayson, J. Kevin; Pichakron, Kullada O.] David Grant Med Ctr, Clin Invest Facil, Travis AFB, CA USA; [Lu, Yi-Cheng] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China		Pichakron, KO (corresponding author), USAF, MC, Dept Surg, David Grant USAF Med Ctr,Lieutenant Colonel, 60 MSGS SGCQ,101 Bodin Circle, Travis Air Force Base, CA 94535 USA.	kullada.pichakron@us.af.mil		Lyeth, Bruce/0000-0003-4811-1474	Henry M. Jackson Foundation [050611]	This research was supported by a grant from the Henry M. Jackson Foundation (050611).	Babcock TA, 2002, J SURG RES, V107, P135, DOI 10.1006/jsre.2002.6498; Bhatia HS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028451; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doughman SD, 2007, CURR DIABETES REV, V3, P198, DOI 10.2174/157339907781368968; Faul M, 2010, TRAUMATIC BRAIN INJU; Fedorova I, 2006, PROSTAG LEUKOTR ESS, V75, P271, DOI 10.1016/j.plefa.2006.07.006; Feng J. F., 2011, BRAIN RES; Fontani G, 2005, EUR J CLIN INVEST, V35, P691, DOI 10.1111/j.1365-2362.2005.01570.x; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Grossman Elan J, 2010, Top Magn Reson Imaging, V21, P379, DOI 10.1097/RMR.0b013e31823e65b8; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jacka FN, 2011, PSYCHOSOM MED, V73, P483, DOI 10.1097/PSY.0b013e318222831a; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Li HB, 1999, BRAIN RES BULL, V48, P113, DOI 10.1016/S0361-9230(98)00157-9; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Shahrokhi N, 2012, PAK J PHARM SCI, V25, P219; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang X, 2003, NEUROREPORT, V14, P2457, DOI 10.1097/00001756-200312190-00033; Weber J. T., 2007, PROG BRAIN RES; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wu A, 2008, NEUROSCIENCE, V155, P751, DOI 10.1016/j.neuroscience.2008.05.061; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Yaman M, 2007, ARCH MED RES, V38, P489, DOI 10.1016/j.arcmed.2007.01.008; Yang CC, 2009, BRAIN INJURY, V23, P299, DOI 10.1080/02699050902788543; Yehuda S, 2002, NEUROBIOL AGING, V23, P843, DOI 10.1016/S0197-4580(02)00074-X; Yimit D, 2012, NUTRITION, V28, P154, DOI 10.1016/j.nut.2011.05.008; Zlotnik A, 2012, INTENS CARE MED, V38, P137, DOI 10.1007/s00134-011-2401-3	42	25	25	0	13	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2013	31	5					647	659		10.3233/RNN-130316			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	216DQ	WOS:000324262100010	23835930				2022-02-06	
J	Zonfrillo, MR; Durbin, DR; Winston, FK; Zhao, HQ; Stineman, MG				Zonfrillo, Mark R.; Durbin, Dennis R.; Winston, Flaura K.; Zhao, Huaqing; Stineman, Margaret G.			Physical Disability After Injury-Related Inpatient Rehabilitation in Children	PEDIATRICS			English	Article						disability; injury; rehabilitation; trauma; functional outcomes	TRAUMATIC BRAIN-INJURY; UNIFORM DATA SYSTEM; QUALITY-OF-LIFE; FUNCTIONAL OUTCOMES; INDEPENDENCE; ADOLESCENTS; ASSOCIATION; MECHANISM; PROGRAMS; IMPACT	OBJECTIVE: To determine the residual physical disability after inpatient rehabilitation for children 7 to 18 years old with traumatic injuries. METHODS: This was a retrospective cohort study of patients aged 7 to 18 years who underwent inpatient rehabilitation for traumatic injuries from 2002 to 2011. Patients were identified from the Uniform Data System for Medical Rehabilitation. Injuries were captured by using standardized Medicare Inpatient Rehabilitation Facility Patient Assessment Instrument codes. Functional outcome was measured with the Functional Independence Measure (FIM) instrument. A validated, categorical grading system of the FIM motor items was used, consisting of clinically relevant levels of physical achievement from grade 1 (need for total assistance) to grade 7 (completely independent for self-care and mobility). RESULTS: A total of 13 798 injured children underwent inpatient rehabilitation across 523 facilities during the 10-year period. After a mean 3-week length of stay, functional limitations were reduced, but children still tended to have residual physical disabilities (median admission grade: 1; median discharge grade: 4). Children with spinal cord injuries, either alone or in combination with other injuries, had lower functional grade at discharge, longer lengths of stay, and more comorbidities at discharge than those with traumatic brain injuries, burns, and multiple injuries (P < .0001 for all comparisons). CONCLUSIONS: Children had very severe physical disability on admission to inpatient rehabilitation for traumatic injuries, and those with spinal cord injuries had persistent disability at discharge. These traumatic events during critical stages of development may result in a substantial care burden over the child's lifespan. Pediatrics 2013;131:e206-e213	[Zonfrillo, Mark R.] Childrens Hosp Philadelphia, Div Emergency Med, Ctr Injury Res & Prevent, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Biostat & Data Management Core, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Durbin, Dennis R.; Winston, Flaura K.] Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; [Zonfrillo, Mark R.; Durbin, Dennis R.; Zhao, Huaqing; Stineman, Margaret G.] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Stineman, Margaret G.] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA; [Winston, Flaura K.; Stineman, Margaret G.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA		Zonfrillo, MR (corresponding author), Childrens Hosp Philadelphia, Div Emergency Med, Ctr Injury Res & Prevent, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	zonfrillo@email.chop.edu	Durbin, Dennis/AAD-7829-2022; Zonfrillo, Mark R./H-9403-2017	Zonfrillo, Mark R./0000-0002-0610-9563	Academic Pediatric Association Young Investigators Award; University of Pennsylvania; National Science Foundation Center for Child Injury Prevention Studies at The Children's Hospital of Philadelphia; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD073241] Funding Source: NIH RePORTER	Supported by the Academic Pediatric Association Young Investigators Award, the Thomas B. and Jeannette E. Laws McCabe Pilot Fund Award at the University of Pennsylvania, and the National Science Foundation Center for Child Injury Prevention Studies at The Children's Hospital of Philadelphia.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Aitken ME, 1999, ARCH PHYS MED REHAB, V80, P889, DOI 10.1016/S0003-9993(99)90079-5; Alexander MS, 2009, SPINAL CORD, V47, P582, DOI 10.1038/sc.2009.18; Allen DD, 2009, SPINAL CORD, V47, P213, DOI 10.1038/sc.2008.94; Anderson CJ, 2009, DEV MED CHILD NEUROL, V51, P826, DOI 10.1111/j.1469-8749.2009.03268.x; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Barnett SD, 2012, J REHABIL RES DEV, V49, P175, DOI 10.1682/JRRD.2010.12.0242; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Burd RS, 2007, J TRAUMA, V62, P1004, DOI 10.1097/01.ta.0000221555.01704.c9; Burd RS, 2009, ACAD EMERG MED, V16, P639, DOI 10.1111/j.1553-2712.2009.00446.x; Centers for Disease Control and Prevention, 10 LEAD CAUS DEATH I; Centers for Medicare & Medicaid Services, INP REH FAC IRF PAT; Chevignard M, 2010, CHILD CARE HLTH DEV, V36, P31, DOI 10.1111/j.1365-2214.2009.00949.x; Dasarathi M, 2011, CHILD CARE HLTH DEV, V37, P418, DOI 10.1111/j.1365-2214.2010.01199.x; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; Dumas HM, 2008, INT J REHABIL RES, V31, P257, DOI 10.1097/MRR.0b013e3282fb7d03; Forsyth RJ, 2010, ARCH DIS CHILD, V95, P554, DOI 10.1136/adc.2009.161083; Garma SI, 2011, J PEDIATR PSYCHOL, V36, P226, DOI 10.1093/jpepsy/jsq037; Granger CV, 2012, AM J PHYS MED REHAB, V91, P289, DOI 10.1097/PHM.0b013e31824ad2fd; Granger CV, 2010, AM J PHYS MED REHAB, V89, P265, DOI 10.1097/PHM.0b013e3181d3eb20; Groeschel S, 2010, INT J DEV NEUROSCI, V28, P481, DOI 10.1016/j.ijdevneu.2010.06.004; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Haider AH, 2011, J PEDIATR SURG, V46, P1557, DOI 10.1016/j.jpedsurg.2011.04.055; Hakmeh W, 2010, ACAD EMERG MED, V17, P809, DOI 10.1111/j.1553-2712.2010.00819.x; Hamilton BB, 1987, REHABILITATION OUTCO, P137; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Jaffe KM, 2008, J TRAUMA, V64, P819, DOI 10.1097/TA.0b013e318165f177; Jette DU, 2005, ARCH PHYS MED REHAB, V86, P373, DOI 10.1016/j.apmr.2004.10.018; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kokoska ER, 2001, J PEDIATR SURG, V36, P100, DOI 10.1053/jpsu.2001.20022; Long C E, 2005, Pediatr Rehabil, V8, P156; Majnemer A, 2009, PHYS OCCUP THER PEDI, V29, P219, DOI 10.1080/01942630903032392; Massagli T L, 2000, Phys Med Rehabil Clin N Am, V11, P169; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; Miller AC, 2012, J NEUROTRAUM, V29, P634, DOI 10.1089/neu.2011.1932; Niewczyk PM, 2010, PEDIATR PHYS THER, V22, P42, DOI 10.1097/PEP.0b013e3181cd17e8; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; Rivara FP, 2012, ARCH PHYS MED REHAB, V93, P381, DOI 10.1016/j.apmr.2011.08.015; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Stallion A, 2007, J TRAUMA, V62, P1262; Stineman MG, 2009, ARCH SURG-CHICAGO, V144, P543, DOI 10.1001/archsurg.2009.37; Stineman MG, 2003, ARCH PHYS MED REHAB, V84, P1647, DOI 10.1053/S0003-9993(03)00317-4; Tepas Joseph J 3rd, 2004, Semin Pediatr Surg, V13, P126, DOI 10.1053/j.sempedsurg.2004.01.009; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Upperman JS, 2010, J TRAUMA, V69, P1304, DOI 10.1097/TA.0b013e3181fa4858; Vogel LC, 2003, J SPINAL CORD MED, V26, P193, DOI 10.1080/10790268.2003.11753682; Wechsler B, 2005, J TRAUMA, V58, P940, DOI 10.1097/01.TA.0000162630.78386.98; Willis CD, 2006, INJURY, V37, P1185, DOI 10.1016/j.injury.2006.07.011; Winthrop AL, 2010, CURR OPIN PEDIATR, V22, P346, DOI 10.1097/MOP.0b013e3283394351; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642; Zatzick DF, 2011, PSYCHIAT SERV, V62, P264, DOI 10.1176/ps.62.3.pss6203_0264; Zidek Kathryn, 2003, Semin Pediatr Neurol, V10, P140, DOI 10.1016/S1071-9091(03)00022-6	53	25	25	0	15	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2013	131	1					E206	E213		10.1542/peds.2012-1418			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	063PO	WOS:000313012400025	23248228	Green Published			2022-02-06	
J	Guingab-Cagmat, JD; Newsom, K; Vakulenko, A; Cagmat, EB; Kobeissy, FH; Zoltewicz, S; Wang, KK; Anagli, J				Guingab-Cagmat, Joy D.; Newsom, Kimberly; Vakulenko, Anatoliy; Cagmat, Emilio B.; Kobeissy, Firas H.; Zoltewicz, Susie; Wang, Kevin K.; Anagli, John			In vitro MS-based proteomic analysis and absolute quantification of neuronal-glial injury biomarkers in cell culture system	ELECTROPHORESIS			English	Article						Absolute mass pectrometric quantitation; Cell culture; GFAP; Proteomics; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; PEPTIDE IMMUNOAFFINITY ENRICHMENT; MAITOTOXIN INDUCES CALPAIN; MASS-SPECTROMETRY; BREAKDOWN PRODUCTS; STATISTICAL-MODEL; ACTIVATION; SERUM; NEUROPROTEOMICS	MS-based proteomics has been the method of choice for biomarker discovery in the field of traumatic brain injury (TBI). Due to its high sensitivity and specificity, MS is now being explored for biomarker quantitative validation in tissue and biofluids. In this study, we demonstrate the use of MS in both qualitative protein identification and targeted detection of acute TBI biomarkers released from degenerating cultured rat cortical mixed neuronal cells, mimicking intracellular fluid in the central nervous system after TBI. Calpain activation was induced by cell treatment with maitotoxin (MTX), a known calcium channel opener. Separate plates of mixed neuronal-glial culture were subjected to excitotoxin N-methyl-D-aspartate (NMDA) and apoptotic inducer staurosporine. Acute TBI biomarkers, GFAP and UCH-L1, were first detected and assessed in the culture media by Western blot. The cell-conditioned media were then trypsinized and subjected to bottom up proteomic analysis. GFAP was readily detected by data-dependent scanning but not UCH-L1. As a proof-of-principle study, rat glia-enriched cell cultures treated with MTX were used to investigate the time-dependent release of GFAP breakdown product by Western blot and for isotope dilution MS absolute quantitation method development. Absolute quantitation of the GFAP release was conducted using the three cortical mixed neuronal cell cultures treated with different agents. Other differentially expressed proteins identified in the glial-enriched and cortical mixed neuronal cell culture models were further analyzed by bioinformatic tools. In summary, this study demonstrates the use of MS in both protein identification and targeted quantitation of acute TBI biomarkers and is the preliminary step toward development of TBI biomarker validation by targeted MS.	[Guingab-Cagmat, Joy D.; Newsom, Kimberly; Vakulenko, Anatoliy; Cagmat, Emilio B.; Kobeissy, Firas H.; Zoltewicz, Susie; Anagli, John] Banyan Biomarkers Inc, Alachua, FL 32615 USA; [Wang, Kevin K.] Univ Florida, Dept Psychiat, Evelyn F & William L McKnight Brain Inst, Gainesville, FL 32611 USA		Guingab-Cagmat, JD (corresponding author), Banyan Biomarkers Inc, 2076 Technol Ave, Alachua, FL 32615 USA.	jguingab@banyanbio.com	Kobeissy, Firas/E-7042-2017	Kobeissy, Firas/0000-0002-5008-6944; Wang, Kevin/0000-0002-9343-6473			Addona TA, 2009, NAT BIOTECHNOL, V27, P633, DOI 10.1038/nbt.1546; Aebersold R, 2003, NATURE, V422, P198, DOI 10.1038/nature01511; Ahn YH, 2009, J PROTEOME RES, V8, P4216, DOI 10.1021/pr900269s; DEARMOND SJ, 1983, BRAIN RES, V262, P275, DOI 10.1016/0006-8993(83)91018-1; Dongre AR, 1997, TRENDS BIOTECHNOL, V15, P418, DOI 10.1016/S0167-7799(97)01110-4; Dutta S, 2002, BIOL CHEM, V383, P785, DOI 10.1515/BC.2002.082; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kobeissy FH, 2008, PROTEOM CLIN APPL, V2, P1467, DOI 10.1002/prca.200800011; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Lumpkins KM, 2008, J TRAUMA, V65, P778, DOI 10.1097/TA.0b013e318185db2d; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Ottens AK, 2008, J NEUROCHEM, V104, P1404, DOI 10.1111/j.1471-4159.2007.05086.x; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Rauh M, 2012, J CHROMATOGR B, V883, P59, DOI 10.1016/j.jchromb.2011.09.030; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Whiteaker JR, 2011, CLIN LAB MED, V31, P385, DOI 10.1016/j.cll.2011.07.004; Whiteaker JR, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005645; Whiteaker JR, 2011, NAT BIOTECHNOL, V29, P625, DOI 10.1038/nbt.1900; Whiteaker JR, 2010, CLIN CHEM, V56, P1373, DOI 10.1373/clinchem.2010.150383; Whiteaker JR, 2010, MOL CELL PROTEOMICS, V9, P184, DOI 10.1074/mcp.M900254-MCP200; Zhang Z., 2010, ANN ADV TECHNOLOGY A; Zhang Z., 2010, J NEUROTRAUM, pA1; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078; Zhao L, 2011, JOVE-J VIS EXP, DOI 10.3791/2812; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351	35	25	25	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	DEC	2012	33	24			SI		3786	3797		10.1002/elps.201200326			12	Biochemical Research Methods; Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	057FT	WOS:000312548900022	23161537				2022-02-06	
J	Syam, SS; Cote, MJ				Syam, Siddhartha S.; Cote, Murray J.			A comprehensive location-allocation method for specialized healthcare services	OPERATIONS RESEARCH FOR HEALTH CARE			English	Article						Design of experiments; Integer programming; Location-allocation; Simulated annealing		This paper focuses on the development, solution, and application of a location-allocation model for specialized health care services such as the treatment and rehabilitation necessary for strokes or traumatic brain injuries. The model is based on our experience with the Department of Veterans Affairs' integrated service networks. The model minimizes the total cost borne by the health system and its patients and incorporates admission acuity levels, service proportion requirements, and admission retention rates. A common resource constraint is introduced at the facility level since treatment of multiple acuity levels involves the pooling of common resources. Realistic instances of the model with 20 potential service locations, 50 admission districts and up to five open treatment units for three levels of severity are solved in about 300 seconds. The applicability of the model is tested by an extensive managerial experiment using data derived from one of the Department of Veterans Affairs specialized healthcare services. We investigate the effects of five critical factors: (1) the degree of service centralization, (2) service level mandates by acuity, (3) lost admission cost by acuity, (4) facility overload penalty cost by acuity and (5) target utilization level by acuity and treatment unit. We examine the countervailing forces present in making healthcare service location decisions and the resulting tradeoffs from the implicitly multiobjective nature of the system. The experiment and analysis demonstrate that the major factors of the experiment have a significant bearing on the optimal assignment of admission districts to treatment units. (C) 2012 Elsevier Ltd. All rights reserved.	[Syam, Siddhartha S.] Marquette Univ, Dept Management, Milwaukee, WI 53201 USA; [Cote, Murray J.] Texas A&M Hlth Sci Ctr, Dept Hlth Policy & Management, College Stn, TX 77843 USA		Syam, SS (corresponding author), Marquette Univ, Dept Management, Milwaukee, WI 53201 USA.	siddhartha.syam@marquette.edu; mjcote@srph.tamhsc.edu					Branas CC, 2000, HEALTH SERV RES, V35, P489; Cornuejols G., 1990, DISCRETE LOCATION TH; Cote Murray J, 2007, Health Care Manag Sci, V10, P253, DOI 10.1007/s10729-007-9018-7; CRAINIC TG, 1993, TRANSPORT SCI, V27, P90, DOI 10.1287/trsc.27.2.90; DASKIN M, 2004, OPERATIONS RES HLTH; ERLENKOTTER D, 1978, OPER RES, V26, P992, DOI 10.1287/opre.26.6.992; Harper PR, 2005, OMEGA-INT J MANAGE S, V33, P141, DOI 10.1016/j.omega.2004.03.011; Johnson DS., 1979, COMPUTERS INTRACTABI; Love R.F., 1988, FACILITIES LOCATION; Mehrez A, 1996, J OPER RES SOC, V47, P612, DOI 10.1057/palgrave.jors.0470502; Muppani VR, 2008, OMEGA-INT J MANAGE S, V36, P609, DOI 10.1016/j.omega.2007.01.006; PRICE WL, 1986, INTERFACES, V16, P17, DOI 10.1287/inte.16.5.17; SCHWEIKHART SB, 1993, SOCIO ECON PLAN SCI, V27, P289, DOI 10.1016/0038-0121(93)90021-A; Stahl JE, 2005, MED DECIS MAKING, V25, P35, DOI 10.1177/0272989X04273137; Syam SS, 2010, OMEGA-INT J MANAGE S, V38, P157, DOI 10.1016/j.omega.2009.08.001; Syam SS, 2002, COMPUT OPER RES, V29, P1173, DOI 10.1016/S0305-0548(01)00023-5	16	25	25	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	2211-6923			OPER RES HEALTH CARE	OPER. RES. HEALTH CARE	DEC	2012	1	4					73	83		10.1016/j.orhc.2012.09.001			11	Health Care Sciences & Services	Emerging Sources Citation Index (ESCI)	Health Care Sciences & Services	V9E7O	WOS:000422245100002		Green Submitted			2022-02-06	
J	Siddiq, I; Park, E; Liu, E; Spratt, SK; Surosky, R; Lee, G; Ando, D; Giedlin, M; Hare, GMT; Fehlings, MG; Baker, AJ				Siddiq, Ishita; Park, Eugene; Liu, Elaine; Spratt, S. Kaye; Surosky, Richard; Lee, Gary; Ando, Dale; Giedlin, Marty; Hare, Gregory M. T.; Fehlings, Michael G.; Baker, Andrew J.			Treatment of Traumatic Brain Injury Using Zinc-Finger Protein Gene Therapy Targeting VEGF-A	JOURNAL OF NEUROTRAUMA			English	Article						Adeno-associated virus; adenovirus; electrophysiology; gene therapy; microvasculature; traumatic brain injury	ENDOTHELIAL GROWTH-FACTOR; ENGINEERED TRANSCRIPTION FACTOR; CLINICAL-TRIALS; ANGIOGENESIS; ACTIVATION; INHIBITION; EXPRESSION; RECOVERY; NEURONS; HIPPOCAMPUS	Vascular endothelial growth factor (VEGF) plays a role in angiogenesis and has been shown to be neuroprotective following central nervous system trauma. In the present study we evaluated the pro-angiogenic and neuroprotective effects of an engineered zinc-finger protein transcription factor transactivator targeting the vascular endothelial growth factor A (VEGF-ZFP). We used two virus delivery systems, adeno-virus and adeno-associated virus, to examine the effects of early and delayed VEGF-A upregulation after brain trauma, respectively. Male Sprague-Dawley rats were subject to a unilateral fluid percussion injury (FPI) of moderate severity (2.2-2.5 atm) followed by intracerebral microinjection of either adenovirus vector (Adv) or an adeno-associated vector (AAV) carrying the VEGF-ZFP construct. Adv-VEGF-ZFP-treated animals had significantly fewer TUNEL positive cells in the injured penumbra of the cortex (p < 0.001) and hippocampus (p = 0.001) relative to untreated rats at 72 h post-injury. Adv-VEGF-ZFP treatment significantly improved fEPSP values (p = 0.007) in the CA1 region relative to injury alone. Treatment with AAV2-VEGF-ZFP resulted in improved post-injury microvascular diameter and improved functional recovery on the balance beam and rotarod task at 30 days post-injury. Collectively, the results provide supportive evidence for the concept of acute and delayed treatment following TBI using VEGF-ZFP to induce angiogenesis, reduce cell death, and enhance functional recovery.	[Park, Eugene] St Michaels Hosp, Dept Trauma Res, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Hare, Gregory M. T.; Baker, Andrew J.] St Michaels Hosp, Dept Anesthesia, Toronto, ON M5B 1W8, Canada; [Siddiq, Ishita; Hare, Gregory M. T.; Fehlings, Michael G.; Baker, Andrew J.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Hare, Gregory M. T.] Univ Toronto, Dept Physiol, Toronto, ON, Canada; [Spratt, S. Kaye; Surosky, Richard; Lee, Gary; Ando, Dale; Giedlin, Marty] Sangamo BioSci Inc, Richmond, CA USA; [Fehlings, Michael G.] Univ Toronto, Div Neurosurg, Krembil Neurosci Ctr, Toronto, ON, Canada; [Fehlings, Michael G.] Univ Toronto, McEwen Ctr Regenerat Med, Toronto, ON, Canada		Park, E (corresponding author), St Michaels Hosp, Dept Trauma Res, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St,7-080 Bond Wing, Toronto, ON M5B 1W8, Canada.	parke@smh.ca	Hare, Greg/AAM-5599-2021	Fehlings, Michael/0000-0002-5722-6364			Atkins CM, 2009, NEUROSCI LETT, V459, P52, DOI 10.1016/j.neulet.2009.04.064; Baumgartner I, 2000, ANN INTERN MED, V132, P880, DOI 10.7326/0003-4819-132-11-200006060-00005; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P471; Burger C, 2004, MOL THER, V10, P302, DOI 10.1016/j.ymthe.2004.05.024; Cammalleri M, 2011, EUR J NEUROSCI, V33, P482, DOI 10.1111/j.1460-9568.2010.07529.x; D'Onofrio PM, 2011, J NEUROTRAUM, V28, P1863, DOI 10.1089/neu.2011.1896; Dai QS, 2004, CIRCULATION, V110, P2467, DOI 10.1161/01.CIR.0000145139.53840.49; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Enomoto T, 2005, J NEUROTRAUM, V22, P783, DOI 10.1089/neu.2005.22.783; Farin A, 2004, ACT NEUR S, V89, P101; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; Hermens WTJMC, 1997, J NEUROSCI METH, V71, P85, DOI 10.1016/S0165-0270(96)00129-X; Lee C, 2010, J NEUROTRAUM, V27, P541, DOI 10.1089/neu.2009.0905; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu PQ, 2001, J BIOL CHEM, V276, P11323, DOI 10.1074/jbc.M011172200; Liu Y, 2010, NEUROBIOL DIS, V37, P384, DOI 10.1016/j.nbd.2009.10.018; Lock M, 2010, HUM GENE THER, V21, P1273, DOI 10.1089/hum.2009.223; Maas AIR, 2004, ACT NEUR S, V89, P113; McCloskey DP, 2008, BRAIN RES BULL, V76, P36, DOI 10.1016/j.brainresbull.2007.11.018; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Price SA, 2006, DIABETES, V55, P1847, DOI 10.2337/db05-1060; Rajagopalan S, 2003, CIRCULATION, V108, P1933, DOI 10.1161/01.CIR.0000093398.16124.29; Rebar EJ, 2002, NAT MED, V8, P1427, DOI 10.1038/nm795; Sakowski SA, 2009, GENE THER, V16, P1292, DOI 10.1038/gt.2009.111; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Skold MK, 2006, EUR J NEUROSCI, V23, P21, DOI 10.1111/j.1460-9568.2005.04527.x; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tolias C.M., 2004, J NEUROTRAUM, V17, P471; Xie DH, 2006, J VASC SURG, V44, P166, DOI 10.1016/j.jvs.2006.03.024; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	40	25	26	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	17					2647	2659		10.1089/neu.2012.2444			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	047QU	WOS:000311856400006	23016562				2022-02-06	
J	Tsuchikawa, D; Nakamachi, T; Tsuchida, M; Wada, Y; Hori, M; Farkas, J; Yoshikawa, A; Kagami, N; Imai, N; Shintani, N; Hashimoto, H; Atsumi, T; Shioda, S				Tsuchikawa, Daisuke; Nakamachi, Tomoya; Tsuchida, Masashi; Wada, Yoshihiro; Hori, Motohide; Farkas, Jozsef; Yoshikawa, Akira; Kagami, Nobuyuki; Imai, Nori; Shintani, Norihito; Hashimoto, Hitoshi; Atsumi, Takashi; Shioda, Seiji			Neuroprotective Effect of Endogenous Pituitary Adenylate Cyclase-Activating Polypeptide on Spinal Cord Injury	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						PACAP; Spinal cord injury; Neuroprotective effect; Knockout mouse	TRAUMATIC BRAIN-INJURY; NEURONAL CELL-DEATH; REACTIVE ASTROCYTES; MESSENGER-RNA; PACAP; PEPTIDE; RATS; EXPRESSION; APOPTOSIS; RECEPTOR	Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuroprotective peptide expressed in the central nervous system. To date, changes in the expression and effect of endogenous PACAP have not been clarified with respect to spinal cord injury (SCI). The aim of this study was to elucidate the expression pattern and function of endogenous PACAP on the contusion model of SCI using heterozygous PACAP knockout (PACAP(+/-)) and wild-type mice. Real-time polymerase chain reaction methods revealed that the level of PACAP mRNA increased gradually for 14 days after SCI and that PAC1R mRNA levels also increased for 7 days compared with intact control mice. PACAP and PAC1R immunoreactivities colabeled with a neuronal marker in the intact spinal cord. Seven days after SCI, PAC1R immunoreactivity was additionally co-expressed with an astrocyte marker. Wild-type mice gradually recovered motor function after 14 days, but PACAP(+/-) mice showed significantly impaired recovery from 3 days compared with wild-type mice. The injury volume at day 7 in PACAP(+/-) mice, and the number of single-stranded DNA-immunopositive cells as a marker of neuronal cell death at day 3 were significantly higher than values measured in wild-type mice. These data suggest that endogenous PACAP is upregulated by SCI and has a neuroprotective effect on the damaged spinal cord.	[Tsuchikawa, Daisuke; Nakamachi, Tomoya; Tsuchida, Masashi; Wada, Yoshihiro; Hori, Motohide; Farkas, Jozsef; Yoshikawa, Akira; Kagami, Nobuyuki; Imai, Nori; Shioda, Seiji] Showa Univ, Sch Med, Dept Anat, Shinagawa Ku, Tokyo 1428555, Japan; [Tsuchikawa, Daisuke; Tsuchida, Masashi; Atsumi, Takashi] Showa Univ, Fujigaoka Hosp, Dept Orthoped Surg, Tokyo, Kanagawa, Japan; [Nakamachi, Tomoya] Showa Univ, Ctr Biotechnol, Shinagawa Ku, Tokyo 1428555, Japan; [Shintani, Norihito; Hashimoto, Hitoshi] Osaka Univ, Lab Mol Neuropharmacol, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan; [Hashimoto, Hitoshi] Kanazawa Univ, Osaka Univ, Ctr Child Mental Dev, United Grad Sch Child Dev, Suita, Osaka 5650871, Japan; [Hashimoto, Hitoshi] Hamamatsu Univ Sch Med, Suita, Osaka 5650871, Japan		Shioda, S (corresponding author), Showa Univ, Sch Med, Dept Anat, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	shioda@med.showa-u.ac.jp	Shintani, Norihito/D-5860-2014; Hashimoto, Hitoshi/D-1209-2010; Shintani, Norihito/N-1600-2019	Shintani, Norihito/0000-0002-7850-9064; Hashimoto, Hitoshi/0000-0001-6548-4016; Shintani, Norihito/0000-0002-7850-9064; YOSHIKAWA, AKIRA/0000-0002-4424-1629	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [24592680] Funding Source: KAKEN		Alexanian AR, 2011, NEUROREHAB NEURAL RE, V25, P873, DOI 10.1177/1545968311416823; ARIMURA A, 1991, ENDOCRINOLOGY, V129, P2787, DOI 10.1210/endo-129-5-2787; ARIMURA A, 1995, FRONT NEUROENDOCRIN, V16, P53, DOI 10.1006/frne.1995.1003; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bracken M. B., 2012, COCHRANE DB SYST REV, V18; Chen WH, 2005, NEUROSCI LETT, V384, P117, DOI 10.1016/j.neulet.2005.04.070; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Das AK, 2011, CURR STEM CELL RES T, V6, P93; Dohi K, 2002, REGUL PEPTIDES, V109, P83, DOI 10.1016/S0167-0115(02)00190-8; Endo K, 2011, J MOL NEUROSCI, V43, P22, DOI 10.1007/s12031-010-9434-x; Fang KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015299; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; GHATEI MA, 1993, J ENDOCRINOL, V136, P159, DOI 10.1677/joe.0.1360159; Hashimoto H, 2001, P NATL ACAD SCI USA, V98, P13355, DOI 10.1073/pnas.231094498; Hashimoto H, 2011, CURR PHARM DESIGN, V17, P985, DOI 10.2174/138161211795589382; Jongsma H, 2000, BRAIN RES, V853, P186, DOI 10.1016/S0006-8993(99)02233-7; Kim WK, 2000, J NEUROSCI, V20, P3622, DOI 10.1523/JNEUROSCI.20-10-03622.2000; Kovesdi E, 2008, NEUROTOX RES, V13, P71, DOI 10.1007/BF03033558; Ma MH, 2001, EXP NEUROL, V169, P239, DOI 10.1006/exnr.2001.7679; Masmoudi-Kouki O, 2011, J NEUROCHEM, V117, P403, DOI 10.1111/j.1471-4159.2011.07185.x; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MOLLER K, 1993, NEUROSCIENCE, V57, P725, DOI 10.1016/0306-4522(93)90018-B; Morino T, 2003, NEUROSCI RES, V46, P309, DOI 10.1016/S0168-0102(03)00095-6; Nakamachi T, 2006, PEPTIDES, V27, P1859, DOI 10.1016/j.peptides.2006.01.007; Nakamachi T, 2011, CURR PHARM DESIGN, V17, P973, DOI 10.2174/138161211795589346; Nakamachi T, 2011, J MOL NEUROSCI, V43, P16, DOI 10.1007/s12031-010-9404-3; Nakamachi T, 2010, ACTA NEUROCHIR SUPPL, V106, P43, DOI 10.1007/978-3-211-98811-4_6; Ohtaki H, 2006, P NATL ACAD SCI USA, V103, P7488, DOI 10.1073/pnas.0600375103; Ohtaki H, 2008, J MOL NEUROSCI, V36, P16, DOI 10.1007/s12031-008-9077-3; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Pettersson LME, 2004, J COMP NEUROL, V471, P85, DOI 10.1002/cne.20015; Seaborn T, 2011, CURR PHARM DESIGN, V17, P204, DOI 10.2174/138161211795049679; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; Shioda S, 2006, ANN NY ACAD SCI, V1070, P550, DOI 10.1196/annals.1317.080; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Stumm R, 2007, J NEUROCHEM, V103, P1666, DOI 10.1111/j.1471-4159.2007.04895.x; Suarez V, 2006, EUR J NEUROSCI, V24, P1555, DOI 10.1111/j.1460-9568.2006.05029.x; Suzuki R, 2003, MOL BRAIN RES, V115, P10, DOI 10.1016/S0169-328X(03)00172-4; Szabadfi K, 2012, NEUROTOX RES, V21, P41, DOI 10.1007/s12640-011-9254-y; Tamas A, 2006, J NEUROTRAUM, V23, P686, DOI 10.1089/neu.2006.23.686; van Landeghem FKH, 2007, ACTA NEUROPATHOL, V113, P683, DOI 10.1007/s00401-007-0208-7; Vaudry D, 2005, PEPTIDES, V26, P2518, DOI 10.1016/j.peptides.2005.05.015; Vaudry D, 2009, PHARMACOL REV, V61, P283, DOI 10.1124/pr.109.001370; Zhang Q, 1995, BRAIN RES, V705, P149, DOI 10.1016/0006-8993(95)01150-1	47	25	25	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696			J MOL NEUROSCI	J. Mol. Neurosci.	NOV	2012	48	3					508	517		10.1007/s12031-012-9817-2			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	008LS	WOS:000308959100005	22674051				2022-02-06	
J	Yang, SG; Ma, YH; Liu, Y; Que, HP; Zhu, CQ; Liu, SJ				Yang, Shuguang; Ma, Yanhong; Liu, Yong; Que, Haiping; Zhu, Changqiang; Liu, Shaojun			Arachidonic Acid: A Bridge between Traumatic Brain Injury and Fracture Healing	JOURNAL OF NEUROTRAUMA			English	Article						arachidonic acid; fracture healing; metabonomics; serum; traumatic brain injury	DOCOSAHEXAENOIC ACID; CALLUS FORMATION; BONE-FRACTURE; PROSTAGLANDINS; MODEL; DIFFERENTIATION; MINERALIZATION; PROLIFERATION; EXPRESSION; REPAIR	Traumatic brain injury (TBI) is associated with enhanced osteogenesis. The aim of this study was to investigate the effect of serum from TBI rats on fracture healing. Results from this study showed that the serum from TBI rats enhanced the expression of bone gamma carboxyglutamate protein (BGLAP), and promoted in vitro proliferation of MC3T3-E1 cells, a mouse osteoblastic cell line. Furthermore, gas chromatography/mass spectrometry (GC/MS) coupled with multivariate statistical analysis was used to identify the changes in global serum metabolites after TBI. We found that arachidonic acid (AA) was significantly enhanced in serum metabolites in TBI subjects, while hydroxybutyric acid, leucine, malic acid, 5-oxyproline, isocitric acid, mannose, and uric acid were reduced. Finally, we examined the effects of AA on BGLAP expression and cell proliferation in MC3T3-E1 cells. We found that BGLAP expression and proliferation of osteoblasts were positively regulated in the presence of AA. These findings suggest that the increased AA in serum after TBI may play a key role in enhancing the speed of fracture healing.	[Yang, Shuguang; Ma, Yanhong; Liu, Yong; Que, Haiping; Zhu, Changqiang; Liu, Shaojun] Inst Basic Med Sci, State Key Lab Prote, Beijing 100850, Peoples R China; [Yang, Shuguang; Ma, Yanhong; Liu, Yong; Que, Haiping; Zhu, Changqiang; Liu, Shaojun] Inst Basic Med Sci, Dept Neurobiol, Beijing 100850, Peoples R China; [Ma, Yanhong] 261st Hosp Chinese PLA, Dept Cardiol, Beijing, Peoples R China		Liu, SJ (corresponding author), Inst Basic Med Sci, State Key Lab Prote, Beijing 100850, Peoples R China.	liusj@bmi.ac.cn			Chinese National Key Project of Basic ResearchNational Basic Research Program of China [2009CB918301]; Chinese National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81000797]	This work was supported by the Chinese National Key Project of Basic Research (2009CB918301), and the Chinese National Natural Science Foundation (81000797).	BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; Cadosch D, 2009, J BONE JOINT SURG AM, V91A, P282, DOI 10.2106/JBJS.G.01613; Coetzee M, 2007, PROSTAG LEUKOTR ESS, V76, P35, DOI 10.1016/j.plefa.2006.10.001; Coetzee M, 2009, CELL BIOCHEM FUNCT, V27, P3, DOI 10.1002/cbf.1526; Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559; Fazzalari NL, 2011, OSTEOPOROSIS INT, V22, P2003, DOI 10.1007/s00198-011-1611-4; Feng B, 2007, J PROTEOME RES, V6, P2161, DOI 10.1021/pr0606326; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; Gautschi OP, 2009, ANZ J SURG, V79, P449, DOI 10.1111/j.1445-2197.2008.04803.x; Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435; Giannoudis PV, 2006, INJURY, V37, pS18, DOI 10.1016/j.injury.2006.08.020; Jagtap VR, 2011, INDIAN J CLIN BIOCHE, V26, P70, DOI 10.1007/s12291-010-0074-2; KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; KLEIN DC, 1970, ENDOCRINOLOGY, V86, P1436, DOI 10.1210/endo-86-6-1436; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Morley J, 2005, INJURY, V36, P363, DOI 10.1016/j.injury.2004.08.028; NAGATA T, 1994, CALCIFIED TISSUE INT, V55, P451, DOI 10.1007/BF00298559; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; Nicholson JK, 2002, NAT REV DRUG DISCOV, V1, P153, DOI 10.1038/nrd728; NORRDIN RW, 1990, PROSTAG LEUKOTR ESS, V41, P139, DOI 10.1016/0952-3278(90)90081-U; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521, DOI 10.1302/0301-620X.69B4.3611150; Rigaux P, 2005, JOINT BONE SPINE, V72, P146, DOI 10.1016/j.jbspin.2004.05.012; Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004; SIGAL E, 1991, AM J PHYSIOL, V260, pL13, DOI 10.1152/ajplung.1991.260.2.L13; Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963; Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525, DOI 10.1302/0301-620X.69B4.3611151; Trentz OA, 2005, CRIT CARE MED, V33, P399, DOI 10.1097/01.CCM.0000152221.87477.21; UEDA K, 1980, J PEDIATR-US, V97, P834, DOI 10.1016/S0022-3476(80)80282-4; Wei YZ, 2008, J PHARM PHARMACOL, V60, P1667, DOI 10.1211/jpp/60.12.0013	34	25	26	1	32	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	17					2696	2705		10.1089/neu.2012.2442			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	047QU	WOS:000311856400011	22867040				2022-02-06	
J	Irintchev, A; Schachner, M				Irintchev, Andrey; Schachner, Melitta			The Injured and Regenerating Nervous System: Immunoglobulin Superfamily Members as Key Players	NEUROSCIENTIST			English	Article						close homologue of L1; injury; L1; myelin-associated glycoprotein; nervous system; neural cell adhesion molecule; peripheral nerve; regeneration; spinal cord	CELL-ADHESION MOLECULE; SPINAL-CORD-INJURY; MYELIN-ASSOCIATED GLYCOPROTEIN; PROMOTE FUNCTIONAL RECOVERY; NEURAL RECOGNITION MOLECULES; RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; EMBRYONIC STEM-CELLS; AXONAL REGENERATION; POLYSIALIC ACID	Understanding restricted functional recovery and designing efficient treatments to alleviate dysfunction after injury of the nervous system remain major challenges in neuroscience and medicine. Numerous molecules of potential significance in neural repair have been identified in vitro, but only few of these have proved to be of major importance in vivo up to now. Among the molecules involved in regeneration are several members of the immunoglobulin superfamily, most notably the neural cell adhesion molecules L1, its close homologue CHL1, and NCAM and, in particular, its polysialic acid glycan moiety. Sufficient evidence is now available to justify the statement that these molecules are major players not only in nervous system development but also in the adult during neural repair and synaptic plasticity. Importantly, insights into the functions of these molecules in promoting or inhibiting functional recovery have allowed the design and assessment of therapeutic approaches in animal models of central nervous system injury that could prove to be applicable in clinical settings.	[Irintchev, Andrey] Univ Jena, Dept Otorhinolaryngol, Neurosci Lab, D-07740 Jena, Germany; [Schachner, Melitta] Univ Hamburg, Zentrum Mol Neurobiol, Hamburg, Germany; [Schachner, Melitta] Rutgers State Univ, Dept Cell Biol & Neurosci, Keck Ctr Collaborat Neurosci, Piscataway, NJ USA		Irintchev, A (corresponding author), Univ Jena, Dept Otorhinolaryngol, Neurosci Lab, Lessingstr 2, D-07740 Jena, Germany.	andrey.irintchev@med.uni-jena.de	Irintchev, Andrey/A-2465-2011	Irintchev, Andrey/0000-0002-4637-1259			Apostolova I, 2006, J NEUROSCI, V26, P7849, DOI 10.1523/JNEUROSCI.1526-06.2006; Atwal JK, 2008, SCIENCE, V322, P967, DOI 10.1126/science.1161151; Aubert I, 1998, J COMP NEUROL, V399, P1; Ballermann M, 2006, EUR J NEUROSCI, V23, P1988, DOI 10.1111/j.1460-9568.2006.04726.x; Barclay AN, 2003, SEMIN IMMUNOL, V15, P215, DOI 10.1016/S1044-5323(03)00047-2; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Bartsch U, 1995, NEURON, V15, P1375, DOI 10.1016/0896-6273(95)90015-2; BARTSCH U, 1989, J COMP NEUROL, V284, P451, DOI 10.1002/cne.902840310; Becker C. G., 2007, MODEL ORGANISMS SPIN; Becker CG, 2007, J NEUROSCI RES, V85, P2793, DOI 10.1002/jnr.21121; Becker CG, 2004, J NEUROSCI, V24, P7837, DOI 10.1523/JNEUROSCI.2420-04.2004; Becker CG, 2001, EXP NEUROL, V169, P438, DOI 10.1006/exnr.2001.7657; Becker T, 2005, MOL CELL NEUROSCI, V30, P265, DOI 10.1016/j.mcn.2005.07.008; Bernreuther C, 2006, J NEUROSCI, V26, P11532, DOI 10.1523/JNEUROSCI.2688-06.2006; Blackmore M, 2006, J NEUROBIOL, V66, P348, DOI 10.1002/neu.20224; Blackmore M, 2006, J NEUROBIOL, V66, P1564, DOI 10.1002/neu.20311; Bonfanti L, 2006, PROG NEUROBIOL, V80, P129, DOI 10.1016/j.pneurobio.2006.08.003; Brummendorf T, 1996, CURR OPIN NEUROBIOL, V6, P584, DOI 10.1016/S0959-4388(96)80089-4; BRUSHART TME, 1988, J NEUROSCI, V8, P1026; Camand E, 2004, EUR J NEUROSCI, V20, P1161, DOI 10.1111/j.1460-9568.2004.03558.x; CAMPBELL DG, 1979, NATURE, V282, P341, DOI 10.1038/282341a0; Carenini S, 1999, GLIA, V27, P203, DOI 10.1002/(SICI)1098-1136(199909)27:3<203::AID-GLIA2>3.3.CO;2-Z; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Chaisuksunt V, 2000, NEUROSCIENCE, V100, P87, DOI 10.1016/S0306-4522(00)00254-2; Chaisuksunt V, 2000, J COMP NEUROL, V425, P382, DOI 10.1002/1096-9861(20000925)425:3<382::AID-CNE4>3.0.CO;2-N; Charles P, 2000, P NATL ACAD SCI USA, V97, P7585, DOI 10.1073/pnas.100076197; Charles P, 2002, BRAIN, V125, P1972, DOI 10.1093/brain/awf216; Chaudhry N, 2006, EXP NEUROL, V202, P238, DOI 10.1016/j.expneurol.2006.06.001; Chen J, 2005, J NEUROTRAUM, V22, P896, DOI 10.1089/neu.2005.22.896; Chen J, 2007, BRAIN, V130, P954, DOI 10.1093/brain/awm049; Chen S, 1999, J NEUROBIOL, V38, P428, DOI 10.1002/(SICI)1097-4695(19990215)38:3<428::AID-NEU10>3.0.CO;2-6; Chipman PH, 2010, EUR J NEUROSCI, V31, P238, DOI 10.1111/j.1460-9568.2009.07049.x; Courtine G, 2008, NAT MED, V14, P69, DOI 10.1038/nm1682; Cui YF, 2010, BRAIN, V133, P189, DOI 10.1093/brain/awp290; CUNNINGHAM BA, 1995, CURR OPIN CELL BIOL, V7, P628, DOI 10.1016/0955-0674(95)80103-0; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Descalzi G, 2009, MOL NEUROBIOL, V40, P253, DOI 10.1007/s12035-009-8085-9; Deumens R, 2007, NEUROSCI LETT, V420, P277, DOI 10.1016/j.neulet.2007.05.015; Di Filippo M, 2008, NEUROPHARMACOLOGY, V55, P353, DOI 10.1016/j.neuropharm.2008.01.012; Dityatev A, 2008, NEURON GLIA BIOL, V4, P197, DOI 10.1017/S1740925X09990111; Doherty P, 2000, MOL CELL NEUROSCI, V16, P283, DOI 10.1006/mcne.2000.0907; Dusart I, 1999, J COMP NEUROL, V408, P399; Duveau V, 2007, NEUROBIOL DIS, V26, P385, DOI 10.1016/j.nbd.2007.01.007; Duveau V, 2010, EUR J NEUROSCI, V32, P89, DOI 10.1111/j.1460-9568.2010.07272.x; El Maarouf A, 2006, P NATL ACAD SCI USA, V103, P16989, DOI 10.1073/pnas.0608036103; Emery DL, 2000, J COMP NEUROL, V424, P521; Fawcett J, 2009, PROG BRAIN RES, V175, P501, DOI 10.1016/S0079-6123(09)17534-9; Fey A, 2010, J NEUROTRAUM, V27, P815, DOI 10.1089/neu.2009.1217; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fox GB, 2001, J NEUROPATH EXP NEUR, V60, P132, DOI 10.1093/jnen/60.2.132; Franz CK, 2005, J NEUROSCI, V25, P2081, DOI 10.1523/JNEUROSCI.4880-04.2005; Franz CK, 2008, BRAIN, V131, P1492, DOI 10.1093/brain/awn039; Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867; Guseva D, 2011, EXP NEUROL, V229, P339, DOI 10.1016/j.expneurol.2011.02.018; Guseva D, 2009, BRAIN, V132, P2180, DOI 10.1093/brain/awp160; Gwak YS, 2011, NEUROPHARMACOLOGY, V60, P799, DOI 10.1016/j.neuropharm.2010.12.030; HILDEBRAND C, 1985, BRAIN RES, V358, P163, DOI 10.1016/0006-8993(85)90960-6; Hillenbrand R, 1999, EUR J NEUROSCI, V11, P813, DOI 10.1046/j.1460-9568.1999.00496.x; Holm J, 1996, EUR J NEUROSCI, V8, P1613, DOI 10.1111/j.1460-9568.1996.tb01306.x; Horinouchi K, 2005, J COMP NEUROL, V482, P386, DOI 10.1002/cne.20398; Hortsch M, 2003, FRONT BIOSCI, V8, pD357, DOI 10.2741/1006; Hoschouer EL, 2009, EXP NEUROL, V216, P22, DOI 10.1016/j.expneurol.2008.10.025; Irving EA, 2005, J CEREBR BLOOD F MET, V25, P98, DOI 10.1038/sj.jcbfm.9600011; Jakovcevski I, 2007, NEUROSCIENCE, V149, P328, DOI 10.1016/j.neuroscience.2007.07.044; Jakovcevski I, 2007, J NEUROSCI, V27, P7222, DOI 10.1523/JNEUROSCI.0739-07.2007; Jucker M, 1996, NEUROSCIENCE, V75, P703, DOI 10.1016/0306-4522(96)00276-X; JUCKER M, 1995, MOL BRAIN RES, V28, P149, DOI 10.1016/0169-328X(94)00206-T; Jung M, 1997, MOL CELL NEUROSCI, V9, P116, DOI 10.1006/mcne.1997.0611; Karimi-Abdolrezaee S, 2010, J NEUROSCI, V30, P1657, DOI 10.1523/JNEUROSCI.3111-09.2010; Kim BG, 2006, EXP NEUROL, V198, P401, DOI 10.1016/j.expneurol.2005.12.010; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; Klementiev B, 2008, EUR J NEUROSCI, V27, P2885, DOI 10.1111/j.1460-9568.2008.06245.x; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; LANGENFELDOSTER B, 1994, J NEUROCYTOL, V23, P591, DOI 10.1007/BF01191554; Lavdas AA, 2010, EXP NEUROL, V221, P206, DOI 10.1016/j.expneurol.2009.10.024; Lee JK, 2010, NEURON, V66, P663, DOI 10.1016/j.neuron.2010.05.002; Loers G, 2005, J NEUROCHEM, V92, P1463, DOI 10.1111/j.1471-4159.2004.02983.x; Loers G, 2007, J NEUROCHEM, V101, P865, DOI 10.1111/j.1471-4159.2006.04409.x; Lundborg G, 2007, ACTA PHYSIOL, V189, P207, DOI 10.1111/j.1748-1716.2006.01653.x; Maness PF, 2007, NAT NEUROSCI, V10, P19, DOI 10.1038/nn1827; Marino P, 2009, EXP NEUROL, V219, P163, DOI 10.1016/j.expneurol.2009.05.009; MARTINI R, 1994, J NEUROSCI, V14, P7180; MARTINI R, 1994, J NEUROCYTOL, V23, P1, DOI 10.1007/BF01189813; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; Mason MRJ, 2003, EUR J NEUROSCI, V18, P789, DOI 10.1046/j.1460-9568.2003.02809.x; Mears S, 2003, J PERIPHER NERV SYST, V8, P91, DOI 10.1046/j.1529-8027.2003.03012.x; Mehanna A, 2010, MOL THER, V18, P34, DOI 10.1038/mt.2009.235; Mehanna A, 2009, BRAIN, V132, P1449, DOI 10.1093/brain/awp128; Meijs MFL, 2004, J NEUROTRAUM, V21, P1415, DOI 10.1089/neu.2004.21.1415; Mishra B, 2010, J NEUROSCI, V30, P12400, DOI 10.1523/JNEUROSCI.6407-09.2010; Murphy JA, 2009, INVEST OPHTH VIS SCI, V50, P861, DOI 10.1167/iovs.08-2334; Nakamura Y, 2011, J BIOL CHEM, V286, P1876, DOI 10.1074/jbc.M110.163493; Nikonenko AG, 2006, EUR J NEUROSCI, V23, P1839, DOI 10.1111/j.1460-9568.2006.04710.x; Omoto S, 2010, J NEUROSCI, V30, P13045, DOI 10.1523/JNEUROSCI.3228-10.2010; Ourednik V, 2009, STEM CELLS, V27, P2846, DOI 10.1002/stem.227; Papastefanaki F, 2007, BRAIN, V130, P2159, DOI 10.1093/brain/awm155; Quarles RH, 2007, J NEUROCHEM, V100, P1431, DOI 10.1111/j.1471-4159.2006.04319.x; Roonprapunt C, 2003, J NEUROTRAUM, V20, P871, DOI 10.1089/089771503322385809; Rougon G, 2003, ANNU REV NEUROSCI, V26, P207, DOI 10.1146/annurev.neuro.26.041002.131014; Runyan SA, 2007, NEUROSCIENCE, V150, P959, DOI 10.1016/j.neuroscience.2007.10.009; Sakai A, 2008, PAIN, V137, P378, DOI 10.1016/j.pain.2007.09.020; Schafer M, 1996, NEURON, V16, P1107, DOI 10.1016/S0896-6273(00)80137-3; Schmid RS, 2008, CURR OPIN NEUROBIOL, V18, P245, DOI 10.1016/j.conb.2008.07.015; Scholz T, 2009, J RECONSTR MICROSURG, V25, P339, DOI 10.1055/s-0029-1215529; Shapiro L, 2007, ANNU REV NEUROSCI, V30, P451, DOI 10.1146/annurev.neuro.29.051605.113034; Simova O, 2006, ANN NEUROL, V60, P430, DOI 10.1002/ana.20948; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; STYREN SD, 1995, EXP NEUROL, V131, P165, DOI 10.1016/0014-4886(95)90038-1; Teng YD, 1999, J NEUROSCI, V19, P7037, DOI 10.1523/JNEUROSCI.19-16-07037.1999; Tomita K, 2007, GLIA, V55, P1498, DOI 10.1002/glia.20566; Troncoso E, 2004, CEREB CORTEX, V14, P332, DOI 10.1093/cercor/bhg131; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Woolhead CL, 1998, J COMP NEUROL, V391, P259; Wu B, 2009, J NEUROTRAUM, V26, P1847, DOI 10.1089/neu.2008.0551; Yamanaka H, 2007, EUR J NEUROSCI, V25, P1097, DOI 10.1111/j.1460-9568.2007.05344.x; Zhang S, 2010, NEUROCHEM INT, V56, P919, DOI 10.1016/j.neuint.2010.03.023; Zhang Y, 2000, MOL CELL NEUROSCI, V16, P71, DOI 10.1006/mcne.2000.0852; Zhang Y, 2005, P NATL ACAD SCI USA, V102, P14883, DOI 10.1073/pnas.0505164102; ZHANG Y, 1995, J COMP NEUROL, V361, P193, DOI 10.1002/cne.903610202; Zhang Y, 2008, RESTOR NEUROL NEUROS, V26, P81	123	25	28	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584			NEUROSCIENTIST	Neuroscientist	OCT	2012	18	5					452	466		10.1177/1073858411419047			15	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	011IC	WOS:000309157300004	21903634				2022-02-06	
J	Krisanova, N; Sivko, R; Kasatkina, L; Borisova, T				Krisanova, N.; Sivko, R.; Kasatkina, L.; Borisova, T.			Neuroprotection by lowering cholesterol: A decrease in membrane cholesterol content reduces transporter-mediated glutamate release from brain nerve terminals	BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE			English	Article						Neuroprotection; Cholesterol; Methyl-beta-cyclodextrin; Ambient glutamate; Transporter-mediated glutamate release; Synaptosomes	PLASMA-MEMBRANE; NMDA RECEPTORS; INDUCED EXCITOTOXICITY; BETA-CYCLODEXTRIN; CORTICAL-NEURONS; RAT-BRAIN; IN-VITRO; STATINS; STROKE; SIMVASTATIN	Background: In our earlier work, a reduction of cholesterol content increased the extracellular glutamate level in rat brain nerve terminals (synaptosomes) that was a result of the lack of transporter-mediated glutamate uptake. The aim of this study was to assess transporter-mediated release of glutamate from cholesterol-deficient synaptosomes. In stroke, cerebral hypoxia/ischemia, and traumatic brain injury, the development of neurotoxicity is provoked by enhanced extracellular glutamate, which is released from nerve cells mainly by glutamate transporter reversal - a distinctive feature of these pathological states. Methods: Laser scanning confocal microscopy, spectrofluorimetry, radiolabeled assay, and glutamate dehydrogenase assay. Results: Cholesterol acceptor methyl-beta-cyclodextrin (15 mM) reduced the cholesterol content in the synaptosomes by one quarter. Transporter-mediated glutamate release from synaptosomes: 1) stimulated by depolarization of the plasma membrane; 2) by means of heteroexchange with competitive transportable inhibitor of glutamate transporters DL-threo-beta-hydroxyaspartate; 3) in low [Na+] medium; and 4) during dissipation of the proton gradient of synaptic vesicles by the protonophore cyanide-p-trifluoromethoxyphenyl-hydrazon (FCCP); was decreased under conditions of cholesterol deficiency by similar to 24, 28, 40, and 17%, respectively. Conclusions: A decrease in the level of membrane cholesterol attenuated transporter-mediated glutamate release from nerve terminals. Therefore, lowering cholesterol may be used in neuroprotection in stroke, ischemia, and traumatic brain injury which are associated with an increase in glutamate uptake reversal. This data may explain the neuroprotective effects of statins in these pathological states and provide one of the mechanisms of their neuroprotective action. However, beside these disorders, lowering cholesterol may cause harmful consequences by decreasing glutamate uptake in nerve terminals. (C) 2012 Elsevier B.V. All rights reserved.	[Krisanova, N.; Sivko, R.; Kasatkina, L.; Borisova, T.] NAS Ukraine, Palladin Inst Biochem, Dept Neurochem, UA-01601 Kiev, Ukraine		Borisova, T (corresponding author), NAS Ukraine, Palladin Inst Biochem, Dept Neurochem, 9 Leontovicha St, UA-01601 Kiev, Ukraine.	tborisov@biochem.kiev.ua	Kasatkina, Ludmila A/O-3953-2017	Kasatkina, Ludmila A/0000-0003-3935-5389; Borisova, Tatiana/0000-0002-6533-1420	National program "Nanotechnology and nanomaterials" [5.18.5.27]	This work was supported by Grant #5.18.5.27 (National program "Nanotechnology and nanomaterials"). We would like to thank Dr. V. Gorchev and Dr. S. Karakhim for the excellent technical assistance and help in confocal microscopy studies. We appreciate Dr. I. Trikash, N. Kanivetz and V. Gumenuk for help in fluorimetry.	Abulrob A, 2005, J NEUROCHEM, V92, P1477, DOI 10.1111/j.1471-4159.2005.03001.x; Berger C, 2008, BRAIN RES REV, V58, P48, DOI 10.1016/j.brainresrev.2007.10.010; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Borisova T, 2011, NEUROCHEM INT, V59, P965, DOI 10.1016/j.neuint.2011.07.007; Borisova T, 2010, CELL MOL NEUROBIOL, V30, P1013, DOI 10.1007/s10571-010-9532-x; Borisova T, 2010, NEUROCHEM INT, V56, P466, DOI 10.1016/j.neuint.2009.12.006; Borlsova TA, 2008, ADV SPACE RES, V42, P1971, DOI 10.1016/j.asr.2008.04.012; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; Butchbach MER, 2004, J BIOL CHEM, V279, P34388, DOI 10.1074/jbc.M403938200; Camargo F, 2001, LIFE SCI, V70, P131, DOI 10.1016/S0024-3205(01)01384-4; Cavelier P, 2005, J PHYSIOL-LONDON, V564, P397, DOI 10.1113/jphysiol.2004.082131; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; CIDON S, 1989, J BIOL CHEM, V264, P8281; Cotman C W, 1974, Methods Enzymol, V31, P445; Dalby NO, 2003, J NEUROPHYSIOL, V90, P786, DOI 10.1152/jn.00118.2003; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Funck VR, 2011, EPILEPSIA, V52, P2094, DOI 10.1111/j.1528-1167.2011.03261.x; Gonzalez MI, 2007, J NEUROCHEM, V103, P1917, DOI 10.1111/j.1471-4159.2007.04881.x; Grewer C, 2008, IUBMB LIFE, V60, P609, DOI 10.1002/iub.98; Hess DC, 2000, NEUROLOGY, V54, P790, DOI 10.1212/WNL.54.4.790; Jabaudon D, 2000, P NATL ACAD SCI USA, V97, P5610, DOI 10.1073/pnas.97.10.5610; Jadot M, 2001, EUR J BIOCHEM, V268, P1392, DOI 10.1046/j.1432-1327.2001.02006.x; Jennings LJ, 1999, AM J PHYSIOL-GASTR L, V277, pG1017, DOI 10.1152/ajpgi.1999.277.5.G1017; Kirsch C, 2003, BIOCHEM PHARMACOL, V65, P843, DOI 10.1016/S0006-2952(02)01654-4; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KRUTH HS, 1980, J LIPID RES, V21, P123; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; LARSON E, 1986, ANAL BIOCHEM, V155, P243, DOI 10.1016/0003-2697(86)90432-X; Monnaert V, 2004, J PHARMACOL EXP THER, V310, P745, DOI 10.1124/jpet.104.067512; Nagaraja TN, 2006, NEUROL RES, V28, P826, DOI 10.1179/174313206X153914; NICHOLLS DG, 1986, NATURE, V321, P772, DOI 10.1038/321772a0; Nishida A, 2004, BIOL PHARM BULL, V27, P813, DOI 10.1248/bpb.27.813; O'Kane RL, 1999, J BIOL CHEM, V274, P31891, DOI 10.1074/jbc.274.45.31891; Phillis JW, 2000, BRAIN RES, V868, P105, DOI 10.1016/S0006-8993(00)02303-9; Ponce J, 2008, STROKE, V39, P1269, DOI 10.1161/STROKEAHA.107.498923; Ramirez C, 2011, J ALZHEIMERS DIS, V24, P161, DOI 10.3233/JAD-2010-101653; Robinson MB, 2006, HANDB EXP PHARM, V175, P251; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; Sierra S, 2011, J ALZHEIMERS DIS, V23, P307, DOI 10.3233/JAD-2010-101179; Sironi L, 2003, ARTERIOSCL THROM VAS, V23, P322, DOI 10.1161/01.ATV.0000044458.23905.3B; Sugiura S, 2007, BRAIN RES, V1181, P125, DOI 10.1016/j.brainres.2007.08.069; Tretter L, 1998, MOL PHARMACOL, V53, P734, DOI 10.1124/mol.53.4.734; Trikash I, 2010, CHEM PHYS LIPIDS, V163, P778, DOI 10.1016/j.chemphyslip.2010.09.003; Tsai HI, 2006, BRAIN RES, V1104, P27, DOI 10.1016/j.brainres.2006.05.081; Wang Q, 2011, EXP NEUROL, V230, P27, DOI 10.1016/j.expneurol.2010.04.006; Wang Q, 2009, EXP NEUROL, V216, P132, DOI 10.1016/j.expneurol.2008.11.016; Wood WG, 2010, ANN NY ACAD SCI, V1199, P69, DOI 10.1111/j.1749-6632.2009.05359.x; Xu YQ, 2012, PROG NEUROBIOL, V97, P1, DOI 10.1016/j.pneurobio.2012.02.002; Yan JQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020945; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhang L, 2005, CIRCULATION, V112, P3486, DOI 10.1161/CIRCULATIONAHA.104.516757; ZLATKIS A, 1953, J LAB CLIN MED, V41, P486; Zoccarato F, 1999, J NEUROCHEM, V72, P625, DOI 10.1046/j.1471-4159.1999.0720625.x	57	25	26	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0925-4439	0006-3002		BBA-MOL BASIS DIS	Biochim. Biophys. Acta-Mol. Basis Dis.	OCT	2012	1822	10					1553	1561		10.1016/j.bbadis.2012.06.005			9	Biochemistry & Molecular Biology; Biophysics; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics; Cell Biology	996AM	WOS:000308056400006	22713486	Bronze			2022-02-06	
J	Wright, AD; Laing, AC				Wright, Alexander D.; Laing, Andrew C.			The influence of headform orientation and flooring systems on impact dynamics during simulated fall-related head impacts	MEDICAL ENGINEERING & PHYSICS			English	Article						Traumatic brain injury; Falls; Compliant floors; Injury Prevention; Head impact biomechanics; Aging	POSTURAL STABILITY; INJURY; HIP; BALANCE; BIOMECHANICS; ACCELERATION; POPULATION; CONCUSSION; PREDICTION; LOCOMOTION	Novel compliant flooring systems are a promising approach for reducing fall-related injuries in seniors, as they may provide up to 50% attenuation in peak force during simulated hip impacts while eliciting only minimal influences on balance. This study aimed to determine the protective capacity of novel compliant floors during simulated 'high severity' head impacts compared to common flooring systems. A headform was impacted onto a common Commercial-Carpet at 1.5, 2.5, and 3.5 m/s in front, back, and side orientations using a mechanical drop tower. Peak impact force applied to the headform (F-max), peak linear acceleration of the headform (g(max)) and Head Injury Criterion (HIC) were determined. For the 3.5 m/s trials, backwards-oriented impacts were associated with the highest F-max and HIC values (p < 0.001); accordingly, this head orientation was used to complete additional trials on three common floors (Resilient Rubber, Residential-Loop Carpet, Berber Carpet) and six novel compliant floors at each impact velocity. ANOVAs indicated that flooring type was associated with all parameters at each impact velocity (p < 0.001). Compared to impacts on the Commercial Carpet, Dunnett's post hoc indicated all variables were smaller (25-80%) for the novel compliant floors (p < 0.001), but larger for Resilient Rubber (31-159%, p < 0.01). This study demonstrates that during 'high severity' simulated impacts, novel compliant floors can substantially reduce the forces and accelerations applied to a headform compared to common floors including carpet and resilient rubber. In combination with reports of minimal balance impairments, these findings support the promise of novel compliant floors as a biomechanically effective strategy for reducing fall-related injuries including traumatic brain injuries and skull fractures. (c) 2011 IPEM. Published by Elsevier Ltd. All rights reserved.	[Laing, Andrew C.] Univ Waterloo, Dept Kinesiol, Fac Appl Hlth Sci, Injury Biomech & Aging Lab, Waterloo, ON N2L 3G1, Canada		Laing, AC (corresponding author), Univ Waterloo, Dept Kinesiol, Fac Appl Hlth Sci, Injury Biomech & Aging Lab, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	actlaing@uwaterloo.ca		Wright, Alexander D./0000-0001-6442-5583	Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC) [386544-2010]; Ontario Graduate Scholarship programOntario Graduate Scholarship	This research was funded in part by an operating grant obtained by ACL from the Natural Sciences and Engineering Research Council of Canada (NSERC; grant # 386544-2010). ADW was supported by the Ontario Graduate Scholarship program.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ASTM, 2004, F129204 ASTM; Chiu AYY, 2003, DISABIL REHABIL, V25, P45, DOI 10.1080/713813432; Cormier J, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4003312; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Cory CZ, 2001, FORENSIC SCI INT, V123, P89, DOI 10.1016/S0379-0738(01)00523-0; Dickinson JI, 2002, GERONTOLOGIST, V42, P552, DOI 10.1093/geront/42.4.552; Dickinson JI, 2001, ENVIRON BEHAV, V33, P279, DOI 10.1177/00139160121972990; Dixon JL, 1993, ASTM STP, V2, P192; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Funk JR, 2011, ANN BIOMED ENG, V39, P766, DOI 10.1007/s10439-010-0183-3; Gardner TN, 1998, MED ENG PHYS, V20, P57, DOI 10.1016/S1350-4533(97)00041-6; Gennarelli TA, 1984, BIOMECH IMPACT TRAUM, P103; Gill J, 2001, J GERONTOL A-BIOL, V56, pM438, DOI 10.1093/gerona/56.7.M438; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Health Canada, 2002, CAN AG POP; Higgins M, 2007, J ATHL TRAINING, V42, P5; HODGSON VR, 1983, 27 STAPP CAR CRASH C; Hrysomallis C, 1999, 17 INT S BIOM SPORTS, P373; Ivancevic VG, 2009, COGN NEURODYNAMICS, V3, P281, DOI 10.1007/s11571-008-9070-0; King AI, 2000, ANNU REV BIOMED ENG, V2, P55, DOI 10.1146/annurev.bioeng.2.1.55; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Klenk J, 2011, MED ENG PHYS, V33, P368, DOI 10.1016/j.medengphy.2010.11.003; Laing AC, 2010, J BIOMECH, V43, P1898, DOI 10.1016/j.jbiomech.2010.03.025; Laing AC, 2009, ACCIDENT ANAL PREV, V41, P642, DOI 10.1016/j.aap.2009.03.001; Lord SR, 2000, GERONTOLOGY, V46, P306, DOI 10.1159/000022182; LORD SR, 1991, J GERONTOL, V46, pM69, DOI 10.1093/geronj/46.3.M69; Lundin-Olsson L, 1998, J AM GERIATR SOC, V46, P758, DOI 10.1111/j.1532-5415.1998.tb03813.x; Mack M G, 2000, Inj Prev, V6, P141, DOI 10.1136/ip.6.2.141; Mackay M, 2007, SADHANA-ACAD P ENG S, V32, P397, DOI 10.1007/s12046-007-0031-9; MacLellan MJ, 2006, EXP BRAIN RES, V173, P531, DOI 10.1007/s00221-006-0398-6; MAKI BE, 1990, J AM GERIATR SOC, V38, P1, DOI 10.1111/j.1532-5415.1990.tb01588.x; Marigold DS, 2005, J NEUROPHYSIOL, V94, P1733, DOI 10.1152/jn.00019.2005; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McHenry BG, 2004, HIC ATB; McLean A. J., 1997, HEAD INJURY, P25; Minns Julian, 2004, Nurs Stand, V18, P33; Nabhani F, 2004, J MATER PROCESS TECH, V153, P139, DOI 10.1016/j.jmatprotec.2004.04.211; Nabhani F, 2002, J MATER PROCESS TECH, V124, P311, DOI 10.1016/S0924-0136(02)00200-5; NAHUM AM, 1975, LARYNGOSCOPE, V85, P140, DOI 10.1288/00005537-197501000-00011; NOCSAE, 2009, 00108M10 NOCSAE; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pickett W, 2001, CAN MED ASSOC J, V165, P288; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Prasad P, 1985, SAE GOV IND M; Redfern MS, 1997, HUM FACTORS, V39, P445, DOI 10.1518/001872097778827043; Robinovitch S.N., 2009, P 19 ANN M INT SOC P; Robinovitch SN, 1998, J ORTHOPAED RES, V16, P309, DOI 10.1002/jor.1100160306; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Shain KS, 2010, CLIN J SPORT MED, V20, P422, DOI 10.1097/JSM.0b013e3181f7db25; Simpson AHRW, 2004, AGE AGEING, V33, P242, DOI 10.1093/ageing/afh071; Singh Anita, 2006, Stapp Car Crash J, V50, P601; *SMARTRISK, 2009, EC BURD INJ CAN; Sran MM, 2008, SPINE, V33, P1856, DOI 10.1097/BRS.0b013e31817bab05; Thomas KE, 2008, J SAFETY RES, V39, P269, DOI 10.1016/j.jsr.2008.05.001; Wright AD, 2011, ACCIDENT ANAL PREV, V43, P1480, DOI 10.1016/j.aap.2011.02.028; Zacker C, 1998, INT J TECHNOL ASSESS, V14, P446, DOI 10.1017/S0266462300011429; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	67	25	25	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1350-4533	1873-4030		MED ENG PHYS	Med. Eng. Phys.	OCT	2012	34	8					1071	1078		10.1016/j.medengphy.2011.11.012			8	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Engineering	009MB	WOS:000309028800007	22172523				2022-02-06	
J	Kreuzer, PM; Landgrebe, M; Schecklmann, M; Staudinger, S; Langguth, B				Kreuzer, Peter M.; Landgrebe, Michael; Schecklmann, Martin; Staudinger, Susanne; Langguth, Berthold		TRI Database Study Grp	Trauma-Associated Tinnitus: Audiological, Demographic and Clinical Characteristics	PLOS ONE			English	Article							OPERATION IRAQI FREEDOM; BRAIN-INJURY; DEPRESSION; ANXIETY; SEVERITY; SENSITIVITY; DYSFUNCTION; INVENTORY; ANNOYANCE; ATTENTION	Background: Tinnitus can result from different etiologies. Frequently, patients report the development of tinnitus after traumatic injuries. However, to which extent this specific etiologic factor plays a role for the phenomenology of tinnitus is still incompletely understood. Additionally, it remains a matter of debate whether the etiology of tinnitus constitutes a relevant criterion for defining tinnitus subtypes. Objective: By investigating a worldwide sample of tinnitus patients derived from the Tinnitus Research Initiative (TRI) Database, we aimed to identify differences in demographic, clinical and audiological characteristics between tinnitus patients with and without preceding trauma. Materials: A total of 1,604 patients were investigated. Assessment included demographic data, tinnitus related clinical data, audiological data, the Tinnitus Handicap Inventory, the Tinnitus Questionnaire, the Beck Depression Inventory, various numeric tinnitus rating scales, and the World Health Organisation Quality of Life Scale (WHOQoL). Results: Our data clearly indicate differences between tinnitus patients with and without trauma at tinnitus onset. Patients suffering from trauma-associated tinnitus suffer from a higher mental burden than tinnitus patients presenting with phantom perceptions based on other or unknown etiologic factors. This is especially the case for patients with whiplash and head trauma. Patients with posttraumatic noise-related tinnitus experience more frequently hyperacousis, were younger, had longer tinnitus duration, and were more frequently of male gender. Conclusions: Trauma before tinnitus onset seems to represent a relevant criterion for subtypization of tinnitus. Patients with posttraumatic tinnitus may require specific diagnostic and therapeutic management. A more systematic and - at best standardized assessment for hearing related sequelae of trauma is needed for a better understanding of the underlying pathophysiology and for developing more tailored treatment approaches as well.	[Kreuzer, Peter M.; Landgrebe, Michael; Schecklmann, Martin; Staudinger, Susanne; Langguth, Berthold] Univ Regensburg, Dept Psychiat & Psychotherapy, Regensburg, Germany; [Landgrebe, Michael] Sozialstiftung Bamberg, Dept Psychiat Psychosomat Med & Psychotherapy, Bamberg, Germany		Kreuzer, PM (corresponding author), Univ Regensburg, Dept Psychiat & Psychotherapy, Regensburg, Germany.	peter.kreuzer@medbo.de	Coelho, Claudia/J-6250-2016; Langguth, Berthold/AAP-2638-2021; Kleinjung, Tobias/AAJ-3141-2020	Coelho, Claudia/0000-0002-2441-0739; Kleinjung, Tobias/0000-0003-3867-234X; Vanneste, Sven/0000-0003-1513-5752	Tinnitus Research Initiative/TRI	The study was supported by the Tinnitus Research Initiative/TRI (www.tinnitusresearch.org). All authors confirm no conflicts of interest in regard to the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamchic L, 2012, FRONT SYST NEUROSCI, V6, DOI 10.3389/fnsys.2012.00018; Andersson G, 2009, J AM ACAD AUDIOL, V20, P315, DOI 10.3766/jaaa.20.5.5; AXELSSON A, 1985, British Journal of Audiology, V19, P271, DOI 10.3109/03005368509078983; Bauer CA, 2001, JARO-J ASSOC RES OTO, V2, P54, DOI 10.1007/s101620010030; Belli S, 2008, EUR ARCH OTO-RHINO-L, V265, P279, DOI 10.1007/s00405-007-0440-8; Boniver Raymond, 2002, Int Tinnitus J, V8, P129; Budd RJ, 1996, J PSYCHOSOM RES, V41, P327, DOI 10.1016/S0022-3999(96)00171-7; Crocetti A, 2009, OTOLARYNG HEAD NECK, V140, P403, DOI 10.1016/j.otohns.2008.11.036; Cronlein T, 2007, PROG BRAIN RES, V166, P227, DOI 10.1016/S0079-6123(07)66021-X; De Ridder D, 2011, P NATL ACAD SCI USA, V108, P8075, DOI 10.1073/pnas.1018466108; Dobie RA, 2003, OTOLARYNG CLIN N AM, V36, P383, DOI 10.1016/S0030-6665(02)00168-8; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Folmer RL, 2003, LARYNGOSCOPE, V113, P821, DOI 10.1097/00005537-200305000-00010; Folmer RL, 1999, OTOLARYNG HEAD NECK, V121, P48, DOI 10.1016/S0194-5998(99)70123-3; Geckle L, 2004, SOLDIER PERCEPTIONS; Gu JW, 2010, J NEUROPHYSIOL, V104, P3361, DOI 10.1152/jn.00226.2010; HALFORD JBS, 1991, J PSYCHOSOM RES, V35, P383, DOI 10.1016/0022-3999(91)90033-K; HALLAM RS, 1988, BRIT J CLIN PSYCHOL, V27, P213, DOI 10.1111/j.2044-8260.1988.tb00778.x; Hesser H, 2009, INT J AUDIOL, V48, P295, DOI 10.1080/14992020802635325; Hiller W, 2006, ARCH OTOLARYNGOL, V132, P1323, DOI 10.1001/archotol.132.12.1323; Hinton DE, 2006, J TRAUMA STRESS, V19, P541, DOI 10.1002/jts.20138; Jacobson G P, 2001, J Am Acad Audiol, V12, P493; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Landgrebe M, 2010, BMC MED INFORM DECIS, V10, DOI 10.1186/1472-6947-10-42; Langguth B, 2007, PROG BRAIN RES, V166, P221, DOI 10.1016/S0079-6123(07)66020-8; Langguth B, 2011, WORLD J BIOL PSYCHIA, V12, P489, DOI 10.3109/15622975.2011.575178; Leske M C, 1981, ASHA, V23, P229; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lewis J E, 2002, J Am Acad Audiol, V13, P339; LEWIS JE, 1994, CLIN OTOLARYNGOL, V19, P50, DOI 10.1111/j.1365-2273.1994.tb01147.x; MacGregor AJ, 2011, J HEAD TRAUMA REHAB, V26, P312, DOI 10.1097/HTR.0b013e3181e94404; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Malouff JM, 2011, CURR PSYCHIAT REP, V13, P31, DOI 10.1007/s11920-010-0163-1; Mao J. C., 2011, J NEUROTRAUMA; Marciano E, 2003, INT J AUDIOL, V42, P4, DOI 10.3109/14992020309056079; Moller AR, 2011, TEXTBOOK OF TINNITUS, P1; Nageris Ben I., 2008, Journal of Basic and Clinical Physiology and Pharmacology, V19, P185; Newman CW, 1996, ARCH OTOLARYNGOL, V122, P143; Nicolas-Puel Cecile, 2006, Int Tinnitus J, V12, P64; Nolle C, 2004, J NEUROTRAUM, V21, P251, DOI 10.1089/089771504322972040; Potier M, 2009, EAR HEARING, V30, P291, DOI 10.1097/AUD.0b013e31819769fc; Quintanilla-Dieck MD, 2009, J PEDIATR-US, V155, P550, DOI 10.1016/j.jpeds.2009.04.053; Rossiter S, 2006, J SPEECH LANG HEAR R, V49, P150, DOI 10.1044/1092-4388(2006/012); Schlee W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027379; Shida S, 1990, Nihon Jibiinkoka Gakkai Kaiho, V93, P1823; Sindhusake Doungkamol, 2004, J Am Acad Audiol, V15, P269; STEER RA, 1986, J CLIN PSYCHOL, V42, P475, DOI 10.1002/1097-4679(198605)42:3<475::AID-JCLP2270420311>3.0.CO;2-D; Stevens C, 2007, INT J AUDIOL, V46, P208, DOI 10.1080/14992020601102329; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner Oliver, 2007, Ann Gen Psychiatry, V6, P26, DOI 10.1186/1744-859X-6-26; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WHO, 1996, WHOQOL BREF INTR ADM; Yankaskas K, 2012, HEAR RES	55	25	27	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 26	2012	7	9							e45599	10.1371/journal.pone.0045599			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	016KP	WOS:000309517300037	23049821	Green Published, gold, Green Submitted			2022-02-06	
J	Resnick, EM; Mallampalli, M; Carter, CL				Resnick, Eileen M.; Mallampalli, Monica; Carter, Christine L.			Current Challenges in Female Veterans' Health	JOURNAL OF WOMENS HEALTH			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; OPERATION IRAQI FREEDOM; PELVIC ORGAN PROLAPSE; MENTAL-HEALTH; URINARY-INCONTINENCE; GENDER-DIFFERENCES; UNITED-STATES; WOMEN; RISK	Women in the U.S. military are technically barred from serving in combat specialties, positions, or units; however, since Operation Desert Storm, women have served in forward positions in greater numbers. This increased involvement in combat zones has resulted in exposures to trauma, injury, and a myriad of environmental hazards associated with modern war. Some of these hazards present new health risks specifically relevant to women who have been deployed to or recently returned from Iraq or Afghanistan or both. To address this evolving public health concern, the Society for Women's Health Research (SWHR) convened a 1-day interdisciplinary scientific conference, with speakers and attendees from civilian, military, and veteran settings. The purpose of the conference was to reveal the state-of-the-science on the health of the female veteran and to focus attention on recent advances in biomedical research related to female veterans' health. The following topics were discussed: mental health (posttraumatic stress disorder [PTSD] and depression), urogenital health, musculoskeletal health, and traumatic brain injury (TBI).	[Resnick, Eileen M.; Mallampalli, Monica; Carter, Christine L.] Soc Womens Hlth Res, Washington, DC 20036 USA		Carter, CL (corresponding author), Soc Womens Hlth Res, 1025 Connecticut Ave NW,Suite 601, Washington, DC 20036 USA.	chris@swhr.org					Anger JT, 2008, UROLOGY, V72, P37, DOI 10.1016/j.urology.2007.11.163; Arellano-Orden V, 2011, NEUROCRIT CARE, V14, P18, DOI 10.1007/s12028-010-9441-3; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Cross JD, 2011, CLIN ORTHOP RELAT R, V469, P1956, DOI 10.1007/s11999-011-1840-z; Cross JD, 2011, J AM ACAD ORTHOP SUR, V19, pS1, DOI 10.5435/00124635-201102001-00002; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Fritel X, 2009, OBSTET GYNECOL, V113, P609, DOI 10.1097/AOG.0b013e3181985312; Graham JE, 2010, ARCH PHYS MED REHAB, V91, P43, DOI 10.1016/j.apmr.2009.09.017; Haskell SG, 2011, WOMEN HEALTH ISS, V21, P92, DOI 10.1016/j.whi.2010.08.001; Kang H, 2005, ANN EPIDEMIOL, V15, P191, DOI 10.1016/j.annepidem.2004.05.009; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kimerling R, 2007, AM J PUBLIC HEALTH, V97, P2160, DOI 10.2105/AJPH.2006.092999; Larsen WI, 2007, INT UROGYNECOL J, V18, P769, DOI 10.1007/s00192-006-0226-3; Larsen WI, 2006, INT UROGYNECOL J, V17, P208, DOI 10.1007/s00192-005-1366-6; Lowe NK, 2003, MIL MED, V168, P569, DOI 10.1093/milmed/168.7.569; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; Masini BD, 2009, J ORTHOP TRAUMA, V23, P261, DOI 10.1097/BOT.0b013e31819dfa04; Mattocks KM, 2010, J WOMENS HEALTH, V19, P2159, DOI 10.1089/jwh.2009.1892; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Morgan CA, 2000, BIOL PSYCHIAT, V47, P891, DOI 10.1016/S0006-3223(99)00307-8; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Rasmusson AM, 2006, BIOL PSYCHIAT, V60, P704, DOI 10.1016/j.biopsych.2006.03.026; Schmidt PJ, 2009, ANN NY ACAD SCI, V1179, P70, DOI 10.1111/j.1749-6632.2009.04982.x; Schmidt PJ, 1998, NEW ENGL J MED, V338, P209, DOI 10.1056/NEJM199801223380401; Schmidt PJ, 2000, AM J OBSTET GYNECOL, V183, P414, DOI 10.1067/mob.2000.106004; Slewa-Younan S, 2008, BRAIN INJURY, V22, P183, DOI 10.1080/02699050801888808; Sohn Min-Woong, 2006, BMC Urol, V6, P30, DOI 10.1186/1471-2490-6-30; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; U.S. Department of Health and Human Services Health Resources and Services Administration, WOM HLTH US 2010; U. S. Department of Veterans Affairs, 2011, WOM VET HLTH CAR CHA; U.S. Department of Veterans Affairs, 2010, CTR WOM VET FACT SHE; Vogt D, 2011, J ABNORM PSYCHOL, V120, P797, DOI 10.1037/a0023452; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yeung JHH, 2011, ARCH SURG-CHICAGO, V146, P436, DOI 10.1001/archsurg.2011.46; Young EA, 2004, BIOL PSYCHIAT, V56, P205, DOI 10.1016/j.biopsych.2004.05.011; Young EA, 2004, ARCH GEN PSYCHIAT, V61, P394, DOI 10.1001/archpsyc.61.4.394	38	25	25	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1540-9996	1931-843X		J WOMENS HEALTH	J. Womens Health	SEP	2012	21	9					895	900		10.1089/jwh.2012.3644			6	Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies	000SR	WOS:000308409200002	22876756	Green Published			2022-02-06	
J	Rohacek, M; Albrecht, M; Kleim, B; Zimmermann, H; Exadaktylos, A				Rohacek, Martin; Albrecht, Marcel; Kleim, Birgit; Zimmermann, Heinz; Exadaktylos, Aristomenis			Reasons for ordering computed tomography scans of the head in patients with minor brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Computed tomography; Minor brain injury; Fear	RULE; PHYSICIANS; TRAUMA	Background: Minor brain injury is a frequent condition. Validated clinical decision rules can help in deciding whether a computed tomogram (CT) of the head is required. We hypothesized that institutional guidelines are not frequently used, and that psychological factors are a common reason for ordering an unnecessary CT. Methods: Physicians at the emergency department of a tertiary care hospital completed an anonymous questionnaire before ordering a CT of the head for a patient presenting with a GCS of 13-15 after a head trauma. Results: Over a period of 10 months, 1018 CTs of the head were performed in patients presenting with a GCS of 13-15 after a head trauma; 168 (16.5%) questionnaires were completed. The most four common reasons for ordering a CT were "to confirm/rule out traumatic intracranial lesion'' (in 94% of all questionnaires), "to expedite diagnosis" (63%) "guidelines" (58%) and "fear of missing a traumatic intracranial lesion" (50%). A positive answer for "fear of being sued" was declared in 21%, and "pressure from the patient or his relatives" in 8% of all questionnaires. Of 71 questionnaires without "guidelines" as a positive answer, there were 40 (56%) positive answers of "fear of missing a traumatic cerebral lesion". Conclusion: Besides guidelines, fear of missing a traumatic intracranial lesion played a role in ordering head CTs. Although the physicians had been instructed in the use of guidelines, including validated clinical decision rules, this did not prevent them from ordering unnecessary CTs. (C) 2012 Elsevier Ltd. All rights reserved.	[Rohacek, Martin; Albrecht, Marcel; Zimmermann, Heinz; Exadaktylos, Aristomenis] Univ Hosp Bern, Dept Emergency Med, Inselspital, CH-3010 Bern, Switzerland; [Kleim, Birgit] Univ Zurich, Dept Clin Psychol, CH-8006 Zurich, Switzerland		Rohacek, M (corresponding author), Univ Hosp Bern, Dept Emergency Med, Inselspital, Freiburgstr, CH-3010 Bern, Switzerland.	martin.rohacek@gmail.com	Kleim, Birgit/AAM-5309-2021				American College of Surgeons Committee on Trauma, 2008, ATLS STUD COURS MAN, P137; Boehnert MU, 2009, J EVAL CLIN PRACT, V15, P1177, DOI 10.1111/j.1365-2753.2009.01348.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Eagles D, 2008, ACAD EMERG MED, V15, P1256, DOI 10.1111/j.1553-2712.2008.00265.x; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Jeret JS, 1993, NEUROSURGERY, V32, P15; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mello MM, 2010, HEALTH AFFAIR, V29, P1569, DOI 10.1377/hlthaff.2009.0807; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Studdert DM, 2005, JAMA-J AM MED ASSOC, V293, P2609, DOI 10.1001/jama.293.21.2609	14	25	26	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	SEP	2012	43	9					1415	1418		10.1016/j.injury.2012.01.001			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	977MK	WOS:000306666100014	22277106				2022-02-06	
J	Rose, SR; Auble, BA				Rose, Susan R.; Auble, Bethany A.			Endocrine changes after pediatric traumatic brain injury	PITUITARY			English	Article						Traumatic brain injury; Hypopituitarism; Precocious puberty; Hypogonadotropic hypogonadism; Central hypothyroidism; Growth hormone deficiency; Adrenal insufficiency; Hyperprolactinemia; Adult; Pediatric	ANTERIOR-PITUITARY FUNCTION; GROWTH-HORMONE DEFICIENCY; CENTRAL HYPOTHYROIDISM; CRANIAL IRRADIATION; SHORT STATURE; CHILDREN; HYPOPITUITARISM; DYSFUNCTION; TBI; INSUFFICIENCY	Traumatic brain injury (TBI) is a very common occurrence in childhood, and can lead to devastating long term consequences. Recent research has focused on the potential endocrine consequences of TBI in adults. The research in children is less robust. This paper reviews current literature regarding TBI and possible hypothalamic and pituitary deficiencies in childhood. Acute endocrine changes are commonly found after TBI in pediatric patients, which can include changes in hypothalamic-pituitary-adrenal axis and antidiuretic hormone production and release. In the long term, both temporary and permanent alterations in pituitary function have been found. About 30% of children have hypopituitarism up to 5 years after injury. Growth hormone deficiency and disturbances in puberty are the most common, but children can also experience ACTH deficiency, diabetes insipidus, central hypothyroidism, and elevated prolactin. Every hormonal axis can be affected after TBI in children, although growth hormone deficiency and alterations in puberty are the most common. Because transient and permanent hypopituitarism is common after TBI, survivors should be screened serially for possible endocrine disturbances. These children should undergo routine surveillance at least 1 year after injury to ensure early detection of deficiencies in hormonal production in order to permit normal growth and development.	[Rose, Susan R.; Auble, Bethany A.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA		Rose, SR (corresponding author), Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 7012, Cincinnati, OH 45229 USA.	susan.rose@cchmc.org					Acerini CL, 2008, J PEDIATR ENDOCR MET, V21, P611; Acerini CL, 2007, HORM RES, V68, P14, DOI 10.1159/000110465; Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; Agha A, 2007, BRIT J NEUROSURG, V21, P210, DOI 10.1080/02688690701253331; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P984, DOI 10.1007/BF03345336; Aleksijevic D, 2011, ENDOCRINE DYSFUNCTIO; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BARZILAY Z, 1988, J MED, V19, P47; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Behan LA, 2007, HORM RES, V68, P18, DOI 10.1159/000110466; Berg C, 2010, EXP CLIN ENDOCR DIAB, V118, P139, DOI 10.1055/s-0029-1225611; BLATT J, 1984, J PEDIATR-US, V104, P182, DOI 10.1016/S0022-3476(84)80989-0; Bolado G. G., 2011, ASSESSMENT PITUITARY; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Bourguignon JP, 1997, J NEUROENDOCRINOL, V9, P193, DOI 10.1046/j.1365-2826.1997.00568.x; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; FAGLIA G, 1979, J CLIN ENDOCR METAB, V48, P989, DOI 10.1210/jcem-48-6-989; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Grumbach MM, 2002, HORM RES, V57, P2, DOI 10.1159/000058094; Hewitt J, 2011, ENDOCRINE SEQUELAE T; Kaulfers AMD, 2010, J PEDIATR-US, V157, P894, DOI 10.1016/j.jpeds.2010.07.004; Kazlauskaite R, 2008, J CLIN ENDOCR METAB, V93, P4245, DOI 10.1210/jc.2008-0710; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; Medic-Stoianoska M, 2007, ENDOCRINE, V31, P268, DOI 10.1007/s12020-007-0037-4; Moraes RB, 2011, ARQ BRAS ENDOCRINOL, V55, P295, DOI 10.1590/S0004-27302011000500001; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Norwood KW, 2010, CLIN PEDIATR, V49, P1044, DOI 10.1177/0009922810376234; Pavlovic D, 2010, EUR J NEUROL, V17, P696, DOI 10.1111/j.1468-1331.2009.02910.x; Poomthavorn P, 2008, ARCH DIS CHILD, V93, P133, DOI 10.1136/adc.2007.121137; Popii V, 2004, CLIN CHIM ACTA, V350, P1, DOI 10.1016/j.cccn.2004.06.007; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; ROMSHE CA, 1984, J PEDIATR-US, V104, P177, DOI 10.1016/S0022-3476(84)80988-9; ROSE SR, 1995, PEDIATR RES, V38, P967, DOI 10.1203/00006450-199512000-00023; Rose SR, 1999, J PEDIATR ENDOCR MET, V12, P167; ROSE SR, 1989, J CLIN ENDOCR METAB, V68, P1086, DOI 10.1210/jcem-68-6-1086; Rose SR, 2001, TRENDS ENDOCRIN MET, V12, P97, DOI 10.1016/S1043-2760(00)00359-3; Rose SR, 2010, J PEDIATR-US, V157, P662, DOI 10.1016/j.jpeds.2010.04.047; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Srinivas R, 2010, CHILD NERV SYST, V26, P647, DOI 10.1007/s00381-009-1038-9; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x	54	25	27	1	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1386-341X	1573-7403		PITUITARY	Pituitary	SEP	2012	15	3					267	275		10.1007/s11102-011-0360-x			9	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	006KB	WOS:000308817000001	22057966				2022-02-06	
J	Sun, S; Lee, D; Lee, NP; Pu, JKS; Wong, STS; Lui, WM; Fung, CF; Leung, GKK				Sun, Stella; Lee, Derek; Lee, Nikki P.; Pu, Jenny K. S.; Wong, Stanley T. S.; Lui, W. M.; Fung, C. F.; Leung, Gilberto K. K.			Hyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomide	JOURNAL OF NEURO-ONCOLOGY			English	Article						Glioma; Temozolomide; Chemoresistance; Hypoxia; Apoptosis; MAPK	TRAUMATIC BRAIN-INJURY; HYPERBARIC-OXYGEN; IN-VIVO; CHEMOTHERAPY ADJUVANT; NORMOBARIC HYPEROXIA; MALIGNANT GLIOMAS; EPITHELIAL-CELLS; GENE-EXPRESSION; MAMMARY-TUMORS; LUNG INJURY	Temozolomide (TMZ) is standard chemotherapy for glioblastoma multiforme (GBM). Intratumoral hypoxia is common in GBM and may be associated with the development of TMZ resistance. Oxygen therapy has previously been reported to potentiate the effect of chemotherapy in cancer. In this study, we investigated whether hyperoxia can enhance the TMZ-induced cytotoxicity of human GBM cells, and whether and how it would resensitize TMZ-resistant GBM cells to TMZ. TMZ-sensitive human GBM cells (D54-S and U87-S) were treated with TMZ to develop isogenic subclones of TMZ-resistant cells (D54-R and U87-R). All cell lines were then exposed to different oxygen levels (1, 21, 40, or 80 %), with or without concomitant TMZ treatment, before assessment of cell cytotoxicity and morphology. Cell death and survival pathways elicited by TMZ and/or hyperoxia were elucidated by western blotting. Our results showed that TMZ sensitivity of both chemo-sensitive and resistant cells was enhanced significantly under hyperoxia. At the cell line-specific optimum oxygen concentration (D54-R, 80 %; U87-R, 40 %), resistant cells had the same response to TMZ as the parent chemosensitive cells under normoxia via the caspase-dependent pathway. Both TMZ and hyperoxia were associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and TMZ-mediated cell death. Overall, hyperoxia enhanced TMZ toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. Induced hyperoxia is a potentially promising approach for treatment of TMZ-resistant GBM.	[Sun, Stella; Lee, Derek; Lee, Nikki P.; Pu, Jenny K. S.; Wong, Stanley T. S.; Lui, W. M.; Fung, C. F.; Leung, Gilberto K. K.] Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Div Neurosurg,Dept Surg, Hong Kong, Hong Kong, Peoples R China		Leung, GKK (corresponding author), Univ Hong Kong, Queen Mary Hosp, Li Ka Shing Fac Med, Div Neurosurg,Dept Surg, 102 Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	gilberto@hkucc.hku.hk	Leung, Gilberto Ka Kit/C-4337-2009	Leung, Gilberto Ka Kit/0000-0003-3147-3057; Wong, Thian Sze/0000-0002-8245-4019	University of Hong KongUniversity of Hong Kong [201007176020]	This work was supported by small project grant from the University of Hong Kong (project code: 201007176020).	Al-Waili NS, 2007, MED HYPOTHESES, V68, P528, DOI 10.1016/j.mehy.2005.12.054; ALAGOZ T, 1995, CANCER, V75, P2313, DOI 10.1002/1097-0142(19950501)75:9<2313::AID-CNCR2820750921>3.0.CO;2-6; Amberger-Murphy V, 2009, CURR CANCER DRUG TAR, V9, P381, DOI 10.2174/156800909788166637; Auger N, 2006, MOL CANCER THER, V5, P2182, DOI 10.1158/1535-7163.MCT-05-0428; Bar EE, 2010, AM J PATHOL, V177, P1491, DOI 10.2353/ajpath.2010.091021; Beppu T, 2002, J NEURO-ONCOL, V58, P47, DOI 10.1023/A:1015832726054; Beppu T, 2003, J NEURO-ONCOL, V61, P161, DOI 10.1023/A:1022169107872; Bocangel DB, 2002, CLIN CANCER RES, V8, P2725; Brat DJ, 2003, ANN INTERN MED, V138, P659, DOI 10.7326/0003-4819-138-8-200304150-00014; Buckley S, 1999, AM J PHYSIOL-LUNG C, V277, pL159, DOI 10.1152/ajplung.1999.277.1.L159; Chakravarti Arnab, 2008, P173; Chinot OL, 2011, ADV THER, V28, P334, DOI 10.1007/s12325-011-0007-3; D'agostino DP, 2009, NEUROSCIENCE, V159, P1011, DOI 10.1016/j.neuroscience.2009.01.062; Fischer JDD, 2011, J PROTEOME RES, V10, P153, DOI 10.1021/pr100677g; Esteller M, 1999, CANCER RES, V59, P793; Granowitz EV, 2005, ANTICANCER RES, V25, P3833; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Kalns J, 1998, ANTICANCER RES, V18, P363; Kawasoe Y, 2009, ONCOL REP, V22, P1045, DOI 10.3892/or_00000534; Konsavage WM, 2012, AM J PHYSIOL-LUNG C, V302, pL27, DOI 10.1152/ajplung.00174.2011; Kumaria A, 2009, BRIT J NEUROSURG, V23, P576, DOI 10.3109/02688690903050352; Le Calve B, 2010, NEOPLASIA, V12, P727, DOI 10.1593/neo.10526; Li LM, 2006, CLIN CANCER RES, V12, P4747, DOI 10.1158/1078-0432.CCR-05-2842; Li LM, 2005, CANCER RES, V65, P7249, DOI 10.1158/0008-5472.CAN-04-4426; Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015823; Moen I, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-446; Moen I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006381; Norden AD, 2006, NEUROLOGIST, V12, P279, DOI 10.1097/01.nrl.0000250928.26044.47; O'Reilly MA, 2000, LAB INVEST, V80, P1845, DOI 10.1038/labinvest.3780195; Oliva CR, 2010, J BIOL CHEM, V285, P39759, DOI 10.1074/jbc.M110.147504; Perez-Espejo MA, 2009, NEUROCIRUGIA, V20, P449; Petrache I, 1999, AM J PHYSIOL-LUNG C, V277, pL589, DOI 10.1152/ajplung.1999.277.3.L589; Petre PM, 2003, J THORAC CARDIOV SUR, V125, P85, DOI 10.1067/mtc.2003.90; Pistollato F, 2010, STEM CELLS, V28, P851, DOI 10.1002/stem.415; Pourgholami MH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-143; Quinn JA, 2009, J CLIN ONCOL, V27, P1262, DOI 10.1200/JCO.2008.18.8417; Romashko J, 2003, FREE RADICAL BIO MED, V35, P978, DOI 10.1016/S0891-5849(03)00494-5; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Singhal AB, 2007, NEUROL RES, V29, P173, DOI 10.1179/016164107X181815; Stuhr LEB, 2004, CANCER LETT, V210, P35, DOI 10.1016/j.canlet.2004.02.012; Stuhr LEB, 2007, J NEURO-ONCOL, V85, P191, DOI 10.1007/s11060-007-9407-2; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Sun S, 2012, J NEURO-ONCOL, V107, P89, DOI 10.1007/s11060-011-0729-8; Takiguchi N, 2001, CANCER CHEMOTH PHARM, V47, P11, DOI 10.1007/s002800000190; Tatarkova Z, 2011, NEUROCHEM RES, V36, P1475, DOI 10.1007/s11064-011-0473-7; Tateda K, 2003, J IMMUNOL, V170, P4209, DOI 10.4049/jimmunol.170.8.4209; Tolias CM, 2009, J NEUROSURG, V110, P607, DOI 10.3171/JNS.2009.110.3.0607a; Zaher TE, 2007, FREE RADICAL BIO MED, V42, P897, DOI 10.1016/j.freeradbiomed.2007.01.021; Zhang Xiang-feng, 2004, Zhonghua Jiehe He Huxi Zazhi, V27, P465	50	25	28	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0167-594X	1573-7373		J NEURO-ONCOL	J. Neuro-Oncol.	SEP	2012	109	3					467	475		10.1007/s11060-012-0923-3			9	Oncology; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Neurosciences & Neurology	001DZ	WOS:000308441700004	22763762	hybrid, Green Published, Green Submitted			2022-02-06	
J	Tator, CH				Tator, Charles H.			Sport Concussion Education and Prevention	JOURNAL OF CLINICAL SPORT PSYCHOLOGY			English	Article						concussion; education; prevention; neuropsychology; sport; athlete	ICE HOCKEY; INJURY PREVENTION; HIGH-SCHOOL; FAIR-PLAY; INTERNATIONAL-CONFERENCE; HEAD-INJURIES; STATEMENT; CHILDREN; RETURN; RULES	There has been a remarkable increase in the past 10 years in the awareness of concussion in the sports and recreation communities. Just as sport participants, their families, coaches, trainers, and sports organizations now know more about concussions, health care professionals are also better prepared to diagnose and manage concussions. As has been stated in the formal articles in this special issue on sport-related concussion, education about concussion is one of the most important aspects of concussion prevention, with the others being data collection, program evaluation, improved engineering, and introduction and enforcement of rules. Unfortunately, the incidence of concussion appears to be rising in many sports and thus, additional sports-specific strategies are required to reduce the incidence, short-term effects, and long term consequences of concussion. Enhanced educational strategies are required to ensure that individual participants, sports organizations, and health care professionals recognize concussions and manage them proficiently according to internationally recognized guidelines. Therefore, this paper serves as a "brief report" on a few important aspects of concussion education and prevention.	[Tator, Charles H.] Toronto Western Hosp, Neurosurg, Toronto, ON, Canada; [Tator, Charles H.] Univ Toronto, Toronto, ON, Canada		Tator, CH (corresponding author), Toronto Western Hosp, Neurosurg, Toronto, ON, Canada.						Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; Adler RH, 2011, PM&R, V3, pS468, DOI 10.1016/j.pmrj.2011.08.006; Agel J, 2007, J ATHL TRAINING, V42, P249; Brunelle JP, 2005, J SCI MED SPORT, V8, P294, DOI 10.1016/S1440-2440(05)80040-4; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Goodman D, 2002, CLIN J SPORT MED, V12, P265, DOI 10.1097/00042752-200209000-00001; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Hoshizaki TB, 2004, NEUROSURGERY, V55, P956, DOI 10.1227/01.NEU.0000137275.50246.0B; Macpherson A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005401.pub2; Macpherson AK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e60; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; MUELLER F, 1996, EPIDEMIOLOGY SPORTS, P41; Mueller FO, 2001, J ATHL TRAINING, V36, P312; Pless IB, 2006, ARCH PEDIAT ADOL MED, V160, P610, DOI 10.1001/archpedi.160.6.610; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Smith AM, 2009, AM SOC TEST MATER, V1516, P291, DOI 10.1520/JAI101857; Tator CH, 2008, CATASTROPHIC INJURIE; Tator CH, 2009, CLIN J SPORT MED, V19, P451, DOI 10.1097/JSM.0b013e3181bd0db6; Tator CH, 2009, CAN J NEUROL SCI, V36, P675, DOI 10.1017/S0317167100008271; Tator CH, 2009, CAN J NEUROL SCI, V36, P405, DOI 10.1017/S031716710000771X; Tator CH, 2009, CAN J NEUROL SCI, V36, P269, DOI 10.1017/S0317167100006922; Tator CH, 2009, PHYS MED REHABIL CLI, V20, P69, DOI 10.1016/j.pmr.2008.10.013	32	25	25	1	1	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1932-9261	1932-927X		J CLIN SPORT PSYCHOL	J. Clin. Sport Psychol.	SEP	2012	6	3					293	301		10.1123/jcsp.6.3.293			9	Psychology, Applied	Emerging Sources Citation Index (ESCI)	Psychology	V22SM	WOS:000215041500006					2022-02-06	
J	Toien, K; Skogstad, L; Ekeberg, O; Myhren, H; Bredal, IS				Toien, Kirsti; Skogstad, Laila; Ekeberg, Oivind; Myhren, Hilde; Bredal, Inger Schou			Prevalence and predictors of return to work in hospitalised trauma patients during the first year after discharge: A prospective cohort study	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Return to work; Injury; Injury severity scale; Life orientation test	ACQUIRED BRAIN-INJURY; QUALITY-OF-LIFE; MAJOR TRAUMA; FOLLOW-UP; FUNCTIONAL RECOVERY; DEPRESSION SCALE; HEALTH SURVEY; OUTCOMES; DETERMINANTS; DISABILITIES	Objective: The aim of the study was to investigate the proportion of patients who return to work and predictors of return to pre-injury level of work participation the first year after trauma. Methods: A prospective single-centre study of 188 patients aged 18-65 years with different degrees of injury severity was carried out in a trauma referral centre. All patients were working or studying full or part time before the injury. The first assessments were performed a median time of 27 days after discharge. Participation in work/education was measured 3 and 12 months after the first assessment with self-report questionnaires. The Hospital Anxiety and Depression Scale (HADS) and Impact of Event Scale (IES) were independent measures of anxiety, depression and post-traumatic stress symptoms (PTS) at baseline and 3 months. The Life Orientation Test Revised (LOT-R) measured optimism and pessimism at baseline. Predictors of return to work were identified by multiple logistic regression analysis. Results: After one year, 131 patients (70%) had returned to the same level of participation in work or education; 95 (50%) had returned at 3 months. Independent predictors of return to work after 3 months were low age, low Injury Severity Score (ISS) score, not needing ventilator treatment and low score for depression symptoms, adjusted for gender (Nagelkerke R square 0.38). Low ISS, absence of serious head injury, low HADS depression score and an optimistic life orientation remained significant predictors of return to work at the same level after 12 months (Nagelkerke R square 0.38). In addition, good physical function (SF-36 PF score > 65) at 3 months was an independent predictor of return to work at 12 months in the 93 patients who had not returned to work at 3 months. Conclusion: Independent predictors of return to work at 3 months were low age, low ISS and absence of depression symptoms. At 12 months, independent predictors of return to work were low ISS, low depression score and an optimistic life orientation. To promote early return to work, trauma patients might be screened for depression symptoms and pessimism, and intervention or treatment provided for those in need. (C) 2011 Elsevier Ltd. All rights reserved.	[Toien, Kirsti; Skogstad, Laila] Oslo Univ Hosp, Div Crit Care, Ulleval, Norway; [Ekeberg, Oivind] Oslo Univ Hosp, Dept Acute Med, Ulleval, Norway; [Ekeberg, Oivind] Univ Oslo, Fac Med, Dept Behav Sci Med, N-0316 Oslo, Norway; [Myhren, Hilde] Oslo Univ Hosp, Intens Care Unit, Ulleval, Norway; [Bredal, Inger Schou] Oslo Univ Hosp, Unit Breast & Endocrine Surg, Ulleval, Norway; [Bredal, Inger Schou] Univ Oslo, Fac Med, Inst Hlth & Soc, N-0316 Oslo, Norway		Toien, K (corresponding author), Oslo Univ Hosp, Div Crit Care, Ulleval, Norway.	kirsti.toien@uus.no					Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Brenneman FD, 1997, J TRAUMA, V42, P778, DOI 10.1097/00005373-199705000-00004; Clay FJ, 2010, J REHABIL MED, V42, P162, DOI 10.2340/16501977-0495; Clay FJ, 2010, INJURY; Davydow DS, 2009, GEN HOSP PSYCHIAT, V31, P428, DOI 10.1016/j.genhosppsych.2009.05.007; Fern KT, 1998, J TRAUMA, V45, P489, DOI 10.1097/00005373-199809000-00010; Gabbe BJ, 2006, J TRAUMA, V61, P1393, DOI 10.1097/01.ta.0000225926.34180.47; Holtslag HR, 2007, CLIN REHABIL, V21, P373, DOI 10.1177/0269215507072084; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Jaquet JB, 2005, PLAST RECONSTR SURG, V115, P1609, DOI 10.1097/01.PRS.0000160697.41738.EA; KIVIOJA AH, 1990, J TRAUMA, V30, P480, DOI 10.1097/00005373-199030040-00020; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Lidal IB, 2007, DISABIL REHABIL, V29, P1341, DOI 10.1080/09638280701320839; Loge JH, 1998, SCAND J SOC MED, V26, P250; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MACKENZIE EJ, 1986, MED CARE, V24, P377, DOI 10.1097/00005650-198605000-00001; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; MacKenzie EJ, 2006, J TRAUMA, V61, P688, DOI 10.1097/01.ta.0000195985.56153.68; Mason S, 2002, J TRAUMA, V53, P98, DOI 10.1097/00005373-200207000-00019; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Myhren H, 2010, CRIT CARE MED, V38, P1554, DOI 10.1097/CCM.0b013e3181e2c8b1; Nes LS, 2006, PERS SOC PSYCHOL REV, V10, P235, DOI 10.1207/s15327957pspr1003_3; OWENS WD, 1978, ANESTHESIOLOGY, V49, P239, DOI 10.1097/00000542-197810000-00003; Polinder S, 2007, B WORLD HEALTH ORGAN, V85, P27, DOI 10.2471/BLT.06.030973; Read KM, 2004, J TRAUMA, V57, P815, DOI 10.1097/01.TA.0000136289.15303.44; Richmond TS, 2009, PSYCHOL MED, V39, P1709, DOI 10.1017/S0033291709005376; ROSS CE, 1995, J HEALTH SOC BEHAV, V36, P230, DOI 10.2307/2137340; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; Schou I, 2004, PSYCHO-ONCOLOGY, V13, P309, DOI 10.1002/pon.747; Soberg HL, 2007, J TRAUMA, V62, P471, DOI 10.1097/TA.0b013e31802e95f4; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; Ware J., 2000, SF 36 HLTH SURVEY MA; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE., 1997, SF 36 HLTH SURVEY MA; Wohlfarth TD, 2003, PSYCHOL ASSESSMENT, V15, P101, DOI 10.1037/1040-3590.15.1.101; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured]	43	25	25	0	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	SEP	2012	43	9					1606	1613		10.1016/j.injury.2011.03.038			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	977MK	WOS:000306666100049	21489524				2022-02-06	
J	Yurkiewicz, IR; Lappan, CM; Neely, ET; Hesselbrock, RR; Girard, PD; Alphonso, AL; Tsao, JW				Yurkiewicz, Ilana R.; Lappan, Charles M.; Neely, Edward T.; Hesselbrock, Roger R.; Girard, Philip D.; Alphonso, Aimee L.; Tsao, Jack W.			Outcomes from a US military neurology and traumatic brain injury telemedicine program	NEUROLOGY			English	Article								Objective: This study evaluated usage of the Army Knowledge Online (AKO) Telemedicine Consultation Program for neurology and traumatic brain injury (TBI) cases in remote overseas areas with limited access to subspecialists. We performed a descriptive analysis of quantity of consults, response times, sites where consults originated, military branches that benefitted, anatomic locations of problems, and diagnoses. Methods: This was a retrospective analysis that searched electronic databases for neurology consults from October 2006 to December 2010 and TBI consults from March 2008 to December 2010. Results: A total of 508 consults were received for neurology, and 131 consults involved TBI. For the most part, quantity of consults increased over the years. Meanwhile, response times decreased, with a mean response time of 8 hours, 14 minutes for neurology consults and 2 hours, 44 minutes for TBI consults. Most neurology consults originated in Iraq (67.59%) followed by Afghanistan (16.84%), whereas TBI consults mainly originated from Afghanistan (40.87%) followed by Iraq (33.91%). The most common consultant diagnoses were headaches, including migraines (52.1%), for neurology cases and mild TBI/concussion (52.3%) for TBI cases. In the majority of cases, consultants recommended in-theater management. After receipt of consultant's recommendation, 84 known neurology evacuations were facilitated, and 3 known neurology evacuations were prevented. Conclusions: E-mail-based neurology and TBI subspecialty teleconsultation is a viable method for overseas providers in remote locations to receive expert recommendations for a range of neurologic conditions. These recommendations can facilitate medically necessary patient evacuations or prevent evacuations for which on-site care is preferable. Neurology (R) 2012;79:1237-1243	[Tsao, Jack W.] USN, Bur Med & Surg, Washington, DC USA; [Tsao, Jack W.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Yurkiewicz, Ilana R.] Harvard Univ, Sch Med, Boston, MA USA; [Lappan, Charles M.] Telehealth, So Reg Med Command, Off Surgeon Gen Teleconsultat Programs Project Ma, Ft Sam Houston, TX USA; [Neely, Edward T.; Alphonso, Aimee L.] Walter Reed Natl Mil Med Ctr, Dept Neurol, Bethesda, MD USA; [Hesselbrock, Roger R.] USAF, Sch Aerosp Med, Aerosp Med Consultat Div, Dayton, OH USA; [Girard, Philip D.] Dept Vet Affairs Ctr, Gainesville, FL USA		Tsao, JW (corresponding author), USN, Bur Med & Surg, Washington, DC USA.	jack.tsao@usuhs.edu			US ArmyUnited States Department of Defense	I.R. Yurkiewicz, C. M. Lappan, E. T. Neely, R. R. Hesselbrock, P. D. Girard, and A. L. Alphonso reports no disclosures. J.W. Tsao has received funding from the US Army to develop a military neurology telemedicine system. Go to Neurology.org for full disclosures.	Awareness, 2011, AW; Bergen P, 2006, WASHINGTON POST 1013; Defense and Veterans Brain Injury Center, 2011, DOD WORLDW NUMB TRAU; Miller TC, 2010, PROPUBLICA      0607; Summerall EL, 2010, TRAUMATIC BRAIN INJU; Vanden Brook T, 2009, US TODAY        0120	6	25	25	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	SEP	2012	79	12					1237	1243		10.1212/WNL.0b013e31826aac33			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	009WK	WOS:000309055900014	22955133				2022-02-06	
J	Chen, CC; Hsu, PW; Lee, ST; Chang, CN; Wei, KC; Wu, CT; Hsu, YH; Lin, TK; Lee, SC; Huang, YC				Chen, Ching-Chang; Hsu, Peng-Wei; Lee, Shih-Tseng; Chang, Chen-Nen; Wei, Kuo-Chen; Wu, Chieh-Tsai; Hsu, Yung-Hsin; Lin, Tzu-Kang; Lee, Sai-Cheung; Huang, Yin-Cheng			Brain surgery in patients with liver cirrhosis Clinical article	JOURNAL OF NEUROSURGERY			English	Article						Child-Turcotte-Pugh class; liver cirrhosis; brain surgery; prognostic factor; neurosurgery; complication	OPEN-HEART-SURGERY; ABDOMINAL OPERATIONS; RISK-FACTORS; MELD SCORE; TRAUMA; COAGULOPATHY; MORTALITY; SURVIVAL; OUTCOMES; INJURY	Object. Liver cirrhosis was identified as an independent predictor of poor outcomes in patients suffering trauma and in those undergoing major surgeries. The aim of this study was to report the authors' experiences treating patients with cirrhosis who undergo brain surgeries. Methods. Between 2004 and 2009, 121 consecutive patients with cirrhosis underwent 144 brain procedures. Patients were categorized as Child-Turcotte-Pugh (referred to as "Child") Class A, B, or C. The patient profiles, including the severity of cirrhosis, reason for surgery, complications, and prognosis factors, were analyzed. Results. In this retrospective study, the overall surgical complication rate for patients with cirrhosis was 52.1% and the mortality rate was 24.3%. For patients with acute traumatic brain injury (TB!), the complication, rebleeding, and mortality rates reached 84.4%, 68.8%, and 37.5%, respectively. Surgery for TBI was a significant risk factor for postoperative complications (p = 0.0002) and postoperative hemorrhage (p < 0.0001). Otherwise, according to the Child classification, the complication rate increased in a stepwise fashion from 38.7% to 60% to 84.2%, the rebleeding rate from 29.3% to 48.0% to 63.2%, and the mortality rate from 5.3% to 38% to 63.2% for Child A, B, and C, respectively. The Child classification was associated with higher risk of complications-Child B vs A OR 2.84(95% CI 1.28-6.29), Child C vs A OR 5.39 (95% CI 1.32-22.02). It was also associated with risk of death-Child C vs A OR 30.43 (95% CI 7.71-120.02), Child B vs A OR 10.88(95% CI 3.42-34.63). Conclusions. Liver cirrhosis is a poor comorbidity factor for brain surgery. The authors' results suggest that the Child classification used independently is a poor prognostic factor; in addition, grave outcomes were observed in patients with TBI. (http://thejns.org/doi/abs/10.3171/2012.4.JNS111338)	Chang Gung Univ, Dept Neurosurg, Kwei Shan, Taiwan; Chang Gung Mem Hosp Linkou, Kwei Shan, Taiwan		Huang, YC (corresponding author), Chang Gung Mem Hosp, 5 Fu Shin St, Tao Yuan 333, Taiwan.	ns3068@hotmail.com		Wu, Chieh-Tsai/0000-0002-8419-3764; Wei, Kuochen/0000-0003-3505-2196			An Y, 2007, EUR SURG RES, V39, P67, DOI 10.1159/000099145; Chen CC, 2009, CLIN NEUROL NEUROSUR, V111, P835, DOI 10.1016/j.clineuro.2009.08.013; Child CG, 1964, LIVER PORTAL HYPERTE, P50; Christmas AB, 2005, AM SURGEON, V71, P996; Dangleben DA, 2006, J AM COLL SURGEONS, V203, P908, DOI 10.1016/j.jamcollsurg.2006.08.001; Demetriades D, 2004, J AM COLL SURGEONS, V199, P538, DOI 10.1016/j.jamcollsurg.2004.06.017; DOBERNECK RC, 1983, AM J SURG, V146, P306, DOI 10.1016/0002-9610(83)90402-6; Fang JF, 2003, J TRAUMA, V54, P1131, DOI 10.1097/01.TA.0000066123.32997.BB; GARRISON RN, 1984, ANN SURG, V199, P648, DOI 10.1097/00000658-198406000-00003; Georgiou C, 2009, WORLD J SURG, V33, P1087, DOI 10.1007/s00268-009-9923-7; Gronbaek H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-16; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Huang HH, 2008, CLIN NEUROL NEUROSUR, V110, P253, DOI 10.1016/j.clineuro.2007.11.010; Kamath PS, 2003, LIVER TRANSPLANT, V9, P19, DOI 10.1053/jlts.2003.50031; Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172; Kaul V, 2000, Curr Treat Options Gastroenterol, V3, P433, DOI 10.1007/s11938-000-0030-y; Kremers WK, 2004, HEPATOLOGY, V39, P764, DOI 10.1002/hep.20083; Mansour A, 1997, SURGERY, V122, P730, DOI 10.1016/S0039-6060(97)90080-5; McCaughan GW, 2000, J GASTROEN HEPATOL, V15, pG90, DOI 10.1046/j.1440-1746.2000.02273.x; McCormick PA, 2000, BEST PRACT RES CL GA, V14, P1009, DOI 10.1053/bega.2000.0144; Shuja F, 2008, J TRAUMA, V65, P975, DOI 10.1097/TA.0b013e3181801cd9; SIRINEK KR, 1987, ARCH SURG-CHICAGO, V122, P271; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Teh SH, 2007, GASTROENTEROLOGY, V132, P1261, DOI 10.1053/j.gastro.2007.01.040; Thielmann M, 2010, EUR J CARDIO-THORAC, V38, P592, DOI 10.1016/j.ejcts.2010.02.042; TINKOFF G, 1990, ANN SURG, V211, P172, DOI 10.1097/00000658-199002000-00009; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wahlstrom K, 2000, AM SURGEON, V66, P1071; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	30	25	26	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	2012	117	2					348	353		10.3171/2012.4.JNS111338			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	978ST	WOS:000306766800028	22631693				2022-02-06	
J	Rattka, M; Brandt, C; Loscher, W				Rattka, Marta; Brandt, Claudia; Loescher, Wolfgang			Do proconvulsants modify or halt epileptogenesis? Pentylenetetrazole is ineffective in two rat models of temporal lobe epilepsy	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						antiepileptogenesis; epileptogenesis; GABA; glutamate; pilocarpine; seizures; status epilepticus	TRAUMATIC BRAIN-INJURY; ACUTE SYMPTOMATIC SEIZURE; STATUS EPILEPTICUS; GABAERGIC INHIBITION; POSTTRAUMATIC EPILEPSY; RECEPTOR ANTAGONIST; PILOCARPINE MODEL; MULTIPLE FACETS; P-GLYCOPROTEIN; ANIMAL-MODELS	In patients at risk of developing epilepsy after an initial precipitating injury to the brain, the epileptogenic latent period may offer a window of opportunity for initiating potential antiepileptogenic therapy in an attempt to prevent epilepsy from developing. One potential target for antiepileptogenesis is the development of neuronal hyperexcitability during the latent period. Surprisingly, some recent studies in models of temporal lobe epilepsy (TLE) have suggested that proconvulsant drugs could have favourable effects on epileptogenesis, resulting in the proposal of pursuing proconvulsant prophylaxis for epileptogenesis. In the present study, we evaluated this provocative hypothesis by experiments with the GABAA receptor antagonist pentylenetetrazole (PTZ) in two TLE models, the intrahippocampal kainate model and the lithiumpilocarpine model in rats. First, we repeatedly determined the PTZ seizure threshold by i.v. infusion of the convulsant during the latent period following intrahippocampal kainate. In line with recent experiments in the lithiumpilocarpine model, the PTZ seizure threshold was significantly decreased over several days following status epilepticus. We then studied whether prolonged infusion of a proconvulsant dose of PTZ at different times after kainate or pilocarpine affected the development of epilepsy. PTZ did not prevent the development of spontaneous recurrent seizures and did not decrease their frequency or severity, but exerted only a moderate disease-modifying effect in that spontaneous seizures in the kainate model were significantly shortened. These data indicate that administration of proconvulsant drugs such as PTZ during the latent period following SE is not a promising strategy for preventing epilepsy.	[Rattka, Marta; Brandt, Claudia; Loescher, Wolfgang] Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany; [Rattka, Marta; Brandt, Claudia; Loescher, Wolfgang] Ctr Syst Neurosci, Hannover, Germany		Loscher, W (corresponding author), Univ Vet Med, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de	Loscher, Wolfgang/G-9824-2016	Loscher, Wolfgang/0000-0002-9648-8973	Deutsche Forschungsgemeinschaft (Bonn, Germany)German Research Foundation (DFG) [Lo 274/10]; Friedrich-Ebert-Stiftung (Bonn, Germany)	We thank Dr Robert S. Sloviter for constructive discussion of our manuscript, Nicole Ernst, Philip Demmer, Julia Hinz and Stefan Obili for skilful technical assistance, and Dr Kathrin Tollner for providing data on SE controls from the pilocarpine models. The study was supported by a grant (Lo 274/10) from the Deutsche Forschungsgemeinschaft (Bonn, Germany). Marta Rattka receives a scholarship from the Friedrich-Ebert-Stiftung (Bonn, Germany).	Armstrong C, 2009, EPILEPSIA, V50, P1657, DOI 10.1111/j.1528-1167.2009.02173.x; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Bankstahl JP, 2008, EPILEPSY RES, V82, P70, DOI 10.1016/j.eplepsyres.2008.07.007; Beghi E, 2010, EPILEPSIA, V51, P671, DOI 10.1111/j.1528-1167.2009.02285.x; Ben-Ari Y, 2005, CURR OPIN NEUROL, V18, P141, DOI 10.1097/01.wco.0000162855.75391.6a; Blaesse P, 2009, NEURON, V61, P820, DOI 10.1016/j.neuron.2009.03.003; Bragin A, 2005, EPILEPSIA, V46, P1592, DOI 10.1111/j.1528-1167.2005.00268.x; Bragin A, 2004, EPILEPSIA, V45, P1017, DOI 10.1111/j.0013-9580.2004.17004.x; Bragin A, 2009, J NEUROSCI, V29, P3660, DOI 10.1523/JNEUROSCI.5309-08.2009; Brandt C, 2010, J NEUROSCI, V30, P8602, DOI 10.1523/JNEUROSCI.0633-10.2010; Chang BS, 2003, NEW ENGL J MED, V349, P1257, DOI 10.1056/NEJMra022308; Chen K, 2007, J NEUROSCI, V27, P46, DOI 10.1523/JNEUROSCI.3966-06.2007; Cossart R, 2005, TRENDS NEUROSCI, V28, P108, DOI 10.1016/j.tins.2004.11.011; Coulter DA, 2002, BRAIN PATHOL, V12, P240; Coulter DA, 2001, INT REV NEUROBIOL, V45, P237; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Dudek FE, 2010, EPILEPSIA, V51, P126, DOI 10.1111/j.1528-1167.2010.02626.x; Dudek FE, 2009, NEUROTHERAPEUTICS, V6, P319, DOI 10.1016/j.nurt.2009.01.020; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; ESPLIN DW, 1956, J PHARMACOL EXP THER, V118, P129; Everett J W, 1989, Monogr Endocrinol, V32, P1; FINN DA, 1994, J PHARMACOL EXP THER, V271, P164; Friedman A, 2011, EPILEPSIA, V52, P19, DOI 10.1111/j.1528-1167.2011.03227.x; Gernert M, 2001, EUR J PHARMACOL, V432, P35, DOI 10.1016/S0014-2999(01)01458-3; Glien M, 2001, EPILEPSY RES, V46, P111, DOI 10.1016/S0920-1211(01)00272-8; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; HALONEN T, 1995, BRAIN RES, V693, P217, DOI 10.1016/0006-8993(95)00744-B; Hesdorffer DC, 2009, EPILEPSIA, V50, P1102, DOI 10.1111/j.1528-1167.2008.01945.x; Jacobs MP, 2009, EPILEPSY BEHAV, V14, P438, DOI 10.1016/j.yebeh.2009.02.036; Khalilov I, 2002, J NEUROPHYSIOL, V88, P523, DOI 10.1152/jn.2002.88.1.523; Khazipov R, 2003, J NEUROSCI, V23, P5337; Klaassen A, 2006, P NATL ACAD SCI USA, V103, P19152, DOI 10.1073/pnas.0608215103; Kohling R, 1998, BRAIN, V121, P1073, DOI 10.1093/brain/121.6.1073; Kohling R, 2002, SCIENCE, V298, P1350; Kohling R, 2000, J NEUROSCI, V20, P6820, DOI 10.1523/JNEUROSCI.20-18-06820.2000; Kucker S, 2010, NEUROBIOL DIS, V37, P661, DOI 10.1016/j.nbd.2009.12.002; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Loscher W, 2009, EUR J PHARMACOL, V610, P1, DOI 10.1016/j.ejphar.2009.03.025; LOSCHER W, 1995, EPILEPSIA, V36, P929, DOI 10.1111/j.1528-1157.1995.tb01637.x; Mann EO, 2008, CURR OPIN NEUROL, V21, P155, DOI 10.1097/WCO.0b013e3282f52f5f; NEHLIG A, 1992, BRAIN RES REV, V17, P139, DOI 10.1016/0165-0173(92)90012-B; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Pitkanen A, 2009, EPILEPSY BEHAV, V14, P16, DOI 10.1016/j.yebeh.2008.09.023; Pitkanen A, 2004, EPILEPSY RES, V61, P119, DOI 10.1016/j.eplepsyres.2004.07.005; Pitkanen A, 2007, EPILEPSIA, V48, P13, DOI 10.1111/j.1528-1167.2007.01063.x; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Pitkanen A, 2010, EPILEPSIA, V51, P2, DOI 10.1111/j.1528-1167.2010.02602.x; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; Potschka H, 2001, EPILEPSIA, V42, P1231, DOI 10.1046/j.1528-1157.2001.01901.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raedt R, 2009, ACTA NEUROL SCAND, V119, P293, DOI 10.1111/j.1600-0404.2008.01108.x; RAMZAN IM, 1985, J PHARMACOL EXP THER, V234, P624; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; Rigoulot MA, 2003, EPILEPSIA, V44, P529, DOI 10.1046/j.1528-1157.2003.50502.x; SHORR EPHRAIM, 1941, SCIENCE, V94, P545, DOI 10.1126/science.94.2449.545-a; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Stefan H, 2006, ACTA NEUROL SCAND, V113, P139, DOI 10.1111/j.1600-0404.2005.00561.x; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; VOHLAND HW, 1976, N-S ARCH PHARMACOL, V293, P277, DOI 10.1007/BF00507350; Wallace MJ, 2003, J PHARMACOL EXP THER, V307, P129, DOI 10.1124/jpet.103.051920; Wallace MJ, 2002, EUR J PHARMACOL, V452, P295, DOI 10.1016/S0014-2999(02)02331-2; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	65	25	25	1	15	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	AUG	2012	36	4					2505	2520		10.1111/j.1460-9568.2012.08143.x			16	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	993XO	WOS:000307893500012	22672239				2022-02-06	
J	de Kloet, AJ; Berger, MAM; Verhoeven, IMAJ; Callenfels, KV; Vlieland, TPMV				de Kloet, A. J.; Berger, M. A. M.; Verhoeven, I. M. A. J.; Callenfels, K. van Stein; Vlieland, T. P. M. Vliet			Gaming supports youth with acquired brain injury? A pilot study	BRAIN INJURY			English	Article						Acquired brain injury; traumatic brain injury; children; youth; rehabilitation; participation; information processing; gaming	RANDOMIZED CLINICAL-TRIAL; VIRTUAL-REALITY; STROKE REHABILITATION; CHILDREN; WII; OUTCOMES	Aim: To explore the effects of usage of the Nintendo Wii on physical, cognitive and social functioning in patients with acquired brain injury (ABI). Methods: This multi-centre, observational proof-of-concept study included children, adolescents and young adults with ABI aged 6-29 years. A standardized, yet individually tailored 12-week intervention with the Nintendo Wii was delivered by trained instructors. The treatment goals were set on an individual basis and included targets regarding physical, mental and/or social functioning. Outcome assessments were done at baseline and after 12 weeks and included: the average number of minutes per week of recreational physical activity; the CAPE (Children's Assessment of Participation and Enjoyment); the ANT (Amsterdam Neuropsychological Tasks); the achievement of individual treatment goals (Goal Attainment Scaling); and quality-of-life (PedsQL; Pediatric Quality of Life Inventory). Statistical analyses included paired t-tests or Wilcoxon-Signed-Rank tests. Results: Fifty patients were included (31 boys and 19 girls; mean age 17.1 years (SD = 4.4)), of whom 45 (90%) completed the study. Significant changes of the amount of physical activity, speed of information processing, attention, response inhibition and visual-motor coordination (p < 0.05) were seen after 12 weeks, whereas there were no differences in CAPE or PedsQL scores. Two-thirds of the patients reported an improvement of the main treatment goal. Conclusion: This study supports the potential benefits of gaming in children and youth with ABI.	[de Kloet, A. J.; Vlieland, T. P. M. Vliet] Sophia Rehabil, The Hague, Netherlands; [de Kloet, A. J.; Berger, M. A. M.; Callenfels, K. van Stein] Hague Univ Appl Sci, The Hague, Netherlands; [Verhoeven, I. M. A. J.] Delft Univ Technol, Delft, Netherlands; [Vlieland, T. P. M. Vliet] Leiden Univ, Med Ctr, Dept Orthopaed, Leiden, Netherlands		de Kloet, AJ (corresponding author), Sophia Revalidatie, Vrederustlaan 180,2543 SW, The Hague, Netherlands.	a.dekloet@sophiarevalidatie.nl	Vlieland, Thea Vliet/AAJ-8119-2020	Vlieland, Thea Vliet/0000-0001-6322-3859	Sponsor Bingo Lottery [HsN090609]; Achmea (Injury Assurances; Apeldoorn); Fonds (The Hague); City of The Hague (Department of Education and Health)	This study was financially supported by the Sponsor Bingo Lottery (HsN090609), Achmea (Injury Assurances; Apeldoorn), Fonds 1818 (The Hague) and City of The Hague (Department of Education and Health) facilitated the purchase of 30 extra Wii sets. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Bedell GM, 2008, BRAIN INJURY, V22, P313, DOI 10.1080/02699050801978948; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Buizer A, 2005, PEDIAT BLOOD CANC, V45, P291; Bult MK, 2010, CLIN REHABIL, V24, P412; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; de Sonneville LMJ, 1999, COMP PSYCH, V6, P187; DeMatteo CA, 2008, ARCH PHYS MED REHAB, V89, P1803, DOI 10.1016/j.apmr.2008.02.025; Deutsch JE, 2008, PHYS THER, V88, P1196, DOI 10.2522/ptj.20080062; Galvin J, 2011, DEV NEUROREHABIL, V14, P112, DOI 10.3109/17518423.2010.535805; Gil-Gomez JA, 2011, J NEUROENG REHABIL, V8, DOI 10.1186/1743-0003-8-30; Hanisch C, 2004, J NEURAL TRANSM, V111, P865, DOI 10.1007/s00702-003-0056-0; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hendriks CM, 1996, ATAG K AMSTERDAMSE T; Joo LY, 2010, J REHABIL MED, V42, P437, DOI 10.2340/16501977-0528; Kalff AC, 2003, J CHILD PSYCHOL PSYC, V44, P1049, DOI 10.1111/1469-7610.00189; King G., 2004, CAPE PAC CHILDRENS A; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Laver KE, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008349.pub3, 10.1002/14651858.CD008349.pub4, 10.1002/14651858.CD008349.pub2]; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Meerhoff S R, 2000, Ned Tijdschr Geneeskd, V144, P1915; Missiuna Cheryl, 2008, Can J Occup Ther, V75, P157; Saposnik G, 2011, STROKE, V42, P1380, DOI 10.1161/STROKEAHA.110.605451; Saposnik G, 2010, STROKE, V41, P1477, DOI 10.1161/STROKEAHA.110.584979; Slaats-Willemse D, 2005, J AM ACAD CHILD PSY, V44, P385, DOI 10.1097/01.chi.0000153227.34473.c7; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Wilken JP, 1994, NIET AANGEBOREN HERS	28	25	25	1	46	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2012	26	7-8					1021	1029		10.3109/02699052.2012.654592			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	957CB	WOS:000305135100014	22632604				2022-02-06	
J	Ma, YY; Prince, DA				Ma, Yunyong; Prince, David A.			Functional alterations in GABAergic fast-spiking interneurons in chronically injured epileptogenic neocortex	NEUROBIOLOGY OF DISEASE			English	Article						Inhibition; Paired recordings; Barrel; Fast-spiking; Epilepsy	INHIBITORY SYNAPTIC-TRANSMISSION; HILAR SOMATOSTATIN INTERNEURONS; ACTION-POTENTIAL PROPAGATION; PAIRED-PULSE DEPRESSION; TRAUMATIC BRAIN-INJURY; DENTATE GRANULE CELLS; AXON INITIAL SEGMENT; V PYRAMIDAL NEURONS; GABA(A) RECEPTOR; RELEASE PROBABILITY	Progress toward developing effective prophylaxis and treatment of posttraumatic epilepsy depends on a detailed understanding of the basic underlying mechanisms. One important factor contributing to epileptogenesis is decreased efficacy of GABAergic inhibition. Here we tested the hypothesis that the output of neocortical fast-spiking (FS) interneurons onto postsynaptic targets would be decreased in the undercut (UC) model of chronic posttraumatic epileptogenesis. Using dual whole-cell recordings in layer IV barrel cortex, we found a marked increase in the failure rate and a very large reduction in the amplitude of unitary inhibitory postsynaptic currents (uIPSCs) from FS cells to excitatory regular spiking (RS) neurons and neighboring FS cells. Assessment of the paired pulse ratio and presumed quantal release showed that there was a significant, but relatively modest, decrease in synaptic release probability and a non-significant reduction in quantal size. A reduced density of boutons on axons of biocytin-filled UC FS cells, together with a higher coefficient of variation of uIPSC amplitude in RS cells, suggested that the number of functional synapses presynaptically formed by FS cells may be reduced. Given the marked reduction in synaptic strength, other defects in the presynaptic vesicle release machinery likely occur, as well. (C) 2012 Elsevier Inc. All rights reserved.	[Ma, Yunyong; Prince, David A.] Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA		Prince, DA (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Room M016,Alway Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	daprince@stanford.edu			National Institutes of Health from National Institute of Neurological Disorders and Stroke [NS012151, NS039579]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS006477, P50NS012151, R56NS039579, P01NS012151, R01NS039579] Funding Source: NIH RePORTER	We thank Ms. Isabel Parada for assistance in immunocytochemical experiments and Professor Michael Gutnick for helpful suggestions. This work was supported by the National Institutes of Health grants NS012151 and NS039579 from National Institute of Neurological Disorders and Stroke.	ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; Andre V, 2001, HIPPOCAMPUS, V11, P452, DOI 10.1002/hipo.1060; Andrioli A, 2007, NEUROSCIENCE, V149, P131, DOI 10.1016/j.neuroscience.2007.07.029; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Arellano JI, 2004, BRAIN, V127, P45, DOI 10.1093/brain/awh004; Ascoli GA, 2008, NAT REV NEUROSCI, V9, P557, DOI 10.1038/nrn2402; Avramescu S, 2008, J NEUROSCI, V28, P6760, DOI 10.1523/JNEUROSCI.0643-08.2008; Bacci A, 2004, NATURE, V431, P312, DOI 10.1038/nature02913; Bacci A, 2006, NEURON, V49, P119, DOI 10.1016/j.neuron.2005.12.014; Bacci A, 2003, J NEUROSCI, V23, P9664; Bacci A, 2003, J NEUROSCI, V23, P859; Bacci A, 2002, P NATL ACAD SCI USA, V99, P17125, DOI 10.1073/pnas.012481899; Bausch SB, 2005, EPILEPSY BEHAV, V7, P390, DOI 10.1016/j.yebeh.2005.07.019; Beierlein M, 2003, J NEUROPHYSIOL, V90, P2987, DOI 10.1152/jn.00283.2003; Bernard C, 2000, EPILEPSIA, V41, pS90, DOI 10.1111/j.1528-1157.2000.tb01564.x; Bianchi MT, 2001, J NEUROSCI, V21, P9083, DOI 10.1523/JNEUROSCI.21-23-09083.2001; Biro AA, 2006, J NEUROSCI, V26, P12487, DOI 10.1523/JNEUROSCI.3106-06.2006; Bodor AL, 2005, J NEUROSCI, V25, P6845, DOI 10.1523/JNEUROSCI.0442-05.2005; BOWERY NG, 1980, NATURE, V283, P92, DOI 10.1038/283092a0; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Brooks-Kayal AR, 1999, J NEUROSCI, V19, P8312; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; Caillard O, 2000, P NATL ACAD SCI USA, V97, P13372, DOI 10.1073/pnas.230362997; CELIO MR, 1986, SCIENCE, V231, P995, DOI 10.1126/science.3945815; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747, DOI 10.1152/jn.1989.61.4.747; Collin T, 2005, CURR OPIN NEUROBIOL, V15, P275, DOI 10.1016/j.conb.2005.05.003; Cossart R, 2005, TRENDS NEUROSCI, V28, P108, DOI 10.1016/j.tins.2004.11.011; Cossart R, 2001, NAT NEUROSCI, V4, P52, DOI 10.1038/82900; Cowan AI, 2004, J NEUROPHYSIOL, V92, P2137, DOI 10.1152/jn.01262.2003; Cox CL, 2000, P NATL ACAD SCI USA, V97, P9724, DOI 10.1073/pnas.170278697; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; Daw MI, 2009, J NEUROSCI, V29, P11112, DOI 10.1523/JNEUROSCI.5760-08.2009; Debanne D, 1997, NATURE, V389, P286, DOI 10.1038/38502; Dinocourt C, 2003, J COMP NEUROL, V459, P407, DOI 10.1002/cne.10622; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Dobrunz LE, 2002, INT J DEV NEUROSCI, V20, P225, DOI 10.1016/S0736-5748(02)00015-1; Dougherty KJ, 2008, J NEUROPHYSIOL, V100, P212, DOI 10.1152/jn.01104.2007; ECHLIN FA, 1959, ELECTROEN CLIN NEURO, V11, P697, DOI 10.1016/0013-4694(59)90110-5; Elfant D, 2008, EUR J NEUROSCI, V27, P104, DOI 10.1111/j.1460-9568.2007.06001.x; FABER DS, 1991, BIOPHYS J, V60, P1288, DOI 10.1016/S0006-3495(91)82162-2; Faria LC, 2010, J NEUROPHYSIOL, V104, P280, DOI 10.1152/jn.00351.2010; Feldmeyer D, 1999, J PHYSIOL-LONDON, V521, P169, DOI 10.1111/j.1469-7793.1999.00169.x; Feldmeyer D, 2005, J NEUROSCI, V25, P3423, DOI 10.1523/JNEUROSCI.5227-04.2005; FLEIDERVISH IA, 1995, J NEUROPHYSIOL, V73, P2591, DOI 10.1152/jn.1995.73.6.2591; FRERKING M, 1995, NEURON, V15, P885, DOI 10.1016/0896-6273(95)90179-5; Galante M, 2003, J NEUROSCI, V23, P11229; Galarreta M, 2002, P NATL ACAD SCI USA, V99, P12438, DOI 10.1073/pnas.192159599; Galarreta M, 2008, CEREB CORTEX, V18, P2296, DOI 10.1093/cercor/bhm253; Gibbs JW, 1997, J NEUROPHYSIOL, V77, P1924, DOI 10.1152/jn.1997.77.4.1924; Gibson JR, 2009, J NEUROSCI, V29, P13883, DOI 10.1523/JNEUROSCI.2457-09.2009; Gibson JR, 1999, NATURE, V402, P75, DOI 10.1038/47035; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 2006, MODELS OF SEIZURES AND EPILEPSY, P477, DOI 10.1016/B978-012088554-1/50040-2; Grubb MS, 2010, NATURE, V465, P1070, DOI 10.1038/nature09160; Halabisky B, 2010, J NEUROPHYSIOL, V104, P2214, DOI 10.1152/jn.00147.2010; Hanse E, 2002, J NEUROSCI, V22, P4381, DOI 10.1523/JNEUROSCI.22-11-04381.2002; HATT H, 1976, J PHYSIOL-LONDON, V259, P367, DOI 10.1113/jphysiol.1976.sp011471; Hirsch JC, 1999, NAT NEUROSCI, V2, P499, DOI 10.1038/9142; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; Houser CR, 2003, HIPPOCAMPUS, V13, P633, DOI 10.1002/hipo.10108; Huguenard JR, 2000, P NATL ACAD SCI USA, V97, P9349, DOI 10.1073/pnas.97.17.9349; Jensen K, 1999, J NEUROPHYSIOL, V82, P42, DOI 10.1152/jn.1999.82.1.42; Jin XM, 2005, J NEUROPHYSIOL, V93, P2117, DOI 10.1152/jn.00728.2004; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Kawaguchi Y, 2002, J NEUROCYTOL, V31, P277, DOI 10.1023/A:1024126110356; Kobayashi M, 2003, J NEUROSCI, V23, P2440; Kravchenko MO, 2006, NEUROSCI LETT, V395, P133, DOI 10.1016/j.neulet.2005.10.070; Kumar SS, 2006, J NEUROSCI, V26, P4613, DOI 10.1523/JNEUROSCI.0064-06.2006; LAMBERT NA, 1993, NEURON, V11, P1057, DOI 10.1016/0896-6273(93)90219-H; LAMBERT NA, 1994, J NEUROPHYSIOL, V72, P121, DOI 10.1152/jn.1994.72.1.121; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; Li HF, 2011, NEUROSCI LETT, V497, P172, DOI 10.1016/j.neulet.2011.02.042; Lisman JE, 2007, NAT REV NEUROSCI, V8, P597, DOI 10.1038/nrn2191; Loup F, 2000, J NEUROSCI, V20, P5401, DOI 10.1523/JNEUROSCI.20-14-05401.2000; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUHMANN HJ, 1995, EPILEPSY RES, V22, P43, DOI 10.1016/0920-1211(95)00032-6; LUSCHER HR, 1990, BIOPHYS J, V58, P1389; Maccaferri G, 2000, J PHYSIOL-LONDON, V524, P91, DOI 10.1111/j.1469-7793.2000.t01-3-00091.x; Magloczky Z, 2005, TRENDS NEUROSCI, V28, P334, DOI 10.1016/j.tins.2005.04.002; Manita S, 2007, BRAIN RES, V1154, P71, DOI 10.1016/j.brainres.2007.03.089; Manseau F, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000492; Marco P, 1997, BRAIN RES BULL, V44, P47, DOI 10.1016/S0361-9230(97)00090-7; Marco P, 1996, BRAIN, V119, P1327, DOI 10.1093/brain/119.4.1327; Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519; Markram H, 1998, NEUROPHARMACOLOGY, V37, P489, DOI 10.1016/S0028-3908(98)00049-5; Marsicano G, 1999, EUR J NEUROSCI, V11, P4213, DOI 10.1046/j.1460-9568.1999.00847.x; Marty S, 2000, J NEUROSCI, V20, P8087; McBain CJ, 2001, NAT REV NEUROSCI, V2, P11, DOI 10.1038/35049047; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Miles R, 1996, NEURON, V16, P815, DOI 10.1016/S0896-6273(00)80101-4; Mitchell SJ, 2003, NEURON, V38, P433, DOI 10.1016/S0896-6273(03)00200-9; Morin F, 1998, J NEUROPHYSIOL, V80, P2836, DOI 10.1152/jn.1998.80.6.2836; Morishita W, 1997, J PHYSIOL-LONDON, V505, P307, DOI 10.1111/j.1469-7793.1997.307bb.x; Oleskevich S, 2000, J PHYSIOL-LONDON, V524, P513, DOI 10.1111/j.1469-7793.2000.00513.x; Oleskevich S, 2002, J PHYSIOL-LONDON, V540, P447, DOI 10.1113/jphysiol.2001.013821; Perrais D, 1999, J NEUROSCI, V19, P578; Pitkanen A, 2009, EPILEPSIA, V50, P21, DOI 10.1111/j.1528-1167.2008.02007.x; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Rempe DA, 1997, J NEUROPHYSIOL, V78, P1504, DOI 10.1152/jn.1997.78.3.1504; RIBAK CE, 1982, J NEUROSCI, V2, P1725; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; RIBAK CE, 1979, SCIENCE, V205, P211, DOI 10.1126/science.109922; Roper SN, 1999, EPILEPSY RES, V37, P63, DOI 10.1016/S0920-1211(99)00035-2; Rosen GD, 1998, CEREB CORTEX, V8, P753, DOI 10.1093/cercor/8.8.753; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916, DOI 10.1152/jn.2000.83.5.2916; Sakaba T, 2008, NEURON, V57, P406, DOI 10.1016/j.neuron.2007.11.029; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Scanziani M, 1998, P NATL ACAD SCI USA, V95, P12004, DOI 10.1073/pnas.95.20.12004; Schwaller B, 2004, MOL CELL NEUROSCI, V25, P650, DOI 10.1016/j.mcn.2003.12.006; Schwarzer C, 1997, NEUROSCIENCE, V80, P1001, DOI 10.1016/S0306-4522(97)00145-0; Scotti AL, 1997, HIPPOCAMPUS, V7, P524; Shah MM, 2004, NEURON, V44, P495, DOI 10.1016/j.neuron.2004.10.011; Silva AV, 2002, BRAIN RES BULL, V58, P417, DOI 10.1016/S0361-9230(02)00811-0; Stewart BA, 2000, P NATL ACAD SCI USA, V97, P13955, DOI 10.1073/pnas.250491397; Sun Qian-Quan, 2005, Thalamus & Related Systems, V3, P261, DOI 10.1017/S1472928807000283; Sun QQ, 2003, J NEUROSCI, V23, P9639; Tamas G, 2000, NAT NEUROSCI, V3, P366, DOI 10.1038/73936; TAUCK DL, 1985, J NEUROSCI, V5, P1016; TRAUB RD, 1982, SCIENCE, V216, P745, DOI 10.1126/science.7079735; Trotter SA, 2006, J NEUROSCI, V26, P10756, DOI 10.1523/JNEUROSCI.2323-06.2006; Tseng GF, 1996, J NEUROPHYSIOL, V75, P248, DOI 10.1152/jn.1996.75.1.248; Uematsu M, 2008, CEREB CORTEX, V18, P315, DOI 10.1093/cercor/bhm056; Ulrich D, 1996, J PHYSIOL-LONDON, V493, P845, DOI 10.1113/jphysiol.1996.sp021427; vandenPol AN, 1996, J NEUROSCI, V16, P4283; Vreugdenhil M, 2003, J NEUROPHYSIOL, V89, P1414, DOI 10.1152/jn.00576.2002; Wang Y, 2002, CEREB CORTEX, V12, P395, DOI 10.1093/cercor/12.4.395; Weimer RM, 2003, NAT NEUROSCI, V6, P1023, DOI 10.1038/nn1118; WILCOX KS, 1994, J NEUROSCI, V14, P1775, DOI 10.1523/JNEUROSCI.14-03-01775.1994; Williamson A, 1999, ANN NEUROL, V45, P92, DOI 10.1002/1531-8249(199901)45:1<92::AID-ART15>3.0.CO;2-N; Wittner L, 2005, BRAIN, V128, P138, DOI 10.1093/brain/awh339; Wittner L, 2001, NEUROSCIENCE, V108, P587, DOI 10.1016/S0306-4522(01)00446-8; Wyeth MS, 2010, J NEUROSCI, V30, P8993, DOI 10.1523/JNEUROSCI.1183-10.2010; Xiang ZX, 2002, J NEUROPHYSIOL, V88, P740, DOI 10.1152/jn.2002.88.2.740; Yamamoto K, 2010, J NEUROPHYSIOL, V104, P1933, DOI 10.1152/jn.00438.2010; Zamecnik J, 2006, BRAIN RES BULL, V68, P474, DOI 10.1016/j.brainresbull.2005.10.008; Zhang NH, 2007, J NEUROSCI, V27, P7520, DOI 10.1523/JNEUROSCI.1555-07.2007; Zhang W, 2009, J NEUROSCI, V29, P14247, DOI 10.1523/JNEUROSCI.3842-09.2009; Zhang W, 2009, J NEUROSCI, V29, P7846, DOI 10.1523/JNEUROSCI.6199-08.2009; Zucker RS, 2002, ANNU REV PHYSIOL, V64, P355, DOI 10.1146/annurev.physiol.64.092501.114547	143	25	27	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUL	2012	47	1					102	113		10.1016/j.nbd.2012.03.027			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	952KP	WOS:000304791700010	22484482	Green Accepted			2022-02-06	
J	Yang, H; Feng, GD; Liang, Z; Vitale, A; Jiao, XY; Ju, G; You, SW				Yang, Hao; Feng, Guo-Dong; Liang, Zhe; Vitale, Angela; Jiao, Xi-Ying; Ju, Gong; You, Si-Wei			In vitro beneficial activation of microglial cells by mechanically-injured astrocytes enhances the synthesis and secretion of BDNF through p38MAPK	NEUROCHEMISTRY INTERNATIONAL			English	Article						Astrocyte; Mechanical injury; Microglial cell; BDNF; p38MAPK; Rat	TUMOR-NECROSIS-FACTOR; NERVE GROWTH-FACTOR; SPINAL-CORD-INJURY; NEUROTROPHIC FACTOR; PROTEIN-KINASE; NEURITE OUTGROWTH; MESSENGER-RNAS; ACUTE NEURODEGENERATION; OXIDATIVE STRESS; INTERFERON-GAMMA	It has long been promulgated that microglial cells serve beneficial roles in the central nervous system (CNS). The beneficial role of microglial cells is considered to be linked with microglial activation and consequent up-regulation of various trophic factors. However, what triggers microglial activation and consequent elevated level of trophic factors, especially brain-derived neurotrophic factor (BDNF), following traumatic CNS injury has become a crucial but elusive issue. Furthermore, an effort still remains in understanding of the cellular and molecular mechanisms underlying the endogenous neuroprotection of activated microglial cells. In this study, we demonstrated that mechanically-injured astrocyte conditioned medium (ACM) could provoke beneficial activation of microglial cells and thus promote the transcription, synthesis and release of BDNF in cultured microglial cells. The microglia-derived BDNF can exerted a demonstrable biological role in promoting neurite outgrowth and intimate terminal contacts of dorsal root ganglion (DRG) neurons co-cultured with microglial cells. Moreover, ACM induced remarkable p38MAPK phosphorylation in cultured microglial cells that preceded the burst of BDNF. Activating p38-MAPK by anisomycin resulted in salutary effects similar to those seen with ACM, whereas specific inhibition of the p38MAPK by SB203580 abrogated all the positive effects of ACM, including BDNF promotion and subsequent neurite outgrowth of DRG neurite outgrowth of DRG neurons and their intimate terminal contacts with microglial cells. Together, our results indicated that the neuroprotection of the microglial source is mainly caused by micro-environmental soluble molecules released from injured astrocytes, and ACM-induced BDNF production and release from microglial cells may be mediated through p38-MAPK signaling pathway. Therefore, these findings may lay a foundation to further investigations on the microglial beneficial activation role in the repair of traumatic CNS injury and neurodegenerative diseases. (c) 2012 Elsevier Ltd. All rights reserved.	[Yang, Hao; Jiao, Xi-Ying; Ju, Gong; You, Si-Wei] Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China; [Feng, Guo-Dong] Fourth Mil Med Univ, Xijing Hosp, Dept Neurol, Xian 710032, Peoples R China; [Liang, Zhe] Emory Univ, Sch Med, Dept Surg & Lab Med, Atlanta, GA 30322 USA; [Vitale, Angela] Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA		Yang, H (corresponding author), Fourth Mil Med Univ, Inst Neurosci, Xian 710032, Peoples R China.	yanghao71_99@yahoo.com; yousiwei@fmmu.edu.cn			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30973088, 30901649]; National Key Basic Research and Development Project (the 973 Project)National Basic Research Program of China [2011CB504402]; 11th Five-special-purpose Program for PLA [O8Z028]	We are grateful to Dr. Kavita Bhat from Emory University School of medicine, USA, for her kind help in the preparation of this manuscript. This work was supported by Natural Science Foundation of China (Nos. 30973088 and 30901649), National Key Basic Research and Development Project (the 973 Project, 2011CB504402) and the 11th Five-special-purpose Program for PLA (O8Z028).	Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Balschun D, 2004, FASEB J, V18, P1788, DOI 10.1096/fj.04-1625fje; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Batchelor PE, 1999, J NEUROSCI, V19, P1708; Bilsland J, 1999, J NEUROSCI METH, V92, P75, DOI 10.1016/S0165-0270(99)00099-0; Buisson A, 2003, CELL MOL NEUROBIOL, V23, P539, DOI 10.1023/A:1025072013107; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; Crown ED, 2006, EXP NEUROL, V199, P397, DOI 10.1016/j.expneurol.2006.01.003; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; De Groot CJA, 1999, J NEUROPATH EXP NEUR, V58, P174, DOI 10.1097/00005072-199902000-00007; Elkabes S, 1998, J NEUROSCI RES, V54, P117, DOI 10.1002/(SICI)1097-4547(19981001)54:1<117::AID-JNR12>3.3.CO;2-8; Gingras J, 1999, J COMP NEUROL, V414, P551; Gomez-Pinilla F, 1990, Neuroreport, V1, P211; Gras G, 2003, BRAIN PATHOL, V13, P211; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Heese K, 1997, NEUROSCI LETT, V231, P83, DOI 10.1016/S0304-3940(97)00545-4; Heese K, 1998, J NEUROCHEM, V70, P699; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Ji RR, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-33; Katoh-Semba R, 2009, NEUROSCIENCE, V163, P352, DOI 10.1016/j.neuroscience.2009.06.011; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; Kumar S, 2003, NAT REV DRUG DISCOV, V2, P717, DOI 10.1038/nrd1177; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lambertsen KL, 2009, J NEUROSCI, V29, P1319, DOI 10.1523/JNEUROSCI.5505-08.2009; Largo C, 1996, J NEUROSCI, V16, P1219; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; Liberto CM, 2004, J NEUROCHEM, V89, P1092, DOI 10.1111/j.1471-4159.2004.02420.x; Luo XG, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-12; Miwa T, 1997, J NEUROSCI RES, V50, P1023; Murer MG, 2001, PROG NEUROBIOL, V63, P71, DOI 10.1016/S0301-0082(00)00014-9; Nakajima K, 2001, J NEUROSCI RES, V65, P322, DOI 10.1002/jnr.1157; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Patel HC, 2003, ANN NY ACAD SCI, V992, P39, DOI 10.1111/j.1749-6632.2003.tb03136.x; Pavelko KD, 2003, J NEUROSCI, V23, P481, DOI 10.1523/JNEUROSCI.23-02-00481.2003; Pearson LL, 2001, INT IMMUNOL, V13, P273, DOI 10.1093/intimm/13.3.273; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Riley CP, 2004, J MOL HISTOL, V35, P771, DOI 10.1007/s10735-004-0778-9; Rimaniol AC, 2000, J IMMUNOL, V164, P5430, DOI 10.4049/jimmunol.164.10.5430; Shah A, 2004, J NEUROSCI METH, V136, P123, DOI 10.1016/j.jneumeth.2004.01.010; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; Shibuya S, 2009, CELL ADHES MIGR, V3, P99, DOI 10.4161/cam.3.1.7372; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; Streit WJ, 2008, FRONT BIOSCI-LANDMRK, V13, P3423; Suzuki H, 2001, NEUROSCI LETT, V312, P95, DOI 10.1016/S0304-3940(01)02198-X; Svensson CI, 2005, J NEUROCHEM, V92, P1508, DOI 10.1111/j.1471-4159.2004.02996.x; Trang T, 2009, J NEUROSCI, V29, P3518, DOI 10.1523/JNEUROSCI.5714-08.2009; Tuttolomondo A, 2008, CURR PHARM DESIGN, V14, P3547, DOI 10.2174/138161208786848829; Tyler WJ, 2002, LEARN MEMORY, V9, P224, DOI 10.1101/lm.51202; Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yang H, 2006, CYTOTECHNOLOGY, V52, P87, DOI 10.1007/s10616-006-9033-4; Yang H, 2011, NEUROCHEM INT, V59, P1010, DOI 10.1016/j.neuint.2011.08.021; Yang H, 2009, CELL MOL NEUROBIOL, V29, P455, DOI 10.1007/s10571-008-9337-3; Yang Hao, 2003, Shi Yan Sheng Wu Xue Bao, V36, P5; Zadran S, 2010, J NEUROSCI, V30, P1086, DOI 10.1523/JNEUROSCI.5120-09.2010; Zhang SE, 2012, J LEUKOCYTE BIOL, V91, P137, DOI 10.1189/jlb.0511268; Zheng Z, 2004, NEUROL RES, V26, P884, DOI 10.1179/016164104X2357	61	25	27	3	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	JUL	2012	61	2					175	186		10.1016/j.neuint.2012.04.020			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	991HH	WOS:000307691600006	22561407				2022-02-06	
J	Arango-Lasprilla, JC; Krch, D; Drew, A; Aragon, CJD; Stevens, LF				Arango-Lasprilla, Juan Carlos; Krch, Denise; Drew, Allison; De los Reyes Aragon, Carlos Jose; Stevens, Lillian Flores			Health-related quality of life of individuals with traumatic brain injury in Barranquilla, Colombia	BRAIN INJURY			English	Article						Quality-of-life; traumatic brain injury; depression; cognition	COPING STRATEGIES; SOCIAL SUPPORT; HEAD-INJURY; VALIDITY; SPANISH; SF-36; COMMUNITY; MODERATE; OUTCOMES; ADULTS	Objective: To assess health-related quality of life (HRQoL) of individuals with traumatic brain injury (TBI) in Barranquilla, Colombia. Participants/methods: Thirty-one individuals with TBI and 61 healthy controls completed the SF-36, a self-report HRQoL measure composed of eight component areas: physical health problems, pain, role limitations due to physical problems or due to emotional problems, emotional well-being, social functioning, energy/fatigue and general health perceptions. Results: The samples were statistically similar with respect to age, gender and education and statistically different with respect to depression, SES, social support and cognition. Compared to healthy controls, individuals with TBI had significantly lower means on all SF-36 sub-scales. However, after adjusting for depression, SES, social support and cognitive performance, significant differences remained on three of the SF-36 sub-scales. Specifically, individuals with TBI had lower adjusted means on Role-Physical (p-value <0.005), Role-Emotional (p-value <0.005) and Bodily Pain (p-value <0.05). Conclusion: Even after controlling for depression, SES, social support and cognitive performance, individuals with TBI living in Barranquilla Colombia report having poorer quality of life across various domains, including Role-Physical, Role-Emotional and Bodily Pain. These findings suggest the need for rehabilitation health professionals to develop and implement culturally-appropriate interventions to improve quality of life in Colombian individuals with TBI.	[Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Richmond, VA 23219 USA; [Krch, Denise] Kessler Fdn Res Ctr, W Orange, NJ USA; [Krch, Denise] UMDNJ New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA; [De los Reyes Aragon, Carlos Jose] Univ Norte, Dept Psychol, Barranquilla, Colombia		Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Theater Row Bldg,4th Floor,Room 4230A,POB 843038,, Richmond, VA 23219 USA.	jcarangolasp@vcu.edu	De los Reyes Aragon, Carlos Jose/P-3516-2019; De los Reyes Aragon, Carlos Jose CDA/E-2585-2015	De los Reyes Aragon, Carlos Jose/0000-0003-4472-0635; De los Reyes Aragon, Carlos Jose CDA/0000-0003-4472-0635	Department of Education, NIDRR [H133P090009]	The contents of this article were developed partially under a grant from the Department of Education, NIDRR grant number H133P090009. However, those contents do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the Federal Government.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Anderson V, 2010, J NEUROTRAUM, V27, P863, DOI 10.1089/neu.2009.1169; Arango-Lasprilla JC, 2010, BRAIN INJURY, V24, P1017, DOI 10.3109/02699052.2010.490516; Augustovski FA, 2008, J CLIN EPIDEMIOL, V61, P1279, DOI 10.1016/j.jclinepi.2008.05.004; Ayuso-Mateos JL, 1999, ACTA PSYCHIAT SCAND, V99, P26, DOI 10.1111/j.1600-0447.1999.tb05381.x; Bedard M, 2003, DISABIL REHABIL, V25, P722, DOI 10.1080/0963828031000090489; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Blair H, 2010, BRAIN INJURY, V24, P833, DOI 10.3109/02699051003789203; BROOKS DN, 1984, CLOSED HEAD INJURY P, P148; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Carnegie Mellon University, LAB STUD STRESS IMM; CELLA DF, 1995, SEMIN ONCOL, V22, P73; COHEN S, 1983, J APPL SOC PSYCHOL, V13, P99, DOI 10.1111/j.1559-1816.1983.tb02325.x; Cunningham JM, 1999, HLTH CARE DISABILITY, P475; Diez-Quevedo C, 2001, PSYCHOSOM MED, V63, P679, DOI 10.1097/00006842-200107000-00021; Donlan W, 2010, PSYCHOL REP, V106, P419, DOI 10.2466/PR0.106.2.419-432; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Horneman G, 2005, INT J REHABIL RES, V28, P245, DOI 10.1097/00004356-200509000-00007; Huebner RA, 2003, AM J OCCUP THER, V57, P177, DOI 10.5014/ajot.57.2.177; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; International Brain Injury Association (IBIA), BRAIN INJ FACTS WORL; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Johnstone B, 2009, BRAIN INJURY, V23, P411, DOI 10.1080/02699050902788501; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Lynch R. T., 1986, APPL REHABILITATION, P262; Machnicki G, 2009, DEMENT GERIATR COGN, V28, P206, DOI 10.1159/000236912; Man DWK, 2004, BRAIN INJURY, V18, P577, DOI 10.1080/02699050310001646143; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Molloy M., 1983, AUSTR REHABILITATION, V7, P34; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; Ostrosky-Solis F, 1999, J INT NEUROPSYCH SOC, V5, P413, DOI 10.1017/S1355617799555045; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Smith LM, 1995, FAMILY SUPPORT PROGR; Souza Ligia Maria Do N, 2007, Dev Neurorehabil, V10, P35, DOI 10.1080/13638490600822239; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Ware J., 2000, SF 36 HLTH SURVEY MA; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Wolters G, 2010, NEUROPSYCHOL REHABIL, V20, P587, DOI 10.1080/09602011003683836; WULSIN L, 2002, PRIM CARE COMPANION, V4, P191, DOI DOI 10.4088/PCC.V04N0504; Zitnay GA, 2005, ACT NEUR S, V93, P131	55	25	28	1	17	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUN	2012	26	6					825	833		10.3109/02699052.2012.655364			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	943EO	WOS:000304103500004	22583173				2022-02-06	
J	Caricato, A; Mignani, V; Bocci, MG; Pennisi, MA; Sandroni, C; Tersali, A; Antonaci, A; de Waure, C; Antonelli, M				Caricato, Anselmo; Mignani, Vittorio; Bocci, Maria Grazia; Pennisi, Mariano Alberto; Sandroni, Claudio; Tersali, Alessandra; Antonaci, Alessandra; de Waure, Chiara; Antonelli, Massimo			Usefulness of transcranial echography in patients with decompressive craniectomy: A comparison with computed tomography scan	CRITICAL CARE MEDICINE			English	Article						brain injury imaging; cerebral hemorrhage; cerebral ultrasound; decompressive craniectomy; sonographic imaging; transcranial echography	CODED DUPLEX-SONOGRAPHY; SPACE-OCCUPYING STROKE; REAL-TIME ULTRASONOGRAPHY; TRAUMATIC BRAIN-INJURY; INTRACEREBRAL HEMORRHAGE; MIDLINE SHIFT; ULTRASOUND; PERFUSION; DIFFERENTIATION; 3RD-VENTRICLE	Objective: To assess the agreement between computed tomography and transcranial sonography in patients after decompressive craniectomy. Design: Prospective study. Setting: The medical intensive care unit of a university-affiliated teaching hospital. Patients: Thirty head-injured patients consecutively admitted to the intensive care unit of "A. Gemelli" Hospital who underwent decompressive craniectomy were studied. Immediately before brain cranial tomography, transcranial ultrasonography was performed. Measurements and Main Results: The mean difference between computed tomography and echography in measuring the dislocation of midline structures was 0.3 +/- 1.6 mm (95% confidence interval 0.2-0.9 mm; intraclass correlation coefficient, 0.979; p < .01). An excellent correlation was found between computed tomography and transcranial sonography in assessing volumes of hyperdense lesions (intraclass correlation coefficient, 0.993; p < .01). Lesions that appear hypodense on computed tomography scan were divided in ischemic and late hemorrhagic. No ischemic lesion was localized on echography; a poor correlation was found between computed tomography and echography in assessing the volume of late hemorrhagic lesions (intraclass correlation coefficient, 0.151; p = .53). A quite good correlation between transcranial ultrasonography and computed tomography was found in measuring lateral ventricles width (intraclass correlation coefficient, 0.967; p < .01). Sensitivity and specificity of transcranial ultrasonography in comparison with computed tomography to detect the position of intracranial pressure catheter was 100% and 78%. Conclusions: Echography may be a valid option to computed tomography in patients with decompressive craniectomy to assess the size of acute hemorrhagic lesions, to measure midline structures and the width of lateral ventricles, and to visualize the tip of the ventricular catheter. (Crit Care Med 2012; 40:1745-1752)	[Caricato, Anselmo; Mignani, Vittorio; Bocci, Maria Grazia; Pennisi, Mariano Alberto; Sandroni, Claudio; Tersali, Alessandra; Antonaci, Alessandra; de Waure, Chiara; Antonelli, Massimo] Catholic Univ, Sch Med, Inst Anesthesiol & Intens Care, Rome, Italy; [de Waure, Chiara] Catholic Univ, Sch Med, Inst Hyg, Rome, Italy		Caricato, A (corresponding author), Catholic Univ, Sch Med, Inst Anesthesiol & Intens Care, Rome, Italy.	anselmo.caricato@rm.unicatt.it	Dewaure, Chiara/K-7192-2016; Sandroni, Claudio/A-7320-2019; Bocci, Maria Grazia/AAL-1170-2020; Antonelli, Massimo/K-9915-2016	Dewaure, Chiara/0000-0002-4346-1494; Sandroni, Claudio/0000-0002-8878-2611; Bocci, Maria Grazia/0000-0001-6100-8442; Antonelli, Massimo/0000-0003-3007-1670; PENNISI, Mariano Alberto/0000-0001-8761-5144			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BECKER A, 1995, NEUROLOGY, V45, pA460; Becker G, 1999, ANN NEUROL, V46, P260, DOI 10.1002/1531-8249(199908)46:2<260::AID-ANA18>3.0.CO;2-6; Becker G, 1993, J Neuroimaging, V3, P41; Becker G, 2001, MOVEMENT DISORD, V16, P23, DOI 10.1002/1531-8257(200101)16:1<23::AID-MDS1003>3.0.CO;2-2; Becker G, 1994, J Neuroimaging, V4, P17; Becker G, 1993, TRANSCRANIAL DOPPLER, P51; Behnke Stefanie, 2002, Eur J Ultrasound, V16, P73, DOI 10.1016/S0929-8266(02)00039-3; Bullock MR, 2006, NEUROSURGERY, V58, P25; Caricato A, 2010, INTENS CARE MED, V36, P1091, DOI 10.1007/s00134-010-1801-0; Coles JP, 2007, BRIT J ANAESTH, V99, P49, DOI 10.1093/bja/aem141; Dohrmann GJ, 1997, NEUROL RES, V19, P317, DOI 10.1080/01616412.1997.11740819; Fatar M, 2008, ULTRASOUND MED BIOL, V34, P1414, DOI 10.1016/j.ultrasmedbio.2008.02.008; Gerriets T, 2001, STROKE, V32, P442, DOI 10.1161/01.STR.32.2.442; Heppner P, 2006, J NEUROSURG, V104, P738, DOI 10.3171/jns.2006.104.5.738; Jungehulsing GJ, 2008, ULTRASOUND MED BIOL, V34, P147, DOI 10.1016/j.ultrasmedbio.2007.07.006; Kern R, 2005, ULTRASOUND MED BIOL, V31, P311, DOI 10.1016/j.ultrasmedbio.2004.12.006; Kern R, 2006, CEREBROVASC DIS, V21, P34; Kern R, 2008, CEREBROVASC DIS, V26, P277, DOI 10.1159/000147456; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Maurer M, 1998, STROKE, V29, P2563, DOI 10.1161/01.STR.29.12.2563; Meyer-Wiethe Karsten, 2009, Cerebrovasc Dis, V27 Suppl 2, P40, DOI 10.1159/000203125; OSTRUP R, 1983, NEUROSURGERY, V12, P225, DOI 10.1227/00006123-198302000-00018; Perez ES, 2009, STROKE, V40, P987, DOI 10.1161/STROKEAHA.108.524249; Pou JAL, 2004, INTENS CARE MED, V30, P1672, DOI 10.1007/s00134-004-2348-8; Santa M, 1990, Zentralbl Neurochir, V51, P194; Sara M, 2009, ULTRASOUND MED BIOL, V35, P169, DOI 10.1016/j.ultrasmedbio.2008.05.008; Seidel G, 1996, J NEUROIMAGING, V6, P227, DOI 10.1111/jon199664227; Seidel G, 1995, J Neuroimaging, V5, P105; SEIDEL G, 1993, STROKE, V24, P1519, DOI 10.1161/01.STR.24.10.1519; Stolz E, 1999, AM J NEURORADIOL, V20, P1567; Stroick M, 2006, ULTRASOUND MED BIOL, V32, P1377, DOI 10.1016/j.ultrasmedbio.2006.05.027; Wijnhoud AD, 2008, ULTRASOUND MED BIOL, V34, P923, DOI 10.1016/j.ultrasmedbio.2007.11.022	33	25	31	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2012	40	6					1745	1752		10.1097/CCM.0b013e318246b6ea			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	946EZ	WOS:000304335600008	22610180				2022-02-06	
J	Purins, K; Enblad, P; Wiklund, L; Lewen, A				Purins, Karlis; Enblad, Per; Wiklund, Lars; Lewen, Anders			Brain Tissue Oxygenation and Cerebral Perfusion Pressure Thresholds of Ischemia in a Standardized Pig Brain Death Model	NEUROCRITICAL CARE			English	Article						Brain tissue oxygenation; Cerebral perfusion pressure; Microdialysis; Threshold levels; Traumatic brain injury	SEVERE HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; MODERATE HYPOTHERMIA; ENERGY-METABOLISM; CARBON-DIOXIDE; BLOOD-FLOW; TENSION; RESUSCITATION	Neurointensive care of traumatic brain injury (TBI) patients is currently based on intracranial pressure (ICP) and cerebral perfusion pressure (CPP) targeted protocols. Monitoring brain tissue oxygenation (B(ti)pO(2)) is of considerable clinical interest, but the exact threshold level of ischemia has been difficult to establish due to the complexity of the clinical situation. The objective of this study was to use the Neurovent-PTO (NV) probe, and to define critical cerebral oxygenation- and CPP threshold levels of cerebral ischemia in a standardized brain death model caused by increasing the ICP in pig. Ischemia was defined by a severe increase of cerebral microdialysis (MD) lactate/pyruvate ratio (L/P ratio > 30). B(ti)pO(2), L/P ratio, Glucose, Glutamate, Glycerol and CPP were recorded using NV and MD probes during gradual increase of ICP by inflation of an epidural balloon catheter with saline until brain death was achieved. Baseline level of B(ti)pO(2) was 22.9 +/- A 6.2 mmHg, the L/P ratio 17.7 +/- A 6.1 and CPP 73 +/- A 17 mmHg. B(ti)pO(2) and CPP decreased when intracranial volume was added. The L/P ratio increased above its ischemic levels, (> 30) when CPP decreased below 30 mmHg and B(ti)pO(2) to < 10 mmHg. A severe increase of ICP leading to CPP below 30 mmHg and B(ti)pO(2) below 10 mmHg is associated with an increase of the L/P ratio, thus seems to be critical thresholds for cerebral ischemia under these conditions.	[Purins, Karlis; Enblad, Per; Lewen, Anders] Uppsala Univ, Neurosurg Sect, Dept Neurosci, S-75185 Uppsala, Sweden; [Wiklund, Lars] Uppsala Univ, Sect Anaesthesia & Intens Care, Dept Surg Sci, S-75185 Uppsala, Sweden		Purins, K (corresponding author), Uppsala Univ, Neurosurg Sect, Dept Neurosci, S-75185 Uppsala, Sweden.	Karlis.Purins@neuro.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348	Swedish Research CouncilSwedish Research CouncilEuropean Commission	The study was supported by The Swedish Research Council. Lars Berglund, Ph.D., Uppsala Clinical Research Center, Uppsala University is acknowledged for statistical analysis. We thank Anders Nordgren, Monica Hall, and Inger Stahl Myllyaho for their excellent laboratory assistance.	Bardt TF, 1998, ACT NEUR S, V71, P153; Baron JC, 2001, CEREBROVASC DIS, V11, P2, DOI 10.1159/000049119; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Cavus E, 2006, RESUSCITATION, V71, P97, DOI 10.1016/j.resuscitation.2006.03.007; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Dings J, 1998, NEUROL RES, V20, pS71; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Hoffman WE, 1996, ANESTH ANALG, V82, P582, DOI 10.1097/00000539-199603000-00027; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Meixensberger J, 2001, NEUROL RES, V23, P801, DOI 10.1179/016164101101199379; Nielsen TH, 2011, NEUROCRIT CARE, V15, P585, DOI 10.1007/s12028-011-9563-2; Nordstrom CH, 2003, ANESTHESIOLOGY, V98, P809, DOI 10.1097/00000542-200304000-00004; Orakcioglu B, 2010, NEUROSURGERY, V67, P1716, DOI 10.1227/NEU.0b013e3181f9bb5b; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Purins K, 2011, CRIT CARE MED, V39, P512, DOI 10.1097/CCM.0b013e318206b824; Purins K, 2010, ACTA NEUROCHIR, V152, P681, DOI 10.1007/s00701-009-0532-x; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schulz MK, 2000, J NEUROSURG, V93, P808, DOI 10.3171/jns.2000.93.5.0808; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Zoremba N, 2007, ANESTH ANALG, V105, P744, DOI 10.1213/01.ane.0000278160.66389.1c	41	25	26	0	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2012	16	3					462	469		10.1007/s12028-012-9675-3			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	949ZX	WOS:000304619000019	22302179				2022-02-06	
J	Maxwell, WL				Maxwell, William L.			Traumatic brain injury in the neonate, child and adolescent human: An overview of pathology	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						TBI; Hematoma; Immature or unmyelinated axons; Myelination; Neuronal injury; Oligodendrocytes; Macrophages and microglia; Inflammatory response; The neurovascular unit	NONDISRUPTIVE AXONAL INJURY; WHITE-MATTER DEVELOPMENT; SITU DNA FRAGMENTATION; INFLICTED HEAD-INJURY; RAT OPTIC-NERVE; YOUNG-CHILDREN; HUMAN FETAL; AXOLEMMAL PERMEABILITY; CYTOSKELETAL CHANGES; CEREBRAL-CORTEX	In the middle of the last century it had been thought that a good recovery of function and behavior would occur after traumatic brain injury (TBI) in very young human beings. A recent major change in thinking states that early childhood TBI may result in a severe compromise of normal brain growth and development such that TBI, rather, may compromise later normal development resulting in a need for very long term patient care and management. The mechanisms of injury and pathology within the injured brain are reviewed and compared between when injury occurs at or close to the time of birth, in an infant, in a young child, in a child between ages 5 and 10, in young and older adolescents and in young adulthood. Our understanding of pathophysiological responses by cells of the human central nervous system has recently greatly increased but has really only served to illustrate the great complexity of interactions between different types of cell within the growing and developing CNS. The hypothesis is developed that the outcome for a very young patient differs with the relative state of development of injured cells at the locus of injury. And that the potential for either repair, re-instatement of normal cellular and organ function or for continued normal development is much reduced after an early brain insult (EBI) compared with TBI in a slightly older child or young adult patient. The advent of increasingly sophisticated non-invasive imaging technology has allowed assessment of the influence and time course of brain pathology both early and late after TBI. This has generated greater confidence on the part of clinicians in forecasting outcomes for an injured patient. But our increased understanding has still not allowed development of therapeutic strategies that might ameliorate the effect of an injury. It is suggested that an improved integration of major clinical and scientific effort needs to be made to appreciate the import of multiple interactions between cells forming the neurovascular unit in order to improve any potential for post-traumatic recovery after TBI in neonates and young children. (C) 2011 ISDN. Published by Elsevier Ltd. All rights reserved.	Univ Glasgow, Sch Med Vet Med & Life Sci, Glasgow G12 8QQ, Lanark, Scotland		Maxwell, WL (corresponding author), Univ Glasgow, Sch Med Vet Med & Life Sci, Thomson Bldg, Glasgow G12 8QQ, Lanark, Scotland.	William.Maxwell@Glasgow.ac.uk					ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Asato MR, 2010, CEREB CORTEX, V20, P2122, DOI 10.1093/cercor/bhp282; Ball G, 2012, CEREB CORTEX, V22, P1016, DOI 10.1093/cercor/bhr176; BALLESTEROS MC, 1993, RADIOGRAPHICS, V13, P611, DOI 10.1148/radiographics.13.3.8316668; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barnea-Goraly N, 2005, CEREB CORTEX, V15, P1848, DOI 10.1093/cercor/bhi062; Barrientos SA, 2011, J NEUROSCI, V31, P966, DOI 10.1523/JNEUROSCI.4065-10.2011; Beirowski B, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-6; Bell JE, 2005, BRAIN, V128, P1070, DOI 10.1093/brain/awh436; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bigler ED, 2011, NEUROREHABILITATION, V28, P63, DOI 10.3233/NRE-2011-0633; Bittigau P, 2003, NEUROTOX RES, V5, P475, DOI 10.1007/BF03033158; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Bonnier C, 2007, J CHILD NEUROL, V22, P519, DOI 10.1177/0883073807302604; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cagin A., 2001, BRAIN, V124, P2014; Case ME, 2008, BRAIN PATHOL, V18, P571, DOI 10.1111/j.1750-3639.2008.00204.x; Case ME, 2008, BRAIN PATHOL, V18, P583, DOI 10.1111/j.1750-3639.2008.00203.x; Case Mary E., 2007, Legal Medicine, V9, P83, DOI 10.1016/j.legalmed.2006.11.017; Christian CW, 2009, PEDIATRICS, V123, P1409, DOI 10.1542/peds.2009-0408; Coleman M, 2005, NAT REV NEUROSCI, V6, P889, DOI 10.1038/nrn1788; Ding XQ, 2008, AM J NEURORADIOL, V29, P1261, DOI 10.3174/ajnr.A1097; DOBBING J, 1973, ARCH DIS CHILD, V48, P757, DOI 10.1136/adc.48.10.757; Dratviman-Storobinsky O, 2008, MOL VIS, V14, P2171; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Emery B, 2010, SCIENCE, V330, P779, DOI 10.1126/science.1190927; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Fitzgerald M, 2010, J NEUROTRAUM, V27, P439, DOI 10.1089/neu.2009.1112; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gerlach R, 2009, PEDIATR EMERG CARE, V25, P164, DOI 10.1097/PEC.0b013e31819a8966; Giedd JN, 2004, ANN NY ACAD SCI, V1021, P77, DOI 10.1196/annals.1308.009; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gilmore JH, 2007, J NEUROSCI, V27, P1255, DOI 10.1523/JNEUROSCI.3339-06.2007; Giza CC, 2006, INDIAN J NEUROTRAUM, V3, P19; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Groeschel S, 2010, INT J DEV NEUROSCI, V28, P481, DOI 10.1016/j.ijdevneu.2010.06.004; Hafiz M Z Mohd, 2011, Med J Malaysia, V66, P95; Hagmann P, 2010, P NATL ACAD SCI USA, V107, P19067, DOI 10.1073/pnas.1009073107; Hamilton N, 2008, GLIA, V56, P734, DOI 10.1002/glia.20649; Hausmann R, 2004, INT J LEGAL MED, V118, P32, DOI 10.1007/s00414-003-0413-4; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; Huang H, 2006, NEUROIMAGE, V33, P27, DOI 10.1016/j.neuroimage.2006.06.009; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Iwata S, 2010, INT J DEV NEUROSCI, V28, P573, DOI 10.1016/j.ijdevneu.2010.07.233; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jakovcevski I, 2005, GLIA, V49, P480, DOI 10.1002/glia.20134; Jakovcevski I, 2009, FRONT NEUROANAT, V3, DOI 10.3389/neuro.05.005.2009; Jette N, 2006, J CEREBR BLOOD F MET, V26, P777, DOI 10.1038/sj.jcbfm.9600226; Johnson MW, 2011, J FORENSIC SCI, V56, P1198, DOI 10.1111/j.1556-4029.2011.01814.x; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Knickmeyer RC, 2008, J NEUROSCI, V28, P12176, DOI 10.1523/JNEUROSCI.3479-08.2008; Koehler RC, 2006, J APPL PHYSIOL, V100, P307, DOI 10.1152/japplphysiol.00938.2005; Kumar S, 2002, BIOPHYS J, V82, P2360, DOI 10.1016/S0006-3495(02)75581-1; LaPlaca MC, 2010, J BIOMECH, V43, P71, DOI 10.1016/j.jbiomech.2009.09.011; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Looney CB, 2007, RADIOLOGY, V242, P535, DOI 10.1148/radiol.2422060133; Lotocki G, 2011, THER HYPOTHERMIA TEM, V1, DOI 10.1089/ther.2010.0011; Mahad DJ, 2009, BRAIN, V132, P1161, DOI 10.1093/brain/awp046; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Mori I, 2005, BRAIN RES, V1057, P186, DOI 10.1016/j.brainres.2005.07.037; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Nimmerjahn A, 2009, J PHYSIOL-LONDON, V587, P1639, DOI 10.1113/jphysiol.2008.167171; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Raja F, 1997, ACTA NEUROPATHOL, V93, P184, DOI 10.1007/s004010050601; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; REIBER GD, 1993, AM J FOREN MED PATH, V14, P201, DOI 10.1097/00000433-199309000-00005; Rezaie Payam, 2002, Neuroembryology, V1, P91, DOI 10.1159/000054268; Robinson RJ, 2011, J NEUROIMAGING, V21, pE189, DOI 10.1111/j.1552-6569.2010.00516.x; ROESSMANN U, 1986, ACTA NEUROPATHOL, V70, P302, DOI 10.1007/BF00686088; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Sarnat HB, 1998, BRAIN DEV-JPN, V20, P88, DOI 10.1016/S0387-7604(97)00111-3; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Staal JA, 2011, J NEUROTRAUM, V28, P841, DOI 10.1089/neu.2010.1658; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stys PK, 2005, J NEUROL SCI, V233, P3, DOI 10.1016/j.jns.2005.03.031; Sulaiman AM, 2011, J NEUROTRAUM, V28, P383, DOI 10.1089/neu.2010.1707; Supekar K, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000157; Susuki K, 2008, EXP BIOL MED, V233, P394, DOI 10.3181/0709-MR-243; Tamnes CK, 2010, CEREB CORTEX, V20, P534, DOI 10.1093/cercor/bhp118; Toro K, 2011, J FORENSIC SCI, V56, P617, DOI 10.1111/j.1556-4029.2010.01674.x; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; Tong K.A., 2008, AJNR, V29, P1; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; Vezina G, 2009, PEDIATR RADIOL, V39, P586, DOI 10.1007/s00247-009-1212-y; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; WAXMAN SG, 1992, BRAIN RES, V574, P105, DOI 10.1016/0006-8993(92)90806-K; White RE, 2010, J COMP NEUROL, V518, P1370, DOI 10.1002/cne.22282; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001	131	25	26	1	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		167	183		10.1016/j.ijdevneu.2011.12.008			17	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800002	22212603				2022-02-06	
J	Cherry, S; Judd, L; Muniz, JC; Elzawahry, H; LaRoche, S				Cherry, Sunil; Judd, Lilith; Muniz, Juan Carlos; Elzawahry, Hoda; LaRoche, Suzette			Safety and Efficacy of Lacosamide in the Intensive Care Unit	NEUROCRITICAL CARE			English	Article						Lacosamide; Non-convulsive status epilepticus; Refractory status epilepticus; Seizures; Hypotension	TRAUMATIC BRAIN-INJURY; NONCONVULSIVE STATUS EPILEPTICUS; ELECTROGRAPHIC SEIZURES; INTRACEREBRAL HEMORRHAGE; INTRAVENOUS LACOSAMIDE; ORAL LACOSAMIDE	Background Seizures are common in critically ill patients and can impact morbidity and mortality. Traditional anti-epileptic drugs (AEDs) in this setting are not always effective and are associated with adverse events and drug interactions. Lacosamide (LCM) is a new AED which is available in parental form although few studies have evaluated the safety and efficacy of LCM in critically ill patients. Methods Critically ill patients at Emory University Hospital who received LCM from April 1, 2009 to February 1, 2010 were retrospectively reviewed. Primary outcome measure was incidence and time to seizure cessation. Adverse effects were also recorded. Results LCM was administered in 24 patients including 13 episodes of refractory status epilepticus (RSE) occurring in 10 patients and for treatment of isolated seizures or following resolution of RSE in an additional 14 patients. Seizure cessation was achieved in 5/13 (38%) episodes of RSE (mean 11.2 h) while there was at least a 50% decrease in seizure frequency in 7/13 (54%). 11/14 patients (76%) who received LCM for treatment of isolated seizures or prevention of seizure recurrence remained seizure free. Three patients experienced a decline in systolic blood pressure (> 20 mmHg) while one patient experienced unexplained fever and one patient had elevation of liver function tests. Conclusions This preliminary data suggests that LCM may be a safe and effective alternative for treatment of seizures in critically ill patients. Further prospective, randomized controlled trials are needed to confirm these findings and further explore the incidence of adverse effects.	[Cherry, Sunil; Judd, Lilith; Muniz, Juan Carlos; Elzawahry, Hoda; LaRoche, Suzette] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA		LaRoche, S (corresponding author), Emory Univ, Sch Med, Dept Neurol, 1365 Clifton Rd,NE Clin A, Atlanta, GA 30322 USA.	Slaroch@emory.edu					Albers JM, 2011, SEIZURE-EUR J EPILEP, V20, P428, DOI 10.1016/j.seizure.2011.01.017; Ben-Menachem E, 2007, EPILEPSIA, V48, P1308, DOI 10.1111/j.1528-1167.2007.01188.x; Beyreuther BK, 2007, CNS DRUG REV, V13, P21, DOI 10.1111/j.1527-3458.2007.00001.x; Biton V, 2008, EPILEPSIA, V49, P418, DOI 10.1111/j.1528-1167.2007.01317.x; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Goodwin H, 2011, NEUROCRIT CARE, V14, P348, DOI 10.1007/s12028-010-9501-8; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; Kellinghaus C, 2010, ACTA NEUROL SCAND, V123, P137; Koubeissi MZ, 2011, ACTA NEUROL SCAND, V123, P142, DOI 10.1111/j.1600-0404.2010.01430.x; Pandian JD, 2004, ARCH NEUROL-CHICAGO, V61, P1090, DOI 10.1001/archneur.61.7.1090; Parkerson KA, 2011, EPILEPSY BEHAV, V20, P48, DOI 10.1016/j.yebeh.2010.10.012; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Rantsch K, 2011, SEIZURE-EUR J EPILEP, V20, P529, DOI 10.1016/j.seizure.2011.03.010; Tilz C, 2010, EPILEPSIA, V51, P316, DOI 10.1111/j.1528-1167.2009.02256.x; Treiman DM, 1998, NEW ENGL J MED, V339, P792, DOI 10.1056/NEJM199809173391202; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Young GB, 1996, NEUROLOGY, V47, P83	22	25	25	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	APR	2012	16	2					294	298		10.1007/s12028-011-9662-0			5	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	949ZS	WOS:000304618500014	22203547				2022-02-06	
J	Iwamura, A; Taoka, T; Fukusumi, A; Sakamoto, M; Miyasaka, T; Ochi, T; Akashi, T; Okuchi, K; Kichikawa, K				Iwamura, Asami; Taoka, Toshiaki; Fukusumi, Akio; Sakamoto, Masahiko; Miyasaka, Toshiteru; Ochi, Tomoko; Akashi, Toshiaki; Okuchi, Kazuo; Kichikawa, Kimihiko			Diffuse vascular injury: convergent-type hemorrhage in the supratentorial white matter on susceptibility-weighted image in cases of severe traumatic brain damage	NEURORADIOLOGY			English	Article						Susceptibility-weighted image; Apparent diffusion coefficient; Diffuse axonal injury; Diffuse vascular injury; Glasgow Coma Scale	HEAD-INJURY; AXONAL INJURY; LESIONS	Susceptibility-weighted image (SWI) is one of the most sensitive methods for detect microbleeding and useful for evaluation of traumatic brain damage. The purpose of this study is to delineate the characteristics and importance of supratentorial deep white matter hemorrhages detected by SWI in cases of traumatic brain damage. Twenty-one consecutive cases with severe traumatic head injury were included in the current study. MRI examinations were made within 1 month after injury. We evaluated the degree and distribution of the supratentorial hemorrhages on SWI retrospectively. We classified the degree of bleeding into four grades: "small hemorrhage," "single bead-like hemorrhage," "convergent-type hemorrhage," and "massive hemorrhage." We then correlated the degree and distribution of the hemorrhage to clinical outcomes. We also evaluated the apparent diffusion coefficient (ADC) image of lobes with "convergent-type hemorrhage." Existence of "massive hemorrhage" correlated with a poor outcome, that is, worse than "severely disabled" on the Glasgow Outcome Scale. The number of lobes affected by "convergent-type hemorrhage" also correlated with poor outcome. There were 45 lobes with "convergent-type hemorrhage" and 27 of them showed increased diffusivity on ADC images. Supratentorial massive hemorrhages and supratentorial convergent-type multiple hemorrhages were associated with poor prognosis after traumatic brain injury. The increased diffusivity in lobes with convergent-type hemorrhages may indicate that congestion of the proximal medullary vein may play some role for these hemorrhages.	[Iwamura, Asami; Taoka, Toshiaki; Fukusumi, Akio; Sakamoto, Masahiko; Miyasaka, Toshiteru; Ochi, Tomoko; Akashi, Toshiaki; Kichikawa, Kimihiko] Nara Med Univ, Dept Radiol, Kashihara, Nara 6348522, Japan; [Iwamura, Asami; Okuchi, Kazuo] Nara Med Univ, Dept Emergency & Crit Care Med, Kashihara, Nara 6348522, Japan		Iwamura, A (corresponding author), Nara Med Univ, Dept Radiol, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.	asami20050512@yahoo.co.jp	Taoka, Toshiaki/A-1637-2016	Taoka, Toshiaki/0000-0001-9227-0240			ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Akiyama Y, 2009, NEUROL MED-CHIR, V49, P97, DOI 10.2176/nmc.49.97; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Blumbergs P.C., 2008, GREENFIELDS NEUROPAT, P733; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Okudera T, 1999, NEUROPATHOLOGY, V19, P93, DOI 10.1046/j.1440-1789.1999.00215.x; Onaya M, 2002, NEUROPATHOLOGY, V22, P243, DOI 10.1046/j.1440-1789.2002.00456.x; Pearl GS, 1998, CLIN LAB MED, V18, P39; Pittella JEH, 2003, J FORENSIC SCI, V48, P626; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Yuan Mei-Kang, 2005, J Chin Med Assoc, V68, P131	16	25	25	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0028-3940			NEURORADIOLOGY	Neuroradiology	APR	2012	54	4					335	343		10.1007/s00234-011-0892-9			9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	912IQ	WOS:000301791000007	21611726	Green Submitted			2022-02-06	
J	Sauter, E; Buckwalter, JA; McKinley, TO; Martin, JA				Sauter, Ellen; Buckwalter, Joseph A.; McKinley, Todd O.; Martin, James A.			Cytoskeletal dissolution blocks oxidant release and cell death in injured cartilage	JOURNAL OF ORTHOPAEDIC RESEARCH			English	Article						cartilage injury; cytoskeleton; chondrocyte death; mitochondria; oxidants	TRAUMATIC BRAIN-INJURY; MITOCHONDRIAL DYSFUNCTION; ACTIN CYTOSKELETON; HUMAN CHONDROCYTES; CHONDRAL EXPLANTS; NITRIC-OXIDE; COMPRESSION; MECHANOTRANSDUCTION; ORGANIZATION; APOPTOSIS	The mechanisms by which articular surface impact causes post-traumatic osteoarthritis are not well understood, but studies of cartilage explants implicate the mitochondrial electron transport chain as a source of oxidants that cause chondrocyte death from mechanical injury. The linkage of mitochondria to the cytoskeleton suggests that they might release oxidants in response to mechanical strain, an effect that disrupting the cytoskeleton would prevent. To test this we investigated the effects of agents that promote the dissolution of microfilaments (cytochalasin B) or microtubules (nocodazole) on oxidant production and chondrocyte death following impact injury. Osteochondral explants treated with cytochalasin B or nocodazole for 4h were impacted (7J/cm2) and stained for oxidant production directly after impact and for cell viability 24h after impact. Surfaces within and outside impact sites were then imaged by confocal microscopy. Both agents significantly reduced impact-induced oxidant release (p<0.05); however, cytochalasin B was more effective than nocodazole (>60% reduction vs. 40% reduction, respectively). Both agents also prevented impact induced cell death. Dissolution of the cytoskeleton by both drugs was confirmed by phalloidin staining and confocal microscopy. These findings show that chondrocyte mortality from impact injury depends substantially on mitochondrialcytoskeletal linkage, suggesting new approaches to stem mechanically induced cartilage degeneration. (C) 2011 Orthopaedic Research Society. (C) 2011 Orthopaedic Research Society Published by Wiley Periodicals, Inc. J Orthop Res 30:593598, 2012	[Sauter, Ellen; Buckwalter, Joseph A.; McKinley, Todd O.; Martin, James A.] Univ Iowa, Iowa City, IA 52242 USA; [Buckwalter, Joseph A.] Vet Affairs Med Ctr, Iowa City, IA 52242 USA		Martin, JA (corresponding author), Univ Iowa, Iowa City, IA 52242 USA.	james-martin@uiowa.edu		Buckwalter, Joseph/0000-0003-4308-7583; Martin, James/0000-0001-5085-0108	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CORT NIH P50 AR055533]; Department of Veterans Affaires; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR025439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [P50AR048939, P50AR055533] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (CORT NIH P50 AR055533), and by a Merit Review Award from the Department of Veterans Affaires.	Ali MH, 2004, AM J PHYSIOL-LUNG C, V287, pL486, DOI 10.1152/ajplung.00389.2003; Baars DC, 2006, BIOMECH MODEL MECHAN, V5, P133, DOI 10.1007/s10237-006-0024-3; Boldogh IR, 2003, MOL BIOL CELL, V14, P4618, DOI 10.1091/mbc.E03-04-0225; Borrelli J, 2009, J ORTHOP RES, V27, P347, DOI 10.1002/jor.20760; Clements KM, 2004, OSTEOARTHR CARTILAGE, V12, P577, DOI 10.1016/j.joca.2004.04.006; D'Lima DD, 2001, OSTEOARTHR CARTILAGE, V9, P712, DOI 10.1053/joca.2001.0468; Durrant LA, 1999, J ANAT, V194, P343, DOI 10.1046/j.1469-7580.1999.19430343.x; Garrido CP, 2009, OSTEOARTHR CARTILAGE, V17, P1244, DOI 10.1016/j.joca.2009.03.007; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Goodwin W, 2010, J ORTHOP RES, V28, P1057, DOI 10.1002/jor.21091; Grishko V, 2009, J BIOL CHEM, V284, P9132, DOI 10.1074/jbc.M804178200; Guilak F, 1995, J BIOMECH, V28, P1529, DOI 10.1016/0021-9290(95)00100-X; Haudenschild DR, 2008, BIORHEOLOGY, V45, P219, DOI 10.3233/BIR-2008-0499; Hurtig M, 2009, J ORTHOP RES, V27, P602, DOI 10.1002/jor.20787; Knight MM, 2006, J BIOMECH, V39, P1547, DOI 10.1016/j.jbiomech.2005.04.006; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lee I, 2001, BIOL CHEM, V382, P1629, DOI 10.1515/BC.2001.198; Lewis JL, 2003, J ORTHOP RES, V21, P881, DOI 10.1016/S0736-0266(03)00039-1; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; Martin JA, 2009, J BONE JOINT SURG AM, V91A, P1890, DOI 10.2106/JBJS.H.00545; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Milentijevic D, 2003, J BIOMECH ENG-T ASME, V125, P594, DOI 10.1115/1.1610021; Ohashi T, 2006, BIORHEOLOGY, V43, P201; Phillips DM, 2004, J ORTHOP RES, V22, P1135, DOI 10.1016/j.orthres.2004.02.002; Suelmann R, 2000, CELL MOTIL CYTOSKEL, V45, P42, DOI 10.1002/(SICI)1097-0169(200001)45:1<42::AID-CM4>3.0.CO;2-C; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Trickey WR, 2004, J ORTHOPAED RES, V22, P131, DOI 10.1016/S0736-0266(03)00150-5; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Wu GJ, 2007, J CELL BIOCHEM, V101, P1520, DOI 10.1002/jcb.21268; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780	30	25	26	0	14	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0736-0266			J ORTHOP RES	J. Orthop. Res.	APR	2012	30	4					593	598		10.1002/jor.21552			6	Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics	887NW	WOS:000299935900014	21928429	Green Accepted, Bronze			2022-02-06	
J	Bitto, A; Polito, F; Irrera, N; Calo, M; Spaccapelo, L; Marini, HR; Giuliani, D; Ottani, A; Rinaldi, M; Minutoli, L; Guarini, S; Squadrito, F; Altavilla, D				Bitto, Alessandra; Polito, Francesca; Irrera, Natasha; Calo, Margherita; Spaccapelo, Luca; Marini, Herbert R.; Giuliani, Daniela; Ottani, Alessandra; Rinaldi, Mariagrazia; Minutoli, Letteria; Guarini, Salvatore; Squadrito, Francesco; Altavilla, Domenica			Protective effects of melanocortins on short-term changes in a rat model of traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						apoptosis; functional recovery; inflammation; melanocortins; neuroprotection; traumatic brain injury	SYSTEMIC INFLAMMATORY RESPONSE; CEREBRAL-ISCHEMIA; HEMORRHAGIC-SHOCK; DELAYED TREATMENT; NEUROPROTECTION; ACTIVATION; RECEPTORS; PEPTIDES; HORMONE; WEIGHT	Objective: Treatment for traumatic brain injury remains elusive despite compelling evidence from animal models for a variety of therapeutic targets. Melanocortins have established neuroprotective effects against experimental ischemic stroke. We investigated whether melanocortin treatment of traumatic brain injury induces neuroprotection and promotes functional recovery. Design: Randomized experiment. Setting: Research laboratory at a university hospital. Subjects: Male Sprague-Dawley rats (n = 215). Interventions: Experimental rat model of diffuse traumatic brain injury, the impact-acceleration model. Measurement and Main Results: Brain tissue nitrites, phosphorylation level of extracellular signal-regulated kinases, and c-jun N-terminal kinases; and expression of active caspase-3, tumor necrosis factor-alpha, BAX, and Bcl-2 as well as serum levels of interleukin-6, high mobility group box-1, interleukin-10, and brain histologic damage were evaluated 24 or 48 hrs after the insult. Sensorimotor orientation and limb use were evaluated at day 7 and learning and memory at days 23-30 after injury. Posttraumatic treatment every 12 hrs with the melanocortin analog [Nle(4), D-Phe(7)]-alpha-melanocyte-stimulating hormone (starting 3 or 6 hrs after injury) inhibited traumatic brain injury-induced upregulation of nitric oxide synthesis, phosphorylation level of extracellular signal-regulated kinases, phosphorylation level of c-jun N-terminal kinases, and active caspase-3; reduced expressions/levels of tumor necrosis factor-alpha, BAX, interleukin-6, and high mobility group box-1; and increased those of Bcl-2 and interleukin-10. These molecular changes were associated with a reduction in brain tissue damage, as highlighted by histopathological findings and improved functional recovery. Pretreatment with the melanocortin MC4 receptor antagonist HS024abated the positive effects of [Nle(4), D-Phe(7)]-alpha-melanocyte-stimulating hormone. Conclusions: Our data indicate that melanocortins protect against traumatic brain injury, in a broad time window and through activation of MC4 receptors, by counteracting the main traumatic brain injury-related mechanisms of damage. These findings could have major clinical implications. (Grit Care Med 2012; 40:945-951)	[Bitto, Alessandra; Irrera, Natasha; Rinaldi, Mariagrazia; Minutoli, Letteria; Squadrito, Francesco; Altavilla, Domenica] Univ Messina, Pharmacol Sect, Dept Clin & Expt Med & Pharmacol, Messina, Italy; [Calo, Margherita] Univ Messina, Dept Expt Sci & Appl Biotechnol, Messina, Italy; [Polito, Francesca; Marini, Herbert R.] Dept Biochem Physiol & Nutr Sci, Sect Physiol & Human Nutr, Messina, Italy; [Spaccapelo, Luca; Giuliani, Daniela; Ottani, Alessandra; Guarini, Salvatore] Univ Modena & Reggio Emilia, Pharmacol Sect, Dept Biomed Sci, Modena, Italy		Squadrito, F (corresponding author), Univ Messina, Pharmacol Sect, Dept Clin & Expt Med & Pharmacol, Messina, Italy.	Francesco.Squadrito@unime.it	Ottani, Alessandra/G-7316-2016; Giuliani, Daniela/B-2968-2016; GUARINI, SALVATORE/O-3139-2013; Marini, Herbert Ryan/U-6004-2019; Irrera, Natasha/K-5411-2018; Bitto, Alessandra/K-8942-2016	Ottani, Alessandra/0000-0002-1676-051X; Giuliani, Daniela/0000-0001-6061-5662; GUARINI, SALVATORE/0000-0002-1164-1706; Marini, Herbert Ryan/0000-0002-8254-177X; Bitto, Alessandra/0000-0001-9300-7532; Irrera, Natasha/0000-0002-1134-7080	Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR), Rome, ItalyMinistry of Education, Universities and Research (MIUR); Italian Ministry of ResearchMinistry of Education, Universities and Research (MIUR)	This work was supported by grants from Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR; project PRIN 2007), Rome, Italy. All authors received funding from the Italian Ministry of Research.	BANKS WA, 1995, PEPTIDES, V16, P1157, DOI 10.1016/0196-9781(95)00043-J; Bazzani C, 2001, J PHARMACOL EXP THER, V297, P1082; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Catania A, 2004, PHARMACOL REV, V56, P1, DOI 10.1124/pr.56.1.1; Catania A, 2008, TRENDS NEUROSCI, V31, P353, DOI 10.1016/j.tins.2008.04.002; Chlu WT, 2007, J CLIN NEUROSCI, V14, P930, DOI 10.1016/j.jocn.2006.08.004; Corander MP, 2009, CIRCULATION, V120, P2260, DOI 10.1161/CIRCULATIONAHA.109.854612; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Giuliani D, 2006, ENDOCRINOLOGY, V147, P1126, DOI 10.1210/en.2005-0692; Giuliani D, 2007, EUR J PHARMACOL, V570, P57, DOI 10.1016/j.ejphar.2007.05.025; Giuliani D, 2006, EUR J PHARMACOL, V538, P48, DOI 10.1016/j.ejphar.2006.03.038; Giuliani D, 2010, ADV EXP MED BIOL, V681, P71, DOI 10.1007/978-1-4419-6354-3_6; Giuliani D, 2009, BRAIN BEHAV IMMUN, V23, P844, DOI 10.1016/j.bbi.2009.03.009; GUARINI S, 1990, CRIT CARE MED, V18, P862, DOI 10.1097/00003246-199008000-00014; Guarini S, 2004, CARDIOVASC RES, V63, P357, DOI 10.1016/j.cardiores.2004.03.029; Guarini S, 2003, CIRCULATION, V107, P1189, DOI 10.1161/01.CIR.0000050627.90734.ED; Guarini S, 1997, BRIT J PHARMACOL, V121, P1454, DOI 10.1038/sj.bjp.0701264; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Magnoni S, 2003, J NEUROTRAUM, V20, P251, DOI 10.1089/089771503321532833; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL JF, 1974, J COMP PHYSIOL PSYCH, V86, P375, DOI 10.1037/h0035941; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Mock C, 2005, J TRAUMA, V59, P1243, DOI 10.1097/01.ta.0000197290.02807.de; Ottani A, 2009, J CEREBR BLOOD F MET, V29, P512, DOI 10.1038/jcbfm.2008.140; Schioth HB, 2001, VITAM HORM, V63, P195, DOI 10.1016/S0083-6729(01)63007-3; Schneider CP, 2004, BBA-MOL BASIS DIS, V1689, P22, DOI 10.1016/j.bbadis.2004.01.003; Tatro JB, 2006, ENDOCRINOLOGY, V147, P1122, DOI 10.1210/en.2005-1573; Tracey KJ, 2007, J CLIN INVEST, V117, P289, DOI 10.1172/JCI30555; U. S. Department of Health and Human Services Centers for Disease Control and Prevention, 2010, TRAUM BRAIN INJ US E; Vila N, 2003, STROKE, V34, P671, DOI 10.1161/01.STR.0000057976.53301.69; Wikberg JES, 2008, NAT REV DRUG DISCOV, V7, P307, DOI 10.1038/nrd2331; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yattoo Gh, 2008, J Trauma Manag Outcomes, V2, P5, DOI 10.1186/1752-2897-2-5	38	25	27	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2012	40	3					945	951		10.1097/CCM.0b013e318236efde			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	895YO	WOS:000300532800031	22036855				2022-02-06	
J	Choi, GS; Kim, OL; Kim, SH; Ahn, SH; Cho, YW; Son, SM; Jang, SH				Choi, Gyu Sik; Kim, Oh Lyong; Kim, Seong Ho; Ahn, Sang Ho; Cho, Yoon Woo; Son, Su Min; Jang, Sung Ho			Classification of Cause of Motor Weakness in Traumatic Brain Injury Using Diffusion Tensor Imaging	ARCHIVES OF NEUROLOGY			English	Article							AXONAL INJURY; CORTICOSPINAL TRACT; BASAL GANGLIA; TRANSTENTORIAL HERNIATION; PYRAMIDAL TRACT; RED NUCLEUS; HEAD-INJURY; RECOVERY; IMPAIRMENT; LESIONS	Background: Many studies have attempted to elucidate the causes of motor weakness in patients with traumatic brain injury (TBI). Most of these studies have focused on the specific cause of motor weakness. However, little is known about the classification and elucidation of the causes of motor weakness in consecutive patients with TBI. Objective: To attempt to classify with diffusion tensor imaging the causes of motor weakness in patients with TBI by conducting an analysis of the injury mechanism of the corticospinal tract (CST). Design: Retrospective study. Setting: Rehabilitation department of a university hospital. Patients: We recruited 41 consecutive patients who showed motor weakness among patients with TBI admitted for rehabilitation. Main Outcome Measures: We classified the causes of weakness according to the injury mechanism of the CST on diffusion tensor imaging. Results: Injury mechanisms of the CST were classified as follows, in order: diffuse axonal injury, 24 patients (58.5%); traumatic intracerebral hemorrhage, 9 patients (21.9%); transtentorial herniation, 6 patients (14.6%); and focal cortical contusion, 4 patients (9.8%). In patients with diffuse axonal injury, the mean number of lesions composing CST injury was 3.6 (range, 2-6) and CST injury locations were as follows: the pons (61%), the cerebral peduncle (50%), the medulla (40%), the posterior limb of the internal capsule (17%), and the corona radiata (13%). Conclusion: We found that diffusion tensor imaging was useful in elucidation and classification of the causes of motor weakness resulting from CST injury in patients with TBI.	[Choi, Gyu Sik; Ahn, Sang Ho; Cho, Yoon Woo; Son, Su Min; Jang, Sung Ho] Yeungnam Univ, Dept Phys Med & Rehabil, Coll Med, Taegu 705717, South Korea; [Kim, Oh Lyong; Kim, Seong Ho] Yeungnam Univ, Dept Neurosurg, Coll Med, Taegu 705717, South Korea		Jang, SH (corresponding author), Yeungnam Univ, Dept Phys Med & Rehabil, Coll Med, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net			National Research Foundation of KoreaNational Research Foundation of Korea; Korean GovernmentKorean Government [KRF-2008-314-E00173]	This work was supported by National Research Foundation of Korea Grant funded by the Korean Government (KRF-2008-314-E00173).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ahn YH, 2006, NEUROREHABILITATION, V21, P239; ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Belhaj-Saif A, 2000, J NEUROPHYSIOL, V83, P3147, DOI 10.1152/jn.2000.83.5.3147; Binder DK, 2004, NEUROSURGERY, V54, P999, DOI 10.1227/01.NEU.0000115674.15497.09; Binder DK, 2004, NEUROSURGERY, V54, P1002; Binkofski F, 1996, ANN NEUROL, V39, P460, DOI 10.1002/ana.410390408; Black K, 2000, BRAIN INJURY, V14, P141, DOI 10.1080/026990500120808; Boto GR, 2001, J NEUROSURG, V94, P224, DOI 10.3171/jns.2001.94.2.0224; Brown AW, 2007, BRAIN INJURY, V21, P673, DOI 10.1080/02699050701468925; DeLisa JA, 1998, REHABILITATION PATIE, P1191; DEMEURISSE G, 1980, EUR NEUROL, V19, P382, DOI 10.1159/000115178; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; Han BS, 2007, NEUROREHABILITATION, V22, P151; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hillier SL, 1997, BRAIN INJURY, V11, P661; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Jang SH, 2010, INT J REHABIL RES, V33, P285, DOI 10.1097/MRR.0b013e32833f0500; Jang SH, 2009, NEUROREHABILITATION, V25, P229, DOI 10.3233/NRE-2009-0519; Jang SH, 2009, NEUROREHABILITATION, V24, P349, DOI 10.3233/NRE-2009-0489; Jang SH, 2009, NEUROREHABILITATION, V24, P273, DOI 10.3233/NRE-2009-0478; JAYAKUMAR PN, 1989, ACTA NEUROCHIR, V97, P114, DOI 10.1007/BF01772820; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; KENNEDY PR, 1990, TRENDS NEUROSCI, V13, P474, DOI 10.1016/0166-2236(90)90079-P; Kunimatsu Akira, 2004, Magn Reson Med Sci, V3, P11, DOI 10.2463/mrms.3.11; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Lotze M, 2006, NEUROREHAB NEURAL RE, V20, P14, DOI 10.1177/1545968305282919; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Neil JJ, 2008, J MAGN RESON IMAGING, V27, P1, DOI 10.1002/jmri.21087; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Pettersson LG, 2000, NEUROSCI RES, V38, P109, DOI 10.1016/S0168-0102(00)00143-7; Skoglund TS, 2005, ACTA ANAESTH SCAND, V49, P337, DOI 10.1111/j.1399-6576.2005.00624.x; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Ward NS, 2006, BRAIN, V129, P809, DOI 10.1093/brain/awl002; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073; Yeo SS, 2010, NEUROREHABILITATION, V27, P373, DOI 10.3233/NRE-2010-0622; YORK DH, 1987, NEUROSURGERY, V20, P70	44	25	25	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	MAR	2012	69	3					363	367		10.1001/archneurol.2011.1930			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	906VQ	WOS:000301377300010	22083801	Bronze			2022-02-06	
J	Duhaime, AC; Holshouser, B; Hunter, JV; Tong, K				Duhaime, Ann-Christine; Holshouser, Barbara; Hunter, Jill V.; Tong, Karen			Common Data Elements for Neuroimaging of Traumatic Brain Injury: Pediatric Considerations	JOURNAL OF NEUROTRAUMA			English	Article						CT; common data elements; MRI; pediatrics; traumatic brain injury	CLOSED HEAD-INJURY; THERAPEUTIC PROCEDURES; WHITE-MATTER; MATURATION; CHILDREN; CT; ADOLESCENCE; GUIDELINES; MANAGEMENT; CHILDHOOD	As part of the Traumatic Brain Injury Common Data Elements project, a large-scale effort to define common data elements across a variety of domains, including neuroimaging, special considerations for pediatric patients were introduced. This article is an extension of that initial work, in which pediatric-specific pathoanatomical entities, technical considerations, interpretation paradigms, and safety considerations were reviewed. The goal of this review was to outline differences and specific information relevant to optimal performance and proper interpretation of neuroimaging in pediatric patients with traumatic brain injury. The long-range goal of this project is to facilitate data sharing as well as to provide critical infrastructure for potential clinical trials in this major public health area.	[Duhaime, Ann-Christine] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Holshouser, Barbara] Loma Linda Univ, Sch Med, Dept Radiol, Loma Linda, CA USA; [Hunter, Jill V.] Texas Childrens Hosp, Baylor Coll Med, Dept Neuroradiol, Houston, TX 77030 USA; [Tong, Karen] Loma Linda Univ, Med Ctr, Loma Linda, CA USA		Duhaime, AC (corresponding author), Massachusetts Gen Hosp, 15 Parkman St,Wang 331, Boston, MA 02114 USA.	aduhaime@partners.org			National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR)	We gratefully acknowledge the valuable contributions of Ramona Hicks for providing the impetus as well as the organization and format for this project and for assistance with manuscript preparation. This project was jointly supported by the National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS) and the United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR).	ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Amis E Stephen Jr, 2007, J Am Coll Radiol, V4, P272, DOI 10.1016/j.jacr.2007.03.002; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bryan YF, 2006, ANESTH ANALG, V102, P1674, DOI 10.1213/01.ane.0000216292.82271.bc; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Girard N, 2007, J NEURORADIOLOGY, V34, P290, DOI 10.1016/j.neurad.2007.07.007; Glenn OA, 2006, AM J NEURORADIOL, V27, P1604; Gorman R, 2002, PEDIATRICS, V110, P836; Goske MJ, 2010, SEMIN ULTRASOUND CT, V31, P57, DOI 10.1053/j.sult.2009.09.007; Hicks R., 2011, J NEUROTRAU IN PRESS; Kanal E, 2007, AM J ROENTGENOL, V188, P1447, DOI 10.2214/AJR.06.1616; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; Miller JH, 2003, AM J ROENTGENOL, V180, P851, DOI 10.2214/ajr.180.3.1800851; Mukherjee P, 2006, NEUROIMAG CLIN N AM, V16, P19, DOI 10.1016/j.nic.2005.11.004; Mukherjee P, 2001, RADIOLOGY, V221, P349, DOI 10.1148/radiol.2212001702; Mukherjee P, 2002, AM J NEURORADIOL, V23, P1445; Nievelstein RAJ, 2010, PEDIATR RADIOL, V40, P1324, DOI 10.1007/s00247-010-1714-7; Penzkofer AK, 2002, AM J ROENTGENOL, V179, DOI 10.2214/ajr.179.2.1790509; Radiologic Society of North America, 2010, SPIK MR IM ACC UND N; Schneider JFL, 2004, NEURORADIOLOGY, V46, P258, DOI 10.1007/s00234-003-1154-2; Strauss KJ, 2010, AM J ROENTGENOL, V194, P868, DOI 10.2214/AJR.09.4091; Strauss KJ, 2009, AM J ROENTGENOL, V192, P1169, DOI 10.2214/AJR.08.2172; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034	27	25	25	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	4					629	633		10.1089/neu.2011.1927			5	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	901SQ	WOS:000300987500002	21671798	Green Published			2022-02-06	
J	Dahlin, AP; Hjort, K; Hillered, L; Sjodin, MOD; Bergquist, J; Wetterhall, M				Dahlin, Andreas P.; Hjort, Klas; Hillered, Lars; Sjodin, Marcus O. D.; Bergquist, Jonas; Wetterhall, Magnus			Multiplexed quantification of proteins adsorbed to surface-modified and non-modified microdialysis membranes	ANALYTICAL AND BIOANALYTICAL CHEMISTRY			English	Article						Microdialysis; On-surface enzymatic digestion (oSED); Mass spectrometry (MS); Cerebrospinal fluid (CSF); Interface/surface analysis; Tri-block copolymer surface modification	TRAUMATIC BRAIN-INJURY; HUMAN VENTRICULAR CSF; PROTEOMIC ANALYSIS; CEREBRAL MICRODIALYSIS; DIALYSIS MEMBRANES; SOLID-SURFACES; ADSORPTION; HEMODIALYSIS; POLYSULFONE; ACTIVATION	A simple and straightforward method for discovery and quantification of proteins adsorbed onto delicate and sensitive membrane surfaces is presented. The adsorbed proteins were enzymatically cleaved while still adsorbed onto the membranes using an on-surface enzymatic digestion (oSED). This was followed by isobaric tagging, nanoliquid chromatography, and tandem mass spectrometry. Protein adsorption on tri-block copolymer Poloxamer 407 surface-modified microdialysis (MD) membranes were compared with protein adsorption on unmodified MD membranes. Ventricular cerebrospinal fluid (vCSF) kept at 37 A degrees C was used as sample matrix. In total, 19 proteins were quantified in two biological replicates. The surface-modified membranes adsorbed 33% less proteins than control membranes and the most abundant proteins were subunits of hemoglobin and clusterin. The adsorption of clusterin on the modified membranes was on average 36% compared to control membranes. The most common protein in vCSF, Albumin, was not identified adsorbed to the surface at all. It was also experimentally verified that oSED, in conjunction with tandem mass spectrometry can be used to quantify femtomole amounts of proteins adsorbed on limited and delicate surfaces, such as MD membranes. The method has great potential and can be used to study much more complex protein adsorption systems than previously reported.	[Dahlin, Andreas P.; Hjort, Klas] Uppsala Univ, Dept Engn Sci, S-75121 Uppsala, Sweden; [Hillered, Lars] Uppsala Univ, Dept Neurosci, Div Neurosurg, Univ Uppsala Hosp, S-75185 Uppsala, Sweden; [Sjodin, Marcus O. D.; Bergquist, Jonas; Wetterhall, Magnus] Uppsala Univ, Dept Phys & Analyt Chem, SE-75124 Uppsala, Sweden		Dahlin, AP (corresponding author), Uppsala Univ, Dept Engn Sci, Box 534, S-75121 Uppsala, Sweden.	Andreas.Dahlin@angstrom.uu.se	Bergquist, Jonas/C-5894-2015	Bergquist, Jonas/0000-0002-4597-041X; Hillered, Lars/0000-0002-2808-9292; Dahlin, Andreas/0000-0002-0041-0902	Uppsala Berzelii Technology Centre for Neurodiagnostics; Swedish Governmental Agency for Innovation SystemsVinnova; Swedish Research CouncilSwedish Research CouncilEuropean Commission [P29797-1, 621-2008-3562]; Swedish Brain Foundation; Selander Foundation; Ahlen Foundation; Uppsala University Hospital	This study was supported by Uppsala Berzelii Technology Centre for Neurodiagnostics, with financing from the Swedish Governmental Agency for Innovation Systems and the Swedish Research Council Grant number P29797-1, 621-2008-3562, the Swedish Brain Foundation, the Selander Foundation, the Ahlen Foundation and the Uppsala University Hospital. We acknowledge CMA Microdialysis for material support.	Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004; Bonomini M, 2006, J PROTEOME RES, V5, P2666, DOI 10.1021/pr060150u; Bruce SJ, 2009, ANAL CHEM, V81, P3285, DOI 10.1021/ac8024569; Currie EPK, 2003, ADV COLLOID INTERFAC, V100, P205, DOI 10.1016/S0001-8686(02)00061-1; Dahlin AP, 2010, ANAL CHEM, V82, P4376, DOI 10.1021/ac1007706; Dumortier G, 2006, PHARM RES-DORDR, V23, P2709, DOI 10.1007/s11095-006-9104-4; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Ishikawa I, 2006, AM J NEPHROL, V26, P372, DOI 10.1159/000094779; Mares J, 2009, KIDNEY INT, V76, P404, DOI 10.1038/ki.2009.138; Mares J, 2009, J PROTEOME RES, V8, P1756, DOI 10.1021/pr800966w; Nakanishi K, 2001, J BIOSCI BIOENG, V91, P233, DOI 10.1016/S1389-1723(01)80127-4; NORDE W, 1986, ADV COLLOID INTERFAC, V25, P267, DOI 10.1016/0001-8686(86)80012-4; Rabe M, 2011, ADV COLLOID INTERFAC, V162, P87, DOI 10.1016/j.cis.2010.12.007; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Sjodin MOD, 2010, J CHROMATOGR B, V878, P2003, DOI 10.1016/j.jchromb.2010.05.036; Stenken JA, 2010, AAPS J, V12, P73, DOI 10.1208/s12248-009-9163-7; Wang XT, 2011, J BIOMAT SCI-POLYM E, V22, P1343, DOI 10.1163/092050610X508400; Wetterhall M, 2010, J CHROMATOGR B, V878, P1519, DOI 10.1016/j.jchromb.2010.04.003; Wisniewski N, 2001, J BIOMED MATER RES, V57, P513, DOI 10.1002/1097-4636(20011215)57:4<513::AID-JBM1197>3.0.CO;2-E	23	25	25	1	25	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1618-2642			ANAL BIOANAL CHEM	Anal. Bioanal. Chem.	FEB	2012	402	6					2057	2067		10.1007/s00216-011-5614-y			11	Biochemical Research Methods; Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	892TL	WOS:000300308400008	22159469				2022-02-06	
J	Song, Y; Bi, L; Zhang, ZY; Huang, ZS; Hou, W; Lu, X; Sun, PX; Han, YS				Song, Yang; Bi, Long; Zhang, Zhenyu; Huang, Zhaosong; Hou, Wei; Lu, Xu; Sun, Pengxiao; Han, Yisheng			Increased levels of calcitonin gene-related peptide in serum accelerate fracture healing following traumatic brain injury	MOLECULAR MEDICINE REPORTS			English	Article						calcitonin gene-related peptide; traumatic brain injury; fracture healing	CEREBROSPINAL-FLUID; HEAD-INJURY; MODEL; BONE; RATS	The mechanisms responsible for the phenomenon of an accelerated speed of fracture healing in patients with traumatic brain injury (TBI) remain unclear. The present study was performed to test the hypothesis that TBI causes changes in calcitonin gene-related peptide (CGRP) levels in sera that enhance fracture healing. A standard closed femoral fracture was produced in rats, which were subjected to additional closed head trauma. The fracture healing was assessed 4 and 8 weeks later using micro-CT. Sera, brain tissues and muscles surrounding the fracture sites collected at 24,48, 72 and 168 h after injury were used to detect the expression of CGRP using ELISA, immunohistochemistry and RT-PCR. Micro-CT demonstrated that fracture healing and mineralization in the TBI-fracture group occurred earlier compared to the fracture-only group. ELISA analysis revealed a high concentration of CGRP in the TBI-fracture group (P<0.05), and immunohistochemistry assay and RT-PCR analysis revealed a significant increase in CGRP in the brain and muscle of the TBI-fracture group at 168 h after fracture (P<0.001). Our results indicate that the mechanism for the enhancement of fracture-healing secondary to traumatic brain injury is correlated to the high levels of CGRP, which may be released from the brain tissue into the serum.	[Song, Yang; Bi, Long; Zhang, Zhenyu; Huang, Zhaosong; Hou, Wei; Lu, Xu; Sun, Pengxiao; Han, Yisheng] Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China		Han, YS (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China.	yishenghan@hotmail.com			NSF of ChinaNational Natural Science Foundation of China (NSFC) [30872634, 30901532]	This study was supported by the NSF of China (Grant no. 30872634 and no. 30901532).	Arrieta-Cruz I, 2007, EXP NEUROL, V205, P449, DOI 10.1016/j.expneurol.2007.03.005; Banerjee Sugato, 2006, BMC Pharmacology, V6, P9, DOI 10.1186/1471-2210-6-9; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gangula PRR, 2000, BIOL REPROD, V62, P1033, DOI 10.1095/biolreprod62.4.1033; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; Gautschi OP, 2009, ANZ J SURG, V79, P449, DOI 10.1111/j.1445-2197.2008.04803.x; Harzenetter MD, 2007, J IMMUNOL, V179, P607, DOI 10.4049/jimmunol.179.1.607; HOLLAND JP, 1994, STROKE, V25, P2055, DOI 10.1161/01.STR.25.10.2055; Huebner AK, 2008, ARCH BIOCHEM BIOPHYS, V473, P210, DOI 10.1016/j.abb.2008.02.013; Imai S, 2002, MICROSC RES TECHNIQ, V58, P61, DOI 10.1002/jemt.10119; Jones Kevin B, 2004, Iowa Orthop J, V24, P123; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521, DOI 10.1302/0301-620X.69B4.3611150; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Shih C, 1997, CLIN ORTHOP RELAT R, P335; Tanaka S, 2009, J CLIN INVEST, V119, P2879, DOI 10.1172/JCI40629; Valentijn K, 1997, BONE, V21, P269, DOI 10.1016/S8756-3282(97)00142-7; Vignery A, 1996, BONE, V18, P331, DOI 10.1016/8756-3282(96)00017-8	22	25	32	2	11	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997			MOL MED REP	Mol. Med. Rep.	FEB	2012	5	2					432	438		10.3892/mmr.2011.645			7	Oncology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Oncology; Research & Experimental Medicine	871DA	WOS:000298716900025	22038198	Bronze			2022-02-06	
J	Belwadi, A; Siegel, JH; Singh, A; Smith, JA; Yang, KH; King, AI				Belwadi, Aditya; Siegel, John H.; Singh, Aadarsh; Smith, Joyce A.; Yang, King H.; King, Albert I.			Finite Element Aortic Injury Reconstruction of Near Side Lateral Impacts Using Real World Crash Data	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						aortic injury; CIREN; accident reconstruction; finite element; isthmus; strain; failure; biomechanics	MOTOR-VEHICLE CRASHES; TRAUMATIC RUPTURE; FAILURE PROPERTIES; MECHANISM; TISSUE	Traumatic rupture of the aorta (TRA) remains the second most common cause of death associated with motor vehicle crashes, only less prevalent than brain injury. On average, nearly 8000 people die annually in the United States due to blunt injury to the aorta. It is observed that over 80% of occupants who suffer an aortic injury die at the scene due to exsanguination into the chest cavity. In the current study, eight near side lateral impacts, in which TRA occurred, were reconstructed using a combination of real world crash data reported in the Crash Injury Research and Engineering Network (CIREN) database, finite element (FE) models of vehicles, and the Wayne State Human Body Model - II (WSHBM). For the eight CIREN cases reconstructed, the high strain regions in the aorta closely matched with the autopsy data provided. The peak average maximum principal strains in all of the eight CIREN cases were localized in the isthmus region of the aorta, distal to the left subclavian artery, and averaged at 22+/-6.2% while the average maximum pressure in the aorta was found to be 117+/-14.7 kPa. [DOI: 10.1115/1.4005684]	[Belwadi, Aditya; Singh, Aadarsh; Yang, King H.; King, Albert I.] Wayne State Univ, Detroit, MI 48201 USA; [Siegel, John H.; Smith, Joyce A.] New Jersey Med Sch UMDNJ, Newark, NJ 07101 USA; [Smith, Joyce A.] Univ Rochester, Med Ctr, Sch Nursing, Rochester, NY 14627 USA		Belwadi, A (corresponding author), Wayne State Univ, Detroit, MI 48201 USA.	adityabn@gmail.com; Jhsiegelmd@aol.com; aadarshdeep@gmail.com; JoyceA_Smith@urmc.rochester.edu; king.yang@wayne.edu; albert.king@wayne.edu			Southern Consortium for Injury Biomechanics (SCIB); Drs. Anthony and Kales scholarship	The authors are grateful to the Southern Consortium for Injury Biomechanics (SCIB) for funding the project. The authors would also like to thank ESTECO North America for providing mode-FRONTIER 4.0. The primary author was supported by the 2009 Drs. Anthony and Kales scholarship.	[Anonymous], 1980, J224 SAE; Augenstein J. S., 1997, SOC AUTOMOT ENG SPEC; Bass C R, 2001, Stapp Car Crash J, V45, P143; Bertrand S, 2008, TRAFFIC INJ PREV, V9, P153, DOI 10.1080/15389580701775777; Bonnet LM, 1903, REV MED, V23, P108; Burkhart HM, 2001, J TRAUMA, V50, P113, DOI 10.1097/00005373-200101000-00020; Demetriades D, 2008, J TRAUMA, V64, P1415, DOI 10.1097/TA.0b013e3181715e32; Franklyn Melanie, 2003, Traffic Inj Prev, V4, P263, DOI 10.1080/15389580309883; Fung Y. C., 1993, BIOMECHANICS MECH PR; Guan F., 2009, P IMECE2009 ASME INT; Hardy WN, 2008, STAPP CAR C, V52, P233; Huang Y., 1994, STAPP CAR CRASH J, P35; Iwamoto M, 2000, Stapp Car Crash J, V44, P281; IWAMOTO M, 2002, P IRCOBI C, P31; Katyal D, 1997, J TRAUMA, V42, P769, DOI 10.1097/00005373-199705000-00002; Lee J B, 2001, Stapp Car Crash J, V45, P79; LIZEE E, 1998, P 42 STAPP CAR CRASH, P115; LUNDEVALL J, 1964, ACTA PATHOL MIC SC, V62, P34, DOI 10.1111/apm.1964.62.1.34; MOHAN D, 1983, J BIOMECH, V16, P31, DOI 10.1016/0021-9290(83)90044-1; MOHAN D, 1982, J BIOMECH, V15, P887, DOI 10.1016/0021-9290(82)90055-0; Niehoff P., 2006, ANN P ASS ADV AUTOMO, V50, P1540; Oppenheim F., 1918, GIBT SPONTANE RUPTUR, P1234; Pesola GR, 2001, AM J EMERG MED, V19, P43, DOI 10.1053/ajem.2001.20021; Plank G.R., 1991, 13 INT TECHN C EXP S, P902; ROBERTS SB, 1970, J BIOMECH, V3, P527, DOI 10.1016/0021-9290(70)90037-0; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schneider LW, 1983, UMTRI83532 NHTSA, V2; Shah C, 2007, THESIS WAYNE STATE U; Shah C S, 2001, Stapp Car Crash J, V45, P161; Shah C. S., 2005, OCC SAF SAF CRIT SYS; Shah C.S., 2007, P 2007 INT RES COUNC, P349; Shah Chirag S, 2006, Stapp Car Crash J, V50, P217; Siegel JH, 2004, J TRAUMA, V57, P760, DOI 10.1097/01.TA.0000147502.50248.C4; Siegel JH, 2010, J TRAUMA, V68, P1375, DOI 10.1097/TA.0b013e3181dcd42d; SMITH RS, 1986, AM J SURG, V152, P660, DOI 10.1016/0002-9610(86)90444-7; SUNDARAM SH, 1977, J BIOMECH, V10, P505, DOI 10.1016/0021-9290(77)90104-X; Viano D., 1989, STAPP CAR CRASH J, P1690; Viano D. C., 1983, P 27 STAPP CAR CRASH, P109; Wang K, 1995, THESIS WAYNE STATE U; ZEHNDER M A, 1960, Thoraxchirurgie, V8, P47; [No title captured]	41	25	26	1	17	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	JAN	2012	134	1							011006	10.1115/1.4005684			10	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	922XO	WOS:000302582100006	22482661				2022-02-06	
J	Heled, E; Hoofien, D; Margalit, D; Natovich, R; Agranov, E				Heled, Eyal; Hoofien, Dan; Margalit, Dana; Natovich, Rachel; Agranov, Eugenia			The Delis-Kaplan Executive Function System Sorting Test as an evaluative tool for executive functions after severe traumatic brain injury: A comparative study	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Executive functions; Delis-Kaplan Executive Function System Sorting Test; Traumatic brain injury; Neuropsychological evaluation	TEST-PERFORMANCE; DEVELOPMENTAL-CHANGES; WISCONSIN; TRAIL; VALIDATION; ATTENTION; VALIDITY; LESION; NORMS	Neuropsychological tests are often used to evaluate executive function (EF) deficits in patients suffering traumatic brain injuries (TBIs). This study compared the sensitivity of three such tests-namely, the Delis-Kaplan Executive Function System Sorting Test (D-KEFS ST), the Wisconsin Card Sorting Test (WCST), and the Trail Making Test (TMT)-in differentiating between severe TBI patients and healthy controls. The differences between the two groups were significant for 5/5 variables evaluated through the D-KEFS ST, for 4/6 variables evaluated through the WCST, and for 2/2 variables evaluated through the TMT. Receiver operating characteristic analysis revealed that the variables "attempted sorts" in the D-KEFS ST and completion time in Part B of the TMT were the most powerful predictors of group assignment, with cutoff points of 9.5 sorts and 84.5 seconds, respectively. Our results highlight the possible value of the D-KEFS ST in the evaluation of postinjury EF deficits in TBI patients.	[Heled, Eyal; Margalit, Dana; Natovich, Rachel] Sheba Med Ctr, Day Treatment Rehabil Unit, Ramat Gan, Israel; [Heled, Eyal; Hoofien, Dan] Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; [Hoofien, Dan] Natl Inst Rehabil Brain Injured, Tel Aviv, Israel; [Agranov, Eugenia] Tel Aviv Univ, Fac Med, Dept Phys Med & Rehabil, IL-69978 Tel Aviv, Israel		Heled, E (corresponding author), Sheba Med Ctr, Day Treatment Rehabil Unit, Ramat Gan, Israel.	eyalheled@walla.com					ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Anderson V, 2002, PRINCIPLES FRONTAL L, P504; Arffa S, 1998, ARCH CLIN NEUROPSYCH, V13, P713; Beatty W W, 1990, J Geriatr Psychiatry Neurol, V3, P163, DOI 10.1177/089198879000300308; Beatty W W, 1996, J Int Neuropsychol Soc, V2, P134; Beatty WW, 1994, NEUROPSYCHOLOGY, V8, P49, DOI 10.1037/0894-4105.8.1.49; BEATTY WW, 1993, J STUD ALCOHOL, V54, P687, DOI 10.15288/jsa.1993.54.687; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Bergquist T, 2009, BRAIN INJURY, V23, P790, DOI 10.1080/02699050903196688; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Davidson PSR, 2008, J CLIN EXP NEUROPSYC, V30, P18, DOI 10.1080/13803390601161166; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; Delis DC., 2001, DELIS KAPLAN EXECUTI; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; Demakis GJ, 2003, NEUROPSYCHOLOGY, V17, P255, DOI 10.1037/0894-4105.17.2.255; Dimitrov M, 1999, NEUROPSYCHOLOGY, V13, P135, DOI 10.1037/0894-4105.13.1.135; Elliott R, 2003, BRIT MED BULL, V65, P49, DOI 10.1093/bmb/65.1.49; Fernandez AL, 2008, SCAND J PSYCHOL, V49, P239, DOI 10.1111/j.1467-9450.2008.00637.x; Fossati P, 2001, PSYCHIAT RES, V104, P145, DOI 10.1016/S0165-1781(01)00307-9; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; GREVE KW, 1995, ARCH CLIN NEUROPSYCH, V10, P265, DOI 10.1016/0887-6177(94)00046-S; Greve KW, 2000, ARCH CLIN NEUROPSYCH, V15, P243, DOI 10.1016/S0887-6177(99)00015-3; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton R.K., 1981, WISCONSIN CARD SORTI; Herman L. E., 2008, CAN J CLIN PHARM, V15, P411; Homack S, 2005, J CLIN EXP NEUROPSYC, V27, P599, DOI 10.1080/13803390490918444; Kaleita TA, 2004, J NEURO-ONCOL, V67, P245, DOI 10.1023/B:NEON.0000021900.29176.58; Kramer JH, 2002, J NEUROL NEUROSUR PS, V72, P217, DOI 10.1136/jnnp.72.2.217; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; LEVINE B, 1995, J CLIN EXP NEUROPSYC, V17, P740, DOI 10.1080/01688639508405164; Lewine RRJ, 1996, AM J PSYCHIAT, V153, P1178; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; McCulloch KL, 2010, J HEAD TRAUMA REHAB, V25, P155, DOI 10.1097/HTR.0b013e3181dc82e7; Niemeier JP, 2007, NEUROPSYCHOL REHABIL, V17, P293, DOI 10.1080/09602010600814729; Nilson L, 1999, CLIN NEUROPSYCHOL, V13, P314, DOI 10.1076/clin.13.3.314.1737; Nixon S.J., 1996, NEUROPSYCHOLOGY CLIN, P9, DOI [DOI 10.1037/10198-001, https://doi.org/10.1037/10198-001]; Nyhus E, 2009, BRAIN COGNITION, V71, P437, DOI 10.1016/j.bandc.2009.03.005; Parmenter BA, 2007, J CLIN EXP NEUROPSYC, V29, P215, DOI 10.1080/13803390600672163; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; PENDLETON MG, 1982, J CLIN PSYCHOL, V38, P392, DOI 10.1002/1097-4679(198204)38:2<392::AID-JCLP2270380232>3.0.CO;2-W; Rabin LA, 2005, ARCH CLIN NEUROPSYCH, V20, P33, DOI 10.1016/j.acn.2004.02.005; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Reitan R.M., 1974, CLIN NEUROPSYCHOLOGY; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schisterman EF, 2005, EPIDEMIOLOGY, V16, P73, DOI 10.1097/01.ede.0000147512.81966.ba; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss DT, 2005, NEUROPSYCHOLOGIA, V43, P396, DOI 10.1016/j.neuropsychologia.2004.06.010; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Vakil E, 2009, CHILD NEUROPSYCHOL, V15, P21, DOI 10.1080/09297040801947069; WALDMANN BW, 1992, J CLIN PSYCHOL, V48, P360, DOI 10.1002/1097-4679(199205)48:3<360::AID-JCLP2270480314>3.0.CO;2-P; Winblad Stefan, 2006, Behav Brain Funct, V2, P16, DOI 10.1186/1744-9081-2-16	57	25	25	0	21	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2012	34	2					151	159		10.1080/13803395.2011.625351			9	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	916EC	WOS:000302079900004	22114911				2022-02-06	
J	Murphy, MP; Carmine, H				Murphy, Mary Pat; Carmine, Helen			Long-term health implications of individuals with TBI: A rehabilitation perspective	NEUROREHABILITATION			English	Article						Traumatic brain injury; health complications; nursing; healthy aging; chronic disease management	TRAUMATIC BRAIN-INJURY; GASTROESOPHAGEAL-REFLUX DISEASE; METABOLIC-SYNDROME; SLEEP DISORDERS; HEAD-INJURY; POSTTRAUMATIC SEIZURES; UNITED-STATES; COMMUNITY; PREVALENCE; MANAGEMENT	Individuals with acquired brain injuries often present with lifelong health challenges. Trauma to the body directly related to the injury, physical and medical sequelae resulting from the brain injury itself, and an increase in the observed onset of physical aging are among the problems which require consideration throughout their lives. For many rehabilitation professionals, issues related to medical stability and health maintenance are unfamiliar and intimidating. As both hospital stays shorten and an existing population of individuals with brain injuries' survival and life expectancy rates increase, rehabilitation professionals have been increasingly challenged by medical issues. Rehabilitation nurses are positioned to best navigate these issues and facilitate needed care coordination, early intervention, and ongoing education for individuals, their families, and other caregivers. This article describes common medical complications related to the initial and related disability and aging in individuals with brain injury including chronic and late emerging complications involving all body systems including spasticity and changing mobility, aspiration and dysphagia, incontinence, diabetes, and acute and chronic pain. Strategies for successful management of these issues in a home or community setting are also discussed. Special attention is paid to falls and fall prevention, issues specific to aging women, and nutrition and weight control. Ways to promote positive health behaviors to preserve function are also explored. Additionally, patient and family education as part of a lifetime management plan is discussed.	[Murphy, Mary Pat; Carmine, Helen] ReMed Recovery Care Ctr, Paoli, PA 19301 USA; [Murphy, Mary Pat; Carmine, Helen] Greater Philadelphia Chapter, Assoc Rehabil Nurses, Philadelphia, PA USA		Murphy, MP (corresponding author), ReMed Recovery Care Ctr, 16 Ind Blvd,Suite 203, Paoli, PA 19301 USA.	mmurphy@remed.com					Adler T., 2011, BRAIN INJURY PROFESS, V8, P22; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Banotai A., 2011, ADV SPEECH LANGUAGE, V16, P6; Bittar RG, 2005, J CLIN NEUROSCI, V12, P12, DOI 10.1016/j.jocn.2004.03.025; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Bushnik T, 2004, J HEAD TRAUMA REHAB, V19, P296, DOI 10.1097/00001199-200407000-00004; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chokroverty S, 2000, NEUROLOGY, V54, pS8; Chua K, 2003, BRAIN INJURY, V17, P469, DOI 10.1080/02699050210154268; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P1182, DOI 10.1016/S0003-9993(96)90145-8; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Flanagan S., 2008, BRAIN INJURY PROFESS, V5, P22; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; FUHRER MJ, 1993, ARCH PHYS MED REHAB, V74, P1172; Gohil B C, 2001, CNS Spectr, V6, P581; Gohil BC, 2001, CNS SPECTRUMS, V6, P589; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Hadjikoutis S, 2000, BRAIN, V123, P1863, DOI 10.1093/brain/123.9.1863; Harrison T, 2007, ADV NURS SCI, V30, P123, DOI 10.1097/01.ANS.0000271103.57290.6e; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hart Robert P, 2003, Curr Pain Headache Rep, V7, P116, DOI 10.1007/s11916-003-0021-5; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hjemdahl P, 2002, CIRCULATION, V106, P2634, DOI 10.1161/01.CIR.0000041502.43564.79; Ishibe N, 2009, J HEAD TRAUMA REHAB, V24, P424, DOI 10.1097/HTR.0b013e3181c13426; Isomaa B, 2003, LIFE SCI, V73, P2395, DOI 10.1016/S0024-3205(03)00646-5; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; Jankovic J., 2007, PARKINSONS DIS MOVEM, P349; Kaltenbach T, 2006, ARCH INTERN MED, V166, P965, DOI 10.1001/archinte.166.9.965; Khoury RM, 1999, AM J GASTROENTEROL, V94, P2069; Martelli MF, 2004, J HEAD TRAUMA REHAB, V19, P10, DOI 10.1097/00001199-200401000-00003; Masel B.E., 2011, CHALLENGE, V5, P9; Masel B.E., 2011, CHALLENGE, V5, P28; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; McGrath JC, 2008, CLIN REHABIL, V22, P635, DOI 10.1177/0269215507086432; Medley A, 2006, BRAIN INJURY, V20, P1403, DOI 10.1080/02699050601082057; Myers K. J., 2009, DYSTONIA PATIENT GUI, P117; Nosek MA, 2006, ARCH PHYS MED REHAB, V87, P320, DOI 10.1016/j.apmr.2005.11.003; O'Suilleabhain P, 2004, J HEAD TRAUMA REHAB, V19, P305, DOI 10.1097/00001199-200407000-00005; Oostra K, 1996, BRAIN INJURY, V10, P459, DOI 10.1080/026990596124313; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Paterson WG, 1996, CAN FAM PHYSICIAN, V42, P925; PEET SM, 1995, BRIT MED J, V311, P1063, DOI 10.1136/bmj.311.7012.1063; Piesman M, 2007, AM J GASTROENTEROL, V102, P2128, DOI 10.1111/j.1572-0241.2007.01348.x; Pluskiewicz W, 1997, ULTRASOUND MED BIOL, V23, P553, DOI 10.1016/S0301-5629(97)00036-7; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; US Department of Health & Human Services, 2004, BREAK BARR HLTH CAR; Verbrugge LM., 2002, J DISABIL POLICY STU, V12, P253, DOI DOI 10.1177/104420730201200405; Walker WC, 2004, J HEAD TRAUMA REHAB, V19, P72, DOI 10.1097/00001199-200401000-00007; Zagaria M.A., 2011, AM J NURSE PRACTITIO, V15, P63; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	58	25	25	2	23	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2012	31	1					85	94		10.3233/NRE-2012-0777			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	976SU	WOS:000306605900009	22523016				2022-02-06	
J	Ozen, LJ; Fernandes, MA				Ozen, Lana J.; Fernandes, Myra A.			Slowing Down after a Mild Traumatic Brain Injury: A Strategy to Improve Cognitive Task Performance?	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Head injury; Traumatic brain injury; Learning and memory; Attention; Executive functions; Everyday functioning; Anxiety	TIME PRESSURE MANAGEMENT; CLOSED-HEAD INJURY; POSTCONCUSSIVE SYNDROME; ATTENTION DEFICITS; DIAGNOSIS THREAT; LONG; SPEED; CONCUSSION; SYMPTOMS; FAILURES	Long-term persistent attention and memory difficulties following a mild traumatic brain injury (TBI) often go undetected on standard neuropsychological tests, despite complaints by mild TBI individuals. We conducted a visual Repetition Detection working memory task to digits, in which we manipulated task difficulty by increasing cognitive load, to identify subtle deficits long after a mild TBI. Twenty-six undergraduate students with a self-report of one mild TBI, which occurred at least 6 months prior, and 31 non-head-injured controls took part in the study. Participants were not informed until study completion that the study's purpose was to examine cognitive changes following a mild TBI, to reduce the influence of "diagnosis threat" on performance. Neuropsychological tasks did not differentiate the groups, though mild TBI participants reported higher state anxiety levels. On our working memory task, the mild TBI group took significantly longer to accurately detect repeated targets on our task, suggesting that slowed information processing is a long-term consequence of mild TBI. Accuracy was comparable in the low-load condition and, unexpectedly, mild TB1 performance surpassed that of controls in the high-load condition. Temporal analysis of target identification suggested a strategy difference between groups: mild TBI participants made a significantly greater number of accurate responses following the target's offset, and significantly fewer erroneous distracter responses prior to target onset, compared with controls. Results suggest that long after a mild TB!, high-functioning young adults invoke a strategy of delaying their identification of targets in order to maintain, and facilitate, accuracy on cognitively demanding tasks.	[Ozen, Lana J.; Fernandes, Myra A.] Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada		Ozen, LJ (corresponding author), Univ Waterloo, Dept Psychol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	lozen@uwaterloo.ca			National Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)	This work was supported by a Discovery grant (M.A.F.) and a post-graduate scholarship (L.J.O.) from the National Sciences and Engineering Research Council of Canada.	Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bopp KL, 2007, J GERONTOL B-PSYCHOL, V62, pP239, DOI 10.1093/geronb/62.5.P239; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Chiaravalloti ND, 2003, J CLIN EXP NEUROPSYC, V25, P489, DOI 10.1076/jcen.25.4.489.13878; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Delis DC, 1987, CALIFORNIA VERBAL LE; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lachapelle J, 2008, BRAIN INJURY, V22, P265, DOI 10.1080/02699050801938983; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ozen LJ, 2011, J INT NEUROPSYCH SOC, V17, P219, DOI 10.1017/S135561771000144X; Pare N, 2009, NEUROPSYCHOL REHABIL, V19, P110, DOI 10.1080/09602010802106486; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; Reason J., 1982, ABSENT MINDED PSYCHO; Reitan RM, 1985, HALSTEADREITAN NEURO; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Sivak S, 2008, BRAIN INJURY, V22, P193, DOI 10.1080/02699050801895431; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spielberger CD., 1970, STATE TRAIT ANXIETY; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Tombaugh TN, 2007, ARCH CLIN NEUROPSYCH, V22, P25, DOI 10.1016/j.acn.2006.06.013; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Villemure R, 2011, BRAIN INJURY, V25, P53, DOI 10.3109/02699052.2010.531881; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Westcott MC, 2005, BRAIN INJURY, V19, P1261, DOI 10.1080/02699050500150104; Winkens I, 2009, CLIN REHABIL, V23, P79, DOI 10.1177/0269215508097855; Winkens I, 2009, ARCH PHYS MED REHAB, V90, P1672, DOI 10.1016/j.apmr.2009.04.016; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	48	25	26	0	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2012	27	1					85	100		10.1093/arclin/acr087			16	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	885TE	WOS:000299802900008	22068441				2022-02-06	
J	Pavawalla, SP; Schmitter-Edgecombe, M; Smith, RE				Pavawalla, Shital P.; Schmitter-Edgecombe, Maureen; Smith, Rebekah E.			Prospective Memory After Moderate-to-Severe Traumatic Brain Injury: A Multinomial Modeling Approach	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; prospective memory; retrospective memory; multinomial modeling	CLOSED-HEAD-INJURY; PROCESSING TREE MODELS; POWER ANALYSIS PROGRAM; RETROSPECTIVE-MEMORY; COMPUTER-PROGRAM; TASK COMPLEXITY; PERFORMANCE; EVENT; RETRIEVAL; ADULTS	Objective: Prospective memory (PM), which can be understood as the processes involved in realizing a delayed intention, is consistently found to be impaired after a traumatic brain injury (TBI). Although PM can be empirically dissociated from retrospective memory, it inherently involves both a prospective component (i.e., remembering that an action needs to be carried out) and retrospective components (i.e., remembering what action needs to be executed and when). This study utilized a multinomial processing tree model to disentangle the prospective (that) and retrospective recognition (when) components underlying PM after moderate-to-severe TBI. Method: Seventeen participants with moderate to severe TBI and 17 age-and education-matched control participants completed an event-based PM task that was embedded within an ongoing computer-based color-matching task. Results: The multinomial processing tree modeling approach revealed a significant group difference in the prospective component, indicating that the control participants allocated greater preparatory attentional resources to the PM task compared to the TBI participants. Participants in the TBI group were also found to be significantly more impaired than controls in the when aspect of the retrospective component. Conclusions: These findings indicated that the TBI participants had greater difficulty allocating the necessary preparatory attentional resources to the PM task and greater difficulty discriminating between PM targets and nontargets during task execution, despite demonstrating intact posttest recall and/or recognition of the PM tasks and targets.	[Pavawalla, Shital P.] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Schmitter-Edgecombe, Maureen] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA; [Smith, Rebekah E.] Univ Texas San Antonio, Dept Psychol, San Antonio, TX USA		Pavawalla, SP (corresponding author), James A Haley Vet Hosp, 13000 Bruce B Downs Blvd,MH&BS 116B, Tampa, FL 33612 USA.	shitalpavawalla@yahoo.com	Smith, Rebekah E/A-6128-2013	Smith, Rebekah/0000-0002-9297-9177	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS47690]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG034965]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [SC1AG034965] Funding Source: NIH RePORTER	We thank the TBI participants and the members of the Head Injury Research Team for their help in collecting and scoring the data and Laura Randol for assistance with manuscript preparation. This study was partially supported by Grant R01 NS47690 from NINDS to MSE and was completed as partial fulfillment of the first author's dissertation requirements at the Department of Psychology, Washington State University. Additional support was provided by Grant AG034965 from the National Institute on Aging to R. E. Smith.	Altgassen M, 2008, J CLIN EXP NEUROPSYC, V30, P777, DOI 10.1080/13803390701779552; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BROOKS DN, 1972, CORTEX, V11, P329; Carlesimo GA, 2004, J INT NEUROPSYCH SOC, V10, P679, DOI 10.1017/S1355617704105079; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Cohen AL, 2008, MEM COGNITION, V36, P149, DOI 10.3758/MC.36.1.149; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Einstein, 2008, PROSPECTIVE MEMORY C, P29; EINSTEIN GO, 1992, PSYCHOL AGING, V7, P471, DOI 10.1037/0882-7974.7.3.471; Einstein GO, 2005, J EXP PSYCHOL GEN, V134, P327, DOI 10.1037/0096-3445.134.3.327; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; Fahy JF., 1993, NEUROPSYCHOLOGY, V7, P136, DOI [10.1037/0894-4105.7.2.136, DOI 10.1037/0894-4105.7.2.136]; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Henry JD, 2007, J CLIN EXP NEUROPSYC, V29, P457, DOI 10.1080/13803390600762717; Horn S. S., EXPT PSYCHO IN PRESS; Jager T, 2008, J GEN PSYCHOL, V135, P4, DOI 10.3200/GENP.135.1.4-22; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Knight RG, 2006, J INT NEUROPSYCH SOC, V12, P8, DOI 10.1017/S1355617706060048; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Kuera H., 1967, COMPUTATIONAL ANAL P; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maylor EA, 2002, MEM COGNITION, V30, P871, DOI 10.3758/BF03195773; McDaniel MA, 2004, J EXP PSYCHOL LEARN, V30, P605, DOI 10.1037/0278-7393.30.3.605; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; McDaniel MA., 1996, PROSPECTIVE MEMORY T, P1; Moshagen M, 2010, BEHAV RES METHODS, V42, P42, DOI 10.3758/BRM.42.1.42; Palmer HM, 2000, BRAIN COGNITION, V44, P103; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Reitan RM, 1992, TRAIL MAKING TEST MA; Roche NL, 2007, NEUROPSYCHOL REHABIL, V17, P314, DOI 10.1080/09602010600831004; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Schmitter-Edgecombe M, 2001, J INT NEUROPSYCH SOC, V7, P615, DOI 10.1017/S1355617701755099; SchmitterEdgecombe M, 1997, NEUROPSYCHOLOGY, V11, P296, DOI 10.1037/0894-4105.11.2.296; Schneider W., 2002, E PRIME REFERENCE GU; Shipley WC, 1940, J PSYCHOL, V9, P371, DOI 10.1080/00223980.1940.9917704; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith G, 2000, MEMORY, V8, P311, DOI 10.1080/09658210050117735; Smith RE, 2005, EXP PSYCHOL, V52, P243, DOI 10.1027/1618-3169.52.4.243; Smith RE, 2004, J EXP PSYCHOL LEARN, V30, P756, DOI 10.1037/0278-7393.30.4.756; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Smith RE, 2006, J EXP PSYCHOL LEARN, V32, P623, DOI 10.1037/0278-7393.32.3.623; Smith RE, 2010, J EXP PSYCHOL LEARN, V36, P1089, DOI 10.1037/a0019183; Smith RE, 2010, DEV PSYCHOL, V46, P230, DOI 10.1037/a0017100; Stahl C, 2007, BEHAV RES METHODS, V39, P267, DOI 10.3758/BF03193157; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1973, PSYCHOL REV, V80, P352, DOI 10.1037/h0020071; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; VAKIL E, 1991, J CLIN EXP NEUROPSYC, V13, P291, DOI 10.1080/01688639108401044; West R, 2001, PSYCHOL AGING, V16, P682, DOI 10.1037//0882-7974.16.4.682; West R, 2005, NEUROPSYCHOLOGIA, V43, P418, DOI 10.1016/j.neuropsychologia.2004.06.012; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson B. A., 1996, BEHAV ASSESSMET DYSE	65	25	29	0	5	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	JAN	2012	26	1					91	101		10.1037/a0025866			11	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	867XI	WOS:000298487700008	21988127	Green Accepted			2022-02-06	
J	Callahan, BL; Ueda, K; Sakata, D; Plamondon, A; Murai, T				Callahan, Brandy L.; Ueda, Keita; Sakata, Daisuke; Plamondon, Andre; Murai, Toshiya			Liberal bias mediates emotion recognition deficits in frontal traumatic brain injury	BRAIN AND COGNITION			English	Article						Emotion; Recognition; Traumatic brain injury; Frontal lobe; Bias	FACIAL AFFECT RECOGNITION; PREFRONTAL CORTEX; HEAD-INJURY; DAMAGE; EXPRESSIONS; SCHIZOPHRENIA; COMMUNICATION; IMPAIRMENT; PERCEPTION; DEPRESSION	It is well-known that patients having sustained frontal-lobe traumatic brain injury (TBI) are severely impaired on tests of emotion recognition. Indeed, these patients have significant difficulty recognizing facial expressions of emotion, and such deficits are often associated with decreased social functioning and poor quality of life. As of yet, no studies have examined the response patterns which underlie facial emotion recognition impairment in TBI and which may lend clarity to the interpretation of deficits. Therefore, the present study aimed to characterize response patterns in facial emotion recognition in 14 patients with frontal TBI compared to 22 matched control subjects, using a task which required participants to rate the intensity of each emotion (happiness, sadness, anger, disgust, surprise and fear) of a series of photographs of emotional and neutral faces. Results first confirmed the presence of facial emotion recognition impairment in TBI, and further revealed that patients displayed a liberal bias when rating facial expressions, leading them to associate intense ratings of incorrect emotional labels to sad, disgusted, surprised and fearful facial expressions. These findings are generally in line with prior studies which also report important facial affect recognition deficits in TBI patients, particularly for negative emotions. (C) 2011 Elsevier Inc. All rights reserved.	[Callahan, Brandy L.; Plamondon, Andre] Univ Laval, Ecole Psychol, Quebec City, PQ G1V 0A6, Canada; [Callahan, Brandy L.] Univ Laval Robert Giffard, Ctr Rech, Quebec City, PQ G1J 2G3, Canada; [Ueda, Keita; Sakata, Daisuke; Murai, Toshiya] Kyoto Univ, Grad Sch Med, Dept Neuropsychiat, Sakyo Ku, Kyoto 6068507, Japan		Callahan, BL (corresponding author), Univ Laval, Ecole Psychol, Pavillon Felix Antoine Savard, Quebec City, PQ G1V 0A6, Canada.	brandy.callahan.1@ulaval.ca	Callahan, Brandy L/E-2483-2011	Callahan, Brandy/0000-0001-5617-2379; Plamondon, Andre/0000-0002-1169-2669	Alzheimer Society of Canada; Centre de recherche sur le cerveau, le comportement et la neuropsychiatrie	Brandy Callahan is supported by a doctoral award from the Alzheimer Society of Canada and an additional research award from the Centre de recherche sur le cerveau, le comportement et la neuropsychiatrie.	Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2003, BRAIN COGNITION, V52, P61, DOI 10.1016/S0278-2626(03)00009-5; Adolphs R, 1996, J NEUROSCI, V16, P7678; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bryson G, 1997, PSYCHIAT RES, V71, P105, DOI 10.1016/S0165-1781(97)00050-4; Burgess P, 1996, BEHAV ASSESSMENT DYS; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Ekman P., 1976, PICTURES FACIAL AFFE; Fellows LK, 2003, BRAIN, V126, P1830, DOI 10.1093/brain/awg180; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Frenkel TI, 2009, COGNITION EMOTION, V23, P688, DOI 10.1080/02699930802076893; Fukui H, 2005, NEUROIMAGE, V24, P253, DOI 10.1016/j.neuroimage.2004.08.028; Gollan JK, 2008, PSYCHIAT RES, V159, P18, DOI 10.1016/j.psychres.2007.06.011; Halberstadt AG, 2011, J NONVERBAL BEHAV, V35, P35, DOI 10.1007/s10919-010-0099-5; Harlow JM, 1848, BOSTON MED SURGICAL, V39, P389, DOI DOI 10.1056/NEJM184812130392001; Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI 10.1080/03637750903310360; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Holmbeck GN, 2002, J PEDIATR PSYCHOL, V27, P87, DOI 10.1093/jpepsy/27.1.87; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kohler CG, 2003, AM J PSYCHIAT, V160, P1768, DOI 10.1176/appi.ajp.160.10.1768; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; Lee SJ, 2009, PSYCHIAT INVEST, V6, P156, DOI 10.4306/pi.2009.6.3.156; Leppanen JM, 2004, PSYCHIAT RES, V128, P123, DOI 10.1016/j.psychres.2004.05.020; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; Malloy P.F., 2001, FRONTAL SYSTEMS BEHA; Matsumoto D, 2007, INT J PSYCHOL, V42, P207, DOI 10.1080/00207590601050926; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Rolls ET, 2008, PROG NEUROBIOL, V86, P216, DOI 10.1016/j.pneurobio.2008.09.001; Soussignan R, 2005, NEUROCASE, V11, P114, DOI 10.1080/13554790590922513; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Walz NC, 1996, AM J MENT RETARD, V101, P282; Wechsler D, 1981, WECHSLER ADULT INTEL; Westermann S, 2010, J BEHAV THER EXP PSY, V41, P96, DOI 10.1016/j.jbtep.2009.10.007; Zald DH, 2010, NEUROPSYCHOLOGIA, V48, P3377, DOI 10.1016/j.neuropsychologia.2010.08.012	48	25	25	1	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	DEC	2011	77	3					412	418		10.1016/j.bandc.2011.08.017			7	Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	855AG	WOS:000297535300011	21945238				2022-02-06	
J	Emery, CA; Kang, J; Schneider, KJ; Meeuwisse, WH				Emery, Carolyn A.; Kang, Jian; Schneider, Kathryn J.; Meeuwisse, Willem H.			Risk of injury and concussion associated with team performance and penalty minutes in competitive youth ice hockey	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORT INJURY; CONSENSUS STATEMENT; BODY CHECKING; PARTICIPATION; RECOVERY; CALGARY; RULES	Objective To determine if there is an association between the risk of all injury or concussion and win-loss records or penalty minutes in competitive youth ice hockey players (ages 11-14). Design, setting, participants This is a secondary data analysis of a 2-year cohort study in Alberta and Quebec on the 2007/2008 (Pee Wee) and 2008/2009 (Bantam) seasons. Main outcome measures Incidence rate ratios (IRRs) were estimated based on Poisson regression for game-related injury and concussion and adjusted for cluster by team. Results A total of 140 teams from Alberta (n=2081) and 137 teams (n=2018) from Quebec were included in the analysis. There were 451 game-related injuries (121 concussions) from Alberta and 280 (62 concussions) from Quebec. For game-related injuries, the IRR between players from teams with more than 50% wins and players with less or equal to 50% wins was 0.78 (95% CI 0.64-0.95) for all injuries, 0.75 (95% CI 0.52-1.08) for concussions, 0.64 (95% CI 0.47-0.88) for injuries resulting in time loss of more than 7 days, and 0.74 (95% CI 0.39-1.40) for concussions resulting in time loss of more than 10 days; adjusting for clustering by team and other important risk factors (ie, province, age, level of play, previous injury, weight and position). There was no association found between the total penalty minutes per game and game-related injury or concussion. Conclusions There was a significant association found between team performance (ie, win/loss/tie record) and injury risk with a 22% lower injury rate and 36% lower injury rate resulting in less than 7 days time loss in Pee Wee and Bantam ice hockey teams winning more than 50% of all season games. Total penalty minutes per game were not associated with injury or concussion rates.	[Emery, Carolyn A.; Schneider, Kathryn J.; Meeuwisse, Willem H.] Univ Calgary, Fac Kinesiol, Roger Jackson Ctr Hlth & Wellness Res, Sport Injury Prevent Res Ctr, Calgary, AB T2N 1N4, Canada; [Emery, Carolyn A.; Kang, Jian] Univ Calgary, Fac Med, Dept Pediat, Alberta Childrens Hosp, Calgary, AB T2N 1N4, Canada; [Emery, Carolyn A.; Meeuwisse, Willem H.] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada		Emery, CA (corresponding author), Univ Calgary, Sport Med Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	caemery@ucalgary.ca	Emery, Carolyn/AAI-2761-2020	Schneider, Kathryn/0000-0002-5951-5899	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Max Bell Foundation; Hockey Calgary; Hockey Edmonton; Hockey Quebec; Hockey Alberta; Hockey Canada; Quebec Ministry of Education, Leisure and Sport; Alberta Heritage FoundationAlberta Heritage Foundation for Medical Research; Department of Pediatrics (Alberta Children's Hospital Foundation), Faculty of Medicine	This study was funded by the Canadian Institutes of Health Research and Max Bell Foundation. This research was possible due to the support from Hockey Calgary, Hockey Edmonton, Hockey Quebec, Hockey Alberta, Hockey Canada and the Quebec Ministry of Education, Leisure and Sport. This research could not have been completed without the support of many Pee Wee players, parents, coaches, team designates, physiotherapists, athletic therapists, student therapists and study physicians. Dr Carolyn Emery is supported by a Population Health Investigator Award from the Alberta Heritage Foundation, a New Investigator Award from the Canadian Institutes of Health Research and a Professorship in Pediatric Rehabilitation from the Department of Pediatrics (Alberta Children's Hospital Foundation), Faculty of Medicine.	Arnason A, 2004, MED SCI SPORT EXER, V36, P278, DOI 10.1249/01.MSS.0000113478.92945.CA; Benson Brian W, 2005, Med Sport Sci, V49, P86, DOI 10.1159/000085393; BERNARD D, 1993, ASTM STP, V1212, P44; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Brunelle JP, 2005, J SCI MED SPORT, V8, P294, DOI 10.1016/S1440-2440(05)80040-4; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Emery CA, 2009, PAED CHILD HEALT-CAN, V14, P439, DOI 10.1093/pch/14.7.439; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Makdissi M, 2009, BRIT J SPORT MED, V43, pI23, DOI 10.1136/bjsm.2009.058206; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; REGNIER G, 1989, ASTM STP, V1050, P84; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; ROY MA, 1989, PHYSICIAN SPORTSMED, V17, P119, DOI 10.1080/00913847.1989.11709735; *STATACORP, 2005, STAT STAT SOFTW COMP; Watson RC, 1996, CLIN J SPORT MED, V6, P108, DOI 10.1097/00042752-199604000-00008	25	25	26	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC	2011	45	16					1289	1293		10.1136/bjsports-2011-090538			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	857BI	WOS:000297688500007	22117019				2022-02-06	
J	Helton, WS; Head, J; Kemp, S				Helton, William S.; Head, James; Kemp, Simon			Natural disaster induced cognitive disruption: Impacts on action slips	CONSCIOUSNESS AND COGNITION			English	Article						Attention; Cognitive disruption; Consciousness; Earthquake; Natural disaster	TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; TASK; MIND; EARTHQUAKE; FAILURES; PERFORMANCE; DEPRESSION; VIGILANCE; DISORDER	Previous research has indicated an increase in stress levels and cognitive intrusions after natural disasters. These previous studies have not, however, assessed the impact disaster induced cognitive disruption has on human performance. In the present report, we investigated the impact of the 7.1 magnitude 2010 Christchurch, New Zealand earthquake on self-reported earthquake-induced cognitive disruption and its relationship to performance on the Sustained Attention to Response Task (SART). Participants who self-reported greater cognitive disruption induced by the earthquake also had higher levels of errors of commission during SART (r = .80, p < .001). This was even the case when controlling for earthquake-induced anxiety, depression, participant sex, and self-reported sleep amount. Post-disaster assessments need to include the impact of the events directly on cognitive self-regulation and conscious thoughts, in addition to more clinical constructs, such as anxiety and depression. (C) 2011 Elsevier Inc. All rights reserved.	[Helton, William S.; Head, James; Kemp, Simon] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand		Helton, WS (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	deak.helton@canterbury.ac.nz		Kemp, Simon/0000-0002-8880-2416			AIKEN EG, 1967, PSYCHOL BULL, V68, P330, DOI 10.1037/h0025123; Annett K., 1967, ACTA PSYCHOL, V27, P420; Bergiannaki JD, 2003, ACTA PSYCHIAT SCAND, V107, P18, DOI 10.1034/j.1600-0447.2003.01467.x; CARDENA E, 1993, AM J PSYCHIAT, V150, P474; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050110034325; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Greene CM, 2009, NEUROPSYCHOLOGIA, V47, P591, DOI 10.1016/j.neuropsychologia.2008.10.003; Helton WS, 2011, CONSCIOUS COGN, V20, P696, DOI 10.1016/j.concog.2010.09.019; Helton WS, 2010, CONSCIOUS COGN, V19, P77, DOI 10.1016/j.concog.2010.01.006; Helton WS, 2009, CONSCIOUS COGN, V18, P600, DOI 10.1016/j.concog.2009.06.002; Helton WS, 2009, J CLIN EXP NEUROPSYC, V31, P39, DOI 10.1080/13803390801978856; Helton WS, 2005, BRIT J PSYCHOL, V96, P249, DOI 10.1348/000712605X38369; Henry JD, 2005, BRIT J CLIN PSYCHOL, V44, P227, DOI 10.1348/014466505X29657; Johnson KA, 2007, NEUROPSYCHOLOGIA, V45, P630, DOI 10.1016/j.neuropsychologia.2006.03.034; Kemp S., 2011, PSYCHOL EFFECT UNPUB; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Mcvay JC, 2010, PSYCHOL BULL, V136, P188, DOI 10.1037/a0018298; Neria Y, 2008, PSYCHOL MED, V38, P467, DOI 10.1017/S0033291707001353; NOLENHOEKSEMA S, 1991, J PERS SOC PSYCHOL, V61, P115, DOI 10.1037/0022-3514.61.1.115; Peebles D, 2004, PROCEEDINGS OF THE SIXTH INTERNATIONAL CONFERENCE ON COGNITIVE MODELING, P231; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Smallwood J, 2004, CONSCIOUS COGN, V13, P657, DOI 10.1016/j.concog.2004.06.003; Smallwood JM, 2003, CONSCIOUS COGN, V12, P452, DOI 10.1016/S1053-8100(03)00018-7; Smallwood J, 2010, PSYCHOL BULL, V136, P202, DOI 10.1037/a0018673; Smallwood J, 2009, EMOTION, V9, P271, DOI 10.1037/a0014855; Smilek D, 2010, NEUROPSYCHOLOGIA, V48, P2564, DOI 10.1016/j.neuropsychologia.2010.05.002	30	25	25	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8100			CONSCIOUS COGN	Conscious. Cogn.	DEC	2011	20	4			SI		1732	1737		10.1016/j.concog.2011.02.011			6	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	851NP	WOS:000297278100070	21397520				2022-02-06	
J	Honeybul, S; Gillett, GR; Ho, KM; Lind, CRP				Honeybul, S.; Gillett, G. R.; Ho, K. M.; Lind, C. R. P.			Neurotrauma and the rule of rescue	JOURNAL OF MEDICAL ETHICS			English	Article							DECOMPRESSIVE CRANIECTOMY	The rule of rescue describes the powerful human proclivity to rescue identified endangered lives, regardless of cost or risk. Deciding whether or not to perform a decompressive craniectomy as a life-saving or 'rescue' procedure for a young person with a severe traumatic brain injury provides a good example of the ethical tensions that occur in these situations. Unfortunately, there comes a point when the primary brain injury is so severe that if the patient survives they are likely to remain severely disabled and fully dependent. The health resource implications of this outcome are significant. By using a web-based outcome prediction model this study compares the long-term outcome and designation of two groups of patients. One group had a very severe injury as adjudged by the model and the other group a less severe injury. At 18 month follow-up there were significant differences in outcome and healthcare requirements. This raises important ethical issues when considering life-saving but non-restorative surgical intervention. The discussion about realistic outcome cannot be dichotomised into simply life or death so that the outcome for the patient must enter the equation. As in other 'rescue situations', the utility of the procedure cannot be rationalised on a mere cost-benefit analysis. A compromise has to be reached to determine at what point either the likely outcome would be unacceptable to the person on whom the procedure is being performed or the social utility gained from the rule of rescue intervention fails to justify the utilitarian value and justice of equitable resource allocation.	[Honeybul, S.; Lind, C. R. P.] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6009, Australia; [Honeybul, S.; Lind, C. R. P.] Royal Perth Hosp, Perth, WA, Australia; [Gillett, G. R.] Univ Otago, Dunedin Hosp, Dunedin, New Zealand; [Gillett, G. R.] Univ Otago, Otago Bioeth Ctr, Dunedin, New Zealand; [Ho, K. M.] Univ Western Australia, Dept Intens Care Med, Perth, WA 6009, Australia; [Ho, K. M.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia; [Lind, C. R. P.] Univ Western Australia, Sch Surg, Perth, WA 6009, Australia		Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA 6009, Australia.	stephen.honeybul@health.wa.gov.au	Lind, Christopher/K-3629-2012; Ho, Kwok M./E-3546-2010	Lind, Christopher/0000-0001-9991-1725; Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; BOCHNER F, 1994, BRIT MED J, V308, P901, DOI 10.1136/bmj.308.6933.901; Cookson R, 2000, J MED ETHICS, V26, P323, DOI 10.1136/jme.26.5.323; Cookson R, 2008, J MED ETHICS, V34, DOI 10.1136/jme.2007.021790; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; DANIELS N, 1986, NEW ENGL J MED, V314, P1380, DOI 10.1056/NEJM198605223142109; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; GILLETT G, 2004, BIOETHICS CLIN; Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424; GILLETT GR, 2001, NZ MED J, V27, P188; Gillett G, 2006, QUT LAW REV, V6, P243; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; Harris J, 1985, VALUE LIFE; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hope T, 2001, J MED ETHICS, V27, P179, DOI 10.1136/jme.27.3.179; Jonsen A R, 1986, Law Med Health Care, V14, P172; KAPLAN RM, 1993, HIPPOCRATIC PREDICAM; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RELMAN AS, 1990, NEW ENGL J MED, V322, P1809, DOI 10.1056/NEJM199006213222510; Sheehan, 2007, J APPL PHILOS, V24, P352, DOI [10.1111/j.1468-5930.2007.00383.x, DOI 10.1111/J.1468-5930.2007.00383.X]	25	25	25	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-6800	1473-4257		J MED ETHICS	J. Med. Ethics	DEC	2011	37	12					707	710		10.1136/medethics-2011-100081			4	Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences	852AB	WOS:000297313100002	21947803	Bronze			2022-02-06	
J	Krol, AL; Mrazik, M; Naidu, D; Brooks, BL; Iverson, GL				Krol, Andrea L.; Mrazik, Martin; Naidu, Dhiren; Brooks, Brian L.; Iverson, Grant L.			Assessment of symptoms in a concussion management programme: Method influences outcome	BRAIN INJURY			English	Article						Head injuries; mild traumatic brain injury; concussions; self-report symptoms	TRAUMATIC BRAIN-INJURY; INTERNATIONAL-CONFERENCE; INTERVIEWER GENDER; STATEMENT; SPORT	Context: Monitoring of subjective symptoms is the foundation of all sport concussion management programmes. The purpose of this study is to examine methodological variables that impact symptom reporting during baseline testing. Objective: To investigate how the administration method of a concussion assessment tool (self-report vs interview) affects the report of symptoms. Design, setting and participants: This was a cross-sectional, semi-randomized study of 117 athletes. Main outcome measurements: Subjects completed the Post-Concussion Scale during pre-season evaluations. Results: A two-factor ANOVA revealed a significant difference in total symptom scores (p=0.02) and number of endorsed symptoms (p=0.02) across administration modes. Athletes had a greater total symptom score and reported a greater number of symptoms in the self-administration condition than in the interview condition. Furthermore, there was a significant difference in symptom reporting across interviewer gender. Athletes endorsed more symptoms when the interviewer was a woman. Conclusions: Because the method of collecting symptoms, as well as interviewer gender, can impact test results, self-report measures may be a better way of obtaining consistent results. Clinicians and researchers should be aware that both the nature and extent of symptom reporting is greater when using questionnaires than when athletes are interviewed.	[Krol, Andrea L.; Mrazik, Martin; Naidu, Dhiren; Brooks, Brian L.] Univ Alberta, Calgary, AB T2W 3E7, Canada; [Brooks, Brian L.] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada; [Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Iverson, Grant L.] Copeman Neurosci Ctr, Vancouver, BC, Canada		Krol, AL (corresponding author), Univ Alberta, 37 10401 19 St SW, Calgary, AB T2W 3E7, Canada.	alkrol@ualberta.ca		Iverson, Grant/0000-0001-7348-9570			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bowling A, 2005, J PUBLIC HEALTH-UK, V27, P281, DOI 10.1093/pubmed/fdi031; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Holtgraves T, 2004, PERS SOC PSYCHOL B, V30, P161, DOI 10.1177/0146167203259930; Hyman H. H., 1954, INTERVIEWING SOCIAL; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; JOHNSON TP, 1993, SEX ROLES, V28, P243, DOI 10.1007/BF00289884; KANE EW, 1993, PUBLIC OPIN QUART, V57, P1, DOI 10.1086/269352; LOCANDER W, 1976, J AM STAT ASSOC, V71, P269, DOI 10.2307/2285297; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Pollner M, 1998, J NERV MENT DIS, V186, P369, DOI 10.1097/00005053-199806000-00008; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Tourangeau R, 1996, PUBLIC OPIN QUART, V60, P275, DOI 10.1086/297751; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wesner ML, 2007, CLIN J SPORT MED, V17, P143, DOI 10.1097/JSM.0b013e31802b4fa6	25	25	25	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2011	25	13-14					1300	1305		10.3109/02699052.2011.624571			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	847MI	WOS:000296976600005	22077535				2022-02-06	
J	Friess, SH; Ralston, J; Eucker, SA; Helfaer, MA; Smith, C; Margulies, SS				Friess, Stuart H.; Ralston, Jill; Eucker, Stephanie A.; Helfaer, Mark A.; Smith, Colin; Margulies, Susan S.			Neurocritical Care Monitoring Correlates With Neuropathology in a Swine Model of Pediatric Traumatic Brain Injury	NEUROSURGERY			English	Article						Neurocritical care monitoring; Pediatric head injury; Swine; Traumatic brain injury model	CEREBRAL-BLOOD-FLOW; CLOSED-HEAD INJURY; TISSUE OXYGEN-TENSION; NEONATAL PIG; INTRACRANIAL-PRESSURE; CORTICAL IMPACT; AXONAL INJURY; CHILDREN; PIGLETS; AUTOREGULATION	BACKGROUND: Small-animal models have been used in traumatic brain injury (TBI) research to investigate the basic mechanisms and pathology of TBI. Unfortunately, successful TBI investigations in small-animal models have not resulted in marked improvements in clinical outcomes of TBI patients. OBJECTIVE: To develop a clinically relevant immature large-animal model of pediatric neurocritical care following TBI. METHODS: Eleven 4-week-old piglets were randomly assigned to either rapid axial head rotation without impact (n = 6) or instrumented sham (n = 5). All animals had an intracranial pressure monitor, brain tissue oxygen tension (PbtO(2)) probe, and cerebral microdialysis probe placed in the frontal lobe and data collected for 6 hours following injury. RESULTS: Injured animals had sustained elevations in intracranial pressure and lactate-pyruvate ratio (LPR), and decreased PbtO(2) compared with sham. PbtO(2) and LPR from separate frontal lobes had strong linear correlation in both sham and injured animals. Neuropathologic examination demonstrated significant axonal injury and infarct volumes in injured animals compared with sham at 6 hours postinjury. Averaged over time, PbtO(2) in both injured and sham animals had a strong inverse correlation with total injury volume. Average LPR had a strong correlation with total injury volume. CONCLUSION: LPR and PbtO(2) can be utilized as serial nonterminal secondary markers in our injury model for neuropathology, and as evaluation metrics for novel interventions and therapeutics in the acute postinjury period. This translational model bridges a vital gap in knowledge between TBI studies in small-animal models and clinical trials in the pediatric TBI population.	[Margulies, Susan S.] Univ Penn, Dept Bioengn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA; [Friess, Stuart H.; Helfaer, Mark A.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Smith, Colin] Western Gen Hosp, Dept Neuropathol, Edinburgh EH4 2XU, Midlothian, Scotland		Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, Sch Engn & Appl Sci, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu	Eucker, Stephanie/AAL-1828-2021	Eucker, Stephanie/0000-0001-9986-5773; Smith, Colin/0000-0002-4507-5132	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08-NS064051, R01-NS39679]; Endowed Chair in Critical Care Medicine; Children's Hospital of Philadelphia; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679, K08NS064051, U01NS069545] Funding Source: NIH RePORTER	This work was supported by NIH grant K08-NS064051 (to S. H. F.), the Endowed Chair in Critical Care Medicine, The Children's Hospital of Philadelphia (to M. A. H.), and NIH grant R01-NS39679 (to S. S. M.).	Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; Armstead WM, 2010, CRIT CARE MED, V38, P1868, DOI 10.1097/CCM.0b013e3181e8ac1a; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bhatia A, 2007, INTENS CARE MED, V33, P1263, DOI 10.1007/s00134-007-0678-z; BLOMQUIST HKS, 1986, J NEUROL NEUROSUR PS, V49, P536, DOI 10.1136/jnnp.49.5.536; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Charalambides C, 2010, CHILD NERV SYST, V26, P215, DOI 10.1007/s00381-009-1031-3; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Duhaime AC, 2007, PEDIATR CRIT CARE ME, V8, P71, DOI 10.1097/01.PCC.0000253552.60687.AC; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Figaji AA, 2009, J NEUROSURG-PEDIATR, V4, P420, DOI 10.3171/2009.6.PEDS096; Figaji AA, 2009, CHILD NERV SYST, V25, P1335, DOI 10.1007/s00381-009-0821-y; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Hagberg H, 2002, DEV NEUROSCI-BASEL, V24, P364, DOI 10.1159/000069040; Hagberg H, 2002, MENT RETARD DEV D R, V8, P30, DOI 10.1002/mrdd.10007; Hamilton BE, 2007, PEDIATRICS, V119, P345, DOI 10.1542/peds.2006-3226; Hanneman SK, 2004, COMPARATIVE MED, V54, P36; HANNON JP, 1990, LAB ANIM SCI, V40, P293; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; LAM M, 1999, AM STAT ASS P BIOM S, P213; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; Timaru-Kast R, 2008, J NEUROTRAUM, V25, P1107, DOI 10.1089/neu.2008.0517; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Wartenberg KE, 2007, CRIT CARE CLIN, V23, P507, DOI 10.1016/j.ccc.2007.06.002; WOOTTON R, 1982, BIOL NEONATE, V41, P209	35	25	25	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	NOV	2011	69	5					1139	1147		10.1227/NEU.0b013e3182284aa1			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	832UV	WOS:000295835300042	21670716	Green Published, Green Accepted, Green Submitted			2022-02-06	
J	Goldfine, AM; Schiff, ND				Goldfine, Andrew M.; Schiff, Nicholas D.			Consciousness: Its Neurobiology and the Major Classes of Impairment	NEUROLOGIC CLINICS			English	Article						Consciousness; Vegetative state; Minimally conscious state; Traumatic brain injury; Arousal	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; VEGETATIVE STATE; GLUCOSE-UTILIZATION; CEREBRAL METABOLISM; RETICULAR-FORMATION; AKINETIC MUTISM; CARDIAC-ARREST; LATE RECOVERY; BLOOD-FLOW	Human consciousness requires brainstem, basal forebrain, and diencephalic areas to support generalized arousal, and functioning thalamocortical networks to respond to environmental and internal stimuli. Disconnection of these interconnected systems, typically from cardiac arrest and traumatic brain injury, can result in disorders of consciousness. Brain injuries can also result in loss of motor output out of proportion to consciousness, resulting in misdiagnoses. The authors review pathology and imaging studies and derive mechanistic models for each of these conditions. Such models may guide the development of target-based treatment algorithms to enhance recovery of consciousness in many of these patients.	[Goldfine, Andrew M.] Weill Cornell Med Coll, Burke Med Res Inst, White Plains, NY 10605 USA; [Goldfine, Andrew M.; Schiff, Nicholas D.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA		Goldfine, AM (corresponding author), Weill Cornell Med Coll, Burke Med Res Inst, 785 Mamaroneck Ave, White Plains, NY 10605 USA.	andygoldfine@gmail.com		Goldfine, Andrew/0000-0003-1962-5564	NIH-NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [51912]; James S McDonnell Foundation; Clinical & Translational Science Center at Weill Cornell Medical College [KL2RR024997]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD051912] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024997] Funding Source: NIH RePORTER	This work was supported by NIH-NICHD 51912, the James S McDonnell Foundation. AMG is supported by grant KL2RR024997 of the Clinical & Translational Science Center at Weill Cornell Medical College.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Bardin JC, 2011, BRAIN, V134, P769, DOI 10.1093/brain/awr005; Bekinschtein T, 2004, J NEUROL NEUROSUR PS, V75, P788, DOI 10.1136/jnnp.2003.034876; Bekinschtein T, 2009, PROG BRAIN RES, V177, P171, DOI 10.1016/S0079-6123(09)17712-9; Bekinschtein TA, 2009, P NATL ACAD SCI USA, V106, P1672, DOI 10.1073/pnas.0809667106; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; BLACKLOCK JB, 1987, J NEUROSURG, V67, P71, DOI 10.3171/jns.1987.67.1.0071; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Brentano F., 1995, PSYCHOL EMPIRICAL ST; Broadbent D.E., 1958, PERCEPTION COMMUNICA, DOI [10.1037/10037-000, DOI 10.1037/10037-000]; Cairns H, 1941, BRAIN, V64, P273, DOI 10.1093/brain/64.4.273; CASTAIGNE P, 1981, ANN NEUROL, V10, P127, DOI 10.1002/ana.410100204; Chollet F, 2011, LANCET NEUROL, V10, P123, DOI 10.1016/S1474-4422(10)70314-8; Clauss P, 2001, SAMJ S AFR MED J, V91, P788; Cruse D, 2010, CURR OPIN NEUROL, V23, P656, DOI 10.1097/WCO.0b013e32833fd4e7; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Eidelberg D, 1997, BRAIN, V120, P1315, DOI 10.1093/brain/120.8.1315; Elliott L, 2005, J NEUROL NEUROSUR PS, V76, P298, DOI 10.1136/jnnp.2004.047357; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Fins JJ, 2003, NAT REV NEUROSCI, V4, P323, DOI 10.1038/nrn1079; Fisher C M, 1983, Clin Neurosurg, V31, P9; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; Garey J, 2003, P NATL ACAD SCI USA, V100, P11019, DOI 10.1073/pnas.1633773100; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Goldfine A.M., 2011, CLIN NEUROPHYSIOL; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; Hart T, 2006, ARCH PHYS MED REHAB, V87, P647, DOI 10.1016/j.apmr.2006.01.016; Holzer M, 2002, NEW ENGL J MED, V346, P549; INGVAR DH, 1970, ARCH NEUROL-CHICAGO, V23, P1; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; JENNETT B, 2002, VEGETATIVE STATE MED; Jones EG, 2002, PHILOS T R SOC B, V357, P1659, DOI 10.1098/rstb.2002.1168; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KATZ DI, 1987, ARCH NEUROL-CHICAGO, V44, P1127, DOI 10.1001/archneur.1987.00520230017007; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Kobylarz EJ, 2005, NEUROPSYCHOL REHABIL, V15, P323, DOI 10.1080/09602010443000605; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; Llinas R, 1998, PHILOS T ROY SOC B, V353, P1841, DOI 10.1098/rstb.1998.0336; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; MAQUET P, 1990, BRAIN RES, V513, P136, DOI 10.1016/0006-8993(90)91099-3; Maquet P, 1997, J NEUROSCI, V17, P2807; Maya-Vetencourt JF, 2008, SCIENCE, V320, P385, DOI 10.1126/science.1150516; McCarthy Michelle M, 2008, J Neurosci, V28, P13488, DOI 10.1523/JNEUROSCI.3536-08.2008; Mega MS, 1997, NEUROPSY NEUROPSY BE, V10, P254; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Mignot E, 2002, NAT NEUROSCI, V5, P1071, DOI 10.1038/nn944; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Panksepp J., 2004, AFFECTIVE NEUROSCIEN; Parvizi J, 2001, COGNITION, V79, P135, DOI 10.1016/S0010-0277(00)00127-X; Paus T, 1997, J COGNITIVE NEUROSCI, V9, P392, DOI 10.1162/jocn.1997.9.3.392; Paus T, 1998, NEUROREPORT, V9, pR37, DOI 10.1097/00001756-199806220-00001; Pfaff D., 2005, BRAIN AROUSAL INFORM; Posner JB, 2007, PLUM POSNERS DIAGNOS; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Schiff ND, 2007, ANN NEUROL, V62, P5, DOI 10.1002/ana.21158; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; Schiff ND, 2009, ANN NY ACAD SCI, V1157, P101, DOI 10.1111/j.1749-6632.2008.04123.x; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Searle J.R., 1983, INTENTIONALITY ESSAY; SEGARRA JM, 1970, ARCH NEUROL-CHICAGO, V22, P408, DOI 10.1001/archneur.1970.00480230026003; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smart CM, 2008, NAT CLIN PRACT NEURO, V4, P448, DOI 10.1038/ncpneuro0823; STERIADE M, 1982, J NEUROPHYSIOL, V48, P352, DOI 10.1152/jn.1982.48.2.352; Steriade M, 2005, BRAIN CONTROL WAKEFU; Stuss DT, 2007, PHILOS T R SOC B, V362, P901, DOI 10.1098/rstb.2007.2096; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; Vanhaudenhuyse A, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.121624; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; [No title captured]	92	25	26	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0733-8619	1557-9875		NEUROL CLIN	Neurol. Clin.	NOV	2011	29	4					723	+		10.1016/j.ncl.2011.08.001			16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	853BN	WOS:000297401300002	22032656	Green Accepted			2022-02-06	
J	Levy, AS; Orlando, A; Hawkes, AP; Salottolo, K; Mains, CW; Bar-Or, D				Levy, A. Stewart; Orlando, Alessandro; Hawkes, Allison P.; Salottolo, Kristin; Mains, Charles W.; Bar-Or, David			Should the Management of Isolated Traumatic Subarachnoid Hemorrhage Differ From Concussion in the Setting of Mild Traumatic Brain Injury?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Subarachnoid hemorrhage; Intensive care unit; Concussion; Mild traumatic brain injury	MINOR HEAD-INJURY; NEW-ORLEANS CRITERIA; CARE-UNIT ADMISSION; INTENSIVE-CARE; MORTALITY; PATIENT; RULE	Background: In the setting of mild traumatic brain injury (TBI), the clinical significance of a traumatic subarachnoid hemorrhage (tSAH) has not been sufficiently studied. We examined the impact of an isolated tSAH on patient outcomes in the mild TBI population. Methods: We retrospectively identified all mild TBI patients (Glasgow Coma Scale score >= 13) who presented to a Level I trauma center over a 10-year period. We compared isolated tSAH patients with isolated concussion patients. chi(2) and logistic regression analyses were used to compare intensive care unit (ICU) admission, ICU length of stay (LOS), hospital LOS, progression of tSAH, in-hospital mortality, and disposition to rehabilitation. Results: There were 1,144 concussion and 117 tSAH patients included in our study. After adjustment, tSAH patients had increased odds of admission to the ICU (odds ratio, [OR] = 8.87; p < 0.0001), yet their ICU LOS was significantly shorter (OR = 0.29; p = 0.01). The overall hospital LOS and mortality rate were not significantly different between the TBI groups. When stratified by age, only the 40-year to 69-year-old tSAH patients had significantly increased adjusted odds of disposition to rehabilitation compared with concussion patients, independent of ICU admission (OR = 7.96; p = 0.004). None of the patients required any neurosurgical interventions. Conclusions: We encourage healthcare facilities to consider revising or creating ICU admission criteria for the mild TBI population to help optimize the utilization of their ICUs. We believe clinicians should place more emphasis on variables such as age, comorbidities, and neurologic condition rather than the presence of a small volume of blood in the subarachnoid space when admitting mild isolated TBI patients to the ICU.	[Orlando, Alessandro; Salottolo, Kristin; Bar-Or, David] Swedish Med Ctr, Trauma Res Dept, Englewood, CO 80113 USA; [Orlando, Alessandro; Hawkes, Allison P.; Salottolo, Kristin; Mains, Charles W.; Bar-Or, David] St Anthony Cent Hosp, Trauma Res Dept, Denver, CO USA; [Mains, Charles W.] St Anthony Cent Hosp, Trauma Serv Dept, Denver, CO USA; [Mains, Charles W.; Bar-Or, David] Rocky Vista Univ, Aurora, CO USA		Bar-Or, D (corresponding author), Swedish Med Ctr, Trauma Res Dept, 501 E Hampden Ave,Room 4-454, Englewood, CO 80113 USA.	dbaror@dmibio.com	Bar-Or, David/AAE-9328-2020		St. Anthony Central Hospital, Denver, Colorado	Supported by St. Anthony Central Hospital, Denver, Colorado.	Boesiger BM, 2005, J EMERG MED, V29, P23, DOI 10.1016/j.jemermed.2005.02.002; BONE RC, 1993, CHEST, V104, P1806, DOI 10.1378/chest.104.6.1806; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; Clement CM, 2006, ANN EMERG MED, V48, P245, DOI 10.1016/j.annemergmed.2006.04.008; Egol A, 1999, CRIT CARE MED, V27, P633; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Esposito TJ, 2005, ANN SURG, V242, P364, DOI 10.1097/01.sla.0000179624.50455.db; Faul M, 2010, TRAUMATIC BRAIN INJU; Holmes JF, 2006, AM J EMERG MED, V24, P167, DOI 10.1016/j.ajem.2005.08.009; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Klein Y, 2010, J TRAUMA, V69, P544, DOI 10.1097/TA.0b013e3181c99936; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; NISHIJIMA DK, 2010, J TRAUMA        0827; OYE RK, 1991, CHEST, V99, P685, DOI 10.1378/chest.99.3.685; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511	21	25	25	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1199	1204		10.1097/TA.0b013e31822067fc			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	849IG	WOS:000297118600025	21841515				2022-02-06	
J	Sut, N; Simsek, O				Sut, Necdet; Simsek, Osman			Comparison of regression tree data mining methods for prediction of mortality in head injury	EXPERT SYSTEMS WITH APPLICATIONS			English	Article						Data mining; Regression tree; Classification; Head injury; Mortality	TRAUMATIC BRAIN-INJURY; CLASSIFICATION; VARIABLES	With this research, we sought to examine the performance of six different regression tree data mining methods to predict mortality in head injury. Using a data set consisting of 1603 head injury cases, we assessed the performance of: the Classification and Regression Trees (CART) method; the Chi-squared Automatic Interaction Detector (CHAID) method; the Exhaustive CHAID (E-CHAID) method; the Quick, Unbiased, Efficient Statistical Tree (QUEST) method; the Random Forest Regression and Classification (RFRC) method; and the Boosted Tree Classifiers and Regression (BTCR) method, in each case based on sensitivity, specificity, positive/negative predictive, and accuracy rates. Next, we compared their areas under the (Receiver Operating Characteristic) ROC curves. Finally, we examined whether they could be grouped in meaningful clusters with hierarchical cluster analysis. Areas under the ROC curves of regression tree data mining methods ranged from 0.801 to 0.954 (p < 0.001 for all). In predicting mortality in head injury under the ROC curve, the BTCR method achieved both the highest area (0.954) and accuracy rate (93.0%), while the CART method achieved both the lowest area (0.801) and accuracy rate (91.1%). All of the regression tree data mining methods were clustered in the same grouping, but the BTCR method was at the origin of the cluster while the CART and QUEST methods produced results that were least like the others. The BTCR, demonstrating a 93.0% accuracy rate and showing statistically significantly differences from the others, may be a helpful tool in medical decision-making for predicting mortality in head injury. (C) 2011 Elsevier Ltd. All rights reserved.	[Sut, Necdet] Trakya Univ, Fac Med, Dept Biostat & Med Informat, TR-22030 Edirne, Turkey; [Simsek, Osman] Trakya Univ, Dept Neurosurg, Fac Med, TR-22030 Edirne, Turkey		Sut, N (corresponding author), Trakya Univ, Fac Med, Dept Biostat & Med Informat, TR-22030 Edirne, Turkey.	nsut@trakya.edu.tr; gosimsek@trakya.edu.tr	Simsek, Osman/D-4906-2012	Simsek, Osman/0000-0002-8716-5187			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Bigs D., 1991, J APPL STAT, V18, P49, DOI 10.1080/02664769100000005; Bilgin CC, 2010, DATA MIN KNOWL DISC, V20, P416, DOI 10.1007/s10618-009-0153-2; Breiman L., 1984, CLASSIFICATION REGRE; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; DAWSONSAUNDERS B, 1993, BASIC CLIN BIOSTATIS; Ho SH, 2004, EXPERT SYST APPL, V27, P97, DOI 10.1016/j.eswa.2003.12.005; Kass GV., 1980, J R STAT SOC C-APPL, V29, P119, DOI DOI 10.2307/2986296; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Li H, 2010, EXPERT SYST APPL, V37, P5895, DOI 10.1016/j.eswa.2010.02.016; Li XB, 2001, INFORMS J COMPUT, V13, P332, DOI 10.1287/ijoc.13.4.332.9732; Loh WY, 1997, STAT SINICA, V7, P815; Michael J.A., 1997, DATA MINING TECHNIQU; Motulsky H., 1995, INTUITIVE BIOSTATIST; Rovlias A, 2004, J NEUROTRAUM, V21, P886, DOI 10.1089/0897715041526249; Schaan M, 2002, J TRAUMA, V52, P667, DOI 10.1097/00005373-200204000-00009; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Spurgeon SEF, 2006, J UROLOGY, V175, P918, DOI 10.1016/S0022-5347(05)00353-8; Ture M, 2005, EXPERT SYST APPL, V29, P583, DOI 10.1016/j.eswa.2005.04.014; 2010, STATSOFT ELECT STAT	20	25	25	0	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0957-4174	1873-6793		EXPERT SYST APPL	Expert Syst. Appl.	NOV-DEC	2011	38	12					15534	15539		10.1016/j.eswa.2011.06.006			6	Computer Science, Artificial Intelligence; Engineering, Electrical & Electronic; Operations Research & Management Science	Science Citation Index Expanded (SCI-EXPANDED)	Computer Science; Engineering; Operations Research & Management Science	824HQ	WOS:000295193400123					2022-02-06	
J	Tsaousides, T; Matsuzawa, Y; Lebowitz, M				Tsaousides, Theodore; Matsuzawa, Yuka; Lebowitz, Matthew			Familiarity and prevalence of Facebook use for social networking among individuals with traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; community integration; head injury; support system; technology	ONLINE SUPPORT; INTERNET USE; SITES; COMMUNICATION; IMPAIRMENT; RECOVERY; MAIL	Objective: To examine use of Facebook among individuals with traumatic brain injury (TBI) and to identify barriers preventing Facebook use. Method: An online survey was developed assessing frequency and barriers to use of Facebook. The survey was distributed electronically to individuals with TBI through four state brain injury associations. Ninety-six individuals with TBI completed the survey (60%% female, age range: 23-70). Results: The relative majority of respondents (60%%) reported using Facebook on a regular basis. Among those who reported not using Facebook, the most commonly reported barriers were security concerns and cognitive deficits. Approximately half of non-users indicated interest in learning to use the site, with 70%% reporting that they would use it more if they were more knowledgeable about it. Both users and non-users indicated that they would be interested in receiving training to learn how to use Facebook better. Conclusions: Social networking sites are increasingly important in creating and maintaining social networks. A significant number of survey respondents expressed interest in further training on Facebook use. Increased use of social networking may have important implications for social integration among individuals with TBI.	[Tsaousides, Theodore; Matsuzawa, Yuka; Lebowitz, Matthew] Mt Sinai Sch Med, New York, NY 10029 USA		Tsaousides, T (corresponding author), Mt Sinai Sch Med, 1 Gustave L Levy Pl,Box 1240, New York, NY 10029 USA.	theodore.tsaousides@mssm.edu			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1R49CE001171-01]; National Institute on Disability and Rehabilitation Services, Office of Special Education and Rehabilitation Services, United States Department of EducationUS Department of Education [H133P050004]; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001171] Funding Source: NIH RePORTER	This study was supported by grant 1R49CE001171-01 from the Centers for Disease Control and Prevention and H133P050004 from the National Institute on Disability and Rehabilitation Services, Office of Special Education and Rehabilitation Services, United States Department of Education. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.	Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Boyd DM, 2007, J COMPUT-MEDIAT COMM, V13, P210, DOI 10.1111/j.1083-6101.2007.00393.x; Carey JC, 2008, CYBERPSYCHOL BEHAV, V11, P188, DOI 10.1089/cpb.2007.0025; Coulson NS, 2007, PATIENT EDUC COUNS, V68, P173, DOI 10.1016/j.pec.2007.06.002; Ehlhardt LA, 2005, BRAIN INJURY, V19, P569, DOI 10.1080/002699050400013550; Ellison NB, 2007, J COMPUT-MEDIAT COMM, V12, P1143, DOI 10.1111/j.1083-6101.2007.00367.x; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; Fogel J, 2009, COMPUT HUM BEHAV, V25, P153, DOI 10.1016/j.chb.2008.08.006; Fraas M, 2008, J PSYCHOLINGUIST RES, V37, P115, DOI 10.1007/s10936-007-9062-y; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Hill WG, 2004, CIN-COMPUT INFORM NU, V22, P282, DOI 10.1097/00024665-200409000-00008; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; Idriss SZ, 2009, ARCH DERMATOL, V145, P46, DOI 10.1001/archdermatol.2008.529; Kilov AM, 2010, BRAIN INJURY, V24, P1135, DOI 10.3109/02699052.2010.490511; Lewis K, 2008, SOC NETWORKS, V30, P330, DOI 10.1016/j.socnet.2008.07.002; Miller SM, 2008, REHABIL COUNS BULL, V51, P148, DOI 10.1177/0034355207311315; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Polomano Rosemary C, 2007, J Pain Palliat Care Pharmacother, V21, P49, DOI 10.1300/J354v21n03_09; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Sheldon, 2008, J MEDIA PSYCHOL, V20, P67, DOI DOI 10.1027/1864-1105.20.2.67; Sohlberg MM, 2003, BRAIN INJURY, V17, P609, DOI 10.1080/0269905031000070189; Steinfield C, 2008, J APPL DEV PSYCHOL, V29, P434, DOI 10.1016/j.appdev.2008.07.002; Subrahmanyam K, 2008, J APPL DEV PSYCHOL, V29, P420, DOI 10.1016/j.appdev.2008.07.003; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Todis B, 2005, BRAIN INJURY, V19, P389, DOI 10.1080/02699050400003957; Vaccaro M, 2007, DISABIL REHABIL-ASSI, V2, P85, DOI 10.1080/17483100601167586; Verburg G, 2003, NEUROREHABILITATION, V18, P113; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Weiss Jacob B, 2007, AMIA Annu Symp Proc, P1151	32	25	25	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2011	25	12					1155	1162		10.3109/02699052.2011.613086			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	829WF	WOS:000295615200002	21961574				2022-02-06	
J	Bie, XD; Chen, YQ; Zheng, XS; Dai, HB				Bie, Xiaodong; Chen, Yueqing; Zheng, Xuesheng; Dai, Haibin			The role of crocetin in protection following cerebral contusion and in the enhancement of angiogenesis in rats	FITOTERAPIA			English	Article						Crocetin; Cerebral contusion; Cell apoptosis; Angiogenesis	TRAUMATIC BRAIN-INJURY; GENE-EXPRESSION; BCL-2; EPIDEMIOLOGY	The protective role of crocetin following cerebral contusion and its effects on the enhancement of angiogenesis in rats was investigated. A total of 60 Sprague-Dawley rats were divided into three groups (n = 20 each): crocetin therapy group (cerebral contusion treated with crocetin), cerebral trauma control group (without treatment), sham operation control group. The effect of crocetin was examined by modified Neurological Severity Scores (mNSS), electron microscopy, terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) procedure, western blotting analysis of Bcl-2 protein expression, microvessel count (MVC), endothelial cell culture and immunocyto-chemistry. The mNSS results indicated that neurological function of therapy group was significantly recovered seven days and fifteen days after the trauma. The TUNEL staining and electron microscopy revealed that crocetin treatment led to an inhibition of neuronal apoptosis 72 h following treatment; this finding was confirmed by western blot analysis of B cell lymphoma/leukemia-2 (Bcl-2) protein expression. Expression levels of vascular endothelial growth factor receptor-2 (VEGFR-2) and serum response factor (SRF) were higher in the crocetin therapy group in comparison to the two other experimental groups. Our results demonstrate that the protective effects of crocetin upon brain injury may be related to its ability to inhibit apoptosis at early stages of the injury and its ability to promote angiogenesis at the sub-acute stage. (C) 2011 Published by Elsevier B.V.	[Chen, Yueqing] Zhejiang Acad Med Sci, Hangzhou, Zhejiang, Peoples R China; [Bie, Xiaodong] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Tradit Chinese Med, Hangzhou 310003, Zhejiang, Peoples R China; [Zheng, Xuesheng] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China; [Dai, Haibin] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Pharm, Hangzhou 310003, Zhejiang, Peoples R China		Chen, YQ (corresponding author), Zhejiang Acad Med Sci, Hangzhou, Zhejiang, Peoples R China.	bie@hzcnc.com		Dai, Haibin/0000-0002-5768-2714	Zhejiang Science and Technology Projects [2008c33061]; Natural Science Foundation of ZhejiangNatural Science Foundation of Zhejiang Province [Y207256]	This work was supported by the Zhejiang Science and Technology Projects (2008c33061 to XD Bie) and by the Natural Science Foundation of Zhejiang (Y207256 to XD Bie).	Ahmad AS, 2005, PHARMACOL BIOCHEM BE, V81, P805, DOI 10.1016/j.pbb.2005.06.007; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chai JY, 2004, FASEB J, V18, P1264, DOI 10.1096/fj.03-1232fje; CONSTANTINO RSS, 2007, EXP CELL RES, V313, P1561; Dong GX, 2001, BRAIN RES, V903, P45, DOI 10.1016/S0006-8993(01)02379-4; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; [皋聪 GAO Cong], 2009, [中国临床药理学与治疗学, Chinese Journal of Clinical Pharmacology and Therapeutics], V14, P421; Giaccio M, 2004, CRIT REV FOOD SCI, V44, P155, DOI 10.1080/10408690490441433; JIANG JR, 2004, MODERN CRANIOCEREBRA, P1; Jin XY, 2008, J ETHNOPHARMACOL, V117, P473, DOI 10.1016/j.jep.2008.02.033; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LIU HJ, 2005, CHIN J CLIN REHABIL, V9, P213; MAO WF, 2005, ANAT CLIN, V10, P30; Ochiai T, 2007, BBA-GEN SUBJECTS, V1770, P578, DOI 10.1016/j.bbagen.2006.11.012; Papandreou MA, 2006, J AGR FOOD CHEM, V54, P8762, DOI 10.1021/jf061932a; Schofield PW, 1997, NEUROLOGY, V49, P30, DOI 10.1212/WNL.49.1.30; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Strauss KI, 2004, NEUROTOX RES, V6, P333, DOI 10.1007/BF03033444; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Yang Shu-Yuan, 2004, Chin J Traumatol, V7, P159; [余卫平 YU Weiping], 2006, [中国病理生理杂志, Chinese Journal of Pathophysiology], V22, P54; ZHANG R, 2009, CHIN J NAT MED, V15, P200; ZHAO MG, 2005, CHIN J CLIN REHABIL, V9, P211; Zheng SG, 2007, J CARDIOVASC PHARM, V50, P519, DOI 10.1097/FJC.0b013e31813c114e; 别晓东, 2003, [中国中西医结合杂志, Chinese Journal of Integrated Traditional and Western Medicine], V23, P296; 刘东博, 2007, [中草药, Chinese Traditional and Herbal Drugs], V38, P1915; 潘德生, 2006, [中华神经外科杂志, Chinese Journal of Neurosurgery], V22, P186	32	25	27	1	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0367-326X	1873-6971		FITOTERAPIA	Fitoterapia	OCT	2011	82	7					997	1002		10.1016/j.fitote.2011.06.001			6	Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	827QK	WOS:000295442800011	21741458				2022-02-06	
J	Jackson, JC; Archer, KR; Bauer, R; Abraham, CM; Song, YN; Greevey, R; Guillamondegui, O; Ely, EW; Obremskey, W				Jackson, James C.; Archer, Kristin R.; Bauer, Rebecca; Abraham, Christine M.; Song, Yanna; Greevey, Robert; Guillamondegui, Oscar; Ely, E. Wesley; Obremskey, William			A Prospective Investigation of Long-Term Cognitive Impairment and Psychological Distress in Moderately Versus Severely Injured Trauma Intensive Care Unit Survivors Without Intracranial Hemorrhage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Trauma; Delirium; Cognitive impairment; Neuropsychological assessment; Pain; Quality of life; PTSD; Depression; Critical care	POSTTRAUMATIC-STRESS-DISORDER; MINI-MENTAL-STATE; INFORMANT QUESTIONNAIRE; ELDERLY IQCODE; DELIRIUM; DECLINE; HEALTH; MILD; VALIDATION; OUTCOMES	Background: The primary objective was to prospectively determine the 12-month prevalence of cognitive impairment and psychologic difficulties in moderately versus severely injured adult trauma intensive care unit (TICU) survivors without intracranial hemorrhage. Methods: We conducted a prospective cohort study in which patients were followed for 1 year after hospital discharge. A total of 173 patients from the Vanderbilt TICU who had an Injury Severity Score (ISS) of > 15 (indicative of moderately severe trauma) were enrolled between July 2006 and June 2007. Patients were screened for delirium on a daily basis in the TICU by study personnel via the confusion assessment method of the ICU, and preexisting cognitive impairment was assessed through a surrogate-based evaluation using the short form of the Informant Questionnaire for Cognitive Decline in the Elderly. Of these patients, 108 were evaluated 1 year after hospital discharge with a comprehensive battery of neuropsychological tests and depression and posttraumatic stress disorder (PTSD) instruments. Cognitive impairment was defined as having two neuropsychological test scores 1.5 SD below the mean or one neuropsychological test score 2 SD below the mean. Results: Fifty-nine patients (55%) demonstrated cognitive impairment at 12-month follow-up, with three of these patients (5.5%) having preexisting impairment. Clinically significant symptoms of depression and PTSD occurred in 40% and 26% of patients, respectively. No significant differences in cognitive impairment (59% vs. 50%), depressive symptoms (35% vs. 44%), and symptoms of PTSD (22% vs. 28%) were identified between moderately (ISS 15-25) and severely (ISS > 25) injured TICU survivors, respectively (all p > 0.05). In addition, multivariate logistic regression analysis found that moderately injured trauma patients had a similar rate of cognitive impairment when compared with those with severe injury at 12-month follow-up (p = 0.25). Conclusion: Long-term cognitive impairment is highly prevalent in TICU survivors without intracranial hemorrhage as are psychologic difficulties. Injury severity, concussion status, and delirium duration were not risk factors for the development of neuropsychological deficits in this cohort. Individuals with moderately severe injuries seem to be as likely as their more severely injured counterparts to experience marked cognitive impairment and psychologic difficulties; thus, screening efforts should focus on this potentially overlooked patient group.	[Jackson, James C.; Ely, E. Wesley] Vanderbilt Univ, Med Ctr, Div Allergy Pulm Crit Care Med, Ctr Hlth Serv Res, Nashville, TN 37232 USA; [Jackson, James C.] Vanderbilt Univ, Med Ctr, Dept Psychiat, Nashville, TN 37232 USA; [Archer, Kristin R.; Bauer, Rebecca; Abraham, Christine M.; Greevey, Robert; Obremskey, William] Vanderbilt Univ, Med Ctr, Div Trauma & Surg Crit Care, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Orthoped & Rehabil, Nashville, TN 37232 USA; [Song, Yanna; Greevey, Robert] Vanderbilt Univ, Med Ctr, Dept Biostat, Nashville, TN 37232 USA; [Jackson, James C.; Greevey, Robert; Ely, E. Wesley] Middle TN VA Med Ctr, Geriatr Educ & Clin Ctr GRECC, Nashville, TN USA		Jackson, JC (corresponding author), Vanderbilt Univ, Med Ctr, Div Allergy Pulm Crit Care Med, Ctr Hlth Serv Res, 6th Floor,Med Ctr E 6109, Nashville, TN 37232 USA.	james.c.jackson@vanderbilt.edu	Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172	Orthopedic Research and Education Foundation	Orthopedic Research and Education Foundation support and Internal Orthopedic Trauma funding was provided for the completion of this study.	Beck AT, 1996, BDI 2 DEPRESSION INV; CRICHLOW RJ, 2010, J BONE JOINT SURG, V88, P1927; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; DAVIDSON JRT, 1991, PSYCHOL MED, V21, P713, DOI 10.1017/S0033291700022352; DAVIDSON JRT, 1996, DAVIDSON TRAUMA SCAL, P1; Davydow DS, 2008, GEN HOSP PSYCHIAT, V30, P421, DOI 10.1016/j.genhosppsych.2008.05.006; Dossett LA, 2009, INJURY, V40, P993, DOI 10.1016/j.injury.2009.03.004; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Ely EW, 2001, J AM GERIATR SOC, V49, pS2; FILDES JJ, 2005, NATL TRAUMA DATA BAN; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GIRARD TD, 2009, AM J RESP CRIT CARE, V179, pA5477; GIRARD TD, 2006, P AM THORAC SOC, V3, pA739; Gordon SM, 2004, INTENS CARE MED, V30, P1997, DOI 10.1007/s00134-004-2418-y; Heaton R. K., 2004, REVISED COMPREHENSIV; Heskestad B, 2008, J TRAUMA, V65, P1309, DOI 10.1097/TA.0b013e31815e40cd; Hilsabeck RC, 2002, HEPATOLOGY, V35, P440, DOI 10.1053/jhep.2002.31257; Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Jackson JC, 2007, CRIT CARE, V11, DOI 10.1186/cc5707; Jackson JC, 2007, J TRAUMA, V62, P80, DOI 10.1097/TA.0b013e31802ce9bd; Jackson JC, 2004, NEUROPSYCHOL REV, V14, P87, DOI 10.1023/B:NERV.0000028080.39602.17; Jackson JC, 2004, INTENS CARE MED, V30, P2009, DOI 10.1007/s00134-004-2422-2; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; JORM AF, 1994, PSYCHOL MED, V24, P145, DOI 10.1017/S003329170002691X; Jorm AF, 2004, INT PSYCHOGERIATR, V16, P275, DOI 10.1017/S1041610204000390; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Mathiesen HK, 2006, ARCH NEUROL-CHICAGO, V63, P533, DOI 10.1001/archneur.63.4.533; MILLER L, 2010, BMC HEALTH SERV RES, V4, P7; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Quale AJ, 2009, INJURY, V40, P498, DOI 10.1016/j.injury.2008.11.006; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Soberg HL, 2010, ARCH PHYS MED REHAB, V91, P481, DOI 10.1016/j.apmr.2009.11.007; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Sukantarat KT, 2005, ANAESTHESIA, V60, P847, DOI 10.1111/j.1365-2044.2005.04148.x; Vardy J, 2006, SUPPORT CARE CANCER, V14, P1111, DOI 10.1007/s00520-006-0037-6; Wechsler D, 1997, WAIS 3 TECHNICAL MAN; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wong DT, 1996, CRIT CARE MED, V24, P1642, DOI 10.1097/00003246-199610000-00007	45	25	26	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2011	71	4					860	866		10.1097/TA.0b013e3182151961			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	833ZT	WOS:000295925700021	21537211				2022-02-06	
J	Hoane, MR; Swan, AA; Heck, SE				Hoane, Michael R.; Swan, Alicia A.; Heck, Sarah E.			The effects of a high-fat sucrose diet on functional outcome following cortical contusion injury in the rat	BEHAVIOURAL BRAIN RESEARCH			English	Article						American diet; Brain injury; Recovery of function; Nutrition; Behavior; TBI	TRAUMATIC BRAIN-INJURY; NICOTINAMIDE TREATMENT; NEUROTROPHIC FACTOR; SATURATED-FAT; COGNITIVE FUNCTION; RECOVERY; PLASTICITY; SENSORIMOTOR; MEMORY	Traumatic brain injury (TBI) is a major public health issue affecting 1.7 million Americans each year, of which approximately 50,000 are fatal. High-fat sucrose (HFS) diets are another public health issue which can lead to obesity, hypertension, and many other debilitating disorders. These two disorders combined can lead to more complicated issues. It has recently been shown that HFS diets can reduce levels of brain-derived neurotrophic factor (BDNF) leading to reductions in neuronal and behavioral plasticity. This reduction in BDNF is suspected of increasing the susceptibility of the brain to injury. To test the effects of a HFS diet on recovery of function post-TBI, male Sprague-Dawley rats were used in this study. Eight weeks prior to TBI, rats were placed on a special HFS diet (n = 14) or a standard rodent diet (n =14). Following this eight-week period, rats were prepared with bilateral frontal cortical contusion injuries (CCI) or sham procedures. Beginning two days post-TBI, animals were tested on a battery of behavioral tests to assess somatosensory dysfunction and spatial memory in the Morris water maze, with a reference memory and a working memory task. Following testing, animals were sacrificed and their brains processed for lesion analysis. The HFS diet worsened performance on the bilateral tactile adhesive removal test in sham animals. Injured animals on the Standard diet had a greater improvement in somatosensory performance in the adhesive removal test and had better performance on the working memory task compared to animals on the HFS diet. The HFS diet also resulted in significantly greater loss of cortical tissue post-CC than in the Standard diet group. This study may aid in determining how nutritional characteristics or habits interact with damage to the brain. (C) 2011 Elsevier B.V. All rights reserved.	[Hoane, Michael R.; Swan, Alicia A.; Heck, Sarah E.] So Illinois Univ Carbondale, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Dept Psychol, Carbondale, IL 62901 USA		Hoane, MR (corresponding author), So Illinois Univ Carbondale, Restorat Neurosci Lab, Ctr Integrat Res Cognit & Neural Sci, Dept Psychol, Carbondale, IL 62901 USA.	mhoane@siu.edu	Swan, Alicia A/O-3536-2018	Swan, Alicia A/0000-0003-2412-0499; Hoane, Michael/0000-0001-7779-2657	SIU-C; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS045647]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER	Research support provided by an SIU-C REACH award and the NIH, NS045647. The authors would like to thank Nick Kaufman for his assistance on the project.	Castren E, 1998, PROG BRAIN RES, V117, P57; CDC, 2010, INJ PREV CONTR TRAUM; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI [10.1089/neu.2008.0744, 10.1089/neu.2008-0744]; Goffus AM, 2010, OXID MED CELL LONGEV, V3, P145, DOI 10.4161/oxim.3.2.11315; Gomez-Pinilla F, 2008, NAT REV NEUROSCI, V9, P568, DOI 10.1038/nrn2421; Granholm AC, 2008, J ALZHEIMERS DIS, V14, P133; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2007, MAGNESIUM RES, V20, P229; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; Hoane MR, 2005, J NEUROTRAUM, V22, P1112, DOI 10.1089/neu.2005.22.1112; Hoane MR, 2005, RESTOR NEUROL NEUROS, V23, P67; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Kuypers NJ, 2010, J NEUROTRAUM, V27, P1275, DOI 10.1089/neu.2010.1327; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; MORRIS LK, 2010, AM J PHYSIOL-REG I, V299, P1082; OGDEN C, 2002, JAMA-J AM MED ASSOC, P288; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; RUTLANDBROWN W, 2003, J HEAD TRAUMA REHAB, V2006, P456; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x	33	25	25	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	SEP 30	2011	223	1					119	124		10.1016/j.bbr.2011.04.028			6	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	790KU	WOS:000292587700017	21549156	Green Accepted			2022-02-06	
J	Armstead, WM; Kiessling, JW; Riley, J; Cines, DB; Higazi, A				Armstead, William M.; Kiessling, J. Willis; Riley, John; Cines, Douglas B.; Higazi, Abd Al-Roof			tPA contributes to impaired NMDA cerebrovasodilation after traumatic brain injury through activation of JNK MAPK	NEUROLOGICAL RESEARCH			English	Article						Newborn; Cerebral circulation; TBI; Plasminogen activators; Signal transduction	N-TERMINAL KINASE; TISSUE-PLASMINOGEN ACTIVATOR; CEREBRAL-BLOOD-FLOW; CHILDREN; ERK; LRP; HEMODYNAMICS; METABOLISM; POTASSIUM; NOC/OFQ	Objective: N-methyl-D-aspartate (NMDA)-induced pial artery dilation (PAD) is reversed to vasoconstriction after fluid percussion brain injury (FPI). Tissue type plasminogen activator (tPA) is up-regulated and the tPA antagonist, EEIIMD, prevents impaired NMDA PAD after FPI. Mitogen-activated protein kinase (MAPK), a family of at least three kinases, ERK, p38, and JNK, is also up-regulated after traumatic brain injury (TBI). We hypothesize that tPA impairs NMDA-induced cerebrovasodilation after FPI in a MAPK isoform-dependent mechanism. Methods: Lateral FPI was induced in newborn pigs. The closed cranial window technique was used to measure pial artery diameter and to collect cerebrospinal fluid (CSF). ERK, p38, and JNK MAPK concentrations in CSF were quantified by ELISA. Results: CSF JNK MAPK was increased by FPI, increased further by tPA, but blocked by JNK antagonists SP600125 and D-JNKI1. FPI modestly increased p38 and ERK isoforms of MAPK. NMDA-induced PAD was reversed to vasoconstriction after FPI, whereas dilator responses to papaverine were unchanged. tPA, in post-FPI CSF concentration, potentiated NMDA-induced vasoconstriction while papaverine dilation was unchanged. SP 600125 and D-JNKI1, blocked NMDA-induced vasoconstriction and fully restored PAD. The ERK antagonist U 0126 partially restored NMDA-induced PAD, while the p38 inhibitor SB203580 aggravated NMDA-induced vasoconstriction observed in the presence of tPA after FPI. Discussion: These data indicate that tPA contributes to impairment of NMDA-mediated cerebrovasodilation after FPI through JNK, while p38 may be protective. These data suggest that inhibition of the endogenous plasminogen activator system and JNK may improve cerebral hemodynamic outcome post-TBI.	[Armstead, William M.; Kiessling, J. Willis; Riley, John] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Armstead, William M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Higazi, Abd Al-Roof] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Clin Biochem, IL-91010 Jerusalem, Israel		Armstead, WM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,JM3, Philadelphia, PA 19104 USA.	armsteaw@uphs.upenn.edu		Riley, John/0000-0002-7932-8935	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS53410, HD57355, HL76406, CA83121, HL76206, HL07971, HL81864, HL77760, HL82545]; University of Pennsylvania Research Foundation; University of Pennsylvania Institute for Translational Medicine and Therapeutics; Israeli Science FoundationIsrael Science Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD057355] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA083121] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL077760, R21HL081864, P01HL076406, R01HL076206, T32HL007971] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053410] Funding Source: NIH RePORTER	This research was supported by grants from the National Institutes of Health, NS53410 and HD57355 (WMA), HL76406, CA83121, HL76206, HL07971, and HL81864 (DBC), and HL77760 and HL82545 (AARH), the University of Pennsylvania Research Foundation (WMA), the University of Pennsylvania Institute for Translational Medicine and Therapeutics (DBC), and the Israeli Science Foundation (AARH).	Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Akkawi S, 2006, AM J PHYSIOL-HEART C, V291, pH1351, DOI 10.1152/ajpheart.01042.2005; Armstead WM, 2008, BRAIN RES, V1231, P121, DOI 10.1016/j.brainres.2008.06.115; Armstead WM, 2009, J CEREBR BLOOD F MET, V29, P524, DOI 10.1038/jcbfm.2008.142; Armstead WM, 2005, DEV BRAIN RES, V156, P139, DOI 10.1016/j.devbraines.2005.02.012; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 2003, EUR J PHARMACOL, V474, P249, DOI 10.1016/S0014-2999(03)02012-0; Armstead WM, 2002, DEV BRAIN RES, V139, P19, DOI 10.1016/S0165-3806(02)00511-4; Armstead WM, 2001, PEPTIDES, V22, P39, DOI 10.1016/S0196-9781(00)00354-5; Borsello T, 2003, EUR J NEUROSCI, V18, P473, DOI 10.1046/j.1460-9568.2003.02757.x; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; COLLEN D, 1991, BLOOD, V78, P3114; Faraci FM, 1998, PHYSIOL REV, V78, P53, DOI 10.1152/physrev.1998.78.1.53; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hirt L, 2004, STROKE, V35, P1738, DOI 10.1161/01.STR.0000131480.03994.b1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kulkarni M, 2002, J NEUROTRAUM, V19, P965, DOI 10.1089/089771502320317113; Laher I, 2001, J CEREBR BLOOD F MET, V21, P887, DOI 10.1097/00004647-200108000-00001; MERCHANT RE, 1999, ANN NY ACAD SCI, V890, P41; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; Muniyappa H, 2008, CELL SIGNAL, V20, P675, DOI 10.1016/j.cellsig.2007.12.003; Nassar T, 2004, BLOOD, V103, P897, DOI 10.1182/blood-2003-05-1685; Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358; Parathath SR, 2006, J CELL SCI, V119, P339, DOI 10.1242/jcs.02734; Park L, 2008, P NATL ACAD SCI USA, V105, P1073, DOI 10.1073/pnas.0708823105; Pawlak R, 2005, P NATL ACAD SCI USA, V102, P443, DOI 10.1073/pnas.0406454102; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P625, DOI 10.1001/archpedi.1990.02150300019014; Thomas S, 2000, ACT NEUR S, V76, P397; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Vavilala Monica S, 2002, Anesthesiol Clin North Am, V20, P247, DOI 10.1016/S0889-8537(01)00012-8; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Yatsushige H, 2007, J NEUROSCI RES, V85, P1436, DOI 10.1002/jnr.21281	36	25	28	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	SEP	2011	33	7					726	733		10.1179/016164110X12807570509853			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	790MI	WOS:000292591700008	21756552	Green Accepted			2022-02-06	
J	Bouzat, P; Francony, G; Thomas, S; Valable, S; Mauconduit, F; Fevre, MC; Barbier, EL; Bernaudin, M; Lahrech, H; Payen, JF				Bouzat, Pierre; Francony, Gilles; Thomas, Sebastien; Valable, Samuel; Mauconduit, Franck; Fevre, Marie-Cecile; Barbier, Emmanuel L.; Bernaudin, Myriam; Lahrech, Hana; Payen, Jean-Francois			Reduced brain edema and functional deficits after treatment of diffuse traumatic brain injury by carbamylated erythropoietin derivative	CRITICAL CARE MEDICINE			English	Article						brain edema; carbamylated erythropoietin; erythropoietin; magnetic resonance diffusion-weighted imaging; magnetic resonance imaging; neurological outcome; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; CULTURED ASTROCYTES; HEAD-INJURY; MODEL; RAT; BARRIER; PROTECTS; RECOVERY; MOTOR; CEPO	Objective: To investigate the effects of carbamylated erythropoietin, a modified erythropoietin lacking erythropoietic activity, on brain edema and functional recovery in a model of diffuse traumatic brain injury. Design: Adult male Wistar rats. Setting: Neurosciences and physiology laboratories. Interventions: Thirty minutes after diffuse traumatic brain injury (impact-acceleration model), rats were intravenously administered with either a saline solution (traumatic brain injury-saline) or carbamylated erythropoietin (50 mu g/kg; traumatic brain injury-carbamylated erythropoietin). A third group received no traumatic brain injury insult (sham-operated). Measurements and Main Results: Three series of experiments were conducted to investigate: 1) the effect of carbamylated erythropoietin on brain edema before and 1 hr after traumatic brain injury using diffusion-weighted magnetic resonance imaging and measurements of apparent diffusion coefficient (n = 10 rats per group), and the phosphorylation level of brain extracellular-regulated kinase-1/-2 was also determined to indicate the presence of an activated cell signaling pathway; 2) the time course of brain edema using magnetic resonance imaging between 4 and 6 hrs postinjury and the gravimetric technique at 6 hrs (n = 10 rats per group); and 3) motor and cognitive function over 10 days post traumatic brain injury, testing acute somato-motor reflexes, adhesive paper removal, and two-way active avoidance (n = 8 rats per group). Compared to traumatic brain injury-saline rats, rats receiving traumatic brain injury-carbamylated erythropoietin showed a significant reduction in brain edema formation at 1 hr that was sustained until 6 hrs when results were comparable with sham-operated rats. This anti-edematous effect of carbamylated erythropoietin was possibly mediated through an early inhibition of extracellular-regulated kinase-1/-2 phosphorylation. Compared to traumatic brain injury-saline rats, traumatic brain injury-carbamylated erythropoietin rats showed improved functional recovery of the acute somato-motor reflexes post traumatic brain injury, took less time to remove adhesive from the forelimbs, and showed higher percentages of correct avoidance responses. Conclusion: Our findings indicate that early posttraumatic administration of carbamylated erythropoietin reduces brain edema development until at least 6 hrs postinjury and improves neurologic recovery. Carbamylated erythropoietin can thus be considered as a potential agent in the treatment of traumatic brain injury-induced diffuse edema. (Crit Care Med 2011; 39: 2099-2105)	[Bouzat, Pierre; Francony, Gilles; Thomas, Sebastien; Mauconduit, Franck; Fevre, Marie-Cecile; Barbier, Emmanuel L.; Lahrech, Hana; Payen, Jean-Francois] INSERM, U836, F-38042 Grenoble, France; [Bouzat, Pierre; Francony, Gilles; Thomas, Sebastien; Mauconduit, Franck; Fevre, Marie-Cecile; Barbier, Emmanuel L.; Lahrech, Hana; Payen, Jean-Francois] Univ Grenoble 1, Grenoble Inst Neurosci, F-38042 Grenoble, France; [Bouzat, Pierre; Francony, Gilles; Thomas, Sebastien; Fevre, Marie-Cecile; Payen, Jean-Francois] Hop Michallon, Dept Anesthesie Reanimat, F-38043 Grenoble, France; [Valable, Samuel; Bernaudin, Myriam] Univ Paris 05, Univ Caen Basse Normandie, CEA, CI NAPS,UMR 6232,CNRS,Equipe CERVOxy, Caen, France		Payen, JF (corresponding author), INSERM, U836, F-38042 Grenoble, France.	jfpayen@ujf-grenoble.fr	valable, samuel/B-7578-2008; Barbier, Emmanuel/E-6302-2011; Bernaudin, Myriam/B-7663-2008; Bouzat, Pierre/L-6881-2014; Lahrech, Hana/M-5229-2018; Bouzat, Pierre/AAC-4105-2019; Payen, Jean-Francois/L-6667-2014	valable, samuel/0000-0003-0355-0270; Barbier, Emmanuel/0000-0002-4952-1240; Bernaudin, Myriam/0000-0003-0778-3397; Bouzat, Pierre/0000-0003-4667-6738; Mauconduit, Franck/0000-0002-0128-061X; Lahrech, Hana/0000-0003-3843-3410	Institut National de la Sante et de la Recherche Medicale (INSERM)Institut National de la Sante et de la Recherche Medicale (Inserm); Institut pour la Recherche sur la Moelle Epiniere et l'Encephale (IRME); Association Francaise contre les Myopathies (AFM)Association Francaise contre les Myopathies; Centre National de la Recherche Scientifique (CNRS)Centre National de la Recherche Scientifique (CNRS); Ministere de l'Education, de la Recherche et de la Technologie, France	Supported, in part, by grants from Institut National de la Sante et de la Recherche Medicale (INSERM), Institut pour la Recherche sur la Moelle Epiniere et l'Encephale (IRME), Association Francaise contre les Myopathies (AFM), Centre National de la Recherche Scientifique (CNRS), and Ministere de l'Education, de la Recherche et de la Technologie, France.	Adembri C, 2008, CRIT CARE MED, V36, P975, DOI 10.1097/CCM.0B013E3181644343; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; FREI HJ, 1973, ACTA NEUROCHIR, V29, P15, DOI 10.1007/BF01414613; Freret T, 2006, EUR J NEUROSCI, V23, P1757, DOI 10.1111/j.1460-9568.2006.04699.x; Gassmann M, 2003, ADV EXP MED BIOL, V543, P323; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Huang H, 2009, J INT MED RES, V37, P511, DOI 10.1177/147323000903700227; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Jayakumar AR, 2008, J NEUROPATH EXP NEUR, V67, P417, DOI 10.1097/NEN.0b013e31816fc9d4; King VR, 2007, EUR J NEUROSCI, V26, P90, DOI 10.1111/j.1460-9568.2007.05635.x; Kirkeby A, 2008, THROMB HAEMOSTASIS, V99, P720, DOI 10.1160/TH07-03-0208; Lapchak PA, 2008, BRAIN RES, V1238, P208, DOI 10.1016/j.brainres.2008.08.017; Lapchak PA, 2008, EXPERT OPIN INV DRUG, V17, P1175, DOI 10.1517/13543784.17.8.1175 ; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lukoyanov NV, 2006, BEHAV BRAIN RES, V173, P229, DOI 10.1016/j.bbr.2006.06.026; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Montero M, 2007, EXP NEUROL, V204, P106, DOI 10.1016/j.expneurol.2006.09.026; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Otani N, 2007, J CLIN NEUROSCI, V14, P42, DOI 10.1016/j.jocn.2005.11.044; Rao KVR, 2010, GLIA, V58, P1490, DOI 10.1002/glia.21023; Shein NA, 2008, J NEUROTRAUM, V25, P112, DOI 10.1089/neu.2007.0358; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Velly L, 2010, PHARMACOL THERAPEUT, V128, P445, DOI 10.1016/j.pharmthera.2010.08.002; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Villa P, 2007, J CEREBR BLOOD F MET, V27, P552, DOI 10.1038/sj.jcbfm.9600370; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925	40	25	28	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	SEP	2011	39	9					2099	2105		10.1097/CCM.0b013e31821cb7b2			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	808TH	WOS:000294000800011	21552121				2022-02-06	
J	Hisley, DM; Gurganus, JC; Drysdale, AW				Hisley, Dixie M.; Gurganus, James C.; Drysdale, Andrew W.			Experimental Methodology Using Digital Image Correlation to Assess Ballistic Helmet Blunt Trauma	JOURNAL OF APPLIED MECHANICS-TRANSACTIONS OF THE ASME			English	Article						ballistic impact; combat helmet; back face deformation; blunt criterion; digital image correlation		As modern helmets have become quite capable of defeating the penetration capabilities of ballistic threats, Soldiers may experience head injuries due to blunt trauma caused by helmet back face deformation (BFD). Possible resulting injuries include skull fracture, hematoma, concussion, contusion, diffuse axonal injury, etc. Some of these injuries have been associated with traumatic brain injury. In order to assess potential injury mechanisms prior to fielding new helmets, we have developed a means to experimentally replicate and measure helmet BFD that can be correlated to injury criteria. In this study, helmet performance test methodology is developed using a digital image correlation (DIC) technique. DIC provides the capability to measure dynamic displacements, thereby providing the ability to calculate deformation, velocity, and acceleration rates. We have shown that digital image correlation is an experimentation technique that accurately captures BFD area and rate of deformation for impacts against combat helmets. We used the DIC data to calculate a new metric; the available energy that could potentially impact a Soldier's head. Our study shows that DIC data upholds the hypothesis that helmet BFD mechanically loads the skull similar to a direct impact from a less-than-lethal projectile or blunt object impact. The available energy obtained from DIC measurements was used to calculate the blunt criterion (BC) for helmet standoff distances of 12.7 mm (0.5 in) and 19.1 mm (0.75 in), which in turn can provide a prediction of the probability of abbreviated injury scale (AIS) levels and, in particular, skull fracture. DIC can be used to provide dynamic helmet performance data that will allow increased understanding of BFD and quantitative assessment and validation of helmet performance results. Knowledge of the conditions leading to head trauma obtained through DIC experimentation should enable the selection of new energy-absorbing materials for helmets; thus, allowing new helmet design candidate performances to be objectively evaluated. Test data and characterization of helmet response could then be used to achieve improved warfighter survivability. [DOI: 10.1115/1.4004332]	[Hisley, Dixie M.; Gurganus, James C.; Drysdale, Andrew W.] USA, Res Lab, Syst Engn & Experimentat Branch, Aberdeen Proving Ground, MD 21005 USA		Hisley, DM (corresponding author), USA, Res Lab, Syst Engn & Experimentat Branch, Aberdeen Proving Ground, MD 21005 USA.	dixie.hisley@us.army.mil; james.gurganus@us.army.mil; andrew.drysdale@us.army.mil			Survivability and Lethality Analysis Directorate of the Army Research Laboratory	Funding for this research was provided by the TILV program, Survivability and Lethality Analysis Directorate of the Army Research Laboratory. The authors would also like to acknowledge the efforts of Scott Williams and Joseph Lee in the completion of this work. This material is declared a work of the U. S. Government and is not subject to copyright protection in the United States. Approved for public release; distribution is unlimited.	Bir C. A., 2000, THESIS WAYNE STATE U; Cannon L, 2001, J R Army Med Corps, V147, P87; CARROLL AW, 1978, ANN SURG, V188, P753, DOI 10.1097/00000658-197812000-00007; COLLINS J, 2007, ARLTR4116; Department of Defense, 1997, MILSTD662F DEP DEF; *GOM, 2009, AR V6 1 US MAN GOM O; *H P WHIT LAB INC, 1995, HPWTP040101B H P WHI; Mahoney PF, 2005, BALLISTIC TRAUMA PRA; MCENTIRE B, 2005, CR200512 USAARL; *NAT I JUST, 1981, 010601 NIJ; Raymond D, 2009, J BIOMECH, V42, P2479, DOI 10.1016/j.jbiomech.2009.07.018; Sturdivan L., 2005, J TRAUMA, V56, P651; Sturdivan L., 2010, COMMUNICATION; WEERASOORIYA T, 2008, P 2008 INT C EXP EXP; Yu J.H., 2010, ARLTR5333	15	25	27	1	19	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0021-8936	1528-9036		J APPL MECH-T ASME	J. Appl. Mech.-Trans. ASME	SEP	2011	78	5							051022	10.1115/1.4004332			7	Mechanics	Science Citation Index Expanded (SCI-EXPANDED)	Mechanics	806GT	WOS:000293795000022					2022-02-06	
J	van Kampen, PJ; Martina, JD; Vos, PE; Hoedemaekers, CWE; Hendricks, HT				van Kampen, P. J.; Martina, J. D.; Vos, P. E.; Hoedemaekers, C. W. E.; Hendricks, H. T.			Potential Risk Factors for Developing Heterotopic Ossification in Patients With Severe Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						autonomic dysregulation; bone fractures; heterotopic ossification; immobilization; risk factors; spasticity; traumatic brain injury	BONE-FORMATION	Background: Heterotopic ossification (HO) is a frequent complication after traumatic brain injury (TBI). The current preliminary study is intended to provide additional data on the potential roles that brain injury severity, concomitant orthopaedic trauma, and specific intensive care complicating events may play in the prediction of HO in patients who have sustained severe TBI. Methods: A prospective cohort study in patients with severe TBI. Results: Ninety-seven of the 176 patients were eligible for follow-up; 13 patients (13%) developed 19 clinically relevant HOs at 1 or more sites. Univariate analysis indicated that patients with HO remained in coma longer (P<.001) and were ventilated during a longer period (P=.002). Autonomic dysregulation (relative risk = 6.11, 95% confidence interval: 2.53-14.76) and surgically treated extremity fractures (relative risk = 5.02, 95% confidence interval: 1.68-15.04) also showed significant associations with the development of HO. Conclusion: Prolonged coma duration and mechanical ventilation, coexistent surgically treated bone fractures and clinical signs of autonomic dysregulation should be given further consideration as potential risk factors for developing clinically relevant HO. Larger-scale studies are needed to develop a valid risk profile that takes into account the interrelationships between variables.	[Hendricks, H. T.] Radboud Univ Nijmegen, Med Ctr, Dept Rehabil Med, NL-6500 HB Nijmegen, Netherlands; [van Kampen, P. J.; Martina, J. D.] Rehabil Ctr Groot Klimmendaal, Arnhem, Netherlands; [Vos, P. E.] Radboud Univ Nijmegen, Med Ctr, Inst Neurol, NL-6500 HB Nijmegen, Netherlands; [Hoedemaekers, C. W. E.] Radboud Univ Nijmegen, Med Ctr, Dept Intens Care Med, NL-6500 HB Nijmegen, Netherlands		Hendricks, HT (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Rehabil Med, Post Box 9011, NL-6500 HB Nijmegen, Netherlands.	h.hendricks@reval.umcn.nl	Hoedemaekers, C.W.E./L-4375-2015; Vos, Pieter/A-6043-2012		Ever Neuro Pharma	Conflict of Interest: Dr Vos serves on a scientific advisory board and received funding for travel and speaker honoraria from Ever Neuro Pharma, serves as a member of the editorial advisory board of The European Journal of Neurology, and has received honoraria for lectures or educational activities not funded by the industry.	*AM COL SURG, 2008, ATLS ADV TRAUM LIF S; Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; *BRAIN TRAUM FDN, 2007, J NEUROTRAUM S1, V24; Chauveau C, 2008, J RECEPT SIG TRANSD, V28, P347, DOI [10.1080/10799890802239762, 10.1080/10799890802239762 ]; Cipriano CA, 2009, J AM ACAD ORTHOP SUR, V17, P689, DOI 10.5435/00124635-200911000-00003; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; CLEMENTS NC, 1993, CHEST, V104, P1526, DOI 10.1378/chest.104.5.1526; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Ebinger T, 2000, J TRAUMA, V48, P1058, DOI 10.1097/00005373-200006000-00010; Flin C., 2002, Annales de Readaptation et de Medecine Physique, V45, P517, DOI 10.1016/S0168-6054(02)00305-7; Fransen M, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001160.PUB2; GARLAND DE, 1983, PHYS THER, V63, P2004, DOI 10.1093/ptj/63.12.2004; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; Gautschi OP, 2009, ANZ J SURG, V79, P449, DOI 10.1111/j.1445-2197.2008.04803.x; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Hunt JL, 2006, J BURN CARE RES, V27, P535, DOI 10.1097/01.BCR.0000226023.58438.14; HURVITZ EA, 1992, ARCH PHYS MED REHAB, V73, P459; Ippolito E, 1999, CLIN ORTHOP RELAT R, P130, DOI 10.1097/00003086-199908000-00018; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARTINA JD, 2006, NEUROREHAB NEURAL RE, V20, P236; MIELANTS H, 1975, ACTA ORTHOP SCAND, V46, P190, DOI 10.3109/17453677508989207; Pape HC, 2000, J ORTHOP TRAUMA, V14, P238, DOI 10.1097/00005131-200005000-00003; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521, DOI 10.1302/0301-620X.69B4.3611150; ROBERTS P H, 1968, Journal of Bone and Joint Surgery British Volume, V50B, P70; Sebastiani GD, 2002, CLIN RHEUMATOL, V21, P173, DOI 10.1007/PL00011219; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; Trentz OA, 2005, CRIT CARE MED, V33, P399, DOI 10.1097/01.CCM.0000152221.87477.21; Tsur A, 1996, BRAIN INJURY, V10, P259, DOI 10.1080/026990596124430; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Warren S B, 1990, Orthop Rev, V19, P603	31	25	25	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2011	26	5					384	391		10.1097/HTR.0b013e3181f78a59			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	814VO	WOS:000294485500007	21321512				2022-02-06	
J	Zhang, XY; Yang, ZJ; Wang, QX; Fan, HR				Zhang, Xiang-yu; Yang, Zi-jian; Wang, Qi-xing; Fan, Hai-rong			Impact of positive end-expiratory pressure on cerebral injury patients with hypoxemia	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							LUNG-PROTECTIVE VENTILATION; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; NEUROSURGICAL PATIENTS; BRAIN; RECRUITMENT; MANEUVER; PEEP	Background: Traumatic brain injury or intracranial hemorrhage patients with acute lung injury/acute respiratory distress syndrome need mechanical ventilation. The use of positive end-expiratory pressure (PEEP) in this situation remains controversial. This study explored the impact of PEEP on intracranial pressure (ICP), cerebral perfusion pressure (CPP), central venous pressure (CVP), and mean arterial pressure (MAP) in cerebral injury patients. Methods: Nine cerebral injury patients with lung injury who needed mechanical ventilation and met the criteria for ICP monitoring were included in this study. Intraventricular catheters were positioned in 1 of the bilateral ventricles and connected to pressure transducers. Invasive arterial pressure and CVP were monitored continuously. Pressure control ventilation was applied during this clinical trial in a stepwise recruitment maneuver (RM) with 3 cm H2O intermittent increments and decrements of PEEP. Results: A total of 28 RMs were completed in 9 patients. Mean values of MAP, CVP, ICP, and CPP 5 minutes after RMs showed no significant differences compared with baseline (P > 0.05). Correlation analysis of all the mean values of MAP, CVP, ICP, and CPP showed significant correlation between MAP and CPP, PEEP and CVP, PEEP and ICP, and PEEP and CPP with all P values less than 0.05. Conclusion: The impact of PEEP on blood pressure, ICP, and CPP varies greatly in cerebral injury patients. Mean arterial pressure and ICP monitoring is of benefit when using PEEP in cerebral injury patients with hypoxemia. (C) 2011 Elsevier Inc. All rights reserved.	[Zhang, Xiang-yu; Yang, Zi-jian; Wang, Qi-xing; Fan, Hai-rong] Tongji Univ, Dept Emergency & Crit Care Med, Shanghai Peoples Hosp 10, Sch Med, Shanghai 200072, Peoples R China		Zhang, XY (corresponding author), Tongji Univ, Dept Emergency & Crit Care Med, Shanghai Peoples Hosp 10, Sch Med, Shanghai 200072, Peoples R China.	xiangyu62@126.com					Bein T, 2002, INTENS CARE MED, V28, P554, DOI 10.1007/s00134-002-1273-y; Caricato A, 2005, J TRAUMA, V58, P571, DOI 10.1097/01.TA.0000152806.19198.DB; David M, 2006, BRIT J ANAESTH, V97, P525, DOI 10.1093/bja/ael215; Fan E, 2008, AM J RESP CRIT CARE, V178, P1156, DOI 10.1164/rccm.200802-335OC; FARGE D, 1995, CHEST, V107, P1095, DOI 10.1378/chest.107.4.1095; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Georgiadis D, 2001, STROKE, V32, P2088, DOI 10.1161/hs0901.095406; Haitsma JJ, 2006, MINERVA ANESTESIOL, V72, P117; Huynh T, 2002, J TRAUMA, V53, P488, DOI 10.1097/00005373-200209000-00016; Lowe GJ, 2006, CURR OPIN CRIT CARE, V12, P3, DOI 10.1097/01.ccx.0000198055.29600.4b; Mascia L, 2005, INTENS CARE MED, V31, P373, DOI 10.1007/s00134-004-2491-2; McGuire G, 1997, CRIT CARE MED, V25, P1059, DOI 10.1097/00003246-199706000-00025; Muench E, 2005, CRIT CARE MED, V33, P2367, DOI 10.1097/01.CCM.0000181732.37319.DF; Qiu Hai-Bo, 2004, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V16, P399; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Stocchetti N, 2008, MINERVA ANESTESIOL, V74, P199; Stonestreet BS, 2000, J APPL PHYSIOL, V88, P1672, DOI 10.1152/jappl.2000.88.5.1672; The Brain Trauma Foundation; The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P479; Wolf S, 2002, ACT NEUR S, V81, P99; Yang Zi-jian, 2008, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V20, P588	20	25	25	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	SEP	2011	29	7					699	703		10.1016/j.ajem.2010.01.042			5	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	818MV	WOS:000294756700001	20825872				2022-02-06	
J	Carlsson, A; Linder, A; Davidsson, J; Hell, W; Schick, S; Svensson, M				Carlsson, Anna; Linder, Astrid; Davidsson, Johan; Hell, Wolfram; Schick, Sylvia; Svensson, Mats			Dynamic Kinematic Responses of Female Volunteers in Rear Impacts and Comparison to Previous Male Volunteer Tests	TRAFFIC INJURY PREVENTION			English	Article						Whiplash; Volunteers; Crash testing; Rear impact; Sled testing	WHIPLASH; DRIVERS; HEAD; FREQUENCY	Objectives: The objective was to quantify dynamic responses of 50th percentile females in rear impacts and compare to those from similar tests with males. The results will serve as a basis for future work with models, criteria, and safety systems. Methods: A rear impact sled test series with 8 female volunteers was performed at velocity changes of 5 and 7 km/h. The following dynamic response corridors were generated for the head, T1 (first thoracic vertebra) and head relative to T1: (1) accelerations in posterior anterior direction, (2) horizontal and vertical displacements, (3) angular displacements for 6 females close to the 50th percentile in size. Additionally, the head-to-head restraint distance and contact time and neck injury criterion (NIC) were extracted from the data set. These data were compared to results from previously performed male volunteer tests, representing the 50th percentile male, in equivalent test conditions. T-tests were performed with the statistical significance level of .05 to quantify the significance of the parameter value differences for the males and females. Results: At 7 km/h, the females showed 29 percent earlier head-to-head restraint contact time (p = .0072); 27 percent shorter horizontal rearward head displacement (p = .0017); 36 percent narrower head extension angle (p = .0281); and 52 percent lower NIC value (p = .0239) than the males in previous tests. This was mainly due to 35 percent shorter initial head-to-head restraint distance for the females (p = .0125). The peak head acceleration in the posterior anterior direction was higher and occurred earlier for the females. Conclusions: The overall result indicated differences in the dynamic response for the female and male volunteers. The results could be used in developing and evaluating a mechanical and/or mathematical average-sized female dummy model for rear impact safety assessment. These models can be used as a tool in the design of protective systems and for further development and evaluation of injury criteria.	[Carlsson, Anna] Chalmers, Appl Mech SAFER, Vehicle Safety Div, Appl Mech SAFER Ctr, SE-41296 Gothenburg, Sweden; [Linder, Astrid] Swedish Natl Rd & Transport Res Inst, VTI, Gothenburg, Sweden; [Hell, Wolfram; Schick, Sylvia] Univ Munich, Inst Legal Med, Dept Biomech & Accid Res, Munich, Germany		Carlsson, A (corresponding author), Chalmers, Appl Mech SAFER, Vehicle Safety Div, Appl Mech SAFER Ctr, SE-41296 Gothenburg, Sweden.	anna.carlsson@chalmers.se	Davidsson, Johan/A-3229-2016; Svensson, Mats Yngve/A-6014-2013	Davidsson, Johan/0000-0002-1717-1514; Svensson, Mats Yngve/0000-0002-8304-1398; Carlsson, Anna/0000-0002-3216-8145	Swedish Governmental Agency for Innovation Systems (VINNOVA)Vinnova	This study was funded by the Swedish Governmental Agency for Innovation Systems (VINNOVA). Special thanks for valuable help to Stefan Horion and Kristin Thorsteinsdottir at LMU and Carsten Reinkemeyer at Allianz.	Bostrom O, 2000, ACCIDENT ANAL PREV, V32, P321, DOI 10.1016/S0001-4575(99)00105-0; BOSTROM O, 1996, IRCOBI C SEPT 11 13; Carlsson A, 2010, IRCOBI C SEPT 15 16; Chapline JF, 2000, ACCIDENT ANAL PREV, V32, P287, DOI 10.1016/S0001-4575(99)00126-8; Croft AC, 2002, IRCOBI C SEPT 18 20; Davidsson J, 1999, 43 STAPP CAR CRASH C; DAVIDSSON J, 1998, IRCOBI C SEPT 16 18; Dolinis J, 1997, INJURY, V28, P173, DOI 10.1016/S0020-1383(96)00186-6; Eichberger A, 1996, IRCOBI C SEPT 11 13; Farmer Charles M, 2003, Traffic Inj Prev, V4, P83, DOI 10.1080/15389580309867; Hell W, 1999, IRCOBI C SEPT 23 24; Jakobsson Lotta, 2004, Traffic Inj Prev, V5, P156, DOI 10.1080/15389580490435989; Jonsson Bertil, 2007, Traffic Inj Prev, V8, P87, DOI 10.1080/15389580600911010; Jonsson B, 2008, TRAFFIC INJ PREV, V9, P568, DOI 10.1080/15389580802308312; Kihlberg JK, 1969, 13 ASS ADV AUT MED O; Krafft M., 1998, IRCOBI C SEPT 16 18; Krafft M., 2002, TRAFFIC INJ PREV, V3, P141, DOI [10.1080/15389580212001, DOI 10.1080/15389580212001]; Krafft Maria, 2003, Traffic Inj Prev, V4, P136, DOI 10.1080/15389580309862; Kullgren A, 2010, IRCOBI C SEPT 15 16; Kullgren A, 2007, 20 ESV C JUN 18 21 L; Kullgren A, 2003, 18 ESV C MAY 19 22 N; Linder A, 2004, IRCOBI C SEPT 22 24; Linder A, 2008, TRAFFIC INJ PREV, V9, P592, DOI 10.1080/15389580802384669; Maag U, 1990, IRCOBI C SEPT 12 14; Minton R, 1997, IRCOBI C SEPT 24 26; Mordaka J., 2003, ACTA POLITECHNICA, V43, P47; MORRIS A, 1996, 40 STAPP CAR CRASH C; NARRAGON EA, 1965, VJ1823R15 CAL INC; NYGREN A, 1985, 10 INT TECHN C EXP S, P1; ONEILL B, 1972, AM J PUBLIC HEALTH N, V62, P399, DOI 10.2105/AJPH.62.3.399; Ono K, 2006, IRCOBI C SEPT 20 22; OTREMSKI I, 1989, INJURY, V20, P349, DOI 10.1016/0020-1383(89)90011-9; Philippens M, 2002, Stapp Car Crash J, V46, P461; Richter M, 2000, EUR SPINE J, V9, P109, DOI 10.1007/s005860050220; *SAE, 2003, J2111 SAE; SCHICK S, 2008, 2 INT C NOV 18 19 ER; SCHNEIDER LW, 1983, UMTRI83531, P53; SCOTT MW, 1993, SAESP93945; SIEGMUND GP, 1997, 41 STAP CAR CRASH C; States JD, 1972, 16 STAPP CAR CRASH C; Stemper BD, 2003, J BIOMECH, V36, P1281, DOI 10.1016/S0021-9290(03)00159-3; Storvik Steven G, 2009, Biomed Sci Instrum, V45, P244; Svensson MY, 1993, SAESP93963; SZABO TJ, 1994, 38 STAP CAR CRASH C; The Whiplash Commission, 2005, WHIPL COMM FIN REP; THOMAS C, 1982, IRCOBI C SEPT 8 10; Vasavada AN, 2008, J BIOMECH, V41, P114, DOI 10.1016/j.jbiomech.2007.07.007; Viano David C, 2003, Traffic Inj Prev, V4, P228, DOI 10.1080/15389580309880; Watanabe Y, 2000, ACCIDENT ANAL PREV, V32, P243, DOI 10.1016/S0001-4575(99)00082-2; Welcher JB, 2001, ACCIDENT ANAL PREV, V33, P289, DOI 10.1016/S0001-4575(00)00043-9; WELSH R, 2001, 45 ASS ADV AUT MED S; ZOBEL J, 1998, IRCOBI C SEPT 16 18; 2004, FED GEG, V69, P74848	53	25	25	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1538-9588			TRAFFIC INJ PREV	Traffic Inj. Prev.	AUG	2011	12	4					347	357		10.1080/15389588.2011.585408			11	Public, Environmental & Occupational Health; Transportation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Transportation	817UN	WOS:000294702200008	21823943				2022-02-06	
J	Degeneffe, CE; Chan, F; Dunlap, L; Man, D; Sung, C				Degeneffe, Charles Edmund; Chan, Fong; Dunlap, Laura; Man, David; Sung, Connie			Development and Validation of the Caregiver Empowerment Scale: A Resource for Working With Family Caregivers of Persons With Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; family; empowerment; caregiving; social support	QUALITY-OF-LIFE; PSYCHOMETRIC VALIDATION; ADULT SIBLINGS; INDIVIDUALS; RELIABILITY; PREDICTORS; PROGRAM; PEOPLE; MEMBER; NEEDS	To use multitrait analysis to determine the measurement structure of the Caregiver Empowerment Scale (CES). Participants: An American sample of 87 adult primary family caregivers of persons with traumatic brain injury (TBI). Results: A four-factor structure was identified including factor 1 (Advocacy Self-Efficacy), factor 2 (Community Self-Efficacy), factor 3 (Caregiver Self-Efficacy), and factor 4 (Personal Self-Efficacy). Conclusions: The CES provides clinicians and researchers a means to assess self-perceived coping abilities of family caregivers of persons with TBI.	[Degeneffe, Charles Edmund] San Diego State Univ, Rehabil Counseling Program, Dept Adm Rehabil & Postsecondary Educ, Interwork Inst, San Diego, CA 92108 USA; [Chan, Fong; Sung, Connie] Univ Wisconsin, Dept Rehabil Psychol & Special Educ, Madison, WI 53706 USA; [Dunlap, Laura] ACT Med Grp, Raleigh, NC USA; [Man, David] Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China		Degeneffe, CE (corresponding author), San Diego State Univ, Rehabil Counseling Program, Dept Adm Rehabil & Postsecondary Educ, Interwork Inst, 3590 Camino del Rio N, San Diego, CA 92108 USA.	cdegenef@mail.sdsu.edu					Bishop M, 2006, AUST J REHABIL COUNS, V12, P73, DOI 10.1375/jrc.12.2.73; Catalano D, 2010, AUST J REHABIL COUNS, V16, P57, DOI 10.1375/jrc.16.2.57; Chapin MH, 2004, DISABIL REHABIL, V26, P1135, DOI 10.1080/09638280410001714772; Cheing GLY, 2010, INT J REHABIL RES, V33, P88, DOI 10.1097/MRR.0b013e32832e9884; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Chronister J, 2010, NEUROREHABILITATION, V27, P49, DOI 10.3233/NRE-2010-0580; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Degeneffe CE, 2009, AUST J REHABIL COUNS, V15, P12, DOI 10.1375/jrc.15.1.12; Degeneffe CE, 2008, J REHABIL, V74, P10; Degeneffe CE, 2010, BRAIN INJURY, V24, P1416, DOI 10.3109/02699052.2010.514317; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; GREENBERG JS, 1993, GERONTOLOGIST, V33, P542, DOI 10.1093/geront/33.4.542; HAYS RD, 1990, BEHAV RES METH INS C, V22, P167, DOI 10.3758/BF03203140; Kendall E, 2003, J VOCAT REHABIL, V19, P31; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowski-Hayner S, 2001, J HEAD TRAUMA REHAB, V16, P1; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/h0080325; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Kreutzer JS, 1989, FAMILY NEEDS QUESTIO; Kritsotakis G, 2010, EUR J CANCER CARE, V19, P45, DOI 10.1111/j.1365-2354.2007.00910.x; Man D, 1999, BRAIN INJURY, V13, P433, DOI 10.1080/026990599121485; Man DWK, 2003, BRAIN INJURY, V17, P437, DOI 10.1080/0269905031000070152; Man DWK, 1998, BRAIN INJURY, V12, P245, DOI 10.1080/026990598122728; Man DWK, 2001, BRAIN INJURY, V15, P961, DOI 10.1080/02699050110065664; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; Rosenthal M., 1989, TRAUMATIC BRAIN INJU, P191; Rubin S. E., 2003, PROFESSIONAL REHABIL, V11, P54; Santa-Barbara J., 2009, CANADIAN J COMMUNITY, V2, P91, DOI DOI 10.7870/CJCMH-1983-0018; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Steffen AM, 2002, J GERONTOL B-PSYCHOL, V57, pP74, DOI 10.1093/geronb/57.1.P74; Stewart AL, 1992, MEASURING FUNCTIONIN; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Ware J, 1997, MAP R WINDOWS MULTIT; Watt T, 2009, QUAL LIFE RES, V18, P483, DOI 10.1007/s11136-009-9460-8; Zeiss AM, 1999, J CLIN GEROPSYCHOLOG, V5, P221, DOI DOI 10.1023/A:1022955817074; Zimmerman MA, 1998, REHABIL PSYCHOL, V43, P3, DOI 10.1037/0090-5550.43.1.3; [No title captured]	38	25	26	0	12	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2011	56	3					243	250		10.1037/a0024465			8	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	809TD	WOS:000294078700009	21787096				2022-02-06	
J	Abdanipour, A; Tiraihi, T; Mirnajafi-Zadeh, J				Abdanipour, Alireza; Tiraihi, Taki; Mirnajafi-Zadeh, Javad			Improvement of the pilocarpine epilepsy model in rat using bone marrow stromal cell therapy	NEUROLOGICAL RESEARCH			English	Article						Epilepsy; Pilocarpine; Epileptogenesis; Convulsion; Bone marrow stromal cells	TEMPORAL-LOBE EPILEPSY; SPONTANEOUS RECURRENT SEIZURES; TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; ADULT-RAT; STATUS EPILEPTICUS; INTRACTABLE EPILEPSY; TRANSPLANTATION; HIPPOCAMPUS; NEURONS	Objective: Temporal lobe epilepsy is one of the most common types of epilepsy. Cytotherapy was tried for several neurological disorders. In this investigation, bone marrow stromal cells (BMSCs) were used in order to evaluate the recovery of epileptic rats induced by pilocarpine. Methods: The rats were divided into four groups: a negative control, treated groups, and epileptic rats treated with the vehicle only. The animals in the chronic phase were monitored for three weeks using Racine scale. BMSCs were labeled with BrdU and injected intravenously. After 6 weeks, the rats were killed and processed in paraffin as well as immunohistochemical techniques. Results: The results of the behavioral test showed that the number of seizures significantly decreased in treatment groups. Histopathology of the tissues from the untreated rats showed cell death and neurophagia. The numerical density of neurons per area was significantly higher in the treated groups than in the untreated ones. BMSCs localized in the hippocampus of the treated animals. Discussion: The results showed that there is structural and functional improvement in the epileptic rats treated with BMSCs.	[Abdanipour, Alireza; Tiraihi, Taki] Tarbiat Modares Univ, Dept Anat Sci, Sch Med Sci, Tehran, Iran; [Tiraihi, Taki] Khatam Al Anbia Hosp, Shafa Neurosci Res Ctr, Tehran, Iran; [Mirnajafi-Zadeh, Javad] Tarbiat Modares Univ, Dept Physiol, Sch Med Sci, Tehran, Iran		Tiraihi, T (corresponding author), Tarbiat Modares Univ, Dept Anat Sci, Sch Med Sci, POB 14155-4838, Tehran, Iran.	takialtr@modares.ac.ir	Mirnajafi-Zadeh, Javad/AAD-4822-2022; abdanipour, Alireza/I-4964-2016; Mirnajafi-Zadeh, Javad/W-5379-2019	abdanipour, Alireza/0000-0002-2975-3423; Mirnajafi-Zadeh, Javad/0000-0003-3946-9052			Aherne WA, 1982, MORPHOMETRY; Bahadori MH, 2001, J NEUROCYTOL, V30, P125, DOI 10.1023/A:1011935122963; Baptiste DC, 2007, PROG BRAIN RES, V161, P217, DOI 10.1016/S0079-6123(06)61015-7; Barker Roger A, 2004, NeuroRx, V1, P472, DOI 10.1007/BF03206631; Barry Frank P, 2003, Novartis Found Symp, V249, P86; Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Black IB, 2001, BLOOD CELL MOL DIS, V27, P632, DOI 10.1006/bcmd.2001.0423; Browne T, 2008, HDB EPILEPSY; Carpentino JE, 2008, J NEUROSCI RES, V86, P512, DOI 10.1002/jnr.21514; Castillo CG, 2008, BEHAV BRAIN RES, V193, P17, DOI 10.1016/j.bbr.2008.04.023; CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; Chawla S, 2002, PEDIATR NEUROL, V27, P186, DOI 10.1016/S0887-8994(02)00416-2; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chen Y, 2006, CELL MOL LIFE SCI, V63, P1649, DOI 10.1007/s00018-006-6019-5; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2006, ADV EXP MED BIOL, V585, P49; Chu K, 2004, BRAIN RES, V1023, P213, DOI 10.1016/j.brainres.2004.07.045; Clarke Emer, 2005, Methods Mol Biol, V290, P173; Costa-Ferro ZSM, 2010, SEIZURE-EUR J EPILEP, V19, P84, DOI 10.1016/j.seizure.2009.12.003; Dezawa M, 2005, EXPERT OPIN BIOL TH, V5, P427, DOI 10.1517/14712598.5.4.427; Dezawa M, 2006, CELL MOL LIFE SCI, V63, P2764, DOI 10.1007/s00018-006-6191-7; Glien M, 2001, EPILEPSY RES, V46, P111, DOI 10.1016/S0920-1211(01)00272-8; Grisolia JS, 2001, EPILEPSY BEHAV, V2, P318, DOI 10.1006/ebeh.2001.0230; Guttinger M, 2005, EPILEPSIA, V46, P1162, DOI 10.1111/j.1528-1167.2005.61804.x; Habisch HJ, 2007, J NEURAL TRANSM, V114, P1395, DOI 10.1007/s00702-007-0748-y; Harvey RL, 2003, PHYS MED REH CLIN N, V14, P143; Hattiangady B, 2006, NEUROSCIENCE, V139, P1369, DOI 10.1016/j.neuroscience.2006.01.058; Hattiangady B, 2008, EXP NEUROL, V212, P468, DOI 10.1016/j.expneurol.2008.04.040; Hauser WA, 2008, EPILEPSIA, V49, P8, DOI 10.1111/j.1528-1167.2008.01443.x; Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307; Hermann Andreas, 2006, Expert Opin Biol Ther, V6, P653, DOI 10.1517/14712598.6.7.653; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Huber A, 2001, P NATL ACAD SCI USA, V98, P7611, DOI 10.1073/pnas.131102898; Jacobs MP, 2001, NEUROLOGY, V57, P1536, DOI 10.1212/WNL.57.9.1536; Khalatbary AR, 2007, NEUROL RES, V29, P21, DOI 10.1179/016164107X165642; Kobayashi M, 2003, J NEUROSCI, V23, P2440; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Leroy C, 2003, EXP NEUROL, V182, P361, DOI 10.1016/S0014-4886(03)00122-5; Li TF, 2007, BRAIN, V130, P1276, DOI 10.1093/brain/awm057; Loscher W, 2008, TRENDS NEUROSCI, V31, P62, DOI 10.1016/j.tins.2007.11.012; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; MCKAY IS, 2004, PHARM BIOCH BEHAV, V78, P111; Meletis K, 2003, TRENDS NEUROSCI, V26, P292, DOI 10.1016/S0166-2236(03)00125-5; Nolte MW, 2008, NEUROBIOL DIS, V31, P342, DOI 10.1016/j.nbd.2008.05.010; Olstorn H, 2007, NEUROSURGERY, V60, P1089, DOI 10.1227/01.NEU.0000255461.91892.0D; Parent JM, 1997, J NEUROSCI, V17, P3727; Pugliatti M, 2007, EPILEPSIA, V48, P2224; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rao MS, 2007, NEUROBIOL DIS, V27, P117, DOI 10.1016/j.nbd.2007.03.016; Raza M, 2001, BRAIN RES, V903, P1, DOI 10.1016/S0006-8993(01)02127-8; Rigoulot MA, 2004, J PHARMACOL EXP THER, V308, P787, DOI 10.1124/jpet.103.057091; Rodi N, 2004, TRENDS MOL MED, V10, P93, DOI 10.1016/j.molmed.2004.01.010; Rosenow F, 2007, EPILEPSIA, V48, P82, DOI 10.1111/j.1528-1167.2007.01359.x; Ruschenschmidt T, 2005, EPILEPSIA, V46, P174, DOI 10.1111/j.1528-1167.2005.01028.x; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Savitz SI, 2002, ANN NEUROL, V52, P266, DOI 10.1002/ana.60000; Seshi B, 2000, BLOOD CELL MOL DIS, V26, P234, DOI 10.1006/bcmd.2000.0301; Shetty AK, 2007, STEM CELLS, V25, P2396, DOI 10.1634/stemcells.2007-0313; Shyu WC, 2007, STROKE, V38, P367, DOI 10.1161/01.STR.0000254463.24655.14; TAKI TM, 1984, AM J ANAT, V171, P415, DOI 10.1002/aja.1001710406; Thompson KW, 2005, NEUROSCIENCE, V133, P1029, DOI 10.1016/j.neuroscience.2005.03.003; Turner DA, 2003, NEUROSURGERY, V52, P632, DOI 10.1227/01.NEU.0000047825.91205.E6; TURSKI L, 1989, SYNAPSE, V3, P154, DOI 10.1002/syn.890030207; Vaquero J, 2006, NEUROSCI LETT, V398, P129, DOI 10.1016/j.neulet.2005.12.072; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Zaman V, 2003, HIPPOCAMPUS, V13, P618, DOI 10.1002/hipo.10091	70	25	27	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUL	2011	33	6					625	632		10.1179/1743132810Y.0000000018			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	783ML	WOS:000292087300009	21708072				2022-02-06	
J	Duffy, AM; Schaner, MJ; Wu, SH; Staniszewski, A; Kumar, A; Arevalo, JC; Arancio, O; Chao, MV; Scharfman, HE				Duffy, Aine M.; Schaner, Michael J.; Wu, Synphen H.; Staniszewski, Agnieszka; Kumar, Asok; Carlos Arevalo, Juan; Arancio, Ottavio; Chao, Moses V.; Scharfman, Helen E.			A selective role for ARMS/Kidins220 scaffold protein in spatial memory and trophic support of entorhinal and frontal cortical neurons	EXPERIMENTAL NEUROLOGY			English	Article						BDNF; Neurotrophin; Sex differences; Spatial memory; Myelin; Oxidative stress	AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; MORRIS WATER TASK; RADIAL-ARM MAZE; NEUROTROPHIC FACTOR; ALZHEIMERS-DISEASE; PREFRONTAL CORTEX; OXIDATIVE STRESS; SEX-DIFFERENCES; MOUSE MODEL	Progressive cortical pathology is common to several neurodegenerative and psychiatric disorders. The entorhinal cortex (EC) and frontal cortex (FC) are particularly vulnerable, and neurotrophins have been implicated because they appear to be protective. A downstream signal transducer of neurotrophins, the ankyrin repeat-rich membrane spanning scaffold protein/Kidins 220 (ARMS) is expressed in the cortex, where it could play an important role in trophic support. To test this hypothesis, we evaluated mice with a heterozygous deletion of ARMS (ARMS' mice). Remarkably, the EC and FC were the regions that demonstrated the greatest defects. Many EC and FC neurons became pyknotic in ARMS(+/-) mice, so that large areas of the EC and FC were affected by 12 months of age. Areas with pyknosis in the EC and FC of ARMS(+/-) mice were also characterized by a loss of immunoreactivity to a neuronal antigen. NeuN, which has been reported after insult or injury to cortical neurons. Electron microscopy showed that there were defects in mitochondria, myelination, and multilamellar bodies in the EC and FC of ARMS(+/-) mice. Although primarily restricted to the EC and FC, pathology appeared to be sufficient to cause functional impairments, because ARMS(+/-) mice performed worse than wild-type on the Morris water maze. Comparisons of males and females showed that female mice were the affected sex in all comparisons. Taken together, the results suggest that the expression of a prominent neurotrophin receptor substrate normally protects the EC and FC, and that ARMS may be particularly important in females. Published by Elsevier Inc.	[Duffy, Aine M.; Schaner, Michael J.; Kumar, Asok; Scharfman, Helen E.] Nathan S Kline Inst Psychiat Res, Ctr Dementia Res, Orangeburg, NY 10962 USA; [Wu, Synphen H.; Chao, Moses V.] NYU, Skirball Inst Biomol Med, Mol Neurobiol Program, Dept Cell Biol,Langone Med Ctr, New York, NY 10016 USA; [Wu, Synphen H.; Chao, Moses V.] NYU, Skirball Inst Biomol Med, Mol Neurobiol Program, Dept Physiol & Neurosci,Langone Med Ctr, New York, NY 10016 USA; [Wu, Synphen H.; Chao, Moses V.] NYU, Skirball Inst Biomol Med, Mol Neurobiol Program, Dept Psychiat,Langone Med Ctr, New York, NY 10016 USA; [Scharfman, Helen E.] NYU, Langone Med Ctr, Dept Child & Adolescent Psychiat, New York, NY 10016 USA; [Staniszewski, Agnieszka; Arancio, Ottavio] Columbia Univ, Med Ctr New York, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Staniszewski, Agnieszka; Arancio, Ottavio] Columbia Univ, Med Ctr New York, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA; [Carlos Arevalo, Juan] Univ Salamanca, Dept Cell Biol & Pathol, INCyL, Salamanca 37007, Spain		Duffy, AM (corresponding author), Nathan S Kline Inst Psychiat Res, Ctr Dementia Res, 140 Old Orangeburg Rd,Bldg 35, Orangeburg, NY 10962 USA.	aduffy@nki.rfmh.org; hscharfman@nki.rfmh.org	Arevalo, Juan Carlos/J-8154-2014; arancio, ottavio/AAB-7959-2019	Arevalo, Juan Carlos/0000-0003-1994-3095; Chao, Moses/0000-0002-6969-3744; arancio, ottavio/0000-0001-6335-164X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-37562, MH-084215, NS-21072, HD-23315, AG-034248]; New York University Langone Medical Center; New York State Office of Mental Health; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD023315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH084215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021072, R01NS037562, R56NS037562, R56NS021072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG034248] Funding Source: NIH RePORTER	This study was supported by NIH NS-37562 and MH-084215 to H.E.S., NIH NS-21072 and HD-23315 to M.V.C., NIH AG-034248 to O.A., the New York University Langone Medical Center CoE Seed Grant Program, and the New York State Office of Mental Health. We thank Dr. Ralph Nixon, Dr. Neil Maclusky, Dr. Daniel Wesson, and Patrice Pearce for their suggestions.	Andreazza AC, 2010, ARCH GEN PSYCHIAT, V67, P360, DOI 10.1001/archgenpsychiatry.2010.22; Arevalo JC, 2004, EMBO J, V23, P2358, DOI 10.1038/sj.emboj.7600253; Arevolo JC, 2006, J BIOL CHEM, V281, P1001, DOI 10.1074/jbc.M504163200; ARNOLD SE, 1995, AM J PSYCHIAT, V152, P738; Arnold SE, 2000, ANN NY ACAD SCI, V911, P275; Astur RS, 2004, BEHAV BRAIN RES, V151, P103, DOI 10.1016/j.bbr.2003.08.024; Astur RS, 1998, BEHAV BRAIN RES, V93, P185, DOI 10.1016/S0166-4328(98)00019-9; Barnes CA, 2000, NEUROBIOL AGING, V21, P613, DOI 10.1016/S0197-4580(00)00163-9; Bimonte-Nelson HA, 2004, NEUROREPORT, V15, P2659, DOI 10.1097/00001756-200412030-00021; Binder DK, 2004, ADV EXP MED BIOL, V548, P34; Bogolepov N N, 1971, Zh Nevropatol Psikhiatr Im S S Korsakova, V71, P1337; Boland B, 2008, J NEUROSCI, V28, P6926, DOI 10.1523/JNEUROSCI.0800-08.2008; Boland Barry, 2006, Molecular Aspects of Medicine, V27, P503, DOI 10.1016/j.mam.2006.08.009; BRAAK H, 1990, ACTA NEUROPATHOL, V80, P479, DOI 10.1007/BF00294607; Brinton RD, 2008, TRENDS NEUROSCI, V31, P529, DOI 10.1016/j.tins.2008.07.003; BUCCI DJ, 1995, BEHAV NEUROSCI, V109, P180, DOI 10.1037/0735-7044.109.1.180; Buckingham BP, 2008, J NEUROSCI, V28, P2735, DOI 10.1523/JNEUROSCI.4443-07.2008; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; Cellerino A, 1997, MOL CELL NEUROSCI, V9, P397, DOI 10.1006/mcne.1997.0641; Chao MV, 2006, CLIN SCI, V110, P167, DOI 10.1042/CS20050163; Davoli MA, 2002, NEUROSCIENCE, V115, P125, DOI 10.1016/S0306-4522(02)00376-7; de Leon MJ, 2007, ANN NY ACAD SCI, V1097, P114, DOI 10.1196/annals.1379.012; De Toledo-Morrell L, 2000, ANN NY ACAD SCI, V911, P240, DOI 10.1111/j.1749-6632.2000.tb06730.x; DeToledo-Morrell L, 2007, PROG BRAIN RES, V163, P741, DOI 10.1016/S0079-6123(07)63040-4; Dolorfo CL, 1998, J COMP NEUROL, V398, P49, DOI 10.1002/(SICI)1096-9861(19980817)398:1<49::AID-CNE4>3.0.CO;2-9; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Drevets WC, 2000, PROG BRAIN RES, V126, P413; DU F, 1993, EPILEPSY RES, V16, P223, DOI 10.1016/0920-1211(93)90083-J; Duffy AM, 2009, NEUROSCIENCE, V161, P1091, DOI 10.1016/j.neuroscience.2009.04.024; Durany N, 2001, SCHIZOPHR RES, V52, P79, DOI 10.1016/S0920-9964(00)00084-0; Finn PF, 2006, NUTRITION, V22, P830, DOI 10.1016/j.nut.2006.04.008; Gawryluk JW, 2010, INT J NEUROPSYCHOPH, V16, P1; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Gresack JE, 2003, BRAIN RES, V982, P98, DOI 10.1016/S0006-8993(03)03000-2; Hayakawa N, 2008, EXP MOL PATHOL, V85, P135, DOI 10.1016/j.yexmp.2008.05.001; Hebert AE, 2002, LEARN MEMORY, V9, P156, DOI 10.1101/lm.48502; Henderson VW, 2010, PROG BRAIN RES, V182, P77, DOI 10.1016/S0079-6123(10)82003-5; HEVNER RF, 1992, J COMP NEUROL, V326, P451, DOI 10.1002/cne.903260310; Hirata-Fukae C, 2008, BRAIN RES, V1216, P92, DOI 10.1016/j.brainres.2008.03.079; Holland D, 2009, P NATL ACAD SCI USA, V106, P20954, DOI 10.1073/pnas.0906053106; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Iglesias T, 2000, J BIOL CHEM, V275, P40048, DOI 10.1074/jbc.M005261200; Irwin RW, 2008, ENDOCRINOLOGY, V149, P3167, DOI 10.1210/en.2007-1227; Jo YS, 2007, J NEUROSCI, V27, P13567, DOI 10.1523/JNEUROSCI.3589-07.2007; Kadriu B, 2009, TOXICOLOGY, V256, P164, DOI 10.1016/j.tox.2008.11.021; Knusel B, 1996, LIFE SCI, V58, P2019, DOI 10.1016/0024-3205(96)00193-2; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; Kong HY, 2001, J NEUROSCI, V21, P176, DOI 10.1523/JNEUROSCI.21-01-00176.2001; Kong JM, 1998, J NEUROSCI, V18, P3241; Kordower JH, 2001, ANN NEUROL, V49, P202, DOI 10.1002/1531-8249(20010201)49:2<202::AID-ANA40>3.3.CO;2-V; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Koyama R, 2005, NEUROSCIENTIST, V11, P282, DOI 10.1177/1073858405278266; Krimer LS, 1997, CEREB CORTEX, V7, P732, DOI 10.1093/cercor/7.8.732; LaBuda CJ, 2002, PHYSIOL BEHAV, V76, P213, DOI 10.1016/S0031-9384(02)00713-8; Lai KO, 2009, CURR OPIN NEUROBIOL, V19, P275, DOI 10.1016/j.conb.2009.04.009; Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032; Leon WC, 2010, LEARN MEMORY, V17, P297, DOI 10.1101/lm.1804410; Lewis DA, 2003, ANN NY ACAD SCI, V1003, P102, DOI 10.1196/annals.1300.007; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lind D, 2005, J NEUROSCI RES, V79, P295, DOI 10.1002/jnr.20354; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; Lopez-Menendez C, 2009, J CELL SCI, V122, P3554, DOI 10.1242/jcs.056473; MAREN S, 1994, BRAIN RES, V661, P25, DOI 10.1016/0006-8993(94)91176-2; Martin LJ, 2007, J COMP NEUROL, V500, P20, DOI 10.1002/cne.21160; Matsuda S, 2009, J NEURAL TRANSM, V116, P395, DOI 10.1007/s00702-009-0194-0; Mayeaux DJ, 2004, PHYSIOL BEHAV, V82, P653, DOI 10.1016/j.physbeh.2004.06.002; McDonald CR, 2009, NEUROLOGY, V73, P457, DOI 10.1212/WNL.0b013e3181b16431; MCNAMARA JO, 2011, TEMPORAL LOBE EPILEP; McTigue DM, 2008, J NEUROCHEM, V107, P1, DOI 10.1111/j.1471-4159.2008.05570.x; McTigue DM, 1998, J NEUROSCI, V18, P5354, DOI 10.1523/JNEUROSCI.18-14-05354.1998; Michel TM, 2007, PSYCHIAT RES, V151, P145, DOI 10.1016/j.psychres.2006.04.013; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Murai KK, 2004, NEUROSCIENTIST, V10, P304, DOI 10.1177/1073858403262221; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Nakazawa K, 2006, NEURON, V50, P183, DOI 10.1016/j.neuron.2006.04.007; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Peng S, 2009, J NEUROSCI, V29, P9321, DOI 10.1523/JNEUROSCI.4736-08.2009; PerrotSinal TS, 1996, BEHAV NEUROSCI, V110, P1309, DOI 10.1037/0735-7044.110.6.1309; Peters A., 1991, FINE STRUCTURE NERVO, V3rd ed.; Petrulis A, 2003, NEUROSCIENCE, V122, P599, DOI 10.1016/j.neuroscience.2003.08.009; Portiansky EL, 2006, EXP NEUROL, V202, P519, DOI 10.1016/j.expneurol.2006.07.014; Postma A, 1999, PSYCHONEUROENDOCRINO, V24, P175, DOI 10.1016/S0306-4530(98)00073-0; POSTMA A, 2004, BRAIN COGN, V54; Puzzo D, 2009, J NEUROSCI, V29, P8075, DOI 10.1523/JNEUROSCI.0864-09.2009; Rajeswari A, 2008, TOXICOL IND HEALTH, V24, P189, DOI 10.1177/0748233708093726; Rajkowska G, 2002, BIPOLAR DISORD, V4, P105, DOI 10.1034/j.1399-5618.2002.01149.x; Rideout HJ, 2004, INT J BIOCHEM CELL B, V36, P2551, DOI 10.1016/j.biocel.2004.05.008; Schafer S, 2007, J NEURAL TRANSM, V114, P387, DOI 10.1007/s00702-006-0580-9; Scharfman HE, 2003, J NEUROSCI, V23, P11641; Scharfman HE, 2005, TRENDS NEUROSCI, V28, P79, DOI 10.1016/j.tins.2004.12.005; Scharfman HE, 2002, J COMP NEUROL, V454, P424, DOI 10.1002/cne.10449; Scharfman HE, 2000, ANN NY ACAD SCI, V911, P305; Scharfman HE, 2006, FRONT NEUROENDOCRIN, V27, P415, DOI 10.1016/j.yfrne.2006.09.004; Scharfman HE, 2006, EPILEPSIA, V47, P1423, DOI 10.1111/j.1528-1167.2006.00672.x; Scharfman Helen E, 2005, Epilepsy Curr, V5, P83, DOI 10.1111/j.1535-7511.2005.05312.x; Scharfman HE, 2009, ENDOCRINOLOGY, V150, P4437, DOI 10.1210/en.2009-0135; SCHENK F, 1985, EXP BRAIN RES, V58, P11; Schroeter ML, 2009, NEUROIMAGE, V47, P1196, DOI 10.1016/j.neuroimage.2009.05.037; Schuessel K, 2005, NEUROBIOL DIS, V18, P89, DOI 10.1016/j.nbd.2004.09.003; Selvamani A, 2010, J NEUROSCI, V30, P6852, DOI 10.1523/JNEUROSCI.0761-10.2010; Selvamani A, 2010, NEUROBIOL AGING, V31, P1618, DOI 10.1016/j.neurobiolaging.2008.08.014; Shah PJ, 2002, BRIT J PSYCHIAT, V180, P434, DOI 10.1192/bjp.180.5.434; Shoval G, 2005, EUR NEUROPSYCHOPHARM, V15, P319, DOI 10.1016/j.euroneuro.2004.12.005; Silachev D N, 2009, Neurosci Behav Physiol, V39, P749, DOI 10.1007/s11055-009-9197-4; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; SKUCAS V, 2009, 2009 NEUR M PLANN SO; Snedecor GW., 1989, STAT METHODS, V8th; Sniderhan LF, 2008, MOL CELL NEUROSCI, V38, P404, DOI 10.1016/j.mcn.2008.04.001; Sohrabji F, 2006, ENDOCRINE, V29, P191, DOI 10.1385/ENDO:29:2:191; Spowart-Manning L, 2005, BEHAV BRAIN RES, V156, P269, DOI 10.1016/j.bbr.2004.05.031; Steffenach HA, 2005, NEURON, V45, P301, DOI 10.1016/j.neuron.2004.12.044; STEWARD O, 1976, J COMP NEUROL, V169, P347, DOI 10.1002/cne.901690306; Sutcliffe JS, 2007, BEHAV BRAIN RES, V177, P117, DOI 10.1016/j.bbr.2006.10.029; Tapia-Arancibia L, 2008, BRAIN RES REV, V59, P201, DOI 10.1016/j.brainresrev.2008.07.007; Terni B, 2010, BRAIN PATHOL, V20, P222, DOI 10.1111/j.1750-3639.2009.00266.x; Thoenen H, 2002, NAT NEUROSCI, V5, P1046, DOI 10.1038/nn938; Tongiorgi E, 2006, MOL NEUROBIOL, V33, P17, DOI 10.1385/MN:33:1:017; Trinchese F, 2004, ANN NEUROL, V55, P801, DOI 10.1002/ana.20101; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; Van't Veer A, 2009, J NEUROSCI RES, V87, P69, DOI 10.1002/jnr.21841; Wang J, 2003, NEUROBIOL DIS, V14, P318, DOI 10.1016/j.nbd.2003.08.009; Wang JF, 2009, BIPOLAR DISORD, V11, P523, DOI 10.1111/j.1399-5618.2009.00717.x; Weickert CS, 2003, MOL PSYCHIATR, V8, P592, DOI 10.1038/sj.mp.4001308; Weickert CS, 2005, MOL PSYCHIATR, V10, P637, DOI 10.1038/sj.mp.4001678; WHITTEN WK, 1968, SCIENCE, V161, P584, DOI 10.1126/science.161.3841.584; Winawer MR, 2007, NEUROSCIENCE, V149, P465, DOI 10.1016/j.neuroscience.2007.06.009; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9; Wizemann TM, 2001, EXPLORING BIOL CONTR; Won SY, 2009, J NEUROIMMUNOL, V214, P83, DOI 10.1016/j.jneuroim.2009.07.005; Wu KL, 2010, J NEUROPATH EXP NEUR, V69, P272, DOI 10.1097/NEN.0b013e3181d1afe4; Wu SH, 2009, DEV NEUROBIOL, V69, P547, DOI 10.1002/dneu.20723; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yazdani U, 2006, EXP NEUROL, V200, P172, DOI 10.1016/j.expneurol.2006.02.002; Zhu JH, 2007, AM J PATHOL, V170, P75, DOI 10.2353/ajpath.2007.060524	138	25	25	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2011	229	2					409	420		10.1016/j.expneurol.2011.03.008			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	774XF	WOS:000291419400026	21419124	Green Accepted			2022-02-06	
J	Namiki, J; Yamazaki, M; Funabiki, T; Hori, S				Namiki, Jun; Yamazaki, Motoyasu; Funabiki, Tomohiro; Hori, Shingo			Inaccuracy and misjudged factors of Glasgow Coma Scale scores when assessed by inexperienced physicians	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Brain injury; Glasgow Coma Scale; Triage; Emergency department; Simulation; Consciousness level	LINEAR-REGRESSION PREDICTION; INTERRATER RELIABILITY; IMPAIRED CONSCIOUSNESS; EMERGENCY-DEPARTMENT; OBSERVER VARIABILITY; INTUBATED PATIENTS; VERBAL SCORE; INJURY; ADULTS; EYE	Objectives: Appropriate triage of a large number of patients with head injury is crucial in the emergency department (ED) as well as in the field. Traumatic brain injury (TBI) is primarily assessed using the Glasgow Coma Scale (GCS) to evaluate consciousness. However, GCS score assignment is far from sufficiently reliable for correct assessment, especially with inexperienced users. The purpose of this study was to reveal what factors are misjudged when assessed by inexperienced medical personnel. Methods: We analyzed GCS eye, verbal, and motor response (EVM) scoring profiles conducted by postgraduate year 1 junior residents (n = 94) before they began residency in specific departments. GCS assessment was tested using a video simulation that portrayed mock patients with eight different levels of consciousness that are frequently encountered in trauma patients. Results: On average, 26 +/- 18% of examinees failed to provide the correct EVM profiles for the eight selected consciousness levels. Primary misjudged GCS factors belonged to two categories: the assessment of "confused conversation (V4)", and the assessment of "withdrawal motor response (M4)". Conclusion: Additional instruction regarding the specific misjudged factors identified in this study may help inexperienced medical personnel improve the reliability of GCS score assignment to casualties with TBI. (C) 2011 Elsevier B.V. All rights reserved.	[Namiki, Jun; Yamazaki, Motoyasu; Funabiki, Tomohiro; Hori, Shingo] Keio Univ Sch Med, Dept Emergency & Crit Care Med, Shinjuku Ku, Tokyo 1608582, Japan		Namiki, J (corresponding author), Keio Univ Sch Med, Dept Emergency & Crit Care Med, Shinjuku Ku, Shinanomachi 35, Tokyo 1608582, Japan.	namiki@sc.itc.keio.ac.jp			General Insurance Association of Japan	The authors thank Mr. Kiyotaka Yasui, Department of Medical Education Center, Keio University School of Medicine, and the medical students at Keio University who are members of the Keio ACLS Popularizing and Promoting Association, for the production of the video simulation. This work was partly supported by the General Insurance Association of Japan.	BRAIN TRAUM FD, 2000, J NEUROTRAUM, V17, P563; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; Crossman J, 1998, INJURY, V29, P435, DOI 10.1016/S0020-1383(98)00079-5; Dunning J, 2004, J NEUROTRAUM, V21, P877, DOI 10.1089/0897715041526122; Elliott M, 1996, J Neurosci Nurs, V28, P213; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Gill M, 2007, ANN EMERG MED, V49, P403, DOI 10.1016/j.annemergmed.2006.03.031; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Heard K, 2004, HUM EXP TOXICOL, V23, P197, DOI 10.1191/0960327104ht436oa; Holdgate Anna, 2006, Emerg Med Australas, V18, P379, DOI 10.1111/j.1742-6723.2006.00867.x; JENNETT B, 1977, LANCET, V1, P878; Juarez V J, 1995, J Neurosci Nurs, V27, P283; LINDSAY KW, 1983, J NEUROSURG, V58, P57, DOI 10.3171/jns.1983.58.1.0057; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; Meredith W, 1998, J TRAUMA, V44, P839, DOI 10.1097/00005373-199805000-00016; *NICE CLIN GUID DE, 2007, NICE CLIN GUID 56 HE, P14; *NICE CLIN GUID DE, 2007, NICE CLIN GUID 56 HE, P22; Riechers RG, 2005, J NEUROTRAUM, V22, P1327, DOI 10.1089/neu.2005.22.1327; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; Sternbach GL, 2000, J EMERG MED, V19, P67, DOI 10.1016/S0736-4679(00)00182-7; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; TESSERIS J, 1991, ACTA NEUROCHIR, V110, P65, DOI 10.1007/BF01402050	26	25	25	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	JUN	2011	113	5					393	398		10.1016/j.clineuro.2011.01.001			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	775HG	WOS:000291449000009	21295908				2022-02-06	
J	Nicol, A; Pollock, A; Kirkwood, G; Parekh, N; Robson, J				Nicol, Alastair; Pollock, Allyson; Kirkwood, Graham; Parekh, Nikesh; Robson, James			Rugby union injuries in Scottish schools	JOURNAL OF PUBLIC HEALTH			English	Article						injuries; rugby union; schools	SPORTS INJURIES; CONCUSSION; HEAD	Background Rugby union is the most popular worldwide collision sport, yet concerns have been raised regarding the safety of the sport due to the physical, high impact nature and an increasing number of injuries. Methods A prospective, cohort study of the incidence, pattern and severity of injuries in rugby players in six Scottish schools during the second half of the 2008-09 season. Definition of injury and severity of injury were taken from International Rugby Board (IRB) consensus guidelines. Injury report forms and exposure data for match play were completed by a nominated staff member. Results Four hundred and seventy consent forms with survey information were returned. Of 37 rugby injuries in the study, 11 occurred during training. Head and face were the most injured body part and sprain/ligament injury the most common injury. Twenty injuries required attendance at Accident & Emergency with one admission. The tackle was the commonest phase of play causing injury. In the 193 matches played, the injury incidence during the match play was 10.8 injuries per 1000 player hours. Conclusions This study confirms the feasibility of collecting relevant injury data in schools rugby in Scotland. The findings are consistent with other studies with respect to incidence and profile of injuries sustained.	[Nicol, Alastair] Univ Edinburgh, Fitness Assessment & Sports Injury Ctr FASIC, Edinburgh EH8 9TJ, Midlothian, Scotland; [Pollock, Allyson; Kirkwood, Graham; Parekh, Nikesh] Univ Edinburgh, Ctr Int Publ Hlth Policy, Edinburgh EH8 9EG, Midlothian, Scotland; [Robson, James] Scottish Rugby Union, Edinburgh EH12 5PJ, Midlothian, Scotland		Nicol, A (corresponding author), Univ Edinburgh, Fitness Assessment & Sports Injury Ctr FASIC, 46 Pleasance, Edinburgh EH8 9TJ, Midlothian, Scotland.	anicnicol@doctors.org.uk		pollock, allyson/0000-0002-7388-3110	Chief Medical Officer Directorate at the Scottish Government; Scottish Rugby Union; University of Edinburgh	This work was supported by the Chief Medical Officer Directorate at the Scottish Government; the Scottish Rugby Union and the University of Edinburgh.	Bottini E, 2000, BRIT J SPORT MED, V34, P94, DOI 10.1136/bjsm.34.2.94; Brooks JHM, 2006, SPORTS MED, V36, P459, DOI 10.2165/00007256-200636060-00001; Caine D, 2006, CLIN J SPORT MED, V16, P500, DOI 10.1097/01.jsm.0000251181.36582.a0; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; FINCH CF, 2001, BRIT J SPORT MED, V35, P85; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Jones SJ, 2004, BRIT J SPORT MED, V38, P159, DOI 10.1136/bjsm.2002.002584; Junge A, 2004, BRIT J SPORT MED, V38, P168, DOI 10.1136/bjsm.2002.003020; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; McIntosh Andrew S, 2005, Med Sport Sci, V49, P120, DOI 10.1159/000085394; McManus A, 2004, J SCI MED SPORT, V7, P438, DOI 10.1016/S1440-2440(04)80261-5; MICHELI LJ, 2003, ENHANCING SAFETY YOU, P1; NATHAN M, 1983, S AFR MED J, V64, P132; Quarrie KL, 2005, BRIT J SPORT MED, V39, P650, DOI 10.1136/bjsm.2004.016022; ROUX CE, 1987, S AFR MED J, V71, P307; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002	22	25	27	2	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1741-3842			J PUBLIC HEALTH-UK	J. Public Health	JUN	2011	33	2					256	261		10.1093/pubmed/fdq047			6	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	770CO	WOS:000291064800015	20581127	Bronze, Green Published			2022-02-06	
J	Rogers, R; Bender, SD; Johnson, SF				Rogers, Richard; Bender, Scott D.; Johnson, Stephanie F.			A Critical Analysis of the MND Criteria for Feigned Cognitive Impairment: Implications for Forensic Practice and Research	PSYCHOLOGICAL INJURY & LAW			English	Article						Malingered neurocognitive dysfunction; Malingering; Feigned cognitive impairment; Slick criteria; Daubert standard	TRAUMATIC BRAIN-INJURY; MALINGERED NEUROCOGNITIVE DYSFUNCTION; RELIABLE DIGIT SPAN; WECHSLER-MEMORY-SCALE; CLASSIFICATION ACCURACY; NEUROPSYCHOLOGICAL ASSESSMENT; ALZHEIMERS-DISEASE; RECOGNITION TEST; RESPONSE BIAS; BASE RATES	Forensic neuropsychology continues to grapple with critical determinations of response styles, including the assessment of malingering. The development of the Malingered Neurocognitive Dysfunction (MND) model has been highly influential for both feigning research and neuropsychological practice. In striving to be a comprehensive model of malingering, MND proposes complex criteria for ascertaining possible, probable, and definite levels. In its critical review, this article suggests the possibility of an MND bias towards the over-classification of malingering. It also examines the limits of MND research to adequately test the MND model. The conceptual and empirical limitations of MND are discussed with reference to theory and neuropsychological practice.	[Rogers, Richard; Johnson, Stephanie F.] Univ North Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA; [Bender, Scott D.] Univ Virginia, Sch Med, Dept Psychiat & Neurobehav Sci, Charlottesville, VA 22908 USA		Rogers, R (corresponding author), Univ North Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA.	Richard.Rogers@unt.edu; sb4qk@virginia.edu; sfjohnson@my.unt.edu					Aguerrevere LE, 2008, ARCH CLIN NEUROPSYCH, V23, P831, DOI 10.1016/j.acn.2008.06.008; American Law Institute, 1962, MOD PEN COD PROP OFF; American Psychiatric Association, 2000, DIAGN STAT MAN, V4th ed; Ardolf BR, 2007, CLIN NEUROPSYCHOL, V21, P899, DOI 10.1080/13825580600966391; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bianchini K, 2005, ARCH CLIN NEUROPSYCH, V20, P365, DOI 10.1016/j.acn.2004.09.003; Boone K. B., 2007, ASSESSMENT FEIGNED C; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Curtis KL, 2009, ASSESSMENT, V16, P401, DOI 10.1177/1073191109338161; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Delis DC, 2007, ARCH CLIN NEUROPSYCH, V22, P589, DOI 10.1016/j.acn.2007.04.001; Dubois B, 2007, LANCET NEUROL, V6, P734, DOI 10.1016/S1474-4422(07)70178-3; Etherton J, 2005, ASSESSMENT, V12, P130, DOI 10.1177/1073191105274859; Faust D, 1998, CRIT ISS NE, P1; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, APPL NEUROPSYCHOL, V15, P161, DOI 10.1080/09084280802324085; Greve KW, 2008, ARCH CLIN NEUROPSYCH, V23, P341, DOI 10.1016/j.acn.2007.12.001; Greve KW, 2007, CLIN NEUROPSYCHOL, V21, P318, DOI 10.1080/13854040500488552; Greve KW, 2007, ASSESSMENT, V14, P12, DOI 10.1177/1073191106295095; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P816, DOI 10.1080/13854040500346610; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve K, 2009, CLIN NEUROPSYCHOL, V23, P343, DOI 10.1080/13854040802054169; Greve KW, 2003, ARCH CLIN NEUROPSYCH, V18, P245, DOI 10.1016/S0887-6177(02)00137-3; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Henry GK, 2007, APPL NEUROPSYCHOL, V14, P267, DOI 10.1080/09084280701719245; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P412, DOI 10.1080/13803390490520319; Langeluddecke PM, 2003, ARCH CLIN NEUROPSYCH, V18, P181, DOI 10.1016/S0887-6177(01)00195-0; Larrabee, 2007, ASSESSMENT MALINGERE, P334; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2009, CLIN NEUROPSYCHOL, V23, P167, DOI 10.1080/13854040801968443; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MELTON GB, 2007, PSYCHOL EVALUATIONS; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Morgan J. E., 2009, NEUROPSYCHOLOGY MALI; National Health Care Anti-Fraud Association, 2008, CONS AL IMP HLTH CAR; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; PANKRATZ L, 1990, CLIN NEUROPSYCHOL, V4, DOI DOI 10.1080/13854049008401832; Pomerantz AM, 2006, ETHICS BEHAV, V16, P253, DOI 10.1207/s15327019eb1603_5; Rogers R, 2000, CONDUCTING INSANITY EVALUATIONS, 2ND EDITION, P1; ROGERS R, 1998, PSYCHOL DESK REFEREN, P57; ROGERS R, 2005, FUNDAMENTALS FORENSI; Rogers R., 2008, CLIN ASSESSMENT MALI; Rogers R., 2011, COMPREHENSIVE HDB PS, V11; Rogers R, 2006, BEHAV SCI LAW, V24, P645, DOI 10.1002/bsl.687; Rogers R, 2011, J PSYCHOPATHOL BEHAV, V33, P355, DOI 10.1007/s10862-011-9222-0; Samra J., 2002, TAKING PSYCHOL LAW 2, V14, P285; Sartorius N, 2002, BMJ-BRIT MED J, V324, P1470, DOI 10.1136/bmj.324.7352.1470; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Vallabhajosula B, 2001, J AM ACAD PSYCHIATRY, V29, P207; Victor T, 2009, CLIN NEUROPSYCHOL, V23, P297, DOI 10.1080/13854040802232682; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	64	25	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1938-971X	1938-9728		PSYCHOL INJ LAW	Psychol. Inj. Law	MAY	2011	4	2	2		SI		147	156		10.1007/s12207-011-9107-2			10	Psychology, Clinical	Emerging Sources Citation Index (ESCI)	Psychology	VB4ED	WOS:000415464400004					2022-02-06	
J	Wood, RL; Alderman, N				Wood, Rodger Ll; Alderman, Nick			Applications of Operant Learning Theory to the Management of Challenging Behavior After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavior management; challenging behavior; cognitive impairment; operant learning theory; traumatic brain injury	AGGRESSIVE-BEHAVIOR; ENVIRONMENTAL DETERMINANTS; REHABILITATION; ESCAPE; REDUCTION; COST; INTERVENTIONS; EXTINCTION; DISORDERS; PROGRAM	For more than 3 decades, interventions derived from learning theory have been delivered within a neurobehavioral framework to manage challenging behavior after traumatic brain injury with the aim of promoting engagement in the rehabilitation process and ameliorating social handicap. Learning theory provides a conceptual structure that facilitates our ability to understand the relationship between challenging behavior and environmental contingencies, while accommodating the constraints upon learning imposed by impaired cognition. Interventions derived from operant learning theory have most frequently been described in the literature because this method of associational learning provides good evidence for the effectiveness of differential reinforcement methods. This article therefore examines the efficacy of applying operant learning theory to manage challenging behavior after TBI as well as some of the limitations of this approach. Future developments in the application of learning theory are also considered.	[Wood, Rodger Ll] Swansea Univ, Dept Psychol, Swansea SA2 8PP, W Glam, Wales; [Alderman, Nick] St Andrews Healthcare, Natl Brain Injury Ctr, Northampton, England; [Alderman, Nick] Kings Coll London, St Andrews Acad Ctr, Northampton, England		Wood, RL (corresponding author), Swansea Univ, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk		Alderman, Nick/0000-0002-8523-4142			ALDERMAN N, 1995, NEUROPSYCHOL REHABIL, V5, P193, DOI 10.1080/09602019508401467; Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; Alderman N, 2003, NEUROPSYCHOL REHABIL, V13, P211, DOI 10.1080/09602010244000327; Alderman N, 2003, STUD NEUROPSYCHOL DE, P171; Alderman N, 2001, BRAIN DAM B, P175; ALDERMAN N, 1991, Brain Injury, V5, P77, DOI 10.3109/02699059108998516; ALDERMAN N, 1994, NEUROPSYCHOL REHABIL, V4, P31, DOI 10.1080/09602019408401454; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; Alderman N, 1999, BRAIN INJURY, V13, P669; Alderman N, 1997, BRAIN INJURY, V11, P79, DOI 10.1080/026990597123683; ALDERMAN N, 1992, PHYSIOTHERAPY, V78, P335; ALDERMAN N, 1991, NEUROPSYCHOL REHABIL, V1, P65, DOI DOI 10.1080/09602019108401380; Alderman N, 2007, BRAIN INJURY, V21, P891, DOI 10.1080/02699050701543560; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BAUMESITER AA, 1978, QUALITY LIFE SEVEREL; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BURKE WH, 1988, INT J REHABIL RES, V11, P235, DOI 10.1097/00004356-198809000-00003; CARR EG, 1977, PSYCHOL BULL, V84, P800, DOI 10.1037/0033-2909.84.4.800; CARR EG, 1980, J APPL BEHAV ANAL, V13, P101, DOI 10.1901/jaba.1980.13-101; Crane A. A., 1991, BEHAV RESIDENTIAL TR, V6, P65; DAY RM, 1988, BEHAV MODIF, V12, P565, DOI 10.1177/01454455880124005; Dayus B, 2000, NEUROPSYCHOL REHABIL, V10, P415, DOI 10.1080/096020100411998; Donaghey CL, 2010, CLIN REHABIL, V24, P195, DOI 10.1177/0269215509353270; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; Eames P, 1996, BRAIN INJURY, V10, P631, DOI 10.1080/026990596124061; Emerson E., 2001, CHALLENGING BEHAV AN; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; Giles GM, 2006, J HEAD TRAUMA REHAB, V21, P168, DOI 10.1097/00001199-200603000-00009; GUESS D, 1991, AM J MENT RETARD, V96, P299; Hegel MT, 2000, BEHAV MODIF, V24, P94, DOI 10.1177/0145445500241005; Howells K, 2009, CRIM BEHAV MENT HEAL, V19, P308, DOI 10.1002/cbm.745; IWATA BA, 1990, J APPL BEHAV ANAL, V23, P11, DOI 10.1901/jaba.1990.23-11; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Knight C, 2008, NEUROPSYCHOL REHABIL, V18, P129, DOI 10.1080/09602010701822381; Kodak T, 2007, J APPL BEHAV ANAL, V40, P167, DOI 10.1901/jaba.2007.43-06; LOVAAS I, 1987, J APPL BEHAV ANAL, V20, P45, DOI 10.1901/jaba.1987.20-45; MACE FC, 1986, APPL RES MENT RETARD, V7, P203; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Manchester D, 1997, BRAIN INJURY, V11, P271; MATEER CA, 1990, NEUROBEHAVIOURAL SEQ; MCGLYNN SM, 1990, PSYCHOL BULL, V108, P420, DOI 10.1037/0033-2909.108.3.420; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER E, 1981, BRIT J CLIN PSYCHOL, V20, P69, DOI 10.1111/j.2044-8260.1981.tb00498.x; Mozzoni MP, 2000, BEHAV INTERVENT, V15, P153, DOI 10.1002/1099-078X(200007/09)15:3<153::AID-BIN52>3.0.CO;2-K; Oliver C, 1999, RES DEV DISABIL, V20, P197, DOI 10.1016/S0891-4222(99)00003-7; PETERS M D, 1992, Brain Injury, V6, P299, DOI 10.3109/02699059209034944; POWELL GE, 1981, BRAIN FUNCTION THERA; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Rahman B, 2010, NEUROPSYCHOL REHABIL, V20, P212, DOI 10.1080/09602010903021097; RAPOFF MA, 1980, J MENT DEFIC RES, V24, P37; REPP AC, 1988, J APPL BEHAV ANAL, V21, P281, DOI 10.1901/jaba.1988.21-281; Rothwell NA, 1999, BRAIN INJURY, V13, P521; Sandman C.A., 1995, MENTAL RETARDATION D, V1, P130, DOI DOI 10.1002/mrdd.1410010209; STEWART I, BRAIN INJ IN PRESS; TANNER BA, 1975, J APPL BEHAV ANAL, V8, P53, DOI 10.1901/jaba.1975.8-53; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Treadwell K, 1996, J HEAD TRAUMA REHAB, V11, P62, DOI 10.1097/00001199-199602000-00008; TURNER JM, 1990, BEHAV RESID TREAT, V90, P15; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; Wilson B., 1989, PRACTICE BEHAV MED; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood R. L. L., 1981, APPL CONDITIONING TH; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746; Wood RL, 2001, NEUROBEHAVIOURAL DIS, P1; WOOD RL, 1984, OUTCOME SEVERE BLUNT; Woodhead E. L., 2008, CLIN CASE STUD, V7, P301; Worthington AD, 2006, BRAIN INJURY, V20, P947, DOI 10.1080/02699050600888314; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Yody BB, 2000, J HEAD TRAUMA REHAB, V15, P1041, DOI 10.1097/00001199-200008000-00006; YOUNGSON HA, 1994, BRAIN INJURY, V8, P23, DOI 10.3109/02699059409150956; ZARCONE JR, 1993, J APPL BEHAV ANAL, V26, P135, DOI 10.1901/jaba.1993.26-135	74	25	26	0	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2011	26	3					202	211		10.1097/HTR.0b013e318217b46d			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	760CY	WOS:000290301800004	21552069				2022-02-06	
J	Helmes, E; Ostbye, T; Steenhuis, RE				Helmes, Edward; Ostbye, Truls; Steenhuis, Runa E.			Incremental contribution of reported previous head injury to the prediction of diagnosis and cognitive functioning in older adults	BRAIN INJURY			English	Article						Dementia; risk factors; head injury; older adults; longitudinal study	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; RISK-FACTORS; NEUROPSYCHOLOGICAL FUNCTION; HEALTH; RECOVERY; PERFORMANCE; DEMENTIA; MILD; METAANALYSIS	Background: Severe brain injuries may be a risk factor for the development of dementia in later life. Less severe incidents with relatively short or even no loss of consciousness may not carry the same prognosis. Objectives: This study used data from the first two waves of the Canadian Study of Health and Ageing (CSHA-1 and CSHA-2) to investigate two questions. (1) Does a history of head injury improve the prediction of the diagnosis of dementia? This analysis was based on the 921 elderly individuals who underwent a clinical assessment in CSHA-2 and, 5 years earlier, had reported whether or not they had had a head injury. (2) Does adding information about a history of head injury improve the prediction of neuropsychological test scores? This second analysis included 585 elderly people who underwent neuropsychological assessment in both waves and who also reported whether or not they had had a history of mild or moderate-to-severe head injury. Results: Results showed that the inclusion of head injury information did not improve the prediction of diagnostic outcome of dementia. Age and overall cognitive status were associated with most neuropsychological test scores, more so than the more limited influence of chronic health problems, which was associated with about half of the neuropsychological measures.	[Helmes, Edward] James Cook Univ, Dept Psychol, Townsville, Qld 4811, Australia; [Ostbye, Truls] Duke Univ, Dept Family & Community Med, Chapel Hill, NC USA		Helmes, E (corresponding author), James Cook Univ, Dept Psychol, Townsville, Qld 4811, Australia.	edward.helmes@jcu.edu.au			Health Canada's National Health Research Development Program (NHRDP); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; Pfizer Canada Inc. through MRC/PMACUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Pfizer Canada Inc. through NHRDP; Bayer Inc.Bayer AG; B.C. Health Research Foundation; Canadian Institute for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Merck-Frosst; Jansen-Ortho	Core funding for Phases 1 & 2 of the CSHA was provided by the Seniors' Independence Research Program through Health Canada's National Health Research Development Program (NHRDP). Funding for analysis of the caregiver component was provided by the Medical Research Council. Additional funding was provided by Pfizer Canada Inc. through the MRC/PMAC, NHRDP, by Bayer Inc., and by the B.C. Health Research Foundation. Core funding for Phase 3 was provided by the Canadian Institute for Health Research (CIHR). Supplementary funding for the caregiver component was obtained from CIHR. Additional funding was provided by Merck-Frosst and by Jansen-Ortho. CSHA was coordinated through the University of Ottawa and Health Canada.	American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 1980, DIAGN STAT MAN MENT; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1996, AM J PSYCHIAT, V153, P7; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; CONWELL Y, 1993, J AM GERIATR SOC, V41, P38, DOI 10.1111/j.1532-5415.1993.tb05945.x; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; FIELDS RB, 1997, HDB NEUROPSYCHOLOGY, P280; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Graham JE, 1996, NEUROEPIDEMIOLOGY, V15, P246, DOI 10.1159/000109914; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HENDERSON AS, 1988, ACTA PSYCHIAT SCAND, V78, P257, DOI 10.1111/j.1600-0447.1988.tb06336.x; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Jellinger KA, 2004, J NEUROL NEUROSUR PS, V75, P511; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McCrea M., 2008, MILD TRAUMATIC BRAIN; McDowell I, 2004, AGING NEUROPSYCHOL C, V11, P149, DOI 10.1080/13825580490511044; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1994, DEMENTIA NORMAL AGIN, P208; Nilsson L.-G., 2001, PERSPECTIVES HUMAN M, P253; Patterson C, 2007, ALZHEIMERS DEMENT, V3, P341, DOI 10.1016/j.jalz.2007.07.001; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rosnick CB, 2004, AGING NEUROPSYCHOL C, V11, P89, DOI 10.1076/anec.11.1.89.29367; Roth M., 1988, CAMDEX CAMBRIDGE EXA; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; STEENHUIS RE, 1995, J CLIN EXP NEUROPSYC, V17, P773, DOI 10.1080/01688639508405166; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; TUOKKO H, 1995, J CLIN EXP NEUROPSYC, V17, P352, DOI 10.1080/01688639508405129; VANBOXTEL MPJ, 1997, PHYS HLTH VASCULAR R; VANDUIJN CM, 1991, INT J EPIDEMIOL, V20, pS4, DOI 10.1093/ije/20.Supplement_2.S4; Wechsler D., 1981, WAIS R MANUAL; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; 1994, NEUROLOGY, V44, P2073; [No title captured]	48	25	27	0	3	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	2011	25	4					338	347		10.3109/02699052.2011.556104			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	739RL	WOS:000288735600003	21314278				2022-02-06	
J	Kasner, SE; Baren, JM; Le Roux, PD; Nathanson, PG; Lamond, K; Rosenberg, SL; Karlawish, J				Kasner, Scott E.; Baren, Jill M.; Le Roux, Peter D.; Nathanson, Pamela G.; Lamond, Katherine; Rosenberg, Stacy L.; Karlawish, Jason			Community Views on Neurologic Emergency Treatment Trials	ANNALS OF EMERGENCY MEDICINE			English	Article							ACUTE STROKE TRIALS; INFORMED-CONSENT; RESUSCITATION RESEARCH; CLINICAL-TRIALS; CONSULTATION; EXCEPTION; QUALITY; VOICES	Study objective: We improve our understanding of the community consultation process for acute neurologic emergency trials conducted under the federal regulations for Exception From Informed Consent (EFIC) for emergency research. Methods: We performed a qualitative study using focus groups to collect data from patients with a previous stroke or brain injury and their families and from young men at risk for traumatic brain injury. Discussions were transcribed, coded, and analyzed for major themes and subthemes. Results: Five focus groups, involving 40 participants, were convened. Major themes included the awareness and understanding of key clinical trial concepts, including prominent concerns about placebo and therapeutic misconception; inability to obtain informed consent and acceptable surrogate decisionmaking; EFIC in emergency research and whether existing regulations are acceptable; specific trial design problems, including comparison to standard of care versus 2 competing active therapies; and community consultation and representation. Conclusion: In this study sample, EFIC trials were deemed appropriate and acceptable for acute neurologic emergency research. Education, along with open discussion about basic clinical research concepts, disease- and trial-specific information, and potential surrogate decisionmaking, was essential to determine the acceptability of an EFIC trial. Approval by institutional review boards was highly regarded as a means of human protection and effective community consultation for such trials. A data repository of information gained from similar qualitative research may help investigators and regulators who wish to plan, conduct, review, and provide oversight for acute neurologic emergency trials under EFIC regulations. [Ann Emerg Med. 2011;57:346-354.]	[Kasner, Scott E.; Rosenberg, Stacy L.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Baren, Jill M.; Nathanson, Pamela G.; Lamond, Katherine] Univ Penn, Dept Emergency Med, Philadelphia, PA 19104 USA; [Le Roux, Peter D.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Karlawish, Jason] Univ Penn, Dept Med, Div Geriatr Med, Philadelphia, PA 19104 USA		Kasner, SE (corresponding author), Univ Penn, Dept Neurol, 3400 Spruce St, Philadelphia, PA 19104 USA.	kasner@mail.med.upenn.edu	Kasner, Scott/C-6109-2011	Nathanson, Pamela/0000-0002-1471-6670	University of Pennsylvania Comprehensive Neuroscience Center	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article that might create any potential conflict of interest. The authors have stated that no such relationships exist. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. Funded by a grant from the University of Pennsylvania Comprehensive Neuroscience Center.	Alexandrov AV, 2006, INT J STROKE, V1, P160, DOI 10.1111/j.1747-4949.2006.00046.x; [Anonymous], 1996, Fed Regist, V61, P51498; Baren JM, 2007, ACAD EMERG MED, V14, P346, DOI 10.1197/j.aem.2007.01.002; Baren JM, 1999, ACAD EMERG MED, V6, P1210, DOI 10.1111/j.1553-2712.1999.tb00135.x; BIROS MH, 2009, RESUSCITATION, V7, P7; Blixen CE, 2005, J MED ETHICS, V31, P608, DOI 10.1136/jme.2004.010488; Chamberlain JM, 2009, ACAD EMERG MED, V16, P763, DOI 10.1111/j.1553-2712.2009.00455.x; Elkins JS, 2006, STROKE, V37, P123, DOI 10.1161/01.STR.0000195149.44390.aa; Flaherty ML, 2008, NEUROLOGY, V71, P1566, DOI 10.1212/01.wnl.0000316196.63704.f5; Halpern SD, 2002, CONTROL CLIN TRIALS, V23, P274, DOI 10.1016/S0197-2456(02)00191-5; Halpern SD, 2001, J ACQ IMMUN DEF SYND, V27, P281, DOI 10.1097/00126334-200107010-00011; Kalviainen R, 2007, EPILEPSIA, V48, P99, DOI 10.1111/j.1528-1167.2007.01364.x; Kasner SE, 2009, NEUROLOGY, V72, P1682, DOI 10.1212/WNL.0b013e3181a55fbe; Kimmelman J, 2007, HASTINGS CENT REP, V37, P36, DOI 10.1353/hcr.2007.0092; Lavori PW, 2007, CLIN TRIALS, V4, P638, DOI 10.1177/1740774507085144; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; McClure KB, 2007, J MED ETHICS, V33, P289, DOI 10.1136/jme.2005.014878; McClure KB, 2003, ACAD EMERG MED, V10, P352, DOI 10.1111/j.1553-2712.2003.tb01348.x; Merchant RM, 2008, ACAD EMERG MED, V15, P581, DOI 10.1111/j.1553-2712.2008.00134.x; Merton R. K., 1990, FOCUSED INTERVIEW MA; Morris MC, 2004, PEDIATRICS, V114, P776, DOI 10.1542/peds.2004-0482; Patton M. Q., 2002, QUALITATIVE RES METH; Ragin DF, 2008, SOC SCI MED, V66, P1379, DOI 10.1016/j.socscimed.2007.10.022; Richardson LD, 2005, ACAD EMERG MED, V12, P1082, DOI 10.1197/j.aem.2005.06.008; Sen Biswas M, 2007, CLIN TRIALS, V4, P258, DOI 10.1177/1740774507079434; Sugarman J, 2005, CLIN TRIALS, V2, P34, DOI 10.1191/1740774505cn066oa; 1996, FED REG, V61, P51531; 2006, FED REG, V167, P51198	28	25	25	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	APR	2011	57	4					346	354		10.1016/j.annemergmed.2010.07.009			9	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Emergency Medicine	747JN	WOS:000289316200010	20875693				2022-02-06	
J	Zhang, BL; Chen, X; Lin, YP; Tan, T; Yang, Z; Dayao, C; Liu, L; Jiang, RC; Zhang, JN				Zhang, Baoliang; Chen, Xin; Lin, Yunpeng; Tan, Tao; Yang, Zhuo; Dayao, Carlos; Liu, Li; Jiang, Rongcai; Zhang, Jianning			Impairment of synaptic plasticity in hippocampus is exacerbated by methylprednisolone in a rat model of traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Long-term potentiation; Dentate gyrus; Interneuron; Methylprednisolone	TEMPORAL-LOBE EPILEPSY; DENTATE GYRUS; SELECTIVE VULNERABILITY; HEAD TRAUMA; DEFICITS; NEURONS; MEMORY; CELLS; LONG	Patients with traumatic brain injury (TBI) exhibit impaired cognitive capability that is exacerbated with methylprednisolone (MP). Since long-term potentiation (LTP) is a leading cellular model underlying learning, we hypothesize that MP disturbs the electrophysiological character in the hippocampus by decreasing the number of inteneurons post-traumatically in the dentate gyrus (DG) and cornu ammonis3 (CA3) regions, resulting in learning deficits. To test this hypothesis, we investigated the alterations of learning abilities and correlated the alternation with hippocampal synaptic plasticity in rats receiving lateral fluid percussion injury (FPI) and being treated with MP. We found that MP aggravates the spatial learning deficiency and changes in the excitability of the DG and cornu ammonis1 (CA1) areas in rats subjected to FPI. The functional and electrophysiological deficits are associated with a decrease in the number of parvalbumin-immunoreactive (PV-IR) and cholecystokinin-immunoreactive (CCK-IR) GABAergic cells. The data suggest that MP therapy may decrease the number of DG interneurons in post-traumatic hippocampus, resulting in the aggravated deficits of learning ability induced by TBI. (C) 2011 Elsevier B.V. All rights reserved.	[Zhang, Jianning] Tianjin Med Univ Gen Hosp, Tianjin Neurol Inst, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Minist Educ,Dept Neurosurg,Tianjin Key Lab Injuri, Tianjin 300052, Peoples R China; [Yang, Zhuo] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China; [Tan, Tao] Tianjin Med Univ, Sch Biomed Engn, Tianjin 300070, Peoples R China		Zhang, JN (corresponding author), Tianjin Med Univ Gen Hosp, Tianjin Neurol Inst, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Minist Educ,Dept Neurosurg,Tianjin Key Lab Injuri, 154 Anshan Rd, Tianjin 300052, Peoples R China.	jianningzhang@hotmail.com	Tan, Tao/F-5535-2010	Tan, Tao/0000-0002-4571-3296	National 973 Projects of ChinaNational Basic Research Program of China [2005CB522605]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81000533]; Tianjin Science and Technology Development Plan [05YFGDSF02500]; Tianjin Natural Science FoundationNatural Science Foundation of Tianjin [033611511]; Tianjin Medical University	We acknowledge Ping Lei, Weiyun Cui, Fanglian Chen, Lei Zhou, Huijie Wei, Liang Wang, Dong Wang, and Xiaonan Wang for excellent technical support. This work is supported by the National 973 Projects of China (grant no. 2005CB522605), National Natural Science Foundation of China (grant no. 81000533), Tianjin Science and Technology Development Plan (grant no. 05YFGDSF02500), Tianjin Natural Science Foundation (grant no. 033611511), and "211 Project" Graduate Innovation Grant of Tianjin Medical University.	ANDREAS R, 1995, AM J PATHOL, V6, P1575; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BENGI A, 2007, EUROPEAN J NEUROSCIE, V5, P1166; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen X, 2009, J NEUROTRAUM, V26, P253, DOI 10.1089/neu.2007.0504; CLAIBORNE BJ, 1986, J COMP NEUROL, V246, P435, DOI 10.1002/cne.902460403; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; FREUND TF, 1996, HIPPOCAMPUS, V6, P345; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; GOLARAI G, 1999, SOC NEUR ANN M 23 28; HALASY K, 1993, EUR J NEUROSCI, V5, P411, DOI 10.1111/j.1460-9568.1993.tb00508.x; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LAURER HL, 2002, ENCY HUMAN BRAIN, P93; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; SHI D, 2009, J NEUROSCI, V2, P393; SLOVITER RS, 1994, ANN NEUROL, V35, P640, DOI 10.1002/ana.410350604; SLOVITER RS, 1994, HIPPOCAMPUS, V4, P250, DOI 10.1002/hipo.450040304; Su ZJ, 2009, J NEUROTRAUM, V26, P1695, DOI 10.1089/neu.2008.0519; Toth Z, 1997, J NEUROSCI, V17, P8106; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052; Yang L, 2007, J NEUROPHYSIOL, V97, P178, DOI 10.1152/jn.01374.2005	28	25	27	1	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 25	2011	1382						165	172		10.1016/j.brainres.2011.01.065			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	745AF	WOS:000289135600018	21276433				2022-02-06	
J	Chen, JA; Wu, XJ; Shao, B; Zhao, W; Shi, W; Zhang, SW; Ni, LC; Shen, AG				Chen, Jian; Wu, Xiujie; Shao, Bai; Zhao, Wei; Shi, Wei; Zhang, Shuangwei; Ni, Lanchun; Shen, Aiguo			Increased Expression of TNF Receptor-Associated Factor 6 After Rat Traumatic Brain Injury	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Traumatic brain injury; TRAF6; Glial proliferation; Apoptosis; Rat	NF-KAPPA-B; ACTIVATION; TRAF6; LIPOPOLYSACCHARIDE; MECHANISMS; INTERLEUKIN-1; APOPTOSIS; REQUIRES; FAMILY; ENZYME	TRAF6 (TNF receptor-associated factor 6), a member of tumor necrosis factor receptor-associated factors family was identified as a molecule that binds to the cytoplasmic domain of CD40. TRAF6 functions as an adaptor, positively regulating the NF-kappa B, JNK pathway. Additionally, some studies have reported that TRAF6 is required for apoptosis within the developing CNS and regulates cell fate decisions by inducing caspase 8-dependent apoptosis. However, its distribution and function in the central nervous system (CNS) lesion are not well understood. In this study, we performed an acute traumatic brain injury model in adult rats. And we mainly examined protein expression and cellular localization of TRAF6 during rat traumatic brain injury (TBI). Western blot analysis showed TRAF6 level significantly improved at 7 days after injury, and then declined during the following days. The protein expression of TRAF6 was further analysed by immunohistochemistry. In comparison to contralateral cerebral cortex, we observed a highly significant accumulation of TRAF6 at the ipsilateral brain. Immunofluorescence double-labeling showed that TRAF6 was co-expressed with NeuN and GFAP. Besides, co-localization of TRAF6/active caspase 3 and TRAF6/proliferating cell nuclear antigen (PCNA) were detected in NeuN and GFAP, respectively. We also examined the expression profiles of proliferating cell nuclear antigen (PCNA) and active caspase 3 whose changes were correlated with the expression profiles of TRAF6. In conclusion, this is the first description of TRAF6 expression in traumatic brains. Our data suggested that TRAF6 might play important roles in CNS pathophysiology after TBI.	[Chen, Jian; Wu, Xiujie; Zhao, Wei; Shi, Wei; Zhang, Shuangwei; Ni, Lanchun; Shen, Aiguo] Nantong Univ, Dept Neurosurg, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China; [Chen, Jian; Wu, Xiujie; Zhao, Wei; Shi, Wei; Zhang, Shuangwei; Ni, Lanchun; Shen, Aiguo] Nantong Univ, Jiangsu Prov Key Lab Neuroregenerat, Nantong 226001, Jiangsu, Peoples R China; [Shao, Bai] Nantong Univ, Affiliated Dongtai Hosp, Dept Neurosurg, Yancheng 224200, Jiangsu, Peoples R China		Chen, JA (corresponding author), Nantong Univ, Dept Neurosurg, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China.	chenjian9079@163.com; shen_aiguo@yahoo.com			Chinese 973 programNational Basic Research Program of China [2011CS910600]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30770488, 30870320, 31070723, 81070275]; Natural Science Foundation of Jiangsu provinceNatural Science Foundation of Jiangsu Province [BK2009156, BK2009157, BK2009161]; Natural science Foundation of Jiangsu Colleges and Universities [09KJB320011]	This study was supported by the Chinese 973 program (2011CS910600); the National Natural Science Foundation of China (No. 30770488, No. 30870320, No. 31070723, and No. 81070275); Natural Science Foundation of Jiangsu province (No. BK2009156, No. BK2009157, and No. BK2009161); Natural science Foundation of Jiangsu Colleges and Universities Grant (09KJB320011).	Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chung JY, 2002, J CELL SCI, V115, P679; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Erhardt L, 1996, EUR HEART J, V17, P1781; Fawcett JW, 1997, CELL TISSUE RES, V290, P371, DOI 10.1007/s004410050943; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; He LS, 2006, J BIOL CHEM, V281, P11235, DOI 10.1074/jbc.M508779200; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; Lamothe B, 2008, J BIOL CHEM, V283, P24871, DOI 10.1074/jbc.M802749200; LOGAN A, 1992, J NEUROSCI, V12, P3828; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lomaga MA, 2000, J NEUROSCI, V20, P7384; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; Morlon A, 2005, HUM MOL GENET, V14, P3751, DOI 10.1093/hmg/ddi405; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Muroi M, 2008, J LEUKOCYTE BIOL, V83, P702, DOI 10.1189/jlb.0907629; Pollet I, 2003, BLOOD, V102, P1740, DOI 10.1182/blood-2003-01-0288; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wong F, 2004, BLOOD, V103, P4520, DOI 10.1182/blood-2003-06-2118; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008	26	25	29	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	MAR	2011	31	2					269	275		10.1007/s10571-010-9617-6			7	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	726VC	WOS:000287753500010	21072581				2022-02-06	
J	Wu, CT; Wen, LL; Wong, CS; Tsai, SY; Chan, SM; Yeh, CC; Borel, CO; Cherng, CH				Wu, Ching-Tang; Wen, Li-Li; Wong, Chih-Shung; Tsai, Shih-Ying; Chan, Shun-Ming; Yeh, Chun-Chang; Borel, Cecil O.; Cherng, Chen-Hwan			Temporal Changes in Glutamate, Glutamate Transporters, Basilar Arteries Wall Thickness, and Neuronal Variability in an Experimental Rat Model of Subarachnoid Hemorrhage	ANESTHESIA AND ANALGESIA			English	Article							TRAUMATIC BRAIN-INJURY; CEREBRAL VASOSPASM; DOWN-REGULATION; ISCHEMIA; RELEASE; GLT-1; GLAST; HIPPOCAMPUS; MECHANISMS; EXPRESSION	BACKGROUND: Glutamate and glutamate transporters (GTs) (including glutamate/aspartate transporter, glutamate transporter-1, and excitatory amino acid carrier 1) have important roles in the pathogenesis of ischemic neurological injury. The changes in glutamate, GTs, and neuronal injury after subarachnoid hemorrhage (SAH) have not been widely investigated. In this study, we examined the changes in extracellular glutamate concentration, GTs, wall thickness of basilar arteries (BAs), and neuronal degeneration in experimental SAH rats. METHODS: An intrathecal microdialysis probe was inserted into male Sprague Dawley rats. SAH was induced using a double-hemorrhage model. To measure glutamate concentrations, extracellular dialysates were collected for 30 minutes before, and daily for 7 days after SAH. Changes in neurological scores, body weight, and BA wall thickness were measured. The neuron degeneration in the hippocampus and the changes of GTs in the cerebral cortex and hippocampus were measured. RESULTS: Glutamate concentrations were significantly higher in SAH rats from day (D) 1 to D7 after SAH compared with the sham rats, especially at D1. A significant body weight reduction and neurological defects were observed at D3 after SAH. The walls of BAs in SAH rats were significantly thicker compared with those of sham rats; the maximum change was observed at D7. Hippocampal neuronal degeneration was observed after SAH and the highest severity was at D7. The expression of GTs was downregulated after SAH and persisted for 7 days. CONCLUSIONS: SAH induced in the double-hemorrhage rat model may produce an excessive and prolonged increase of extracellular glutamate concentrations and downregulation of GTs, which are accompanied by BA wall thickness, and hippocampal neuronal degeneration. (Anesth Analg 2011;112:666-73)	[Wu, Ching-Tang; Chan, Shun-Ming; Yeh, Chun-Chang; Cherng, Chen-Hwan] Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Anesthesiol, Taipei, Taiwan; [Wen, Li-Li] En Chu Kong Hosp, Dept Clin Lab, Taipei, Taiwan; [Wong, Chih-Shung] Cathay Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Tsai, Shih-Ying] Taipei Med Univ, Grad Inst Med Sci, Sch Med, Taipei, Taiwan; [Tsai, Shih-Ying] Taipei Med Univ, Dept Physiol, Sch Med, Taipei, Taiwan; [Borel, Cecil O.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA		Cherng, CH (corresponding author), Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Anesthesiol, Taipei, Taiwan.	cherng1018@yahoo.com.tw	Wu, Zhi-Fu/ABE-6379-2020		National Science Council, Taiwan, Republic of ChinaMinistry of Science and Technology, Taiwan [NSC 95-2314-B-016-049]	Supported by the National Science Council (NSC 95-2314-B-016-049), Taiwan, Republic of China.	Chen JC, 2005, NEUROPHARMACOLOGY, V49, P703, DOI 10.1016/j.neuropharm.2005.05.002; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Fergusen S, 2007, NEUROSURGERY, V60, P658, DOI 10.1227/01.NEU.0000255396.23280.31; Germano A, 2007, J NEUROTRAUM, V24, P732, DOI 10.1089/neu.2006.0181; Han F, 2008, NEUROSCI LETT, V430, P275, DOI 10.1016/j.neulet.2007.11.021; Jeon H, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-103; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Macdonald RL, 2007, NAT CLIN PRACT NEURO, V3, P256, DOI 10.1038/ncpneuro0490; MITANI A, 1992, NEUROSCIENCE, V48, P307, DOI 10.1016/0306-4522(92)90492-K; Nishizawa Y, 2001, LIFE SCI, V69, P369, DOI 10.1016/S0024-3205(01)01142-0; Park S, 2004, STROKE, V35, P2412, DOI 10.1161/01.STR.0000141162.29864.e9; Prunell GF, 2003, NEUROSURGERY, V52, P165, DOI 10.1097/00006123-200301000-00022; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Rao VLR, 2000, NEUROCHEM INT, V36, P531, DOI 10.1016/S0197-0186(99)00153-9; Rosengart AJ, 2007, J NEUROSURG, V107, P253, DOI 10.3171/JNS-07/08/0253; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Sabri M, 2008, BRAIN RES, V1238, P163, DOI 10.1016/j.brainres.2008.08.031; Schmitt A, 1997, J NEUROSCI, V17, P1, DOI 10.1523/jneurosci.17-01-00001.1997; Seckin H, 2008, SURG NEUROL, V70, P344, DOI 10.1016/j.surneu.2007.07.052; Suarez JI, 2006, NEW ENGL J MED, V354, P387, DOI 10.1056/NEJMra052732; Sung CS, 2004, BRAIN RES, V1015, P145, DOI 10.1016/j.brainres.2004.04.068; Susarla BTS, 2004, J NEUROCHEM, V91, P1151, DOI 10.1111/j.1471-4159.2004.02791.x; Van Landeghem FKH, 2001, GLIA, V35, P167, DOI 10.1002/glia.1082; VelazFaircloth M, 1996, AM J PHYSIOL-CELL PH, V270, pC67, DOI 10.1152/ajpcell.1996.270.1.C67; Yeh TH, 2005, NEUROBIOL DIS, V18, P476, DOI 10.1016/j.nbd.2004.12.011; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zemke D, 2007, VASC MED, V12, P243, DOI 10.1177/1358863x07081316; Zhou CM, 2004, J CEREBR BLOOD F MET, V24, P419, DOI 10.1097/00004647-200404000-00007	30	25	26	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2011	112	3					666	673		10.1213/ANE.0b013e318207c51f			8	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	726DG	WOS:000287698400032	21233495				2022-02-06	
J	Scherer, MR; Shelhamer, MJ; Schubert, MC				Scherer, Matthew R.; Shelhamer, Mark J.; Schubert, Michael C.			Characterizing high-velocity angular vestibulo-ocular reflex function in service members post-blast exposure	EXPERIMENTAL BRAIN RESEARCH			English	Article						Blast; Traumatic brain injury; Angular vestibulo-ocular reflex; Scleral search coil	DYNAMIC VISUAL-ACUITY; INJURY-INDUCED NEUROTRAUMA; PASSIVE HEAD MOVEMENTS; VESTIBULAR NEURITIS; BLAST INJURY; BRAIN-INJURY; SEARCH-COIL; COMPENSATION; RESPONSES; NEURONS	Blasts (explosions) are the most common mechanism of injury in modern warfare. Traumatic brain injury (TBI) and dizziness are common sequelae associated with blasts, and many service members (SMs) report symptoms worsen with activity. The purpose of this study was to measure angular vestibulo-ocular reflex gain (aVOR) of blast-exposed SMs with TBI during head impulse testing. We also assessed their symptoms during exertion. Twenty-four SMs recovering from TBI were prospectively assigned to one of two groups based on the presence or absence of dizziness. Wireless monocular scleral search coil and rate sensor were used to characterize active and passive yaw and pitch head and eye rotations. Visual analog scale (VAS) was used to monitor symptoms during fast walking/running. For active yaw head impulses, aVOR gains were significantly lower in the symptomatic group (0.79 +/- A 0.15) versus asymptomatic (0.87 +/- A 0.18), but not for passive head rotation. For pitch head rotation, the symptomatic group had both active (0.915 +/- A 0.24) and passive (0.878 +/- A 0.22) aVOR gains lower than the asymptomatic group (active 1.03 +/- A 0.27, passive 0.97 +/- A 0.23). Some SMs had elevated aVOR gain. VAS scores for all symptoms were highest during exertion. Our data suggest symptomatic SMs with TBI as a result of blast have varied aVOR gain during high-velocity head impulses and provide compelling evidence of pathology affecting the vestibular system. Potential loci of injury in this population include the following: disruption of pathways relaying vestibular efference signals, differential destruction of type I vestibular hair cells, or selective damage to irregular afferent pathways-any of which may explain the common discrepancy between reports of vestibular-like symptoms and laboratory testing results. Significantly reduced pitch aVOR in symptomatic SMs and peak symptom severity during exertional testing support earlier findings in the chronic blast-exposed active duty SMs.	[Scherer, Matthew R.; Shelhamer, Mark J.; Schubert, Michael C.] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA; [Shelhamer, Mark J.] Johns Hopkins Sch Med, Dept Biomed Engn, Baltimore, MD 21287 USA; [Scherer, Matthew R.] Univ Maryland, Sch Med, Dept Phys Therapy & Rehabil Sci, Baltimore, MD 21201 USA		Schubert, MC (corresponding author), Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA.	mschube1@jhmi.edu			NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K23 DC007926-04] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K23DC007926] Funding Source: NIH RePORTER		ABELN W, 1981, BRAIN RES, V222, P458, DOI 10.1016/0006-8993(81)91055-6; Aw ST, 2001, NEUROLOGY, V57, P768, DOI 10.1212/WNL.57.5.768; Black FO, 1996, AM J OTOL, V17, P401; BRANTBERG K, 1990, AM J OTOLARYNG, V11, P345, DOI 10.1016/0196-0709(90)90066-5; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cullen KE, 2004, CURR OPIN NEUROBIOL, V14, P698, DOI 10.1016/j.conb.2004.10.002; Cullen KE, 2004, J NEUROPHYSIOL, V91, P1919, DOI 10.1152/jn.00988.2003; Della Santina CC, 2002, ARCH OTOLARYNGOL, V128, P1044, DOI 10.1001/archotol.128.9.1044; Department of Veterans Affairs/ Department of Defense ( VA/ DoD), 2009, VA DOD CLIN PRACT GU; Eggert Thomas, 2007, Dev Ophthalmol, V40, P15; FERNANDEZ C, 1976, J NEUROPHYSIOL, V39, P970, DOI 10.1152/jn.1976.39.5.970; Furman JM, 2000, PHYS THER, V80, P179, DOI 10.1093/ptj/80.2.179; Goldberg J.M., 1985, Progress in Clinical and Biological Research, V176, P231; Gottshall K, 2009, ASS RES OT MIDW M BA; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; GROSSMAN GE, 1988, EXP BRAIN RES, V70, P470; Herdman SJ, 2003, ARCH OTOLARYNGOL, V129, P819, DOI 10.1001/archotol.129.8.819; Hoffer M, 2008, VESTIBULAR DIFFERENC; Hoffer Michael E, 2009, Int Tinnitus J, V15, P115; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hullar TE, 2005, J NEUROPHYSIOL, V93, P2777, DOI 10.1152/jn.01002.2004; Husni EA, 1966, JAMA-J AM MED ASSOC, V196, P101; Klam F, 2003, ANN NY ACAD SCI, V1004, P271, DOI 10.1196/annals.1303.024; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Leigh J.R., 2006, NEUROLOGY EYE MOVEME; Mitchell J, 2004, MANUAL THER, V9, P220, DOI 10.1016/j.math.2004.03.005; NADOL JB, 1995, OTOLARYNG HEAD NECK, V112, P162, DOI 10.1016/S0194-5998(95)70316-0; PAIGE GD, 1989, ACTA OTO-LARYNGOL, V108, P1, DOI 10.3109/00016488909107385; Park HJ, 2005, ACTA OTO-LARYNGOL, V125, P852, DOI 10.1080/00016480510033667; Roberts D, 2008, PROCEEDINGS OF THE EYE TRACKING RESEARCH AND APPLICATIONS SYMPOSIUM (ETRA 2008), P197, DOI 10.1145/1344471.1344519; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; Roy FD, 2004, LARYNGOSCOPE, V114, P1190, DOI 10.1097/00005537-200407000-00011; Roy JE, 2001, J NEUROSCI, V21, P2131, DOI 10.1523/JNEUROSCI.21-06-02131.2001; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; Scherer M, 2008, J VESTIBUL RES-EQUIL, V18, P147; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; SCHUBERT M, 2009, ASS RES OT MIDW M BA; Schubert MC, 2004, PHYS THER, V84, P373, DOI 10.1093/ptj/84.4.373; Schubert MC, 2008, ARCH PHYS MED REHAB, V89, P500, DOI 10.1016/j.apmr.2007.11.010; Schubert MC, 2006, JARO-J ASSOC RES OTO, V7, P329, DOI 10.1007/s10162-006-0047-6; Strupp M, 1998, NEUROLOGY, V51, P838, DOI 10.1212/WNL.51.3.838; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; VONHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464, DOI 10.1007/BF00622503; Walker MF, 1999, ANN NY ACAD SCI, V871, P205, DOI 10.1111/j.1749-6632.1999.tb09186.x; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wiener SI, 2002, COGNITIVE BRAIN RES, V14, P75, DOI 10.1016/S0926-6410(02)00062-9	48	25	26	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819			EXP BRAIN RES	Exp. Brain Res.	FEB	2011	208	3					399	410		10.1007/s00221-010-2490-1			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	705GU	WOS:000286117700008	21113582	Green Accepted			2022-02-06	
J	Tucha, L; Tucha, O; Sontag, TA; Stasik, D; Laufkotter, R; Lange, KW				Tucha, Lara; Tucha, Oliver; Sontag, Thomas A.; Stasik, Dorota; Laufkoetter, Rainer; Lange, Klaus W.			Differential Effects of Methylphenidate on Problem Solving in Adults With ADHD	JOURNAL OF ATTENTION DISORDERS			English	Article						ADHD; adulthood; problem solving; Tower of London; verbal fluency; methylphenidate	DEFICIT HYPERACTIVITY DISORDER; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; STRIATAL COGNITIVE DEFICITS; CLOSED-HEAD-INJURY; NEUROPSYCHOLOGICAL PERFORMANCE; VERBAL FLUENCY; RESPONSE-INHIBITION; PARKINSONS-DISEASE; TESTS; DYSFUNCTION	Objective: Two studies were performed to assess both divergent and convergent thinking in adults with ADHD. Method: The first study compared the problem-solving abilities of healthy participants (N = 144) and unmedicated adults with ADHD (N = 144). In the second study, problem-solving abilities of adults with diagnosed ADHD (N = 22) were examined twice, that is, on and off methylphenidate (MPH), and compared with the performance of a healthy control group (N = 22). Convergent thinking was measured using a Tower of London task, whereas divergent thinking was assessed using verbal fluency tasks. Results: Adults with ADHD off MPH displayed marked deficits of both divergent and convergent thinking. MPH treatment resulted in a marked improvement of convergent thinking, while no effect of medication was found regarding divergent thinking. Conclusion: Pharmacological treatment of adults with ADHD revealed a differential effect of MPH on problem solving abilities. (I. of Att. Dis. 2011; 15(2) 161-173)	[Tucha, Lara] Univ Groningen, Fac Behav & Social Sci, Dept Psychol, NL-9712 TS Groningen, Netherlands; [Sontag, Thomas A.; Stasik, Dorota; Lange, Klaus W.] Univ Regensburg, Dept Expt Psychol, D-8400 Regensburg, Germany; [Laufkoetter, Rainer] Univ Regensburg, Dept Psychiat, D-8400 Regensburg, Germany		Tucha, L (corresponding author), Univ Groningen, Fac Behav & Social Sci, Dept Psychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands.	L.I.Tucha@rug.nl	Tucha, Oliver/AAD-1403-2019				AMABILE TM, 1983, J PERS SOC PSYCHOL, V45, P357, DOI 10.1037/0022-3514.45.2.357; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Aron AR, 2003, BIOL PSYCHIAT, V54, P1465, DOI 10.1016/S0006-3223(03)00609-7; Aschenbrenner S., 2000, REGENSBURGER WORTFLU; Barkley R. A., 2006, ATTENTION DEFICIT HY, P248; BARKLEY RA, 1991, J ABNORM CHILD PSYCH, V19, P149, DOI 10.1007/BF00909976; BARKLEY RA, 1998, ATTENTION DEFICIT HY, P164; Barkley Russell Alan, 2006, ATTENTION DEFICIT HY, V3rd; Ben-Yishay Y, 1983, REHABILITATION HEAD, P367; Benson D.F., 1986, FRONTAL LOBES; BENSON DF, 1991, J CHILD NEUROL, V6, pS9, DOI 10.1177/0883073891006001S02; Berg D, 1999, NEUROLOGY, V53, P1026, DOI 10.1212/WNL.53.5.1026; Bezeau S, 2001, J CLIN EXP NEUROPSYC, V23, P399, DOI 10.1076/jcen.23.3.399.1181; Biederman J, 2006, AM J PSYCHIAT, V163, P1730, DOI 10.1176/appi.ajp.163.10.1730; BOLLA KI, 1990, J CLIN PSYCHOL, V46, P623, DOI 10.1002/1097-4679(199009)46:5<623::AID-JCLP2270460513>3.0.CO;2-C; Boonstra AM, 2005, PSYCHOL MED, V35, P1097, DOI 10.1017/S003329170500499X; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; COHEN J, 1988, STAT POWER ANAL BEHA, pR21; COOK EH, 1995, AM J HUM GENET, V56, P993; Corbett B, 1999, ARCH CLIN NEUROPSYCH, V14, P373, DOI 10.1016/S0887-6177(98)00037-7; CRAMON DYV, 1993, NEUROPSYCHOLOGISCHE, P123; Culbertson WC, 1998, ASSESSMENT, V5, P215, DOI 10.1177/107319119800500302; DESROSIERS G, 1987, INT J CLIN NEUROPSYC, V9, P162; Dinn WM, 2001, BRAIN COGNITION, V46, P114, DOI 10.1016/S0278-2626(01)80046-4; DUPAUL GJ, 1998, ATTENTION DEFICIT HY, P510; Epstein JN, 2001, J CLIN EXP NEUROPSYC, V23, P362, DOI 10.1076/jcen.23.3.362.1186; Faraone SV, 2000, BIOL PSYCHIAT, V48, P9, DOI 10.1016/S0006-3223(00)00889-1; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; GRAFMAN J, 1999, SCI PRACT NEUROPSYCH, P321; GURD JM, 1989, NEUROPSYCHOLOGIA, V27, P743, DOI 10.1016/0028-3932(89)90120-6; Hamsher K., 1989, MULTILINGUAL APHASIA; Hanes KR, 1996, ARCH CLIN NEUROPSYCH, V11, P185, DOI 10.1016/0887-6177(95)00034-8; Hodgson TL, 2002, NEUROPSYCHOLOGIA, V40, P411, DOI 10.1016/S0028-3932(01)00099-9; HOLDNACK JA, 1995, NEUROPSY NEUROPSY BE, V8, P282; Hollingsworth DE, 2001, J COGNITIVE NEUROSCI, V13, P298, DOI 10.1162/08989290151137359; HOPKINS J, 1979, J CHILD PSYCHOL PSYC, V20, P209, DOI 10.1111/j.1469-7610.1979.tb00504.x; Horton A M Jr, 1996, Appl Neuropsychol, V3, P181, DOI 10.1207/s15324826an0303&4_12; HYND GW, 1990, ARCH NEUROL-CHICAGO, V47, P919, DOI 10.1001/archneur.1990.00530080107018; HYND GW, 1993, J CHILD NEUROL, V8, P339, DOI 10.1177/088307389300800409; Jenkins M, 1998, CLIN NEUROPSYCHOL, V12, P74, DOI 10.1076/clin.12.1.74.1725; Johnson DE, 2001, ARCH CLIN NEUROPSYCH, V16, P587; KLEE SH, 1986, PSYCHIAT ANN, V16, P52, DOI 10.3928/0048-5713-19860101-12; Kline P, 2000, HDB PSYCHOL TESTING, V2nd; KONIG F, 1986, DIAGNOSTICA, V4, P345; Kovner R, 1998, INT J NEUROSCI, V96, P225, DOI 10.3109/00207459808986470; KRAMPEN G, 1993, TESTS TRENDS, V10, P11; Kuperman S, 2001, Ann Clin Psychiatry, V13, P129, DOI 10.3109/10401230109148958; LaHoste GJ, 1996, MOL PSYCHIATR, V1, P121; LANGE KW, 1992, PSYCHOPHARMACOLOGY, V107, P394, DOI 10.1007/BF02245167; Lange KW, 2003, J NEURAL TRANSM, V110, P983, DOI 10.1007/s00702-003-0011-0; Lange KW, 1995, J NEURAL TRANSM-SUPP, P423; LEHRL S, 1995, ACTA NEUROL SCAND, V91, P335, DOI 10.1111/j.1600-0404.1995.tb07018.x; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; LINDENBERGER U, 1993, PSYCHOL AGING, V8, P207, DOI 10.1037/0882-7974.8.2.207; LOU HC, 1984, ARCH NEUROL-CHICAGO, V41, P825, DOI 10.1001/archneur.1984.04050190031010; Lovejoy DW, 1999, J INT NEUROPSYCH SOC, V5, P222, DOI 10.1017/S1355617799533055; LUER G, 1992, ALLGEMEINE PSYCHOL, P189; Luria A.R., 1973, WORKING BRAIN; MARTIN A, 1994, NEUROPSYCHOLOGIA, V32, P1487, DOI 10.1016/0028-3932(94)90120-1; McCann B S, 2000, Semin Clin Neuropsychiatry, V5, P191, DOI 10.1053/scnp.2000.6730; Mehta MA, 2000, J PSYCHOPHARMACOL, V14, P299, DOI 10.1177/026988110001400314; MERCUGLIANO M, 1995, MRDD RES REV, V1, P220; MORRIS RG, 1988, J NEUROL NEUROSUR PS, V51, P757, DOI 10.1136/jnnp.51.6.757; OWEN AM, 1995, NEUROPSYCHOLOGY, V9, P126, DOI 10.1037/0894-4105.9.1.126; OWEN AM, 1992, BRAIN, V115, P1727, DOI 10.1093/brain/115.6.1727; Pantelis C, 1997, BRAIN, V120, P1823, DOI 10.1093/brain/120.10.1823; PARKIN AJ, 1994, NEUROPSYCHOLOGIA, V32, P1523, DOI 10.1016/0028-3932(94)90124-4; PASQUIER F, 1995, J NEUROL NEUROSUR PS, V58, P81, DOI 10.1136/jnnp.58.1.81; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Riccio CA, 2004, ARCH CLIN NEUROPSYCH, V19, P661, DOI 10.1016/j.acn.2003.09.001; Riordan HJ, 1999, ARCH CLIN NEUROPSYCH, V14, P217, DOI 10.1016/S0887-6177(98)00015-8; Robbins TW, 1998, J INT NEUROPSYCH SOC, V4, P474, DOI 10.1017/s1355617798455073; ROBBINS TW, 1994, J NEUROL NEUROSUR PS, V57, P79, DOI 10.1136/jnnp.57.1.79; Rowe H.A.H., 1985, PROBLEM SOLVING INTE; Ruprecht-Dorfler P, 2003, NEUROIMAGE, V18, P416, DOI 10.1016/S1053-8119(02)00035-6; SALTHOUSE TA, 1993, J GERONTOL, V48, pP245, DOI 10.1093/geronj/48.5.P245; Schmelkin L.P., 1991, MEASUREMENT DESIGN A; Schweitzer JB, 2004, BIOL PSYCHIAT, V56, P597, DOI 10.1016/j.biopsych.2004.07.011; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SILVERSTEIN SM, 1995, NEUROPSYCHOLOGY, V9, P157, DOI 10.1037/0894-4105.9.2.157; SIMON HA, 1975, COGNITIVE PSYCHOL, V7, P268, DOI 10.1016/0010-0285(75)90012-2; SINGER HS, 1993, NEUROLOGY, V43, pA409; Smith E. E., 2007, COGNITIVE PSYCHOL MI; Sohlberg MM, 2001, ANN NY ACAD SCI, V931, P359; Spreen O, 1991, COMPENDIUM NEUROPSYC; Sternberg R. J, 1985, IQ TRIARCHIC THEORY; STERNBERG RJ, 1981, J PERS SOC PSYCHOL, V41, P37, DOI 10.1037/0022-3514.41.1.37; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370; Tucha O, 2006, J NEURAL TRANSM, V113, P1575, DOI 10.1007/s00702-005-0437-7; Tucha O, 2004, TOWER LONDON; Tucha Oliver, 2005, Cogn Neuropsychiatry, V10, P231, DOI 10.1080/13546800444000047; Turner DC, 2005, PSYCHOPHARMACOLOGY, V178, P286, DOI 10.1007/s00213-004-1993-5; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494; Walker AJ, 2000, J CLIN EXP NEUROPSYC, V22, P115, DOI 10.1076/1380-3395(200002)22:1;1-8;FT115; Wasserstein J, 2001, ANN NY ACAD SCI, V931, P376; WENDER PH, 1995, ATTENTION DEFICIT HY; Weyandt LL, 1998, DEV NEUROPSYCHOL, V14, P643, DOI 10.1080/87565649809540734; WIEDERHOLT WC, 1993, J AM GERIATR SOC, V41, P639, DOI 10.1111/j.1532-5415.1993.tb06738.x; Wilens TE, 2004, J CLIN PSYCHIAT, V65, P1301, DOI 10.4088/JCP.v65n1003; Willams C, 1999, BRIT J GEN PRACT, V49, P563; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7; ZAMETKIN AJ, 1993, ARCH GEN PSYCHIAT, V50, P333; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001; Zimmermann P, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P110; Zimmermann P, 1993, COMPUTERIZED NEUROPS; [No title captured]	109	25	25	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1087-0547	1557-1246		J ATTEN DISORD	J. Atten. Disord.	FEB	2011	15	2					161	173		10.1177/1087054709356391			13	Psychology, Developmental; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	714XZ	WOS:000286846300008	20484710	Green Published			2022-02-06	
J	Zhu, WJ; Zhang, J; Zhang, ZG				Zhu, Wenjing; Zhang, Jing; Zhang, Zigui			Effects of Fluoride on Synaptic Membrane Fluidity and PSD-95 Expression Level in Rat Hippocampus	BIOLOGICAL TRACE ELEMENT RESEARCH			English	Article						Fluoride; Hippocampus; Membrane fluidity; Neurotoxicity; Oxidative stress; PSD-95	TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; PROTEIN; NEUTROPHILS; FLUOROSIS; RECEPTOR; DENSITY; NEURONS; SYSTEM; AREAS	The objective of this study is to investigate the neurotoxicity of drinking water fluorosis on rat hippocampus. Just weaning male Sprague-Dawley rats were randomly divided into four groups and given 15, 30, and 60 mg/L NaF solution and distilled water, respectively, for 9 months. The fluidity of brain synaptic membrane and expression level of postsynaptic density 95 (PSD-95) were tested. Results showed that the fluidity of brain synaptic membrane decreased gradually with increasing of fluoride concentration, and it was significantly decreased (P < 0.05) in moderate-fluoride group compared with control group, and expression level of PSD-95 was significantly decreased (P < 0.01) in moderate-fluoride group when compared with that of control group. These results indicate that decrease of synaptic membrane fluidity and PSD-95 expression level may be the molecular basis of central nervous system damage caused by fluoride intoxication; PSD-95 in CA3 region of hippocampus is probably a target molecule for fluoride.	[Zhu, Wenjing; Zhang, Jing; Zhang, Zigui] Zhejiang Normal Univ, Inst Ecol, Jinhua 321004, Peoples R China		Zhang, ZG (corresponding author), Zhejiang Normal Univ, Inst Ecol, Jinhua 321004, Peoples R China.	zzg@zjnu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30871295]; Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [Y207751]	This research was sponsored by the National Natural Science Foundation of China (Grant No. 30871295) and Natural Science Foundation of Zhejiang Province (Grant No. Y207751).	Bhatnagar Maheep, 2002, Indian Journal of Experimental Biology, V40, P546; Cayabyab FS, 2000, EUR J NEUROSCI, V12, P1949, DOI 10.1046/j.1460-9568.2000.00083.x; Chen P, 2007, MOL PHARMACOL, V72, P40, DOI 10.1124/mol.107.034942; Choubisa SL, 2009, FLUORIDE, V42, P210; CULLIS PR, 1985, BIOCH LIPIDS MEMBRAN, P25; de la Monte SM, 2000, CELL MOL LIFE SCI, V57, P1471, DOI 10.1007/PL00000630; DELLABIANCA V, 1988, BIOCHEM BIOPH RES CO, V150, P955, DOI 10.1016/0006-291X(88)90722-X; Ehrlich I, 2007, P NATL ACAD SCI USA, V104, P4176, DOI 10.1073/pnas.0609307104; ERIK K, 1987, CLIN CHEM, V33, P253; Gao Q, 2008, TOXICOL IN VITRO, V22, P837, DOI 10.1016/j.tiv.2007.12.017; Gascon S, 2008, MOL PSYCHIATR, V13, P99, DOI 10.1038/sj.mp.4002017; Gorczyca D, 2007, J NEUROSCI, V27, P1033, DOI 10.1523/JNEUROSCI.3160-06.2007; Guan ZZ, 1998, NEUROTOXICOL TERATOL, V20, P537, DOI 10.1016/S0892-0362(97)00136-0; He Y, 2008, FLUORIDE, V41, P192; HENSLEY K, 1994, FREE RADICAL BIO MED, V17, P321, DOI 10.1016/0891-5849(94)90018-3; Krapivinsky G, 2006, NEURON, V52, P485, DOI 10.1016/j.neuron.2006.09.033; Lang SB, 2007, J NEUROSCI, V27, P1097, DOI 10.1523/JNEUROSCI.3590-06.2007; Lechuga-Sancho AM, 2006, ENDOCRINOLOGY, V147, P5314, DOI 10.1210/en.2006-0766; Li G, 2000, FLUORIDE, V33, P14; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; Ranjan R, 2009, FLUORIDE, V42, P88; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Shila S, 2005, TOXICOLOGY, V210, P25, DOI 10.1016/j.tox.2005.01.003; Su JJ, 2006, J NEUROL SCI, V243, P21, DOI 10.1016/j.jns.2005.11.006; TOPER R, 1987, BIOCHIM BIOPHYS ACTA, V931, P262, DOI 10.1016/0167-4889(87)90215-1; Trivedi MH, 2009, FLUORIDE, V42, P29; Tsuriel S, 2006, PLOS BIOL, V4, P1572, DOI 10.1371/journal.pbio.0040271; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang ZG, 2008, FLUORIDE, V41, P139	31	25	25	1	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0163-4984	1559-0720		BIOL TRACE ELEM RES	Biol. Trace Elem. Res.	FEB	2011	139	2					197	203		10.1007/s12011-010-8654-9			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	706DQ	WOS:000286198100009	20217272				2022-02-06	
J	Armstead, WM; Kiessling, JW; Riley, J; Kofke, WA; Vavilala, MS				Armstead, William M.; Kiessling, J. Willis; Riley, John; Kofke, W. Andrew; Vavilala, Monica S.			Phenylephrine Infusion Prevents Impairment of ATP- and Calcium-Sensitive Potassium Channel-Mediated Cerebrovasodilation after Brain Injury in Female, but Aggravates Impairment in Male, Piglets through Modulation of ERK MAPK Upregulation	JOURNAL OF NEUROTRAUMA			English	Article						cerebral circulation; newborn; potassium channels; signal transduction	CEREBRAL-BLOOD-FLOW; K-ATP; ARTERY OCCLUSION; ISCHEMIC BRAIN; PIAL-ARTERIES; ADRENOMEDULLIN; HYPOTENSION; NEWBORN; FLUID; AUTOREGULATION	Traumatic brain injury (TBI) contributes to morbidity in children and boys, and hypotension worsens outcome. Extracellular signal-related kinase (ERK) mitogen-activated protein kinase (MAPK) is upregulated more in males and reduces cerebral blood flow (CBF) after fluid percussion injury (FPI). Increased cerebral perfusion pressure (CPP) via phenylephrine (Phe) sex-dependently improves impairment of the cerebral autoregulation seen after FPI through modulation of ERK MAPK upregulation, which is aggravated in males, but is blocked in females. Activation of ATP- and calcium-sensitive (Katp and Kca) channels produces cerebrovasodilation and contributes to autoregulation, both of which are impaired after FPI. Using piglets equipped with a closed cranial window, we hypothesized that potassium channel functional impairment after FPI is prevented by Phe in a sex-dependent manner through modulation of ERK MAPK upregulation. The Katp and Kca agonists cromakalim and NS 1619 produced vasodilation that was impaired after FPI more in males than in females. Phe prevented reductions in cerebrovasodilation after cromakalim and NS 1619 in females, but reduced dilation after these potassium channel agonists were given to males after FPI. Co-administration of U 0126, an ERK antagonist, and Phe fully restored dilation to cromakalim, calcitonin gene-related peptide (CGRP), and NS 1619, in males after FPI. These data indicate that Phe sex-dependently prevents impairment of Katp and Kca channel-mediated cerebrovasodilation after FPI in females, but aggravates impairment in males, through modulation of ERK MAPK upregulation. Since autoregulation of CBF is dependent on intact functioning of potassium channels, these data suggest a role for sex-dependent mechanisms in the treatment of cerebral autoregulation impairment after pediatric TBI.	[Armstead, William M.; Kiessling, J. Willis; Kofke, W. Andrew] Univ Penn, Dept Anesthesiol & Crit Care, Philadelphia, PA 19104 USA; [Armstead, William M.] Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; [Kofke, W. Andrew] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol Pediat & Neurol Surg, Seattle, WA 98195 USA		Armstead, WM (corresponding author), Univ Penn, Dept Anesthesiol & Crit Care, 3620 Hamilton Walk,JM3, Philadelphia, PA 19104 USA.	armsteaw@uphs.upenn.edu		Riley, John/0000-0002-7932-8935	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD57355]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD057355] Funding Source: NIH RePORTER	This research was supported by grant HD57355 from the National Institutes of Health.	Armstead WM, 2007, J CEREBR BLOOD F MET, V27, P1702, DOI 10.1038/sj.jcbfm.9600473; Armstead WM, 2010, CRIT CARE MED, V38, P1868, DOI 10.1097/CCM.0b013e3181e8ac1a; Armstead WM, 2010, J NEUROTRAUM, V27, P391, DOI 10.1089/neu.2009.1094; Armstead WM, 2009, J CEREBR BLOOD F MET, V29, P524, DOI 10.1038/jcbfm.2008.142; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1999, BRAIN RES, V816, P158, DOI 10.1016/S0006-8993(98)01146-9; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 2000, MICROCIRCULATION, V7, P225, DOI 10.1080/713773978; BASKAYA MK, 1995, J CEREBR BLOOD F MET, V15, P827, DOI 10.1038/jcbfm.1995.103; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; DOBBING J, 1974, PEDIATRICS, V53, P2; Dogan A, 1997, J CEREBR BLOOD F MET, V17, P19, DOI 10.1097/00004647-199701000-00004; Faraci FM, 1998, PHYSIOL REV, V78, P53, DOI 10.1152/physrev.1998.78.1.53; Ishikawa S, 2009, ANESTH ANALG, V108, P1631, DOI 10.1213/ane.0b013e31819d94e3; Juhl L, 2006, EUR J PHARMACOL, V538, P101, DOI 10.1016/j.ejphar.2006.03.005; Laher I, 2001, J CEREBR BLOOD F MET, V21, P887, DOI 10.1097/00004647-200108000-00001; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Miyashita K, 2006, ENDOCRINOLOGY, V147, P1642, DOI 10.1210/en.2005-1038; Robertson CL, 2001, J NEUROTRAUM, V18, P861, DOI 10.1089/089771501750451785; Ross J, 2003, AM J PHYSIOL-REG I, V285, pR149, DOI 10.1152/ajpregu.00003.2003; Salvucci A, 2000, BRAIN RES, V887, P406, DOI 10.1016/S0006-8993(00)03079-1; WANG XK, 1995, P NATL ACAD SCI USA, V92, P11480, DOI 10.1073/pnas.92.25.11480; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	24	25	27	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2011	28	1					105	111		10.1089/neu.2010.1581			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	710DT	WOS:000286491800010	20964536	Green Published			2022-02-06	
J	Jia, YL; Grafe, MR; Gruber, A; Alkayed, NJ; Wang, RKK				Jia, Yali; Grafe, Marjorie R.; Gruber, Andras; Alkayed, Nabil J.; Wang, Ruikang K.			In vivo optical imaging of revascularization after brain trauma in mice	MICROVASCULAR RESEARCH			English	Article						Traumatic brain injury; Cerebral blood flow; Revascularization; EETs; Soluble epoxide hydrolase; Optical imaging	VESSEL FORMATION; BLOOD PERFUSION; ANGIOGENESIS; MECHANISMS; INJURY; MORPHOGENESIS; EXPRESSION; GENE	Revascularization following brain trauma is crucial to the repair process. We used optical micro-angiography (OMAG) to study endogenous revascularization in living mice following brain injury. OMAG is a volumetric optical imaging method capable of in vivo mapping of localized blood perfusion within the scanned tissue beds down to capillary level imaging resolution. We demonstrated that OMAG can differentiate revascularization progression between traumatized mice with and without soluble epoxide hydrolase (sEH) gene deletion. The time course of revascularization was determined from serial imaging of the traumatic region in the same mice over a one-month period of rehabilitation. Restoration of blood volume at the lesion site was more pronounced in sEH knockout mice than in wild-type mice as determined by OMAG. These OMAG measurements were confirmed by histology and showed that the sEH knockout effect may be involved in enhancing revascularization. The correlation of OMAG with histology also suggests that OMAG is a useful imaging tool for real-time in vivo monitoring of post-traumatic revascularization and for evaluating agents that inhibit or promote endogenous revascularization during the recovery process in small rodents. Published by Elsevier Inc.	[Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Jia, Yali; Gruber, Andras; Wang, Ruikang K.] Oregon Hlth & Sci Univ, Sch Med, Dept Biomed Engn, Portland, OR 97239 USA; [Grafe, Marjorie R.] Oregon Hlth & Sci Univ, Sch Med, Dept Pathol, Portland, OR 97239 USA; [Alkayed, Nabil J.; Wang, Ruikang K.] Oregon Hlth & Sci Univ, Sch Med, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA		Wang, RKK (corresponding author), Univ Washington, Dept Bioengn, 3720 15th Ave NE, Seattle, WA 98195 USA.	wangrk@uw.edu	Wang, Ruikang K./L-3889-2019	Wang, Ruikang K./0000-0001-5169-8822; Jia, Yali/0000-0002-2784-1905; Gruber, Andras/0000-0001-6212-2247	National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL093140]; National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB009682]; National Institute of Deafness and other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01 DC010201]; American Heart AssociationAmerican Heart Association [0855733G]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL093140] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB009682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS044313, R01NS070837, P30NS061800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC010201] Funding Source: NIH RePORTER	This work was supported in part by research grants from the National Heart, Lung, and Blood Institute (R01 HL093140), the National Institute of Biomedical Imaging and Bioengineering (R01 EB009682), the National Institute of Deafness and other Communication Disorders (R01 DC010201), and the American Heart Association (0855733G).	ARNOLD F, 1991, PHARMACOL THERAPEUT, V52, P407, DOI 10.1016/0163-7258(91)90034-J; Briers JD, 2001, PHYSIOL MEAS, V22, pR35, DOI 10.1088/0967-3334/22/4/201; Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158; Carmeliet Peter, 2002, P1; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; ELLIS EF, 1990, AM J PHYSIOL, V259, pH1171, DOI 10.1152/ajpheart.1990.259.4.H1171; Fercher AF, 2003, REP PROG PHYS, V66, P239, DOI 10.1088/0034-4885/66/2/204; FINA L, 1990, BLOOD, V75, P2417; Folkman J, 1998, CIRCULATION, V97, P1108, DOI 10.1161/01.CIR.97.12.1108; Frontczak-Baniewicz M, 2003, ACTA NEUROBIOL EXP, V63, P65; Iliff JJ, 2009, FUTUR NEUROL, V4, P179, DOI 10.2217/14796708.4.2.179; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Lipowsky HH, 2005, MICROCIRCULATION, V12, P5, DOI 10.1080/10739680590894966; Mazur G, 2004, FOLIA HISTOCHEM CYTO, V42, P241; McDonald DM, 2003, NAT MED, V9, P713, DOI 10.1038/nm0603-713; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Morisseau C, 2005, ANNU REV PHARMACOL, V45, P311, DOI 10.1146/annurev.pharmtox.45.120403.095920; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Patan S, 2001, CIRC RES, V89, P723, DOI 10.1161/hh2001.097870; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schaerer L, 2000, AM J DERMATOPATH, V22, P140, DOI 10.1097/00000372-200004000-00009; Tomlins PH, 2005, J PHYS D APPL PHYS, V38, P2519, DOI 10.1088/0022-3727/38/15/002; Wang RKK, 2007, OPT EXPRESS, V15, P11402, DOI 10.1364/OE.15.011402; Wang RK, 2007, OPT EXPRESS, V15, P4083, DOI 10.1364/OE.15.004083; Zhang CY, 2002, STROKE, V33, P2957, DOI 10.1161/01.STR.0000037787.07479.9A; Zhang WR, 2008, STROKE, V39, P2073, DOI 10.1161/STROKEAHA.107.508325	27	25	25	1	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0026-2862	1095-9319		MICROVASC RES	Microvasc. Res.	JAN	2011	81	1					73	80		10.1016/j.mvr.2010.11.003			8	Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology	710HK	WOS:000286501600009	21075124	Green Accepted			2022-02-06	
J	Schultz, BA; Cifu, DX; McNamee, S; Nichols, M; Carne, W				Schultz, Billie A.; Cifu, David X.; McNamee, Shane; Nichols, Michelle; Carne, William			Assessment and treatment of common persistent sequelae following blast induced mild traumatic brain injury	NEUROREHABILITATION			English	Article						Blast injury; polytrauma; rehabilitation	POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; COGNITIVE REHABILITATION; POSTCONCUSSIVE SYMPTOMS; BEHAVIORAL TREATMENT; CLINICAL MANAGEMENT; SERVICE MEMBERS; EYE INJURIES; SLEEP; IRAQ	The ongoing wars in Iraq and Afghanistan and terrorist activity worldwide have been associated with an increased incidence of blast injuries. While blast injuries share similarities with blunt or penetrating traumatic injuries, there are unique mechanistic elements of blast injury that create increased vulnerability to damage of specific organs. This review highlights the mechanism of blast-related injury, describes the common sequelae of blast exposure that may impact rehabilitation care, and summarizes the intervention strategies for these blast-related sequelae.	[Schultz, Billie A.; McNamee, Shane] Hunter Holmes McGuire Vet Med Ctr, Dept Phys Med & Rehabil, Richmond, VA USA; [Schultz, Billie A.; Cifu, David X.; McNamee, Shane; Nichols, Michelle; Carne, William] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Nichols, Michelle; Carne, William] Henry M Jackson Fdn, Hunter Holmes McGuire Vet Med Ctr, Def & Vet Brain Injury Ctr, Richmond, VA USA; [Cifu, David X.] US Dept Vet Affairs, Phys Med & Rehabil Program Off, Washington, DC USA		Schultz, BA (corresponding author), Hunter Holmes McGuire Vet Med Ctr, Dept Phys Med & Rehabil, Richmond, VA USA.	schultz.billie@mayo.edu	Nichols, Michelle/AAV-2740-2020	Nichols, Michelle/0000-0002-2078-9649; Cifu, David/0000-0003-1600-9387			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; [Anonymous], 2005, NIH Consens State Sci Statements, V22, P1; [Anonymous], 2007, SCREENING EVALUATION; [Anonymous], 2010, ACT DUT MIL PERS STR; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Becker WJ, 2010, HEADACHE, V50, P698, DOI 10.1111/j.1526-4610.2010.01648.x; Belanger HG, 2011, CLIN NEUROPSYCHOL, V1, P1; Bergemalm PO, 2001, ACTA OTO-LARYNGOL, V121, P724, DOI 10.1080/00016480152583674; Binder WJ, 2000, OTOLARYNG HEAD NECK, V123, P669, DOI 10.1067/mhn.2000.110960; Bogduk N, 2009, LANCET NEUROL, V8, P959, DOI 10.1016/S1474-4422(09)70209-1; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cifu D.X., 2009, CRIT REV PHYS REHABI, V21, P197, DOI DOI 10.1615/CRITREVPHYSREHABI1MED.V2113-4.10; Cifu DX, 2010, AM J PHYS MED REHAB, V89, P688, DOI 10.1097/PHM.0b013e3181e722ad; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Cullen DK, 2011, NEUROIMAGE, V54, pS37, DOI 10.1016/j.neuroimage.2010.10.076; Daniel J.H., 2010, IEEE SENS 2010 C WAI; Darley DS, 2010, DISASTER MED PUBLIC, V4, P145, DOI 10.1001/dmphp.D-08-00057R2; Defense Manpower Data Center, 2010, CTS DEPL FIL BAS REP; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Department of Veterans Affairs/ Department of Defense ( VA/ DoD), 2009, VA DOD CLIN PRACT GU; Difede J, 2002, CYBERPSYCHOL BEHAV, V5, P529, DOI 10.1089/109493102321018169; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Fausti SA, 2009, J REHABIL RES DEV, V46, P797, DOI 10.1682/JRRD.2008.09.0118; Ferrari MD, 2001, LANCET, V358, P1668, DOI 10.1016/S0140-6736(01)06711-3; Fitzgerald DC, 1996, J TRAUMA, V40, P488, DOI 10.1097/00005373-199603000-00034; Garman R.H., 2011, J NEUROTRAUMAM; GARTH RJN, 1995, INJURY, V26, P363, DOI 10.1016/0020-1383(95)00042-8; Germain A, 2007, BEHAV RES THER, V45, P627, DOI 10.1016/j.brat.2006.04.009; Gervil M, 1998, CEPHALALGIA, V18, P342, DOI 10.1046/j.1468-2982.1998.1806342.x; Goadsby PJ, 2010, LANCET NEUROL, V9, P285, DOI 10.1016/S1474-4422(10)70005-3; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Headache Classification Committee of the International Headache Society, 2004, CEPHALALGIA S1, V24, P115; Henry JA, 2005, J REHABIL RES DEV, V42, P95, DOI 10.1682/JRRD.2005.01.0005; Henry James A, 2008, Trends Amplif, V12, P188, DOI 10.1177/1084713808321184; Henry James A, 2008, Trends Amplif, V12, P170, DOI 10.1177/1084713808319941; HERDMAN SJ, 1993, ARCH OTOLARYNGOL, V119, P450; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kaufman Y., 2001, PEDIATR NEUROL, V41, P469; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Lanius R.A., 2010, EUROPEAN J PSYCHOTRA, V1, P54; LARSON EB, 1980, JAMA-J AM MED ASSOC, V243, P359, DOI 10.1001/jama.243.4.359; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Martin BC, 2000, HEADACHE, V40, P204, DOI 10.1046/j.1526-4610.2000.00030.x; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Morin CM, 2006, SLEEP, V29, P1398, DOI 10.1093/sleep/29.11.1398; Morin CM, 1993, INSOMNIA PSYCHOL ASS; Morin CM, 2003, INSOMNIA CLIN GUIDE; Morley MG, 2010, DISASTER MED PUBLIC, V4, P154, DOI 10.1001/dmp.v4n2.hra10003; NEWMAN CW, 1990, EAR HEARING, V11, P430, DOI 10.1097/00003446-199012000-00004; Ohayon M M, 2000, Semin Clin Neuropsychiatry, V5, P56; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; PAHOR AL, 1981, J LARYNGOL OTOL, V95, P399, DOI 10.1017/S0022215100090873; PELI E, 2000, VISION REHABILITATIO, P104; Pizzamiglio L, 2006, RESTOR NEUROL NEUROS, V24, P337; Plurad DS, 2011, MIL MED, V176, P276, DOI 10.7205/MILMED-D-10-00147; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Ruff Robert L, 2010, F1000 Med Rep, V2, P64, DOI 10.3410/M2-64; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2009, PM&R, V1, P23, DOI 10.1016/j.pmrj.2008.10.003; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Spoormaker VI, 2008, SLEEP MED REV, V12, P169, DOI 10.1016/j.smrv.2007.08.008; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thach AB, 2000, OPHTHALMOLOGY, V107, P844, DOI 10.1016/S0161-6420(00)00029-4; VA/DoD, 2010, VA DOD CLIN PRACT GU; VA Office of Public Health and Environmental Hazards, 2010, AN VA HLTH CAR UT OP; van Liempt S, 2006, INT CLIN PSYCHOPHARM, V21, P193, DOI 10.1097/00004850-200607000-00001; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vincent MB, 2010, HEADACHE, V50, P705, DOI 10.1111/j.1526-4610.2010.01643.x; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Weber M, 2010, BRAIN INJURY, V24, P1364, DOI 10.3109/02699052.2010.507110; Writer BW, 2009, J NEUROPSYCH CLIN N, V21, P362, DOI 10.1176/appi.neuropsych.21.4.362; Xydakis MS, 2007, NEW ENGL J MED, V357, P830, DOI 10.1056/NEJMc076071; Yetkin S, 2010, PSYCHIAT CLIN NEUROS, V64, P309, DOI 10.1111/j.1440-1819.2010.02084.x; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	101	25	25	1	13	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2011	28	4					309	320		10.3233/NRE-2011-0659			12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	795VL	WOS:000293004900001	21725164				2022-02-06	
J	Kawai, N; Maeda, Y; Kudomi, N; Yamamoto, Y; Nishiyama, Y; Tamiya, T				Kawai, Nobuyuki; Maeda, Yukito; Kudomi, Nobuyuki; Yamamoto, Yuka; Nishiyama, Yoshihiro; Tamiya, Takashi			Focal Neuronal Damage in Patients with Neuropsychological Impairment after Diffuse Traumatic Brain Injury: Evaluation Using C-11-Flumazenil Positron Emission Tomography with Statistical Image Analysis	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; flumazenil; neuronal loss; positron emission tomography; traumatic brain injury	CEREBRAL GLUCOSE-METABOLISM; ACUTE VEGETATIVE STATE; HEAD-INJURY; AXONAL INJURY; FDG-PET; DEFICITS; HYPOMETABOLISM; PERFORMANCE; SEVERITY; ATROPHY	This study was conducted to identify the regional neuronal damage occurring in patients with neuropsychological impairment following diffuse traumatic brain injury (TBI) compared with normal control subjects. In addition, measures of the neuropsychological tests were correlated with regional C-11-flumazenil (FMZ) binding potential (BP) reductions to clarify the relationship between cognitive impairment and regional neuronal damage. We performed C-11-flumazenil positron emission tomography (FMZ-PET) studies using three-dimensional stereotactic surface projection (3D-SSP) statistical image analysis in eight diffuse axonal injury (DAI) patients (mean age 29.1 +/- 11.1 years, range 19-46 years). All patients underwent assessment with the Wechsler Adult Intellectual Scale-Third Edition (WAIS-III) to evaluate general intelligence. Twenty healthy control subjects (mean age 24.4 +/- 2.8 years, range 22-30 years) were also studied to obtain a normal database for 3D-SSP. Group comparisons showed significant regional low FMZ uptake in the bilateral medial frontal gyri, the anterior cingulate gyri, and the thalamus. Individual analysis also showed decreased FMZ uptake in these regions; however, the distribution and extent of low FMZ uptake were different in each individual patient. Full-scale IQ (FIQ) and performance IQ (PIQ) negatively correlated with the degree of FMZ BP reduction (BZR index) in the right thalamus. FIQ, verbal IQ (VIQ), and PIQ also negatively correlated with the BZR index in the left medial frontal gyrus. DAI uniformly induced neuronal damage in the medial frontal cortex and the thalamus, which may be related to underlying cognitive impairments in diffuse TBI patients. Future studies to confirm a common area of focal neuronal damage and a direct correlation with neuropsychological testing may validate the use of FMZ-PET for the functional diagnosis of neuropsychological impairments after TBI.	[Kawai, Nobuyuki; Tamiya, Takashi] Kagawa Univ, Fac Med, Dept Neurol Surg, Miki, Kagawa 7610793, Japan; [Maeda, Yukito; Yamamoto, Yuka; Nishiyama, Yoshihiro] Kagawa Univ, Fac Med, Dept Radiol, Miki, Kagawa 7610793, Japan; [Kudomi, Nobuyuki] Kagawa Univ, Fac Med, Dept Med Phys, Miki, Kagawa 7610793, Japan		Kawai, N (corresponding author), Kagawa Univ, Fac Med, Dept Neurol Surg, 1750-1 Miki Cho, Miki, Kagawa 7610793, Japan.	nobu@kms.ac.jp			Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; General Insurance Association of Japan	This work was supported in part by grants from the Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, and the General Insurance Association of Japan. The authors appreciate the excellent technical support of the radiological technologist at our institution.	ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Haier RJ, 2004, NEUROIMAGE, V23, P425, DOI 10.1016/j.neuroimage.2004.04.025; Heiss WD, 2000, STROKE, V31, P366, DOI 10.1161/01.STR.31.2.366; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; ICHISE M, 1994, J NUCL MED, V35, P217; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Klumpers UMH, 2008, J CEREBR BLOOD F MET, V28, P579, DOI 10.1038/sj.jcbfm.9600554; Kuroda S, 2004, J NUCL MED, V45, P943; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1994, J NUCL MED, V35, pP33; Mizumura S, 2003, ANN NUCL MED, V17, P289, DOI 10.1007/BF02988523; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Rudolf J, 2002, EUR J NEUROL, V9, P671, DOI 10.1046/j.1468-1331.2002.00468.x; Rudolf J, 2000, LANCET, V355, P115, DOI 10.1016/S0140-6736(99)04280-4; SAMSON Y, 1985, EUR J PHARMACOL, V110, P247, DOI 10.1016/0014-2999(85)90218-3; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Stamatakis EA, 2002, J NUCL MED, V43, P476; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Yamauchi H, 2007, ANN NEUROL, V61, P454, DOI 10.1002/ana.21104; Yamauchi H, 2009, STROKE, V40, P3730, DOI 10.1161/STROKEAHA.109.560011; Zhang J, 2010, J NEUROTRAUM, V27, P35, DOI 10.1089/neu.2009.1049	37	25	26	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2131	2138		10.1089/neu.2010.1464			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400002	21138392				2022-02-06	
J	Thaler, S; Choragiewicz, TJ; Rejdak, R; Fiedorowicz, M; Turski, WA; Tulidowicz-Bielak, M; Zrenner, E; Schuettauf, F; Zarnowski, T				Thaler, Sebastian; Choragiewicz, Tomasz J.; Rejdak, Robert; Fiedorowicz, Michal; Turski, Waldemar A.; Tulidowicz-Bielak, Maria; Zrenner, Eberhart; Schuettauf, Frank; Zarnowski, Tomasz			Neuroprotection by acetoacetate and beta-hydroxybutyrate against NMDA-induced RGC damage in rat-possible involvement of kynurenic acid	GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						beta-hydroxybutyrate; Acetoacetate; Retinal ganglion cells; Kynurenic acid; Neuroprotection	RETINAL GANGLION-CELLS; ASPARTATE-INDUCED NEUROTOXICITY; TRAUMATIC BRAIN-INJURY; INHIBITION IN-VIVO; KETOGENIC DIET; KETONE-BODIES; THERAPEUTIC INTERVENTION; GLYCOLYSIS INHIBITION; NEUROTROPHIC FACTOR; ENERGY-METABOLISM	Purpose This study investigated the effects of systemically administered lithium acetoacetate (ACA) and sodium beta-hydroxybutyrate (BHB) in a rat model of N-methyl-D-aspartate (NMDA)-induced damage of retinal ganglion cells (RGC). Additionally, the influence of ACA and BHB on kynurenic acid (KYNA) production was assessed in vitro in bovine retinal slices. Methods Female adult Brown Norway rats in groups of 5-8 animals were used. ACA and BHB were administered intraperitoneally once a day for 21 consecutive days, and phosphate buffered saline (PBS) was administered to control animals. After 2 weeks, the animals received intraocular NMDA (2 mu l of a 10 mM solution in PBS) or intraocular PBS as a control. On day 19, retinal ganglion cells were labeled retrogradely with hydroxystilbamidine. Two days later, RGC density (cells per mm(2)) was assessed on retinal flatmounts. Additionaly, bovine retinal slices were incubated with NMDA and ACA or BHB at concentrations of 1.0 mM and 3.0 mM, and de novo KYNA production was measured using HPLC. Results Intraperitoneal ACA (250 mg/kg) or BHB (291.2 mg/kg) significantly protected RGC against NMDA-induced neurodegeneration. De novo KYNA production in bovine retinal slices was lowered by NMDA. Both ACA and BHB at a concentration of 3.0 mM significantly reduced the effects of NMDA. Conclusions ACA and BHB had a significant dose-dependent neuroprotective effect on RGC in a rat model of NMDA-induced RGC damage. Both ketone bodies also significantly attenuated NMDA-induced reduction of retinal KYNA production in vitro, suggesting that this mechanism may be essential for the neuroprotective effects of ACA and BHB in vivo. Our results imply that ketone bodies may represent an additional treatment option in chronic neurodegenerative disorders of the eye.	[Zarnowski, Tomasz] Med Univ, Dept Ophthalmol, PL-20079 Lublin, Poland; [Thaler, Sebastian; Choragiewicz, Tomasz J.; Rejdak, Robert; Fiedorowicz, Michal; Zrenner, Eberhart; Schuettauf, Frank] Univ Tubingen, Ctr Ophthalmol, Tubingen, Germany; [Choragiewicz, Tomasz J.; Rejdak, Robert; Tulidowicz-Bielak, Maria; Zarnowski, Tomasz] Med Univ, Tadeusz Krwawicz Chair Ophthalmol, PL-20079 Lublin, Poland; [Choragiewicz, Tomasz J.; Rejdak, Robert; Tulidowicz-Bielak, Maria; Zarnowski, Tomasz] Med Univ, Hosp Eye, PL-20079 Lublin, Poland; [Rejdak, Robert; Fiedorowicz, Michal] PAS Med Res Ctr, Dept Expt Pharmacol, Warsaw, Poland; [Turski, Waldemar A.] Inst Agr Med, Dept Toxicol, Lublin, Poland		Zarnowski, T (corresponding author), Med Univ, Dept Ophthalmol, Chmielna 1, PL-20079 Lublin, Poland.	zarnowskit@poczta.onet.pl	Fiedorowicz, Michal/L-1538-2018; Fiedorowicz, Michal/O-9779-2019; Zarnowski, Tomasz/AAM-6460-2020	Fiedorowicz, Michal/0000-0001-5755-3608; Fiedorowicz, Michal/0000-0001-5755-3608; Zarnowski, Tomasz/0000-0002-6978-7417; Turski, Waldemar/0000-0002-5805-5106	EUEuropean Commission [LSHG-CT-2005-512036]; Kerstan FoundationEuropean Commission	Supported by the EU (integrated project EVI-GENORET LSHG-CT-2005-512036).; MF and TC received support from the Kerstan Foundation in the form of a research fellowship. The authors thank Dr T. Kocki (Lublin, Poland) for technical assistance and Dr M. Gasior (USA) for valuable help in designing the experiments.	Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Casson RJ, 2006, CLIN EXP OPHTHALMOL, V34, P54, DOI 10.1111/j.1442-9071.2006.01146.x; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dardzinski BJ, 2000, PEDIATR RES, V48, P248, DOI 10.1203/00006450-200008000-00021; DEVIVO DC, 1978, ANN NEUROL, V3, P331, DOI 10.1002/ana.410030410; Donevan SD, 2003, EPILEPSIA, V44, P1274, DOI 10.1046/j.1528-1157.2003.07203.x; Dong CJ, 2008, INVEST OPHTH VIS SCI, V49, P4515, DOI 10.1167/iovs.08-2078; Gasior M, 2006, BEHAV PHARMACOL, V17, P431, DOI 10.1097/00008877-200609000-00009; Haces ML, 2008, EXP NEUROL, V211, P85, DOI 10.1016/j.expneurol.2007.12.029; Hodgkins PS, 1998, DEV NEUROSCI-BASEL, V20, P408, DOI 10.1159/000017338; Hodgkins PS, 1998, EUR J NEUROSCI, V10, P1986, DOI 10.1046/j.1460-9568.1998.00208.x; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; Kido N, 2000, BRAIN RES, V884, P59, DOI 10.1016/S0006-8993(00)02887-0; Klocker N, 1998, J NEUROSCI, V18, P1038; Lipton SA, 2007, CURR DRUG TARGETS, V8, P621, DOI 10.2174/138945007780618472; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; Massieu L, 2001, NEUROSCIENCE, V106, P669, DOI 10.1016/S0306-4522(01)00323-2; Masuda R, 2005, J NEUROSCI RES, V80, P501, DOI 10.1002/jnr.20464; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mejia-Toiber J, 2006, NEUROCHEM RES, V31, P1399, DOI 10.1007/s11064-006-9189-5; Morizane C, 1997, EUR J PHARMACOL, V328, P45, DOI 10.1016/S0014-2999(97)83026-9; Noh HS, 2006, J NEUROSCI RES, V83, P702, DOI 10.1002/jnr.20736; Pernet V, 2007, J NEUROCHEM, V103, P1481, DOI 10.1111/j.1471-4159.2007.04843.x; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Schuettauf F, 2005, GRAEF ARCH CLIN EXP, V243, P1036, DOI 10.1007/s00417-005-1152-7; Schuettauf F, 2006, EXP EYE RES, V83, P1128, DOI 10.1016/j.exer.2006.05.021; Seki M, 2008, PROG BRAIN RES, V173, P495, DOI 10.1016/S0079-6123(08)01134-5; SHIBATA K, 1988, J CHROMATOGR-BIOMED, V430, P376, DOI 10.1016/S0378-4347(00)83173-4; SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666; Sinha SR, 2005, NEUROLOGIST, V11, P161, DOI 10.1097/01.nrl.0000160818.58821.d2; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Thio LL, 2000, NEUROLOGY, V54, P325, DOI 10.1212/WNL.54.2.325; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Tsukada H, 2005, NEUROPSYCHOPHARMACOL, V30, P1861, DOI 10.1038/sj.npp.1300732; TURSKI WA, 1988, BRAIN RES, V454, P164, DOI 10.1016/0006-8993(88)90815-3; Veech RL, 2001, IUBMB LIFE, V51, P241; Zarnowski T, 2006, J NEURAL TRANSM, V113, P1367, DOI 10.1007/s00702-005-0423-0; Zhao Z, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-29; Ziegler DR, 2003, NEUROCHEM RES, V28, P1793, DOI 10.1023/A:1026107405399	42	25	25	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0721-832X	1435-702X		GRAEF ARCH CLIN EXP	Graefes Arch. Clin. Exp. Ophthalmol.	DEC	2010	248	12					1729	1735		10.1007/s00417-010-1425-7			7	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	687WW	WOS:000284810000007	20532550	hybrid, Green Published			2022-02-06	
J	Turner, B; Fleming, J; Parry, J; Vromans, M; Cornwell, P; Gordon, C; Ownsworth, T				Turner, Ben; Fleming, Jennifer; Parry, Julie; Vromans, Monique; Cornwell, Petrea; Gordon, Cassandra; Ownsworth, Tamara			Caregivers of Adults With Traumatic Brain Injury: The Emotional Impact of Transition From Hospital to Home	BRAIN IMPAIRMENT			English	Article						rehabilitation; brain injury; discharge; anxiety; depression; stress	ANXIETY STRESS SCALES; QUALITY-OF-LIFE; STROKE PATIENTS; FAMILY CAREGIVERS; INFORMAL CAREGIVERS; 1ST MONTH; BURDEN; CARE; PREDICTORS; DEPRESSION	Primary Objective: To explore levels of depression, anxiety, stress and strain symptomatology experienced by caregivers of adults with traumatic brain injury (FBI) during the phase of transition from hospital to home. Research Design: Prospective study with data collected at three time-points: pre-discharge, 1-month post-discharge, and 3-months post-discharge. Methods and Procedures: Twenty-nine caregivers of adults with TBI (mean age 48 years), recruited on patient discharge from rehabilitation, completed the Caregiver Strain Index and the Depression, Anxiety and Stress Scale at the three time points. Results. Paired t tests showed significantly lower levels of caregiver strain at one month compared to pre-discharge, and significantly less strain and depression symptoms at 3-month follow-up compared to pre-discharge. Non-significant reductions were observed in level of stress and anxiety across the follow-up time points. Independent group t tests found that female caregivers experienced greater strain than male caregivers at 3 months post-discharge, and caregivers who were immediate family members of the patient experienced greater anxiety than those who were spouses/partners of the patient at 1-month follow-up. Conclusions. The rate of depressive symptoms in caregivers of people with TBI was greater than the general population, and strain was prevalent during the transition period. The results suggest more specific caregiver support and preparation is needed before patient discharge from hospital, and that adequate time spent in rehabilitation is beneficial for caregiver wellbeing.	[Turner, Ben] Acquired Brain Injury Outreach Serv, Brisbane, Qld, Australia; [Turner, Ben; Fleming, Jennifer; Parry, Julie; Vromans, Monique; Cornwell, Petrea; Gordon, Cassandra] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia; [Gordon, Cassandra; Ownsworth, Tamara] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia; [Fleming, Jennifer] Ctr Functioning & Hlth Res, Queensland Hlth, Australia		Turner, B (corresponding author), Acquired Brain Injury Outreach Serv, POB 6053, Buranda, Qld 4102, Australia.	Ben_J_Turner@health.qld.gov.au	Fleming, Jennifer M/B-4436-2011; Ownsworth, Tamara/ABB-6961-2021; Cornwell, Petrea/AAE-5547-2019	Ownsworth, Tamara/0000-0003-1835-7094; 	Australian Postgraduate AwardAustralian Government	The first author was in receipt of an Australian Postgraduate Award at the time of conducting this research. The authors thank two anonymous reviewers for useful comments during the preparation of the manuscript.	Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; *AUSTR BUR STAT, 1998, AUSTR STAND CLASS OC; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Bugge C, 1999, STROKE, V30, P1517, DOI 10.1161/01.STR.30.8.1517; Bull MJ., 1992, QUAL HEALTH RES, V2, P27; Chumbler NR, 2004, INT J GERIATR PSYCH, V19, P944, DOI 10.1002/gps.1187; COHEN J, 1988, STAT POWER ANAL BEHA, pR21; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544; Davis LC, 2009, J HEAD TRAUMA REHAB, V24, P145, DOI 10.1097/HTR.0b013e3181a0b291; Devilly G.J, 2007, EFFECT SIZE GENERATO; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fraser C, 1999, J Neurosci Nurs, V31, P9; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; Grant JS, 2004, BRAIN INJURY, V18, P797, DOI 10.1080/02699050410001671766; Han B, 1999, STROKE, V30, P1478, DOI 10.1161/01.STR.30.7.1478; Hankey GJ, 2004, BMJ-BRIT MED J, V328, P1085, DOI 10.1136/bmj.328.7448.1085; Kalra L, 2004, BMJ-BRIT MED J, V328, P1099, DOI 10.1136/bmj.328.7448.1099; Kasuya RT, 2000, POSTGRAD MED, V108, P119, DOI 10.3810/pgm.2000.12.1324; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; King RB, 2001, RES NURS HEALTH, V24, P307, DOI 10.1002/nur.1032; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Lovibond SH., 1995, MANUAL DEPRESSION AN, V2nd; Low JTS, 1999, SOC SCI MED, V49, P711, DOI 10.1016/S0277-9536(99)00194-X; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; McCullagh E, 2005, STROKE, V36, P2181, DOI 10.1161/01.STR.0000181755.23914.53; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; MITCHLEY M, 1996, CLIN REHABIL, V10, P3; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Norup A, 2010, BRAIN INJURY, V24, P81, DOI 10.3109/02699050903508200; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; Olofsson A, 2005, CLIN REHABIL, V19, P433, DOI 10.1191/0269215505cr788oa; Ownsworth T, 2009, BRAIN IMPAIR, V10, P149, DOI 10.1375/brim.10.2.149; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Schlossberg N.K., 1984, COUNSELLING ADULTS T; Slade T., 2007, MENTAL HLTH AUSTR; Stuckey JC, 1996, GERONTOLOGIST, V36, P686, DOI 10.1093/geront/36.5.686; TEASDALE B, 1974, LANCET, P281; Tooth L, 2005, BRAIN INJURY, V19, P963, DOI 10.1080/02699050500110785; Turner BJ, 2008, DISABIL REHABIL, V30, P1153, DOI 10.1080/09638280701532854; *UB FDN ACT INC UN, 1997, FIM INSTR; van den Heuvel ETP, 2001, CLIN REHABIL, V15, P669, DOI 10.1191/0269215501cr446oa; Yee JL, 2000, GERONTOLOGIST, V40, P147, DOI 10.1093/geront/40.2.147	49	25	25	2	17	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646	1839-5252		BRAIN IMPAIR	Brain Impair.	DEC	2010	11	3					281	292		10.1375/brim.11.3.281			12	Clinical Neurology; Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	710VJ	WOS:000286544800004		Green Published			2022-02-06	
J	Fabbri, A; Servadei, F; Marchesini, G; Stein, SC; Vandelli, A				Fabbri, Andrea; Servadei, Franco; Marchesini, Giulio; Stein, Sherman C.; Vandelli, Alberto			Predicting intracranial lesions by antiplatelet agents in subjects with mild head injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; ATHEROSCLEROTIC CARDIOVASCULAR-DISEASE; EMERGENCY-DEPARTMENT; COMPUTED-TOMOGRAPHY; ELDERLY-PATIENTS; NICE GUIDELINES; RULE; HEMORRHAGE; MANAGEMENT; PROPOSAL	Background The effect of pre-injury antiplatelet treatment in the risk of intracranial lesions in subjects after mild head injury (Glasgow Coma Scale (GCS) 14-15) is uncertain. Methods The potential risk was determined, considering its increasing use in guidelines on cardiovascular disease prevention, and ageing of the trauma population in Europe. Patients The interaction of antiplatelet therapy with the prediction variables of main decision aids was analysed in 14 288 consecutive adolescent and adult subjects with mild head injury. Measurements Any intracranial lesion at CT scan was selected as an outcome measure in a multivariable logistic regression analysis. Results Intracranial lesions were demonstrated in 880 cases (6.2%), with an unfavourable outcome at 6 months in 86 (0.6%). Antiplatelet drugs were recorded in 10% of the entire cohort (24.7% in the group over 65 years). They increased the risk of intracranial lesions in the univariate analysis (OR 2.6; 95% CI 2.2 to 3.1), interacting with age in the multivariate analysis (antiplatelet OR 2.7 (1.9 to 3.7); age >= 75 years 1.4 (1.0 to 1.9)). The inclusion of these two variables with those included in previous decision aids for CT scanning (GCS, neurodeficit, post-traumatic seizures, suspected skull fracture, vomiting, loss of consciousness, coagulopathy) predicted intracranial lesions with a sensitivity of 99.7% (95% CI 98.9 to 99.8) and a specificity of 54.0% (95% CI 53.1 to 54.8), with a CT ordering rate of 49.3% (undetermined events 0.2:1000). Interpretation Antiplatelet drugs need to be considered in future prediction models on mild head injury, considering their increasing use and progressive ageing of the trauma population.	[Fabbri, Andrea; Vandelli, Alberto] Presidio Osped Morgagni Pierantoni, Azienda USL Forli, Dipartimento Emergenza, I-47100 Forli, Italy; [Servadei, Franco] Univ Parma, Azienda Osped, Unita Operativa Neurochirurg, I-43100 Parma, Italy; [Marchesini, Giulio] Univ Bologna, I-40126 Bologna, Italy; [Stein, Sherman C.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA		Fabbri, A (corresponding author), Presidio Osped Morgagni Pierantoni, Azienda USL Forli, Dipartimento Emergenza, Via Forlanini 34, I-47100 Forli, Italy.	dr.andrea.fabbri@gmail.com	Fabbri, Andrea/K-9994-2016	Fabbri, Andrea/0000-0002-9837-4638; Marchesini, Giulio/0000-0003-2407-9860; Servadei, Franco/0000-0002-3595-3464			Bramley R, 2002, CLIN RADIOL, V57, P151, DOI 10.1053/crad.2001.0868; DEROSA M, 2007, COLLANA RAPPORTI ARN, P47; Dunning J, 2004, EMERG MED J, V21, P404, DOI 10.1136/emj.2004.014944; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; GIANNOUDIS PV, 2009, J TRAUMA, V40, P362, DOI DOI 10.1016/J.INJURY.2008.10.016; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; *ISS AIFA, 2008, OSS NAZ SULL MED US; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jagoda A, 2008, ANN EMERG MED, V52, pS3, DOI 10.1016/j.annemergmed.2008.04.030; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; National Institute for Clinical Excellence, 2007, CLIN GUID; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Patrono C, 2004, EUR HEART J, V25, P166, DOI 10.1016/j.ehj.2003.10.013; REYMOND MA, 1992, NEUROSURG REV, V15, P21, DOI 10.1007/BF02352062; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Shravat BP, 2006, EMERG MED J, V23, P109, DOI 10.1136/emj.2004.022327; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; STROOBANDT G, 1995, ACTA NEUROCHIR, V137, P6, DOI 10.1007/BF02188772; Sultan HY, 2004, EMERG MED J, V21, P420, DOI 10.1136/emj.2003.011353; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631	32	25	25	1	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2010	81	11					1275	1279		10.1136/jnnp.2009.197467			5	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	669ML	WOS:000283354800238	20643657	Green Submitted			2022-02-06	
J	Olson-Madden, JH; Brenner, L; Harwood, JEF; Emrick, CD; Corrigan, JD; Thompson, C				Olson-Madden, Jennifer H.; Brenner, Lisa; Harwood, Jeri E. F.; Emrick, Chad D.; Corrigan, John D.; Thompson, Caitlin			Traumatic Brain Injury and Psychiatric Diagnoses in Veterans Seeking Outpatient Substance Abuse Treatment	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						alcohol; drug; psychiatric diagnosis; substance abuse; traumatic brain injury; veteran	RISK-FACTORS; ALCOHOL-USE; PREVALENCE; IDENTIFICATION; RELIABILITY; VALIDITY; OUTCOMES; TBI; 1ST	Objectives: Explore the incidence of traumatic brain injury (TBI) in veterans seeking outpatient substance abuse treatment and the association between TBI and psychiatric diagnoses. MainMeasure: The Ohio State University TBI identification method (OSU TBI-ID) was administered to veterans with positive TBI-4 screens; substance-related and psychiatric diagnoses were extracted from the medical record. Participants: Over an 18-month period, 247 veterans completed the TBI-4. Of the 136 who screened positive, 70 were administered the OSU TBI-ID. Results: On the basis of the TBI-4, 55% (95% CI: 49%-61%) of veterans screened positive for a history of TBI. The OSU TBI-ID was used to confirm screening results. Those who completed the OSU TBI-ID sustained an average of 3.4 lifetime TBIs. For each additional TBI sustained, after initial injury, there was an estimated 9% increase in the number of psychiatric diagnoses documented (99% CI: 1%-17%). For each additional documented psychiatric diagnosis, there was an estimated increase of 11% in the number of injuries sustained (99% CI: 1%-22%). Also, 54% (38/70) had a positive history of TBI prior to adulthood. Conclusion: These results emphasize the need for TBI screening in this vulnerable population, as well as the importance of increasing brain injury awareness among those abusing substances and their care providers. These findings also highlight the need for specialized services for those with TBI and co-occurring substance misuse aimed at decreased future TBIs or negative psychiatric outcomes or both. Further study is needed to clarify best practices.	[Olson-Madden, Jennifer H.; Brenner, Lisa] Mental Illness Res Educ & Clin Ctr, VA VISN 19, Denver, CO 80220 USA; [Olson-Madden, Jennifer H.] Univ Colorado, Denver Sch Med, Dept Psychiat, Aurora, CO USA; [Brenner, Lisa] Univ Colorado, Denver Sch Med, Dept Psychiat Neurol Phys Med & Rehabil, Aurora, CO USA; [Harwood, Jeri E. F.] Univ Colorado, Denver Sch Med, Dept Pediat, Aurora, CO USA; [Emrick, Chad D.] Affairs Med Ctr, Eastern Colorado Healthcare Syst Outpatient Subst, Denver, CO USA; [Thompson, Caitlin] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14627 USA; [Thompson, Caitlin] Canandaigua VA Med Ctr, Canandaigua, NY USA; [Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA		Olson-Madden, JH (corresponding author), Mental Illness Res Educ & Clin Ctr, VA VISN 19, 1055 Clermont St, Denver, CO 80220 USA.	jennifer.olson-madden@va.gov	Brenner, Lisa A./AAG-2442-2019; Corrigan, John D./E-2921-2011		VA VISN 19 MIRECC	This project was supported by the VA VISN 19 MIRECC.	Basco MR, 2000, AM J PSYCHIAT, V157, P1599, DOI 10.1176/appi.ajp.157.10.1599; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Brenner LA, 2008, J HEAD TRAUMA REHAB, V23, P401, DOI 10.1097/01.HTR.0000341436.59627.a5; Corrigan J.D., 2005, REHABILITATION TRAUM, P133; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Felde AB, 2006, BRAIN INJURY, V20, P41, DOI 10.1080/02699050500309718; Institute of Medicine, 2009, GULF WAR HLTH, V7; Ivins BJ, 2003, J TRAUMA, V55, P617, DOI 10.1097/01.TA.0000052368.97573.D4; Jorge RE, 2005, CURR OPIN PSYCHIATR, V18, P289, DOI 10.1097/01.yco.0000165600.90928.92; Karon SL, 2007, J HEAD TRAUMA REHAB, V22, P350, DOI 10.1097/01.HTR.0000300230.13490.11; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; Miller N. S., 2005, TXB TRAUMATIC BRAIN, P509; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; Tate PS, 1999, BRAIN INJURY, V13, P767; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; *US DEP HHS, HEAD FACTS PHYS MILD; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Walker R, 2007, J HEAD TRAUMA REHAB, V22, P360, DOI 10.1097/01.HTR.0000300231.90619.50; Wiedemayer H, 2002, BRAIN INJURY, V16, P323, DOI 10.1080/02699050110102077	45	25	25	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2010	25	6					470	479		10.1097/HTR.0b013e3181d717a7			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	679HA	WOS:000284151300009	20414130				2022-02-06	
J	Llompart-Pou, JA; Perez, G; Raurich, JM; Riesco, M; Brell, M; Ibanez, J; Perez-Barcena, J; Abadal, JM; Homar, J; Burguera, B				Antonio Llompart-Pou, Juan; Perez, Gerardo; Maria Raurich, Joan; Riesco, Maria; Brell, Marta; Ibanez, Javier; Perez-Barcena, Jon; Maria Abadal, Josep; Homar, Javier; Burguera, Bartolome			Loss of Cortisol Circadian Rhythm in Patients with Traumatic Brain Injury: A Microdialysis Evaluation	NEUROCRITICAL CARE			English	Article						Traumatic brain injury; Cortisol; Brain interstitial cortisol; Microdialysis; Circadian rhythm		Traumatic brain injury (TBI) is commonly associated with disturbances of the hypothalamic-pituitary-adrenal axis secretion. Cerebral microdialysis techniques have been recently applied to measure brain interstitial cortisol levels. We evaluated for the first time the circadian rhythm of cortisol secretion at 08:00, 16:00, and 24:00 h in the acute phase of TBI by determination of total serum and brain interstitial cortisol levels (microdialysis samples) in 10 patients with TBI. Non-parametric Friedman's two way analysis of variance test was used. Mean age was 29.8 +/- A 13.6 years. Median Glasgow Coma Scale score after resuscitation was 5 (range 3-10). No differences were found in total serum (P = 0.26) and brain interstitial cortisol (P = 0.77) in the whole sample. Intraindividual analysis showed that circadian variability was lost in all patients, both in serum and brain interstitial cortisol samples in the acute phase after TBI. In our series, circadian variability of cortisol evaluated by serum and cerebral microdialysis samples seems to be lost in TBI patients.	[Antonio Llompart-Pou, Juan; Maria Raurich, Joan; Perez-Barcena, Jon; Maria Abadal, Josep; Homar, Javier] Hosp Univ Son Dureta, Serv Med Intens, Palma De Mallorca 07014, Illes Balears, Spain; [Perez, Gerardo; Riesco, Maria] Hosp Univ Son Dureta, Anal Clin, Palma De Mallorca 07014, Illes Balears, Spain; [Burguera, Bartolome] Hosp Univ Son Dureta, Endocrinol IUNICS CAIBER, Palma De Mallorca 07014, Illes Balears, Spain		Llompart-Pou, JA (corresponding author), Hosp Univ Son Dureta, Serv Med Intens, Andrea Doria 55, Palma De Mallorca 07014, Illes Balears, Spain.	juanantonio.llompart@ssib.es		Ibanez, Javier/0000-0003-3735-8332	Spanish government: Fondo de Investigacion Sanitaria [FIS PI070307]	This research was supported by a public grant from the Spanish government: Fondo de Investigacion Sanitaria (FIS PI070307) awarded to Dr J. Perez Barcena. This public institution will not gain or lose financially from the publication of this manuscript in any way.	*AM ASS NEUR SURG, 2007, J NEUROTRAUMA S1, V24, pS71; CHROUSOS GP, 1995, NEW ENGL J MED, V332, P1351, DOI 10.1056/NEJM199505183322008; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Cohen J, 2009, CRIT CARE RESUSC, V11, P287; Cohen J, 2009, CRIT CARE, V13, DOI 10.1186/cc8184; JENNETT B, 1975, LANCET, V7905, P480; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Llompart-Pou JA, 2010, J ENDOCRINOL INVEST, V33, P368, DOI 10.1007/BF03346605; Llompart-Pou JA, 2008, NEUROCRIT CARE, V9, P230, DOI 10.1007/s12028-008-9115-6; Maiya B, 2008, INTENS CARE MED, V34, P468, DOI 10.1007/s00134-007-0902-x; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Paul T, 2007, CHRONOBIOL INT, V24, P45, DOI 10.1080/07420520601142569; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Schwarz S, 2003, J NEUROL NEUROSUR PS, V74, P725, DOI 10.1136/jnnp.74.6.725; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x	15	25	27	0	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	OCT	2010	13	2					211	216		10.1007/s12028-010-9399-1			6	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	653LS	WOS:000282093500008	20593248				2022-02-06	
J	Lee, SY; Choi, YC; Kim, JH; Kim, WJ				Lee, Seung-Yeob; Choi, Young-Chul; Kim, Jeong-Ho; Kim, Won-Joo			Serum neuron-specific enolase level as a biomarker in differential diagnosis of seizure and syncope	JOURNAL OF NEUROLOGY			English	Article						Neuron-specific enolase; Seizure; Syncope	CREUTZFELDT-JAKOB-DISEASE; TRAUMATIC BRAIN-INJURY; TONIC-CLONIC SEIZURES; CEREBROSPINAL-FLUID; NONEPILEPTIC SEIZURES; EPILEPTIC SEIZURES; AMERICAN ACADEMY; ISCHEMIC-STROKE; S-100 PROTEIN; RAT-BRAIN	Patients who experience a single generalized tonic-clonic seizure or syncope may have similar clinical symptoms, which can cause difficulty in the differential diagnosis. The aim of this study was to examine whether serum neuron-specific enolase (NSE) has diagnostic relevance as a biochemical marker for these disorders. Serum NSE levels were analyzed following a loss of consciousness in patients who were diagnosed with a seizure (n = 52) and syncope (n = 42) compared with normal controls (n = 91). NSE was 14.97 +/- A 7.57 ng/dl for the seizure group, 10.15 +/- A 3.22 ng/dl for the syncope group, and 10.03 +/- A 1.28 ng/dl for the control group. The seizure group showed a significantly increased serum NSE (p < 0.05) compared to the syncope and control groups. By receiver operating characteristic (ROC) curve analysis, the cut-off value with the highest diagnostic accuracy was defined as 11.5 ng/ml with a sensitivity of 0.58 and specificity of 0.91. The NSE values of the syncope and control groups showed no significant differences. Syncope may not influence diffuse brain damage. Serum NSE measurement may be a helpful test for the identification and diagnosis of a seizure rather than syncope.	[Lee, Seung-Yeob; Choi, Young-Chul; Kim, Won-Joo] Yonsei Univ Coll Med, Gangnam Severance Hosp, Dept Neurol, Seoul 135720, South Korea; [Kim, Jeong-Ho] Yonsei Univ Coll Med, Gangnam Severance Hosp, Dept Clin Pathol, Seoul 135720, South Korea		Kim, WJ (corresponding author), Yonsei Univ Coll Med, Gangnam Severance Hosp, Dept Neurol, 146-92 Dogok Dong, Seoul 135720, South Korea.	kzoo@yuhs.ac		Choi, Young-Chul/0000-0001-5525-6861; Kim, Jeong-Ho/0000-0003-2479-0548; Kim, Won-Joo/0000-0002-5850-010X			Aksamit AJ, 2001, NEUROLOGY, V57, P728, DOI 10.1212/WNL.57.4.728; Anand N, 2005, CEREBROVASC DIS, V20, P213, DOI 10.1159/000087701; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bergfeldt L, 2003, HEART, V89, P353, DOI 10.1136/heart.89.3.353; Britton JW, 2006, CLIN AUTON RES, V16, P18, DOI 10.1007/s10286-006-0277-z; Britton JW, 2004, CLIN AUTON RES, V14, P148, DOI 10.1007/s10286-004-0184-0; Buttner T, 1999, J NEUROL, V246, P459, DOI 10.1007/s004150050383; Chen DK, 2005, NEUROLOGY, V65, P668, DOI 10.1212/01.wnl.0000178391.96957.d0; Cuthill FM, 2005, SEIZURE-EUR J EPILEP, V14, P293, DOI 10.1016/j.seizure.2005.04.006; DeGiorgio CM, 1999, NEUROLOGY, V52, P746, DOI 10.1212/WNL.52.4.746; FRANCIS A, 1983, BRAIN RES, V263, P89, DOI 10.1016/0006-8993(83)91203-9; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; HARDEMARK HG, 1988, STROKE, V19, P1140, DOI 10.1161/01.STR.19.9.1140; Kohira I, 2000, ACTA NEUROL SCAND, V102, P385, DOI 10.1034/j.1600-0404.2000.102006385.x; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Massabki PS, 2003, J RHEUMATOL, V30, P2606; McKeon A, 2006, LANCET NEUROL, V5, P171, DOI 10.1016/S1474-4422(06)70350-7; Oh SH, 2003, ARCH NEUROL-CHICAGO, V60, P37, DOI 10.1001/archneur.60.1.37; PAHLMAN S, 1984, TUMOUR BIOL, V5, P127; Petramfar P, 2009, EPILEPSY BEHAV, V15, P330, DOI 10.1016/j.yebeh.2009.04.016; PRINZ RA, 1982, SURGERY, V92, P887; Rabinowicz AL, 1996, EPILEPSIA, V37, P122, DOI 10.1111/j.1528-1157.1996.tb00002.x; Schreiber SS, 1999, EXP NEUROL, V159, P329, DOI 10.1006/exnr.1999.7147; Sheldon R, 2002, J AM COLL CARDIOL, V40, P142, DOI 10.1016/S0735-1097(02)01940-X; Sulter G, 1998, NEUROSCI LETT, V253, P71, DOI 10.1016/S0304-3940(98)00595-3; Tumani H, 1999, EPILEPSIA, V40, P713, DOI 10.1111/j.1528-1157.1999.tb00768.x; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd	28	25	28	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354			J NEUROL	J. Neurol.	OCT	2010	257	10					1708	1712		10.1007/s00415-010-5608-2			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	661CJ	WOS:000282700300017	20532546				2022-02-06	
J	McCarthy, TJ; De Taboada, L; Hildebrandt, PK; Ziemer, EL; Richieri, SP; Streeter, J				McCarthy, Thomas J.; De Taboada, Luis; Hildebrandt, Paul K.; Ziemer, Ellen L.; Richieri, Steven P.; Streeter, Jackson			Long-Term Safety of Single and Multiple Infrared Transcranial Laser Treatments in Sprague-Dawley Rats	PHOTOMEDICINE AND LASER SURGERY			English	Article							NEUROLOGICAL DEFICITS; SPONTANEOUS TUMORS; EMBOLIC STROKES; ISCHEMIC-STROKE; BRAIN-TUMORS; THERAPY; RABBITS; LIGHT; MICE	Background and Objective: Growing interest exists in the use of near-infrared laser therapies for the treatment of numerous neurologic conditions, including acute ischemic stroke, traumatic brain injury, Parkinson's disease, and Alzheimer's disease. In consideration of these trends, the objective of this study was to evaluate the long-term safety of transcranial laser therapy with continuous-wave (CW) near-infrared laser light (wavelength, 808 +/- 10 nm, 2-mm diameter) with a nominal radiant power of 70 mW; power density, 2,230 mW/cm(2), and energy density, 268 J/cm(2) at the scalp (10 mW/cm(2) and 1.2 J/cm(2) at the cerebral cortical surface) in healthy Sprague-Dawley rats. Materials and Methods: In this study, 120 anesthetized rats received sequential transcranial laser treatments to the right and left parietal areas of the head on the same day (minimum of 5 min between irradiation of each side), on either Day 1 or on each of Days 1, 3, and 5. Sixty anesthetized rats served as sham controls. Rats were evaluated 1 year after treatment for abnormalities in clinical hematology and brain and pituitary gland histopathology. Results: No toxicologically important differences were found in the clinical hematology results between sham-control and laser-treated rats for any hematologic parameters examined. All values fell within historic control reference ranges for aged Sprague-Dawley rats. Similarly, brain and pituitary gland histopathology showed no treatment-related abnormalities or induced neoplasia. Conclusions: Single and multiple applications of transcranial laser therapy with 808-nm CW laser light at a nominal power density of 10 mW/cm(2) at the surface of the cerebral cortex appears to be safe in Sprague-Dawley rats 1 year after treatment.	[McCarthy, Thomas J.; De Taboada, Luis; Richieri, Steven P.; Streeter, Jackson] PhotoThera Inc, Carlsbad, CA 92008 USA; [Hildebrandt, Paul K.] Colorado Histo Prep, Ft Collins, CO USA; [Ziemer, Ellen L.] Rougemont Preclin Serv LLC, Bahama, NC USA		McCarthy, TJ (corresponding author), PhotoThera Inc, 5925 Priestly Dr,Suite 120, Carlsbad, CA 92008 USA.	tmccarthy@photothera.com		De Taboada, Luis/0000-0002-0153-6419	PhotoThera, Inc., Carlsbad, CA	This study was funded by PhotoThera, Inc., Carlsbad, CA Drs. McCarthy and Streeter, Mr. DeTaboada, and Mr. Richieri are employees of PhotoThera, Inc. Each holds equity interests in PhotoThera, Inc.	Desmet KD, 2006, PHOTOMED LASER SURG, V24, P121, DOI 10.1089/pho.2006.24.121; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Giknis MLA, 2004, COMPILATION SPONTANE; GOPINATH C, 1986, FOOD CHEM TOXICOL, V24, P113, DOI 10.1016/0278-6915(86)90345-5; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; KRINKE G, 1985, J COMP PATHOL, V95, P175, DOI 10.1016/0021-9975(85)90004-0; Krinke GJ, 2000, TOXICOL PATHOL, V28, P178, DOI 10.1177/019262330002800123; *LAB CORP AM, 2003, HEM RANG SPRAG DAWL; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2008, STROKE, V39, P3073, DOI 10.1161/STROKEAHA.108.516393; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; MITSUMORI K, 1987, VET PATHOL, V24, P50, DOI 10.1177/030098588702400109; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; PREJEAN JD, 1973, CANCER RES, V33, P2768; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Yarbrough C, 2009, J AM ACAD DERMATOL, V60, P877, DOI 10.1016/j.jaad.2008.10.050; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	20	25	25	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1549-5418	1557-8550		PHOTOMED LASER SURG	Photomed. Laser Surg.	OCT	2010	28	5					663	667		10.1089/pho.2009.2581			5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	668FA	WOS:000283252800014	20961232				2022-02-06	
J	Clauss, RP				Clauss, R. P.			Neurotransmitters in Coma, Vegetative and Minimally Conscious States, pharmacological interventions	MEDICAL HYPOTHESES			English	Article							TRAUMATIC BRAIN-INJURY; MAGNETIC-RESONANCE-SPECTROSCOPY; AMINO-ACIDS; CIRCADIAN-RHYTHMS; AWAKE RAT; GLUTAMATE; ZOLPIDEM; ASPARTATE; ISCHEMIA; RELEASE	Articles on pharmacological interventions in disorders of consciousness after brain damage are increasingly appearing in the medical literature. This hypothesis links disorders of consciousness to the depletion of oxygen reliant neurotransmitters based in two biochemical axes, the amino acid axis (glutamate/ GABA) and the monoamine axis (dopamine/noradrenalin and serotonin). After a brain injury, an immediate response inside the brain constitutes a surge of amino acids such as glutamate, GABA and others. Glutamate is excitatory and GABA inhibitory. The inhibitory response dominates and the brain becomes suppressed, leading to a loss in consciousness which reduces oxygen requirements. In time, GABA depletes after increased usage and leakage from the brain into the blood. If it cannot be restored sufficiently in some parts of the brain, a secondary response in these regions occurs which makes GABA receptors oversensitive to GABA, so that decreased GABA levels can maintain their suppressive effect. This occurs in prolonged disorders of consciousness as in the Vegetative State, which can be broken by agents such as zolpidem in some patients. In addition to amino acids, monoamine systems such as dopamine are essential to cognition and motor function. Their depletion or the suppression of brain regions in which they function, are proposed as contributors to disorders of consciousness. Reports of successful arousals after amino acid and monoamine based therapies supports the hypothesis that depletion of these brain chemicals may play a fundamental role in disorders of consciousness. (C) 2010 Elsevier Ltd. All rights reserved.	Royal Surrey Cty Hosp, Dept Nucl Med, Guildford GU2 7XX, Surrey, England		Clauss, RP (corresponding author), Royal Surrey Cty Hosp, Dept Nucl Med, Guildford GU2 7XX, Surrey, England.	rclauss@royalsurrey.nhs.uk					ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; Cardinali DP, 1998, NEUROCHEM RES, V23, P607, DOI 10.1023/A:1022426519297; Castaneda TR, 2004, J PINEAL RES, V36, P177, DOI 10.1046/j.1600-079X.2003.00114.x; Clark JF, 2006, MED HYPOTHESES, V67, P506, DOI 10.1016/j.mehy.2006.02.047; Clauss R, 2006, NEUROREHABILITATION, V21, P23; Clauss RP, 2004, ARZNEIMITTELFORSCH, V54, P641; Clauss RP, 2000, S AFR MED J, V90, P68; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; COOPER AJL, 1979, J BIOL CHEM, V254, P4982; Dawson LA, 2000, BRAIN RES BULL, V53, P767, DOI 10.1016/S0361-9230(00)00363-4; de Prado BM, 2000, J PINEAL RES, V29, P209; Du B, 2008, NEUROL REGENERAT RES, V3, P1673; ERECINSKA M, 1993, J NEUROCHEM, V60, P1696, DOI 10.1111/j.1471-4159.1993.tb13393.x; Fernstrom JD, 2005, J NUTR, V135, p1539S, DOI 10.1093/jn/135.6.1539S; Fridman EA, 2009, BRAIN INJURY, V23, P172, DOI 10.1080/02699050802649662; Goddard AW, 2010, DEPRESS ANXIETY, V27, P339, DOI 10.1002/da.20642; Grimes MA, 2009, METABOLISM, V58, P129, DOI 10.1016/j.metabol.2008.08.015; Hall SD, 2010, CLIN NEUROPHYSIOL, V121, P549, DOI 10.1016/j.clinph.2009.11.084; HARDEBO JE, 1980, ANN NEUROL, V8, P1, DOI 10.1002/ana.410080102; Hawkins RA, 2009, AM J CLIN NUTR, V90, p867S, DOI 10.3945/ajcn.2009.27462BB; Higuchi T, 1996, NEUROSURGERY, V38, P121, DOI 10.1097/00006123-199601000-00030; JENNETT B, 1977, LANCET, V1, P878; Lee DH, 2005, KOREAN J RADIOL, V6, P64, DOI 10.3348/kjr.2005.6.2.64; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; Matsuda W, 2005, NEUROPSYCHOL REHABIL, V15, P414, DOI 10.1080/09602010443000588; Newsholme P, 2003, BRAZ J MED BIOL RES, V36, P153, DOI 10.1590/S0100-879X2003000200002; Niimura K, 1999, NEUROLOGY, V52, P792, DOI 10.1212/WNL.52.4.792; NILSSON GE, 1991, AM J PHYSIOL, V261, pR32, DOI 10.1152/ajpregu.1991.261.1.R32; Nilsson GE, 2004, J CEREBR BLOOD F MET, V24, P475, DOI 10.1097/00004647-200405000-00001; NILSSON GE, 1990, AM J PHYSIOL, V259, pR376, DOI 10.1152/ajpregu.1990.259.2.R376; Nyakala NE, 2010, ARZNEIMITTEL-FORSCH, V60, P681; OLDENDORF WH, 1971, AM J PHYSIOL, V221, P1629, DOI 10.1152/ajplegacy.1971.221.6.1629; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; REINHARD DL, 1997, ARCH PHYS MED REHAB, V78, P109; SAGER TN, 1995, J CEREBR BLOOD F MET, V15, P639, DOI 10.1038/jcbfm.1995.79; Sanger DJ, 1999, PHARMACOL BIOCHEM BE, V64, P269, DOI 10.1016/S0091-3057(99)00081-7; Sara M, 2007, BRAIN INJURY, V21, P101, DOI 10.1080/02699050601151761; Sara M, 2009, ARCH PHYS MED REHAB, V90, P1245, DOI 10.1016/j.apmr.2009.01.012; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; Shadan FF, 2004, SOUTH MED J, V97, P791, DOI 10.1097/00007611-200408000-00025; Siegel JM, 2003, SCI AM, V289, P92, DOI 10.1038/scientificamerican1103-92; Smith Y, 2008, MOVEMENT DISORD, V23, pS534, DOI 10.1002/mds.22027; Suzuki M, 2002, J NEUROTRAUM, V19, P285, DOI 10.1089/08977150252807027; Taira T, 2009, PROG BRAIN RES, V177, P317, DOI 10.1016/S0079-6123(09)17721-X; Tapiero H, 2002, BIOMED PHARMACOTHER, V56, P446, DOI 10.1016/S0753-3322(02)00285-8; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Waagepetersen HS, 2005, NEUROCHEM INT, V47, P92, DOI 10.1016/j.neuint.2005.04.012; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Witte OW, 1997, ADV NEUROL, V73, P207; Wroblewski Bruno, 1993, Brain Injury, V7, P353, DOI 10.3109/02699059309034962; Aviles-Reyes RX, 2010, J NEUROCHEM, V112, P854, DOI 10.1111/j.1471-4159.2009.06535.x; Yogeeswari P, 2005, CURR DRUG METAB, V6, P127, DOI 10.2174/1389200053586073; Young GB, 2009, ANN NY ACAD SCI, V1157, P32, DOI 10.1111/j.1749-6632.2009.04471.x; Zafonte RD, 1998, BRAIN INJURY, V12, P617	59	25	29	0	6	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	SEP	2010	75	3					287	290		10.1016/j.mehy.2010.03.005			4	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	647IF	WOS:000281611100005	20347531				2022-02-06	
J	Rapoport, MJ; Mitchell, RA; McCullagh, S; Herrmann, N; Chan, F; Kiss, A; Feinstein, A; Lanctot, KL				Rapoport, Mark J.; Mitchell, Robert A.; McCullagh, Scott; Herrmann, Nathan; Chan, Florance; Kiss, Alex; Feinstein, Anthony; Lanctot, Krista L.			A Randomized Controlled Trial of Antidepressant Continuation for Major Depression Following Traumatic Brain Injury	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							PLACEBO-CONTROLLED TRIAL; ILLNESS RATING-SCALE; STAR-ASTERISK-D; MAINTENANCE TREATMENT; HEAD-INJURY; SERTRALINE; DISORDERS; OUTCOMES; RECURRENCE; CITALOPRAM	Objective: This study examines whether continuation therapy with citalopram can prevent a relapse following remission of major depression due to traumatic brain injury. Method: After 65 subjects with DSM-IV- diagnosed major depression following traumatic brain injury were treated with open-label citalopram (20 mg to 50 mg/d), 25 subjects (38.5%) met criteria for remission. Of those, 21 (84.0%) were randomly assigned to either same-dose citalopram or placebo and followed monthly over 40 weeks. Remission was defined as a Hamilton Depression Rating Scale (HDRS) score of <= 7 or a Clinical Global Impressions-Improvement rating of "much improved" or better. The main outcome variable was the presence of relapse, as defined by meeting criteria for major depressive episode according to the DSM-IV and an HDRS score >= 16. Data were collected from February 16, 2005, to May 5, 2008. Results: Ten subjects were randomly assigned to citalopram and 11 to placebo. There were 3 dropouts, including 1 for adverse drug effects (diarrhea). Relapse occurred in 11 subjects (52.4%), with a mean +/- SD time to relapse of 23.52 +/- 16.6 weeks. The groups did not differ in relapse rates (drug: 50.0% [5/10] vs placebo: 54.5% [6/11], Fisher exact test, P = .835) or time to relapse (log rank test chi(2) = 0.148, P = .700). Conclusions: The present study suggests important limitations of continuation pharmacotherapy in the prevention of relapse of major depression following traumatic brain injury. Trial Registration: clinicaltrials.gov Identifier: NCT00162916 J Clin Psychiatry 2010;71(9):1125-1130 (C) Copyright 2010 Physicians Postgraduate Press, Inc.	[Rapoport, Mark J.; Mitchell, Robert A.; McCullagh, Scott; Herrmann, Nathan; Chan, Florance; Kiss, Alex; Feinstein, Anthony; Lanctot, Krista L.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Toronto, ON M5S 1A1, Canada		Rapoport, MJ (corresponding author), 2075 Bayview Ave,Rm FG37, Toronto, ON M4N 3M5, Canada.	mark.rapoport@sunnybrook.ca	Lanctot, Krista L./AAY-4820-2020; Rapoport, Mark/AAD-8581-2020	Lanctot, Krista L./0000-0001-7024-6637; 	AbbottAbbott Laboratories; Lundbeck CanadaLundbeck Corporation; Neurochem; Pfizer CanadaPfizer; Janssen-Ortho; Eli LillyEli Lilly; WyethWyeth; Ontario Neurotrauma Foundation (ONF) [2004-ABI-DEP-03]; Ontario Mental Health Foundation (OMHF); AstraZenecaAstraZeneca; Eli Lilly CanadaEli Lilly; BrainCells Inc; ServierServier	Dr Rapoport has received honoraria from Janssen-Ortho. Dr Lanctot is a consultant for the Worker's Safety Insurance Board (WSIB) of Ontario and the Royal Bank of Canada Insurance and has received grant research support from Abbott, Lundbeck Canada, Neurochem, Pfizer Canada, Janssen-Ortho, Eli Lilly, and Wyeth. Ms Chan is a former employee of Sunnybrook Health Sciences Center and is currently an employee of Wyeth. Drs McCullagh, Herrmann, Kiss, and Feinstein and Mr Mitchell have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.; Funding provided by the Ontario Neurotrauma Foundation (ONF-grant # 2004-ABI-DEP-03) and the Ontario Mental Health Foundation (OMHF).; The authors thank John Iazzetta, PharmD, for assistance with randomization and blinding of the capsules; Anthony Levitt, MD, FRCPC, for scholarly advice; Ayal Schaffer, MD, FRCPC, for scholarly advice; Andrea Phillips, BA, for assistance with ethics review, coordinating subjects, data management, and writing; and Carla Zucchero-Sarracini, BA, for assistance with ethics review, coordinating subjects, data management, and writing, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada. Dr Levitt has received grant/research support from AstraZeneca and Eli Lilly Canada and has received honoraria from Pfizer. Dr Schaffer has received grant/research support from AstraZeneca, BrainCells Inc, and Servier; has received honoraria from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Lundbeck, and Pfizer; and is a member of the speakers/advisory boards for AstraZeneca, Bristol-Myers Squibb, and Eli Lilly. Dr lazzetta and Mss Phillips and Zucchero-Sarracini have no personal affiliations or financial relationships with any commercial interest to disclose relative to the article.	Alamo C, 2007, ACTA NEUROPSYCHIATR, V19, P291, DOI 10.1111/j.1601-5215.2007.00187.x; Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Carrasco JL, 2005, INT J CLIN PRACT, V59, P1428, DOI 10.1111/j.1368-5031.2005.00681.x; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Dombrovski AY, 2007, J AFFECT DISORDERS, V103, P77, DOI 10.1016/j.jad.2007.01.020; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Fava M, 2008, AM J PSYCHIAT, V165, P342, DOI 10.1176/appi.ajp.2007.06111868; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FIRST MB, 1996, CLIN RES VERSIONS; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; Geddes JR, 2003, LANCET, V361, P653, DOI 10.1016/S0140-6736(03)12599-8; Gelenberg AJ, 2003, BIOL PSYCHIAT, V54, P806, DOI 10.1016/S0006-3223(02)01971-6; Guy W., 1976, CLIN GLOBAL IMPRESSI; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2001, BRAIN INJURY, V15, P189; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Judd LL, 1997, ARCH GEN PSYCHIAT, V54, P989; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keller MB, 1998, JAMA-J AM MED ASSOC, V280, P1665, DOI 10.1001/jama.280.19.1665; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kocsis JH, 2002, ARCH GEN PSYCHIAT, V59, P723, DOI 10.1001/archpsyc.59.8.723; Koran LM, 2001, J AFFECT DISORDERS, V65, P27, DOI 10.1016/S0165-0327(00)00272-X; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lepine JP, 2004, AM J PSYCHIAT, V161, P836, DOI 10.1176/appi.ajp.161.5.836; LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532-5415.1968.tb02103.x; MILLER MD, 1992, PSYCHIAT RES, V41, P237, DOI 10.1016/0165-1781(92)90005-N; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Robinson RG, 2002, ARCH GEN PSYCHIAT, V59, P23, DOI 10.1001/archpsyc.59.1.23; SILVER JM, 1994, SYNOPSIS NEUROPSYCHI, P279; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; TURNERSTOKES L, 2003, REHABILITATION FOLLO	45	25	25	0	4	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 240008, MEMPHIS, TN 38124 USA	0160-6689			J CLIN PSYCHIAT	J. Clin. Psychiatry	SEP	2010	71	9					1125	1130		10.4088/JCP.09m05086blu			6	Psychology, Clinical; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	661EF	WOS:000282705700003	20441723				2022-02-06	
J	Spentzas, T; Henricksen, J; Patters, AB; Chaum, E				Spentzas, Thomas; Henricksen, Jared; Patters, Andrea B.; Chaum, Edward			Correlation of intraocular pressure with intracranial pressure in children with severe head injuries	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						tonometry; intraocular pressure; intracranial pressure; traumatic brain injury	CEREBROSPINAL-FLUID PRESSURE; NERVE SHEATH DIAMETER; GLAUCOMA; PATIENT	Objective: To determine whether there was a correlation between tonometric measurements of the intraocular pressure and transducer measurements of the intracranial pressure in the acute setting, and whether intraocular pressure can be used as a surrogate measure of intracranial pressure. Children with traumatic brain injuries commonly develop increased intracranial pressure requiring surgical placement of a pressure transducer to measure the intracranial pressure during the acute recovery period. The increased intracranial pressure may cause engorgement of the orbital compartments via dilation of the episcleral veins and manifest as increased intraocular pressure. Design: Prospective study. Setting: Tertiary academic pediatric intensive care unit. Patients: Children admitted with severe traumatic brain injury. Interventions: Tonometric intraocular pressure measurements. Measurements and Main Results: We performed an Institutional Review Board-approved, prospective study on 36 children (age range, 2.9-15.1 yrs) with traumatic brain injuries, requiring intracranial pressure monitoring. A total of 274 intraocular pressure measurements were made after placement of the pressure transducer, and concordance between the sites of injury and measurement was documented. The average age of the patients was 8.3 yrs. The mean intraocular pressure, intracranial pressure difference was -0.5 +/- 0.68 cm H2O, and the variance was 29.88 (SD, 5.47). The 95% confidence interval was between -11.22 and 10.22. With concordance between the sites of measurement and injury, the mean IOP, intracranial pressure difference was -0.02 +/- 0.61 cm H2O (variance, 23.28; SD, 4.82; 95% confidence interval, -9.47 to 9.42). Concordance reduced the variance of the intraocular pressure, intracranial pressure discrepancy by 20.3%. The Pearson intraocular pressure-intracranial pressure regression coefficient and the Krippendorff's alpha reliability estimate analyses indicated good agreement. The patient's age or PaCO2 did not influence the intraocular pressure, intracranial pressure difference. Using 20 cm H2O as a normal intracranial pressure cutoff, the intraocular pressure had a specificity of 0.7 and sensitivity of 0.97; with concordance, the values improved to 0.78 and 0.96, respectively. Conclusions: Tonometry is a useful screening surrogate measure of intracranial pressure in children with traumatic brain injuries, but seems to lack the accuracy necessary for close management of intracranial pressure in the acute posttraumatic period. (Pediatr Crit Care Med 2010; 11:593-598)	[Spentzas, Thomas; Henricksen, Jared; Patters, Andrea B.; Chaum, Edward] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN USA; [Chaum, Edward] Univ Tennessee, Hlth Sci Ctr, Dept Biomed Engn, Memphis, TN USA; [Chaum, Edward] Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Memphis, TN USA		Spentzas, T (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN USA.	Tom.Spentzas@gmail.com	Chaum, Edward/AAR-1512-2021	Chaum, Edward/0000-0003-3542-8376			Abegg M, 2008, KLIN MONATSBL AUGENH, V225, P441, DOI 10.1055/s-2008-1027307; ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; Ballantyne J, 1999, CLIN RADIOL, V54, P740, DOI 10.1016/S0009-9260(99)91176-5; Berdahl JP, 2008, OPHTHALMOLOGY, V115, P763, DOI 10.1016/j.ophtha.2008.01.013; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Ceruti P, 2008, J GLAUCOMA, V17, P62, DOI 10.1097/IJG.0b013e318133a82e; Chen WT, 2003, NEUROLOGY, V61, P1265, DOI 10.1212/01.WNL.0000092022.95447.93; Czarnik T, 2009, INJURY, V40, P33, DOI 10.1016/j.injury.2008.10.010; Dickerman RD, 1999, NEUROL RES, V21, P243, DOI 10.1080/01616412.1999.11740925; DRUMMOND SR, 2009, INT OPHTHALMOL 0408; Firsching R, 2000, J NEUROSURG, V93, P33, DOI 10.3171/jns.2000.93.1.0033; GOLDMANN H, 1957, Ophthalmologica, V134, P221; Han Y, 2008, ANN NEUROL, V64, P221, DOI 10.1002/ana.21416; Hanneman SK, 2008, AACN ADV CRIT CARE, V19, P223, DOI 10.1097/01.AACN.0000318125.41512.a3; Hayes AF, 2007, COMMUN METHODS MEAS, V1, P77, DOI 10.1080/19312450709336664; Korber F, 2005, ROFO-FORTSCHR RONTG, V177, P229, DOI 10.1055/s-2004-813936; Krippendorff K., 2018, CONTENT ANAL INTRO I; Lashutka MK, 2004, ANN EMERG MED, V43, P585, DOI 10.1016/j.annemergmed.2003.12.006; Le A, 2009, ANN EMERG MED, V53, P785, DOI 10.1016/j.annemergmed.2008.11.025; Lee LA, 2004, CAN J ANAESTH, V51, P388, DOI 10.1007/BF03018245; Lirng JF, 2003, AM J NEURORADIOL, V24, P700; Morgan WH, 2008, J GLAUCOMA, V17, P408, DOI 10.1097/IJG.0b013e31815c5f7c; NEUENDORF K.A., 2017, CONTENT ANAL GUIDEBO; Newman WD, 2002, BRIT J OPHTHALMOL, V86, P1109, DOI 10.1136/bjo.86.10.1109; Nowroozzadeh MH, 2009, AM J OPHTHALMOL, V147, P945, DOI 10.1016/j.ajo.2009.01.002; Patel DK, 2008, ANN OPHTHALMOL, V40, P177; Sajjadi SA, 2006, ANN NEUROL, V59, P867, DOI 10.1002/ana.20856; Sheeran P, 2000, LANCET, V355, P899, DOI 10.1016/S0140-6736(99)02768-3; Wostyn P, 2008, CLIN NEUROL NEUROSUR, V110, P101, DOI 10.1016/j.clineuro.2007.10.011	29	25	28	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2010	11	5					593	598		10.1097/PCC.0b013e3181ce755c			6	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	647PA	WOS:000281629300007	20081553				2022-02-06	
J	Walz, NC; Yeates, KO; Taylor, HG; Stancin, T; Wade, SL				Walz, Nicolay Chertkoff; Yeates, Keith Owen; Taylor, H. Gerry; Stancin, Terry; Wade, Shari L.			Theory of mind skills I year after traumatic brain injury in 6-to 8-year-old children	JOURNAL OF NEUROPSYCHOLOGY			English	Article							APPEARANCE-REALITY DISTINCTION; CHILDHOOD HEAD-INJURY; FALSE BELIEF; 2ND-ORDER BELIEFS; SOCIAL COMPETENCE; ATTRIBUTION; OUTCOMES; ADULTS; 5-YEAR-OLD; DISORDER	This study examined the longer-term effects of traumatic brain injury (TBI) on theory of mind (ToM) skills of children who were between the ages of 5 and 7 years at the time of injury. Fifty-two children with orthopaedic injury, 30 children with moderate TBI, and 12 children with severe TBI were evaluated approximately I year post-injury (mean age = 6.98 years, SD = 0.59, range = 6.02-8.26). Children with severe TBI did not engage in representation of first- and second-order mental states at a developmental level comparable to their peers, suggesting stagnation or lack of development, as well as regression of putatively existing ToM skills. Age, task-specific cognitive demands, and verbal abilities were strong predictors of ToM performance. However, even after taking those factors into account, children with severe TBI had poorer ToM performance than children with orthopaedic injuries.	[Walz, Nicolay Chertkoff] Cincinnati Childrens Hosp Med Ctr, Div Behav Med & Clin Psychol, Dept Pediat, Cincinnati, OH 45229 USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Res Inst, Nationwide Childrens Hosp, Columbus, OH 43210 USA; [Yeates, Keith Owen] Ctr Biobehav Hlth, Columbus, OH USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Pediat Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Stancin, Terry] MetroHlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Pediat Rehabil, Cincinnati, OH USA; [Walz, Nicolay Chertkoff; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA		Walz, NC (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Behav Med & Clin Psychol, Dept Pediat, MLC 10006,2800 Winslow Ave, Cincinnati, OH 45229 USA.	nicolay.walz@cchmc.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	CCHMC [K23 HD046690, R01 HD42729]; State of Ohio Emergency Medical Services; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD046690] Funding Source: NIH RePORTER	Supported by a CCHMC GCRC CReFF award and grant K23 HD046690 to Dr Walz, grant R01 HD42729 to Dr Wade, and Trauma Research grants from the State of Ohio Emergency Medical Services to Dr Taylor. The authors wish to acknowledge the contributions of Christine Abraham, Andrea Beebe, Lori Bernard, Anne Birnbaum, Beth Bishop, Tammy Matecun, Karen Oberjohn, Elizabeth Roth, Elizabeth Shaver, and Maegan Swartwout in data collection and coding. The Cincinnati Children's Medical Center Trauma Registry, Rainbow Pediatric Trauma Center, Rainbow Babies & Children's Hospital, Columbus Children's Hospital Trauma Program, and MetroHealth Center Department of Pediatrics and Trauma Registry provided assistance with recruitment.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Blair C, 2002, AM PSYCHOL, V57, P111, DOI 10.1037//0003-066X.57.2.111; Bloom P, 2000, COGNITION, V77, pB25, DOI 10.1016/S0010-0277(00)00096-2; Carlson SM, 2001, CHILD DEV, V72, P1032, DOI 10.1111/1467-8624.00333; *CDCP NAT CTR INJ, 2000, TRAUM BRAIN INJ US A; Coull GJ, 2006, SOC DEV, V15, P548; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2009, J CLIN EXP NEUROPSYC, V31, P835, DOI 10.1080/13803390802572419; Elliott C. D., 1990, DIFFERENTIAL ABILITY; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FLAVELL JH, 1983, COGNITIVE PSYCHOL, V15, P95, DOI 10.1016/0010-0285(83)90005-1; FLAVELL JH, 1986, MONOGR SOC RES CHILD, V51, pR1, DOI 10.2307/1165866; GOPNIK A, 1988, CHILD DEV, V59, P26, DOI 10.2307/1130386; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; HOGREFE GJ, 1986, CHILD DEV, V57, P567, DOI 10.2307/1130337; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Ladd GW, 1999, ANNU REV PSYCHOL, V50, P333, DOI 10.1146/annurev.psych.50.1.333; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Martin I, 2005, APHASIOLOGY, V19, P712, DOI 10.1080/02687030500172203; Merrell KM., 2002, HOME COMMUNITY SOCIA; Merrell KW, 2001, PSYCHOL SCHOOLS, V38, P313, DOI 10.1002/pits.1021; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; PERNER J, 1985, J EXP CHILD PSYCHOL, V39, P437, DOI 10.1016/0022-0965(85)90051-7; Roeyers H, 2001, J CHILD PSYCHOL PSYC, V42, P271, DOI 10.1111/1469-7610.00718; Snodgrass C, 2006, BRAIN INJURY, V20, P825, DOI 10.1080/02699050600832585; Stancin T, 2008, J DEV BEHAV PEDIATR, V29, P253, DOI 10.1097/DBP.0b013e31816b6b0f; SULLIVAN K, 1994, DEV PSYCHOL, V30, P395, DOI 10.1037/0012-1649.30.3.395; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; Taylor M, 2008, RETHINK GLOB, V14, P1; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 2004, NEUROREHABILITATION, V19, P245; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Walz NC, 2009, DEV NEUROPSYCHOL, V34, P507, DOI 10.1080/87565640902964490; Wiig EH, 1985, TEST LANGUAGE COMPET; WIMMER H, 1983, COGNITION, V13, P103, DOI 10.1016/0010-0277(83)90004-5; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	42	25	25	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1748-6645	1748-6653		J NEUROPSYCHOL	J. Neuropsychol.	SEP	2010	4		2				181	195		10.1348/174866410X488788			15	Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	670DO	WOS:000283401600004	20307379	Green Accepted			2022-02-06	
J	Moriyama, M; Jayakumar, AR; Tong, XY; Norenberg, MD				Moriyama, M.; Jayakumar, A. R.; Tong, X. Y.; Norenberg, M. D.			Role of Mitogen-Activated Protein Kinases in the Mechanism of Oxidant-Induced Cell Swelling in Cultured Astrocytes	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						astrocytes; cell signalling; cell volume regulation; edema; oxidative stress	SUPEROXIDE-DISMUTASE ACTIVITY; OXIDATIVE STRESS; CEREBRAL EDEMA; SIGNAL-TRANSDUCTION; GLIOMA-CELLS; NITRIC-OXIDE; BRAIN-INJURY; GLIAL-CELLS; IN-VITRO; MITOCHONDRIAL INTEGRITY	Cytotoxic brain edema, usually a consequence of astrocyte swelling, is an important complication of stroke, traumatic brain injury, hepatic encephalopathy, and other neurological disorders. Although mechanisms underlying astrocyte swelling are not fully understood, oxidative stress (OS) has generally been considered an important factor in its pathogenesis. To better understand the mechanism(s) by which OS causes cell swelling, we examined the potential involvement of mitogen-activated protein kinases (MAPKs) in this process. Cultures exposed to the oxidant H2O2 (10, 25, 50 mu M) for different time periods (1-24 hr) significantly increased cell swelling in a triphasic manner. Swelling was initially observed at 10 min (peaking at 30 min), which was followed by cell shrinkage at 1 hr. A subsequent increase in cell volume occurred at approximately 6 hr, and the rise lasted for at least 24 hr. Cultures exposed to H2O2 caused the activation of MAPKs (ERK1/2, JNK and p38-MAPK), whereas inhibition of MAPKs diminished cell swelling induced by 10 and 25 mu M H2O2. These findings suggest that activation of MAPKs is an important factor in the mediation of astrocyte swelling following oxidative stress. (C) 2010 Wiley-Liss, Inc.	[Moriyama, M.; Jayakumar, A. R.; Tong, X. Y.; Norenberg, M. D.] Univ Miami, Sch Med, Dept Pathol, Miami, FL 33101 USA; [Moriyama, M.] Osaka Prefecture Univ, Lab Integrat Physiol Vet Sci, Osaka, Japan; [Jayakumar, A. R.; Norenberg, M. D.] Vet Affairs Med Ctr, Miami, FL 33125 USA; [Norenberg, M. D.] Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA		Norenberg, MD (corresponding author), Univ Miami, Sch Med, Dept Pathol D 33, POB 016960, Miami, FL 33101 USA.	mnorenbe@med.miami.edu		Moriyama, Mitsuaki/0000-0001-8123-8835	Department of Veterans AffairsUS Department of Veterans Affairs; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DK063311]; American Association for the Study of Liver Disease/American Liver Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK063311] Funding Source: NIH RePORTER	Contract grant sponsor: Merit Review from the Department of Veterans Affairs; Contract grant sponsor: National Institutes of Health; Contract grant number: DK063311; Contract grant sponsor: American Association for the Study of Liver Disease/American Liver Foundation (to A.R.J.).	Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Andersen GO, 2004, AM J PHYSIOL-HEART C, V286, pH1354, DOI 10.1152/ajpheart.00549.2003; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.0.CO;2-P; Blei AT, 1999, J HEPATOL, V31, P771, DOI 10.1016/S0168-8278(99)80361-4; Bouaboula M, 1999, FEBS LETT, V449, P61, DOI 10.1016/S0014-5793(99)00395-6; Brahma B, 2000, J NEUROCHEM, V74, P1263; Buege J A, 1978, Methods Enzymol, V52, P302; CHAN PH, 1989, ANN NY ACAD SCI, V559, P237; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; Chen CJ, 2000, J NEUROCHEM, V75, P1557, DOI 10.1046/j.1471-4159.2000.0751557.x; Chen SH, 2001, EUR J PHARMACOL, V414, P177, DOI 10.1016/S0014-2999(01)00792-0; CUBELLS JF, 1994, J NEUROSCI, V14, P2260, DOI 10.1523/jneurosci.14-04-02260.1994; Czaja MJ, 2003, HEPATOLOGY, V37, P1405, DOI 10.1053/jhep.2003.50233; DUCIS I, 1989, BRAIN RES, V493, P362, DOI 10.1016/0006-8993(89)91171-2; Faraci FM, 2006, J APPL PHYSIOL, V100, P739, DOI 10.1152/japplphysiol.01044.2005; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; HALLBRUCKER C, 1993, EUR J BIOCHEM, V211, P449, DOI 10.1111/j.1432-1033.1993.tb17570.x; Harvey, 2005, NEPHRON PHYSIOL, V99, P1, DOI DOI 10.1159/000081796); Hazell AS, 1997, NEUROCHEM RES, V22, P1443, DOI 10.1023/A:1021994126329; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; HYSLOP PA, 1988, J BIOL CHEM, V263, P1665; JAKUBOVICZ DE, 1989, BRAIN RES, V485, P215, DOI 10.1016/0006-8993(89)90564-7; Javadov S, 2006, J PHARMACOL EXP THER, V317, P1036, DOI 10.1124/jpet.105.100107; Jayakumar AR, 2008, J NEUROCHEM, V104, P135; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; Jayakumar AR, 2008, J BIOL CHEM, V283, P33874, DOI 10.1074/jbc.M804016200; JUURLINK BHJ, 1985, DEV NEUROSCI-BASEL, V7, P263, DOI 10.1159/000112295; Kahle KT, 2009, PHYSIOLOGY, V24, P257, DOI 10.1152/physiol.00015.2009; Karageuzyan KG, 1998, BIOCHEMISTRY-MOSCOW+, V63, P1226; Kim SO, 2004, EUR J PHARMACOL, V487, P81, DOI 10.1016/j.ejphar.2003.12.037; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KIMELBERG HK, 1987, J PHYSIOL-PARIS, V82, P294; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Kondo T, 1997, J NEUROSCI, V17, P4180; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lennon AM, 2002, BIOCHEM PHARMACOL, V63, P163, DOI 10.1016/S0006-2952(01)00826-7; LEVINE RL, 1990, METHOD ENZYMOL, V186, P464; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Ligtenberg JJM, 1998, INTENS CARE MED, V24, P644, DOI 10.1007/s001340050634; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Luo YQ, 2000, ANTIOXID REDOX SIGN, V2, P449, DOI 10.1089/15230860050192224; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; Marmarou A, 2003, ACT NEUR S, V86, P7; Mazzio EA, 2004, J APPL TOXICOL, V24, P99, DOI 10.1002/jat.954; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Mielke K, 2000, MOL BRAIN RES, V75, P128, DOI 10.1016/S0169-328X(99)00308-3; Mizuhashi S, 2000, JPN J PHARMACOL, V84, P339, DOI 10.1254/jjp.84.339; Morbidelli L, 2003, CURR PHARM DESIGN, V9, P521, DOI 10.2174/1381612033391405; Murthy CRK, 2001, J NEUROSCI RES, V66, P282, DOI 10.1002/jnr.1222; Norenberg MD, 2007, METAB BRAIN DIS, V22, P219, DOI 10.1007/s11011-007-9062-5; Norenberg MD, 2009, METAB BRAIN DIS, V24, P103, DOI 10.1007/s11011-008-9113-6; Norenberg MD, 2005, METAB BRAIN DIS, V20, P303, DOI 10.1007/s11011-005-7911-7; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Panickar KS, 2009, NEUROCHEM INT, V55, P98, DOI 10.1016/j.neuint.2008.12.022; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Paucard A, 2005, FUND CLIN PHARMACOL, V19, P57, DOI 10.1111/j.1472-8206.2004.00297.x; Petty MA, 1996, EUR J PHARMACOL, V307, P149, DOI 10.1016/0014-2999(96)00235-X; Rao KVR, 2003, METAB BRAIN DIS, V18, P113, DOI 10.1023/A:1023858902184; REMACLE J, 1995, MUTAT RES-DNAGING G, V316, P103, DOI 10.1016/0921-8734(95)90004-7; Ringel F, 2006, J NEUROTRAUM, V23, P1693, DOI 10.1089/neu.2006.23.1693; Robb SJ, 1999, J NEUROSCI RES, V56, P166, DOI 10.1002/(SICI)1097-4547(19990415)56:2<166::AID-JNR6>3.3.CO;2-J; Rosenblum WI, 2007, J NEUROPATH EXP NEUR, V66, P771, DOI 10.1097/nen.0b013e3181461965; SAHA N, 1993, BIOCHEM J, V296, P701, DOI 10.1042/bj2960701; Santandreu FM, 2008, CELL PHYSIOL BIOCHEM, V22, P757, DOI 10.1159/000185559; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Schlenker T, 2000, GASTROENTEROLOGY, V118, P395, DOI 10.1016/S0016-5085(00)70222-8; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; Sinke AP, 2008, J NEUROCHEM, V106, P2302, DOI 10.1111/j.1471-4159.2008.05549.x; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; Smith-Pearson PS, 2008, FREE RADICAL BIO MED, V45, P1178, DOI 10.1016/j.freeradbiomed.2008.07.015; Snabaitis AK, 2000, CIRC RES, V86, P214, DOI 10.1161/01.RES.86.2.214; STAUB F, 1994, J CEREBR BLOOD F MET, V14, P1030, DOI 10.1038/jcbfm.1994.135; Suffredini AF, 1998, SCHWEIZ MED WSCHR, V128, P1444; Suzuki Y, 2002, BRAIN RES, V945, P242, DOI 10.1016/S0006-8993(02)02806-8; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Tan S, 1999, J NEUROPATH EXP NEUR, V58, P972, DOI 10.1097/00005072-199909000-00007; Tang HW, 1996, J APPL TOXICOL, V16, P187, DOI 10.1002/(SICI)1099-1263(199605)16:3<187::AID-JAT329>3.0.CO;2-Y; Thorburne SK, 1996, J NEUROCHEM, V67, P1014; Trackey JL, 2001, J NEUROCHEM, V79, P445, DOI 10.1046/j.1471-4159.2001.00584.x; Tsai KL, 1997, J PHYSIOL-LONDON, V502, P161, DOI 10.1111/j.1469-7793.1997.161bl.x; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; VANDERMEULEN JA, 1987, LANCET, V2, P306; Wegrzynowicz M, 2007, NEUROCHEM INT, V50, P883, DOI 10.1016/j.neuint.2006.12.003; Westman J, 2000, AMINO ACIDS, V19, P339, DOI 10.1007/s007260070065; Widmer R, 2007, ARCH BIOCHEM BIOPHYS, V464, P1, DOI 10.1016/j.abb.2007.03.027; Wong JA, 2001, AM J PHYSIOL-REG I, V281, pR561, DOI 10.1152/ajpregu.2001.281.2.R561; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210; Zhao HY, 2004, J PHYSIOL-LONDON, V560, P123, DOI 10.1113/jphysiol.2004.066423; Zwingmann C, 2000, DEV NEUROSCI-BASEL, V22, P463, DOI 10.1159/000017476	90	25	27	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG 15	2010	88	11					2450	2458		10.1002/jnr.22400			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	632PL	WOS:000280436600014	20623534				2022-02-06	
J	Walker, CT; Marky, AH; Petraglia, AL; Ali, T; Chow, N; Zlokovic, BV				Walker, Corey T.; Marky, Andrew H.; Petraglia, Anthony L.; Ali, Tracy; Chow, Nienwen; Zlokovic, Berislav V.			Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact	BRAIN RESEARCH			English	Article						Activated protein C analog; Traumatic brain injury; Neuroprotection; Hemorrhage	TISSUE-PLASMINOGEN ACTIVATOR; HUMAN BRAIN ENDOTHELIUM; SPINAL-CORD-INJURY; RECEPTOR; APOPTOSIS; STROKE; RATS; MICE; NEUROGENESIS; HEMORRHAGE	The anticoagulant activated protein C (APC) protects neurons and vascular cells from injury through its direct cytoprotective effects that are independent of its anticoagulant action. Wild-type recombinant murine APC (wt-APC) exerts significant neuroprotection in mice if administered early after traumatic brain injury (TBI). Here, we compared efficacy and safety of a late therapy for TBI with wt-APC and 3K3A-APC, an APC analog with similar to 80% reduced anticoagulant activity but normal cytoprotective activity, using a controlled cortical impact model of TBI. Mice received 0.8 mg/kg intraperitoneally of recombinant murine 3K3A-APC, wt-APC or saline at 6, 12, 24 and 48 h after injury. 3K3A-APC (n=15) relative to wt-APC (n=15) improved motor and sensorimotor recovery within the first three days post-trauma as demonstrated by rotarod (p<0.05) and beam balance test (p<0.05), respectively. Both, wt-APC and 3K3A-APC reduced the lesion volume seven days after injury by 36% (n=8; p<0.01) and 56% (n=8; p<0.01), respectively, compared to saline (n=8). Three days post-TBI, the hemoglobin levels in the injured brain were increased by similar to 3-fold after wt-APC treatment compared to saline indicating an increased risk for intracerebral bleeding. In contrast, comparable levels of brain hemoglobin in 3K3A-APC-treated and saline-treated mice suggested that 3K3A-APC treatment did not increase risk for bleeding after TBI. Thus, compared to wt-APC, 3K3A-APC is more efficacious and safer therapy for TBI with no risk for intracerebral hemorrhage. (C) 2010 Elsevier B.V. All rights reserved.	[Walker, Corey T.; Marky, Andrew H.; Zlokovic, Berislav V.] Univ Rochester, Ctr Neurodegenerat & Vasc Brain Disorders, Med Ctr, Rochester, NY 14642 USA; [Petraglia, Anthony L.] Univ Rochester, Dept Neurosurg, Med Ctr, Rochester, NY 14642 USA; [Ali, Tracy; Chow, Nienwen] ZZ Biotech LLC, Rochester, NY USA		Zlokovic, BV (corresponding author), Univ Rochester, Ctr Neurodegenerat & Vasc Brain Disorders, Med Ctr, Arthur Kornberg Med Res Bldg,601 Elmwood Ave,Box, Rochester, NY 14642 USA.	Berislav_Zlokovic@URMC.Rochester.edu			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL63290, HL81528]; ZZ Biotech; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL081528, R01HL063290] Funding Source: NIH RePORTER	This work is supported by the National Institute of Health grants HL63290 and HL81528 and ZZ Biotech.	Bernard GR, 2001, CRIT CARE MED, V29, P2051, DOI 10.1097/00003246-200111000-00003; Cheng T, 2003, NAT MED, V9, P338, DOI 10.1038/nm826; Cheng T, 2006, NAT MED, V12, P1278, DOI 10.1038/nm1498; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Domotor E, 2003, BLOOD, V101, P4797, DOI 10.1182/blood-2002-12-3680; Feistritzer C, 2005, BLOOD, V105, P3178, DOI 10.1182/blood-2004-10-3985; Finigan JH, 2005, J BIOL CHEM, V280, P17286, DOI 10.1074/jbc.M412427200; Gale AJ, 2002, J BIOL CHEM, V277, P28836, DOI 10.1074/jbc.M204363200; Gorbacheva L, 2010, NEUROSCIENCE, V165, P1138, DOI 10.1016/j.neuroscience.2009.11.027; Gorbacheva L, 2009, J NEUROCHEM, V111, P967, DOI 10.1111/j.1471-4159.2009.06380.x; Griffin JH, 2002, SEMIN HEMATOL, V39, P197, DOI 10.1053/shem.2002.34093; Guo H, 2004, NEURON, V41, P563, DOI 10.1016/S0896-6273(04)00019-4; Guo H, 2009, J NEUROCHEM, V109, P116, DOI 10.1111/j.1471-4159.2009.05921.x; Guo H, 2009, EUR J NEUROSCI, V29, P1119, DOI 10.1111/j.1460-9568.2009.06664.x; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Han MH, 2008, NATURE, V451, P1076, DOI 10.1038/nature06559; Hirose K, 2000, ANN SURG, V232, P272, DOI 10.1097/00000658-200008000-00018; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Liu D, 2004, NAT MED, V10, P1379, DOI 10.1038/nm1122; Mosnier LO, 2007, BLOOD, V109, P3161, DOI 10.1182/blood-2006-09-003004; Mosnier LO, 2004, BLOOD, V104, P1740, DOI 10.1182/blood-2004-01-0110; Mosnier LO, 2003, BIOCHEM J, V373, P65, DOI 10.1042/BJ20030341; Petraglia AL, 2010, NEUROSURGERY, V66, P165, DOI 10.1227/01.NEU.0000363148.49779.68; Riewald M, 2002, SCIENCE, V296, P1880, DOI 10.1126/science.1071699; Shibata M, 2001, CIRCULATION, V103, P1799, DOI 10.1161/01.CIR.103.13.1799; Taoka Y, 1998, J NEUROSCI, V18, P1393; Thiyagarajan M, 2008, J NEUROSCI, V28, P12788, DOI 10.1523/JNEUROSCI.3485-08.2008; Wang L, 1997, J CEREBR BLOOD F MET, V17, P136, DOI 10.1097/00004647-199702000-00002; Wang YM, 2009, STROKE, V40, P1864, DOI 10.1161/STROKEAHA.108.536680; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Yamauchi T, 2006, STROKE, V37, P1081, DOI 10.1161/01.STR.0000206280.30972.21; Yesilirmak DC, 2008, BRAIN RES, V1210, P56, DOI 10.1016/j.brainres.2008.02.088; Zhong ZH, 2009, J CLIN INVEST, V119, P3437, DOI 10.1172/JCI38476; Zlokovic BV, 2005, ANN NEUROL, V58, P474, DOI 10.1002/ana.20602	35	25	25	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 6	2010	1347						125	131		10.1016/j.brainres.2010.05.075			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	639LC	WOS:000280975300014	20513369	Green Accepted			2022-02-06	
J	Brown, JB; Stassen, NA; Cheng, JD; Sangosanya, AT; Bankey, PE; Gestring, ML				Brown, Joshua B.; Stassen, Nicole A.; Cheng, Julius D.; Sangosanya, Ayodele T.; Bankey, Paul E.; Gestring, Mark L.			Trauma Center Designation Correlates With Functional Independence After Severe But Not Moderate Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma (AAST)	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma (AAST)		Traumatic brain injury; Trauma center designation; Functional outcome; National Trauma Databank	GLASGOW COMA SCALE; AMERICAN-COLLEGE; LEVEL-I; UNITED-STATES; CENTER VOLUME; MORTALITY; SURGEONS; IMPACT; VERIFICATION; OUTCOMES	Background: The mortality of traumatic brain injury (TBI) continues to decline, emphasizing functional outcomes. Trauma center designation has been linked to survival after TBI, but the impact on functional outcomes is unclear. The objective was to determine whether trauma center designation influenced functional outcomes after moderate and severe TBI. Methods: Trauma subjects presenting to an American College of Surgeons (ACS) Level I or II trauma center with a Glasgow Coma Score (GCS) <= 12 who survived to discharge were identified using the National Trauma Databank (2002-2006). Outcomes were functional independence (FI) defined as a modified functional independence measure (FIM) of 12, and independent expression (IE) defined as a FIM component of 4. These were compared between Level I and Level II centers in subjects with both moderate (GCS 9-12) and severe (GCS <= 8) TBI using stepwise logistic regression to adjust for demographics, injuries, and comorbidities. Results: Analysis identified 25,170 subjects (72% severe TBI). After adjusting for covariates, ACS Level I designation was associated with FI (odds ratio: 1.16; confidence interval: 1.07-1.24, p < 0.01) and IE (1.10; 1.03-1.17, p < 0.01) after severe TBI. Trauma center designation was not associated with FI or IE after moderate TBI. Conclusions: ACS trauma center designation is significantly associated with FI and IE after severe, but not moderate TBI. Prospective study is warranted to verify and explore factors contributing to this discrepancy.	[Brown, Joshua B.; Stassen, Nicole A.; Cheng, Julius D.; Sangosanya, Ayodele T.; Bankey, Paul E.; Gestring, Mark L.] Univ Rochester, Sch Med, Dept Surg, Rochester, NY 14642 USA		Gestring, ML (corresponding author), Univ Rochester, Sch Med, Dept Surg, 601 Elmwood Ave,Box SURG, Rochester, NY 14642 USA.	mark_gestring@urmc.rochester.edu		Brown, Joshua/0000-0002-6936-035X			*AD HOC TRAUM REG, 2007, NAT TRAUM DAT REF MA; American College of : Surgeons Committee on Trauma, 2007, RES OPT CAR INJ PAT; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cooper A, 2000, J TRAUMA, V48, P16, DOI 10.1097/00005373-200001000-00004; Cornwell EE, 2003, ARCH SURG-CHICAGO, V138, P838, DOI 10.1001/archsurg.138.8.838; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Cudnik MT, 2009, J TRAUMA, V66, P1321, DOI 10.1097/TA.0b013e3181929e2b; Demetriades D, 2006, J AM COLL SURGEONS, V202, P212, DOI 10.1016/j.jamcollsurg.2005.09.027; Demetriades D, 2005, ANN SURG, V242, P512, DOI 10.1097/01.sla.0000184169.73614.09; DiRusso S, 2001, J TRAUMA, V51, P294, DOI 10.1097/00005373-200108000-00011; DuBose JJ, 2008, ARCH SURG-CHICAGO, V143, P1213, DOI 10.1001/archsurg.143.12.1213; Ehrlich PF, 2002, J TRAUMA, V53, P811, DOI 10.1097/00005373-200211000-00001; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Greenwald BND, 2009, MT SINAI J MED, V76, P182, DOI 10.1002/msj.20103; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; London JA, 2003, J TRAUMA, V54, P16, DOI 10.1097/00005373-200301000-00003; Marcin JP, 2004, CRIT CARE MED, V32, P1477, DOI 10.1097/01.CCM.0000127781.08985.03; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mullins RJ, 1998, J TRAUMA, V44, P609, DOI 10.1097/00005373-199804000-00009; Mullins RJ, 1996, J TRAUMA, V40, P536, DOI 10.1097/00005373-199604000-00004; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Nirula R, 2006, J TRAUMA, V61, P268, DOI 10.1097/01.ta.0000230305.36456.4e; Piontek FA, 2003, J TRAUMA, V54, P1041, DOI 10.1097/01.TA.0000061107.55798.31; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	32	25	25	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2010	69	2					263	269		10.1097/TA.0b013e3181e5d72e			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	638JN	WOS:000280890800004	20699734				2022-02-06	
J	Sjodin, MOD; Bergquist, J; Wetterhall, M				Sjodin, Marcus O. D.; Bergquist, Jonas; Wetterhall, Magnus			Mining ventricular cerebrospinal fluid from patients with traumatic brain injury using hexapeptide ligand libraries to search for trauma biomarkers	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						Cerebrospinal fluid; Hexapeptide ligand library; Traumatic brain injury; Proteomics; Mass spectrometry	SEVERE HEAD-INJURY; PROTEOMIC ANALYSIS; PROTEIN; SERUM; CSF; DISCOVERY; MARKERS; INTERLEUKIN-6; NEUROTRAUMA; MECHANISMS	Traumatic brain injury (TBI) is an acute event resulting from external force to the brain and is a majorcause of death and disability associated with high health care costs in the western world. Additional injuries, originating from the secondary molecular events after the initial intensive care, may be limited by the use of objective biomarkers to provide the best treatment and patient prediction outcome. In this study, hexapeptide ligand libraries (HLL) have been used for the enrichment of suggested protein biomarkers for TBI in cerebrospinal fluid (CSF). HLL have the potential to enrich low abundant proteins and simultaneously reduce the high abundant proteins, rendering a sample with significantly reduced dynamic range. The CSF proteome from two TBI inflicted patients have been extensively mapped using a large initial sample volume obtained by extraventricular drainage. Shotgun proteomics, in combination with isoelectric focusing (IEF) and nano-LC-MS/MS, identified 339 unique proteins (MudPIT scoring p <= 0.05) with a protein overlap of 130 between the patients. As much as 45% of the proteins reported in the literature to be associated with degenerative/regenerative processes occurring after a trauma to the head were identified. Out of the most prominent potential protein biomarkers, such as neuron specific enolase, glial fibrillary acidic protein, myelin basic protein, creatine kinase B-type and S-100 beta, all except myelin basic protein were detected in the study. This study shows the possibility of using HLL as a tool for screening of low abundant protein biomarkers in human CSF. (C) 2010 Elsevier B.V. All rights reserved.	[Sjodin, Marcus O. D.; Bergquist, Jonas; Wetterhall, Magnus] Uppsala Univ, Dept Phys & Analyt Chem, SE-75124 Uppsala, Sweden		Sjodin, MOD (corresponding author), Uppsala Univ, Dept Phys & Analyt Chem, Husargatan 3,POB 599, SE-75124 Uppsala, Sweden.	marcus.sjodin@kemi.uu.se	Bergquist, Jonas/C-5894-2015	Bergquist, Jonas/0000-0002-4597-041X	Uppsala Berzelii Technology Center for Neurodiagnostics; Swedish Governmental Agency for Innovation SystemsVinnova [P29797-1]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [P29797-1, VR 621-2008-3562]	This research was supported by Uppsala Berzelii Technology Center for Neurodiagnostics, with financing from the Swedish Governmental Agency for Innovation Systems and the Swedish Research Council, both with grant number P29797-1. The Swedish Research Council (VR 621-2008-3562) are also greatly acknowledged for financial support.	Ahn SM, 2007, PROTEOM CLIN APPL, V1, P1004, DOI 10.1002/prca.200700217; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Boschetti E, 2009, PROTEOMICS, V9, P1492, DOI 10.1002/pmic.200800389; Castagna A, 2005, J PROTEOME RES, V4, P1917, DOI 10.1021/pr050153r; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; D'Ambrosio C, 2008, J PROTEOME RES, V7, P3461, DOI 10.1021/pr800193y; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Govorukhina NI, 2003, J CHROMATOGR A, V1009, P171, DOI 10.1016/S0021-9673(03)00921-X; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Guerrier L, 2007, J CHROMATOGR A, V1176, P192, DOI 10.1016/j.chroma.2007.11.007; Guerrier L, 2008, NAT PROTOC, V3, P883, DOI 10.1038/nprot.2008.59; Han YY, 2000, PEDIATR RES, V47, p57A; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Huhmer AF, 2006, DIS MARKERS, V22, P3; Ichibangase T, 2009, BIOMED CHROMATOGR, V23, P480, DOI 10.1002/bmc.1139; Is M, 2007, J CLIN NEUROSCI, V14, P1163, DOI 10.1016/j.jocn.2006.05.020; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Roche S, 2008, PROTEOM CLIN APPL, V2, P428, DOI 10.1002/prca.200780040; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Sennels L, 2007, J PROTEOME RES, V6, P4055, DOI 10.1021/pr070339l; Shore PM, 2007, J NEUROTRAUM, V24, P75, DOI 10.1089/neu.2006.0062; Shores KS, 2007, J PROTEOME RES, V6, P3739, DOI 10.1021/pr070293w; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; STEPHANE R, 2008, PROTEOM CLIN APPL, V2, P428; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Thulasiraman V, 2005, ELECTROPHORESIS, V26, P3561, DOI 10.1002/elps.200500147; Uzan M, 2006, ACTA NEUROCHIR, V148, P1157, DOI 10.1007/s00701-006-0887-1; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777	38	25	26	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	JUL 15	2010	878	22					2003	2012		10.1016/j.jchromb.2010.05.036			10	Biochemical Research Methods; Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	629OU	WOS:000280210300014	20542479				2022-02-06	
J	Kallakuri, S; Kreipke, CW; Schafer, PC; Schafer, SM; Rafols, JA				Kallakuri, S.; Kreipke, C. W.; Schafer, P. C.; Schafer, S. M.; Rafols, J. A.			BRAIN CELLULAR LOCALIZATION OF ENDOTHELIN RECEPTORS A AND B IN A RODENT MODEL OF DIFFUSE TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						endothelin (ET)-1; vasoreactivity; immunoreactivity; immunofluorescence; sensorimotor cortex; hippocampus	CEREBRAL-ARTERY OCCLUSION; PULMONARY-HYPERTENSION; AXONAL INJURY; RAT-BRAIN; EXPRESSION; ASTROCYTES; MICROCIRCULATION; ANTAGONIST; SUBTYPE; CORTEX	Endothelin-1 exerts potent vasoconstrictor and vasodilatory effects through its actions on its receptors A (ETrA) and B (ETrB), respectively. While ETrA and B have classically been thought to be expressed on vascular cell types, more recent evidcence suggests that, particularly following brain injury, their expression may be seen in other, non-vascular cell types. To date no studies have comprehensively studied the cellular location of endothlelin receptors following traumatic brain injury (TBI). Therefore, this study investigates the cellular localization of ETrA and B in normal and traumatized brains using an impact acceleration device. Adult male Sprague Dawley rats were subjected to TBI by weight drop (450 g) from either 1.5, a distance known to elicit mild TBI in the absence of changed in cerebral blood flow (CBF) or 2 m, a distance shown to cause a significant reduction in CBF. One set of impacted brains were processed for Western determination of ETrA and B expression. Another set were processed for immunofluorescence (IF). For IF, ETrA and ETrB antibodies were combined with cell markers for neurons, astrocytes, microglia, oligodendrocytes, smooth muscle cells and endothelial cells of blood vessels. While ETrA and B was upregulated after more moderate to severe injury (2 m) overall receptor expression was unchanged in response to mild trauma (1.5 m). Double labeling IF confirmed prominent ETrA and ETrB labeling in NeuN labeled pyramidal neurons and interneurons in sensorymotor cortex (smCx) and hippocampus (hipp) post TBI. ETrA rather than ETrB was preferentially co-localized in vascular smooth muscle cells. After injury, a subpopulation of astrocytes in white matter co-localized ETrA but not ETrB. Localization of either receptor in endothelial cells was sparse. No prominent IF was detected in microglia and oligodendrocytes. Taken together with previous findings in other pathological states that show an apparent shift in the localization of ETrA and B, the observed receptor shifts in this work may underlie the ET-1- mediated pathotrajectory of TBI including hypoperfusion. Published by Elsevier Ltd on behalf of IBRO.	[Kallakuri, S.; Kreipke, C. W.; Schafer, P. C.; Schafer, S. M.; Rafols, J. A.] Wayne State Univ, Dept Anat & Cell Biol, Sch Med, Detroit, MI 48201 USA		Rafols, JA (corresponding author), Wayne State Univ, Dept Anat & Cell Biol, Sch Med, 9312 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.	jrafols@med.wayne.edu					ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; Armstead WM, 2001, J NEUROTRAUM, V18, P1039, DOI 10.1089/08977150152693737; BARONE FC, 1994, J CEREBR BLOOD F MET, V14, P337, DOI 10.1038/jcbfm.1994.41; Barone FC, 2000, J CARDIOVASC PHARM, V36, pS357, DOI 10.1097/00005344-200036001-00104; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cacoub P, 1997, CARDIOVASC RES, V33, P196, DOI 10.1016/S0008-6363(96)00189-7; Cazaubon S, 1997, J NEUROSCI, V17, P6203; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; CLOZEL M, 1992, BIOCHEM BIOPH RES CO, V186, P867, DOI 10.1016/0006-291X(92)90826-7; Dawson DA, 1999, NEUROCHEM RES, V24, P1499, DOI 10.1023/A:1021139713026; EHRENREICH H, 2005, SCIENCE, V309, P392; FEUERSTEIN G, 1994, PEPTIDES, V15, P467, DOI 10.1016/0196-9781(94)90207-0; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FUKURODA T, 1994, BRIT J PHARMACOL, V113, P336, DOI 10.1111/j.1476-5381.1994.tb16901.x; Galley HF, 2004, BRIT J ANAESTH, V93, P105, DOI 10.1093/bja/aeh163; Gresle MM, 2006, BRAIN RES, V1110, P13, DOI 10.1016/j.brainres.2006.06.111; Hawkins BT, 2005, PHARMACOL REV, V57, P173, DOI 10.1124/pr.57.2.4; HAYNES WG, 1994, LANCET, V344, P852, DOI 10.1016/S0140-6736(94)92827-4; Hill BJF, 2000, J PHARMACOL EXP THER, V295, P484; HORI S, 1992, ENDOCRINOLOGY, V130, P1885, DOI 10.1210/en.130.4.1885; Ihling C, 2001, CIRCULATION, V104, P864, DOI 10.1161/hc3301.094742; IVY DD, 1994, J CLIN INVEST, V93, P2141, DOI 10.1172/JCI117210; Just A, 2004, AM J PHYSIOL-RENAL, V286, pF660, DOI 10.1152/ajprenal.00368.2003; Kallakuri S, 2003, EXP BRAIN RES, V148, P419, DOI 10.1007/s00221-002-1307-2; Kallakuri S, 2007, NEUROL RES, V29, P362, DOI 10.1179/016164107X204675; Kasemsri T, 1997, AM J PHYSIOL-HEART C, V273, pH2639; Koyama Y, 1996, GLIA, V16, P342, DOI 10.1002/(SICI)1098-1136(199604)16:4<342::AID-GLIA6>3.0.CO;2-1; Kreipke CW, 2007, NEUROL RES, V29, P604, DOI 10.1179/016164107X166317; Kreipke CW, 2006, MICROVASC RES, V71, P197, DOI 10.1016/j.mvr.2006.02.002; Kreipke CW, 2010, NEUROL RES, V32, P209, DOI 10.1179/174313209X414515; Kurokawa K, 1997, J COMP NEUROL, V389, P348, DOI 10.1002/(SICI)1096-9861(19971215)389:2<348::AID-CNE11>3.0.CO;2-H; Lazarini F, 1996, J NEUROCHEM, V66, P459; Legos JJ, 2008, EXP NEUROL, V212, P53, DOI 10.1016/j.expneurol.2008.03.011; LI JS, 1994, HYPERTENSION, V24, P183, DOI 10.1161/01.HYP.24.2.183; Lo ACY, 2005, J CEREBR BLOOD F MET, V25, P998, DOI 10.1038/sj.jcbfm.9600108; Loo LS, 2002, NEUROSCIENCE, V112, P993, DOI 10.1016/S0306-4522(02)00043-X; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSAULT R, 1990, BIOCHEM BIOPH RES CO, V171, P301, DOI 10.1016/0006-291X(90)91392-6; MCMURRAY JJ, 1992, CIRCULATION, V85, P1374, DOI 10.1161/01.CIR.85.4.1374; Naidoo V, 2004, J CHEM NEUROANAT, V27, P87, DOI 10.1016/j.jchemneu.2003.12.002; Nakagomi S, 2000, NEUROSCIENCE, V101, P441, DOI 10.1016/S0306-4522(00)00345-6; NOOTENS M, 1995, J AM COLL CARDIOL, V26, P1581, DOI 10.1016/0735-1097(95)00399-1; ORLEANSJUSTE PD, 1990, BIOCHEM PHARMACOL, V39, pR21, DOI 10.1016/0006-2952(90)90419-L; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Peters C. M., 2001, Society for Neuroscience Abstracts, V27, P2046; Petrov T, 2002, NEUROSCIENCE, V115, P275, DOI 10.1016/S0306-4522(02)00345-7; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; POVLISHOCK JT, 1983, AM J PATHOL, V110, P148; Prasanna G, 2002, INVEST OPHTH VIS SCI, V43, P2704; Rafols JA, 2007, NEUROL RES, V29, P339, DOI 10.1179/016164107X204648; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; RANDALL MD, 1989, BRIT J PHARMACOL, V98, P685, DOI 10.1111/j.1476-5381.1989.tb12644.x; Rogers SD, 2003, GLIA, V41, P180, DOI 10.1002/glia.10173; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; Siren AL, 2000, NEUROCHEM RES, V25, P957, DOI 10.1023/A:1007552408463; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; STEWART DJ, 1991, ANN INTERN MED, V114, P464, DOI 10.7326/0003-4819-114-6-464; TEERLINK JR, 1994, CIRCULATION, V90, P2510, DOI 10.1161/01.CIR.90.5.2510; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; Zimmermann M, 1998, NEUROSURGERY, V43, P863, DOI 10.1097/00006123-199810000-00083	62	25	26	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUL 14	2010	168	3					820	830		10.1016/j.neuroscience.2010.01.018			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	608UM	WOS:000278611500023	20144696				2022-02-06	
J	Hagen, EM; Eide, GE; Rekand, T; Gilhus, NE; Gronning, M				Hagen, E. M.; Eide, G. E.; Rekand, T.; Gilhus, N. E.; Gronning, M.			Traumatic spinal cord injury and concomitant brain injury: a cohort study	ACTA NEUROLOGICA SCANDINAVICA			English	Article						epidemiology; etiology; incidence; traumatic brain injury; traumatic spinal cord injury	BLOOD-ALCOHOL LEVEL; HEAD-INJURY; CLASSIFICATION; EPIDEMIOLOGY; PREDICTORS; MORTALITY; MODERATE; SWEDEN	Objective - To assess the temporal trends in the incidence and demographic characteristics of traumatic spinal cord injury (TSCI) with clinical concomitant traumatic brain injury (TBI), in an unselected, geographically defined cohort, 1952-2001. Material and methods - The patients were identified from hospital records. TBI was classified as none, mild, moderate, and severe. Results - Of 336 patients, 157 (46.7%) patients had a clinical concomitant TBI. Clinical TBI was classified as mild in 30.1%, moderate in 11.0% and severe in 5.7%. The average annual incidence increased from 3.3 per million in the first decade to 10.7 per million in the last. Alcohol was the strongest risk factor of clinical TBI (OR = 3.69) followed by completeness of TSCI (OR = 2.18). Conclusions - The incidence of TSCI with concomitant TBI has increased during the last 50 years. Alcohol and completeness of injury are strong risk factors. Increased awareness of dual diagnoses is necessary.	[Hagen, E. M.; Rekand, T.; Gilhus, N. E.; Gronning, M.] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway; [Hagen, E. M.; Gilhus, N. E.; Gronning, M.] Univ Bergen, Dept Clin Med, Bergen, Norway; [Eide, G. E.] Haukeland Hosp, Clin Res Ctr, N-5021 Bergen, Norway; [Eide, G. E.] Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Bergen, Norway		Hagen, EM (corresponding author), Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.	ellen.merete.hagen@helse-bergen.no	Rekand, Tiina/V-7189-2019; Hagen, Ellen Merete/F-8841-2014; Rekand, Tiina/A-6201-2008	Hagen, Ellen Merete/0000-0002-6925-6747; Rekand, Tiina/0000-0002-2506-9501			Abelson-Mitchell N, 2008, J CLIN NURS, V17, P46, DOI 10.1111/j.1365-2702.2007.01941.x; Ahlm K, 2009, ACCIDENT ANAL PREV, V41, P129, DOI 10.1016/j.aap.2008.10.002; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; AYYOUB Z, 2003, SPINAL CORD MED PRIN, P509; Barker RN, 2009, SPINAL CORD, V47, P149, DOI 10.1038/sc.2008.82; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; DEVIVO MJ, 2003, SPINAL CORD MED PRIN, P79; Elovic E, 1999, TOP SPINAL CORD INJ, V5, P1, DOI DOI 10.1310/V75J-RE76-20GH-X7BY; Hagen EM, 2010, SPINAL CORD, V48, P313, DOI 10.1038/sc.2009.133; Hagen EM, 2009, SPINAL CORD, V47, P367, DOI 10.1038/sc.2008.118; Hagen EM, 2010, J NEUROL NEUROSUR PS, V81, P368, DOI 10.1136/jnnp.2009.178798; Hagen EM, 2005, ACTA NEUROL SCAND, V112, P42, DOI 10.1111/j.1600-0404.2005.00430.x; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; Kleinbaum D.G., 2002, LOGISTIC REGRESSION; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; Lydersen S, 2009, STAT MED, V28, P1159, DOI 10.1002/sim.3531; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; Rehn M, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-1; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stockwell T, 2002, J STUD ALCOHOL, V63, P372, DOI 10.15288/jsa.2002.63.372; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; Turner AP, 2006, REHABIL PSYCHOL, V51, P78, DOI 10.1037/0090-5550.51.1.78; ZAFONTE RD, 2002, SPINAL CORD MED, P261	33	25	27	1	5	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	JUL	2010	122			190			51	57		10.1111/j.1600-0404.2010.01376.x			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	605IO	WOS:000278341400010	20586736				2022-02-06	
J	Schmitt, KRL; Boato, F; Diestel, A; Hechler, D; Kruglov, A; Berger, F; Hendrix, S				Schmitt, Katharina R. L.; Boato, Francesco; Diestel, Antje; Hechler, Daniel; Kruglov, Andrei; Berger, Felix; Hendrix, Sven			Hypothermia-Induced Neurite Outgrowth is Mediated by Tumor Necrosis Factor-Alpha	BRAIN PATHOLOGY			English	Article						brain slices; hypothermia; TNF-alpha; neurite outgrowth; traumatic brain injury; regeneration	MICE LACKING; TNF-ALPHA; CEREBRAL-ISCHEMIA; IL-6 RELEASE; BRAIN-INJURY; CELLS; ACTIVATION; GROWTH; INFLAMMATION; CYTOTOXICITY	Systemic or brain-selective hypothermia is a well-established method for neuroprotection after brain trauma. There is increasing evidence that hypothermia exerts beneficial effects on the brain and may also support regenerative responses after brain damage. Here, we have investigated whether hypothermia influences neurite outgrowth in vitro via modulation of the post-injury cytokine milieu. Organotypic brain slices were incubated: deep hypothermia (2 h at 17 degrees C), rewarming (2 h up to 37 degrees C), normothermia (20 h at 37 degrees C). Neurite density and cytokine release (IL 1beta, IL-6, IL-10, and TNF-alpha) were investigated after 24 h. For functional analysis mice deficient in NT-3/NT-4 and TNF-alpha as well as the TNF-alpha inhibitor etanercept were used. Hypothermia led to a significant increase of neurite outgrowth, which was independent of neurotrophin signaling. In contrast to other cytokines investigated, TNF-alpha secretion by organotypic brain slices was significantly increased after deep hypothermia. Moreover, hypothermia-induced neurite extension was abolished after administration of the TNF-alpha inhibitor and in TNF-alpha knockout mice. We demonstrate that TNF-alpha is responsible for inducing neurite outgrowth in the context of deep hypothermia and rewarming. These data suggest that hypothermia not only exerts protective effects in the CNS but may also support neurite outgrowth as a potential mechanism of regeneration.	[Schmitt, Katharina R. L.] Deutsch Herzzentrum Berlin, Dept Pediat Cardiol, Clin Congenital Heart Dis & Pediat Cardiol, D-13353 Berlin, Germany; [Boato, Francesco; Hechler, Daniel; Hendrix, Sven] Charite, Ctr Anat, Inst Cell Biol & Neurobiol, Berlin, Germany; [Diestel, Antje; Berger, Felix] Charite, Dept Pediat Cardiol, Berlin, Germany; [Kruglov, Andrei] German Rheumatism Res Ctr DRFZ, AG Inflammat Biol, Berlin, Germany; [Hendrix, Sven] Univ Hasselt, Dept Funct Morphol, Hasselt, Belgium; [Hendrix, Sven] Univ Hasselt, Inst Biomed, Hasselt, Belgium		Schmitt, KRL (corresponding author), Deutsch Herzzentrum Berlin, Dept Pediat Cardiol, Clin Congenital Heart Dis & Pediat Cardiol, Augustenburger Pl 1, D-13353 Berlin, Germany.	kschmitt@dhzb.de	Kruglov, Andrey/AAP-2023-2021; Kruglov, Andrey A/F-7543-2017; Hendrix, Sven/F-4059-2010	Kruglov, Andrey A/0000-0002-4597-2087; Hendrix, Sven/0000-0003-2344-7369; Boato, Francesco/0000-0001-9741-8021; Berger, Felix/0000-0001-7881-1557	European union (EFRE)European Commission; Hasselt University [BOF09NI07]	The authors wish to thank Doreen Ludecke for excellent technical assistance and Anne Gale for editing the manuscript. NT-3 and NT-4 knockout mice [NT-3<SUP>+/+</SUP>/NT-4<SUP>-/-</SUP> and NT-3 +/-/NT-4<SUP>-/-</SUP>] were a kind gift from G. Lewin, Max-Delbruck Center for Molecular Medicine, Berlin-Buch, Germany, respectively. This study was supported in part by grants from the European union (EFRE) to KS and SH and by Hasselt University to SH (BOF09NI07). FB is a member of the Marie-Curie network CORTEX, DH was a member of GRK1258.	Abe K, 2003, BLOOD, V101, P1477, DOI 10.1182/blood.V101.4.1477; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Christian E, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E9; Clarke P, 2001, ONCOGENE, V20, P6910, DOI 10.1038/sj.onc.1204842; Diestel A, 2009, VASC PHARMACOL, V51, P246, DOI 10.1016/j.vph.2009.06.006; Diestel A, 2008, CRYOBIOLOGY, V57, P216, DOI 10.1016/j.cryobiol.2008.08.005; Ehrlich MP, 2002, ANN THORAC SURG, V73, P191, DOI 10.1016/S0003-4975(01)03273-8; Eyupoglu IY, 2003, BRAIN RES PROTOC, V11, P1, DOI 10.1016/S1385-299X(02)00186-1; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; Genovese T, 2006, J PHARMACOL EXP THER, V316, P1006, DOI 10.1124/jpet.105.097188; Ginis I, 2002, J CEREBR BLOOD F MET, V22, P142, DOI 10.1097/00004647-200202000-00002; Golz G, 2006, EUR J NEUROSCI, V24, P2721, DOI 10.1111/j.1460-9568.2006.05155.x; Goldberg DJ, 1996, PERSPECT DEV NEUROBI, V4, P183; Hechler D, 2006, BRAIN RES REV, V52, P160, DOI 10.1016/j.brainresrev.2006.01.005; Hendrix S, 2007, J NEUROIMMUNOL, V184, P113, DOI 10.1016/j.jneuroim.2006.11.020; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Heppner FL, 1998, EUR J NEUROSCI, V10, P3284, DOI 10.1046/j.1460-9568.1998.00379.x; Holtje M, 2009, FASEB J, V23, P1115, DOI 10.1096/fj.08-116855; Jiang JY, 2006, J NEUROTRAUM, V23, P1847, DOI 10.1089/neu.2006.23.1847; Kirov SA, 2004, NEUROSCIENCE, V127, P69, DOI 10.1016/j.neuroscience.2004.04.053; Koizumi H, 1998, PATHOL INT, V48, P93, DOI 10.1111/j.1440-1827.1998.tb03877.x; Larsson K, 2005, SPINE, V30, P621, DOI 10.1097/01.brs.0000155410.48700.9e; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Marschinke F, 2008, BRAIN RES, V1215, P30, DOI 10.1016/j.brainres.2008.03.070; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; McGuire TR, 2001, BONE MARROW TRANSPL, V28, P889, DOI 10.1038/sj.bmt.1703238; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; POPOV VI, 1992, NEUROSCIENCE, V48, P45, DOI 10.1016/0306-4522(92)90336-Z; Schmitt FC, 2006, NEUROBIOL DIS, V23, P689, DOI 10.1016/j.nbd.2006.05.008; Schmitt KRL, 2007, NEUROSCI RES, V59, P68, DOI 10.1016/j.neures.2007.05.011; Schmitt KRL, 2006, NEUROSCI LETT, V404, P309, DOI 10.1016/j.neulet.2006.05.064; Schmitt KRL, 2007, J NEUROIMMUNOL, V189, P7, DOI 10.1016/j.jneuroim.2007.06.010; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Wang Y, 2002, BRAIN RES, V934, P7, DOI 10.1016/S0006-8993(02)02278-3	42	25	25	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	JUL	2010	20	4					771	779		10.1111/j.1750-3639.2009.00358.x			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	606BX	WOS:000278396800008	20070303	Green Published			2022-02-06	
J	Weaver, AS; Su, YP; Begun, DL; Miller, JD; Alford, AI; Goldstein, SA				Weaver, Aaron S.; Su, Yu-Ping; Begun, Dana L.; Miller, Joshua D.; Alford, Andrea I.; Goldstein, Steven A.			The effects of axial displacement on fracture callus morphology and MSC homing depend on the timing of application	BONE			English	Article						Mesenchymal stem cells; Mechanical strain; Fracture healing; MSC homing; Rat model	MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; TRAUMATIC BRAIN INJURY; BONE-MARROW; OSTEOGENESIS IMPERFECTA; LONG BONES; IN-VIVO; TISSUE; DISTRACTION; BIOLOGY	The local mechanical environment and the availability of mesenchymal stem cells (MSC) have both been shown to be important factors in bone fracture healing. This study was designed to investigate how the timing of an applied axial displacement across a healing fracture affects callus properties as well as the migration of systemically introduced MSC. Bilateral osteotomies were created in male, Sprague-Dawley rats. Exogenous MSC were injected via the tail vein, and a controlled micro-motion was applied to one defect starting 0, 3, 10, or 24 days after surgery. The results showed that fractures stimulated 10 days after surgery had more mineral, less cartilage, and greater mechanical properties at 48 days than other groups. Populations of MSC were found in osteotomies 48 days after surgery, with the exception of the group that was stimulated 10 days after surgery. These results demonstrate that the timing of mechanical stimulation affects the physical properties of the callus and the migration of MSC to the fracture site. Published by Elsevier Inc.	[Goldstein, Steven A.] Univ Michigan, Orthopaed Res Labs, Dept Orthopaed Surg, Ann Arbor, MI 48109 USA; [Weaver, Aaron S.] NASA, Glenn Res Ctr, Cleveland, OH USA; [Su, Yu-Ping] Natl Yang Ming Univ, Sch Med, Dept Surg, Taipei 112, Taiwan		Goldstein, SA (corresponding author), Univ Michigan, Orthopaed Res Labs, Dept Orthopaed Surg, 109 Zina Pitcher Pl,Room 2001, Ann Arbor, MI 48109 USA.	stevegld@umich.edu		Su, Yu-Ping/0000-0002-5390-4113	Department of DefenseUnited States Department of Defense [W81XWH-06-1-0107]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AR51504]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR051504] Funding Source: NIH RePORTER	We would like to thank Kathy Sweet, Bonnie Nolan, Charles Roehm, Dennis Kayner, Jaclynn Kreider, John Baker, Rochele Taylor, Michael Paschke, Stephanie A. Goldstein, Ralph Zade, David Lee, Srikanth Volvalou, and Eric Lee for their enormous contributions to this work. The study was funded by grants from the Department of Defense (W81XWH-06-1-0107) and the National Institutes of Health (AR51504).	Arinzeh TL, 2003, J BONE JOINT SURG AM, V85A, P1927, DOI 10.2106/00004623-200310000-00010; Aubin JE, 1999, J CELL BIOCHEM, V72, P396, DOI 10.1002/(SICI)1097-4644(19990301)72:3<396::AID-JCB9>3.0.CO;2-6; Case ND, 2003, TISSUE ENG, V9, P587, DOI 10.1089/107632703768247296; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Claes L, 2002, J ORTHOP RES, V20, P1099, DOI 10.1016/S0736-0266(02)00044-X; CLAES LE, 1995, CLIN BIOMECH, V10, P227, DOI 10.1016/0268-0033(95)99799-8; Claes LE, 1998, CLIN ORTHOP RELAT R, pS132; Day S. M., 2000, ORTHOPAEDIC BASIC SC, P371; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7; EINHORN TA, 1990, J BONE JOINT SURG AM, V72A, P1374, DOI 10.2106/00004623-199072090-00016; FROST HM, 1989, CLIN ORTHOP RELAT R, P283; Gardner MJ, 2006, J ORTHOP RES, V24, P1679, DOI 10.1002/jor.20230; GOODSHIP AE, 1985, J BONE JOINT SURG BR, V67, P650, DOI 10.1302/0301-620X.67B4.4030869; Hansen-Algenstaedt N, 2003, J ORTHOP RES, V21, P805, DOI 10.1016/S0736-0266(03)00060-3; HOLBEIN O, 1995, J ORTHOP RES, V13, P629, DOI 10.1002/jor.1100130420; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Kaspar D, 2003, J ORTHOP RES, V21, P320, DOI 10.1016/S0736-0266(02)00134-1; Kon E, 2000, J BIOMED MATER RES, V49, P328; Kraus KH, 2006, VET SURG, V35, P232, DOI 10.1111/j.1532-950X.2006.00142.x; LENNON DP, 1995, EXP CELL RES, V219, P211, DOI 10.1006/excr.1995.1221; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lucas TS, 1997, CLIN ORTHOP RELAT R, P267; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; MCKIBBIN B, 1978, J BONE JOINT SURG BR, V60, P150, DOI 10.1302/0301-620X.60B2.350882; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Petite H, 2000, NAT BIOTECHNOL, V18, P959, DOI 10.1038/79449; RHINELANDER FW, 1974, CLIN ORTHOP RELAT R, P34; WALLACE AL, 1994, CLIN ORTHOP RELAT R, P281; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Weiss S, 2002, J BONE MINER RES, V17, P1280, DOI 10.1359/jbmr.2002.17.7.1280; WOLF JW, 1981, J BONE JOINT SURG AM, V63, P805, DOI 10.2106/00004623-198163050-00016; Yamaji T, 2001, J Orthop Sci, V6, P571, DOI 10.1007/s007760100014; Zhang P, 2007, J BONE MINER RES, V22, P1979, DOI 10.1359/JBMR.070803; Zimmermann G, 2005, BONE, V36, P779, DOI 10.1016/j.bone.2005.02.011	37	25	25	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	8756-3282	1873-2763		BONE	Bone	JUL	2010	47	1					41	48		10.1016/j.bone.2010.03.008			8	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	615QN	WOS:000279150400005	20303421	Green Accepted			2022-02-06	
J	Yoganandan, N; Baisden, JL; Maiman, DJ; Gennarelli, TA; Guan, YB; Pintar, FA; Laud, P; Ridella, SA				Yoganandan, Narayan; Baisden, Jamie L.; Maiman, Dennis J.; Gennarelli, Thomas A.; Guan, Yabo; Pintar, Frank A.; Laud, Prakash; Ridella, Stephen A.			Severe-to-fatal head injuries in motor vehicle impacts	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Angular acceleration; Brain injuries; Contact loading; Impact biomechanics; Head trauma	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; UNITED-STATES; CRASHES; ASSOCIATION; COLLISIONS; ASSAULT; FALL; RISK	Severe-to-fatal head injuries in motor vehicle environments were analyzed using the United States Crash Injury Research and Engineering Network database for the years 1997-2006. Medical evaluations included details and photographs of injury, and on-scene, trauma bay, emergency room, intensive care unit, radiological, operating room, in-patient, and rehabilitation records. Data were synthesized on a case-by-case basis. X-rays, computed tomography scans, and magnetic resonance images were reviewed along with field evaluations of scene and photographs for the analyses of brain injuries and skull fractures. Injuries to the parenchyma, arteries, brainstem, cerebellum, cerebrum, and loss of consciousness were included. In addition to the analyses of severe-to-fatal (AIS4+) injuries, cervical spine, face, and scalp trauma were used to determine the potential for head contact. Fatalities and survivors were compared using nonparametric tests and confidence intervals for medians. Results were categorized based on the mode of impact with a focus on head contact. Out of the 3178 medical cases and 169 occupants sustaining head injuries, 132 adults were in frontal (54), side (75), and rear (3) crashes. Head contact locations are presented for each mode. A majority of cases clustered around the mid-size anthropometry and normal body mass index (BMI). Injuries occurred at change in velocities (Delta V) representative of US regulations. Statistically significant differences in Delta V between fatalities and survivors were found for side but not for frontal impacts. Independent of the impact mode and survivorship, contact locations were found to be superior to the center of gravity of the head, suggesting a greater role for angular than translational head kinematics. However, contact locations were biased to the impact mode: anterior aspects of the frontal bone and face were involved in frontal impacts while temporal-parietal regions were involved in side impacts. Because head injuries occur at regulatory Delta V in modern vehicles and angular accelerations are not directly incorporated in crashworthiness standards, these findings from the largest dataset in literature, offer a field-based rationale for including rotational kinematics in injury assessments. In addition. it may be necessary to develop injury criteria and evaluate dummy biofidelity based on contact locations as this parameter depended on the impact mode. The current field-based analysis has identified the importance of both angular acceleration and contact location in head injury assessment and mitigation. Published by Elsevier Ltd.	[Yoganandan, Narayan; Baisden, Jamie L.; Maiman, Dennis J.; Gennarelli, Thomas A.; Guan, Yabo; Pintar, Frank A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Laud, Prakash] Med Coll Wisconsin, Dept Biostat, Milwaukee, WI 53226 USA; [Ridella, Stephen A.] US Dept Transportat, NHTSA, Washington, DC USA		Yoganandan, N (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	yoga@mcw.edu					ADAMS JH, 1984, LANCET, V2, P1420; American Association for Automotive Medicine, 1990, ABBR INJ SCAL; Augenstein Jeffrey, 2003, Annu Proc Assoc Adv Automot Med, V47, P561; Bazarian JJ, 2004, ANN EMERG MED, V44, P142, DOI 10.1016/j.annemergmed.2004.03.029; Gennarelli T, 2002, P IRCOBI MUN GERM, P223; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENNARELLI TA, 1987, P 31 STAPP CAR CRASH, P49; Hodgson VR, 1983, P 27 STAPP CAR CRASH, P225; IMAJO T, 1992, AM J FOREN MED PATH, V13, P169; Imajo T, 1996, AM J FOREN MED PATH, V17, P324, DOI 10.1097/00000433-199612000-00010; IMAJO T, 1984, AM J FOREN MED PATH, V5, P217, DOI 10.1097/00000433-198409000-00005; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; McGwin G, 2003, J TRAUMA, V54, P1182, DOI 10.1097/01.TA.0000056165.49112.F4; MCLEAN AJ, 1995, J NEUROTRAUM, V12, P621, DOI 10.1089/neu.1995.12.621; MEANEY D, 1994, P IRCOBI LYON FRANC; Morris A, 1995, ACCIDENT ANAL PREV, V27, P749, DOI 10.1016/0001-4575(95)00020-8; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Siegel JH, 2001, J TRAUMA, V51, P975, DOI 10.1097/00005373-200111000-00024; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stitzel Joel D, 2007, Annu Proc Assoc Adv Automot Med, V51, P395; STRICH SJ, 1961, LANCET, V2, P443; Tagliaferri F, 2009, J TRAUMA, V66, P727, DOI 10.1097/TA.0b013e31815edefd; Wang Stewart C, 2003, Annu Proc Assoc Adv Automot Med, V47, P545; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Yoganandan N, 2005, ACCIDENT ANAL PREV, V37, P505, DOI 10.1016/j.aap.2005.01.002; Yoganandan N, 2007, ACCIDENT ANAL PREV, V39, P22, DOI 10.1016/j.aap.2006.05.014; Yoganandan N, 2009, J TRAUMA, V66, P309, DOI 10.1097/TA.0b013e3181692104; Zhang Jiangyue, 2006, Annu Proc Assoc Adv Automot Med, V50, P1	29	25	25	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575			ACCIDENT ANAL PREV	Accid. Anal. Prev.	JUL	2010	42	4					1370	1378		10.1016/j.aap.2010.02.017			9	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	607LD	WOS:000278504700051	20441854				2022-02-06	
J	Gandia-Martinez, F; Martinez-Gil, I; Andaluz-Ojeda, D; de Lamo, FB; Parra-Morais, L; Diez-Gutierrez, F				Gandia-Martinez, F.; Martinez-Gil, I.; Andaluz-Ojeda, D.; Bobillo de Lamo, F.; Parra-Morais, L.; Diez-Gutierrez, F.			Analysis of early tracheostomy and its impact on development of pneumonia, use of resources and mortality in neurocritically ill patients	NEUROCIRUGIA			Spanish	Article						Tracheostomy; Early tracheostomy; Neurocritically ill patients; Ventilator-associated pneumonia	CRITICALLY-ILL; PERCUTANEOUS TRACHEOSTOMY; SURGICAL TRACHEOSTOMY; TRAUMA PATIENTS; TRACHEOTOMY; METAANALYSIS; INTUBATION; DURATION; OUTCOMES; COHORT	Objective. We analyze the most suitable time to perform tracheostomy in neurocritically ill patients. We compare morbimortality and use of resources between those patients in which tracheostomy was done early (<= 9 days) and those in which it was perform later (>9 days), in a selected group of patients. Material and methods. We made an observational prospective study involving a group of patients diagnosed as traumatic brain injury (TBI) or stroke, whose tracheostomy was performed during their stay at the Intensive Care Unit. We compared two groups: a) early tracheostomy (during first 9 days of ICU stay); b) late tracheostomy (made on 10th day or later). As variables, we studied: demographic data, severity of illness at admission, admittance department, diagnosis, length of intubation, length of mechanical ventilation (LMV), sedation and antibiotic treatment needs, ventilator-associated pneumonia (VAP) events, ICU length of stay and mortality. We calculated relative risk of suffering from pneumonia and made a multivariate logistic regression to establish which factors were associated with an increased risk of developing pneumonia. Statistical signification p < 0.05. Results. We analyzed 118 patients, 60% with TBI. Mean length of intubation before tracheostomy was 12 days and mean LMV was 20 days. 94 VAP events were diagnosed in 81 patients (68.6%). Early tracheostomy group showed lower length of mechanical ventilation and ICU stay, lower length of sedation and antibiotic treatment, and less pneumonia events (p<0,001). The precocity of tracheostomy didn't have any influence either on hospital length of stay (p=0.844), ICU mortality (p=0.924) or in-hospital mortality (p=0.754). At the TBI group mean age was lower (p<0.001), tracheostomy was made later (p=0.026), and patients needed a longer sedation (p=0.001) and a longer antibiotic treatment (p=0.002). Length of intubation (p=0.034, OR 1.177) and ICU length of stay (p=0.003, OR 1.100) were factors independently associated with development of pneumonia. Relative risk of suffering from pneumonia when tracheostomy was made after 9 days of ICU stay was 1.55 (IC 95%: 1.10-2.16). The number needed to treat (NNT) for early tracheostomy avoiding one pneumonia event was 3.13. VAP was not associated with a higher ICU (p=0.558) or in-hospital mortality (p=0.370). Conclusions. Early tracheostomy (<= 9 days) provides significant advantages in neurocritically ill patients: it shortens length of mechanical ventilation and ICU stay and decreases antibiotic and sedatives requirements. Although later tracheostomy is not directly related with mortality, it increases considerably the risk of suffering from pneumonia, particularly in patients with TBI. These clinical circumstances should be evaluated individually in each patient, so the best time to perform tracheostomy in neurocritically ill patients could be established.	[Gandia-Martinez, F.; Martinez-Gil, I.; Andaluz-Ojeda, D.; Bobillo de Lamo, F.; Parra-Morais, L.; Diez-Gutierrez, F.] Hosp Clin Univ Valladolid, Serv Med Intens, Valladolid, Spain		Gandia-Martinez, F (corresponding author), Hosp Clin Univ, Serv Med Intens, Ave Ramon & Cajal 3, Valladolid 47005, Spain.	fgandia@saludcastillayleon.es					Ahmed Nasim, 2007, Surg Infect (Larchmt), V8, P343, DOI 10.1089/sur.2006.065; Arabi Y, 2004, CRIT CARE, V8, pR347, DOI 10.1186/cc2924; Armstrong PA, 1998, SURGERY, V124, P763, DOI 10.1067/msy.1998.91224; Barquist ES, 2006, J TRAUMA, V60, P91, DOI 10.1097/01.ta.0000196743.37261.3f; Bouderka MA, 2004, J TRAUMA, V57, P251, DOI 10.1097/01.TA.0000087646.68382.9A; Boynton JH, 2004, CRIT CARE, V8, pR261, DOI 10.1186/cc2885; Brook A D, 2000, Am J Crit Care, V9, P352; Browd SR, 2005, NEUROCRIT CARE, V2, P268, DOI 10.1385/NCC:2:3:268; CHIALIN H, 2005, CRITICAL CARE, V9, pR46, DOI DOI 10.1186/CC3018; Diaz-Reganon G, 2008, ANAESTHESIA, V63, P1198, DOI 10.1111/j.1365-2044.2008.05606.x; Freeman BD, 2005, CRIT CARE MED, V33, P2513, DOI 10.1097/01.CCM.0000186369.91799.44; Freeman BD, 2000, CHEST, V118, P1412, DOI 10.1378/chest.118.5.1412; Frutos-Vivar F, 2005, CRIT CARE MED, V33, P290, DOI 10.1097/01.CCM.0000150026.85210.13; Goettler CE, 2006, J TRAUMA, V60, P991, DOI 10.1097/01.ta.0000217270.16860.32; Griffiths J, 2005, BMJ-BRIT MED J, V330, P1243, DOI 10.1136/bmj.38467.485671.E0; Groves DS, 2007, CURR OPIN CRIT CARE, V13, P90, DOI 10.1097/MCC.0b013e328011721e; Gurkin MA, 2002, AM SURGEON, V68, P324; HEFFNER JE, 1989, CHEST, V96, P186, DOI 10.1378/chest.96.1.186; Heffner JE, 2001, CHEST, V120, p477S, DOI 10.1378/chest.120.6_suppl.477S; HEFFNER JE, 1993, AM REV RESPIR DIS, V147, P768, DOI 10.1164/ajrccm/147.3.768; Huttner HB, 2006, CEREBROVASC DIS, V21, P159, DOI 10.1159/000090527; Koh WY, 1997, ANAESTH INTENS CARE, V25, P365, DOI 10.1177/0310057X9702500407; Kollef MH, 1999, CRIT CARE MED, V27, P1714, DOI 10.1097/00003246-199909000-00003; Lee JC, 2005, CRIT CARE, V9, DOI 10.1186/cc3759; Major KM, 2003, AM J SURG, V186, P615, DOI 10.1016/j.amjsurg.2003.08.012; Milanchi S, 2008, J TRAUMA, V65, P73, DOI 10.1097/TA.0b013e31814693f2; Moller MG, 2005, AM J SURG, V189, P293, DOI 10.1016/j.amjsurg.2005.01.002; Qureshi AI, 2000, CRIT CARE MED, V28, P1383, DOI 10.1097/00003246-200005000-00020; Rello J, 2003, CHEST, V124, P2239, DOI 10.1378/chest.124.6.2239; RODRIGUEZ JL, 1990, SURGERY, V108, P655; Rumbak MJ, 2004, CRIT CARE MED, V32, P1689, DOI 10.1097/01.CCM.0000134835.05161.B6; Scales DC, 2008, CRIT CARE MED, V36, P2547, DOI 10.1097/CCM.0b013e31818444a5; Schauer JM, 2009, J TRAUMA, V66, P220, DOI 10.1097/TA.0b013e31816073e3; Silvester W, 2006, CRIT CARE MED, V34, P2145, DOI 10.1097/01.CCM.0000229882.09677.FD; Sugerman HJ, 1997, J TRAUMA, V43, P741, DOI 10.1097/00005373-199711000-00002; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	36	25	29	0	1	ELSEVIER ESPANA SLU	BARCELONA	AV JOSEP TARRADELLAS, 20-30, 1ERA PLANTA, BARCELONA, CP-08029, SPAIN	1130-1473	2340-6305		NEUROCIRUGIA	Neurocirugia	JUN	2010	21	3					211	221					11	Neurosciences; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	623OT	WOS:000279752400003	20571724				2022-02-06	
J	Li, Y; Hawkins, BE; DeWitt, DS; Prough, DS; Maret, W				Li, Yuan; Hawkins, Bridget E.; DeWitt, Douglas S.; Prough, Donald S.; Maret, Wolfgang			The relationship between transient zinc ion fluctuations and redox signaling in the pathways of secondary cellular injury: Relevance to traumatic brain injury	BRAIN RESEARCH			English	Article						Zinc; Pheochromocytoma (PC12) cells; Traumatic brain injury; Rapid stretch injury; Oxidative stress; Metallothionein	STRETCH-INDUCED INJURY; NITRIC-OXIDE; OXIDATIVE STRESS; METALLOTHIONEIN; CELLS; HIPPOCAMPUS; PATHOPHYSIOLOGY; HOMEOSTASIS; ACTIVATION; MECHANISMS	A major obstacle that hampers the design of drug therapy for traumatic brain injury is the incomplete understanding of the biochemical pathways that lead to secondary cellular injury and contribute to cell death. One such pathway involves reactive species that generate potentially cytotoxic zinc ion fluctuations as a major executor of neuronal, and possibly glial, cell death. Whether zinc ions released during traumatic brain injury are toxic or protective is controversial but can be approached by investigating the exact concentrations of free zinc ions, the thresholds of compromised zinc buffering capacity, and the mechanism of cellular homeostatic control of zinc. Rapidly stretch-injured rat pheochromocytoma (PC12) cells express cellular zinc ion fluctuations that depend on the production of nitric oxide. Chelation of cellular zinc ions after rapid stretch injury, however, increases cellular reactive oxygen species. In a rat model of traumatic brain injury, parasagittal fluid percussion, analysis of the metal load of metallothionein was used as an indicator of changes in cellular zinc ion concentrations. The combined results from the cellular and in vivo investigations caution against interpreting zinc ion fluctuations in the early phase (24 h) after injury as a primarily cytotoxic event. (C) 2010 Elsevier B.V. All rights reserved.	[Li, Yuan; Maret, Wolfgang] Univ Texas Med Branch, Div Human Nutr, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA; [Hawkins, Bridget E.; DeWitt, Douglas S.; Prough, Donald S.; Maret, Wolfgang] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA		Li, Y (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 677 Huntington Ave,Bldg 2,Rm 133, Boston, MA 02115 USA.	yuan@hsph.harvard.edu	Prough, Donald S/G-5793-2013; Hawkins, Bridget/H-4933-2015	Prough, Donald S/0000-0001-7994-532X; Hawkins, Bridget/0000-0002-1887-3657	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS042849]; National Institutes of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES007254]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32ES007254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042849] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health grant NS042849 (to DSP), and in part by a predoctoral fellowship (to BEH) from the National Institutes of Environmental Health Sciences training grant ES007254. We thank Margaret A. Parsley for her technical assistance and Dr. Alai Tan for help with the statistical analyses.	Adamo AM, 2010, NEUROTOX RES, V17, P1, DOI 10.1007/s12640-009-9067-4; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.0741951.x; Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; Aras MA, 2009, J NEUROCHEM, V110, P106, DOI 10.1111/j.1471-4159.2009.06106.x; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Atahan E, 2010, BIOL TRACE ELEM RES, V137, P206, DOI 10.1007/s12011-009-8568-6; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Bozym RA, 2006, ACS CHEM BIOL, V1, P103, DOI 10.1021/cb500043a; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Calderone A, 2004, J NEUROSCI, V24, P9903, DOI 10.1523/JNEUROSCI.1713-04.2004; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Cima RR, 2006, AM J PHYSIOL-GASTR L, V290, pG250, DOI 10.1152/ajpgi.00501.2004; Cortese MM, 2008, FREE RADICAL BIO MED, V44, P2002, DOI 10.1016/j.freeradbiomed.2008.02.013; Cuajungco MP, 2003, BRAIN RES REV, V41, P44, DOI 10.1016/S0165-0173(02)00219-9; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dietrich A, 1998, BEHAV NEUROSCI, V112, P1043, DOI 10.1037/0735-7044.112.5.1043; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; Dineley KE, 2008, J NEUROCHEM, V106, P2184, DOI 10.1111/j.1471-4159.2008.05536.x; Doering P, 2007, NEUROSCIENCE, V150, P93, DOI 10.1016/j.neuroscience.2007.09.066; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Fekete A, 2008, FREE RADICAL BIO MED, V44, P1010, DOI 10.1016/j.freeradbiomed.2007.11.022; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Frederickson CJ, 2004, NEUROSCIENTIST, V10, P18, DOI 10.1177/1073858403255840; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Grady CL, 2003, HIPPOCAMPUS, V13, P572, DOI 10.1002/hipo.10114; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Haase H, 2004, ANAL BIOCHEM, V333, P19, DOI 10.1016/j.ab.2004.04.039; Hall ED, 1988, J NEUROTRAUM, V5, P81, DOI 10.1089/neu.1988.5.81; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hao Q, 2005, J ALZHEIMERS DIS, V8, P161; Hellmich HL, 2008, NEUROSCI LETT, V440, P155, DOI 10.1016/j.neulet.2008.05.068; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; KATAYAMA T, 1990, ANGIOLOGY, V41, P479, DOI 10.1177/000331979004100610; Kesner RP, 2006, BIOL PSYCHOL, V73, P3, DOI 10.1016/j.biopsycho.2006.01.004; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Krezel A, 2007, BIOCHEM J, V402, P551, DOI 10.1042/BJ20061044; Krezel A, 2006, J BIOL INORG CHEM, V11, P1049, DOI 10.1007/s00775-006-0150-5; Lee JY, 2008, J NEUROSCI, V28, P10919, DOI 10.1523/JNEUROSCI.3421-08.2008; Li Y, 2008, J ANAL ATOM SPECTROM, V23, P1055, DOI 10.1039/b802220h; Li Y, 2009, EXP CELL RES, V315, P2463, DOI 10.1016/j.yexcr.2009.05.016; Liaudet L, 1998, J INFECT DIS, V177, P127, DOI 10.1086/513813; MARET W, 1995, NEUROCHEM INT, V27, P111, DOI 10.1016/0197-0186(94)00173-R; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MARET W, 1994, P NATL ACAD SCI USA, V91, P237, DOI 10.1073/pnas.91.1.237; Maret W, 1999, P NATL ACAD SCI USA, V96, P1936, DOI 10.1073/pnas.96.5.1936; Maret W, 2008, EXP GERONTOL, V43, P363, DOI 10.1016/j.exger.2007.11.005; Maret W, 2006, ANTIOXID REDOX SIGN, V8, P1419, DOI 10.1089/ars.2006.8.1419; Maret W, 2009, CHEM REV, V109, P4682, DOI 10.1021/cr800556u; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sensi SL, 2009, NAT REV NEUROSCI, V10, P780, DOI 10.1038/nrn2734; Spahl DU, 2003, P NATL ACAD SCI USA, V100, P13952, DOI 10.1073/pnas.2335190100; St Croix CM, 2002, AM J PHYSIOL-LUNG C, V282, pL185, DOI 10.1152/ajplung.00267.2001; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Turan B, 1997, AM J PHYSIOL-HEART C, V272, pH2095, DOI 10.1152/ajpheart.1997.272.5.H2095; Yang Y, 2001, P NATL ACAD SCI USA, V98, P5556, DOI 10.1073/pnas.101123298; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	66	25	25	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 12	2010	1330						131	141		10.1016/j.brainres.2010.03.034			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	599FP	WOS:000277896800013	20303343	Green Accepted			2022-02-06	
J	Demakis, GJ; Rimland, CA				Demakis, George J.; Rimland, Casey A.			Untreated Mild Traumatic Brain Injury in a Young Adult Population	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Brain injury; Neuropsychology; Treatment; Young adult	UNITED-STATES; EPIDEMIOLOGY	The current study was conducted to determine (a) the demographic and injury characteristics of individuals who did not receive treatment for mild brain injury and (b) the reasons these individuals do not receive or seek treatment. In a large sample of undergraduate students initially surveyed via an on-line questionnaire (n = 1,853), 35% of those who responded to a subsequent survey acknowledged that they had experienced at least one mild traumatic brain injury (TBI) for which they were not treated. Compared with those who were treated for each TBI, those who were untreated were more likely to be men and were less likely to report persisting symptoms 3 months after the injury. There were no differences in demographics or injury characteristics (e.g., length of time unconscious) between groups. Of those with an untreated TBI, the most common reasons for not seeking treatment were that the symptoms resolved quickly and that they were neither bothersome nor disruptive. Findings are discussed in terms of research on recovery from mild TBI.	[Demakis, George J.; Rimland, Casey A.] Univ N Carolina, Dept Psychol, Charlotte, NC 28223 USA		Demakis, GJ (corresponding author), Univ N Carolina, Dept Psychol, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	gdemakis@uncc.edu		Rimland, Casey/0000-0002-5187-6921			Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Wang PS, 2005, ARCH GEN PSYCHIAT, V62, P629, DOI 10.1001/archpsyc.62.6.629	13	25	25	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2010	25	3					191	196		10.1093/arclin/acq004			6	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	587MC	WOS:000276995600004	20197295	Bronze			2022-02-06	
J	Gardner, A; Shores, EA; Batchelor, J				Gardner, Andrew; Shores, E. Arthur; Batchelor, Jennifer			Reduced Processing Speed in Rugby Union Players Reporting Three or More Previous Concussions	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Sports-related concussion; Computerized neuropsychological tests	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; RECOVERY; HISTORY; MANAGEMENT; RETURN	The issue pertaining to the effect of multiple self-reported sports-related concussions on cognitive function is controversial. Although this topic has received increased attention in the literature recently, the issue remains unresolved. Evidence supporting a detrimental cognitive effect has been reported at a sub-concussive level and following one, two, and three or more previous concussions. However, numerous studies have been unable to replicate these findings. Additionally, discrepancies between neuropsychological testing formats have been identified, where studies utilizing traditional tests tend to support the notion of detrimental cognitive effects whereas studies with computerized tests have tended to demonstrate no effect. The present study sought to examine possible detrimental cognitive effects in a sample of adult male rugby union players who reported a history of three or more concussions (n = 34) compared with those who reported no previous concussions (n = 39). A computerized neuropsychological battery and a traditional neuropsychological measure of processing speed were administered for this purpose. Findings revealed that there were differences between groups on two processing speed measures from both traditional and computerized tests. Athletes with a history of multiple concussions performed significantly lower on these measures than those with no history of concussion. These results provide further evidence to suggest that a history of three or more self-reported concussions in active athletes may have a detrimental effect on cognitive function. Future research may focus on identifying moderating factors in an attempt to resolve some of the conflicting findings and identify potential athletes at risk for sustaining cognitive deficits.	[Gardner, Andrew; Shores, E. Arthur; Batchelor, Jennifer] Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia		Shores, EA (corresponding author), Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia.	arthur.shores@mq.edu.au	Gardner, Andrew/J-5162-2013	Batchelor, Jennifer/0000-0003-4438-4993; Gardner, Andrew/0000-0001-5031-5586; Shores, Edwin A/0000-0003-1553-5131	Macquarie University	Supported by Macquarie University Postgraduate Research Fund.	Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Randolph C, 2005, J ATHL TRAINING, V40, P139; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT	35	25	25	0	19	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2010	25	3					174	181		10.1093/arclin/acq007			8	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	587MC	WOS:000276995600002	20202986	Bronze			2022-02-06	
J	Pavlovic, D; Pekic, S; Stojanovic, M; Zivkovic, V; Djurovic, B; Jovanovic, V; Miljic, N; Medic-Stojanoska, M; Doknic, M; Miljic, D; Djurovic, M; Casanueva, F; Popovic, V				Pavlovic, D.; Pekic, S.; Stojanovic, M.; Zivkovic, V.; Djurovic, B.; Jovanovic, V.; Miljic, N.; Medic-Stojanoska, M.; Doknic, M.; Miljic, D.; Djurovic, M.; Casanueva, F.; Popovic, V.			Chronic cognitive sequelae after traumatic brain injury are not related to growth hormone deficiency in adults	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						brain injury; cognition; growth hormone deficiency; hypopituitarism; neuroendocrine dysfunction	ANEURYSMAL SUBARACHNOID HEMORRHAGE; GH-RELEASING HORMONE; FUNCTIONAL CONNECTIVITY; FACTOR-I; HYPOPITUITARISM; PERFORMANCE; DYSFUNCTION; RECEPTORS; REPLACEMENT; HIPPOCAMPUS	Objective: The objective of the study was to asses the possible influence of hypothalamo-pituitary deficiencies, and growth hormone (GH) deficiency in particular, on cognition in adult patients with traumatic brain injury (TBI). TBI is a recently identified risk factor for cognitive deficits and hypopituitarism. Even the patients with favorable outcome after TBI may present with persistent bodily, psychosocial, and cognitive impairments, resembling patients with untreated partial or complete pituitary insufficiency. Design: We performed retrospective and cross-sectional study of endocrine and cognitive function in TBI in 61 patients (aged 37.7 +/- 1.7 years) of both sexes (44 m,17 f), at least 1 year after TBI (3.9 +/- 0.6 years). Serum insulin-like growth factor 1 (IGF-I), thyroxin, thyroid-stimulating hormone (TSH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), testosterone (in men), prolactin, and cortisol were measured, and GH secretion was assessed by growth hormone releasing hormone (GHRH) + growth hormone releasing peptide-6 (GHRP-6) test. Cognitive function was assessed by using a standard neuropsychological battery. Results: GH deficiency (GHD) and GH insufficiency (GHI) were found in 20 patients (32.8%). After adjustment for confounders [age, body mass index (BMI), education level, time elapsed from TBI], there were no significant differences in results of neuropsychological tests between patients with TBI with GHD, GHI, and normal GH secretion. There were no correlations of neuropsychological variables with stimulated peak GH secretion or IGF-I level. Conclusions: GHD persists long after the TBI, independently of trauma severity and age at traumatic event. GH secretion is more sensitive to TBI than other pituitary hormones. No evidence is found for an association of cognitive function impairment and somatotropic axis impairment in adult patients tested more than 1 year after the TBI.	[Pavlovic, D.] Univ Clin Ctr, Inst Neurol, Belgrade 11000, Serbia; [Pekic, S.; Stojanovic, M.; Zivkovic, V.; Doknic, M.; Miljic, D.; Djurovic, M.; Popovic, V.] Univ Clin Ctr, Inst Endocrinol, Belgrade 11000, Serbia; [Djurovic, B.; Jovanovic, V.] Univ Clin Ctr, Inst Neurosurg, Belgrade 11000, Serbia; [Miljic, N.] Fac Med, Inst Med Stat & Hlth Res, Belgrade, Serbia; [Medic-Stojanoska, M.] Univ Novi Sad, Inst Endocrinol, Novi Sad 21000, Serbia; [Casanueva, F.] Univ Santiago de Compostela, Endocrine Sect, Complejo Hosp, Santiago De Compostela, Spain		Pavlovic, D (corresponding author), Univ Clin Ctr, Inst Neurol, Dr Subotica 6, Belgrade 11000, Serbia.	dpavlovic53@hotmail.com	Pekic, Sandra/S-7175-2016		Ministry of Science of Republic of SerbiaMinistry of Education, Science & Technological Development, Serbia [145019]	This study was supported by a grant from the Ministry of Science of Republic of Serbia (Project 145019).	ADEM A, 1989, BRAIN RES, V503, P299, DOI 10.1016/0006-8993(89)91678-8; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Bulow B, 2002, CLIN ENDOCRINOL, V56, P183, DOI 10.1046/j.0300-0664.2001.01461.x; Clayton P, 2007, GROWTH HORM IGF RES, V17, P369, DOI 10.1016/j.ghir.2007.04.010; DANIEL PM, 1959, LANCET, V2, P927; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Fernandez S, 2007, GROWTH HORM IGF RES, V17, P89, DOI 10.1016/j.ghir.2007.01.006; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gentry LR., 1996, MAGNETIC RESONANCE I, P611; Heaton RK, 1981, MANUAL WISCONSIN CAR; Kaplan E.F., 1978, BOSTON NAMING TEST; Kelestimur F, 2006, CLIN ENDOCRINOL, V64, P667, DOI 10.1111/j.1365-2265.2006.02525.x; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; LAI ZN, 1991, BRAIN RES, V546, P222, DOI 10.1016/0006-8993(91)91485-J; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Link K, 2006, CLIN ENDOCRINOL, V65, P617, DOI 10.1111/j.1365-2265.2006.02637.x; Micic D, 1998, J CLIN ENDOCR METAB, V83, P2569, DOI 10.1210/jc.83.7.2569; Nyberg F, 2000, FRONT NEUROENDOCRIN, V21, P330, DOI 10.1006/frne.2000.0200; Nyberg F, 1996, HORM RES, V45, P18, DOI 10.1159/000184753; Oertel H, 2004, PSYCHONEUROENDOCRINO, V29, P839, DOI 10.1016/S0306-4530(03)00151-3; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Ranganath C, 2005, HIPPOCAMPUS, V15, P997, DOI 10.1002/hipo.20141; Reitan R.M., 1993, HALSTEADREITAN NEURO; Rey A., 1964, EXAMEN CLIN PSYCHOL; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; SmithSeemiller L, 1997, BRAIN INJURY, V11, P191; Soares CDN, 1999, ARQ NEURO-PSIQUIAT, V57, P182; Stein T, 2000, AM J NEURORADIOL, V21, P1397; Svensson AL, 2008, P NATL ACAD SCI USA, V105, P7304, DOI 10.1073/pnas.0802531105; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; VANCE ML, 1994, NEW ENGL J MED, V330, P1651, DOI 10.1056/NEJM199406093302306; Vogenthaler D R, 1987, Brain Inj, V1, P113	35	25	28	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1351-5101	1468-1331		EUR J NEUROL	Eur. J. Neurol.	MAY	2010	17	5					696	702		10.1111/j.1468-1331.2009.02910.x			7	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	582NE	WOS:000276603700012	20050894				2022-02-06	
J	Pasvogel, AE; Miketova, P; Moore, IM				Pasvogel, Alice E.; Miketova, Petra; Moore, Ida M. (Ki)			Differences in CSF Phospholipid Concentration by Traumatic Brain Injury Outcome	BIOLOGICAL RESEARCH FOR NURSING			English	Article						phospholipids; traumatic brain injury; membrane damage; outcome	HUMAN CEREBROSPINAL-FLUID; FREE FATTY-ACIDS; INTERSTITIAL GLYCEROL; APOPTOSIS	Traumatic brain injury (TBI) is a leading cause of morbidity and mortality. A cascade of events is initiated with TBI that leads to degradation of the membrane lipid bilayer of neurons and neuroglia. The purpose of this study was to (a) describe changes in the cerebrospinal fluid (CSF) phospholipid concentration over time for those who survived and those who died following TBI; and (b) determine whether there were differences in the CSF phospholipid concentration between those who survived and those who died following TBI. Thirty-nine CSF samples were obtained from 10 participants who sustained a TBI. Following extraction, phospholipids were separated and quantified by normal-phase high performance liquid chromatography with ultraviolet detector. For those who died, the highest median concentration was on Day 1 after TBI for lysophosphatidylcholine and on Day 4 after TBI for phosphatidylethanolamine, phosphatidylserine, phosphatidylcholine, and sphingomyelin. For those who survived, the highest median concentration was on Day 1 after TBI for phosphatidylcholine, on Day 3 after TBI for phosphatidylethanolamine and phosphatidylserine, on Day 4 after TBI for sphingomyelin, and on Day 5 after TBI for lysophosphatidylcholine. There were significant differences in the concentrations of phosphatidylethanolamine and phosphatidylserine on Days 1-2 and of phosphatidylethanolamine, phosphatidylcholine, and sphingomyelin on Days 3-4 after TBI between those who survived and died, with the highest concentrations in those who died. These findings provide preliminary evidence of greater disruption of central nervous system membrane phospholipids in participants who died after TBI.	[Pasvogel, Alice E.; Miketova, Petra; Moore, Ida M. (Ki)] Univ Arizona, Coll Nursing, Tucson, AZ 85721 USA		Pasvogel, AE (corresponding author), Univ Arizona, Coll Nursing, 1305 N Martin, Tucson, AZ 85721 USA.	pasvogel@nursing.arizona.edu			Beta Mu Chapter, Sigma Theta Tau International	This study was supported by a grant from Beta Mu Chapter, Sigma Theta Tau International.	CHEN SF, 1985, J CHROMATOGR, V344, P297, DOI 10.1016/S0378-4347(00)82030-7; Farooqui AA, 2006, PHARMACOL REV, V58, P591, DOI 10.1124/pr.58.3.7; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; ILLINGWORTH DR, 1971, J NEUROCHEM, V18, P769, DOI 10.1111/j.1471-4159.1971.tb12006.x; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Koch S, 2001, J LIPID RES, V42, P1143; KUNZ F, 1972, Z NEUROL, V203, P259, DOI 10.1007/BF00316117; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Parsons L., 1997, J NEUROTRAUM, V14, P784; Pasvogel AE, 2008, BIOL RES NURS, V10, P113, DOI 10.1177/1099800408323218; Peerdeman SM, 2003, INTENS CARE MED, V29, P1825, DOI 10.1007/s00134-003-1850-8; Pilitsis JG, 2003, NEUROSCI LETT, V349, P136, DOI 10.1016/S0304-3940(03)00803-6; Uzan M, 2006, ACTA NEUROCHIR, V148, P1157, DOI 10.1007/s00701-006-0887-1; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131	17	25	25	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1099-8004			BIOL RES NURS	Biol. Res. Nurs.	APR	2010	11	4					325	331		10.1177/1099800409346056			7	Nursing	Science Citation Index Expanded (SCI-EXPANDED)	Nursing	574NF	WOS:000275996100002	20338895				2022-02-06	
J	Bhagia, V; Gilkison, C; Fitts, RH; Zgaljardic, DJ; High, WM; Masel, BE; Urban, RJ; Mossberg, KA				Bhagia, Vinita; Gilkison, Charles; Fitts, Robert H.; Zgaljardic, Dennis J.; High, Walter M., Jr.; Masel, Brent E.; Urban, Randall J.; Mossberg, Kurt A.			Effect of recombinant growth hormone replacement in a growth hormone deficient subject recovering from mild traumatic brain injury: A case report	BRAIN INJURY			English	Article						Closed head injury; hypopituitarism; cognition; oxygen consumption; GH deficiency	QUALITY-OF-LIFE; PITUITARY FUNCTION; BODY-COMPOSITION; GH REPLACEMENT; ADULT PATIENTS; EXERCISE; RELIABILITY; DYSFUNCTION; VELOCITY; GLUCAGON	Objective: To assess the effects of growth hormone (GH) replacement in an individual who sustained mild traumatic brain injury (mTBI) as an adult and was found to have GH deficiency by glucagon stimulation testing. Participant: A 43-year old woman who sustained a mild TBI at age 37 years. She was 6.8 years post-injury when she began supplementation. Intervention: Recombinant human GH (rhGH) subcutaneously per day for 1 year. Main outcome measures: Single fibre muscle function was evaluated from muscle biopsies. Body composition, muscle strength and peak aerobic capacity were also measured. In addition, neuropsychological tests of memory, processing speed and motor dexterity and speed, as well as a self-report depression inventory were administered. All assessments were performed at baseline and after 6 and 12 months of rhGH replacement therapy. Results: Single muscle fibre changes were greatest at 6 months. Body composition showed continuous improvement. Muscle strength improved for knee extension. Peak oxygen consumption increased at 6 months and total work and ventilatory equivalents continued to improve at 12 months. Significant improvements in neuropsychological test performance were not found, with the exception of performance on a test of motor dexterity and speed. Conclusion: rhGH replacement in a subject with GH deficiency after mild TBI improves muscle force production, body composition and aerobic capacity. Reliable improvements on tests of cognition were not found in this subject.	[Bhagia, Vinita; Gilkison, Charles; Zgaljardic, Dennis J.; Urban, Randall J.; Mossberg, Kurt A.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Fitts, Robert H.] Marquette Univ, Milwaukee, WI 53233 USA; [Zgaljardic, Dennis J.; Masel, Brent E.] Transit Learning Ctr, Galveston, TX USA; [High, Walter M., Jr.] Univ Kentucky, Lexington, KY USA		Mossberg, KA (corresponding author), Univ Texas Med Branch, 301 Univ Blvd, Galveston, TX 77555 USA.	kmossber@utmb.edu		Fitts, Robert/0000-0001-9674-1118	Moody Endowment; National Center for Research Resources, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 00073]; USPHSUnited States Department of Health & Human ServicesUnited States Public Health Service; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000071] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000073] Funding Source: NIH RePORTER	This work was partially funded by the generous support of the Moody Endowment. Recombinant growth hormone was supplied by Pfizer, Inc. Studies were conducted on the General Clinical Research Center (GCRC) at the University of Texas Medical Branch at Galveston, funded by grant M01 RR 00073 from the National Center for Research Resources, NIH and USPHS. We gratefully acknowledge Renee Pearcy for editorial assistance.	Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Aimaretti G, 2005, THESCIENTIFICWORLDJO, V5, P777, DOI 10.1100/tsw.2005.100; BEAVER WL, 1986, J APPL PHYSIOL, V60, P2020, DOI 10.1152/jappl.1986.60.6.2020; Beck AT, 1987, BECK DEPRESSION INVE; Benton A., 1978, MULTILINGUAL APHASIA; Beshyah SA, 1999, CLIN ENDOCRINOL, V50, P1, DOI 10.1046/j.1365-2265.1999.00682.x; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918, DOI 10.1093/ajcn/55.5.918; BJORK S, 1989, ACTA PAEDIATR SCAND, P55; Bondanelli M, 2007, J NEUROTRAUM, V24, P1687, DOI 10.1089/neu.2007.0343; Centers for Disease Control Prevention [CDC], 2007, TRAUM BRAIN INJ; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1919, DOI 10.1210/jc.84.6.1919; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; Delis D.C., 2000, CALIFORNIA VERBAL LE; DELORME TL, 1945, J BONE JOINT SURG, V27, P645; Einaudi S, 2007, CURR OPIN PEDIATR, V19, P465, DOI 10.1097/MOP.0b013e3281ab6eeb; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; Gotherstrom G, 2001, J CLIN ENDOCR METAB, V86, P4657, DOI 10.1210/jc.86.10.4657; GRINDELAND RE, 1994, AM J PHYSIOL, V267, pR316, DOI 10.1152/ajpregu.1994.267.1.R316; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; IOM, 2009, GULF WAR HLTH, V7; Ives JC, 2007, J ATHL TRAINING, V42, P431; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; KLOVE H, 1963, MED CLINICS N AM; Leon-Carrion J, 2007, BRAIN INJURY, V21, P871, DOI 10.1080/02699050701484849; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LINDERMAN JK, 1994, AM J PHYSIOL, V267, pR365, DOI 10.1152/ajpregu.1994.267.2.R365; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jcem.77.6.8263155; Mossberg KA, 2005, AM J PHYS MED REHAB, V84, P492, DOI 10.1097/01.phm.0000166883.97562.cd; Mossberg KA, 2002, BRAIN INJURY, V16, P789, DOI 10.1080/02699050210131894; MOSSBERG KA, 2003, BRAIN INJURY, V17, P266; Mossberg KA, 2008, J CLIN ENDOCR METAB, V93, P2581, DOI 10.1210/jc.2008-0368; Osterreith P., 1993, CLIN NEUROPSYCHOL, V7, P9; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Reitan R, 1969, MANUAL ADM NEUROPSYC; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Sesmilo Gemma, 2007, Hormones (Athens), V6, P132; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Widrick JJ, 1998, J APPL PHYSIOL, V85, P1949, DOI 10.1152/jappl.1998.85.5.1949; Widrick JJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1690; Yuen KCJ, 2009, J CLIN ENDOCR METAB, V94, P2702, DOI 10.1210/jc.2009-0299	48	25	26	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2010	24	3					560	567		10.3109/02699051003601705			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	574JR	WOS:000275985800012	20184413				2022-02-06	
J	Bai, CH; Chen, JR; Chiu, HC; Chou, CC; Chau, LY; Pan, WH				Bai, Chyi-Huey; Chen, Jiunn-Rong; Chiu, Hou-Chang; Chou, Chia-Chi; Chau, Lee-Young; Pan, Wen-Harn			Shorter GT repeat polymorphism in the heme oxygenase-1 gene promoter has protective effect on ischemic stroke in dyslipidemia patients	JOURNAL OF BIOMEDICAL SCIENCE			English	Article							CORONARY-ARTERY-DISEASE; TRAUMATIC BRAIN-INJURY; MICROSATELLITE POLYMORPHISM; OXIDATIVE STRESS; CARDIOVASCULAR-DISEASE; RISK-FACTORS; RAT-BRAIN; EXPRESSION; BILIRUBIN; ATHEROSCLEROSIS	Background: The microsatellite polymorphism of heme oxygenase (HO)-1 gene promoter has been shown to be associated with the susceptibility to ischemic event, including coronary artery disease (CAD), myocardial infarction, and peripheral vascular disease. We aimed to examine whether the length of (GT)(n) repeats in HO-1 gene promoter is associated with ischemic stroke in people with CAD risk factors, especially low level of HDL. Methods: A total of 183 consecutive firstever ischemic stroke inpatients and 164 non-stroke patients were screened for the length of (GT)(n) repeats in HO-1 promoter. The long (L) and short (S) genotype are defined as the averaged repeat number > 26 and <= 26, respectively. Results: Stroke patients tended to have more proportions of hypertension, diabetics and genotype L, than those of genotype S. Patients with genotype L of HO-1 gene promoter have higher stroke risk in comparison with genotype S especially in dyslipidemia individuals. The significant differences on stroke risk in multivariate odds ratios were found especially in people with low HDL-C levels. Conclusions: Subjects carrying longer (GT)(n) repeats in HO-1 gene promoter may have greater susceptibility to develop cerebral ischemic only in the presence of low HDL-C, suggesting the protective effects in HO-1 genotype S in the process of ischemic stroke, particularly in subjects with poor HDL-C status.	[Chau, Lee-Young; Pan, Wen-Harn] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Bai, Chyi-Huey] Shin Kong WHS Mem Hosp, Cent Lab, Taipei, Taiwan; [Bai, Chyi-Huey] Taipei Med Univ, Sch Publ Hlth, Taipei, Taiwan; [Chen, Jiunn-Rong] Changhua Christian Hosp, Yunlin Branch, Yun Lin Cty, Taiwan; [Chiu, Hou-Chang] Shin Kong WHS Mem Hosp, Dept Neurol, Taipei, Taiwan; [Chou, Chia-Chi] Chang Gung Mem Hosp, Dept Internal Med, Chilung, Taiwan		Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei, Taiwan.	lyc@ibms.sinica.edu.tw; pan@ibms.sinica.edu.tw	Pan, Wen-Harn/F-9972-2010; Chau, Lee-Young/N-7659-2018	Pan, Wen-Harn/0000-0001-9136-0658; Chau, Lee-Young/0000-0002-6316-2328	Shin Kong WHS Memorial Hospital [SKH-8302-98-NDR-07]; National Science CouncilMinistry of Science and Technology, Taiwan [NSC95-2314-B341-002]	This study was supported by grants from Shin Kong WHS Memorial Hospital (SKH-8302-98-NDR-07) and the National Science Council (NSC95-2314-B341-002). The greatest appreciation should go to the patients who have been participated this study.	BERG A, 1981, INT J SPORTS MED, V2, P121, DOI 10.1055/s-2008-1034596; Bergeron M, 1997, J CEREBR BLOOD F MET, V17, P647; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Carr FJ, 2002, J CEREBR BLOOD F MET, V22, P767, DOI 10.1097/00004647-200207000-00001; Chalmers J, 2000, Heart Dis, V2, pS13; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Chen YH, 2004, EUR HEART J, V25, P39, DOI 10.1016/j.ehj.2003.10.009; Chen YH, 2002, HUM GENET, V111, P1, DOI 10.1007/s00439-002-0769-4; Dick P, 2005, EUR J CLIN INVEST, V35, P731, DOI 10.1111/j.1365-2362.2005.01580.x; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Exner M, 2001, J ENDOVASC THER, V8, P433, DOI 10.1583/1545-1550(2001)008<0433:HOGPMP>2.0.CO;2; Funk M, 2004, THROMB RES, V113, P217, DOI 10.1016/j.thromres.2004.03.003; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; Ginsberg HN, 2002, CIRCULATION, V106, P2137, DOI 10.1161/01.CIR.0000035280.64322.31; Hoekstra KA, 2004, BIOCHEM CELL BIOL, V82, P351, DOI 10.1139/O04-006; Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250; Idriss NK, 2008, J AM COLL CARDIOL, V52, P971, DOI 10.1016/j.jacc.2008.06.019; Ishikawa K, 2001, J Atheroscler Thromb, V8, P63; Ishikawa K, 2001, CIRC RES, V88, P506, DOI 10.1161/01.RES.88.5.506; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; Kajimura M, 2003, FASEB J, V17, P506, DOI 10.1096/fj.02-0359fje; Kaneda H, 2002, ARTERIOSCL THROM VAS, V22, P1680, DOI 10.1161/01.ATV.0000033515.96747.6F; Kawamura K, 2005, ARTERIOSCL THROM VAS, V25, P155, DOI 10.1161/01.ATV.0000148405.18071.6a; Kimpara T, 1997, HUM GENET, V100, P145, DOI 10.1007/s004390050480; KUTTY RK, 1994, GENOMICS, V20, P513, DOI 10.1006/geno.1994.1213; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; Le W, 1999, J NEUROSCI RES, V56, P652; Liu XM, 2002, CARDIOVASC RES, V55, P396, DOI 10.1016/S0008-6363(02)00410-8; Lublinghoff N, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-36; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Maritim AC, 2003, J BIOCHEM MOL TOXIC, V17, P24, DOI 10.1002/jbt.10058; Morgan L, 2005, BRIT J NEUROSURG, V19, P317, DOI 10.1080/02688690500305456; Morita T, 2005, ARTERIOSCL THROM VAS, V25, P1786, DOI 10.1161/01.ATV.0000178169.95781.49; Nofer JR, 2002, ATHEROSCLEROSIS, V161, P1, DOI 10.1016/S0021-9150(01)00651-7; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; SCHWERTNER HA, 1994, CLIN CHEM, V40, P18; Sheu CC, 2009, INTENS CARE MED, V35, P1343, DOI 10.1007/s00134-009-1504-6; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729	40	25	26	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1021-7770	1423-0127		J BIOMED SCI	J. Biomed. Sci.	FEB 23	2010	17								12	10.1186/1423-0127-17-12			8	Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	570RS	WOS:000275696300001	20175935	Green Published, gold			2022-02-06	
J	Macrae, D; Pappachan, J; Grieve, R; Parslow, R; Nadel, S; Schindler, M; Baines, P; Fortune, PM; Slavik, Z; Goldman, A; Truesdale, A; Betts, H; Allen, E; Snowdon, C; Percy, D; Broadhead, M; Quick, T; Peters, M; Morris, K; Tasker, R; Elbourne, D				Macrae, Duncan; Pappachan, John; Grieve, Richard; Parslow, Roger; Nadel, Simon; Schindler, Margrid; Baines, Paul; Fortune, Peter-Marc; Slavik, Zdenek; Goldman, Allan; Truesdale, Ann; Betts, Helen; Allen, Elizabeth; Snowdon, Claire; Percy, Deborah; Broadhead, Michael; Quick, Tara; Peters, Mark; Morris, Kevin; Tasker, Robert; Elbourne, Diana			Control of hyperglycaemia in paediatric intensive care (CHiP): study protocol	BMC PEDIATRICS			English	Article							ACUTE MYOCARDIAL-INFARCTION; RESPIRATORY-DISTRESS-SYNDROME; ISCHEMIC BRAIN-DAMAGE; DIABETES-MELLITUS; CLINICAL-TRIALS; INSULIN THERAPY; STRESS HYPERGLYCEMIA; HEAD-INJURY; RISK-FACTOR; GLUCOSE	Background: There is increasing evidence that tight blood glucose (BG) control improves outcomes in critically ill adults. Children show similar hyperglycaemic responses to surgery or critical illness. However it is not known whether tight control will benefit children given maturational differences and different disease spectrum. Methods/Design: The study is an randomised open trial with two parallel groups to assess whether, for children undergoing intensive care in the UK aged <= 16 years who are ventilated, have an arterial line in-situ and are receiving vasoactive support following injury, major surgery or in association with critical illness in whom it is anticipated such treatment will be required to continue for at least 12 hours, tight control will increase the numbers of days alive and free of mechanical ventilation at 30 days, and lead to improvement in a range of complications associated with intensive care treatment and be cost effective. Children in the tight control group will receive insulin by intravenous infusion titrated to maintain BG between 4 and 7.0 mmol/l. Children in the control group will be treated according to a standard current approach to BG management. Children will be followed up to determine vital status and healthcare resources usage between discharge and 12 months post-randomisation. Information regarding overall health status, global neurological outcome, attention and behavioural status will be sought from a subgroup with traumatic brain injury (TBI). A difference of 2 days in the number of ventilator-free days within the first 30 days post-randomisation is considered clinically important. Conservatively assuming a standard deviation of a week across both trial arms, a type I error of 1% (2-sided test), and allowing for non-compliance, a total sample size of 1000 patients would have 90% power to detect this difference. To detect effect differences between cardiac and non-cardiac patients, a target sample size of 1500 is required. An economic evaluation will assess whether the costs of achieving tight BG control are justified by subsequent reductions in hospitalisation costs. Discussion: The relevance of tight glycaemic control in this population needs to be assessed formally before being accepted into standard practice.	[Macrae, Duncan; Betts, Helen] Royal Brompton Hosp, Paediat Intens Care Unit, London SW3 6NP, England; [Pappachan, John] Southampton Univ Hosp NHS Trust, Paediat Intens Care Unit, Southampton SO16 6YD, Hants, England; [Grieve, Richard] Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England; [Parslow, Roger] Univ Leeds, Ctr Biostat & Epidemiol, Paediat Epidemiol Grp, Leeds LS2 9JT, W Yorkshire, England; [Nadel, Simon] Imperial Healthcare NHS Trust, Paediat Intens Care Unit, London WC2, England; [Schindler, Margrid] Bristol Royal Hosp Children, Paediat Intens Care Unit, Bristol BS2 8BJ, Avon, England; [Baines, Paul] Alder Hey Childrens Hosp, Paediat Intens Care Unit, Liverpool L12 2AP, Merseyside, England; [Fortune, Peter-Marc] Royal Manchester Childrens Hosp, Paediat Intens Care Unit, Manchester M27 4HA, Lancs, England; [Goldman, Allan] Great Ormond St Childrens Hosp, Cardiac Intens Care Unit, London WC1N 3JH, England; [Truesdale, Ann; Allen, Elizabeth; Percy, Deborah] Univ London London Sch Hyg & Trop Med, Med Stat Unit, London WC1E 7HT, England; [Peters, Mark] Great Ormond St Childrens Hosp, Paediat Intens Care Unit, London WC1 3JH, England; [Morris, Kevin] Birmingham Childrens Hosp NHS Fdn Trust, Paediat Intens Care Unit, Birmingham B4 6NH, W Midlands, England; [Tasker, Robert] Univ Cambridge, Dept Paediat, Cambridge B2 0QQ, England; [Elbourne, Diana] Univ London London Sch Hyg & Trop Med, Med Stat Unit, London WC1E 7HI, England		Macrae, D (corresponding author), Royal Brompton Hosp, Paediat Intens Care Unit, Sydney St, London SW3 6NP, England.	D.macrae@rbht.nhs.uk	Peters, Mark/AAD-7518-2019; Tasker, Robert C/R-5837-2019; Macrae, Duncan/AAC-9564-2020; Parslow, Roger/AAV-1477-2020	Peters, Mark/0000-0003-3653-4808; Macrae, Duncan/0000-0002-7158-6585; Parslow, Roger/0000-0002-3945-5294; Tasker, Robert/0000-0003-3647-8113; Snowdon, Claire/0000-0002-9133-5476; Grieve, Richard/0000-0001-8899-1301			Anderson RE, 1999, STROKE, V30, P160, DOI 10.1161/01.STR.30.1.160; Angus DC, 2005, AM J RESP CRIT CARE, V172, P1358, DOI 10.1164/rccm.2508009; [Anonymous], 2000, N ENGL J MED, V342, P1301; [Anonymous], PAEDIAT INTENSIVE CA; ARDIGO D, 2000, CLIN SCI, V99, P37; Ardigo Diego, 2004, Current Drug Targets - Inflammation and Allergy, V3, P455, DOI 10.2174/1568010042634488; Branco Ricardo G, 2005, Pediatr Crit Care Med, V6, P470, DOI 10.1097/01.PCC.0000161284.96739.3A; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Ceriello A, 2005, EUR HEART J, V26, P328, DOI 10.1093/eurheartj/ehi049; Ceriello A, 2002, DIABETES, V51, P1076, DOI 10.2337/diabetes.51.4.1076; CERIELLO A, 2002, DIABETES, V51, P1938; Chiaretti A, 1998, CHILD NERV SYST, V14, P455, DOI 10.1007/s003810050259; CORNBLATH M, 1990, PEDIATRICS, V85, P834; CURLEY MAQ, 2005, PEDIAT CRIT CARE M S, V6, P150; Curtis L., 2007, UNIT COSTS HLTH SOCI; Das UN, 2002, CRIT CARE, V6, P389; Das UN, 2002, NUTRITION, V18, P526, DOI 10.1016/S0899-9007(02)00767-0; Das UN, 2001, NUTRITION, V17, P409, DOI 10.1016/S0899-9007(01)00518-4; DIETRICH WD, 1993, STROKE, V24, P111, DOI 10.1161/01.STR.24.1.111; Esposito K, 2002, CIRCULATION, V106, P2067, DOI 10.1161/01.CIR.0000034509.14906.AE; Faustino EV, 2005, J PEDIATR-US, V146, P30, DOI 10.1016/j.jpeds.2004.08.076; Ferrando A A, 1999, Curr Opin Clin Nutr Metab Care, V2, P171, DOI 10.1097/00075197-199903000-00014; Ferrando AA, 1999, ANN SURG, V229, P11, DOI 10.1097/00000658-199901000-00002; Field D, 2005, PEDIATRICS, V115, P926, DOI 10.1542/peds.2004-1209; Furnary Anthony P, 2004, Endocr Pract, V10 Suppl 2, P21; Furnary AP, 1999, ANN THORAC SURG, V67, P352, DOI 10.1016/S0003-4975(99)00014-4; Gearhart MM, 2006, AACN ADV CRIT CARE, V17, P50, DOI 10.1097/00044067-200601000-00007; Hall NJ, 2004, J PEDIATR SURG, V39, P898, DOI 10.1016/j.jpedsurg.2004.02.005; HALVERSONSTEELE B, 2004, PEDIATRIC CRITICAL C; HAYBITTLE JL, 1971, BRIT J RADIOL, V44, P793, DOI 10.1259/0007-1285-44-526-793; Hoxworth JM, 1999, BRAIN RES, V821, P467, DOI 10.1016/S0006-8993(98)01332-8; *I HEALTHC IMPR, SURV SEPS CAMP; Jenkins KJ, 2002, J THORAC CARDIOV SUR, V123, P110, DOI 10.1067/mtc.2002.119064; Katsura K, 2004, BRAIN RES, V1030, P133, DOI 10.1016/j.brainres.2004.10.007; Lacroix J, 2005, PEDIATR CRIT CARE ME, V6, P126; LANGE P, 1989, EUR RESPIR J, V2, P14; Leteurtre S, 1999, MED DECIS MAKING, V19, P399, DOI 10.1177/0272989X9901900408; Li PA, 1998, BRAIN RES, V804, P36, DOI 10.1016/S0006-8993(98)00651-9; Malmberg K, 1999, CIRCULATION, V99, P2626, DOI 10.1161/01.CIR.99.20.2626; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; McManus LM, 2001, J LEUKOCYTE BIOL, V70, P395; OLIVER MF, 1968, LANCET, V1, P710; Paret G, 1999, J ACCID EMERG MED, V16, P186; PAYMENT B, 2008, HEALTH, P9; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Pham TN, 2005, J TRAUMA, V59, P1148, DOI 10.1097/01.ta.0000188933.16637.68; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; Rayner CK, 1999, DIGEST DIS SCI, V44, P279, DOI 10.1023/A:1026642114971; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Russo A, 1999, EUR J CLIN INVEST, V29, P512, DOI 10.1046/j.1365-2362.1999.00487.x; Russo A, 1997, GUT, V41, P494, DOI 10.1136/gut.41.4.494; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Srinivasan Vijay, 2004, Pediatr Crit Care Med, V5, P329, DOI 10.1097/01.PCC.0000128607.68261.7C; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vriesendorp TM, 2004, EUR J VASC ENDOVASC, V28, P520, DOI 10.1016/j.ejvs.2004.08.006; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72; NHS INFORM STANDARDS	59	25	25	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2431			BMC PEDIATR	BMC Pediatr.	FEB 5	2010	10								5	10.1186/1471-2431-10-5			14	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	566UX	WOS:000275399800001	20137090	Green Published, Green Accepted, gold			2022-02-06	
J	Crowe, LM; Anderson, V; Catroppa, C; Babl, FE				Crowe, Louise M.; Anderson, Vicki; Catroppa, Cathy; Babl, Franz E.			Head injuries related to sports and recreation activities in school-age children and adolescents: Data from a referral centre in Victoria, Australia	EMERGENCY MEDICINE AUSTRALASIA			English	Article						Australian Rules football; head injury; sport	TRAUMATIC BRAIN-INJURY; CONCUSSION; EMERGENCY; IMPACT	Objectives: Head injuries (HI) in children are common and even mild HI can lead to ongoing cognitive and behavioural changes. We set out to determine the causes of sport-related HI in school-age children presenting to a large urban ED as a basis for future interventions. Method: Identification and medical record review of all sport-related HI in children aged 6-16 years at a tertiary children's hospital ED in Victoria, Australia, over a 1 year period. Information was collected on demographics, injury variables and radiology findings. HI were classified as mild, moderate and severe based on GCS and radiography reports. Results: Over 12 months there were 406 HI in school-age children. Seventy per cent were male. A large number of HI (129; 33%) were related to sports. Of these, most were classified as mild and 13% were classified as moderate or severe. Among a range of sports, Australian Rules football was associated with more than 30% of all HI attributable to a sport and recreation cause. Equestrian activities were the main cause of moderate HI. Conclusion: The present study identified sports as a major cause of HI in the Victorian paediatric emergency setting with Australian Rules football the most commonly involved sport. Further prevention initiatives should consider targeting Australian Rules football and equestrian activities.	[Crowe, Louise M.; Anderson, Vicki; Catroppa, Cathy; Babl, Franz E.] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Crowe, Louise M.; Anderson, Vicki; Catroppa, Cathy] Univ Melbourne, Dept Behav Sci, Melbourne, Vic 3010, Australia; [Anderson, Vicki; Babl, Franz E.] Royal Childrens Hosp, Melbourne, Vic, Australia		Crowe, LM (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	louise.crowe@mcri.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436; Crowe, Louise/0000-0003-4619-9708	Murdoch Childrens Research Institute	The present study was supported by a small grant from the Murdoch Childrens Research Institute.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; *AUSTR BUR STAT, 2008, SPORT RECR STAT OV A; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BOND GR, 1995, PEDIATRICS, V95, P487; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Cameron PA, 2004, ANZ J SURG, V74, P424, DOI 10.1111/j.1445-1433.2004.03029.x; Cassell E, 2007, HAZARD VISU, V65, P1; Finch C, 1998, BRIT J SPORT MED, V32, P220, DOI 10.1136/bjsm.32.3.220; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Hillier SL, 1997, BRAIN INJURY, V11, P649; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McManus Alexandra, 2006, Health Promot J Austr, V17, P67; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Mitra B, 2007, J PAEDIATR CHILD H, V43, P154, DOI 10.1111/j.1440-1754.2007.01035.x; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE G, 1974, LANCET, V2, P81; World Health Organization, 1992, INT CLASS DIS	23	25	25	0	10	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1742-6731			EMERG MED AUSTRALAS	Emerg. Med. Australas.	FEB	2010	22	1					56	61		10.1111/j.1742-6723.2009.01249.x			6	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	554BA	WOS:000274409300008	20015247				2022-02-06	
J	Seyfried, DM; Han, YX; Yang, DM; Ding, J; Shen, LH; Savant-Bhonsale, S; Chopp, M				Seyfried, Donald M.; Han, Yuxia; Yang, Dongmei; Ding, Jennifer; Shen, Li Hong; Savant-Bhonsale, Smita; Chopp, Michael			Localization of bone marrow stromal cells to the injury site after intracerebral hemorrhage in rats Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						bone marrow stromal cell; intracerebral hemorrhage; rat	TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA; THERAPEUTIC BENEFIT; FUNCTIONAL RECOVERY; STEM-CELLS; STROKE; TRANSPLANTATION	Object. Previous studies demonstrated that intravascular injection of bone marrow stromal cells (BMSCs) significantly improved neurological functional recovery in a rat model of intracerebral hemorrhage (ICH). To further investigate the fate of transplanted cells, we examined the effect of male rat BMSCs administered to female rats after ICH. Methods. Twenty-seven female Wistar rats were subjected to ICH surgery. At 24 hours after ICH, these rats were randomly divided into 3 groups and injected intravenously with I ml phosphate-buffered saline or 0.5 million or I million male rat BMSCs in phosphate-buffered saline. To evaluate the neurological functional Outcome, each rat was subjected to a series of behavioral tests (modified neurological severity score and corner turn test) at 1, 7, and 14 days after ICH. The rats were anesthetized intraperitoneally and killed, and the brain tissues were processed at Day 14 after ICH. Immunohistochemistry and in situ hybridization were used to identify cell-specific markers. Results. The male rat BMSCs significantly improved the neurological functional outcome and also significantly diminished tissue loss when intravenously transplanted into the rats after ICH. Immunoassay for bromodeoxyuridine (BrdU) and neuronal markers demonstrated a significant increase in the number of BrdU-positive cells, which indicated endogenous neurogenesis, and a significant increase in the number of cells positive for immature neuronal markers. In situ hybridization showed that more BMSCs resided around the hematoma of the rats treated with the I-million-cell dose compared with the 0.5-million-cell-dose group. In addition, a subfraction of Y chromosome-positive cells were co-immunostained with the neuronal marker microtubule-associated protein-2 or the astrocytic marker glial fibrillary acidic protein. Conclusions. Male rat BMSCs improve neurological outcome and increase histochemical parameters of neurogenesis when administered to female rats after ICH. This study has shown that the intravenously administered male rat BMSCs enter the brain, migrate to the perihematomal area, and express parenchymal markers. (DOI: 10.3171/2009.2.JNS08907)	[Seyfried, Donald M.; Han, Yuxia; Yang, Dongmei; Ding, Jennifer] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Shen, Li Hong; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Savant-Bhonsale, Smita] Theradigm Inc, Dept Neurobiol, Baltimore, MD USA		Seyfried, DM (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsdos@neuro.hfh.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NSO58581]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS058581] Funding Source: NIH RePORTER	This work was supported by internal (departmental) funds and NIH Grant NSO58581. The authors report no conflict of interest concerning the materials or methods used ill this Study or the findings specified ill this paper.	Broderick J, 2007, CIRCULATION, V116, pE391, DOI 10.1161/CIRCULATIONAHA.107.183689; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Cheung RTF, 2007, REV RECENT CLIN TRIA, V2, P174, DOI 10.2174/157488707781662751; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Harvey Richard L, 2003, Phys Med Rehabil Clin N Am, V14, pS143, DOI 10.1016/S1047-9651(02)00058-X; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lindvall O, 2004, STROKE, V35, P2691, DOI 10.1161/01.STR.0000143323.84008.f4; Liu H, 2006, BRAIN, V129, P2734, DOI 10.1093/brain/awl207; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; MacLellan CL, 2008, J CEREBR BLOOD F MET, V28, P516, DOI 10.1038/sj.jcbfm.9600548; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Seyfried D, 2006, J NEUROSURG, V104, P313, DOI 10.3171/jns.2006.104.2.313; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; Seyfried DM, 2008, BRAIN RES, V1224, P12, DOI 10.1016/j.brainres.2008.05.080; Shen LH, 2007, STROKE, V38, P2150, DOI 10.1161/STROKEAHA.106.481218; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Shintani A, 2007, BRAIN RES, V1186, P48, DOI 10.1016/j.brainres.2007.09.086; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0	25	25	27	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2010	112	2					329	335		10.3171/2009.2.JNS08907			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	550CX	WOS:000274107000019	19284233	Green Accepted			2022-02-06	
J	Kalish, H; Phillips, TM				Kalish, Heather; Phillips, Terry M.			Analysis of neurotrophins in human serum by immunoaffinity capillary electrophoresis (ICE) following traumatic head injury"	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						CE; Head trauma; Immunoaffinity; Neurotrophins; Serum	INDUCED FLUORESCENCE DETECTION; NERVE GROWTH-FACTOR; BRAIN-INJURY; MASS-SPECTROMETRY; FACTOR EXPRESSION; UP-REGULATION; RAT-BRAIN; CHILDREN; NEURONS; BDNF	Neurotrophins, including brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), neutrotrophin-3 (NT-3), neurotrophin-4 (NT-4). anti beta-nerve growth factor (beta-NGF), play an active role in the development. maintenance and survival of cells of the central nervous system (CNS). Previous research has indicated that a decrease in concentrations of these neurotrophins is often associated with cell death and ultimately patient demise. However, much of the research conducted analyses of samples taken directly from the CNS, ie., of samples that are not readily available in clinical trauma centers. In an attempt to obtain a method for evaluating neurotrophins in a more readily accessible matrix, i.e. serum, a precise and accurate immunoaffinity capillary electrophoresis (ICE) method was developed and applied to measure neurotrophins in serum from patients with various degrees of head injury. The five neurotrophins of interest were extracted and concentrated by specific immunochemically immobilized antibodies. bound directly to the capillary wall, and eluted and separated in approximately 10 min. NT-3, BDNF. CNTF and beta-NGF showed a marked decrease in concentration as the severity of the head injury increased: mild versus severe: 91% decrease tot NT-3; 93 % decrease for BDNF; 93 % decrease for CNTF, and a 87% decrease for beta-NGF. This decrease in concentration is consistent with the neuro-protective roles that neurotrophins play in the maintenance and survival of neuronal cells. The results obtained by the ICE method were closely comparable with those generated by a commercially available ELISA method. Published by Elsevier B V.	[Kalish, Heather; Phillips, Terry M.] Natl Inst Biomed Imaging & Bioengn, Ultramicro Immunodiagnost Sect, Lab Bioengn & Phys Sci, NIH, Bethesda, MD USA		Kalish, H (corresponding author), Natl Inst Biomed Imaging & Bioengn, Ultramicro Immunodiagnost Sect, Lab Bioengn & Phys Sci, NIH, Bldg 13,Room 3E42,13 South Dr, Bethesda, MD USA.				National Institute of Biomedical Imaging and Bioengineering, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [ZIAEB000018] Funding Source: NIH RePORTER	This research was supported by the Intramural Research Program of the National Institute of Biomedical Imaging and Bioengineering, NIH.	Altria KD, 1999, J CHROMATOGR A, V856, P443, DOI 10.1016/S0021-9673(99)00830-4; Benavente F, 2007, ANAL BIOANAL CHEM, V387, P2633, DOI 10.1007/s00216-007-1119-0; Chen HX, 2008, ANAL CHEM, V80, P9583, DOI 10.1021/ac801859e; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chiaretti A, 2008, J TRAUMA, V65, P80, DOI 10.1097/TA.0b013e31805f7036; Chiaretti A, 2008, EUR J PAEDIATR NEURO, V12, P195, DOI 10.1016/j.ejpn.2007.07.016; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Guzman NA, 2008, ELECTROPHORESIS, V29, P3259, DOI 10.1002/elps.200800058; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; Jaworska M, 2009, J PHARMACEUT BIOMED, V50, P90, DOI 10.1016/j.jpba.2009.03.031; Kalish H, 2009, J SEP SCI, V32, P1605, DOI 10.1002/jssc.200900047; Kazanis I, 2004, EXP NEUROL, V186, P221, DOI 10.1016/j.expneurol.2003.12.004; Kim DH, 2005, NEUROCRIT CARE, V3, P71, DOI 10.1385/NCC:3:1:071; Kunnemeyer J, 2009, ELECTROPHORESIS, V30, P1766, DOI [10.1002/elps.200800831, 10.1002/elps.2008-00831]; Lee N, 2005, NEUROSCI LETT, V374, P161, DOI 10.1016/j.neulet.2004.10.048; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Muller A, 2007, BRAIN, V130, P3308, DOI 10.1093/brain/awm257; Pan HC, 2007, J CLIN NEUROSCI, V14, P1089, DOI 10.1016/j.jocn.2006.08.008; Phillips TM, 1997, J CHROMATOGR B, V697, P101, DOI 10.1016/S0378-4347(97)00132-1; Phillips TM, 2004, ELECTROPHORESIS, V25, P1652, DOI 10.1002/elps.200305873; Phillips TM, 2003, BIOMED CHROMATOGR, V17, P182, DOI 10.1002/bmc.240; Phillips TM, 2001, LUMINESCENCE, V16, P145, DOI 10.1002/bio.645.abs; Phillips TM, 1998, ELECTROPHORESIS, V19, P2991, DOI 10.1002/elps.1150191632; PHILLIPS TM, 1992, ANAL TECHNIQUES IMMU; Rost B, 2005, REGUL PEPTIDES, V124, P19, DOI 10.1016/j.regpep.2004.06.024; Royo NC, 2007, NEUROSCIENCE, V148, P359, DOI 10.1016/j.neuroscience.2007.06.014; Royo NC, 2006, EUR J NEUROSCI, V23, P1089, DOI 10.1111/j.1460-9568.2006.04642.x; Shah JP, 2005, J APPL PHYSIOL, V99, P1977, DOI 10.1152/japplphysiol.00419.2005; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; Shetty AK, 2004, J NEUROSCI RES, V78, P520, DOI 10.1002/jnr.20302; Shulga A, 2008, J NEUROSCI, V28, P6996, DOI 10.1523/JNEUROSCI.5268-07.2008; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; Weissinger EM, 2009, MINI-REV MED CHEM, V9, P627, DOI 10.2174/138955709788167583; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yokota H, 2005, NEUROSCI LETT, V377, P170, DOI 10.1016/j.neulet.2004.11.093	40	25	28	1	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232			J CHROMATOGR B	J. Chromatogr. B	JAN 15	2010	878	2			SI		194	200		10.1016/j.jchromb.2009.10.022			7	Biochemical Research Methods; Chemistry, Analytical	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	551PG	WOS:000274220900010	19896422	Green Accepted			2022-02-06	
J	Bie, XD; Han, J; Dai, HB				Bie, Xiao-Dong; Han, Jue; Dai, Hai-Bin			Effects of hydroxysafflor yellow A on the experimental traumatic brain injury in rats	JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH			English	Article						hydroxysafflor yellow A; traumatic brain injury; ATPase; SOD; t-PA; MMP-9	ISCHEMIA-REPERFUSION INJURY; OXIDATIVE STRESS; MITOCHONDRIAL DAMAGE; MECHANISMS; PROTECTS; HEART	This paper explores the effects of hydroxysafflor yellow A (HSYA) on traumatic brain injury (TBI). Rats were divided into four groups: control, TBI, TBI combined with HSYA, and TBI combined with nimodipine. Saline, HSYA, or nimodipine was i.v. injected at 30min before and 6h after the onset of TBI. The contusion volume of brain, mitochondrial ATPase activity, brain malondialdehyde (MDA) content, and the concentrations of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in the blood plasma were investigated. The results showed that the inhibitory rate of HSYA at a dose of 4mg/kg was 59.2% compared with the TBI group. After the insult by TBI for 48h, the activity of Na+, K+-ATPase, Ca2+-ATPase, and Mg2+-ATPase decreased to 31, 35, and 38% of control group. HSYA increased these ATPase activities by 162, 96, and 131% of TBI group. HSYA also increased superoxide dismutase activity and decreased MDA content in the right parietal lobe adjacent to contusion foci in TBI rats. HSYA enhanced the t-PA activity by 64.64%, decreased the PAI-1 activity by 71.88%, and decreased the MMP-9 expression to 49.11% in the hippocampus of the TBI group at 12h. In conclusion, HSYA may exert a potential therapeutic strategy to improve the outcome following TBI injury.	[Dai, Hai-Bin] Zhejiang Univ, Dept Pharm, Affiliated Hosp 2, Coll Med, Hangzhou 310009, Zhejiang, Peoples R China; [Bie, Xiao-Dong] Zhejiang Univ, Dept Tradit Chinese Med, Affiliated Hosp 2, Coll Med, Hangzhou 310009, Zhejiang, Peoples R China; [Han, Jue] Zhanongkou Community Med Care Ctr, Hangzhou 310004, Zhejiang, Peoples R China		Dai, HB (corresponding author), Zhejiang Univ, Dept Pharm, Affiliated Hosp 2, Coll Med, Hangzhou 310009, Zhejiang, Peoples R China.	haibindai@zju.edu.cn		Dai, Haibin/0000-0002-5768-2714	Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [Y207256]; Zhejiang Provincial Scientific Foundation of China [2008C33061]; Zhejiang Province Traditional Chinese Medicine Foundation of China [2004C092, 2008YA021]	This project was supported by grants from the Zhejiang Provincial Natural Science Foundation of China (Y207256), the Zhejiang Provincial Scientific Foundation of China (2008C33061), and the Zhejiang Province Traditional Chinese Medicine Foundation of China (2004C092, 2008YA021).	Anup R, 1999, INDIAN J BIOCHEM BIO, V36, P266; Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; Blaustein M. P., 1977, AM J PHYSIOL, V1, P165; Borges N, 2004, INT J NEUROSCI, V114, P217, DOI 10.1080/00207450490249419; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; CORDIS GA, 1993, J CHROMATOGR, V632, P97, DOI 10.1016/0021-9673(93)80031-3; ENGELKE M, 1992, PHARMACOL TOXICOL, V71, P343, DOI 10.1111/j.1600-0773.1992.tb00559.x; Jang YY, 2000, PHARMACOL RES, V42, P361, DOI 10.1006/phrs.2000.0705; Kohler HP, 2000, NEW ENGL J MED, V342, P1792, DOI 10.1056/NEJM200006153422406; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Liu YN, 2008, CLIN EXP PHARMACOL P, V35, P211, DOI 10.1111/j.1440-1681.2007.04814.x; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh TK, 1996, LAB INVEST, V74, P315; MESELHY MR, 1993, CHEM PHARM BULL, V41, P1796, DOI 10.1248/cpb.41.1796; Seckin Sule, 2001, Research Communications in Molecular Pathology and Pharmacology, V109, P299; Tian JW, 2008, PHARMACOLOGY, V82, P121, DOI 10.1159/000141653; Tian JW, 2005, NEUROSCI LETT, V374, P92, DOI 10.1016/j.neulet.2004.10.030; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wei XB, 2005, NEUROSCI LETT, V386, P58, DOI 10.1016/j.neulet.2005.05.069; Wei YH, 2002, EXP BIOL MED, V227, P671, DOI 10.1177/153537020222700901; Zhu HB, 2005, J ASIAN NAT PROD RES, V7, P607, DOI 10.1080/10286020310001625120; Zhu HB, 2003, PLANTA MED, V69, P429, DOI 10.1055/s-2003-39714	25	25	26	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1028-6020			J ASIAN NAT PROD RES	J. Asian Nat. Prod. Res.		2010	12	3					239	247	PII 920383890	10.1080/10286020903510636			9	Plant Sciences; Chemistry, Applied; Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Plant Sciences; Chemistry; Pharmacology & Pharmacy	594WJ	WOS:000277569900011	20390772				2022-02-06	
J	Cernak, I; Chang, T; Ahmed, FA; Cruz, MI; Vink, R; Stoica, B; Faden, AI				Cernak, Ibolja; Chang, Taeun; Ahmed, Farid A.; Cruz, Maria I.; Vink, Robert; Stoica, Bogdan; Faden, Alan I.			Pathophysiological Response to Experimental Diffuse Brain Trauma Differs as a Function of Developmental Age	DEVELOPMENTAL NEUROSCIENCE			English	Article						Diffuse traumatic brain injury; Brain, immature; Motor deficit; Brain edema	GLUTATHIONE-PEROXIDASE ACTIVITY; FREE MAGNESIUM CONCENTRATION; IMMATURE BRAIN; HEAD-INJURY; MAGNETIC-RESONANCE; ENERGY-METABOLISM; HYPOXIA-ISCHEMIA; AXONAL INJURY; RAT PUPS; MODEL	The purpose of experimental models of traumatic brain injury (TBI) is to reproduce selected aspects of human head injury such as brain edema, contusion or concussion, and functional deficits, among others. As the immature brain may be particularly vulnerable to injury during critical periods of development, and pediatric TBI may cause neurobehavioral deficits, our aim was to develop and characterize as a function of developmental age a model of diffuse TBI (DTBI) with quantifiable functional deficits. We modified a DTBI rat model initially developed by us in adult animals to study the graded response to injury as a function of developmental age - 7-, 14- and 21-day-old rats compared to young adult (3-month-old) animals. Our model caused motor deficits that persisted even after the pups reached adulthood, as well as reduced cognitive performance 2 weeks after injury. Moreover, our model induced prominent edema often seen in pediatric TBI, particularly evident in 7- and 14-day-old animals, as measured by both the wet weight/dry weight method and diffusion-weighted MRI. Blood-brain barrier permeability, as measured by the Evans blue dye technique, peaked at 20 min after trauma in all age groups, with a second peak found only in adult animals at 24 h after injury. Phosphorus MR spectroscopy showed no significant changes in the brain energy metabolism of immature rats with moderate DTBI, in contrast to significant decreases previously identified in adult animals. Copyright (C) 2010 S. Karger AG, Basel	[Cernak, Ibolja; Chang, Taeun; Ahmed, Farid A.; Cruz, Maria I.; Stoica, Bogdan; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Chang, Taeun] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Cernak, Ibolja; Ahmed, Farid A.] Johns Hopkins Univ, Appl Phys Lab, Biomed Business Area, Natl Secur Technol Dept, Laurel, MD USA; [Stoica, Bogdan; Faden, Alan I.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA; [Vink, Robert] Univ Adelaide, Dept Pathol, Adelaide, SA, Australia		Faden, AI (corresponding author), Univ Maryland, Sch Med, STAR Organized Res Ctr, HSF 2,247,20 S Penn St, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	STOICA, BOGDAN/H-9782-2013; Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	STOICA, BOGDAN/0000-0002-2501-6434; Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Chang, Taeun/0000-0002-1797-8449; Ibolja, Cernak/0000-0003-3214-698X			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Ahmed F, 2009, BRAIN BEHAV IMMUN, V23, P355, DOI 10.1016/j.bbi.2008.11.007; Armstead William M, 2005, Pathophysiology, V12, P5, DOI 10.1016/j.pathophys.2005.01.002; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blomgren K, 2003, BIOCHEM BIOPH RES CO, V304, P551, DOI 10.1016/S0006-291X(03)00628-4; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; DEKOSKY ST, 1998, SEMIN CLIN NEUROPSYC, V3, P176; Dennis M, 2000, J COMMUN DISORD, V33, P321, DOI 10.1016/S0021-9924(00)00028-9; Derugin N, 1998, NEUROSCI RES, V32, P349, DOI 10.1016/S0168-0102(98)00096-0; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; DUFFY TE, 1975, J NEUROCHEM, V24, P271, DOI 10.1111/j.1471-4159.1975.tb11875.x; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122, DOI 10.1152/ajplegacy.1949.157.1.122; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1999, MAGNESIUM RES, V12, P269; HIDA K, 1991, MAGNET RESON MED, V22, P128, DOI 10.1002/mrm.1910220113; Li FH, 1996, DRUG TODAY, V32, P615; Liu CL, 2004, NEUROSCIENCE, V127, P113, DOI 10.1016/j.neuroscience.2004.03.062; LUSTYIK G, 1985, SCAN ELECTRON MICROS, P323; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCPHERSON GK, 1980, J BIOMECH, V13, P9, DOI 10.1016/0021-9290(80)90003-2; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Potts Mathew B, 2006, NeuroRx, V3, P143; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Robertson CL, 2004, DEV BRAIN RES, V151, P141, DOI 10.1016/j.devbrainres.2004.04.007; SCHMUED L, 1990, BRAIN RES, V526, P127, DOI 10.1016/0006-8993(90)90258-D; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schuchmann S, 2005, EUR J NEUROSCI, V21, P2721, DOI 10.1111/j.1460-9568.2005.04109.x; SUZUKI N, 1992, MAGNET RESON MED, V24, P205, DOI 10.1002/mrm.1910240202; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Towfighi J, 1998, DEV BRAIN RES, V109, P169, DOI 10.1016/S0165-3806(98)00077-7; Tsuru-Aoyagi K, 2009, ANN NEUROL, V65, P540, DOI 10.1002/ana.21600; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Vink R, 1996, J NEUROCHEM, V66, P2477; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Waters KA, 2004, NEUROSIGNALS, V13, P162, DOI 10.1159/000077523; Yakovlev Alexander G, 2004, NeuroRx, V1, P5, DOI 10.1602/neurorx.1.1.5	49	25	25	2	10	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2010	32	5-6					442	453		10.1159/000320085			12	Developmental Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Developmental Biology; Neurosciences & Neurology	725RO	WOS:000287663900012	20948187				2022-02-06	
J	Hux, K; Bush, E; Zickefoose, S; Holmberg, M; Henderson, A; Simanek, G				Hux, Karen; Bush, Erin; Zickefoose, Samantha; Holmberg, Michelle; Henderson, Ambyr; Simanek, Gina			Exploring the study skills and accommodations used by college student survivors of traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; school reintegration; accommodations; learning strategies	CHILDREN; MILD; ADOLESCENTS; OUTCOMES; SCHOOL; REHABILITATION; CHILDHOOD; SUCCESS; TBI	Primary objective: Survivors of severe traumatic brain injury (TBI) recovering sufficiently to attend post-secondary institutions often display learning skills differing from those of traditional students, because of this, many use formal and informal accommodations and learning strategies to support academic performance and social integration. Professionals know little about how accommodations and learning strategies affect educational experiences of college student survivors, how best to apply accommodations and learning strategies, how much survivors embrace them, the extent to which they facilitate college success or how they evolve over time. The purpose of this study was to explore these issues. Research design: The researchers collected and analysed qualitative data using a multiple case study design. Methods and procedures: Collected data included interviews, artifacts and field notes from four college student survivors, members of their families, college instructors and personnel from institution's offices for students with disabilities. Main outcomes and results: Findings suggest challenges, learning strategies, future perspectives and the need for academic accommodations fluctuate and evolve for many years post-injury. Findings also suggest some survivors perceive their learning capabilities more positively than do others associated with them, leading to questions about whether over-accommodation occurs and the potential negative ramifications associated with this practice.	[Hux, Karen; Bush, Erin; Zickefoose, Samantha; Holmberg, Michelle; Henderson, Ambyr; Simanek, Gina] Univ Nebraska, Barkley Mem Ctr, Lincoln, NE 68583 USA		Hux, K (corresponding author), Univ Nebraska, Barkley Mem Ctr 351, Lincoln, NE 68583 USA.	khux1@unl.edu	Hux, Karen/AAQ-2078-2020; Bush, Erin/I-9606-2016	Bush, Erin/0000-0003-1710-8619	University of Nebraska [26-1710-9001-001]	Funding for this project came in part from the University of Nebraska David Fund, Grant # 26-1710-9001-001.	Arroyos-Jurado E, 2008, INTERV SCH CLIN, V43, P252, DOI 10.1177/1053451208314907; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; BLEIBERG J, 2001, ROAD REHABILITATIO 3; BOULDIN K. V., 2005, ENGL J, V94, P52; Bowen JM, 2005, PREV SCH FAIL, V49, P34, DOI 10.3200/PSFL.49.4.34-41; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; CAVE B. K, 2004, CLEARING HOUSE, V77, P169; Creswell J.W ., 2007, QUAL INQ; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Glang A, 2008, J HEAD TRAUMA REHAB, V23, P243, DOI 10.1097/01.HTR.0000327256.46504.9f; GUBA E, 1988, QUALITATIVE APPROACH, P215; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hux K, 1996, INTERV SCH CLIN, V31, P158, DOI 10.1177/105345129603100305; Lefebvre H, 2005, BRAIN INJURY, V19, P585, DOI 10.1080/02699050400025026; Marschark M, 2000, J HEAD TRAUMA REHAB, V15, P1227, DOI 10.1097/00001199-200012000-00004; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Sohlberg M., 2001, COGNITIVE REHABILITA; Strauss A., 2008, BASICS QUALITATIVE R, DOI 10.1080/13504620500081384.; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Todis B, 2008, J HEAD TRAUMA REHAB, V23, P252, DOI 10.1097/01.HTR.0000327257.84622.bc; Wilbur R, 2007, J CLIN EXP NEUROPSYC, V29, P682, DOI 10.1080/13803390600932120; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Ylvisaker M, 2008, NEUROPSYCHOL REHABIL, V18, P713, DOI 10.1080/09602010802201832; WEFT QDA FREE QUALIT	30	25	25	0	12	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JAN	2010	24	1					13	26		10.3109/02699050903446823			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	554AA	WOS:000274406700002	20001479				2022-02-06	
J	Lajiness-O'Neill, R; Erdodi, L; Bigler, ED				Lajiness-O'Neill, Renee; Erdodi, Laszlo; Bigler, Erin D.			Memory and Learning in Pediatric Traumatic Brain Injury: A Review and Examination of Moderators of Outcome	APPLIED NEUROPSYCHOLOGY			English	Article						learning; memory; outcome; pediatric; traumatic brain injury	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; TEST-CHILDRENS VERSION; WORKING-MEMORY; COGNITIVE REHABILITATION; HEAD-INJURY; 1ST YEAR; PERFORMANCE; RECOVERY; PREDICTORS; MANAGEMENT	This article reviews empirically supported assessment methods to examine impairments in memory and learning following pediatric traumatic brain injury (TBI). Critical factors affecting outcome are explored with an emphasis on an examination of age at injury. The article closes with discussion of current evidence-based interventions for deficits in memory and learning following pediatric TBI.	[Lajiness-O'Neill, Renee; Erdodi, Laszlo] Eastern Michigan Univ, Dept Psychol, Ypsilanti, MI 48197 USA; [Lajiness-O'Neill, Renee] Henry Ford Hlth Syst, Dept Behav Serv, Div Neuropsychol, Detroit, MI USA; [Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA		Lajiness-O'Neill, R (corresponding author), Eastern Michigan Univ, Dept Psychol, 537 F Mark Jefferson, Ypsilanti, MI 48197 USA.	rlajines@emich.edu					Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Alexander AI, 2005, ARCH CLIN NEUROPSYCH, V20, P587, DOI 10.1016/j.acn.2004.12.005; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Beddeley AD., 1974, PSYCHOL LEARN MOTIV, V8, P47, DOI [DOI 10.1016/S0079-7421(08)60452-1, 10.1016/S0079-7421(08)60452-1]; Bigler ED, 1996, J LEARN DISABIL, V29, P512, DOI 10.1177/002221949602900506; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Chambless DL, 1998, J CONSULT CLIN PSYCH, V66, P7, DOI 10.1037/0022-006X.66.1.7; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coffey C. E., 1998, TXB PEDIAT NEUROPSYC, P1093; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Delis DC., 1994, CALIFORNIA VERBAL LE; Donders J, 2004, J INT NEUROPSYCH SOC, V10, P482, DOI 10.1017/S1355617704104025; Donders J, 2007, PEDIATRIC NEUROPSYCHOLOGICAL INTERVENTION: A CRITICAL REVIEW OF SCIENCE AND PRACTICE, P91; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; FLETCHER JM, 1985, J EXP CHILD PSYCHOL, V40, P244, DOI 10.1016/0022-0965(85)90088-8; Glang A, 2008, J HEAD TRAUMA REHAB, V23, P243, DOI 10.1097/01.HTR.0000327256.46504.9f; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; Gonzalez-Rothi L. J., 2006, J INT NEUROPSYCH SOC, V21, P812; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; Graham DI, 2001, BRAIN, V124, P1261, DOI 10.1093/brain/124.7.1261; Guthrie E, 1999, CHILD ADOL PSYCH CL, V8, P807; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; Jin C, 2004, CNS SPECTRUMS, V9, P217, DOI 10.1017/S1092852900009019; Kibby M, 2008, CHILD NEUROPSYCHOL, V14, P525, DOI 10.1080/09297040701821752; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Limond J, 2005, J CHILD PSYCHOL PSYC, V46, P339, DOI 10.1111/j.1469-7610.2004.00397.x; Lowther JL, 2004, ARCH CLIN NEUROPSYCH, V19, P105, DOI 10.1016/S0887-6177(02)00222-6; Mandalis A, 2007, DEV NEUROPSYCHOL, V32, P683, DOI 10.1080/87565640701376045; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; Melton AK, 2005, APHASIOLOGY, V19, P353, DOI 10.1080/02687030444000804; Mottram L, 2006, DEV NEUROPSYCHOL, V30, P865, DOI 10.1207/s15326942dn3003_6; Nelson J E, 2002, Pediatr Rehabil, V5, P37, DOI 10.1080/1363849021000007088; Paniak C, 1997, CLIN NEUROPSYCHOL, V11, P198, DOI 10.1080/13854049708407051; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Rey A., 1964, EXAMEN CLIN PSYCHOL; REYNOLDS C. R., 2007, TEST MEMORY LEARNING; Reynolds C.R., 1994, TEST MEMORY LEARNING; Riccio CA, 2007, APPL NEUROPSYCHOL, V14, P255, DOI 10.1080/09084280701719203; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; SCHACTER DL, 2000, J CLIN EXPT NEUROPSY, V8, P727; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sheslow D., 1990, WIDE RANGE ASSESSMEN; Sheslow DA, 2003, WIDE RANGE ASSESSMEN; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Verger K, 2000, BRAIN INJURY, V14, P495; Ward H, 2002, J CLIN EXP NEUROPSYC, V24, P458, DOI 10.1076/jcen.24.4.458.1032; Ward H, 2007, CHILD NEUROPSYCHOL, V13, P219, DOI 10.1080/09297040600910003; WILSON BA, 1993, J CLIN EXP NEUROPSYC, V15, P474, DOI 10.1080/01688639308402572; Wilson BA, 1991, RIVERMEAD BEHAV MEMO; Woodward H, 1998, APPL NEUROPSYCHOL, V5, P113, DOI 10.1207/s15324826an0503_1; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009	74	25	25	1	9	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2010	17	2					83	92	PII 922182556	10.1080/09084281003708837			10	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	596CX	WOS:000277662800002	20467947				2022-02-06	
J	Pahatouridis, D; Alexiou, GA; Zigouris, A; Mihos, E; Drosos, D; Voulgaris, S				Pahatouridis, Dimitrios; Alexiou, George A.; Zigouris, Andreas; Mihos, Evaggelos; Drosos, Dimitrios; Voulgaris, Spyridon			Coagulopathy in moderate head injury. The role of early administration of low molecular weight heparin	BRAIN INJURY			English	Article						Moderate head injury; coagulopathy; disseminated intravascular coagulation; low molecular weight heparin; Intravascular microthrombosis; deep venous thrombosis	DISSEMINATED INTRAVASCULAR COAGULATION; BRAIN-INJURY; TRAUMA; SYSTEM	Introduction: Abnormalities in blood coagulation are relatively common after traumatic brain injury (TBI). We prospectively studied the safety of the early antithrombotic prophylaxis with low molecular weight heparin. Methods: We prospectively evaluated 61 patients with moderate TBI. Patients requiring surgical treatment and/or with injuries in other systems were excluded. Coagulation studies included among others prothrombin time (PT), plasma fibrinogen levels and D-dimer levels. Blood samples were collected on admission and 24 h, 48 h, and 72 h later. Prophylaxis was started within 24 hours with tinzaparin. Results: In 42 of 61 patients a form of disseminated intravascular coagulation (DIC) was detected. The severity of head injury was correlated with the severity of the coagulation disorders. The PT was prolonged in the first two days. Plasma fibrinogen levels dropped initially and increased to above normal values 2-3 days later. D-dimer levels were significantly elevated and in 19 patients remained elevated throughout the study period. Clinical manifestations of DIC were not observed. Conclusions: Patients with moderate TBI are at a serious risk of developing brain intravascular microthrombosis. Our study supports the early use of low molecular weight heparin.	[Pahatouridis, Dimitrios; Alexiou, George A.; Zigouris, Andreas; Mihos, Evaggelos; Drosos, Dimitrios; Voulgaris, Spyridon] Univ Hosp Ioannina, Dept Neurosurg, Ioannina, Greece		Alexiou, GA (corresponding author), Aetideon 52, Holargos 11561, Attikis, Greece.	alexiougrg@yahoo.gr	Alexiou, George A/B-3995-2012	Alexiou, George A/0000-0003-0257-4481			AUER L, 1978, ACTA NEUROCHIR, V43, P51, DOI 10.1007/BF01809225; BROWD SR, 2004, PROPHYLAXIS DEEP VEN, V17; GRAHAM DI, 1971, LANCET, V1, P265; Haagh W A J J M, 2006, Ned Tijdschr Geneeskd, V150, P2530; Hess JR, 2006, J TRAUMA, V60, pS12, DOI 10.1097/01.ta.0000199545.06536.22; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; KARRICK MM, 2005, J TRAUMA, V58, P725; Keller M S, 2001, Semin Pediatr Surg, V10, P12, DOI 10.1053/spsu.2001.19381; Kleindienst A, 2003, ACTA NEUROCHIR, V145, P1085, DOI 10.1007/s00701-003-0142-y; May AK, 1997, AM SURGEON, V63, P233; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; REILLY P, 2005, HEAD INJURY PATHOPHY; Sawauchi S, 2001, NEUROL SURG TOKYO, V29, P131; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327, DOI 10.1055/s-0037-1616068; WAFAISADE A, 2009, NEUROCRIT CARE  1006	18	25	27	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	10					1189	1192		10.3109/02699052.2010.490510			4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	667MJ	WOS:000283197100005	20642324				2022-02-06	
J	Ptyushkin, P; Vidmar, G; Burger, H; Marincek, C				Ptyushkin, Pavel; Vidmar, Gaj; Burger, Helena; Marincek, Crt			Use of the International Classification of Functioning, Disability and Health (ICF) in patients with traumatic brain injury	BRAIN INJURY			English	Article						ICF; traumatic brain injury; rehabilitation; linking rules	CORE SETS; REHABILITATION; LINKING; QUESTIONNAIRE; PARTICIPATION; LIMITATIONS; VALIDATION; DISORDERS; PROFILES	Introduction: Many tools exist for assessing the functioning of a patient with traumatic brain injury. Possible benefits of the ICF in TBI rehabilitation are currently under discussion. Goal: The study explored to what extend the ICF is useful to organize existing clinical information and to retrospectively evaluate the effect of interventions in patients with TBI. Method: A retrospective patient record study was conducted. Medical records of 100 patients admitted to the Slovenian University Rehabilitation Institute from 2007-2009 were linked to the ICF. Results: The majority of the functional problems at the level of body functions corresponded to mental and movement-related functions. Within the list of activities and participation, the patients experienced more difficulties in tasks that require intellectual effort, communicational ability, mobility and self-care. The ICF detected substantial improvement after rehabilitation regarding body functions and activities related to mobility and self-care and little improvement regarding mental functions and related activities. Some important environmental factors were also identified. Conclusions: The translation of the information about functioning into the ICF format provided a well-structured functional profile of the selected group of patients in a language-independent format. ICF also clearly outlined the environmental factors important for the recovery and functioning.	[Ptyushkin, Pavel; Vidmar, Gaj; Burger, Helena; Marincek, Crt] Univ Rehabil Inst, European Project MURINET, Ljubljana, Slovenia; [Ptyushkin, Pavel] Univ Lucerne, Dept Hlth Sci & Hlth Policy, Nottwil, Switzerland; [Ptyushkin, Pavel] Swiss Parapleg Res SPF, Nottwil, Switzerland		Ptyushkin, P (corresponding author), Univ Rehabil Inst, European Project MURINET, Ljubljana, Slovenia.	pavel.ptyushkin@yandex.ru	Vidmar, Gaj/H-5950-2011	Vidmar, Gaj/0000-0002-5682-3124			Alachini B, 2010, EUR J PHYS REHAB MED, V46, P27; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Bernabeu M, 2009, NEUROREHAB NEURAL RE, V23, P464, DOI 10.1177/1545968308328725; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; CAMERON ID, 2009, APPL ICF ASSESSMENT; Cieza A, 2005, J REHABIL MED, V37, P212, DOI 10.1080/16501970510040263; Cieza A, 2002, J REHABIL MED, V34, P205, DOI 10.1080/165019702760279189; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Ehrenfors R, 2009, DISABIL REHABIL, V31, P1392, DOI 10.1080/09638280802621366; Fries W, 2008, REHABILITATION, V47, P265, DOI 10.1055/s-2008-1081473; Grill E, 2006, AM J PHYS MED REHAB, V85, P640, DOI 10.1097/01.phm.0000228537.17239.7f; *I PUBL HLTH REP S, BOLN OBR ZAR POSK ZA; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Koskinen S, 2007, J REHABIL MED, V39, P467, DOI 10.2340/16501977-0077; Larkins Brigette, 2007, Seminars in Speech and Language, V28, P334, DOI 10.1055/s-2007-986530; Leonardi M, 2009, INT J REHABIL RES, V32, P167, DOI 10.1097/MRR.0b013e32831e4587; Post MWM, 2008, J REHABIL MED, V40, P620, DOI 10.2340/16501977-0223; PTYUSHKIN P, 2009, REHABILITACIJA, V8, P49; RAGGI A, 2010, INT J REHABILITATION; Raggi A, 2010, INT J REHABIL RES, V33, P225, DOI 10.1097/MRR.0b013e3283375e53; Raggi A, 2009, INT J REHABIL RES, V32, P148, DOI 10.1097/MRR.0b013e32831e4573; Scarponi F, 2009, DISABIL REHABIL, V31, pS134, DOI 10.3109/09638280903317906; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265; 2007, ZDRAVSTVENI STAT LET	25	25	29	1	25	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	13-14					1519	1527		10.3109/02699052.2010.523054			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	691QV	WOS:000285096800001	20973629				2022-02-06	
J	Ramkumar, NA; Elliott, TR				Ramkumar, Neeta A.; Elliott, Timothy R.			Family caregiving of persons following neurotrauma: Issues in research, service and policy	NEUROREHABILITATION			English	Article						Caregivers; neurotrauma; spinal cord injury; brain injury; rehabilitation	PROBLEM-SOLVING ABILITIES; PUBLIC-HEALTH; BRAIN-INJURY; INTERVENTION; ADJUSTMENT; BEHAVIOR; QUALITY; BURDEN; IMPACT	Family caregivers of persons following neurotrauma function as de facto extensions of our health care system. Their challenges may result in negative consequences for their physical and mental health, which directly impacts the well-being of their care-recipient. In this paper, we survey current practices in providing caregiver support, outline considerations for developing collaborative interventions, and make recommendations for assessing intervention effectiveness consistent with the nature of the adjustment processes among caregivers and care recipients.	[Elliott, Timothy R.] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77845 USA		Elliott, TR (corresponding author), Texas A&M Univ, Dept Educ Psychol, 4225 TAMU, College Stn, TX 77845 USA.	telliott@tamu.edu	Elliott, Timothy R./I-5301-2012	Elliott, Timothy R./0000-0002-6608-7714	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD037661] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000191] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD37661, R01 HD037661] Funding Source: Medline; NCIPC CDC HHS [R49/CE000191, R49 CE000191] Funding Source: Medline		BERRY JW, 2009, NAT VIOL INJ PREV RE, P11; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; CARTER R, 2008, PREVENTING CHRONIC D, V5, P1; Chwalisz K., 2010, HDB REHABILITATION P, P301; D'Zurilla T.J., 1999, PROBLEM SOLVING THER, V2nd edn; *DEP HLTH HUM SERV, 2005, SURG GEN WORKSH WOM; Donelan K, 2001, WOMEN HEALTH ISS, V11, P185, DOI 10.1016/S1049-3867(01)00080-9; Elliott TR, 2009, BEHAV RES THER, V47, P548, DOI 10.1016/j.brat.2009.03.006; Elliott TR, 2009, J CLIN PSYCHOL, V65, P406, DOI 10.1002/jclp.20527; Elliott TR, 1999, REHABIL PSYCHOL, V44, P104, DOI 10.1037/0090-5550.44.1.104; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Gitlin LN, 2003, PSYCHOL AGING, V18, P361, DOI 10.1037/0882-7974.18.3.361; Glass TA, 2006, SOC SCI MED, V62, P1650, DOI 10.1016/j.socscimed.2005.08.044; Hayes AM, 2007, CLIN PSYCHOL REV, V27, P715, DOI 10.1016/j.cpr.2007.01.008; Horowitz A, 1985, Annu Rev Gerontol Geriatr, V5, P194; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; Kosciulek JF, 2000, J DISABIL POLICY STU, V11, P82, DOI DOI 10.1177/104420730001100204; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; Kurylo MF, 2001, J COUNS DEV, V79, P275, DOI 10.1002/j.1556-6676.2001.tb01972.x; Kwok OM, 2008, REHABIL PSYCHOL, V53, P370, DOI 10.1037/a0012765; Lollar DJ, 2003, ANNU REV PUBL HEALTH, V24, P195, DOI 10.1146/annurev.publhealth.24.100901.140844; Lollar D, 2008, REHABIL PSYCHOL, V53, P122, DOI 10.1037/0090-5550.53.2.122; Mechanic D, 1998, MILBANK Q, V76, P281, DOI 10.1111/1468-0009.00089; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Sander A. M., 2005, REHABILITATION TRAUM, P156; Sander AM, 2009, J HEAD TRAUMA REHAB, V24, P248, DOI 10.1097/HTR.0b013e3181ad593a; Schulz R, 2009, REHABIL PSYCHOL, V54, P1, DOI 10.1037/a0014932; Shewchuk R, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P553, DOI 10.1037/10361-026; Stull DE, 2008, QUAL LIFE RES, V17, P47, DOI 10.1007/s11136-007-9290-5; Talley RC, 2007, AM J PUBLIC HEALTH, V97, P224, DOI 10.2105/AJPH.2004.059337; US Department of Health and Human Services, 2000, HLTH PEOPL 2010; Vitaliano PP, 2004, CURR DIR PSYCHOL SCI, V13, P13, DOI 10.1111/j.0963-7214.2004.01301004.x; Vitaliano PP, 2003, PSYCHOL BULL, V129, P946, DOI 10.1037/0033-2909.129.6.946; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2006, REHABIL PSYCHOL, V51, P179, DOI 10.1037/0090-5550.51.3.179	38	25	26	1	9	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	27	1					105	112		10.3233/NRE-2010-0585			8	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	629GA	WOS:000280182000010	20634605	Green Accepted			2022-02-06	
J	Redpath, SJ; Williams, WH; Hanna, D; Linden, MA; Yates, P; Harris, A				Redpath, S. J.; Williams, W. H.; Hanna, D.; Linden, M. A.; Yates, P.; Harris, A.			Healthcare professionals' attitudes towards traumatic brain injury (TBI): The influence of profession, experience, aetiology and blame on prejudice towards survivors of brain injury	BRAIN INJURY			English	Article						Attitudes; traumatic brain injury; healthcare professionals; prejudice; helping behaviour	AUTOBIOGRAPHICAL MEMORY; STAFFS PERCEPTIONS; PERCEIVED STIGMA; ATTRIBUTIONS; PERSONALITY; PREDICTORS; SEVERITY; EMOTION; NURSES	Primary objective: To investigate the attitudes of healthcare professionals towards individuals with traumatic brain injury (TBI) and their relationship to intended healthcare behaviour. Research design: An independent groups design utilized four independent variables; aetiology, group, blame and gender to explore attitudes towards survivors of brain injury. The dependent variables were measured using the Prejudicial Evaluation and Social Interaction Scale (PESIS) and Helping Behaviour Scale (HBS). Methods and procedures: A hypothetical vignette based methodology was used. Four hundred and sixty participants (131 trainee nurses, 94 qualified nurses, 174 trainee doctors, 61 qualified doctors) were randomly allocated to one of six possible conditions. Main outcomes and results: Regardless of aetiology, if an individual is to blame for their injury, qualified healthcare professionals have more prejudicial attitudes than those entering the profession. There is a significant negative relationship between prejudice and helping behaviour for qualified healthcare professionals. Conclusions: Increased prejudicial attitudes of qualified staff are related to a decrease in intended helping behaviour, which has the potential to impact negatively on an individual's recovery post-injury.	[Redpath, S. J.] Abertawe Bro Morgannwg Univ Hlth Board, Cymru, Wales; [Williams, W. H.] Univ Exeter, Sch Psychol, Exeter, Devon, England; [Hanna, D.] Queens Univ Belfast, Sch Psychol, Belfast BT7 1NN, Antrim, North Ireland; [Linden, M. A.] Queens Univ Belfast, Nursing & Midwifery Res Unit, Belfast BT7 1NN, Antrim, North Ireland; [Yates, P.; Harris, A.] Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England		Redpath, SJ (corresponding author), Morriston Hosp, Dept Neuropsychol, Swansea SA6 6NL, W Glam, Wales.	simon.redpath@abm-tr.wales.nhs.uk	Linden, Mark/L-7754-2019	Linden, Mark/0000-0002-3832-4102; Hanna, Donncha/0000-0003-3382-4842; williams, huw/0000-0003-0670-2620	Economic and Social Research Council (ESRC)UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [res 062 23 0135]; ESRCUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/E002692/1] Funding Source: UKRI; Economic and Social Research CouncilUK Research & Innovation (UKRI)Economic & Social Research Council (ESRC) [ES/E002692/1] Funding Source: researchfish	W. H. Williams was supported by a grant from Economic and Social Research Council (ESRC) res 062 23 0135.	Bessell AL, 2008, J INT NEUROPSYCH SOC, V14, P63, DOI 10.1017/S1355617708080065; Cohen J., 2013, STAT POWER ANAL BEHA; Corrigan PW, 1999, AM PSYCHOL, V54, P765, DOI 10.1037/0003-066X.54.9.765; Doyal Len, 2006, Int J Surg, V4, P146, DOI 10.1016/j.ijsu.2006.06.023; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; FRANKS JA, 2002, BRIT J CLIN GOVERNAN, V7, P34; Hair JF, 1995, MULTIVARIATE DATA AN; Haslam S.A., 2001, PSYCHOL ORG SOCIAL I; HOPCUTT B, 2008, NATL SERVICE FRAMEWO; Jahoda A, 2005, J INTELL DISABIL RES, V49, P544, DOI 10.1111/j.1365-2788.2005.00693.x; KELLY JA, 1987, J MED EDUC, V62, P549; Linden MA, 2007, ARCH CLIN NEUROPSYCH, V22, P665, DOI 10.1016/j.acn.2007.04.009; Linden MA, 2005, BRAIN INJURY, V19, P1011, DOI 10.1080/02699050500110314; Mackay N, 2005, BRIT J CLIN PSYCHOL, V44, P255, DOI 10.1348/014466505X29620; Mallery P., 2003, SPSS WINDOWS STEP ST, V4th; MANCHESTER D, 2006, BRAIN INJURY, V20, P1029; Markham D, 2003, BRIT J CLIN PSYCHOL, V42, P243, DOI 10.1348/01446650360703366; McClure J, 2008, BRAIN INJURY, V22, P639, DOI 10.1080/02699050802255585; McClure J, 2006, BRAIN INJURY, V20, P1029, DOI 10.1080/02699050600909870; McKinlay A, 2001, J ADV NURS, V34, P107, DOI 10.1046/j.1365-2648.2001.3411728.x; McManus IC, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-29; Perlick DA, 2001, PSYCHIAT SERV, V52, P1613, DOI 10.1176/appi.ps.52.12.1613; Perlick DA, 2001, PSYCHIAT SERV, V52, P1627, DOI 10.1176/appi.ps.52.12.1627; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Redpath SJ, 2004, BRAIN INJURY, V18, P861, DOI 10.1080/02699050410001671838; REDPATH SJ, 2008, THESIS QUEENS U BELF; Sirey JA, 2001, PSYCHIAT SERV, V52, P1615, DOI 10.1176/appi.ps.52.12.1615; Stewart D, 1999, J ADV NURS, V30, P740, DOI 10.1046/j.1365-2648.1999.01140.x; Weigel L, 2006, BRIT J CLIN PSYCHOL, V45, P205, DOI 10.1348/014466505X67510; WEINER B, 1985, PSYCHOL REV, V92, P548, DOI 10.1037/0033-295X.92.4.548; Weiner B., 1986, ATTRIBUTION THEORY M; Williams WH, 1998, NEUROPSYCHOL REHABIL, V8, P43, DOI 10.1080/713755551; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1016/S0960-9822(02)01374-X, 10.1080/09602010244000444]; Williams WH, 1999, NEUROPSYCHOL REHABIL, V9, P421, DOI 10.1080/096020199389482; WRIGHT SG, 2005, NURSING STAND, V19, P46	35	25	25	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	6					802	811		10.3109/02699051003709623			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	620MT	WOS:000279504700002	20455671				2022-02-06	
J	Singh, S; Hota, D; Prakash, A; Khanduja, KL; Arora, SK; Chakrabarti, A				Singh, Surjit; Hota, Debasish; Prakash, Ajay; Khanduja, Krishan L.; Arora, Sunil K.; Chakrabarti, Amitava			Allopregnanolone, the active metabolite of progesterone protects against neuronal damage in picrotoxin-induced seizure model in mice	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						Progesterone; Allopregnanolone picrotoxin; Seizures; Indomethacin; DNA fragmentation; 5-alpha reductase	AMYGDALA-KINDLED SEIZURES; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; HIPPOCAMPAL-NEURONS; CELL-DEATH; ANTICONVULSANT ACTIVITY; GABA(A) RECEPTORS; FEMALE RATS; APOPTOSIS; KAINATE	Progesterone exerts anti-seizure effect against several chemoconvulsants. However, there is no published report on the interaction between progesterone and picrotoxin (M). The present study evaluated the effects of progesterone and its active metabolite, allopregnanolone against PTX-induced seizures, brain lipid peroxidation and DNA fragmentation in male mice. Finasteride, a 5 alpha-reductase inhibitor and indomethacin, an inhibitor of 3 infinity-hydroxysteroid dehydrogenase were assessed against progesterone's effects on PTX-induced seizures, brain lipid peroxidation and DNA fragmentation. M produced clonic-tonic seizures in mice with CD50 and CD97 of 2.4 and 4.0 mg/kg, i.p. respectively. Progesterone significantly countered PTX-induced seizures, with ED50 of 78.30 mg/kg and ED97 of 200 mg/kg. Progesterone antagonized M-induced DNA fragmentation. Finasteride (200 mg/kg) and indomethacin (1 mg/kg) reversed the anti-seizure and anti-DNA fragmentation effects of progesterone. Allopregnanolone, also protected against M-induced seizures and DNA fragmentation. There was no significant change in the brain lipid peroxidation parameters in any of the treatment groups. It may be concluded that progesterone protects against M-induced seizures and DNA fragmentation through its active metabolites allopregnanolone and 5 alpha-pregnan-3,20-dione. However, it appears from the present study that, the neuroprotection with progesterone is primarily on account of allopregnalone. The therapeutic potential of allopregnanolone deserves to be evaluated clinically. (C) 2009 Elsevier Inc. All rights reserved.	[Singh, Surjit; Hota, Debasish; Prakash, Ajay; Chakrabarti, Amitava] Postgrad Inst Med Educ & Res, Dept Pharmacol, Chandigarh 160012, India		Chakrabarti, A (corresponding author), PGIMER, Dept Pharmacol 4046, PN Chuttani Block, Chandigarh 160012, India.	amitavachakrabarti315@yahoo.com		SINGH, SURJIT/0000-0002-8990-3235			Acharya MM, 2005, INDIAN J CLIN BIOCHE, V20, P56, DOI 10.1007/BF02893043; Aggarwal R, 2008, J PHARM PHARMACOL, V60, P731, DOI 10.1211/jpp.60.6.0008; Auger CJ, 2002, J NEUROENDOCRINOL, V14, P561, DOI 10.1046/j.1365-2826.2002.00809.x; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; FILIPKOWSKI RK, 1994, NEUROREPORT, V5, P1538, DOI 10.1097/00001756-199407000-00032; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; GIORGI O, 1991, EUR J PHARMACOL, V193, P363, DOI 10.1016/0014-2999(91)90152-G; Guerra-Araiza C, 2003, J NEUROENDOCRINOL, V15, P984, DOI 10.1046/j.1365-2826.2003.01088.x; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; HETMAN M, 1995, EXP NEUROL, V136, P53, DOI 10.1006/exnr.1995.1083; Hoffman GE, 2003, EXP NEUROL, V182, P124, DOI 10.1016/S0014-4886(03)00104-3; Ibanez C, 2003, ENDOCRINOLOGY, V144, P2902, DOI 10.1210/en.2002-0073; Kokate TG, 1999, J PHARMACOL EXP THER, V288, P679; KONO Y, 1978, ARCH BIOCHEM BIOPHYS, V186, P189, DOI 10.1016/0003-9861(78)90479-4; Lambert JJ, 2003, PROG NEUROBIOL, V71, P67, DOI 10.1016/j.pneurobio.2003.09.001; LANDGREN S, 1987, ACTA PHYSIOL SCAND, V131, P33, DOI 10.1111/j.1748-1716.1987.tb08202.x; Leonhardt SA, 2003, STEROIDS, V68, P761, DOI 10.1016/S0039-128X(03)00129-6; LITCHFIELD ST, 1949, J PHARMACOL EXP THER, V96, P99; Lonsdale D, 2007, NEUROSCI LETT, V411, P147, DOI 10.1016/j.neulet.2006.10.023; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LuCK H., 1963, VERLAG CHEMIE, P885; Mackenzie L, 2002, CLIN NEUROPHYSIOL, V113, P586, DOI 10.1016/S1388-2457(02)00040-8; NICOLETTI F, 1985, EPILEPSIA, V26, P252, DOI 10.1111/j.1528-1157.1985.tb05414.x; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pistritto G, 2009, EXP NEUROL, V217, P302, DOI 10.1016/j.expneurol.2009.03.008; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; Reddy DS, 2004, J PHARMACOL EXP THER, V310, P230, DOI 10.1124/jpet.104.065268; Rhodes ME, 2005, EPILEPSY BEHAV, V6, P320, DOI 10.1016/j.yebeh.2005.02.006; Rogawski MA, 2004, EPILEPSY SCI FDN CLI, P319; Sambrook J., 2003, MOL CLONING LAB MANU; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; SMITH SS, 1987, BRAIN RES, V422, P52, DOI 10.1016/0006-8993(87)90539-7; Velisek L, 2006, MODELS OF SEIZURES AND EPILEPSY, P127, DOI 10.1016/B978-012088554-1/50013-X; Willingham MC, 1999, J HISTOCHEM CYTOCHEM, V47, P1101, DOI 10.1177/002215549904700901; Zhang LX, 1998, MOL BRAIN RES, V55, P198, DOI 10.1016/S0169-328X(97)00316-1	39	25	25	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	JAN	2010	94	3					416	422		10.1016/j.pbb.2009.10.003			7	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	551RK	WOS:000274226500013	19840816				2022-02-06	
J	Nagel, A; Graetz, D; Vajkoczy, P; Sarrafzadeh, AS				Nagel, Alexandra; Graetz, Daniela; Vajkoczy, Peter; Sarrafzadeh, Asita S.			Decompressive Craniectomy in Aneurysmal Subarachnoid Hemorrhage: Relation to Cerebral Perfusion Pressure and Metabolism	NEUROCRITICAL CARE			English	Article						Subarachnoid hemorrhage; Decompressive craniectomy; Intracranial hypertension; Microdialysis; Cerebral metabolism	TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE; TISSUE OXYGEN; MICRODIALYSIS; HEMICRANIECTOMY; ISCHEMIA; EDEMA; HYPERTENSION	Outcome is poor in aneurysmal subarachnoid hemorrhage (SAH) patients with intracranial hypertension. As one treatment option for increased intracranial pressure (ICP), decompressive craniectomy (DC) is discussed. Its impact on cerebral metabolism and outcome in SAH patients is evaluated in this pilot study. A prospectively collected database of cerebral metabolism in SAH patients was analyzed retrospectively for individuals developing high ICP (> 20 mmHg > 6 h/day, n = 18). Patients with intracranial hypertension were classified into groups with (n = 7) and without DC (n = 11). An age-matched control group was established (n = 89). Cerebral perfusion pressure (CPP) and high ICP treatment were analyzed for 7 days after SAH (or 72 h after craniectomy, respectively). Cerebral microdialysates were analyzed hourly. Twelve-month outcome was evaluated. Groups were comparable for age, WFNS grade, and outcome. ICP was significantly reduced by DC (P < 0.01), however, in 43% of patients the effect was transient. An increase in the lactate/pyruvate ratio (P < 0.001) and glycerol levels (> 200 mu M) was observed before DC. In the DC group, glucose (P = 0.005) and pyruvate (P = 0.04) were higher, while glycerol levels were lower (P = 0.007) compared to the non-DC group, reflecting better aerobic glucose utilization and reduced cellular stress. Outcome was poor in all SAH patients with intracranial hypertension. Although glucose utilization was improved after DC, no improvement in outcome could be shown for this small patient population. Future studies will have to demonstrate whether markers of cerebral crisis may support the decision for DC in aneurysmal SAH patients.	[Sarrafzadeh, Asita S.] Charite Univ Med Berlin, Charite Campus Virchow Med Ctr, Clin Neurosurg, D-13353 Berlin, Germany; [Nagel, Alexandra; Graetz, Daniela; Vajkoczy, Peter; Sarrafzadeh, Asita S.] Charite Univ Med Berlin, Dept Neurosurg, D-13353 Berlin, Germany		Sarrafzadeh, AS (corresponding author), Charite Univ Med Berlin, Charite Campus Virchow Med Ctr, Clin Neurosurg, Augustenburger Pl 1, D-13353 Berlin, Germany.	alexandra.nagel@charite.de; asita.sarrafzadeh@charite.de					BAILES JE, 1990, J NEUROSURG, V72, P559, DOI 10.3171/jns.1990.72.4.0559; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Boret H, 2006, ACTA ANAESTH SCAND, V50, P252, DOI 10.1111/j.1399-6576.2005.00862.x; Brunner E., 2002, NONPARAMETRIC ANAL L; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; D'Ambrosio AL, 2005, NEUROSURGERY, V56, P12, DOI 10.1227/01.NEU.0000144820.38439.63; DRAKE CG, 1988, J NEUROSURG, V68, P985; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Heuer GG, 2004, J NEUROSURG, V101, P408, DOI 10.3171/jns.2004.101.3.0408; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Jaeger M, 2005, ACT NEUR S, V95, P117; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; JENNETT B, 1975, LANCET, V1, P480; Kilincer C, 2005, CLIN NEUROL NEUROSUR, V107, P412, DOI 10.1016/j.clineuro.2004.09.018; Lanzino G, 1999, J NEUROSURG, V90, P1018, DOI 10.3171/jns.1999.90.6.1018; LeRoux PD, 1996, NEUROSURGERY, V38, P887, DOI 10.1097/00006123-199605000-00006; Marion DW, 2004, CRIT CARE MED, V32, pS43, DOI 10.1097/01.CCM.0000110731.69637.16; Mitka M, 2001, JAMA-J AM MED ASSOC, V286, P2084, DOI 10.1001/jama.286.17.2084; Nagel A, 2009, J NEUROSURG, V111, P94, DOI 10.3171/2009.1.JNS08587; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Sarrafzadeh A, 2003, STROKE, V34, P1382, DOI 10.1161/01.STR.0000074036.97859.02; Sarrafzadeh AS, 2004, STROKE, V35, P638, DOI 10.1161/01.STR.0000116101.66624.F1; Sarrafzadeh AS, 2002, ACTA NEUROCHIR SUPPL, V81, P319; Schirmer CM, 2007, STROKE, V38, P987, DOI 10.1161/01.STR.0000257962.58269.e2; Scozzafava J, 2007, NEUROCRIT CARE, V6, P49, DOI 10.1385/NCC:6:1:49; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Strege RJ, 2003, NEUROL RES, V25, P510, DOI 10.1179/016164103101201742; TEASDALE G, 1974, LANCET, V2, P81; Tseng MY, 2006, NEUROSURG FOCUS, V21, pE10, DOI DOI 10.3171/F0C.2006.21.3.10; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Ziai WC, 2003, J NEUROSURG ANESTH, V15, P25, DOI 10.1097/00008506-200301000-00005	34	25	25	0	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2009	11	3					384	394		10.1007/s12028-009-9269-x			11	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	521SH	WOS:000271943800015	19714498				2022-02-06	
J	van 't Ent, D; van Beijsterveldt, CEM; Derks, EM; Hudziak, JJ; Veltman, DJ; Todd, RD; Boomsma, DI; De Geus, EJC				van 't Ent, D.; van Beijsterveldt, C. E. M.; Derks, E. M.; Hudziak, J. J.; Veltman, D. J.; Todd, R. D.; Boomsma, D. I.; De Geus, E. J. C.			NEUROIMAGING OF RESPONSE INTERFERENCE IN TWINS CONCORDANT OR DISCORDANT FOR INATTENTION AND HYPERACTIVITY SYMPTOMS	NEUROSCIENCE			English	Article						functional MRI; Stroop task; flanker task; ADHD; genetic risk; environmental risk	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; OPERATING CHARACTERISTIC ANALYSIS; DOPAMINE TRANSPORTER GENOTYPE; CHILD-BEHAVIOR CHECKLIST; PURE CONDUCT DISORDER; CLOSED-HEAD INJURY; BRAIN ABNORMALITIES; SUSTAINED ATTENTION; UNAFFECTED SIBLINGS; STRIATAL ACTIVATION	Attention deficit hyperactivity disorder (ADHD) is to a large extent influenced by genetic factors, but environmental influences are considered important as well. To distinguish between functional brain changes underlying primarily genetically and environmentally mediated ADHD, we used functional magnetic resonance imaging (fMRI) to compare response interference in monozygotic twins highly concordant or discordant for attention problems (AP). AP scores were assessed longitudinally with the Child Behavior Check List attention problem scale (CBCL-AP). Response interference was measured during two executive function paradigms; a color-word Stroop and a flanker task. The neuroimaging results indicated that, across the entire sample, children with high CBCL-AP scores, relative to children with low CBCL-AP scores, showed decreased activation to response interference in dorsolateral prefrontal, parietal and temporal brain regions. Increased activation was noted in the premotor cortex and regions associated with visual selective attention processing, possibly reflecting compensatory mechanisms to maintain task performance. Specific comparisons of high and low scoring concordant twin pairs suggest that AP of genetic origin was characterized by decreased activation of the left dorsolateral prefrontal cortex during the Stroop task and right parietal lobe during the flanker task. In contrast, comparison of twins from discordant monozygotic pairs, suggests that AP of environmental origin was characterized by decreased activation in left and right temporal lobe areas, but only during Stroop interference. The finding of distinct brain activation changes to response interference in inattention/hyperactivity of "genetic" versus "environmental" origin, indicates that genetic and environmental risk factors for attention/hyperactivity problems affect the brain in different ways. (C) 2009 IBRO. Published by Elsevier Ltd. All rights reserved.	[van 't Ent, D.; van Beijsterveldt, C. E. M.; Hudziak, J. J.; Boomsma, D. I.; De Geus, E. J. C.] Vrije Univ Amsterdam, Dept Biol Psychol, NL-1081 BT Amsterdam, Netherlands; [Derks, E. M.] Univ Med Ctr Utrecht, Dept Psychiat, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands; [Hudziak, J. J.] Univ Vermont, Dept Psychiat, Burlington, VT USA; [Veltman, D. J.] Vrije Univ Amsterdam Med Ctr, Dept Psychiat, Amsterdam, Netherlands; [Veltman, D. J.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Todd, R. D.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA		van 't Ent, D (corresponding author), Vrije Univ Amsterdam, Dept Biol Psychol, Boechorststr 1, NL-1081 BT Amsterdam, Netherlands.	d.vant.ent@psy.vu.nl	Boomsma, Dorret I/AAX-4470-2020; de Geus, Eco J.C./M-9318-2015; Derks, Eske M/A-1652-2017	de Geus, Eco J.C./0000-0001-6022-2666; Derks, Eske M/0000-0002-6292-6883; van 't Ent, Dennis/0000-0003-2001-1375; van Beijsterveldt, Toos/0000-0002-6617-4201	NWO/SPINetherlands Organization for Scientific Research (NWO) [56-464-14192]; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RO1 MH58799-03]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 MH66148-01]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH058799, R21MH066148] Funding Source: NIH RePORTER	We thank Hanne Lehn, Niels van Strien, Hester van den Akker and Marit de Haas for help with MRI data collection. Funded by NWO/SPI 56-464-14192; NIMH, RO1 MH58799-03; NIH R21 MH66148-01.	ACHENBACH TM, 1991, MONOGR SOC RES CHILD, V56, pR5; Achenbach TM, 2003, J CLIN CHILD ADOLESC, V32, P328, DOI 10.1207/S15374424JCCP3203_02; American Psychiatric Association, 1994, DIAGN STAT MAN DIS D; Arend I, 2008, BRAIN, V131, P2140, DOI 10.1093/brain/awn135; Auerbach JG, 2001, PSYCHIATR GENET, V11, P31, DOI 10.1097/00041444-200103000-00006; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Bhutta AT, 2001, TRENDS NEUROSCI, V24, P129, DOI 10.1016/S0166-2236(00)01747-1; Boomsma D, 2002, NAT REV GENET, V3, P872, DOI 10.1038/nrg932; Boomsma DI, 2002, TWIN RES, V5, P401, DOI 10.1375/136905202320906174; Booth JR, 2005, J CHILD PSYCHOL PSYC, V46, P94, DOI 10.1111/j.1469-7610.2004.00337.x; Brieber S, 2007, J CHILD PSYCHOL PSYC, V48, P1251, DOI 10.1111/j.1469-7610.2007.01799.x; Brookes K, 2006, MOL PSYCHIATR, V11, P934, DOI 10.1038/sj.mp.4001869; Brookes KJ, 2006, ARCH GEN PSYCHIAT, V63, P74, DOI 10.1001/archpsyc.63.1.74; Buitelaar J K, 2000, Ned Tijdschr Geneeskd, V144, P1716; Bush G, 2005, BIOL PSYCHIAT, V57, P1273, DOI 10.1016/j.biopsych.2005.01.034; Bush G, 1999, BIOL PSYCHIAT, V45, P1542, DOI 10.1016/S0006-3223(99)00083-9; Cao QJ, 2008, BRAIN RES, V1219, P159, DOI 10.1016/j.brainres.2008.04.028; Carmona S, 2005, NEUROSCI LETT, V389, P88, DOI 10.1016/j.neulet.2005.07.020; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; Castellanos FX, 2003, AM J PSYCHIAT, V160, P1693, DOI 10.1176/appi.ajp.160.9.1693; CHEN WJ, 1994, J CONSULT CLIN PSYCH, V62, P1017, DOI 10.1037/0022-006X.62.5.1017; Constable RT, 2004, NEUROIMAGE, V22, P11, DOI 10.1016/j.neuroimage.2004.01.001; Derks EM, 2006, COMPR PSYCHIAT, V47, P116, DOI 10.1016/j.comppsych.2005.05.006; Derks EM, 2008, BEHAV GENET, V38, P11, DOI 10.1007/s10519-007-9178-8; Dickstein SG, 2006, J CHILD PSYCHOL PSYC, V47, P1051, DOI 10.1111/j.1469-7610.2006.01671.x; Doyle AE, 2006, J CLIN PSYCHIAT, V67, P21; Durston S, 2005, MOL PSYCHIATR, V10, P678, DOI 10.1038/sj.mp.4001649; Durston S, 2004, J AM ACAD CHILD PSY, V43, P332, DOI 10.1097/00004583-200403000-00016; Durston S, 2003, MENT RETARD DEV D R, V9, P184, DOI 10.1002/mrdd.10079; Durston S, 2003, BIOL PSYCHIAT, V53, P871, DOI 10.1016/S0006-3223(02)01904-2; Durston S, 2008, J AM ACAD CHILD PSY, V47, P61, DOI 10.1097/chi.0b013e31815a5f17; Durston S, 2006, BIOL PSYCHIAT, V60, P1062, DOI 10.1016/j.biopsych.2005.12.020; Ellison-Wright I, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-51; Ent DV, 2007, NEUROIMAGE, V35, P1004, DOI 10.1016/j.neuroimage.2007.01.037; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Fassbender C, 2006, CLIN PSYCHOL REV, V26, P445, DOI 10.1016/j.cpr.2006.01.003; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; Gerring J, 2000, BRAIN INJURY, V14, P205; Giedd JN, 2001, ANN NY ACAD SCI, V931, P33; Goldman LS, 1998, JAMA-J AM MED ASSOC, V279, P1100, DOI 10.1001/jama.279.14.1100; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Hill DE, 2003, NEUROPSYCHOLOGY, V17, P496, DOI 10.1037/0894-4105.17.3.496; Homack S, 2004, ARCH CLIN NEUROPSYCH, V19, P725, DOI 10.1016/j.acn.2003.09.003; Hudziak JJ, 2004, J CHILD PSYCHOL PSYC, V45, P1299, DOI 10.1111/j.1469-7610.2004.00314.x; Hudziak JJ, 2000, J AM ACAD CHILD PSY, V39, P469, DOI 10.1097/00004583-200004000-00016; Hudziak JJ, 2005, AM J PSYCHIAT, V162, P1614, DOI 10.1176/appi.ajp.162.9.1614; Huizink AC, 2006, NEUROSCI BIOBEHAV R, V30, P24, DOI 10.1016/j.neubiorev.2005.04.005; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; Kahn RS, 2003, J PEDIATR-US, V143, P104, DOI 10.1016/S0022-3476(03)00208-7; Kates WR, 2002, PSYCHIAT RES-NEUROIM, V116, P63, DOI 10.1016/S0925-4927(02)00066-5; Konrad K, 2006, BIOL PSYCHIAT, V59, P643, DOI 10.1016/j.biopsych.2005.08.013; Krain AL, 2006, CLIN PSYCHOL REV, V26, P433, DOI 10.1016/j.cpr.2006.01.005; Lansbergen MM, 2007, NEUROPSYCHOLOGY, V21, P251, DOI 10.1037/0894-4105.21.2.251; Lasky-Su J, 2008, AM J MED GENET B, V147B, P1345, DOI 10.1002/ajmg.b.30867; Leh SE, 2008, INT J BIOMED IMAGING, V2008, DOI 10.1155/2008/789539; Lehn H, 2007, J AM ACAD CHILD PSY, V46, P83, DOI 10.1097/01.chi.0000242244.00174.d9; Linnet KM, 2003, AM J PSYCHIAT, V160, P1028, DOI 10.1176/appi.ajp.160.6.1028; Lou HC, 2004, DEV MED CHILD NEUROL, V46, P179; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2002, J AM ACAD CHILD PSY, V41, P563, DOI 10.1097/00004583-200205000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P443, DOI 10.1097/01.chi.0000156661.38576.0f; Mulder MJ, 2008, J AM ACAD CHILD PSY, V47, P68, DOI 10.1097/chi.0b013e31815a56dc; Mullane JC, 2009, CHILD NEUROPSYCHOL, V15, P321, DOI 10.1080/09297040802348028; Neuman RJ, 1999, J AM ACAD CHILD PSY, V38, P25, DOI 10.1097/00004583-199901000-00016; Overmeyer S, 2001, PSYCHOL MED, V31, P1425, DOI 10.1017/S0033291701004706; Peterson BS, 2000, ARCH GEN PSYCHIAT, V57, P364, DOI 10.1001/archpsyc.57.4.364; Powell AL, 1997, NEUROPSY NEUROPSY BE, V10, P151; Qiu AQ, 2009, AM J PSYCHIAT, V166, P74, DOI 10.1176/appi.ajp.2008.08030426; Rietveld MJH, 2004, J CHILD PSYCHOL PSYC, V45, P577, DOI 10.1111/j.1469-7610.2004.00247.x; Rietveld MJH, 2003, AM J MED GENET B, V117B, P102, DOI 10.1002/ajmg.b.10024; Rubia K, 1999, AM J PSYCHIAT, V156, P891, DOI 10.1176/ajp.156.6.891; Rubia K, 2008, AM J PSYCHIAT, V165, P889, DOI 10.1176/appi.ajp.2008.07071084; Rubia K, 2009, AM J PSYCHIAT, V166, P83, DOI 10.1176/appi.ajp.2008.08020212; Schubert R, 2005, PEDIATR NEUROL, V32, P1, DOI 10.1016/j.pediatrneurol.2004.06.007; Seidman LJ, 2005, BIOL PSYCHIAT, V57, P1263, DOI 10.1016/j.biopsych.2004.11.019; Semrud-Clikeman M, 2000, J AM ACAD CHILD PSY, V39, P477, DOI 10.1097/00004583-200004000-00017; Sergeant JA, 2002, BEHAV BRAIN RES, V130, P3, DOI 10.1016/S0166-4328(01)00430-2; SHAFFER D, 1993, J AM ACAD CHILD PSY, V32, P643, DOI 10.1097/00004583-199305000-00023; Shaw P, 2007, P NATL ACAD SCI USA, V104, P19649, DOI 10.1073/pnas.0707741104; Shaw P, 2007, ARCH GEN PSYCHIAT, V64, P921, DOI 10.1001/archpsyc.64.8.921; Smith AB, 2008, J CHILD PSYCHOL PSYC, V49, P977, DOI 10.1111/j.1469-7610.2008.01870.x; Smith AB, 2006, AM J PSYCHIAT, V163, P1044, DOI 10.1176/appi.ajp.163.6.1044; Sowell ER, 2003, LANCET, V362, P1699, DOI 10.1016/S0140-6736(03)14842-8; Stins JF, 2005, CHILD NEUROPSYCHOL, V11, P191, DOI 10.1080/092970490911351; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Tamm L, 2004, J AM ACAD CHILD PSY, V43, P1430, DOI 10.1097/01.chi.0000140452.51205.8d; Thapar A, 1999, BRIT J PSYCHIAT, V174, P105, DOI 10.1192/bjp.174.2.105; Vaidya CJ, 2005, AM J PSYCHIAT, V162, P1605, DOI 10.1176/appi.ajp.162.9.1605; Valera EM, 2007, BIOL PSYCHIAT, V61, P1361, DOI 10.1016/j.biopsych.2006.06.011; van Mourik R, 2005, J CHILD PSYCHOL PSYC, V46, P150, DOI 10.1111/j.1469-7610.2004.00345.x; Vance A, 2007, MOL PSYCHIATR, V12, P826, DOI 10.1038/sj.mp.4001999; Verhulst F, 1996, HANDLEIDING CBCL 4 1; Wait JWV, 2002, J TROP PEDIATRICS, V48, P294, DOI 10.1093/tropej/48.5.294; Wang HX, 2007, PEPTIDES, V28, P547, DOI 10.1016/j.peptides.2006.10.006; Wascher E, 1999, J COGNITIVE NEUROSCI, V11, P214, DOI 10.1162/089892999563346; Willemssen R, 2004, PSYCHOPHYSIOLOGY, V41, P762, DOI 10.1111/j.1469-8986.2004.00201.x; ZAMETKIN AJ, 1990, NEW ENGL J MED, V323, P1361, DOI 10.1056/NEJM199011153232001; Zang YF, 2005, BRAIN DEV-JPN, V27, P544, DOI 10.1016/j.braindev.2004.11.009; Zhu CZ, 2008, NEUROIMAGE, V40, P110, DOI 10.1016/j.neuroimage.2007.11.029	100	25	25	0	16	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	NOV 24	2009	164	1			SI		16	29		10.1016/j.neuroscience.2009.01.056			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	517JI	WOS:000271609000003	19409224	Green Accepted			2022-02-06	
J	MacNevin, CJ; Atif, F; Sayeed, I; Stein, DG; Liotta, DC				MacNevin, Christopher J.; Atif, Fahim; Sayeed, Iqbal; Stein, Donald G.; Liotta, Dennis C.			Development and Screening of Water-Soluble Analogues of Progesterone and Allopregnanolone in Models of Brain Injury	JOURNAL OF MEDICINAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MALE-RATS; CORTICAL CONTUSION; CONTROLLED-TRIAL; HEAD-INJURY; FEMALE RATS; CELL-DEATH; EDEMA; EXPRESSION; INDUCTION	Preclinical and clinical research findings have revealed that the hormone progesterone, when acutely administered, can dramatically reduce cerebral edema, inflammation, tissue necrosis, and programmed cell death following traumatic brain injury (TBI). The poor aqueous solubility of progesterone, however, limits its potential use as a therapeutic. Several chemically novel analogues of progesterone and its natural metabolite allopregnanolone have been synthesized and screened using both in vitro and whole animal models of TBI. The new derivatives demonstrated greatly improved solubility and select compounds have shown equivalent effectiveness to progesterone in reducing cerebral edema after TBI.	[MacNevin, Christopher J.; Liotta, Dennis C.] Emory Univ, Dept Chem, Atlanta, GA 30322 USA; [Atif, Fahim; Sayeed, Iqbal; Stein, Donald G.] Emory Univ, Sch Med, Dept Emergency Med, Brain Res Lab, Atlanta, GA 30322 USA		Liotta, DC (corresponding author), Emory Univ, Dept Chem, 1515 Dickey Dr,Emerson Bldg Room 403, Atlanta, GA 30322 USA.	dliotta@emory.edu	Stein, Donald/AAJ-5139-2020		Department of DefenseUnited States Department of Defense	We thank the Department of Defense for funding support.	ADEOTI SB, 1989, TETRAHEDRON, V45, P3717, DOI 10.1016/S0040-4020(01)89233-4; Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; Alderson P, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001048.pub2, DOI 10.1002/14651858.CD001048.PUB2]; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; BACH G, 1968, CAN J CHEMISTRY, V46, P733, DOI 10.1139/v68-123; Brann DW, 2005, NEUROENDOCRINOLOGY, V81, P120, DOI 10.1159/000086405; Chan JR, 1998, P NATL ACAD SCI USA, V95, P10459, DOI 10.1073/pnas.95.18.10459; CHAO TC, 1994, AM J REPROD IMMUNOL, V32, P43, DOI 10.1111/j.1600-0897.1994.tb00877.x; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Comin MJ, 2004, TETRAHEDRON, V60, P11851, DOI 10.1016/j.tet.2004.09.097; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Davies A R, 2005, Crit Care Resusc, V7, P238; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Finkelstein E., 2006, INCIDENCE EC BURDEN; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Guo QM, 2006, EXP NEUROL, V198, P469, DOI 10.1016/j.expneurol.2005.12.013; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; KHOURI N, 1991, J PHARM SCI-US, V80, P661, DOI 10.1002/jps.2600800710; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; LUCHE JL, 1978, J CHEM SOC CHEM COMM, P601, DOI 10.1039/c39780000601; LUCHE JL, 1978, J AM CHEM SOC, V100, P2226, DOI 10.1021/ja00475a040; MANCERA O, 1953, J AM CHEM SOC, V75, P1286, DOI 10.1021/ja01102a006; Mani SK, 2006, NEUROSCIENCE, V138, P773, DOI 10.1016/j.neuroscience.2005.07.034; Marin-Husstege M, 2004, DEV NEUROSCI-BASEL, V26, P245, DOI 10.1159/000082141; Marmarou A, 2006, ACTA NEUROCHIR SUPPL, V96, P24; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Pierson RC, 2005, MOL BRAIN RES, V138, P105, DOI 10.1016/j.molbrainres.2004.10.047; PURDY RH, 1990, J MED CHEM, V33, P1572, DOI 10.1021/jm00168a008; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Shen H, 2005, NEUROPHARMACOLOGY, V49, P573, DOI 10.1016/j.neuropharm.2005.04.026; Shimamura K, 1995, J REPROD FERTIL, V105, P253, DOI 10.1530/jrf.0.1050253; Sim FJ, 2002, J NEUROSCI, V22, P2451, DOI 10.1523/JNEUROSCI.22-07-02451.2002; SOLOWAY AH, 1953, J AM CHEM SOC, V75, P2356, DOI 10.1021/ja01106a020; SUBRAMANIAN M, 1993, NEUROSCI LETT, V155, P151, DOI 10.1016/0304-3940(93)90695-H; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; VanLandingham JW, 2006, NEUROPHARMACOLOGY, V51, P1078, DOI 10.1016/j.neuropharm.2006.07.015; VARASI M, 1987, J ORG CHEM, V52, P4235, DOI 10.1021/jo00228a016; Verkman AS, 2000, EXP PHYSIOL, V85, p233S, DOI 10.1111/j.1469-445X.2000.tb00028.x; WIELAND P, 1950, HELV CHIM ACTA, V33, P2215, DOI 10.1002/hlca.19500330730; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	62	25	35	1	20	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0022-2623	1520-4804		J MED CHEM	J. Med. Chem.	OCT 8	2009	52	19					6012	6023		10.1021/jm900712n			12	Chemistry, Medicinal	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Pharmacology & Pharmacy	501EF	WOS:000270361600023	19791804				2022-02-06	
J	Sherer, M; Yablon, SA; Nakase-Richardson, R				Sherer, Mark; Yablon, Stuart A.; Nakase-Richardson, Risa			Patterns of Recovery of Posttraumatic Confusional State in Neurorehabilitation Admissions After Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Confusion; Rehabilitation	HEAD-INJURY; AMNESIA; SCALE; ORIENTATION; SEVERITY	Objective: To provide preliminary descriptions of patterns of resolution of symptoms of acute confusion after traumatic brain injury (TBI). Design: Prospective, descriptive, cohort Study. Setting: Inpatient neurorehabilitation unit. Participants: Patients (N=107) meeting criteria for posttraumatic confusional state at admission to inpatient rehabilitation. Interventions: Not applicable. Main Outcome Measure: Patterns of resolution of posttraumatic confusional state symptoms over the first 3 confusion assessment protocol evaluations for patients with mild, moderate, and severe confusion. Results: Posttraumatic confusional state symptoms resolving earliest were psychotic-type symptoms, decreased daytime arousal, and nighttime sleep disturbance. Fluctuation and cognitive impairment were the 2 most persistent symptoms. Seventy-three percent of patients showed improvement of I or more symptoms from the first to third evaluation. Confusion severity groups did not significantly differ on indices of injury severity (Glasgow Coma Scale score, time to follow commands) but did differ on functional status at discharge from inpatient rehabilitation. Conclusions: While posttraumatic confusional state is a heterogeneous disorder, there is a predictable pattern of symptom resolution. Differences in patients' confusion severity and patterns of symptoms may relate to differing underlying neural injury.	[Sherer, Mark] TIRR Mem Hermann, Dept Res, Houston, TX 77030 USA; [Sherer, Mark] Baylor Coll Med, Houston, TX 77030 USA; [Yablon, Stuart A.] Methodist Rehabil Ctr, Jackson, MS USA; [Nakase-Richardson, Risa] James A Haley Vet Affairs Med Ctr, Tampa, FL USA		Sherer, M (corresponding author), TIRR Mem Hermann, Dept Res, 1333 Moursund, Houston, TX 77030 USA.	Mark.Sherer@memorialhermann.org			U.S. Department of Education National Institute on Disability and Rehabilitation ResearchUS Department of Education [H133A020514, H133A070043]	Supported by the U.S. Department of Education National Institute on Disability and Rehabilitation Research (grant nos. H133A020514 and H133A070043).	CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; ELLENBERG JH, 1996, ARCH NEUROL-CHICAGO, V53, P792; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; NAKASERICHARDSO.R, 2006, J INT NEUROPSYCHO S1, V12, P215; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sherer M, 2008, ARCH PHYS MED REHAB, V89, P42, DOI 10.1016/j.apmr.2007.08.128; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Weir N, 2006, BRAIN INJURY, V20, P927, DOI 10.1080/02699050600832684	13	25	25	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2009	90	10					1749	1754		10.1016/j.apmr.2009.05.011			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	507UA	WOS:000270879400016	19801066				2022-02-06	
J	Su, ZJ; Han, DD; Sun, B; Qiu, JH; Li, Y; Li, M; Zhang, T; Yang, Z				Su, Zhangjie; Han, Dadong; Sun, Bo; Qiu, Jiaheng; Li, Ying; Li, Mu; Zhang, Tao; Yang, Zhuo			Heat Stress Preconditioning Improves Cognitive Outcome after Diffuse Axonal Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; heat shock protein; heat stress; learning and memory	LONG-TERM POTENTIATION; TRAUMATIC BRAIN-INJURY; MORRIS WATER MAZE; SHOCK PRETREATMENT; HIPPOCAMPUS; SCOPOLAMINE; INDUCTION; PROTEIN; MEMORY	This study investigates the influence of heat stress preconditioning on cognitive outcome for rats with diffuse axonal injury (DAI), and attempts to examine the underlying mechanisms. Wistar rats were divided into four groups: rats subjected to heat stress preconditioning 24 h before induction of DAI (n = 10; HSDAI group), a DAI alone group (n = 10), a heat stress alone group (n = 10), and a sham-injury group (n = 10). From day 14 post-injury, the rats' learning abilities and memory were tested using the Morris water maze (MWM) task, followed by long-term potentiation (LTP) recording of the hippocampus. In addition, hematoxylin and eosin staining (H&E) and immunohistochemical staining (IHC) were conducted to determine the presence of brain lesions and expression of heat shock protein 70 (HSP70) at 24 h, and on days 14 and 20 post-injury. The rats in the DAI group displayed impaired MWM performance and attenuated LTP compared to the sham group (p<0.05); the rats in the HSDAI and HS groups showed significant improvement in both MWM and LTP compared with the DAI group (p<0.05), and no significant differences with the sham group (p>0.05). Following injury, retraction balls, shrunken neurons, and HSP70 expression were visible in the brains of rats from the DAI and HSDAI groups; recovery was expedited in the rats belonging to the HSDAI group, as these pathological changes were alleviated, coincident with higher expression of HSP70. The rats' abilities for learning and memory were impaired following DAI; this may be due to the disconnection of brain regions, damage to neurons in the hippocampus, and a decrease in synaptic plasticity. Heat stress preconditioning is able to significantly attenuate this cognitive impairment, possibly mediated by the neuroprotective effect of HSP70.	[Yang, Zhuo] Nankai Univ, Sch Med, Neurophysiol Lab, Tianjin 300071, Peoples R China; [Qiu, Jiaheng; Zhang, Tao] Nankai Univ, Minist Educ, Key Lab Bioact Mat, Coll Life Sci, Tianjin 300071, Peoples R China; [Li, Mu] Tianjin First Cent Hosp, Dept Neurosurg, Tianjin, Peoples R China		Yang, Z (corresponding author), Nankai Univ, Sch Med, Neurophysiol Lab, 94 Weijin Rd, Tianjin 300071, Peoples R China.	zhuoyang@nankai.edu.cn			Municipal Science Foundation Research of Tianjin [06YFJMJC09400]; National Basic Research Program of ChinaNational Basic Research Program of China [2007CB914803]	This work was partly supported by the Municipal Science Foundation Research of Tianjin ( no. 06YFJMJC09400 to Z.Y.), and the National Basic Research Program of China ( no. 2007CB914803 to T.Z.). We thank Dr. Alexander Gerhard for his expert editorial review of this manuscript.	Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cernak I, 2004, NEUROBIOL DIS, V17, P29, DOI 10.1016/j.nbd.2004.05.011; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Gerges NZ, 2004, J NEUROSCI, V24, P4758, DOI 10.1523/JNEUROSCI.0594-04.2004; Hung CH, 2004, NEUROSCI LETT, V364, P63, DOI 10.1016/j.neulet.2004.02.074; Kelty JD, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0004.2002; Leggio MG, 2006, BRAIN RES BULL, V70, P347, DOI 10.1016/j.brainresbull.2006.06.006; [李峰 Li Feng], 2005, [中华创伤杂志, Chinese Journal of Trauma], V21, P254; LI Y, 2008, CHIN J CONT NEUROL N, V8, P75; Lin YW, 2004, BRAIN RES, V999, P222, DOI 10.1016/j.brainres.2003.11.057; Lynch MA, 2004, PHYSIOL REV, V84, P87, DOI 10.1152/physrev.00014.2003; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miyamoto E, 2006, J PHARMACOL SCI, V100, P433, DOI 10.1254/jphs.CPJ06007X; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Myhrer T, 2003, BRAIN RES REV, V41, P268, DOI 10.1016/S0165-0173(02)00268-0; Okada T, 2003, EUR J NEUROSCI, V17, P341, DOI 10.1046/j.1460-9568.2003.02458.x; Pal J, 2006, J NEUROSCI METH, V153, P283, DOI 10.1016/j.jneumeth.2005.11.004; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; Sato K, 2002, NEUROSCIENCE, V109, P745, DOI 10.1016/S0306-4522(01)00494-8; SU ZJ, 2008, J BRAIN NERV DIS, V16, P153; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5	23	25	26	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2009	26	10					1695	1706		10.1089/neu.2008.0519			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	507CT	WOS:000270829200008	19785543				2022-02-06	
J	Frederick, RI; Bowden, SC				Frederick, Richard I.; Bowden, Stephen C.			The Test Validation Summary	ASSESSMENT			English	Article						psychological testing; malingering; predictive power; test utilities	MEMORY MALINGERING TOMM; TRAUMATIC BRAIN-INJURY; MIXED GROUP VALIDATION; BASE-RATE PROBLEM; STRUCTURED INVENTORY; HEAD-INJURY; NEUROCOGNITIVE DYSFUNCTION; CLASSIFICATION ACCURACY; COGNITIVELY INTACT; DIAGNOSTIC SIGNS	Common rates employed in classificatory testing are the true positive rate (TPR), false positive rate (FPR), positive predictive power (PPP), and negative predictive power (NPP). FPR and TPR are estimated from research samples representing populations to be distinguished by classificatory testing. PPP and NPP are used by clinicians to classify test takers into populations. PPP and NPP depend on the base rate (BR) of population members in the clinician's sample. The authors introduce the test validation summary (TVS) as a means to report within a single graph the FPR and TPR and the ranges of PPP and NPP across all potential sample BRs for any chosen cut score. The authors investigate how the TVS has other applications, including the estimation of local BR for the condition of interest and the estimation of standard errors for FPR and TPR when estimated across multiple independent validation studies of the classificatory test.	[Frederick, Richard I.] US Med Ctr Fed Prisoners, Dept Psychol, Springfield, MO 65807 USA; [Bowden, Stephen C.] Univ Melbourne, Melbourne, Vic 3010, Australia		Frederick, RI (corresponding author), US Med Ctr Fed Prisoners, Dept Psychol, 1900 W Sunshine St, Springfield, MO 65807 USA.	rickfrederick@gmail.com					Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; BALDESSARINI RJ, 1983, ARCH GEN PSYCHIAT, V40, P569; Bolan B, 2002, J CLIN EXP NEUROPSYC, V24, P154, DOI 10.1076/jcen.24.2.154.1000; Bowden SC, 1998, NEUROPSYCHOL REHABIL, V8, P243, DOI 10.1080/713755573; BROWN GW, 1976, AM J DIS CHILD, V130, P56, DOI 10.1001/archpedi.1976.02120020058009; Cohen J., 2013, STAT POWER ANAL BEHA; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Cragar DE, 2006, CLIN NEUROPSYCHOL, V20, P552, DOI 10.1080/13854040590947380; DAWES RM, 1967, J CLIN PSYCHOL, V23, P403, DOI 10.1002/1097-4679(196710)23:4<403::AID-JCLP2270230402>3.0.CO;2-N; DAWES RM, 1966, PSYCHOL BULL, V66, P63, DOI 10.1037/h0023584; Delain SL, 2003, ASSESSMENT, V10, P370, DOI 10.1177/1073191103259156; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; Duncan A, 2005, ASSESSMENT, V12, P123, DOI 10.1177/1073191105275512; Edens JF, 1999, J AM ACAD PSYCHIATRY, V27, P387; ELWOOD RW, 1993, CLIN PSYCHOL REV, V13, P409, DOI 10.1016/0272-7358(93)90012-B; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Fleiss J.L., 1981, STAT METHODS RATES P; Frederick R. I., 1991, PSYCHOL ASSESSMENT J, V3, P596, DOI DOI 10.1037/1040-3590.3.4.596; Frederick RI, 2000, BEHAV SCI LAW, V18, P693, DOI 10.1002/bsl.432; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gierok SD, 2005, ARCH CLIN NEUROPSYCH, V20, P755, DOI 10.1016/j.acn.2005.04.008; GREEN P, 2007, DETECTION NONCREDIBL, P50; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Griner P F, 1981, Ann Intern Med, V94, P557; Haber AH, 2006, CLIN NEUROPSYCHOL, V20, P524, DOI 10.1080/13854040590967595; Hill S. K., 2003, J FORENSIC NEUROPSYC, P1, DOI [10.1300/J151v03n03_01, DOI 10.1300/J151V03N03_01]; HLATKY MA, 1984, AM J MED, V77, P64, DOI 10.1016/0002-9343(84)90437-6; Lewis JL, 2002, PSYCHOL ASSESSMENT, V14, P170, DOI 10.1037//1040-3590.14.2.170; McCaffrey R.J., 2003, J FORENSIC NEUROPSYC, V3, P45, DOI [https://doi.org/10.1300/J151v03n03_03, DOI 10.1300/J151V03N03_03]; MEEHL PE, 1955, PSYCHOL BULL, V52, P194, DOI 10.1037/h0048070; Merckelbach H, 2003, ARCH CLIN NEUROPSYCH, V18, P145, DOI 10.1016/S0887-6177(01)00191-3; Miller H.A., 2001, MILLER FORENSIC ASSE; Mitrushina M., 2005, HDB NORMATIVE DATA N, V2nd; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Moss A, 2003, BRAIN INJURY, V17, P377, DOI 10.1080/0269905031000070125; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, V3; O'Bryant SE, 2003, CLIN NEUROPSYCHOL, V17, P69, DOI 10.1076/clin.17.1.69.15624; O'Bryant SE, 2006, CLIN NEUROPSYCHOL, V20, P533, DOI 10.1080/13854040590967568; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rogers R, 2004, PSYCHOL ASSESSMENT, V16, P139, DOI 10.1037/1040-3590.16.2.139; Rogers R., 1992, STRUCTURED INTERVIEW; ROGERS R, 2004, EVALUATION COMPETENC; ROHLING ML, 2007, DETECTION NONCREDIBL, P453; RORER LG, 1982, J CONSULT CLIN PSYCH, V50, P419, DOI 10.1037/0022-006X.50.3.419; Rosenfeld B, 2000, ARCH CLIN NEUROPSYCH, V15, P349, DOI 10.1016/S0887-6177(99)00025-6; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; SOPER HV, 1988, J CLIN EXP NEUROPSYC, V10, P255, DOI 10.1080/01688638808408240; Straus SE., 2005, EVIDENCE BASED MED P, V3rd; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481; Widows M. R., 2005, STRUCTURED INVENTORY; Wilkinson L, 1999, AM PSYCHOL, V54, P594, DOI 10.1037/0003-066X.54.8.594; Woods SP, 2003, J CLIN EXP NEUROPSYC, V25, P431, DOI 10.1076/jcen.25.3.431.13800; Zakzanis KK, 1998, J CLIN EXP NEUROPSYC, V20, P419, DOI 10.1076/jcen.20.3.419.821; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	64	25	26	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911			ASSESSMENT	Assessment	SEP	2009	16	3					215	236		10.1177/1073191108325005			22	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	482YS	WOS:000268927400001	18838580				2022-02-06	
J	Levy, A; Bercovich-Kinori, A; Alexandrovich, AG; Tsenter, J; Trembovler, V; Lund, FE; Shohami, E; Stein, R; Mayo, L				Levy, Ayelet; Bercovich-Kinori, Adi; Alexandrovich, Alexander G.; Tsenter, Jeanna; Trembovler, Victoria; Lund, Frances E.; Shohami, Esther; Stein, Reuven; Mayo, Lior			CD38 Facilitates Recovery from Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						CD38; head trauma; microglia	CLOSED-HEAD-INJURY; CYCLIC ADP-RIBOSE; NEURONAL CELL-DEATH; OBJECT RECOGNITION; IN-VIVO; T-CELL; REACTIVE ASTROCYTES; SIGNAL-TRANSDUCTION; COGNITIVE DEFICITS; RESIDENT MICROGLIA	Traumatic brain injury (TBI) is a major cause of death and disability worldwide. It causes progressive tissue atrophy and consequent neurological dysfunctions. TBI is accompanied by neuroinflammation, a process mediated largely by microglia. CD38 is an ectoenzyme that promotes transmembrane signaling via the synthesis of potent calcium mobilizing agents or via its receptor activity. CD38 is expressed in the brain in various cell types including microglia. In previous studies, we showed that CD38 regulates microglial activation and response to chemokines. In view of the important role of neuroinflammation in TBI and the effects of CD38 on microglial responses, the present study examines the role of CD38 in the recovery of mice from closed head injury (CHI), a model of focal TBI. For this purpose, CD38-deficient and wild-type (WT) mice were subjected to a similar severity of CHI and the effect of the injury on neurobehavioral and cognitive functions was assessed by the Neurological Severity Score (NSS) and the Object Recognition Test, at various time points post-injury. The results show that recovery after CHI (as indicated by the NSS) was significantly lower in CD38-deficient mice than in WT mice and that the object recognition performance after injury was significantly impaired in injured CD38-deficient mice than in WT mice. In addition, we also observed that the amount of activated microglia/macrophages at the injury site was significantly lower in CD38-deficient mice compared with WT mice. Taken together, our findings indicate that CD38 plays a beneficial role in the recovery of mice from CHI and that this effect is mediated, at least in part, via the effect of CD38 on microglia responses.	[Levy, Ayelet; Bercovich-Kinori, Adi; Stein, Reuven; Mayo, Lior] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiol, IL-69978 Ramat Aviv, Israel; [Alexandrovich, Alexander G.; Tsenter, Jeanna; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel; [Lund, Frances E.] Univ Rochester, Dept Med, Div Allergy Immunol & Rheumatol, Rochester, NY USA		Stein, R (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiol, IL-69978 Ramat Aviv, Israel.	reuvens@post.tau.ac.il		Mayo, Lior/0000-0002-1296-6692	Israel Science FoundationIsrael Science Foundation [643/02]; Israel Ministry of Science, Culture Sport; Adams Super-Center for Brain Research; Adams Super-Center for Brain Research [2007061]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AI063399]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI063399] Funding Source: NIH RePORTER	This work was supported by the Israel Science Foundation (643/02 to R. S.), Israel Ministry of Science, Culture & Sport (Eshkol Foundation to L. M.), Adams Super-Center for Brain Research (to R. S.), U. S.-Israel Binational Science Foundation (2007061 to R. S.), and National Institutes of Health(R01 AI063399 to F. E. L.).	Adriouch S, 2007, J IMMUNOL, V179, P186, DOI 10.4049/jimmunol.179.1.186; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Akirav I, 2006, CEREB CORTEX, V16, P1759, DOI 10.1093/cercor/bhj114; AKIYAMA H, 1994, BRAIN RES, V635, P257, DOI 10.1016/0006-8993(94)91447-8; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arque G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002575; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Ceni C, 2003, BIOCHEM J, V370, P175, DOI 10.1042/BJ20020604; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; Dammermann W, 2005, J BIOL CHEM, V280, P21394, DOI 10.1074/jbc.M413085200; Deaglio S, 2001, LEUKEMIA RES, V25, P1, DOI 10.1016/S0145-2126(00)00093-X; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Franco L, 2006, J NEUROCHEM, V99, P165, DOI 10.1111/j.1471-4159.2006.04031.x; Frasca L, 2006, BLOOD, V107, P2392, DOI 10.1182/blood-2005-07-2913; Garden GA, 2006, J NEUROIMMUNE PHARM, V1, P127, DOI 10.1007/s11481-006-9015-5; Gregorini A, 2006, CELL BIOL INT, V30, P727, DOI 10.1016/j.cellbi.2006.05.004; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guse AH, 2004, CURR MED CHEM, V11, P847, DOI 10.2174/0929867043455602; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Krebs C, 2005, J IMMUNOL, V174, P3298, DOI 10.4049/jimmunol.174.6.3298; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KUMAGAI MA, 1995, J EXP MED, V181, P1101, DOI 10.1084/jem.181.3.1101; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lee HC, 2000, CHEM IMMUNOL, V75, P39; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; Lund FE, 1999, J IMMUNOL, V162, P2693; Lund FE, 1998, IMMUNOL REV, V161, P79, DOI 10.1111/j.1600-065X.1998.tb01573.x; Lund FE, 2006, INT IMMUNOL, V18, P1029, DOI 10.1093/intimm/dxl037; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Malavasi F, 2008, PHYSIOL REV, V88, P841, DOI 10.1152/physrev.00035.2007; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; Mayo L, 2007, CELL DEATH DIFFER, V14, P183, DOI 10.1038/sj.cdd.4401989; Mayo L, 2008, J IMMUNOL, V181, P92, DOI 10.4049/jimmunol.181.1.92; MIZUGUCHI M, 1995, BRAIN RES, V697, P235, DOI 10.1016/0006-8993(95)00885-T; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nadler Y, 2008, GLIA, V56, P552, DOI 10.1002/glia.20638; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Partida-Sanchez S, 2004, J IMMUNOL, V172, P1896, DOI 10.4049/jimmunol.172.3.1896; Partida-Sanchez S, 2003, MICROBES INFECT, V5, P49, DOI 10.1016/S1286-4579(02)00055-2; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Reshef A, 2008, J NEUROTRAUM, V25, P569, DOI 10.1089/neu.2007.0341; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Silvennoinen O, 1996, J IMMUNOL, V156, P100; Simard AR, 2007, J COMP NEUROL, V504, P716, DOI 10.1002/cne.21469; Soulet D, 2008, CURR OPIN PHARMACOL, V8, P508, DOI 10.1016/j.coph.2008.04.002; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yamada M, 1997, BRAIN RES, V756, P52, DOI 10.1016/S0006-8993(97)00117-0; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672; Ying WJ, 2007, FRONT BIOSCI-LANDMRK, V12, P2728, DOI 10.2741/2267	76	25	27	2	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1521	1533		10.1089/neu.2008.0746			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200009	19257806	Green Published			2022-02-06	
J	Paci, GM; Sise, MJ; Sise, CB; Sack, DI; Shackford, SR; Kureshi, SA; Osler, TM; Yale, RS; Riccoboni, ST; Peck, KA; O'Reilly, EB				Paci, Gabrielle M.; Sise, Michael J.; Sise, C. Beth; Sack, Daniel I.; Shackford, Steven R.; Kureshi, Sohaib A.; Osler, Turner M.; Yale, Randall S.; Riccoboni, Steven T.; Peck, Kimberly A.; O'Reilly, Eamon B.			Preemptive Craniectomy With Craniotomy: What Role in the Management of Severe Traumatic Brain Injury?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		Traumatic brain injury; Craniectomy; Craniotomy	DECOMPRESSIVE CRANIECTOMY; PROPENSITY SCORE	Background: Patients with severe traumatic brain injury (TBI) require aggressive management to prevent secondary brain injury. "Preemptive" craniectomy (CE)-craniectomy performed as a primary procedure in conjunction with craniotomy-has been used as prophylaxis for secondary injury, but the indications and outcomes of craniectomy used for this purpose are not well defined. Methods: To evaluate the role of CE in the management of TBI, we retrospectively reviewed 62 consecutive patients who underwent CE in a 78-month period at our level I trauma center. A cohort of patients who underwent craniotomy only (CO) during this period was compared with the CE group for TBI patterns, indications for operation, and outcomes. Multivariable logistic regression and matched propensity score analysis were used to test the association between CE and survival. The rate of CE was determined by individual neurosurgeons. Results: Of 197 patients with brain injuries who underwent craniotomy, 62 (31.5%) had CE and 135 (68.5%) had CO. Mean age for CE versus CO was 41 years versus 51 years (p < 0.01). Mean admission Glasgow Coma Score was lower in CE versus CO (7.6 vs. 11.8, p < 0.001); Injury Severity Score was higher (30.2 vs. 26.3, p < 0.01). The indication for operation for CE compared with CO was subdural hematoma in 41 (66.1%) versus 87 (64.4%, p = 0.82), epidural hematoma in 2 (3.2%) versus 26 (19.3%, p < 0.0 1), and cerebral contusion or hematoma in 15 (24.2%) versus 8 (5.9%, p < 0.001). Postoperative intracranial pressure was monitored in 48 (77.4%) CE and 44 (32.6%) CO patients (p < 0.001). Intracranial pressure <20 was maintained in 26 (54.2%) after CE and in 31 (70.5%) after CO (p = 0.12). In the CE group, 26 (42%) died compared with 31 (26%, p < 0.01) in the CO group. When adjusted for severity of injury, however, there was no significant difference in mortality between the two groups (p = 0.134). The CE rate obtained by a neurosurgeon varied from 8.6% to 75.0% (p < 0.001). Conclusion: CE was used in patients with more severe injuries, and particularly in those with more severe head injuries. When adjusted for injury severity, CE was not associated with worsened survival, and therefore may reasonably be included in the armamentarium of neurotrauma care. Use of CE by our neurosurgeons, however, varied significantly. These findings underscore the need for practice guidelines based on randomized trials to fully evaluate the role of CE in the management of TBI.	[Paci, Gabrielle M.; Sise, Michael J.; Sise, C. Beth; Sack, Daniel I.; Shackford, Steven R.; Kureshi, Sohaib A.; Osler, Turner M.; Yale, Randall S.; Riccoboni, Steven T.; Peck, Kimberly A.; O'Reilly, Eamon B.] Scripps Mercy Hosp, Div Trauma, San Diego, CA 92103 USA		Sise, MJ (corresponding author), Scripps Mercy Hosp, Div Trauma, 4077 5th Ave, San Diego, CA 92103 USA.	sise.mike@scrippshealth.org		Riccoboni, Steven/0000-0001-6028-9406			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BRITT RH, 1978, NEUROSURGERY, V2, P195, DOI 10.1227/00006123-197805000-00001; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; *CDCP, 2008, TRAUM BRAIN INJ; Cooper P R, 1976, Surg Neurol, V5, P25; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Greenland S, 2008, MODERN EPIDEMIOLOGY, P418; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Jagannathan J, 2007, J NEUROSURG, V106, P268, DOI 10.3171/ped.2007.106.4.268; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; Leuven E., 2003, PSMATCH2 STATA MODUL; Marion DW, 2006, NEUROSURGERY, V58, P655; PETERSON SL, 2008, TRAUMA, P871; RORABECK CH, 1984, J BONE JOINT SURG BR, V66, P93, DOI 10.1302/0301-620X.66B1.6693486; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Saggi B, 1998, J TRAUMA, V45, P597, DOI 10.1097/00005373-199809000-00033; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sauerbrei W, 1999, J R STAT SOC A STAT, V162, P71, DOI 10.1111/1467-985X.00122; Schneider GH, 2002, ACT NEUR S, V81, P77; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Sturmer T, 2006, J CLIN EPIDEMIOL, V59, P437, DOI 10.1016/j.jclinepi.2005.07.004; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Wyrzykowski AD, 2008, TRAUMA, P851	26	25	25	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2009	67	3					531	536		10.1097/TA.0b013e3181b840e8			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	493IL	WOS:000269729900020	19741396				2022-02-06	
J	Adams, EN; Marks, A; Lizer, MH				Adams, Erin N.; Marks, Alla; Lizer, Mitsi H.			Carbamazepine-induced hyperammonemia	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article						Anticonvulsants; Carbamazepine; Desmopressin acetate; Guanfacine; Hyperammonemia; Olanzapine; Quetiapine; Topiramate; Toxicity	VALPROIC ACID; ENCEPHALOPATHY; ASTERIXIS; CARNITINE	Purpose. A case of carbamazepine-induced hyperammonemia is presented. Summary. A 26-year-old man with bipolar disorder, seizures, and mild mental retardation secondary to a traumatic brain injury began treatment with carbamazepine for aggression and seizure control. After three weeks of carbamazepine therapy, the patient arrived at the emergency department (ED) with severe agitation and aggressive behavior. His oral medications included topiramate, carbamazepine, olanzapine, quetiapine, guanfacine, and desmopressin acetate. The patient's medications had been stable for at least six months except for the addition of carbamazepine one month before his arrival at the ED. Upon admission, the patient's vital signs were found to be within normal limits, as were his liver profile results, complete blood count, thyroid-stimulating-hormone level, and serum chemistry panel. His serum carbamazepine concentration was 3.9 mu g/mL (reference range, 4-12 mu g/mL), and his serum ammonia concentration was 127 mu g/dL (reference range, 19-60 mu g/dL). Carbamazepine was discontinued upon admission, and the patient was treated with oral lactulose. Since carbamazepine was discontinued and had been prescribed for bipolar disorder, his olanzapine dosage was increased, and trazodone was added at bedtime for insomnia. Of note, the patient had been on carbamazepine therapy one year earlier and had experienced the same adverse event. He had also developed elevated serum ammonia levels while on valproic acid. The patient's serum ammonia level returned to normal by hospital day 4, and he was discharged to his group home. Conclusion. A 26-year-old man with bipolar disorder developed hyperammonemia three weeks after initiating carbamazepine therapy.	[Adams, Erin N.; Marks, Alla] Shenandoah Univ, Bernard J Dunn Sch Pharm, Div Technol Educ, Winchester, VA 22601 USA		Adams, EN (corresponding author), Shenandoah Univ, Bernard J Dunn Sch Pharm, Div Technol Educ, Hlth Profess Bldg,Room 145,1775 N Sector Court, Winchester, VA 22601 USA.	eadams@su.edu					Alqahtani S, 2007, CAN MED ASSOC J, V177, P568, DOI 10.1503/cmaj.061272; AMBROSETTO G, 1984, ACTA NEUROL SCAND, V69, P186, DOI 10.1111/j.1600-0404.1984.tb07799.x; Bjornsson E, 2008, ACTA NEUROL SCAND, V118, P281, DOI 10.1111/j.1600-0404.2008.01009.x; BROWN JR, 2006, TXB THERAPEUTICS DRU, P1358; Carr RB, 2007, AM J PSYCHIAT, V164, P1020, DOI 10.1176/appi.ajp.164.7.1020; Clay AS, 2007, CHEST, V132, P1368, DOI 10.1378/chest.06-2940; Endo F, 2004, J NUTR, V134, p1605S, DOI 10.1093/jn/134.6.1605S; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; Hamer HM, 2000, NEUROLOGY, V54, P230, DOI 10.1212/WNL.54.1.230; KLASCO RK, DRUGDEX SYSTEM; LAUB MC, 1986, EPILEPSIA, V27, P559, DOI 10.1111/j.1528-1157.1986.tb03584.x; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; *NAT UR CYCL DIS F, WHAT IS UR CYCL DIS; *NOV, 2008, TEGR CARB PACK INS; OHTANI Y, 1982, J PEDIATR-US, V101, P782, DOI 10.1016/S0022-3476(82)80320-X; Raja M, 2002, J CLIN PSYCHOPHARM, V22, P631, DOI 10.1097/00004714-200212000-00019; RIVELLI M, 1988, AM J PSYCHIAT, V145, P269; SEASE JM, 2008, PHARMACOTHERAPY PATH, P645; Verrotti A, 2002, METAB BRAIN DIS, V17, P367, DOI 10.1023/A:1021918104127; Wadzinski J, 2007, J AM BOARD FAM MED, V20, P499, DOI 10.3122/jabfm.2007.05.070062; WEINER DL, PEDIAT INBORN ERRORS; WILLIAMS CA, 1984, NEUROLOGY, V34, P550, DOI 10.1212/WNL.34.4.550; Yee Jennie L., 2005, Journal of Pharmacy Technology, V21, P348	23	25	25	1	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	AUG 15	2009	66	16					1468	1470		10.2146/ajhp080454			3	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	482UO	WOS:000268914500012	19667003				2022-02-06	
J	Sher, L				Sher, Leo			A model of suicidal behavior in war veterans with posttraumatic mood disorder	MEDICAL HYPOTHESES			English	Article							TRAUMATIC BRAIN-INJURY; STRESS-DISORDER; DEPRESSED-PATIENTS; MAJOR DEPRESSION; RISK-FACTORS; COMORBIDITY; ANXIETY; HEALTH; PREDICTORS; MILITARY	Many wars have been fought during the history of civilization. About 30 armed conflicts are occurring now around the globe involving more than 25 countries. Many war veterans have symptoms of posttraumatic stress disorder (PTSD) and major depressive disorder (MDD) including suicidal ideation and behavior. PTSD is frequently comorbid with MDD. I have previously proposed that some or all individuals diagnosed with comorbid PTSD and MDD have a separate psychobiological condition that can be termed "posttraumatic mood disorder" (PTMD). This idea was based on the fact that a significant number of studies suggested that patients suffering from comorbid PTSD and MDD differed clinically and biologically from individuals with PTSD alone or MDD alone. Individuals with comorbid PTSD and MDD are characterized by greater severity of symptoms, increased suicidality and the higher level of impairment in social and occupational functioning compared to individuals with PTSD alone or MDD alone. Neurobiological evidence supporting the concept of PTMD includes the findings from neuroendocrine challenge, cerebrospinal fluid, neuroimaging, sleep and other studies. In this paper, I propose a model of suicidal behavior in war veterans with PTMD. The model consists of the following components: (1) genetic factors; (2) prenatal development; (3) biological and psychosocial influences from birth to mobilization/deployment; (4) mobilization/pre-deployment stress; (5) combat stress, traumatic brain injury, and physical injury: (6) post-deployment stress; (7) biological and psychosocial influences after the deployment; (8) trigger (precipitant) of a suicidal act; and (9) suicidal act. The first four components determine vulnerability to combat stress. The first seven components determine predisposition to suicidal behavior, a key element that differentiates PTMD patients who are at high risk from those at lower risk. Suicidal behavior in PTMD can be attributed to the coincidence of a trigger with a predisposition for suicidal behavior. Suicide prevention in war veterans with PTMD should focus on (1) improvement in recognition of PTMD; (2) treating symptoms of PTMD; (3) preventing a relapse when the patient is in remission; (4) treating suicidal ideation; (5) treating comorbid psychiatric conditions including alcohol and drug abuse; (6) treating medical and neurological disorders including traumatic brain injury; and (7) social support. It is extremely important to understand PTMD, to optimize assessment and treatment for people with PTMD, and to identify processes that facilitate recovery from exposure to traumatic events. Every nation, every generation, faces traumas that cause suicide. The world needs to deal with this and it is one thing that the world can come together on. (C) 2009 Elsevier Ltd. All rights reserved.	Columbia Univ, New York State Psychiat Inst, Dept Psychiat, New York, NY 10032 USA		Sher, L (corresponding author), Columbia Univ, New York State Psychiat Inst, Dept Psychiat, 1051 Riverside Dr,Suite 2917,Box 42, New York, NY 10032 USA.	LS2003@columbia.edu					Breslau N, 1998, ADVERSITY, STRESS AND PSYCHOPATHOLOGY, P319; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brown AS, 2000, AM J PSYCHIAT, V157, P190, DOI 10.1176/appi.ajp.157.2.190; Brown TA, 2001, J ABNORM PSYCHOL, V110, P585, DOI 10.1037//0021-843X.110.4.585; Bryant RA, 2005, PSYCHOL SCI, V16, P749, DOI 10.1111/j.1467-9280.2005.01608.x; Engel SM, 2005, PAEDIATR PERINAT EP, V19, P334, DOI 10.1111/j.1365-3016.2005.00676.x; Flint Jonathan, 2008, Novartis Found Symp, V289, P23; Ghafoori B, 2008, J TRAUMA DISSOCIATIO, V9, P85, DOI 10.1080/15299730802073726; Glover V, 2002, BRIT J PSYCHIAT, V180, P389, DOI 10.1192/bjp.180.5.389; Godleski L, 2008, BEHAV SCI LAW, V26, P271, DOI 10.1002/bsl.811; Hampton T, 2007, JAMA-J AM MED ASSOC, V298, P2732, DOI 10.1001/jama.298.23.2732; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kaplan MS, 2007, J EPIDEMIOL COMMUN H, V61, P619, DOI 10.1136/jech.2006.054346; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Koenen KC, 2008, J AFFECT DISORDERS, V105, P109, DOI 10.1016/j.jad.2007.04.021; Koren D, 2006, CNS SPECTRUMS, V11, P616, DOI 10.1017/S1092852900013675; KRAMER TL, 1994, SUICIDE LIFE-THREAT, V24, P58; Landrigan PJ, 2008, MT SINAI J MED, V75, P129, DOI 10.1002/msj.20032; Mills PD, 2008, JT COMM J QUAL PATIE, V34, P482, DOI 10.1016/S1553-7250(08)34061-6; Mittendorfer-Rutz E, 2004, LANCET, V364, P1135, DOI 10.1016/S0140-6736(04)17099-2; Nad S, 2008, J NERV MENT DIS, V196, P79, DOI [10.1097/NMD.0b013e1815faa5f, 10.1097/NMD.0b013e31815faa5f]; Nugent NR, 2008, AM J MED GENET C, V148C, P127, DOI 10.1002/ajmg.c.30169; Oquendo M, 2005, AM J PSYCHIAT, V162, P560, DOI 10.1176/appi.ajp.162.3.560; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Reyes Gilbert., 2008, ENCY PSYCHOL TRAUMA; Rihmer Z, 2007, CURR OPIN PSYCHIATR, V20, P17, DOI 10.1097/YCO.0b013e3280106868; Riordan DV, 2006, BRIT J PSYCHIAT, V189, P502, DOI 10.1192/bjp.bp.105.015974; Rona RJ, 2009, J PSYCHIATR RES, V43, P649, DOI 10.1016/j.jpsychires.2008.09.006; Rosen GM, 2004, POSTTRAUMATIC STRESS, P15, DOI [10.1002/9780470713570.ch2, DOI 10.1002/9780470713570]; Rosenman S, 2002, AUST NZ J PSYCHIAT, V36, P515, DOI 10.1046/j.1440-1614.2002.01039.x; Sareen J, 2005, J NERV MENT DIS, V193, P450, DOI 10.1097/01.nmd.0000168263.89652.6b; Sher L, 2008, Minerva Pediatr, V60, P1393; Sher L, 2005, CAN J PSYCHIAT, V50, P127, DOI 10.1177/070674370505000215; Sher L, 2005, MED HYPOTHESES, V65, P205, DOI 10.1016/j.mehy.2005.03.014; Sher L, 2004, Forsch Komplementarmed Klass Naturheilkd, V11, P354, DOI 10.1159/000082817; Sher L, 2005, EUR NEUROPSYCHOPHARM, V15, P203, DOI 10.1016/j.euroneuro.2004.09.009; Sher L, 2004, J AFFECT DISORDERS, V82, P53, DOI 10.1016/j.jad.2003.09.012; Sher L, 2004, QJM-INT J MED, V97, P677, DOI 10.1093/qjmed/hch106; Sher L, 2004, QJM-INT J MED, V97, P1, DOI 10.1093/qjmed/hch003; Sher L, 2003, FORSCH KOMP KLAS NAT, V10, P61, DOI 10.1159/000071664; SHER L, 2003, TXB MED PSYCHIAT, P701; Simpson G, 2002, PSYCHOL MED, V32, P687, DOI 10.1017/S0033291702005561; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Tarrier N, 2004, SOC PSYCH PSYCH EPID, V39, P927, DOI 10.1007/s00127-004-0828-3; Thompson C, 2001, BRIT J PSYCHIAT, V179, P450, DOI 10.1192/bjp.179.5.450; URSANO RJ, 2008, PSYCH TIMES, V25; Yehuda R, 2006, PSYCHOBIOLOGY POSTTR; Zivin K, 2007, AM J PUBLIC HEALTH, V97, P2193, DOI 10.2105/AJPH.2007.115477	48	25	25	1	11	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877	1532-2777		MED HYPOTHESES	Med. Hypotheses	AUG	2009	73	2					215	219		10.1016/j.mehy.2008.12.052			5	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Research & Experimental Medicine	462LN	WOS:000267354200029	19327892				2022-02-06	
J	Ouellet, MC; Morin, CM; Lavoie, A				Ouellet, Marie-Christine; Morin, Charles M.; Lavoie, Andre			Volunteer Work and Psychological Health Following Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						psychological adjustment; traumatic brain injury; volunteerism; work	QUALITY-OF-LIFE; MULTIDIMENSIONAL FATIGUE INVENTORY; COMMUNITY INTEGRATION; RETURN; DEPRESSION; VALIDATION; INSOMNIA; SATISFACTION; EMPLOYMENT; FREQUENCY	Objectives: To compare the long-term psychological functioning of 3 groups of survivors of traumatic brain injury (TBI): (1) those who report being regularly active either by working or studying, (2) those who are not competitively employed but are active volunteers, and (3) those who report neither working, studying, nor volunteering. Participants and Procedure: Two hundred eight participants aged 16 years and older with minor to severe TBI were classified as (1) Working/Studying (N = 78), (2) Volunteering (N = 54), or (3) Nonactive (N = 76). Main Outcome Measures: Measures of psychological distress (anxiety depression, cognitive disturbance, irritability/anger), fatigue, sleep disturbance, and perception of pain. Results: Survivors of TBI who report being active through work, studies, or volunteering demonstrate a significantly higher level of psychological adjustment than persons who report no activity. Even among participants who are unable to return to work and are declared on long-term disability leave, those who report engaging in volunteer activities present significantly better psychological functioning than participants who are nonactive. Conclusion: Volunteering is associated with enhanced psychological well-being and should be encouraged following TBI.	[Ouellet, Marie-Christine] CHA, Hop Enfants Jesus, CHAUQ, Ctr Rech, Quebec City, PQ G1J 1Z4, Canada; [Ouellet, Marie-Christine] McGill Univ, Dept Surg, Div Surg Res, Montreal, PQ H3A 2T5, Canada; [Morin, Charles M.] Univ Laval, Ecole Psychol, Quebec City, PQ, Canada		Ouellet, MC (corresponding author), CHA, Hop Enfants Jesus, CHAUQ, Ctr Rech, Pavillon Notre Dame,Local H-042 1401,18E Rue, Quebec City, PQ G1J 1Z4, Canada.	marie-christine.ouellet@mail.mcgill.ca	Morin, Charles M./A-4700-2008; Morin, Charles/G-1021-2011	Morin, Charles M./0000-0002-8649-8895; Ouellet, Marie-Christine/0000-0003-3477-1893	Fonds de Recherche en Sante du QuebecFonds de la Recherche en Sante du Quebec; Fondation de l'Hopital de I'Enfant-Jesus, Quebec, Canada	Collection of the data and preparation of this article was supported by fellowship's awarded to the first author by the Fonds de Recherche en Sante du Quebec and the Fondation de l'Hopital de I'Enfant-Jesus, Quebec, Canada (Dr Ouellet).	Audet N, 2001, ENQUETE SOCIALE SANT; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Blais FC, 1997, ENCEPHALE, V23, P447; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dyster-Aas J, 2007, J REHABIL MED, V39, P49, DOI 10.2340/16501977-0005; Fillion L, 2003, CANCER NURS, V26, P143, DOI 10.1097/00002820-200304000-00008; Gervais M, 1999, ETUDE EXPLORATOIRE B; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Holzner B, 2003, CANCER-AM CANCER SOC, V97, P1564, DOI 10.1002/cncr.11253; Holzner B, 2002, ANN ONCOL, V13, P965, DOI 10.1093/annonc/mdf122; ILFELD FW, 1976, PSYCHOL REP, V39, P1215, DOI 10.2466/pr0.1976.39.3f.1215; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; KINNEY WB, 1992, ARCH PHYS MED REHAB, V73, P863; Lindqvist KS, 1996, ACCIDENT ANAL PREV, V28, P209, DOI 10.1016/0001-4575(95)00065-8; McCrimmon S, 2006, BRAIN INJURY, V20, P1037, DOI 10.1080/02699050600909656; MORIN CM, 1993, J CONSULT CLIN PSYCH, V61, P137, DOI 10.1037/0022-006X.61.1.137; Morrow-Howell Nancy, 2003, J Gerontol B Psychol Sci Soc Sci, V58, pS137; Musick MA, 1999, J GERONTOL B-PSYCHOL, V54, pS173, DOI 10.1093/geronb/54B.3.S173; Musick MA, 2003, SOC SCI MED, V56, P259, DOI 10.1016/S0277-9536(02)00025-4; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Preville M, 1992, DETRESSE PSYCHOL DET; ROBINSON N, 1995, DEV PSYCHOPATHOL, P162; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Szymanski EM, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P499, DOI 10.1037/10361-023; Thoits PA, 1995, J HLTH SOC BEHAV, P53; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Van Willigen M, 2000, J GERONTOL B-PSYCHOL, V55, pS308, DOI 10.1093/geronb/55.5.S308; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	37	25	26	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2009	24	4					262	271		10.1097/HTR.0b013e3181a68b73			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	506SK	WOS:000270796000005	19625865				2022-02-06	
J	Sargin, D; Hassouna, I; Sperling, S; Siren, AL; Ehrenreich, H				Sargin, Derya; Hassouna, Imam; Sperling, Swetlana; Siren, Anna-Leena; Ehrenreich, Hannelore			Uncoupling of Neurodegeneration and Gliosis in a Murine Model of Juvenile Cortical Lesion	GLIA			English	Article						neurotrauma; brain atrophy; erythropoietin; oligodendrocytes; microglia; schizophrenia	TRAUMATIC BRAIN-INJURY; UNBIASED STEREOLOGICAL ESTIMATION; RECOMBINANT-HUMAN-ERYTHROPOIETIN; GLUTAMIC-ACID DECARBOXYLASE; BIPOLAR DISORDER; PREFRONTAL CORTEX; HEAD-INJURY; OPTICAL FRACTIONATOR; ONSET SCHIZOPHRENIA; FUNCTIONAL RECOVERY	A small experimental cryolesion to the right parietal cortex of juvenile mice causes late-onset global brain atrophy with memory impairments, reminiscent of cognitive decline, and progressive brain matter loss in schizophrenia. However, the cellular events underlying this global neurodegeneration are not understood. Here we show, based on comprehensive stereological analysis, that early unilateral lesion causes immediate and lasting bilateral increase in the number of microglia in cingulate cortex and hippocampus, consistent with a chronic low-grade inflammatory process. Whereas the total number of neurons and astrocytes in these brain regions remain unaltered, pointing to a non-gliotic neurodegeneration (as seen in schizophrenia), the subgroup of parvalbumin-positive inhibitory GABAergic interneurons is increased bilaterally in the hippocampus, as is the expression of the GABA-synthesizing enzyme GAD67. Moreover, unilateral parietal lesion causes a decrease in the expression of synapsin1, suggesting impairment of presynaptic functions/neuroplasticity. Reduced expression of the myelin protein cyclic nucleotide phosphodiesterase, reflecting a reduction of oligodendrocytes, may further contribute to the observed brain atrophy. Remarkably, early intervention with recombinant human erythropoietin (EPO), a hematopoietic growth factor with multifaceted neuroprotective properties (intraperitoneal injection of 5000 IU/kg body weight every other day for 3 weeks), prevented all these neurodegenerative changes. To conclude, unilateral parietal lesion of juvenile mice induces a non-gliotic neurodegenerative process, susceptible to early EPO treatment. Although the detailed mechanisms remain to be defined, these profound EPO effects open new ways for prophylaxis and therapy of neuropsychiatric diseases, e.g. schizophrenia. (C) 2008 Wiley-Liss, Inc.	[Sargin, Derya; Hassouna, Imam; Sperling, Swetlana; Ehrenreich, Hannelore] Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany; [Siren, Anna-Leena] Univ Wurzburg, Dept Neurosurg, D-97080 Wurzburg, Germany		Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Div Clin Neurosci, Hermann Rein Str 3, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de	Siren, Anna-Leena/AAE-1374-2019	Siren, Anna-Leena/0000-0002-2217-0081; Ehrenreich, Hannelore/0000-0001-8371-5711	Max-Planck-SocietyMax Planck Society; DFG Center for Molecular Physiology of the Brain (CMPB)German Research Foundation (DFG)	This study has been supported by the Max-Planck-Society as well as by the DFG Center for Molecular Physiology of the Brain (CMPB). DS has a Max-Planck fellowship.	AbdelMalik P, 2003, ARCH GEN PSYCHIAT, V60, P231, DOI 10.1001/archpsyc.60.3.231; Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; AKBARIAN S, 1995, ARCH GEN PSYCHIAT, V52, P258, DOI 10.1001/archpsyc.1995.03950160008002; Benes FM, 2001, NEUROPSYCHOPHARMACOL, V25, P1, DOI 10.1016/S0893-133X(01)00225-1; Bernstein HG, 2007, ANN NY ACAD SCI, V1096, P120, DOI 10.1196/annals.1397.077; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Blum BP, 2002, INT J NEUROPSYCHOPH, V5, P159, DOI 10.1017/S1461145702002894; Bogerts B, 1999, EUR ARCH PSY CLIN N, V249, P2; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Constantinidis C, 2002, NAT NEUROSCI, V5, P175, DOI 10.1038/nn799; Cullheim S, 2007, BRAIN RES REV, V55, P89, DOI 10.1016/j.brainresrev.2007.03.012; Czeh B, 2005, NEUROPSYCHOPHARMACOL, V30, P67, DOI 10.1038/sj.npp.1300581; Davis KL, 2003, LANCET, V362, P758, DOI 10.1016/S0140-6736(03)14297-3; Dracheva S, 2006, NEUROBIOL DIS, V21, P531, DOI 10.1016/j.nbd.2005.08.012; Ehrenreich H, 2007, MOL PSYCHIATR, V12, P206, DOI 10.1038/sj.mp.4001907; Ehrenreich H, 2004, MOL PSYCHIATR, V9, P42, DOI 10.1038/sj.mp.4001442; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Hakak Y, 2001, P NATL ACAD SCI USA, V98, P4746, DOI 10.1073/pnas.081071198; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593; Ho BC, 2003, ARCH GEN PSYCHIAT, V60, P585, DOI 10.1001/archpsyc.60.6.585; Ho L, 2001, NEUROSCI LETT, V298, P191, DOI 10.1016/S0304-3940(00)01753-5; Hof PR, 2003, BIOL PSYCHIAT, V53, P1075, DOI 10.1016/S0006-3223(03)00237-3; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Karoutzou G, 2008, MOL PSYCHIATR, V13, P245, DOI 10.1038/sj.mp.4002096; Keuker JIH, 2001, BRAIN RES PROTOC, V7, P211, DOI 10.1016/S1385-299X(01)00064-2; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lappe-Siefke C, 2003, NAT GENET, V33, P366, DOI 10.1038/ng1095; Lewis DA, 2005, NAT REV NEUROSCI, V6, P312, DOI 10.1038/nrn1648; Li WP, 2004, ANN NEUROL, V56, P767, DOI 10.1002/ana.20274; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; McAllister, 1998, Semin Clin Neuropsychiatry, V3, P211; Miller KR, 2007, NEURON GLIA BIOL, V3, P245, DOI 10.1017/S1740925X08000136; Nagasaka T, 2007, BRAIN TUMOR PATHOL, V24, P1, DOI 10.1007/s10014-006-0209-6; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.3.CO;2-1; Perry VH, 2007, NAT REV IMMUNOL, V7, P161, DOI 10.1038/nri2015; Pol HEH, 2008, SCHIZOPHRENIA BULL, V34, P354, DOI 10.1093/schbul/sbm168; Rao SG, 2000, J NEUROSCI, V20, P485, DOI 10.1523/JNEUROSCI.20-01-00485.2000; Schwartz M, 2006, TRENDS NEUROSCI, V29, P68, DOI 10.1016/j.tins.2005.12.005; Siren AL, 2006, BRAIN, V129, P480, DOI 10.1093/brain/awh703; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sugawa M, 2002, NEUROSCI RES, V44, P391, DOI 10.1016/S0168-0102(02)00161-X; Sun Y, 2005, STROKE, V36, P1672, DOI 10.1161/01.STR.0000173406.04891.8c; Suzuki M, 2002, SCHIZOPHR RES, V55, P41, DOI 10.1016/S0920-9964(01)00224-9; Thompson PM, 2001, P NATL ACAD SCI USA, V98, P11650, DOI 10.1073/pnas.201243998; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; van Berckel BN, 2008, BIOL PSYCHIAT, V64, P820, DOI 10.1016/j.biopsych.2008.04.025; Vawter MP, 2002, MOL PSYCHIATR, V7, P571, DOI 10.1038/sj.mp.4001158; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Volk DW, 2000, ARCH GEN PSYCHIAT, V57, P237, DOI 10.1001/archpsyc.57.3.237; Wang X, 2002, J NEUROSCI, V22, P9185; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wilke M, 2001, NEUROIMAGE, V13, P814, DOI 10.1006/nimg.2001.0751; Xue YQ, 2007, NEUROSCIENCE, V146, P1245, DOI 10.1016/j.neuroscience.2007.02.004; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036	61	25	25	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	MAY	2009	57	7					693	702		10.1002/glia.20797			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	435VV	WOS:000265372300001	18985736				2022-02-06	
J	Burke, HS; Degeneffe, CE; Olney, MF				Burke, Hillary S.; Degeneffe, Charles E.; Olney, Marjorie F.			A New Disability for Rehabilitation Counselors: Iraq War Veterans with Traumatic Brain Injury and Post-Traumatic Stress Disorder	JOURNAL OF REHABILITATION			English	Article							EXPOSURE THERAPY; VIRTUAL-REALITY	Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) are considered the "signature" injuries of military personnel serving in the Iraq war. An alarming number of returning veterans are incurring a combination of these two disabilities. TBI and PTSD combined presents an array of challenges for injured persons that are experienced differently by those separately affected by TBI or PTSD. Hence, the combination of TBI and PTSD presents a new disability classification for the rehabilitation counseling profession. There is an acute need to develop and facilitate specialized care and rehabilitative services for veterans impacted by this nascent disability. We highlight neurobiological, behavioral, and physiological characteristics associated with combat-incurred TBI/PTSD injuries. Additionally, we offer recommendations for rehabilitation counseling professionals and researchers to consider in response to our review of the current system of veteran care, common barriers to rehabilitation and societal re-integration, and available resources for military personnel impacted by TBI and PTSD.	[Burke, Hillary S.; Degeneffe, Charles E.; Olney, Marjorie F.] San Diego State Univ, San Diego, CA 92182 USA		Degeneffe, CE (corresponding author), San Diego State Univ, 5500 Campanile Dr, San Diego, CA 92182 USA.	cdegenef@mail.sdsu.edu					*ARM NEWS SERV, 2007, ARM LAUNCH CHAIN TEA; BERGFELD C, 2006, BUSINESS WEEK   0706; Bilmes Linda J., 2008, WASHINGTON POST 0309; *CA COMM FDN, 2008, INV WOUNDS WAR PSYCH; CRAINE M, 2008, 2007 COMP GRANT TRAI; *DEF LINK, 2008, OP IR FREED US CAS S; Defense and Veterans Brain Injury Center, 2007, DVBIC FACT SHEET; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Fairweather A., 2007, DEFINING NEW AGE VET; *FORC HLTH PROT RE, TBI PTSD QUICK FACTS; Hall L. K., 2008, COUNSELING MILITARY; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; *IR BOD COUNT, 2008, DOC CIV DEATHS VIOL; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kraft Heidi S., 2007, RULE NUMBER 2 LESSON; LEE C, 2008, WASHINGTON POST 0516; Levin A., 2008, PSYCHIAT NEWS, V43, P23; Litz B. T., UNIQUE CIRCUMSTANCES; McNally R. J., 1999, PTSD RES Q, V10, P1; *PAT UK, 2007, STRESS PTSD; Paunovic N, 2001, BEHAV RES THER, V39, P1183, DOI 10.1016/S0005-7967(00)00093-0; Perna RB, 2003, J HEAD TRAUMA REHAB, V18, P201; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; Sherman MD, 2006, J MARITAL FAM THER, V32, P479, DOI 10.1111/j.1752-0606.2006.tb01622.x; Summerall E. L., 2008, TRAUMATIC BRAIN INJU; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; *US DEP DEF, 2008, OP IR FRED MIL DEATH; *US DEP VET AFF, 2007, VA POL SYST CAR ADM; *US DEP VET AFF, 2007, VA POL SYST CAR FREQ; *US DEP VET AFF, 2007, VA POL SYST CAR FAC; Walshe DG, 2003, CYBERPSYCHOL BEHAV, V6, P329, DOI 10.1089/109493103322011641; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WILLIS A, 2007, TRENDS TREATMENT AM; WONG E, 2008, NY TIMES        0215; Wood DP, 2007, CYBERPSYCHOL BEHAV, V10, P309, DOI 10.1089/cpb.2006.9951; Woodruff L, 2007, INSTANT FAMILYS JOUR; YEOMAN B, 2008, WOUNDED VETS COME HO; 2007, CBS NEWS        1113	40	25	25	0	15	NATL REHABILITATION ASSOC-NRA	ALEXANDRIA	633 S WASHINGTON ST, ALEXANDRIA, VA 22314-4109 USA	0022-4154			J REHABIL	J. Rehabil.	APR-JUN	2009	75	3			SI		5	14					10	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	472TC	WOS:000268154100002					2022-02-06	
J	Maisano, X; Carpentino, J; Becker, S; Lanza, R; Aaron, G; Grabel, L; Naegele, JR				Maisano, Xu; Carpentino, Joseph; Becker, Sandy; Lanza, Robert; Aaron, Gloster; Grabel, Laura; Naegele, Janice R.			Embryonic Stem Cell-Derived Neural Precursor Grafts for Treatment of Temporal Lobe Epilepsy	NEUROTHERAPEUTICS			English	Article; Proceedings Paper	4th Workshop on New Horizons in the Development of Antiepileptic Drugs	MAR 05-07, 2008	Dublin, IRELAND			Seizures; ES; cell therapy; hilus; hippocampus; GABA; interneuron; Sox1; GFP; sonic hedgehog	INDUCED STATUS EPILEPTICUS; PILOCARPINE-INDUCED SEIZURES; STABLE TRANSGENE EXPRESSION; MEDIAL GANGLIONIC EMINENCE; IN-VITRO DIFFERENTIATION; DENTATE GRANULE CELLS; DIRECTED DIFFERENTIATION; INHIBITORY INTERNEURONS; ADENOSINE KINASE; VENTRAL TELENCEPHALON	Complex partial seizures arising from mesial temporal lobe structures are a defining feature of mesial temporal lobe epilepsy (TLE). For many TLE patients, there is an initial traumatic head injury that is the precipitating cause of epilepsy. Severe TLE can be associated with neuropathological changes, including hippocampal sclerosis, neurodegeneration in the dentate gyrus, and extensive reorganization of hippocampal circuits. Learning disabilities and psychiatric conditions may also occur in patients with severe TLE for whom conventional anti-epileptic drugs are ineffective. Novel treatments are needed to limit or repair neuronal damage, particularly to hippocampus and related limbic regions in severe TLE and to suppress temporal lobe seizures. A promising therapeutic strategy may be to restore inhibition of dentate gyrus granule neurons by means of cell grafts of embryonic stem cell-derived GABAergic neuron precursors. "Proof-of-concept" studies show that human and mouse embryonic stem cell-derived neural precursors can survive, migrate, and integrate into the brains of rodents in different experimental models of TLE. In addition, studies have shown that hippocampal grafts of cell lines engineered to release GABA or other anticonvulsant molecules can suppress seizures. Furthermore, transplants of fetal GABAergic progenitors from the mouse or human brain have also been shown to suppress the development of seizures. Here, we review these relevant studies and highlight areas of future research directed toward producing embryonic stem cell-derived GABAergic interneurons for cell-based therapies for treating TLE.	[Naegele, Janice R.] Wesleyan Univ, Dept Biol, Hall Atwater Lab, Neurosci & Behav Program, Middletown, CT 06459 USA; [Carpentino, Joseph] Univ Florida, McKnight Brain Inst, Program Stem Cell Biol & Regenerat Med, Gainesville, FL 32610 USA; [Becker, Sandy; Lanza, Robert] Adv Cell Technol Inc, Worcester, MA 01605 USA		Naegele, JR (corresponding author), Wesleyan Univ, Dept Biol, Hall Atwater Lab, Neurosci & Behav Program, 52 Lawn Ave, Middletown, CT 06459 USA.	jnaegele@wesleyan.edu		Naegele, Janice/0000-0001-5151-0543; Lanza, Robert/0000-0002-3047-3074	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042826] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS042826, R01 NS042826-01A1, NS42826] Funding Source: Medline		Alvarez-Dolado M, 2006, J NEUROSCI, V26, P7380, DOI 10.1523/JNEUROSCI.1540-06.2006; Anderson SA, 2002, CEREB CORTEX, V12, P702, DOI 10.1093/cercor/12.7.702; Anderson SA, 2001, DEVELOPMENT, V128, P353; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; BEKENSTEIN JW, 1993, SCIENCE, V259, P97, DOI 10.1126/science.8093417; BENGZON J, 1993, EXP NEUROL, V122, P143, DOI 10.1006/exnr.1993.1115; Bernreuther C, 2006, J NEUROSCI, V26, P11532, DOI 10.1523/JNEUROSCI.2688-06.2006; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Boison D, 2008, PROG NEUROBIOL, V84, P249, DOI 10.1016/j.pneurobio.2007.12.002; Borges K, 2003, EXP NEUROL, V182, P21, DOI 10.1016/S0014-4886(03)00086-4; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Buckmaster PS, 2002, EPILEPSY RES, V48, P43, DOI 10.1016/S0920-1211(01)00318-7; Buckmaster PS, 1999, J NEUROSCI, V19, P9519; Buckmaster PS, 2002, J COMP NEUROL, V445, P360, DOI 10.1002/cne.10183; Bumanglag AV, 2008, J COMP NEUROL, V510, P561, DOI 10.1002/cne.21801; Butt SJB, 2007, J NEUROSCI, V27, P11847, DOI 10.1523/JNEUROSCI.3525-07.2007; Butt SJB, 2005, NEURON, V48, P591, DOI 10.1016/j.neuron.2005.09.034; BUZSAKI G, 1988, P NATL ACAD SCI USA, V85, P9327, DOI 10.1073/pnas.85.23.9327; Cai C, 2007, DEV DYNAM, V236, P3255, DOI 10.1002/dvdy.21306; Carpentino JE, 2008, J NEUROSCI RES, V86, P512, DOI 10.1002/jnr.21514; Casarosa S, 1999, DEVELOPMENT, V126, P525; Choi YS, 2007, J NEUROSCI, V27, P2999, DOI 10.1523/JNEUROSCI.4913-06.2007; Chu K, 2004, BRAIN RES, V1023, P213, DOI 10.1016/j.brainres.2004.07.045; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Denham M, 2006, AM J PHYSIOL-LUNG C, V290, pL1210, DOI 10.1152/ajplung.00427.2005; DETLEV B, 2007, CURR NEUROPHARMACOL, V5, P115; Ding S, 2004, NAT BIOTECHNOL, V22, P833, DOI 10.1038/nbt987; Dinocourt C, 2003, J COMP NEUROL, V459, P407, DOI 10.1002/cne.10622; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Eiges R, 2001, CURR BIOL, V11, P514, DOI 10.1016/S0960-9822(01)00144-0; Eiraku M, 2008, CELL STEM CELL, V3, P519, DOI 10.1016/j.stem.2008.09.002; Engel J, 1999, ARCH NEUROL-CHICAGO, V56, P1338, DOI 10.1001/archneur.56.11.1338; Englund U, 2002, P NATL ACAD SCI USA, V99, P17089, DOI 10.1073/pnas.252589099; Finley MFA, 1996, J NEUROSCI, V16, P1056; Flames N, 2007, J NEUROSCI, V27, P9682, DOI 10.1523/JNEUROSCI.2750-07.2007; FRAICHARD A, 1995, J CELL SCI, V108, P3181; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Fukuda H, 2006, STEM CELLS, V24, P763, DOI 10.1634/stemcells.2005-0137; Gabriel S, 2004, J NEUROSCI, V24, P10416, DOI 10.1523/JNEUROSCI.2074-04.2004; Gaspard N, 2008, NATURE, V455, P351, DOI 10.1038/nature07287; Gernert M, 2002, EXP NEUROL, V176, P183, DOI 10.1006/exnr.2002.7914; Giudice A, 2008, CELL STEM CELL, V2, P422, DOI 10.1016/j.stem.2008.04.003; Goetz AK, 2006, P NATL ACAD SCI USA, V103, P11063, DOI 10.1073/pnas.0510926103; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; Gropp M, 2006, METHOD ENZYMOL, V420, P64, DOI 10.1016/S0076-6879(06)20005-3; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; Hamaguchi I, 2000, J VIROL, V74, P10778, DOI 10.1128/JVI.74.22.10778-10784.2000; Hattiangady B, 2004, NEUROBIOL DIS, V17, P473, DOI 10.1016/j.nbd.2004.08.008; HELLER AC, 2008, SURG NEUROL     0529; Jessberger S, 2005, EXP NEUROL, V196, P342, DOI 10.1016/j.expneurol.2005.08.010; Jiao YQ, 2007, EXP NEUROL, V205, P569, DOI 10.1016/j.expneurol.2007.03.025; Jutila L, 2001, AM J NEURORADIOL, V22, P1490; Kempermann G, 2006, NEURON, V52, P935, DOI 10.1016/j.neuron.2006.12.004; Kobayashi M, 2003, J NEUROSCI, V23, P2440; Lauren HB, 2005, J NEUROCHEM, V94, P1384, DOI 10.1111/j.1471-4159.2005.03274.x; Leroy C, 2004, J PHYSIOL-LONDON, V557, P473, DOI 10.1113/jphysiol.2003.059246; Li H, 2008, P NATL ACAD SCI USA, V105, P9397, DOI 10.1073/pnas.0802876105; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Li TF, 2008, J CLIN INVEST, V118, P571, DOI 10.1172/JCI33737; Li TF, 2007, BRAIN, V130, P1276, DOI 10.1093/brain/awm057; Liew CG, 2007, STEM CELLS, V25, P1521, DOI 10.1634/stemcells.2006-0634; Loscher W, 2008, TRENDS NEUROSCI, V31, P62, DOI 10.1016/j.tins.2007.11.012; Longo BM, 1997, NEUROSCI LETT, V226, P163, DOI 10.1016/S0304-3940(97)00267-X; Loring DW, 2007, NEUROPSYCHOL REV, V17, P413, DOI 10.1007/s11065-007-9043-9; Loscher W, 1998, J NEUROSCI RES, V51, P196; Manabe T, 2007, CELL DEATH DIFFER, V14, P1080, DOI 10.1038/sj.cdd.4402106; Manabe T, 2005, J NEUROCHEM, V94, P723, DOI 10.1111/j.1471-4159.2005.03261.x; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; Marin O, 2000, J NEUROSCI, V20, P6063; MATHERN GW, 1995, J NEUROSURG, V82, P220, DOI 10.3171/jns.1995.82.2.0220; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Nishimura T, 2005, NEUROSCIENCE, V134, P691, DOI 10.1016/j.neuroscience.2005.04.013; Oka Masahiro, 2006, V329, P273; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Passier R, 2005, STEM CELLS, V23, P772, DOI 10.1634/stemcells.2004-0184; Pitkanen A, 1998, EPILEPSY RES, V32, P233, DOI 10.1016/S0920-1211(98)00055-2; Raedt R, 2007, SEIZURE-EUR J EPILEP, V16, P565, DOI 10.1016/j.seizure.2007.05.003; Ren G, 2007, EXP NEUROL, V208, P26, DOI 10.1016/j.expneurol.2007.07.016; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Ribak CE, 2000, J COMP NEUROL, V428, P240, DOI 10.1002/1096-9861(20001211)428:2<240::AID-CNE4>3.0.CO;2-Q; Ribak CE, 2002, PROG BRAIN RES, V136, P319; Ruschenschmidt T, 2005, EPILEPSIA, V46, P174, DOI 10.1111/j.1528-1167.2005.01028.x; Sartipy P, 2008, PHARMACOL RES, V58, P152, DOI 10.1016/j.phrs.2008.06.002; Scharfman HE, 2007, EPILEPSIA, V48, P33, DOI 10.1111/j.1528-1167.2007.01065.x; Scheffler B, 2006, BRAIN PATHOL, V16, P155, DOI 10.1111/j.1750-3639.2006.00010.x; Schinder AF, 2004, PHYSIOLOGY, V19, P253, DOI 10.1152/physiol.00012.2004; Schwartzkroin PA, 1997, EPILEPSIA, V38, P853, DOI 10.1111/j.1528-1157.1997.tb01250.x; Shetty AK, 1997, EXP NEUROL, V143, P231, DOI 10.1006/exnr.1996.6363; Shetty AK, 2007, HIPPOCAMPUS, V17, P943, DOI 10.1002/hipo.20311; Shetty AK, 2007, STEM CELLS, V25, P2396, DOI 10.1634/stemcells.2007-0313; Siemen Henrike, 2008, V423, P131, DOI 10.1007/978-1-59745-194-9_8; Sloviter RS, 2006, J COMP NEUROL, V494, P944, DOI 10.1002/cne.20850; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; Steiner B, 2008, NEUROSCIENCE, V154, P521, DOI 10.1016/j.neuroscience.2008.04.023; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; Takahashi T, 2003, CIRCULATION, V107, P1912, DOI 10.1161/01.CIR.0000064899.53876.A3; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Thompson KW, 2005, NEUROSCIENCE, V133, P1029, DOI 10.1016/j.neuroscience.2005.03.003; Thompson KW, 2004, EPILEPSIA, V45, P4, DOI 10.1111/j.0013-9580.2004.29503.x; Trinh HH, 2006, EUR J NEUROSCI, V24, P2967, DOI 10.1111/j.1460-9568.2006.05194.x; Vallier L, 2004, STEM CELLS, V22, P2, DOI 10.1634/stemcells.22-1-2; Vezzani A, 1999, TRENDS NEUROSCI, V22, P25, DOI 10.1016/S0166-2236(98)01284-3; Walter C, 2007, J NEUROSCI, V27, P7541, DOI 10.1523/JNEUROSCI.0431-07.2007; Wang JM, 2005, J NEUROSCI, V25, P4706, DOI 10.1523/JNEUROSCI.4520-04.2005; Watanabe K, 2005, NAT NEUROSCI, V8, P288, DOI 10.1038/nn1402; Wernig M, 2004, J NEUROSCI, V24, P5258, DOI 10.1523/JNEUROSCI.0428-04.200; Westmoreland JJ, 2001, BIOCHEM BIOPH RES CO, V284, P674, DOI 10.1006/bbrc.2001.5031; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Wichterle H, 2001, DEVELOPMENT, V128, P3759; Wichterle H, 1999, NAT NEUROSCI, V2, P461, DOI 10.1038/8131; Wonders CP, 2008, DEV BIOL, V314, P127, DOI 10.1016/j.ydbio.2007.11.018; Yao S, 2006, P NATL ACAD SCI USA, V103, P6907, DOI 10.1073/pnas.0602280103; Ying QL, 2003, NAT BIOTECHNOL, V21, P183, DOI 10.1038/nbt780; Yun K, 2002, DEVELOPMENT, V129, P5029; Zeng JM, 2007, STEM CELLS, V25, P1055, DOI 10.1634/stemcells.2006-0616; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhang SC, 2006, BRAIN PATHOL, V16, P132, DOI 10.1111/j.1750-3639.2006.00008.x; Zhao Y, 2008, J COMP NEUROL, V510, P79, DOI 10.1002/cne.21772	120	25	30	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	APR	2009	6	2					263	277		10.1016/j.nurt.2009.01.011			15	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Pharmacology & Pharmacy	425TL	WOS:000264659900008	19332319	Green Accepted, Green Submitted, Green Published			2022-02-06	
J	Straume-Naesheim, TM; Andersen, TE; Holme, IMK; McIntosh, AS; Dvorak, J; Bahr, R				Straume-Naesheim, Truls M.; Andersen, Thor Einar; Holme, Ingar Morten K.; McIntosh, Andrew S.; Dvorak, Jiri; Bahr, Roald			DO MINOR HEAD IMPACTS IN SOCCER CAUSE CONCUSSIVE INJURY? A PROSPECTIVE CASE-CONTROL STUDY	NEUROSURGERY			English	Article						Brain injury; Closed head trauma; Neuropsychological tests	COLLEGIATE FOOTBALL PLAYERS; PROFESSIONAL FOOTBALL; COGNITIVE IMPAIRMENT; NCAA CONCUSSION; ELITE FOOTBALL; NECK INJURIES; SPORTS; TRAUMA; BRAIN; TESTS	OBJECTIVE: Our objective was to determine whether minor head trauma in elite soccer matches causes measurable impairment in brain function. METHODS: Baseline neuropsychological testing was completed by professional soccer players in the Norwegian elite league, Tippeligaen, before the 2004 and 2005 seasons (n = 462). A player who experienced a head impact during a league match completed a follow-up test the next day (head impact group). Videotapes of all impacts were collected and reviewed. A group of players without head impacts was also tested after a league match to serve as controls (matched control group; n = 47). RESULTS: A total of 228 impacts were identified, and 44 (19.3%) of these were followed up with a CogSport test (CogState, Ltd., Charlton South, Australia; the players who were tested tended to have more severe injuries, but there were only 6 cases with loss of consciousness). The head impact group had a greater change in reaction time from baseline to follow-up compared with the matched control group with regard to the 3 simplest tasks. The largest deficits were seen among the players reporting acute symptoms after the impact, but deficits were also demonstrated among asymptomatic players. Players who experienced 1 or more head impacts during the 2004 season showed a reduction in neuropsychological performance when tested before the 2005 season. However, none of these players was impaired when compared with the test manufacturer's normative data. CONCLUSION: A reduced neuropsychological performance was found after minor head impacts in soccer, even in allegedly asymptomatic players. However, the long-term cognitive consequences are uncertain.	[Straume-Naesheim, Truls M.; Andersen, Thor Einar; Holme, Ingar Morten K.; McIntosh, Andrew S.; Bahr, Roald] Norwegian Sch Sports Sci, Oslo Sports Trauma Res Ctr, Dept Sports Med, N-0806 Oslo, Norway; [McIntosh, Andrew S.] Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia; [Dvorak, Jiri] Schulthess Clin, FIFA Med Assessment & Res Ctr, Zurich, Switzerland		Straume-Naesheim, TM (corresponding author), Norwegian Sch Sports Sci, Oslo Sports Trauma Res Ctr, Dept Sports Med, POB 4014,Ulleval Stad NO, N-0806 Oslo, Norway.	truls.straume-nesheim@nih.no	Bahr, Roald/B-6964-2014	Bahr, Roald/0000-0001-5725-4237; Andersen, Thor Einar/0000-0003-4172-4518			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Andersen TE, 2004, BRIT J SPORT MED, V38, P626, DOI 10.1136/bjsm.2003.007955; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Babbs C F, 2001, ScientificWorldJournal, V1, P281; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2005, SPORTS NEUROPSYCHOLO, P240; Darby D, 2002, NEUROLOGY, V59, P1042, DOI 10.1212/WNL.59.7.1042; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Falleti MG, 2003, J SLEEP RES, V12, P265, DOI 10.1111/j.1365-2869.2003.00363.x; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; Naunheim RS, 2003, MED SCI SPORT EXER, V35, P1406, DOI 10.1249/01.MSS.0000078933.84527.AE; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Rahnama N, 2002, BRIT J SPORT MED, V36, P354, DOI 10.1136/bjsm.36.5.354; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Silbert BS, 2004, BRIT J ANAESTH, V92, P814, DOI 10.1093/bja/aeh157; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; Straume-Naesheim TM, 2008, NEUROSURGERY, V62, P1297, DOI 10.1227/01.neu.0000333301.34189.3d; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	40	25	25	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2009	64	4					719	725		10.1227/01.NEU.0000340681.12949.6D			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	427MN	WOS:000264783500034	19349829	Green Submitted			2022-02-06	
J	Olivecrona, M; Zetterlund, B; Rodling-Wahlstrom, M; Naredi, S; Koskinen, LOD				Olivecrona, Magnus; Zetterlund, Bo; Rodling-Wahlstrom, Marie; Naredi, Silvana; Koskinen, Lars-Owe D.			Absence of electroencephalographic seizure activity in patients treated for head injury with an intracranial pressure-targeted therapy	JOURNAL OF NEUROSURGERY			English	Article						continuous EEG; head injury; seizure	TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; NONCONVULSIVE STATUS EPILEPTICUS; CONTINUOUS EEG; HEMORRHAGE; PRINCIPLES; EDEMA	Object. The authors prospectively studied the occurrence of clinical and nonclinical electroencephalographically verified seizures during treatment with an intracranial pressure (ICP)-targeted protocol in patients with traumatic brain injury (TBI). Methods. All patients treated for TBI at the Department of Neurosurgery, University Hospital Umea, Sweden, were eligible for the stud. The inclusion was consecutive and based on the availability of the electroencephalographic (EEG) monitoring equipment. Patients were included irrespective of pupil size, pupil reaction, or level of consciousness as long as their first measured cerebral perfusion pressure was > 10 mm Hg. The patients were treated in a protocol-guided manner with an ICP-targeted treatment based on the Lund concept. The patients were continuously sedated with midazolam, fentanyl, propofol, or thiopental, or combinations thereof. Five-lead continuous EEG monitoring was performed with the electrodes at F3, F4, P3, P4, and a midline reference. Sensitivity was set at 100 mu V per cm and filter settings 0.5-70 Hz. Amplitude-integrated EEG recording and relative band power trends were displayed. The trends were analyzed offline by trained clinical neurophysiologists. Results. Forty-seven patients (mean age 40 years) were studied. Their median Glasgow Coma Scale score at the time of sedation and intubation was 6 (range 3-15). In 8.5% of the patients clinical seizures were observed before sedation and intubation. Continuous EEG monitoring was performed for a total of 7334 hours. During this time neither EEG nor clinical seizures were observed. Conclusions. Our protocol-guided ICP targeted treatment seems to protect patients with severe TBI from clinical and subclinical seizures and thus reduces the risk of secondary brain injury. (DOI: 10.3171/2008.4.17538)	[Olivecrona, Magnus; Koskinen, Lars-Owe D.] Univ Hosp, Dept Neurosurg, SE-90185 Umea, Sweden; [Zetterlund, Bo] Univ Hosp, Dept Clin Neurophysiol, SE-90185 Umea, Sweden; [Rodling-Wahlstrom, Marie; Naredi, Silvana] Univ Hosp, Dept Anaesthesiol, SE-90185 Umea, Sweden		Olivecrona, M (corresponding author), Univ Hosp, Dept Neurosurg, SE-90185 Umea, Sweden.	magnus.olivecrona@vll.se	Koskinen, Lars-Owe/AAQ-8957-2020	Koskinen, Lars-Owe/0000-0003-3528-8502; Olivecrona, Magnus/0000-0001-8457-4711; Naredi, Silvana/0000-0002-4409-6089	Department of Neurosciences at Umea University; Umea University Hospital General Foundation; Capio Research Foundation; Tore Nilssons Foundation	This study was supported by grants from the Department of Neurosciences at Umea University, Umea University Hospital General Foundation, Capio Research Foundation, and Tore Nilssons Foundation.	ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen Jan, 2002, Curr Neurol Neurosci Rep, V2, P534, DOI 10.1007/s11910-002-0042-1; Grande P O, 1997, Acta Anaesthesiol Scand Suppl, V110, P36; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; GRANDMAISON F, 1991, ELECTROEN CLIN NEURO, V79, P264, DOI 10.1016/0013-4694(91)90121-J; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P14, DOI 10.1097/00004691-199901000-00002; JORDAN KG, 1995, NEUROL CLIN, V13, P579, DOI 10.1016/S0733-8619(18)30035-5; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P332, DOI 10.1097/00004691-199907000-00005; Kollevold T, 1976, J Oslo City Hosp, V26, P99; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; LABAR DR, 1991, ELECTROEN CLIN NEURO, V78, P325, DOI 10.1016/0013-4694(91)90094-K; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; LOWENSTEIN DH, 1992, NEUROLOGY, V42, P100, DOI 10.1212/WNL.42.1.100; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; PAYEN D, 1990, CRIT CARE MED, V18, P392, DOI 10.1097/00003246-199004000-00008; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Privitera Michael D., 1994, Emergency Medicine Clinics of North America, V12, P1089; Procaccio F, 2001, Curr Opin Crit Care, V7, P74, DOI 10.1097/00075198-200104000-00004; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; Scheuer ML, 2002, EPILEPSIA, V43, P114, DOI 10.1046/j.1528-1157.43.s.3.7.x; Spencer E M, 1990, Intensive Care World, V7, P34; SYNEK VM, 1988, CLIN ELECTROENCEPHAL, V19, P160, DOI 10.1177/155005948801900310; Theilen HJ, 2000, CRIT CARE MED, V28, P3522, DOI 10.1097/00003246-200010000-00029; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2002, J NEUROSURG, V97, P84, DOI 10.3171/jns.2002.97.1.0084; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Young GB, 1996, NEUROLOGY, V47, P83	39	25	26	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2009	110	2					300	305		10.3171/2008.4.17538			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	399GI	WOS:000262788000015	18759609	Green Submitted			2022-02-06	
J	Adeleye, AO; Olowookere, KG; Olayemi, OO				Adeleye, A. O.; Olowookere, K. G.; Olayemi, O. O.			Clinicoepidemiological Profiles and Outcomes during First Hospital Admission of Head Injury Patients in Ikeja, Nigeria A Prospective Cohort Study	NEUROEPIDEMIOLOGY			English	Article						Head injury, Nigeria; Clinicoepidemiological profiles	TRAUMATIC BRAIN-INJURIES; CARE; PERSPECTIVE; HYPOTENSION; MANAGEMENT; PATTERN; IBADAN; KENYA	Background: Although head injury ( HI) is a major public health problem in Nigeria and other low and middle income countries of the world, there is a paucity of data from these societies. This is largely due to under-reporting. We carried out a prospective study of the clinicoepidemiological profiles and outcomes following the first hospitalization of a cohort of head-injured patients in Ikeja, Nigeria, a metropolitan African city. Methods: In an 8-month period from May until December 2005, data from all HI cases seen in our neurosurgical unit were prospectively recorded for subsequent analysis. These include demographics, mechanism of injury, pre-neurosurgical care received, severity of injury using the Glasgow Coma Scale, presence of hemodynamic instability, pupillary anomalies and associated systemic injuries, cranial computed tomography (CT) findings and the number of surgical interventions, as well as outcomes after the first hospital admission using the Glasgow Outcome Scale. Determinants of outcome were explored using the chi(2) test and the level of significance was put at p = 0.05. Results: There were 143 cases of HI, which is about one fifth of our total workload, including 122 males and 21 females aged 0.5-85 years (mean age 29.15). The majority (88%) were either school children or low income earners. Road accidents accounted for 75% of the cases; three quarter of the cases had some initial care in other health facilities before the arrival in our unit, at an average of 33 h. Mild, moderate and severe HI accounted for 60, 18 and 22%, respectively. About a quarter of the patients sustained other systemic injuries. Cranial CT scanning was obtainable in 40 patients (28%); 9 of these revealed surgical mass lesions, of whom 5 had life-saving operations. Many well-known determinants of a poor outcome of HI were prevalent in this study group and found to have a significantly adverse effect on patient outcome. Conclusions: HI is a major public health problem in Nigeria, taking up at least one fifth of the neurosurgical workload. The prehospital emergency medical service is poorly organized. Determinants of a poor outcome of HI are highly prevalent, including poor accessibility to cranial CT scanning, absence or inadequacy of logistics for neurocritical care and an inadequate number of neurosurgeons. Copyright (C) 2008 S. Karger AG, Basel	[Adeleye, A. O.] Univ Ibadan, Dept Surg, Div Neurosurg, Coll Med, Ibadan, Nigeria; [Adeleye, A. O.] Univ Coll Ibadan Hosp, Ibadan, Nigeria; [Olayemi, O. O.] Univ Ibadan, Coll Med, Dept Obstet & Gynecol, Ibadan, Nigeria; [Olowookere, K. G.] Lagos State Univ, Teaching Hosp, Dept Surg, Ikeja, Nigeria		Adeleye, AO (corresponding author), Univ Ibadan, Dept Surg, Div Neurosurg, Coll Med, PMB 5116, Ibadan, Nigeria.	femdoy@yahoo.com					ADELOYE A, 1976, INT SURG, V61, P478; Adeloye A, 1997, E AFR MED J, V74, P822; ADEOLU AA, 2005, INTERNET J EPIDEMIOL, V2, pN2; Akang EEU, 2002, MED SCI LAW, V42, P160, DOI 10.1177/002580240204200207; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; Basso A, 2001, WORLD J SURG, V25, P1174; Broessner G, 2007, CRIT CARE MED, V35, P2025, DOI 10.1097/01.ccm.0000281449.07719.2b; CHI JH, 2003, SEMIN NEUROSURG, V23, P71; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; Elesha S O, 2002, Niger Postgrad Med J, V9, P38; Huynh T, 2006, AM SURGEON, V72, P1162; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Igun GO, 2000, E AFR MED J, V77, P9; JENNETT B, 1973, LANCET, V1, P480; Joshipura MK, 2003, INJURY, V34, P686, DOI 10.1016/S0020-1383(03)00163-3; Liko O., 1996, Papua New Guinea Medical Journal, V39, P100; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MUHAMMAD I, 1990, E AFR MED J, V67, P447; Muyembe VM, 1998, E AFR MED J, V75, P364; NWAGOMBE NJ, 2001, E AFR MED J, V78, P238; Odebode TO, 2004, PEDIATR SURG INT, V20, P348, DOI 10.1007/s00383-004-1196-5; OHAEGBULAM SC, 1978, AFR J MED MED SCI, V7, P23; Otieno T, 2004, INJURY, V35, P1228, DOI 10.1016/j.injury.2004.03.013; Raja IA, 2001, WORLD J SURG, V25, P1230; Shokunbi T, 1994, West Afr J Med, V13, P38; SILVERSTON P, 1989, BRIT MED J, V298, P711, DOI 10.1136/bmj.298.6675.711; Solagberu B A, 2003, West Afr J Med, V22, P177; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; TEASDALE G, 1974, LANCET, V2, P81; Thanni L O A, 2006, Afr Health Sci, V6, P104; Tiesman H, 2007, J NEUROTRAUM, V24, P1189, DOI 10.1089/neu.2006.0196	31	25	25	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350	1423-0208		NEUROEPIDEMIOLOGY	Neuroepidemiology		2009	32	2					136	141		10.1159/000182821			6	Public, Environmental & Occupational Health; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Public, Environmental & Occupational Health; Neurosciences & Neurology	395UL	WOS:000262548900009	19088486				2022-02-06	
J	Alexandersen, A; Dalen, K; Bronnick, K				Alexandersen, Alice; Dalen, Knut; Bronnick, Kolbojrn			Prediction of driving ability after inconclusive neuropsychological investigation	BRAIN INJURY			English	Article						Central nervous system diseases; neuropsychological tests; executive functions; on-road evaluation; automobile driving	TRAUMATIC BRAIN-INJURY; ALZHEIMER-TYPE; DEMENTIA; PERFORMANCE; ATTENTION; COMPETENCE; DRIVERS; FITNESS; RETURN	Objective: The aim of the present study was to investigate the predictive value of neuropsychological tests for on-road evaluation outcome after inconclusive assessment. Methods and procedures: Thirty-five patients were assessed neurologically, neuropsychologically by traditional clinical tests and by on-road evaluation. Simple univariate tests, logistic regression and ROC-curve analysis were used to investigate the predictive power of different neuropsychological tests. Main outcomes and results: Six measures from the California Computerized Assessment Package (CalCAP) and the Digit-Symbol test from Wechsler Adult Intelligence Scale predicted the outcome of the on-road evaluation. A logistic regression analysis showed that a model with two variables from CalCAP and the Digit Symbol test predicted the results of the on-road driving evaluation with an overall accuracy of 84.8%. Conclusions: The findings indicate that the outcome of on-road assessment is most related to cognitive skills such as attention and processing speed in combination with cognitive flexibility.	[Alexandersen, Alice] Stavanger Univ Hosp, Div Med, Dept Phys Med & Rehabil, N-4022 Stavanger, Norway; [Dalen, Knut] Univ Bergen, Dept Biol & Med Psychol, N-5020 Bergen, Norway; [Bronnick, Kolbojrn] Stavanger Univ Hosp, Norwegian Ctr Movement Disorders, N-4022 Stavanger, Norway		Alexandersen, A (corresponding author), Stavanger Univ Hosp, Div Med, Dept Phys Med & Rehabil, Rektor Berntsensgt 12, N-4022 Stavanger, Norway.	alice.alexandersen@sus.no		Bronnick, Kolbjorn/0000-0002-9156-1633			Adler G, 2005, J SAFETY RES, V36, P399, DOI 10.1016/j.jsr.2005.07.005; Barkley RA, 2002, J INT NEUROPSYCH SOC, V8, P655, DOI 10.1017/S1355617702801345; Bieliauskas LA, 2005, BRAIN INJURY, V19, P221, DOI 10.1080/02699050400017213; Brooks DJ, 2006, J ADDICT DIS, V25, P15, DOI 10.1300/J069v25n04_02; Brooks N, 2005, BRAIN INJURY, V19, P165, DOI 10.1080/02699050410001720004; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; Chang L, 2003, ANTIVIR THER, V8, P17; Daigneault G, 2002, J CLIN EXP NEUROPSYC, V24, P221, DOI 10.1076/jcen.24.2.221.993; Duchek JM, 1997, ALZ DIS ASSOC DIS, V11, P48, DOI 10.1097/00002093-199706001-00011; FIELD A., 2006, DISCOVERING STAT USI; GALSKI T, 1992, AM J OCCUP THER, V46, P324, DOI 10.5014/ajot.46.4.324; Galski T, 2000, J HEAD TRAUMA REHAB, V15, P895, DOI 10.1097/00001199-200006000-00004; Hawley CA, 2001, J NEUROL NEUROSUR PS, V70, P761, DOI 10.1136/jnnp.70.6.761; HEATON R, 1990, PAR STAFF WCST CV4 W; Hunt LA, 1997, ALZ DIS ASSOC DIS, V11, P13, DOI 10.1097/00002093-199706001-00004; Kakaiya R, 2000, POSTGRAD MED, V107, P229, DOI 10.3810/pgm.2000.03.953; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Lundqvist A, 2001, BRAIN INJURY, V15, P981, DOI 10.1080/02699050110065637; Lundqvist A, 2008, BRAIN INJURY, V22, P295, DOI 10.1080/02699050801966133; Lundqvist A, 2007, BRAIN INJURY, V21, P1109, DOI 10.1080/02699050701651660; Lundqvist A, 1997, APPL NEUROPSYCHOL, V4, P220, DOI 10.1207/s15324826an0404_3; *MARK DEP SPSS INC, 1999, SPSS STAT PACK SOC S; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; MCCORMACK PD, 1964, CAN J PSYCHOLOGY, V18, P43, DOI 10.1037/h0083285; MILLER EN, 1990, CALIFORNIA COMPUTERI; *NAT HLTH SERV O N, 1997, GUID US HLTH CERT DR; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; Reger MA, 2004, NEUROPSYCHOLOGY, V18, P85, DOI 10.1037/0894-4105.18.1.85; Reitan R.M., 1993, HALSTEADREITAN NEURO; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; Schanke AK, 2000, SCAND J PSYCHOL, V41, P113, DOI 10.1111/1467-9450.00179; Schanke Anne-Kristine, 1995, Tidsskrift for den Norske Laegeforening, V115, P1349; Schanke Anne-Kristine, 1999, Tidsskrift for den Norske Laegeforening, V119, P954; Schmidt I W, 1996, Appl Neuropsychol, V3, P155, DOI 10.1207/s15324826an0303&4_8; Shawaryn MA, 2002, ARCH PHYS MED REHAB, V83, P1123, DOI 10.1053/apmr.2002.33730; Taylor MJ, 2001, J INT NEUROPSYCH SOC, V7, P867, DOI 10.1017/S1355617701777107; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; Whelihan WM, 2005, ARCH CLIN NEUROPSYCH, V20, P217, DOI 10.1016/j.acn.2004.07.002	41	25	25	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	4					313	321	PII 909310802	10.1080/02699050902788428			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	425MY	WOS:000264643000006	19274519				2022-02-06	
J	Bay, E; Sikorskii, A; Gao, FL				Bay, Esther; Sikorskii, Alla; Gao, Fuli			Functional Status, Chronic Stress, and Cortisol Response After Mild-to-Moderate Traumatic Brain Injury	BIOLOGICAL RESEARCH FOR NURSING			English	Article						chronic stress; functional status; traumatic brain injury; depressive symptoms; allostatic load	COMPETENCE RATING-SCALE; POSTCONCUSSIVE SYMPTOMS; RISK-FACTORS; HEAD-INJURY; DEPRESSION; RELIABILITY; DISABILITY; DISORDERS; AWARENESS; RECOVERY	It is well known that individuals experience difficulties with depressive symptoms and functional status after traumatic brain injury. However, it is unclear what the relationship is between these 2 phenomena and whether there is a biological explanation for. In this secondary analysis, we examined whether depressive symptoms explained postinjury functional status and whether chronic stress and salivary cortisol influenced this relationship. Participants included 75 persons within 24 months of their injury dates who were evaluated or treated in specialty clinics. All participants and a family member or significant other completed survey data, and 50 of the participants provided cortisol data. Results indicated that chronic stress, measured using Cohen's Perceived Stress Scale, completely mediated the relationship between depressive symptoms, measured using the Center for Epidemiological Studies Depression Scale, and psychological functioning, measured using the Patient Competency Rating Scale. Furthermore, those who provided cortisol data displayed hypocortisolemia in their 12-hr profile. Results froth this analysis suggest that interventions focused on addressing the chronic stress experience may be important in limiting depressive symptoms and improving psychological functioning. Longitudinal study of this phenomenon is required to understand the progression of chronic stress after traumatic brain injury.	[Bay, Esther; Sikorskii, Alla; Gao, Fuli] Michigan State Univ, Coll Nursing, E Lansing, MI 48824 USA		Bay, E (corresponding author), Michigan State Univ, Coll Nursing, A417 W Fee, E Lansing, MI 48824 USA.	baye@msu.edu					Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; Bay Esther, 2006, Care Manag J, V7, P3, DOI 10.1891/cmaj.7.1.3; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bay E, 2007, ARCH PSYCHIAT NURS, V21, P2, DOI 10.1016/j.apnu.2006.07.005; Bay Esther, 2005, J Neurosci Nurs, V37, P4; Bay Esther, 2004, Res Theory Nurs Pract, V18, P213, DOI 10.1891/rtnp.18.2.213.61278; Bay Esther, 2007, J Neurosci Nurs, V39, P43; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; *CDCP, 2007, TRAUM BRAIN INJ FACT; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cohen S, 1995, MEASURING STRESS GUI; *COMBI, 2005, PCRS PROP; Conrad CD, 2004, NEUROSCIENCE, V125, P759, DOI 10.1016/j.neuroscience.2004.01.049; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dudley WN, 2004, NURS RES, V53, P59, DOI 10.1097/00006199-200401000-00009; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Flesher MR, 2001, BRAIN INJURY, V15, P879, DOI 10.1080/02699050110065682; Gaab J, 2005, PSYCHONEUROENDOCRINO, V30, P599, DOI 10.1016/j.psyneuen.2005.02.001; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Karlamangla AS, 2006, PSYCHOSOM MED, V68, P500, DOI 10.1097/01.psy.0000221270.93985.82; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2; Kraemer HC, 2006, AM J GERIAT PSYCHIAT, V14, P325, DOI 10.1097/01.JGP.0000201816.26786.5b; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; MacKinnon D P, 2000, Prev Sci, V1, P173, DOI 10.1023/A:1026595011371; MAIO R, 2006, ACAD EMERG MED, V13, pS1; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; McBeth J, 2007, ARTHRITIS RHEUM-US, V56, P360, DOI 10.1002/art.22336; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; McEwen B., 2002, END STRESS WE KNOW I; McEwen BS, 2003, BIOL PSYCHIAT, V54, P200, DOI 10.1016/S0006-3223(03)00177-X; MCNAIR DM, 1964, J ABNORM SOC PSYCH, V69, P620, DOI 10.1037/h0040902; MCNAIR DM, 2002, PROFILE MOOD STATES; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Miller MM, 2006, ANN NY ACAD SCI, V1071, P294, DOI 10.1196/annals.1364.023; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Sapolsky R, 2003, SCI AM, V289, P86, DOI 10.1038/scientificamerican0903-86; *SAS SOFTW, 2002, SAS SYST WIND, V9; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; Sherman EMS, 2000, BRAIN INJURY, V14, P621; SOBEL ME, 1990, PSYCHOMETRIKA, V55, P495, DOI 10.1007/BF02294763; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; TEASDALE G, 1974, LANCET, V2, P81; Tsigos C, 2002, J PSYCHOSOM RES, V53, P865, DOI 10.1016/S0022-3999(02)00429-4; Vitaz TW, 2003, SURG NEUROL, V60, P285, DOI 10.1016/S0090-3019(03)00378-1; WHITEGBADEBO D, 1993, J NEUROTRAUM, V10, P297, DOI 10.1089/neu.1993.10.297; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organization, 2001, INT CLASS FUNCT ICF; Yang CH, 2004, J NEUROSCI, V24, P11029, DOI 10.1523/JNEUROSCI.3968-04.2004	69	25	25	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1099-8004	1552-4175		BIOL RES NURS	Biol. Res. Nurs.	JAN	2009	10	3					213	225		10.1177/1099800408326453			13	Nursing	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Nursing	386UH	WOS:000261907600003	19015162				2022-02-06	
J	Broglio, SP; Sosnoff, JJ; Rosengren, KS; McShane, K				Broglio, Steven P.; Sosnoff, Jacob J.; Rosengren, Karl S.; McShane, Kate			A Comparison of Balance Performance: Computerized Dynamic Posturography and a Random Motion Platform	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Posture; Rehabilitation	POSTURAL CONTROL; DEVELOPMENTAL PERSPECTIVE; SENSORY ORGANIZATION; PARKINSONS-DISEASE; CONCUSSION; STABILITY; GAIT; DISORDERS; DEFICITS	Objective: To establish the clinical utility of the PROPRIO 5000 as a balance assessment device by establishing convergent validity with the NeuroCom sensory organization test (SOT). Design: Cross-sectional. Setting: Balance research laboratory. Participants: Young adults (N=40; 21.1 +/- 1.4y). Interventions: Not applicable. Main Outcome Measures: Performance on each of the 6 NeuroCom SOT testing conditions and PROPRIO 5000 dynamic motion analysis score. Results: Correlational analyses between output variables yielded significant relationships between the dynamic motion analysis score from the 0 to 10 second (r=-.38), 10 to 20 second (r=-.34), and 20 to 30 second (r=-.35) intervals and the SOT composite balance score. Conclusions: The initial stages of the PROPRIO 5000 and the NeuroCom SOT battery may evaluate similar aspects of postural control. However, as the magnitude of PROPRIO perturbations increased, the relationship between the devices diverged and the complete PROPRIO assessment is not thought to pair with the SOT assessment. Differences between the 2 devices may be associated with varying degrees of test difficulty and the necessary Postural control strategies involved in responding to continual balance perturbations (PROPRIO 5000) or to different sensory inputs (SOT).	[Broglio, Steven P.; Sosnoff, Jacob J.; Rosengren, Karl S.; McShane, Kate] Univ Illinois, Dept Kinesiol & Community Hlth, Champaign, IL USA; [Rosengren, Karl S.] Univ Illinois, Dept Psychol, Champaign, IL USA		Broglio, SP (corresponding author), Dept Kinesiol & Community Hlth, 906 Goodwin Ave, Urbana, IL 61801 USA.	broglio@uiuc.edu	Sosnoff, Jacob/P-3397-2019	Sosnoff, Jacob/0000-0002-0286-9207; Rosengren, Karl/0000-0003-1448-1282			Amiridis IG, 2003, NEUROSCI LETT, V350, P137, DOI 10.1016/S0304-3940(03)00878-4; Arokoski JPA, 2006, GAIT POSTURE, V23, P45, DOI 10.1016/j.gaitpost.2004.11.017; Black FO, 2001, CURR OPIN OTOLARYNGO, V9, P314, DOI DOI 10.1097/00020840-200110000-00011; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Doyle RJ, 2007, GAIT POSTURE, V25, P166, DOI 10.1016/j.gaitpost.2006.03.004; FORDSMITH CD, 1995, ARCH PHYS MED REHAB, V76, P77, DOI 10.1016/S0003-9993(95)80047-6; Frzovic D, 2000, ARCH PHYS MED REHAB, V81, P215, DOI 10.1053/apmr.2000.0810215; GAGON I, 2006, PHYS OCCUP THER PEDI, V26, P23; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HIRABAYASHI S, 1995, BRAIN DEV-JPN, V17, P111, DOI 10.1016/0387-7604(95)00009-Z; Hirsch MA, 2003, ARCH PHYS MED REHAB, V84, P1109, DOI 10.1016/S0003-9993(03)00046-7; Horak F., 1996, HDB PHYSL EXERCISE R, DOI 10.1002/cphy.cp120107; Horak FB, 2006, AGE AGEING, V35, P7, DOI 10.1093/ageing/afl077; KUO AD, 1993, PROG BRAIN RES, V97, P349; *LOG INC, 1992, 3D MOUS HEAD TRACK T; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Morton SM, 2004, NEUROSCIENTIST, V10, P247, DOI 10.1177/1073858404263517; Nallegowda M, 2004, AM J PHYS MED REHAB, V83, P898, DOI 10.1097/01.PHM.0000146505.18244.43; Nashner L.M., 1993, HDB BALANCE FUNCTION, P261; Nashner L.M., 1997, HDB BALANCE FUNCTION, P280; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; NASHNER LM, 1982, J NEUROSCI, V2, P536; Peterka R J, 1990, J Vestib Res, V1, P73; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Romberg M.H, 1853, MANUAL NERVOUS DIS M, V2nd; Rosengren KS, 2007, GAIT POSTURE, V25, P215, DOI 10.1016/j.gaitpost.2006.03.009; Schapira AHV, 2004, JAMA-J AM MED ASSOC, V291, P358, DOI 10.1001/jama.291.3.358; Shimada H, 2003, AM J PHYS MED REHAB, V82, P511, DOI 10.1097/01.PHM.0000064726.59036.CB; SHUMWAYCOOK A, 1985, J MOTOR BEHAV, V17, P131; SIMS EL, J APPL BIOM IN PRESS; Whitney SL, 2006, ARCH PHYS MED REHAB, V87, P402, DOI 10.1016/j.apmr.2005.11.002	32	25	26	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2009	90	1					145	150		10.1016/j.apmr.2008.06.025			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	397IY	WOS:000262657600020	19154841				2022-02-06	
J	Capitani, E; Rosci, C; Saetti, MC; Laiacona, M				Capitani, Erminio; Rosci, Chiara; Saetti, Maria Cristina; Laiacona, Marcella			Mirror asymmetry of Category and Letter fluency in traumatic brain injury and Alzheimer's patients	NEUROPSYCHOLOGIA			English	Article						Verbal fluency; Traumatic brain injury; Alzheimer's disease	VERBAL FLUENCY; SEMANTIC MEMORY; PERFORMANCE; DEMENTIA	In this study we contrasted the Category fluency and Letter fluency performance of 198 normal subjects, 57 Alzheimer's patients and 57 patients affected by traumatic brain injury (TBI). The aim was to check whether, besides the prevalence of Category fluency deficit often reported among Alzheimer's patients, the TBI group presented the opposite dissociation. According to some recent claims, in fact, the deficit of TBI would be equally severe for both fluency types. The inquiry followed different approaches for data analysis, including the evaluation of a unique index (Fluency Type Index or FTI), independent of the overall fluency and aimed at expressing at individual subject level the relationship between Category and Letter fluency. The results confirmed that Alzheimer's patients are more defective on Category than Letter fluency, and also clearly indicated that an opposite pattern applies to TBI patients. TBI seems to cause a relatively more severe impairment of Letter than Category fluency, probably due to its impact on the frontal lobe structures. We discuss whether, on the basis of the statistical distribution of our data, it is worth considering as homogeneous populations broadly defined groups as Alzheimer's or TBI patients. (C) 2008 Elsevier Ltd. All rights reserved.	[Capitani, Erminio; Saetti, Maria Cristina] Univ Milan, Milan, Italy; [Rosci, Chiara] S Paolo Hosp, Milan, Italy; [Laiacona, Marcella] Veruno Med Ctr, S Maugeri Fdn, Veruno, Italy		Capitani, E (corresponding author), Univ Milan, Milan, Italy.	erminio.capitani@unimi.it		SAETTI, MARIA CRISTINA/0000-0001-5867-5981	Milan University	This project was partly supported by a PRIN 2005 Grant to E.C. and by a FIRST Grant from Milan University. Rita Frosio and Micol Vecchio kindly assisted with the collection of normal subjects' data. Monica Fabiani, Valeria Masiello and Daniela Sacco assisted with the examination of TBI patients. Preliminary findings were presented at the 46th Annual Meeting of the Academy of Aphasia, Turku, 2008.; Rosemary Allpress revised the English text.	ACKERMANN H, 1985, MEHRIMENSIONALE NICH; Beldarrain MG, 1999, NEUROLOGY, V52, P1853, DOI 10.1212/WNL.52.9.1853; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Henry JD, 2004, NEUROPSYCHOLOGIA, V42, P1212, DOI 10.1016/j.neuropsychologia.2004.02.001; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Jurado MA, 2000, BRAIN INJURY, V14, P789; LAIACONA M, 1989, CORTEX, V25, P261, DOI 10.1016/S0010-9452(89)80042-5; METHA C, 2004, STATXACT; MONSCH AU, 1992, ARCH NEUROL-CHICAGO, V49, P1253, DOI 10.1001/archneur.1992.00530360051017; MURPHY RB, 1948, ANN MATH STAT, V19, P581, DOI 10.1214/aoms/1177730154; NATRELLA MG, 1966, EXPT STAT; NEBES RD, 1984, J ABNORM PSYCHOL, V93, P321, DOI 10.1037/0021-843X.93.3.321; OBER BA, 1986, J CLIN EXP NEUROPSYC, V8, P75, DOI 10.1080/01688638608401298; Reverberi C, 2006, NEUROPSYCHOLOGIA, V44, P469, DOI 10.1016/j.neuropsychologia.2005.05.011; ROY SN, 1953, ANN MATH STAT, V24, P513, DOI 10.1214/aoms/1177728912; Schwartz S, 2003, BRAIN LANG, V87, P400, DOI 10.1016/S0093-934X(03)00141-X; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Suhr JA, 1998, ARCH CLIN NEUROPSYCH, V13, P447, DOI 10.1016/S0887-6177(97)00040-1; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Wilks SS, 1941, ANN MATH STAT, V12, P91, DOI 10.1214/aoms/1177731788	20	25	25	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JAN	2009	47	2					423	429		10.1016/j.neuropsychologia.2008.09.016			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	413TL	WOS:000263815300015	18929584				2022-02-06	
J	Fait, P; McFadyen, BJ; Swaine, B; Cantin, JF				Fait, P.; McFadyen, B. J.; Swaine, B.; Cantin, J. F.			Alterations to locomotor navigation in a complex environment at 7 and 30 days following a concussion in an elite athlete	BRAIN INJURY			English	Article						Attention; locomotion; multi-tasking; executive functioning; mild traumatic brain injury; sport	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COLLEGIATE FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; POSTURAL STABILITY; NCAA CONCUSSION; ATTENTION; GAIT; RECOVERY; DEFICITS	Primary objective: To compare the locomotor capacity during (1) unobstructed walking and (2) the circumvention of fixed obstacles with and without a simultaneous visual task in an elite athlete before and after a sports-related concussion. Research design: Case report. Methods and procedures: Gait analysis and clinical neuropsychological measures were taken pre- and at 7 and 30 days post-injury in an 18 year old male junior hockey player. The task consisted of walking along an unobstructed or obstructed path with or without a visual interference task. Measurements included dual tasks costs, response errors, maximal gait speed and minimal clearance with the obstacle. Main outcome and results: Although the athlete was symptom-free and neuropsychological test results returned to baseline relatively quickly, he showed continued errors in the interference task, abnormally small obstacle clearance distances and decreased maximal gait speed up to 30 days after the concussion. Conclusions: Concussion can result in persistent planning and attention deficits in ecologically valid, complex environments. This report suggests that functional assessment within an ecological context could be an innovative way to evaluate concussed athletes before sending them back to play, even in the absence of medically related symptoms or abnormal neuropsychological test results.	[Fait, P.; McFadyen, B. J.] Univ Laval, Fac Med, Dept Rehabil, Quebec City, PQ G1K 7P4, Canada; [Fait, P.; McFadyen, B. J.; Cantin, J. F.] Ctr Interdisciplinary Res Rehabil & Social Integr, Quebec City, PQ, Canada; [Swaine, B.] Univ Montreal, Fac Med, Ecole Readaptat, Montreal, PQ H3C 3J7, Canada; [Cantin, J. F.] Quebec Rehabil Inst, Quebec City, PQ, Canada		McFadyen, BJ (corresponding author), CIRRIS IRDPQ, 525 Boul, Hamel, PQ G1M 2S8, Canada.	brad.mcfadyen@rea.ulaval.ca		McFadyen, Bradford/0000-0003-1992-4927; Fait, Philippe/0000-0002-2554-9273	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	This study was supported in part by the Canadian Institutes for Health Research and the Natural Sciences and Engineering Research Council of Canada (BJ McFadyen).	Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Centers for Disease Control and Prevention and National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Chou LS, 2004, GAIT POSTURE, V20, P245, DOI 10.1016/j.gaitpost.2003.09.007; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Gerin-Lajoie M, 2005, MOTOR CONTROL, V9, P242, DOI 10.1123/mcj.9.3.242; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Golden CJ, 1978, STROOP COLOR WORD TE; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; KEATLEY MA, 2000, SYMPTOM QUESTI UNPUB; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McFadyen BJ, 2003, J HEAD TRAUMA REHAB, V18, P512, DOI 10.1097/00001199-200311000-00005; Miller E. N., 1990, CALCAP CALIFORNIA CO; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Robertson I., 1994, TEST EVERYDAY ATTENT; Smith A., 1982, SYMBOL DIGIT MODALIT; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; Wade LD, 1997, ARCH PHYS MED REHAB, V78, P1107, DOI 10.1016/S0003-9993(97)90136-2; Wai-Hang JL, 2002, ARE YOU LEFT HANDED; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	40	25	25	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	4					362	369	PII 909310678	10.1080/02699050902788485			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	425MY	WOS:000264643000012	19274521				2022-02-06	
J	Jamous, MA; Aziz, HA; Al Kaisy, F; Eloqayli, H; Azab, M; Al-Jarrah, M				Jamous, Mohammad A.; Aziz, Hani Abdel; Al Kaisy, Farouk; Eloqayli, Haytham; Azab, Mohammed; Al-Jarrah, Muhammed			Conservative Management of Acute Epidural Hematoma in a Pediatric Age Group	PEDIATRIC NEUROSURGERY			English	Article						Acute epidural hematoma; Children; Head injury; Conservative treatment	EXTRADURAL HEMATOMAS; CHILDREN	Objective: Craniotomy and evacuation is the standard treatment of acute epidural hematoma (EDH). Here, the authors report their experience in nonoperative management of acute EDH in children with mild head injury. Methods: The authors retrospectively reviewed charts of patients with conservatively treated EDH at the Department of Neurosurgery, King Abdulla University Hospital, Irbid, Jordan, between August 2003 and October 2007. All patients had a Glasgow Coma Scale score of 14 or 15, and an initial computerized tomography (CT) scan demonstrating an EDH with or without skull fractures. Follow-up included neurological examination and brain CT. Results: Six children (3 boys, 3 girls) with acute EDH were successfully managed at our department without surgical intervention. The Glasgow Outcome Scale score of all patients was 5, with no posttraumatic sequelae. Follow-up brain CT showed complete resolution of the EDH within 2-3 months. Conclusions: Our results demonstrated that pediatric EDH can be managed nonoperatively. The pronounced increase in the number of CT examinations for patients with head injuries has resulted in a greater proportion of EDH detected in conscious patients. We recommend such treatment be performed in specialized pediatric neurosurgical centers under close neurological observation. Copyright (C) 2009 S. Karger AG, Basel	[Jamous, Mohammad A.] Jordan Univ Sci & Technol, Sch Med, Dept Neurosci, Irbid 22110, Jordan; [Al-Jarrah, Muhammed] Jordan Univ Sci & Technol, Fac Appl Med Sci, Dept Physiotherapy, Irbid 22110, Jordan; [Azab, Mohammed] Jordan Univ Sci & Technol, Fac Med, Dept Toxicol & Forens Sci, Irbid 22110, Jordan		Jamous, MA (corresponding author), Jordan Univ Sci & Technol, Sch Med, Dept Neurosci, POB 3030, Irbid 22110, Jordan.	mojamous@yahoo.com	Solebo, Colette N/B-6615-2008	Solebo, Colette N/0000-0001-9764-2541; eloqayli, haytham/0000-0003-0021-0887; Al-Jarrah, Muhammed/0000-0003-2948-6932			Bejjani GK, 1996, PEDIATR NEUROSURG, V25, P302, DOI 10.1159/000121144; Cayli S, 1998, NEUROSURG REV, V21, P226, DOI 10.1007/BF01105776; CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004; Cheung PSY, 2007, INJURY, V38, P76, DOI 10.1016/j.injury.2006.08.059; Ciurea AV, 2007, CHILD NERV SYST, V23, P335, DOI 10.1007/s00381-006-0230-4; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; McLaurin R, 1989, PEDIATRIC NEUROSURGE, P277; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; PILLAY R, 1995, S AFR MED J, V85, P672; SCHUTZMAN SA, 1993, ANN EMERG MED, V22, P535, DOI 10.1016/S0196-0644(05)81938-9; Servadei F, 1988, Brain Inj, V2, P87, DOI 10.3109/02699058809150935	11	25	26	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.		2009	45	3					181	184		10.1159/000218200			4	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	459GX	WOS:000267090700003	19440005				2022-02-06	
J	Rutherford, A; Stephens, R; Fernie, G; Potter, D				Rutherford, Andrew; Stephens, Richard; Fernie, Gordon; Potter, Douglas			Do UK university football club players suffer neuropsychological impairment as a consequence of their football (soccer) play?	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Concussion; Heading; Head trauma; Neuropsychological impairment; Neuropsychology	TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; AMATEUR BOXING LEAD; HEAD-INJURY; SERUM CONCENTRATIONS; BONFERRONI PROCEDURE; BIOCHEMICAL MARKERS; MULTIPLE TESTS; DAMAGE S-100B; CONCUSSION	Male players from football and rugby clubs and sportsmen from a variety of noncontact sports clubs at a UK university were compared on biographical and neuropsychological test measures. A data analysis paradigm was developed and employed to control the inflation of Type 1 error rate due to multiple hypotheses testing. Rugby players sustained most head injuries in their chosen sport, but neuropsychological tests of attention, memory, and executive function provided no evidence of performance impairment attributable to the number of head injuries sustained or the football, rugby, or noncontact sport groups. Footballers' heading frequency was related to the number of football head injuries sustained, but no relationship was detected between footballers' heading frequency and their neuropsychological test performance. Following discussion of pertinent methodological limitations it is concluded that there was no evidence in this dataset of neuropsychological impairment consistent with either mild head injury incidence or football heading frequency. However, a need for further research examining the long-term neuropsychological consequences of such head injuries was identified.	[Rutherford, Andrew] Univ Keele, Sch Psychol, Keele ST5 5BG, Staffs, England; [Fernie, Gordon] Univ Liverpool, Liverpool L69 3BX, Merseyside, England; [Potter, Douglas] Univ Dundee, Dundee, Scotland		Rutherford, A (corresponding author), Univ Keele, Sch Psychol, Keele ST5 5BG, Staffs, England.	a.rutherford@psy.keele.ac.uk	Stephens, Richard/C-4062-2009	Stephens, Richard/0000-0002-5851-8975	Wellcome TrustWellcome TrustEuropean Commission [054248]	This research was funded by the Wellcome Trust, Grant 054248.	Abreau F, 1990, NEUROPSYCHOLOGY, V4, P175, DOI 10.1037/0894-4105.4.3.175; Adams J, 2007, CLIN J SPORT MED, V17, P304, DOI 10.1097/JSM.0b013e31803202c8; Aiken L. S., 2013, APPL MULTIPLE REGRES, DOI 10.4324/9780203774441; ANZIL F, 1979, 1 INT C SPORTS MED A, P643; Asken MJ, 1998, PHYSICIAN SPORTSMED, V26, P37, DOI 10.3810/psm.1998.11.1190; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Barth J T, 2000, Dent Clin North Am, V44, P67; Barth JT, 1989, MILD HEAD INJURY, P257; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0; Bernhard G, 2004, STAT PAP, V45, P1, DOI 10.1007/BF02778266; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; CHRISTENSEN PR, 1960, ALTERNATE USES FORM; Crawford J. R., 1992, HDB NEUROPSYCHOLOGIC; *DEP HLTH, 2008, ALC ADV; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; DUNNETT CW, 1992, J AM STAT ASSOC, V87, P162, DOI 10.2307/2290465; DVORAK J, 2005, BRIT J SPORT MED, V39, P1; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; FIFA, 2006, FIFA BIG COUNT 2006; Fox K, 2004, SPORT LEISURE RESULT; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; FULLER CW, 2005, BR J SPORTS MED S1, V39, P3; Golden CJ, 1978, STROOP COLOR WORD TE; GREEN G, 1996, US FOOTBALL SPORTS M, P191; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HOCHBERG Y, 1995, J STAT PLAN INFER, V48, P141, DOI 10.1016/0378-3758(95)00005-T; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Hochberg Y., 1987, MULTIPLE COMP PROCED; HOLLAND BS, 1988, PSYCHOL BULL, V104, P145, DOI 10.1037/0033-2909.104.1.145; Hunt M, 1990, Br J Sports Med, V24, P265; Iverson G L, 2000, Appl Neuropsychol, V7, P247, DOI 10.1207/S15324826AN0704_7; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Jaeger RG, 1998, HERPETOLOGICA, V54, pS64; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; Kelly JP, 1997, NEUROLOGY, V48, P581; Keppel G., 2004, DESIGN ANAL RES HDB, V4th ed.; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Marshall SW, 2001, J ATHL TRAINING, V36, P334; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; OCARROLL RE, 1987, BRIT J CLIN PSYCHOL, V26, P315, DOI 10.1111/j.2044-8260.1987.tb01367.x; Olejnik S, 1997, J EDUC BEHAV STAT, V22, P389, DOI 10.3102/10769986022004389; Parsons OA, 1998, J STUD ALCOHOL, V59, P180, DOI 10.15288/jsa.1998.59.180; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Reitan RM, 1997, NEUROPSYCHOL REV, V7, P3, DOI 10.1007/BF02876970; Riding RJ, 2003, BRIT J EDUC PSYCHOL, V73, P149, DOI 10.1348/00070990360626912; ROM DM, 1990, BIOMETRIKA, V77, P663, DOI 10.2307/2337008; Rutherford A, 2005, J CLIN EXP NEUROPSYC, V27, P299, DOI 10.1080/13803390490515504; Rutherford A, 2005, APPL COGNITIVE PSYCH, V19, P477, DOI 10.1002/acp.1091; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; RUTHERFORD A, 1992, BRIT J MATH STAT PSY, V45, P197, DOI 10.1111/j.2044-8317.1992.tb00988.x; Rutherford A, 2001, INTRO ANOVA ANCOVA G; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; Shadish WR., 2002, EXPT QUASI EXPT DESI; SHAFFER JP, 1986, J AM STAT ASSOC, V81, P826, DOI 10.2307/2289016; SHAFFER JP, 1995, ANNU REV PSYCHOL, V46, P561, DOI 10.1146/annurev.ps.46.020195.003021; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI33, DOI 10.1136/bjsm.2005.019059; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI26, DOI 10.1136/bjsm.2005.019042; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; SMITH T, 1995, OCCUPATIONAL HYGIENE, P308; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stephens R, 2005, CHILD NEUROPSYCHOL, V11, P513, DOI 10.1080/092970490959629; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Washington RL, 2001, PEDIATRICS, V107, P1205; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; WEIGHTMAN D, 1974, BRIT J SPORT MED, V8, P183; Westfall P. H., 1999, MULTIPLE COMP MULTIP; Westfall P.H., 1993, RESAMPLING BASED MUL; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143; ZIMMERMAN P, 1995, TEST ATTENTIONAL PER	94	25	25	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2009	31	6					664	681		10.1080/13803390802484755			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	482JV	WOS:000268883300004	19048428				2022-02-06	
J	Saunders, LL; Selassie, AW; Hill, EG; Nicholas, JS; Horner, MD; Corrigan, JD; Lackland, DT				Saunders, Lee L.; Selassie, Anbesaw W.; Hill, Elizabeth G.; Nicholas, Joyce S.; Horner, Michael David; Corrigan, John D.; Lackland, Daniel T.			A population-based study of repetitive traumatic brain injury among persons with traumatic brain injury	BRAIN INJURY			English	Article						Brain injuries; epilepsy; seizures; epidemiology; survival analysis	PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; SOCIOECONOMIC-STATUS; UNITED-STATES; HEAD TRAUMA; RATES; HOSPITALIZATION; COLLEGIATE; SEIZURES; OUTCOMES	Primary objective: The objective was to estimate and compare the hazards of repetitive traumatic brain injury (RTBI) events as a function of the index TBI severity, in a cohort of TBI hospital discharges include in the South Carolina Traumatic Brain Injury Follow-up Registry. Research design: Retrospective cohort. Methods and procedures: There were 4357 persons with TBI who were followed from the index hospital discharge through 31 December 2005 for RTBI events through the statewide hospital discharge (HD) and emergency department (ED) records. Prentice, Williams, Peterson total time/conditional probability model (PWP-CP) for recurrent events survival analysis was used to assess RTBI as a function of index TBI severity. Main outcomes and results: Index TBI severity approached significance in its relationship with RTBI, with persons with a severe index TBI experiencing events at a higher rate than those with a mild/moderate index TBI. Among the other covariates evaluated, epilepsy/seizure disorder, race, gender, payer status, cause of injury and having a prior history of TBI were associated with RTBI. Conclusions: While TBI severity approached significance with RTBI, other variables, such as epilepsy/seizure disorder, seem to have a more significant relationship with RTBI.	[Saunders, Lee L.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA; [Selassie, Anbesaw W.; Hill, Elizabeth G.; Nicholas, Joyce S.; Lackland, Daniel T.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA; [Horner, Michael David] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; [Horner, Michael David] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA		Saunders, LL (corresponding author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,Suite 117,MSC 700, Charleston, SC 29425 USA.	saundel@musc.edu			Division of Injury Response, National Center for Injury Prevention and Control (CIPC), Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU421926]	This study was supported by Grant No. U17/CCU421926 from the Division of Injury Response, National Center for Injury Prevention and Control (CIPC), Centers for Disease Control and Prevention (CDC) ( PI: Anbesaw W. Selassie). The study was performed pursuant to a jointly financed cooperative arrangement between the NCPIC, the National Center for Chronic Disease Prevention and Health Promotion, CDC and the Social Security Administration (SSA), Office of Disability Income and Support Programs. The opinions and conclusions expressed are solely the authors' and should not be construed as representing the opinions or policy of CDC, SSA, or any agency of the federal government.	ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Betz ME, 2005, ANN EMERG MED, V46, P544, DOI 10.1016/j.annemergmed.2005.07.009; Birken CS, 2006, CAN MED ASSOC J, V175, P867, DOI 10.1503/cmaj.051207; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BUTLER JA, 2001, CENTRAL NERVOUS SYST; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cubbin C, 2002, ANNU REV PUBL HEALTH, V23, P349, DOI 10.1146/annurev.publhealth.23.100901.140548; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; d'Errico A, 2007, OCCUP ENVIRON MED, V64, P325, DOI 10.1136/oem.2006.027839; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HOSMER DW, 2008, APPL SURV AN REGR MO; Kelly J., 1997, MMWR-MORBID MORTAL W, V46, P224; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LIN D, 1993, J AM STAT ASSOC, V84, P1074; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; PRENTICE RL, 1981, BIOMETRIKA, V68, P373, DOI 10.1093/biomet/68.2.373; *S CAR STAT BUDG C, 2006, S CAR POP REP; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Swaine BR, 2007, PEDIATRICS, V119, P749, DOI 10.1542/peds.2006-1186; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107	33	25	25	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	11					866	872	PII 915242880	10.1080/02699050903283213			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300002	20100122				2022-02-06	
J	Wallace, D				Wallace, Duncan			Improvised explosive devices and traumatic brain injury: the military experience in Iraq and Afghanistan	AUSTRALASIAN PSYCHIATRY			English	Article						Afghanistan; blast injury; improvised explosive devices; Iraq; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; VIETNAM HEAD-INJURY; UNITED-STATES; BLAST INJURY; WAR; FREEDOM; BATTLEFIELD; CONCUSSION; CASUALTIES; SYMPTOMS	Objective: The current conflicts in Iraq and Afghanistan have seen frequent use of improvised explosive devices resulting in thousands of casualties, with traumatic brain injuries particularly common. The recent literature is reviewed to provide information to clinicians on the management of this condition. Method: A Medline search from 2001-2008, using the terms Afghanistan, blast injury, improvised explosive devices, Iraq and traumatic brain injury, was performed. Results: The United States military experience predominates in the literature. The use of body armour and other advances has led to improved survival rates among blast injury victims. Resultant neuropsychiatric injuries, in particular traumatic brain injuries, are discussed. There is debate about the prevalence of traumatic brain injuries. The diagnosis, management, relationship with posttraumatic stress disorder and prognosis of traumatic brain injury are reviewed. Conclusions: Traumatic brain injury has been described as the 'signature wound' of the current conflicts in Iraq and Afghanistan. While this term is highly debatable and probably unhelpful, clinicians need to know about this condition to provide the best management.	Prince Wales Hosp, Kiloh Ctr, Randwick, NSW 2031, Australia		Wallace, D (corresponding author), Prince Wales Hosp, Kiloh Ctr, Randwick, NSW 2031, Australia.	duncan.wallace@sesiahs.health.nsw.gov.au		Wallace, Duncan/0000-0002-2636-2814			Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Burnham G, 2006, LANCET, V368, P1421, DOI 10.1016/S0140-6736(06)69491-9; Cooke BB, 2008, PERSPECT PSYCHIATR C, V44, P54, DOI 10.1111/j.1744-6163.2008.00148.x; Crabtree J, 2006, J BURN CARE RES, V27, P576, DOI 10.1097/01.BCR.0000235459.60000.A5; Danis DM, 2005, J EMERG NURS, V31, P447, DOI 10.1016/j.jen.2005.08.005; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Eastridge BJ, 2006, J TRAUMA, V61, P1366, DOI 10.1097/01.ta.0000245894.78941.90; Fox CJ, 2005, J VASC SURG, V41, P638, DOI 10.1016/j.jvs.2005.01.010; Friedemann-Sanchez G, 2008, ARCH PHYS MED REHAB, V89, P171, DOI 10.1016/j.apmr.2007.10.017; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Hodgetts T, 2007, J R Army Med Corps, V153, P252; Holcomb JB, 2006, J TRAUMA, V60, P397, DOI 10.1097/01.ta.0000203581.75241.f1; *IR BOD COUNT, IR BOD COUNT; Jones E, 2002, BMJ-BRIT MED J, V324, P321, DOI 10.1136/bmj.324.7333.321; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; METZ T, 2008, US ARMY MIL NEW 0604; *MIN DEF, UN KINGD MIN DEF; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Montgomery SP, 2005, J AM COLL SURGEONS, V201, P7, DOI 10.1016/j.jamcollsurg.2005.03.038; Nelson TJ, 2008, J TRAUMA, V65, P212, DOI 10.1097/01.ta.0000196010.50246.9a; Neuhaus SJ, 2006, ANZ J SURG, V76, P637, DOI 10.1111/j.1445-2197.2006.03795.x; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Peake JB, 2005, NEW ENGL J MED, V352, P219, DOI 10.1056/NEJMp048312; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; SCHWAB K, 1993, NEUROLOGY, V43, P95, DOI 10.1212/WNL.43.1_Part_1.95; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; *US DEP DEF, PERS MIL CAS STAT MI; *US DEP DEF, 2008, US MIL CAS OP IR FRE; Walters TJ, 2005, MIL MED, V170, P770, DOI 10.7205/MILMED.170.9.770; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wenke JC, 2005, MIL MED, V170, P776, DOI 10.7205/MILMED.170.9.776; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003	43	25	24	1	3	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1039-8562	1440-1665		AUSTRALAS PSYCHIATRY	Australas. Psychiatry		2009	17	3					218	224		10.1080/10398560902878679			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	467TP	WOS:000267766300007	19404818				2022-02-06	
J	Donat, CK; Schuhmann, MU; Voiqt, C; Nieber, K; Deuther-Conrad, W; Brust, P				Donat, Cornelius K.; Schuhmann, Martin U.; Voiqt, Cornelia; Nieber, Karen; Deuther-Conrad, Winnie; Brust, Peter			Time-dependent alterations of cholinergic markers after experimental traumatic brain injury	BRAIN RESEARCH			English	Article						CCI; Traumatic brain injury; AChR; vAChT; Cholinergic system; Autoradiography	VESICULAR ACETYLCHOLINE TRANSPORTER; CONTROLLED CORTICAL IMPACT; MUSCARINIC RECEPTOR SUBTYPES; FLUID-PERCUSSION INJURY; RAT-BRAIN; NICOTINIC RECEPTORS; HEAD-INJURY; THALAMIC NUCLEI; BINDING; RELEASE	Traumatic brain injury (TBI) is one of the leading causes of death and disability. Cognitive deficits are believed to be connected with impairments of the cholinergic system. The present study was conducted to evaluate the cholinergic system in a model of focal brain injury with special attention to the time course of posttraumatic events in critical brain regions. Three groups of male Sprague-Dawley rats (post-TBI survival time: 2 h, 24 h and 72 h) were subjected to sham-operation (control) or controlled cortical impact injury. Receptor densities were determined on frozen ipsilateral sagittal brain sections with [H-3]epibatidine (nicotinic acetylcholine receptors) and [H-3]QNB (muscarinic acetylcholine receptors). The density of the vesicular acetylcholine transporter (vAChT) was evaluated with (-) [H-3]vesamicol. Compared to control, vAChT was lowered (up to 50%) at each time point after trauma, with reductions in olfactory tubercle, basal forebrain, motor cortex, putamen, thalamic and hypothalamic areas and the gigantocellular reticular nucleus. Time-dependent reductions of about 20% of nAChR-density in the thalamus, hypothalamus, olfactory tubercle, gigantocellular reticular nucleus and motor cortex were observed post-TBI at 24 and 72 h. The same brain regions showed reductions of mAChR at 24 and 72 h after trauma with additional decreases in the corpus callosurn, basal forebrain and anterior olfactory nucleus. in conclusion, cholinergic markers showed significant time-dependent impairments after TBI. Considering the role of the cholinergic system for cognitive processes in the brain, it seems likely that these impairments contribute to clinically relevant cognitive deficits. (C) 2008 Elsevier B.V. All rights reserved.	[Donat, Cornelius K.; Deuther-Conrad, Winnie; Brust, Peter] Inst Interdisciplinary Isotope Res, D-04318 Leipzig, Germany; [Schuhmann, Martin U.; Voiqt, Cornelia] Univ Leipzig, Dept Neurosurg, Leipzig, Germany; [Nieber, Karen] Univ Leipzig, Inst Pharm, Leipzig, Germany		Donat, CK (corresponding author), Inst Interdisciplinary Isotope Res, Permoserstr 15, D-04318 Leipzig, Germany.	donat@iif-leipzig.de	Deuther-Conrad, Winnie/B-7558-2015	Deuther-Conrad, Winnie/0000-0003-3168-3062; , Peter/0000-0001-5555-7058			ALTAR CA, 1988, SYNAPSE, V2, P486, DOI 10.1002/syn.890020504; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; AUBERT I, 1994, J NEUROSCI, V14, P2476; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BIEGON A, 1989, NEUROBIOL AGING, V10, P305, DOI 10.1016/0197-4580(89)90040-7; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349, DOI 10.1152/jn.1946.9.5.349; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Buttermann AE, 1998, TOXICOL LETT, V101, P17, DOI 10.1016/S0378-4274(98)00160-X; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Custers FGJ, 1997, EUR J PHARMACOL, V338, P177, DOI 10.1016/S0014-2999(97)81946-2; Darreh-Shori T, 2004, J NEUROCHEM, V88, P1102, DOI 10.1046/j.1471-4159.2003.02230.x; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; Deuther-Conrad W, 2006, SYNAPSE, V59, P201, DOI 10.1002/syn.20232; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Donat CK, 2007, BRAIN INJURY, V21, P1031, DOI 10.1080/02699050701630359; EARLEY B, 1995, NEUROCHEM INT, V26, P559, DOI 10.1016/0197-0186(95)00004-R; Fass U, 2000, NEUROREPORT, V11, P931, DOI 10.1097/00001756-200004070-00007; Fujita M, 2003, EUR J NUCL MED MOL I, V30, P1620, DOI 10.1007/S00259-003-1320-0; GERZANICH V, 1995, MOL PHARMACOL, V48, P774; Gill TM, 2000, J NEUROSCI, V20, P4745, DOI 10.1523/JNEUROSCI.20-12-04745.2000; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; Gotohda T, 2001, INT J LEGAL MED, V115, P121, DOI 10.1007/s004140000185; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hasselmo ME, 1999, TRENDS COGN SCI, V3, P351, DOI 10.1016/S1364-6613(99)01365-0; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; HUSTVEIT O, 1994, JPN J PHARMACOL, V64, P57, DOI 10.1254/jjp.64.57; Ichikawa T, 1997, J CHEM NEUROANAT, V13, P23, DOI 10.1016/S0891-0618(97)00021-5; Iida Y, 2004, J NUCL MED, V45, P878; IMPERATO A, 1993, EUR J PHARMACOL, V238, P135, DOI 10.1016/0014-2999(93)90518-M; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jett DA, 2002, NEUROTOXICOL TERATOL, V24, P805, DOI 10.1016/S0892-0362(02)00314-8; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; Kaufer D, 1998, NATURE, V393, P373, DOI 10.1038/30741; Kaufer D, 1999, CHEM-BIOL INTERACT, V119, P349, DOI 10.1016/S0009-2797(99)00046-0; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kochanek PM, 2006, DEV NEUROSCI-BASEL, V28, P244, DOI 10.1159/000094151; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; Marutle A, 1998, BRAIN RES, V801, P143, DOI 10.1016/S0006-8993(98)00558-7; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCREE RC, 1995, NEUROIMAGE, V2, P55, DOI 10.1006/nimg.1995.1008; Merenda A, 2008, J NEUROTRAUM, V25, P527, DOI 10.1089/neu.2007.0359; Moor E, 1998, EUR J PHARMACOL, V359, P119, DOI 10.1016/S0014-2999(98)00642-6; Mortazavi S, 1999, ANESTHESIOLOGY, V90, P1070, DOI 10.1097/00000542-199904000-00021; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Perry DC, 2002, J NEUROCHEM, V82, P468, DOI 10.1046/j.1471-4159.2002.00951.x; PERRY DC, 1995, J PHARMACOL EXP THER, V275, P1030; Perry E, 1999, TRENDS NEUROSCI, V22, P273, DOI 10.1016/S0166-2236(98)01361-7; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Prado VF, 2006, NEURON, V51, P601, DOI 10.1016/j.neuron.2006.08.005; Rothberg BS, 1996, ALCOHOL CLIN EXP RES, V20, P1613, DOI 10.1111/j.1530-0277.1996.tb01706.x; Sabri O, 2008, EUR J NUCL MED MOL I, V35, pS30, DOI 10.1007/s00259-007-0701-1; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; Sall JM, 1996, EXP NEUROL, V139, P257, DOI 10.1006/exnr.1996.0099; SCHAFER MKH, 1994, J MOL NEUROSCI, V5, P1, DOI 10.1007/BF02736691; Schmanke TD, 2001, DEV BRAIN RES, V131, P127, DOI 10.1016/S0165-3806(01)00248-6; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Scremin OU, 1996, LIFE SCI, V58, P2011, DOI 10.1016/0024-3205(96)00192-0; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; Shohami E, 2000, J MOL MED-JMM, V78, P228, DOI 10.1007/s001090000104; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Sihver W, 1998, NEUROSCIENCE, V85, P1121, DOI 10.1016/S0306-4522(97)00652-0; Szutowicz A, 2006, METAB BRAIN DIS, V21, P149, DOI 10.1007/s11011-006-9007-4; SZYMUSIAK R, 1995, SLEEP, V18, P478, DOI 10.1093/sleep/18.6.478; Taylor AN, 2008, J NEUROTRAUM, V25, P311, DOI 10.1089/neu.2007.0486; Tellez S, 1997, J NEUROCHEM, V68, P778; Tenovuo OS, 2006, CURR DRUG THER, V1, P187, DOI 10.2174/157488506776930932; Terry AV, 2006, NEUROSCIENCE, V140, P1277, DOI 10.1016/j.neuroscience.2006.03.011; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tribollet E, 2004, NEUROSCIENCE, V124, P405, DOI 10.1016/j.neuroscience.2003.09.028; Valles A, 2006, NEUROBIOL DIS, V22, P312, DOI 10.1016/j.nbd.2005.11.015; Vaupel DB, 2007, NEUROIMAGE, V34, P1352, DOI 10.1016/j.neuroimage.2006.10.036; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; WALKER PD, 1993, J NEUROSCI RES, V36, P588, DOI 10.1002/jnr.490360511; WATSON M, 1986, J PHARMACOL EXP THER, V237, P419; Witgen BM, 2006, J NEUROTRAUM, V23, P1320, DOI 10.1089/neu.2006.23.1320; WURTMAN RJ, 1992, TRENDS NEUROSCI, V15, P117, DOI 10.1016/0166-2236(92)90351-8; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	97	25	27	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 30	2008	1246						167	177		10.1016/j.brainres.2008.09.059			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	396NE	WOS:000262597600018	18848922				2022-02-06	
J	Shein, NA; Grigoriadis, N; Horowitz, M; Umschwief, G; Alexandrovich, AG; Simeonidou, C; Grigoriadis, S; Touloumi, O; Shohami, E				Shein, Na'ama A.; Grigoriadis, Nikolaos; Horowitz, Michal; Umschwief, Gali; Alexandrovich, Alexander G.; Simeonidou, Constantina; Grigoriadis, Savuas; Touloumi, Olga; Shohami, Esther			Microglial involvement in neuroprotection following experimental traumatic brain injury in heat-acclimated mice	BRAIN RESEARCH			English	Article						Cytokines; Glia; Neuroprotection; Neurotrophin; Preconditioning	EXPRESSION; ERYTHROPOIETIN; DISEASE; MODEL; RAT	Brain-derived neurotrophic factor (BDNF) conveys neuroprotection in various settings of experimental central nervous system injury. Using a model of endogenous neuroprotection, induced in mice by chronic exposure to moderate ambient heat (heat acclimation, HA), we have previously shown that neuroprotection following traumatic brain injury involves reduced post-injury tumor necrosis factor alpha (TNF alpha) expression. As glial cells play a pivotal role in post-injury inflammation on one hand, and are also capable of inducing neuroprotection by harboring trophic factors and BDNF in particular, the effects of injury and HA on overall BDNF content at the trauma area, gliosis and glial BDNF expression were investigated. Western blotting indicated higher overall BDNF levels in HA sham-operated mice. Following injury, a decrease was observed in the HA group only, reaching levels similar to normothermic mice. Immunohistochemical studies demonstrated BDNF-positive resting microglia in non-injured HA but not normothermic animals. Post-injury astrocytosis and microglial immunoreactivity were enhanced in the HA group. Particularly, an increase in the amount of ramified microglia was observed within the penumbra, accompanied by a concomitant decrease in globular microglia, a major source of pro-inflammatory mediators. BDNF labeling on and around microglia and their processes was intensified in HA mice. Furthermore, BDNF immunoreactivity in HA mice was evident in the degenerated edges of axons. These findings, taken together with the growing body of evidence indicating the neuroprotective potential of both BDNF and microglia, suggest a possible role of these cells in HA-induced neuroprotection. (C) 2008 Elsevier B.V. All rights reserved.	[Shein, Na'ama A.; Horowitz, Michal; Umschwief, Gali] Hebrew Univ Jerusalem, Dept Physiol, IL-91905 Jerusalem, Israel; [Shein, Na'ama A.; Umschwief, Gali; Alexandrovich, Alexander G.; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91905 Jerusalem, Israel; [Grigoriadis, Nikolaos; Touloumi, Olga] AHEPA Univ Hosp, Dept Neurol, Thessaloniki, Greece; [Simeonidou, Constantina] AHEPA Univ Hosp, Dept Physiol, Thessaloniki, Greece; [Grigoriadis, Nikolaos; Simeonidou, Constantina; Touloumi, Olga] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece; [Grigoriadis, Savuas] Hebrew Univ Jerusalem, Hadassah Univ Hosp, Dept Neurosurg, Jerusalem, Israel		Horowitz, M (corresponding author), Hebrew Univ Jerusalem, Dept Physiol, IL-91905 Jerusalem, Israel.	horowitz@cc.huji.ac.il; esty@cc.huji.ac.il					Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P329; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; Shein NA, 2008, J NEUROTRAUM, V25, P112, DOI 10.1089/neu.2007.0358; Shein NA, 2007, PROG BRAIN RES, V161, P353, DOI 10.1016/S0079-6123(06)61025-X; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SHOHAMI E, 1994, ACTA NEUROCHIR, P443; Simic G, 2000, EXP NEUROL, V165, P12, DOI 10.1006/exnr.2000.7448; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	12	25	25	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 9	2008	1244						132	141		10.1016/j.brainres.2008.09.032			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	384YH	WOS:000261779600014	18835383				2022-02-06	
J	Abate, MG; Trivedi, M; Fryer, TD; Smielewski, P; Chatfield, DA; Williams, GB; Aigbirhio, F; Carpenter, TA; Pickard, JD; Menon, DK; Coles, JP				Abate, M. Giulia; Trivedi, Monica; Fryer, Tim D.; Smielewski, Piotr; Chatfield, Doris A.; Williams, Guy B.; Aigbirhio, Franklin; Carpenter, T. Adrian; Pickard, John D.; Menon, David K.; Coles, Jonathan P.			Early Derangements in Oxygen and Glucose Metabolism Following Head Injury: The Ischemic Penumbra and Pathophysiological Heterogeneity	NEUROCRITICAL CARE			English	Article						Head injury; Oxygen metabolism; Glucose metabolism; Ischemia; Positron emission tomography; Traumatic penumbra	CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; HYPERVENTILATION; O-15; BURDEN; DAMAGE	Introduction Conclusive evidence of cerebral ischemia following head injury has been elusive. We aimed to use O-15 and (18)Fluorodeoxyglucose positron emission tomography (PET) to investigate pathophysiological derangements following head injury. Results Eight patients underwent PET within 24 h of injury to map cerebral blood flow (CBF), cerebral oxygen metabolism (CMRO2), oxygen extraction fraction (OEF), and cerebral glucose metabolism (CMRglc). Physiological regions of interest (ROI) were generated for each subject using a range of OEF values from very low (< 10), low (10-30), normal range (30-50), high (50-70), and critically high (70%). We applied these ROIs to each subject to generate data that would examine the balance between blood flow and metabolism across the injured brain independent of structural injury. Discussion Compared to the normal range, brain regions with higher OEF demonstrate a progressive CBF reduction (P < 0.01), CMRO2 increase (P < 0.05), and no change in CMRglc, while regions with lower OEF are associated with reductions in CBF, CMRO2, and CMRglc (P < 0.01). Although all subjects demonstrate a decrease in CBF with increases in OEF > 70%, CMRO2 and CMRglc were generally unchanged. One subject demonstrated a reduction in CBF and small fall in CMRO2 within the high OEF region (> 70%), combined with a progressive increase in CMRglc. Conclusions The low CBF and maintained CMRO2 in the high OEF ROIs is consistent with classical cerebral ischemia and the presence of an 'ischemic penumbra' following early head injury, while the metabolic heterogeneity that we observed suggests significant pathophysiological complexity. Other mechanisms of energy failure are clearly important and further study is required to delineate the processes involved.	[Abate, M. Giulia; Trivedi, Monica; Fryer, Tim D.; Chatfield, Doris A.; Williams, Guy B.; Aigbirhio, Franklin; Carpenter, T. Adrian; Pickard, John D.; Menon, David K.; Coles, Jonathan P.] Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; [Abate, M. Giulia; Trivedi, Monica; Chatfield, Doris A.; Menon, David K.; Coles, Jonathan P.] Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England; [Abate, M. Giulia] Univ Milano Bicocca, Coll Med, HS Gerardo, I-20052 Monza, Italy; [Smielewski, Piotr; Pickard, John D.] Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England		Coles, JP (corresponding author), Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Box 65, Cambridge CB2 2QQ, England.	jpc44@wbic.cam.ac.uk		Smielewski, Peter/0000-0001-5096-3938; Coles, Jonathan/0000-0003-4013-679X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986, G0001237] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G0600986, G9439390] Funding Source: UKRI		BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2006, J CEREBR BLOOD F MET, V26, P48, DOI 10.1038/sj.jcbfm.9600179; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HUANG SC, 1980, AM J PHYSIOL, V238, pE69, DOI 10.1152/ajpendo.1980.238.1.E69; JENNETT B, 1975, LANCET, V1, P480; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PHELPS ME, 1979, J NUCL MED, V20, P328; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Schwarzmaier S, 2006, J NEUROTRAUM, V23, P769; Smielewski Peter, 1800, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; TEASDALE G, 1974, LANCET, V2, P81; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6	28	25	26	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2008	9	3					319	325		10.1007/s12028-008-9119-2			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	367HC	WOS:000260542100007	18563636				2022-02-06	
J	Clausen, F; Marklund, N; Lewen, A; Hillered, L				Clausen, Fredrik; Marklund, Niklas; Lewen, Anders; Hillered, Lars			The Nitrone Free Radical Scavenger NXY-059 Is Neuroprotective when Administered after Traumatic Brain Injury in the Rat	JOURNAL OF NEUROTRAUMA			English	Article						learning and memory; neuroprotection animal studies; NXY-059; oxidative stress; traumatic brain injury	TERT-BUTYL-NITRONE; FOCAL CEREBRAL-ISCHEMIA; CORTICAL CONTUSION INJURY; SEVERE HEAD-INJURY; FLUID-PERCUSSION; OXIDATIVE DAMAGE; S-PBN; TRAPPING COMPOUND; ARTERY OCCLUSION; NEURONAL INJURY	Reactive oxygen species (ROS) are important contributors to the secondary injury cascade following traumatic brain injury (TBI), and ROS inhibition has consistently been shown to be neuroprotective following experimental TBI. NXY-059, a nitrone free radical trapping compound, has been shown to be neuroprotective in models of ischemic stroke but has not been evaluated in experimental TBI. In the present Study, a continuous 24-h intravenous infusion of NXY-059 or vehicle was initiated 30 min following a severe lateral fluid percussion brain injury (FPI) in adult rats (n=22), and histological and behavioral outcomes were evaluated. Sham-injured animals (n = 22) receiving identical drug infusion were used as controls. Visuospatial learning was evaluated in the Morris water maze at post-injury days 11-14, followed by a probe trial (memory test) at day 18. The animals were sacrificed at day 18, and loss of hemispheric brain tissue was measured in microtubule-associated protein (MAP)-2 stained sections. Brain-injured, NXY-059-treated animals showed a significant reduction of visuospatial learning deficits when compared to the brain-injured, vehicle-treated control animals (p < 0.05). NXY-059-treated animals significantly reduced the loss of hemispheric tissue compared to brain-injured controls (43.0 +/- 11 mm(3) versus 74.4 +/- 19 mm(3), respectively; p < 0.01). The results show that post-injury treatment with NXY-059 significantly attenuated the loss of injured brain tissue and improved cognitive outcome, suggesting a major role for ROS in the pathophysiology of TBI.	[Clausen, Fredrik; Marklund, Niklas; Lewen, Anders; Hillered, Lars] Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden		Clausen, F (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, Entrance 85,2nd Floor, S-75185 Uppsala, Sweden.	Fredrik.clausen@neurokir.uu.se		Hillered, Lars/0000-0002-2808-9292; Clausen, Fredrik/0000-0003-3592-4417; Marklund, Niklas/0000-0002-9797-5626			CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CARNEY JM, 1991, J MOL NEUROSCI, V3, P47, DOI 10.1007/BF02896848; CHENG HY, 1993, FREE RADICAL BIO MED, V14, P243, DOI 10.1016/0891-5849(93)90021-L; Clausen F, 2005, ACTA NEUROCHIR, V147, P775, DOI 10.1007/s00701-005-0550-2; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clemens JA, 2000, FREE RADICAL BIO MED, V28, P1526, DOI 10.1016/S0891-5849(00)00258-6; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Edenius Charlotte, 2002, J Stroke Cerebrovasc Dis, V11, P34, DOI 10.1053/jscd.2002.123973; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gahm C, 2005, NEUROSURGERY, V57, P1272, DOI 10.1227/01.NEU.0000187317.32529.06; Green AR, 2006, BRAIN RES, V1072, P224, DOI 10.1016/j.brainres.2005.12.035; Hainsworth AH, 2008, J CEREBR BLOOD F MET, V28, P24, DOI 10.1038/sj.jcbfm.9600517; HALL BH, 1990, BROOKINGS PAP ECO AC, P85; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hensley K, 2000, FREE RADICAL BIO MED, V28, P1456, DOI 10.1016/S0891-5849(00)00252-5; Hino K, 2005, BRAIN RES, V1053, P77, DOI 10.1016/j.brainres.2005.06.062; Kawamata T, 1997, ACT NEUR S, V70, P191; Kondo T, 1996, NEUROSCI LETT, V215, P103, DOI 10.1016/S0304-3940(96)12954-2; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kuroda S, 1999, J CEREBR BLOOD F MET, V19, P778, DOI 10.1097/00004647-199907000-00008; Lees KR, 2006, NEW ENGL J MED, V354, P588, DOI 10.1056/NEJMoa052980; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lyden PD, 2007, STROKE, V38, P2262, DOI 10.1161/STROKEAHA.106.472746; Marklund N, 2002, J NEUROTRAUM, V19, P1139, DOI 10.1089/08977150260337958; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marshall JWB, 2003, STROKE, V34, P2228, DOI 10.1161/01.STR.0000087790.79851.A8; Marshall JWB, 2003, BRAIN RES, V972, P119, DOI 10.1016/S0006-8993(03)02511-3; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nilsson D, 2007, J CLIN PHARMACOL, V47, P264, DOI 10.1177/0091270006293752; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Papadakis M, 2006, STROKE, V37, P2189, DOI 10.1161/01.STR.0000230598.31774.7a; SCHULZ JB, 1995, J NEUROCHEM, V64, P2239; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Shuaib A, 2007, NEW ENGL J MED, V357, P562, DOI 10.1056/NEJMoa070240; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; Sydserff SG, 2002, BRIT J PHARMACOL, V135, P103, DOI 10.1038/sj.bjp.0704449; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Villa RF, 1997, PHARMACOL REV, V49, P99; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Yang Y, 2000, EXP NEUROL, V163, P39, DOI 10.1006/exnr.2000.7364; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; YUE TL, 1992, BRAIN RES, V574, P193, DOI 10.1016/0006-8993(92)90816-R; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V152, P349, DOI 10.1111/j.1748-1716.1994.tb09816.x; Zhao ZG, 2001, BRAIN RES, V909, P46, DOI 10.1016/S0006-8993(01)02618-X	64	25	25	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1449	1457		10.1089/neu.2008.0585			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500006	19118455				2022-02-06	
J	Erkonen, G; Lamb, F; Tobias, JD				Erkonen, Gwen; Lamb, Fred; Tobias, Joseph D.			High-dose Dexmedetomidine-induced Hypertension in a Child with Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Dexmedetomidine; Hypertension; Traumatic brain injury	CEREBRAL-BLOOD-FLOW; INTRACRANIAL-PRESSURE; SEDATION; CARE	Introduction Dexmedetomidine is a centrally acting alpha(2)-adrenergic agonist which is currently FDA-approved for the short-term (less than 24 h) sedation of adults during mechanical ventilation. Discussion Given its beneficial physiologic properties, there has been increasing use of this agent in the pediatric population. As with any agent used for sedation in the Pediatric ICU setting, dose escalations may be necessary. Unlike benzodiazepines and opioids, there are limited data regarding the administration of dexmedetomidine above the current package insert dosing recommendations of 0.7 mu g/kg/h. Results We report a 2-year-old child with traumatic brain injury who developed hypertension following the administration of a dexmedetomidine infusion at 4 mu g/kg/h for several hours. Investigation into the etiology of the hypertension was negative and the blood pressure returned to baseline with a decrease in the infusion rate. Conclusion Subsequent to this, no further issues with hypertension were noted.	[Tobias, Joseph D.] Univ Missouri, Dept Anesthesiol, Columbia, MO 65212 USA; [Erkonen, Gwen; Lamb, Fred] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; [Tobias, Joseph D.] Univ Missouri, Dept Pediat, Columbia, MO 65212 USA		Tobias, JD (corresponding author), Univ Missouri, Dept Anesthesiol, 3W-27G Hlth Sci Ctr,1 Hosp Dr, Columbia, MO 65212 USA.	Tobiasj@health.missouri.edu					Aryan HE, 2006, BRAIN INJURY, V20, P791, DOI 10.1080/02699050600789447; BLOOR BC, 1992, ANESTHESIOLOGY, V77, P1134, DOI 10.1097/00000542-199212000-00014; Chrysostomou C, 2005, PEDIATR CARDIOL, V26, P651, DOI 10.1007/s00246-005-0683-3; Chrysostomou C, 2006, PEDIATR CRIT CARE ME, V7, P126, DOI 10.1097/01.PCC.0000200967.76996.07; Drummond JC, 2008, ANESTHESIOLOGY, V108, P225, DOI 10.1097/01.anes.0000299576.00302.4c; Hammer GB, 2005, PEDIATR ANESTH, V15, P616, DOI 10.1111/j.1460-9592.2005.01656.x; Hammer GB, 2008, ANESTH ANALG, V106, P79, DOI 10.1213/01.ane.0000297421.92857.4e; KARLSSON BR, 1990, ANESTH ANALG, V71, P125; Mason KP, 2008, PEDIATR ANESTH, V18, P403, DOI 10.1111/j.1460-9592.2008.02468.x; Mason KP, 2008, PEDIATR ANESTH, V18, P393, DOI 10.1111/j.1460-9592.2008.02451.x; Mason KP, 2006, ANESTH ANALG, V103, P57, DOI 10.1213/01.ane.0000216293.16613.15; Prielipp RC, 2002, ANESTH ANALG, V95, P1052, DOI 10.1097/00000539-200210000-00048; Spitzfaden AC, 1999, PEDIATR NEUROSURG, V31, P194, DOI 10.1159/000028861; Talke P, 1997, ANESTH ANALG, V85, P358, DOI 10.1097/00000539-199708000-00021; Tobias JD, 2004, SOUTH MED J, V97, P451, DOI 10.1097/00007611-200405000-00007; Tobias JD, 2007, PEDIATR CRIT CARE ME, V8, P115, DOI 10.1097/01.PCC.0000257100.31779.41; Venn RM, 1999, ANAESTHESIA, V54, P1136, DOI 10.1046/j.1365-2044.1999.01114.x; VIRTANEN R, 1988, EUR J PHARMACOL, V150, P9, DOI 10.1016/0014-2999(88)90744-3; Walker J, 2006, J BURN CARE RES, V27, P206, DOI 10.1097/01.BCR.0000200910.76019.CF; Wheeler A, 2005, AM J PAIN MANAGE, V15, P15; ZORNOW MH, 1992, ANESTH ANALG, V75, P232; 2003, PEDIAT CRIT CARE MED, V4, pS34	22	25	27	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2008	9	3					366	369		10.1007/s12028-008-9102-y			4	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	367HC	WOS:000260542100015	18491236				2022-02-06	
J	Lunsman, M; Edwards, JD; Andel, R; Small, BJ; Ball, KK; Roenker, DL				Lunsman, Melissa; Edwards, Jerri D.; Andel, Ross; Small, Brent J.; Ball, Karlene K.; Roenker, Daniel L.			What Predicts Changes in Useful Field of View Test Performance?	PSYCHOLOGY AND AGING			English	Article						UFOV; useful field of view; longitudinal; random effects; speed of processing	DIGIT-SYMBOL-SUBSTITUTION; COGNITIVE TRAINING TRIAL; TRAUMATIC BRAIN-INJURY; ADULT AGE-DIFFERENCES; OLDER-ADULTS; VISUAL-ATTENTION; DRIVING PERFORMANCE; EVERYDAY PERFORMANCE; PROCESSING SPEED; DRIVERS	The Useful Field of View Test (UFOV) has been used as ail examination of age-related changes in visual Processing and cognition and as an indicator of everyday performance outcomes, particularly driving, for over 20 years. How UFOV performance changes with age and what may impact such changes have not previously been investigated longitudinally. Predictors of change in UFOV performance over a 5-year period among control group participants (N = 690) from the Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) stud), were examined. Random effects models were estimated with 4-subtest-total UFOV as the outcome and with baseline age. education, gender. race, visual acuity. depressive symptoms. mental status, and self-rated health. as well as attrition, as predictors. UFOV performance generally followed a curvilinear pattern. improving and then declining over time. Only increased age was consistently related to greater declines in UFOV performance over time. UFOV and Digit Symbol Substitution subtest, a standard measure of cognitive speed, had similar trajectories of change. The implications of these results are discussed.	[Lunsman, Melissa; Edwards, Jerri D.; Andel, Ross; Small, Brent J.] Univ S Florida, Sch Aging Studies, Tampa, FL 33620 USA; [Ball, Karlene K.] Univ Alabama Birmingham, Edward R Roybal Ctr Translat Res Aging & Mobil, Dept Psychol, Birmingham, AL USA; [Roenker, Daniel L.] Western Kentucky Univ, Dept Psychol, Bowling Green, KY USA		Edwards, JD (corresponding author), Univ S Florida, Sch Aging Studies, 4202 E Fowler Ave,MHC 1326, Tampa, FL 33620 USA.	jedwards1@cas.usf.edu		Edwards, Jerri/0000-0002-5117-3863; Small, Brent/0000-0002-7444-4689; Andel, Ross/0000-0003-4083-4790; Ball, Karlene/0000-0003-1811-9870	NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [U01NR004507, U01NR004508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG022838, U01AG014276, R03AG024082, U01AG014260, U01AG014282, U01AG014263, U01AG014289] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R03 AG024082, U01 AG014260-04, 5 P30 AG022838, U01 AG014260, U01 AG14282, U01 AG014289, U01 AG014263, U01 AG014276, P30 AG022838, U01 AG14289, U01 AG14263, U01 AG014282, U01 AG14260] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [U01 NR004507, U01 NR04507, U01 NR04508, U01 NR004508] Funding Source: Medline		Anstey KJ, 2003, J EXP PSYCHOL GEN, V132, P470, DOI 10.1037/0096-3445.132.3.470; BALL K, 1990, CLIN VISION SCI, V5, P113; BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; Ball K, 1993, J Am Optom Assoc, V64, P71; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Ball K, 2007, J GERONTOL B-PSYCHOL, V62, P19, DOI 10.1093/geronb/62.special_issue_1.19; Ball KK, 2006, J AM GERIATR SOC, V54, P77, DOI 10.1111/j.1532-5415.2005.00568.x; BALL KK, 1988, J OPT SOC AM A, V5, P2210, DOI 10.1364/JOSAA.5.002210; BALL KK, 2008, MAINTAINING PR UNPUB; BERES CA, 1981, J GERONTOL, V36, P591, DOI 10.1093/geronj/36.5.591; BERGEN JR, 1983, NATURE, V303, P696, DOI 10.1038/303696a0; Broman AT, 2004, INVEST OPHTH VIS SCI, V45, P2955, DOI 10.1167/iovs.04-0219; Duchek JM, 1998, J GERONTOL B-PSYCHOL, V53, pP130, DOI 10.1093/geronb/53B.2.P130; Edwards JD, 2005, J CLIN EXP NEUROPSYC, V27, P529, DOI 10.1080/13803390490515432; Edwards JD, 2005, AGING MENT HEALTH, V9, P262, DOI 10.1080/13607860412331336788; Edwards JD, 2002, GERONTOLOGY, V48, P329, DOI 10.1159/000065259; Edwards JD, 2006, ARCH CLIN NEUROPSYCH, V21, P275, DOI 10.1016/j.acn.2006.03.001; Finkel D, 2007, PSYCHOL AGING, V22, P558, DOI 10.1037/0882-7974.22.3.558; Fisk GD, 2002, ARCH PHYS MED REHAB, V83, P469, DOI 10.1053/apmr.2002.31179; Fisk GD, 2002, J HEAD TRAUMA REHAB, V17, P16, DOI 10.1097/00001199-200202000-00004; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Goode KT, 1998, J CLIN PSYCHOL MED S, V5, P425, DOI 10.1023/A:1026206927686; Hinton-Bayre A, 2005, PSYCHOL ASSESSMENT, V17, P237, DOI 10.1037/1040-3590.17.2.237; Hoffman L, 2005, PSYCHOL AGING, V20, P610, DOI 10.1037/0882-7974.20.4.610; Hoyer WJ, 2004, PSYCHOL AGING, V19, P211, DOI 10.1037/0882-7974.19.1.211; Jobe JB, 2001, CONTROL CLIN TRIALS, V22, P453, DOI 10.1016/S0197-2456(01)00139-8; Lemke U, 2005, AGING NEUROPSYCHOL C, V12, P57, DOI 10.1080/13825580590925116; MacDonald SWS, 2003, J GERONTOL B-PSYCHOL, V58, pP187, DOI 10.1093/geronb/58.3.P187; Myers RS, 2000, PERCEPT MOTOR SKILL, V91, P279, DOI 10.2466/PMS.91.5.279-290; Novack TA, 2006, BRAIN INJURY, V20, P455, DOI 10.1080/02699050600664541; OWSLEY C, 1995, VISION RES, V35, P579, DOI 10.1016/0042-6989(94)00166-J; Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574; OWSLEY C, 1991, PSYCHOL AGING, V6, P403, DOI 10.1037/0882-7974.6.3.403; Owsley C, 2004, J AM GERIATR SOC, V52, P1901, DOI 10.1111/j.1532-5415.2004.52516.x; Owsley C, 2002, GERONTOLOGY, V48, P254, DOI 10.1159/000058360; Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083; PLUDE DJ, 1981, J GERONTOL, V36, P598, DOI 10.1093/geronj/36.5.598; RABBITT P, 1965, J GERONTOL, V20, P233, DOI 10.1093/geronj/20.2.233; Rabbitt P, 2004, J GERONTOL B-PSYCHOL, V59, pP84, DOI 10.1093/geronb/59.2.P84; RABBITT P, 1965, BEHAV AGING NERVOUS; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Richards E, 2006, VISION RES, V46, P4217, DOI 10.1016/j.visres.2006.08.011; Riolo L., 2003, PHYS OCCUPATIONAL TH, V22, P15; Rizzo M, 1997, ARCH NEUROL-CHICAGO, V54, P545, DOI 10.1001/archneur.1997.00550170027011; Roenker DL, 2003, HUM FACTORS, V45, P218, DOI 10.1518/hfes.45.2.218.27241; SALTHOUSE TA, 1992, J GERONTOL, V47, pP121, DOI 10.1093/geronj/47.3.P121; SANDERS A F, 1970, Ergonomics, V13, P101, DOI 10.1080/00140137008931124; Scalf PE, 2007, J GERONTOL B-PSYCHOL, V62, P32, DOI 10.1093/geronb/62.special_issue_1.32; SCHAIE KW, 1989, PSYCHOL AGING, V4, P443, DOI 10.1037/0882-7974.4.4.443; SCIALFA CT, 1987, PSYCHOL AGING, V2, P14, DOI 10.1037/0882-7974.2.1.14; Seiple W, 1996, VISION RES, V36, P1859, DOI 10.1016/0042-6989(95)00288-X; Sekuler AB, 2000, EXP AGING RES, V26, P103, DOI 10.1080/036107300243588; SEKULER R, 1986, J OPT SOC AM A, V3, P864, DOI 10.1364/JOSAA.3.000864; Shawaryn MA, 2002, ARCH PHYS MED REHAB, V83, P1123, DOI 10.1053/apmr.2002.33730; Sims RV, 2001, J AGING HEALTH, V13, P430, DOI 10.1177/089826430101300306; Stalvey BT, 1999, J APPL GERONTOL, V18, P460, DOI 10.1177/073346489901800404; Uc EY, 2006, ANN NEUROL, V60, P407, DOI 10.1002/ana.20958; VERRIEST G, 1985, OCCUPATIONAL VISUAL, V2; Wechsler D., 1981, WAIS R MANUAL; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; Wolinsky FD, 2006, J GERONTOL A-BIOL, V61, P1324, DOI 10.1093/gerona/61.12.1324; Wolinsky FD, 2006, J GERONTOL B-PSYCHOL, V61, pS281, DOI 10.1093/geronb/61.5.S281; WOOD JM, 1995, OPTOMETRY VISION SCI, V72, P115, DOI 10.1097/00006324-199502000-00010; Wood KM, 2005, GERONTOLOGY, V51, P131, DOI 10.1159/000082199	64	25	25	0	26	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0882-7974	1939-1498		PSYCHOL AGING	Psychol. Aging	DEC	2008	23	4					917	927		10.1037/a0013466			11	Gerontology; Psychology, Developmental	Social Science Citation Index (SSCI)	Geriatrics & Gerontology; Psychology	387YR	WOS:000261988000022	19140660	Green Accepted			2022-02-06	
J	Lemoyne, R; Coroian, C; Mastroianni, T; Grundfest, W				Lemoyne, Robert; Coroian, Cristian; Mastroianni, Timothy; Grundfest, Warren			VIRTUAL PROPRIOCEPTION	JOURNAL OF MECHANICS IN MEDICINE AND BIOLOGY			English	Article						Virtual proprioception; wireless accelerometers; gait analysis; gait rehabilitation; locomotion; proprioception; hemiparetic gait; traumatic brain injury	EVOKED MOTOR-RESPONSES; PHYSICAL-ACTIVITY; HUMAN WALKING; GAIT ANALYSIS; INTERLIMB COORDINATION; ENERGY-EXPENDITURE; OLDER-ADULTS; ACCELEROMETRY; TRUNK; ACCELERATIONS	Virtual proprioception represents a novel means of developing cortical reorganization of alternative strategies for hemiparetic gait. Fundamentals of the device are motor control plasticity, aftereffect, and visual-based biofeedback. Two wireless three-dimensional (3D) microelectromechanical systems (MEMS) accelerometers are placed on the femur ( upper leg) of both the affected and unaffected limbs above the lateral epicondyle next to the knee joint. The acceleration data from the two wireless 3D MEMS accelerometers are fed back to the user in real time by visual output from a portable laptop PC. Given the virtual proprioception feedback, the user can then adjust the original gait while walking to an improved alternative gait strategy. First, hemiparetic gait is comprehensively discussed. The inherent roles of proprioception with locomotion and issues with traumatic brain injury are considered. Then, the technology advance of accelerometers and gait analysis is detailed. Virtual proprioception is tested and evaluated, while demonstrating the capacity to improve disparities in hemiparetic gait during real time.	[Lemoyne, Robert; Grundfest, Warren] Univ Calif Los Angeles, Biomed Engn IDP, Los Angeles, CA 90095 USA; [Coroian, Cristian] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Mastroianni, Timothy] Cognit Engn, Pittsburgh, PA USA		Lemoyne, R (corresponding author), Univ Calif Los Angeles, Biomed Engn IDP, 5121 Engn 5,Box 951600, Los Angeles, CA 90095 USA.	rlemoyne@ucla.edu	LeMoyne, Robert/AAI-9686-2020	LeMoyne, Robert/0000-0003-3587-3250			Aiello E, 2005, P ANN INT IEEE EMBS, P7703, DOI 10.1109/IEMBS.2005.1616297; Aminian K, 1999, MED BIOL ENG COMPUT, V37, P304, DOI 10.1007/BF02513304; Auvinet B, 2002, GAIT POSTURE, V16, P124, DOI 10.1016/S0966-6362(01)00203-X; Besier TF, 2003, J BIOMECH, V36, P1159, DOI 10.1016/S0021-9290(03)00087-3; Brandt T, 1999, LANCET, V354, P746, DOI 10.1016/S0140-6736(99)03179-7; Brunnekreef JJ, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-17; Capaday C, 1999, J NEUROPHYSIOL, V81, P129, DOI 10.1152/jn.1999.81.1.129; CAPADAY C, 1987, J PHYSIOL-LONDON, V392, P513, DOI 10.1113/jphysiol.1987.sp016794; Culhane KM, 2005, AGE AGEING, V34, P556, DOI 10.1093/ageing/afi192; DIETZ V, 1989, NEUROSCI LETT, V106, P350, DOI 10.1016/0304-3940(89)90189-4; DIETZ V, 1992, EXP BRAIN RES, V89, P229; DIETZ V, 1987, J PHYSIOL-LONDON, V386, P149, DOI 10.1113/jphysiol.1987.sp016527; Dietz V., 2001, Neural Plasticity, V8, P83, DOI 10.1155/NP.2001.83; Dietz V, 2001, NEUROREPORT, V12, P2743, DOI 10.1097/00001756-200108280-00030; DIETZ V, 1992, PHYSIOL REV, V72, P33, DOI 10.1152/physrev.1992.72.1.33; DIETZ V, 1989, J NEUROPHYSIOL, V62, P680, DOI 10.1152/jn.1989.62.3.680; Dietz V, 2002, NAT REV NEUROSCI, V3, P781, DOI 10.1038/nrn939; Dobkin BH, 2003, CLIN SCI NEUROLOGIC; Duysens J, 1996, J NEUROPHYSIOL, V76, P301, DOI 10.1152/jn.1996.76.1.301; DUYSENS J, 1990, EXP BRAIN RES, V82, P351; Finney R. L., 1990, CALCULUS; Growney E, 1997, GAIT POSTURE, V6, P147, DOI 10.1016/S0966-6362(97)01114-4; HANSEN PD, 1988, EXP BRAIN RES, V73, P627, DOI 10.1007/BF00406622; Hester T, 2006, BSN 2006: International Workshop on Wearable and Implantable Body Sensor Networks, Proceedings, P5; Hoos MB, 2004, EUR J CLIN NUTR, V58, P1425, DOI 10.1038/sj.ejcn.1601991; Horak FB, 2001, J NEUROPHYSIOL, V86, P575, DOI 10.1152/jn.2001.86.2.575; Huang H, 2006, J NEUROENG REHABIL, V3, DOI 10.1186/1743-0003-3-11; Jafari R, 2005, PROCEEDINGS OF MOBIQUITOUS 2005, P479; JANKOWSKA E, 1981, TRENDS NEUROSCI, V4, P230, DOI 10.1016/0166-2236(81)90072-2; Jones KE, 2001, NEUROREPORT, V12, P4029, DOI 10.1097/00001756-200112210-00035; KADABA MP, 1989, J ORTHOPAED RES, V7, P849, DOI 10.1002/jor.1100070611; Kavanagh JJ, 2004, GAIT POSTURE, V20, P291, DOI 10.1016/j.gaitpost.2003.10.004; Kavanagh JJ, 2006, J BIOMECH, V39, P2863, DOI 10.1016/j.jbiomech.2005.09.012; Lackner JR, 2000, TRENDS COGN SCI, V4, P279, DOI 10.1016/S1364-6613(00)01493-5; LEE JA, 2007, C P IEEE ENG MED BIO, V1, P483; LEMOYNE R, 2007, 3 ANN THER STRAT NEU; LEMOYNE R, 2005, UCLA COMMUNICATION N; LEMOYNE R, 2007, UCLA BRAIN RES I NEU; LEMOYNE R, 2007, IGERT STUD RES S PIT; Lord SE, 2005, STROKE, V36, P1457, DOI 10.1161/01.STR.0000170698.20376.2e; Mansfield A, 2003, MED ENG PHYS, V25, P879, DOI 10.1016/S1350-4533(03)00116-4; Mayagoitia RE, 2002, J BIOMECH, V35, P537, DOI 10.1016/S0021-9290(01)00231-7; Menz HB, 2003, GAIT POSTURE, V18, P35, DOI 10.1016/S0966-6362(02)00159-5; Menz HB, 2003, AGE AGEING, V32, P137, DOI 10.1093/ageing/32.2.137; Moe-Nilssen R, 2005, GAIT POSTURE, V21, P164, DOI 10.1016/j.gaitpost.2004.01.013; Moe-Nilssen R, 2004, J BIOMECH, V37, P121, DOI 10.1016/S0021-9290(03)00233-1; Moe-Nilssen R, 1998, CLIN BIOMECH, V13, P328, DOI 10.1016/S0268-0033(98)00090-4; NAKAMURA S, 1996, NUMERICAL ANAL GRAPH; Pang MYC, 2000, J PHYSIOL-LONDON, V528, P389, DOI 10.1111/j.1469-7793.2000.00389.x; Pang MYC, 2001, J PHYSIOL-LONDON, V533, P617, DOI 10.1111/j.1469-7793.2001.0617a.x; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Perry J, 1992, GAIT ANAL NORMAL PAT; Saremi K, 2006, NEUROREHAB NEURAL RE, V20, P297, DOI 10.1177/1545968306287171; SAUNDERS JBDM, 1953, J BONE JOINT SURG AM, V35-A, P543, DOI 10.2106/00004623-195335030-00003; SCHOMBURG ED, 1990, NEUROSCI RES, V7, P265, DOI 10.1016/0168-0102(90)90008-3; Schubert M, 1997, EXP BRAIN RES, V115, P234, DOI 10.1007/PL00005693; Schubert M, 1999, EXP BRAIN RES, V126, P583, DOI 10.1007/s002210050767; SINKJAER T, 1994, BRAIN, V117, P355, DOI 10.1093/brain/117.2.355; Sinkjaer T, 1996, J NEUROPHYSIOL, V76, P1112, DOI 10.1152/jn.1996.76.2.1112; Takahashi CD, 2001, J NEUROPHYSIOL, V86, P1047, DOI 10.1152/jn.2001.86.2.1047; Vaillancourt DE, 2000, CLIN NEUROPHYSIOL, V111, P2046, DOI 10.1016/S1388-2457(00)00467-3; vandenBogert AJ, 1996, J BIOMECH, V29, P949, DOI 10.1016/0021-9290(95)00155-7; vanEmmerik REA, 1996, J BIOMECH, V29, P1175, DOI 10.1016/0021-9290(95)00128-X; Waters RL, 1999, GAIT POSTURE, V9, P207, DOI 10.1016/S0966-6362(99)00009-0; Yoshimura I, 2002, INT ORTHOP, V26, P303, DOI 10.1007/s00264-002-0379-8; Zhang K, 2004, MED SCI SPORT EXER, V36, P883, DOI 10.1249/01.MSS.0000126585.40962.22; Zhang K, 2003, OBES RES, V11, P33, DOI 10.1038/oby.2003.7; Zijlstra W, 2004, CLIN BIOMECH, V19, P819, DOI 10.1016/j.clinbiomech.2004.05.005; Zijlstra W, 2003, GAIT POSTURE, V18, P1, DOI 10.1016/S0966-6362(02)00190-X	69	25	25	0	5	WORLD SCIENTIFIC PUBL CO PTE LTD	SINGAPORE	5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE	0219-5194	1793-6810		J MECH MED BIOL	J. Mech. Med. Biol.	SEP	2008	8	3					317	338		10.1142/S0219519408002693			22	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	389LM	WOS:000262094100002					2022-02-06	
J	Rasmussen, IA; Xu, J; Antonsen, IK; Brunner, J; Skandsen, T; Axelson, DE; Berntsen, EM; Lydersen, S; Haberg, A				Rasmussen, Inge-Andre, Jr.; Xu, Jian; Antonsen, Ida Kristin; Brunner, Jan; Skandsen, Toril; Axelson, David E.; Berntsen, Erik M.; Lydersen, Stian; Haberg, Asta			Simple Dual Tasking Recruits Prefrontal Cortices in Chronic Severe Traumatic Brain Injury Patients, But Not in Controls	JOURNAL OF NEUROTRAUMA			English	Article						anterior cingulate cortex; attention; executive; MRI; white matter injury	SURFACE-BASED ANALYSIS; WORKING-MEMORY; DIVIDED ATTENTION; NEURAL BASIS; FUNCTIONAL NEUROANATOMY; SEARCH EFFICIENCY; EXECUTIVE CONTROL; VISUAL-SEARCH; HEAD-INJURY; TOP-DOWN	The ability to carry out two tasks simultaneously, dual tasking, is specifically impaired after traumatic brain injury (TBI). The aim of the present study was to investigate the neuronal correlates to this increased dual cost in chronic severe TBI patients (n = 10) compared to healthy controls (n = 11) using functional magnetic resonance imaging (fMRI) at 3 Tesla (T). The tasks were a visual search and a simple two-fingers button press motor task. Performance data demonstrated similar and significant dual task interference in both TBI patients and controls using a linear mixed model. However, principal component analysis showed that TBI patients and controls could be classified into different categories based on motor activity in the single compared to the dual task condition, thus reflecting the increased variability in the performance in the TBI group. Random effects between-group analysis demonstrated significantly reduced activation in the TBI group in both single task conditions in the occipital and posterior cingulate cortices, and for the visual task also in the thalami. This pattern was reversed in the dual task condition with significantly increased activation of a predominantly left lateralized prefrontal-anterior midline-parietal network in the TBI group compared to the controls. The increase in activation occurred within regions described to be engaged in healthy volunteers as dual task cost increases. This finding points to substitution, functional reorganization within the primary network subserving the task, following TBI, and demonstrates more effortful processing. Recruitment of these additional prefrontal resources may be connected to serial rather than parallel processing in low level dual tasking in TBI. Thus, in severe TBI, low level dual task performance depends on increased attentional and executive guidance.	[Rasmussen, Inge-Andre, Jr.; Xu, Jian; Berntsen, Erik M.; Haberg, Asta] NTNU, Dept Circulat & Med Imaging, N-7489 Trondheim, Norway; [Xu, Jian; Antonsen, Ida Kristin; Haberg, Asta] St Olavs Hosp, Dept Radiol, Trondheim, Norway; [Brunner, Jan; Skandsen, Toril] St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Skandsen, Toril] NTNU, Dept Neurosci, N-7489 Trondheim, Norway; [Lydersen, Stian] NTNU, Dept Canc Res & Mol Med, Unit Appl Clin Res, N-7489 Trondheim, Norway; [Axelson, David E.] MRI Consulting, Kingston, ON, Canada		Haberg, A (corresponding author), NTNU, Dept Circulat & Med Imaging, N-7489 Trondheim, Norway.	asta.haberg@ntnu.no	Berntsen, Erik Magnus/AAM-7134-2020; Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338; Brunner, Jan Ferenc/0000-0002-8576-678X			Adcock RA, 2000, P NATL ACAD SCI USA, V97, P3567, DOI 10.1073/pnas.060588897; Anderson EJ, 2007, EXP BRAIN RES, V180, P289, DOI 10.1007/s00221-007-0860-0; Arciniegas David B, 2004, Phys Med Rehabil Clin N Am, V15, P177, DOI 10.1016/S1047-9651(03)00104-9; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; BADDELEY AD, 1991, BRAIN, V114, P2521, DOI 10.1093/brain/114.6.2521; Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Boynton GM, 1996, J NEUROSCI, V16, P4207, DOI 10.1523/jneurosci.16-13-04207.1996; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Brouwer W, 2001, BRAIN COGNITION, V46, P54, DOI 10.1016/S0278-2626(01)80033-6; Brouwer WH, 2002, J HEAD TRAUMA REHAB, V17, P1, DOI 10.1097/00001199-200202000-00003; Bunge SA, 2000, P NATL ACAD SCI USA, V97, P3573, DOI 10.1073/pnas.050583797; Buschman TJ, 2007, SCIENCE, V315, P1860, DOI 10.1126/science.1138071; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Collette F, 2005, COGNITIVE BRAIN RES, V24, P237, DOI 10.1016/j.cogbrainres.2005.01.023; CREPEAU F, 1993, J CLIN EXP NEUROPSYC, V15, P73; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Donner TH, 2002, NEUROIMAGE, V15, P16, DOI 10.1006/nimg.2001.0951; Dreher JC, 2003, CEREB CORTEX, V13, P329, DOI 10.1093/cercor/13.4.329; Erickson KI, 2005, NEUROIMAGE, V28, P967, DOI 10.1016/j.neuroimage.2005.06.047; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Goldberg TE, 1998, NEUROIMAGE, V7, P296, DOI 10.1006/nimg.1998.0338; Handford Martin, 1987, WALLY; Herath P, 2001, CEREB CORTEX, V11, P796, DOI 10.1093/cercor/11.9.796; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Kiebel SJ, 2000, NEUROIMAGE, V11, P656, DOI 10.1006/nimg.1999.0542; Klingberg T, 1998, CEREB CORTEX, V8, P593, DOI 10.1093/cercor/8.7.593; Klingberg T, 2000, PROG BRAIN RES, V126, P95; Knudsen EI, 2007, ANNU REV NEUROSCI, V30, P57, DOI 10.1146/annurev.neuro.30.051606.094256; Koechlin E, 1999, NATURE, V399, P148, DOI 10.1038/20178; Kriegeskorte N, 2001, NEUROIMAGE, V14, P329, DOI 10.1006/nimg.2001.0831; Kubler A, 2006, J COGNITIVE NEUROSCI, V18, P1331, DOI 10.1162/jocn.2006.18.8.1331; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Leonards U, 2000, J COGNITIVE NEUROSCI, V12, P61, DOI 10.1162/089892900564073; LOGIE RH, 1990, ACTA PSYCHOL, V75, P55, DOI 10.1016/0001-6918(90)90066-O; Logie RH, 2004, NEUROPSYCHOLOGY, V18, P504, DOI 10.1037/0894-4105.18.3.504; Lotze M, 2006, NEUROREHAB NEURAL RE, V20, P14, DOI 10.1177/1545968305282919; Marois R, 2005, TRENDS COGN SCI, V9, P296, DOI 10.1016/j.tics.2005.04.010; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Moore T, 2001, P NATL ACAD SCI USA, V98, P1273, DOI 10.1073/pnas.021549498; Muller NG, 2003, NEUROIMAGE, V20, P1578, DOI 10.1016/S1053-8119(03)00416-6; Nobre AC, 2003, NEUROIMAGE, V18, P91, DOI 10.1006/nimg.2002.1329; Norman D. A., 1986, ATTENTION ACTION WIL; Nunez A, 2007, ADV ANAT EMBRYOL CEL, V187, P1; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PASHLER H, 1994, J EXP PSYCHOL HUMAN, V20, P330, DOI 10.1037/0096-1523.20.2.330; Passingham RE, 1996, PHILOS T ROY SOC B, V351, P1473, DOI 10.1098/rstb.1996.0132; Perry RJ, 1999, BRAIN, V122, P383, DOI 10.1093/brain/122.3.383; Prigatano GP, 2004, BRAIN INJURY, V18, P661, DOI 10.1080/02699050310001646170; Rasmussen IA, 2006, ACTA NEUROPSYCHIATR, V18, P216, DOI 10.1111/j.1601-5215.2006.00145.x; Repovs G, 2006, NEUROSCIENCE, V139, P5, DOI 10.1016/j.neuroscience.2005.12.061; Sato T, 2001, NEURON, V30, P583, DOI 10.1016/S0896-6273(01)00304-X; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; SKANDSEN T, 2008, CLIN REHABI IN PRESS; Smith EE, 2001, P NATL ACAD SCI USA, V98, P2095, DOI 10.1073/pnas.98.4.2095; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stelzel C, 2006, PSYCHOL RES-PSYCH FO, V70, P514, DOI 10.1007/s00426-005-0013-7; Szameitat AJ, 2006, PSYCHOL RES-PSYCH FO, V70, P541, DOI 10.1007/s00426-005-0015-5; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Tomita H, 1999, NATURE, V401, P699, DOI 10.1038/44372; TREISMAN A, 1991, J EXP PSYCHOL HUMAN, V17, P652, DOI 10.1037/0096-1523.17.3.652; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Wolfe JM, 1996, NATURE, V380, P587, DOI 10.1038/380587a0; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; [No title captured], DOI DOI 10.1016/S0079-7421(08)60452-1	71	25	26	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2008	25	9					1057	1070		10.1089/neu.2008.0520			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	360JX	WOS:000260054900002	18729718				2022-02-06	
J	Gillette, Y; Depompei, R				Gillette, Yvonne; Depompei, Roberta			Do PDAs enhance the organization and memory skills of students with cognitive disabilities?	PSYCHOLOGY IN THE SCHOOLS			English	Article							TRAUMATIC BRAIN-INJURY; PORTABLE ELECTRONIC DEVICES; ASSISTIVE-TECHNOLOGY; REHABILITATION; AIDS; PEOPLE; IMPAIRMENT; COMPUTER	The project studied the on-time behavior of 35 Students with intellectual disabilities (ID) or traumatic brain injury (TBI) under three conditions - times and tasks list, paper planner, and two different personal data assistants (PDAs). Students participated for two 4-week periods, receiving one morning reminder during Period I and no reminders during Period 2. Students were on time more often using a PDA compared to a list (p <.024) or a planner (p <.002). Students were on time 50% more often in Period I with a single daily morning reminder as compared to no reminder across all conditions. When applying results, clinicians and researchers should note that only the alarm function prompting on-time behavior was studied, and the influence of the small sample size and short time frame. Future researchers will find a framework for studying PDAs and cell phones with larger samples. over longer time periods, and with a wider range of functions. (C) 2008 Wiley Periodicals, Inc.	[Gillette, Yvonne; Depompei, Roberta] Univ Akron, Akron, OH 44325 USA		Gillette, Y (corresponding author), Univ Akron, Polsky Bldg 188B, Akron, OH 44325 USA.	yg@uakron.edu					Bergman MM, 2002, J HEAD TRAUMA REHAB, V17, P431, DOI 10.1097/00001199-200210000-00005; BLOSSER JL, 2002, PEDIAT TRAUMATIC BRA; BRYEN DN, 2005, 6 ANN COL I C DENV C; CAREY A, 2005, MENT RETARD, V43, P32; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Constantinidou F., 2004, TRAUMATIC BRAIN INJU, P337; Davies DK, 2002, MENT RETARD, V40, P358, DOI 10.1352/0047-6765(2002)040<0358:EITMSO>2.0.CO;2; DePompei R, 2004, LEARNING COGNITIVE C; Derer K., 1996, Journal of Special Education Technology, V13, P62; DOWDS M, 2005, 6 ANN COL I C DENV C; Epstein J. N., 2001, Journal of Special Education Technology, V16, P19; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Fuhrer MJ, 2001, AM J PHYS MED REHAB, V80, P528, DOI 10.1097/00002060-200107000-00013; Gillette Y, 2004, NEUROREHABILITATION, V19, P233; GILLETTE Y, 2005, TECHN PERS DIS CSUN; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Hart T, 2003, BRAIN INJURY, V17, P401, DOI 10.1080/0269905021000038438; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hilbe J. M., 2007, NEGATIVE BINOMIAL RE; Holme SA, 1997, AM J OCCUP THER, V51, P42, DOI 10.5014/ajot.51.1.42; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kirsch NL, 2004, J HEAD TRAUMA REHAB, V19, P366, DOI 10.1097/00001199-200409000-00002; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; LoPresti EF, 2004, NEUROPSYCHOL REHABIL, V14, P5, DOI 10.1080/09602010343000101; Miller S.A., 2002, COGNITIVE DEV, V4th; Bryen DN, 2007, INTELLECT DEV DISAB, V45, P1, DOI 10.1352/1934-9556(2007)45[1:CPUBAW]2.0.CO;2; PARENTE R, 2001, EXTERNAL AIDS UNPUB; PARENTE R, 1991, COGNITIVE REHABILITA, P147; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; SCHERER MJ, 1990, J APPL REHABIL COUNS, V21, P36; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg MM, 2007, J MED SPEECH-LANG PA, V15, pXV; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Stickel MS, 2002, DISABIL REHABIL, V24, P115, DOI 10.1080/09638280110066794; Van Hulle A, 2006, BRAIN INJURY, V20, P101, DOI 10.1080/02699050500309684; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; WILSON BA, 1991, NEUROPSYCHOL REHABIL, V1, P117, DOI DOI 10.1080/09602019108401386; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P181; [No title captured]	46	25	25	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0033-3085	1520-6807		PSYCHOL SCHOOLS	Psychol. Schools	AUG	2008	45	7					665	677		10.1002/pits.20316			13	Psychology, Educational	Social Science Citation Index (SSCI)	Psychology	334WM	WOS:000258252100007					2022-02-06	
J	Hata, JS; Shelsky, CR; Hindman, BJ; Smith, TC; Simmons, JS; Todd, MM				Hata, J. Steven; Shelsky, Constance R.; Hindman, Bradley J.; Smith, Thomas C.; Simmons, Jonathan S.; Todd, Michael M.			A prospective, observational clinical trial of fever reduction to reduce systemic oxygen consumption in the setting of acute brain injury	NEUROCRITICAL CARE			English	Article						fever; oxygen consumption; brain injuries; hypothermia; shivering; critical care	BODY-TEMPERATURE; ACUTE STROKE; THERAPEUTIC HYPOTHERMIA; METABOLIC-RATE; HEAD-INJURY; HYPERTHERMIA; MEPERIDINE; THRESHOLD; INCREASES; MORTALITY	Introduction Fever after acute brain injury appears to be a detrimental factor, associated with impaired neurological outcomes. This study assessed physiological changes in systemic oxygen consumption (VO2) during cutaneous cooling after severe brain injury. Methods This prospective, observational, clinical study evaluated ten, critically ill, brain-injured patients requiring mechanical ventilation with a core body temperature of greater or equal to 38 degrees C. Febrile patients failing to defervesce after acetaminophen underwent indirect calorimetry for a 1-hour baseline period followed by a 4 h cooling period. The Arctic Sun (R) Temperature Management System (Medivance (R)) directed core temperature to a goal of 36 degrees C. Results The patients had a mean age of 32 years (95% CI 23, 40), Glasgow Coma Scale of 6 (95% CI 5,7), and APACHE 2 score of 19 (95% CI 15, 22), with 8 of 10 patients suffering traumatic brain injuries. The baseline 1-h core temperature was significantly reduced from 38.6 degrees +/- 0.9 to 36.3 degrees +/- 1.2 degrees C (P < 0.0001) over 4 h. Two cohorts were identified based upon the presence or absence of shivering. Within the non-shivering cohort, systemic VO2 was significantly reduced from 415 +/- 123 to 308 +/- 115 ml/min (-27 +/- 18%) (P < 0.05). In contrast, those with shivering showed no significant reduction in VO2, despite significantly decreasing core temperature. The overall percentage change of VCO2 correlated with VO2 (r(2) = 0.91). Conclusion Fever reduction in acute brain injury appears to significantly reduce systemic VO2, but is highly dependent on shivering control.	[Hata, J. Steven] Univ Iowa Hosp & Clin, Dept Anesthesia, Div Crit Care, Iowa City, IA 52242 USA; [Hata, J. Steven; Simmons, Jonathan S.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Anesthesia, Div Crit Care, Iowa City, IA 52242 USA		Hata, JS (corresponding author), Univ Iowa Hosp & Clin, Dept Anesthesia, Div Crit Care, Iowa City, IA 52242 USA.	steven-hata@uiowa.edu	Hata, J./ABI-1484-2020	Simmons, Jonathan/0000-0003-2806-0331; Hindman, Bradley/0000-0003-2242-7980	Medivance(R)	Financial support: Medivance (R) provided grant support for this investigation	Al-Senani FM, 2004, RESUSCITATION, V62, P143, DOI 10.1016/j.resuscitation.2004.02.016; Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Arroliga A, 2005, CHEST, V128, P496, DOI 10.1378/chest.128.2.496; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BUSIJA DW, 1988, AM J PHYSIOL, V255, pH343, DOI 10.1152/ajpheart.1988.255.2.H343; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; De Witte J, 2002, ANESTHESIOLOGY, V96, P467, DOI 10.1097/00000542-200202000-00036; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; FRANK SM, 1995, ANESTHESIOLOGY, V82, P83, DOI 10.1097/00000542-199501000-00012; Geffroy A, 2004, INTENS CARE MED, V30, P785, DOI 10.1007/s00134-004-2280-y; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gozzoli V, 2004, INTENS CARE MED, V30, P401, DOI 10.1007/s00134-003-2087-2; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Holzer M, 2002, NEW ENGL J MED, V346, P549; Iaizzo PA, 1999, J NEUROSURG ANESTH, V11, P231, DOI 10.1097/00008506-199910000-00002; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kammersgaard LP, 2002, STROKE, V33, P1759, DOI 10.1161/01.STR.0000019910.90280.F1; Kasner SE, 2002, STROKE, V33, P130, DOI 10.1161/hs0102.101477; LANIER WL, 1989, ANESTHESIOLOGY, V71, P87, DOI 10.1097/00000542-198907000-00016; Lenhardt R, 1999, AM J MED, V106, P550, DOI 10.1016/S0002-9343(99)00068-6; MANTHOUS CA, 1995, AM J RESP CRIT CARE, V151, P210, DOI 10.1164/ajrccm.151.1.7812556; MANTHOUS CA, 1995, AM J RESP CRIT CARE, V151, P10, DOI 10.1164/ajrccm.151.1.7812538; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MATTHEWS DSF, 1995, ARCH DIS CHILD, V72, P507, DOI 10.1136/adc.72.6.507; Mayer SA, 2001, NEUROLOGY, V56, P292, DOI 10.1212/WNL.56.3.292; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; Nemoto EM, 2005, ADV EXP MED BIOL, V566, P83; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; RALLEY FE, 1988, CAN J ANAESTH, V35, P332, DOI 10.1007/BF03010851; RAURICH JM, 1994, JPEN-PARENTER ENTER, V18, P521, DOI 10.1177/0148607194018006521; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; ROSA G, 1995, ACTA ANAESTH SCAND, V39, P90, DOI 10.1111/j.1399-6576.1995.tb05598.x; Sessler DI, 2001, ANESTHESIOLOGY, V95, P531, DOI 10.1097/00000542-200108000-00040; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SLADEN RN, 1995, J CARDIOTHOR VASC AN, V9, P147, DOI 10.1016/S1053-0770(05)80185-5; Sweney MT, 2001, ANESTHESIOLOGY, V95, P1089, DOI 10.1097/00000542-200111000-00011; Talke P, 1997, ANESTHESIOLOGY, V87, P835, DOI 10.1097/00000542-199710000-00017	39	25	25	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2008	9	1					37	44		10.1007/s12028-007-9015-1			8	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	340PM	WOS:000258657500008	17985248				2022-02-06	
J	Statler, KD; Swank, S; Abildskov, T; Bigler, ED; White, HS				Statler, Kimberly D.; Swank, Seth; Abildskov, Tracy; Bigler, Erin D.; White, H. Steve			Traumatic brain injury during development reduces minimal clonic seizure thresholds at maturity	EPILEPSY RESEARCH			English	Article						head injury; controlled cortical impact; seizure threshold; developing rat; rodent	CONTROLLED CORTICAL IMPACT; FLUID PERCUSSION INJURY; EARLY POSTTRAUMATIC SEIZURES; HEAD-INJURY; STATUS EPILEPTICUS; EPILEPSY; CHILDREN; RAT; MICE; MODEL	Post-traumatic seizures affect 12-35% of children after traumatic brain injury (TBI) and are associated with worse cognitive and functional outcome, even after adjustment for severity of injury. Unfortunately, experimental models of pediatric post-traumatic epilepsy are lacking, and pathogenesis remains poorly understood. We have applied a standard model of TBI in immature rats to determine the effect of TBI on electroconvulsive seizure thresholds later in life. Mate rats underwent controlled cortical impact to left parietal cortex on post-natal day (PND) 16-18. Hindbrain, forebrain, and limbic seizure thresholds were assessed, respectively, by tonic hindlimb extension (THE), minimal. clonic, and partial psychomotor seizure responses during adolescence (PND 34-40) and at maturity (PND 60-63). Post-traumatic seizure thresholds were compared to those obtained in age- and litter-matched sham craniotomy and naive controls. TBI during immaturity had no clear effect on THE seizure thresholds. In contrast, TBI towered minimal. clonic seizure thresholds at maturity (p < 0.05 vs. sham or naive rats), but not during adolescence. Consequently, minimal clonic seizure thresholds increased with age for sham and naive rats but remained similar for TBI rats during adolescence and at maturity. TBI also tended to tower partial psychomotor seizure thresholds, which were determined only during adolescence (p < 0.1 vs. naive). Controlled cortical impact causes both focal cortical injury at the site of impact and ipsilateral hippocampal neuronal death. Since minimal. clonic seizures are mediated by the forebrain, partial psychomotor seizures by the limbic system, and THE seizures by the brainstem, the observed pattern of changes in post-traumatic seizure thresholds is not surprising. The apparent age-dependent effects of TBI, however, are unexpected and likely due to a combination of attenuated maturational increases and progressive epileptogenesis. Additional study is needed to delineate the relative contributions of these processes. Given the sustained reduction in post-traumatic minimal clonic seizure thresholds, controlled cortical impact may hold promise as an experimental model of pediatric post-traumatic epilepsy. (C) 2008 Elsevier B.V. All rights reserved.	[Statler, Kimberly D.; Swank, Seth] Univ Utah, Sch Med, Dept Pediat Crit Care, Salt Lake City, UT 84158 USA; [Bigler, Erin D.] Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84158 USA; [White, H. Steve] Univ Utah, Coll Pharm, Anticonvulsant Drug Dev Program, Salt Lake City, UT 84158 USA; [Statler, Kimberly D.; White, H. Steve] Univ Utah, Coll Pharm, Dept Pharmacol & Toxicol, Salt Lake City, UT 84158 USA; [Statler, Kimberly D.; Bigler, Erin D.; White, H. Steve] Univ Utah, Inst Brain, Salt Lake City, UT 84158 USA; [Abildskov, Tracy; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Abildskov, Tracy; Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA		Statler, KD (corresponding author), Univ Utah, Sch Med, Dept Pediat Crit Care, POB 581289,295 Chipeta Way, Salt Lake City, UT 84158 USA.	kim.statler@hsc.utah.edu		White, H. Steve/0000-0003-4550-4408	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12-HD 0141001]; Primary Children's Medical Center Foundation; University of Utah Children's Health Research Center; CHRCDA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001410] Funding Source: NIH RePORTER	We thank the National Institutes of Health (K12-HD 0141001), the Primary Children's Medical Center Foundation, and the University of Utah Children's Health Research Center for support of this project. Dr. Statler is a CHRCDA awardee, a Primary Children's Medical Center Foundation Scholar, and a University of Utah Pediatric Clinical and Translational Research Scholar.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS72; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Barton ME, 2001, EPILEPSY RES, V47, P217, DOI 10.1016/S0920-1211(01)00302-3; Ben-Ari Y, 2006, LANCET NEUROL, V5, P1055, DOI 10.1016/S1474-4422(06)70626-3; BROWNING RA, 1981, EPILEPSIA, V22, P583, DOI 10.1111/j.1528-1157.1981.tb04130.x; BROWNING RA, 1985, FED PROC, V44, P2425; BROWNING RA, 1986, LIFE SCI, V39, P857, DOI 10.1016/0024-3205(86)90367-X; Cha BH, 2004, BRAIN DEV-JPN, V26, P394, DOI 10.1016/j.braindev.2003.12.006; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eells JB, 2004, NEUROSCIENCE, V123, P279, DOI 10.1016/j.neuroscience.2003.08.015; Finney DJ, 1971, PROBIT ANAL STAT TRE; FREEMAN FG, 1981, BRAIN RES BULL, V7, P629, DOI 10.1016/0361-9230(81)90109-X; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Golarai G, 2001, J NEUROSCI, V21, P8523, DOI 10.1523/JNEUROSCI.21-21-08523.2001; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hopkins RO, 1997, NEUROPSYCHOL REV, V7, P87, DOI 10.1023/B:NERV.0000005946.46506.a9; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; LOSCHER W, 1986, EPILEPSIA, V27, P657, DOI 10.1111/j.1528-1157.1986.tb03592.x; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nishi RA, 2007, J NEUROTRAUM, V24, P674, DOI 10.1089/neu.2006.0204; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; Onyszchuk G, 2007, J NEUROSCI METH, V160, P187, DOI 10.1016/j.jneumeth.2006.09.007; Otto JE, 2004, EPILEPSIA, V45, P1009, DOI 10.1111/j.0013-9580.2004.65703.x; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Pryce CR, 2003, NEUROSCI BIOBEHAV R, V27, P57, DOI 10.1016/S0149-7634(03)00009-5; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Schweinhardt P, 2003, J NEUROSCI METH, V129, P105, DOI 10.1016/S0165-0270(03)00192-4; SMOTHERMAN WP, 1983, DEV PSYCHOBIOL, V16, P169, DOI 10.1002/dev.420160303; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Toth Z, 1997, J NEUROSCI, V17, P8106; White HS, 2002, NEUROLOGY, V59, pS7, DOI 10.1212/WNL.59.9_suppl_5.S7; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; WOODBURY LA, 1952, ARCH INT PHARMACOD T, V92, P97; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	42	25	25	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	AUG	2008	80	2-3					163	170		10.1016/j.eplepsyres.2008.04.001			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	341QE	WOS:000258728900008	18490145	Green Accepted			2022-02-06	
J	Rowson, S; McNeely, DE; Brolinson, PG; Duma, SM				Rowson, Steven; McNeely, David E.; Brolinson, P. Gunnar; Duma, Stefan M.			Biomechanical analysis of football neck collars	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						stinger; neck collar; football; brachial plexus	PROFESSIONAL FOOTBALL; LATERAL FLEXION; HYPEREXTENSION; CONCUSSION; INJURIES; PLAYERS; IMPACTS	Objective: To determine the load-limiting capabilities of protective neck collars used in football through dynamic impact testing. Design: A 50th-percentile male Hybrid III dummy was used in 48 dynamic impact tests comparing the Cowboy Collar, Bullock Collar, and Kerr Collar. A control and each collar were tested at two velocities (5 m/s and 7 m/s), three impact locations (front, top, and side of the helmet), and two shoulder pad positions (normal and raised). Setting: Research laboratory. Patients: None. Interventions: None. Independent variables were the neck collars, impact velocity, and shoulder pad position. Main Outcome Measurements: In addition to range of motion, upper and lower neck forces and moments were measured. Results: With the top impact location, it was found that the Kerr Collar and Bullock Collar reduced head accelerations and force transmission through the neck. With the front impact location, all the collars reduced lower neck moment. The Kerr Collar was also capable of reducing the lower neck force and upper neck moment. With the side impact location, the Kerr Collar substantially reduced lower neck moment. Conclusions: These reductions in loads correlate with the degree to which each collar restricted the motion of the head and neck. By restricting the range of motion of the neck and,redistributing load to the shoulders, neck loads can be effectively lowered.	[Rowson, Steven; McNeely, David E.; Duma, Stefan M.] Virginia Tech, Wake Forest Ctr Injury Biomech, Blacksburg, VA 24061 USA; [Brolinson, P. Gunnar] Edward Via Coll Osteopath Med, Blacksburg, VA 24061 USA		Rowson, S (corresponding author), Virginia Tech, Wake Forest Ctr Injury Biomech, 100F Randolph Hall,MC 0238, Blacksburg, VA 24061 USA.	srowson@vt.edu	Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596			Clancy W G Jr, 1977, Am J Sports Med, V5, P209, DOI 10.1177/036354657700500508; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Gorden JA, 2003, J ATHL TRAINING, V38, P209; HALL G, 1998, SOC AUTOMOTIVE ENG, V98, P1141; HERSHMAN EB, 1990, CLIN SPORT MED, V9, P311; HOVIS WD, 1994, MED SCI SPORT EXER, V26, P872; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; ROBERTSON WC, 1979, JAMA-J AM MED ASSOC, V241, P1480, DOI 10.1001/jama.241.14.1480; Rowson S, 2007, BIOMED SCI INSTRUM, V43, P200; SALLIS RE, 1992, PHYSICIAN SPORTSMED, V20, P47, DOI 10.1080/00913847.1992.11947521	11	25	25	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2008	18	4					316	321		10.1097/JSM.0b013e31817f016a			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	325DK	WOS:000257568300002	18614882				2022-02-06	
J	Vilar-Lopez, R; Gomez-Rio, M; Santiago-Ramajo, S; Rodriguez-Fernandez, A; Puente, AE; Perez-Garcia, M				Vilar-Lopez, Raquel; Gomez-Rio, Manuel; Santiago-Ramajo, Sandra; Rodriguez-Fernandez, Antonio; Puente, Antonio E.; Perez-Garcia, Miguel			Malingering detection in a Spanish population with a known-groups design	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; TOMM; Dot Counting Test; Spanish speakers; poor effort; insufficient effort	TRAUMATIC BRAIN-INJURY; DOT COUNTING TEST; FORENSIC NEUROPSYCHOLOGY; CLINICAL-NEUROPSYCHOLOGY; HEAD-INJURY; MEMORY; PERFORMANCE; TOMM; TESTS; RATES	Malingering detection has become a topic of increased interest in the US over the last years. However, this development has not been matched in Europe. For example, in Spain there is insufficient evidence to support the use of reliable and valid malingering tests. In this study, we tested the applicability of two malingering detection tests (Test of Memory Malingering (TOMM) and Dot Counting Test) in a Spanish sample. The sample included three groups of patients (30 non-compensation seeking, 14 compensation seeking non-suspected of malingering, and 10 suspected of malingering) and a group of analog students (n = 54). Tests' results were able to discriminate between the groups of malingerers (both patients and analogs) and non-malingerers (both compensation seeking and non-compensation seeking). However, the TOMM achieved a higher overall classification rate than the Dot Counting Test. Our results encourage the use of the TOMM as an indicator of malingering with Spanish population. (C) 2008 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	[Vilar-Lopez, Raquel; Santiago-Ramajo, Sandra; Perez-Garcia, Miguel] Univ Granada, Dept Personalidad Evaluac & Tratamiento Psicol, Granada, Spain; [Gomez-Rio, Manuel; Rodriguez-Fernandez, Antonio] Hosp Univ Virgen Nieves, Nucl Med Serv, Granada, Spain; [Puente, Antonio E.] Univ N Carolina, Wilmington, NC 28401 USA; [Perez-Garcia, Miguel] Univ Granada, Inst Neurosci, E-18071 Granada, Spain		Vilar-Lopez, R (corresponding author), Univ Granada, Dept Personalidad Evaluac & Tratamiento Psicol, Granada, Spain.	raquelvilarlopez@hotmail.com	Vilar-Lopez, Raquel/I-7847-2016; Santiago-Ramajo, Sandra/H-6801-2015; Garcia, Miguel Perez/F-9630-2010; Rodriguez-Fernandez, Antonio/AAB-3469-2019	Vilar-Lopez, Raquel/0000-0001-9639-0143; Santiago-Ramajo, Sandra/0000-0002-6358-6155; Garcia, Miguel Perez/0000-0003-4775-7556; 			Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Benedet M.J., 1998, TAVEC TEST APRENDIZA; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bigler ED, 2006, ARCH CLIN NEUROPSYCH, V21, P503, DOI 10.1016/j.acn.2006.03.008; Binks PG, 1997, ARCH CLIN NEUROPSYCH, V12, P41, DOI 10.1016/S0887-6177(96)00019-4; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; BRICKENKAMP R, 1962, TEST D2; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Duncan A, 2005, ASSESSMENT, V12, P123, DOI 10.1177/1073191105275512; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gierok SD, 2005, ARCH CLIN NEUROPSYCH, V20, P755, DOI 10.1016/j.acn.2005.04.008; Golden CJ, 1978, STROOP COLOR WORD TE; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P117, DOI 10.1016/j.acn.2005.06.009; Haber AH, 2006, CLIN NEUROPSYCHOL, V20, P524, DOI 10.1080/13854040590967595; Hilsabeck RC, 2005, ARCH CLIN NEUROPSYCH, V20, P1025, DOI 10.1016/j.acn.2005.05.003; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Larrabee G.J., 2005, FORENSIC NEUROPSYCHO; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lee A, 2000, CLIN NEUROPSYCHOL, V14, P303, DOI 10.1076/1385-4046(200008)14:3;1-P;FT303; LEZACK MD, 1995, NEUROPSYCHOLOGICAL A; MCCAFFREY RJ, 1997, PRACTICE FORENSIC NE; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; O'Bryant SE, 2004, ARCH CLIN NEUROPSYCH, V19, P489, DOI 10.1016/j.acn.2003.07.001; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Ramirez RM, 2004, REV NEUROLOGIA, V38, P28, DOI 10.33588/rn.3801.2003533; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; Rose FE, 1998, ARCH CLIN NEUROPSYCH, V13, P349, DOI 10.1016/S0887-6177(97)00025-5; SEISDEDOS N, 2000, CAMBIOS TEST FLEXIBI; Slick D.J., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P109, DOI 10.1076/clin.16.2.109.13237; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Vilar-Lopez R, 2007, ARCH CLIN NEUROPSYCH, V22, P379, DOI 10.1016/j.acn.2007.01.012; Wechsler D., 1997, WECHSLER ADULT INTEL, VIII; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005; Wolfson, 1993, HALSTEAD REITAN NEUR; Yanez YT, 2006, ARCH CLIN NEUROPSYCH, V21, P161, DOI 10.1016/j.acn.2005.07.009; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	53	25	26	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	2008	23	4					365	377		10.1016/j.acn.2008.01.007			13	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	320CJ	WOS:000257211000001	18343087	Bronze			2022-02-06	
J	Wang, Y; Rubel, EW				Wang, Y.; Rubel, E. W.			Rapid regulation of microtubule-associated protein 2 in dendrites of nucleus laminaris of the chick following deprivation of afferent activity	NEUROSCIENCE			English	Article						deafferentation; dendritic plasticity; afferent regulation; cytoskeleton	STEM AUDITORY NUCLEI; ATROPHY FOLLOWING DEAFFERENTATION; INTERAURAL TIME DIFFERENCES; ACUTE HIPPOCAMPAL SLICES; TRAUMATIC BRAIN-INJURY; AVIAN COCHLEAR NUCLEUS; INTRACELLULAR CALCIUM; RAT HIPPOCAMPUS; N-LAMINARIS; MAP2	Differential innervation of segregated dendritic domains in the chick nucleus laminaris (NL), composed of third-order auditory neurons, provides a unique model to study synaptic regulation of dendritic structure. Altering the synaptic input to one dendritic domain affects the structure and length of the manipulated dendrites while leaving the other set of unmanipulated dendrites largely unchanged. Little is known about the effects of neuronal input on the cytoskeletal structure of NL dendrites and whether changes in the cytoskeleton are responsible for dendritic remodeling following manipulations of synaptic input. In this study, we investigate changes in the immunoreactivity of high-molecular weight microtubule associated protein 2 (MAP2) in NL dendrites following two different manipulations of their afferent input. Unilateral cochlea removal eliminates excitatory synaptic input to the ventral dendrites of the contralateral NL and the dorsal dendrites of the ipsilateral NL. This manipulation produced a dramatic decrease in MAP2 immunoreactivity in the deafferented dendrites. This decrease was detected as early as 3 h following the surgery, well before any degeneration of afferent axons. A similar decrease in MAP2 immunoreactivity in deafferented NL dendrites was detected following a midline transection that silences the excitatory synaptic input to the ventral dendrites on both sides of the brain. These changes were most distinct in the caudal portion of the nucleus where individual deafferented dendritic branches contained less immunoreactivity than intact dendrites. Our results suggest that the cytoskeletal protein MAP2, which is distributed in dendrites, perikarya, and postsynaptic densities, may play a role in deafferentation-induced dendritic remodeling. (c) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.	[Wang, Y.; Rubel, E. W.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Sch Med, Virginia Merrill Bloedel Hearing Res Ctr, Seattle, WA 98195 USA		Rubel, EW (corresponding author), Univ Washington, Dept Otolaryngol Head & Neck Surg, Sch Med, Virginia Merrill Bloedel Hearing Res Ctr, Box 357923, Seattle, WA 98195 USA.	rubel@u.washington.edu		Wang, Yuan/0000-0003-4347-7063	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P30 DC004661-07, DC03829, R01 DC003829-10, P30 DC004661-09, DC00018, P30 DC004661-08, R01 DC003829, R01 DC003829-08, T32 DC000018, R01 DC003829-09, DC04661, P30 DC004661] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC003829, P30DC004661, T32DC000018] Funding Source: NIH RePORTER		Arias C, 1997, EXP BRAIN RES, V116, P467, DOI 10.1007/PL00005774; BENES FM, 1977, BRAIN RES, V122, P1, DOI 10.1016/0006-8993(77)90658-8; BIGOT D, 1991, EUR J NEUROSCI, V3, P551, DOI 10.1111/j.1460-9568.1991.tb00842.x; Bjorkblom B, 2005, J NEUROSCI, V25, P6350, DOI 10.1523/JNEUROSCI.1517-05.2005; BORN DE, 1991, BRAIN RES, V557, P37, DOI 10.1016/0006-8993(91)90113-A; BORN DE, 1985, J COMP NEUROL, V231, P435, DOI 10.1002/cne.902310403; BURGER RM, 2008, SENSES COMPREHENSIVE, P613; CARR CE, 1988, P NATL ACAD SCI USA, V85, P8311, DOI 10.1073/pnas.85.21.8311; CARR CE, 1990, J NEUROSCI, V10, P3227; DEITCH JS, 1984, J COMP NEUROL, V229, P66, DOI 10.1002/cne.902290106; DEITCH JS, 1989, J COMP NEUROL, V281, P234, DOI 10.1002/cne.902810207; Faddis BT, 1997, J NEUROSCI, V17, P951; FELIPO V, 1993, J NEUROCHEM, V60, P1626, DOI 10.1111/j.1471-4159.1993.tb13384.x; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134; HENDRY SHC, 1992, VISUAL NEUROSCI, V9, P445, DOI 10.1017/S0952523800011251; Hoskison MM, 2007, NEUROSCIENCE, V145, P66, DOI 10.1016/j.neuroscience.2006.11.034; Hoskison MM, 2006, EXP NEUROL, V202, P302, DOI 10.1016/j.expneurol.2006.06.010; JOSEPH AW, 1993, J NEUROPHYSIOL, V69, P1197, DOI 10.1152/jn.1993.69.4.1197; Kelley MS, 1997, J COMP NEUROL, V389, P469; KOWALSKI RJ, 1993, J BIOL CHEM, V268, P9847; Ohkawa N, 2007, J CELL SCI, V120, P1447, DOI 10.1242/jcs.001461; OVERHOLT EM, 1992, J NEUROSCI, V12, P1698; PARKS TN, 1975, J COMP NEUROL, V164, P435, DOI 10.1002/cne.901640404; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Rubel EW, 2004, SPR HDB AUD, V23, P8; RUBEL EW, 1981, J COMP NEUROL, V202, P397, DOI 10.1002/cne.902020309; RUBEL EW, 1990, J NEUROBIOL, V21, P169, DOI 10.1002/neu.480210112; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; SERRANO L, 1984, BIOCHEMISTRY-US, V23, P4675, DOI 10.1021/bi00315a024; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; SMITH DJ, 1979, J COMP NEUROL, V186, P213, DOI 10.1002/cne.901860207; SMITH ZDJ, 1981, J COMP NEUROL, V203, P309, DOI 10.1002/cne.902030302; Sorensen SA, 2006, J NEUROSCI, V26, P1539, DOI 10.1523/JNEUROSCI.3807-05.2006; Steward O, 1999, J NEUROSCI, V19, P7834; Swann JW, 2000, HIPPOCAMPUS, V10, P617, DOI 10.1002/1098-1063(2000)10:5<617::AID-HIPO13>3.0.CO;2-R; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Vaillant AR, 2002, NEURON, V34, P985, DOI 10.1016/S0896-6273(02)00717-1; YAMAUCHI PS, 1993, J NEUROCHEM, V60, P817, DOI 10.1111/j.1471-4159.1993.tb03225.x; ZIRPEL L, 1995, J NEUROPHYSIOL, V74, P1355, DOI 10.1152/jn.1995.74.3.1355; Zirpel L, 1996, J NEUROPHYSIOL, V76, P4127, DOI 10.1152/jn.1996.76.6.4127	42	25	26	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	JUN 12	2008	154	1					381	389		10.1016/j.neuroscience.2008.02.032			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	315IP	WOS:000256872300034	18440716	Green Accepted			2022-02-06	
J	Kemp, CD; Cotton, BA; Johnson, JC; Ellzey, M; Pinson, CW				Kemp, Clinton D.; Cotton, Bryan A.; Johnson, J. Chad; Ellzey, Michelle; Pinson, C. Wright			Donor conversion and organ yield in traumatic brain injury patients: Missed opportunities and missed organs	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	World Transplant Congress	JUL 22-27, 2006	Boston, MA			organ yield; traumatic brain injury; donation; donor	SUBARACHNOID HEMORRHAGE; POTENTIAL DONOR; GUNSHOT WOUNDS; UNITED-STATES; DONATION; DEATH; MANAGEMENT; TRANSPLANTATION; CONSEQUENCES; PROCUREMENT	Background: The purpose of this study was to define donation patterns and lost donor opportunities in severe traumatic brain injury (TBI) patients. Methods: The trauma registry was queried for all deaths after severe TBI in 2004; this was cross matched with the regional organ procurement organization database and subjected to post hoc statistical analysis. Results: One hundred thirty-five patients met criteria for inclusion. Forty percent had isolated TBI. Forty-two patients (31%) were eligible for deceased donation. Seventeen eligible patients (40%) did not convert to donation, 15 from family declining. Twenty-five eligible patients (60%) donated 85 organs (yield 3.4 organs/donor). Yield was similar in both isolated TBI (3.2) and patients with head injuries (3.5). Ineligible patients had higher admission Glasgow Coma Scale scores, lower head Abbreviated Injury Scale scores, and were more likely to develop cardiovascular or pulmonary dysfunction (p < 0.05). Of the 25 donors, 48% did not donate hearts and 84% did not donate lungs, despite the absence of chest trauma in the majority of patients. Conclusion: Less than one-third of severe TBI patients were identified as eligible organ donors and only 40% actually donated. Half of all donors fail to donate hearts and over 80% fail to donate lungs. Within this population, opportunities may exist to improve both donor conversion and organ yield.	[Kemp, Clinton D.; Cotton, Bryan A.; Johnson, J. Chad] Vanderbilt Univ, Med Ctr, Dept Surg, Div Trauma Emergency Surg & Surg Crit Care, Nashville, TN USA; [Pinson, C. Wright] Vanderbilt Univ, Med Ctr, Div Hepatobiliary Surg & Liver Transplantat, Nashville, TN USA; [Ellzey, Michelle] Tennessee Donor Serv, Nashville, TN USA		Cotton, BA (corresponding author), VUMC Trauma, Dept Surg, 1211 21st Ave S,404 Med Arts Bldg, Nashville, TN 37212 USA.	bryan.cotton@vanderbilt.edu	Cotton, Bryan/A-7107-2009				Abadie A, 2006, J HEALTH ECON, V25, P599, DOI 10.1016/j.jhealeco.2006.01.003; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; Ciccone AM, 2002, J THORAC CARDIOV SUR, V123, P429, DOI 10.1067/mtc.2002.120732; COTTON BA, 2005, EVALUATION MANAGEMEN; COTTON BA, 2005, DECLARATION BRAIN DE; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; *DEP HLTH HUM SERV, 2005 ANN REP US ORG; Dutton Richard P, 2003, Curr Opin Crit Care, V9, P503, DOI 10.1097/00075198-200312000-00007; ELLZEY M, 2007, VANDERBILT U MED CTR; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; Fiser SM, 2001, J THORAC CARDIOV SUR, V122, P1257, DOI 10.1067/mtc.2001.116464; Gortmaker SL, 1996, CRIT CARE MED, V24, P432, DOI 10.1097/00003246-199603000-00012; Howard RJ, 2005, TRANSPLANTATION, V80, P564, DOI 10.1097/01.tp.0000168156.79847.46; JACOBS DG, 1995, AM SURGEON, V61, P647; Karamlou T, 2005, J HEART LUNG TRANSPL, V24, P29, DOI 10.1016/j.healun.2003.10.009; Kemp CD, 2006, J AM COLL SURGEONS, V203, pS36, DOI 10.1016/j.jamcollsurg.2006.05.090; KENNEDY AP, 1992, J TRAUMA, V33, P516, DOI 10.1097/00005373-199210000-00005; Kompanje EJO, 2006, INTENS CARE MED, V32, P217, DOI 10.1007/s00134-005-0001-9; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; MACKENZIE DJ, 1993, AM SURGEON, V59, P764; MACKERSIE RC, 1991, ANN SURG, V213, P143, DOI 10.1097/00000658-199102000-00009; Macmillan CSA, 2002, INTENS CARE MED, V28, P1012, DOI 10.1007/s00134-002-1382-7; Malangoni MA, 1996, J TRAUMA, V40, P632, DOI 10.1097/00005373-199604000-00019; McLean KM, 2006, J AM COLL SURGEONS, V203, pS91, DOI 10.1016/j.jamcollsurg.2006.05.238; Parker M, 2002, CRIT CARE, V6, P399; Ranjan D, 2006, AM J TRANSPLANT, V6, P199, DOI 10.1111/j.1600-6143.2005.01150.x; Razek T, 2000, SURG CLIN N AM, V80, P1021, DOI 10.1016/S0039-6109(05)70111-0; ROSS S, 1989, J TRAUMA, V29, P1036; Salim A, 2001, ARCH SURG-CHICAGO, V136, P1377, DOI 10.1001/archsurg.136.12.1377; Sque M, 2005, TRANSPLANT P, V37, P543, DOI 10.1016/j.transproceed.2004.11.038; Williams MA, 2003, CRIT CARE MED, V31, P1568, DOI 10.1097/01.CCM.0000063090.21056.A6	33	25	27	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2008	64	6					1573	1580		10.1097/TA.0b013e318068fc2f			8	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	313MG	WOS:000256744100028	18545126				2022-02-06	
J	Straume-Naesheim, TM; Andersen, TE; Jochum, M; Dvorak, J; Bahr, R				Straume-Naesheim, Truls Martin; Andersen, Thor Einar; Jochum, Marianne; Dvorak, Jiri; Bahr, Roald			Minor head trauma in soccer and serum levels of S100B	NEUROSURGERY			English	Article						brain injury; closed head trauma; S100 proteins; soccer	NEURON-SPECIFIC ENOLASE; POST-CONCUSSION SYMPTOMS; BRAIN-INJURY; S-100B PROTEIN; NEUROPSYCHOLOGICAL IMPAIRMENT; BIOCHEMICAL MARKERS; FOOTBALL SOCCER; ELITE PLAYERS; DAMAGE S-100B; ELIMINATION	OBJECTIVE: To compare the serum levels of S100B after head trauma with the effect of heading, high-intensity exercise, and playing in a league match. Heading and head trauma in soccer have been suspected to cause brain impairment. The protein S100B is a marker of acute neuronal tissue damage. METHODS: Baseline S100B was measured in 535 Norwegian professional soccer players. Two hundred twenty-eight head impacts were registered from 352 league matches. Three teams (n = 48) performed a high-intensity exercise session without heading and a low-intensity session with heading exercises. A blood sample was drawn from each participant within 1 hour (131) after the session, and another sample (1312) was drawn after a match or training session. The players were assigned to four groups: Head Impact (n = 65), Match Control (match participants without head impact, n = 49), High-intensity Exercise (n = 35), and Heading (n = 36). RESULTS: Serum S100B increased from baseline to B1 for all groups. The increase for the match groups (Head Impact and Match Control) was significantly higher than for both training groups. However, no significant differences between the Head Impact and Match Control groups or between the two training groups were found. A total of 39 players (33.9%) had elevated B1 values (>= 0.12 ng/ml) after a match, but these findings were equally distributed between the Match Control and Head Impact groups. CONCLUSION: Both soccer training and soccer matches cause a transient increase in S100B. There is a possible additive effect of activity with high intensity and heading, but minor head impacts do not seem to cause an additional increase.	[Straume-Naesheim, Truls Martin; Andersen, Thor Einar; Bahr, Roald] Norwegian Sch Sports Sci, Dept Sports Med, Oslo SportsTrauma & Res Ctr, NO-0806 Oslo, Norway; [Jochum, Marianne] Univ Munich, Dept Clin Chem & Clin Biochem, Munich, Germany; [Dvorak, Jiri] Med Assessment & Res Ctr, Dept Neurol, Schulthess Clin, Int Federat Assoc Football, Zurich, Switzerland		Straume-Naesheim, TM (corresponding author), Norwegian Sch Sports Sci, Dept Sports Med, Oslo SportsTrauma & Res Ctr, POB 4014 Ulleval Stad, NO-0806 Oslo, Norway.	truls.straume-nesheim@nih.no	Bahr, Roald/B-6964-2014	Andersen, Thor Einar/0000-0003-4172-4518; Bahr, Roald/0000-0001-5725-4237			ABDULRAHMAN A, 1979, ACTA PHYSIOL SCAND, V107, P227, DOI 10.1111/j.1748-1716.1979.tb06467.x; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Andersen TE, 2004, BRIT J SPORT MED, V38, P626, DOI 10.1136/bjsm.2003.007955; Anderson RE, 2002, ACTA ANAESTH SCAND, V46, P1179; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Arnason A, 2004, MED SCI SPORT EXER, V36, P278, DOI 10.1249/01.MSS.0000113478.92945.CA; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Babbs C F, 2001, ScientificWorldJournal, V1, P281; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dietrich MO, 2003, CAN J APPL PHYSIOL, V28, P710, DOI 10.1139/h03-054; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Fehrenbach E, 2006, SPORTS MED, V36, P373, DOI 10.2165/00007256-200636050-00001; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; FULLER CW, 2005, BR J SPORTS MED S1, V39, P3; Guskiewicz KM, 2002, AM J SPORT MED, V30, P630; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hanin I, 1996, NAT MED, V2, P1307, DOI 10.1038/nm1296-1307; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Korfias S, 2006, CURR MED CHEM, V13, P3719, DOI 10.2174/092986706779026129; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; MDE OD, 2004, CLIN J SPORT MED, V14, P368; Mussack T, 2003, EUR J MED RES, V8, P457; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Mussack T, 2000, ACT NEUR S, V76, P393; Mussack T, 2006, CLIN CHEM LAB MED, V44, P1140, DOI 10.1515/CCLM.2006.190; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pershin Boris B, 2002, Russ J Immunol, V7, P2; Powell JW, 1999, J ATHL TRAINING, V34, P277; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; REILLY T, 2003, SCI SOCCER, P59; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Scaccianoce S, 2004, BRAIN RES, V1004, P208, DOI 10.1016/j.brainres.2004.01.028; SHARMA HS, 1991, NEUROSCI RES, V10, P211; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Steinacker JM, 2004, EUR J APPL PHYSIOL, V91, P382, DOI 10.1007/s00421-003-0960-x; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; Stroick M, 2006, CURR MED CHEM, V13, P3053, DOI 10.2174/092986706778521751; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Watson P, 2005, AM J PHYSIOL-REG I, V288, pR1689, DOI 10.1152/ajpregu.00676.2004; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	67	25	27	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2008	62	6					1297	1305		10.1227/01.neu.0000333301.34189.3d			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	334MS	WOS:000258226500027	18824996	Green Accepted			2022-02-06	
J	Schmitter-Edgecombe, M; Rueda, AD				Schmitter-Edgecombe, Maureen; Rueda, Alicia D.			Time estimation and episodic memory following traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; POSTTRAUMATIC AMNESIA; DURATION JUDGMENTS; TEMPORAL-LOBE; ATTENTION; PERCEPTION; ORIENTATION; CLOCK	The ability to accurately estimate the passage of time plays an important role in helping to structure daily activities. In this study, we used a prospective verbal time estimation paradigm to investigate time perception in 27 moderate to severe traumatic brain injury (TBI) participants and 27 controls. Verbal time estimations were made for filled intervals both within (i.e., <30 s) and beyond the time frame of working memory. We found that the TBI participants exhibited normal or near-normal estimates of time passage for duration up to 25 s. In contrast, for durations that exceeded working memory, the TBI group perceived less time as having passed than actually had passed as the TBI group significantly underestimated time when compared to controls. This pattern of data was interpreted as being due to episodic memory dysfunction.	[Schmitter-Edgecombe, Maureen; Rueda, Alicia D.] Washington State Univ, Dept Psychol, Pullman, WA 99164 USA		Schmitter-Edgecombe, M (corresponding author), Washington State Univ, Dept Psychol, Pullman, WA 99164 USA.	schmitter-e@wsu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS47690] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS047690] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Bauer LO, 2001, DRUG ALCOHOL DEPEN, V63, P87, DOI 10.1016/S0376-8716(00)00195-2; Benton AL, 1994, MULTILINGUAL APHASIA; Block R.A., 1990, COGNITIVE MODELS PSY, P1; Block RA, 1998, PSYCHOL AGING, V13, P584, DOI 10.1037/0882-7974.13.4.584; Block RA, 1999, DEV REV, V19, P183, DOI 10.1006/drev.1998.0475; BROWN SW, 1985, PERCEPT PSYCHOPHYS, V38, P115, DOI 10.3758/BF03198848; Brown SW, 1997, PERCEPT PSYCHOPHYS, V59, P1118, DOI 10.3758/BF03205526; *CEDR CORP, 1999, SUPERLAB PRO BET VER; Chaston A, 2004, BRAIN COGNITION, V55, P286, DOI 10.1016/j.bandc.2004.02.013; CHURCH RM, 1984, ANN NY ACAD SCI, V423, P566, DOI 10.1111/j.1749-6632.1984.tb23459.x; COHEN BH, 2000, EXPLAINING PSYCHOL S; CURTON ED, 1974, J EXP PSYCHOL, V103, P861, DOI 10.1037/h0037352; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FRAISSE P, 1984, ANNU REV PSYCHOL, V35, P1, DOI 10.1146/annurev.ps.35.020184.000245; GERMAN DJ, 1990, NATL COLL ED TEST AD; GIBBON J, 1984, ANN NY ACAD SCI, V423, P52, DOI 10.1111/j.1749-6632.1984.tb23417.x; Gunstad John, 2006, Journal of Integrative Neuroscience, V5, P75, DOI 10.1142/S0219635206001045; Harrington DL, 1998, J NEUROSCI, V18, P1085; HICKS RE, 1976, AM J PSYCHOL, V89, P719, DOI 10.2307/1421469; HICKS RE, 1976, AM J PSYCHOL, V89, P303, DOI 10.2307/1421413; HORNSTEI.AD, 1969, J EXP PSYCHOL, V79, P561, DOI 10.1037/h0026870; JONES MR, 1989, PSYCHOL REV, V96, P459, DOI 10.1037/0033-295X.96.3.459; KIELHOFNER G, 1977, AM J OCCUP THER, V31, P235; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Kinsbourne M., 2000, NEUROBEHAV LANGUAGE, P315; Kinsbourne M., 1990, NEUROPSYCHOLOGICAL I, P319, DOI DOI 10.1017/CBO9780511665547.017; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Lee GP, 1997, CLIN NEUROPSYCHOL, V11, P59, DOI 10.1080/13854049708407030; LEIGH G, 1976, PERCEPT MOTOR SKILL, V43, P899, DOI 10.2466/pms.1976.43.3.899; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lewis PA, 2006, BEHAV PROCESS, V71, P226, DOI 10.1016/j.beproc.2005.12.009; Majdan A, 1996, J CLIN EXP NEUROPSYC, V18, P416, DOI 10.1080/01688639608408998; Mangels JA, 1998, COGNITIVE BRAIN RES, V7, P15, DOI 10.1016/S0926-6410(98)00005-6; MARSHALL MJ, 1989, PERCEPT MOTOR SKILL, V69, P1159, DOI 10.2466/pms.1989.69.3f.1159; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MECK WH, 1984, BEHAV NEUROSCI, V98, P3, DOI 10.1037/0735-7044.98.1.3; Meck WH, 1996, COGNITIVE BRAIN RES, V3, P227, DOI 10.1016/0926-6410(96)00009-2; Meck WH, 2002, BRAIN COGNITION, V48, P195, DOI 10.1006/brcg.2001.1313; MEYERS CA, 1992, NEUROPSY NEUROPSY BE, V5, P28; Mimura M, 2000, J INT NEUROPSYCH SOC, V6, P517, DOI 10.1017/S1355617700655017; Morin C, 2005, COGNITIVE BRAIN RES, V22, P305, DOI 10.1016/j.cogbrainres.2004.09.001; Myers J. L., 2003, RES DESIGN STAT ANAL; NICHELLI P, 1993, COGNITIVE BRAIN RES, V1, P87, DOI 10.1016/0926-6410(93)90014-V; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Perbal S, 2001, NEUROREPORT, V12, P939, DOI 10.1097/00001756-200104170-00015; Perbal S, 2000, NEUROCASE, V6, P347, DOI 10.1093/neucas/6.4.347; POLYUKHOV AM, 1989, Z GERONTOL, V22, P79; Rammsayer T, 2001, PSYCHON B REV, V8, P270, DOI 10.3758/BF03196161; Rao SM, 2001, NAT NEUROSCI, V4, P317, DOI 10.1038/85191; RAO SM, 1984, ARCH NEUROL-CHICAGO, V41, P625, DOI 10.1001/archneur.1984.04210080033010; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RICHARDS W, 1973, ACTA PSYCHOL, V37, P279, DOI 10.1016/0001-6918(73)90020-6; SCHNEIBEL RS, 1997, DEV PREFRONTAL CORTE, P241; Seri Y, 2002, BRAIN COGNITION, V48, P553, DOI 10.1006/brcg.2001.1416; Sevigny MC, 2003, BRAIN COGNITION, V53, P351, DOI 10.1016/S0278-2626(03)00141-6; SHAW C, 1994, NEUROPSYCHOLOGIA, V32, P857, DOI 10.1016/0028-3932(94)90023-X; Smith A., 1991, SYMBOL DIGIT MODALIT; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; THOMAS EAC, 1975, PERCEPT PSYCHOPHYS, V17, P363, DOI 10.3758/BF03199347; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; VENABLE S D, 1991, Physical and Occupational Therapy in Geriatrics, V9, P31, DOI 10.1300/J148V09N03_04; Venneri A, 1998, BRAIN COGNITION, V37, P169; Wearden J. H, 2004, ACTA NEUROBIOLOGIAE, V64, P313; Wearden JH, 2003, TIME AND MIND II: INFORMATION PROCESSING PERSPECTIVES, P21; Wechsler D., 1997, WECHSLER MEMORY SCAL; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLIAMS JM, 1989, J CLIN EXP NEUROPSYC, V11, P713, DOI 10.1080/01688638908400927; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Zachary R., 1991, SHIPLEY I LIVING SCA; Zakay D, 1997, CURR DIR PSYCHOL SCI, V6, P12, DOI 10.1111/1467-8721.ep11512604; Zakay D., 1996, ADV PSYCHOL, V115, P143, DOI [10.1016/S0166-4115(96), DOI 10.1016/S0166-4115(96)80057-4, 10.1016/S0166-4115(96)80057-4]; Zakay D., 1990, COGNITIVE MODELS PSY, P59	76	25	25	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	2008	30	2					212	223		10.1080/13803390701363803			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	264UY	WOS:000253317100010	18938673				2022-02-06	
J	Gfroerer, SD; Wade, SL; Wu, M				Gfroerer, Susan Davies; Wade, Shari L.; Wu, Michelle			Parent perceptions of school-based support for students with traumatic brain injuries	BRAIN INJURY			English	Article						traumatic brain injury; parent perception; return to school; school services; school support	HEAD-INJURY; PREDICTORS; RECOVERY; SEQUELAE; TERM; TBI	Primary objective: To determine whether parents believe schools provided necessary support to their children who sustained traumatic brain injuries. Research design: Interview, to determine parent perceptions. Methods and procedure: Sixty-six primary caregivers of school-age children who experienced a TBI within the previous 2 years were interviewed regarding what types of special support were needed by and provided for their children during the 3 months immediately following school re-entry. They then rated how difficult it was to obtain support or services from the school and how satisfied they were with the support or services. Main outcomes and results: The majority of participants did not perceive the need for school-based services, even when the injury was severe. Almost all students whose parents perceived a need for an adjusted schedule were granted that accommodation, but few students received school-based counselling or behavioural support. Conclusions: Results indicated that participants perceived relatively few school-based supports, particularly given the actual academic, behavioural and social challenges experienced by children who have sustained a TBI. Schools and hospitals must take steps to ensure appropriate post-head injury support services.	[Gfroerer, Susan Davies] Univ Dayton, Dept Counselor Educ & Human Serv, Dayton, OH 45469 USA; [Wade, Shari L.; Wu, Michelle] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Wade, Shari L.] Univ Cincinnati, Cincinnati, OH USA		Gfroerer, SD (corresponding author), Univ Dayton, Dept Counselor Educ & Human Serv, 300 Coll Pk, Dayton, OH 45469 USA.	gfroersd@notes.udayton.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40942-02, R21 HD040942] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR523224] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD040942] Funding Source: NIH RePORTER		Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; BOLL TJ, 1997, HDB CLIN CHILD NEURO, P140; CLARK E, 1992, SCHOOL PSYCHOL REV, V21, P246; CLARK E, 1997, CHILDRENS NEEDS, V2, P815; Dykeman B, 2003, J INSTRUCTIONAL PSYC, P225; Ewing-Cobbs L, 1990, TRAUMATIC BRAIN INJU, P107; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHERJANZEN E, 1997, HDB CHILD CLIN NEURO, P452; Glang A, 2004, NEUROREHABILITATION, V19, P219; GLANG A, 2006, J HEAD TRAUMA REHAB, V21, P408; JELLINGER K, 1983, PEDIAT HEAD TRAUMA, P87; KIM YM, 2000, EARLY CHILD DEV CARE, V160, P133; Leith KH, 2004, BRAIN INJURY, V18, P1191, DOI 10.1080/02699050410001719943; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Mohr JD, 2005, PREV SCH FAIL, V49, P53, DOI 10.3200/PSFL.49.4.53-57; *NAT INF CTR CHILD, 2004, FS18 NICCYD; Peck CA, 2004, RES PRACT PERS SEV D, V29, P135, DOI 10.2511/rpsd.29.2.135; Ravet J, 2007, RES PAP EDUC, V22, P333, DOI [10.1080/02671520701497589, DOI 10.1080/02671520701497589]; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; Teeter P.A., 1997, CHILD NEUROPSYCHOLOG; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; TONKS J, 2007, BRAIN IMPAIR, V8, P143, DOI DOI 10.1375/BRIM.8.2.143; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	31	25	25	1	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	9					649	656		10.1080/02699050802227162			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	336NS	WOS:000258371600002	18608201	Green Accepted			2022-02-06	
J	Tschuor, C; Asmis, LM; Lenzlinger, PM; Tanner, M; Harter, L; Keel, M; Stocker, R; Stover, JF				Tschuor, Christoph; Asmis, Lars M.; Lenzlinger, Philipp M.; Tanner, Martina; Haerter, Luc; Keel, Marius; Stocker, Reto; Stover, John F.			In vitro norepinephrine significantly activates isolated platelets from healthy volunteers and critically ill patients following severe traumatic brain injury	CRITICAL CARE			English	Article							HYDROXYETHYL STARCH SOLUTIONS; P-SELECTIN EXPRESSION; HEMODYNAMIC DEPRESSION; GLUTAMATE UPTAKE; BLOOD-PLATELETS; HEAD-INJURY; VIVO; INFLAMMATION; MECHANISMS; RELEASE	Introduction Norepinephrine, regularly used to increase systemic arterial blood pressure and thus improve cerebral perfusion following severe traumatic brain injury (TBI), may activate platelets. This, in turn, could promote microthrombosis formation and induce additional brain damage. Methods The objective of this study was to investigate the influence of norepinephrine on platelets isolated from healthy volunteers and TBI patients during the first two post-traumatic weeks. A total of 18 female and 18 male healthy volunteers of different age groups were recruited, while 11 critically ill TBI patients admitted consecutively to our intensive care unit were studied. Arterial and jugular venous platelets were isolated from norepinephrine-receiving TBI patients; peripheral venous platelets were studied in healthy volunteers. Concentration-dependent functional alterations of isolated platelets were analyzed by flow cytometry, assessing changes in surface P-selectin expression and platelet-derived microparticles before and after in vitro stimulation with norepinephrine ranging from 10 nM to 100 mu M. The thrombin receptor-activating peptide (TRAP) served as a positive control. Results During the first week following TBI, norepinephrine-mediated stimulation of isolated platelets was significantly reduced compared with volunteers (control). In the second week, the number of P-selectin-and microparticle-positive platelets was significantly decreased by 60% compared with the first week and compared with volunteers. This, however, was associated with a significantly increased susceptibility to norepinephrine-mediated stimulation, exceeding changes observed in volunteers and TBI patients during the first week. This pronounced norepinephrine-induced responsiveness coincided with increased arterio-jugular venous difference in platelets, reflecting intracerebral adherence and signs of cerebral deterioration reflected by elevated intracranial pressure and reduced jugular venous oxygen saturation. Conclusion Clinically infused norepinephrine might influence platelets, possibly promoting microthrombosis formation. In vitro stimulation revealed a concentration-and time-dependent differential level of norepinephrine-mediated platelet activation, possibly reflecting changes in receptor expression and function. Whether norepinephrine should be avoided in the second post-traumatic week and whether norepinephrine-stimulated platelets might induce additional brain damage warrant further investigations.	[Tschuor, Christoph; Tanner, Martina; Stocker, Reto; Stover, John F.] Univ Zurich Hosp, Surg Intens Care Med, CH-8091 Zurich, Switzerland; [Asmis, Lars M.] Univ Zurich Hosp, Inst Clin Hematol, CH-8091 Zurich, Switzerland; [Lenzlinger, Philipp M.; Haerter, Luc; Keel, Marius] Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland		Stover, JF (corresponding author), Univ Zurich Hosp, Surg Intens Care Med, Raemistr 100, CH-8091 Zurich, Switzerland.	john.stover@access.unizh.ch	Asmis, Lars M/H-4011-2019				Akkerman JWN, 2006, SEMIN THROMB HEMOST, V32, P295, DOI 10.1055/s-2006-939442; Aliprandi A, 2005, J CEREBR BLOOD F MET, V25, P513, DOI 10.1038/sj.jcbfm.9600039; Chen G, 2006, ACTA ANAESTH SCAND, V50, P1089, DOI 10.1111/j.1399-6576.2006.01138.x; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; DEIGHTON NM, 1988, J CARDIOVASC PHARM, V12, P332, DOI 10.1097/00005344-198809000-00011; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Gambim MH, 2007, CRIT CARE, V11, DOI 10.1186/cc6133; Gries A, 2001, ACTA ANAESTH SCAND, V45, P449, DOI 10.1034/j.1399-6576.2001.045004449.x; HAMILTON CA, 1987, N-S ARCH PHARMACOL, V335, P534; Hikasa Y, 1998, FUNDAM CLIN PHARM, V12, P498, DOI 10.1111/j.1472-8206.1998.tb00978.x; HOFFMAN B B, 1990, P187; HOLLISTER AS, 1983, J CLIN INVEST, V72, P1498, DOI 10.1172/JCI111106; Holme PA, 1997, ARTERIOSCL THROM VAS, V17, P646, DOI 10.1161/01.ATV.17.4.646; Hsiao G, 2004, EUR J PHARMACOL, V487, P159, DOI 10.1016/j.ejphar.2004.01.026; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Johnston AJ, 2004, INTENS CARE MED, V30, P45, DOI 10.1007/s00134-003-2032-4; JONES CR, 1986, CLIN SCI, V70, P147, DOI 10.1042/cs0700147; Jurk K, 2005, SEMIN THROMB HEMOST, V31, P381, DOI 10.1055/s-2005-916671; Kalsch T, 2007, BASIC RES CARDIOL, V102, P460, DOI 10.1007/s00395-007-0667-y; Kaushansky K, 2005, J CLIN INVEST, V115, P3339, DOI 10.1172/JCI26674; Klinger MHF, 2002, J INTERF CYTOK RES, V22, P913, DOI 10.1089/10799900260286623; LARSSON PT, 1994, CIRCULATION, V89, P1951, DOI 10.1161/01.CIR.89.5.1951; Leytin V, 2002, CRIT CARE MED, V30, P2771, DOI 10.1097/00003246-200212000-00025; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Lupia E, 2006, J AM COLL CARDIOL, V48, P2195, DOI 10.1016/j.jacc.2006.04.106; Maeda T, 1997, ACT NEUR S, V70, P102; Mathew JP, 2006, ANN THORAC SURG, V81, P1644, DOI 10.1016/j.athoracsur.2005.12.070; Merten M, 2000, CIRCULATION, V102, P1931, DOI 10.1161/01.CIR.102.16.1931; Michelson AD, 2000, METHODS, V21, P259, DOI 10.1006/meth.2000.1006; Michelson AD, 1996, P NATL ACAD SCI USA, V93, P11877, DOI 10.1073/pnas.93.21.11877; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Offermanns S, 2006, CIRC RES, V99, P1293, DOI 10.1161/01.RES.0000251742.71301.16; Rainesalo S, 2003, NEUROCHEM INT, V43, P389, DOI 10.1016/S0197-0186(03)00026-3; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; SEGAWA H, 1981, ARCH NEUROL-CHICAGO, V38, P265, DOI 10.1001/archneur.1981.00510050031002; Siegel-Axel DI, 2007, SEMIN THROMB HEMOST, V33, P128, DOI 10.1055/s-2007-969025; Thaler U, 2005, ANAESTHESIA, V60, P554, DOI 10.1111/j.1365-2044.2005.04184.x; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Tsai CS, 2004, EUR J ANAESTH, V21, P871, DOI 10.1017/S0265021504000213; Vaccaro M, 2007, CEPHALALGIA, V27, P35, DOI 10.1111/j.1468-2982.2006.01234.x; von Hundelshausen P, 2007, CIRC RES, V100, P27, DOI 10.1161/01.RES.0000252802.25497.b7; WIEDMER T, 1990, BIOCHEMISTRY-US, V29, P623, DOI 10.1021/bi00455a005	44	25	28	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2008	12	3							R80	10.1186/cc6931			12	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	326CK	WOS:000257635300019	18564410	gold, Green Published, Green Accepted			2022-02-06	
J	Vilar-Lopez, R; Gomez-Rio, M; Caracuel-Romero, A; Llamas-Elvira, J; Perez-Garcia, M				Vilar-Lopez, Raquel; Gomez-Rio, Manuel; Caracuel-Romero, Alfonso; Llamas-Elvira, Jose; Perez-Garcia, Miguel			Use of specific malingering measures in a Spanish sample	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SYMPTOM VALIDITY TEST; TRAUMATIC BRAIN-INJURY; SIMULATED MEMORY IMPAIRMENT; FORCED-CHOICE METHOD; REY 15-ITEM TEST; NEUROPSYCHOLOGICAL TESTS; CROSS-VALIDATION; HEAD-INJURY; PERFORMANCE; PROFILES	There are an increasing number of tests available for detecting malingering. However, these tests have not been validated for using in Spanish speakers. The purpose of this study is to explore the value of three specific malingering tests in the Spanish population. This study used a known-groups design, together with a group of analog students. The results show that both the Victoria Symptom Validity Test and the b Test can be used to detect malingering in Spanish population. However, some restrictions must be applied when the Rey 15-Item Test is administered and interpreted.	[Vilar-Lopez, Raquel; Caracuel-Romero, Alfonso; Perez-Garcia, Miguel] Univ Granada, Dept Personalidad Evaluac & Tratamiento, Granada, Spain; [Gomez-Rio, Manuel; Llamas-Elvira, Jose] Hosp Univ Nieves, Granada, Spain		Vilar-Lopez, R (corresponding author), Univ N Carolina, Dept Psychol, Wilmington, NC 28403 USA.	vilarlopez@uncw.edu	Caracuel, Alfonso/V-3695-2019; Vilar-Lopez, Raquel/I-7847-2016; Garcia, Miguel Perez/F-9630-2010	Caracuel, Alfonso/0000-0002-9738-8456; Vilar-Lopez, Raquel/0000-0001-9639-0143; Garcia, Miguel Perez/0000-0003-4775-7556; Llamas-Elvira, Jose Manuel/0000-0002-4661-5030			ARNETT PA, 1995, CLIN NEUROPSYCHOL, V9, P17, DOI 10.1080/13854049508402052; Bender SD, 2004, ARCH CLIN NEUROPSYCH, V19, P49, DOI 10.1016/S0887-6177(02)00165-8; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Boone K., 2002, B TEST MANUAL; Boone KB, 2000, ARCH CLIN NEUROPSYCH, V15, P227, DOI 10.1016/S0887-6177(99)00014-1; BUREREYES A, 2007, 115 ANN C AM PSYCH A; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; GOLDBERG JO, 1986, J CLIN PSYCHOL, V42, P792, DOI 10.1002/1097-4679(198609)42:5<792::AID-JCLP2270420519>3.0.CO;2-8; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; GUILMETTE TJ, 1994, CLIN NEUROPSYCHOL, V8, P283, DOI 10.1080/13854049408404135; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; Hilsabeck RC, 2005, ARCH CLIN NEUROPSYCH, V20, P1025, DOI 10.1016/j.acn.2005.05.003; HISCOCK CK, 1994, J PSYCHOPATHOL BEHAV, V16, P95, DOI 10.1007/BF02232721; Holmquist LA, 2002, ARCH CLIN NEUROPSYCH, V17, P143, DOI 10.1016/S0887-6177(00)00106-2; Inman TH, 1998, PSYCHOL ASSESSMENT, V10, P128, DOI 10.1037/1040-3590.10.2.128; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lee A, 2000, CLIN NEUROPSYCHOL, V14, P303, DOI 10.1076/1385-4046(200008)14:3;1-P;FT303; Lee G. P., 1992, PSYCHOL ASSESSMENT, V4, P43, DOI DOI 10.1037/1040-3590.4.1.43; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Macciocchi SN, 2006, ARCH CLIN NEUROPSYCH, V21, P395, DOI 10.1016/j.acn.2006.06.003; Martin RC, 1996, J CLIN EXP NEUROPSYC, V18, P265, DOI 10.1080/01688639608408281; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; Merten T, 2005, ARCH CLIN NEUROPSYCH, V20, P719, DOI 10.1016/j.acn.2005.04.004; MILLIS SR, 1995, CLIN NEUROPSYCHOL, V9, P241, DOI 10.1080/13854049508400486; O'Bryant SE, 2004, ARCH CLIN NEUROPSYCH, V19, P489, DOI 10.1016/j.acn.2003.07.001; Puente A. E., 2000, HDB MULTICULTURAL ME, P419; PUENTE AE, 2000, HDB PSYCHOL ASSESSME, P527; Rey, 1964, EXAMEN CLINIQUE PSYC; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; ROGERS R, 1983, J PSYCHIAT LAW, V11, P443, DOI 10.1177/009318538301100404; ROGERS R, 2003, HDB PSYCHOL, V11, P109; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; Schretlen D., 1991, PSYCHOL ASSESSMENT J, V3, P667, DOI [10.1037/1040-3590.3.4.667, DOI 10.1037/1040-3590.3.4.667]; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 2003, CLIN NEUROPSYCHOL, V17, P390, DOI 10.1076/clin.17.3.390.18090; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Strauss E, 2002, ARCH CLIN NEUROPSYCH, V17, P423, DOI 10.1016/S0887-6177(01)00126-3; Strauss E, 1999, CLIN NEUROPSYCHOL, V13, P420, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT420; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Taylor LA, 2003, BRAIN INJURY, V17, P295, DOI 10.1080/0269905021000038401; THOMPSON GB, 2002, J FORENSIC NEUROPSYC, V2, P43; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; VICTORIA S, 1997, PSYCHOL ASSESSMENT R; Vilar-Lopez R, 2007, ARCH CLIN NEUROPSYCH, V22, P379, DOI 10.1016/j.acn.2007.01.012; VILARLOPEZ R, 2007, THESIS U GRANADA GRA; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	54	25	27	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2008	30	6					710	722		10.1080/13803390701684562			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	323SS	WOS:000257469300011	18612877				2022-02-06	
J	Winqvist, S; Luukinen, H; Jokelainen, J; Lehtilahti, M; Nayha, S; Hillbom, M				Winqvist, Satu; Luukinen, Heikki; Jokelainen, Jari; Lehtilahti, Maria; Nayha, Simo; Hillbom, Matti			Recurrent traumatic brain injury is predicted by the index injury occurring under the influence of alcohol	BRAIN INJURY			English	Article						recurrent traumatic brain injury; alcohol drinking; adolescents; young adults	HEAD-INJURY; DRINKING; RISK; POPULATION; EPIDEMIOLOGY; CONSUMPTION; CONCUSSION; PATTERNS; TRENDS; ONSET	Background: Little is known of the role of alcohol intoxication as a risk factor for recurrent traumatic brain injuries (TBI). This study was a population-based longitudinal study to investigate this problem. Methods: The record linkage technique was used and data gathered from the Finnish Hospital Discharge Register, hospital records and by a questionnaire of family characteristics regarding the 12 058 subjects forming the Northern Finland Birth Cohort of 1966. Excluded were TBI subjects injured before the age of 12 years. Results: Of the 236 patients who had survived their first (mainly mild) TBI, 21 had had a recurrent TBI and three of them two recurrent TBIs during the follow-up period (from 1978-2000). An alcohol-related first injury (RR 4.41, 95% CI 1.53-12.70) and urban place of birth (RR 4.39, 95% CI 1.68-11.48) were significant independent predictors of recurrent TBI. A significant positive correlation between the first and recurrent TBIs with respect to alcohol involvement (rs = 0.61, p = 0.003) was observed. Conclusions: A first TBI related to alcohol drinking is predictive of recurrent TBI, which will often similarly be alcohol-related. The risk of recurrent injury seems to extend over several years after the first TBI. To prevent recurrence, efforts should be made to identify those with an alcohol-related first TBI. A brief intervention focused on drinking habits is needed as an immediate preventive measure.	[Winqvist, Satu; Lehtilahti, Maria; Hillbom, Matti] Oulu Univ Hosp, Dept Neurol, FIN-90029 Oys, Finland; [Winqvist, Satu; Lehtilahti, Maria; Hillbom, Matti] Univ Oulu, Dept Neurol, Oulu, Finland; [Luukinen, Heikki; Jokelainen, Jari; Nayha, Simo] Univ Oulu, Dept Publ Hlth Sci & Gen Practice, Oulu, Finland; [Luukinen, Heikki; Jokelainen, Jari; Nayha, Simo] Oulu Univ Hosp, Unit Gen Practice, FIN-90029 Oys, Finland		Winqvist, S (corresponding author), Oulu Univ Hosp, Dept Neurol, FIN-90029 Oys, Finland.	satu.winqvist@oulu.fi		Jokelainen, Jari/0000-0003-4629-0560	Neurology Foundation; Maire Taponen Foundation ( Finland)	This research was supported by the Neurology Foundation and Maire Taponen Foundation ( Finland).	ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BLONDELL RD, 2005, COMPREHENSIVE HDB AL, P321; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1995, ANN EMERG MED, V26, P221; Donovan JE, 2007, PREV SCI, V8, P192, DOI 10.1007/s11121-007-0072-7; Drubach D A, 1993, Md Med J, V42, P989; Dunn C, 2003, J TRAUMA, V54, P707, DOI 10.1097/01.TA.0000030625.63338.B2; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HILLBOM M, 1986, J NEUROL NEUROSUR PS, V49, P1348, DOI 10.1136/jnnp.49.12.1348; Hingson RW, 2000, JAMA-J AM MED ASSOC, V284, P1527, DOI 10.1001/jama.284.12.1527; HONKANEN R, 1976, ANN CHIR GYNAECOL FE, V65, P287; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Johnston JJE, 2004, EMERG MED J, V21, P185, DOI 10.1136/emj.2003.006130; Kraus JF, 1993, HEAD INJURY, P1; LAMMINPAA A, 1990, ACTA PSYCHIAT SCAND, V81, P468, DOI 10.1111/j.1600-0447.1990.tb05483.x; Lintonen T, 2000, HEALTH EDUC RES, V15, P261, DOI 10.1093/her/15.3.261; MAIO RF, 1994, ALCOHOL CLIN EXP RES, V18, P261, DOI 10.1111/j.1530-0277.1994.tb00011.x; McLeod R, 1999, ADDICTION, V94, P1719, DOI 10.1046/j.1360-0443.1999.941117199.x; Pitkanen T, 2005, ADDICTION, V100, P652, DOI 10.1111/j.1360-0443.2005.01053.x; Rantakallio P, 1988, Paediatr Perinat Epidemiol, V2, P59, DOI 10.1111/j.1365-3016.1988.tb00180.x; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Savola O, 2005, ALCOHOL ALCOHOLISM, V40, P269, DOI 10.1093/alcalc/agh159; Vinson DC, 2003, J STUD ALCOHOL, V64, P358, DOI 10.15288/jsa.2003.64.358; Watt K, 2004, ADDICTION, V99, P1262, DOI 10.1111/j.1360-0443.2004.00823.x; WINQVIST S, 2006, J ADOLESCENCE HLTH, V39, P275; Winter T, 2002, ALCOHOL ALCOHOLISM, V37, P330, DOI 10.1093/alcalc/37.4.330; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	32	25	25	0	5	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2008	22	10					780	785		10.1080/02699050802339397			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	347MJ	WOS:000259145400008	18787988				2022-02-06	
J	Acerini, CL; Tasker, RC				Acerini, Carlo L.; Tasker, Robert C.			Traumatic brain injury induced hypothalamic-pituitary dysfunction: a paediatric perspective	PITUITARY			English	Article						traumatic brain injury; hypopituitarism; pituitary dysfunction; growth hormone deficiency	GROWTH-HORMONE DEFICIENCY; POSTTRAUMATIC HYPOPITUITARISM; HEAD-INJURY; LONG-TERM; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; PRECOCIOUS PUBERTY; DIABETES-INSIPIDUS; CHILDREN; ABNORMALITIES	In survivors of traumatic brain injury (TBI), impairment in anterior pituitary hormone function may be an important cause of long-term morbidity. Histopathological evidence from post-mortem studies suggests that the hypothalamic-pituitary structures are vulnerable to damage following head injury. Pituitary dysfunction, present months or years after injury, is now well recognised in adults, however, little evidence is known about this potential complication in children and adolescents. This article reviews the available paediatric data, which shows that hypopituitarism may occur after both mild and severe TBI, with growth hormone and gonadotrophin deficiencies appearing to be most common abnormalities. Central precocious puberty has also been documented. There are, however, few published data within a population of children with TBI on the incidence or prevalence of hypopituitarism, nor on its natural history or response to hormone replacement, and prospective studies are needed. Given the critical role of anterior pituitary hormones in the regulation of growth, pubertal and neurocognitive development in childhood, early detection of hormone abnormalities following TBI is important. We propose that a multidisciplinary approach to follow-up and endocrine assessment is required for the long-term management and rehabilitation of children and adolescents who survive moderate to severe head injury.	[Acerini, Carlo L.; Tasker, Robert C.] Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England		Acerini, CL (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Level 8,Box 116, Cambridge CB2 2QQ, England.	cla22@cam.ac.uk	Tasker, Robert C/R-5837-2019	Acerini, Carlo/0000-0003-2121-5871; Tasker, Robert/0000-0003-3647-8113			Acerini CL, 2006, EUR J ENDOCRINOL, V155, P663, DOI 10.1530/eje.1.02284; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Barbeau C, 1998, ARCH PEDIATRIE, V5, P274, DOI 10.1016/S0929-693X(97)89368-2; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; BARZILAY Z, 1988, J MED, V19, P47; Benoit R, 2000, J TRAUMA, V49, P477, DOI 10.1097/00005373-200009000-00015; Benvenga S, 2004, AM J MED, V116, P767, DOI 10.1016/j.amjmed.2003.12.038; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BLENDONOHY P M, 1991, Brain Injury, V5, P63, DOI 10.3109/02699059108998513; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; CORTE FD, 1998, CRIT CARE MED, V26, P1419; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cryan E., 1918, DTSCH MED WOCHENSCHR, V44, P1261; DANIEL PM, 1959, LANCET, V2, P927; EDWARDS OM, 1986, MEDICINE, V65, P281; EICHLER I, 1998, J ENDOCRINOL INVEST, V33, P409; Einaudi S, 2006, J PEDIATR ENDOCR MET, V19, P691; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; GIRARD J, 1977, J PEDIATR-US, V90, P241, DOI 10.1016/S0022-3476(77)80637-9; GROSSMAN WF, 1994, J REPROD MED, V39, P738; HARPER CG, 1986, J CLIN PATHOL, V39, P769, DOI 10.1136/jcp.39.7.769; Holbrook TL, 2005, J TRAUMA, V58, P764, DOI 10.1097/01.TA.0000159247.48547.7D; Keenan HT, 2006, PEDIATRICS, V117, P1291, DOI 10.1542/peds.2005-1883; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; LAFRANCHI SH, 1979, AM J DIS CHILD, V133, P739, DOI 10.1001/archpedi.1979.02130070075016; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mariani R, 1996, ARCH PEDIATRIE, V3, P796, DOI 10.1016/0929-693X(96)82164-6; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; MILLER WL, 1980, NEW ENGL J MED, V302, P724, DOI 10.1056/NEJM198003273021305; Mooney DP, 2004, J TRAUMA, V57, P1241, DOI 10.1097/01.TA.0000106694.75576.69; Nemergut EC, 2005, J NEUROSURG, V103, P448, DOI 10.3171/jns.2005.103.3.0448; Niederland T, 2007, J NEUROTRAUM, V24, P119, DOI 10.1089/neu.2005.369ER; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; PAXSON CL, 1976, PEDIATRICS, V57, P893; Popovic V, 2005, GROWTH HORM IGF RES, V15, P177, DOI 10.1016/j.ghir.2005.02.003; SHAUL PW, 1985, AM J DIS CHILD, V139, P467, DOI 10.1001/archpedi.1985.02140070041029; SOCKALOSKY JJ, 1987, J PEDIATR-US, V110, P373, DOI 10.1016/S0022-3476(87)80497-3; SURTEES R, 1987, HORM RES, V28, P5, DOI 10.1159/000180918; TANRIVERDI F, 2006, J CLIN ENDOCR METAB, V91, P2015; Tasker RC, 2006, EMERG MED J, V23, P519, DOI 10.1136/emj.2005.028779; VALENTA LJ, 1980, AM J MED, V68, P614, DOI 10.1016/0002-9343(80)90314-9; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; YAMANAKA C, 1993, EUR J PEDIATR, V152, P99, DOI 10.1007/BF02072482	52	25	28	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1386-341X	1573-7403		PITUITARY	Pituitary	DEC	2007	10	4					373	380		10.1007/s11102-007-0052-8			8	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	250ML	WOS:000252304100008	17570066				2022-02-06	
J	Garcia-Molina, A; Tirapu-Ustarroz, J; Roig-Rovira, T				Garcia-Molina, Alberto; Tirapu-Ustarroz, Javier; Roig-Rovira, Teresa			Ecological validity and assessment of executive function	ANALES DE PSICOLOGIA			Spanish	Article						executive functions; ecological validity; brain injury; dysexecutive syndrome	FRONTAL-LOBE DAMAGE; TRAUMATIC BRAIN-INJURY; DUAL-TASK PERFORMANCE; NEUROPSYCHOLOGICAL TESTS; COMMUNITY INTEGRATION; DYSEXECUTIVE SYNDROME; SCHIZOPHRENIA; DEFICITS; LESIONS; SCORES	Ecological validity has become an increasingly important focus in neuropsychological assessment with particular relevance for the executive functions. Appropriate assessment of executive functions is critical to predict successful everyday functioning and psychosocial integration. This article reviews the research in ecological validity of neuropsychological assessment of executive function. The research suggests that many executive tests have a moderate level of ecological validity when predicting everyday cognitive functioning. Environmental cognitive demands and compensatory strategy use do appear to affect the ability of neuropsychological tests to predict real world behaviour. This paper discusses the ecological validity of assessment of executive functions and implications for the future assessment of executive functioning. Further research is required to identify the role of several variables in determining the ecological validity of clinical neuropsychological tests of executive function. Some suggestions were offered for the purpose of guiding clinical research.	[Garcia-Molina, Alberto; Roig-Rovira, Teresa] Inst Univ Neurorehabilitacio Guttmann UAB, Badalona 08916, Spain; [Tirapu-Ustarroz, Javier] Serv Neuropsicol, Navarra, Spain		Garcia-Molina, A (corresponding author), Inst Univ Neurorehabilitacio Guttmann UAB, Cami Can Ruti S-N, Badalona 08916, Spain.	agarciam.investigacio@guttmann.com					Acker MB, 1989, NEUROPSYCHOLOGY, V3, P123, DOI 10.1037//0894-4105.3.3.123; Acker MB, 1990, NEUROPSYCHOLOGY EVER, P19; Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bird CM, 2004, BRAIN, V127, P914, DOI 10.1093/brain/awh108; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1996, CORTEX, V32, P241, DOI 10.1016/S0010-9452(96)80049-9; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Cripe L. I., 1998, ECOLOGICAL VALIDITY, P171; Dimitrov M, 1996, CORTEX, V32, P357, DOI 10.1016/S0010-9452(96)80057-8; Duncan John, 1995, P721; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; Franzen M. D., 1998, ECOLOGICAL VALIDITY, P91; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Goel V, 1997, BRAIN, V120, P1805, DOI 10.1093/brain/120.10.1805; Goldberg E, 2000, J CLIN EXP NEUROPSYC, V22, P56, DOI 10.1076/1380-3395(200002)22:1;1-8;FT056; Goldberg E., 2002, CEREBRO EJECUTIVO LO; GOLDBERG TE, 1988, INT J NEUROSCI, V42, P51, DOI 10.3109/00207458808985758; GOLDBERG TE, 1988, SCHIZOPHRENIA BULL, V14, P179, DOI 10.1093/schbul/14.2.179; GOLDEN CH, 1974, STROOP COLOUR WORD T; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Jarvis PE., 1994, HALSTEAD REITAN NEUR; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Long C.J., 1995, ADV MED PSYCHOTHERAP, V8, P59; LONG CJ, 1998, ECOLOGICAL VALIDITY, P1; Luria A.R., 1973, WORKING BRAIN INTRO; Mahurin RK, 1998, PSYCHIAT RES, V79, P139, DOI 10.1016/S0165-1781(98)00031-6; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V0005, P00213, DOI DOI 10.1037/0894-4105.5.3.213; MCPHEETERS HL, 1984, COMMUNITY MENT HLT J, V20, P44; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; MESULAM MM, 1986, ANN NEUROL, V19, P320, DOI 10.1002/ana.410190403; Metzler C, 2000, NEUROPSYCHOLOGIA, V38, P363, DOI 10.1016/S0028-3932(99)00097-4; Millis S R, 1994, Int J Neurosci, V79, P165; Munoz Cespedes J. M., 2001, REHABILITACION NEURO; Munoz P., 2000, REV COMPLUTENSE ED, V11, P39, DOI 10.17151/hpsal.2016.21.2.4; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Odhuba RA, 2005, BRIT J CLIN PSYCHOL, V44, P269, DOI 10.1348/014466505X29431; Poole JH, 1999, PSYCHIAT RES, V85, P161, DOI 10.1016/S0165-1781(98)00146-2; Robertson I., 1994, TEST EVERYDAY ATTENT; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sbordone R. J., 1998, ECOLOGICAL VALIDITY, P15; Sbordone RJ, 1999, STUD NEUROPSYCHOL DE, P227; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHORDONE RJ, 1997, NEUROPSYCHOLOGY HDB, V1, P365; STOKES N, 2003, BRAIN INJURY, V17, P174; THURSTONE LL, 1962, THURSTONE WORD FLUEN; TIRAPU J, 1996, ANAL PSIQUIATRIA, V12, P397; Tirapu-Ustarroz J, 2002, REV NEUROLOGIA, V34, P673, DOI 10.33588/rn.3407.2001311; Verdejo A, 2004, REV NEUROLOGIA, V39, P60, DOI 10.33588/rn.3901.2004229; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; WANG PL, 1986, CLIN NEUROPSYCHOLOGY; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson B., 1999, BEHAVIOURAL INATTENT BEHAV INATTENTION TE; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014; Woodard CB, 2004, J PERINAT NEONAT NUR, V18, P329, DOI 10.1097/00005237-200410000-00003; [No title captured]	70	25	32	3	22	UNIV MURCIA	MURCIA	SOC ESPANOLA HISTORIA AGRARIA, CAMPUS ESPINARDO, MURCIA, 30100, SPAIN	0212-9728	1695-2294		AN PSICOL-SPAIN	An. Psicol.	DEC	2007	23	2					289	299					11	Psychology; Psychology, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	324SN	WOS:000257538700016					2022-02-06	
J	Srinivasan, S; Lim, CCT; Thirugnanam, U				Srinivasan, Sheila; Lim, C. C. Tchoyoson; Thirugnanam, Umapathi			Paroxysmal autonomic instability with dystonia	CLINICAL AUTONOMIC RESEARCH			English	Article						dysautonomia; PAID syndrome; diencephalic seizures	TRAUMATIC BRAIN-INJURY; DIENCEPHALIC SEIZURES; SYMPATHETIC STORMS; CORPUS-CALLOSUM; EPILEPSY; DYSAUTONOMIA; HYPERTHERMIA; HYPOTHERMIA; AGENESIS	Paroxysmal autonomic instability with dystonia, an under-recognized and poorly understood phenomenon of episodic central dysautonomia is associated with various cerebral insults. Treatment options include benzodiazepines, opioids, and gabapentin. Using an illustrative case, we discuss presentation, pathomechanisms, and management of this condition.	[Srinivasan, Sheila; Lim, C. C. Tchoyoson; Thirugnanam, Umapathi] Natl Inst Neurosci, Dept Neuroradiol, Singapore 308433, Singapore; [Lim, C. C. Tchoyoson] Natl Univ Singapore, Dept Diagnost Imaging, Singapore 117548, Singapore		Srinivasan, S (corresponding author), Natl Inst Neurosci, Dept Neuroradiol, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	sheila_srinivasan@nni.com.sg		Lim, CC Tchoyoson/0000-0001-9355-6988			Baguley IJ, 2007, J NEUROL NEUROSUR PS, V78, P539, DOI 10.1136/jnnp.2006.096388; Baumgartner C, 2001, EPILEPTIC DISORD, V3, P103; Benarroch E.E., 1997, CLIN AUTONOMIC DISOR, P17; BENARROCH EE, 1997, CLIN AUTONOMIC DISOR, P421; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; COLICE GL, 1984, AM REV RESPIR DIS, V130, P941; Diesing TS, 2006, MOVEMENT DISORD, V21, P868, DOI 10.1002/mds.20831; FEUERMAN T, 1988, J NEUROSURG, V68, P297, DOI 10.3171/jns.1988.68.2.0297; FOX RH, 1973, BRIT MED J, V2, P693, DOI 10.1136/bmj.2.5868.693; GIROUD M, 1988, CHILD NERV SYST, V4, P252, DOI 10.1007/BF00270925; Goh KYC, 1999, PEDIATR NEUROL, V21, P742, DOI 10.1016/S0887-8994(99)00069-7; HIRAYAMA K, 1994, ARCH NEUROL-CHICAGO, V51, P494, DOI 10.1001/archneur.1994.00540170070018; Penfield W, 1929, ARCH NEURO PSYCHIATR, V22, P358, DOI 10.1001/archneurpsyc.1929.02220020174010; Rey M, 2005, J CARDIOTHOR VASC AN, V19, P654, DOI 10.1053/j.jvca.2005.07.008; ROPEER AH, 1997, CLIN AUTONOMIC DISOR, P791; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SHAPIRO WR, 1969, BRAIN, V92, P423, DOI 10.1093/brain/92.2.423; SPYER KM, 1999, AUTONOMIC FAILURE TX, P46; TALMAN WT, 1985, ANN NEUROL, V18, P1, DOI 10.1002/ana.410180102; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Thorley RR, 2001, ARCH PHYS MED REHAB, V82, P246, DOI 10.1053/apmr.2001.18698	23	25	29	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0959-9851			CLIN AUTON RES	Clin. Auton. Res.	DEC	2007	17	6					378	381		10.1007/s10286-007-0428-x			4	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	241FC	WOS:000251641300009	17636370				2022-02-06	
J	Takamiya, M; Fujita, S; Saigusa, K; Aoki, Y				Takamiya, Masataka; Fujita, Sachiko; Saigusa, Kiyoshi; Aoki, Yasuhiro			Simultaneous detections of 27 cytokines during cerebral wound healing by multiplexed bead-based immunoassay for wound age estimation	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; growth factors; head trauma; molecular biological approaches; traumatic brain injury	HUMAN BRAIN-INJURY; SUSPENSION ARRAY TECHNOLOGY; NITRIC-OXIDE SYNTHASE; ENDOTHELIAL-CELLS; GROWTH-FACTOR; RAT-BRAIN; EXPRESSION; MICROGLIA; INTERLEUKIN-1-BETA; ASTROCYTES	Quantification of 27 cytokines following cerebral wounding was performed for wound age estimation. The cytokines evaluated included interleukin (IL)-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IL-12 p40, IL-12 p70, IL-15, IL-17, IL-18, basic fibroblast growth factor (bFGF), granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), Interferon-gamma (IFN-gamma), keratinocyte derived cytokine (KC), leukemia inhibitory factor (LIF), macrophage-colony stimulating factor (M-CSF), monokine inducible by interferon gamma (MIG), macrophage inflammatory protein (MIP)-1 alpha, MIP 2, platelet-derived growth factor BB (PDGF BB), regulated upon activation, normal T-cell expressed, and secreted (Rantes), tumor necrosis factor -alpha (TNF-alpha), and vascular endothelial growth factor (VEGF). The proliferation of glial cells as well as the infiltration of inflammatory cells were also evaluated. Although astroglia proliferated from 72 hours post-injury, inflammatory cell dynamics were generally steady. Among cytokines analyzed in the present study, IL-1 beta, IL-5, IL-6, IL-12 p40, G-CSF, IFN-gamma, KC, LIF, MIP 2, and PDGF BB increased during the early phase of cerebral wound healing, and M-CSF increased during the middle phase, while IL-15, IL-18, and MIG increased during the late phase. In contrast, IL-1 alpha, IL-10, IL-12 p70, and TNF-alpha were suppressed throughout the cerebral wound healing process. Based on our findings, quantitative cytokine analyses at the cerebral wound site may be a useful tool for wound age estimation. Further, this study suggests that multiplex data gained from the same sample using a single methodology demonstrates highly accurate cytokine interactions during the process of cerebral wound healing.	[Takamiya, Masataka; Fujita, Sachiko; Aoki, Yasuhiro] Iwate Med Univ, Sch Med, Dept Legal Med, Morioka, Iwate 020, Japan; [Saigusa, Kiyoshi] Iwate Med Univ, Ctr Gen Educ, Dept Biol, Morioka, Iwate, Japan		Takamiya, M (corresponding author), Iwate Med Univ, Sch Med, Dept Legal Med, 19-1 Uchimaru, Morioka, Iwate 020, Japan.	mtakamiy@iwate-med.ac.jp					Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Bonmann E, 1997, NEUROSCI LETT, V230, P109, DOI 10.1016/S0304-3940(97)00485-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bugga L, 1998, J NEUROBIOL, V36, P509, DOI 10.1002/(SICI)1097-4695(19980915)36:4<509::AID-NEU5>3.0.CO;2-#; Davies CA, 1999, J CEREBR BLOOD F MET, V19, P87, DOI 10.1097/00004647-199901000-00010; Di Prospero NA, 1998, J NEUROCYTOL, V27, P491, DOI 10.1023/A:1006995624754; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Grau V, 1997, GLIA, V19, P181, DOI 10.1002/(SICI)1098-1136(199703)19:3<181::AID-GLIA1>3.0.CO;2-2; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hausmann R, 2001, INT J LEGAL MED, V114, P338, DOI 10.1007/s004140000199; Hausmann Roland, 2002, Leg Med (Tokyo), V4, P79, DOI 10.1016/S1344-6223(02)00003-2; Kellar KL, 2002, EXP HEMATOL, V30, P1227, DOI 10.1016/S0301-472X(02)00922-0; Krupinski J, 1997, STROKE, V28, P564, DOI 10.1161/01.STR.28.3.564; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Lund Frances E., 2005, V8, P25; Mandy FF, 2001, CLIN LAB MED, V21, P713; Nolan JP, 2001, CELL MOL BIOL, V47, P1241; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Orihara Y, 2002, INT J LEGAL MED, V116, P92, DOI 10.1007/s00414-001-0265-8; Orihara Yoshiyuki, 2003, Leg Med (Tokyo), V5 Suppl 1, pS278; PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Rasley A, 2004, J NEUROVIROL, V10, P171, DOI 10.1080/13550280490444119; Saukko P, 2004, KNIGHTS FORENSIC PAT, P174; SAWADA M, 1993, NEUROSCI LETT, V155, P175, DOI 10.1016/0304-3940(93)90701-L; Schaffer M, 1998, BRIT J SURG, V85, P444; Takamiya M, 2003, INT J LEGAL MED, V117, P46, DOI 10.1007/s00414-002-0354-3	30	25	28	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2007	24	12					1833	1844		10.1089/neu.2007.0336			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	245BR	WOS:000251910000006	18159995				2022-02-06	
J	Tontisirin, N; Armstead, W; Waitayawinyu, P; Moore, A; Udomphorn, Y; Zimmerman, JJ; Chesnut, R; Vavilala, MS				Tontisirin, Nuj; Armstead, William; Waitayawinyu, Pichaya; Moore, Anne; Udomphorn, Yuthana; Zimmerman, Jerry J.; Chesnut, Randall; Vavilala, Monica S.			Change in cerebral autoregulation as a function of time in children after severe traumatic brain injury: a case series	CHILDS NERVOUS SYSTEM			English	Article						pediatric traumatic brain injury; cerebral autoregulation; cerebral blood flow; pediatric trauma	HEAD-INJURY; BLOOD-FLOW; METABOLISM	Objective The objective of this study was to describe changes in cerebral autoregulation after severe pediatric traumatic brain injury (TBI). Materials and methods Two cerebral autoregulation tests were performed during the first 10 days after severe TBI in children < 16 years. Cerebral autoregulation was quantified using the mean autoregulatory index (mARI). Results Nine (five males/four females) children (10 +/- 5 years) with severe (admission Glasgow Coma Scale (GCS), 5 +/- 2) TBI were enrolled. Thirty (3/9) percent of initial exams revealed impaired cerebral autoregulation; all three had returned to intact cerebral autoregulation on second exam. However, in three of nine (33%) patients, cerebral autoregulation worsened on second exam. Of the factors examined, worsening mARI on second exam was associated with worsening head computed tomography (CT) lesion. Conclusions Cerebral autoregulation often changed and worsened during the first 9 days after severe pediatric TBI. Worsening cerebral autoregulation may mirror worsening TBI.	Univ Washington, Harborview Med Ctr, Dept Anesthesiol, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Dept Pediat, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Cerebrovasc Lab, Seattle, WA 98104 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Penn, Dept Anesthesiol, Philadelphia, PA 19104 USA		Vavilala, MS (corresponding author), Univ Washington, Harborview Med Ctr, Dept Anesthesiol, 325 9th Ave,POB 359724, Seattle, WA 98104 USA.	vavilala@u.washington.edu		Chesnut, Randall/0000-0001-6377-3666	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23/HD044632] Funding Source: Medline		AINSLIE PN, 2006, AM J PHYSIOL-HEART C, V292, P976; Cremer OL, 2004, ANESTHESIOLOGY, V100, P1101, DOI 10.1097/00000542-200405000-00011; DOHMEN C, 2006, STROKE, V22, P1; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kaiser JR, 2005, PEDIATR RES, V58, P931, DOI 10.1203/01.pdr.0000182180.80645.0c; LAM AM, 1995, ANESTHESIOLOGY, V82, P1536, DOI 10.1097/00000542-199506000-00035; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Mandera M, 2002, CHILD NERV SYST, V18, P124, DOI 10.1007/s00381-002-0572-5; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NISHIZAMA H, 1993, ACTA ANAESTH SCAND, V40, P1149; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P162; Sahuquillo J, 1998, ACT NEUR S, V71, P233; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Sundgreen C, 2001, STROKE, V32, P128, DOI 10.1161/01.STR.32.1.128; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vavilala MS, 2001, J NEUROSURG ANESTH, V13, P233, DOI 10.1097/00008506-200107000-00009; VAVILALA MS, 2004, PEDIATR CRIT CARE ME, V5, P298; Wintermark M, 2006, J NEURORADIOLOGY, V33, P27, DOI 10.1016/S0150-9861(06)77225-X	21	25	25	0	1	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	OCT	2007	23	10					1163	1169		10.1007/s00381-007-0339-0			7	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	208CO	WOS:000249297600012	17429655				2022-02-06	
J	Lange, RT; Iverson, GL; Franzen, MD				Lange, Rael T.; Iverson, Grant L.; Franzen, Michael D.			Short-term neuropsychological outcome following uncomplicated mild TBI : Effects of day-of-injury intoxication and pre-injury alcohol abuse	NEUROPSYCHOLOGY			English	Article; Proceedings Paper	23rd Annual Meeting of the National-Academy-of-Neuropsychology	2003	Dallas, TX	Natl Acad Neuropsychol		alcohol intoxication; alcohol abuse; mild TBI; neuropsychological outcome	TRAUMATIC BRAIN-INJURY; SUBSTANCE-ABUSE; HEAD-INJURY; POLYSUBSTANCE ABUSE; ETHANOL; LEVEL; ASSOCIATION; VIOLENCE; MODEL	Research suggests that individuals who are intoxicated at the time of traumatic brain injury (TBI) have worse cognitive outcome compared with those who are sober. Worse outcome in patients with day-ofinjury intoxication might (a) be related to the increased magnitude of brain injury resulting from a variety of negative responses not present following TBI in nonintoxicated individuals, or (b) reflect the effect of pre-injury alcohol abuse that is prevalent in individuals intoxicated at the time of injury. Most studies in this area have focused on patients with moderate to severe TBIs, and on medium- to long-term neuropsychological outcome. The purpose of this study was to examine the relative contributions of day-of-injury intoxication versus pre-injury alcohol abuse on short-term cognitive recovery following mild TBI. Participants were 169 patients with uncomplicated mild TBIs who were assessed on 13 cognitive measures within 7 days postinjury. The prevalence of intoxication at the time of injury was 54.4%. The prevalence of possible pre-injury alcohol abuse was 46.2%. Overall, the results suggest that pre-injury alcohol abuse, compared with day-of-injury alcohol intoxication, had the most influence on short-term neuropsychological outcome from uncomplicated mild TBI. However, the influence of pre-injury alcohol abuse was considered small at best.	Riverview Hosp, British Columbia Mental Hlth & Addict Serv, Res Dept, Coquitlam, BC V3C 4J2, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA		Lange, RT (corresponding author), Riverview Hosp, British Columbia Mental Hlth & Addict Serv, Res Dept, Room 124-ADMIN Bldg,Main Floor,2601 Lougheed High, Coquitlam, BC V3C 4J2, Canada.	rlange@bcmhs.bc.ca		Iverson, Grant/0000-0001-7348-9570			Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Altura BM, 1999, ALCOHOL, V19, P119, DOI 10.1016/S0741-8329(99)00025-7; Barker LH, 1999, J INT NEUROPSYCH SOC, V5, P593, DOI 10.1017/S1355617799577023; Benedict, 2001, HOPKINS VERBAL LEARN; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benton AL, 1994, MULTILINGUAL APHASIA; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Biros MH, 1999, ACAD EMERG MED, V6, P1088, DOI 10.1111/j.1553-2712.1999.tb00109.x; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; BOMBARDIER CH, 1995, WESTERN J MED, V162, P150; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; BRISMAR B, 1983, ACTA CHIR SCAND, V149, P11; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Canadian Institute for Health Information, 2002, ONT TRAUM REG B ALC; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; COWIE SE, 2005, DOCUMENTATION SUBSTA; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; Fein G, 1998, ALCOHOL CLIN EXP RES, V22, p196S, DOI 10.1111/j.1530-0277.1998.tb04000.x; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Gururaj G, 2004, J Indian Med Assoc, V102, P157; Heaton R., 2000, WISCONSIN CARD SORTI; Heaton R. K., 2004, REVISED COMPREHENSIV; HEINEMANN AW, 1991, ARCH PHYS MED REHAB, V72, P482; Iverson G.L., 2006, BRAIN INJURY MED PRI, P333; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; JERNIGAN T, 1992, IMAGING ALCOHOL RES, P121; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; Mautes AEM, 2001, ACTA NEUROCHIR, V143, P51, DOI 10.1007/s007010170138; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P306, DOI 10.1097/00002060-199907000-00002; Miller Norman S., 1994, P471; Mitrushina MN, 1999, HDB NORMATIVE DATA N; Nixon SJ, 1999, PSYCHOL SCI, V10, P181, DOI 10.1111/1467-9280.00130; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Reitan RM, 1992, TRAIL MAKING TEST MA; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Sullivan EV, 1996, ALCOHOL CLIN EXP RES, V20, P348, DOI 10.1111/j.1530-0277.1996.tb01651.x; Tate PS, 1999, BRAIN INJURY, V13, P767; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Tureci E, 2004, NEUROL RES, V26, P108, DOI 10.1179/016164104225013699; Wechsler D, 1987, MEMORY SCALE REVISED; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; Zink BJ, 2001, ALCOHOL CLIN EXP RES, V25, P916; [No title captured], DOI DOI 10.1037/0894-4105.7.3.296; [No title captured]	67	25	25	0	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	SEP	2007	21	5					590	598		10.1037/0894-4105.21.5.590			9	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Conference Proceedings Citation Index - Science (CPCI-S)	Psychology; Neurosciences & Neurology	205HO	WOS:000249104800008	17784807				2022-02-06	
J	Laudi, S; Donaubauer, B; Busch, T; Kerner, T; Bercker, S; Bail, H; Feldheiser, A; Haas, N; Kaisers, U				Laudi, Sven; Donaubauer, Bernd; Busch, Thito; Kerner, Thoralf; Bercker, Sven; Bail, Hermann; Feldheiser, Aarne; Haas, Norbert; Kaisers, Udo			Low incidence of multiple organ failure after major trauma	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						multiple organ failure; ARDS; major trauma; trauma care; lung protection	RESPIRATORY-DISTRESS-SYNDROME; MECHANICAL VENTILATION; RISK-FACTORS; INFLAMMATORY MEDIATORS; DYSFUNCTION SYNDROME; POLYTRAUMA PATIENTS; BRAIN-INJURY; LUNG INJURY; FRACTURES; MORTALITY	Background: In major trauma patients, multiple organ failure (MCF) is considered a leading cause of death. Acute lung injury is deemed a "pacemaker" of MOF The purpose of this study was to determine if incidence of organ failure and mortality in multiple trauma patients can be reduced by implementation of tung-protective strategies. Methods: All critically ill multiple trauma patients admitted to the ICU of a major trauma center in Berlin, Germany from January 199 to December 2002 were analyzed retrospectively. Patients were ventilated pressure controlled with low tidal volumes and adequate PEEP. Results: n = 287 patients were included. The most frequent injuries were traumatic brain injury (TBI-68%), chest trauma (68%), and lung contusions (55%). Injury severity score (ISS) was 32 +/- 19 (mean +/- standard deviation), polytraumaschluessel (PTS) 34 +/- 19, and APACHE II 14 +/- 7. During their ICU-stay 16 patients died, 9 (56%) from TBI. Single-organ-failure occurred in n = 69 patients (24%, mortality 5%), two-organ-failure in n = 22 (8%, mortality 14%), and MCIF in n = 9 (3%, mortality 13%); one patient died from MOF 14 days after trauma. The number of days on mechanical ventilation increased depending on the number of organs failed (R = 0.618, p < 0.001). Seven patients (2%) fulfilled ARDS criteria for longer than 24 h despite optimized ventilatory settings, one died of irreversible shock. Patients with MOF had a significantly increased ICU-LOS (35 +/- 15 days) compared to patients without organ failure (11 +/- 11 days; p<0.001). Conclusion: The low incidence of MOF in our series of trauma patients suggests that MOF may be prevented in some patients by implementation of lung-protective strategies. The improved outcome was associated with an increased ICU-LOS. (C) 2007 Elsevier Ltd. All. rights reserved.	Univ Leipzig, Fac Med, Dept Anesthesiol & Intens Care Med, D-04103 Leipzig, Germany; Charite Univ Med Ctr, Dept Anesthesiol & Intens Care Med, D-13353 Berlin, Germany; Charite Univ Med Ctr, Dept Trauma & Reconstruct Surg, D-13353 Berlin, Germany		Kaisers, U (corresponding author), Univ Klinikum Leipzig, Klin & Poliklin Anaesthesiol & Intensivtherapie, Liebigstr 20, D-04103 Leipzig, Germany.	udo.kaisers@medizin.uni-leipzig.de	Feldheiser, Aarne/AAH-1503-2019; bercker, sven/B-9278-2009; Busch, Thilo/J-8258-2015	Feldheiser, Aarne/0000-0002-0014-8879; 			AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Aufmkolk M, 1997, UNFALLCHIRURG, V100, P477, DOI 10.1007/s001130050145; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; Bone RC, 1996, ANN INTERN MED, V125, P680, DOI 10.7326/0003-4819-125-8-199610150-00009; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; DeLong WG, 2004, CLIN ORTHOP RELAT R, P57, DOI 10.1097/01.blo.0000130840.64528.1e; Dereeper E, 1998, RESUSCITATION, V36, P15, DOI 10.1016/S0300-9572(97)00080-4; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Durham RM, 2003, J TRAUMA, V55, P608, DOI 10.1097/01.TA.0000092378.10660.D1; FAIST E, 1983, J TRAUMA, V23, P775, DOI 10.1097/00005373-198309000-00002; Giannoudis PV, 2003, INJURY, V34, P397, DOI 10.1016/S0020-1383(02)00416-3; GORIS RJA, 1982, J TRAUMA, V22, P895, DOI 10.1097/00005373-198211000-00002; Grotz MRW, 2004, INJURY, V35, P1077, DOI 10.1016/j.injury.2004.05.025; Haas N P, 2001, Kongressbd Dtsch Ges Chir Kongr, V118, P421; Hadfield RJ, 2001, RESUSCITATION, V49, P279, DOI 10.1016/S0300-9572(00)00364-6; Hager DN, 2006, CRIT CARE MED, V34, P1554, DOI 10.1097/01.CCM.0000216183.25478.03; Khadaroo RG, 2002, CRIT CARE CLIN, V18, P127, DOI 10.1016/S0749-0704(03)00069-1; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Levine JH, 1996, WORLD J SURG, V20, P471, DOI 10.1007/s002689900074; Lewandowski K, 1997, INTENS CARE MED, V23, P819, DOI 10.1007/s001340050418; Michaels AJ, 2004, CRIT CARE CLIN, V20, P83, DOI 10.1016/S0749-0704(03)00099-X; Moore F, 2004, POSTINJURY MULTIPLE, P1397; Moore FA, 1996, J TRAUMA, V40, P501, DOI 10.1097/00005373-199604000-00001; Nast-Kolb D, 2001, J TRAUMA, V51, P835, DOI 10.1097/00005373-200111000-00003; Navarrete-Navarro P, 2001, INTENS CARE MED, V27, P1133, DOI 10.1007/s001340100955; Pape HC, 2002, J TRAUMA, V53, P452, DOI 10.1097/00005373-200209000-00010; Ranieri VM, 2000, JAMA-J AM MED ASSOC, V284, P43, DOI 10.1001/jama.284.1.43; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; REGEL G, 1994, UNFALLCHIRURG, V97, P211; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; REGEL G, 1993, UNFALLCHIRURG, V96, P350; REGEL G, 1995, J TRAUMA, V38, P70, DOI 10.1097/00005373-199501000-00020; Sauaia A, 1998, J TRAUMA, V45, P291, DOI 10.1097/00005373-199808000-00014; SAUAIA A, 1994, ARCH SURG-CHICAGO, V129, P39; Sauaia A, 1996, WORLD J SURG, V20, P392, DOI 10.1007/s002689900062; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; TRAN DD, 1993, SURGERY, V114, P21	40	25	25	1	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	SEP	2007	38	9					1052	1058		10.1016/j.injury.2007.03.020			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	219CG	WOS:000250061700009	17572416				2022-02-06	
J	Liu, D; McIlvain, HB; Fennell, M; Dunlop, J; Wood, A; Zaleska, MM; Graziani, EI; Pong, K				Liu, Danni; McIlvain, H. Beal; Fennell, Myles; Dunlop, John; Wood, Andrew; Zaleska, Margaret M.; Graziani, Edmund I.; Pong, Kevin			Screening of immunophilin ligands by quantitative analysis of neurofilament expression and neurite outgrowth in cultured neurons and cells	JOURNAL OF NEUROSCIENCE METHODS			English	Article						amyotrophic lateral sclerosis; immunophilin ligands; neurite outgrowth; neuronal survival; neuroregeneration; Parkinson's disease; spinal cord injury; stroke	TRAUMATIC BRAIN-INJURY; PEPTIDYL-PROLYL ISOMERASE; LONG-TERM POTENTIATION; CIS-TRANS ISOMERASE; SPINAL-CORD-INJURY; CYCLOSPORINE-A; IMMUNOSUPPRESSANT FK506; BINDING-PROTEIN; NONIMMUNOSUPPRESSIVE IMMUNOPHILIN; MITOCHONDRIAL DYSFUNCTION	Immunophilins are protein receptors for the immunosuppressant drugs FK506, cyclosporin A (CsA), and rapamycin. Two categories of immunophilins are the FK506-binding proteins (FKBPs), which bind to FK506, rapamycin, and CCI-779 and the cyclophilins, which bind to CsA. Reports have shown that immunophilins are expressed in the brain and spinal cord, are 10-100-fold higher in CNS tissue than immune tissue, and their expression is increased following nerve injury, suggesting that their chemical ligands may have therapeutic utility in the treatment of neurodegenerative diseases. In this study, we report the development and utility of a rapid neurofilament (NF) enzyme-linked immunosorbent assay (ELISA) to quantify neuronal survival and the Cellomics ArrayScan platform to quantify neurite outgrowth following treatment with immunophilin ligands. Cultured neurons or F-11 cells were treated with various immunophilin ligands for 72 or 96 h and their promotion of neuronal survival and neurite outgrowth were determined. The results showed that all immunophilin ligands, in a concentration-dependent manner, significantly increased neuronal survival and neurite outgrowth, when compared to control cultures. Taken together, these results demonstrate the potential utility of the neurofilament ELISA and Cellomics ArrayScan platform to efficiently quantify neurotrophic effects of immunophilin ligands on cultured neurons and cell lines. (c) 2007 Elsevier B.V. All rights reserved.	Wyeth Res, Neurosci Discovery Res, Princeton, NJ 08543 USA; Wyeth Res, Chem & Screening Sci, Pearl River, NY USA		Pong, K (corresponding author), Wyeth Res, Neurosci Discovery Res, CN 8000, Princeton, NJ 08543 USA.	pongk@wyeth.com		Graziani, Edmund/0000-0003-4742-3900			Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ARMISTEAD DM, 1992, Patent No. 9219593; Avramut M, 2001, DEV BRAIN RES, V132, P151, DOI 10.1016/S0165-3806(01)00307-8; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Birge RB, 2004, NEUROSCIENCE, V124, P351, DOI 10.1016/j.neuroscience.2003.10.013; Chen QS, 2002, NEUROBIOL LEARN MEM, V77, P354, DOI 10.1006/nlme.2001.4034; Choo YS, 2004, HUM MOL GENET, V13, P1407, DOI 10.1093/hmg/ddh162; Costantini LC, 2000, EXP NEUROL, V164, P60, DOI 10.1006/exnr.2000.7417; Costantini LC, 2001, EUR J NEUROSCI, V13, P1085, DOI 10.1046/j.0953-816x.2001.01473.x; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Dubowchik GM, 2001, ORG LETT, V3, P3987, DOI 10.1021/ol0166909; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FRANCEL PC, 1987, J NEUROCHEM, V48, P1624, DOI 10.1111/j.1471-4159.1987.tb05711.x; Gold BG, 2004, J NEUROSCI RES, V77, P367, DOI 10.1002/jnr.20165; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guo X, 2001, EUR J NEUROSCI, V13, P1683, DOI 10.1046/j.0953-816x.2001.01542.x; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Julien JP, 1998, PROG NUCLEIC ACID RE, V61, P1, DOI 10.1016/S0079-6603(08)60823-5; Kano Y, 2002, NEUROCHEM RES, V27, P1655, DOI 10.1023/A:1021639128120; Keep M, 2001, BRAIN RES, V894, P327, DOI 10.1016/S0006-8993(01)02012-1; KITAMURA Y, 1994, J NEUROIMMUNOL, V50, P221; Klettner A, 2001, MOL BRAIN RES, V97, P21, DOI 10.1016/S0169-328X(01)00286-8; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212, DOI 10.1097/01.wbc.0000037994.34930.bc; Lee MK, 1996, ANNU REV NEUROSCI, V19, P187, DOI 10.1146/annurev.ne.19.030196.001155; Lench NJ, 1997, HUM GENET, V99, P547, DOI 10.1007/s004390050404; LIU D, 2004, SOC NEUROSCI ABSTR, V35; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; LYONS WE, 1995, J NEUROSCI, V15, P2985; McIlvain HB, 2006, BRAIN RES, V1077, P16, DOI 10.1016/j.brainres.2005.12.130; NIXON RA, 1992, CELL MOTIL CYTOSKEL, V22, P81, DOI 10.1002/cm.970220202; NIXON RA, 1998, BIOESSAYS, V98, P229; Ohuchi T, 2002, J NEUROSCI METH, V118, P1, DOI 10.1016/S0165-0270(02)00116-4; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Parker EM, 2000, NEUROPHARMACOLOGY, V39, P1913, DOI 10.1016/S0028-3908(00)00028-9; Pong K, 2001, EXP NEUROL, V171, P84, DOI 10.1006/exnr.2001.7747; Pong K, 2003, CNS NEUROL DISORD-DR, V2, P349, DOI 10.2174/1568007033482652; Price RD, 2005, EUR J PHARMACOL, V509, P11, DOI 10.1016/j.ejphar.2004.12.023; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Ravikumar B, 2002, HUM MOL GENET, V11, P1107, DOI 10.1093/hmg/11.9.1107; Ravikumar B, 2003, HUM MOL GENET, V12, P985, DOI 10.1093/hmg/ddg109; Rosenstiel P, 2003, J NEUROTRAUM, V20, P297, DOI 10.1089/089771503321532888; Ross DT, 2001, NEUROSCI LETT, V297, P113, DOI 10.1016/S0304-3940(00)01683-9; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sauer H, 1999, BRAIN RES, V842, P109, DOI 10.1016/S0006-8993(99)01851-X; Schreyer DJ, 1997, J NEUROSCI METH, V72, P137, DOI 10.1016/S0165-0270(96)02171-1; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; Sharkey J, 1996, STROKE, V27, P2282, DOI 10.1161/01.STR.27.12.2282; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Simpson PB, 2001, ANAL BIOCHEM, V298, P163, DOI 10.1006/abio.2001.5346; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Skotnicki J. S., 1994, U.S. Pat, Patent No. [5,362,718, 5362718]; Small SL, 1996, ANN NEUROL, V40, P575, DOI 10.1002/ana.410400406; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Summers MY, 2006, J ANTIBIOT, V59, P184, DOI 10.1038/ja.2006.26; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Terashima A, 2000, NEUROPHARMACOLOGY, V39, P1920, DOI 10.1016/S0028-3908(00)00015-0; Wang M S, 1999, J Spinal Cord Med, V22, P287; WOOD A, 2004, SOC NEUROSCI ABSTR; Yabe T, 2002, J NEUROSCI RES, V68, P161, DOI 10.1002/jnr.10210; Young L, 1999, J NEUROSCI METH, V93, P81, DOI 10.1016/S0165-0270(99)00134-X; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zhang CY, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-15-j0002.2001; 1996, Patent No. 9640633	70	25	30	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUL 30	2007	163	2					310	320		10.1016/j.jneumeth.2007.03.018			11	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	188UW	WOS:000247945800013	17490751				2022-02-06	
J	Ribbers, GM				Ribbers, G. M.			Traumatic Brain Injury Rehabilitation in the Netherlands: Dilemmas and Challenges	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Netherlands; rehabilitation; traumatic brain injury		Traumatic brain injury (TBI) is the number one cause of mortality and morbidity in young adults in modern Western societies. This article discusses TBI rehabilitation in the Netherlands. Facts and figures on rehabilitation as well as on the epidemiology of TBI and its silent epidemic in the Netherlands are presented. The Dutch healthcare system is described, and strengths and weaknesses of TBI rehabilitation are discussed.	[Ribbers, G. M.] Rijndam Rehabil Ctr, NL-3001 KD Rotterdam, Netherlands; [Ribbers, G. M.] Erasmus MC, Rotterdam, Netherlands		Ribbers, GM (corresponding author), Rijndam Rehabil Ctr, POB 23181, NL-3001 KD Rotterdam, Netherlands.	g.ribbers@rijndam.nl	Ribbers, Gerard M/C-1454-2014; Ribbers, Gerard/N-3623-2019	Ribbers, Gerard M/0000-0002-6114-349X; 			Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P1, DOI 10.1111/j.1468-1331.2005.01202.x; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; *CTR BUR STAT VOOR, 2006, GEZ ZORG CIJF; Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511; DURGIN CJ, 1993, STAFF DEV CLIN INTER; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; HORN LJ, 1995, MED REHABILITATION T; *INSP GEZ, 1997, EEN DEUR VERD COORD; *LAND COORD PUNT N, 1996, PUBL LAND COORD PUNT; Matser EJT, 2000, PHYSICIAN SPORTSMED, V28, P87, DOI 10.3810/psm.2000.01.645; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; *MIN HLTH WELF SPO, 2004, INT PUBL SER HLTH E, V1; *MIN HLTH WELF SPO, 2004, NEW HLTH INS SYST BR; OUDEJANS SCC, 2005, HDB KWALITEIT ZORG, V46, P46; *PRISM, 2004, PUBL PRISM; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; VANBALEN HGG, 1997, THESIS KATHOLIEKE U; VANBEECK EF, 1998, THESIS ERASMUS MED C; VANDENBRINK WA, 2000, THESIS ERASMUS MED C; 1997, PROBLEMATIEK MENSEN; 2006, REVALICLATIE BRANCHE	24	25	25	1	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2007	22	4					234	238		10.1097/01.HTR.0000281839.07968.32			5	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	V87BQ	WOS:000205885400007	17667066				2022-02-06	
J	Shimamura, M; Sato, N; Sata, M; Wakayama, K; Ogihara, T; Morishita, R				Shimamura, Munehisa; Sato, Naoyuki; Sata, Masataka; Wakayama, Kouji; Ogihara, Toshio; Morishita, Ryuichi			Expression of hepatocyte growth factor and c-Met after spinal cord injury in rats	BRAIN RESEARCH			English	Article						spinal cord injury; hepatocyte growth factor; c-Met	FOCAL CEREBRAL-ISCHEMIA; DELAYED NEURONAL DEATH; NEUROTROPHIC FACTOR; GENE-TRANSFER; UP-REGULATION; BRAIN; CELLS; HGF; RECEPTOR; OVEREXPRESSION	Since hepatocyte growth factor (HGF) plays a pivotal role in the development of the central nervous system and pathological conditions, we examined the long-term changes in the mRNA and protein expression of HGF and its receptor c-Met after spinal cord injury (SCI) in rats. HGF mRNA was significantly increased from 7 days after.SCI in the injured segment, and the peak was at 7 days after SCI as assessed by real-time RT-PCR. Importantly, c-met mRNA expression was up-regulated from I day after SCI, and reached a peak at 14 days after SCI. Although up-regulation of HGF and c-met mRNA expression in the injured segment gradually decreased, the increased expression level persisted until 56 days after SCI. Consistent with HGF mRNA expression, HGF protein level was significantly increased mainly in the injured region, which persisted until 56 days after SCI. Immunohistochemistry showed that most of GFAP-positive reactive astrocytes expressed HGF and c-Met both on 14 days and 56 days after SCI. Staining with the mitotic indicator, bromodeoxyuridine (BrdU), revealed that a small number of BrdU-incorporated cells were co-localized with HGF/ GFAP-positive or c-Met/GFAP-positive cells both on 14 and 56 days. These data suggest that HGF and c-Met were up-regulated mainly in the reactive astrocytes around the injured region in the subacute to chronic stage of spinal cord injury. Since HGF plays a critical role in neurotrophic activity, activation of the HGF/c-Met signaling system might be involved in the process of post-traumatic regeneration. (C) 2007 Elsevier B.V. All rights reserved.	Osaka Univ, Grad Sch Med, Dept Clin Gene Therapy, Suita, Osaka 5650871, Japan; Univ Tokyo, Grad Sch Med, Dept Adv Clin Sci & Therapeut, Tokyo, Japan; Osaka Univ, Grad Sch Med, Dept Geriatr Med, Suita, Osaka 565, Japan		Morishita, R (corresponding author), Osaka Univ, Grad Sch Med, Dept Clin Gene Therapy, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	morishit@cgt.med.osaka-u.ac.jp					BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Hamanoue M, 1996, J NEUROSCI RES, V43, P554, DOI 10.1002/(SICI)1097-4547(19960301)43:5<554::AID-JNR5>3.0.CO;2-H; Hayashi K, 2001, GENE THER, V8, P1167, DOI 10.1038/sj.gt.3301498; Hiebert GW, 2002, J NEUROSCI RES, V69, P160, DOI 10.1002/jnr.10275; HONDA S, 1995, MOL BRAIN RES, V32, P197, DOI 10.1016/0169-328X(95)00075-4; Ikeda O, 2001, ACTA NEUROPATHOL, V102, P239; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; Kato S, 2003, ACTA NEUROPATHOL, V106, P112, DOI 10.1007/s00401-003-0708-z; Kokuzawa J, 2003, MOL CELL NEUROSCI, V24, P190, DOI 10.1016/S1044-7431(03)00160-X; Machide M, 2000, J BIOL CHEM, V275, P31392, DOI 10.1074/jbc.M002817200; Miyazawa T, 1998, J CEREBR BLOOD F MET, V18, P345, DOI 10.1097/00004647-199804000-00001; Morishita R, 2004, CURR GENE THER, V4, P199; Nagayama T, 2004, BRAIN RES, V999, P155, DOI 10.1016/j.brainres.2003.11.052; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Ruitenberg MJ, 2004, NEUROBIOL DIS, V15, P394, DOI 10.1016/j.nbd.2003.11.018; Rush S, 2007, EXP CELL RES, V313, P121, DOI 10.1016/j.yexcr.2006.09.018; Satake K, 2000, NEUROREPORT, V11, P3877, DOI 10.1097/00001756-200011270-00054; Shimamura M, 2006, HYPERTENSION, V47, P742, DOI 10.1161/01.HYP.0000208598.57687.3e; Shimamura M, 2005, J GENE MED, V7, P1468, DOI 10.1002/jgm.793; Shimamura M, 2004, CIRCULATION, V109, P424, DOI 10.1161/01.CIR.0000109496.82683.49; Shimazaki K, 2003, BRAIN RES, V962, P105, DOI 10.1016/S0006-8993(02)03975-6; Sun W, 2002, J NEUROSCI, V22, P6537; Sun W, 2002, MOL BRAIN RES, V103, P36, DOI 10.1016/S0169-328X(02)00168-7; Tai MH, 2003, EXP NEUROL, V183, P508, DOI 10.1016/S0014-4886(03)00130-4; Tsuzuki N, 2001, NEUROL RES, V23, P417, DOI 10.1179/016164101101198659; Tuszynski MH, 1996, EXP NEUROL, V137, P157, DOI 10.1006/exnr.1996.0016; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; YAMADA T, 1994, BRAIN RES, V637, P308, DOI 10.1016/0006-8993(94)91250-5; YAMAGATA T, 1995, BIOCHEM BIOPH RES CO, V210, P231, DOI 10.1006/bbrc.1995.1651; Yan HL, 2002, J NEUROSCI RES, V69, P597, DOI 10.1002/jnr.10323; Zhou LJ, 2003, J NEUROSCI RES, V74, P221, DOI 10.1002/jnr.10718	32	25	32	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 2	2007	1151						188	194		10.1016/j.brainres.2007.03.022			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	172TW	WOS:000246828300019	17425951				2022-02-06	
J	Gao, JL; Coggeshall, RE; Chung, JM; Wang, JG; Wu, P				Gao, Junling; Coggeshall, Richard E.; Chung, Jin Mo; Wang, Jigong; Wu, Ping			Functional motoneurons develop from human neural stem cell transplants in adult rats	NEUROREPORT			English	Article						human neural stem cell; innervation; motoneuron disease; myelin; synapse; transplantation	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; MOTOR-NEURONS; NEUROTROPHIC FACTORS; CHOLINERGIC NEURONS; DIFFERENTIATION; RECOVERY; SPECIFICATION; SURVIVAL; GROWTH	We have shown previously that primed human fetal neural stem cells, after transplantation into rat spinal cords, differentiated into cholinergic motoneurons that sent axons to contact medial gastrocnemius myocytes. Here we demonstrate that (i) axons from the transplanted cells are cholinergic and myelinated, (ii) putative synapses form on transplanted somata and dendrites in the ventral horn, (iii) human fetal neural stem cells transplantation led to normal electromyograms from medial gastrocnemius muscles, and (iv) the gait of transplanted animals was much improved. Accumulatively, our data indicate that some transplanted human fetal neural stem cells in adult motoneuron-deficient ventral horns differentiate into relatively normal motoneurons that are integrated into spinal and peripheral circuitry These findings are steps towards the long-term goal of providing stem cell transplants for motoneuron loss.	Univ Texas, Med Branch, Dept Cell Biol & Neurosci, Galveston, TX 77555 USA		Wu, P (corresponding author), Univ Texas, Med Branch, Dept Cell Biol & Neurosci, Galveston, TX 77555 USA.	piwu@utmb.edu	wu, Ping/G-8958-2011		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31680, NS11255, NS10161, NS046025] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS031680, R01NS046025, P01NS011255] Funding Source: NIH RePORTER		Barberi T, 2003, NAT BIOTECHNOL, V21, P1200, DOI 10.1038/nbt870; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; Corti S, 2006, HUM MOL GENET, V15, P167, DOI 10.1093/hmg/ddi446; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Deshpande DM, 2006, ANN NEUROL, V60, P32, DOI 10.1002/ana.20901; Gao J, 2005, NEUROSCIENCE, V131, P257, DOI 10.1016/j.neuroscience.2004.10.033; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Hamada M, 2006, NEUROBIOL DIS, V22, P509, DOI 10.1016/j.nbd.2005.12.020; Kerr DA, 2003, J NEUROSCI, V23, P5131; Kuo HC, 2003, BIOL REPROD, V68, P1727, DOI 10.1095/biolreprod.102.012195; Li XJ, 2005, NAT BIOTECHNOL, V23, P215, DOI 10.1038/nbt1063; Llado J, 2004, MOL CELL NEUROSCI, V27, P322, DOI 10.1016/j.mcn.2004.07.010; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Miles GB, 2004, J NEUROSCI, V24, P7848, DOI 10.1523/JNEUROSCI.1972-04.2004; NIETOSAMPEDRO M, 1987, ANN NY ACAD SCI, V495, P108, DOI 10.1111/j.1749-6632.1987.tb23670.x; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Renoncourt Y, 1998, MECH DEVELOP, V79, P185, DOI 10.1016/S0925-4773(98)00189-0; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shin S, 2005, STEM CELLS DEV, V14, P266, DOI 10.1089/scd.2005.14.266; Soundararajan P, 2006, J NEUROSCI, V26, P3256, DOI 10.1523/JNEUROSCI.5537-05.2006; Svendsen CN, 1998, J NEUROSCI METH, V85, P141, DOI 10.1016/S0165-0270(98)00126-5; Tarasenko YI, 2004, J NEUROSCI RES, V78, P625, DOI 10.1002/jnr.20316; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Wu P, 2002, NAT NEUROSCI, V5, P1271, DOI 10.1038/nn974; Wu P, 2002, GENE THER, V9, P245, DOI 10.1038/sj.gt.3301646	25	25	28	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	APR 16	2007	18	6					565	569		10.1097/WNR.0b013e3280b10c2c			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	155WM	WOS:000245609300008	17413658				2022-02-06	
J	Ankeny, DP; Popovich, PG				Ankeny, Daniel P.; Popovich, Phillip G.			Central nervous system and non-central nervous system antigen vaccines exacerbate neuropathology caused by nerve injury	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						autoimmunity; mouse; neuroinflammation; neurotrauma; peripheral nerve injury; T cells	SPINAL-CORD-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; FACIAL MOTOR NUCLEUS; AUTOREACTIVE T-CELLS; INCOMPLETE FREUNDS-ADJUVANT; TUMOR-NECROSIS-FACTOR; IMMUNE SURVEILLANCE; NEURONAL SURVIVAL	Previously, we showed that autoimmune (central nervous system myelin-reactive) T cells exacerbate tissue damage and impair neurological recovery after spinal cord injury. Conversely, independent studies have shown T cell-mediated neuroprotection after spinal cord injury or facial nerve axotomy (FNAx). The antigen specificity of the neuroprotective T cells has not been investigated after FNAx. Here, we compared the neuroprotective capacity of autoimmune and non-autoimmune lymphocytes after FNAx. Prior to axotomy, C57BL/6 mice were immunized with myelin basic protein, myelin oligodendrocyte glycoprotein (MOG) or ovalbumin (a non-self antigen) emulsified in complete Freund's adjuvant (CFA). FNAx mice receiving injections of phosphate-buffered saline (PBS) only (unimmunized) or PBS/CFA emulsions served as controls. At 4 weeks after axotomy, bilateral facial motor neuron counts were obtained throughout the facial motor nucleus using unbiased stereology (optical fractionator). The data show that neuroantigen immunizations and 'generic' lymphocyte activation (e.g. PBS/CFA or ovalbumin/CFA immunizations) exacerbated neuron loss above that caused by FNAx alone. We also found that nerve injury potentiated the effector potential of autoimmune lymphocytes. Indeed, prominent forelimb and hindlimb motor deficits were accompanied by disseminated neuroinflammation and demyelination in FNAx mice receiving subencephalitogenic immunization with MOG. FNAx or neuroantigen (MOG or myelin basic protein) immunization alone did not cause these pathological changes. Thus, irrespective of the antigens used to trigger an immune response, neuropathology was enhanced when the immune system was primed in parallel with nerve injury. These data have important implications for therapeutic vaccination in clinical neurotrauma and neurodegeneration.	Ohio State Univ, Coll Med, Ctr Brain & Spinal Cord Repair, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Inst Behav Med Res, Columbus, OH 43210 USA		Popovich, PG (corresponding author), 333 W 10th Ave,2078 Graves Hall, Columbus, OH 43210 USA.	Phillip.Popovich@osumc.edu	Popovich, Phillip/C-9187-2009	Popovich, Phillip/0000-0003-1329-7395	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32AI055411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045758, R01NS047175] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32 AI55411] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30-NS045758, NS047175] Funding Source: Medline		Aktas O, 2005, NEURON, V46, P421, DOI 10.1016/j.neuron.2005.03.018; ANDO DG, 1989, CELL IMMUNOL, V124, P132, DOI 10.1016/0008-8749(89)90117-2; Angelov DN, 1998, GLIA, V24, P155; Ankeny DP, 2006, J NEUROCHEM, V99, P1073, DOI 10.1111/j.1471-4159.2006.04147.x; ANTEL JP, 1994, ANN NEUROL, V35, P341, DOI 10.1002/ana.410350315; Bohatschek M, 2004, J COMP NEUROL, V470, P382, DOI 10.1002/cne.20017; Brabb T, 1997, J IMMUNOL, V159, P497; Brisebois M, 2006, J IMMUNOL, V177, P2403, DOI 10.4049/jimmunol.177.4.2403; Byram SC, 2004, J NEUROSCI, V24, P4333, DOI 10.1523/JNEUROSCI.5276-03.2004; Byram SC, 2006, CLIN NEUROSCI RES, V6, P86, DOI 10.1016/j.cnr.2006.06.001; Cabarrocas J, 2003, EUR J IMMUNOL, V33, P1174, DOI 10.1002/eji.200323492; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; CUA DJ, 1995, J IMMUNOL, V155, P4052; Dai XD, 2003, J NEUROSCI, V23, P5846; Dittel BN, 1999, J IMMUNOL, V162, P6392; Dowdell KC, 1999, J NEUROIMMUNOL, V100, P243, DOI 10.1016/S0165-5728(99)00211-8; DSOUZA S, 1995, J NEUROSCI, V15, P7293; Falcone M, 1997, J EXP MED, V185, P901, DOI 10.1084/jem.185.5.901; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Ferri CC, 1998, J NEUROBIOL, V34, P1; Galiano M, 2001, EUR J NEUROSCI, V14, P327, DOI 10.1046/j.0953-816x.2001.01647.x; GENAIN CP, 1994, J CLIN INVEST, V94, P1339, DOI 10.1172/JCI117454; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Gimsa U, 2000, BRAIN PATHOL, V10, P365; Gimsa U, 2001, J NEUROIMMUNOL, V119, P73, DOI 10.1016/S0165-5728(01)00343-5; Giuliani F, 2003, J IMMUNOL, V171, P368, DOI 10.4049/jimmunol.171.1.368; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; Ha GK, 2006, J NEUROIMMUNOL, V172, P1, DOI 10.1016/j.jneuroim.2005.10.012; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2001, J CLIN INVEST, V108, P591, DOI 10.1172/JCI200112837; Hayes KC, 2002, J NEUROTRAUM, V19, P753, DOI 10.1089/08977150260139129; Heeger PS, 2000, J IMMUNOL, V164, P5771, DOI 10.4049/jimmunol.164.11.5771; Hofstetter HH, 2003, J NEUROIMMUNOL, V134, P25, DOI 10.1016/S0165-5728(02)00358-2; Hofstetter HH, 2002, J IMMUNOL, V169, P117, DOI 10.4049/jimmunol.169.1.117; Hottinger AF, 2000, J NEUROSCI, V20, P5587, DOI 10.1523/JNEUROSCI.20-15-05587.2000; Jones TB, 2005, J NEUROSCI, V25, P6576, DOI 10.1523/JNEUROSCI.0305-05.2005; Jones TB, 2004, J NEUROSCI, V24, P3752, DOI 10.1523/JNEUROSCI.0406-04.2004; Jones TB, 2002, J NEUROSCI, V22, P2690, DOI 10.1523/JNEUROSCI.22-07-02690.2002; Juedes AE, 2000, J IMMUNOL, V164, P419, DOI 10.4049/jimmunol.164.1.419; Kalla R, 2001, J COMP NEUROL, V436, P182; Karpus WJ, 1998, J IMMUNOL, V161, P2667; Kawakami N, 2004, J EXP MED, V199, P185, DOI 10.1084/jem.20031064; Kigerl KA, 2006, J COMP NEUROL, V494, P578, DOI 10.1002/cne.20827; Kil K, 1999, J NEUROIMMUNOL, V98, P201, DOI 10.1016/S0165-5728(99)00057-0; Kipnis J, 2002, J NEUROIMMUNOL, V130, P78, DOI 10.1016/S0165-5728(02)00219-9; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; KONNO H, 1990, ACTA NEUROPATHOL, V80, P521, DOI 10.1007/BF00294613; KORBO L, 1990, J NEUROSCI METH, V31, P93, DOI 10.1016/0165-0270(90)90153-7; Lafaille JJ, 1997, J EXP MED, V186, P307, DOI 10.1084/jem.186.2.307; Lake J, 1999, J PATHOL, V187, P259, DOI 10.1002/(SICI)1096-9896(199901)187:2<259::AID-PATH212>3.0.CO;2-H; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; LEE JM, 1955, P SOC EXP BIOL MED, V89, P263; Ling CY, 2006, J NEUROSCI, V26, P731, DOI 10.1523/JNEUROSCI.3502-05.2006; LYMAN WD, 1986, CELL IMMUNOL, V102, P217, DOI 10.1016/0008-8749(86)90340-0; Mariotti R, 2002, EXP NEUROL, V176, P133, DOI 10.1006/exnr.2002.7908; McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003; McPhail LT, 2004, EXP NEUROL, V188, P331, DOI 10.1016/j.expneurol.2004.04.010; Mendel I, 1996, EUR J IMMUNOL, V26, P2470, DOI 10.1002/eji.1830261030; Meyer AL, 1996, J IMMUNOL, V157, P4230; MIZRACHI Y, 1983, PARAPLEGIA, V21, P287, DOI 10.1038/sc.1983.48; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; MOLLESTON MC, 1993, ADV NEUROL, V59, P337; Neumann H, 2002, TRENDS NEUROSCI, V25, P313, DOI 10.1016/S0166-2236(02)02154-9; Nguyen KB, 1997, J NEUROPATH EXP NEUR, V56, P58, DOI 10.1097/00005072-199701000-00006; Nitsch R, 2004, J NEUROSCI, V24, P2458, DOI 10.1523/JNEUROSCI.4703-03.2004; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; Pewe L, 2002, J IMMUNOL, V168, P1547, DOI 10.4049/jimmunol.168.4.1547; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; PHILLIPS MJ, 1995, NEUROPATH APPL NEURO, V21, P189, DOI 10.1111/j.1365-2990.1995.tb01050.x; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Popovich PG, 1998, NEUROSCIENTIST, V4, P71, DOI 10.1177/107385849800400203; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; Raivich G, 1998, J NEUROSCI, V18, P5804; Raivich G, 2002, EXP NEUROL, V178, P186, DOI 10.1006/exnr.2002.8024; Ryan M, 1998, INT IMMUNOL, V10, P651, DOI 10.1093/intimm/10.5.651; SCHMIED M, 1993, AM J PATHOL, V143, P446; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; Serpe CJ, 2000, J NEUROSCI RES, V62, P273, DOI 10.1002/1097-4547(20001015)62:2<273::AID-JNR11>3.3.CO;2-3; Serpe CJ, 2003, BRAIN BEHAV IMMUN, V17, P393, DOI 10.1016/S0889-1591(03)00028-X; SGROI D, 1986, J IMMUNOL, V137, P1850; Sroga JM, 2003, J COMP NEUROL, V462, P223, DOI 10.1002/cne.10736; STREIT WJ, 1989, J NEUROIMMUNOL, V21, P117, DOI 10.1016/0165-5728(89)90167-7; VOSKUHL RR, 1993, AUTOIMMUNITY, V15, P137, DOI 10.3109/08916939309043888; Wolf SA, 2002, J NEUROIMMUNOL, V133, P72, DOI 10.1016/S0165-5728(02)00367-3	88	25	25	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	APR	2007	25	7					2053	2064		10.1111/j.1460-9568.2007.05458.x			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	155UP	WOS:000245604200015	17439492				2022-02-06	
J	Davis, DP; Kene, M; Vilke, GM; Sise, MJ; Kennedy, F; Eastman, AB; Velky, T; Hoyt, DB				Davis, Daniel P.; Kene, Mamata; Vilke, Gary M.; Sise, Michael J.; Kennedy, Frank; Eastman, A. Brent; Velky, Thomas; Hoyt, David B.			Head-injured patients who "talk and die": The San Diego perspective	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	64th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-24, 2005	Atlanta, GA	Amer Assoc Surg Trauma			COMA SCALE SCORE; ENDOTRACHEAL INTUBATION; TRAUMA PATIENTS; FIELD; MODERATE; HEPARIN; DEATHS; SYSTEM	Background: Head-injured patients who "talk and die" are potentially salvageable, making their early identification important. This study uses a large, comprehensive database to explore risk factors for head-injured patients who deteriorate after their initial presentation. Methods: Patients with a head Abbreviated Injury Score (AIS) score of 3+ and a preadmission verbal Glasgow Coma Scale (GCS) score of 3+ were identified from our county trauma registry during a 16-year period. Survivors and nonsurvivors were compared with regard to demographics, initial clinical presentation, and various risk factors. Logistic regression was used to explore the impact of multiple factors on outcome, including the significance of a change in GCS score from field to arrival. In addition, patients were stratified by injury severity and hospital day of death to further define the relationship between outcome and multiple clinical variables. Results: A total of 7,443 patients were identified with head AIS 3+ and verbal GCS score 3+. Overall mortality was 6.1%. About one-third of deaths occurred on the first hospital day, with more than one-third occurring after hospital day 5. Logistic regression revealed an association between mortality and older age, more violent mechanisms of injury (fall, gunshot wound, pedestrian versus automobile), greater injury severity (higher head AIS and Injury Severity Score), lower GCS score, and hypotension. In addition, mortality was associated with a decrease in GCS score from field to arrival, the use of anticoagulants, and a diagnosis of pulmonary embolus. Two important groups of "talk-and-die" patients were identified. Early deaths occurred in younger patients with more critical extracranial injuries. Anticoagulant use was also an independent risk factor in these early deaths. Later deaths occurred in older patients with less significant extracranial injuries. Pulmonary embolus also appeared to be an important contributor to late mortality. Conclusions: More severe injuries and use of anticoagulants are independent risk factors for early death in potentially salvageable traumatic brain injury patients, whereas older age and pulmonary embolus are associated with later deaths.	Univ Calif San Diego, Mercy Air Med Serv, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Mercy Air Med Serv, Dept Surg, San Diego, CA 92103 USA; Scripps Mercy Hosp, Dept Surg, San Diego, CA USA; Sharp Mem Hosp & Rehabil Ctr, Dept Surg, San Diego, CA 90034 USA; Scripps La Jolla Hosp, Dept Surg, San Diego, CA USA; Palomar Hosp, Dept Surg, San Diego, CA USA		Davis, DP (corresponding author), Univ Calif San Diego, Mercy Air Med Serv, Dept Emergency Med, 200 W Arbor Dr 8676, San Diego, CA 92103 USA.	davismd@cox.net					Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2005, J TRAUMA, V58, P933, DOI 10.1097/01.TA.0000162731.53812.58; Demetriades D, 2005, J AM COLL SURGEONS, V201, P343, DOI 10.1016/j.jamcollsurg.2005.05.003; Dunn LT, 2003, J TRAUMA, V54, P497, DOI 10.1097/01.TA.0000030627.71453.CD; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Ginzburg E, 2003, BRIT J SURG, V90, P1338, DOI 10.1002/bjs.4309; Hadfield RJ, 2001, RESUSCITATION, V49, P279, DOI 10.1016/S0300-9572(00)00364-6; Kibayashi K, 2000, Leg Med (Tokyo), V2, P175, DOI 10.1016/S1344-6223(00)80021-8; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; Meislin H, 1997, J TRAUMA, V43, P433, DOI 10.1097/00005373-199709000-00008; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; RAMADAN A, 1986, NEUROCHIRURGIE, V32, P423; REILLY PL, 1975, LANCET, V2, P375; Reilly PL, 2001, J CLIN NEUROSCI, V8, P398, DOI 10.1054/jocn.2001.0916; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; WRIGHT PJ, 1989, ANAESTHESIA, V44, P219, DOI 10.1111/j.1365-2044.1989.tb11227.x	23	25	25	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2007	62	2					277	281		10.1097/TA.0b013e31802ef4a3			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	137ZY	WOS:000244333300001	17297312				2022-02-06	
J	Kamsler, A; Avital, A; Greenberger, V; Segal, M				Kamsler, Ariel; Avital, Avi; Greenberger, Varda; Segal, Menahem			Aged SOD overexpressing mice exhibit enhanced spatial memory while lacking hippocampal neurogenesis	ANTIOXIDANTS & REDOX SIGNALING			English	Article							LONG-TERM POTENTIATION; TRAUMATIC BRAIN-INJURY; RAT DENTATE GYRUS; ADULT-RAT; SUPEROXIDE DISMUTASE; ENVIRONMENTAL ENRICHMENT; SYNAPTIC PLASTICITY; AGING HIPPOCAMPUS; NEURONS; CELLS	The recent finding that hippocampal slices from aged mice overexpressing the gene for superoxide dismutase (SOD) exhibit long-term potentiation (LTP) of reactivity to afferent stimulation that is significantly larger than that produced in aged wild-type (wt) mice has encouraged the exploration of the effects of reactive oxygen species (ROS) on learning in aged mice. In addition, young-adult and aged wt and SOD transgenic mice were used in an attempt to correlate adult neurogenesis with spatial learning. Aged wt and SOD mice exhibited a 90% reduction in doublecortin-labeled new dentate gyrus neurons as compared to young mice, with no significant difference between genotypes. In addition, aged SOD mice exhibited better performance than wt controls in both reference and working memory tasks in a water maze. These findings provide a behavioral measure to demonstrate that excessive production of H2O2 is beneficial in aged mice.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel		Kamsler, A (corresponding author), MIT, Picower Ctr Learning & Memory, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	kamsler@mit.edu	Avital, Avraham/I-2163-2016; SEGAL, MENAHEM/K-1577-2012	Avital, Avraham/0000-0002-0691-153X; Kamlser, Ariel/0000-0002-6199-8906			Akman C, 2004, EPILEPSY BEHAV, V5, P446, DOI 10.1016/j.yebeh.2004.03.008; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Ambrogini P, 2000, NEUROSCI LETT, V286, P21, DOI 10.1016/S0304-3940(00)01074-0; BARNES CA, 1988, NEUROBIOL AGING, V9, P563, DOI 10.1016/S0197-4580(88)80114-3; Bondolfi L, 2004, NEUROBIOL AGING, V25, P333, DOI 10.1016/S0197-4580(03)00083-6; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Bruel-Jungerman E, 2005, EUR J NEUROSCI, V21, P513, DOI 10.1111/j.1460-9568.2005.03875.x; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Cui X, 2006, J NEUROSCI RES, V84, P647, DOI 10.1002/jnr.20899; Deisseroth K, 2004, NEURON, V42, P535, DOI 10.1016/S0896-6273(04)00266-1; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Driscoll I, 2006, NEUROSCIENCE, V139, P1173, DOI 10.1016/j.neuroscience.2006.01.040; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gahtan E, 1998, EUR J NEUROSCI, V10, P538, DOI 10.1046/j.1460-9568.1998.00058.x; Gross CG, 2000, NAT REV NEUROSCI, V1, P67, DOI 10.1038/35036235; Hu DY, 2006, J NEUROSCI, V26, P3933, DOI 10.1523/JNEUROSCI.5566-05.2006; Jaako-Movits K, 2005, EUR J NEUROSCI, V22, P2871, DOI 10.1111/j.1460-9568.2005.04481.x; Kamsler A, 2003, J NEUROSCI, V23, P10359; Kawai T, 2004, J CEREBR BLOOD F MET, V24, P548, DOI 10.1097/00004647-200405000-00009; Kempermann G, 2002, EUR J NEUROSCI, V16, P129, DOI 10.1046/j.1460-9568.2002.02042.x; Kim H, 2006, BRAIN DEV-JPN, V28, P109, DOI 10.1016/j.braindev.2005.05.008; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; Lee HH, 2006, BRAIN DEV-JPN, V28, P147, DOI 10.1016/j.braindev.2005.05.007; Levkovitz Y, 1999, J NEUROSCI, V19, P10977, DOI 10.1523/JNEUROSCI.19-24-10977.1999; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu L, 2003, EXP NEUROL, V183, P600, DOI 10.1016/S0014-4886(03)00248-6; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; McDonald HY, 2005, NEUROSCI LETT, V385, P70, DOI 10.1016/j.neulet.2005.05.022; Merrill DA, 2003, J COMP NEUROL, V459, P201, DOI 10.1002/cne.10616; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Pourie G, 2006, NEUROSCIENCE, V140, P1369, DOI 10.1016/j.neuroscience.2006.02.083; Raber J, 2004, RADIAT RES, V162, P39, DOI 10.1667/RR3206; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Scerri C, 2006, PSYCHOPHARMACOLOGY, V184, P540, DOI 10.1007/s00213-005-0086-4; Serrano F, 2004, AGEING RES REV, V3, P431, DOI 10.1016/j.arr.2004.05.002; Shimazu K, 2006, LEARN MEMORY, V13, P307, DOI 10.1101/lm.76006; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Snyder JS, 2005, NEUROSCIENCE, V130, P843, DOI 10.1016/j.neuroscience.2004.10.009; Ueda S, 2005, NEUROSCIENCE, V135, P395, DOI 10.1016/j.neuroscience.2005.06.065; Van Kampen JM, 2004, EUR J NEUROSCI, V19, P2377, DOI 10.1111/j.0953-816X.2004.03342.x; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Wang R, 2004, NEUROSCIENCE, V126, P305, DOI 10.1016/j.neuroscience.2004.03.048; Wati H, 2006, NEUROSCI LETT, V399, P171, DOI 10.1016/j.neulet.2006.01.056; Winocur G, 2006, HIPPOCAMPUS, V16, P296, DOI 10.1002/hipo.20163; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	50	25	25	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1523-0864	1557-7716		ANTIOXID REDOX SIGN	Antioxid. Redox Signal.	FEB	2007	9	2					181	189		10.1089/ars.2007.9.181			9	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism	126GJ	WOS:000243500400003	17115939				2022-02-06	
J	Francisco, GE; Latorre, JM; Ivanhoe, CB				Francisco, Gerard E.; Latorre, Juan M.; Ivanhoe, Cindy B.			Intrathecal baclofen therapy for spastic hypertonia in chronic traumatic brain injury	BRAIN INJURY			English	Article						spastic hypertonia; baclofen; brain injuries		Objective: To describe the outcome of intrathecal baclofen ( ITB) therapy in treating spastic hypertonia and its sequelae in individuals with chronic (> 14 years) traumatic brain injuries ( TBI). Design: Case series. Setting: Free- standing rehabilitation hospital. Participants: Three adult males who received a TBI 14, 17.1, and 19.9 years prior to receiving ITB pump. Outcome measures: Modified Ashworth Scale ( MAS); Functional Independence Measure ( FIM)- mobility scores; and informal functional evaluation. Intervention: ITB therapy. Results: MAS scores of the five most hypertonic muscles in the affected lower limbs improved following of ITB therapy. FIM- mobility scores did not change from baseline, but certain functional domains improved, such as gait, transfers, and sitting; decreased assistance for activities of daily living ( ADL) and nursing care; decreased painful spasms; and increased community mobility and participation in recreational activities. Conclusion: ITB therapy is still beneficial even > 14 years after TBI onset. In spite of the absence of improvement in FIM scores, functional enhancements in areas not measured by traditional scales can still be achieved. This suggests that in this patient population consideration for ITB therapy should not be based solely on conventional assessment scales.	TIRR Hosp, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Houston, TX USA		Francisco, GE (corresponding author), TIRR Hosp, 1333 Moursund St, Houston, TX 77030 USA.	gerard.e.francisco@uth.tmc.edu					Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Meythaler JA, 2001, ARCH PHYS MED REHAB, V82, P1155, DOI 10.1053/apmr.2001.25141; Meythaler JM, 2004, J HEAD TRAUMA REHAB, V19, P101, DOI 10.1097/00001199-200403000-00003; Rawicki B, 1999, J NEUROSURG, V91, P733, DOI 10.3171/jns.1999.91.5.0733; Rifici C, 1994, Funct Neurol, V9, P29; Yablon SA, 1996, NEUROLOGY, V47, P939, DOI 10.1212/WNL.47.4.939	7	25	26	0	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	3					335	338		10.1080/02699050701311018			4	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	168IW	WOS:000246518400009	17453762				2022-02-06	
J	Karunanayaka, PR; Holland, SK; Yuan, W; Altaye, M; Jones, BV; Michaud, LJ; Walz, NC; Wade, SL				Karunanayaka, Prasanna R.; Holland, Scott K.; Yuan, Weihong; Altaye, Mekibib; Jones, Blaise V.; Michaud, Linda J.; Walz, Nicolay Chertkoff; Wade, Shari L.			Neural substrate differences in language networks and associated language-related behavioral impairments in children with TBI: A preliminary fMRI investigation	NEUROREHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; POSITRON EMISSION TOMOGRAPHY; VERBAL WORKING-MEMORY; LONG-TERM OUTCOMES; CLOSED-HEAD-INJURY; EVENT-RELATED FMRI; FUNCTIONAL MRI; SENTENCE COMPREHENSION; TEMPORAL-LOBE; PREFRONTAL CORTEX	The present study examined whether functional MRI (fMRI) can identify changes in the neural substrates of language in young children following traumatic brain injury (TBI). Eight children with TBI (F/M = 3/5, age (Mean +/- SD) = 7.98 +/- 1 years, range = 6-9 years) and a comparison group of nine children with orthopedic injuries (OI) (F/M = 4/5, age (Mean +/- SD) = 7.4 +/- 1 years, range = 6-9 years) participated in an fMRI study of covert verb generation (VG). Results revealed significantly different BOLD signal activation in perisylvian language areas between the groups, after accounting for potential confounders such as verbal fluency and executive function. We also found significant associations between the BOLD signal activation and performance on language-specific neuropsychological tests (NEPSY verbal fluency score, Verbal IQ) and Glasgow Coma Scale (GCS) score. This study suggests that children with TBI have significantly different brain activation patterns in language circuitry compared to children with orthopedic injuries. Although we found clear differences in brain activation between the two groups, conventional MR images showed no evidence of structural abnormalities in five of eight children with TBI. Our study demonstrates the feasibility and potential utility of fMRI as a means of quantifying changes associated with language deficits in future pediatric TBI studies.	[Karunanayaka, Prasanna R.; Holland, Scott K.; Yuan, Weihong; Altaye, Mekibib; Jones, Blaise V.] Cincinnati Childrens Hosp, Med Ctr, Imaging Res Ctr, Dept Radiol,Pediat Neuroimaging Res Consortium, Cincinnati, OH 45229 USA; [Michaud, Linda J.; Walz, Nicolay Chertkoff; Wade, Shari L.] UC Coll Med, Cincinnati, OH USA; [Michaud, Linda J.; Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Walz, Nicolay Chertkoff] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Behav Med & Psychol, Cincinnati, OH 45229 USA; [Holland, Scott K.; Yuan, Weihong; Jones, Blaise V.] Univ Cincinnati, Coll Med, Cincinnati, OH USA		Karunanayaka, PR (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Imaging Res Ctr, Dept Radiol,Pediat Neuroimaging Res Consortium, 3333 Burnet Ave ML 5031, Cincinnati, OH 45229 USA.	Prasana.Karunanayaka@cchmc.org	Altaye, Mekibib/N-5274-2015	Holland, Scott/0000-0003-3719-0875	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R43HD044279, R01HD038578] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR008084, M01-RR 08084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD038578, R43 HD044279, R01-HD044279, R01 HD042729, R01-HD38578] Funding Source: Medline		Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Awh E, 1996, PSYCHOL SCI, V7, P25, DOI 10.1111/j.1467-9280.1996.tb00662.x; Behrmann M, 2004, CURR OPIN NEUROBIOL, V14, P212, DOI 10.1016/j.conb.2004.03.012; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Booth JR, 2000, DEV NEUROPSYCHOL, V18, P139, DOI 10.1207/S15326942DN1802_1; Braver TS, 2001, NEUROIMAGE, V14, P48, DOI 10.1006/nimg.2001.0791; Brizzolara D, 2002, NEUROPSYCHOLOGIA, V40, P620, DOI 10.1016/S0028-3932(01)00158-0; Bullmore ET, 2000, NEUROIMAGE, V11, P289, DOI 10.1006/nimg.2000.0544; Byars AW, 2002, J CHILD NEUROL, V17, P885, DOI 10.1177/08830738020170122201; CABEZA R, 2001, HDB FUNCTIONAL NEURO; Cabeza Roberto, 2000, Current Opinion in Neurology, V13, P415, DOI 10.1097/00019052-200008000-00008; Calhoun VD, 2001, HUM BRAIN MAPP, V14, P140, DOI 10.1002/hbm.1048; Caplan D, 2000, HUM BRAIN MAPP, V9, P65; Catani M, 2005, ANN NEUROL, V57, P8, DOI 10.1002/ana.20319; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chein JM, 2003, J NEUROLINGUIST, V16, P315, DOI 10.1016/S0911-6044(03)00021-6; Chiu CYP, 2005, NEUROREPORT, V16, P883, DOI 10.1097/00001756-200506210-00002; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Detre JA, 1998, NEUROLOGY, V50, P926, DOI 10.1212/WNL.50.4.926; Elliot C. D., 1990, INTRO TECHNICAL HDB; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Friederici AD, 2003, CEREB CORTEX, V13, P170, DOI 10.1093/cercor/13.2.170; Friston KJ, 2002, NEUROIMAGE, V16, P513, DOI 10.1006/nimg.2001.1044; Friston KJ, 2003, NEUROIMAGE, V19, P1273, DOI 10.1016/S1053-8119(03)00202-7; Gabrieli JDE, 1997, SCIENCE, V276, P264, DOI 10.1126/science.276.5310.264; Gaillard WD, 2000, NEUROLOGY, V54, P180, DOI 10.1212/WNL.54.1.180; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Hallett T L, 1997, Pediatr Rehabil, V1, P219; HART J, 1990, ANN NEUROL, V27, P226, DOI 10.1002/ana.410270303; Hashimoto R, 2002, NEURON, V35, P589, DOI 10.1016/S0896-6273(02)00788-2; Holland SK, 2001, NEUROIMAGE, V14, P837, DOI 10.1006/nimg.2001.0875; Horwitz B, 1998, P NATL ACAD SCI USA, V95, P8939, DOI 10.1073/pnas.95.15.8939; Inui T, 1998, NEUROREPORT, V9, P3325, DOI 10.1097/00001756-199810050-00032; Jacola LM, 2006, NEUROPEDIATRICS, V37, P46, DOI 10.1055/s-2006-923934; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jung SH, 2005, ARCH PHYS MED REHAB, V86, P2218, DOI 10.1016/j.apmr.2005.04.015; Just MA, 1996, SCIENCE, V274, P114, DOI 10.1126/science.274.5284.114; Karunanayaka PR, 2007, NEUROIMAGE, V34, P349, DOI 10.1016/j.neuroimage.2006.08.028; Kemp, 1998, NEPSY DEV NEUROPSYCH; KINGSTONE RCA, 2001, HDB FUNCTIONAL NEURO; Korkman M, 2001, DEV NEUROPSYCHOL, V20, P331, DOI 10.1207/S15326942DN2001_2; Kuperberg GR, 2000, J COGNITIVE NEUROSCI, V12, P321, DOI 10.1162/089892900562138; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Liepert J, 2005, STROKE, V36, P2648, DOI 10.1161/01.STR.0000189629.10603.02; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McKeown MJ, 1998, HUM BRAIN MAPP, V6, P160, DOI 10.1002/(SICI)1097-0193(1998)6:3<160::AID-HBM5>3.0.CO;2-1; Mechelli A, 2003, J COGNITIVE NEUROSCI, V15, P925, DOI 10.1162/089892903770007317; Morse S, 1999, Pediatr Rehabil, V3, P139; Muller RA, 1998, ARCH NEUROL-CHICAGO, V55, P1113, DOI 10.1001/archneur.55.8.1113; Muzik O, 2000, NEUROIMAGE, V12, P538, DOI 10.1006/nimg.2000.0651; Nakai T, 1999, NEUROSCI LETT, V263, P33, DOI 10.1016/S0304-3940(99)00103-2; Newman AJ, 2001, J PSYCHOLINGUIST RES, V30, P339, DOI 10.1023/A:1010499119393; Ni W, 2000, J COGNITIVE NEUROSCI, V12, P120, DOI 10.1162/08989290051137648; Papanicolaou AC, 2001, J CHILD NEUROL, V16, P241; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Penny WD, 2004, NEUROIMAGE, V22, P1157, DOI 10.1016/j.neuroimage.2004.03.026; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; PONER M, 1991, J COGNITIVE NEUROSCI, V3, P303; Price CJ, 2000, J ANAT, V197, P335, DOI 10.1046/j.1469-7580.2000.19730335.x; Pugh KR, 1996, NEUROIMAGE, V4, P159, DOI 10.1006/nimg.1996.0067; RAUSCH R, 1993, ARCH NEUROL-CHICAGO, V50, P812, DOI 10.1001/archneur.1993.00540080023008; Ravizza SM, 2004, NEUROIMAGE, V22, P562, DOI 10.1016/j.neuroimage.2004.01.039; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; Sakai KL, 2002, NEURON, V35, P1177, DOI 10.1016/S0896-6273(02)00873-5; Schapiro MB, 2004, NEUROREPORT, V15, P2575, DOI 10.1097/00001756-200412030-00003; Schmithorst VJ, 2006, NEUROIMAGE, V31, P1366, DOI 10.1016/j.neuroimage.2006.01.010; Schmithorst VJ, 2006, NEUROIMAGE, V29, P254, DOI 10.1016/j.neuroimage.2005.07.020; Schmithorst VJ, 2004, MAGN RESON MED, V51, P399, DOI 10.1002/mrm.10706; Schmithorst VJ, 2001, IEEE T MED IMAGING, V20, P535, DOI 10.1109/42.929619; Scott SK, 2000, BRAIN, V123, P2400, DOI 10.1093/brain/123.12.2400; Shaywitz BA, 2007, ANN NEUROL, V61, P363, DOI 10.1002/ana.21093; Solodkin A, 2004, CEREB CORTEX, V14, P1246, DOI 10.1093/cercor/bhh086; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Staudt M, 2001, NEUROLOGY, V57, P122, DOI 10.1212/WNL.57.1.122; Stromswold K, 1996, BRAIN LANG, V52, P452, DOI 10.1006/brln.1996.0024; Szaflarski JP, 2006, ANN NEUROL, V59, P796, DOI 10.1002/ana.20817; Szaflarski JP, 2006, HUM BRAIN MAPP, V27, P202, DOI 10.1002/hbm.20177; Szaflarski JP, 2004, EPILEPSY BEHAV, V5, P244, DOI 10.1016/j.yebeh.2004.01.002; Talairach J., 1988, COPLANAR STEREOTAXIC, P122; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; Wilke M, 2002, HUM BRAIN MAPP, V17, P48, DOI 10.1002/hbm.10053; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404; Yuan WH, 2006, EPILEPSIA, V47, P593, DOI 10.1111/j.1528-1167.2006.00474.x	94	25	25	0	19	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	5					355	369					15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	258HW	WOS:000252860000003	18162699				2022-02-06	
J	Roche, NL; Moody, A; Szabo, K; Fleming, JM; Shum, DHK				Roche, Nadine L.; Moody, Anna; Szabo, Krisztina; Fleming, Jennifer M.; Shum, David H. K.			Prospective memory in adults with traumatic brain injury: An analysis of perceived reasons for remembering and forgetting	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SELF-AWARENESS; REHABILITATION; DEFICITS	Reasons for prospective remembering and forgetting after traumatic brain injury (TBI) were investigated using Ellis' (1996) five phases of prospective memory as a framework. Participants were 38 individuals with severe TBI and 34 controls. Participants self-rated their perceived reasons for prospective remembering and forgetting using section C of the Comprehensive Assessment of Prospective Memory (CAPM). Significant others also rated participants using the same scale. Analyses were conducted to examine the effect of group membership (TBI or control) on reported reasons for prospective remembering and forgetting. Findings highlighted the TBI group's difficulties with encoding, performance interval, and execution phases of prospective remembering.	Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld 4072, Australia; Griffith Univ, Sch Psychol & Appl Cognit Neurosci Res, Nathan, Qld 4111, Australia		Fleming, JM (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld 4072, Australia.	j.fleming@uq.edu.au	Shum, David/A-3914-2008; Fleming, Jennifer M/B-4436-2011	Shum, David/0000-0002-4810-9262; 			Andrewes DG, 1998, NEUROPSYCHOL REHABIL, V8, P377, DOI 10.1080/713755582; Baddeley A. D., 2002, HDB MEMORY DISORDERS, P3; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; Cohen G, 1993, MEMORY CURRENT ISSUE; Cohen G., 1996, MEMORY REAL WORLD; DALLABARBA G, 1993, HDB NEUROPSYCHOLOGY, V8, P239; Dobbs AR, 1996, PROSPECTIVE MEMORY T, P199; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORTUNE N, 1999, DEFINITION INCIDENCE; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; GOLDSTEIN LH, 1992, BRIT J CLIN PSYCHOL, V31, P75, DOI 10.1111/j.2044-8260.1992.tb00969.x; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; HERRMANN DJ, 1982, PSYCHOL BULL, V92, P434, DOI 10.1037/0033-2909.92.2.434; Hutchinson J, 1997, TOP LANG DISORD, V18, P45, DOI 10.1097/00011363-199711000-00006; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Mateer C. A., 1999, COGNITIVE NEUROREHAB, P314; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; McDaniel MA., 1996, PROSPECTIVE MEMORY T, P1; Neulinger K., 2002, BRAIN IMPAIR, V3, P1, DOI [10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; O'Connell ME, 2003, NEUROREHABILITATION, V18, P9; PARENTE R, 1991, COGNITIVE REHABILITA, P147; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; THOMPSON SBN, 1996, BRIT J OCCUPATIONAL, V59, P418; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; WAUGH N, 1999, THESIS GRIFFITH U QU; Wilson BA, 2003, STUD NEUROPSYCHOL DE, P71; WINOGRAD E, 1987, PRACTICAL ASPECTS ME, V1, P348; [No title captured]	43	25	26	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2007	17	3					314	334		10.1080/09602010600831004			21	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	165IQ	WOS:000246298500003	17474059				2022-02-06	
J	Winqvist, S; Jokelainen, J; Luukinen, H; Hillbom, M				Winqvist, Satu; Jokelainen, Jari; Luukinen, Heikki; Hillbom, Matti			Parental alcohol misuse is a powerful predictor for the risk of traumatic brain injury in childhood	BRAIN INJURY			English	Article						alcohol; drinking habits; family history of alcohol misuse; traumatic brain injury; adolescents	SELF-REPORTED DRINKING; HEAD-INJURY; CHILDREN; RELIABILITY; ABUSE; STUDENTS; ONSET	Background: Although the positive relationship between parental alcohol use and children's injuries is well established, it is not known whether parental alcohol misuse is a risk factor for traumatic brain injuries ( TBIs) of their children and whether subjects with childhood TBI have hazardous drinking habits in adolescence. Methods: The authors conducted a longitudinal cohort study at Oulu University Hospital. The cohort consisted of 12 058 subjects born in 1966, of which 207 had sustained TBI before the age of 14 years. Data on parental alcohol problems were obtained from the Finnish Hospital Discharge Register and the adolescents' drinking habits were analysed based on a postal inquiry at the age of 14 years. Results: Parental alcohol misuse (RR 1.99, CI 1.19 - 3.33) and male gender (RR 1.53, CI 1.12 - 2.08) significantly predicted the risk of childhood TBI. Drinking to intoxication at the age of 14 was significantly associated with parental alcohol misuse (RR 1.62, CI 1.34 - 1.96), belonging to a one-parent family (RR 1.80, CI 1.61 - 2.02) and mild TBI (RR 1.67, CI 1.20 - 2.33). Conclusions: It was observed that parental alcohol misuse is a major risk factor for TBI in children and drinking to intoxication is a common drinking pattern of adolescents who have sustained TBI in childhood.	Oulu Univ Hosp, Dept Neurol, FIN-90029 Oys, Finland; Univ Oulu, Dept Neurol, Oulu, Finland; Univ Oulu, Dept Publ Hlth Sci & Gen Practice, Oulu, Finland; Univ Hosp Oulu, Unit Gen Practice, Oulu, Finland		Winqvist, S (corresponding author), Oulu Univ Hosp, Dept Neurol, Box 25, FIN-90029 Oys, Finland.	satu.winqvist@oulu.fi		Jokelainen, Jari/0000-0003-4629-0560			Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BIJUR PE, 1992, JAMA-J AM MED ASSOC, V17, P3166; Bjarnason T, 2003, J STUD ALCOHOL, V64, P200, DOI 10.15288/jsa.2003.64.200; Chalder M, 2006, ALCOHOL ALCOHOLISM, V41, P107, DOI 10.1093/alcalc/agh215; Conners NA, 2004, AM J DRUG ALCOHOL AB, V30, P85, DOI [10.1081/ADA-120029867, 10.1081/ADA-120026258]; Crandall M, 2006, J SURG RES, V133, P7, DOI 10.1016/j.jss.2006.02.027; Dantzer C, 2006, J AM COLL HEALTH, V55, P83, DOI 10.3200/JACH.55.2.83-90; DIKMEN SS, 1995, ANN EMERG MED, V26, P221; Droomers M, 2003, J EPIDEMIOL COMMUN H, V57, P704, DOI 10.1136/jech.57.9.704; Dunn C, 2003, J TRAUMA, V54, P707, DOI 10.1097/01.TA.0000030625.63338.B2; Gruenewald PJ, 2006, J STUD ALCOHOL, V67, P738, DOI 10.15288/jsa.2006.67.738; Hartman CA, 2006, J STUD ALCOHOL, V67, P657, DOI 10.15288/jsa.2006.67.657; HINGSON RW, 2000, JAMA-J AM MED ASSOC, V27, P1527; Johnson TP, 2001, ADDICTION, V96, P1187, DOI 10.1046/j.1360-0443.2001.968118711.x; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Kuendig H, 2006, ALCOHOL ALCOHOLISM, V41, P464, DOI 10.1093/alcalc/agl018; Kuntsche S, 2006, ALCOHOL ALCOHOLISM, V41, pI37, DOI 10.1093/alcalc/agl074; Lintonen T, 2004, ALCOHOL ALCOHOLISM, V39, P362, DOI 10.1093/alcalc/agh071; Lintonen T, 2000, HEALTH EDUC RES, V15, P261, DOI 10.1093/her/15.3.261; Makela P, 2003, J STUD ALCOHOL, V64, P589; Max JE, 1997, BRAIN INJURY, V11, P699; Rantakallio P, 1997, INT J EPIDEMIOL, V26, P837, DOI 10.1093/ije/26.4.837; Ross LT, 2001, SUBST USE MISUSE, V36, P609, DOI 10.1081/JA-100103563; Rubin DM, 2003, PEDIATRICS, V111, P1382, DOI 10.1542/peds.111.6.1382; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Sosin DM, 1996, BRAIN INJURY, V10, P47; Swan MC, 2004, ALCOHOL RES, V9, P59; Tait RJ, 2005, DRUG ALCOHOL DEPEN, V79, P365, DOI 10.1016/j.drugalcdep.2005.03.016; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Van Zundert RMP, 2006, J FAM PSYCHOL, V20, P456, DOI 10.1037/0893-3200.20.3.456; Villalba-Cota J, 2004, ANN TROP PAEDIATR, V24, P53, DOI 10.1179/027249304225013259; Widom CS, 2001, ALCOHOL RES HEALTH, V25, P52; WINQVIST S, 2006, J ADOLESCENT HEALTH, V39, pE1; Winter T, 2002, ALCOHOL ALCOHOLISM, V37, P330, DOI 10.1093/alcalc/37.4.330	35	25	25	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	10					1079	1085		10.1080/02699050701553221			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600011	17852100				2022-02-06	
J	Harrison, G; Whitley, E; Rasmussen, F; Lewis, G; Dalman, C; Gunnell, D				Harrison, Glynn; Whitley, Elise; Rasmussen, Finn; Lewis, Glyn; Dalman, Christina; Gunnell, David			Risk of schizophrenia and other non-affective psychosis among individuals exposed to head injury: Case control study	SCHIZOPHRENIA RESEARCH			English	Article						schizophrenia; head injury; psychosis; case control	TRAUMATIC BRAIN-INJURY; ASSOCIATION; DISORDER; EPILEPSY	Studies of the risk of schizophrenia and related non-affective psychoses among individuals exposed to head injury have reported conflicting findings. The diagnostic specificity of reported associations remains unclear and the effects of sex, genetic vulnerability and timing of exposures are also uncertain. The authors used a comprehensive range of data derived from the linkage of several Swedish registers to investigate associations of head injury with schizophrenia and other non-affective psychoses. We carried out a nested case control study drawn from a cohort of 785,051 men and women born between 1973 and 1980. After head injury exposure, there was a small increase in the risk (OR 1.37 (CI 1.14-1.66)) of non-schizophrenic, non-affective psychoses but not schizophrenic disorder (OR 1.10 CI 0.82 to 1.47). There was no critical period effect for exposures in early childhood, the association with non-affective psychosis being observed only in those exposed to head injury after age 10. There was no evidence that associations differed in males and females or in those with, and those without, a family history of psychosis. We conclude that it is unlikely that head injury causes schizophrenia. There is a small but significant risk of non-schizophrenic psychotic disorders but this is not associated with early age of injury or family history of psychosis. Further research is needed to clarify the potential roles of social and biological intermediary factors. (c) 2006 Elsevier B.V All rights reserved.	Karolinska Inst, Dept Publ Hlth Sci, SE-17176 Stockholm, Sweden; Univ Bristol, Acad Unit Psychiat, Bristol BS6 6JL, Avon, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Stockholm Ctr Publ Hlth, S-11891 Stockholm, Sweden		Rasmussen, F (corresponding author), Karolinska Inst, Dept Publ Hlth Sci, SE-17176 Stockholm, Sweden.	finn.rasmussen@ki.se	Lewis, Glyn/E-9944-2012	Lewis, Glyn/0000-0001-5205-8245; Whitley, Elise/0000-0002-0297-9078; Dalman, Christina/0000-0002-3579-2357; Rasmussen, Finn/0000-0001-7915-7809			AbdelMalik P, 2003, ARCH GEN PSYCHIAT, V60, P231, DOI 10.1001/archpsyc.60.3.231; ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; David AS, 2005, J NEUROL NEUROSUR PS, V76, pI53, DOI 10.1136/jnnp.2004.060475; DAVISON D, 1969, BRIT J PSYCHIAT, V4, P113; Deb S, 1999, AM J PSYCHIAT, V156, P374; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Garety PA, 2001, PSYCHOL MED, V31, P189, DOI 10.1017/S0033291701003312; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Gunnell D, 2003, AM J EPIDEMIOL, V158, P291, DOI 10.1093/aje/kwg118; Harrison G, 2003, PSYCHOL MED, V33, P723, DOI 10.1017/S0033291703007591; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Nielsen AS, 2002, SCHIZOPHR RES, V55, P93, DOI 10.1016/S0920-9964(01)00205-5; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Sachdev P, 1998, AM J PSYCHIAT, V155, P325, DOI 10.1176/ajp.155.3.325; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; StataCorp, 2003, STAT STAT SOFTW REL; Tienari P, 2004, BRIT J PSYCHIAT, V184, P216, DOI 10.1192/bjp.184.3.216; WARDASZKO H, 1966, J NEUROL NEUROSUR PS, V16, P101	20	25	26	0	13	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0920-9964	1573-2509		SCHIZOPHR RES	Schizophr. Res.	DEC	2006	88	1-3					119	126		10.1016/j.schres.2006.07.001			8	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	115FJ	WOS:000242719900015	16935470				2022-02-06	
J	Huang, SJ; Hong, WC; Han, YY; Chen, YS; Wen, CS; Tsai, YS; Tu, YK				Huang, Sheng-Jean; Hong, Wei-Chen; Han, Yin-Yi; Chen, Yuan-Sen; Wen, Chung-Shi; Tsai, Yi-Shin; Tu, Yong-Kwang			Clinical outcome of severe head injury using three different ICP and CPP protocol-driven therapies	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						severe head injury; protocol-driven therapy; intracranial hypertension; cerebral perfusion pressure	TRAUMATIC BRAIN-INJURY; CEREBRAL PERFUSION-PRESSURE; RESPIRATORY-DISTRESS-SYNDROME; INTRACRANIAL-PRESSURE; TARGETED THERAPY; PILOT TRIAL; MANAGEMENT; ISCHEMIA	In the past 5 years, cerebral perfusion pressure (CPP) management has become the standard in the treatment of severe bead injuries. Guidelines published in 2000 suggest that CPP should be at least 70 mmHg; however, there is still debate about the optimal CPP. The purpose of the present study was to evaluate the effectiveness of these three widely used therapies: (i) intracranial pressure (ICP) targeted; (ii) CPP-targeted with CPP > 70 mmHg; and (iii) modified CPP-targeted (mCPP) therapy with CPP > 60 mmHg. The clinical procedures, complications and outcomes of patients in the different groups were compared. Data, including patient age, sex, initial Glasgow Coma Scale, ICP, CPP, fluid status, amount of mannitol and vasopressor used, daily fluid intake and output, complications and clinical results, were collected from 213 patients with severe head injuries over a 12-year period. Patients were categorized into three groups (ICP, CPP, mCPP) according to the treatment protocol used. Retrospective data collection was performed by chart review. The mortality rate was 28.6%, 14.3% and 13.5% in the ICP, CPP, and mCPP groups, respectively. Highest intake/output ratio, amount of vasopressor used and pulmonary complications were seen in the CPP patients. The mCPP patients showed the best clinical outcome and lowest complication rate. Although CPP-targeted therapy is the most recommended therapeutic protocol, our data show that patients treated with modified CPP-target therapy with CPP > 60 mmHg have better clinical outcomes and fewer complications. (c) 2006 Elsevier Ltd. All rights reserved.	Natl Taiwan Univ, Div Neurosurg, Coll Med & Hosp, Taipei 10764, Taiwan		Tu, YK (corresponding author), Natl Taiwan Univ, Div Neurosurg, Coll Med & Hosp, 7 Chung Shan S Rd, Taipei 10764, Taiwan.	yktu@ha.mc.ntu.edu.tw		HAN, YIN-YI/0000-0001-8831-7835; Tu, Yong-kwang/0000-0003-2113-1176			BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P559; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P493; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Klein D G, 1999, Crit Care Nurs Clin North Am, V11, P209; Macmillan CSA, 2001, J NEUROL NEUROSUR PS, V70, P101, DOI 10.1136/jnnp.70.1.101; MAPSTONE TB, 1996, CONT NEUROSURG, V18, P1; Marion DW, 1997, CONT NEUROSURG, V19, P1; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1990, ADV BRAIN RESUSCITAT, P315; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1987, NEUROSURGERY, V21, P147, DOI 10.1227/00006123-198708000-00003; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SAHUQUILLO J, 1993, ACTA NEUROCHIR, V122, P204, DOI 10.1007/BF01405530; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P479, DOI DOI 10.1089/NEU.2000.17.479	32	25	26	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	OCT	2006	13	8					818	822		10.1016/j.jocn.2005.11.034			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	099LR	WOS:000241596700003	16908157				2022-02-06	
J	Sherer, M; Stouter, J; Hart, T; Nakase-Richardson, R; Olivier, J; Manning, E; Yablon, SA				Sherer, Mark; Stouter, Josephine; Hart, Tessa; Nakase-Richardson, Risa; Olivier, Jake; Manning, Edward; Yablon, Stuart A.			Computed tomography findings and early cognitive outcome after traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; computed tomography; neuropsychological outcome	HEAD-INJURY; LESIONS; MILD; SEQUELAE; 1-YEAR	Primary objective: To examine the relationship between CT abnormalities and early neuropsychological outcome following traumatic brain injury (TBI) using quantitative CT analyses, data reduction methods for neuropsychological results and specific hypotheses based on literature review. Research design: Observational, prospective cohort study using acute (emergency) CT data and neuropsychological test data from 89 participants with TBI who were hospitalized for rehabilitation. Methods and procedures: Principal components analysis with varimax rotation was used to reduce data from a standard battery of eight neuropsychological tests administered after clearance of post-traumatic amnesia (1 month post-TBI on average). Bivariate correlations were used to examine relationships of three factors (verbal memory, cognitive processing speed and verbal working memory) to quantitative volumetric analysis of CT scan abnormalities (size, number and location). Specific hypotheses as to CT predictors of poor performance on each factor were tested using multivariable linear regression that included injury severity and demographic variables. Main results: Eighty-nine per cent of participants had some pathology on initial CT. Age, education and time to follow commands (TFC), an index of overall injury severity, were significantly associated with the neuropsychological factors. However, none of the specific hypotheses about CT scan variables and cognitive outcome were strongly supported by the data. There was a trend for any CT abnormality to predict slower speed of processing and for higher number of brain lesions to predict worse memory performance. Conclusions: Despite the precision added by quantitative CT analysis, CT findings did not improve on demographic factors and TFC in predicting early cognitive outcome of TBI. Imaging methods that are more sensitive to white matter integrity may be needed to develop pathophysiologic predictors of TBI outcome.	Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; Moss Rehabil Res Inst, Philadelphia, PA USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA 19107 USA		Sherer, M (corresponding author), Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	marks@mmrcrehab.org	Olivier, Jake/D-2034-2012	Olivier, Jake/0000-0002-3144-4507			Alex BV, 1996, NEUROTRAUMA, P119; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Bruce DA, 2000, CHILD NERV SYST, V16, P755, DOI 10.1007/PL00013720; Cihangiroglu M, 2002, NEUROL RES, V24, P7, DOI 10.1179/016164102101199440; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; Fiser SM, 1998, AM SURGEON, V64, P1088; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GOLDMANRAKIC PS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P72; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Hamster K., 1983, MULTILINGUAL APHASIA; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Liu Wei-guo, 2004, Chin J Traumatol, V7, P175; MILNER B, 1970, BIOL MEM, V23, P31; Reitan R, 1985, HALSTEAD REITAN NEUR; Rey A., 1964, EXAMEN CLIN PSYCHOL; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith A., 1982, SYMBOL DIGIT MODALIT; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Taylor E., 1959, PSYCHOL APPRAISAL CH; Tranel D., 2002, HDB MEMORY DISORDERS; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VILKKI J, 1992, J CLIN EXP NEUROPSYC, V14, P518, DOI 10.1080/01688639208402841; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1981, WAIS R MANUAL; WILBERGER JE, 2000, HEAD INJURY, P27; Young RJ, 2002, NEUROIMAG CLIN N AM, V12, P189, DOI 10.1016/S1052-5149(02)00003-5	34	25	26	1	2	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2006	20	10					997	1005		10.1080/02699050600677055			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	093FA	WOS:000241152100001	17046799				2022-02-06	
J	Wright, WL; Geocadin, RG				Wright, Wendy L.; Geocadin, Romergryko G.			Postresuscitative intensive care: Neuroprotective strategies after cardiac arrest	SEMINARS IN NEUROLOGY			English	Article						postresuscitation; cardiopulmonary-cerebral resuscitation (CPCR); cardiac arrest	CEREBRAL-BLOOD-FLOW; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CLINICAL-TRIAL; CRITICALLY-ILL PATIENTS; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CARDIOPULMONARY-RESUSCITATION; THROMBOLYTIC THERAPY; COMATOSE SURVIVORS; NEUROLOGICAL RECOVERY	Cardiac arrest is a common disease in the United States, and many patients will die as a result of the neurological damage suffered during the anoxic period, or will live in a neurologically debilitated state. When cardiopulmonary-cerebral resuscitation results in the return of spontaneous circulation, intensive care is required to optimize neurological recovery. Such "brain-oriented" therapies include routine care, such as positioning and maintenance of volume status; optimization of cerebral perfusion, with the use of vasopressors if needed; management of increased intracranial pressure with agents such as hypertonic saline; assuring adequate oxygenation and avoiding hypercapnia; aggressive fever control; intensive glucose control, with the use of an insulin drip if needed; and management of seizures if they occur. To date, no neuroprotectant medications have been shown to improve neurological outcome. Induced moderate therapeutic hypothermia is utilized as a neuroprotective maneuver. Future treatment options and-advanced monitoring techniques are also discussed. Further study to optimize neuroprotective strategies when treating patients who survive cardiac arrest is needed.	Emory Univ Hosp, Dept Neurol, Atlanta, GA 30322 USA; Emory Univ Hosp, Dept Neurosurg, Atlanta, GA 30322 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD USA		Wright, WL (corresponding author), Emory Univ Hosp, Dept Neurol, 1365B Clifton Rd,NE,Suite 2200, Atlanta, GA 30322 USA.				NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01-HL-EB 71568] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44-NS-38016] Funding Source: Medline		ARNOLDUS EPJ, 1995, ANN NEUROL, V38, P697, DOI 10.1002/ana.410380427; Ausina A, 1998, ACT NEUR S, V71, P1; Bell DD, 2005, CAN J ANAESTH, V52, P309, DOI 10.1007/BF03016069; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bhardwaj A, 2004, HDB NEUROCRITICAL CA; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; Bottiger B W, 2001, Curr Opin Crit Care, V7, P176; BOTTIGER BW, 1995, CIRCULATION, V92, P2572, DOI 10.1161/01.CIR.92.9.2572; Bottiger BW, 2001, LANCET, V357, P1583, DOI 10.1016/S0140-6736(00)04726-7; Buunk G, 2000, NETH J MED, V57, P106, DOI 10.1016/S0300-2977(00)00059-0; CELESIA GG, 1988, ARCH NEUROL-CHICAGO, V45, P781, DOI 10.1001/archneur.1988.00520310099023; COHAN SL, 1989, STROKE, V20, P761, DOI 10.1161/01.STR.20.6.761; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Eisenburger P, 2001, Curr Opin Crit Care, V7, P184, DOI 10.1097/00075198-200106000-00007; Goh WC, 2002, BRIT J ANAESTH, V88, P719, DOI 10.1093/bja/88.5.719; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; Grubb NR, 2001, HEART, V85, P6, DOI 10.1136/heart.85.1.6; Gueugniaud PY, 1998, NEW ENGL J MED, V339, P1595, DOI 10.1056/NEJM199811263392204; HEKMATPANAH J, 1973, NEUROLOGY, V23, P174, DOI 10.1212/WNL.23.2.174; Herlitz J, 2000, EUR HEART J, V21, P1251, DOI 10.1053/euhj.2000.2150; JASTREMSKI M, 1989, JAMA-J AM MED ASSOC, V262, P3427, DOI 10.1001/jama.262.24.3427; Jorgensen EO, 1999, RESUSCITATION, V41, P145, DOI 10.1016/S0300-9572(99)00039-8; KARIMAN K, 1983, J APPL PHYSIOL, V55, P1057, DOI 10.1152/jappl.1983.55.4.1057; KELSEY SF, 1991, CONTROL CLIN TRIALS, V12, P525; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Koehler R C, 1985, Crit Care Clin, V1, P205; KRAUSE GS, 1986, AM HEART J, V111, P768, DOI 10.1016/0002-8703(86)90114-6; KRUMHOLZ A, 1988, NEUROLOGY, V38, P401, DOI 10.1212/WNL.38.3.401; Krumholz A, 2002, NEUROLOGY, V58, P515, DOI 10.1212/WNL.58.4.515; LEE SK, 1989, RESUSCITATION, V17, P105; Lewis KS, 2004, ANN PHARMACOTHER, V38, P1243, DOI 10.1345/aph.1D211; Lindner KH, 1997, LANCET, V349, P535, DOI 10.1016/S0140-6736(97)80087-6; LONGSTRETH WT, 1983, ANN INTERN MED, V98, P588, DOI 10.7326/0003-4819-98-5-588; Longstreth WT, 2002, NEUROLOGY, V59, P506, DOI 10.1212/WNL.59.4.506; LONGSTRETH WT, 1993, NEUROLOGY, V43, P2534, DOI 10.1212/WNL.43.12.2534; LONGSTRETH WT, 2001, NEUROLOGY GEN MED, P151; Mullner M, 1996, STROKE, V27, P59, DOI 10.1161/01.STR.27.1.59; O'Neil BJ, 1996, CARDIAC ARREST SCI P, P84; Parsons MW, 2002, ANN NEUROL, V52, P20, DOI 10.1002/ana.10241; Pusswald G, 2000, RESUSCITATION, V47, P241, DOI 10.1016/S0300-9572(00)00240-9; Ropper Allan H., 1993, P11; SAFAR P, 1993, ANN EMERG MED, V22, P324, DOI 10.1016/S0196-0644(05)80463-9; Safar P, 1996, CRIT CARE MED, V24, pS3; SAKABE T, 1987, INTENS CARE MED, V13, P256, DOI 10.1007/BF00265114; SCHOLZ KH, 1992, AM J CARDIOL, V69, P724, DOI 10.1016/0002-9149(92)90494-J; Schreiber W, 2002, RESUSCITATION, V52, P63, DOI 10.1016/S0300-9572(01)00432-4; SIEBER FE, 1992, CRIT CARE MED, V20, P104, DOI 10.1097/00003246-199201000-00022; STERZ F, 1992, RESUSCITATION, V24, P27, DOI 10.1016/0300-9572(92)90171-8; STERZ F, 1990, STROKE, V21, P1178, DOI 10.1161/01.STR.21.8.1178; Stiell IG, 2001, LANCET, V358, P105, DOI 10.1016/S0140-6736(01)05328-4; Sundgreen C, 2001, STROKE, V32, P128, DOI 10.1161/01.STR.32.1.128; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VANCAMPEN LCMC, 1994, AM J CARDIOL, V73, P953, DOI 10.1016/0002-9149(94)90137-6; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303; Werhahn KJ, 1997, MOVEMENT DISORD, V12, P216, DOI 10.1002/mds.870120212; WIJDICKS EFM, 1994, ANN NEUROL, V35, P239, DOI 10.1002/ana.410350219; Williams LS, 2002, NEUROLOGY, V59, P67, DOI 10.1212/WNL.59.1.67; WOO E, 1988, STROKE, V19, P185, DOI 10.1161/01.STR.19.2.185; YOUNG GB, 1990, NEUROLOGY, V40, P1843, DOI 10.1212/WNL.40.12.1843; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007; 2000, CIRCULATION S1, V102, P166	65	25	25	0	2	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235			SEMIN NEUROL	Semin. Neurol.	SEP	2006	26	4					396	402		10.1055/s-2006-948320			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	075OX	WOS:000239896200006	16969740				2022-02-06	
J	Sheng, WW; Li, CT; Zhang, WP; Yuan, YM; Hu, H; Fang, SH; Zhang, L; Wei, EQ				Sheng, Wen-Wen; Li, Cheng-Tan; Zhang, Wei-Ping; Yuan, Yu-Mei; Hu, Hua; Fang, San-Hua; Zhang, Lei; Wei, Er-Qing			Distinct roles of CysLT(1) and CysLT(2) receptors in oxygen glucose deprivation-induced PC12 cell death	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						cysteinyl leukotriene receptor; leukotriene; oxygen glucose deprivation; rat pheochromocytoma cells (PC12 cells)	CYSTEINYL LEUKOTRIENE RECEPTOR-1; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; MOLECULAR-CLONING; 5-LIPOXYGENASE; ANTAGONIST; ACTIVATION; EXPRESSION; PROTECTS; ACID	Cysteinyl leukotrienes are involved in ischemic brain injury, and their receptors (CysLT(1) and CysLT(2)) have been cloned. To clarify which subtype mediates the ischemic neuronal injury, we performed permanent transfection to increase CysLT(1) and CysLT(2) receptor expressions in PC12 cells. Oxygen glucose deprivation (OGD)-induced cell death was detected by Hoechst 33258 and propidium iodide fluorescent staining as well as by flow cytometry. OGD induced late phase apoptosis mainly and necrosis minimally. Over-expression of CysLT(1) receptor decreased and over-expression of CysLT2 receptor increased OGD-induced cell death. An agonist LTD4 (10(-7) M) also induced apoptosis, especially in CysLT(2) receptor over-expressing cells. A selective CysLT(1) receptor antagonist montelukast did not affect OGD- induced apoptosis; while non-selective CysLT receptor antagonist Bay u9773 inhibited OGD-induced apoptosis, especially in CysLT(2) receptor over- expressing cells. Thus, CysLT(1) and CysLT(2) receptors play distinct roles in OGD-induced PC12 cell death; CysLT, attenuates while CysLT(2) facilitates the cell death. (c) 2006 Elsevier Inc. All rights reserved.	Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China; Zhejiang Univ, Sch Med, Dept Neurosurg, Affiliated Hosp 2, Hangzhou 310009, Peoples R China		Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China.	weieq2001@yahoo.com	Zhang, Lei/F-2603-2011				Arai K, 2001, BRAIN RES, V904, P167, DOI 10.1016/S0006-8993(01)02491-X; Beller TC, 2004, J BIOL CHEM, V279, P46129, DOI 10.1074/jbc.M407057200; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Cao GD, 2004, J NEUROSCI, V24, P6189, DOI 10.1523/JNEUROSCI.1426-04.2004; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Ge QF, 2006, J NEUROCHEM, V97, P992, DOI 10.1111/j.1471-4159.2006.03828.x; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Helgadottir A, 2005, AM J HUM GENET, V76, P505, DOI 10.1086/428066; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; Hui YQ, 2001, J BIOL CHEM, V276, P47489, DOI 10.1074/jbc.M107556200; Jiang XH, 2005, SURF REV LETT, V12, P59, DOI 10.1142/S0218625X05006792; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Kumasawa F, 2005, EUR J PHARMACOL, V517, P11, DOI 10.1016/j.ejphar.2005.05.001; Liu Y, 2003, J CELL MOL MED, V7, P49, DOI 10.1111/j.1582-4934.2003.tb00202.x; Martin V, 2001, BIOCHEM PHARMACOL, V62, P1193, DOI 10.1016/S0006-2952(01)00774-2; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249, DOI 10.1152/ajpheart.1995.268.3.H1249; Perng DW, 2006, AM J RESP CELL MOL, V34, P101, DOI 10.1165/rcmb.2005-0068OC; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Shishido Y, 2001, PHARMACOL BIOCHEM BE, V69, P469, DOI 10.1016/S0091-3057(01)00572-X; Song Y, 2004, NEUROREPORT, V15, P2181, DOI 10.1097/00001756-200410050-00007; Tabakman R, 2004, J NEUROSCI RES, V75, P499, DOI 10.1002/jnr.20008; Tomimoto H, 2002, ACTA NEUROPATHOL, V104, P601, DOI 10.1007/s00401-002-0590-0; Yu GL, 2005, BRAIN RES, V1053, P116, DOI 10.1016/j.brainres.2005.06.046; Yu GL, 2005, PHARMACOLOGY, V73, P31, DOI 10.1159/000081072; ZENG LH, 2001, ACTA PHARMACOL SINIC, V36, P148; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088; Zhang WP, 2002, ACTA PHARMACOL SIN, V23, P871	31	25	33	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	JUL 21	2006	346	1					19	25		10.1016/j.bbrc.2006.05.023			7	Biochemistry & Molecular Biology; Biophysics	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Biophysics	056TX	WOS:000238549100004	16756959				2022-02-06	
J	Lew, HL; Poole, JH; Castaneda, A; Salerno, RM; Gray, M				Lew, Henry L.; Poole, John H.; Castaneda, Annabel; Salerno, Rose Marie; Gray, Max			Prognostic value of evoked and event-related potentials in moderate to severe brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; cognition; EEG; event-related potentials; evoked potentials; neurology; posttraumatic coma; prognosis; rehabilitation; specificity and sensitivity	PREDICTING OUTCOMES; HEAD-INJURY; EEG	Clinicians are often expected to project patients' clinical outcomes to allow effective planning for future care. This can be a challenge in patients with moderate to severe traumatic brain injury (TBI) who are often unable to participate reliably in clinical evaluations. With recent advances in computer instrumentation and signal processing, evoked potentials and event-related potentials show increasing promise as powerful tools for prognosticating the trajectory of recovery and ultimate outcome from the TBI. Short- and middle-latency evoked potentials can now effectively predict coma outcomes in patients with acute TBI. Long-latency event-related potential components hold promise in predicting recovery of higher order cognitive abilities.	Stanford Univ, VA Palo Alto Hlth Care Syst, Comprehens Rehabil Ctr, PM&R Serv, Palo Alto, CA 94304 USA; Def & Vet Brain Injury Ctr, Palo Alto, CA USA		Lew, HL (corresponding author), Stanford Univ, VA Palo Alto Hlth Care Syst, Comprehens Rehabil Ctr, PM&R Serv, MS-B117,3801 Miranda Ave, Palo Alto, CA 94304 USA.	henrylew@.stanford.edu					Bressler S.L., 2002, HDB BRAIN THEORY NEU, P412; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Clark C. R., 1992, Brain Injury, V6, P509, DOI 10.3109/02699059209008148; Connolly JF, 2000, INT J PSYCHOPHYSIOL, V38, P55, DOI 10.1016/S0167-8760(00)00130-6; DUNCAN CC, 2005, INT J PSYCHOPHYSIOL; Giaquinto S, 2004, FUNCT NEUROL, V19, P219; Kane NM, 1996, INTENS CARE MED, V22, P39, DOI 10.1007/BF01728329; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Lew HL, 2005, AM J PHYS MED REHAB, V84, P393, DOI 10.1097/01.phm.0000163703.91647.a7; Lew HL, 2005, J REHABIL RES DEV, V42, P29, DOI 10.1682/JRRD.2004.05.0056; Lew HL, 2005, BRAIN INJURY, V19, P177, DOI 10.1080/02699050400017171; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Lew HL, 1999, AM J PHYS MED REHAB, V78, P367, DOI 10.1097/00002060-199907000-00014; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI [10.1097/00002060-200301000-00009, 10.1097/01.PHM.0000043771.90606.81]; LEW HL, 2005, NEUROREHABILITATION; LEW HL, IN PRESS J HEAD TRAU; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; Marchand Y, 2002, CLIN NEUROPHYSIOL, V113, P1715, DOI 10.1016/S1388-2457(02)00224-9; Mazzini Letizia, 2004, Phys Med Rehabil Clin N Am, V15, P163, DOI 10.1016/S1047-9651(03)00101-3; MULLIE A, 1988, LANCET, V1, P137; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ozbudak-Demir S, 1999, ARCH PHYS MED REHAB, V80, P252, DOI 10.1016/S0003-9993(99)90134-X; RAPPAPORT M, 1990, CLIN ELECTROENCEPHAL, V21, P188, DOI 10.1177/155005949002100406; Reuter B., 1989, TOPOGRAPHIC BRAIN MA, P192; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Stam CJ, 2003, AM J ELECTRONEUROD T, V43, P211, DOI 10.1080/1086508X.2003.11079444; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; Wang JT, 2004, CAN J NEUROL SCI, V31, P438, DOI 10.1017/S0317167100003619; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006	34	25	26	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2006	21	4					350	360		10.1097/00001199-200607000-00006			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	064SJ	WOS:000239109100006	16915010				2022-02-06	
J	Son, BC; Lee, SW; Choi, ES; Sung, JH; Hong, JT				Son, Byung Chul; Lee, Sang Won; Choi, Eun Seok; Sung, Jae Hoon; Hong, Jae Taek			Motor cortex stimulation for central pain following a traumatic brain injury	PAIN			English	Article						central pain; traumatic brain injury; motor cortex stimulation	POSTSTROKE PAIN; ELECTRICAL-STIMULATION; THALAMIC PAIN; PATIENT; SENSATION; LESION; AREA; PET	Central pain can occur in any lesions along the central nervous system affecting the spinothalamocortical pathway. Although diverse etiologies have been reported to cause central pain, there are few reports on the occurrence and surgical treatment of central pain following a traumatic brain injury (TBI). This paper describes the occurrence of central pain following a severe TBI, in which the diagnosis of central pain was typically delayed due to the patient's decreased ability to express his pain for severe aphasia as a neurological sequela. The severe burning pain, deep pressure-like pain, and deep mechanical allodynia, which presented over the contralateral side to the TBI, were successfully relieved with motor cortex stimulation (MCS). The analgesic effect of stimulation was found to be long lasting and was still present at the 12-month follow up. As shown in this patient, the occurrence of central pain syndrome should be considered by physicians caring for TBI patients, and a comprehensive, systematic study will be needed to determine the prevalence of central pain after a TBI. (c) 2006 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	Catholic Univ Korea, St Vincents Hosp, Dept Neurosurg, Suwon, South Korea; Catholic Univ Korea, St Marys Hosp, Dept Rehabil, Taejon, South Korea		Son, BC (corresponding author), Catholic Univ Korea, St Vincents Hosp, Dept Neurosurg, Suwon, South Korea.	sbc@catholic.ac.kr		Hong, Jae Taek/0000-0001-6453-0439			ARMAND J, 1982, PROG BRAIN RES, V57, P329, DOI 10.1016/S0079-6123(08)64136-9; BERTHIER M, 1988, ANN NEUROL, V24, P41, DOI 10.1002/ana.410240109; BIEMOND A, 1956, ARCH NEURO PSYCHIATR, V75, P231, DOI 10.1001/archneurpsyc.1956.02330210011001; BOIVIE J, 1992, SYMP PAIN R, P363; BOIVIE J, 1991, SYMP PAIN R, P65; BONICA JJ, 1991, SYMP PAIN R, P13; CRAIG AD, 1994, NATURE, V372, P770, DOI 10.1038/372770a0; Craig AD, 1999, J COMP NEUROL, V404, P221; Craig AD, 1996, NATURE, V384, P258, DOI 10.1038/384258a0; Craig AD, 2000, NAT NEUROSCI, V3, P184, DOI 10.1038/72131; DAVIDOFF RA, 1990, NEUROLOGY, V40, P332; Davis KD, 1999, J NEUROPHYSIOL, V81, P1970, DOI 10.1152/jn.1999.81.4.1970; Gabriel, 1993, NEUROBIOLOGY CINGULA, P313; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; Garcia-Larrea L, 1997, STEREOT FUNCT NEUROS, V68, P141, DOI 10.1159/000099915; H Merskey, 1994, CLASSIFICATION CHRON, P43; Helmchen C, 2002, PAIN, V98, P325, DOI 10.1016/S0304-3959(02)00139-2; Katayama Y, 1998, J NEUROSURG, V89, P585, DOI 10.3171/jns.1998.89.4.0585; Mailis A, 2002, PAIN, V98, P331, DOI 10.1016/S0304-3959(02)00156-2; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Mesulam M., 1985, CEREB CORTEX, V4, P179, DOI [10.1007/978-1-4757-9619-3_5, DOI 10.1007/978-1-4757-9619-3_5]; MICHEL D, 1990, REV NEUROL-FRANCE, V146, P405; MYERSON BA, 1993, ACTA NEUROCHIR SUPP, V58, P150; Nguyen JP, 1997, ADV STER F, V12, P54; Nguyen JP, 1999, PAIN, V82, P245, DOI 10.1016/S0304-3959(99)00062-7; PEYRON R, 1995, PAIN, V62, P275, DOI 10.1016/0304-3959(94)00211-V; Ploner M, 1999, PAIN, V81, P211, DOI 10.1016/S0304-3959(99)00012-3; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Saitoh Y, 2000, J NEUROSURG, V92, P150, DOI 10.3171/jns.2000.92.1.0150; Saitoh Y, 2004, J NEUROSURG, V100, P935, DOI 10.3171/jns.2004.100.5.0935; SCHMAHMANN JD, 1992, ARCH NEUROL-CHICAGO, V49, P1032, DOI 10.1001/archneur.1992.00530340048017; Son BC, 2003, J NEUROSURG, V98, P175, DOI 10.3171/jns.2003.98.1.0175; TSUBOKAWA T, 1993, J NEUROSURG, V78, P393, DOI 10.3171/jns.1993.78.3.0393; Tsubokawa T, 1998, TXB STEREOTACTIC FUN, P1547; WISENDANGER M, 1969, ERGEB PHYSL, V61, P72; Yezierski RL., 2002, SURG MANAGEMENT PAIN, P42; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141; [No title captured]	38	25	25	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	JUL	2006	123	1-2					210	216		10.1016/j.pain.2006.02.028			7	Anesthesiology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology	059PX	WOS:000238745800026	16616421				2022-02-06	
J	Carney, ML; Ullrich, P; Esselman, P				Carney, ML; Ullrich, P; Esselman, P			Early unplanned transfers from inpatient rehabilitation	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						rehabilitation; complications; prospective payment system; length of stay	MEDICAL REHABILITATION; STROKE REHABILITATION; RISK-FACTORS; COMPLICATIONS; MORTALITY; LENGTH; INJURY; STAY	Objective: To identify characteristics of patients who transfer off inpatient rehabilitation to a surgical or medical unit before completion of their rehabilitation program. Design: A retrospective 9-yr chart review of patients transferred off the rehabilitation unit at a regional level 1 trauma center due to medical complications. Results: Of 3072 patient admissions, 250 (8%) were transferred to an acute medical or surgical unit, and 55 (22%) of those transfers were within 3 days. Of the 250 patients, 33% had traumatic brain injury, 23% had spinal cord injury, 24% had stroke, 2% had amputations, 18% were in other diagnostic groups, and 23% were > 64 yrs of age. When patients transferred early, only 47% were ultimately discharged to home, compared with approximately 72% of all discharges. The most common reasons for early transfer in these patients were infection (22%) and pulmonary complications (14%). Risk factors for early discharge included age of > 64 yrs, spinal cord injury, or amputation. Conclusion: Patients admitted to the inpatient rehabilitation unit who have spinal cord injuries, amputations, or are > 4 yrs old may have more medical/surgical complications. More detailed study of this patient population may help reduce the number of early transfers off the inpatient rehabilitation unit.	Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98104 USA		Esselman, P (corresponding author), Univ Washington, Harborview Med Ctr, Dept Rehabil Med, 325 9th Ave,Box 359740, Seattle, WA 98104 USA.						Centers for Medicare & Medicaid Services (CMS) HHS, 2004, Fed Regist, V69, P25752; Chen D, 1999, ARCH PHYS MED REHAB, V80, P1397, DOI 10.1016/S0003-9993(99)90250-2; Davenport RJ, 1996, STROKE, V27, P415, DOI 10.1161/01.STR.27.3.415; Deshpande AA, 1997, ARCH PHYS MED REHAB, V78, P350, DOI 10.1016/S0003-9993(97)90224-0; Deutsch A, 2002, AM J PHYS MED REHAB, V81, P133, DOI 10.1097/00002060-200202000-00010; KIM SR, 2005, AM J PHYS MED REHABI, V84, P199; Lai SM, 1998, NEUROEPIDEMIOLOGY, V17, P21, DOI 10.1159/000026150; Lai SM, 1999, NEUROEPIDEMIOLOGY, V18, P210, DOI 10.1159/000026213; Medicare Payment Advisory Commission, 1999, REP C MED PAYM POL; Ottenbacher KJ, 2004, JAMA-J AM MED ASSOC, V292, P1687, DOI 10.1001/jama.292.14.1687; Ottenbacher KJ, 2000, AM J PUBLIC HEALTH, V90, P1920, DOI 10.2105/AJPH.90.12.1920; Roth EJ, 2001, STROKE, V32, P523, DOI 10.1161/01.STR.32.2.523; SIEGLER EL, 1994, ARCH INTERN MED, V154, P2185, DOI 10.1001/archinte.154.19.2185; SONG KM, 2004, SEATTLE TIMES   0730; Stineman MG, 2003, ARCH PHYS MED REHAB, V84, P712, DOI 10.1016/S0003-9993(03)04850-5; YAP KKP, 2002, SINGAPORE MED J, V43, P470	16	25	26	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAY	2006	85	5					453	460		10.1097/01.phm.0000214279.04759.45			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	037QG	WOS:000237161300007	16628154				2022-02-06	
J	Law, AS; Logie, RH; Pearson, DG				Law, AS; Logie, RH; Pearson, DG			The impact of secondary tasks on multitasking in a virtual environment	ACTA PSYCHOLOGICA			English	Article						multitasking; working memory; phonological loop; central executive	TRAUMATIC BRAIN-INJURY; STRATEGY APPLICATION; WORKING-MEMORY; SIMPLIFIED VERSION; RANDOM GENERATION; INNER SPEECH; TOWER; INTERRUPTIONS; BEHAVIOR; DEFICITS	One experiment is described that examined the possible involvement of working memory in the Virtual Errands Test (McGeorge et al. (2001). Using virtual environments in the assessment of executive dysfunction. Presence, 10, 375-383), which requires participants to complete errands within a virtual environment, presented on a computer screen. Time was limited, therefore participants had to swap between tasks (multitask) efficiently to complete the errands. Forty-two undergraduates participated, all attempting the test twice. On one of these occasions they were asked to perform a concurrent task throughout (order of single and dual-task conditions was counterbalanced). The type of secondary task was manipulated between groups. Twenty-one participants were asked to randomly generate months of the year aloud in the dual-task condition, while another 21 were asked to suppress articulation by repeating the word "December". An overall dual-task effect on the Virtual Errands Test was observed, although this was qualified by an interaction with the order of single and dual-task conditions. Analysis of the secondary task data showed a drop in performance (relative to baseline) under dual-task conditions, and that drop was greater for the random generation group than the articulatory suppression group. These data are interpreted as suggesting that the central executive and phonological loop components of working memory are implicated in this test of multitasking. (c) 2005 Elsevier B.V. All rights reserved.	Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; Univ Edinburgh, PPLS, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Aberdeen, Sch Psychol, Aberdeen, Scotland		Law, AS (corresponding author), Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland.	a.s.law@stir.ac.uk	Logie, Robert H/C-6965-2009; Pearson, David G/C-4908-2008	Logie, Robert/0000-0003-4532-9312; Pearson, David/0000-0002-2912-0976; Law, Anna/0000-0002-0926-1309			Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Baddeley A, 2001, J EXP PSYCHOL GEN, V130, P641, DOI 10.1037//0096-3445.130.4.641; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5, DOI 10.1080/713755608; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Barrouillet P, 2004, J EXP PSYCHOL GEN, V133, P83, DOI 10.1037/0096-3445.133.1.83; Burgess PW, 2000, CONTROL OF COGNITIVE PROCESSES: ATTENTION AND PERFORMANCE XVIII, P465; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Chisholm CD, 2000, ACAD EMERG MED, V7, P1239, DOI 10.1111/j.1553-2712.2000.tb00469.x; Crepeau F, 1996, BRAIN COGNITION, V32, P266; Emerson MJ, 2003, J MEM LANG, V48, P148, DOI 10.1016/S0749-596X(02)00511-9; Fortin S, 2003, CORTEX, V39, P273, DOI 10.1016/S0010-9452(08)70109-6; Gilhooly K.J., 1999, THINK REASONING, V5, P339, DOI [10.1080/135467899393977, DOI 10.1080/135467899393977]; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; Goschke T, 2000, CONTROL OF COGNITIVE PROCESSES: ATTENTION AND PERFORMANCE XVIII, P331; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Law AS, 2004, ACTA PSYCHOL, V116, P285, DOI 10.1016/j.actpsy.2004.04.003; LAW AS, 2004, THESIS U ABERDEEN; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Logie RH, 2004, NEUROPSYCHOLOGY, V18, P504, DOI 10.1037/0894-4105.18.3.504; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; Miyake A, 2004, ACTA PSYCHOL, V115, P123, DOI 10.1016/j.actpsy.2003.12.004; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Owen AM, 1997, PROG NEUROBIOL, V53, P431, DOI 10.1016/S0301-0082(97)00042-7; Phillips LH, 2003, EUR J COGN PSYCHOL, V15, P291, DOI 10.1080/09541440244000148; Phillips LH, 2001, Q J EXP PSYCHOL-A, V54, P579, DOI 10.1080/02724980042000237; Phillips LH, 1999, MEMORY, V7, P209, DOI 10.1080/741944066; Rohrer D, 2003, PSYCHON B REV, V10, P96, DOI 10.3758/BF03196472; Rohrer D, 1998, MEM COGNITION, V26, P731, DOI 10.3758/BF03211393; SALWAY AFS, 1991, THESIS U ABERDEEN SC; Seshadri S, 2001, MANAGE SCI, V47, P647, DOI 10.1287/mnsc.47.5.647.10481; Shah, 1999, MODELS WORKING MEMOR, DOI DOI 10.1017/CBO9781139174909.005; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Towse JN, 1997, EUR J COGN PSYCHOL, V9, P381, DOI 10.1080/713752566; Towse JN, 1998, BEHAV RES METH INS C, V30, P583, DOI 10.3758/BF03209475; Ward G, 1997, Q J EXP PSYCHOL-A, V50, P49, DOI 10.1080/027249897392224; Wilson B.A., 1997, METHODOLOGY FRONTAL, P239	39	25	25	0	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0001-6918	1873-6297		ACTA PSYCHOL	Acta Psychol.	MAY	2006	122	1					27	44		10.1016/j.actpsy.2005.09.002			18	Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	032YP	WOS:000236813100003	16307711	Green Submitted			2022-02-06	
J	Starkstein, SE; Jorge, R; Mizrahi, R				Starkstein, Sergio E.; Jorge, Ricardo; Mizrahi, Romina			The prevalence, clinical correlates and treatment of apathy in Alzheimer's disease	EUROPEAN JOURNAL OF PSYCHIATRY			English	Article						dementia; Alzheimer's disease; geriatric; psychiatry; apathy	TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; NEUROPSYCHIATRIC INVENTORY; DEMENTIA; DEPRESSION; TRIAL; METHYLPHENIDATE; IRRITABILITY; AMANTADINE; MOTIVATION	The aim for this article is to review the frequency, clinical correlates and treatment of apathy in Alzheimer's disease. Apathy is currently defined as diminished motivation as expressed in poor goal-oriented behaviours and cognitions. A structured clinical interview and a specific set of diagnostic criteria to diagnose apathy in dementia have been recently validated. There are several valid and reliable scales to measure the severity of apathy in adults with neuropsychiatric disorders. Apathy is present in about 20% of patients with mild dementia and in 60% of those with severe dementia. Among patients with Alzheimer's disease, apathy is significantly associated with older age, the presence of depression, and more severe cognitive and functional deficits, and also predicts a faster cognitive and functional decline. The mechanism of apathy in neuropsychiatric disorders is still unknown, but several studies suggest an important role for frontal lobe and basal ganglia dysfunction. There are no specific randomized controlled trials of psychoactive compounds to treat apathy in neuropsychiatric disorders. Evidence from case reports and small case series suggest the usefulness of psychostimulants to treat apathy in traumatic brain injury, whereas pharmacological trials for behavioural and psychological problems in dementia suggest that anticholinesterases may have some efficacy.	Fremantle Hosp, Fremantle, WA 6959, Australia; Univ Western Australia, Sch Psychiat & Clin Neurosci, Nedlands, WA 6009, Australia; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Psychiat, Iowa City, IA USA; PET Ctr Addict & Mental Hlth, Clarke Div, Toronto, ON, Canada		Starkstein, SE (corresponding author), Fremantle Hosp, Educ Bldg T-7, Fremantle, WA 6959, Australia.	ses@cyllene.uwa.edu.au	Mizrahi, Romina/H-9530-2013	Mizrahi, Romina/0000-0001-6667-7928			Aalten P, 2003, DEMENT GERIATR COGN, V15, P99, DOI 10.1159/000067972; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Boyle JR, 1999, NEW FOREST, V17, P1; BURNS A, 1990, J NERV MENT DIS, V178, P20, DOI 10.1097/00005053-199001000-00004; Cummings Jeffrey L, 2005, Am J Geriatr Pharmacother, V3, P137, DOI 10.1016/S1543-5946(05)80020-0; Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Fahn S., 1987, RECENT DEV PARKINSON, P153; Freo U, 2002, J NEURAL TRANSM, V109, P857, DOI 10.1007/s007020200070; Frisoni GB, 1999, DEMENT GERIATR COGN, V10, P130, DOI 10.1159/000017113; Habib M, 2004, J NEUROPSYCH CLIN N, V16, P509, DOI 10.1176/appi.neuropsych.16.4.509; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Landes AM, 2001, J AM GERIATR SOC, V49, P1700, DOI 10.1046/j.1532-5415.2001.49282.x; Lee HCB, 2003, INT REV PSYCHIATR, V15, P359, DOI 10.1080/09540260310001606746; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; LEVY R, IN PRESS CEREB CORTE; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P708, DOI 10.1176/appi.ajp.157.5.708; Marin RA, 2005, TXB TRAUMATIC BRAIN, P337; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1994, J NERV MENT DIS, V182, P235, DOI 10.1097/00005053-199404000-00008; Marit RS, 2005, J HEAD TRAUMA REHAB, V20, P377, DOI 10.1097/00001199-200507000-00009; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Mirakhur A, 2004, INT J GERIATR PSYCH, V19, P1035, DOI 10.1002/gps.1203; Newburn G, 2005, BRAIN INJURY, V19, P149, DOI 10.1080/02699050410001719989; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Politis AM, 2004, INT J GERIATR PSYCH, V19, P1087, DOI 10.1002/gps.1215; Ready RE, 2004, J NEUROL NEUROSUR PS, V75, P1323, DOI 10.1136/jnnp.2003.032284; Robert PH, 2002, INT J GERIATR PSYCH, V17, P1099, DOI 10.1002/gps.755; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; Starkstein SE, 2005, J NEUROL NEUROSUR PS, V76, P1070, DOI 10.1136/jnnp.2004.052795; Starkstein SE, 2000, INT PSYCHOGERIATR, V12, P135, DOI 10.1017/S1041610200006918; Starkstein SE, 2001, AM J PSYCHIAT, V158, P872, DOI 10.1176/appi.ajp.158.987.872; Starkstein SE, 1995, EUR J NEUROL, V2, P540, DOI 10.1111/j.1468-1331.1995.tb00171.x; STARKSTEIN SE, IN PRESS J NEUROL NE; Strauss ME, 2002, NEUROPSY NEUROPSY BE, V15, P176, DOI 10.1097/01.WNN.0000020010.79870.C3; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 2002, J HEAD TRAUMA REHAB, V17, P284, DOI 10.1097/00001199-200208000-00003; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014	40	25	26	0	8	EUROPEAN JOURNAL OF PSYCHIATRY	ZARAGOZA	FAC MED, DEPT PSYCHIATRY PROF A LOBO, DOMINGO MIRAL S-N, 50009 ZARAGOZA, SPAIN	0213-6163			EUR J PSYCHIAT	Eur. J. Psychiat.	APR-JUN	2006	20	2					96	106					11	Psychiatry	Social Science Citation Index (SSCI)	Psychiatry	070HY	WOS:000239513700005		Green Submitted, gold			2022-02-06	
J	Figg, RE; Stouffer, CW; Vander Kolk, WE; Connors, RH				Figg, RE; Stouffer, CW; Vander Kolk, WE; Connors, RH			Clinical efficacy of serial computed tomographic scanning in pediatric severe traumatic brain injury	PEDIATRIC SURGERY INTERNATIONAL			English	Article						traumatic brain injury; computed tomography; pediatric trauma	CLOSED-HEAD-INJURY; TRANSPORT; CHILDREN; ADOLESCENTS; MORBIDITY	The purpose of this study is to determine whether serial computed tomography (CT) scans of the head lead to operative intervention in pediatric patients with severe traumatic brain injury (TBI). Serial CT scans are those done in addition to the initial CT scan and one follow up CT scan in the first 24-48 h. This study is a retrospective review from January 1990 to December 2003. The hospital course was reviewed for 942 pediatric patients with traumatic brain injuries. Of these, 40 patients were identified who met the following criteria: age less than 18, admission, Glasgow Coma Scale (GCS) <= 8, intra-cranial pressure (ICP) monitoring during hospitalization, no craniotomy at admission, and at least one serial CT scan after the first 48 h. One hundred fifteen serial CT scans were ordered. Eighty-seven were ordered for routine follow up, 24 were ordered for increased ICP, and 4 were ordered for neurologic change. One craniotomy and one burr hole were performed based on serial CT scans ordered for increased ICP. Serial CT scans, beyond the initial and follow-up scans, have a limited role in children with severe TBI. In this series, only serial CT scans ordered for increased ICP (21%) and neurologic deterioration (3%) led to operative interventions. Serial scans ordered for routine follow-up (76%) resulted in no operative interventions.	Med Educ & Res Ctr, MSU Gen Surg Residency, Grand Rapids, MI 49503 USA; Michigan State Univ, Dept Surg, Grand Rapids, MI USA; Spectrum Hlth, Trauma Serv, Grand Rapids, MI 49503 USA; Michigan State Univ, DeVos Childrens Hosp, Dept Pediat Surg, Grand Rapids, MI 49503 USA		Stouffer, CW (corresponding author), Med Educ & Res Ctr, MSU Gen Surg Residency, 221 Michigan NE Suite 200A, Grand Rapids, MI 49503 USA.	Stouff17@yahoo.com					*AM ASS NEUR SURG, 2000, J NEUROTRAUM, V7, P597; American College of Surgeons Committee on Trauma, 1997, ADV TRAUM LIF SUPP D; BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; CHIN LS, 2004, SABISTON TXB SURG, P2152; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER P, 1993, NEUROSURG CLIN N AM, V3, P659; COPE DN, 1988, ARCH PHYS MED REHAB, V69, P483; Evans A, 1995, Am J Crit Care, V4, P106; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; Gruen JP, 1996, SURG CLIN N AM, V76, P905, DOI 10.1016/S0039-6109(05)70487-4; KANTER RK, 1992, PEDIATRICS, V90, P893; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; MAYER T, 1981, JAMA-J AM MED ASSOC, V245, P719; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; SMITH I, 1990, CRIT CARE MED, V18, P278, DOI 10.1097/00003246-199003000-00006; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038	19	25	27	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0179-0358	1437-9813		PEDIATR SURG INT	Pediatr. Surg. Int.	MAR	2006	22	3					215	218		10.1007/s00383-005-1560-0			4	Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Surgery	022CQ	WOS:000236032700002	16328336				2022-02-06	
J	Liu, JT; Tyan, YS; Lee, YK; Wang, JT				Liu, JT; Tyan, YS; Lee, YK; Wang, JT			Emergency management of epidural haematoma through burr hole evacuation and drainage. A preliminary report	ACTA NEUROCHIRURGICA			English	Article						suction under negative pressure; burr hole drainage; epidural haematoma	EXTRADURAL HEMATOMA; COMPUTERIZED-TOMOGRAPHY; COMATOSE PATIENTS; RESOLUTION	Background. Blood clot evacuation through an osteoplastic craniotomy, a procedure requiring neurosurgical expertise and modern medical facilities, is the accepted method for treatment of a pure traumatic epidural haematoma following closed head injury. In certain emergency situations and/or in less sophisticated settings, however, use of this procedure may not be feasible. The present study was undertaken to ascertain whether placement of a burr hole and drainage under negative pressure constituted a rapid, effective and safe approach to manage patients with simple epidural haematomas. Methods. Thirteen patients suffering from a traumatic epidural haematoma were treated from January, 1999 to October, 2002. Twelve patients presented with skull fracture but no fracture was depressed. Placement of flexible tubes through a burr hole, followed by continuous suction under negative pressure, enabled aspiration of the clot and drainage of the cavity. In 8 cases, the procedure was performed under local anaesthesia with 2% Xylocaine (TM) and with intravenous sedation with propofol as needed. The operative procedure was accomplished within 30min, and the drainage tube was left in place for 3-5 days. CT scans were performed daily from days 1 to 5. Results. In 11 of 13 cases, clots were evacuated successfully and patients regained consciousness within 2 hours. Recoveries occurred without significant sequelae. In the remaining 2 cases, the drainage tube was found to be obstructed by a blood clot such that the haematoma was unaffected. A traditional craniotomy was performed within 8-12 hours, and these 2 patients recovered consciousness within the subsequent 6 hours. Conclusion. Burr hole evacuation followed by drainage under negative pressure is a safe and effective method for emergency management of a pure traumatic epidural haematoma. To assure safety patients given this procedure should be monitored by daily CT scans. Decompressive craniotomy should be performed if consciousness does not improve within several hours.	Chung Shan Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan; Chung Shan Med Univ Hosp, Dept Radiol, Taichung, Taiwan; Chung Shan Med Univ Hosp, Dept Nucleomed, Taichung, Taiwan		Liu, JT (corresponding author), Chung Shan Med Univ Hosp, Dept Neurosurg, 110 Chen Kuo N Rd,Sect 1, Taichung, Taiwan.	cshy654@csh.org.tw					BAYKANER K, 1988, SURG NEUROL, V30, P339, DOI 10.1016/0090-3019(88)90195-4; Bejjani GK, 1996, PEDIATR NEUROSURG, V25, P302, DOI 10.1159/000121144; BORZONE M, 1979, SURG NEUROL, V11, P277; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004; Cohen JE, 1996, J TRAUMA, V41, P120, DOI 10.1097/00005373-199607000-00019; CORDOBES F, 1981, J NEUROSURG, V54, P179, DOI 10.3171/jns.1981.54.2.0179; Firsching R, 1997, NEUROL RES, V19, P257, DOI 10.1080/01616412.1997.11740810; GREENBERG J, 1985, NEUROSURGERY, V17, P48, DOI 10.1227/00006123-198507000-00008; Heiskanen O, 1975, Surg Neurol, V4, P23; HOOPER R, 1959, BRIT J SURG, V47, P71, DOI 10.1002/bjs.18004720114; JAMIESON KG, 1968, J NEUROSURG, V29, P13, DOI 10.3171/jns.1968.29.1.0013; JONES NR, 1993, BRIT J NEUROSURG, V7, P465, DOI 10.3109/02688699308995068; KAYE CI, 1985, J CRAN GENET DEV BIO, P259; Malek AM, 1997, PEDIATR NEUROSURG, V26, P160; MARSHALL LF, 1985, NEUROSURGERY, V16, P606; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P363, DOI 10.1007/BF00327488; REIDER-GROSWASSER I, 1991, Brain Injury, V5, P17, DOI 10.3109/02699059108998507; ROBERSON FC, 1979, SURG NEUROL, V12, P161; SEELIG JM, 1984, NEUROSURGERY, V15, P617, DOI 10.1227/00006123-198411000-00001; WEAVER D, 1981, J NEUROSURG, V54, P248, DOI 10.3171/jns.1981.54.2.0248; Wester K, 1999, NEUROSURGERY, V44, P495, DOI 10.1097/00006123-199903000-00034	22	25	30	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2006	148	3					313	317		10.1007/s00701-005-0723-z			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	018BL	WOS:000235737700017	16437186				2022-02-06	
J	Bramwell, KJ; Haizlip, J; Pribble, C; VanDerHeyden, TC; Witte, M				Bramwell, KJ; Haizlip, J; Pribble, C; VanDerHeyden, TC; Witte, M			The effect of etomidate on intracranial pressure and systemic blood pressure in pediatric patients with severe traumatic brain injury	PEDIATRIC EMERGENCY CARE			English	Article						etomidate; induction; sedation; intracranial hypertension; intubation	RAPID-SEQUENCE INTUBATION; HEAD-INJURY; ANESTHESIA; INDUCTION	Objective: To evaluate the effects of single-dose etomidate in pediatric patients with intracranial hypertension after severe traumatic brain injury. Methods: Patients admitted to the pediatric intensive care unit with severe traumatic brain injury were enrolled with the informed consent of their guardians. The experimental intervention was a single dose of etomidate 0.3 mg/kg intravenously. This dosage was administered only when enrolled patients had acute elevations of intracranial pressure (ICP) to over 20 mm Hg for over 5 minutes. ICP and mean arterial pressure (MAP) were monitored continuously. ICP and MAP values for 6 consecutive 5-minute intervals after etomidate administration were averaged for all patients and compared with baseline. Results: Eight patients were enrolled. Mean ICP after etomidate administration was significantly lower than baseline ICP for each 5-minute interval (P < 0.05). The mean MAP for all patients increased from baseline during the first 5-minute interval, but this change was not statistically significant. No patient's MAP decreased below baseline at any time point. Conclusions: In pediatric patients with severe traumatic brain injury, single-dose etomidate administration resulted in statistically significant reductions in ICP and improvement in cerebral perfusion pressure without significantly altering MAP.	St Lukes Reg Med Ctr, Boise, ID USA; Univ Utah, Div Pediat Crit Care, Salt Lake City, UT USA; Univ Utah, Div Pediat Crit Care & Pediat Anesthesiol, Dept Pediat, Salt Lake City, UT USA; Cottage Hlth Syst, Santa Barbara, CA USA		Bramwell, KJ (corresponding author), 250 Bobwhite Court 340, Boise, ID 83706 USA.	kbramwell@emidaho.com					Absalom A, 1999, ANAESTHESIA, V54, P861; BINGHAM RM, 1985, BRIT J ANAESTH, V7, P843; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DEARDEN NM, 1985, BRIT J ANAESTH, V57, P361, DOI 10.1093/bja/57.4.361; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; DONMEZ A, 1988, J CARDIOTHOR VASC AN, V12, P182; FRAGEN RJ, 1984, ANESTHESIOLOGY, V61, P652, DOI 10.1097/00000542-198412000-00004; Guldner G, 2003, ACAD EMERG MED, V10, P134, DOI 10.1111/j.1553-2712.2003.tb00030.x; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; MCDOWELL RH, 1997, J CLIN ANESTH, V7, P273; MODICA PA, 1992, CAN J ANAESTH, V39, P236, DOI 10.1007/BF03008783; MOSS E, 1979, BRIT J ANAESTH, V51, P347, DOI 10.1093/bja/51.4.347; NEWBY DM, 1983, LANCET, V321, P1381; Plewa MC, 1997, AM J EMERG MED, V15, P98, DOI 10.1016/S0735-6757(97)90066-8; RENOU AM, 1978, BRIT J ANAESTH, V50, P1047, DOI 10.1093/bja/50.10.1047; SEBEL PS, 1983, LANCET, V2, P62; Skinner HJ, 1998, ANAESTHESIA, V53, P702, DOI 10.1046/j.1365-2044.1998.396-az0506.x; Smith DC, 2000, J EMERG MED, V18, P13, DOI 10.1016/S0736-4679(99)00154-7; Sokolove PE, 2000, PEDIATR EMERG CARE, V16, P18, DOI 10.1097/00006565-200002000-00005; Tobias J D, 2000, Pediatr Crit Care Med, V1, P100, DOI 10.1097/00130478-200010000-00002; WATT I, 1984, ANAESTHESIA, V39, P973, DOI 10.1111/j.1365-2044.1984.tb08885.x	21	25	27	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	FEB	2006	22	2					90	93		10.1097/01.pec.0000199563.64264.3a			4	Emergency Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine; Pediatrics	014AH	WOS:000235450600002	16481923				2022-02-06	
J	Kaviani, A; Ouriel, K; Kashyap, VS				Kaviani, A; Ouriel, K; Kashyap, VS			Infected carotid pseudoaneurysm and carotid-cutaneous fistula as a late complication of carotid artery stenting	JOURNAL OF VASCULAR SURGERY			English	Article							NECK IRRADIATION; REPAIR; STENOSIS; THERAPY; INJURY; HEAD	Carotid stenosis after neck irradiation is a well-described entity. A 78-year-old mail presented with left eye amaurosis fugax 11 years after radical neck dissection and neck irradiation for mucoepidermoid carcinoma. The patient underwent carotid artery stenting for a high-grade stenosis of the left internal carotid artery. Twenty months after the procedure, a pulsatile neck mass developed with intermittent arterial bleeding. After control of the bleeding, lie underwent resection of the left carotid bifurcation, including the indwelling stent and reconstruction with a saphenous vein interposition graft. A pectoralis myocutaneous flap was used for wound closure. To this case, localized infection of the stented carotid artery led to mycotic degeneration, pseudoaneurysm formation, and erosion to the skill surface. As carotid artery stenting becomes more widely used, previously unreported late complications associated with this procedure are likely to become apparent, and continued close follow-up is warranted.	Cleveland Clin Fdn, Dept Vasc Surg, Cleveland, OH 44195 USA		Kashyap, VS (corresponding author), Cleveland Clin Fdn, Dept Vasc Surg, S40,9500 Euclid Ave, Cleveland, OH 44195 USA.	kashyav@ccf.org		Kashyap, Vikram/0000-0003-1780-979X			Abayomi OK, 2004, ORAL ONCOL, V40, P872, DOI 10.1016/j.oraloncology.2003.12.005; Akiyama Y, 2005, J TRAUMA, V58, P624, DOI 10.1097/01.TA.0000096662.79685.EA; Baril DT, 2004, J VASC SURG, V40, P1024, DOI 10.1016/j.jvs.2004.08.019; Carmody BJ, 1999, J VASC SURG, V30, P1045, DOI 10.1016/S0741-5214(99)70042-X; Cohen James, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P110, DOI 10.1097/00020840-200404000-00010; Ecker Robert D, 2005, Neurosurg Focus, V18, pe8; Houdart E, 2001, STROKE, V32, P118, DOI 10.1161/01.STR.32.1.118; Kashyap VS, 1999, J VASC SURG, V29, P90, DOI 10.1016/S0741-5214(99)70351-4; McCready RA, 2004, J VASC SURG, V40, P1020, DOI 10.1016/j.jvs.2004.07.034; McNeil JD, 2002, J VASC SURG, V36, P187, DOI 10.1067/mva.2002.125020; Rockman CB, 1996, AM J SURG, V172, P191, DOI 10.1016/S0002-9610(96)00150-X; Simental A, 2003, AM J OTOLARYNG, V24, P417, DOI 10.1016/S0196-0709(03)00088-7; Steele SR, 2004, AM J SURG, V187, P594, DOI 10.1016/j.amjsurg.2004.01.014; Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127	14	25	27	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0741-5214			J VASC SURG	J. Vasc. Surg.	FEB	2006	43	2					379	382		10.1016/j.jvs.2005.10.058			4	Surgery; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Surgery; Cardiovascular System & Cardiology	014PN	WOS:000235492300039	16476618	Bronze			2022-02-06	
J	Movsesyan, VA; Faden, AI				Movsesyan, VA; Faden, AI			Neuroprotective effects of selective group II mGluR activation in brain trauma and traumatic neuronal injury	JOURNAL OF NEUROTRAUMA			English	Article						agonist; brain trauma; mGluR; neuronal cell death	METABOTROPIC GLUTAMATE RECEPTORS; SPINAL-CORD INJURY; EXCITATORY AMINO-ACID; RAT HIPPOCAMPAL SLICES; D-ASPARTATE RECEPTORS; IN-VITRO; CELL-DEATH; NMDA RECEPTORS; MOLECULAR CHARACTERIZATION; SIGNAL-TRANSDUCTION	The effects of group II mGluR activation by selective agonist (-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate (LY379268) were examined in a mouse model of controlled cortical impact (CCI)-induced brain injury and in primary neuronal/glial and neuronal cultures subjected to mechanical trauma. Systemic administration of LY379268 to mice at 30 min after CCI significantly improved both motor and cognitive recovery as compared with vehicle-treated control animals. LY379268 also significantly reduced cell death induced by mechanical injury in rat neuronal/glial and neuronal cultures, as measured by lactate dehydrogenase (LDH) release assay. The neuroprotective effect of LY379268 in vitro was abolished by co-administration of the mGluR2/3 antagonist (s)-alpha-ethylglutamic acid (EGLU); however, co-application of selective mGluR3 antagonist beta-N-acetyl-aspartyl-glutamate (NAAG) had no significant influence in the same system. Together, these findings demonstrate the neuroprotective activity of group 11 mGluR activation and underscore the role of the mGluR2 subtype for this effect.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA		Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3900 Reservoir Rd NW,Res Bldg,Rm EP 12, Washington, DC 20007 USA.	fadena@georgetown.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD040677] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS37313] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD040677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER		ABE T, 1992, J BIOL CHEM, V267, P13361; Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Allen JW, 2001, EXP NEUROL, V169, P449, DOI 10.1006/exnr.2001.7672; Allen JW, 2000, CELL DEATH DIFFER, V7, P470, DOI 10.1038/sj.cdd.4400678; Anwyl R, 1999, BRAIN RES REV, V29, P83, DOI 10.1016/S0165-0173(98)00050-2; BIRRELL GJ, 1993, NEUROPHARMACOLOGY, V32, P1351, DOI 10.1016/0028-3908(93)90030-7; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; Bond A, 1999, NEUROSCI LETT, V273, P191, DOI 10.1016/S0304-3940(99)00663-1; Bond A, 1998, NEUROREPORT, V9, P1191, DOI 10.1097/00001756-199804200-00042; Bond A, 2000, J PHARMACOL EXP THER, V294, P800; BRUNO V, 1995, EUR J NEUROSCI, V7, P1906, DOI 10.1111/j.1460-9568.1995.tb00712.x; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; Bruno V, 2000, J NEUROSCI, V20, P6413, DOI 10.1523/JNEUROSCI.20-17-06413.2000; BUISSON A, 1995, NEUROPHARMACOLOGY, V34, P1081, DOI 10.1016/0028-3908(95)00073-F; CHIAMULERA C, 1992, EUR J PHARMACOL, V216, P335, DOI 10.1016/0014-2999(92)90382-E; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; COPANI A, 1995, MOL PHARMACOL, V47, P890; DiIorio P, 1996, J NEUROCHEM, V67, P302; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1997, J NEUROTRAUM, V14, P885, DOI 10.1089/neu.1997.14.885; Ferraguti F, 1999, EUR J NEUROSCI, V11, P2073, DOI 10.1046/j.1460-9568.1999.00626.x; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Henrich-Noack P, 1998, NEUROREPORT, V9, P985, DOI 10.1097/00001756-199804200-00006; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; Iacovelli L, 2002, J NEUROCHEM, V82, P216, DOI 10.1046/j.1471-4159.2002.00929.x; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; Kornhuber J, 1997, BIOL PSYCHIAT, V41, P135, DOI 10.1016/S0006-3223(96)00047-9; Lea PM, 2005, BRIT J PHARMACOL, V145, P527, DOI 10.1038/sj.bjp.0706219; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MCDONALD JW, 1992, EUR J PHARMACOL, V215, P353, DOI 10.1016/0014-2999(92)90058-C; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Meli E, 2002, PHARMACOL BIOCHEM BE, V73, P439, DOI 10.1016/S0091-3057(02)00834-1; Mills CD, 2001, J NEUROCHEM, V79, P835, DOI 10.1046/j.1471-4159.2001.00630.x; MINAKAMI R, 1993, BIOCHEM BIOPH RES CO, V194, P622, DOI 10.1006/bbrc.1993.1866; Monn JA, 1999, J MED CHEM, V42, P1027, DOI 10.1021/jm980616n; Movsesyan VA, 2004, J NEUROCHEM, V89, P1528, DOI 10.1111/j.1471-4159.2004.02451.x; Movsesyan VA, 2001, J PHARMACOL EXP THER, V296, P41; Mukhin A, 1996, J NEUROSCI, V16, P6012; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Mukhin AG, 1998, J NEUROSCI RES, V51, P748, DOI 10.1002/(SICI)1097-4547(19980315)51:6<748::AID-JNR8>3.0.CO;2-B; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; O'Leary DM, 2000, BRIT J PHARMACOL, V131, P1429, DOI 10.1038/sj.bjp.0703715; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; OLNEY JW, 1989, BIOL PSYCHIAT, V26, P505, DOI 10.1016/0006-3223(89)90072-3; OPITZ T, 1994, NEUROPHARMACOLOGY, V33, P715, DOI 10.1016/0028-3908(94)90178-3; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PIN JP, 1992, P NATL ACAD SCI USA, V89, P10331, DOI 10.1073/pnas.89.21.10331; PIN JP, 1993, CURR DRUGS NEURODEGE, V1, P111; Poli A, 2003, J NEUROSCI, V23, P6023, DOI 10.1523/JNEUROSCI.23-14-06023.2003; SACAAN AI, 1992, NEUROSCI LETT, V139, P77, DOI 10.1016/0304-3940(92)90862-2; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; Schoepp DD, 1999, NEUROPHARMACOLOGY, V38, P1431, DOI 10.1016/S0028-3908(99)00092-1; Shapiro BK, 2001, MENT RETARD DEV D R, V7, P13, DOI 10.1002/1098-2779(200102)7:1<13::AID-MRDD1003>3.0.CO;2-1; SILIPRANDI R, 1992, EUR J PHARMACOL, V219, P173, DOI 10.1016/0014-2999(92)90598-X; Stover JF, 2003, J NEUROTRAUM, V20, P315, DOI 10.1089/089771503765172273; TANABE Y, 1993, J NEUROSCI, V13, P1372; VIGNES M, 1995, NEUROPHARMACOLOGY, V34, P973, DOI 10.1016/0028-3908(95)00093-L; WATKINS J, 1994, TRENDS PHARMACOL SCI, V15, P333, DOI 10.1016/0165-6147(94)90028-0; Wigmore MA, 1998, BRIT J PHARMACOL, V123, P667, DOI 10.1038/sj.bjp.0701662; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q	75	25	26	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2006	23	2					117	127		10.1089/neu.2006.23.117			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	020HX	WOS:000235900600001	16503796				2022-02-06	
J	Vadeboncoeur, TF; Davis, DP; Ochs, M; Poste, JC; Hoyt, DB; Vilke, GM				Vadeboncoeur, TF; Davis, DP; Ochs, M; Poste, JC; Hoyt, DB; Vilke, GM			The ability of paramedics to predict aspiration in patients undergoing prehospital rapid sequence intubation	JOURNAL OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the National-Association-of-Emergency-Medical-Services-Physicians	JAN 13-15, 2005	Naples, FL	Natl Assoc Emergency Med Serv Phys		aspiration; prehospital; EMS; paramedics; rapid sequence intubation; airway management; traumatic brain injury; head trauma	ENDOTRACHEAL INTUBATION; TRAUMA PATIENTS; HEAD; PNEUMONIA; HYPOTENSION; FIELD; INDUCTION; INJURY	One of the purported benefits to invasive prehospital airway management is the prevention of aspiration; however, aspiration events may occur before the arrival of prehospital personnel. We explore the timing of aspiration in patients with severe traumatic brain injury (TBI) undergoing paramedic rapid sequence intubation (RSI). Severely head-injured (Glasgow Coma Scale [GCS] score 3-8) adults were prospectively enrolled into the San Diego Paramedic RSI Trial. As part of the prehospital data collection tool, paramedics prospectively assessed for clinical evidence of aspiration before RSI (pre-intubation), aspiration events occurring during RSI (peri-RSI), and regurgitation of vomitus or blood after intubation (post-intubation). Data were abstracted from worksheets used during the RSI procedure, a telephone debriefing by one of the principal investigators immediately after delivery of the patient, and San Diego County prehospital and trauma databases. The incidence of pre-intubation aspiration, peri-RSI aspiration, and post-intubation regurgitation of vomitus or blood were determined. Patients with and without pre-intubation aspiration were compared with regard to pre- and post-intubation hypoxia and the rate of aspiration pneumonia. Logistic regression was used to explore the association between pre-intubation aspiration and various demo-graphic and clinical factors. The results showed that pre-intubation aspiration was noted by paramedics in 72/269 patients in whom complete data were available. Peri-RSI aspiration was reported in one patient; there were no reported cases of post-intubation regurgitation of vomitus or blood. Patients in the pre-intubation aspiration group required more intubation attempts, had a higher incidence of desaturations and lower pre- and post-intubation SaO(2) values, and were more frequently diagnosed with aspiration pneumonia. Pre-intubation aspiration was associated with severe TBI, GCS score of 3, younger age, and the absence of alcohol intoxication despite controlling for age, gender, GCS, Head AIS (Abbreviated Injury Score), and serum ethanol. It is concluded that paramedics seem to be able to accurately assess for aspiration in patients undergoing prehospital RSI. The vast majority of aspiration events seem to occur before the arrival of prehospital personnel. Alteration in consciousness from TBI may carry a higher risk of aspiration than with other causes, such as alcohol intoxication. (c) 2006 Elsevier Inc.	Univ Calif San Diego, Med Ctr, Dept Emergency Med, San Diego, CA 92103 USA; San Diego Cty EMS, San Diego, CA USA; UCSD Muir Coll, San Diego, CA USA; Univ Calif San Diego, Dept Surg, Div Trauma, San Diego, CA USA		Davis, DP (corresponding author), Univ Calif San Diego, Med Ctr, Dept Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.						ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; Atkinson JLD, 2000, MAYO CLIN PROC, V75, P37, DOI 10.4065/75.1.37; Berrouane Y, 1998, J HOSP INFECT, V40, P275, DOI 10.1016/S0195-6701(98)90303-6; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; Cazzadori A, 1997, RESP MED, V91, P193, DOI 10.1016/S0954-6111(97)90038-X; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Davis DP, 2005, J TRAUMA, V59, P484, DOI 10.1097/00005373-200508000-00037; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Doran J V, 1995, Prehosp Disaster Med, V10, P259; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; Hatley T, 1998, J Emerg Med, V16, P731, DOI 10.1016/S0736-4679(98)00087-0; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; KOCH W, 1874, ARCH KLIN CHIR, V17, P190; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Kramer S P, 1896, Ann Surg, V23, P163, DOI 10.1097/00000658-189601000-00031; LEVASSEUR JE, 1989, J NEUROSURG, V71, P573, DOI 10.3171/jns.1989.71.4.0573; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Pace SA, 2000, ANN EMERG MED, V35, P568, DOI 10.1016/S0196-0644(00)70029-1; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; POLIS A, 1894, REV CHIR, V14, P645; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; Sing RF, 1996, ACAD EMERG MED, V3, P41, DOI 10.1111/j.1553-2712.1996.tb03301.x; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Sirvent JM, 2000, INTENS CARE MED, V26, P1369, DOI 10.1007/s001340000611; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; SMITH JP, 1985, JAMA-J AM MED ASSOC, V253, P544, DOI 10.1001/jama.253.4.544; Spaite DW, 2003, ANN EMERG MED, V42, P729, DOI 10.1016/S0196-0644(03)00822-9; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; VILKE GM, 2004, PREHOSP EMERG CARE, V8, P88; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; Wang HE, 2002, ANN EMERG MED, V40, P168, DOI 10.1067/mem.2002.126370; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Woratyla S P, 1995, Conn Med, V59, P643	42	25	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	FEB	2006	30	2					131	136		10.1016/j.jemermed.2005.04.019			6	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine	028GQ	WOS:000236475500001	16567245				2022-02-06	
S	Chopp, M; Li, Y		Fisher, JP		Chopp, Michael; Li, Yi			Transplantation of bone marrow stromal cells for treatment of central nervous system diseases	TISSUE ENGINEERING	Advances in Experimental Medicine and Biology		English	Article; Proceedings Paper	2nd International Tissue Engineering Conference	MAY 22-27, 2005	Crete, GREECE				FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; STROKE-INDUCED NEUROGENESIS; MESENCHYMAL STEM-CELLS; ARTERY OCCLUSION; PROGENITOR CELLS; RAT-BRAIN; INTRACEREBRAL TRANSPLANTATION; SUBVENTRICULAR ZONE; THERAPEUTIC BENEFIT		Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI 48063 USA		Chopp, M (corresponding author), Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS042345, R01 NS045041] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045041, P01NS042345] Funding Source: NIH RePORTER		Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Chen HI, 2003, SENSOR ACTUAT B-CHEM, V92, P6, DOI 10.1016/S0925-4005(03)00125-4; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, STROKE, V33, P401; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Cohen-Cory S, 2002, SCIENCE, V298, P770, DOI 10.1126/science.1075510; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; Darsalia V, 2005, STROKE, V36, P1790, DOI 10.1161/01.STR.0000173151.36031.be; Dormady SP, 2001, J HEMATOTH STEM CELL, V10, P125, DOI 10.1089/152581601750098372; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Fok-Seang J, 1998, EUR J NEUROSCI, V10, P2400, DOI 10.1046/j.1460-9568.1998.00251.x; FOURNIER GA, 1981, INVEST OPHTH VIS SCI, V21, P351; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; GAO Q, 2005, IN PRESS NEUROSCIENC; GARCIA JH, 1993, AM J PATHOL, V142, P623; Gourmala NG, 1999, NEUROSCIENCE, V88, P1255, DOI 10.1016/S0306-4522(98)00295-4; Guegan C, 1998, MOL BRAIN RES, V55, P133, DOI 10.1016/S0169-328X(97)00372-0; Hamano K, 2000, CELL TRANSPLANT, V9, P439, DOI 10.1177/096368970000900315; Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097-4652(199603)166:3<585::AID-JCP13>3.0.CO;2-6; KELLY JP, 1985, PRINCIPLES NEURAL SC; Kempermann G, 2000, Prog Brain Res, V127, P35; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Koc ON, 2001, BONE MARROW TRANSPL, V27, P235, DOI 10.1038/sj.bmt.1702791; Li Y, 1999, BRAIN RES, V838, P1, DOI 10.1016/S0006-8993(99)01502-4; LI Y, 1992, STROKE, V23, P1292, DOI 10.1161/01.STR.23.9.1292; Li Y, 1998, STROKE, V29, P1972, DOI 10.1161/01.STR.29.9.1972; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2002, J NEUROL SCI, V193, P137, DOI 10.1016/S0022-510X(01)00657-8; Li Y, 1997, J CEREBR BLOOD F MET, V17, P846, DOI 10.1097/00004647-199708000-00003; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LI Y, 1995, AM J PATHOL, V146, P1045; Li Y, 2001, CELL TRANSPLANT, V10, P31; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; LICHTENWALNER RJ, 2005, J CEREB BLOOD F 0615; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mandalfino P, 2000, J NEUROL, V247, P691, DOI 10.1007/s004150070112; McIntosh K, 2002, BONE MARROW TRANSPL, V29, pS65; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Rohwedel J, 1998, DEV BIOL, V201, P167, DOI 10.1006/dbio.1998.9002; Rossini PM, 2004, RESTOR NEUROL NEUROS, V22, P193; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Seyfried D, 2006, J NEUROSURG, V104, P313, DOI 10.3171/jns.2006.104.2.313; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; Tamada Y, 2000, J OCUL PHARMACOL TH, V16, P271, DOI 10.1089/jop.2000.16.271; THEODOSIS DT, 1999, CONTRIBUTION ASTROCY, P175; Tse WT, 2003, TRANSPLANTATION, V75, P389, DOI 10.1097/01.TP.0000045055.63901.A9; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Wang Lei, 2002, Hematology, V7, P113; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Zhang J, 2004, BRAIN RES, V1030, P19, DOI 10.1016/j.brainres.2004.09.061; ZHANG J, 2005, IN PRESS EXP NEUROL; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0; Zhang QJ, 2002, INT J RF MICROW C E, V12, P2, DOI 10.1002/mmce.10027; Zhang RL, 2004, J CEREBR BLOOD F MET, V24, P441, DOI 10.1097/00004647-200404000-00009; Zhang RL, 2003, NEUROSCIENCE, V116, P373, DOI 10.1016/S0306-4522(02)00696-6; Zhang RL, 1997, BRAIN RES, V766, P83, DOI 10.1016/S0006-8993(97)00580-5; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang ZG, 2004, NEUROIMAGE, V23, P281, DOI 10.1016/j.neuroimage.2004.05.019; Zhang ZG, 1997, J CEREBR BLOOD F MET, V17, P1081, DOI 10.1097/00004647-199710000-00010; ZHANG ZG, 1995, J NEUROL SCI, V128, P22, DOI 10.1016/0022-510X(94)00216-B; Zhang ZG, 2001, J CEREBR BLOOD F MET, V21, P541, DOI 10.1097/00004647-200105000-00008; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002	87	25	29	0	6	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	0065-2598	2214-8019	0-387-32664-2	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2006	585						49	64					16	Cell Biology; Engineering, Biomedical; Medicine, Research & Experimental	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Engineering; Research & Experimental Medicine	BFG57	WOS:000241729000004	17120776				2022-02-06	
B	Graber, KD; Prince, DA		Pitkanen, A; Schwartzkroin, PA; Moshe, SL		Graber, Kevin D.; Prince, David A.			Chronic Partial Cortical Isolation	MODELS OF SEIZURES AND EPILEPSY			English	Article; Book Chapter							ISOLATED CEREBRAL-CORTEX; TRAUMATIC BRAIN-INJURY; HUMAN DYSPLASTIC NEOCORTEX; FLUID PERCUSSION INJURY; V PYRAMIDAL NEURONS; IN-VITRO; EPILEPTIFORM DISCHARGES; RAT NEOCORTEX; HEAD TRAUMA; LAYER-V		[Graber, Kevin D.; Prince, David A.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA		Graber, KD (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.						AGHAJANIAN GK, 1989, SYNAPSE, V3, P331, DOI 10.1002/syn.890030406; Andermann E., 1964, EPILEPSIA, V10, P415; ANDERSEN P, 1980, J PHYSIOL-LONDON, V305, P279, DOI 10.1113/jphysiol.1980.sp013363; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Avoli M, 1999, ANN NEUROL, V46, P816, DOI 10.1002/1531-8249(199912)46:6<816::AID-ANA3>3.0.CO;2-O; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BURNS BD, 1954, J PHYSIOL-LONDON, V125, P427, DOI 10.1113/jphysiol.1954.sp005170; BURNS BD, 1979, PROC R SOC SER B-BIO, V203, P347, DOI 10.1098/rspb.1979.0002; BURNS BD, 1951, J PHYSIOL-LONDON, V112, P156, DOI 10.1113/jphysiol.1951.sp004517; Cajal S.Ry., 1928, DEGENERATION REGENER, P656; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747, DOI 10.1152/jn.1989.61.4.747; CHIAIA NL, 1992, DEV BRAIN RES, V66, P244, DOI 10.1016/0165-3806(92)90086-C; CHOW KL, 1964, NEUROPSYCHOLOGIA, V2, P175, DOI 10.1016/0028-3932(64)90003-X; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; CONNORS BW, 1984, NATURE, V310, P685, DOI 10.1038/310685a0; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Antuono M, 2004, BRAIN, V127, P1626, DOI 10.1093/brain/awh181; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P735, DOI 10.1113/jphysiol.1991.sp018733; Douglas RJ, 2004, ANNU REV NEUROSCI, V27, P419, DOI 10.1146/annurev.neuro.27.070203.144152; DOW RS, 1962, ELECTROEN CLIN NEURO, V14, P399, DOI 10.1016/0013-4694(62)90116-5; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; DUNCAN JA, 1968, EXP NEUROL, V20, P268, DOI 10.1016/0014-4886(68)90101-5; ECHLIN FA, 1954, T AM NEUROL ASSOC, P75; ECHLIN FA, 1962, NEUROLOGY, V12, P551, DOI 10.1212/WNL.12.8.551; ECHLIN FA, 1963, ARCH NEUROL-CHICAGO, V9, P154, DOI 10.1001/archneur.1963.00460080064009; ECHLIN FA, 1959, ELECTROEN CLIN NEURO, V11, P697, DOI 10.1016/0013-4694(59)90110-5; ECHLIN FRANCIS A., 1961, TRANS AMER NEUROL ASSOC, V86, P209; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Engel J, 2003, NEUROLOGY, V60, P538, DOI 10.1212/01.WNL.0000055086.35806.2D; ERNFORS P, 1991, NEURON, V7, P165, DOI 10.1016/0896-6273(91)90084-D; FARRANCE ML, 1975, P W PHARMACOL SOC, V18, P51; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Freund TF, 2003, TRENDS NEUROSCI, V26, P489, DOI 10.1016/S0166-2236(03)00227-3; FUKUDA A, 1992, DEV BRAIN RES, V65, P101, DOI 10.1016/0165-3806(92)90013-M; GALVAN M, 1982, BRAIN RES, V241, P75, DOI 10.1016/0006-8993(82)91230-6; GOLDRING S, 1961, J NEUROPHYSIOL, V24, P633, DOI 10.1152/jn.1961.24.6.633; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Graber KD, 1999, EPILEPSIA, V40, P31; Graber KD, 1998, NEUROLOGY, V50, pA140; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Graber Kevin D., 2002, Epilepsia, V43, P21; Graber Kevin D., 2003, Epilepsia, V44, P204; GRAFSTEIN B, 1957, ELECTROEN CLIN NEURO, V9, P723, DOI 10.1016/0013-4694(57)90096-2; GREEN JR, 1973, EPILEPSIA, V14, P223, DOI 10.1111/j.1528-1157.1973.tb03959.x; GREEN JR, 1973, EPILEPSIA, V14, P233, DOI 10.1111/j.1528-1157.1973.tb03960.x; GREEN JR, 1970, BRAIN, V93, P57, DOI 10.1093/brain/93.1.57; GREEN JR, 1970, LIFE SCI, V9, P481, DOI 10.1016/0024-3205(70)90203-1; GRUNER JE, 1974, J COMP NEUROL, V154, P1, DOI 10.1002/cne.901540102; GUTNICK MJ, 1982, J NEUROPHYSIOL, V48, P1321, DOI 10.1152/jn.1982.48.6.1321; HALPERN LM, 1972, EXPT MODELS EPILEPSY, P197; HAMMOND EJ, 1980, EPILEPSIA, V21, P3, DOI 10.1111/j.1528-1157.1980.tb04039.x; Hernandez TD, 1997, NEUROLOGY, V48, P803, DOI 10.1212/WNL.48.4.803; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; HWA GGC, 1989, NEUROSCI LETT, V98, P189, DOI 10.1016/0304-3940(89)90508-9; Jin XM, 2005, J NEUROPHYSIOL, V93, P2117, DOI 10.1152/jn.00728.2004; Kharatishvili I, 2003, EPILEPSIA, V44, P36; Kharazia VN, 2001, NEUROSCIENCE, V102, P23, DOI 10.1016/S0306-4522(00)00467-X; KIM HG, 1995, J NEUROPHYSIOL, V74, P1810, DOI 10.1152/jn.1995.74.4.1810; KOYAMA I, 1977, CAN J PHYSIOL PHARM, V55, P523, DOI 10.1139/y77-074; KRNJEVIC K, 1970, ELECTROEN CLIN NEURO, V29, P269, DOI 10.1016/0013-4694(70)90139-2; KRNJEVIC K, 1969, J PHYSIOL-LONDON, V203, pP44; LANGE SC, 1980, EPILEPSIA, V21, P251, DOI 10.1111/j.1528-1157.1980.tb04070.x; Li HF, 2005, J NEUROPHYSIOL, V93, P146, DOI 10.1152/jn.00665.2004; Li HF, 2002, J NEUROPHYSIOL, V88, P2, DOI 10.1152/jn.00507.2001; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUHMANN HJ, 1991, J NEUROPHYSIOL, V65, P247, DOI 10.1152/jn.1991.65.2.247; LUHMANN HJ, 1990, DEV BRAIN RES, V54, P287, DOI 10.1016/0165-3806(90)90152-O; Marco P, 1997, EXP BRAIN RES, V114, P1, DOI 10.1007/PL00005608; MarinPadilla M, 1997, J NEUROPATH EXP NEUR, V56, P219, DOI 10.1097/00005072-199703000-00001; MATSUMOTO H, 1964, EXP NEUROL, V9, P305, DOI 10.1016/0014-4886(64)90026-3; MATTIA D, 1995, NEUROLOGY, V45, P1391, DOI 10.1212/WNL.45.7.1391; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Prince D A, 1965, Epilepsia, V6, P226, DOI 10.1111/j.1528-1157.1965.tb03791.x; Prince D.A., 2000, SOC NEUR ABSTR, V26, P1779; PRINCE DA, 1981, BRAIN RES, V210, P323, DOI 10.1016/0006-8993(81)90905-7; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; PRINCE DA, 1971, ELECTROEN CLIN NEURO, V31, P469, DOI 10.1016/0013-4694(71)90168-4; PRINCE DA, 1968, EXP NEUROL, V21, P467, DOI 10.1016/0014-4886(68)90066-6; PURPURA DP, 1961, EXP NEUROL, V4, P377, DOI 10.1016/0014-4886(61)90025-5; QIAN N, 1990, P NATL ACAD SCI USA, V87, P8145, DOI 10.1073/pnas.87.20.8145; REIFFENSTEIN RJ, 1972, ELECTROEN CLIN NEURO, V33, P215, DOI 10.1016/0013-4694(72)90048-X; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Schauwecker PE, 2000, EXP NEUROL, V161, P139, DOI 10.1006/exnr.1999.7251; Schwartzkroin P A, 1986, Adv Neurol, V44, P991; SCOVILLE WB, 1960, AM J PSYCHIAT, V117, P525, DOI 10.1176/ajp.117.6.525; SHARPLESS SK, 1962, ELECTROEN CLIN NEURO, V14, P244, DOI 10.1016/0013-4694(62)90034-2; Sharpless SK, 1969, BASIC MECH EPILEPSIE, P329; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; SOMOGYI P, 1985, BRAIN RES, V332, P143, DOI 10.1016/0006-8993(85)90397-X; SPEHLMANN R, 1971, ARCH NEUROL-CHICAGO, V24, P401, DOI 10.1001/archneur.1971.00480350035003; SPEHLMANN R, 1970, ELECTROEN CLIN NEURO, V28, P99; SUZUKI H, 1964, ELECTROEN CLIN NEURO, V17, P405, DOI 10.1016/0013-4694(64)90164-6; Tamas G, 2004, CEREB CORTEX, V14, P823, DOI 10.1093/cercor/bhh051; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; TETZLAFF W, 1991, J NEUROSCI, V11, P2528; Topolnik L, 2003, CEREB CORTEX, V13, P883, DOI 10.1093/cercor/13.8.883; Toth Z, 1997, J NEUROSCI, V17, P8106; Ueda Y, 1998, EXP NEUROL, V153, P123, DOI 10.1006/exnr.1998.6869; WARD AA, 1972, EXPT MODELS EPILEPSY, P13; WILLIAMS RS, 1979, ARCH NEUROL-CHICAGO, V36, P134, DOI 10.1001/archneur.1979.00500390052004; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408; WONG RKS, 1979, SCIENCE, V204, P1228, DOI 10.1126/science.451569; WRIGHT MK, 1954, ELECTROEN CLIN NEURO, V6, P635, DOI 10.1016/0013-4694(54)90090-5; Yang L, 1997, J NEUROPHYSIOL, V78, P2804, DOI 10.1152/jn.1997.78.5.2804; Yang L, 1998, NEUROSCI LETT, V257, P33, DOI 10.1016/S0304-3940(98)00798-8; Yang L, 2000, EPILEPSIA, V41, P1507; Zilles K., 1985, CORTEX RAT STEREOTAX	114	25	25	0	0	ELSEVIER ACADEMIC PRESS INC	SAN DIEGO	525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA			978-0-08-045702-4; 978-0-12-088554-1				2006							477	493		10.1016/B978-012088554-1/50040-2			17	Neurosciences	Book Citation Index – Science (BKCI-S)	Neurosciences & Neurology	BCT46	WOS:000311355400040					2022-02-06	
J	Kennedy, RE; Livingston, L; Riddick, A; Marwitz, JH; Kreutzer, JS; Zasler, ND				Kennedy, RE; Livingston, L; Riddick, A; Marwitz, JH; Kreutzer, JS; Zasler, ND			Evaluation of the neurobehavioral functioning inventory as a depression screening tool after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; screening; structured interview; traumatic brain injury	PSYCHIATRIC-DISORDERS; NATIONAL-INSTITUTE; MAJOR DEPRESSION; INDIVIDUALS; PREVALENCE; DISABILITY; AWARENESS; ADULTS	Objective: To examine the utility of the Neurobehavioral Functioning Inventory (NFI) for diagnosing depression in a rehabilitation setting. Design: In a prospective study, a structured clinical interview (Structured Clinical Interview for DSM-IV-TR) was used to identify DSM-IV-defiried major depressive disorder (MDD) symptoms among patients with traumatic brain injury (TBI). NFI Depression scale items were compared with DSM-IV diagnosis obtained by the Structured Clinical Interview for DSM-IV Axis I Disorders. Setting: Outpatient neuropsychology clinic at a university hospital, private outpatient physical medicine and rehabilitation clinic, and a long-term specialized living assistance program. Participants: Participants consisted of 78 patients with TBI who were at least 3 months postinjury and 18 years of age or older. Main Outcome Measures: Structured Clinical Interview for DSM-IV Axis I Disorders and the NFI. Results: Psychiatric diagnostic interview with the Structured Clinical Interview for DSM-IV Axis I Disorders indicated that 50% of patients with TBI in our sample had at least one of the following in their lifetime: MDD, MDD due to general medical condition, dysthymia, or adjustment disorder with depressed mood. Thirty percent met diagnostic criteria for current MDD with or without general medical condition. Analyses of the NFI items revealed that individuals with depression endorsed greater levels of problems than did those without depression on 14 of the 32 items related to the DSM-IV symptom domains for depression (P < .00156 with Bonferroni correction). In predicting the diagnosis of depression using individual NFI items, the classification rate based on the Random Forests estimate was 83%. Conclusion: Findings indicate that the NFI items differentiated between depressed and non-depressed patients with TBI. Imposing minimal burden on patients and staff, the NFI appears to have good predictive value in diagnosing major depression. In clinical practice and research, the NFI is a potentially valuable screening tool for identifying major depression in persons with TBI.	Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA		Kennedy, RE (corresponding author), Virginia Commonwealth Univ, Dept Psychiat, Box 980032, Richmond, VA 23298 USA.	rkennedy@vcu.edu	Kennedy, Richard/K-1525-2018	Kennedy, Richard/0000-0003-4638-126X			Al-Adawi S, 2004, J NEUROPSYCH CLIN N, V16, P435, DOI 10.1176/appi.neuropsych.16.4.435; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Babin PR, 2003, BRAIN INJURY, V17, P889, DOI 10.1080/0269905031000088595; Beck A. T., 1993, BECK DEPRESSION INVE; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Deb S, 1999, AM J PSYCHIAT, V156, P374; Derogatis L R, 1974, Mod Probl Pharmacopsychiatry, V7, P79; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1991, AM J PSYCHIAT, V148, P1172; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; First M.B., 1996, STRUCTURED CLIN INTE; FIRST MB, BACKGROUND ARTICLES; FIRST MB, SCID FREQUENTLY ASKE; Gasquoine P., 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187, https://doi.org/10.1037/0894-4105.6.3.187]; Gaynes BN, 2004, ANN INTERN MED, V140, P822, DOI 10.7326/0003-4819-140-10-200405180-00015; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; KATHOL RG, 1990, AM J PSYCHIAT, V147, P1021; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; MCDANIEL JS, 2000, PSYCHIAT CARE MED PA, P149; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Silberstein Morry, 2002, Neurosurg Focus, V13, pecp2, DOI 10.3171/foc.2002.13.1.6; Skodol A, 2000, HDB PSYCHIAT MEASURE, P45; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; TEASDALE G, 1974, LANCET, V2, P81; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wallace CA, 2000, BRAIN INJURY, V14, P549; Wing J. K., 1974, MEASUREMENT CLASSIFI; World Health Organization, 1993, COMP INT DIAGN INT V; 2004, RANDOM FOREST BREIMA; [No title captured]	46	25	27	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2005	20	6					512	526		10.1097/00001199-200511000-00004			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	986YF	WOS:000233484900004	16304488				2022-02-06	
J	King, DR; Cohn, SM; Proctor, KG				King, DR; Cohn, SM; Proctor, KG			Resuscitation with a hemoglobin-based oxygen carrier after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	63rd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Japanese-Association-for-Acute-Medicine	SEP 29-OCT 02, 2004	Maui, HI	Amer Assoc Surg Trauma, Japanese Assoc Acute Med		colloid; hemoglobin-based oxygen carrier (HBOC); intracranial pressure; oxygenation; swine	UNCONTROLLED HEMORRHAGIC-SHOCK; SMALL-VOLUME RESUSCITATION; TISSUE OXYGENATION; IMPROVES SURVIVAL; LIVER TRAUMA; SWINE MODEL; HBOC-201; PRESSURE; HYPOTENSION; VASOPRESSIN	Background. Traumatic brain injury (TBI) remains an exclusionary criterion in nearly every clinical trial involving hemoglobin-based oxygen carriers (HBOCs) for traumatic hemorrhage. Furthermore, most HBOCs are vasoactive, and use of pressors in the setting of hemorrhagic shock is generally contraindicated. The purpose of this investigation was to test the hypothesis that low-volume resuscitation with a vasoactive HBOC (hemoglobin glutamer-200 [bovine], HBOC-301; Oxyglobin, BioPure, Inc., Cambridge, MA) would improve outcomes after severe TBI and hemorrhagic shock. Methods: In Part 1, anesthetized swine received TBI and hemorrhage (30 +/- 2 mL/kg, n = 15). After 30 minutes, lactated Ringer's (LR) solution (n = 5), HBOC (n = 5), or 10 mL/kg of LR + HBOC (n = 5) was titrated to restore systolic blood pressure to >= 100 mm Hg and heart rate (HR) to <= 100 beats/min. After 60 minutes, fluid was given to maintain mean arterial pressure (MAP) at >= 70 nun Hg and heterologous whole blood (red blood cells [RBCs], 10 mL/kg) was transfused. for hemoglobin at <= 5 g/dL. After 90 minutes, mannitol (MAN, 1 g/kg) was given for intracranial pressure >= 20 min Hg, LR solution was given to maintain cerebral perfusion pressure at >= 70 min Hg, and RBCs were given for hemoglobin of <= 5 g/dL. In Part 2, after similar TBI and resuscitation with either LR + MAN + RBCs (n = 3) or HBOC alone (n = 3), animals underwent attempted weaning, extubation, and monitoring for 72 hours. Results: In Part 1, relative to resuscitation with LR + MAN + RBCs, LR + HBOC attenuated intracranial pressure (12 +/- 1 min Hg vs. 33 +/- 6 mm Hg), improved cerebral perfusion pressure in the initial 4 hours (89 +/- 6 nun Hg vs. 60 +/- 3 mm Hg), and improved brain tissue PO2 (34.2 +/- 3.6 min Hg vs. 16.1 +/- 1.6 mm Hg; all p < 0.05). Cerebrovascular reactivity and intracranial compliance were improved with LR + HBOC (p < 0.05) and fluid requirements were reduced (30 +/- 12 vs. 280 +/- 40 mL/kg; p < 0.05). Lactate and base excess corrected faster with LR + HBOC despite a 40% reduction in cardiac index. With HBOC alone and LR + HBOC, MAP and HR rapidly corrected and remained normal during observation; however, with HBOC alone, lactate clearance was slower and systemic oxygen extraction was transiently icreased. In Part 2, resuscitation with HBOC alone allowed all animals to wean and extubate, whereas none in the LR + MAN + RBCs group was able to wean and extubate. At 72 hours, no HBOC animal had detectible neurologic deficits and all had normal hemodynamics. Conclusion: The use of HBOC-301 supplemented by a crystalloid bolus was clearly superior to the standard of care (LR + MAN + RBCs) after TBI. This may represent a new indication for HBOCs. Use of HBOC eliminated the need for RBC transfusions and mannitol. The inherent vasopressor effect of HBOCs, especially when used alone, may misguide initial resuscitation, leading to transient poor global tissue perfusion despite restoration of MAP and HR. This suggests that MAP and HR are inadequate endpoints with HBOC resuscitation. HBOC use alone after TBI permitted early extubation and excellent 72-hour outcomes.	Univ Miami, Sch Med, Ryder Trauma Ctr,Res Inst, Div Trauma & Surg Crit Care,Dewitt Daughtry Famil, Miami, FL 33136 USA		Proctor, KG (corresponding author), Univ Miami, Sch Med, Ryder Trauma Ctr,Res Inst, Div Trauma & Surg Crit Care,Dewitt Daughtry Famil, 1800 NW 10th Ave, Miami, FL 33136 USA.	kproctor@miami.edu	Proctor, Kenneth/AAA-2199-2022	Proctor, Kenneth/0000-0003-1326-6628; King, David/0000-0003-1028-1478	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM08749-0] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008749] Funding Source: NIH RePORTER		Cothren CC, 2004, TRANSFUSION MED, V14, P241, DOI 10.1111/j.0958-7578.2004.00502.x; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Hare GMT, 2004, ANESTH ANALG, V99, P528, DOI 10.1213/01.ANE.0000136769.65960.D1; JAVID M, 1964, J NEUROSURG, V21, P1059, DOI 10.3171/jns.1964.21.12.1059; Katz LM, 2002, RESUSCITATION, V54, P77, DOI 10.1016/S0300-9572(02)00053-9; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Knudson MM, 2003, J TRAUMA, V54, P242, DOI 10.1097/01.TA.0000037776.28201.75; Lee SK, 2002, ACAD EMERG MED, V9, P969; Levy JH, 2003, EXPERT OPIN BIOL TH, V3, P509, DOI 10.1517/14712598.3.3.509; Malhotra AK, 2004, J TRAUMA, V56, P1049, DOI 10.1097/01.TA.0000127765.75643.66; Malhotra AK, 2003, J TRAUMA, V54, P915, DOI 10.1097/01.TA.0000061000.74343.E1; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Manley GT, 2003, ADV EXP MED BIOL, V530, P311; Manning JE, 2000, SHOCK, V13, P152, DOI 10.1097/00024382-200013020-00010; McNeil JD, 2001, J TRAUMA, V50, P1063, DOI 10.1097/00005373-200106000-00015; Muir W, 2001, J VET PHARMACOL THER, V24, P447, DOI 10.1046/j.1365-2885.2001.0363a.x; Raedler C, 2004, ANESTH ANALG, V98, P1759, DOI 10.1213/01.ANE.0000117150.29361.5A; Roberts IG, 2003, COCHRANE DB SYST REV, V2; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Sampson JB, 2003, J TRAUMA, V55, P747, DOI 10.1097/01.TA.0000084519.47163.77; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; York GB, 2003, J TRAUMA, V55, P873, DOI 10.1097/01.TA.0000092681.17874.6F	22	25	25	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2005	59	3					553	560		10.1097/01.ta.0000177711.52191.62			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	014BZ	WOS:000235455000001	16361895				2022-02-06	
J	Clausen, F; Hillered, L				Clausen, F; Hillered, L			Intracranial pressure changes during fluid percussion, controlled cortical impact and weight drop injury in rats	ACTA NEUROCHIRURGICA			English	Article						controlled cortical impact; fluid percussion injury; intra cranial pressure; rat; traumatic brain injury; weight drop injury	TRAUMATIC BRAIN-INJURY; MODEL; ISCHEMIA	Background. In traumatic brain injury research, the fluid percussion injury (FPI) model in the rat is widely used. The injury is graded based on indirect criteria, such as the extracranial pressure wave and/or physiological responses to the injury. We designed this study to investigate if the extracranially monitored pressure in the FPI-device corresponded to the actual intracranial situation. Severe controlled cortical impact (CCI) and severe weight drop injury (WDI) were studied for comparison. Method. We tested the correlation between the extra- and intracranial pressures during severe FPI in rat (2.6-2.9 atm), using pressure probes ( diameter 0.34 mm) with high frequency (500Hz) and high pressure range (1-5 atm). The probes were inserted into either of the lateral ventricles in FPI and in the contralateral lateral ventricle in CCI and WDI to compare the ictal pressure pulses between the models. Findings. FPI showed a time lag between the extracranial, intracranial ipsilateral and intracranial contralateral pressure curves respectively, reflecting the different distances between the pressure source and the individual pressure probes. There was a high degree of correlation (r = 0.994, p < 0.0001) between the extra- and intracranial pressure pulses, once corrected for the time lag. We found no significant differences between the extracranial and the intracranial peak pressure in either ventricle in FPI. In CCI and WDI the contralateral pressure pulses were significantly smaller than in FPI. CCI resulted in higher pressure peaks than WDI, due to higher impact velocity. Conclusions. The extracranial pressure pulse appears to be a good estimate of the intraventricular pressure pulse generated during FPI. Severe CCI and WDI generated intraventricular pressure pulses of much lower magnitude than FPI, explaining the lesser degree of brain stem involvement in the former models.	Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden		Clausen, F (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden.	fredrik.clausen@neurokir.uu.se		Clausen, Fredrik/0000-0003-3592-4417			DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Hayes R L, 1987, Brain Inj, V1, P93, DOI 10.3109/02699058709034449; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LIU Y, 1992, BRAIN RES, V586, P121, DOI 10.1016/0006-8993(92)91380-W; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; MATSUSHIMA K, 1995, STROKE, V26, P1052; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER J D, 1987, Neurological Research, V9, P198; MILLER J D, 1987, Neurological Research, V9, P193; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stalhammar D, 1987, Brain Inj, V1, P73, DOI 10.3109/02699058709034448; Tindall G T, 1975, Clin Neurosurg, V22, P332; TOMIDA S, 1987, J CEREBR BLOOD F MET, V7, P773, DOI 10.1038/jcbfm.1987.133; Zwienenberg M, 1999, J NEUROTRAUM, V16, P1095, DOI 10.1089/neu.1999.16.1095	25	25	26	0	4	SPRINGER WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	JUL	2005	147	7					775	780		10.1007/s00701-005-0550-2			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	938AK	WOS:000229972100024	15900397				2022-02-06	
J	Stapp, JM; Sjoelund, V; Lassiter, HA; Feldhoff, RC; Feldhoff, PW				Stapp, JM; Sjoelund, V; Lassiter, HA; Feldhoff, RC; Feldhoff, PW			Recombinant rat IL-1 beta and IL-6 synergistically enhance C3 mRNA levels and complement component C3 secretion by H-35 rat hepatoma cells	CYTOKINE			English	Article						complement 3; cytokines; H-35 hepatoma cells; interleukins; rats	TRAUMATIC BRAIN INJURY; LIVER EPITHELIAL-CELLS; ACUTE-PHASE RESPONSE; NEONATAL-RATS; RECEPTOR ANTAGONIST; NECROSIS-FACTOR; GROWTH-FACTOR; TNF-ALPHA; CYTOKINE; INTERLEUKIN-6	Hepatic synthesis of complement component C3 is regulated in part by inflammatory cytokines. Rat models are frequently employed to investigate pathogenic roles of complement and cytokines. However, cytokines obtained from species other than the rat were used in previous studies of cytokine regulation of C3 synthesis in rat hepatocytes or hepatoma cells. It is not known whether these prior reports predict hepatocellular responses evoked by rat cytokines. Therefore, H-35 rat hepatoma cells were employed to measure the effect of recombinant rat IL-1 beta, IL-6, IFN-gamma, and TNF-alpha on C3 protein secretion and C3 mRNA levels quantified by ELISA and quantitative RT-PCR. Compared to untreated control cells, H-35 cells treated with IL-1 beta, IL-6, and IFN-gamma increased C3 secretion approximately 10-, 4-, and 2-fold, respectively. TNF-alpha was toxic, precluding further analysis. IL-1 beta and IL-6 demonstrated synergy with respect to the quantity and rate of increase of C3 mRNA measured and the magnitude of C3 protein secretion. Previous reports using non-rat cytokines did not consistently predict H-35 responses to rat cytokines. Consequently, we recommend the use of rat cytokines in rat models that include analysis of cytokine-mediated events. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Louisville, Dept Pediat, Div Neonatal Med, Sch Med, Louisville, KY 40202 USA; Univ Louisville, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Sch Med, Kosair Childrens Hosp Res Inst, Louisville, KY 40202 USA		Lassiter, HA (corresponding author), Univ Louisville, Dept Pediat, Div Neonatal Med, Sch Med, 571 S Floyd St,Suite 300, Louisville, KY 40202 USA.	hal.lassiter@louisville.edu	Sjoelund, Virginie/E-8432-2012; Sjoelund, Virginie/T-9266-2019	Sjoelund, Virginie/0000-0002-7929-5950			Akita N, 2003, NEUROSURGERY, V52, P395, DOI 10.1227/01.NEU.0000043710.61233.B4; ALPER CA, 1969, SCIENCE, V163, P286, DOI 10.1126/science.163.3864.286; Andrews E, 2003, CYTOKINE, V23, P164, DOI 10.1016/S1043-4666(03)00219-9; ANTHONY R, 1989, EUR J IMMUNOL, V19, P1405, DOI 10.1002/eji.1830190809; BAUMANN H, 1993, J IMMUNOL, V151, P4248; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; CHAVEZCARTAYA RE, 1995, TRANSPLANTATION, V59, P1047, DOI 10.1097/00007890-199504150-00023; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; COEL FS, 1988, COMPLEMENT SYSTEM, P44; Colten H. R., 1998, HUMAN COMPLEMENT SYS, P217; Cowell RM, 2003, J NEUROSCI, V23, P9459; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; FALUS A, 1990, MOL IMMUNOL, V27, P197, DOI 10.1016/0161-5890(90)90115-G; FALUS A, 1990, IMMUNOL LETT, V24, P227, DOI 10.1016/0165-2478(90)90001-7; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Guiguet M, 1997, ANAL BIOCHEM, V247, P441, DOI 10.1006/abio.1997.2101; Imm MD, 2002, NEUROSCI LETT, V325, P175, DOI 10.1016/S0304-3940(02)00271-9; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; KOJ A, 1995, INT J BIOCHEM CELL B, V27, P39, DOI 10.1016/1357-2725(94)00058-1; Lassiter HA, 1997, PEDIATR RES, V42, P128, DOI 10.1203/00006450-199707000-00020; LASSITER HA, 2000, HEMATOLOGIC PROBLEMS, P343; Ling YL, 2001, WORLD J GASTROENTERO, V7, P667; LININGTON C, 1989, BRAIN, V112, P895, DOI 10.1093/brain/112.4.895; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; Meistrell ME, 1997, SHOCK, V8, P341; Mizuno M, 2000, CLIN EXP IMMUNOL, V119, P368; Nicola NA, 1994, GUIDEBOOK CYTOKINES; PERLMUTTER DH, 1988, INFLAMMATION BASIC P, P75; Platel D, 1996, CYTOKINE, V8, P895, DOI 10.1006/cyto.1996.0120; PLATEL D, 1994, EUR CYTOKINE NETW, V5, P405; Silverstein FS, 1997, NEUROCHEM INT, V30, P375, DOI 10.1016/S0197-0186(96)00072-1; Stammberger U, 2000, J THORAC CARDIOV SUR, V120, P1078, DOI 10.1067/mtc.2000.111175; Suffredini AF, 1999, J CLIN IMMUNOL, V19, P203, DOI 10.1023/A:1020563913045; TETI G, 1993, INFECT IMMUN, V61, P227, DOI 10.1128/IAI.61.1.227-235.1993; Vakeva AP, 1998, CIRCULATION, V97, P2259, DOI 10.1161/01.CIR.97.22.2259; Wright MS, 2001, IMMUNOL LETT, V76, P119, DOI 10.1016/S0165-2478(01)00180-8; Xi GH, 2001, STROKE, V32, P162, DOI 10.1161/01.STR.32.1.162	38	25	25	0	1	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-4666	1096-0023		CYTOKINE	Cytokine	APR 21	2005	30	2					78	85		10.1016/j.cyto.2004.12.007			8	Biochemistry & Molecular Biology; Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Immunology	917TJ	WOS:000228491800005	15804599				2022-02-06	
J	Edouard, AR; Vanhille, E; Le Moigno, S; Benhamou, D; Mazoit, JX				Edouard, AR; Vanhille, E; Le Moigno, S; Benhamou, D; Mazoit, JX			Non-invasive assessment of cerebral perfusion pressure in brain injured patients with moderate intracranial hypertension	BRITISH JOURNAL OF ANAESTHESIA			English	Article						brain, cerebral perfusion pressure; brain, intracranial pressure; complications, traumatic brain injury; monitoring, jugular venous oxygen saturation; monitoring, transcranial Doppler ultrasonography	CRITICAL CLOSING PRESSURE; ZERO-FLOW PRESSURE; TRANSCRANIAL DOPPLER; HEAD-INJURY; CIRCULATION; ARTERIES; THERAPY; INSULTS	Background. A non-invasive estimation of cerebral perfusion pressure (CPP) using transcranial Doppler sonography was assessed in brain-injured patients by comparing conventional measurements of CPP (difference between mean arterial pressure and intracranial pressure) (CPPm) with the difference between AP(mean) and the critical closing pressure of the cerebral circulation (CPPe). Methods. Twenty adults with bilateral and diffuse brain injuries were included in the study. CPPe was estimated using a formula combining the phasic values of flow velocities and arterial pressure. In group A (n=10) the comparison was repeatedly performed under stable conditions. In group B (n=10) the comparison was performed during a CO2 reactivity test. Covariance analysis was used to assess the relationships. Results. In group A, CPPe and CPPm were correlated (slope, 0.76; intercept, +10.9; 95% CI, -3.5 to +25.4). During the increase in intracranial pressure (group B) (+1.9 (sd 1.5) mm Hg per mm Hg of Pe'(co2)) the relationship persisted (slope, 0.55; intercept, +32.6; 95% CI, +16.3 to +48.9) but the discrepancy between the two variables increased as reflected by the increase in bias and variability. Conclusion. Non-invasive estimation of CPP can be used for brain monitoring of head-injured patients, but the accuracy of the method may depend on the level of intracranial hypertension.	Hop Bicetre, Serv Anesthesie Reanimat, F-94725 Le Kremlin Bicetre, France; Hop Bicetre, UPRES EA 3540, F-94725 Le Kremlin Bicetre, France		Edouard, AR (corresponding author), Hop Bicetre, Serv Anesthesie Reanimat, F-94725 Le Kremlin Bicetre, France.	alain.edouard@bct.ap-hop-paris.fr	Benhamou, Dan/ABG-7935-2021				Belfort MA, 2000, HYPERTENS PREGNANCY, V19, P331, DOI 10.1081/PRG-100101995; Belfort MA, 1999, AM J OBSTET GYNECOL, V181, P402, DOI 10.1016/S0002-9378(99)70569-7; Benmalek F, 1999, INTENS CARE MED, V25, P399, DOI 10.1007/s001340050865; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Buhre W, 2003, BRIT J ANAESTH, V90, P291, DOI 10.1093/bja/aeg073; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHESNUT RM, 1997, J TRAUMA S, V42, P4; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; CLARK WC, 1989, NEUROSURGERY, V25, P20; Czosnyka M, 1999, J NEUROL NEUROSUR PS, V66, P606, DOI 10.1136/jnnp.66.5.606; De Deyne C S, 2001, Curr Opin Anaesthesiol, V14, P475, DOI 10.1097/00001503-200110000-00003; EVANS DH, 1988, ULTRASOUND MED BIOL, V14, P103, DOI 10.1016/0301-5629(88)90176-7; FESSLER RD, 1993, ANN EMERG MED, V22, P998, DOI 10.1016/S0196-0644(05)82741-6; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hancock SM, 2003, ANESTH ANALG, V96, P847, DOI 10.1213/01.ANE.0000047273.85729.A7; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Kaups KL, 1998, J TRAUMA, V45, P884, DOI 10.1097/00005373-199811000-00007; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lewis SB, 2001, NEUROSURGERY, V48, P369, DOI 10.1097/00006123-200102000-00026; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; May AK, 1997, AM SURGEON, V63, P233; Michel E, 1997, J CEREBR BLOOD F MET, V17, P1127, DOI 10.1097/00004647-199710000-00015; PINHEIRO J, 2001, MIXED EFFECTS MODELS, P30; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosner MJ, 1996, CRIT CARE MED, V24, P1274, DOI 10.1097/00003246-199607000-00040; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Schmidt EA, 2000, ACT NEUR S, V76, P451; *SFAR, 1997, ANN FR ANESTH, V18, P1; Sherman RW, 2002, BRIT J ANAESTH, V89, P687, DOI 10.1093/bja/aef247; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P479, DOI DOI 10.1089/NEU.2000.17.479; Thees C, 2002, ANESTHESIOLOGY, V96, P595, DOI 10.1097/00000542-200203000-00014; Weyland A, 2000, J NEUROSURG ANESTH, V12, P210, DOI 10.1097/00008506-200007000-00002	34	25	29	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	FEB	2005	94	2					216	221		10.1093/bja/aei034			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	885WR	WOS:000226188500014	15591334	Bronze			2022-02-06	
J	Deidrick, KKM; Farmer, JE				Deidrick, Kathleen K. M.; Farmer, Janet E.			School Reentry Following Traumatic Brain Injuryv	PREVENTING SCHOOL FAILURE			English	Article						education; pediatric; school reentry; traumatic brain injury (TBI)	LONG-TERM OUTCOMES; ACADEMIC-ACHIEVEMENT; CHILDREN; ADOLESCENTS; STUDENTS; REHABILITATION; SUPPORT; YOUTH; REINTEGRATION; PERFORMANCE	Successful school reentry following traumatic brain injury (TBI) is critical to recovery. Physical, cognitive, behavioral, academic, and social problems can affect a child's school performance after a TBI. However, early intervention has the potential to improve child academic outcomes and promote effective coping with any persistent changes in functioning. The purpose of this article is to review the topic of school reentry after a childhood TBI. The authors describe 4 essential principles to planning a positive reentry to school: assessment, multidisciplinary teaming, facilitation of peer interactions, and planning for the provision and withdrawal of support. The authors delineate a sequence of steps for promoting school reentry and review existing school reentry programs. The authors also discuss barriers to the school reentry process and possible solutions. The article concludes with a case study that highlights some of the challenges of school reentry and the benefits of using interactive videoconferencing to link rehabilitation and communitybased treatment teams during the reentry process.	[Deidrick, Kathleen K. M.; Farmer, Janet E.] Univ Missouri, Hlth Psychol, Columbia, MO 65211 USA; [Deidrick, Kathleen K. M.; Farmer, Janet E.] Univ Missouri, Thompson Family Ctr Autism & Neurodev, Columbia, MO 65211 USA		Deidrick, KKM (corresponding author), Univ Missouri, Hlth Psychol, Columbia, MO 65211 USA.						Alexander J, 2001, N C Med J, V62, P359; Bohnert AM, 1997, DEV NEUROPSYCHOL, V13, P477, DOI 10.1080/87565649709540688; Catroppa C, 1999, Pediatr Rehabil, V3, P167; Clark E, 1996, J LEARN DISABIL, V29, P549, DOI 10.1177/002221949602900509; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Donders J, 1997, Pediatr Rehabil, V1, P179; Doster J, 2001, Tenn Med, V94, P100; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 2004, HANDBOOK OF PEDIATRIC PSYCHOLOGY IN SCHOOL SETTINGS, P313; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Farmer JE, 1997, REHABIL PSYCHOL, V42, P273; Farmer JE, 2002, DEV NEUROPSYCHOL, V22, P455, DOI 10.1207/S15326942DN2202_2; Farmer JE, 2001, CLIN PEDIATR, V40, P93, DOI 10.1177/000992280104000205; FARMER JE, 1995, SCHOOL PSYCHOL REV, V24, P230; Farmer JE, 1996, J LEARN DISABIL-US, V29, P532, DOI 10.1177/002221949602900508; Gillett J, 2004, NEUROREHABILITATION, V19, P207; Glang A, 2004, NEUROREHABILITATION, V19, P219; Hooper S R, 2001, N C Med J, V62, P350; Hooper S. R., 2001, HDB PSYCHOL SERVICES, P267; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; La Greca AM, 2002, J DEV BEHAV PEDIATR, V23, DOI 10.1097/00004703-200208000-00013; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lash M, 2004, NEUROREHABILITATION, V19, P173; Madan-Swain A, 2004, HANDBOOK OF PEDIATRIC PSYCHOLOGY IN SCHOOL SETTINGS, P637; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; McDonald S, 1998, APHASIOLOGY, V12, P1076, DOI 10.1080/02687039808249472; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Missouri Department of Elementary and Secondary Education, 2001, UND STUD TRAUM BRAIN; Savage RC, 2001, NEUROREHABILITATION, V16, P49; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; SEMRUDCLIKEMAN M, 2001, TRAUMATIC BRAIN INJU; SEXSON SB, 1993, J LEARN DISABIL, V26, P115, DOI 10.1177/002221949302600204; Sohlberg MM, 1998, APHASIOLOGY, V12, P1047, DOI 10.1080/02687039808249469; Sohlberg MM, 2001, J HEAD TRAUMA REHAB, V16, P498, DOI 10.1097/00001199-200110000-00008; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor HG, 2003, REHABIL PSYCHOL, V48, P227, DOI 10.1037/0090-5550.48.4.227; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; Vaughn SL, 2001, J HEAD TRAUMA REHAB, V16, P20, DOI 10.1097/00001199-200102000-00005; Verburg G, 2003, NEUROREHABILITATION, V18, P113; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Warschausky S, 2003, REHABIL PSYCHOL, V48, P250, DOI 10.1037/0090-5550.48.4.250; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Ylvisaker M, 2001, J HEAD TRAUMA REHAB, V16, P76, DOI 10.1097/00001199-200102000-00009; Ylvisaker M, 1998, TRAUMATIC BRAIN INJU, P369	51	25	25	0	0	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1045-988X	1940-4387		PREV SCH FAIL	Prev. Sch. Fail.		2005	49	4					23	33		10.3200/PSFL.49.4.23-33			11	Education & Educational Research	Emerging Sources Citation Index (ESCI)	Education & Educational Research	V2Y9C	WOS:000218037100005					2022-02-06	
J	Tomita, M; Holman, BJ; Santoro, CP; Santoro, TJ				Tomita, Michiyo; Holman, Brita J.; Santoro, Christopher P.; Santoro, Thomas J.			Astrocyte production of the chemokine macrophage inflammatory protein-2 is inhibited by the spice principle curcumin at the level of gene transcription	JOURNAL OF NEUROINFLAMMATION			English	Article								Background: In neuropathological processes associated with neutrophilic infiltrates, such as experimental allergic encephalitis and traumatic injury of the brain, the CXC chemokine, macrophage inflammatory protein-2 (MIP-2) is thought to play a pivotal role in the induction and perpetuation of inflammation in the central nervous system (CNS). The origin of MIP-2 in inflammatory disorders of the brain has not been fully defined but astrocytes appear to be a dominant source of this chemokine. Curcumin is a spice principle in, and constitutes approximately 4 percent of, turmeric. Curcumin's immunomodulating and antioxidant activities suggest that it might be a useful adjunct in the treatment of neurodegenerative illnesses characterized by inflammation. Relatively unexplored, but relevant to its potential therapeutic efficacy in neuroinflammatory syndromes is the effect of curcumin on chemokine production. To examine the possibility that curcumin may influence CNS inflammation by mechanisms distinct from its known anti-oxidant activities, we studied the effect of this spice principle on the synthesis of MIP-2 by astrocytes. Methods: Primary astrocytes were prepared from neonatal brains of CBA/CaJ mice. The cells were stimulated with lipopolysaccharide in the presence or absence of various amount of curcumin or epigallocatechin gallate. MIP-2 mRNA was analyzed using semi-quantitative PCR and MIP-2 protein production in the culture supernatants was quantified by ELISA. Astrocytes were transfected with a MIP-2 promoter construct, pGL3-MIP-2, and stimulated with lipopolysaccharide in the presence or absence of curcumin. Results: The induction of MIP-2 gene expression and the production of MIP-2 protein were inhibited by curcumin. Curcumin also inhibited lipopolysaccharide-induced transcription of the MIP-2 promoter reporter gene construct in primary astrocytes. However MIP-2 gene induction by lipopolysaccharide was not inhibited by another anti-oxidant, epigallocatechin gallate. Conclusion: Our results indicate that curcumin potently inhibits MIP-2 production at the level of gene transcription and offer further support for its potential use in the treatment of inflammatory conditions of the CNS.	[Tomita, Michiyo; Santoro, Thomas J.] Univ N Dakota, Sch Med & Hlth Sci, Dept Med, Grand Forks, ND 58201 USA; [Holman, Brita J.] Boston Univ, Chestnut Hill, MA 02467 USA; [Santoro, Christopher P.] Loyola Univ, Chicago, IL 60626 USA; [Santoro, Thomas J.] Fargo VA Med Ctr, Res Serv, Fargo, ND 58102 USA		Tomita, M (corresponding author), Univ N Dakota, Sch Med & Hlth Sci, Dept Med, 501 North Columbia Rd, Grand Forks, ND 58201 USA.	mtomita@medicine.nodak.edu; bjholman@bu.edu; csantor@luc.edu; tsantoro@medicine.nodak.edu			Arthritis Foundation	This study was, in part, supported by the North Central Chapter of the Arthritis Foundation.	Ambegaokar SS, 2003, NEUROENDOCRINOL LETT, V24, P469; Arbiser JL, 1998, MOL MED, V4, P376, DOI 10.1007/BF03401744; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Das R, 2003, J BIOL CHEM, V278, P28593, DOI 10.1074/jbc.M303445200; Diab A, 1999, INFECT IMMUN, V67, P2590, DOI 10.1128/IAI.67.5.2590-2601.1999; FRANZOSO G, 1994, J EXP MED, V180, P1445, DOI 10.1084/jem.180.4.1445; Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1; HUANG MT, 1988, CANCER RES, V48, P5941; Kang BY, 1999, EUR J PHARMACOL, V384, P191, DOI 10.1016/S0014-2999(99)00690-1; Kang BY, 1999, BRIT J PHARMACOL, V128, P380, DOI 10.1038/sj.bjp.0702803; Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Monsonego A, 2003, SCIENCE, V302, P834, DOI 10.1126/science.1088469; Nygardas PT, 2000, EUR J IMMUNOL, V30, P1911, DOI 10.1002/1521-4141(200007)30:7<1911::AID-IMMU1911>3.0.CO;2-E; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Otto VI, 2002, J NEUROCHEM, V80, P824, DOI 10.1046/j.0022-3042.2001.00748.x; Pan MH, 2000, BIOCHEM PHARMACOL, V60, P1665, DOI 10.1016/S0006-2952(00)00489-5; Pousset F, 2001, J NEUROCHEM, V79, P726, DOI 10.1046/j.1471-4159.2001.00569.x; Santoro T, 1995, GENOMICS, V30, P558, DOI 10.1006/geno.1995.1277; SANTORO TJ, 1988, J EXP MED, V167, P1713, DOI 10.1084/jem.167.5.1713; Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744; Sreejayan Rao M. N., 1997, J PHARM PHARMACOL, V49, P105; Sreejayan Rao MN, 1994, J PHARM PHARMACOL, V46, P1013; Tomita M, 2002, PHYTOTHER RES, V16, P36, DOI 10.1002/ptr.834; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200	25	25	27	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.		2005	2								8	10.1186/1742-2094-2-8			7	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	V29PC	WOS:000208759300008	15733321	gold, Green Published			2022-02-06	
J	Teng, ZP; Chen, J; Chau, LY; Galunic, N; Regan, RF				Teng, ZP; Chen, J; Chau, LY; Galunic, N; Regan, RF			Adenoviral transfer of the heme oxygenase-1 gene protects striatal astrocytes from heme-mediated oxidative injury	NEUROBIOLOGY OF DISEASE			English	Article						free radical; hemoglobin; hemorrhage; iron; mouse; oxidative stress; stroke	EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; TRAUMATIC BRAIN-INJURY; RAT-BRAIN; HEMOGLOBIN TOXICITY; OXIDANT STRESS; HAMSTER FIBROBLASTS; CORTICAL ASTROCYTES; TIN-PROTOPORPHYRIN; IN-VITRO; INDUCTION	Heme oxygenase-1 (HO-1) is induced in the CNS after hemorrhage, and may have an effect on injury to surrounding tissue. Hemin, the preferred substrate of HO, is a neurotoxin that is present in intracranial hematomas. In a prior study, we observed that HO inhibitors increased the vulnerability of cultured cortical astrocytes to heme-mediated oxidative injury. To investigate the effect of HO more specifically, we used an adenoviral vector encoding the human HO-1 gene to specifically increase HO-1 expression. Incubation with 100 MOI of the HO-1 adenovirus (Adv-HHO-1) for 24 h increased both HO-1 protein and HO activity; a control adenovirus lacking the HO-1 gene had no effect. Using a DNA probe that was specific for human HO-1, 80.5 +/- 7.2% of astrocytes were observed to be infected by in situ hybridization. The cell death produced by 30-60 muM hemin was significantly reduced by pretreatment with 100 MOI Adv-HHO-1, as assessed by LDH release, propidium iodide exclusion, and MTT reduction assay. The threefold increase in cell protein oxidation produced by hemin was also attenuated in cultures pretreated with Adv-HHO-1. These results support the hypothesis that HO-1 protects astrocytes from heme-mediated oxidative injury. Specifically increasing astrocytic HO-1 by gene transfer may have a beneficial effect on hemorrhagic CNS injury. (C) 2004 Elsevier Inc. All rights reserved.	Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA; Acad Sinica, Inst Biochem Sci, Div Cardiovasc Res, Taipei, Taiwan		Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Emergency Med, 1020 Sansom St,239 Thompson Bldg, Philadelphia, PA 19107 USA.	Raymond.Regan@jefferson.edu	Chau, Lee-Young/N-7659-2018	Chau, Lee-Young/0000-0002-6316-2328	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042273] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS042273] Funding Source: Medline		ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; BALLA G, 1992, J BIOL CHEM, V267, P18148; Boehning D, 2003, NEURON, V40, P129, DOI 10.1016/S0896-6273(03)00596-8; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen J, 2004, BIOCHEM BIOPH RES CO, V318, P88, DOI 10.1016/j.bbrc.2004.03.187; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; daSilva JL, 1996, J LAB CLIN MED, V128, P290, DOI 10.1016/S0022-2143(96)90030-X; Dennery PA, 1997, J BIOL CHEM, V272, P14937, DOI 10.1074/jbc.272.23.14937; Dennery PA, 1998, J CLIN INVEST, V101, P1001, DOI 10.1172/JCI448; Dennery PA, 1996, AM J PHYSIOL-LUNG C, V271, pL672, DOI 10.1152/ajplung.1996.271.4.L672; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dwyer BE, 1998, J NEUROCHEM, V71, P2497; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Goldstein L, 2003, J NEUROSCI RES, V73, P113, DOI 10.1002/jnr.10633; GRUNDEMAR L, 1997, TRENDS PHARMACOL SCI, P18; HARRINGTON JP, 1993, INT J BIOCHEM, V25, P661, DOI 10.1016/0020-711X(93)90350-N; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Iyer S, 1998, J BIOL CHEM, V273, P2692, DOI 10.1074/jbc.273.5.2692; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; Kaizu T, 2003, KIDNEY INT, V63, P1393, DOI 10.1046/j.1523-1755.2003.00882.x; KAJIKAWA H, 1979, Neurologia Medico-Chirurgica, V19, P61, DOI 10.2176/nmc.19.61; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; LETARTE PB, 1993, J NEUROSURG, V79, P252, DOI 10.3171/jns.1993.79.2.0252; LINDEN DJ, 1993, J NEUROPHYSIOL, V70, P2673, DOI 10.1152/jn.1993.70.6.2673; LUO D, 1994, EUR J PHARMACOL, P267; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Mautes AEM, 1998, BRAIN RES, V795, P17, DOI 10.1016/S0006-8993(98)00230-3; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; MEFFERT MK, 1994, NEURON, V13, P1225, DOI 10.1016/0896-6273(94)90060-4; NATH KA, 1994, J LAB CLIN MED, V123, P461; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; NUTTER LM, 1994, J LAB CLIN MED, V123, P506; Panahian N, 1999, J NEUROCHEM, V72, P1187; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Quan S, 2002, J CELL BIOCHEM, V85, P410, DOI 10.1002/jcb.10147; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236; Regan RF, 2002, NEUROSCIENCE, V113, P985, DOI 10.1016/S0306-4522(02)00243-9; REGAN RF, 1993, NEUROSCI LETT, V153, P219, DOI 10.1016/0304-3940(93)90326-G; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; SMITH A, 1993, J BIOL CHEM, V268, P7365; STOCKER R, 1990, FREE RADICAL RES COM, V9, P101, DOI 10.3109/10715769009148577; STOCKER R, 1987, SCIENCE; Suttner DM, 1999, FASEB J, V13, P1800, DOI 10.1096/fasebj.13.13.1800; Takizawa S, 1998, J CEREBR BLOOD F MET, V18, P559, DOI 10.1097/00004647-199805000-00011; TRAKSHEL GM, 1988, ARCH BIOCHEM BIOPHYS, V260, P732, DOI 10.1016/0003-9861(88)90503-6; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; VANDEPUTTE C, 1994, CELL BIOL TOXICOL, V10, P415, DOI 10.1007/BF00755791; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; Wagner KR, 2000, CELL MOL BIOL, V46, P597; Weng YH, 2003, J BIOL CHEM, V278, P50999, DOI 10.1074/jbc.M307644200; Xi GH, 2002, NEUROSURG CLIN N AM, V13, P371, DOI 10.1016/S1042-3680(02)00007-4; Zager RA, 1997, KIDNEY INT, V51, P728, DOI 10.1038/ki.1997.104	58	25	26	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	NOV	2004	17	2					179	187		10.1016/j.nbd.2004.07.009			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	866EV	WOS:000224757500007	15474356				2022-02-06	
J	Van den Heuvel, C; Donkin, JJ; Finnie, JW; Blumbergs, PC; Kuchel, T; Koszyca, B; Manavis, J; Jones, NR; Reilly, PL; Vink, R				Van den Heuvel, C; Donkin, JJ; Finnie, JW; Blumbergs, PC; Kuchel, T; Koszyca, B; Manavis, J; Jones, NR; Reilly, PL; Vink, R			Downregulation of amyloid precursor protein (APP) expression following post-traumatic cyclosporin-A administration	JOURNAL OF NEUROTRAUMA			English	Article						amyloid precursor protein; cyclosporin-A; head injury model; immunocytochemistry; RT-PCR; sheep; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NERVE GROWTH-FACTOR; ALZHEIMERS-DISEASE; SECRETED FORMS; UP-REGULATION; BETA-PROTEIN; MESSENGER-RNA; KINASE-C; AXONAL DAMAGE; CELL-SURFACE	The aim of these studies was to assess and quantitate the effects of cyclosporin-A (CyA) on brain APP messenger RNA and neuronal perikaryal APP antigen expression following controlled focal head impact in sheep. Impact results in a significant increase in both APP mRNA and neuronal perikaryal APP antigen expression. Post-traumatic administration of CyA (intrathecal 10 mg/kg) resulted in a reduction in APP mRNA and neuronal perikaryal antigen expression. At 2 h postinjury, CyA treatment caused a statistically significant (p < 0.05) 1.3 +/- 0.1-fold decrease in APP mRNA in the central gray matter of impacted sheep compared to untreated impacted sheep. A more profound reduction in APP mRNA synthesis (1.6 +/- 0.2 fold) was evident at 6 h (P < 0.05). The mean percentage brain area with APP immunoreactive neuronal perikarya at 6 h post-injury was 94.5% in untreated impacted animals, 10.0% in CyA-treated impacted animals, 5.5% in untreated non-impacted animals, and 6% in CyA-treated non-impacted controls. These results demonstrate that CyA has a downregulatory effect on increased APP expression caused by TBI.	Univ Adelaide, Dept Pathol, Adelaide, SA 5005, Australia; Hanson Inst, Ctr Neurol Dis, Adelaide, SA, Australia; IMVS, Vet Div, Adelaide, SA, Australia; Royal Adelaide Hosp, Dept Neurosurg, Adelaide, SA, Australia		Van den Heuvel, C (corresponding author), Univ Adelaide, Dept Pathol, GPO Box 498, Adelaide, SA 5005, Australia.	corinna.vandenheuvel@adelaide.edu.au	Vink, Robert/S-5616-2019; Vink, Robert/J-7351-2012	Vink, Robert/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; , Corinna/0000-0003-0664-8935			Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Caputi A, 1997, J NEUROCHEM, V68, P2523; CLARRIS HJ, 1994, J NEUROSCI RES, V38, P248, DOI 10.1002/jnr.490380303; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DOYLE E, 1990, NEUROSCI LETT, V115, P97, DOI 10.1016/0304-3940(90)90524-D; Furukawa K, 1996, J NEUROCHEM, V67, P1882, DOI 10.1046/j.1471-4159.1996.67051882.x; Furukawa K, 1996, NATURE, V379, P74, DOI 10.1038/379074a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GITTER BD, 1995, EUR J PHARM-MOLEC PH, V289, P439, DOI 10.1016/0922-4106(95)90152-3; GOODMAN Y, 1994, EXP NEUROL, V128, P1, DOI 10.1006/exnr.1994.1107; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Helekar SA, 1997, P NATL ACAD SCI USA, V94, P5432, DOI 10.1073/pnas.94.10.5432; HUBER G, 1993, BRAIN RES, V603, P348, DOI 10.1016/0006-8993(93)91261-P; Ishida A, 1997, NEUROREPORT, V8, P2133, DOI 10.1097/00001756-199707070-00009; JIN LW, 1994, J NEUROSCI, V14, P5461; Johnson D, 1997, EDN, V42, P94; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Lee RKK, 2000, ANN NY ACAD SCI, V920, P261; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lewis SB, 1996, J NEUROTRAUM, V13, P505, DOI 10.1089/neu.1996.13.505; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mattson MP, 1999, J NEUROCHEM, V73, P532, DOI 10.1046/j.1471-4159.1999.0730532.x; MILWARD EA, 1992, NEURON, V9, P129, DOI 10.1016/0896-6273(92)90228-6; MOYA KL, 1994, DEV BIOL, V161, P597, DOI 10.1006/dbio.1994.1055; MUCKE L, 1994, BRAIN RES, V666, P151, DOI 10.1016/0006-8993(94)90767-6; OHSAWA I, 1995, BIOCHEM BIOPH RES CO, V213, P52, DOI 10.1006/bbrc.1995.2097; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Parks JK, 2001, J NEUROCHEM, V76, P1050, DOI 10.1046/j.1471-4159.2001.00112.x; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pyrzynska B, 2001, NEUROCHEM INT, V38, P409, DOI 10.1016/S0197-0186(00)00105-4; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; ROCH JM, 1994, P NATL ACAD SCI USA, V91, P7450, DOI 10.1073/pnas.91.16.7450; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Seo JH, 2001, BIOL PSYCHIAT, V49, P240, DOI 10.1016/S0006-3223(00)01124-0; SLACK BE, 1993, ANN NY ACAD SCI, V695, P128, DOI 10.1111/j.1749-6632.1993.tb23040.x; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Takahashi T, 2001, J INVEST DERMATOL, V117, P605, DOI 10.1046/j.0022-202x.2001.01452.x; TREJO J, 1994, J BIOL CHEM, V269, P21682; Van den Heuvel C, 2000, J NEUROTRAUM, V17, P1041, DOI 10.1089/neu.2000.17.1041; Van den Heuvel C, 1999, EXP NEUROL, V159, P441, DOI 10.1006/exnr.1999.7150; Van den Heuvel C, 2000, J CLIN NEUROSCI, V7, P140; WOLF BA, 1995, J BIOL CHEM, V270, P4916, DOI 10.1074/jbc.270.9.4916; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	54	25	25	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2004	21	11					1562	1572		10.1089/0897715042441783			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	872IL	WOS:000225200800004	15684649				2022-02-06	
J	Fujihara, S; Brucki, SMD; Rocha, MSG; Carvalho, AA; Piccolo, AC				Fujihara, S; Brucki, SMD; Rocha, MSG; Carvalho, AA; Piccolo, AC			Prevalence of presenile dementia in a tertiary outpatient clinic	ARQUIVOS DE NEURO-PSIQUIATRIA			English	Article						presenile dementia; vascular dementia; Alzheimer's disease; epidemiology	INTERNATIONAL WORKSHOP; VASCULAR DEMENTIA; FRONTOTEMPORAL DEMENTIA; ALZHEIMERS-DISEASE; DIAGNOSIS; SERVICES; CRITERIA; BRAZIL; YOUNG	There are very few reports about prevalence of presenile dementia in Brazil. We reviewed files of patients evaluated with early onset of cognitive impairment in our institution. Among 141 patients (61% males) there was no difference between gender by age at onset or at first evaluation. We have observed an increasing number of patients after 50 years. The most frequent causes were: vascular dementia (36.9%), Alzheimer's disease (20.3%) and traumatic brain injury (9.2%). There was difference among dementia type by age of onset and first evaluation, educational level and length of dementia. These results may be compared with those from other neurologic services in order to replicate or confirm these results.	Hosp Santa Marcelina, Sao Paulo, Brazil		Fujihara, S (corresponding author), Rua Humberto Primo 740-123, BR-04018032 Sao Paulo, Brazil.	sbrucki@uol.com.br	ROCHA, MARIA SHEILA G/G-6645-2012; Brucki, Sonia MD/B-5736-2014; Brucki, Sonia/L-4201-2019; ROCHA, MARIA SHEILA GUIMARAES/AAK-7584-2020	ROCHA, MARIA SHEILA G/0000-0003-4312-3994; Brucki, Sonia MD/0000-0002-8303-6732; Brucki, Sonia/0000-0002-8303-6732; ROCHA, MARIA SHEILA GUIMARAES/0000-0003-4312-3994			Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014; BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416; CAIXETA L, 2003, ARQ NEUROPSIQUIAT S2, V61, pS19; CANINEU PR, 2003, ARQ NEURO-PSIQUIAT, V61, pS21; DELANY N, 1995, INT J GERIATR PSYCH, V10, P597, DOI 10.1002/gps.930100710; Elberling TV, 2002, NEUROLOGY, V59, P1259, DOI 10.1212/WNL.59.8.1259; ENGELHARDT E, 2001, ARQ NEUROPSIQUIAT S3, V59, pS3; Harvey RJ, 2003, J NEUROL NEUROSUR PS, V74, P1206, DOI 10.1136/jnnp.74.9.1206; Harvey RJ, 1998, YOUNG ONSET DEMENTIA; HOFFMAN A, 1991, INT J EPIDEMIOL, V20, P736; Ikeda M, 2001, NEUROLOGY, V57, P839, DOI 10.1212/WNL.57.5.839; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; KOKMEN E, 1989, NEUROLOGY, V39, P773, DOI 10.1212/WNL.39.6.773; MCGONIGAL G, 1993, BRIT MED J, V306, P680, DOI 10.1136/bmj.306.6879.680; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; McKeith IG, 1999, NEUROLOGY, V53, P902, DOI 10.1212/WNL.53.5.902; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NEWENS AJ, 1993, PSYCHOL MED, V23, P631, DOI 10.1017/S0033291700025411; Panegyres PK, 2000, MED J AUSTRALIA, V173, P279, DOI 10.5694/j.1326-5377.2000.tb125651.x; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Silva DW, 2002, ARQ NEURO-PSIQUIAT, V60, P996; Takada LT, 2003, ARQ NEURO-PSIQUIAT, V61, P925, DOI 10.1590/S0004-282X2003000600007; TREVES T, 1986, ARCH NEUROL-CHICAGO, V43, P26, DOI 10.1001/archneur.1986.00520010022014; Vale FAC, 2002, ARQ NEURO-PSIQUIAT, V60, P548, DOI 10.1590/S0004-282X2002000400006; Varma AR, 2002, ACTA NEUROL SCAND, V105, P261, DOI 10.1034/j.1600-0404.2002.1o148.x; Woodburn K J, 1999, Health Bull (Edinb), V57, P384	27	25	30	0	4	ASSOC ARQUIVOS NEURO- PSIQUIATRIA	SAO PAULO SP	PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL	0004-282X	1678-4227		ARQ NEURO-PSIQUIAT	Arq. Neuro-Psiquiatr.	SEP	2004	62	3A					592	595		10.1590/S0004-282X2004000400005			4	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	853AV	WOS:000223799400005	15334214	Green Submitted, Green Published, gold			2022-02-06	
J	Pou, JAL; Centellas, JMA; Sans, MP; Barcena, JP; Vivas, MC; Ramirez, JH; Juve, JI				Pou, JAL; Centellas, JMA; Sans, MP; Barcena, JP; Vivas, MC; Ramirez, JH; Juve, JI			Monitoring midline shift by transcranial color-coded sonography in traumatic brain injury - A comparison with cranial computerized tomography	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; transcranial color-coded sonography; midline shift	SPACE-OCCUPYING STROKE; DUPLEX-SONOGRAPHY; HEAD-INJURY; 3RD-VENTRICLE	Objective. Transcranial color-coded duplex sonography (TCCDS) is a non invasive bedside technique that allows the determination of midline shift (MLS). The purpose of our study was to compare MLS measurements using TCCDS with those obtained with cranial computerized tomography (CT) in patients with traumatic brain injury (TBI). Design. Prospective study. Settings. Intensive care unit in a university hospital. Patients. Forty-one traumatic brain-injured patients (35 men and 6 women). Interventions. A total of 60 studies were conducted with a time interval between the cranial CT and the TCCDS studies of 322+/-216 min. Results. The coefficient of correlation between MLS measured by CT and TCCDS was 0.88, the bias was 0.12 mm, the precision was 1.08 mm and the limits of agreement were +2.33 to -2.07 mm. There were no statistically significant differences in MLS measured by the two techniques in terms of: sex, age or type of lesion according to the Traumatic Coma Data Bank classification. Conclusion. The TCCDS is a non-invasive bedside technique that is valid for determining MLS in patients with traumatic brain injury. Due to the risks involved in the transportation of traumatic brain-injured patients to the radiology department, this bedside technique is specially interesting in these patients.	Hosp Univ Son Dureta, Serv Med Intensiva, Palma de Mallorca, Baleares, Spain; Hosp Univ Son Dureta, Unidad Coronaria, Palma de Mallorca, Baleares, Spain; Hosp Univ Son Dureta, Serv Radiodiagnost, Palma de Mallorca, Baleares, Spain		Pou, JAL (corresponding author), Hosp Univ Son Dureta, Serv Med Intensiva, Palma de Mallorca, Baleares, Spain.	ja_llompart@hotmail.com					BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MURSCH K, 1995, ULTRASCHALL MED, V16, P65, DOI 10.1055/s-2007-1003989; QUATTROCCHI KB, 1991, SURG NEUROL, V35, P183, DOI 10.1016/0090-3019(91)90069-L; Seidel G, 1996, J NEUROIMAGING, V6, P227, DOI 10.1111/jon199664227; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Stolz E, 1999, AM J NEURORADIOL, V20, P1567; Woydt M, 1996, ZBL NEUROCHIR, V57, P129; Zipper SG, 2002, EUR J NEUROL, V9, P1, DOI 10.1046/j.1468-1331.2002.00272.x	10	25	27	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	AUG	2004	30	8					1672	1675		10.1007/s00134-004-2348-8			4	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	842OT	WOS:000223014400026	15197433				2022-02-06	
J	Donders, J; Minnema, MT				Donders, J; Minnema, MT			Performance discrepancies on the California Verbal Learning Test-Children's Version (CVLT-C) in children with traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; learning; memory; proactive interference; processing speed	HEAD-INJURY; EXECUTIVE FUNCTION; WISC-III; PROACTIVE-INTERFERENCE; FRONTAL-LOBE; MEMORY; FREQUENCY; EPILEPSY; DEFICITS; TERM	One hundred sixty-seven children with traumatic brain injury (TBI), selected from an 8-year series of consecutive referrals to a Midwestern rehabilitation hospital, completed the California Verbal Learning Test-Children's Version (CVLT-C) and the Wechsler Intelligence Scale for Children-Third Edition (WISC-III) within I year after injury. A large proactive interference (PI) effect, defined as performance on the second list that was at least 1.5 standard deviations below that on the 1st one, was statistically significantly more common in this clinical sample (2 1%) than in the CVLT-C standardization sample (11%). Other performance discrepancies, including retroactive interference, rapid forgetting, and retrieval problems, occurred at approximately the same rate in the clinical and standardization samples. Children with anterior cerebral lesions were about 3 times less likely to have a large PI effect than children without such lesions, but the former group performed worse on the first CVLT-C list. The impact of pediatric TBI on a wide range of CVLT-C quantitative variables was mediated by speed of information processing, as assessed by the WISC-III Processing Speed factor index. It is concluded that failure to release from PI is somewhat common, although certainly not universal, in children with TBI. Unlike with adults, anterior cerebral lesions are not associated selectively with an increased risk for PI after pediatric TBI but rather with a reduced efficiency of allocation of cognitive resources. Deficits in speed of information processing appear to be primarily responsible for the learning deficits on the CVLT-C after pediatric TBI.	Mary Free Bed Hosp & Rehabil Ctr, Psychol Serv, Grand Rapids, MI 49503 USA; Calvin Coll, Dept Psychol, Grand Rapids, MI 49506 USA		Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jdonders@mfbrc.com					DELIS D, 1994, CALIFORNIA VERBAL LE; Donders J, 2001, CHILD NEUROPSYCHOL, V7, P99, DOI 10.1076/chin.7.2.99.3126; Donders J, 1996, CHILD NEUROPSYCHOL, V2, P185, DOI 10.1080/09297049608402251; Donders J, 1999, J INT NEUROPSYCH SOC, V5, P26, DOI 10.1017/S1355617799511041; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V13, P1305; Gioia GA IP, 2000, BEHAV RATING INVENTO; Hanten G, 2002, CHILD NEUROPSYCHOL, V8, P107, DOI 10.1076/chin.8.2.107.8729; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Kail R, 2002, CHILD DEV, V73, P1703, DOI 10.1111/1467-8624.00500; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McDonald CR, 2001, ARCH CLIN NEUROPSYCH, V16, P571, DOI 10.1016/S0887-6177(00)00068-8; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Numan B, 2000, J CLIN PSYCHOL, V56, P553, DOI 10.1002/(SICI)1097-4679(200004)56:4<553::AID-JCLP8>3.0.CO;2-Q; Precourt S, 2002, DEV NEUROPSYCHOL, V21, P173, DOI 10.1207/S15326942DN2102_4; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Schinka JA, 1998, PSYCHOL ASSESSMENT, V10, P171, DOI 10.1037/1040-3590.10.2.171; SMITH ML, 1995, NEUROPSYCHOLOGIA, V33, P275; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; TEASDALE G, 1974, LANCET, V2, P81; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483; White DA, 2001, NEUROPSYCHOLOGY, V15, P221, DOI 10.1037/0894-4105.15.2.221; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Williams J, 2001, CHILD NEUROPSYCHOL, V7, P15, DOI 10.1076/chin.7.1.15.3148; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	29	25	25	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2004	10	4					482	488		10.1017/S1355617704104025			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	833VA	WOS:000222367200002	15327727				2022-02-06	
J	Pugliesi, DMC; Cunha, RF; Delbem, ACB; Sundefeld, MLMM				Pugliesi, DMC; Cunha, RF; Delbem, ACB; Sundefeld, MLMM			Influence of the type of dental trauma on the pulp vitality and the time elapsed until treatment: a study in patients aged 0-3 years	DENTAL TRAUMATOLOGY			English	Article						dental trauma; primary teeth; dental luxation; crown fracture	PERMANENT SUCCESSORS; PARENTAL AWARENESS; PRIMARY DENTITION; PRIMARY INCISORS; TEETH; MANAGEMENT; CHILDREN; SEQUELAE	The purpose of the present study was to determine the influence of the type of trauma on the pulp vitality and the time elapsed until seeking dental care in children aged 0-3 years seen at the Baby Clinic of the Aracatuba Dental School, UNESP. A total of 1813 records were analyzed. Two hundred and three patients, corresponding to 302 traumatized teeth, were assessed clinically and radiographically. Hard-tissue injuries were the most frequent (52%), with a predominance of enamel crown fractures (41.4%), followed by concussions (12.6%) and intrusions (11.6%). Clinical and radiographic examination revealed that 72% of the traumatized teeth maintained pulp vitality. In the case of supporting-tissue lesions, 51.1% of the patients sought care within 1-15 days after injury, while in the case of hard-tissue injuries, 52.7% sought care only after 16 days. The results showed that supporting-tissue injuries had a significant influence on the faster seeking of dental care.	UNESP, Sch Dent, Dept Pediat Dent, BR-16015050 Aracatuba, SP, Brazil; UNESP, Sch Dent, Extens Course Pediat Dent, BR-16015050 Aracatuba, SP, Brazil		Cunha, RF (corresponding author), UNESP, Sch Dent, Dept Pediat Dent, Rua Jose Bonifacio 1193, BR-16015050 Aracatuba, SP, Brazil.	cunha@foa.unesp.br	Delbem, Alberto/P-4011-2019; Delbem, Alberto C B/E-8621-2012; Cunha, Robson/E-9650-2014	Delbem, Alberto/0000-0002-8159-4853; Delbem, Alberto C B/0000-0002-8159-4853; Cunha, Robson/0000-0002-0849-3247			ANDREASEN J O, 1985, Endodontics and Dental Traumatology, V1, P45; Andreasen J O, 1972, Int J Oral Surg, V1, P235, DOI 10.1016/S0300-9785(72)80042-5; Ben Bassat Y, 1985, Pediatr Dent, V7, P37; BENBASSAT Y, 1989, J DENT CHILD, V56, P112; BENNETT DT, 1964, BRIT DENT J, V116, P52; Borum MK, 1998, ENDOD DENT TRAUMATOL, V14, P31; Cardoso M, 2002, DENT TRAUMATOL, V18, P129, DOI 10.1034/j.1600-9657.2002.00030.x; Cunha R F, 2001, J Clin Pediatr Dent, V25, P199; Cunha RF, 2000, J DENT CHILD, V67, P89; Cunha RF, 2001, DENT TRAUMATOL, V17, P210; Dale RA, 2000, EMERG MED CLIN N AM, V18, P521, DOI 10.1016/S0733-8627(05)70141-3; FRIED I, 1995, J DENT CHILD, V62, P256; Fried Irwin, 1996, Pediatric Dentistry, V18, P145; GARCIA-GODOY F, 1987, Endodontics and Dental Traumatology, V3, P126; GARCIAGODOY F, 1989, ENDOD DENT TRAUMATOL, V5, P180; HOLAN G, 1992, ENDOD DENT TRAUMATOL, V8, P12; Holan Gideon, 1999, Pediatric Dentistry, V21, P242; JOHO JP, 1980, J DENT CHILD, V47, P167; Kahabuka FK, 2001, DENT TRAUMATOL, V17, P109, DOI 10.1034/j.1600-9657.2001.017003109.x; Mackie I C, 1996, Dent Update, V23, P69; ONETTO JE, 1994, ENDOD DENT TRAUMATOL, V10, P223; Osuji O O, 1996, Int Dent J, V46, P165; RAPHAEL SL, 1990, AUST DENT J, V35, P130, DOI 10.1111/j.1834-7819.1990.tb05878.x; Sae-Lim V, 2001, DENT TRAUMATOL, V17, P71, DOI 10.1034/j.1600-9657.2001.017002071.x; Sae-Lim V, 1999, ENDOD DENT TRAUMATOL, V15, P37; Soporowski Nancy Jo, 1994, Pediatric Dentistry, V16, P96; Tahmassebi J F, 1999, Dent Update, V26, P138; Wilson C F, 1995, Dent Clin North Am, V39, P133	28	25	28	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	JUN	2004	20	3					139	142		10.1111/j.1600-4469.2004.00242.x			4	Dentistry, Oral Surgery & Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Dentistry, Oral Surgery & Medicine	821CF	WOS:000221436600003	15144444				2022-02-06	
J	Fisher, AJ; Donnelly, SC; Pritchard, G; Dark, JH; Corris, PA				Fisher, AJ; Donnelly, SC; Pritchard, G; Dark, JH; Corris, PA			Objective assessment of criteria for selection of donor lungs suitable for transplantation	THORAX			English	Article							LIBERALIZATION; INTERLEUKIN-8	Background: Donor organ shortage severely limits lung transplantation as a therapeutic option, yet many potential donor lungs are deemed unsuitable by clinical selection criteria. Methods: Of 39 consecutive potential donor lungs, 14 were accepted and 25 excluded by clinical selection criteria. All were evaluated prospectively by clinical assessment, bronchoscopy, and bronchoalveolar lavage (BAL) to evaluate objectively the discrimination of pulmonary infection and injury. Results: Accepted donors were significantly younger than those excluded ( mean (SD) age 36.7 (15.3) years v 49.5 (13.2) years; p = 0.009, unpaired t test) and were more likely to have suffered traumatic brain death (50% v 20%; p = 0.07, Fisher's exact test). Oxygenation (PaO2: FiO(2)) was higher in accepted donors than in excluded donors (median (range) 63.2 (48 - 82.5) kPa v 43.1 (7.7 - 71.7) kPa; p = 0.0001, Mann-Whitney test). Positive formal BAL culture was more frequent in accepted donors (75%) than in those excluded (43%; p = 0.1, Fisher's exact test). There was no significant difference in the percentage and concentration of neutrophils in BAL fluid between accepted and excluded donors ( median (range) 37.9 (0 - 96.9)% and 44.6 (0 - 1190) x 10(3)/ ml v 36 (1 - 98.1)% and 46 (0.2 - 1457) x10(3)/ml), nor in the BAL fluid concentration of tumour necrosis factor-alpha (140 (0 - 340) pg/ml v 160 (0 - 760) pg/ml) or interleukin 8 (810 (33 - 17 600) pg/ml v 540 (0 - 15 110) pg/ml). Conclusion: Current selection criteria are poor discriminators of pulmonary injury and infection and lead to the exclusion of potentially usable donor lungs.	Newcastle Univ, Freeman Hosp, Dept Cardiopulm Transplantat & Immunobiol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Newcastle Univ, Freeman Hosp, Transplantat Res Grp, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Univ Coll Dublin, Conway Inst, Dublin 2, Ireland; St Vincents Hosp, Dept Med & Therapeut, Dublin 4, Ireland		Corris, PA (corresponding author), Freeman Rd Hosp, Dept Thorac Med, High Heaton, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.	paul.corris@ncl.ac.uk	Fisher, Andrew J/A-2160-2012	Donnelly, Seamas/0000-0001-7145-1843			Anyanwu AC, 2002, HEART, V87, P449, DOI 10.1136/heart.87.5.449; Aziz TM, 2002, ANN THORAC SURG, V73, P1599, DOI 10.1016/S0003-4975(02)03420-3; Bhorade SM, 2000, J HEART LUNG TRANSPL, V19, P1199, DOI 10.1016/S1053-2498(00)00215-1; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; Fisher AJ, 1998, THORAX, V53, P818, DOI 10.1136/thx.53.10.818; Fisher AJ, 2001, AM J RESP CRIT CARE, V163, P259, DOI 10.1164/ajrccm.163.1.2005093; Fisher AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8; Grover FL, 1997, AM J SURG, V173, P523, DOI 10.1016/S0002-9610(97)00004-4; KRON IL, 1993, ANN SURG, V217, P518, DOI 10.1097/00000658-199305010-00012; Pierre AF, 2002, J THORAC CARDIOV SUR, V123, P421, DOI 10.1067/mtc.2002.120345; SHUMWAY SJ, 1994, ANN THORAC SURG, V57, P92, DOI 10.1016/0003-4975(94)90371-9; Starnes VA, 1999, ANN THORAC SURG, V68, P2279, DOI 10.1016/S0003-4975(99)01155-8; SUNDARESAN S, 1995, J THORAC CARDIOV SUR, V109, P1075, DOI 10.1016/S0022-5223(95)70190-7; Takada M, 1998, TRANSPLANTATION, V65, P1533, DOI 10.1097/00007890-199806270-00001; Trulock EP, 1997, AM J RESP CRIT CARE, V155, P789, DOI 10.1164/ajrccm.155.3.9117010; *UKTSSA, 1996, CARD ORG TRANSPL AUD; Ware LB, 2002, LANCET, V360, P619, DOI 10.1016/S0140-6736(02)09774-X; Weill D, 2002, J HEART LUNG TRANSPL, V21, P555, DOI 10.1016/S1053-2498(01)00415-6; Weill D, 2002, CHEST, V121, P2029, DOI 10.1378/chest.121.6.2029; Winton T L, 1992, Semin Thorac Cardiovasc Surg, V4, P79	20	25	26	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376	1468-3296		THORAX	Thorax	MAY 1	2004	59	5					434	437		10.1136/thx.2003.007542			4	Respiratory System	Science Citation Index Expanded (SCI-EXPANDED)	Respiratory System	815WQ	WOS:000221072800015	15115876	Green Published, Bronze			2022-02-06	
J	Meade, MA; Taylor, LA; Kreutzer, JS; Marwitz, JH; Thomas, V				Meade, MA; Taylor, LA; Kreutzer, JS; Marwitz, JH; Thomas, V			A preliminary study of acute family needs after spinal cord injury: Analysis and implications	REHABILITATION PSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; ACUTE-CARE PERIOD; EMOTIONAL-REACTIONS; QUALITY; LIFE; MARRIAGES; OUTCOMES; PATIENT; STAFF	Objective: To address the paucity of research on family needs following spinal cord injury (SCI). Study Design: Prospective cross-sectional design. Setting: Inpatient SCI rehabilitation unit within a Level I trauma center. Participants: Family members of 17 inpatients with SCI. Main Outcome Measure: Family Needs Questionnaire (FNQ). Results: Eighteen of the 40 FNQ needs were rated as important or very important by 100% of the respondents. Health Information Needs were rated as most important and Instrumental Support Needs as least important. Involvement With Care Needs were most often met, whereas Emotional Support Needs were most often unmet. Conclusions: The FNQ is a promising measure of family members' needs after SCI and treatment planning and program evaluation tool. Findings affirm that family education is important during rehabilitation.	Virginia Commonwealth Univ, Med Ctr, Div Rehabil Psychol & Neuropsychol, Dept Phys Med & Rehabil, Richmond, VA 23298 USA		Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Med Ctr, Div Rehabil Psychol & Neuropsychol, Dept Phys Med & Rehabil, POB 980542, Richmond, VA 23298 USA.	jskreutz@hsc.vcu.edu					Campbell C H, 1988, Rehabil Nurs, V13, P320; Chan RCK, 2000, DISABIL REHABIL, V22, P764, DOI 10.1080/09638280050200269; Chan RCK, 2000, SPINAL CORD, V38, P687, DOI 10.1038/sj.sc.3101085; CLEVELAND M, 1980, FAM RELAT, V29, P558, DOI 10.2307/584472; Devivo Michael J., 1995, P289; DEVIVO MJ, 1995, ARCH PHYS MED REHAB, V76, P130, DOI 10.1016/S0003-9993(95)80022-0; DEVIVO MJ, 1992, ARCH PHYS MED REHAB, V73, P156; Eastwood EA, 1999, ARCH PHYS MED REHAB, V80, P1457, DOI 10.1016/S0003-9993(99)90258-7; ELGHATIT AZ, 1976, ARCH PHYS MED REHAB, V57, P470; ELGHATIT AZ, 1975, J CHRON DIS, V28, P383, DOI 10.1016/0021-9681(75)90034-X; Engli M, 1993, J Neurosci Nurs, V25, P78; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; Gill M, 1999, Crit Care Nurs Q, V22, P1; Hart G, 1981, Rehabil Nurs, V6, P11; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreuter M, 2000, SPINAL CORD, V38, P2, DOI 10.1038/sj.sc.3100933; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MOLTER NC, 1979, HEART LUNG, V8, P323; Moules S, 1999, BRAIN INJURY, V13, P983; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; Stanton G M, 1984, J Neurosurg Nurs, V16, P253; Stebbins P, 1998, J REHABIL, V64, P15; Sullivan J, 1990, Crit Care Nurs Clin North Am, V2, P407; TRIESCHMANN RB, 1980, SPINAL CORD INJURIES; TUCKER S, 1987, TOP ACUTE CARE TRAUM, V1, P86; Vargo F., 1984, J APPL REHABIL COUNS, V15, P28; Weitzenkamp DA, 1997, ARCH PHYS MED REHAB, V78, P822, DOI 10.1016/S0003-9993(97)90194-5; WELLER DJ, 1977, SOC WORK HEALTH CARE, V3, P7, DOI 10.1300/J010v03n01_02; WELLER DJ, 1977, SOC WORK HEALTH CARE, V2, P369, DOI 10.1300/J010v02n04_01; Witol AD, 1996, NEUROREHABILITATION, V7, P175, DOI 10.3233/NRE-1996-7303; WOLFER JA, 1970, NURS RES, V19, P402, DOI 10.1097/00006199-197009000-00005	38	25	25	0	5	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2004	49	2					150	155		10.1037/0090-5550.49.2.150			6	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	819BS	WOS:000221288800009					2022-02-06	
J	Brown, M; Gordon, WA				Brown, M; Gordon, WA			Empowerment in measurement: "Muscle," "Voice," and subjective quality of life as a gold standard	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Conference	APR, 2002	Geroge Washington Univ, Washington, DC	Rehabilitat Res & Training Ctr, NIDRR	Geroge Washington Univ	disabled persons; physician-patient relations; quality of life; rehabilitation	TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROGRAMS; GOAL-ATTAINMENT; INTERNATIONAL CLASSIFICATION; DISABILITY RESEARCH; REHABILITATION; PARTICIPATION; MODELS; EPIDEMIOLOGY; SATISFACTION	Measurement and assessment, occurring within both research and clinical service contexts, typically involve an imbalance of power between professionals and persons with disabilities. Power is evidenced in who controls decisions about measurement and whose perspective-the subjective values of the measured person or the objective or normative values of the measurer-is given primacy. The consequences of this imbalance are discussed with respect to both sides of the power relationship. For clinicians, evaluators, and researchers, who typically hold most, if not all of the power in measurement, the process may produce data that meet the highest professional standards. However, the utility of such data is limited in addressing many purposes. For research participants and service recipients, who typically have little if any control of measurement, the measurement process may be disempowering, because measures focus on areas of life that may be of little relevance to what they see as important. In effect, both sides lose, to the degree that resulting data are less revealing than would be the case in a more balanced power relationship. Methods are discussed for reducing power imbalances to improve the utility and efficacy of measurement.	Mt Sinai Med Ctr, Dept Rehabil Med, New York, NY 10029 USA		Gordon, WA (corresponding author), Mt Sinai Med Ctr, Dept Rehabil Med, Box 1240,1 Gustave L Levy Pl, New York, NY 10029 USA.	wayne.gordon@mssm.edu					Andrews F. M., 1976, SOCIAL INDICATORS WE; Badley E M, 1987, Int Disabil Stud, V9, P122; Badley E M, 1987, Int Rehabil Med, V8, P118; BADLEY EM, 1995, DISABIL REHABIL, V17, P53, DOI 10.3109/09638289509166628; Bickenbach JE, 1999, SOC SCI MED, V48, P1173, DOI 10.1016/S0277-9536(98)00441-9; BIGELOW DA, 1990, PSYCHOSOC REHABIL, V14, P94; BOYCE W, 1998, CANADIAN J REHABILIT, V12, P85; Brandt EN, 1997, ENABLING AM ASSESSIN; Brown M, 1999, MT SINAI J MED, V66, P160; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; BUTTERWORTH J, 1997, QUALITY LIFE APPL PE, V2, P59; CALSYN RJ, 1978, COMMUNITY MENT HLT J, V14, P300, DOI 10.1007/BF00778605; CAMPBELL M, 1998, CANADIAN J REHABILIT, V12, P95; Carpenter L, 2001, Can J Occup Ther, V68, P16; Clark M S, 1983, Int Rehabil Med, V5, P41; CLINE DW, 1973, AM J PSYCHIAT, V130, P105, DOI 10.1176/ajp.130.1.105; DEMBO T, 1964, REHABIL LIT, V25, P231; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M., 2002, QUAL LIFE RES, V11, P672; Donnelly Catherine, 2002, Can J Occup Ther, V69, P84; FERRANS CE, 1985, ADV NURS SCI, V8, P15, DOI 10.1097/00012272-198510000-00005; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; Forbes D A, 1998, J Gerontol Nurs, V24, P34; GORDON WA, 1995, AM PSYCH ASS 103 ANN; GORDON WA, 1998, LIVING LIFE TRAUMATI; HEAVLIN WD, 1982, COMMUNITY MENT HLT J, V18, P230, DOI 10.1007/BF00754339; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; HOLBURN S, 2002, PERSON CENTERED PLAN; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; KIRESUK TJ, 1982, DRUG INTEL CLIN PHAR, V16, P145, DOI 10.1177/106002808201600210; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; KROGH K, 1998, CAN J REHABIL, V12; LAFERRIERE L, 1978, AM J COMMUN PSYCHOL, V6, P271, DOI 10.1007/BF00894357; Law M, 1990, Can J Occup Ther, V57, P82; Law M, 1994, Can J Occup Ther, V61, P191; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MALEC JF, 1993, BRAIN INJURY, V7, P383, DOI 10.3109/02699059309029682; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; McColl M A, 2000, Can J Occup Ther, V67, P22; MENCHETTI BM, 1995, PERSON CENTERED PLAN; MOUNT B, 1997, MOVING PERSONAL FUTU; MOUNT B, 1988, ITS NEVER TOO EARLY; NAGI S, 1975, SWITZER MEMORIAL SER, V1; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; NAGI SZ, 1969, DISABILITY REHABILAT; OTTENBACHER KJ, 1993, AM J OCCUP THER, V47, P349, DOI 10.5014/ajot.47.4.349; POLLOCK N, 1993, AM J OCCUP THER, V47, P298, DOI 10.5014/ajot.47.4.298; Pollock N, 1990, Can J Occup Ther, V57, P77; Ripat J, 2001, Can J Occup Ther, V68, P247; Rushton PW, 2002, ARCH PHYS MED REHAB, V83, P771, DOI 10.1053/apmr.2002.32636; Schalock R.L., 2002, HDB QUALITY LIFE HUM; Stucki G, 2002, DISABIL REHABIL, V24, P932, DOI 10.1080/09638280210148594; Toomey M, 1995, Can J Occup Ther, V62, P242; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; vanBalen HGG, 1996, DISABIL REHABIL, V18, P181, DOI 10.3109/09638289609166298; White GW, 2002, REHABIL PSYCHOL, V47, P438, DOI 10.1037//0090-5550.47.4.438; WHITTY RW, 1985, SOFTW MICROSYST, V4, P2, DOI 10.1049/sm.1985.0002; *WHO, 1999, INT CLASSFUNCT DISB; Whyte W. F. E, 1991, PARTICIPATORY ACTION; WILLER B, 1976, AM J PUBLIC HEALTH, V66, P1197, DOI 10.2105/AJPH.66.12.1197; WOOD PH, 1980, MONOGRAPH, V12; WOOD PHN, 1980, WHO CHRON, V34, P376; World Health Organization, 1980, INT CLASS IMP DIS HA; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640; Wressle Ewa, 2002, Can J Occup Ther, V69, P40; Zimmerman MA, 1995, AM J COMMUN PSYCHOL, V23, P581, DOI 10.1007/BF02506983	70	25	25	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4		2			S13	S20		10.1016/j.apmr.2003.08.110			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Rehabilitation; Sport Sciences	812FL	WOS:000220825300003	15083418				2022-02-06	
J	Dix, ES; Esposito, D; Spinosa, F; Olson, N; Chapman, S				Dix, ES; Esposito, D; Spinosa, F; Olson, N; Chapman, S			Implementation of community consultation for waiver of informed consent in emergency research: One institutional review board's experience	JOURNAL OF INVESTIGATIVE MEDICINE			English	Article						waiver of consent; emergency research; community consultation	FOOD	Background: This article describes how one Institutional Review Board (IRB) chose to implement the issue of waiver of consent for a research study involving brain trauma victims brought to an emergency department. Methods: Presentations were conducted in the state of Mississippi among cultural and ethnic groups representative of Mississippi's demographic composition. Individuals from the neurotrauma research team, including neurosurgeons and nurse study coordinators, conducted all of the presentations. One IRB member served as an objective "community liaison" and attended all presentations. This individual administered evaluation forms to attendees that measured their levels of comprehension and acceptance for the use of waiver of consent in the brain trauma study. Results: All of the 137 attendees in 7 community consultation meetings gave their approval for the use of "waiver of consent." Continued community consultations are planned for the duration of the brain trauma study. Conclusion: Based on our experience, we conclude that in collaborating with local IRBs, research teams can successfully develop strategies for obtaining "acceptable community consultations" as required by regulatory mandates. We suggest that standardized community consultation guidelines be developed for obtaining waivers of informed consent in emergency research. Such criteria should form the basis for local IRBs to obtain their respective community consultations.	Univ Mississippi, Med Ctr, Dept Prevent Med, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Neurosurg, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Inst Review Board, Jackson, MS 39216 USA; Univ Mississippi, Med Ctr, Dept Med, Jackson, MS 39216 USA		Dix, ES (corresponding author), Univ Mississippi, Med Ctr, Dept Prevent Med, 2500 N State St, Jackson, MS 39216 USA.	edix@prevmed.umsmed.edu					*AM MED ASS, E8085 AM MED ASS; [Anonymous], 1996, Fed Regist, V61, P51498; Baren JM, 1999, ACAD EMERG MED, V6, P1210, DOI 10.1111/j.1553-2712.1999.tb00135.x; Biros MH, 1999, ACAD EMERG MED, V6, P1272, DOI 10.1111/j.1553-2712.1999.tb00144.x; Ellis GB, 1996, 9701 OPRR; Kremers MS, 1999, ANN EMERG MED, V33, P224, DOI 10.1016/S0196-0644(99)70399-9; *NAT COMM PROT HUM, 1979, OPRR PUBL; Shah AN, 2003, ANN EMERG MED, V41, P72, DOI 10.1067/mem.2003.14	8	25	26	0	0	B C DECKER INC	HAMILTON	20 HUGHSON ST SOUTH, PO BOX 620, L C D 1, HAMILTON, ONTARIO L8N 3K7, CANADA	1081-5589			J INVEST MED	J. Invest. Med.	MAR	2004	52	2					113	116		10.2310/6650.2004.17646			4	Medicine, General & Internal; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Research & Experimental Medicine	806EH	WOS:000220416700011	15068227				2022-02-06	
J	Moran, C; Gillon, G				Moran, C; Gillon, G			Language and memory profiles of adolescents with traumatic brain injury	BRAIN INJURY			English	Article							CLOSED-HEAD INJURY; WORKING MEMORY; INDIVIDUAL-DIFFERENCES; LINGUISTIC HUMOR; COMPREHENSION; CHILDREN; TRANSPARENCY; EXPLANATION; PERFORMANCE; FAMILIARITY	The performance of adolescents who suffered a traumatic brain injury in childhood, on language comprehension tasks with varying working memory demands, was examined. It was hypothesized that adolescents with a traumatic brain injury would perform more poorly than their non-injured peers, particularly on those tasks with high working memory demands. A case study design allowed for both group and intra-participant comparisons. A battery of language comprehension and working memory tasks was administered to six adolescents aged 12-16 years. Their performance was compared with six individually age-matched peers with typical development and to the normative data of the standardized tests. Intra-participant performance was examined by comparing results across language tasks that varied in working memory demands. Analysis revealed that individuals with traumatic brain injury performed poorly compared with their age-matched peers. However, the pattern of listening comprehension impairment differed across individuals and marked variability within the comprehension profiles for some individuals with traumatic brain injury was evident. Language comprehension tasks with high working memory demands generally posed the most difficulty for individuals with traumatic brain injury.	Univ Canterbury, Fac Sci, Dept Speech & Language Therapy, Christchurch 1, New Zealand		Moran, C (corresponding author), Univ Canterbury, Fac Sci, Dept Speech & Language Therapy, Private Bag 4800, Christchurch 1, New Zealand.	c.moran@spth.canterbury.ac.nz		Gillon, Gail/0000-0001-9501-8147			DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P89; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Docking K, 1999, BRAIN INJURY, V13, P953; Dunn L.M., 1997, PEABODY PICTURE VOCA, V3rd Edition; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Frank EM, 1997, J MED SPEECH-LANG PA, V5, P97; Hammill D. D., 1994, TEST ADOLESCENT ADUL; Hartley L. L, 1995, COGNITIVE COMMUNICAT; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; HOOVER WA, 1990, READ WRIT, V2, P127, DOI 10.1007/BF00401799; Johnson, 1989, LANG SPEECH HEAR SER, V20, P420, DOI [10.1044/0161-1461.2004.420, DOI 10.1044/0161-1461.2004.420]; JORDAN FM, 1995, APHASIOLOGY, V9, P23, DOI 10.1080/02687039508248686; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; Jordan FM, 1996, BRAIN INJURY, V10, P729, DOI 10.1080/026990596123990; JUST MA, 1992, PSYCHOL REV, V99, P122, DOI 10.1037/0033-295X.99.1.122; KING J, 1991, J MEM LANG, V30, P580, DOI 10.1016/0749-596X(91)90027-H; MCDOWELL L, 1992, ANTIPODE, V24, P56, DOI 10.1111/j.1467-8330.1992.tb00428.x; MIYAKE A, 1995, COGNITIVE NEUROPSYCH, V12, P651, DOI 10.1080/02643299508252012; MORAN CA, 2002, THESIS; Nippold M., 1998, LATER LANGUAGE DEV S; NIPPOLD MA, 1993, J SPEECH HEAR RES, V36, P728, DOI 10.1044/jshr.3604.728; NIPPOLD MA, 1988, J SPEECH HEAR RES, V31, P466, DOI 10.1044/jshr.3103.466; NIPPOLD MA, 1995, J SPEECH HEAR RES, V38, P426, DOI 10.1044/jshr.3802.426; *NZ COUNC ED RES, 1994, PROGR ACH TESTS; SEMEL W, 1995, CLIN EVALUATION LANG; STOLTZFUS ER, 1996, WORKING MEMORY HUMAN; TEASDALE G, 1974, LANCET, V2, P81; Turkstra LS, 1999, LANG SPEECH HEAR SER, V30, P132, DOI 10.1044/0161-1461.3002.132; Turkstra LS, 1998, J SPEECH LANG HEAR R, V41, P137, DOI 10.1044/jslhr.4101.137; TURKSTRA LS, 1995, BRAIN INJURY, V5, P329; TURNER ML, 1989, J MEM LANG, V28, P127, DOI 10.1016/0749-596X(89)90040-5; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wiig E. H., 1989, TEST LANGUAGE COMPET	34	25	25	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	2004	18	3					273	288		10.1080/02699050310001617415			16	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	763NH	WOS:000188091900004	14726286				2022-02-06	
J	Kondratyev, A; Gale, K				Kondratyev, A; Gale, K			Latency to onset of status epilepticus determines molecular mechanisms of seizure-induced cell death	MOLECULAR BRAIN RESEARCH			English	Article						apoptosis; necrosis; neurodegeneration; rhinal cortex; limbic seizures; calpain; caspase-3; DNA fragmentation	TRAUMATIC BRAIN-INJURY; EVOKED LIMBIC SEIZURES; ACID-INDUCED SEIZURES; METHYL-D-ASPARTATE; ALPHA-II-SPECTRIN; NEURONAL DEATH; KAINIC ACID; DNA FRAGMENTATION; CASPASE-3-LIKE PROTEASE; CEREBRAL-ISCHEMIA	The molecular mechanisms mediating degeneration in response to neuronal insults, including damage evoked by prolonged seizure activity, show substantial variability across laboratories and injury models. Here we investigate the extent to which the proportion of cell death occurring by apoptotic vs. necrotic mechanisms may be shifted by changing the temporal parameters of the insult. In initial studies with continuous seizures (status epilepticus, SE), signs of apoptotic degeneration were most clearly observed when SE occurred following a long latency (>86 min) after injection of kainic acid as compared with a short-latency SE (<76 min). Therefore, in this study we directly compared short- with long-latency SE for the expression of molecular markers for apoptosis and necrosis in an especially vulnerable brain region (rhinal cortex). Molecular markers of apoptosis (DNA fragmentation, cleavage of ICAD, an inhibitor of "caspase-activated DNase" (CAD), and prevalence of a caspase-generated fragment of alpha-spectrin) were detected following long-latency SE. Short-latency SE resulted in expression of predominantly necrotic features of cell death, such as "non-ladder" pattern of genomic DNA degradation, prevalence of a calpain-generated alpha-spectrin fragment, and absence of ICAD cleavage. Silver staining revealed no significant difference in the extent and spatial distribution of degeneration between long- or short-latency SE. These data indicate that the latency to onset of SE determines the extent to which apoptotic or necrotic mechanisms contribute to the degeneration following SE. The presence of a long latency period, during which multiple brief seizure episodes may occur, favors the occurrence of apoptotic cell death. It is possible that the absence of such "preconditioning" period in short-latency SE favors predominantly necrotic profile. (C) 2003 Elsevier B.V. All rights reserved.	Georgetown Univ, Dept Pediat, Washington, DC 20057 USA; Georgetown Univ, Dept Pharmacol, Washington, DC 20057 USA		Kondratyev, A (corresponding author), Georgetown Univ, Dept Pediat, W208 Res Bldg,3970 Reservoir Rd Nw, Washington, DC 20057 USA.	kondrata@georgetown.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020576] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 02040] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20576] Funding Source: Medline		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Araki T, 2002, J NEUROSCI RES, V69, P614, DOI 10.1002/jnr.10356; BEDNARSKI E, 1995, BRAIN RES, V694, P147, DOI 10.1016/0006-8993(95)00851-G; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Chen J, 1998, J NEUROSCI, V18, P4914; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Colbourne F, 1999, J NEUROSCI, V19, P4200; Covolan L, 2000, EPILEPSY RES, V41, P9, DOI 10.1016/S0920-1211(00)00122-4; Ebert U, 2002, EPILEPSIA, V43, P86, DOI 10.1046/j.1528-1157.43.s.5.39.x; Faddis BT, 1997, J NEUROSCI, V17, P951; Faherty CJ, 1999, MOL BRAIN RES, V70, P159, DOI 10.1016/S0169-328X(99)00143-6; Fujikawa DG, 2000, NEUROSCIENCE, V98, P41, DOI 10.1016/S0306-4522(00)00085-3; Fujikawa DG, 1999, EUR J NEUROSCI, V11, P1605, DOI 10.1046/j.1460-9568.1999.00573.x; Fujikawa DG, 2000, EPILEPSIA, V41, pS9, DOI 10.1111/j.1528-1157.2000.tb01549.x; Henshall DC, 2000, BRAIN RES, V858, P290, DOI 10.1016/S0006-8993(99)02452-X; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Kondratyev A, 2000, MOL BRAIN RES, V75, P216, DOI 10.1016/S0169-328X(99)00292-2; Kondratyev A, 2002, NEUROSCI LETT, V319, P145, DOI 10.1016/S0304-3940(02)00004-6; Kondratyev A, 2001, NEUROSCI LETT, V310, P13, DOI 10.1016/S0304-3940(01)02055-9; Kondratyev A, 2001, MOL BRAIN RES, V91, P1, DOI 10.1016/S0169-328X(01)00099-7; Lee P, 2002, EPILEPSIA, V43, P14, DOI 10.1046/j.1528-1157.43.s.6.7.x; Li H, 2000, STROKE, V31, P176, DOI 10.1161/01.STR.31.1.176; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newcomb JK, 2000, METH MOL B, V144, P219; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; POLLARD H, 1994, NEUROREPORT, V5, P1053, DOI 10.1097/00001756-199405000-00009; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; Puig B, 2002, NEUROSCI LETT, V321, P182, DOI 10.1016/S0304-3940(01)02518-6; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Sankar R, 1998, J NEUROSCI, V18, P8382; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; Sloviter RS, 1996, J COMP NEUROL, V366, P516, DOI 10.1002/(SICI)1096-9861(19960311)366:3<516::AID-CNE10>3.0.CO;2-N; SPERK G, 1983, NEUROSCIENCE, V10, P1301, DOI 10.1016/0306-4522(83)90113-6; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; [No title captured]	43	25	35	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	FEB 5	2004	121	1-2					86	94		10.1016/j.molbrainres.2003.11.005			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	779VL	WOS:000189322200009	14969739				2022-02-06	
J	Felderhoff-Mueser, U; Buhrer, C; Groneck, P; Obladen, M; Bartmann, P; Heep, A				Felderhoff-Mueser, U; Buhrer, C; Groneck, P; Obladen, M; Bartmann, P; Heep, A			Soluble Fas (CD95/Apo-1), soluble Fas ligand, and activated caspase 3 in the cerebrospinal fluid of infants with posthemorrhagic and nonhemorrhagic hydrocephalus	PEDIATRIC RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; NEURODEGENERATION FOLLOWING TRAUMA; PROGRAMMED CELL-DEATH; DEVELOPING RAT-BRAIN; TNF-ALPHA; MEDIATED APOPTOSIS; DOWN-REGULATION; IFN-GAMMA; IN-VITRO; EXPRESSION	Hydrocephalus may result in loss of tissue associated with neuronal degeneration, axonal damage, and reactive gliosis. The soluble form of the anti-apoptotic regulator Fas (sFas) and the pro-apoptotic factors soluble FasL (sFasL) and activated caspase 3 were studied in the cerebrospinal fluid of infants with hydrocephalus. Fifteen preterm infants with posthemorrhagic hydrocephalus undergoing serial reservoir puncture and seven term or near-term infants with nonhemorrhagic hydrocephalus and shunt surgery were included in the study. Twenty-four age-matched patients with lumbar puncture for the exclusion of meningitis served as controls. Elevated levels of sFas were observed in infants with posthemorrhagic hydrocephalus [median (range), 131 ng/mL (51-279 ng/mL)] and in nonhemorrhagic hydrocephalus [127 ng/mL (35-165 ng/mL)]. sFas concentrations were highest in a subgroup of eight patients with posthemorrhagic hydrocephalus developing periventricular leukomalacia [164 ng/mL (76-227 ng/mL)]. In contrast, in 24 control infants, sFas was low, in 15 cases below detection limit (0.5 ng/mL) and in nine cases, 24 ng/mL (20-43 ng/mL). sFasL and activated caspase 3 did not differ from control infants in all groups of patients. Increased intrathecal release of sFas in the cerebrospinal fluid of infants with hydrocephalus may serve as an indicator of brain injury from progressive ventricular dilatation.	Childrens Hosp, Dept Neonatol, Charite, D-13353 Berlin, Germany; Cologne Childrens Hosp, Dept Neonatol, D-50735 Cologne, Germany; Univ Bonn, Dept Neonatol, D-53113 Bonn, Germany		Felderhoff-Mueser, U (corresponding author), Childrens Hosp, Dept Neonatol, Charite, Augustenburger Pl, D-13353 Berlin, Germany.		Felderhoff-Muser, Ursula/AAU-9682-2020				Bechmann I, 2000, GLIA, V32, P25, DOI 10.1002/1098-1136(200010)32:1<25::AID-GLIA30>3.0.CO;2-Y; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; CASCINO I, 1995, J IMMUNOL, V154, P2706; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Choi C, 1999, J IMMUNOL, V162, P1889; Ciusani E, 1998, J NEUROIMMUNOL, V82, P5, DOI 10.1016/S0165-5728(97)00177-X; Del Bigio MR, 1998, EXP NEUROL, V154, P157, DOI 10.1006/exnr.1998.6922; Dowling P, 1996, J EXP MED, V184, P1513, DOI 10.1084/jem.184.4.1513; DSOUZA S, 1996, J EXP MED, V184, P2362; Ertel W, 1997, J NEUROIMMUNOL, V80, P93, DOI 10.1016/S0165-5728(97)00139-2; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Felderhoff-Mueser U, 2001, ARCH DIS CHILD, V84, P369, DOI 10.1136/adc.84.4.369; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; FUKUMIZU M, 1995, PEDIATR NEUROL, V13, P230, DOI 10.1016/0887-8994(95)00183-G; GOPINATH G, 1979, J NEUROL SCI, V43, P333, DOI 10.1016/0022-510X(79)90013-3; HARRIS NG, 1994, CHILD NERV SYST, V10, P293, DOI 10.1007/BF00335166; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Heep A, 2002, ARCH DIS CHILD-FETAL, V87, pF34, DOI 10.1136/fn.87.1.F34; Heep A, 2001, CHILD NERV SYST, V17, P47, DOI 10.1007/s003810000363; Hentze H, 2001, BIOCHEM BIOPH RES CO, V283, P1111, DOI 10.1006/bbrc.2001.4918; Hochhaus F, 2001, BMC Pediatr, V1, P2, DOI 10.1186/1471-2431-1-2; HUGHES DPM, 1995, J EXP MED, V182, P1395, DOI 10.1084/jem.182.5.1395; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; LEVENE MI, 1981, ARCH DIS CHILD, V56, P900, DOI 10.1136/adc.56.12.900; Matsuki Y, 2002, CELL DEATH DIFFER, V9, P626, DOI 10.1038/sj.cdd.4401016; Miyan JA, 1998, EUR J PEDIATR SURG, V8, P43, DOI 10.1055/s-2008-1071253; Mogi M, 1996, NEUROSCI LETT, V220, P195, DOI 10.1016/S0304-3940(96)13257-2; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nakashima K, 1999, J NEUROTRAUM, V16, P143, DOI 10.1089/neu.1999.16.143; Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476; Sabri F, 2001, J NEUROIMMUNOL, V114, P197, DOI 10.1016/S0165-5728(00)00424-0; Spanaus KS, 1998, EUR J IMMUNOL, V28, P4398, DOI 10.1002/(SICI)1521-4141(199812)28:12<4398::AID-IMMU4398>3.3.CO;2-P; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Tarkowski E, 1999, STROKE, V30, P321, DOI 10.1161/01.STR.30.2.321; Tullberg M, 1998, NEUROLOGY, V50, P1122, DOI 10.1212/WNL.50.4.1122; Van Landeghem FKH, 2002, PEDIATR RES, V51, P129, DOI 10.1203/00006450-200202000-00003; Volpe J J, 2001, NEUROLOGY NEWBORN, P428; Yang JT, 1999, CLIN BIOCHEM, V32, P673, DOI 10.1016/S0009-9120(99)00077-6	43	25	25	0	1	INT PEDIATRIC RESEARCH FOUNDATION, INC	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA	0031-3998			PEDIATR RES	Pediatr. Res.	NOV	2003	54	5					659	664		10.1203/01.PDR.0000084114.83724.65			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	736GJ	WOS:000186162800006	12867600	Bronze			2022-02-06	
J	Wang, K; Walz, W				Wang, K; Walz, W			Unusual topographical pattern of proximal astrogliosis around a cortical devascularizing lesion	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						GFAP; glial cells; ischemia; reactive astrocyte; S100 beta; vimentin	ADULT-RAT-BRAIN; REACTIVE ASTROCYTES; GLIAL-CELLS; S-100 PROTEIN; HIPPOCAMPUS; INJURY; GFAP; VIMENTIN; EXPRESSION; IMMUNOHISTOCHEMISTRY	Class II vessels were disrupted on the cortical surface of adult rats within a circular 5-mm-diameter area. This consistently resulted in the formation of a conical lesion by day 1, with a cystic cavity forming by day 21. Four markers were used to identify the glial response surrounding the lesion. The antibody used against S100beta marked the largest astrocytic pool in the gray matter of the cerebral cortex; only similar to5% of astrocytes were glial fibrillary acidic protein (GFAP)(+) in control animals. GFAP served as a marker for distal reactive gliosis and vimentin (VIM) for proximal gliosis. Isolectin B4 was used as an additional marker to distinguish VIM+ microglia from astrocytes inside the lesion area. Three immunohisto-chemically distinct areas of reactive astrocytes surrounding the lesion were found within 24 hr of injury and lasted through day 6. The first area, in contrast to focal traumatic injuries, consisted of a 196-mum-thick boundary layer of S100beta(+) cells immediately surrounding the lesion that never expressed GFAP or VIM by day 6. This boundary layer turns into a GFAP(+) glial limitans encasing the cystic cavity by day 21. A second unusual extended area around the base of the lesion reaching partly into the corpus callosum consisted of S100beta(+)/GFAP(+)/VIM+ cells. This region appears to be compatible with the local or proximal gliotic response usually found completely surrounding other focal-type injuries. The proximal response at the base of the lesion developed over the first 3 days in the following sequence: S100beta(+)/GFAP(-)/VIM- to S100beta(+)/GFAP(+)/VIM- to S100beta(+)/GFAP(+)/VIM+. Ninety percent of the astrocytes in this area express VIM. This is very high compared with findings in stab-wound preparations, where only 10% of astrocytes (surrounding entire lesion) are found to be VIM+. A third region, consistent with a remote or distal reactive gliotic response, demonstrated staining for S100beta and had increased GFAP contents throughout the neocortical hemisphere. Cells in this region were never found to be VIM+. Among S100beta(+) cells close to the boundary region, more than 80% expressed detectable GFAP by 2 days after lesioning. S100beta(+) cells 1 mm more laterally (distal to lesion) did not express GFAP to the same level until day 6. Thus, we find three immunohistochemically distinct populations of reactive astrocytes surrounding the focal ischemic lesion. In contrast to the case for stab-wound traumatic injury, the response closest to and surrounding the lesion did not up-regulate GFAP or VIM by day 6. The proximal response was, instead, more remote and only at the base of the lesion, extending partly into the corpus callosum. (C) 2003 Wiley-Liss, Inc.	Univ Saskatchewan, Dept Physiol, Saskatoon, SK S7N 5E5, Canada		Walz, W (corresponding author), Univ Saskatchewan, Dept Physiol, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	walz@sask.usask.ca					Alonso G, 2001, GLIA, V34, P253, DOI 10.1002/glia.1059; Bar T, 1980, VASCULAR SYSTEM CERE; BAUDIER J, 1985, J NEUROCHEM, V44, P76, DOI 10.1111/j.1471-4159.1985.tb07115.x; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; Bordey A, 2001, J NEUROPHYSIOL, V85, P1719, DOI 10.1152/jn.2001.85.4.1719; Cerutti SM, 2000, CELL BIOL INT, V24, P35, DOI 10.1006/cbir.1999.0451; Chabot Sophie, 2002, P379; CHVATAL A, 1995, EUR J NEUROSCI, V7, P129, DOI 10.1111/j.1460-9568.1995.tb01027.x; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; GONG C, 2002, SOC NEUR ABSTR, V28; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Hinterkeuser S, 2000, EUR J NEUROSCI, V12, P2087, DOI 10.1046/j.1460-9568.2000.00104.x; ISOBE T, 1983, BIOCHEM INT, V6, P419; Jabs R, 1997, NEUROSCIENCE, V81, P847, DOI 10.1016/S0306-4522(97)00207-8; JANECZKO K, 1993, INT J DEV NEUROSCI, V11, P139, DOI 10.1016/0736-5748(93)90074-N; JANECZKO K, 1994, INT J DEV NEUROSCI, V12, P431, DOI 10.1016/0736-5748(94)90027-2; KITAMURA T, 1987, BRAIN RES, V423, P189, DOI 10.1016/0006-8993(87)90839-0; KRESSIN K, 1995, GLIA, V15, P173, DOI 10.1002/glia.440150210; LAYWELL ED, 1991, ANN NY ACAD SCI, V633, P122; Li WEI, 1998, EUR J NEUROSCI, V10, P2444, DOI 10.1046/j.1460-9568.1998.00253.x; LUDWIN SK, 1976, J COMP NEUROL, V165, P197, DOI 10.1002/cne.901650206; Malhotra Sudarshan K., 1994, Biomedical Letters, V49, P273; Malhotra Sudarshan K., 2002, P17; Martinez G, 1998, INT J DEV NEUROSCI, V16, P519, DOI 10.1016/S0736-5748(98)00035-5; MIYAKE T, 1989, BRAIN RES, V489, P31, DOI 10.1016/0006-8993(89)90005-X; MIYAKE T, 1992, BRAIN RES, V586, P53, DOI 10.1016/0006-8993(92)91370-T; PETITO CK, 1990, J CEREBR BLOOD F MET, V10, P850, DOI 10.1038/jcbfm.1990.141; Savchenko VL, 2000, NEUROSCIENCE, V96, P195, DOI 10.1016/S0306-4522(99)00538-2; SCHIFFER D, 1993, INT J DEV NEUROSCI, V11, P269, DOI 10.1016/0736-5748(93)90085-R; SCHMIDTKASTNER R, 1990, J CHEM NEUROANAT, V3, P179; SCHROETER M, 1995, EXP BRAIN RES, V106, P1; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; SEIFERT G, 1995, EUR J NEUROSCI, V7, P1872, DOI 10.1111/j.1460-9568.1995.tb00708.x; SOFRONIEW MV, 1983, BRAIN RES, V289, P370, DOI 10.1016/0006-8993(83)90045-8; STEINDLER DA, 1993, ANNU REV NEUROSCI, V16, P445, DOI 10.1146/annurev.ne.16.030193.002305; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; Vazquez-Chona F, 1999, BRAIN RES, V838, P45, DOI 10.1016/S0006-8993(99)01679-0; Vinesi P, 1997, MOL CHEM NEUROPATHOL, V32, P129, DOI 10.1007/BF02815172; Walz W, 1998, NEUROSCI LETT, V257, P127, DOI 10.1016/S0304-3940(98)00813-1; Walz W, 1999, J NEUROSCI RES, V56, P595, DOI 10.1002/(SICI)1097-4547(19990615)56:6<595::AID-JNR5>3.3.CO;2-X; Walz W, 2000, GLIA, V31, P95, DOI 10.1002/1098-1136(200008)31:2<95::AID-GLIA10>3.0.CO;2-6; Yang HY, 1997, EXP NEUROL, V146, P199, DOI 10.1006/exnr.1997.6518; Zhou M, 2000, MOL BRAIN RES, V76, P121, DOI 10.1016/S0169-328X(99)00341-1; [No title captured]	45	25	27	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	AUG 15	2003	73	4					497	506		10.1002/jnr.10683			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	707QH	WOS:000184521000008	12898534				2022-02-06	
J	Crago, BR; Nelson, LA; Davis, M; Arnold, L; Thrasher, JD				Crago, BR; Nelson, LA; Davis, M; Arnold, L; Thrasher, JD			Psychological, neuropsychological, and electrocortical effects of mixed mold exposure	ARCHIVES OF ENVIRONMENTAL HEALTH			English	Article						dose-response relationship; neuropsychological testing; Symptom Checklist-90-R; quantitative electroencephalograph; toxic encephalopathy; toxic mold	AMERICAN ACADEMY; HYPERSENSITIVITY PNEUMONITIS; STACHYBOTRYS CHARTARUM; QUANTITATIVE EEG; NEUROLOGY; MYCOTOXICOSIS; DEPRESSION; OUTBREAK; INJURY; HEALTH	The authors assessed the psychological, neuropsychological, and electrocortical effects of human exposure to mixed colonies of toxigenic molds. Patients (N = 182) with confirmed mold-exposure history completed clinical interviews, a symptom checklist (SCL-90-R), limited neuropsychological testing, quantitative electroencephalogram (QEEG) with neurometric analysis, and measures of mold exposure. Patients reported high levels of physical, cognitive, and emotional symptoms. Ratings on the SCL-90-R were "moderate" to "severe," with a factor reflecting situational depression accounting for most of the variance. Most of the patients were found to suffer from acute stress, adjustment disorder, or post-traumatic stress. Differential diagnosis confirmed an etiology of a combination of external stressors, along with organic metabolically based dysregulation of emotions and decreased cognitive functioning as a result of toxic or metabolic encephalopathy. Measures of toxic mold exposure predicted QEEG measures and neuropsychological test performance. QEEG results included narrowed frequency bands and increased power in the alpha and theta bands in the frontal areas of the cortex. These findings indicated a hypoactivation of the frontal cortex, possibly due to brainstem involvement and insufficient excitatory input from the reticular activating system. Neuropsychological testing revealed impairments similar to mild traumatic brain injury. In comparison with premorbid estimates of intelligence, findings of impaired functioning on multiple cognitive tasks predominated. A dose-response relationship between measures of mold exposure and abnormal neuropsychological test results and QEEG measures suggested that toxic mold causes significant problems in exposed individuals. Study limitations included lack of a comparison group, patient selection bias, and incomplete data sets that did not allow for comparisons among variables.	Neurobehav Hlth Serv, Tucson, AZ 85712 USA; Progress Hlth Care Grp, Benson, AZ USA; Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA; ImmunTox LLC, Benson, AZ USA; Sam 1 Trust, Alto, NM USA		Crago, BR (corresponding author), Neurobehav Hlth Serv, 5363 E Pima St,Suite 100, Tucson, AZ 85712 USA.	bcbrain1@msn.com					Anyanwu Ebere, 2002, Int J Adolesc Med Health, V14, P67; Anyanwu Ebere C, 2003, ScientificWorldJournal, V3, P281; AUGER P, 2001, BIOAEROSOLS FUNGI MY, P131; Austin MP, 2001, BRIT J PSYCHIAT, V178, P200, DOI 10.1192/bjp.178.3.200; Baldo Juliana V, 2002, Appl Neuropsychol, V9, P193, DOI 10.1207/S15324826AN0904_1; CALLENDER TJ, 1993, ENVIRON RES, V60, P295, DOI 10.1006/enrs.1993.1039; CROFT WA, 1986, ATMOS ENVIRON, V20, P549, DOI 10.1016/0004-6981(86)90096-X; Croft WA, 2002, J ENVIRON BIOL, V23, P301; DELIS DC, 2001, DELISKAPLAN EXECUTIV; Derogatis L. R., 1994, SCL 90 R ADM SCORING, VThird; Ebbehoj NE, 2002, INDOOR AIR, V12, P273, DOI 10.1034/j.1600-0668.2002.02141.x; ELLIOTT CL, 1992, J ABNORM PSYCHOL, V101, P572, DOI 10.1037/0021-843X.101.3.572; Fan LL, 2002, CURR OPIN PEDIATR, V14, P323, DOI 10.1097/00008480-200206000-00008; FLANNIGAN B, 1991, J APPL BACTERIOL, V70, pS61; GORDON WA, 1999, BIOAEROSOLS FUNGI MY, P94; Gray MR, 2003, ARCH ENVIRON HEALTH, V58, P410; Gunnbjornsdottir MI, 2003, RESP MED, V97, P302, DOI 10.1053/rmed.2002.1389; HARTMANN DE, 1995, NEUROPSYCHOLOGICAL T; Hebben N., 2002, ESSENTIALS NEUROPSYC; Heuser G, 1998, TOXICOL IND HEALTH, V14, P813, DOI 10.1177/074823379801400604; Hodgson MJ, 1998, J OCCUP ENVIRON MED, V40, P241, DOI 10.1097/00043764-199803000-00006; Hoffman DA, 1999, J NEUROPSYCH CLIN N, V11, P401, DOI 10.1176/jnp.11.3.401; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; Jaakkola MS, 2002, ENVIRON HEALTH PERSP, V110, P543, DOI 10.1289/ehp.02110543; Johanning E, 1996, INT ARCH OCC ENV HEA, V68, P207; JOHN ER, 1977, FUNCTIONAL NEUROSCIE, V2; Johnstone J., 2003, Journal of Neurotherapy, V7, P31, DOI 10.1300/J184v07n03_02; Kilburn K.H., 2002, EUR J ONCOL, V7, P197; Kurup VP, 2000, MICROBES INFECT, V2, P1101, DOI 10.1016/S1286-4579(00)01264-8; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; *NXLINK LTD, 2001, NXLINK NEUR AN SYST; Patel AM, 2001, J ALLERGY CLIN IMMUN, V108, P661; Persson R, 2000, NEUROTOXICOLOGY, V21, P667; *PSYCH CORP, 1997, WECHSL AD INT SCAL; Rosen I, 1997, DEMENT GERIATR COGN, V8, P110, DOI 10.1159/000106615; SANFORD J, 1995, INTERMEDIATE VISUAL; Savilahti R, 2000, ARCH ENVIRON HEALTH, V55, P405, DOI 10.1080/00039890009604038; Schore A.N., 1994, AFFECT REGULATION OR; Seuri M, 2000, INDOOR AIR, V10, P138, DOI 10.1034/j.1600-0668.2000.010003138.x; *STATS INC, 1984, STAT 6 0 WIND; Thatcher RW, 2003, CLIN ELECTROENCEPHAL, V34, P39, DOI 10.1177/155005940303400203; Thatcher RW, 1999, CLIN ELECTROENCEPHAL, V30, P94, DOI 10.1177/155005949903000304; VANSWEDEN B, 1993, ELECTROENCEPHALOGRAP, P643; Ziem G, 1997, ENVIRON HEALTH PERSP, V105, P417, DOI 10.2307/3433348; Zureik M, 2002, BMJ-BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	45	25	25	0	6	HELDREF PUBLICATIONS	WASHINGTON	1319 EIGHTEENTH ST NW, WASHINGTON, DC 20036-1802 USA	0003-9896			ARCH ENVIRON HEALTH	Arch. Environ. Health	AUG	2003	58	8					452	463		10.3200/AEOH.58.8.452-463			12	Environmental Sciences; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED)	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	833FT	WOS:000222322600001	15259424				2022-02-06	
J	Iino, M; Nakatome, M; Ogura, Y; Fujimura, H; Kuroki, H; Inoue, H; Ino, Y; Fujii, T; Terao, T; Matoba, R				Iino, M; Nakatome, M; Ogura, Y; Fujimura, H; Kuroki, H; Inoue, H; Ino, Y; Fujii, T; Terao, T; Matoba, R			Real-time PCR quantitation of FE65 a beta-amyloid precursor protein-binding protein after traumatic brain injury in rats	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						real-time PCR; diffuse axonal injury; FE65; beta-APP; NSE	DIFFUSE AXONAL INJURY; NEURON-SPECIFIC ENOLASE; INTERLEUKIN-1-BETA MESSENGER-RNA; POLYMERASE-CHAIN-REACTION; FLUID-PERCUSSION MODEL; CLOSED-HEAD INJURY; NECROSIS-FACTOR-ALPHA; ALZHEIMERS-DISEASE; ALTERED EXPRESSION; APOLIPOPROTEIN-E	In cases of traumatic brain injury (TBI) in which the patient survived for only a short period of time and was without macroscopic changes at autopsy, it is difficult to diagnose TBI. To detect early diagnostic markers of diffuse axonal injury (DAI), real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) in an experimental head trauma model of rat was chosen. The beta-amyloid precursor protein (beta-APP) is a well-known diagnostic marker of DAI which can be detected by immunolabeling as early as 1.5 h after injury. beta-APP has a binding protein, FE65, which is expressed in the brain of Alzheimer's disease patients along with beta-APP, but no involvement with brain injury has been reported. Neuron-specific enolase (NSE) is also a useful marker of DAI. We found that FE65 expression increased dramatically as early as 30 min after injury and decreased after peaking 1 h post-injury, although NSE showed no significant changes. These results suggest that real-time PCR of FE65 mRNA is useful for the diagnosis of DAI in forensic cases.	Osaka Univ, Dept Legal Med, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Neurol, Grad Sch Med, Osaka, Japan		Iino, M (corresponding author), Osaka Univ, Dept Legal Med, Grad Sch Med, 2-2 F3 Yamadaoka, Suita, Osaka 5650871, Japan.	iino@legal.med.osaka-u.ac.jp	Iino, Morio/N-9135-2013				AbouHamden A, 1997, J NEUROTRAUM, V14, P699, DOI 10.1089/neu.1997.14.699; ADAMS JH, 1984, LANCET, V2, P1420; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Aldape K, 2002, BRAIN PATHOL, V12, P54; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bodjarian N, 1997, NEUROREPORT, V8, P3951, DOI 10.1097/00001756-199712220-00020; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; COCHRAN E, 1991, AM J PATHOL, V139, P485; Delatour B, 2001, AM J PATHOL, V158, P1585, DOI 10.1016/S0002-9440(10)64113-2; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Ermekova KS, 1998, ADV EXP MED BIOL, V446, P161; ESPOSITO F, 1990, DEV NEUROSCI-BASEL, V12, P373, DOI 10.1159/000111865; FAN L, 1995, MOL BRAIN RES, V30, P125; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gotohda T, 2001, INT J LEGAL MED, V115, P121, DOI 10.1007/s004140000185; Graham DI, 1997, BRAIN PATHOL, V7, P1285; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; HATFIELD RH, 1992, BRAIN RES, V577, P249, DOI 10.1016/0006-8993(92)90280-M; Hausmann R, 2000, INT J LEGAL MED, V113, P70, DOI 10.1007/PL00007711; Hausmann R, 2000, INT J LEGAL MED, V113, P288, DOI 10.1007/s004149900126; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; Hausmann R, 2001, INT J LEGAL MED, V114, P338, DOI 10.1007/s004140000199; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hu QB, 1998, HUM GENET, V103, P295, DOI 10.1007/s004390050820; Hu QB, 2000, J NEUROSCI RES, V60, P73, DOI 10.1002/(SICI)1097-4547(20000401)60:1<73::AID-JNR8>3.0.CO;2-S; IMAJO T, 1984, AM J FOREN MED PATH, V5, P217, DOI 10.1097/00000433-198409000-00005; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; Ishida K, 2000, FORENSIC SCI INT, V113, P127, DOI 10.1016/S0379-0738(00)00252-8; KARKELA J, 1993, J NEUROL SCI, V116, P100, DOI 10.1016/0022-510X(93)90095-G; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; Kita T, 2000, INT J LEGAL MED, V113, P221, DOI 10.1007/s004149900095; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Lambert JC, 2000, NEUROSCI LETT, V293, P29, DOI 10.1016/S0304-3940(00)01477-4; Li R, 1998, AM J FOREN MED PATH, V19, P129, DOI 10.1097/00000433-199806000-00006; Li X, 2000, BRAIN RES PROTOC, V5, P211, DOI 10.1016/S1385-299X(00)00015-5; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MARANGOS PJ, 1978, BRAIN RES, V150, P117, DOI 10.1016/0006-8993(78)90657-1; Marmarou A, 1990, Adv Neurol, V52, P233; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masumura M, 2000, J NEUROTRAUM, V17, P123, DOI 10.1089/neu.2000.17.123; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MURRAY GI, 1993, J CLIN PATHOL, V46, P993, DOI 10.1136/jcp.46.11.993; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; Nogami M, 1998, FORENSIC SCI INT, V94, P97, DOI 10.1016/S0379-0738(98)00060-7; Ogata M, 1999, INT J LEGAL MED, V113, P19, DOI 10.1007/s004140050273; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; Orihara Y, 2000, Nihon Hoigaku Zasshi, V54, P361; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Orihara Y, 2002, INT J LEGAL MED, V116, P92, DOI 10.1007/s00414-001-0265-8; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Schreiber SS, 1999, EXP NEUROL, V159, P329, DOI 10.1006/exnr.1999.7147; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIGEMATSU K, 1992, AM J PATHOL, V140, P787; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SIMEONE A, 1994, DEV NEUROSCI-BASEL, V16, P53, DOI 10.1159/000112088; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; STRICH SJ, 1961, LANCET, V2, P443; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; TORNHEIM PA, 1983, J NEUROSURG, V59, P431, DOI 10.3171/jns.1983.59.3.0431; Wang XK, 2000, J NEUROSCI RES, V59, P238, DOI 10.1002/(SICI)1097-4547(20000115)59:2<238::AID-JNR10>3.0.CO;2-G; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	87	25	31	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0937-9827	1437-1596		INT J LEGAL MED	Int. J. Legal Med.	JUN	2003	117	3					153	159		10.1007/s00414-003-0370-y			7	Medicine, Legal	Science Citation Index Expanded (SCI-EXPANDED)	Legal Medicine	701AQ	WOS:000184143700004	12707777				2022-02-06	
J	Shohami, E; Yatsiv, I; Alexandrovich, A; Haklai, R; Elad-Sfadia, G; Grossman, R; Biegon, A; Kloog, Y				Shohami, E; Yatsiv, I; Alexandrovich, A; Haklai, R; Elad-Sfadia, G; Grossman, R; Biegon, A; Kloog, Y			The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						traumatic brain injury; Ras; S-trans; trans-farnesylthiosalicylic acid (FTS); NMDA receptors; neuroprotection	TRAUMATIC BRAIN INJURY; ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR; NMDA RECEPTORS; MAP KINASE; H-RAS; MICE; PHOSPHORYLATION; PATHWAYS; SUBUNIT	Traumatic brain injury activates N-methyl-(D)-aspartate receptors (NMDAR) inducing activation of the Ras protein (a key regulator of cell growth, survival, and death) and its effectors. Thus, trauma-induced increase in active Ras-GTP might contribute to traumatic brain injury pathology. Based on this hypothesis, a new concept of neuroprotection is proposed, examined here by investigating the effect of the Ras inhibitor S-trans, trans-farnesylthiosalicylic acid (FTS) in a mouse model of closed head injury (CHI). Mice subjected to CHI were treated systemically 1 h later with FrS (5 mg/kg) or vehicle. After I h, Ras-GTP in the contused hemisphere showed a significant (3.8-fold) increase, which was strongly inhibited by FrS (82% inhibition) or by the NMDA-receptor antagonist MK-801 (53%). Both drugs also decreased active (phosphorylated) extracellular signal-regulated kinase. ITS prevented the CHI-induced reduction in NMDAR binding in cortical, striatal, and hippocampal regions, measured by [H-3]-MK-801 autoradiography, and decreased lesion size by 50%. It also reduced CHI-induced neurologic deficits, indicated by the highly significant (P < 0.0001) 60% increase in extent of recovery. Thus, FTS provided long-term neuroprotection after CHI, rescuing NMDAR binding in the contused hemisphere and profoundly reducing neurologic deficits. These findings suggest that nontoxic Ras inhibitors such as FTS may qualify as neuroprotective drugs.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Pediat Intens Care Unit, IL-91120 Jerusalem, Israel; Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Chaim Sheba Med Ctr, Dept Neurosurg, IL-52621 Tel Hashomer, Israel; Lawrence Berkeley Natl Lab, Dept Funct Imaging, Berkeley, CA USA		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il					Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Biegon A, 2002, J NEUROCHEM, V82, P924, DOI 10.1046/j.1471-4159.2002.01050.x; BOWERY NG, 1988, BRIT J PHARMACOL, V93, P944, DOI 10.1111/j.1476-5381.1988.tb11484.x; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Dalakas MC, 1995, ANN NEUROL S, V37, P2; Elad-Sfadia G, 2002, J BIOL CHEM, V277, P37169, DOI 10.1074/jbc.M205698200; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Ferrer I, 2002, ACTA NEUROPATHOL, V103, P391, DOI 10.1007/s00401-001-0481-9; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Goebel DJ, 2001, EXP EYE RES, V72, P547, DOI 10.1006/exer.2001.0981; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; Jansen B, 1999, J MOL MED-JMM, V77, P792, DOI 10.1007/s001099900052; Kaminska B, 1999, MOL CELL NEUROSCI, V13, P405, DOI 10.1006/mcne.1999.0757; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Kloog, 1999, Expert Opin Investig Drugs, V8, P2121, DOI 10.1517/13543784.8.12.2121; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Paxinos G., 1997, MOUSE BRAIN STEREOTA; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rosenblum K, 1997, J NEUROSCI, V17, P5129; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008	39	25	26	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	2003	23	6					728	738		10.1097/01.WCB.0000067704.86573.83			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	689JY	WOS:000183489900011	12796721	Bronze			2022-02-06	
J	Karmy-Jones, R; DuBose, R; King, S				Karmy-Jones, R; DuBose, R; King, S			Traumatic rupture of the innominate artery	EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY			English	Article						blunt innominate artery; trauma	AORTIC-ARCH; ENDOVASCULAR REPAIR; BLUNT INJURIES; MANAGEMENT	Objective: Blunt traumatic rupture of the innominate artery is uncommon. We reviewed our experience to correlate the impact of patient stability, presence of associated injuries and location of the injury within the artery with outcome. Methods: A retrospective review was performed of patients admitted between January 1, 1998 and December 17, 2002 with traumatic innominate artery rupture. Injuries were defined as proximal if they were less than or equal to 0.5 cm from the origin, distal if less than or equal to 0.5 cm from the bifurcation and middle if in between. Results: Over the 5-year study period, 66 patients were admitted with aortic or great vessel injury, including eight with blunt innommate artery disruption. Of the blunt innominate injuries, six involved the origin (five repaired by ascending aortic -innominate artery graft followed by over-sewing of the injury site, one by ligation alone), one middle (treated by interposition graft) and one distal (managed with resection and primary anastomosis). Four of the patients with proximal injuries had evidence of active bleeding (large expanding hematoma and/or frank bleeding) requiring control of the injury site prior to reconstruction. All patients had associated injuries (including closed head injury in three and splenic rupture in two). The only mortality occurred in a patient who presented in shock, and suffered tracheal rupture and severe blunt cardiac injury requiring cardiopulmonary bypass. The remaining patients were stable on presentation. Diagnosis was suspected after chest Xray demonstrated widened mediastinum and was confirmed with either angiography or computer tomography scan. There were no complications in the survivors. Neither cardiopulmonary bypass nor aorto-carotid shunting was utilized in these cases. Conclusions: Patients with blunt innommate artery rupture who survive to admission are usually stable and the diagnosis is suggested by initial chest radiograph. The injuries are usually proximal, requiring aortic-distal innominate bypass. Cardiopulmonary bypass is required only if there is evidence of heart failure (either before or after partial occlusion of the aorta) or to manage specific associated injuries. (C) 2003 Elsevier Science B.V. All rights reserved.	Harborview Med Ctr, Dept Surg, Sect Thorac Vasc Surg, Seattle, WA 98104 USA		Karmy-Jones, R (corresponding author), Harborview Med Ctr, Dept Surg, Sect Thorac Vasc Surg, Box 359796,325 9th Ave, Seattle, WA 98104 USA.	karmy@u.washington.edu					Axisa BM, 2000, J ENDOVASC THER, V7, P245, DOI 10.1583/1545-1550(2000)007<0245:EROAIA>2.3.CO;2; Carter YM, 2002, ANN THORAC SURG, V73, P294, DOI 10.1016/S0003-4975(01)02866-1; Chandler TA, 1999, EUR J VASC ENDOVASC, V18, P80, DOI 10.1053/ejvs.1999.0871; Chen MYM, 2001, J TRAUMA, V51, P1166, DOI 10.1097/00005373-200112000-00024; GRAHAM JM, 1982, J TRAUMA, V22, P647, DOI 10.1097/00005373-198208000-00001; Hemmila MR, 1999, J TRAUMA, V46, P505, DOI 10.1097/00005373-199903000-00029; HOFF SJ, 1994, AM SURGEON, V60, P151; JOHNSTON RH, 1993, J VASC SURG, V17, P134, DOI 10.1016/0741-5214(93)90017-G; Keene J J, 2001, J Extra Corpor Technol, V33, P114; KELLY JP, 1985, ANN THORAC SURG, V40, P551, DOI 10.1016/S0003-4975(10)60347-5; LETSOU G, 1989, J TRAUMA, V29, P104, DOI 10.1097/00005373-198901000-00023; McCoy DW, 1997, AM SURGEON, V63, P761; NICHOLLS SC, 2002, THORACIC TRAUMA CRIT, P303; PATE JW, 1993, ANN THORAC SURG, V55, P586, DOI 10.1016/0003-4975(93)90255-G; Pretre R, 1993, Ann Vasc Surg, V7, P470, DOI 10.1007/BF02002132; ROSENBERG JM, 1989, ANN THORAC SURG, V48, P508, DOI 10.1016/S0003-4975(10)66851-8; SHAH PM, 1987, AM J SURG, V154, P202, DOI 10.1016/0002-9610(87)90179-6; Stover S, 2001, AM SURGEON, V67, P757; Weiman DS, 1998, AM SURGEON, V64, P383	19	25	25	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1010-7940	1873-734X		EUR J CARDIO-THORAC	Eur. J. Cardio-Thorac. Surg.	MAY	2003	23	5					782	787		10.1016/S1010-7940(03)00032-0			6	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Cardiovascular System & Cardiology; Respiratory System; Surgery	687TW	WOS:000183393900020	12754033	Bronze			2022-02-06	
J	Muller, M; Bianchi, O; Erulku, S; Stock, C; Schwerdtfeger, K				Muller, M; Bianchi, O; Erulku, S; Stock, C; Schwerdtfeger, K		Homburg Traumatic Brain Injury Grp	Changes in linear dynamics of cerebrovascular system after severe traumatic brain injury	STROKE			English	Article						cerebral circulation; head injury; transfer; ultrasonography, Doppler, transcranial	ARTERIAL BLOOD-PRESSURE; CEREBRAL AUTOREGULATION; FLOW VELOCITY; INTRACRANIAL-PRESSURE; MATHEMATICAL-MODEL; PHASE RELATIONSHIP; OCCLUSIONS; CO2	Background and Purpose - We sought to describe the dynamic changes in the cerebrovascular system after traumatic brain injury by transfer function estimation and coherence. Methods - In 42 healthy volunteers ( mean +/- SD age, 37 +/- 17 years; range, 17 to 65 years), spontaneous fluctuations of middle cerebral artery blood flow velocity and of finger blood pressure ( BP) were simultaneously recorded over a period of 10 minutes under normocapnic and hypocapnic conditions to generate normative spectra of coherence, phase shift, and gain over the frequency range of 0 to 0.25 Hz. Similar recordings were performed in 24 patients with severe traumatic brain injury ( Glasgow Coma Scale score less than or equal to8; mean +/- SD age, 50 +/- 20 years) serially on days 1, 3, 5, and 8 after trauma. Cranial perfusion pressure was kept at >70 mm Hg. Each blood flow velocity/BP recording was related to the presence or absence of middle cerebral artery territory brain parenchyma lesions on cranial CT performed within a close time frame. Results - In controls, hypocapnia decreased coherence (0.0 to 0.20 Hz), increased phase shift ( 0.0 to 0.17 Hz), and decreased gain in the frequency range of 0.0 to 0.11 Hz but increased gain at frequencies of 0.20 to 0.25 Hz ( P < 0.01 for all frequency ranges reported). In patients with traumatic brain injury, 102 investigations were possible. Compared with controls, coherence was increased in the frequency range <0.03 Hz and between 0.13 and 0.25 Hz in both normocapnia and hypocapnia, irrespective of the CT findings. Gain was unchanged in normocapnia and in the absence of a CT lesion. Gain was decreased in hypocapnia at frequencies >0.12 Hz irrespective of the presence/absence of a CT lesion. Phase shift decreased rapidly between 0.06 and 0.13 Hz under hypocapnic conditions and under normocapnic conditions in the presence of a CT lesion ( P < 0.01). Conclusions - Use of spontaneous fluctuations of blood flow velocity and BP to assess the cerebrovascular system dynamically requires consideration of the PaCO2 level. In different conditions, including severe traumatic brain injury, the cerebrovascular system behaves linearly only in parts of the investigated frequency range.	Saarland Univ Hosp, Dept Neurol, D-66421 Homburg, Germany; Univ Saarland, Inst Appl Math, D-6600 Saarbrucken, Germany; Saarland Univ Hosp, Dept Neurosurg, Homburg, Germany		Muller, M (corresponding author), Saarland Univ Hosp, Dept Neurol, Kirrberger Str, D-66421 Homburg, Germany.						BIRCH AA, 1995, STROKE, V26, P834, DOI 10.1161/01.STR.26.5.834; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Giller CA, 1997, NEUROL RES, V19, P634; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; Hu HH, 1999, J CEREBR BLOOD F MET, V19, P460, DOI 10.1097/00004647-199904000-00012; Hughson RL, 2001, STROKE, V32, P2403, DOI 10.1161/hs1001.097225; Kirkham SK, 2001, PHYSIOL MEAS, V22, P461, DOI 10.1088/0967-3334/22/3/305; Kuo TBJ, 1998, J CEREBR BLOOD F MET, V18, P311, DOI 10.1097/00004647-199803000-00010; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; MITIS GD, 2002, ANN BIOMED ENG, V30, P555; MULLER M, 1995, STROKE, V26, P96, DOI 10.1161/01.STR.26.1.96; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; Panerai RB, 1999, PHYSIOL MEAS, V20, P265, DOI 10.1088/0967-3334/20/3/304; Panerai RB, 2002, PHYSIOL MEAS, V23, P59, DOI 10.1088/0967-3334/23/1/306; Panerai RB, 1999, AM J PHYSIOL-HEART C, V277, pH1089, DOI 10.1152/ajpheart.1999.277.3.H1089; Panerai RB, 2001, AM J PHYSIOL-HEART C, V280, pH2162, DOI 10.1152/ajpheart.2001.280.5.H2162; Reinhard M, 2001, CLIN PHYSIOL, V21, P229, DOI 10.1046/j.1365-2281.2001.00322.x; RINGELSTEIN EB, 1988, STROKE, V19, P963, DOI 10.1161/01.STR.19.8.963; Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012; TEASDALE G, 1974, LANCET, V2, P81; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; URSINO M, 1991, ANN BIOMED ENG, V19, P15, DOI 10.1007/BF02368459; WIDDER B, 1986, EUR ARCH PSY CLIN N, V236, P162, DOI 10.1007/BF00380944; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233	26	25	26	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	MAY	2003	34	5					1197	1202		10.1161/01.STR.0000068409.81859.C5			6	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Cardiovascular System & Cardiology	673NB	WOS:000182586100019	12677012	Bronze			2022-02-06	
J	Quinones-Hinojosa, A; Malek, JY; Ames, A; Ogilvy, CS; Maynard, KI				Quinones-Hinojosa, A; Malek, JY; Ames, A; Ogilvy, CS; Maynard, KI			Metabolic effects of hypothermia and its neuroprotective effects on the recovery of metabolic and electrophysiological function in the ischemic retina in vitro	NEUROSURGERY			English	Article						cerebral ischemia; energy metabolism; neuroprotection; stroke; temperature-dependent	TRANSIENT FOREBRAIN ISCHEMIA; CEREBRAL ENERGY-METABOLISM; TRAUMATIC BRAIN INJURY; MILD HYPOTHERMIA; FOCAL ISCHEMIA; RABBIT RETINA; MODERATE HYPOTHERMIA; MAGNETIC-RESONANCE; HYPOXIA-ISCHEMIA; HEAD-INJURY	OBJECTIVE: Reduction in energy usage has been investigated as the mechanism by which hypothermia provides protection during ischemia. We describe, experiments using hypothermia in the rabbit retina in Vitro that show a correlation between energy usage and neuroprotection., hypothermia-induced reductions in METHODS: We examined energy metabolism and electrophysiological function under control/nonischemic conditions during I or 2 hours of "ischemia" (induced by, decreasing glucose from 6 to 1 mmol/L and oxygen from,95 to 15%) and during 3 to conditions. Glucose utilization and lactate production 4 hours of "return-to-control", were measured as indices of energy metabolism, and light-evoked compound action potentials were monitored to assess functional recovery. RESULTS: Nonischemic retinas subjected to both mild (33 +/- 0.5degreesC) hypothermia exhibited a decrease of 38% in the rate of glucose utilization and lactate production compared with normothermic retinas (36 +/- 0.5degreesC) (analysis,of variance, P < 0.001). In retinas that were made ischemic, mild or moderate hypothermia further reduced the rates of glucose utilization (18 and 39%, respectively) and lactate production (21 and 28%, respectively) (P < 0.001 for glucose, P < 0.01 for lactate). Retinas that had, been mildly or moderately hypothermic during ischemia exhibited improved recovery of glucose utilization (65 and 57%, respectively) and lactate production (72 and 74%, respectively) compared with normothermic retinas (18% for glucose and 54% for lactate; repeated-measures analysis of variance, P < 0.001). Recovery of compound action potentials for retinas kept at 36, 33, and 30degreesC was 15, 36, and 53%, respectively (repeated-measures analysis of variance, P < 0.001). CONCLUSION: Our studies in an avascular neuronal ischemia de that hypothermia protects against ischemic injury. We interpret the smaller reductions hypothermia energy generation and usage caused by ischemia when the retinas were mic as evidence that hypothermia had reduced energy requirements more than energy production, and we propose that this at least in part explains its protection.	Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neurosurg Serv,Neurophysiol Lab, Boston, MA 02115 USA		Quinones-Hinojosa, A (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 505 Parnassus Ave,M-779, San Francisco, CA 94143 USA.	quinones@neurosurg.ucsf.edu		Mayberg, Marc/0000-0002-6718-7143	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-01732] Funding Source: Medline		Adachi K, 1998, EUR J PHARMACOL, V350, P53, DOI 10.1016/S0014-2999(98)00317-3; AGARDH CD, 1992, ACTA NEUROPATHOL, V83, P379, DOI 10.1007/BF00713529; AMES A, 1995, J CEREBR BLOOD F MET, V15, P433, DOI 10.1038/jcbfm.1995.54; AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992; AMES A, 1990, PREPARATIONS VERTEBR, P183; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Berger R, 1998, DEV BRAIN RES, V105, P67, DOI 10.1016/S0165-3806(97)00165-X; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; Clifton G, 2000, J NEUROSURG, V93, P718; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colbourne F, 1997, MOL NEUROBIOL, V14, P171, DOI 10.1007/BF02740655; Conroy BP, 1998, ANESTHESIOLOGY, V88, P390, DOI 10.1097/00000542-199802000-00018; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Edwards AD, 1996, NEUROPATH APPL NEURO, V22, P494, DOI 10.1111/j.1365-2990.1996.tb01122.x; FABEROWSKI N, 1989, INVEST OPHTH VIS SCI, V30, P2309; FIELD J, 1994, ANESTHESIOLOGY, V7, P117; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; KAMME F, 1995, EUR J NEUROSCI, V7, P2007, DOI 10.1111/j.1460-9568.1995.tb00623.x; Kamme F, 1996, MOL BRAIN RES, V43, P51, DOI 10.1016/S0169-328X(96)00151-9; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; KARIBE H, 1994, BRAIN RES, V649, P12, DOI 10.1016/0006-8993(94)91043-X; KOCHS E, 1995, EUR J ANAESTH, V12, P67; LANIER WL, 1995, J NEUROSURG ANESTH, V7, P216, DOI 10.1097/00008506-199507000-00021; LAPTOOK AR, 1995, STROKE, V26, P1240, DOI 10.1161/01.STR.26.7.1240; LAPTOOK AR, 1995, PEDIATR RES, V38, P919, DOI 10.1203/00006450-199512000-00015; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; LIN BW, 1995, STROKE, V26, P1634, DOI 10.1161/01.STR.26.9.1634; LO EH, 1992, STROKE, V23, P889, DOI 10.1161/01.STR.23.6.889; LUST WD, 1989, BRAIN RES, V489, P12; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Markgraf CG, 2001, J NEUROSURG, V95, P979, DOI 10.3171/jns.2001.95.6.0979; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Maynard K I, 1998, J Stroke Cerebrovasc Dis, V7, P287, DOI 10.1016/S1052-3057(98)80045-1; Maynard KI, 1996, NEUROREPORT, V8, P81, DOI 10.1097/00001756-199612200-00017; Maynard KI, 1998, NEUROSCI LETT, V249, P159, DOI 10.1016/S0304-3940(98)00416-9; Maynard KI, 1998, NEUROREPORT, V9, P4141, DOI 10.1097/00001756-199812210-00026; Maynard KI, 1999, ANN NY ACAD SCI, V890, P240, DOI 10.1111/j.1749-6632.1999.tb07999.x; MAYNARD KI, 1995, NEUROREPORT, V6, P850, DOI 10.1097/00001756-199504190-00006; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MINAMISAWA H, 1990, ANN NEUROL, V28, P26, DOI 10.1002/ana.410280107; Mori K, 1998, NEUROL RES, V20, P719; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Quinones-Hinojosa A, 1999, J NEUROSCI METH, V90, P107, DOI 10.1016/S0165-0270(99)00068-0; Quinones-Hinojosa A., 1998, Society for Neuroscience Abstracts, V24, P1506; QUINONESHINOJOS.A, 1999, AM ASS NEUR SURG ANN; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; Riepe MW, 1997, STROKE, V28, P2006, DOI 10.1161/01.STR.28.10.2006; ROSOMOFF HL, 1956, J NEUROSURG, V13, P332; Soukup J, 2002, NEUROL RES, V24, P161, DOI 10.1179/016164102101199710; STYS PK, 1992, J CEREBR BLOOD F MET, V12, P977, DOI 10.1038/jcbfm.1992.135; TAYLOR CP, 1993, NEUROSCIENCE, V52, P555, DOI 10.1016/0306-4522(93)90405-5; Taylor DL, 2002, PEDIATR RES, V51, P13, DOI 10.1203/00006450-200201000-00005; Toyoda T, 1996, NEUROSURGERY, V39, P1200, DOI 10.1097/00006123-199612000-00024; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Williams GD, 1997, PEDIATR RES, V42, P700, DOI 10.1203/00006450-199711000-00024; XUE D, 1992, BRAIN RES, V587, P66, DOI 10.1016/0006-8993(92)91428-H; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919; ZAGER EL, 1988, J NEUROSURG, V69, P568, DOI 10.3171/jns.1988.69.4.0568; Zeevalk GD, 1996, J PHARMACOL EXP THER, V279, P332; ZORNOW MH, 1995, J NEUROSURG ANESTH, V7, P148, DOI 10.1097/00008506-199504000-00022	71	25	25	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2003	52	5					1178	1186		10.1227/01.NEU.0000057836.64972.A0			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	675CU	WOS:000182676100046	12699563				2022-02-06	
J	Hoshino, S; Kobayashi, S; Furukawa, T; Asakura, T; Teramoto, A				Hoshino, S; Kobayashi, S; Furukawa, T; Asakura, T; Teramoto, A			Multiple immunostaining methods to detect traumatic axonal injury in the rat fluid-percussion brain injury model	NEUROLOGIA MEDICO-CHIRURGICA			English	Article; Proceedings Paper	59th Annual Meeting of the Japan-Neurosurgical-Society	OCT, 2000	FUKUOKA, JAPAN	Japan Neurosurg Soc		axonal injury; beta-amyloid precursor protein; head injury; immunohistochemistry; neurofilament; rat	AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; ALZHEIMERS-DISEASE; NEUROFILAMENT SUBUNITS; BETA-PROTEIN; APP; ANTIBODIES; DIAGNOSIS; MARKER; IMMUNOREACTIVITY	Immunohistochemistry using beta-amyloid precursor protein (APP) N-terminus antibodies is routinely used to detect traumatic axonal injury (TAI). The temporal and regional distributions of APP C- and N-terminus immunoreactivity were investigated in rats with experimental brain injury and compared to distribution of neurofilament (NF) immunoreactivity. Male Sprague-Dawley rats underwent right lateral fluid-percussion (FP) brain injury or sham injury. Six FP injury rats and two control rats were transcardially fixed with 10% formalin at 1, 6, 24, and 48 hours, and 1 and 2 weeks after injury and serial 6 pm-thick paraffin sections were prepared. At 6 hours after injury, APP C-terminus immunostaining labeled small neurons and axonal deposits in the injured parasagittal cortex, striatum, thalami, and dorsal medulla, whereas APP N-terminus and NF immunostaining showed few axonal deposits in the parasagittal cortex. At 24-48 hours post-injury, marked axonal damage, including axonal swelling and bulbs, was observed in the injured cerebral hemisphere, cerebellar white matter, and medulla. NF immunostaining was most sensitive for axonal damage in the injured deep cortical layers, cerebellum, and medulla. At 1-2 weeks after injury, APP N-terminus immunostaining mainly showed dot-like axonal profiles in the injured thalamus. APP C-terminus immunoreactivity may serve as an early marker of TAI, and the C-terminal fragments of APP may be involved in the evolution of TAI because C-terminal fragments of APP are neurotoxic and pro-apoptotic. Multiple immunostaining methods may be required to fully recognize the extent of TAI.	Chiba Hokusoh Hosp, Nippon Med Sch, Dept Neurosurg, Chiba, Japan; Nippon Med Coll, Dept Neurosurg, Tokyo 113, Japan		Hoshino, S (corresponding author), Heiwadai Hosp, Dept Neurosurg, Abiko, Chiba, Japan.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Aplin AE, 1996, J NEUROCHEM, V67, P699; Barnes NY, 1998, J NEUROSCI, V18, P5869; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FUKUCHI KI, 1994, EXP NEUROL, V127, P253, DOI 10.1006/exnr.1994.1101; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; MarquezSterling NR, 1997, J NEUROSCI, V17, P140, DOI 10.1523/JNEUROSCI.17-01-00140.1997; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pierce JES, 1996, J NEUROSCI, V16, P1083; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	38	25	32	0	0	JAPAN NEUROSURGICAL SOC	TOKYO	C/O AKAMON-MAE IWATA BLDG, 5-27-8 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105			NEUROL MED-CHIR	Neurol. Med.-Chir.	APR	2003	43	4					165	173		10.2176/nmc.43.165			9	Clinical Neurology; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	669JN	WOS:000182348300001	12760494	Bronze			2022-02-06	
J	Keenan, MA; Fuller, DA; Whyte, J; Mayer, N; Esquenazi, A; Fidler-Sheppard, R				Keenan, MA; Fuller, DA; Whyte, J; Mayer, N; Esquenazi, A; Fidler-Sheppard, R			The influence of dynamic polyelectromyography in formulating a surgical plan in treatment of spastic elbow flexion deformity	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; elbow; electromyography; rehabilitation; surgery	UPPER-LIMB SPASTICITY; BOTULINUM-TOXIN	Objective: To determine the influence of motor-control analysis with dynamic electromyography on surgical planning in patients with spastic elbow flexion deformity. Design: Prospective observational design. Setting: A Traumatic Brain Injury Model Systems-affiliated specialty referral center for the evaluation and treatment of mobility problems associated with neurologic injury and disease. Participants: Twenty-one patients with spastic elbow flexion deformity. Interventions: Two surgeons each formulated a detailed surgical plan for each individual muscle-tendon unit. Patients then underwent motor-control analysis in which kinetic and polyelectromyographic data were collected by using a standard protocol. Each surgeon formulated another surgical plan after independently reviewing the laboratory study. Main Outcome Measures: The frequency of change and degree of agreement in the surgical plans after review of the laboratory data were used as measures of the effect of the laboratory studies. Results: Fifty-seven percent of the surgical plans were changed after the motor-control study. The frequency of change did not differ by clinical experience. There was a trend toward higher agreement between surgeons after the study than before. Conclusions: Detailed electromyographic motor-control analysis alters surgical planning for patients with spastic elbow flexion deformity. Clinical assessment alone does not accurately identify the muscles responsible for the deformity or dysfunction. More clinical experience does not result in greater accuracy. Motor-control analysis produces higher agreement between surgeons in planning surgery.	Thomas Jefferson Univ, Sch Med, Albert Einstein Med Ctr, Mossrehab Hosp,Inst Mobil Evaluat & Treatment, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Sch Med, Moss Rehabil Res Inst, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Sch Med, Dept Orthopaed Surg, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Sch Med, Dept Rehabil Med, Philadelphia, PA 19107 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Cooper Hosp, Dept Orthopaed Surg, Camden, NJ 08103 USA		Keenan, MA (corresponding author), Univ Penn, Dept Orthopaed Surg, 2 Silverstein,3400 Spruce St, Philadelphia, PA 19104 USA.		Keenan, Mary Ann/ABB-1551-2020	Whyte, John/0000-0002-4381-1474			Bae DS, 2001, J PEDIATR ORTHOPED, V21, P580, DOI 10.1097/00004694-200109000-00005; Bhakta BB, 1996, J NEUROL NEUROSUR PS, V61, P30, DOI 10.1136/jnnp.61.1.30; Friedman A, 2000, AM J PHYS MED REHAB, V79, P53, DOI 10.1097/00002060-200001000-00012; Fuller DA, 2002, FOOT ANKLE INT, V23, P738, DOI 10.1177/107110070202300810; HISEY MS, 1998, OPERATIVE HAND SURG, P287; Keenan MA, 1996, J HEAD TRAUMA REHAB, V11, P57, DOI 10.1097/00001199-199608000-00008; KEENAN MAE, 1990, J HAND SURG-AM, V15A, P607, DOI 10.1016/S0363-5023(09)90023-5; KEENAN MAE, 1990, J HAND SURG-AM, V15A, P340, DOI 10.1016/0363-5023(90)90120-G; LEE GA, 2001, CHAPMANS ORTHOPAEDIC, P3201; MCDAID P, 2001, CHAPMANS ORTHOPAEDIC, P1809; MEALS RA, 1988, J BONE JOINT SURG AM, V70A, P1081, DOI 10.2106/00004623-198870070-00017; MITAL MA, 1979, J BONE JOINT SURG AM, V61, P515, DOI 10.2106/00004623-197961040-00005; Panizza M, 2000, FUNCT NEUROL, V15, P147; REIMERS J, 1990, CLIN ORTHOP RELAT R, P35; SHERK HH, 1977, CLIN ORTHOP RELAT R, P151; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306	16	25	25	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					291	296		10.1053/apmr.2003.50099			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	643QV	WOS:000180872700021	12601663				2022-02-06	
J	O'Bryant, SE; Hilsabeck, RC; Fisher, JM; McCaffrey, RJ				O'Bryant, SE; Hilsabeck, RC; Fisher, JM; McCaffrey, RJ			Utility of the trail making test in the assessment of malingering in a sample of mild traumatic brain injury litigants	CLINICAL NEUROPSYCHOLOGIST			English	Article							VERBAL-LEARNING TEST; HEAD-INJURY; PERFORMANCE	The Trail Making Test (TMT) is one of the most commonly administered tests in neuropsychological assessments. It has been shown to be a valid indicator of brain damage due to traumatic brain injury (TBI), as well as a number of other neuropathological conditions. TMT error and ratio scores have been suggested as possible markers of malingering. The present study examined the utility of various TMT scores as malingering measures in 94 TBI litigants. Litigants were divided into those suspected of (n=27) and those not suspected of malingering (n=67) based on scores obtained on the Test of Memory Malingering and/or the Rey 15-Item Test. TMT errors did not discriminate between suspected and nonsuspected malingerers: however, the overall level of performance on the TMT was suppressed in suspected malingerers. The TMT ratio score was significantly lower in litigants suspected of malingering, although the clinical utility of this ratio is minimal. Results of the present study suggest using caution when interpreting TMT scores as markers of malingering in TBI litigants.	SUNY Albany, Albany, NY 12222 USA; Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79409 USA; Brain Injury Consultants Inc, Fairport, NY USA; Albany Psychol Associates, Albany, NY USA		McCaffrey, RJ (corresponding author), SUNY Albany, Dept Psychol, 1400 Washington Ave, Albany, NY 12222 USA.	rm188@albany.edu	Hilsabeck, Robin/ABC-5093-2020	O'Bryant, Sid/0000-0003-0582-5266			Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Guilmette T J, 1990, Arch Clin Neuropsychol, V5, P373, DOI 10.1016/0887-6177(90)90016-I; Iverson GL, 2000, J CLIN EXP NEUROPSYC, V22, P191, DOI 10.1076/1380-3395(200004)22:2;1-1;FT191; King JH, 1998, J CLIN EXP NEUROPSYC, V20, P603, DOI 10.1076/jcen.20.5.603.1124; LAMBERTY GJ, 1994, NEUROPSY NEUROPSY BE, V7, P230; LeesHaley PR, 1996, ARCH CLIN NEUROPSYCH, V11, P45, DOI 10.1016/0887-6177(95)00011-9; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; Rasmusson DX, 1998, CLIN NEUROPSYCHOL, V12, P169, DOI 10.1076/clin.12.2.169.2005; REITAN RM, 1993, HEALSTEAD REITAN NEU; Rey A., 1964, EXAMEN CLIN PSYCHOL; Ruff RM, 1999, STUD NEUROPSYCHOL DE, P315; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; SILBERFARB PM, 1980, AM J PSYCHIAT, V137, P597; STARKSTEIN SE, 1988, J NEUROL NEUROSUR PS, V51, P1259, DOI 10.1136/jnnp.51.10.1259; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 2000, ARCH CLIN NEUROPSYCH, V15, P415, DOI 10.1016/S0887-6177(99)00033-5; Tombaugh T.N., 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; van Gorp WG, 1999, J CLIN EXP NEUROPSYC, V21, P245	22	25	27	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	2003	17	1					69	74		10.1076/clin.17.1.69.15624			6	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	707XM	WOS:000184535300006	12854012				2022-02-06	
J	Haldorsen, T; Waterloo, K; Dahl, A; Mellgren, SI; Davidsen, PE; Molin, PK				Haldorsen, T; Waterloo, K; Dahl, A; Mellgren, SI; Davidsen, PE; Molin, PK			Symptoms and cognitive dysfunction in patients with the late whiplash syndrome	APPLIED NEUROPSYCHOLOGY			English	Article						late whiplash syndrome; symptoms; rivermead post-concussion symptoms questionnaire; cognitive dysfunction	MINOR HEAD-INJURY; COMMON WHIPLASH; CEREBRAL SYMPTOMS; FOLLOW-UP; NECK	The aim of the study was to record the severity of symptoms in patients with the late whiplash syndrome and to assess how the symptom load affected the performance on a simple psychometric test. The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) with an additional question on neck pain, modified RPQ (mRPQ), and the Short Test of Mental Status (STMS) were applied on 40 chronic whiplash patients. Symptoms reported by the whiplash group were compared to those of 50 normal controls. The patients scored significantly higher than the controls on all symptoms listed in the mRPQ. The most frequent symptoms reported by the whiplash group were neck pain, headache, "taking longer to think, "forgetfulness, poor concentration, and fatigue. Total score of STMS was significantly lower (p = .0001) in the patients. There was a statistically significant association (p. 0001) between the total scores of mRPQ and STMS indicating that a high symptom load is associated with a poor performance on STMS. The study illustrates that various symptoms, in addition to neck and head pain, may have an impact on cognitive functions when evaluated by an easily administrated test like STMS.	Univ Tromso Hosp, Dept Neurol, N-9038 Tromso, Norway; Univ Tromso, Dept Psychol, Tromso, Norway		Haldorsen, T (corresponding author), Univ Tromso Hosp, Dept Neurol, N-9038 Tromso, Norway.	nevrtoh@unn.no		Molin, Pal Kristian/0000-0002-3319-4177			BALLA JI, 1982, CULT MED PSYCHIAT, V6, P191, DOI 10.1007/BF00051428; BARRETT K, 1995, J ACCID EMERG MED, V12, P173; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; EVANS RW, 1996, NEUROLOGY TRAUMA, P439; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Hasvold Toralf, 1993, Scandinavian Journal of Primary Health Care, V11, P219, DOI 10.3109/02813439308994834; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Karlsborg M, 1997, ACTA NEUROL SCAND, V95, P65, DOI 10.1111/j.1600-0404.1997.tb00071.x; Kessels RPC, 1998, ACTA NEUROL SCAND, V97, P188; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KISCHKA U, 1991, EUR NEUROL, V31, P136, DOI 10.1159/000116663; KOKMEN E, 1987, MAYO CLIN PROC, V62, P281, DOI 10.1016/S0025-6196(12)61905-3; Moss NE., 1994, CLIN REHABIL, V8, P149; OLSNES BT, 1989, ACTA NEUROL SCAND, V80, P584, DOI 10.1111/j.1600-0404.1989.tb03931.x; RADANOV BP, 1994, J NEUROL NEUROSUR PS, V57, P486, DOI 10.1136/jnnp.57.4.486; Radanov BP, 1999, J NEUROL NEUROSUR PS, V66, P485, DOI 10.1136/jnnp.66.4.485; RADANOV BP, 1993, ARCH NEUROL-CHICAGO, V50, P87, DOI 10.1001/archneur.1993.00540010081022; Schmand B, 1998, J NEUROL NEUROSUR PS, V64, P339, DOI 10.1136/jnnp.64.3.339; Smed A, 1997, ACTA NEUROL SCAND, V95, P73, DOI 10.1111/j.1600-0404.1997.tb00072.x; SPITZER WO, 1995, SPINE, V20, pS1; Waterloo K, 1997, EUR J NEUROL, V4, P171, DOI 10.1111/j.1468-1331.1997.tb00323.x	23	25	25	0	6	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2003	10	3					170	175		10.1207/S15324826AN1003_06			6	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	780NL	WOS:000189387500006	12890644				2022-02-06	
J	Menzel, M; Soukup, J; Henze, D; Clausen, T; Marx, T; Hillman, A; Miko, I; Grond, S; Rieger, A				Menzel, M; Soukup, J; Henze, D; Clausen, T; Marx, T; Hillman, A; Miko, I; Grond, S; Rieger, A			Brain tissue oxygen monitoring for assessment of autoregulation: Preliminary results suggest a new hypothesis	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						brain tissue oxygen; monitoring; autoregulation; cerebral perfusion pressure	CEREBRAL PERFUSION-PRESSURE; SEVERE HEAD-INJURY; BLOOD-FLOW-VELOCITY; INTRACRANIAL-PRESSURE; SUBSTRATE DELIVERY; FELINE BRAIN; SATURATION; ISCHEMIA; TENSION; PH	Brain tissue oxygen monitoring (PtiO2 (Neurotrend, Codman, Germany) was employed in addition to standard intracranial pressure (ICP) and cerebral perfusion pressure (CPP) monitoring in seven patients with severe neuronal damage of heterogeneous etiology. The correlation between PtiO2 changes and CPP fluctuations during periods of 30 minutes were analyzed, when CPP was above 70 mmHg and lower than 100 mmHg. A new ratio, the CPP-oxygen-reactivity (COR) index was calculated as COR = Deltap(ti)O(2)%/DeltaCPP%. The patient COR values were compared to those found in the brain of six noninjured anesthetized piglets. The analysis was performed to determine the significance of synchronous fluctuations of CPP and PtiO2, when CPP is above the lower threshold of autoregulation. The correlation between CPP variations and p(ti)O(2) variations was found to be strong (R-mean 0.74 +/- 0.17) in the patients and was weak in the uninjured animals (R-mean = 0.38 +/- 0.43). The CORmean was 2.05 +/- 0.57 in patients and 0.78 +/- 0.6 in the animals. In the injured brain of our patients, we observed an unexpectedly close correlation between PtiO2 and CPP variations when CPP levels were within a therapeutically targeted range (70 to 100 mmHg). In a porcine model, we could not find this relationship in the noninjured brain. We speculate that an increased COR might be indicative for an impaired local pressure autoregulation. The preliminary data suggest that COR values above "I" might be pathologic. However, the reported sample sizes are too small to provide sufficient statistical power to justify inferential statistical analyses. As such, results are presented with descriptive statistics only, and should be regarded as a hypothesis.	Univ Halle Wittenberg, Dept Anesthesiol & Intens Care, D-06097 Halle An Der Saale, Germany; Univ Halle Wittenberg, Dept Neurosurg, D-06097 Halle An Der Saale, Germany; Univ Debrecen, Dept Expt Surg, H-4012 Debrecen, Hungary		Menzel, M (corresponding author), Univ Halle Wittenberg, Dept Anesthesiol & Intens Care, Magdeburger Str 16, D-06097 Halle An Der Saale, Germany.						Al-Rawi PG, 2000, ZBL NEUROCHIR, V61, P74, DOI 10.1055/s-2000-8263; BARZO P, 1993, NEUROSURGERY, V32, P611; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Cruz J, 1988, Acta Neurochir Suppl (Wien), V42, P35; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; Cruz J, 2000, J NEUROSURG, V93, P158; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Gopinath SP, 1999, NEUROSURGERY, V44, P1273, DOI 10.1097/00006123-199906000-00066; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HAUERBERG J, 1993, J NEUROSURG ANESTH, V5, P258; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hoffman WE, 1996, NEUROL RES, V18, P54, DOI 10.1080/01616412.1996.11740378; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371, DOI 10.1152/ajpheart.1978.234.4.H371; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; LAPTOOK AR, 1994, PEDIATR RES, V35, P436, DOI 10.1203/00006450-199404000-00010; Lassen N A, 1966, Res Publ Assoc Res Nerv Ment Dis, V41, P205; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Mascia L, 2000, INTENS CARE MED, V26, P202, DOI 10.1007/s001340050046; MATTA BF, 1994, ANESTH ANALG, V79, P745; Meixensberger J, 1998, ACT NEUR S, V71, P260; Menzel M, 2000, ZBL NEUROCHIR, V61, P181, DOI 10.1055/s-2000-15598; Menzel M, 1998, J NEUROTRAUM, V15, P265, DOI 10.1089/neu.1998.15.265; MURR R, 1995, NEUROL RES, V17, P329, DOI 10.1080/01616412.1995.11740338; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; Prat R, 1998, ACT NEUR S, V71, P123; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; Sahuquillo J, 1998, ACT NEUR S, V71, P233; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Stocchetti N, 1998, ACT NEUR S, V71, P162; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van den Brink WA, 1998, ACT NEUR S, V71, P190; VanSantbrink EJP, 1997, J CLIN ENDOCR METAB, V82, P3597, DOI 10.1210/jc.82.11.3597; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zhi DS, 1999, SURG NEUROL, V52, P393, DOI 10.1016/S0090-3019(99)00101-9	51	25	26	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2003	15	1					33	41		10.1097/00008506-200301000-00006			9	Anesthesiology; Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology; Surgery	629UZ	WOS:000180070800006	12499980				2022-02-06	
J	Jang, SH; Han, BS; Chang, YM; Byun, WM; Lee, J; Ahn, SH				Jang, SH; Han, BS; Chang, YM; Byun, WM; Lee, J; Ahn, SH			Functional MRI evidence for motor cortex reorganization adjacent to a lesion in a primary motor cortex	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						functional magnetic resonance imaging; motor recovery; brain injury; motor cortex	HAND AREA; RECOVERY; PLASTICITY; STROKE; LOCALIZATION; GYRUS	Objective: The object of this study was to verify motor cortex reorganization in patients with primary motor cortex injury using functional magnetic resonance imaging. Design: Ten control subjects and two patients with primary motor cortex injury, caused by a traumatic brain injury in patient 1 and meningioma in patient 2, were evaluated. Functional magnetic resonance imaging was performed using the blood oxygenation level-dependent technique at 1.5 T with hand movements. Results: The contralateral primary sensorimotor cortex was activated by unaffected hand movements. However, only the contralateral primary sensory cortex in patient 1 and the premotor area in patient 2 were activated by affected hand movements, which were totally absent in control subjects. Conclusion: We believe that the hand motor function of injured primary motor cortex was shifted into the primary sensory cortex in patient 1 and premotor area in patient 2. In conclusion, this finding may reflect a functional reorganization of the motor area in patients with a primary motor cortex injury.	Yeungnam Univ, Sch Med, Dept Phys Med & Rehabil, Nam Ku, Taegu 705717, South Korea; Yeungnam Univ, Sch Med, Dept Diagnost Radiol, Nam Ku, Taegu 705717, South Korea; Yeungnam Univ, Sch Med, Dept Neurol, Nam Ku, Taegu 705717, South Korea; Kyungpook Natl Univ, Sch Med, Dept Radiol, Taegu, South Korea		Jang, SH (corresponding author), Yeungnam Univ, Sch Med, Dept Phys Med & Rehabil, Nam Ku, 317-1,Daemyungdong, Taegu 705717, South Korea.		Han, Bong Soo/AAL-6704-2020				BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Boroojerdi B, 1999, CLIN NEUROPHYSIOL, V110, P699, DOI 10.1016/S1388-2457(98)00027-3; Caramia MD, 1998, NEUROLOGY, V51, P196, DOI 10.1212/WNL.51.1.196; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; Cramer SC, 2000, STROKE, V31, P668, DOI 10.1161/01.STR.31.3.668; DAVIDOFF RA, 1990, NEUROLOGY, V40, P332; Duffau H, 2000, ANN NEUROL, V47, P132, DOI 10.1002/1531-8249(200001)47:1<132::AID-ANA23>3.0.CO;2-0; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; JANE JA, 1967, J NEUROSURG, V26, P244, DOI 10.3171/jns.1967.26.2.0244; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Nudo RJ, 1999, REV NEUROL, V155, P713; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144, DOI 10.1152/jn.1996.75.5.2144; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Rossini PM, 1998, NEUROREPORT, V9, P2141, DOI 10.1097/00001756-199806220-00043; Rouiller EM, 1998, EUR J NEUROSCI, V10, P729, DOI 10.1046/j.1460-9568.1998.00075.x; RUSSELL JR, 1961, NEUROLOGY, V11, P96, DOI 10.1212/WNL.11.2.96; Seitz RJ, 1997, ADV NEUROL, V73, P321; SEITZ RJ, 1995, NEUROREPORT, V6, P742, DOI 10.1097/00001756-199503270-00009; Stroemer RP, 1998, STROKE, V29, P2381, DOI 10.1161/01.STR.29.11.2381; Strupp JP, 1996, NEUROIMAGE, V3, pS607; WEILLER C, 1993, ANN NEUROL, V33, P181; YORK DH, 1987, NEUROSURGERY, V20, P70; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	25	25	25	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV	2002	81	11					844	847		10.1097/00002060-200211000-00007			4	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	607FP	WOS:000178781700007	12394996				2022-02-06	
J	Bergman, MM				Bergman, MM			The benefits of a cognitive orthotic in brain injury rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assistive technology; brain injury rehabilitation; cognitive orthotic; computers		Background: Properly designed software can be compensatory; and possibly remedial, for people with significant deficits from traumatic brain injury (FBI). objective: This article will provide a historical overview of the use of microcomputers in brain injury rehabilitation. Emphasis will be placed on the evolution of compensatory assistive technology for overcoming cognitive impairments, with theoretical discussion of the design considerations for an effective cognitive orthotic. Conclusions: Discussion win focus on findings and observations made with a particular multifunction cognitive orthotic system to assist people with TBI in the performance of ecologically relevant activities. Additional observations win address the impact of the current US health care environment on technological innovation.	Lankenau Hosp, Wynnewood, PA USA		Bergman, MM (corresponding author), Lankenau Med Off, Bldg E,100 E Lancaster Ave,Suite 564, Wynnewood, PA 19096 USA.						*ALL TECHN ASS, 1994, COMPUTER RESOURCES P; Batchelor J, 1988, J HEAD TRAUMA REHAB, V3, P78, DOI DOI 10.1097/00001199-198809000-00012; Berg H, 1998, BIOELECTROCH BIOENER, V45, P1; Bergman M M, 2000, Appl Neuropsychol, V7, P76, DOI 10.1207/S15324826AN0702_2; BERGMAN MM, 1991, NEUROPSYCHOLOGY, V5, P25; BERGMAN MM, 1997, Patent No. 5601432; BERGMAN MM, 1999, Patent No. 5890905; BERGMAN MM, 1999, Patent No. 5879162; BERGMAN MM, 1991, J HEAD TRAUMA REHAB, V6, P100; BRACY OL, 1983, COGNITIVE REHABILITA, V1, P7; Chute DL, 1988, NEUROPSYCHOLOGY, V2, P41, DOI 10.1037//0894-4105.2.1.41; COLE E, 1987, COGNITIVE REHABILITA, V5, P29; FISHER L, 1989, COGNITIVE APPROACHES; FOWLER R, 1972, REHABILITATION COUNS, V15, P80; FRANZEN M D, 1991, Neuropsychology Review, V2, P29, DOI 10.1007/BF01108846; GIANUTSOS R, 1980, J REHABIL, V46, P36; GLISKY EL, 1995, HDB MEMORY DISORDERS; Gookin D., 1994, WORD WINDOWS 6 DUMMI; GORMAN P, 2003, IN PRESS NEUROREHABI; JONES G, 1979, B BRIT PSYCHOL SOC, V32, P167; KERNER M, 1985, COGNITIVE REHABILITA, V3, P26; KIRSCH NL, 1987, J HEAD TRAUMA REHAB, V2, P77; Levinson R, 1997, J HEAD TRAUMA REHAB, V12, P85, DOI 10.1097/00001199-199704000-00010; LEVINSON R, 1995, P 2 INT C AI PLANN S; LYNCH WJ, 1986, J HEAD TRAUMA REHAB, V1, P77; LYNCH WJ, 1983, COGN REHABIL, V1, P19; LYNCH WJ, 1990, J HEAT TRAUMA REHABI, V5, P96; LYNCH WJ, 1992, J HEAD TRAUMA REHAB, V7, P107; MARKS C, 1986, COGNITIVE REHABILITA, V4, P20; Matthews E, 1991, GLOBAL BIOGEOCHEM CY, V5, P3, DOI 10.1029/90GB02311; *MERR WEBST INC, 1989, WEBST 9 NEW COLL DIC; PARENTE R, 1994, NEUROREHABILITATION, V4, P187; PEPITONE P, 1992, HEADLINES        MAY, P26; STOLL C, 1995, SILICONE SNAKE OIL 2; WEINRICH M, 1988, ADV NEUROLOGY; WEINRICH M, 1998, ADV NEUROLOGY; Wilson B, 1984, EVERYDAY MEMORY ACTI, P207; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284; [No title captured]	39	25	25	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2002	17	5					431	445		10.1097/00001199-200210000-00005			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	610DD	WOS:000178944700005	12802253				2022-02-06	
J	Ohhashi, G; Tani, S; Murakami, S; Kamio, M; Abe, T; Ohtuki, J				Ohhashi, G; Tani, S; Murakami, S; Kamio, M; Abe, T; Ohtuki, J			Problems in health management of professional boxers in Japan	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							MILD HEAD-INJURY; CONCUSSION; SEQUELAE; SPORTS; GUIDELINES; SYMPTOMS; BRAIN	Objective: To investigate whether the incidence of boxing accidents is higher in Japan than in other countries. Method: A nationwide survey of boxers was conducted. Results: A total of 632 boxers responded. Most Japanese boxers were relatively mature when they started boxing (mean starting age of 19.2 years). A high percentage of boxers was found three weight divisions higher than previously reported. Many boxers stated that losing weight was not a big problem. It was found that a punch that turns the head can cause serious physical damage, and it was clarified that only a simple punch, rather than accumulated damage from multiple punches, can cause cerebral concussion. Severe shock causing retrograde amnesia is very rare after a fight and disappears relatively quickly. Many additional symptoms are related to damage to the hearing organs, such as hearing difficulties, tinnitus, and vertigo, but these symptoms also resolve quickly. Many boxers experience memory disturbance, not just after a fight but in daily life. Conclusion: The approach to boxing has become more oriented towards the method of practice and scientific training, rather than psychological factors, which used to be emphasised.	Jikei Univ, Sch Med, Dept Neurol Surg, Minato Ku, Tokyo 1058461, Japan; Nihon Univ, Sch Med, Dept Emergency & Crit Care Med, Tokyo 102, Japan		Ohhashi, G (corresponding author), Jikei Univ, Sch Med, Dept Neurol Surg, Minato Ku, 3-25-8 Nishishinbashi, Tokyo 1058461, Japan.						Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; *BAS MAG CO, 2000, JAP BOX YB 2000; *BAS MAG CO, 1990, JAP BOX YB 1990; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 1995, BOXING MED, P19; ENZENAUER RW, 1994, JAMA-J AM MED ASSOC, V272, P1821, DOI 10.1001/jama.1994.03520230031028; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Fiore DC, 1996, JAMA-J AM MED ASSOC, V276, P954; GRONWALL D, 1975, LANCET, V2, P995; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; HOLZGRAEFE M, 1992, INT J SPORTS MED, V13, P616, DOI 10.1055/s-2007-1024576; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Leclerc S, 1999, BRIT J SPORT MED, V33, P426, DOI 10.1136/bjsm.33.6.426; LUNDBERG GD, 1994, JAMA-J AM MED ASSOC, V271, P1790, DOI 10.1001/jama.271.22.1790; LUNDBERG GD, 1985, AM J FOREN MED PATH, V6, P192, DOI 10.1097/00000433-198509000-00004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; MORRISON RG, 1986, JAMA-J AM MED ASSOC, V255, P2475, DOI 10.1001/jama.255.18.2475; OCONNOR F, 1991, MIL MED, V156, P391, DOI 10.1093/milmed/156.8.391; Pearn J, 1998, J PAEDIATR CHILD H, V34, P311, DOI 10.1046/j.1440-1754.1998.00231.x; Ryan AJ, 1998, CLIN SPORT MED, V17, P155, DOI 10.1016/S0278-5919(05)70070-3; RYAN AJ, 1987, CLIN SPORT MED, V6, P31; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Sawauchi S, 1996, NEUROL SURG TOKYO, V24, P905; SCHMIDTOLSEN S, 1990, AM J SPORT MED, V18, P98, DOI 10.1177/036354659001800117; SWARTZBERG D, 1995, JAMA-J AM MED ASSOC, V274, P784, DOI 10.1001/jama.1995.03530100018006; TANI S, 1994, 1994 INT C REC ADV N, P1065; TANI S, 2001, J JAPANESE SOC CLIN, V19, P413; Warburton N, 1998, J MED ETHICS, V24, P56, DOI 10.1136/jme.24.1.56	33	25	28	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	OCT	2002	36	5					346	352		10.1136/bjsm.36.5.346			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	602RN	WOS:000178518400009	12351332	Green Published, Bronze			2022-02-06	
J	Yeiser, EC; Vanlandingham, JW; Levenson, CW				Yeiser, EC; Vanlandingham, JW; Levenson, CW			Moderate zinc deficiency increases cell death after brain injury in the rat	NUTRITIONAL NEUROSCIENCE			English	Article						apoptosis; CNS; macrophages; microglia; trauma; TUNEL	GROWTH-INHIBITORY FACTOR; CENTRAL-NERVOUS-SYSTEM; NEURONAL DEATH; STAB WOUNDS; MONOCLONAL-ANTIBODIES; CEREBRAL-ISCHEMIA; APOPTOSIS; MICROGLIA; MECHANISMS; SUPPLEMENTATION	Zinc supplementation has been used clinically to reduce Zn losses and protein turnover in patients suffering from traumatic brain injury. Despite the known role of zinc in cell survival and integrity, the influence of zinc status on central nervous system wound healing in the weeks and months after brain injury has not been addressed. In this investigation, we examined cell death after unilateral cortical stab wounds in adult rats (n = 5 per group) that were provided diets containing adequate zinc (30 mg Zn/kg diet), supplemental zinc (180 mg/kg), or moderately deficient zinc (5 mg/kg). Four weeks following the brain injury there was a 1.82-2.65-fold increase in terminal deoxynucleotidyl transferase-mediated biotinylated dUTP nick-end labeling (TUNEL)-positive cells with DNA fragmentation at the site of injury in animals receiving a moderately zinc deficient diet compared to animals receiving a zinc-adequate or supplemented diet (p0.05). Examination of the nuclear morphology of these cells suggested the presence of both apoptosis and necrosis. Immunohistochemistry showed that the TUNEL-positive cells expressed both ED-1 and OX-42, identifying them as microglia/macrophages. Thus it appears that adequate zinc status may be necessary to minimize the amount of neuroimmune cell death after brain injury.	Florida State Univ, Biomed Res Facil 237, Program Neurosci, Tallahassee, FL 32306 USA; Florida State Univ, Dept Nutr Food & Exercise Sci, Tallahassee, FL 32306 USA		Levenson, CW (corresponding author), Florida State Univ, Biomed Res Facil 237, Program Neurosci, Tallahassee, FL 32306 USA.			Levenson, Cathy W/0000-0003-4463-3136	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK50472] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R29DK050472] Funding Source: NIH RePORTER		Bagchi M, 2001, MOL CELL BIOCHEM, V221, P49, DOI 10.1023/A:1010946517651; BOJE KM, 1992, BRAIN RES, V587, P250, DOI 10.1016/0006-8993(92)91004-X; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Conti AC, 1998, J NEUROSCI, V18, P5663; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Falchuk KH, 1998, MOL CELL BIOCHEM, V188, P41, DOI 10.1023/A:1006808119862; FAURE H, 1991, BIOL TRACE ELEM RES, V30, P37, DOI 10.1007/BF02990340; FLARIS NA, 1993, GLIA, V7, P34, DOI 10.1002/glia.440070108; Fraker PJ, 1997, P SOC EXP BIOL MED, V215, P229, DOI 10.3181/00379727-215-44132; FREDERICKSON CJ, 1983, BRAIN RES, V273, P335, DOI 10.1016/0006-8993(83)90858-2; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Fukamachi Y, 1998, BIOCHEM BIOPH RES CO, V246, P364, DOI 10.1006/bbrc.1998.8621; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1987, J NEUROSCI RES, V18, P155, DOI 10.1002/jnr.490180123; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HOZUMI I, 1990, BRAIN RES, V534, P291, DOI 10.1016/0006-8993(90)90142-X; HOZUMI I, 1995, BRAIN RES, V688, P143, DOI 10.1016/0006-8993(95)00522-R; Hozumi I, 1996, BRAIN RES, V741, P197, DOI 10.1016/S0006-8993(96)00912-2; Kermer P, 1999, CELL TISSUE RES, V298, P383, DOI 10.1007/s004410050061; Kim EY, 1999, EUR J NEUROSCI, V11, P327, DOI 10.1046/j.1460-9568.1999.00437.x; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Lees GJ, 1998, BRAIN RES, V799, P108, DOI 10.1016/S0006-8993(98)00483-1; LEVENSON CW, 1994, ANAL BIOCHEM, V221, P243, DOI 10.1006/abio.1994.1408; Libonati JP, 2000, NUTR NEUROSCI, V3, P425, DOI 10.1080/1028415X.2000.11747342; Manev H, 1997, EXP NEUROL, V146, P171, DOI 10.1006/exnr.1997.6510; Martin LJ, 1998, BRAIN RES BULL, V46, P281, DOI 10.1016/S0361-9230(98)00024-0; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; MCINTOSH TK, 1990, ACT NEUR S, V51, P329; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McMahon RJ, 1998, P NATL ACAD SCI USA, V95, P4841, DOI 10.1073/pnas.95.9.4841; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Rains TM, 1998, PHYSIOL BEHAV, V65, P473, DOI 10.1016/S0031-9384(98)00182-6; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; RINK A, 1995, AM J PATHOL, V147, P1575; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; TONDER N, 1990, NEUROSCI LETT, V109, P247, DOI 10.1016/0304-3940(90)90002-Q; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WILCOX BJ, 1995, J COMP NEUROL, V359, P573, DOI 10.1002/cne.903590405; Yeiser EC, 1999, NEUROSCI LETT, V277, P75, DOI 10.1016/S0304-3940(99)00825-3; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25; ZALEWSKI PD, 1993, BIOCHEM J, V296, P403, DOI 10.1042/bj2960403; ZALEWSKI PD, 1991, BIOCHEM INT, V24, P1093	50	25	26	0	1	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1028-415X			NUTR NEUROSCI	Nutr. Neurosci.	OCT	2002	5	5					345	352		10.1080/1028415021000033811			8	Neurosciences; Nutrition & Dietetics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Nutrition & Dietetics	603FT	WOS:000178548700006	12385597				2022-02-06	
J	Vincent, VAM; Robinson, CC; Simsek, D; Murphy, GM				Vincent, VAM; Robinson, CC; Simsek, D; Murphy, GM			Macrophage colony stimulating factor prevents NMDA-induced neuronal death in hippocampal organotypic cultures	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; caspase-3; hippocampus; macrophage colony stimulating factor; neurotoxicity; NMDA	METHYL-D-ASPARTATE; OSTEOPETROTIC OP/OP MICE; MESSENGER-RNA EXPRESSION; NECROSIS-FACTOR-ALPHA; DELAYED CELL-DEATH; ALZHEIMERS-DISEASE; MICROGLIAL CELLS; SLICE CULTURES; IN-VITRO; CASPASE-3 ACTIVATION	Macrophage colony stimulating factor (M-CSF) and its receptor are up-regulated in the brain in Alzheimer's disease (AD), in transgenic mouse models for AD, and experimental models for traumatic and ischemic brain injury. M-CSF induces activation and proliferation of microglial cells and expression of proinflammatory cytokines. We examined the role of M-CSF in excitotoxic neuronal cell death in organotypic hippocampal cultures. NMDA treatment induced neuronal apoptosis and caspase-3 activation in organotypic hippocampal cultures, whereas treatment with M-CSF protected hippocampal neurons from NMDA-induced apoptosis. Caspase-3 activation was inhibited by M-CSF treatment to the same degree as with the caspase inhibitor Z-VAD-FMK. These results suggest that M-CSF has neuroprotective properties through inhibition of caspase-3 that could promote neuronal survival after excitotoxic insult. The role of M-CSF in neurological disease should be reevaluated as a microglial activator with potentially neuroprotective effects.	Stanford Univ, Sch Med, Neurosci Res Labs, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA		Murphy, GM (corresponding author), Stanford Univ, Sch Med, Neurosci Res Labs, Dept Psychiat & Behav Sci, MSLS P-104, Stanford, CA 94305 USA.	gmurphy@leland.stanford.edu					Adamec E, 1999, BRAIN RES, V849, P67, DOI 10.1016/S0006-8993(99)02004-1; AKIYAMA H, 1994, BRAIN RES, V639, P171, DOI 10.1016/0006-8993(94)91779-5; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; ALOISI F, 1992, J IMMUNOL, V149, P2358; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; BEREZOVSKAYA O, 1995, INT J DEV NEUROSCI, V13, P285, DOI 10.1016/0736-5748(95)00013-7; Bruccoleri A, 2000, J NEUROSCI RES, V62, P146, DOI 10.1002/1097-4547(20001001)62:1<146::AID-JNR15>3.0.CO;2-L; Bruno V, 2000, EUR J PHARMACOL, V399, P117, DOI 10.1016/S0014-2999(00)00367-8; Carenini S, 2001, J CELL BIOL, V152, P301, DOI 10.1083/jcb.152.2.301; Castellano C, 2001, CURR DRUG TARGETS, V2, P273, DOI 10.2174/1389450013348515; Chen J, 1998, J NEUROSCI, V18, P4914; Czapiga M, 1999, J NEUROSCI RES, V56, P644, DOI 10.1002/(SICI)1097-4547(19990615)56:6<644::AID-JNR10>3.0.CO;2-9; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Engidawork E, 2001, NEUROSCI LETT, V303, P79, DOI 10.1016/S0304-3940(01)01618-4; Estus S, 1997, J NEUROSCI, V17, P7736; Fedoroff S, 1997, NEUROSCI BIOBEHAV R, V21, P187, DOI 10.1016/S0149-7634(96)00009-7; Gahwiler BH, 1997, TRENDS NEUROSCI, V20, P471, DOI 10.1016/S0166-2236(97)01122-3; GIULIAN D, 1988, J NEUROSCI, V8, P4707; Gorman AM, 1998, NEUROREPORT, V9, pR49, DOI 10.1097/00001756-199807130-00001; Hailer NP, 1996, GLIA, V18, P319, DOI 10.1002/(SICI)1098-1136(199612)18:4<319::AID-GLIA6>3.0.CO;2-S; Hao AJ, 2001, J NEUROSCI RES, V64, P79, DOI 10.1002/jnr.1056; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Heyen JRR, 2000, MOL BRAIN RES, V77, P138, DOI 10.1016/S0169-328X(00)00042-5; Hirashima Y, 1999, BRAIN RES, V849, P109, DOI 10.1016/S0006-8993(99)02009-0; Huppertz B, 1999, ANAT EMBRYOL, V200, P1, DOI 10.1007/s004290050254; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P1397, DOI 10.1517/13543784.9.6.1397; Kondratyev A, 2000, MOL BRAIN RES, V75, P216, DOI 10.1016/S0169-328X(99)00292-2; Laake JH, 1999, BRAIN RES PROTOC, V4, P173, DOI 10.1016/S1385-299X(99)00021-5; Le DA, 2001, DRUG AGING, V18, P717, DOI 10.2165/00002512-200118100-00001; LEE SC, 1993, J IMMUNOL, V150, P594; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Liu XH, 1999, BRAIN RES, V851, P94, DOI 10.1016/S0006-8993(99)02126-5; Lue LF, 2001, GLIA, V35, P72, DOI 10.1002/glia.1072; Marin N, 2000, MECH AGEING DEV, V119, P63, DOI 10.1016/S0047-6374(00)00172-X; Masumura M, 2000, MOL BRAIN RES, V80, P219, DOI 10.1016/S0169-328X(00)00163-7; MATSUSHIMA GK, 1994, CELL, V78, P645, DOI 10.1016/0092-8674(94)90529-0; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Michaelson MD, 1996, DEVELOPMENT, V122, P2661; Mitrasinovic OM, 2001, J BIOL CHEM, V276, P30142, DOI 10.1074/jbc.M104265200; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Murase S, 1998, J NEUROSCI, V18, P10481; Murphy GM, 1998, J BIOL CHEM, V273, P20967, DOI 10.1074/jbc.273.33.20967; Murphy GM, 2000, AM J PATHOL, V157, P895, DOI 10.1016/S0002-9440(10)64603-2; NAITO M, 1991, AM J PATHOL, V139, P657; Namura S, 1998, J NEUROSCI, V18, P3659; Ni BH, 1997, J NEUROSCI, V17, P1561; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOHAVA K, 1992, EUR J IMMUNOL, V22, P2539, DOI 10.1002/eji.1830221012; RAIVICH G, 1991, J NEUROSCI RES, V30, P682, DOI 10.1002/jnr.490300412; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; Ray AM, 2000, BRAIN RES, V867, P62, DOI 10.1016/S0006-8993(00)02230-7; Roth KA, 2001, J NEUROPATH EXP NEUR, V60, P829, DOI 10.1093/jnen/60.9.829; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Schmidt-Kastner R, 2000, MOL BRAIN RES, V79, P88, DOI 10.1016/S0169-328X(00)00104-2; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Selznick LA, 1999, J NEUROPATH EXP NEUR, V58, P1020, DOI 10.1097/00005072-199909000-00012; Shimohama S, 2000, APOPTOSIS, V5, P9, DOI 10.1023/A:1009625323388; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; Tenneti L, 2000, J NEUROCHEM, V74, P134, DOI 10.1046/j.1471-4159.2000.0740134.x; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Torp R, 1998, NEUROBIOL DIS, V5, P245, DOI 10.1006/nbdi.1998.0201; Velier JJ, 1999, J NEUROSCI, V19, P5932, DOI 10.1523/JNEUROSCI.19-14-05932.1999; Wang YQ, 1999, J NEUROSCI RES, V57, P616, DOI 10.1002/(SICI)1097-4547(19990901)57:5<616::AID-JNR4>3.0.CO;2-E; Wegiel J, 1998, BRAIN RES, V804, P135, DOI 10.1016/S0006-8993(98)00618-0; Wellington CL, 2000, CLIN GENET, V57, P1, DOI 10.1034/j.1399-0004.2000.570101.x; WITMERPACK MD, 1993, J CELL SCI, V104, P1021; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; Zhu Y, 2001, NEUROCHEM INT, V38, P227, DOI 10.1016/S0197-0186(00)00084-X	75	25	27	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	SEP	2002	82	6					1388	1397		10.1046/j.1471-4159.2002.01087.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	589YW	WOS:000177790000008	12354286				2022-02-06	
J	Zauner, A; Clausen, T; Alves, OL; Rice, A; Levasseur, J; Young, HF; Bullock, R				Zauner, A; Clausen, T; Alves, OL; Rice, A; Levasseur, J; Young, HF; Bullock, R			Cerebral metabolism after fluid-percussion injury and hypoxia in a feline model	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; hypoxia; cerebral metabolism; brain chemistry; cat	SEVERE HEAD-INJURY; TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; SUBSTRATE DELIVERY; INTRACELLULAR PH; CORTICAL IMPACT; OXYGEN-TENSION; TISSUE OXYGEN; BLOOD-FLOW; ISCHEMIA	Object. Currently, there are no good clinical tools to identify the onset of secondary brain injury and/or hypoxia after traumatic brain injury (TBI). The aim of this study was to evaluate simultaneously early changes of cerebral metabolism, acid-base homeostasis, and oxygenation, as well as their interrelationship after TBI and arterial hypoxia. Methods. Cerebral biochemistry and O-2 supply were measured simultaneously in a feline model of fluid-percussion injury (FPI) and secondary hypoxic injury. After FPI, brain tissue PO, decreased from 33 +/- 5 mm Hg to 10 +/- 4 mm Hg and brain tissue PCO2 increased from 55 +/- 2 mm Hg to 81 +/- 9 mm Hg, whereas cerebral pH fell from 7.1 +/- 0.06 to 6.84 +/- 0.14 (p < 0.05 for all three measures). After 40 minutes of hypoxia, brain tissue PO2 and pH decreased further to 0 mm Hg and 6.48 +/- 0.28, respectively (p < 0.05), whereas brain tissue PCO2, remained high at 83 13 turn Hg. Secondary hypoxic injury caused a drastic increase in cerebral lactate from 513 69 muM/L to 3219 +/- 490 muM/L (p < 0.05). The lactate/glucose ratio increased from 0.7 +/- 0.1 to 9.1 +/- 2 after hypoxia was introduced. The O-2 consumption decreased significantly from 18.5 +/- 1.1 mul/mg/hr to 13.2 +/- 2.1 mul/mg/hr after hypoxia was induced. Conclusions. Cerebral metabolism, O-2 supply, and acid-base balance were severely compromised ultra-early after TBI, and they declined further if arterial hypoxia was present. The complexity of pathophysiological changes and their interactions after TBI might explain why specific therapeutic attempts that are aimed at the normalization of only one component have failed to improve outcome in severely head injured patients.	Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA		Zauner, A (corresponding author), Univ Calif Los Angeles, Box 951721, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183, DOI 10.1152/jappl.1967.23.2.183; COMBS DJ, 1990, STROKE, V21, P936, DOI 10.1161/01.STR.21.6.936; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hutchinson PJ, 1999, NEUROL RES, V21, P352, DOI 10.1080/01616412.1999.11740943; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Murr R, 1996, ACTA NEUROCHIR, V138, P928, DOI 10.1007/BF01411281; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SIESJO BK, 1973, ARCH NEUROL-CHICAGO, V29, P400, DOI 10.1001/archneur.1973.00490300062008; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1973, SCAND J CLIN LAB INV, V32, P97, DOI 10.3109/00365517309084335; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017; Zauner A, 1997, NEUROL RES, V19, P265, DOI 10.1080/01616412.1997.11740812; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	36	25	25	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	2002	97	3					643	649		10.3171/jns.2002.97.3.0643			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	593JA	WOS:000177986400019	12296649				2022-02-06	
J	Herskovits, EH; Gerring, JP; Davatzikos, C; Bryan, RN				Herskovits, EH; Gerring, JP; Davatzikos, C; Bryan, RN			Is the spatial distribution of brain lesions associated with closed-head injury in children predictive of subsequent development of posttraumatic stress disorder?	RADIOLOGY			English	Article						brain, injuries; brain, MR; children, central nervous system	CHILDHOOD SEXUAL ABUSE; POSITRON-EMISSION-TOMOGRAPHY; SCRIPT-DRIVEN IMAGERY; HIPPOCAMPAL VOLUME; BLOOD-FLOW; DATABASE; PTSD; COMORBIDITY; ADOLESCENTS; WOMEN	PURPOSE: To determine whether there is an association between the spatial distributions of lesions detected at magnetic resonance (MR) imaging of the brain in children, adolescents, and young adults after closed-head injury (CHI) and development of the reexperiencing symptoms of posttraumatic stress disorder (PTSD). MATERIALS AND METHODS: Data obtained in 94 subjects without a history of PTSD as determined by parental interview were analyzed. MR images were obtained 3 months after CHI. Lesions were manually delineated and registered to the Talairach coordinate system. Mann-Whitney analysis of lesion distribution and PTSD status at I year (again, as determined by parental interview) was performed, consisting of an analysis of lesion distribution versus the major symptoms of PTSD: reexperiencing, hyperarousal, and avoidance. RESULTS: Of the 94 subjects, 41 met the PTSD reexperiencing criterion and nine met all three PTSD criteria. Subjects who met the reexperiencing criterion had fewer lesions in limbic system structures (eg, the cingulum) on the right than did subjects who did not meet this criterion (Mann-Whitney, P = .003). CONCLUSION: Lesions induced by CHI in the limbic system on the right may inhibit subsequent manifestation of PTSD reexperiencing symptoms in children, adolescents, and young adults. (C) RSNA, 2002.	Johns Hopkins Med Inst, Div Neuroradiol, Baltimore, MD 21287 USA; Johns Hopkins Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; Johns Hopkins Univ Hosp, Dept Psychiat, Baltimore, MD 21205 USA; Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA		Herskovits, EH (corresponding author), Johns Hopkins Med Inst, Div Neuroradiol, 600 N Wolfe St, Baltimore, MD 21287 USA.		Davatzikos, Christos/ABE-2057-2021	Davatzikos, Christos/0000-0002-1025-8561	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG013743] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG13743] Funding Source: Medline		American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; Bremner J D, 1999, Semin Clin Neuropsychiatry, V4, P249; Bremner JD, 1999, AM J PSYCHIAT, V156, P1787; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; Brodmann K ., 1909, VERGLEICHENDE LOKALI; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Davatzikos C, 1997, COMPUT VIS IMAGE UND, V66, P207, DOI 10.1006/cviu.1997.0605; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Herskovits EH, 2000, METHOD INFORM MED, V39, P291; KELLY D, 1973, BRIT J PSYCHIAT, V123, P133, DOI 10.1192/bjp.123.2.133; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Letovsky SI, 1998, AM J NEURORADIOL, V19, P1869; Lipschitz DS, 1999, J AM ACAD CHILD PSY, V38, P385, DOI 10.1097/00004583-199904000-00010; Lucey JV, 1997, BRIT J PSYCHIAT, V171, P346, DOI 10.1192/bjp.171.4.346; Megalooikonomou V, 2000, HUM BRAIN MAPP, V10, P61, DOI 10.1002/(SICI)1097-0193(200006)10:2<61::AID-HBM20>3.0.CO;2-9; Newport DJ, 2000, CURR OPIN NEUROBIOL, V10, P211, DOI 10.1016/S0959-4388(00)00080-5; Nowinski WL., 1997, ELECT CLIN BRAIN ATL; Rauch SL, 1996, ARCH GEN PSYCHIAT, V53, P380; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Rauch SL, 1997, ANN NY ACAD SCI, V821, P83, DOI 10.1111/j.1749-6632.1997.tb48271.x; Rauch SL., 1998, CNS SPECTRUMS, V3, P30, DOI [10. 1017/S1092852900007306, DOI 10.1017/S1092852900007306, 10.1017/S1092852900007306]; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; SACK WH, 1993, J AM ACAD CHILD PSY, V32, P431, DOI 10.1097/00004583-199303000-00027; Schuff N, 1997, ANN NY ACAD SCI, V821, P516, DOI 10.1111/j.1749-6632.1997.tb48319.x; Shin LM, 1999, AM J PSYCHIAT, V156, P575; Shin LM, 1997, ARCH GEN PSYCHIAT, V54, P233; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; Stein MB, 1997, PSYCHOL MED, V27, P951, DOI 10.1017/S0033291797005242; Stein MB, 1997, ANN NY ACAD SCI, V821, P76, DOI 10.1111/j.1749-6632.1997.tb48270.x; Talairach J., 1988, COPLANAR STEREOTAXIC; Villarreal G, 2001, Semin Clin Neuropsychiatry, V6, P131, DOI 10.1053/scnp.2001.21840; WEINGARTEN SM, 1999, PSYCHOSURGERY; WILSON J T L, 1990, Brain Injury, V4, P349; Zubieta JK, 1999, J PSYCHIAT RES, V33, P259, DOI 10.1016/S0022-3956(98)00060-0	39	25	25	0	0	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	AUG	2002	224	2					345	351		10.1148/radiol.2242011439			7	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Radiology, Nuclear Medicine & Medical Imaging	576UY	WOS:000177025400009	12147826				2022-02-06	
J	Hicken, BL; Putzke, JD; Novack, T; Sherer, M; Richards, JS				Hicken, BL; Putzke, JD; Novack, T; Sherer, M; Richards, JS			Life satisfaction following spinal cord and traumatic brain injury: A comparative study	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						head injury; life satisfaction; pain; quality of life; spinal cord injury	QUALITY-OF-LIFE; FUNCTIONAL INDEPENDENCE MEASURE; LONG-TERM ADJUSTMENT; WELL-BEING MEASURES; PHYSICAL-DISABILITY; CHRONOLOGICAL AGE; SOCIAL SUPPORT; HEALTH-STATUS; IMPAIRMENT; COMMUNITY	The current study was designed to examine the predictive validity of several factors that are common to spinal cord injury (SCI) and traumatic brain injury (TBI) populations to overall life satisfaction. We examined several demographic and functional predictors (1) within each group separately and (2) using both groups while controlling for unique predictors within groups. Participants included 190 and 57 individuals with SCI and TBI, respectively. To minimize the influence of injury duration, we assessed life satisfaction at I-year postinjury in both groups. Functional disability (Functional Impairment Measure [FIM]) was the only common predictor within groups. For the TBI group, marital status was also a significant predictor of life satisfaction. None of the other predictors examined was significant among the SCI group. After functional disability and marital status were controlled, overall life satisfaction did not differ between groups. Total explained variance in life satisfaction was low in both groups, 9% and 25% in the SCI and TBI groups, respectively. Future directions are discussed.	Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA		Richards, JS (corresponding author), Spain Rehabil Ctr, 1717 6th Ave S,Room 529, Birmingham, AL 35233 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007420] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD07420-10] Funding Source: Medline		BACH JR, 1994, ARCH PHYS MED REHAB, V75, P626, DOI 10.1016/0003-9993(94)90183-X; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; CLAYTON KS, 1994, ARCH PHYS MED REHAB, V75, P633, DOI 10.1016/0003-9993(94)90184-8; Crewe N M, 1992, J Am Paraplegia Soc, V15, P14; CRISP R, 1992, AUST PSYCHOL, V27, P43, DOI 10.1080/00050069208257573; CUSHMAN LA, 1992, PARAPLEGIA, V30, P690, DOI 10.1038/sc.1992.135; DECKER SD, 1985, AM J OCCUP THER, V39, P740, DOI 10.5014/ajot.39.11.740; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; Dijkers MPJM, 1999, ARCH PHYS MED REHAB, V80, P867, DOI 10.1016/S0003-9993(99)90076-X; Dowler R, 2001, J Spinal Cord Med, V24, P87; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hamilton BB, 1987, REHABILITATION OUTCO, P137; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HEINEMANN AW, 1995, REHABIL PSYCHOL, V40, P125; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Heinemann AW, 1991, RATING SCALE ANAL FU; KINNEY WB, 1992, ARCH PHYS MED REHAB, V73, P863; Krause JS, 1997, REHABIL PSYCHOL, V42, P287, DOI 10.1037/0090-5550.42.4.287; Krause JS, 1998, REHABIL PSYCHOL, V43, P282, DOI 10.1037/0090-5550.43.4.282; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MCCOLL MA, 1994, PARAPLEGIA, V32, P261, DOI 10.1038/sc.1994.46; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; PENTLAND W, 1995, PARAPLEGIA, V33, P367, DOI 10.1038/sc.1995.84; Post MWM, 1998, SCAND J REHABIL MED, V30, P23; Post MWM, 1998, ARCH PHYS MED REHAB, V79, P395, DOI 10.1016/S0003-9993(98)90139-3; Post MWM, 1999, PSYCHOL HEALTH, V14, P679, DOI 10.1080/08870449908410757; Putzke JD, 2001, J CLIN PSYCHOL MED S, V8, P101, DOI 10.1023/A:1009555910604; PUTZKE JD, 2000, IN PRESS ARCH PHYS M; PUTZKE JD, 2001, IN PRESS ARCH PHYS M; Rasch Georg, 1980, PROBABILISTIC MODELS; Richards JS, 1999, ARCH PHYS MED REHAB, V80, P1501; SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162; Stover S. L., 1995, SPINAL CORD INJURY C; Vogel LC, 1998, ARCH PHYS MED REHAB, V79, P1496, DOI 10.1016/S0003-9993(98)90409-9; Warren L, 1996, J REHABIL RES DEV, V33, P404; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124	44	25	25	0	5	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.	MAY-JUN	2002	39	3					359	365					7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	575NY	WOS:000176955300007	12173756				2022-02-06	
J	Wilson, MS; Hamm, RJ				Wilson, MS; Hamm, RJ			Effects of fluoxetine on the 5-HT1A receptor and recovery of cognitive function after traumatic brain injury in rats	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; serotonin; 5-HT; 5-HT1A; fluoxetine; learning; Morris water maze; rats	FLUID-PERCUSSION MODEL; EXTRACELLULAR RELEASE; SEROTONIN RECEPTOR; MOTOR RECOVERY; MESSENGER-RNA; IN-VITRO; IMPAIRMENT; WAY-100635; ANTAGONIST; PREVENTS	Objective: This study examined the effects of chronic administration of fluoxetine, a selective serotonin reuptake inhibitor, on cognitive performance and 5-HT1A receptor immunoreactivity following traumatic brain injury. Design: Rats received a moderate severity of lateral fluid percussive injury or sham injury 24 hr after surgical preparation. Fluoxetine or vehicle was administered chronically on postinjury days 1-15. Motor performance and Morris water maze performance were assessed on postinjury days 1-5 and 11-15, respectively. Results: Results indicated that chronic fluoxetine treatment did not affect motor or maze performance. Injured groups showed significantly higher 5-HT1A receptor immunoreactivity on postinjury day 15 than sham-injured rats, and fluoxetine treatment did not alter 5-HT1A receptor immunoreactivity. Conclusions: These results indicate that chronic postinjury fluoxetine administration did not influence the recovery of motor or Morris water maze performance following lateral fluid percussive injury. They also indicate that injury-induced changes in the 5-HT1A receptor may contribute to traumatic brain injury-induced cognitive deficits.	Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA		Hamm, RJ (corresponding author), Virginia Commonwealth Univ, Dept Psychol, POB 842018, Richmond, VA 23284 USA.						Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; ALTMAN HJ, 1988, NEUROBIOL AGING, V9, P627, DOI 10.1016/S0197-4580(88)80124-6; Boast C, 1999, NEUROBIOL LEARN MEM, V71, P259, DOI 10.1006/nlme.1998.3886; BOYESON MG, 1993, AM J PHYS MED REHAB, V72, P286, DOI 10.1097/00002060-199310000-00007; BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; BRILEY M, 1990, PHARMACOPSYCHIATRY, V23, P75, DOI 10.1055/s-2007-1014538; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Carli M, 1997, BRAIN RES, V774, P167, DOI 10.1016/S0006-8993(97)81700-3; Carli M, 1999, NEUROPHARMACOLOGY, V38, P1165, DOI 10.1016/S0028-3908(99)00038-6; CARLI M, 1992, BRIT J PHARMACOL, V105, P720, DOI 10.1111/j.1476-5381.1992.tb09045.x; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Duman RS, 1998, BIOL PSYCHIAT, V44, P324, DOI 10.1016/S0006-3223(98)00031-6; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; GLOBUS MYT, 1992, STROKE, V23, P1595, DOI 10.1161/01.STR.23.11.1595; Gould E, 1999, NEUROPSYCHOPHARMACOL, V21, pS46, DOI 10.1038/sj.npp.1395369; HALL H, 1981, EUR J PHARMACOL, V70, P393, DOI 10.1016/0014-2999(81)90172-2; Harder JA, 2000, NEUROPHARMACOLOGY, V39, P547, DOI 10.1016/S0028-3908(99)00179-3; Helsley S, 1998, PROG NEURO-PSYCHOPH, V22, P1179, DOI 10.1016/S0278-5846(98)00068-2; Hilton G, 1994, Orthop Nurs, V13, P25, DOI 10.1097/00006416-199407000-00006; HOVDA DA, 1983, SOC NEUR ABSTR, V9, P1001; HUNTER AJ, 1989, BIOCHEM SOC T, V17, P79, DOI 10.1042/bst0170079; KMIECIAKKOLADA K, 1987, POL J PHARMACOL PHAR, V39, P47; Liang KC, 1998, CHINESE J PHYSIOL, V41, P33; MCENTEE WJ, 1991, PSYCHOPHARMACOLOGY, V103, P143, DOI 10.1007/BF02244194; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MENESES A, 1995, PHARMACOL BIOCHEM BE, V52, P341, DOI 10.1016/0091-3057(95)00102-3; Meneses A, 1999, NEUROBIOL LEARN MEM, V71, P207, DOI 10.1006/nlme.1998.3866; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NIBUYA M, 1995, J NEUROSCI, V15, P7539; PAPPIUS HM, 1987, J NEUROCHEM, V49, P321, DOI 10.1111/j.1471-4159.1987.tb03433.x; Pappius HM, 1995, NEUROCHEM RES, V20, P1311, DOI 10.1007/BF00992506; PERUCHE B, 1994, J NEURAL TRANSM-PARK, V8, P73, DOI 10.1007/BF02250918; RICHELSON E, 1984, PSYCHOPHARMACOL BULL, V20, P213; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; SIRVIO J, 1994, PROG NEUROBIOL, V43, P363, DOI 10.1016/0301-0082(94)90060-4; SLOAN R L, 1992, Brain Injury, V6, P315, DOI 10.3109/02699059209034945; STARK P, 1985, J CLIN PSYCHIAT, V46, P7; Suchanek B, 1998, EUR J PHARMACOL, V355, P95, DOI 10.1016/S0014-2999(98)00469-5; Vaidya VA, 1997, J NEUROSCI, V17, P2785; WROBLEWSKI BA, 1992, AM J PSYCHIAT, V149, P273	44	25	26	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAY	2002	81	5					364	372		10.1097/00002060-200205000-00009			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	543XX	WOS:000175129200007	11964577				2022-02-06	
J	Liu, H; Goodman, JC; Robertson, CS				Liu, H; Goodman, JC; Robertson, CS			The effects of L-arginine on cerebral hemodynamics after controlled cortical impact injury in the mouse	JOURNAL OF NEUROTRAUMA			English	Article						L-arginine; cerebral hemodynamics; controlled cortical impact injury; intracranial hypertension; mouse; traumatic brain injury	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; RATS; RESPONSES	Traumatic brain injury (TBI) induces vascular changes that may influence neurological outcome by causing the brain to be more susceptible to secondary ischemic insults. In rat models of TBI, L-arginine administration has been shown to restore cerebral blood flow and improve neurological outcome. The purpose of this study was to determine if hypoperfusion occurs in a mouse model of TBI and if L-arginine administration has the same beneficial effects after injury in the mouse. C57BL6 mice were anesthetized with isoflurane, intubated and mechanically ventilated, and underwent a 3-m/sec, 1.5-mm deformation cortical impact injury. Five minutes after injury, L-arginine, 300 mg/kg, or saline were administered. Arterial blood pressure, intracranial pressure, and laser Doppler flow at the impact site were monitored for 3 h after the injury. The cerebral hemodynamic effects of the TBI induced by cortical impact injury were similar to that previously observed in rats. Intracranial hypertension, with ICP peaking at 46 +/- 2 mm Hg, and systemic hypotension both contributed to a reduction in CPP. In addition, LDF decreased significantly at the impact site. L-Arginine administration restored LDF to near baseline levels without increasing ICP. These studies demonstrate that cerebral hemodynamics can be measured in mouse models of TBI. The changes in cerebral hemodynamics are relatively simlar to those see in the rat model of cortical impact injury and suggest an important role for nitric oxide metabolism in the maintenance of cerebral blood flow following TBI.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; W China Univ Med Sci, Univ Hosp 1, Dept Surg, Chengdu, Peoples R China		Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin St,944, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS 38660] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER		Champion HC, 2000, AM J PHYSIOL-HEART C, V278, pH8, DOI 10.1152/ajpheart.2000.278.1.H8; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171, DOI 10.1152/jn.2000.83.4.2171; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DALKARA T, 1995, J CEREBR BLOOD F MET, V15, P631, DOI 10.1038/jcbfm.1995.78; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; LIU H, 2000, J NEUROTRAUM, V17, P945; Lu YC, 1997, MOL CHEM NEUROPATHOL, V30, P125, DOI 10.1007/BF02815154; Michael LH, 1995, AM J PHYSIOL-HEART C, V269, pH2147, DOI 10.1152/ajpheart.1995.269.6.H2147; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; STATLER KD, 2000, CRIT CARE MED SA53, V28; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; WADA K, 1997, J NEUROTRAUM, V14, P760; WU CC, 1995, BRIT J PHARMACOL, V114, P1666, DOI 10.1111/j.1476-5381.1995.tb14955.x	17	25	26	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2002	19	3					327	334		10.1089/089771502753594891			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	534BC	WOS:000174563900004	11939500				2022-02-06	
J	Ferrari, R; Constantoyannis, C; Papadakis, N				Ferrari, R; Constantoyannis, C; Papadakis, N			Cross-cultural study of symptom expectation following minor head injury in Canada and Greece	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						minor head injury; mild traumatic brain injury; concussion; symptom expectation	RHEUMATOID-ARTHRITIS; SEQUELAE; WHIPLASH; TRAUMA	Objectives: The purpose of the present study is to compare the frequency and nature of expected symptoms in Greece (a country where the chronic post-concussive syndrome is largely unknown) with that in Canada. Methods: A symptom checklist was administered to two subject groups selected from local companies in Patras, Greece, and Edmonton, Canada, respectively. Subjects were asked to imagine having suffered head trauma with loss of consciousness in a motor vehicle accident and to check off symptoms, they expected might arise from the injury. For symptoms they anticipated, they were asked to select the period of time they expected those symptoms to persist. Results: In both the Greek and Edmontonian groups, the pattern of symptoms anticipated closely resembled the acute symptoms commonly reported by accident victims with minor head injury. Yet, while many Edmontonians also anticipated symptoms to last months or years, very few Greek subjects selected any symptoms as being likely to persist in a chronic manner. Conclusions: In Greece, despite the frequent experience of minor head injury in motor vehicle accidents, there is a very low rate of expectation of any chronic sequelae from such an injury, contrasting greatly with the response shown in Canada, where the prevalence of the chronic post-concussive syndrome is higher. Symptom expectation in some countries may be an important factor in the development of the chronic post-concussive syndrome. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Hosp Patras, Dept Neurosurg, Patras, Greece		Ferrari, R (corresponding author), 12779-50 St, Edmonton, AB T5A 4L8, Canada.	rferrari@powersurfr.com		Constantoyannis, Constantine/0000-0003-3030-8439			ANDONOPOULOS AP, 1987, RHEUMATOL INT, V7, P101, DOI 10.1007/BF00270461; AUBREY JB, 1989, J NEUROL NEUROSUR PS, V52, P842, DOI 10.1136/jnnp.52.7.842; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Ferrari R, 1999, CLIN EXP RHEUMATOL, V17, P321; FERRARI R, 2001, IN PRESS CLIN NEUROL; FERRRI R, 1999, WHIPLASH ENCY FACTS; Hewlett S, 1995, Arthritis Care Res, V8, P4, DOI 10.1002/art.1790080104; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MADIANOS MG, 1993, PSYCHOTHER PSYCHOSOM, V60, P177, DOI 10.1159/000288691; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; PINCUS T, 1983, ARTHRITIS RHEUM-US, V26, P1346, DOI 10.1002/art.1780261107	18	25	25	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	DEC	2001	103	4					254	259		10.1016/S0303-8467(01)00161-5			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Surgery	508VK	WOS:000173110300015	11714575				2022-02-06	
J	Ohman, J; Braakman, R; Legout, V				Ohman, J; Braakman, R; Legout, V		Traumatic Brain Injury Study Grp	Repinotan (BAY x 3702): A 5HT(1A) agonist in traumatically brain injured patients	JOURNAL OF NEUROTRAUMA			English	Article						5HT(1A) agonist; intracranial pressure; preliminary GOS scores; repinotan; safety; severe traumatic brain injury	SEVERE HEAD-INJURY; GUIDELINES; MANAGEMENT; COMA	Repinotan is a high-affinity, selective, full agonist of the 5HT(1A)-receptor subtype with neuroprotective properties. This paper presents the results of a randomized, double-blind, placebo-controlled study examining the safety and tolerability of three different doses of repinotan in patients with severe traumatic brain injury. Sixty patients were enrolled to receive repinotan (0.5, 1.25, or 2.50 mg/day) or placebo, by continuous Lv. infusion for 7 days. Repinotan treatment had no apparent adverse effects on intracranial pressure, hemodynamic parameters or laboratory parameters. No seizures occurred during treatment, and the incidence and severity of adverse events was as expected for this indication. No serious adverse events were considered related to drug treatment, with the possible exception of one case of inappropriate ADH secretion. No further safety concerns were raised during the 3 months following treatment. On a descriptive basis, the proportion of patients having good outcome or moderate disability (Glasgow Outcome Scale) was somewhat greater in repinotan-treated patients (60%) than in placebo (50%).	Helsinki Univ Hosp, Dept Neurosurg, FIN-00170 Helsinki, Finland; Bayer Pharma, Puteaux La Defense, France		Ohman, J (corresponding author), Helsinki Univ Hosp, Dept Neurosurg, Unioninkatu 38, FIN-00170 Helsinki, Finland.			Ohman, Juha/0000-0002-6592-1367			BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; Bullock MR, 1996, J NEUROTRAUM, V13, P643; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; De Vry Jean, 1997, Drugs of the Future, V22, P341; DEVRY J, 1995, PSYCHOPHARMACOLOGY, V121, P1; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Dunn L T, 1997, Expert Opin Investig Drugs, V6, P1511, DOI 10.1517/13543784.6.10.1511; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; HORVATH E, 1997, SOC NEUR ABSTR, V23, P745; HORVATH E, 1997, J NEUROTRAUM, V14, P800; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; Jennett BFrankowskiR, 1990, HDB CLIN NEUROLOGY, V13, P1; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; RELLING MV, 1989, CLIN PHARMACY, V8, P852	23	25	26	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2001	18	12					1313	1321		10.1089/08977150152725614			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	504RE	WOS:000172869000002	11780862				2022-02-06	
J	Kieslich, M; Marquardt, G; Galow, G; Lorenz, R; Jacobi, G				Kieslich, M; Marquardt, G; Galow, G; Lorenz, R; Jacobi, G			Neurological and mental outcome after severe head injury in childhood: a long-term follow-up of 318 children	DISABILITY AND REHABILITATION			English	Article							EVOKED-POTENTIALS; RISK-FACTORS; PREDICTION	Purpose: Identification of prognostic risk factors in paediatric head injury. Method: Long-term follow-up of 318 children with severe head injuries with a mean follow-up period of 8 years and 9 months. The neurological and mental outcome was classified by the Glasgow Outcome Scale and the Frankfurt Mental Outcome Scale. Results: Prognostic risk factors were a primary post-traumatic vigilance disturbance longer than 24 hours, less than seven points on the Glasgow Coma Scale, an increased intracranial pressure with cerebral perfusion pressure below 50 mmHg, age at accident younger than 2 years, physical abuse and the development of post-traumatic epilepsy. Conclusions: The infant brain is more vulnerable to lasting deficits and is more prone to post-traumatic seizure development. Post-traumatic epilepsy itself causes a deterioration in outcome because of the developmental disturbance at epilepsy onset and often unfavourable course. Physically abused children with their often multiple and repeated head injuries are predestined for poor outcome.	Univ Frankfurt, Dept Paediat, D-6000 Frankfurt, Germany; Univ Frankfurt, Dept Neurosurg, D-6000 Frankfurt, Germany		Kieslich, M (corresponding author), Univ Frankfurt, Dept Paediat, D-6000 Frankfurt, Germany.						DUSSER A, 1989, ELECTROEN CLIN NEURO, V73, P85, DOI 10.1016/0013-4694(89)90187-9; Gjerris F, 1986, Acta Neurochir Suppl (Wien), V36, P155; GORDON NS, 1983, NEUROPEDIATRICS, V14, P3, DOI 10.1055/s-2008-1059545; HANS P, 1989, J NEUROSURG, V71, P54, DOI 10.3171/jns.1989.71.1.0054; HENDRICK EB, 1968, J TRAUM, V8, P547; JACOBI G, 1988, KLIN PADIATR, V200, P359, DOI 10.1055/s-2008-1033735; JACOBI G, 1983, EXTR PAEDIAT, V7, P275; JENNETT B, 1973, DEV MED CHILD NEUROL, V15, P56; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; JENNETT WB, 1975, LANCET, V325, P480; KAISER G, 1984, NEUROPEDIATRICS, V15, P68, DOI 10.1055/s-2008-1052344; KARNAZE DS, 1985, NEUROLOGY, V35, P1122, DOI 10.1212/WNL.35.8.1122; KIESLICH M, 1995, LANCET, V345, P187, DOI 10.1016/S0140-6736(95)90188-4; KRETSCHMER H, 1983, NEUROPEDIATRICS, V14, P176, DOI 10.1055/s-2008-1059574; OTTAVIANI F, 1986, ELECTROEN CLIN NEURO, V65, P196, DOI 10.1016/0168-5597(86)90054-7; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; ROBERTS AH, 1976, P ROY SOC MED, V1, P137; RUIJS MBM, 1993, NEUROPEDIATRICS, V24, P307, DOI 10.1055/s-2008-1071562; RUIJS MBM, 1993, EUR J PEDIATR, V152, P844, DOI 10.1007/BF02073384; Shokunbi T, 1994, West Afr J Med, V13, P38; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; WAGSTYL J, 1987, J PEDIATR SURG, V22, P127, DOI 10.1016/S0022-3468(87)80427-X; WARD JD, 1994, PEDIATR NEUROSURG, V20, P183, DOI 10.1159/000120784; [No title captured]	25	25	26	0	4	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0963-8288			DISABIL REHABIL	Disabil. Rehabil.	OCT	2001	23	15					665	669					5	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	481AN	WOS:000171496300003	11720116				2022-02-06	
J	Fischer, K; Zhang, F; Angel, MF; Lineaweaver, WC				Fischer, K; Zhang, F; Angel, MF; Lineaweaver, WC			Injuries associated with mandible fractures sustained in motor vehicle collisions	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							FACIAL FRACTURES; MAXILLOFACIAL INJURIES	Motor vehicle collisions are second only to altercations as the most common cause of mandible fractures. This article details in a retrospectively studied group the incidence of isolated mandible fractures and associated injuries in patients who were involved in motor vehicle collisions. This group consisted of 148 patients with mandible fractures listed in the University of Mississippi's trauma registry during the past 5 years. In almost all patients, associated injuries occurred with mandible fractures that were caused by motor vehicle collisions, with an incidence of 99.3 percent. Facial and head lacerations and facial fractures were the leading associated injuries, occurring in more than half of the patients who had a mandible fracture. Closed head injury is the major life-threatening associated injury and cause of mortality. The life-threatening injuries occurred in 64.8 percent of patients in this study. The mortality rate in this group of patients was 8.1 percent. These data suggest that mandible fractures from motor vehicle collisions should never be viewed as an isolated injury but rather as part of a spectrum of significant and sometimes life-threatening injuries that require thorough trauma evaluation at the time of presentation.	Univ Mississippi, Med Ctr, Dept Surg, Div Plast Surg, Jackson, MS 39216 USA		Lineaweaver, WC (corresponding author), Univ Mississippi, Med Ctr, Dept Surg, Div Plast Surg, 2500 N State St, Jackson, MS 39216 USA.						ALLAN BP, 1990, INT J ORAL MAX SURG, V19, P268, DOI 10.1016/S0901-5027(05)80417-5; Azevedo AB, 1998, J TRAUMA, V45, P1084, DOI 10.1097/00005373-199812000-00020; Bayles SW, 1997, ARCH OTOLARYNGOL, V123, P1304; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; FRIDRICH KL, 1992, J ORAL MAXIL SURG, V50, P586, DOI 10.1016/0278-2391(92)90438-6; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; HAUG RH, 1994, J ORAL MAXIL SURG, V52, P729, DOI 10.1016/0278-2391(94)90488-X; HAUG RH, 1990, J ORAL MAXIL SURG, V48, P926, DOI 10.1016/0278-2391(90)90004-L; LIM LH, 1993, BRIT J PLAST SURG, V46, P635, DOI 10.1016/0007-1226(93)90191-D; LUCE EA, 1979, PLAST RECONSTR SURG, V63, P26, DOI 10.1097/00006534-197901000-00005; Marciani RD, 1999, J ORAL MAXIL SURG, V57, P119, DOI 10.1016/S0278-2391(99)90221-5; Murray J F, 1975, Clin Plast Surg, V2, P131; *NAT CTR HLTH STAT, 1987, INT CLASS DIS ICD 9, V1, P146; OLSON RA, 1982, J ORAL MAXIL SURG, V40, P23, DOI 10.1016/S0278-2391(82)80011-6; Poole G V, 1991, J Miss State Med Assoc, V32, P83; REATH DB, 1989, J TRAUMA, V29, P806, DOI 10.1097/00005373-198906000-00018; Surkin J, 2000, SPINE, V25, P716, DOI 10.1097/00007632-200003150-00011	17	25	27	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	AUG	2001	108	2					328	331		10.1097/00006534-200108000-00006			4	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	456RW	WOS:000170096900006	11496169				2022-02-06	
J	Fujita, R; Yoshida, A; Mizuno, K; Ueda, H				Fujita, R; Yoshida, A; Mizuno, K; Ueda, H			Cell density-dependent death mode switch of cultured cortical neurons under serum-free starvation stress	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						necrosis; apoptosis; ATP; annexin V; caspase; PARP	TRAUMATIC BRAIN INJURY; POLY(ADP-RIBOSE) POLYMERASE; APOPTOSIS; RAT; ACTIVATION; NECROSIS; CASPASES; STROKE; FATE	1. Cell death mode switch of cortical neurons from E17 rats was studied. Cells rapidly died under the serum-free condition. The time-course of cell death was markedly delayed by increasing cell density for primary culture in the trypan blue exclusion, LDH release, and MTT assays. 2. By analyzing cell death by the use of double staining using PI/TUNEL and PI/Annexin V combinations, the mode in the low density culture was found to be necrosis, while that in the high density culture was apoptosis. 3. The intracellular ATP level after the start of serum-free culture rapidly decline to 25% of 0-time level in the low density culture, but it was 60% in the high density culture. Both oligomycin and zVAD-fmk markedly decreased ATP levels and the population of TUNEL-positive neurons, while 3-aminobenzamide slightly increased these indices. 4. Thus, it is strongly suggested that the cell death mode switch from necrosis to apoptosis is closely related to intracellular ATP levels, and some conditioned medium factors observed in the high density culture may affect both ATP level and cell death mode switch.	Nagasaki Univ, Sch Pharmaceut Sci, Dept Mol Pharmacol & Neurosci, Nagasaki 8528521, Japan		Ueda, H (corresponding author), Nagasaki Univ, Sch Pharmaceut Sci, Dept Mol Pharmacol & Neurosci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Eguchi Y, 1997, CANCER RES, V57, P1835; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Hamabe W, 2000, MOL BRAIN RES, V78, P186, DOI 10.1016/S0169-328X(00)00074-7; Lam TT, 1997, RES COMMUN MOL PATH, V95, P241; Lee YJ, 2000, FREE RADICAL BIO MED, V29, P684, DOI 10.1016/S0891-5849(00)00366-X; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; MARTIN SJ, 1995, J EXP MED, V182, P1; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, P1; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Plaschke K, 2000, NEUROSCI LETT, V284, P109, DOI 10.1016/S0304-3940(00)00988-5; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; RINK A, 1995, AM J PATHOL, V147, P1575; Sasaki Y, 1998, CELL MOL NEUROBIOL, V18, P487, DOI 10.1023/A:1026375225275; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; UEDA H, 1999, P 16 YOK 21 CENT FOR, P83; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	25	25	27	0	1	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340			CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	AUG	2001	21	4					317	324		10.1023/A:1012645920229			8	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	503JV	WOS:000172796100002	11775063				2022-02-06	
J	Rizzo, AA; Buckwalter, JG; McGee, JS; Bowerly, T; van der Zaag, C; Neumann, U; Thiebaux, M; Kim, L; Pair, J; Chua, C				Rizzo, AA; Buckwalter, JG; McGee, JS; Bowerly, T; van der Zaag, C; Neumann, U; Thiebaux, M; Kim, L; Pair, J; Chua, C			Virtual environments for assessing and rehabilitating cognitive/functional performance - A review of projects at the USC Integrated Media Systems Center	PRESENCE-TELEOPERATORS AND VIRTUAL ENVIRONMENTS			English	Article							MENTAL ROTATION; GENDER DIFFERENCES; SEX-DIFFERENCES; DEMENTIA; ABILITY	Virtual reality (VR) technology offers new options for the creation of sophisticated tools that could be applied in the areas of assessment and rehabilitation of cognitive and functional processes. VR systems allow for the precise presentation and control of dynamic, multisensory, three-dimensional (3-D) stimulus environments, as well as the recording of all behavioral responses that occur within them. Assessment and rehabilitation scenarios that would be difficult if not impossible to deliver using conventional neuropsychological methods are now being developed that take advantage of these VR assets. If empirical studies demonstrate effectiveness, virtual environments (VEs) could be of considerable value for better understanding, measuring, and treating persons with impairments due to traumatic brain injury, neurological disorders, and learning disabilities. This article describes the progress of a VR research program at the USC Integrated Media Systems Center and Information Sciences Institute that has developed and investigated the use of a series of VEs designed to target (i) molecular visuospatial skills using a 3-D, projection-based ImmersaDesk system, and (ii) attention (and soon memory and executive functioning) processes within ecologically valid functional scenarios utilizing a head-mounted display (HMD). Results from completed research, rationales and methodology of works in progress, and our plan for future work is presented. Our primary vision has been to develop VR systems that target cognitive processes and functional skills that are of relevance to a wide range of patient populations with central nervous system (CNS) dysfunction, as well as for the assessment of unimpaired performance. We have also sought to select cognitive/functional targets that intuitively appear well matched to the specific assets available with currently available VR technology.	Univ So Calif, Integrated Media Syst Ctr, Los Angeles, CA 90089 USA; So Calif Permanente Med Grp, Dept Res & Evaluat, Pasadena, CA 91101 USA; Fuller Grad Sch Psychol, Pasadena, CA 91101 USA; Univ So Calif, Sch Gerontol, Los Angeles, CA 90089 USA; Univ So Calif, Inst Informat Sci, Marina Del Rey, CA 90292 USA		Rizzo, AA (corresponding author), Univ So Calif, Integrated Media Syst Ctr, Los Angeles, CA 90089 USA.		McGee, Jocelyn/ABA-7532-2020				Army Individual Test Battery, 1944, MAN DIR SCOR; BENTON A L, 1978, Archives of Neurology, V35, P364; Brown DJ, 1997, COMMUN ACM, V40, P72, DOI 10.1145/257874.257891; CASEY MB, 1995, DEV PSYCHOL, V31, P697, DOI 10.1037/0012-1649.31.4.697; COLE KC, 1998, LOS ANGELES TIM 0314, pA19; Delgado AR, 1996, MEM COGNITION, V24, P504, DOI 10.3758/BF03200938; DELIS D, 1983, CALIFORNIA VERBAL LE; GAINOTTI G, 1992, J CLIN EXP NEUROPSYC, V14, P239, DOI 10.1080/01688639208402826; GOUCHIE C, 1991, PSYCHONEUROENDOCRINO, V16, P323, DOI 10.1016/0306-4530(91)90018-O; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; Kennedy RS, 1993, INT J AVIAT PSYCHOL, V3, P203, DOI [10.1207/s15327108ijap0303_3, DOI 10.1207/S15327108IJAP0303_3]; KENNEDY RS, 1984, MOTION HIST QUESTION; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MASTERS MS, 1993, BEHAV GENET, V23, P337, DOI 10.1007/BF01067434; McGee JS, 2000, CYBERPSYCHOL BEHAV, V3, P469, DOI 10.1089/10949310050078931; MCGEORGE P, 2000, COMMUNICATION   1212; Miller BL, 1997, NEUROLOGY, V48, P937, DOI 10.1212/WNL.48.4.937; Mitrushina MN, 1999, HDB NORMATIVE DATA N; *NAT I DIS REH RES, NOT FIN LONG RANG PL; *NAT SCI FDN, PA98168 NSF; NEWCOMBE N, 1983, SEX ROLES, V9, P530; Nunnally JC., 1993, PSYCHOMETRIC THEORY, V3; PETERS M, 1995, BRAIN COGNITION, V28, P39, DOI 10.1006/brcg.1995.1032; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Qubeck WJ, 1997, PERCEPT MOTOR SKILL, V85, P323; RICHARDSON JTE, 1994, PERCEPT MOTOR SKILL, V78, P435, DOI 10.2466/pms.1994.78.2.435; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; RIZZO AA, 1997, VIRTUAL REALITY NEUR, P123; RIZZO AA, IN PRESS HDB VIRTUAL; ROSE FD, 1996, P 1 EUR C DIS VIRT R, P5; Sattler J. M., 1988, ASSESSMENT CHILDREN; SHEPARD RN, 1971, SCIENCE, V171, P701, DOI 10.1126/science.171.3972.701; Signorino M, 1996, ARCH GERONTOL GERIAT, V23, P139, DOI 10.1016/0167-4943(96)00714-5; SILVERMAN I, 1993, ETHOL SOCIOBIOL, V14, P257, DOI 10.1016/0162-3095(93)90021-9; Stephanidis C, 1998, INT J HUM-COMPUT INT, V10, P107, DOI 10.1207/s15327590ijhc1002_2; VANDENBERG SG, 1978, PERCEPT MOTOR SKILL, V47, P599, DOI 10.2466/pms.1978.47.2.599; VOYER D, 1995, PSYCHOL BULL, V117, P250, DOI 10.1037/0033-2909.117.2.250; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; Wohlschlager A, 1998, J EXP PSYCHOL HUMAN, V24, P397, DOI 10.1037/0096-1523.24.2.397; [No title captured]	41	25	25	0	16	M I T PRESS	CAMBRIDGE	FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA	1054-7460			PRESENCE-TELEOP VIRT	Presence-Teleoper. Virtual Env.	AUG	2001	10	4					359	374		10.1162/1054746011470226			16	Computer Science, Cybernetics; Computer Science, Software Engineering	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Computer Science	492AT	WOS:000172143800003					2022-02-06	
J	Keidel, M; Rieschke, P; Stude, P; Eisentraut, R; van Schayck, R; Diener, HC				Keidel, M; Rieschke, P; Stude, P; Eisentraut, R; van Schayck, R; Diener, HC			Antinociceptive reflex alteration in acute posttraumatic headache following whiplash injury	PAIN			English	Article						posttraumatic headache; whiplash injury; inhibitory temporalis reflex; exteroceptive suppression; antinociceptive brainstem reflex; central pain processing	TEMPORALIS MUSCLE-ACTIVITY; TENSION-TYPE HEADACHE; EXTEROCEPTIVE SUPPRESSION PERIODS; JAW-CLOSING MUSCLES; MENTAL NERVE-STIMULATION; MEDULLARY DORSAL HORN; NUCLEUS RAPHE MAGNUS; ELECTRICAL-STIMULATION; SILENT PERIODS; OPENING REFLEX	Brainstem-mediated antinociceptive inhibitory reflexes of the temporalis muscle were investigated in 82 patients (47 F, 35 M, mean age 28.3 years, SD 9.4) with acute posttraumatic headache (PH) following whiplash injury but without neurological deficits, bone injury of the cervical spine or a combined direct head trauma on average 5 days after the acceleration trauma. Latencies and durations of the early and late exteroceptive suppression (ES1 and ES2) and the interposed EMG burst (IE) of the EMG of the voluntarily contracted right temporalis muscle evoked by ipsilateral stimulation of the second and third branches of the trigeminal nerve were analyzed and compared to a cohort of 82 normal subjects (43 F, 39 M, mean age 27.7 years, SD 7.1). Highly significant reflex alterations were found in patients with PH with a shortening of ES2 duration with delayed onset and premature ending as the primary parameter of this study, a moderate prolongation of ES1 and IE duration and a delayed onset of IE. The latency of ES1 was not significantly changed. These findings indicate that acute PH in whiplash injury is accompanied by abnormal antinociceptive brainstem reflexes. We conclude that the abnormality of the trigeminal inhibitory temporalis reflex is abed on a transient dysfunction of the brainstem-mediated reflex circuit mainly of the late polysynaptic pathways. The reflex abnormalities are considered as a neurophysiological correlate of the posttraumatic (cervico)-cephalic pain syndrome. They point to an altered central pain control in acute PH due to whiplash injury. (C) 2001 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved.	Univ Essen Gesamthsch, Dept Neurol, D-45122 Essen, Germany; Vanderbilt Univ, Med Ctr, Dept Anesthesiol, Nashville, TN USA; Univ Jena, Dept Neurol, D-6900 Jena, Germany		Keidel, M (corresponding author), Univ Essen Gesamthsch, Dept Neurol, Hufelandstr 55, D-45122 Essen, Germany.						AGHAJANIAN GK, 1980, NEUROSCIENCE, V5, P2155, DOI 10.1016/0306-4522(80)90132-3; ANDERSEN RK, 1978, CAN J PHYSIOL PHARM, V56, P157, DOI 10.1139/y78-021; BASBAUM AI, 1978, ANN NEUROL, V4, P451, DOI 10.1002/ana.410040511; Bendtsen L, 1996, CEPHALALGIA, V16, P251, DOI 10.1046/j.1468-2982.1996.1604251.x; BENDTSEN L, 1993, CEPHALALGIA, V13, P184, DOI 10.1046/j.1468-2982.1993.1303184.x; Bendtsen L, 1996, ELECTROMYOGR MOTOR C, V101, P418, DOI 10.1016/0924-980X(96)96532-7; BOISMARE F, 1985, J AUTONOM NERV SYST, V13, P137, DOI 10.1016/0165-1838(85)90030-X; BOTTIN D, 1989, CEPHALAGIA, V9, P115; Breig, 1960, BIOMECHANICS CENTRAL; Cadden SW, 1999, J ORAL REHABIL, V26, P952, DOI 10.1046/j.1365-2842.1999.00457.x; CADDEN SW, 1994, ARCH ORAL BIOL, V39, P473, DOI 10.1016/0003-9969(94)90143-0; Connemann BJ, 1997, ELECTROMYOGR MOTOR C, V105, P53, DOI 10.1016/S0924-980X(96)96549-2; Cruccu G, 1998, EXP BRAIN RES, V118, P564, DOI 10.1007/s002210050312; CRUCCU G, 1989, BRAIN, V112, P1333, DOI 10.1093/brain/112.5.1333; CRUCCU G, 1986, BRAIN RES, V371, P298, DOI 10.1016/0006-8993(86)90366-5; DENOORDHOUT AM, 1995, CEPHALALGIA, V15, P301, DOI 10.1046/j.1468-29821995.1504301.x; DESMEDT JE, 1976, BRAIN RES, V106, P21, DOI 10.1016/0006-8993(76)90070-6; DEVISSER BWO, 1990, BRAIN, V113, P781, DOI 10.1093/brain/113.3.781; DOSTROVSKY JO, 1983, J NEUROPHYSIOL, V49, P948, DOI 10.1152/jn.1983.49.4.948; DOSTROVSKY JO, 1982, BRAIN RES, V252, P287, DOI 10.1016/0006-8993(82)90396-1; Ellrich J, 1997, BRAIN RES, V764, P214, DOI 10.1016/S0006-8993(97)00459-9; GOBEL H, 1991, CEPHALALGIA, V11, P65; GOBEL H, 1993, CEPHALALGIA, V13, P15, DOI 10.1046/j.1468-2982.1993.1301015.x; GODAUX E, 1975, BRAIN RES, V85, P447, DOI 10.1016/0006-8993(75)90819-7; Hansen PO, 1999, CLIN NEUROPHYSIOL, V110, P1290, DOI 10.1016/S1388-2457(99)00031-0; Hansen PO, 1998, ACTA NEUROL SCAND, V97, P204; KEIDEL M, 1994, NERVENARZT, V65, P241; KEIDEL M, 1993, ELECTROEN CLIN NEURO, V87, P18; KEIDEL M, 1996, NEUROLOGICAL DISORDE, P65; KEIDEL M, 1993, CEPHALALGIA, V13, P106; KEIDEL M, 2000, HEADACHES, P765; LIGHT AR, 1992, INITIAL PROCESSING P; Lipchik GL, 1997, HEADACHE, V37, P368, DOI 10.1046/j.1526-4610.1997.3706368.x; Lipchik GL, 1996, PAIN, V64, P467, DOI 10.1016/0304-3959(95)00174-3; MASON P, 1985, BRAIN RES REV, V10, P137, DOI 10.1016/0165-0173(85)90003-7; NAKASHIMA K, 1994, HEADACHE, V34, P455, DOI 10.1111/j.1526-4610.1994.hed3408455.x; NAKASHIMA K, 1991, CEPHALALGIA, V11, P23, DOI 10.1046/j.1468-2982.1991.1101023.x; NAKASHIMA K, 1990, ACTA NEUROL SCAND, V81, P407; NAKASHIMA K, 1990, CLIN NEUROL, V30, P133; PAULUS W, 1992, HEADACHE, V32, P41, DOI 10.1111/j.1526-4610.1992.hed3201041.x; PAULUS W, 1991, CEPHALALGIA, V11, P32, DOI 10.1177/0333102491011S1117; Pollmann W, 1997, CEPHALALGIA, V17, P801, DOI 10.1046/j.1468-2982.1997.1708801.x; RAMADAN NM, 2000, HEADACHES, P771; Romaniello A, 2000, EXP BRAIN RES, V132, P306, DOI 10.1007/s002210000353; SCHAFFAR N, 1984, NEUROSCI LETT, V44, P31, DOI 10.1016/0304-3940(84)90216-7; Schepelmann K, 1998, ELECTROEN CLIN NEURO, V107, P196, DOI 10.1016/S0013-4694(98)00059-5; SCHOENEN J, 1994, BRAIN RES, V657, P214, DOI 10.1016/0006-8993(94)90970-9; SCHOENEN J, 1987, NEUROLOGY, V37, P1834, DOI 10.1212/WNL.37.12.1834; SCHOENEN J, 1991, CEPHALALGIA, V11, P16, DOI 10.1177/0333102491011S1109; SCHOENEN J, 1991, CEPHALALGIA, V11, P87, DOI 10.1046/j.1468-2982.1991.1102087.x; SCHOENEN J, 2000, HEADACHES, P579; SCHOPFLIN G, 1992, NEW HUNG QUART, V33, P3; SESSLE BJ, 1986, PAIN, V27, P219, DOI 10.1016/0304-3959(86)90213-7; SPITZER WO, 1995, SPINE, V20, pS2; Strenge H, 1996, FUNCT NEUROL, V11, P17; TURKER KS, 1988, J ORAL REHABIL, V15, P91, DOI 10.1111/j.1365-2842.1988.tb00149.x; WALLASCH TM, 1991, CEPHALALGIA, V11, P109, DOI 10.1046/j.1468-2982.1991.1102109.x; WALLASCH TM, 1991, CEPHALALGIA, V11, P83, DOI 10.1177/0333102491011S1145; WALLASCH TM, 1993, HEADACHE, V33, P121, DOI 10.1111/j.1526-4610.1993.hed3303121.x; WALLASCH TM, 1989, NERVENHEILKUNDE, V9, P58; Wang KL, 1999, PAIN, V82, P253, DOI 10.1016/S0304-3959(99)00058-5; WANG W, 1994, PAIN, V59, P327, DOI 10.1016/0304-3959(94)90018-3; WANG W, 1995, THESIS U LIEGE LIEGE; Welch KMA, 1996, CEPHALALGIA, V16, P216; WILLIS WD, 1982, PROGR SENSORY PHYSL, V3; YU SKJ, 1973, ARCH ORAL BIOL, V18, P861, DOI 10.1016/0003-9969(73)90056-3; ZWART JA, 1995, HEADACHE, V35, P338, DOI 10.1111/j.1526-4610.1995.hed3506338.x	67	25	26	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0304-3959			PAIN	Pain	JUN	2001	92	3					319	326		10.1016/S0304-3959(01)00272-X			8	Anesthesiology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology	444FR	WOS:000169389900001	11376904				2022-02-06	
J	Watanabe, Y; Shiel, A; McLellan, DL; Kurihara, M; Hayashi, K				Watanabe, Y; Shiel, A; McLellan, DL; Kurihara, M; Hayashi, K			The impact of traumatic brain injury on family members living with patients: a preliminary study in Japan and the UK	DISABILITY AND REHABILITATION			English	Article							BLUNT HEAD-INJURY; SOCIAL SUPPORT; RELATIVES; STRESS	Purpose: To ascertain the views of families living with TBI patients about the nature of the problems experienced as a result of TBI, and to compare the views of Japanese family members (J-FM) and British family members (B-FM) in order to rnd out whether there were cultural differences in family response to TBI. Methods: Family members involved in providing care were identified by the patients. Face to face interviews were conducted with all 18 carers in B-FM and four carers in J-FM. The remaining eight carers in J-FM participated in the postal questionnaire. Questionnaires were developed to explore the nature of problems and the involvement of family such as social embarrassment. Results: Problems arising in families were almost the same reported from both groups. However families in B-FM were likely to know more about how to cope with these problems. Family members in J-FM reported more statistically significant increases in social embarrassment than those in B-FM. Conclusion: The preliminary results showed that family members living with TBI patients in both groups had experienced problems. Appropriate rehabilitation services should be developed to help families as well as TBI patients in Japan.	Saga Med Sch, Dept Orthopaed Surg, Saga, Japan; Univ Southampton, Rehabil Res Unit, Southampton, Hants, England; Juzenkai Hosp, Neurosurg Unit, Nagasaki, Japan		Watanabe, Y (corresponding author), Natl Nagasaki Hosp, Dept Rehabil, 6-41 Sakuragi Cho, Nagasaki 8500835, Japan.	yuriko@zc4.so-net.ne.jp					ABE J, 2000, SOGO RIHABIRITESHON, V28, P141; ASAHARA K, 1995, JAPANESE J NURSING R, V28, P49; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Campbell C H, 1988, Rehabil Nurs, V13, P320; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KAYAMORI R, 1995, SOGO RIHABIRITESHON, V23, P665; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/h0080325; Kosciulek JF, 1999, INT J REHABIL RES, V22, P269, DOI 10.1097/00004356-199912000-00003; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEAF LE, 1993, BRAIN INJURY, V7, P543, DOI 10.3109/02699059309008182; Leathem J, 1996, BRAIN INJURY, V10, P27; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Matsufuji T, 1999, MICROPOR MESOPOR MAT, V32, P159, DOI 10.1016/S1387-1811(99)00101-8; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NIINA R, 1992, SHINSHINIGAKU, V32, P324; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Ohta T, 1974, No Shinkei Geka, V2, P623; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Simpson G, 2000, BRAIN INJURY, V14, P125, DOI 10.1080/026990500120790; *SPSS, SPSS BAS 8 0J WIND U; TAKAI Y, 2000, SOGO REHABIRITESHON, V28, P11; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Watanabe Y, 2000, CLIN REHABIL, V14, P172, DOI 10.1191/026921500666833742; WATANABE Y, 1999, JAPANESE J REHABILIT, V36, P180; WATANABE Y, 1998, P 1 AS REH MED ASS C, P80; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	32	25	29	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	JUN	2001	23	9					370	378					9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	431UL	WOS:000168650100002	11394587				2022-02-06	
J	Stebbins, P; Pakenham, KI				Stebbins, P; Pakenham, KI			Irrational schematic beliefs and psychological distress in caregivers of people with traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article							SOCIAL SUPPORT; FAMILY NEEDS; HEAD-INJURY; STRESS; INVENTORY; PATIENT; HEALTH	Objective: To investigate the relation between irrational schematic beliefs and psychological distress in caregivers of persons with traumatic brain injury (TBI). Design: Cross-sectional mail survey. Participants: One hundred sixteen caregivers of persons with TBI living in the Australian states of Victoria and Queensland who were members of community support groups and brain injury associations. Measures: The Irrational Beliefs Inventory, Brief Symptom Inventory, income satisfaction, degree of personality and behavior change in the TBI individual, and injury severity. Results: Hierarchical regression analyses showed that after controlling for the effects of characteristics of the caregiving situation and the individual with TBI, greater adherence to irrational beliefs was related to higher levels of global psychological distress. Specifically, irrational beliefs related to Worrying were associated with all areas of psychological distress. Conclusion: Results support the cognitive theory proposal that irrational beliefs play an important role in the adaptation to TBI caregiving. Findings suggest the inclusion of cognitive therapy strategies in interventions for caregivers.	Univ Queensland, Sch Psychol, Behav Res & Therapy Ctr, Brisbane, Qld 4072, Australia		Pakenham, KI (corresponding author), Univ Queensland, Sch Psychol, Behav Res & Therapy Ctr, Brisbane, Qld 4072, Australia.		Pakenham, Kenneth/A-9973-2008	Pakenham, Kenneth/0000-0002-8653-4593			Abrams M., 1994, BRIT J GUIDANCE COUN, V22, P39, DOI [10.1080/03069889400760051, DOI 10.1080/03069889400760051]; Beck J.S., 1995, COGNITIVE THERAPY BA; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Ellis A., 1975, NEW GUIDE RATIONAL L; Emmelkamp, 1994, EUROPEAN J PSYCHOL A, V10, P15; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Folkman S., 1984, STRESS; Frosch S, 1997, BRAIN INJURY, V11, P891; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HARRAN SM, 1991, J RATION-EMOT COGN-B, V9, P265; Howlett B, 1994, J RATION-EMOT COGN-B, V12, P205, DOI DOI 10.1007/BF02354548; JACOBS H, 1989, TRAUMATIC BRAIN INJU, P425; Jones R.G, 1968, DISS ABSTR INT B, V29, P4379; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kosciulek JF, 1997, BRAIN INJURY, V11, P821, DOI 10.1080/026990597123034; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Leathem J, 1996, BRAIN INJURY, V10, P27; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LICHTENBERG JW, 1992, J COUNS DEV, V71, P157, DOI 10.1002/j.1556-6676.1992.tb02191.x; MCNAUGHTON ME, 1995, J NERV MENT DIS, V183, P78, DOI 10.1097/00005053-199502000-00003; MUIR C, 1984, BEHAV ASSESSMENT REH, P89; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; Panting A, 1972, REHABILITATION, V38, P33; PERLESZ A, 1992, AUSTR NZ J FAMILY TH, V13, P145, DOI DOI 10.1002/J.1467-8438.1992.TB00910.X; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Selye H., 1974, STRESS DISTRESS; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; SHORKEY CT, 1977, EDUC PSYCHOL MEAS, V37, P527, DOI 10.1177/001316447703700232; Stebbins P, 1998, J REHABIL, V64, P15; STEBBINS P, 1997, THESIS DEAKIN U MELB; STEBBINS P, 1997, AUSTR J REHABILITATI, V3, P30; WAALAND PK, 1993, BRAIN INJURY, V7, P135, DOI 10.3109/02699059309008167; Willer B S, 1993, NeuroRehabilitation, V3, P40, DOI 10.3233/NRE-1993-3206; Zanetti O, 1998, INT J GERIATR PSYCH, V13, P358, DOI 10.1002/(SICI)1099-1166(199806)13:6<358::AID-GPS772>3.0.CO;2-J	42	25	26	0	11	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2001	46	2					178	194		10.1037/0090-5550.46.2.178			17	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	472DX	WOS:000170969200006					2022-02-06	
J	Wallen, MA; Mackay, S; Duff, SM; McCartney, LC; O'Flaherty, SJ				Wallen, MA; Mackay, S; Duff, SM; McCartney, LC; O'Flaherty, SJ			Upper-limb function in Australian children with traumatic brain injury: A controlled, prospective study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						arm; brain injuries; disabled children; rehabilitation	CLOSED HEAD-INJURY; MOTOR; RECOVERY; COHORT; PRESCHOOLERS; ADOLESCENTS; PERFORMANCE; SEVERITY; SCALE	Objective: To describe upper-limb function in children with mild and severe traumatic brain injury (TBI), by using both quantitative and qualitative measures. Design: Controlled, prospective cohort study with assessment points initially, at 6 months, and at 2 years after TBI. Setting: A tertiary pediatric trauma center in Australia. Patients: Fifty-one children, ranging in age up to 14 years, who were consecutive admissions with TBI. On the basis of initial and persisting abnormal coma score and persistence of posttraumatic amnesia, they were assigned to either a mild (n = 26) or a severely injured (n = 25) group. Thirty children admitted with non-TBI trauma were recruited as a control group. Main Outcome Measures: Quantitative measures included Bruininks-Oseretsky Test of Motor Proficiency and Peabody Developmental Motor Scales. Qualitative measures included Brunnstrom Recovery Stages (adapted), categoric scales of muscle tone, grasp used when handwriting, quality of writing product, bilateral activity, and splint use. Results: There was little difference between the groups on the standardized assessments for subjects who could complete the tests. Qualitative measures showed the severe TBI group to have more difficulties with gross arm control, hand control, and hand function. Conclusion: Children with severe TBI experience more and persisting difficulties with upper-limb function. It is essential to include both quantitative and qualitative measures in this type of research.	New Childrens Hosp, Occupat Therapy Dept, Parramatta, NSW 2124, Australia; New Childrens Hosp, Rehabil Dept, Parramatta, NSW 2124, Australia		Wallen, MA (corresponding author), New Childrens Hosp, Occupat Therapy Dept, POB 3515, Parramatta, NSW 2124, Australia.			Wallen, Margaret/0000-0002-8040-5053			BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Folio MR, 1983, PEABODY DEV MOTOR SC; HALEY S M, 1991, Physical and Occupational Therapy in Pediatrics, V11, P1; HEIDEN JS, 1983, PHYS THER, V63, P1946, DOI 10.1093/ptj/63.12.1946; HINDERER K A, 1989, Physical and Occupational Therapy in Pediatrics, V9, P81; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Marosszeky NEV, 1998, PTA PROTOCOL GUIDELI; MAROSSZEKY NEV, 1993, CLIN NEUROPSYCHOL, V7, P86; MASSAGLI TL, 1994, PEDIATR ANN, V23, P29, DOI 10.3928/0090-4481-19940101-08; MAYER T, 1981, CHILD BRAIN, V8, P189; O'Flaherty SJ, 2000, ARCH PHYS MED REHAB, V81, P723, DOI 10.1016/S0003-9993(00)90100-X; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SCOTT AD, 1983, OCCUPATIONAL THERAPY, P97; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; STOKES NA, 1990, AM J OCCUP THER, V44, P334, DOI 10.5014/ajot.44.4.334; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; WESSON DE, 1989, J TRAUMA, V29, P589, DOI 10.1097/00005373-198905000-00008; [No title captured]	28	25	25	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2001	82	5					642	649		10.1053/apmr.2001.22620			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	429RR	WOS:000168531200013	11346842				2022-02-06	
J	Danet, M; Raymond, J; Roy, D				Danet, M; Raymond, J; Roy, D			Distal superior cerebellar artery aneurysm presenting with cerebellar infarction: Report of two cases	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							TRAUMATIC ANEURYSM; FALSE ANEURYSM; INJURY; NERVE; BRAIN	We report two cases of aneurysm of the distal branches of the superior cerebellar artery presenting with cerebellar infarction, In both cases, the diagnosis required close correlation of the findings from different imaging techniques, as catheter angiography failed to opacify the lesions. In one patient endovascular parent vessel occlusion was performed, whereas in the second patient the aneurysm thrombosed spontaneously, We describe the clinical and radiologic presentation of these aneurysms and discuss their pathogenesis, diagnosis, and treatment.	CHUM, Notre Dame Hosp, Dept Radiol, Montreal, PQ H2L 4M1, Canada		Roy, D (corresponding author), CHUM, Notre Dame Hosp, Dept Radiol, 1560 Sherbrooke St E, Montreal, PQ H2L 4M1, Canada.		Raymond, Jean/D-3940-2011				AGOSTINIS C, 1992, NEUROLOGY, V42, P457, DOI 10.1212/WNL.42.2.457; ASARI S, 1977, J NEUROSURG, V46, P795, DOI 10.3171/jns.1977.46.6.0795; BOZBOGA M, 1996, ACTA NEUROCHIR, V138, P1913; Chaloupka JC, 1996, AM J NEURORADIOL, V17, P1338; COCKRILL HH, 1977, J NEUROSURG, V46, P377, DOI 10.3171/jns.1977.46.3.0377; COLLINS TE, 1992, NEUROSURGERY, V30, P258, DOI 10.1227/00006123-199202000-00020; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; GACS G, 1983, J NEUROSURG, V58, P63, DOI 10.3171/jns.1983.58.1.0063; Jackson MR, 1997, J TRAUMA, V43, P159, DOI 10.1097/00005373-199707000-00041; MABUCHI S, 1992, NEUROSURGERY, V30, P284, DOI 10.1227/00006123-199202000-00027; OBrien D, 1997, ARCH PHYS MED REHAB, V78, P883, DOI 10.1016/S0003-9993(97)90205-7; OIATT JH, 1992, J NEUROSURG, V77, P799; PAPO I, 1977, SURG NEUROL, V7, P15; Piepgras D. G., 1993, BRAIN SURG, P1083; Proust F, 1997, J NEUROSURG, V87, P950, DOI 10.3171/jns.1997.87.6.0950; QUATTROCCHI KB, 1990, NEUROSURGERY, V27, P476, DOI 10.1227/00006123-199009000-00025; Stoodley MA, 1998, NEUROSURG CLIN N AM, V9, P549; YOSHIMOTO T, 1979, CEREBRAL ANEURYSMS, P14	18	25	27	0	1	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	APR	2001	22	4					717	720					4	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	423CA	WOS:000168156800024	11290485				2022-02-06	
J	Abraham, KE; McGinty, JF; Brewer, KL				Abraham, KE; McGinty, JF; Brewer, KL			Spinal and supraspinal changes in opioid mRNA expression are related to the onset of pain behaviors following excitotoxic spinal cord injury	PAIN			English	Article						dynorphin; enkephalin; quisqualic acid; spinal cord injury	MESSENGER-RNA EXPRESSION; DORSAL HORN NEURONS; PERIPHERAL INFLAMMATION; TRAUMATIC INJURY; DYNORPHIN-A; RECEPTOR ANTAGONISTS; RAT MODEL; NMDA; IMMUNOREACTIVITY; HYPERALGESIA	Excitotoxic spinal cord injury (SCI) causes anatomic, physiologic and molecular changes within the spinal cord and brain. Intraspinal injection of quisqualic acid (QUIS) produces an excitotoxic injury that leads to the onset of behavioral syndromes, believed to be related to the clinical condition of chronic pain. The opioid system, classically involved in the suppression of pain transmission, has been associated with the onset of pain-related behaviors and changes in spinal opioid peptide expression have been demonstrated in various models of SCI and chronic pain. Recently, changes in opioid peptide expression have been demonstrated in both spinal and supraspinal areas following excitotoxic SCI. Therefore, the purpose of this study was to examine changes in opioid peptide gene expression as they relate to the onset of pain behaviors following excitotoxic SCI. Male, Long-Evans rats were given an intraspinal injection of 1.2 mul of 125 mM QUIS and allowed to survive for 10 days, a duration sufficient for the development of pain-related behaviors. Animals were assessed daily for the presence of excessive grooming behavior, i.e. self-directed biting and scratching resulting in damage to superficial and deeper layers of the skin. Animals were also tested for thermal hypersensitivity using a cold plate apparatus on days 5, 7, and 10 following QUIS injection. After sacrifice, quantitative in situ hybridization was performed on regions of the spinal cord surrounding the lesion site as well as whole brain sections through various levels of the thalamus and cortex. Spinal preproenkephalin (PPE) and preprodynorphin (PPD) expression was significantly increased in animals that developed excessive grooming behaviors vs. those that did not. For PPE, this difference was seen bilaterally, in areas of cord caudal to the site of injury. For PPD, this difference was seen only ipsilateral to the site of injection, rostral to the site of injury. In addition, PPE expression in the anterior cingulate cortex and PPD expression in the contralateral parietal cortex were significantly higher in grooming vs. non-grooming animals. These results support previous conclusions that both spinal and supraspinal regulation of endogenous opioid peptide expression plays a role in the response to or onset of post-SCI pain. These results also suggest that the opioid peptides are regulated independently and serve different functions in response to SCI. (C) 2001 International Association for the Study of Pain. Published by Elsevier Science B.V. All rights reserved.	E Carolina Univ, Brody Sch Med, Div Res, Dept Emergency Med, Greenville, NC 27858 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA; E Carolina Univ, Sch Med, Dept Anat & Cell Biol, Greenville, NC 27858 USA		Brewer, KL (corresponding author), E Carolina Univ, Brody Sch Med, Div Res, Dept Emergency Med, Physicians Quadrangle,Bldg M, Greenville, NC 27858 USA.	brewerk@mail.ecu.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 03982] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA003982] Funding Source: NIH RePORTER		Abraham KE, 2000, NEUROSCIENCE, V99, P189, DOI 10.1016/S0306-4522(00)00150-0; ATTAL N, 1989, BRAIN RES, V494, P276, DOI 10.1016/0006-8993(89)90596-9; BAKSHI R, 1990, BRAIN RES, V507, P1, DOI 10.1016/0006-8993(90)90512-A; BAKSHI R, 1990, NEUROSCI LETT, V110, P113, DOI 10.1016/0304-3940(90)90797-D; BERIC A, 1988, PAIN, V34, P109, DOI 10.1016/0304-3959(88)90155-8; Beric A, 1997, PAIN, V72, P295, DOI 10.1097/00006396-199709000-00001; Bethea J. R., 1999, Society for Neuroscience Abstracts, V25, P1443; Bian D, 1998, NEUROSCI LETT, V241, P79, DOI 10.1016/S0304-3940(98)00051-2; Bian D, 1999, BRAIN RES, V831, P55, DOI 10.1016/S0006-8993(99)01393-1; Brewer K. L., 1997, Society for Neuroscience Abstracts, V23, P438; BUCHSBAUM MS, 1977, NATURE, V270, P620, DOI 10.1038/270620a0; CAUDLE RM, 1988, J PHARMACOL EXP THER, V246, P508; CAUDLE RM, 1987, BRAIN RES, V435, P1, DOI 10.1016/0006-8993(87)91579-4; COX BM, 1985, NEUROPEPTIDES, V5, P571, DOI 10.1016/0143-4179(85)90082-4; Dancausse H. A., 1995, Society for Neuroscience Abstracts, V21, P231; DAVIDOFF G, 1987, PAIN, V29, P39, DOI 10.1016/0304-3959(87)90176-X; Demirel G, 1998, SPINAL CORD, V36, P25, DOI 10.1038/sj.sc.3100523; DRAISCI G, 1991, BRAIN RES, V560, P186, DOI 10.1016/0006-8993(91)91231-O; EIDE PK, 1995, NEUROSURGERY, V37, P1080, DOI 10.1227/00006123-199512000-00007; ELSOBKY A, 1976, NATURE, V263, P783, DOI 10.1038/263783a0; FADEN AI, 1984, BRIT J PHARMACOL, V81, P271, DOI 10.1111/j.1476-5381.1984.tb10074.x; FADEN AI, 1990, ANN NEUROL, V27, P67, DOI 10.1002/ana.410270111; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; GRACELY RH, 1983, NATURE, V306, P264, DOI 10.1038/306264a0; GREVERT P, 1983, BIOL PSYCHOL, V18, P1093; Hao JX, 1996, PAIN, V66, P279; Hao JX, 1998, EXP BRAIN RES, V118, P259, DOI 10.1007/s002210050280; HELTON TE, 1993, MOL CELL NEUROSCI, V4, P319, DOI 10.1006/mcne.1993.1042; HYLDEN JLK, 1991, PAIN, V44, P187, DOI 10.1016/0304-3959(91)90136-L; KAYSER V, 1991, BRAIN RES, V567, P197, DOI 10.1016/0006-8993(91)90796-X; Kennedy P, 1997, SPINAL CORD, V35, P814, DOI 10.1038/sj.sc.3100569; KNOX RJ, 1987, BRAIN RES, V415, P21, DOI 10.1016/0006-8993(87)90265-4; KOSTERLITZ HW, 1985, PROC R SOC SER B-BIO, V225, P27, DOI 10.1098/rspb.1985.0048; Laughlin TM, 1997, PAIN, V72, P253, DOI 10.1016/S0304-3959(97)00046-8; Laughlin TM, 1999, PAIN, V80, P37, DOI 10.1016/S0304-3959(98)00191-2; Liu SL, 1997, BRAIN RES, V756, P160, DOI 10.1016/S0006-8993(97)00137-6; LONG JB, 1994, J PHARMACOL EXP THER, V269, P358; MELZACK R, 1978, PAIN, V4, P195, DOI 10.1016/0304-3959(77)90133-6; MILLAN MJ, 1986, PAIN, V27, P303, DOI 10.1016/0304-3959(86)90158-2; Morrow TJ, 2000, EXP NEUROL, V161, P220, DOI 10.1006/exnr.1999.7246; NOGUCHI K, 1992, NEUROSCIENCE, V46, P561, DOI 10.1016/0306-4522(92)90144-Q; NOGUCHI K, 1991, MOL BRAIN RES, V10, P227, DOI 10.1016/0169-328X(91)90065-6; RUDA MA, 1988, P NATL ACAD SCI USA, V85, P622, DOI 10.1073/pnas.85.2.622; Ruda MA, 1995, PROG BRAIN RES, V104, P349; SHARMA HS, 1993, NEUROPHARMACOLOGY, V32, P711, DOI 10.1016/0028-3908(93)90085-H; Siddall PJ, 1997, SPINAL CORD, V35, P69, DOI 10.1038/sj.sc.3100365; SMITH AJW, 1994, MOL BRAIN RES, V21, P359, DOI 10.1016/0169-328X(94)90268-2; STEVENS CW, 1986, J PHARMACOL EXP THER, V238, P833; WANG JQ, 1995, J PHARMACOL EXP THER, V273, P909; Wilson SP, 1999, P NATL ACAD SCI USA, V96, P3211, DOI 10.1073/pnas.96.6.3211; XU XJ, 1992, PAIN, V48, P279, DOI 10.1016/0304-3959(92)90070-R; YAKSH TL, 1987, J NEUROSURG, V67, P157, DOI 10.3171/jns.1987.67.2.0157; YAKSH TL, 1988, PROG BRAIN RES, V77, P371; Yezierski RP, 1998, PAIN, V75, P141, DOI 10.1016/S0304-3959(97)00216-9; Yezierski RP, 1996, J CEREBR BLOOD F MET, V16, P996, DOI 10.1097/00004647-199609000-00025; YEZIERSKI RP, 1993, J NEUROTRAUM, V10, P445, DOI 10.1089/neu.1993.10.445	56	25	25	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	FEB 1	2001	90	1-2					181	190		10.1016/S0304-3959(00)00402-4			10	Anesthesiology; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology; Neurosciences & Neurology	406CY	WOS:000167198400022	11166985				2022-02-06	
J	Corrigan, JD				Corrigan, JD			Conducting statewide needs assessments for persons with traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						needs assessment; public policy; traumatic brain injury	UNITED-STATES	The Traumatic Brain Injury Act of 1996 (Public Law 104-166) gave new authority to the Health Resources and Services Administration (HRSA) in the United States Department of Health and Human Services (DHHS) to establish a grant program for states to assist in addressing the needs of persons with traumatic brain injury (TBI). The resulting State Demonstration Grant Program has made available two categories of grants: planning and implementation. Planning grants are awarded to assist states in building infrastructure through the development of four core components. One of the core components is a statewide needs and resource assessment encompassing the full spectrum of services, from initial acute treatment through rehabilitation and long-term community supports. In 1999. assessments completed in 11 states were subjected to a comparative analysis to identify trends across states and to extract salient issues for the State Demonstration Grant Program. This article summarizes the context of the HRSA-funded needs assessments and contrasts the methods of needs assessment utilized. Over-arching issues are discussed, including exemplary qualitative and quantitative methods. and the diversity of theoretical models employed in designing assessments and interpreting findings. Several limitations in approaches were also identified, including shortcomings of convenience samples for conducting mail surveys and the unlikely validity of using a needs and resource discrepancy approach to identify gaps in services.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Traumat Brain Injury Tech Assistance Ctr, Silver Spring, MD USA		Corrigan, JD (corresponding author), Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.						Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; *CDCP, 1999, TRAUM BRAIN INJ PUBL; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; DIGRE PG, 1994, J HEAD TRAUMA REHAB, V9, P12; GOODALL P, 1994, J HEAD TRAUMA REHAB, V9, P61; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; ROSEN B, 1994, J HEAT TRAUMA REHABI, V9, P2; Schootman M, 2000, BRAIN INJURY, V14, P373; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *US GEN ACC OFF, 1998, TRAUM BRAIN INJ PROG; WRIGHT B, 1993, WHAT LEGISLATORS NEE	14	25	25	0	2	ASPEN PUBL INC	GAITHERSBURG	200 ORCHARD RIDGE DR, STE 200, GAITHERSBURG, MD 20878 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2001	16	1					1	19		10.1097/00001199-200102000-00004			19	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	403ZC	WOS:000167072100006	11277847				2022-02-06	
J	Maryniak, O; Manchanda, R; Velani, A				Maryniak, O; Manchanda, R; Velani, A			Methotrimeprazine in the treatment of agitation in acquired brain injury patients	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; HALOPERIDOL; BEHAVIOR; REHABILITATION; EFFICACY; SCALE	Medical management of the agitation associated with acquired brain injury (ABI) has been problematic. At least 12 distinct drugs are currently recommended in the medical literature. In recent years, on the ABI in-patient rehabilitation unit, methotrimeprazine (MTZ) has come to be the preferred drug and is used routinely for effective treatment of agitation. The objective of this paper is to describe the use and safety of MTZ in the rehabilitation of ABI patients. A retrospective chart review of all patients discharged from the ABI unit over a course of 2 years was conducted. In addition to demographics such a aetiology of ABI, sex, age, length of stay, Glasgow Coma Scale, length of posttraumatic amnesia and others, a detailed analysis was made of the multidisciplinary progress notes to determine the daily agitation status and the daily use of psychotropic medication. All notes on side effects and adverse reactions were carefully documented. 120 first admission recent ABI patients were discharged in the 2-year study period. Of these, 69 (57%) had some level of agitation and 56 (48%) were treated with MTZ, in doses of 2-50 mg up to four times daily. Agitation was controlled in most cases. In only two cases were significant side effects noted. While MTZ has been used as a safe and effective neuroleptic in psychiatry for over 40 years, this is the first report of its use in treating agitation in ABI.	Univ Western Ontario, Dept Phys Med & Rehabil, London, ON, Canada; Univ Western Ontario, Dept Psychiat, London, ON, Canada; St Josephs Hlth Care London, London, England; London Hlth Sci Ctr, London, England		Maryniak, O (corresponding author), Parkwood Hosp, 801 Commiss Rd E, London, ON N6C 5J1, Canada.	olemar.medart@sympatico.ca					AARON H, 1967, MED LETT DRUGS THER, V9, P49; BAKCHINE S, 1989, NEUROLOGY, V39, P777, DOI 10.1212/WNL.39.6.777; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Bryois C, 1996, Rev Med Suisse Romande, V116, P713; CARDENAS DD, 1992, PHYS MED REH CLIN N, V3, P273; Chandler M C, 1988, Brain Inj, V2, P309; Chater S, 1998, PALLIATIVE MED, V12, P255, DOI 10.1191/026921698671831786; CIFU DX, 1997, P 22 ANN POSTGR COUR, P104; COPE DN, 1996, MED REHABILITATION T, P573; CORRIGAN JD, 1994, J CLIN EXP NEUROPSYC, V16, P386, DOI 10.1080/01688639408402649; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; COURVOISIER S, 1958, COMPTES RENDU SCEANC, V7, P1378; Dombovy Mary L., 1992, Archives of Physical Medicine and Rehabilitation, V73, P975; ELLIOTT FA, 1977, ANN NEUROL, V1, P489, DOI 10.1002/ana.410010516; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FRASER HF, 1963, CLIN PHARMACOL THER, V4, P596; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P917, DOI 10.1016/S0003-9993(97)90050-2; GERLACH J, 1991, SCHIZOPHRENIA BULL, V17, P289, DOI 10.1093/schbul/17.2.289; GUALTIEREI CT, 1993, BRAIN INJURY REHABIL, P264; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; HIRSCH J, 1993, HEADLINES        MAR, P10; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; LAMBERT PA, 1964, ENCEPHALE, V1, P262; Levine A M, 1988, Brain Inj, V2, P165, DOI 10.3109/02699058809150940; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SARWER-FONER G J, 1961, Med Serv J Can, V17, P798; TELATIN I, 1959, JAMA-J AM MED ASSOC, V170, P1349; WILCOCK GK, 1987, LANCET, V1, P929; Wilkinson R, 1999, BRAIN INJURY, V13, P1025; Wroblewski BA, 1997, BRAIN INJURY, V11, P37, DOI 10.1080/026990597123791	32	25	25	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2001	15	2					167	174		10.1080/026990501458399			8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	398BG	WOS:000166733800008	11260766				2022-02-06	
J	Gosepath, K; Nafe, B; Ziegler, E; Mann, WJ				Gosepath, K; Nafe, B; Ziegler, E; Mann, WJ			Neurofeedback training as a therapy for tinnitus	HNO			German	Article						therapy of tinnitus; neurofeedback; electrical activity of the brain tinnitusquestionaire; biofeedback	AUDITORY-CORTEX; BIOFEEDBACK; MECHANISMS; DIAGNOSIS; SYSTEM	Background and objective: Biofeedback is known as a possibility to control physiologic processes like body temperature or heart frequency. Neurofeedback is a form of biofeedback linked to aspects of the electrical activity of the brain such as frequency, location or amplitude of specific EEG activity. It has been successfully used in patients with closed head injury, hyperactivity disorder or epilepsy. Patients/methods: In this study 40 patients with tinnitus were treated with neurofeedback. They trained to upregulate the amplitude of their alpha -activity and downregulate the amplitude of beta -activity during muscle relaxation and acoustic orientation on sounds or music in order to suppress their tinnitus. Results: After 15 sessions of training 24 patients with a duration of their tinnitus for an average of 1 year showed significant increase of alpha -amplitudes while 16 patients with duration of their tinnitus on an average of 7 years showed a decrease of beta -amplitudes without any change in alpha -activity. After the training all patients had a significant reduction of the score in the tinnitusquestionaire of Gobel and Hiller. In a control-group of 15 persons without tinnitus we didn't see any changes of alpha- or beta -amplitudes during the same training. Conclusions: In conclusion neurofeedback is a new therapy for patients with tinnitus. Patients get the possibility of selfcontrol and therefore of influence on their disease.	Romerwallklin, Klin Neurootol Erkrankungen, D-55131 Mainz, Germany		Gosepath, K (corresponding author), Romerwallklin, Klin Neurootol Erkrankungen, Romerwall 51-55, D-55131 Mainz, Germany.						Andersson G, 1999, BRIT J AUDIOL, V33, P201, DOI 10.3109/03005369909090101; Arnold W, 1996, ORL J OTO-RHINO-LARY, V58, P195, DOI 10.1159/000276835; BISCHOFF C, 1995, PSYCHOTHERAPEUT, V40, P179; EBE M, 1994, LEITFADEN EEG PRAXIS, P68; GOEBEL G, 1995, OTO RHINO LARYN NOVA, V5, P178, DOI 10.1159/000313202; GOEBEL G, 1994, DIAGNOSTICA, V40, P155; HAZELL JWP, 1990, J OTOLARYNGOL, V19, P11; HAZELL JWP, 1995, TINNITUS MECH, P57; Hoke ES, 1998, AUDIOL NEURO-OTOL, V3, P300, DOI 10.1159/000013802; HOKE M, 1989, HEARING RES, V37, P281, DOI 10.1016/0378-5955(89)90028-2; HOKE M, 1991, ACTA OTO-LARYNGOL, P176; HOUSE JW, 1981, J LARYNGOL OTOL, P178; JASTREBOFF PJ, 1993, BRIT J AUDIOL, V27, P7, DOI 10.3109/03005369309077884; JASTREBOFF PJ, 1990, NEUROSCI RES, V8, P221, DOI 10.1016/0168-0102(90)90031-9; KIRSCH CA, 1989, PSYCHOSOM MED, V51, P209, DOI 10.1097/00006842-198903000-00009; KIRSCH CA, 1987, BIOFEEDBACK SELF-REG, V12, P295, DOI 10.1007/BF00998721; Kotchoubey B, 1999, CLIN NEUROPHYSIOL, V110, P683, DOI 10.1016/S1388-2457(99)00005-X; KRONER B, 1981, BIOFEEDBACK THERAPIE, P112; Lenarz T, 1998, LARYNGO RHINO OTOL, V77, P54, DOI 10.1055/s-2007-996932; Lockwood AH, 1998, NEUROLOGY, V50, P114, DOI 10.1212/WNL.50.1.114; Lubar JF, 1997, APPL PSYCHOPHYS BIOF, V22, P111, DOI 10.1023/A:1026276228832; LUBAR JF, 1995, BIOFEEDBACK SELF-REG, V20, P83, DOI 10.1007/BF01712768; Norena A, 1999, CLIN NEUROPHYSIOL, V110, P666, DOI 10.1016/S1388-2457(98)00034-0; OLSCHEWSKI A, 1996, PROGR MUSKELENTSPANN; Sataloff RT, 1996, AM J OTOL, V17, P909; SCHAAF H, 2000, RETRAINING TINNITUST, P82; SEIFERT AR, 1975, BIOL PSYCHOL, V3, P157, DOI 10.1016/0301-0511(75)90033-2; Shulman A, 1996, P 5 INT TINN SEM POR, P539; STERMAN MB, 1972, ELECTROEN CLIN NEURO, V33, P89, DOI 10.1016/0013-4694(72)90028-4; Sterman MB, 1996, BIOFEEDBACK SELF-REG, V21, P3, DOI 10.1007/BF02214147; WallhausserFranke E, 1997, NEUROREPORT, V8, P725, DOI 10.1097/00001756-199702100-00029; WallhausserFranke E, 1996, NEUROREPORT, V7, P1585, DOI 10.1097/00001756-199607080-00010; WILHELM K, 1999, PSYCHOL HEUTE, V26, P18; Zenner HP, 1998, HNO, V46, P699, DOI 10.1007/s001060050299	34	25	25	0	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0017-6192	1433-0458		HNO	HNO	JAN	2001	49	1					29	+		10.1007/s001060050704			7	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Otorhinolaryngology	398DK	WOS:000166741100006	11219406				2022-02-06	
J	Karmy-Jones, R; Carter, YM; Nathens, A; Brundage, S; Meissner, MH; Borsa, J; Demirer, S; Jurkovich, G				Karmy-Jones, R; Carter, YM; Nathens, A; Brundage, S; Meissner, MH; Borsa, J; Demirer, S; Jurkovich, G			Impact of presenting physiology and associated injuries on outcome following traumatic rupture of the thoracic aorta	AMERICAN SURGEON			English	Article							LEFT-HEART BYPASS; TREATMENT PRIORITIES; HIGH-RISK; REPAIR; ISTHMUS; EXPERIENCE; MANAGEMENT; PARAPLEGIA; EMERGENCY	We hypothesized that the predominant factor influencing outcome of traumatic rupture of the thoracic aorta (TRA) was the degree of shock on presentation and associated injuries. We reviewed our experience with TRA over a 15-year period. Patients were classified as "unstable" if presenting systolic blood pressure was <90 mm Hg or if it decreased to <90 mm Hg after admission. We determined the presence of closed head injury, cardiac risk factors, a preoperative acute lung injury (ALI). The influence of these factors on mortality, postoperative adult respiratory distress syndrome (ARDS), and paralysis was analyzed. One hundred thirty-six patients were admitted with TRA. One hundred twenty underwent operative repair with a mortality of 31 per cent. Operative mortality was significantly higher in unstable patients (62%) versus stable patients (17%, P = 0.001), in patients with cardiac risk factors (71%) versus those without (24%, P = 0.001), and in patients with preoperative free rupture (83%) with versus those without (19%, P = 0.001). Free rupture was the cause of hypotension in only 10 of 42 unstable patients, with the remainder being due to other causes. Preoperative ALI was associated with a marked increase in postoperative ARDS (47% with vs 9% without, P = 0.001) but not operative mortality. Mechanical circulatory support (MCS) was used in 59 cases, none of whom experienced paralysis, whereas eight of 61 operated on without MCS developed paralysis (P = 0.001). When logistic regression was applied the use of MCS was not determined to be statistically significant. However, preoperative instability was found to be a significant predictor of postoperative paralysis with the risk being increased 5.5 times (confidence interval 3.3-10). The predominant factor influencing mortality, postoperative ARDS, and paralysis was preoperative instability and associated injuries. In patients who are hypotensive, other injuries should take precedence over repair of TRA. Patients who are stable but who have cardiac or pulmonary risk factors may be better managed by a period of nonoperative management until their condition improves.	Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; Univ Washington, Div Cardiothorac Surg, Seattle, WA 98195 USA; Univ Washington, Dept Radiol, Seattle, WA 98195 USA		Karmy-Jones, R (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, 325 9th Ave,Box 359796, Seattle, WA 98104 USA.						Attar S, 1999, ANN THORAC SURG, V67, P959, DOI 10.1016/S0003-4975(99)00174-5; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BORMAN KR, 1982, AM J SURG, V144, P728, DOI 10.1016/0002-9610(82)90559-1; Camp PC, 1997, J TRAUMA, V43, P413, DOI 10.1097/00005373-199709000-00004; CLARK DE, 1990, J TRAUMA, V30, P701, DOI 10.1097/00005373-199006000-00008; COWLEY RA, 1990, J THORAC CARDIOV SUR, V100, P652; DEBYDUPONT G, 1999, OXFORD TXB CRITICAL, P54; Fabian TC, 1998, ANN SURG, V227, P666, DOI 10.1097/00000658-199805000-00007; Fabian TC, 1997, J TRAUMA, V42, P374, DOI 10.1097/00005373-199703000-00003; FORBES AD, 1994, ARCH SURG-CHICAGO, V129, P494; FULLERTON DA, 1993, ANN THORAC SURG, V56, P579, DOI 10.1016/0003-4975(93)90908-Z; Hudson H M 2nd, 1991, Ann Vasc Surg, V5, P445; LEE RB, 1992, AM SURGEON, V58, P37; MAGGISANO R, 1995, ANN VASC SURG, V9, P44, DOI 10.1007/BF02015316; MATTOX KL, 1985, ANN THORAC SURG, V40, P456, DOI 10.1016/S0003-4975(10)60100-2; Mattox KL, 1997, J TRAUMA, V42, P353, DOI 10.1097/00005373-199703000-00001; PARMLEY LF, 1958, CIRCULATION, V17, P1086, DOI 10.1161/01.CIR.17.6.1086; Pate JW, 1999, WORLD J SURG, V23, P59, DOI 10.1007/s002689900565; PATE JW, 1995, WORLD J SURG, V19, P119, DOI 10.1007/BF00316994; PATE JW, 1995, ANN THORAC SURG, V59, P90, DOI 10.1016/0003-4975(94)00719-N; PATE JW, 1994, ANN THORAC SURG, V57, P530, DOI 10.1016/0003-4975(94)90540-1; Pezzella AT, 1998, CURR PROB SURG, V35, P652; READ RA, 1993, ARCH SURG-CHICAGO, V128, P746; SACCO WJ, 1988, COMPUT BIOL MED, V18, P419, DOI 10.1016/0010-4825(88)90059-5; Sweeney MS, 1997, ANN THORAC SURG, V64, P384, DOI 10.1016/S0003-4975(97)00561-4; Tatou E, 2000, ANN THORAC SURG, V69, P70, DOI 10.1016/S0003-4975(99)01054-1; VONOPPELL UO, 1994, ANN THORAC SURG, V58, P585, DOI 10.1016/0003-4975(94)92270-5; Wahl WL, 1999, J TRAUMA, V47, P254, DOI 10.1097/00005373-199908000-00006; YOUNG JN, 1989, WESTERN J MED, V150, P662	29	25	30	0	1	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	JAN	2001	67	1					61	66					6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	395RA	WOS:000166594000015	11206899				2022-02-06	
J	Kurtz, MM; Moberg, PJ; Mozley, LH; Swanson, CL; Gur, RC; Gur, RE				Kurtz, MM; Moberg, PJ; Mozley, LH; Swanson, CL; Gur, RC; Gur, RE			Effectiveness of an attention- and memory-training program on neuropsychological deficits in schizophrenia	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						schizophrenia; cognitive; rehabilitation; symptoms; outcome	REMEDIATION; DEFINITION; VALIDATION	The effect of two cognitive remediation procedures developed for closed head injury, Attention Process Training (APT) and Prospective Memory Training (PROMT), on neuropsychological deficits in schizophrenia was investigated. Six patients with schizophrenia, varying in baseline intellectual function and symptoms, were studied; three in a remediation condition and three in a non-remediated control condition. Results were evaluated individually for each of the three treated patients. Two of three remediation, treated subjects showed marked improvement on tests of sustained and divided attention. Untreated patients showed little evidence of change in neuropsychological test performance across a similar time interval, when tested on a subset of the measures administered to remediation-treated patients The results of this study are discussed with a view toward future studies using larger sample sizes with homogeneous subject populations.	Univ Penn, Sch Med, Dept Psychiat, Brain Behav Lab, Philadelphia, PA 19104 USA		Kurtz, MM (corresponding author), Inst Living, Schizophrenia Rehabil Program, 400 Washington St, Hartford, CT 06106 USA.		Gur, Ruben/K-1999-2019	Gur, Ruben/0000-0002-9657-1996	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019112, P30MH043880, P50MH043880] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH01336, MH19112, MH43880] Funding Source: Medline		American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789; ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P784; BELLACK AS, 1990, AM J PSYCHIAT, V147, P650; BENEDICT RHB, 1989, BRIT J CLIN PSYCHOL, V28, P187, DOI 10.1111/j.2044-8260.1989.tb00832.x; CORNBLATT BA, 1994, SCHIZOPHRENIA BULL, V20, P31, DOI 10.1093/schbul/20.1.31; DILLER L, 1987, NEUROBEHAVIORAL RECO, P146; Golden CJ, 1978, STROOP COLOR WORD TE; Gordon M, 1983, GORDON DIAGNOSTIC SY; GREEN MF, 1993, AM J PSYCHIAT, V150, P178; Green MF, 1996, AM J PSYCHIAT, V153, P321; GUR RE, 1991, AM J PSYCHIAT, V148, P472; Heinrichs RW, 1998, NEUROPSYCHOLOGY, V12, P426, DOI 10.1037/0894-4105.12.3.426; Medalia A, 1998, SCHIZOPHRENIA BULL, V24, P147, DOI 10.1093/oxfordjournals.schbul.a033306; OVERALL JR, 1980, J OPER PSYCHIATR, V11, P48; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; SOHLBERG M, 1986, PROSPECTIVE MEMORY P; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; Sohlberg M.M., 1986, ATTENTION PROCESS TR; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Sohlberg MM, 2000, J CLIN EXP NEUROPSYC, V22, P656, DOI 10.1076/1380-3395(200010)22:5;1-9;FT656; Stuss DT, 1988, CLIN NEUROPSYCHOL, V2, P246, DOI [DOI 10.1080/13854048808520107, 10.1080/13854048808520107]; Wechsler D., 1981, WAIS R MANUAL; WESULAM MM, 1985, PRINCIPLES BEHAV NEU; WILSON B, 1989, J CLIN EXP NEUROPSYC, V11, P855, DOI 10.1080/01688638908400940; Winograd E., 1988, PRACTICAL ASPECTS ME, V1, P348	27	25	27	0	8	DEMOS MEDICAL PUBLISHING	NEW YORK	386 PARK AVE SOUTH, STE 201, NEW YORK, NY 10016 USA	0888-4390			NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair		2001	15	1					75	80		10.1177/154596830101500110			6	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	466BH	WOS:000170624100010	11527282				2022-02-06	
J	Manasse, NJ; Hux, K; Rankin-Erickson, JL				Manasse, NJ; Hux, K; Rankin-Erickson, JL			Speech recognition training for enhancing written language generation by a traumatic brain injury survivor	BRAIN INJURY			English	Article							LEARNING-DISABILITIES; VERBAL IMPAIRMENT; STUDENTS; TECHNOLOGY	Impairments in motor functioning, language processing, and cognitive status may impact the written language performance of traumatic brain injury (TBI) survivors. One strategy to minimize the impact of these impairments is to use a speech recognition system. The purpose of this study was to explore the effect of mild dysarthria and mild cognitive-communication deficits secondary to TBI on a 19-year-old survivor's mastery and use of such a system-specifically, Dragon NaturallySpeaking(R). Data included the % of the participant's words accurately perceived by the system over time, the participant's accuracy over time in using commands for navigation and error correction, and quantitative and qualitative changes in the participant's written texts generated with and without the use of the speech recognition system. Results showed that Dragon NaturallySpeaking(R) was similar to 80% accurate in perceiving words spoken by the participant, and the participant quickly and easily mastered all navigation and error correction commands presented. Quantitatively, the participant produced a greater amount of text using traditional word processing and a standard keyboard than using the speech recognition system. Minimal qualitative differences appeared between writing samples. Discussion of factors that may have contributed to the obtained results and that may affect the generalization of the findings to other TBI survivors is provided.	Univ Nebraska, Barkley Mem Ctr Special Educ & Commun Disorders, Lincoln, NE 68583 USA		Hux, K (corresponding author), Univ Nebraska, Barkley Mem Ctr Special Educ & Commun Disorders, 318E Barkley Mem Ctr, Lincoln, NE 68583 USA.		Hux, Karen/AAQ-2078-2020				ALWANG G, 1998, PC MAGAZINE, V17, P199; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; COLEMAN C L, 1991, AAC (Augmentative and Alternative Communication), V7, P34, DOI 10.1080/07434619112331275663; De la Paz S, 1999, LEARN DISABILITY Q, V22, P173, DOI 10.2307/1511284; HIGGINS EL, 1995, LEARN DISABILITY Q, V18, P159, DOI 10.2307/1511202; Hux K, 1996, INTERV SCH CLIN, V31, P158, DOI 10.1177/105345129603100305; HUX K, IN PRESS AUGMENTATIV; MacArthur CA, 1996, J LEARN DISABIL, V29, P344, DOI 10.1177/002221949602900403; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; WOODCOCK RW, 1989, WEOODCOCKJOHNSON TES; Yorkston K. M., 1996, SENTENCE INTELLIGIBI; Yorkston K.M., 1981, ASSESSMENT INTELLIGI; YOUDIN M, 1980, MED PROG TECHNOL, V7, P139	14	25	25	0	5	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2000	14	11					1015	1034					20	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	373UC	WOS:000165306800007	11104141				2022-02-06	
J	Craighead, MW; Boutin, H; Middlehurst, KML; Allan, SM; Brooks, N; Kimber, I; Rothwell, NJ				Craighead, MW; Boutin, H; Middlehurst, KML; Allan, SM; Brooks, N; Kimber, I; Rothwell, NJ			Influence of corticotrophin releasing factor on neuronal cell death in vitro and in vivo	BRAIN RESEARCH			English	Article						CRF; neuronal toxicity; cortical neurons; ischaemia; NMDA; AMPA	FOCAL CEREBRAL-ISCHEMIA; MESSENGER-RNA; FACTOR CRF; RAT; RECEPTOR; BRAIN; HORMONE; INJURY; SEIZURES; AMYGDALA	Several studies have demonstrated that antagonists of the corticotrophin releasing factor (CRF) receptor markedly inhibit experimentally induced excitotoxic, ischaemic and traumatic brain injury in the rat, and that CRF expression is elevated in response to experimentally induced stroke or traumatic brain injury. CRF is also induced by the pro-inflammatory cytokine interleukin 1 (IL-1), which participates in various forms of neurodegeneration. The aim of this study was to test the hypothesis that CRF is toxic directly in vivo or in vitro. In primary cultures of rat cortical neurons, exposure to CRF (10 pM-100 nM) for 24 h failed to cause cell death directly, or to modify the neurotoxic effects of N-methyl-D-aspartate (NMDA). Similarly, infusion of CRF (0.3-5 mug) into specific brain regions of the rat did not induce cell death and did not significantly alter the neuronal damage produced by infusion of excitatory amino acids. These data demonstrate that CRF is not directly neurotoxic, and suggest that either CRF mediates neuronal damage by indirect actions (e.g. on the vasculature) and/or that CRF is not the endogenous ligand which contributes to neurodegeneration through activation of CRF receptors. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Zeneca Cent Toxicol Lab, Macclesfield SK10 4TJ, Cheshire, England		Craighead, MW (corresponding author), Univ Manchester, Sch Biol Sci, 1-124 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	mqbssmwc@man.ac.uk	Boutin, Herve/C-4532-2011; Allan, Stuart/AAL-1245-2020	Boutin, Herve/0000-0002-0029-5246; Allan, Stuart/0000-0001-9646-4456			ALDENHOFF JB, 1983, SCIENCE, V221, P875, DOI 10.1126/science.6603658; Allan SM, 2000, P NATL ACAD SCI USA, V97, P5580, DOI 10.1073/pnas.090464197; BARAM TZ, 1992, ANN NEUROL, V31, P488, DOI 10.1002/ana.410310505; Casadevall M, 1999, AM J PHYSIOL-GASTR L, V276, pG1016, DOI 10.1152/ajpgi.1999.276.4.G1016; EHLERS CL, 1983, BRAIN RES, V278, P332, DOI 10.1016/0006-8993(83)90266-4; FISHER LA, 1983, REGUL PEPTIDES, V5, P153, DOI 10.1016/0167-0115(83)90123-4; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Kostich WA, 1998, MOL ENDOCRINOL, V12, P1077, DOI 10.1210/me.12.8.1077; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; LEI S, 1993, BRIT J PHARMACOL, V108, P941, DOI 10.1111/j.1476-5381.1993.tb13490.x; Li H, 1998, INT J BIOCHEM CELL B, V30, P1389, DOI 10.1016/S1357-2725(98)00093-4; Lundkvist J, 1996, EUR J PHARMACOL, V309, P195, DOI 10.1016/0014-2999(96)00337-8; LYONS MK, 1991, BRAIN RES, V545, P339, DOI 10.1016/0006-8993(91)91310-W; Roe SY, 1998, EUR J NEUROSCI, V10, P553, DOI 10.1046/j.1460-9568.1998.00064.x; ROTHWELL NJ, 1989, AM J PHYSIOL, V256, pE111, DOI 10.1152/ajpendo.1989.256.1.E111; Schoeffter P, 1999, FUNDAM CLIN PHARM, V13, P484, DOI 10.1111/j.1472-8206.1999.tb00007.x; STRIJBOS PJLM, 1994, BRAIN RES, V656, P405, DOI 10.1016/0006-8993(94)91485-0; Turnbull AV, 1995, BRAIN BEHAV IMMUN, V9, P253, DOI 10.1006/brbi.1995.1026; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; WONG ML, 1995, NEUROREPORT, V6, P1785, DOI 10.1097/00001756-199509000-00019	20	25	27	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	OCT 27	2000	881	2					139	143		10.1016/S0006-8993(00)02759-1			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	368BV	WOS:000090098500005	11036151				2022-02-06	
J	Lanham, RA; Weissenburger, JE; Schwab, KA; Rosner, MM				Lanham, RA; Weissenburger, JE; Schwab, KA; Rosner, MM			A longitudinal investigation of the concordance between individuals with traumatic brain injury and family or friend ratings on the Katz Adjustment Scale	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						awareness; concordance; DVHIP; Katz Adjustment Scale (KAS); Neurobehavioral Rating Scale (NBRS); traumatic brain injury	CLOSED-HEAD-INJURY; IMPAIRED AWARENESS; BEHAVIORAL LIMITATIONS; SIGNIFICANT OTHERS; PRACTICAL SCALE; RELATIVES; REHABILITATION; CONSCIOUSNESS; QUESTIONNAIRE; DYSFUNCTION	Changes in the level of agreement (concordance) between self and family or friend reporting on the Katz Adjustment Scale (KAS) from 6 to 12 months postinjury were assessed in 55 individuals with traumatic brain injury (IwTBI). Although the concordance between self and family/friend reports significantly increased over the course of recovery, possibly reflecting improvements in awareness, the concordance showed limited relationship to measures of injury severity and neuropsychological functioning. Concordance did not significantly relate to clinicians' ratings of inaccurate insight and self-appraisal on the awareness item from the Neurobehavioral Rating Scale (NBRS). Clinicians' ratings of awareness demonstrated only limited relationship to measures of injury severity and neuropsychological functioning, as well. Although similar results in the literature have been interpreted as demonstrating that awareness, defined as concordance, is possibly a unique construct separate from injury severity and neuropsychological functioning, an alternative hypothesis is presented concerning other noninjury factors that may affect the level of agreement in problem reporting between IwTBI and family/friend informants.	Vet Affairs Med Ctr, Def & Vet Head Injury Program, Dept Traumat Brain Injury, Minneapolis, MN USA; Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Washington, DC 20307 USA; Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Def & Vet Head Injury Program, Lackland AFB, TX 78236 USA		Lanham, RA (corresponding author), Vet Affairs Med Ctr, Def & Vet Head Injury Program, Dept Traumat Brain Injury, Minneapolis, MN USA.						BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; CURTISS G, 1999, UNPUB FACTOR STRUCTU; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Flashman, 1998, Semin Clin Neuropsychiatry, V3, P201; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; FLEMING JM, 1996, BRAIN INJURY, V10, P15; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Freeston MH, 1997, PSYCHOL REP, V81, P419, DOI 10.2466/pr0.1997.81.2.419; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GOLDBERG E, 1991, AWARENESS DEFICIT BR, P152; GOREN DA, 1993, BRAIN INJURY, V7, P219; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; Heilman K.M., 1991, AWARENESS DEFICIT BR, P53; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Herbert CM, 1989, CLIN REHABIL, V3, P125; JACKSON DN, 1961, EDUC PSYCHOL MEAS, V21, P771, DOI 10.1177/001316446102100402; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lewis L., 1991, AWARENESS DEFICIT BR, P223; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MALIA K, 1997, J COGN REHABIL, V5, P10; McCrae RR, 1998, J PERS, V66, P285, DOI 10.1111/1467-6494.00013; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Meana M, 1997, OBSTET GYNECOL, V90, P583, DOI 10.1016/S0029-7844(98)80136-1; Mesulam M., 1985, PRINCIPLES BEHAV NEU; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Prigatano G. P., 1991, BNI Q, V7, P27; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHERER M, 1997, J INT NEUROPSYCH SOC, V3, P75; Snyder D. K., 1997, MANUAL MARITAL SATIS; Spangenberg JJ, 1999, J PSYCHOL, V133, P253, DOI 10.1080/00223989909599738; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55; Stuss D., 1991, AWARENESS DEFICIT BR, P63; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Weinstein EA, 1955, DENIAL ILLNESS	61	25	25	0	5	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2000	15	5					1123	1138		10.1097/00001199-200010000-00006			16	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	359DT	WOS:000089596800006	10970933				2022-02-06	
J	Henry-Feugeas, MC; Azouvi, P; Fontaines, A; Denys, P; Bussels, B; Maaz, F; Samson, Y; Schouman-Claeys, E				Henry-Feugeas, MC; Azouvi, P; Fontaines, A; Denys, P; Bussels, B; Maaz, F; Samson, Y; Schouman-Claeys, E			MRI analysis of brain atrophy after severe closed-head injury: relation to clinical status	BRAIN INJURY			English	Article							CT-SCAN; VOLUME	The purpose of this study was to determine the clinical correlates of supratentorial ventricular dilations and of corpus callosal atrophy at the subacute stage after a severe closed-head injury (CHI). Thirty-three CHI patients underwent MRI 2 months or more after injury. Morphometric measures were compared to clinical data (coma score, coma duration and Glasgow Outcome Scale). There were numerous significant correlations between clinical data and mid-third ventricle and frontal hems measurements. Fewer significant correlations were found with the lateral ventricle bodies and the corpus callosal body. There was no significant correlation with the posterior part of the corpus callosum and of the ventricles. Corpus callosum atrophy correlated significantly with anterior and deep ventricular dilatation. In conclusion, the best indicator of clinical status was ventriculomegaly, and particularly third ventricle enlargement, which probably reflects the extent of both anterior and deep white matter lesions.	Hop Bichat Claude Bernard, Dept Radiol, F-75877 Paris 18, France; Raymond Poincare Hosp, Garches, France; CEA, Serv Hosp Frederic Joliot, F-91406 Orsay, France		Henry-Feugeas, MC (corresponding author), Hop Bichat Claude Bernard, Dept Radiol, 46 Rue Henri Huchard, F-75877 Paris 18, France.		samson, yves/C-5647-2013	samson, yves/0000-0002-8080-1427; DENYS, Pierre/0000-0002-4831-6499			ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; Azouvi P., 1993, ANN READAPTATION MED, V36, P1; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; ENDO M, 1991, NEURORADIOLOGY, V33, P269; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; GOMORI JM, 1984, NEURORADIOLOGY, V26, P21, DOI 10.1007/BF00328197; JENNETT B, 1995, LANCET, V345, P480; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PENN RD, 1978, ANN NEUROL, V3, P216, DOI 10.1002/ana.410030306; REIDERGROSWASSE.I, 1992, AM J ROENTGENOL, V160, P147; Talairach J., 1967, ATLAS ANATOMIE STERE; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZATZ LM, 1983, PSYCHIAT RES, V8, P207, DOI 10.1016/0165-1781(83)90064-1	17	25	25	0	1	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2000	14	7					597	604					8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	335AV	WOS:000088220600001	10914642				2022-02-06	
J	Shohami, E; Mechoulam, R				Shohami, E; Mechoulam, R			Dexanabinol (HU-211): A nonpsychotropic cannabinoid with neuroprotective properties	DRUG DEVELOPMENT RESEARCH			English	Article						dexanabinol; NMDA-antagonist; TNF-inhibitor; brain injury; stroke	CLOSED-HEAD INJURY; TUMOR-NECROSIS-FACTOR; NONCOMPETITIVE NMDA ANTAGONIST; BRAIN-DAMAGE; RECEPTOR ANTAGONIST; SEPTIC SHOCK; OPTIC-NERVE; RAT; ISCHEMIA; MECHANISMS	The synthetic cannabinoid (+)-(6aS,10aS)-11-hydroxy-Delta-8-tetrahydrocannabinol 1',1'dimethylheptyl (dexanabinol, HU-211) is inactive as a cannabimimetic, but exhibits pharmacological properties characteristic of an N-methyl-D-aspartate (NMDA)-receptor antagonist. It blocks NMDA-receptors stereospecifically by interacting with a site close to, but distinct from, that of uncompetitive NMDA-receptor antagonists and from the recognition sites of glutamate, glycine, and polyamines. HU-211 inhibits the synthesis of tumor necrosis factor alpha (TNF alpha) and possesses antioxidant properties. HU-211 blocked NMDA-induced Ca-45 uptake by primary neuronal cultures of rat forebrain and protected the same neuronal cultures against NMDA and glutamate neurotoxicity. Moreover, HU-211 effectively scavenged peroxy radicals in vitro and protected cultured neurons from the toxic effects of reactive oxygen species (ROS). In addition, HU-211 markedly suppressed in vitro TNF alpha production and nitric oxide (NO) generation (by > 90%) by both murine peritoneal macrophages and rat alveolar macrophage cell line exposed to lipopolysaccharide (LPS). Since glutamate, ROS and TNF alpha. are implicated in the pathophysiology of various acute conditions, the promising results showing neuroprotection by HU-211, acting via multiple mechanisms, led to a series of studies in which the drug was given to experimental animals. In the present review we discuss results from experiments describing the potential use of HU-211 as a neuroprotective agent in models of traumatic brain injury, stroke, optic nerve injury, pneumacocal meningitis, sepsis, and soman toxicity. In addition, HU-211 was introduced into clinical trials for traumatic brain injury and the successful results of two phases of clinical trials in head injured patients are also shown. Drug Dev. Res. 50:211-215, 2000. (C) 2000 Wiley-Liss, Inc.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Med Chem, IL-91120 Jerusalem, Israel		Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.						BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; Bass R, 1996, J INFECT DIS, V173, P735, DOI 10.1093/infdis/173.3.735; BELAYEV L, 1995, BRAIN RES, V702, P266, DOI 10.1016/0006-8993(95)01127-9; BELAYEV L, 1995, MOL CHEM NEUROPATHOL, V25, P19, DOI 10.1007/BF02815084; BIEGON A, 1995, NEUROL RES, V17, P275, DOI 10.1080/01616412.1995.11740326; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; ESHHAR N, 1993, NEUROREPORT, V5, P237, DOI 10.1097/00001756-199312000-00013; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; Filbert MG, 1999, ANN NY ACAD SCI, V890, P505, DOI 10.1111/j.1749-6632.1999.tb08032.x; Gallily R, 1997, J PHARMACOL EXP THER, V283, P918; KNOLLER N, 1998, C NEUR SURG OCT 7 19; Leker RR, 1999, J NEUROL SCI, V162, P114, DOI 10.1016/S0022-510X(98)00301-3; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LITTLE PJ, 1989, PHARMACOL BIOCHEM BE, V32, P661, DOI 10.1016/0091-3057(89)90014-2; MECHOULAM R, 1990, TETRAHEDRON-ASYMMETR, V1, P315, DOI 10.1016/S0957-4166(00)86322-3; MECHOULAM R, 1988, EXPERIENTIA, V44, P762, DOI 10.1007/BF01959156; MEEHOULAM R, 1992, MARIJUANA CANNABINOI, P1; NADLER V, 1993, NEUROSCI LETT, V162, P43, DOI 10.1016/0304-3940(93)90555-Y; NADLER V, 1993, BRAIN RES, V622, P79, DOI 10.1016/0006-8993(93)90804-V; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Striem S, 1997, EUR J PHARMACOL, V338, P205, DOI 10.1016/S0014-2999(97)81923-1; Sun AY, 1998, J BIOMED SCI, V5, P401; TRACEY KJ, 1991, CIRC SHOCK, V35, P123; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; Yoles E, 1996, J NEUROTRAUM, V13, P49, DOI 10.1089/neu.1996.13.49	34	25	27	0	4	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0272-4391			DRUG DEVELOP RES	Drug Dev. Res.	JUL-AUG	2000	50	3-4					211	215		10.1002/1098-2299(200007/08)50:3/4<211::AID-DDR3>3.0.CO;2-G			5	Chemistry, Medicinal; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	359TK	WOS:000089628000003					2022-02-06	
J	Cascio, C; Guarneri, R; Russo, D; De Leo, G; Guarneri, M; Piccoli, F; Guarneri, P				Cascio, C; Guarneri, R; Russo, D; De Leo, G; Guarneri, M; Piccoli, F; Guarneri, P			Pregnenolone sulfate, a naturally occurring excitotoxin involved in delayed retinal cell death	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; pregnenolone sulfate; NMDA receptors; DNA fragmentation; superoxide dismutase; thiobarbituric acid-reactive substances; progesterone; dehydroepiandrosterone; dehydroepiandrosterone sulfate ester; 17 beta-estradiol	METHYL-D-ASPARTATE; TRAUMATIC BRAIN INJURY; AMYLOID BETA-PEPTIDE; RAT RETINA; HIPPOCAMPAL-NEURONS; LIPID-PEROXIDATION; NERVOUS-SYSTEM; NITRIC-OXIDE; SUPEROXIDE PRODUCTION; NEURAL APOPTOSIS	The present study was designed to investigate the neurosteroid pregnenolone sulfate (PS), known for its ability to modulate NMDA receptors and interfere with acute excitotoxicity, in delayed retinal cell death. Three hours after exposure of the isolated and intact retina to a 30-min PS pulse, DNA fragmentation as assessed by genomic DNA gel electrophoresis and a modified in situ terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labeling (TUNEL) method appeared concurrently with an increase in superoxide dismutase (SOD) activity and thiobarbituric acid-reactive substances (TBARS) levels. At 7 h, the increased amount of DNA laddering was accompanied by a higher number of TUNEL-positive cells in the inner nuclear and ganglion cell layers. Necrotic signs were characterized by DNA smear migration, lactate dehydrogenase (LDH) release, and damage mainly in the inner nuclear layer. PS-induced delayed cell death was markedly reduced by the NMDA receptor antagonists 4-(3-phosphonopropyl)-2-piperazinecarboxylic acid and 3 alpha-hydroxy-5 beta-pregnan-20-one sulfate but completely blocked after concomitant addition of the non-NMDA receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione. Steroids with antioxidant properties (progesterone, dehydroepiandrosterone and its sulfate ester, and 17 beta-estradiol) differently prevented PS-induced delayed cell death. Cycloheximide treatment protected against DNA fragmentation and LDH release but failed to prevent the rise in SOD activity and TBARS level. We conclude that a brief PS pulse causes delayed cell death in a slowly evolving apoptotic fashion characterized by a cycloheximide-sensitive death program downstream of reactive oxygen species generation and lipid peroxidation, turning into secondary necrosis in a retinal cell subset.	CNR, Ist Biol Sviluppo, I-90100 Palermo, Italy; CNR, Ist Metodol Diagnost Avanzata, Lab Elettromicroscopia, I-90100 Palermo, Italy; Univ Palermo, Dipartimento Biopatol & Metodol Biomed, Sez Biol & Genet, Palermo, Italy; Univ Palermo, Ist Neuropsichiat, Palermo, Italy; Univ Palermo, Fac Med & Chirurg, Palermo, Italy		Guarneri, P (corresponding author), CNR, Ist Biol Sviluppo, Via Ugo La Malfa 153, I-90100 Palermo, Italy.	pguarneri@ibs.pa.cnr.it	Patrizia, Guarneri/AAO-3595-2020; cascio, caterina/AAY-2588-2020	Patrizia, Guarneri/0000-0001-8288-5217; GUARNERI, Marco/0000-0002-0447-6861			Araghiniknam M, 1996, LIFE SCI, V59, pPL147, DOI 10.1016/0024-3205(96)00396-7; ARAGNO M, 1994, FREE RADICAL RES, V21, P427, DOI 10.3109/10715769409056595; Baulieu E.E., 1987, RECEPTOR RECEPTOR IN, P89; Baulieu EE, 1997, RECENT PROG HORM RES, V52, P1; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Bonne C, 1998, GEN PHARMACOL, V30, P275, DOI 10.1016/S0306-3623(97)00357-1; BOULTON M, 1991, PROG RETIN RES, V11, P125, DOI 10.1016/0278-4327(91)90027-Y; BRAUGHLER JM, 1986, J NEUROTRAUM, V9, P1; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Buege J A, 1978, Methods Enzymol, V52, P302; CHAN PH, 1990, ACT NEUR S, V51, P245; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DAVID P, 1988, EXP EYE RES, V46, P657, DOI 10.1016/S0014-4835(88)80054-X; DREYER EB, 1995, NEUROREPORT, V6, P942, DOI 10.1097/00001756-199504190-00029; Duarte CB, 1998, GEN PHARMACOL-VASC S, V30, P289, DOI 10.1016/S0306-3623(97)00360-1; Dufort I, 1996, DNA CELL BIOL, V15, P481, DOI 10.1089/dna.1996.15.481; DUGAN LL, 1995, J NEUROSCI, V15, P6377; Fischer AJ, 1998, J COMP NEUROL, V393, P1; FLOOD JF, 1995, P NATL ACAD SCI USA, V92, P10806, DOI 10.1073/pnas.92.23.10806; Fujimura M, 1999, J NEUROSCI, V19, P3414; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Green PS, 1997, J STEROID BIOCHEM, V63, P229, DOI 10.1016/S0960-0760(97)00124-6; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; GUAMERI P, 1994, J NEUROCHEM, V63, P86; Guarneri P, 1998, EUR J NEUROSCI, V10, P1752, DOI 10.1046/j.1460-9568.1998.00191.x; GUARNERI P, 1995, BRAIN RES, V683, P65, DOI 10.1016/0006-8993(95)00343-O; Guarneri P, 1998, J NEUROSCI RES, V54, P787, DOI 10.1002/(SICI)1097-4547(19981215)54:6<787::AID-JNR6>3.0.CO;2-#; GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; IRWIN RP, 1994, J PHARMACOL EXP THER, V271, P677; Joo CK, 1999, INVEST OPHTH VIS SCI, V40, P713; Keller JN, 1998, J NEUROSCI, V18, P687; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kristal BS, 1996, J BIOL CHEM, V271, P6033, DOI 10.1074/jbc.271.11.6033; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; Lam TT, 1999, INVEST OPHTH VIS SCI, V40, P2391; Leist M, 1997, MOL MED, V3, P750, DOI 10.1007/BF03401713; LI PK, 1995, COGNITIVE BRAIN RES, V2, P251, DOI 10.1016/0926-6410(95)90016-0; Lipton SA, 1998, NEUROSCIENTIST, V4, P345, DOI 10.1177/107385849800400516; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lu YM, 1996, J NEUROSCI, V16, P5457; MAIONE S, 1992, EUR J PHARMACOL, V219, P477, DOI 10.1016/0014-2999(92)90493-N; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; MANEV H, 1989, MOL PHARMACOL, V36, P106; Mark RJ, 1997, J NEUROCHEM, V68, P255; MATHIS C, 1994, PSYCHOPHARMACOLOGY, V116, P201, DOI 10.1007/BF02245063; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; Maurice T, 1997, EUR J PHARMACOL, V328, P9, DOI 10.1016/S0014-2999(97)83020-8; Maurice T, 1997, BEHAV BRAIN RES, V83, P159, DOI 10.1016/S0166-4328(97)86061-5; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Morrison RS, 1998, MENT RETARD DEV D R, V4, P157; MOSINGER JL, 1989, EXP NEUROL, V105, P110, DOI 10.1016/0014-4886(89)90178-7; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; OSTEEN WK, 1977, EXP EYE RES, V25, P361, DOI 10.1016/0014-4835(77)90103-8; Pang Z, 1997, J NEUROSCI, V17, P3064; PAOLETTI F, 1990, METHOD ENZYMOL, V186, P209; Park-Chung M, 1997, MOL PHARMACOL, V52, P1113, DOI 10.1124/mol.52.6.1113; PARKCHUNG MJ, 1994, MOL PHARMACOL, V46, P146; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; REGO AC, 1995, ARCH BIOCHEM BIOPHYS, V321, P127, DOI 10.1006/abbi.1995.1377; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; RINK A, 1995, AM J PATHOL, V147, P1575; Rosenbaum DM, 1998, INVEST OPHTH VIS SCI, V39, P2132; Rosenbaum PS, 1997, CLIN NEUROSCI, V4, P224; Sapolsky, 1996, Stress, V1, P1, DOI 10.3109/10253899609001092; Singer CA, 1996, NEUROSCI LETT, V212, P13, DOI 10.1016/0304-3940(96)12760-9; Vallee M, 1997, P NATL ACAD SCI USA, V94, P14865, DOI 10.1073/pnas.94.26.14865; Weaver CE, 1997, P NATL ACAD SCI USA, V94, P10450, DOI 10.1073/pnas.94.19.10450; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YOON YH, 1989, ARCH OPHTHALMOL-CHIC, V107, P409, DOI 10.1001/archopht.1989.01070010419037; Zeevalk GD, 1996, J PHARMACOL EXP THER, V279, P332	80	25	25	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2000	74	6					2380	2391		10.1046/j.1471-4159.2000.0742380.x			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	312XG	WOS:000086968800018	10820199				2022-02-06	
J	Furukawa, Y; Okada, M; Akaike, N; Hayashi, T; Nabekura, J				Furukawa, Y; Okada, M; Akaike, N; Hayashi, T; Nabekura, J			Reduction of voltage-dependent magnesium block of N-methyl-D-aspartate receptor-mediated current by in vivo axonal injury	NEUROSCIENCE			English	Article						in vivo; axonal injury; NMDA; voltage-dependent Mg2+ block; motoneuron; time-course	PROTEIN-KINASE-C; NMDA-RECEPTOR; SENSORY NEURONS; GLUTAMATE NEUROTOXICITY; COLCHICINE APPLICATION; APLYSIA NEURONS; BRAIN INJURY; CELL-CULTURE; MG2+ BLOCK; SUBUNIT	The post-traumatic change of the voltage-dependent Mg2+ block of N-methyl-D-aspartate response was investigated using nystatin perforated patch recording mode under the voltage-clamp condition. Motor neurons of the dorsal motor nucleus of vagus nerve were freshly dissociated from rat brain at 2 h to 10 days after receiving axonal crush injuries in vivo at the neck. The reduction of voltage-dependent Mg2+ block of N-methyl-D-aspartate response became evident at more than 12 h after the injury, sustained for at least five days and recovered within 10 days. Other characteristics examined such as reversal potentials, the Hill coefficient and EC50 of N-methyl-D-aspartate-induced current were not affected by axonal injury. The Mg2+ block of N-methyl-D-aspartate response was not affected at all by local application of colchicine onto the vagal axon in in vivo condition, suggesting that axonal injury, but not the blockade of the axonal flow, is responsible for the change of the sensitivity of N-methyl-D-aspartate response to extracellular Mg2+. In addition, the reduction of Mg2+ block by the nerve injury persisted regardless of the presence of protein kinase C modulators, such as 10(-6) M chelerythrine and 10(-7) M calphostin C, Therefore alteration of protein kinase C activity after axonal injury is not responsible for the maintenance of the reduced Mg2+ block. These findings suggest that injured neurons acquire immature characteristics of plasticity with respect to the sensitivity of N-methyl-D-aspartate receptors to extracellular Mg2+ or a long-term increase in the susceptibility to Ca2+ excitotoxicity. (C) 2000 IBRO. Published by Elsevier Science Ltd.	Kyushu Univ, Grad Sch Med Sci, Dept Cellular & Syst Physiol, Fukuoka 8128582, Japan; Univ Tokyo, Fac Med, Brain Res Inst, Dept Neurophysiol, Tokyo 1130033, Japan; St Marys Hosp, Dept Neurosurg, Fukuoka 8308543, Japan		Nabekura, J (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Cellular & Syst Physiol, Fukuoka 8128582, Japan.		Okada, Masayoshi/ABE-9020-2020	Okada, Masayoshi/0000-0001-8515-7143			AKAIKE N, 1994, JPN J PHYSIOL, V44, P433, DOI 10.2170/jjphysiol.44.433; AMBRON RT, 1995, J NEUROSCI, V15, P3440; Ambron RT, 1996, J NEUROSCI, V16, P7469; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; Burne JF, 1997, NEURON, V18, P223, DOI 10.1016/S0896-6273(00)80263-9; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GUNSTREAM JD, 1995, J NEUROSCI, V15, P439; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; ISHII T, 1993, J BIOL CHEM, V268, P2836; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kuner T, 1996, J NEUROSCI, V16, P3549; Levey MS, 1996, J NEUROSCI, V16, P6878; LUSTIG HS, 1992, NEUROSCI LETT, V143, P229, DOI 10.1016/0304-3940(92)90271-8; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MURPHY TH, 1994, J NEUROSCI, V14, P1320, DOI 10.1523/JNEUROSCI.14-03-01320.1994; Nabekura J, 1996, J NEUROPHYSIOL, V76, P2455, DOI 10.1152/jn.1996.76.4.2455; NABEKURA J, 1994, BRAIN RES, V648, P152, DOI 10.1016/0006-8993(94)91915-1; PIEHL F, 1995, EUR J NEUROSCI, V7, P2101, DOI 10.1111/j.1460-9568.1995.tb00632.x; PILAR G, 1972, SCIENCE, V177, P1116, DOI 10.1126/science.177.4054.1116; REGAN RF, 1991, NEUROSCIENCE, V43, P585, DOI 10.1016/0306-4522(91)90317-H; Rosenberg M, 1997, J NEUROSCI, V17, P6629; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SIMAN R, 1989, J NEUROSCI, V9, P1579; Tandon A, 1996, J NEUROCHEM, V66, P1033; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WAXMAN SG, 1994, J NEUROPHYSIOL, V72, P466, DOI 10.1152/jn.1994.72.1.466; WU W, 1993, DEV BIOL, V158, P456, DOI 10.1006/dbio.1993.1203; Xu TL, 1996, J PHYSIOL-LONDON, V496, P491, DOI 10.1113/jphysiol.1996.sp021701; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; Yu XM, 1998, NATURE, V396, P469, DOI 10.1038/24877; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	42	25	26	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	96	2					385	392		10.1016/S0306-4522(99)00553-9			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	289JT	WOS:000085618000015	10683578				2022-02-06	
J	Rothoerl, RD; Brawanski, A; Woertgen, C				Rothoerl, RD; Brawanski, A; Woertgen, C			S-100B protein serum levels after controlled cortical impact injury in the rat	ACTA NEUROCHIRURGICA			English	Article						S-100B; traumatic brain injury; rat		S-100B is described to provide information about the severity of brain damage in man. Estimation of serum markers appears to be an easy method of obtaining information regarding severity and outcome after head injury. However less is known about the post traumatic time course of this protein in the serum. The aim of this study was to provide further information about the posttraumatic enzymekinetik. 65 male Wistar rats were subjected to severe cortical impact injury (100 PSI, 2 mm deformation). Blood samples were drawn directly after trauma, then after 1 h, 6 h, 12 h, 24 h, and 48 h. In sham operated animals blood samples were drawn directly after craniotomy, then after 6 h and after 48 h. Also compared were S-100B serum levels at different severities in 20 rats (45 PSI, 75 PSI; 2 mm deformity) after controlled cortical impact to sham operated animals. S-100B serum levels were estimated with a commercially available enzyme immune-assay (DAKO(R)). The mean serum level in the sham group was 0,38 mu g/l. Serum levels at 100 PSI differed statistically significantly directly after trauma up to 24 h. The 48 h S-100B levels showed no significant difference in the sham group. Serum levels at different severities differed significantly from the sham group, but did not differ concerning level of severity. The controlled cortical impact model is able to produce a raised serum level of the S-100B protein for 24 hours. Different trauma severities were not reflected.	Univ Regensburg, Dept Neurosurg, D-93053 Regensburg, Germany		Rothoerl, RD (corresponding author), Univ Regensburg, Dept Neurosurg, Franz Josef Str Allee 11, D-93053 Regensburg, Germany.						Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1997, NEUROTRAUMA; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HARDEMARK HG, 1989, ACTA NEUROCHIR, V99, P135, DOI 10.1007/BF01402322; HARDEMARK HG, 1989, J NEUROSURG, V71, P727, DOI 10.3171/jns.1989.71.5.0727; HIDAKA H, 1983, J BIOL CHEM, V258, P2705; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; KATO K, 1985, BIOCHIM BIOPHYS ACTA, V842, P146, DOI 10.1016/0304-4165(85)90196-5; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1991, J NEUROSURG, V75, pS15; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Rothoerl RD, 1999, BRAIN INJURY, V13, P387; SEMBA R, 1987, BRAIN RES, V401, P9, DOI 10.1016/0006-8993(87)91156-5; STEFANSSON K, 1982, AM J PATHOL, V106, P261; STEFANSSON K, 1982, NATURE, V295, P63, DOI 10.1038/295063a0; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	31	25	29	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2000	142	2					199	203		10.1007/s007010050024			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	288UP	WOS:000085583100022	10795895				2022-02-06	
J	Sherrill-Pattison, S; Donders, J; Thompson, E				Sherrill-Pattison, S; Donders, J; Thompson, E			Influence of demographic variables on neuropsychological test performance after traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							CLOSED-HEAD INJURY; COMPREHENSIVE NORMS; CLINICAL UTILITY; EDUCATION; AGE; RECOVERY; REITAN	The validity of correcting for demographic variables when considering neuropsychological test scores was evaluated in a sample of 136 patients with traumatic brain injury (TBI) who had been screened carefully for premorbid or comorbid confounding factors. When considered in concert with neurological variables, age and education accounted for a significant proportion of the variance in raw scores on the Category Test and the Trail Making Test in the complete sample. Gender did not affect level of test performance. Correcting neuropsychological test scores for demographic variables did not significantly alter their success in identifying patients with severe TBI, but did lead to greater accuracy when classifying individuals with mild-moderate TBI. This investigation concluded that norms that consider the demographic background of the individual are likely to reflect more accurately the neuropsychological status of patients with TBI than interpretations that are based exclusively on raw data.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; Adler Sch Profess Psychol, Chicago, IL USA		Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BORNSTEIN RA, 1988, DEV NEUROPSYCHOL, V4, P17, DOI 10.1080/87565648809540386; Crawford JR, 1997, CLIN NEUROPSYCHOL, V11, P345, DOI 10.1080/13854049708400463; DEFILIPPIS NA, 1987, BOOKLET CATEGORY TES; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Fastenau PS, 1996, J CLIN EXP NEUROPSYC, V18, P444; Fastenau PS, 1998, J CLIN EXP NEUROPSYC, V20, P906, DOI 10.1076/jcen.20.6.906.1104; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Heaton RK, 1996, J CLIN EXP NEUROPSYC, V18, P449, DOI 10.1080/01688639608409001; Heaton RK, 1991, COMPREHENSIVE NORMS; Heaton RK, 1996, NEUROPSYCHOLOGICAL A, P141; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LECKLITER IN, 1989, J CLIN PSYCHOL, V45, P484, DOI 10.1002/1097-4679(198907)45:4<484::AID-JCLP2270450402>3.0.CO;2-L; MARTIN TA, IN PRESS REHABILITAT; Moses JA, 1999, ARCH CLIN NEUROPSYCH, V14, P445, DOI 10.1016/S0887-6177(98)00030-4; Reitan R M, 1997, Appl Neuropsychol, V4, P16, DOI 10.1207/s15324826an0401_3; Reitan R.M., 1993, HALSTEADREITAN NEURO; REITAN RM, 1995, CLIN NEUROPSYCHOL, V9, P151, DOI 10.1080/13854049508401597; ShuttleworthJordan AB, 1997, CLIN NEUROPSYCHOL, V11, P205, DOI 10.1080/13854049708407053; TEASDALE G, 1974, LANCET, V2, P81; Vanderploeg RD, 1997, CLIN NEUROPSYCHOL, V11, P210, DOI 10.1080/13854049708407054; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wiegner S, 1999, J CLIN EXP NEUROPSYC, V21, P159, DOI 10.1076/jcen.21.2.159.925; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205	30	25	25	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2000	14	4					496	503		10.1076/clin.14.4.496.7196			8	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	398CD	WOS:000166737600006	11262719				2022-02-06	
J	Westergren, H; Farooque, M; Olsson, Y; Holtz, A				Westergren, H; Farooque, M; Olsson, Y; Holtz, A			Motor function changes in the rat following severe spinal cord injury - Does treatment with moderate systemic hypothermia improve functional outcome?	ACTA NEUROCHIRURGICA			English	Article						hypothermia; rat; spinal cord injury; treatment	TRAUMATIC BRAIN INJURY; COMPRESSION INJURY; NEUROLOGICAL RECOVERY; BEHAVIORAL DEFICITS; CORTICAL IMPACT; TEMPERATURE; PROTECTION; IMMUNOHISTOCHEMISTRY; MANAGEMENT; CONTUSION	Systemic hypothermia exerts neuroprotective effects following trauma and ischemia caused by vascular occlusion in the brain. In the spinal cord similar effects have been demonstrated following ischemia after aortic occlusion. We have previously presented protective effects on several morphological parameters in the early period after the injury, using an established spinal cord compression injury model and systemic hypothermia. In the present study we have evaluated the effects on motor function following severe spinal cord compression trauma and treatment with moderate systemic hypothermia. Thirty Sprague Dawley rats were randomized into three groups: In group 1 (n = 4), the animals underwent a hypothermic procedure, including a 2 h hypothermic period with a body temperature of 30 degrees C, following the initial laminectomy. In group 2 (n = 12) a 50 g compression was applied to the spinal cords for 5 min, after which the animals were kept under normothermic anesthesia for 3 h. In group 3 (n = 14), the animals underwent the same trauma procedure as in group 2 and the same hypothermic procedure as in group 1. The animals were allowed to survive for 14 days, during which the motor function was recorded. This degree of trauma results in a non-reversible paraplegia, and the addition of systemic hypothermia as described above did not alter the neurological recovery as measured by two different methods of recording the motor function up to two weeks after injury. All animals survived in group 1. However, the mortality rates in group 2 were 25% and in group 3, 50%, respectively, which mirrors the severity of the trauma. The application of systemic hypothermia and the lack of experimental therapeutic success highlight the difficulties of transferring experimental beneficial neuroprotective effects to a clinically useful treatment method. In this experimental set-up the effects of the severe primary injury may overshadow the effects of the secondary injury mechanisms, which limits the therapeutic possibilities of systemic hypothermic treatment.	Univ Uppsala Hosp, Dept Neurosurg, Neurosurg Sect, S-75185 Uppsala, Sweden; Univ Uppsala Hosp, Res Grp Neuropathol, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Genet & Pathol, Uppsala, Sweden		Westergren, H (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, Neurosurg Sect, S-75185 Uppsala, Sweden.			Westergren, Hans/0000-0002-4052-9692			ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; BERNTMAN L, 1981, ANESTHESIOLOGY, V55, P495, DOI 10.1097/00000542-198111000-00003; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; Farooque M, 1999, ACTA NEUROPATHOL, V98, P22, DOI 10.1007/s004010051047; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GUTTMANN L, 1973, SPINAL CORD INJURIES, P135; HANSEBOUT RR, 1992, SPINAL CORD DYSFUNCT, P59; HOLTZ A, 1989, SURG NEUROL, V31, P350, DOI 10.1016/0090-3019(89)90066-9; Holtz Anders, 1995, Upsala Journal of Medical Sciences, V100, P93; LEVI R, 1996, THESIS KAROLINSKA I; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; LI GL, 1997, SPINAL CORD COMPRESS, P683; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARTINEZARIZALA A, 1992, J NEUROTRAUM, V9, pS497; MAUNEY MC, 1995, ANN THORAC SURG, V59, P245, DOI 10.1016/0003-4975(94)00815-O; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P467, DOI 10.1111/j.1600-0404.1988.tb03689.x; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; SALZMAN S, 1994, NEUROBIOLOGY CENTRAL, P123; TATOR C, 1999, NEUROSURG FOCUS, V6, P1; TATOR CH, 1995, PARAPLEGIA, V33, P254, DOI 10.1038/sc.1995.58; Tator CH, 1998, NEUROSURGERY, V42, P696, DOI 10.1097/00006123-199804000-00007; TATOR CH, 1973, J NEUROSURG, V39, P52, DOI 10.3171/jns.1973.39.1.0052; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TATOR CH, 1979, NEURAL TRAUMA, P363; TOSCANO J, 1988, PARAPLEGIA, V26, P143, DOI 10.1038/sc.1988.23; Westergren H, 1999, SPINAL CORD, V37, P696, DOI 10.1038/sj.sc.3100920; Westergren H, 1998, J NEUROTRAUM, V15, P943, DOI 10.1089/neu.1998.15.943; Yu WR, 1999, ACTA NEUROPATHOL, V98, P15, DOI 10.1007/s004010051046; Yu WR, 1999, NEUROPATHOLOGY, V19, P172, DOI 10.1046/j.1440-1789.1999.00227.x	37	25	26	0	2	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		2000	142	5					567	573		10.1007/s007010050471			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	338YV	WOS:000088451600020	10898365				2022-02-06	
J	Olby, NJ; Sharp, NJH; Munana, KR; Papich, MG				Olby, NJ; Sharp, NJH; Munana, KR; Papich, MG			Chronic and acute compressive spinal cord lesions in dogs due to intervertebral disc herniation are associated with elevation in lumbar cerebrospinal fluid glutamate concentration	JOURNAL OF NEUROTRAUMA			English	Article						cerebrospinal fluid; dog; excitotoxicity; glutamate; spinal-cord compression; spinal cord injury	EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN INJURY; BLOOD-FLOW; LIQUID-CHROMATOGRAPHY; CSF GLUTAMATE; CELL-CULTURE; RELEASE; DISEASE; RAT; MICRODIALYSIS	Acute injury to the central nervous system initiates a series of biochemical events that cause secondary tissue damage. The accumulation of excessive concentrations of glutamate in the extracellular space causes excitotoxic damage, and is incriminated as a mediator of this secondary tissue damage, The aim of this study was to measure the concentration of glutamate in cerebrospinal fluid (CSF) obtained from the cerebellomedullary cistern and lumbar subarachnoid space in dogs with acute and chronic compressive injuries of the cervical and thoracolumbar spinal cord, and to correlate the glutamate concentration with injury severity. The results demonstrate that focal injuries of the spinal cord do not affect the glutamate concentration in CSF taken from the cerebellomedullary cistern, However, dogs with severe, acute thoracolumbar disc herniations have two- to 10-fold increases in glutamate concentration in their lumbar CSF at intervals of >12 h after injury, Moreover, the severity of their clinical signs is directly related to the glutamate concentration. Dogs with chronic compressive thoracolumbar lesions have a two-fold elevation of CSF glutamate concentration, suggesting that excitotoxicity may also be a component of chronic spinal cord compression.	N Carolina State Univ, Coll Vet Med, Dept Compan Anim & Special Species, Raleigh, NC 27606 USA; N Carolina State Univ, Coll Vet Med, Dept Anat Physiol Sci & Radiol, Raleigh, NC 27606 USA		Olby, NJ (corresponding author), N Carolina State Univ, Coll Vet Med, Dept Compan Anim & Special Species, 4700 Hillsborough St, Raleigh, NC 27606 USA.			Munana, Karen/0000-0001-9592-6276; Papich, Mark/0000-0002-7591-7898; Olby, Natasha/0000-0003-1349-3484			AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; BAILEY CS, 1985, AM J VET RES, V46, P1162; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BONDOLI A, 1981, RESUSCITATION, V9, P119, DOI 10.1016/0300-9572(81)90021-6; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; BUCHAN AM, 1992, BRAIN RES, V574, P171, DOI 10.1016/0006-8993(92)90814-P; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BUNGE RP, 1993, ADV NEUROL, V59, P75; CHAMBERLAIN MC, 1995, J NEURO-ONCOL, V25, P135, DOI 10.1007/BF01057757; CHOI DW, 1987, J NEUROSCI, V7, P357; DAVSON H, 1967, PHYSL CEREBROSPINAL; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; FERNSTROM MH, 1981, LIFE SCI, V29, P2119, DOI 10.1016/0024-3205(81)90669-X; Fillenz M, 1995, BEHAV BRAIN RES, V71, P51, DOI 10.1016/0166-4328(95)00045-3; GRIFFITHS IR, 1978, NEUROLOGY, V28, P1145, DOI 10.1212/WNL.28.11.1145; HANSEN H J, 1952, Acta Orthop Scand Suppl, V11, P1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; Matsumoto K, 1996, J CEREBR BLOOD F MET, V16, P114, DOI 10.1097/00004647-199601000-00014; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; OLBY NJ, 1994, J SMALL ANIM PRACT, V35, P345, DOI 10.1111/j.1748-5827.1994.tb01713.x; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; PENCALET P, 1993, J NEUROSURG, V78, P603, DOI 10.3171/jns.1993.78.4.0603; Podell M, 1997, AM J VET RES, V58, P451; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; SARWAR G, 1988, J ASSOC OFF ANA CHEM, V71, P1172; SHAW PJ, 1995, NEURODEGENERATION, V4, P209, DOI 10.1006/neur.1995.0026; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; Spranger M, 1996, ARCH NEUROL-CHICAGO, V53, P992, DOI 10.1001/archneur.1996.00550100066016; SUGIYAMA K, 1989, NEUROSCIENCE, V32, P779, DOI 10.1016/0306-4522(89)90298-4; THOMSON CE, 1990, J AM VET MED ASSOC, V196, P1841; THOMSON CE, 1989, J SMALL ANIM PRACT, V30, P685, DOI 10.1111/j.1748-5827.1989.tb01917.x; Wheeler S.J., 1994, SMALL ANIMAL SPINAL, V2nd; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Yamamoto K, 1998, NEUROREPORT, V9, P1655, DOI 10.1097/00001756-199805110-00072	41	25	27	0	6	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1999	16	12					1215	1224		10.1089/neu.1999.16.1215			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	266WC	WOS:000084322400008	10619199				2022-02-06	
J	Gilad, GM; Gilad, VH				Gilad, GM; Gilad, VH			Novel polyamine derivatives as neuroprotective agents	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							ORNITHINE DECARBOXYLASE ACTIVITY; SYMPATHETIC NEURONS; AXONAL INJURY; CEREBRAL-ISCHEMIA; RAT; BRAIN; REGENERATION; FOREBRAIN; SURVIVAL; DAMAGE	The induction of an early increase in polyamine metabolism, termed "the polyamine response," is now recognized to have a critical role in the reaction of neurons to injury. Several studies in experimental animals have demonstrated that treatment with the naturally occurring polyamines spermine, spermidine, and putrescine can protect neurons from dying after the infliction of various types of neurotrauma, including mechanical injuries, neurotoxic insults, and ischemia. These findings led us to synthesize a series of polyamine derivatives of 1-aminoindan and 1-aminotetralin and to determine their effects in several in vitro and in vivo models of neurotrauma. Some of the novel compounds proved to be potent neuroprotective in these models, and one of them, N,N-di-(4-aminobutyl)-1-aminoindan, was superior to the others and to the natural polyamines themselves. We conclude that compounds based on the novel polyamine-based structures we synthesized have therapeutic potential as neuroprotective agents.	Assaf Harofeh Med Ctr, Neurosci Lab, IL-70300 Zerifin, Israel		Gilad, GM (corresponding author), Assaf Harofeh Med Ctr, Neurosci Lab, PO Beer Yaakov, IL-70300 Zerifin, Israel.		Gilad, Gad M/E-7193-2010				Abe K, 1997, BRAIN RES, V766, P281, DOI 10.1016/S0006-8993(97)00750-6; DESIDERIO MA, 1988, J NEUROCHEM, V51, P25, DOI 10.1111/j.1471-4159.1988.tb04830.x; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; GILAD GM, 1983, EXP NEUROL, V81, P158, DOI 10.1016/0014-4886(83)90165-6; GILAD GM, 1983, BRAIN RES, V273, P191, DOI 10.1016/0006-8993(83)91113-7; GILAD GM, 1988, DEV BRAIN RES, V38, P175, DOI 10.1016/0165-3806(88)90042-9; GILAD GM, 1989, LIFE SCI, V44, P1963, DOI 10.1016/0024-3205(89)90409-8; GILAD GM, 1989, INT J DEV NEUROSCI, V7, P641, DOI 10.1016/0736-5748(89)90023-3; GILAD GM, 1992, BIOCHEM PHARMACOL, V44, P401, DOI 10.1016/0006-2952(92)90428-L; GILAD GM, 1991, EXP NEUROL, V111, P349, DOI 10.1016/0014-4886(91)90102-I; GILAD GM, 1993, MOL CHEM NEUROPATHOL, V18, P197, DOI 10.1007/BF03160034; GILAD GM, 1989, BRAIN RES, V508, P215; GILAD GM, 1995, LIFE SCI, V85, pPL41; GILAD GM, 1997, Patent No. 5646188; GILAD GM, 1983, NERVOUS SYSTEM REGEN, P437; Grafstein B, 1978, NEURONAL PLASTICITY, P155; HALL ED, 1987, CNS TRAUMA, V3, P281; HARA H, 1993, PROG NEUROBIOL, V40, P645, DOI 10.1016/0301-0082(93)90009-H; KANJE M, 1986, BRAIN RES, V381, P24, DOI 10.1016/0006-8993(86)90685-2; Lieberman A R, 1971, Int Rev Neurobiol, V14, P49, DOI 10.1016/S0074-7742(08)60183-X; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; MELDRUM BS, 1985, CALCIUM ENTRY BLOCKE, P183; NORDSTROM CH, 1978, STROKE, V9, P335, DOI 10.1161/01.STR.9.4.335; PASCHEN W, 1988, NEUROCHEM PATHOL, V9, P1; PRESTON E, 1993, NEUROSCI LETT, V149, P75, DOI 10.1016/0304-3940(93)90351-K; SABRI MI, 1988, AM SOC NEUR ABSTR, V19, P89; SEILER N, 1990, INT J BIOCHEM, V22, P211, DOI 10.1016/0020-711X(90)90332-W; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TETZLAFF W, 1985, EXP NEUROL, V89, P679, DOI 10.1016/0014-4886(85)90016-0; TETZLAFF W, 1986, PROCESSES RECOVERY N, P3	30	25	26	0	4	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	OCT	1999	291	1					39	43					5	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	238QK	WOS:000082721100006	10490884				2022-02-06	
J	Fontani, G; Maffei, D; Cameli, S; Polidori, P				Fontani, G; Maffei, D; Cameli, S; Polidori, P			Reactivity and event-related potentials during attentional tests in athletes	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY AND OCCUPATIONAL PHYSIOLOGY			English	Article						event-related potentials; CNV; P3; reaction time; athletes	ELICITED P300-COMPLEX PF-P300; CONTINGENT NEGATIVE-VARIATION; CLOSED HEAD-INJURY; MENTAL CHRONOMETRY; EVOKED-POTENTIALS; VISUAL-ATTENTION; BRAIN POTENTIALS; REACTION-TIME; P300; PSYCHOPHYSIOLOGY	A series of attentional tests involving reaction times (RTs) was administered to 12 high-level young (age 17-18 years) volleyball players. During the tests, event-related potentials were recorded by electroencephalogram. In a simple reaction-time test (SRT), the subjects had to respond to a letter that appeared on a white screen. Other tests (attentional shifting tests) consisted of a go/no-go reaction time and a choice reaction time (CRT), divided into a short-latency CRT and a long-latency CRT. In the pre-stimulus period of these tests, there is a shift from broad attention to selective attention, represented by a crowding of black points on the computer screen, followed by the appearance of a letter in the centre of the crowding. The results show that RT increased from SRT to CRT. In the attentional shifting tests, averaged waves of event-related potentials showed a contingent-negative-variation-like wave that was closely related to selective attention (selective attention wave, SAW) before the onset of the stimulus. After the stimulus, a P3 complex was recorded. Correlations were found between the SAW amplitude and P3 latency and amplitude, and between these parameters and RT and its variability. Higher SAW and P3 amplitudes were accompanied by a shorter RT and a lower variability. The characteristics and the correlations that exist between the various parameters are consistent with a possible use of these tests in the analysis of the attentional styles of athletes, and in the evaluation of their progress with training.	Univ Siena, Ist Fisiol Umana, I-53100 Siena, Italy; Catholic Univ Rome, Ctr Med Sport, Rome, Italy; Federaz Italiana Pallavolo, Comitato Olimp Nazl Italiano, Rome, Italy		Fontani, G (corresponding author), Univ Siena, Ist Fisiol Umana, Via A Moro, I-53100 Siena, Italy.						Allport D. A., 1992, ATTENTION PERFORM, V14, P183; ANZENEDER CP, 1997, SDS RIV CULTURA SPOR, V16, P53; ARITO H, 1990, IND HEALTH, V28, P97, DOI 10.2486/indhealth.28.97; BIRBAUMER N, 1990, PHYSIOL REV, V70, P1, DOI 10.1152/physrev.1990.70.1.1; Buckolz E, 1980, Can J Appl Sport Sci, V5, P146; CASTIELLO U, 1992, INT J SPORT PSYCHOL, V23, P301; CEI A, 1991, MOVIMENTO, V7, P154; COLES MGH, 1989, PSYCHOPHYSIOLOGY, V26, P251, DOI 10.1111/j.1469-8986.1989.tb01916.x; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; DEHOUSSE JP, 1986, RECHERCHES PSYCHOL S, P213; Donald M W, 1980, Prog Brain Res, V54, P615, DOI 10.1016/S0079-6123(08)61681-7; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; DONCHIN E, 1986, PSYCHOPHYSIOLOGY SYS, P702; DUNCANJOHNSON CC, 1981, PSYCHOPHYSIOLOGY, V18, P207; FONTANI G, 1994, FISIOLOGIA PALLAVOLO; GLINER JA, 1979, MED SCI SPORT EXER, V11, P155; HALGREN E, 1980, SCIENCE, V210, P803, DOI 10.1126/science.7434000; HILLYARD SA, 1967, ELECTROEN CLIN NEURO, V22, P297, DOI 10.1016/0013-4694(67)90199-X; HORST RL, 1980, MEM COGNITION, V8, P476, DOI 10.3758/BF03211144; Hull C. L., 1951, ESSENTIALS BEHAV; Kolev V, 1997, NEUROREPORT, V8, P2061, DOI 10.1097/00001756-199705260-00050; Kugler CFA, 1996, J GERONTOL A-BIOL, V51, pB3, DOI 10.1093/gerona/51A.1.B3; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LOW MD, 1966, PERCEPT MOTOR SKILL, V22, P443, DOI 10.2466/pms.1966.22.2.443; MCCLELLAND JL, 1979, PSYCHOL REV, V86, P287, DOI 10.1037/0033-295X.86.4.287; NAATANEN R, 1975, BIOL PSYCHOL, V2, P237, DOI 10.1016/0301-0511(75)90038-1; NOUGIER V, 1991, INT J SPORT PSYCHOL, V22, P307; NOUGIER V, 1987, RECHERCHES APS, V2, P209; Picton TW, 1988, HDB ELECTROENCEPHALO, V3, P361; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; POLICH J, 1989, BIOMED PHARMACOTHER, V43, P439; POLICH J, 1989, SPRINGER SERIES BRAI, V2, P331; Posner, 1978, CHRONOMETRIC EXPLORA; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; RENAULT B, 1982, SCIENCE, V215, P1413, DOI 10.1126/science.7063853; RIPOLL H, 1988, INT J SPORT PSYCHOL, V19, P9; RITTER W, 1972, ELECTROEN CLIN NEURO, V33, P547, DOI 10.1016/0013-4694(72)90245-3; ROSSI B, 1992, J HUM MOVEMENT STUD, V23, P17; ROSSI B, 1991, INT J SPORT PSYCHOL, V22, P128; RUCHKIN DS, 1975, PSYCHOPHYSIOLOGY, V12, P591, DOI 10.1111/j.1469-8986.1975.tb00052.x; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; SAMAR VJ, 1995, BRAIN COGNITION, V27, P398, DOI 10.1006/brcg.1995.1028; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; SMITH ME, 1990, ELECTROEN CLIN NEURO, V76, P235, DOI 10.1016/0013-4694(90)90018-F; SQUIRES KC, 1976, SCIENCE, V193, P1142, DOI 10.1126/science.959831; STARKES JL, 1983, J SPORT PSYCHOL, V5, P189, DOI 10.1123/jsp.5.2.189; SUTTON S, 1965, SCIENCE, V150, P1187, DOI 10.1126/science.150.3700.1187; TAGHAVY A, 1988, INT J NEUROSCI, V38, P179, DOI 10.3109/00207458809000495; TAGHAVY A, 1988, INT J NEUROSCI, V39, P261, DOI 10.3109/00207458808985713; TECCE JJ, 1972, PSYCHOL BULL, V77, P73, DOI 10.1037/h0032177; TECCE JJ, 1969, SCIENCE, V164, P331, DOI 10.1126/science.164.3877.331; TECCE JJ, 1982, ELECTROENCEPHALOGRAP, P543; TECCE JJ, 1970, ATTENTION CONTEMPORA, P331; TUETING P, 1971, PSYCHOPHYSIOLOGY, V7, P385; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; WALTER W G, 1965, Br J Physiol Opt, V22, P1; WALTER WG, 1964, NATURE, V203, P380, DOI 10.1038/203380a0; WEI JH, 1990, CHINESE SCI BULL, V35, P227; YINGLING CD, 1984, ELECTROEN CLIN NEURO, V59, P72, DOI 10.1016/0168-5597(84)90022-4; ZANI A, 1991, INT J SPORT PSYCHOL, V22, P376; ZANI A, 1990, AIESEP 88 WORLD C HU, P325	61	25	26	0	4	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0301-5548			EUR J APPL PHYSIOL O	Eur. J. Appl. Physiol. Occup. Physiol.	SEP	1999	80	4					308	317		10.1007/s004210050597			10	Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Physiology; Sport Sciences	231FT	WOS:000082298000008	10483800				2022-02-06	
J	Laatsch, L; Pavel, D; Jobe, T; Lin, Q; Quintana, JC				Laatsch, L; Pavel, D; Jobe, T; Lin, Q; Quintana, JC			Incorporation of SPECT imaging in a longitudinal cognitive rehabilitation therapy programme	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; RECOVERY	In this clinical study, five consecutive referrals to a cognitive rehabilitation therapy (CRT) programme were followed in a longitudinal protocol involving a resting SPECT and neuropsychological evaluation at pre-treatment, post-treatment, and post non-treatment intervals. All clients had acquired brain injury and initially demonstrated neuropsychological deficits and various degrees of hypoperfusion on SPECT. Statistical Parametric Mapping (SPM) was used to evaluate change in successive SPECT images. Following CRT, all clients were able to return to productive employment or schooling. Examination of the neuropsychological testing results revealed significant improvement in performance following CRT which were generally maintained during the non-treatment period. SPM analysis of the SPECT data revealed that, in a majority of cases, most of the significant increases in relative cerebral blood flow redistribution were seen during the treatment period, rather than the non-treatment period. The results suggest that, even in individuals who are more than 2 years post-brain damage, relative increases in rCBF can be demonstrated following individualized CRT and that most of these changes can be related to improvements on neuropsychological tests.	Univ Illinois, Coll Med, Chicago, IL 60612 USA		Laatsch, L (corresponding author), Univ Illinois, Coll Med, 901 S Wolcott Ave,Room W-130, Chicago, IL 60612 USA.						BACHYRITA P, 1992, J NEURO REHAB, V6, P191; Bigler ED, 1996, J LEARN DISABIL-US, V29, P515, DOI 10.1177/002221949602900507; BOLGER JF, 1980, CLIN NEUROPSYCHOLOGY, V4, P66; BRACY OE, 1994, SOFT TOOLS COGNITIVE; BROWN L, 1990, TEST NONVERBAL INTEL; CHOCA J, 1993, ADAPTIVE COMPUTERIZE; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; Christensen C K, 1987, J Diabet Complications, V1, P45, DOI 10.1016/S0891-6632(87)80079-X; COSTA DC, 1994, NEW TRENDS NUCL NEUR; DELIS D, 1987, CALIFORNIA VERBAL LE; ELLE P, 1985, LANCET, V2, P50; FIRSTON K, 1995, HUMAN BRAIN MAPPING, V1, P214; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GIANUTSOS R, 1991, Brain Injury, V5, P353, DOI 10.3109/02699059109008108; GIANUTSOS R, 1996, COMPUTER PROGRAMS CO, V7; GOLDEN C, 1978, STROOP TEST; Heaton R.K., 1981, WISCONSIN CARD SORTI; Heaton RK, 1991, COMPREHENSIVE NORMS; Klonoff PS, 1989, J HEAD TRAUMA REHAB, V4, P37; KNOPMAN DS, 1984, ANN NEUROL, V15, P530, DOI 10.1002/ana.410150604; Laatsch L, 1997, BRAIN INJURY, V11, P851; LAATSCH L, 1983, COGNITIVE REHABILITA, V1, P15; LAATSCH L, 1985, COGNITIVE REHABILITA; Luria A. R., 1981, WORKING BRAIN; MEYERS T, 1995, REY COMPLEX FIGURE T; PANTANO P, 1992, INT J NEUROSCI, V66, P153; PARENTE M, 1996, RETRAINING COGNITION; PAVEL D, 1996, RADIOLOGY, P201; PAVEL DG, 1997, J NUCL MED S, V38, P280; Umile EM, 1998, BRAIN INJURY, V12, P577; Wechsler D, 1987, MEMORY SCALE REVISED; WECHSLER D, 1987, WECSHLER ADULT INTEL	32	25	27	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1999	13	8					555	570		10.1080/026990599121304			16	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	239YW	WOS:000082799200001	10901685				2022-02-06	
J	Wilkinson, AE; Bridges, LR; Sivaloganathan, S				Wilkinson, AE; Bridges, LR; Sivaloganathan, S			Correlation of survival time with size of axonal swellings in diffuse axonal injury	ACTA NEUROPATHOLOGICA			English	Article						diffuse axonal injury; head injury; beta-amyloid precursor protein immunohistochemistry; forensic neuropathology	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN INJURY; CLOSED-HEAD INJURY; NEUROFILAMENT SUBUNITS; BETA-APP; DAMAGE; MARKER	Widespread damage to axons in the white matter of the brain is a well-recognised consequence of nonmissile head injury. This diffuse axonal injury is characterised by a gradual swelling of the axon associated with an accumulation of cellular organelles and proteins. We have investigated the relationship between the size of the swellings of the damaged axon with survival time in postmortem brain tissue. Sixty-six cases of head injury with known length of post-traumatic survival were selected for study, and immunohistochemistry for beta-amyloid precursor protein (beta APP) was carried out. The minimum diameter of the beta APP-immunolabelled damaged axons was measured in micrometers using the IBAS image analysis system. There was a strong, positive and significant relationship between the mean size of axonal swelling and survival time which plateaued at around 85 h post injury. With longer survival times the situation becomes more complex. beta APP immunolabelling of damaged axons can contribute evidence about trauma and post-injury survival time in the forensic setting but should always be assessed with other evidence.	Univ Leeds, Sch Med, Gen Infirm, Div Clin Sci Pathol Sci, Leeds LS2 9JT, W Yorkshire, England		Wilkinson, AE (corresponding author), Univ Leeds, Sch Med, Gen Infirm, Div Clin Sci Pathol Sci, Algernon Firth Bldg, Leeds LS2 9JT, W Yorkshire, England.						ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; STRICH SJ, 1961, LANCET, V2, P443; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	17	25	28	0	5	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	AUG	1999	98	2					197	202		10.1007/s004010051069			6	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	220DD	WOS:000081648500012	10442560				2022-02-06	
J	Johns, JS; Cifu, DX; Keyser-Marcus, L; Jolles, PR; Fratkin, MJ				Johns, JS; Cifu, DX; Keyser-Marcus, L; Jolles, PR; Fratkin, MJ			Impact of clinically significant heterotopic ossification on functional outcome after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							SEVERE HEAD-INJURY; BONE-FORMATION; LENGTH; STAY	Objective: To assess heterotopic ossification's (HO) impact on functional outcome after TBI. Design: Retrospective with matched control group, single center. Setting: TBI Model System of Care at the Medical College of Virginia of Virginia Commonwealth University, Richmond, VA. Participants: Twenty-six patients with TBI and triple-phase bone scan confirmed HO were matched with 26 patients without clinical evidence of HO. Main outcome measures: Acute and rehabilitation lengths of stay (LOS), Admission and Discharge Functional Independence Measure (FIM) scores, FIM change, FIM efficiency (FIM gains per week), and discharge disposition. Results: The two groups had similar acute care LOS. Patients with HO had significantly longer inpatient rehabilitation LOS and significantly lower FIM mobility and activities of daily living subscale scores on admission and discharge. FIM efficiency was significantly lower for the group with HO. Significantly fewer patients with HO were able to be discharged to home. Conclusions: HO is associated with a poorer functional outcome; however, it is not clear whether HO causes the decreased function or whether it may serve more generally as an indicator Of those patients who will not progress as far or as rapidly during inpatient rehabilitation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Radiol, Div Nucl Med, Richmond, VA 23298 USA		Cifu, DX (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, POB 980667, Richmond, VA 23298 USA.			Keyser-Marcus, Lori/0000-0001-6014-2500; Cifu, David/0000-0003-1600-9387			AYERS DC, 1986, J BONE JOINT SURG AM, V68A, P1423, DOI 10.2106/00004623-198668090-00016; BUSCHBACHER R, 1992, AM J PHYS MED REHAB, V71, P86, DOI 10.1097/00002060-199204000-00005; CITTAPIETROLUNGO TJ, 1992, ARCH PHYS MED REHAB, V73, P258; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Crawford C M, 1986, J Burn Care Rehabil, V7, P323, DOI 10.1097/00004630-198607000-00005; Englander JS, 1996, J HEAD TRAUMA REHAB, V11, P15, DOI 10.1097/00001199-199610000-00003; FINERMAN GAM, 1981, METAB BONE DIS RELAT, V4, P337; FREED JH, 1982, PARAPLEGIA, V20, P208, DOI 10.1038/sc.1982.39; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; Gennarelli T A, 1988, Brain Inj, V2, P175, DOI 10.3109/02699058809150942; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1994, TOP GERIATR REHABIL, V9, P72; Hamilton BB, 1987, REHABILITATION OUTCO, P137; High WM, 1996, J HEAD TRAUMA REHAB, V11, P85, DOI 10.1097/00001199-199610000-00008; Hossack D W, 1967, Med J Aust, V1, P326; JENNETT B, 1976, LANCET, V1, P1031; JENSEN LL, 1988, AM J PHYS MED, V66, P351; Keith R A, 1987, Adv Clin Rehabil, V1, P6; LAL S, 1989, ARCH PHYS MED REHAB, V70, P387; ORZEL JA, 1985, J NUCL MED, V26, P125; Rogers R C, 1988, Brain Inj, V2, P169, DOI 10.3109/02699058809150941; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120, DOI 10.1302/0301-620X.63B1.7204466; SINGER BR, 1993, BRIT J HOSP MED, V49, P247; SPIELMAN G, 1983, ARCH PHYS MED REHAB, V64, P539; SUZUKI Y, 1974, RADIOLOGY, V111, P663, DOI 10.1148/111.3.663; VARGHESE G, 1992, PHYS MED REH CLIN N, V3, P407; Warren S B, 1990, Orthop Rev, V19, P603; 1995, GUIDE UNIFORM DATA S	29	25	26	0	0	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1999	14	3					269	276		10.1097/00001199-199906000-00007			8	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	203XY	WOS:000080734500007	10381979				2022-02-06	
J	Abrous, DN; Rodriguez, J; le Moal, M; Moser, PC; Barneoud, P				Abrous, DN; Rodriguez, J; le Moal, M; Moser, PC; Barneoud, P			Effects of mild traumatic brain injury on immunoreactivity for the inducible transcription factors c-Fos, c-Jun, JunB, and Krox-24 in cerebral regions associated with conditioned fear responding	BRAIN RESEARCH			English	Article						traumatic brain injury; inducible transcription factor; rat; conditioned freezing response; amygdala; hippocampus	RIGHT PARIETAL CORTEX; POSTTRAUMATIC-STRESS-DISORDER; MEDIAL PREFRONTAL CORTEX; D-ASPARTATE RECEPTORS; NERVOUS-SYSTEM; MESSENGER-RNA; DIFFERENTIAL CONTRIBUTION; BASAL EXPRESSION; FREEZING DEFICIT; CONTEXTUAL CUES	We have previously demonstrated that mild traumatic brain injury (TBI) of the right parietal cortex results in a relatively selective deficit in conditioned fear responding. However, this behavioural deficit is very consistent and unrelated to the extent of the cortical necrotic lesion. We were therefore interested in determining if other brain regions might show a consistent response to mild TBI, and therefore, more reliably relate to the behavioural change. Increased expression of inducible transcription factors (ITFs) has been used to study which brain regions respond to a variety of events. In the present study, we examined the expression patterns of immunoreactivity (IR) for four ITFs (c-Fos, c-Jun, JunB, and Krox-24) at 3 h after mild fluid percussion TBI. Changes in ITF expression were only observed ipsilateral to the side of TBI. The dearest changes were observed in brain regions known to be involved in conditioned fear responding, such as the amygdala complex and hippocampal formation and several cortical regions. In contrast, no changes in IR for any of the ITFs were observed in the striatum, nucleus accumbens, nucleus basalis magnocellularis, septum or periacqueductal grey. Unlike the extent of visible damage to the cortex at the site of impact, the overexpression of ITFs showed a notable consistency between animals subjected to TBI, This consistency in regions known to be involved in conditioned fear responding (i.e,, amygdala complex and hippocampal formation) lead us to suggest that it is these changes, rather than the more variable cortical necrotic lesion, that is responsible for the behavioural deficits we observe following mild TBI. Importantly, our results demonstrate that like the hippocampus, the amygdala is a sub-cortical structure particularly sensitive to the effects of mild brain trauma and underline the fact that cerebral regions distant from the location of the fluid impact can be affected. (C) 1999 Published by Elsevier Science B.V. All rights reserved.	Synthelabo Rech, Cent Nervous Syst Res Dept, F-92500 Rueil Malmaison, France; INSERM, U259, F-33077 Bordeaux, France		Barneoud, P (corresponding author), Synthelabo Rech, Cent Nervous Syst Res Dept, 31 Ave PV Couturier,BP110, F-92225 Bagneux, France.		LE MOAL, Michel/B-5125-2008; Abrous, Nora-Djoher/N-6977-2017	Moser, Paul/0000-0002-6887-3508; abrous, nora/0000-0002-8589-305X			ARMONY JL, 1995, BEHAV NEUROSCI, V109, P246, DOI 10.1037/0735-7044.109.2.246; Armony JL, 1997, TRENDS COGN SCI, V1, P28, DOI 10.1016/S1364-6613(97)01007-3; Beckmann AM, 1997, NEUROCHEM INT, V31, P477, DOI 10.1016/S0197-0186(96)00136-2; BRENNAN PA, 1992, NEUROSCIENCE, V49, P2277; CORODIMAS KP, 1995, BEHAV NEUROSCI, V109, P613, DOI 10.1037/0735-7044.109.4.613; Dave JR, 1997, NEUROREPORT, V8, P395, DOI 10.1097/00001756-199701200-00002; Davis M, 1997, ANN NY ACAD SCI, V821, P305, DOI 10.1111/j.1749-6632.1997.tb48289.x; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; DAVIS M, 1994, INT REV NEUROBIOL, V36, P225, DOI 10.1016/S0074-7742(08)60305-0; Desjardins S, 1997, NEUROBIOL AGING, V18, P37, DOI 10.1016/S0197-4580(96)00206-0; DRAGUNOW M, 1995, BRAIN RES REV, V21, P1, DOI 10.1016/0165-0173(95)00003-L; DRAGUNOW M, 1990, BRAIN RES, V527, P41, DOI 10.1016/0006-8993(90)91058-O; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; DRAGUNOW M, 1993, INT J DEV NEUROSCI, V11, P249, DOI 10.1016/0736-5748(93)90083-P; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; FANSELOW MS, 1994, PSYCHON B REV, V1, P429, DOI 10.3758/BF03210947; Ferrer I, 1997, NEUROREPORT, V8, P2483, DOI 10.1097/00001756-199707280-00014; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Frysztak RJ, 1991, CEREB CORTEX, V1, P418, DOI 10.1093/cercor/1.5.418; GASS P, 1992, NEUROSCIENCE, V48, P315, DOI 10.1016/0306-4522(92)90493-L; Grillon C, 1996, MOL PSYCHIATR, V1, P278; HAMM RJ, 1995, J NEUROTRAUM, V12, P307, DOI 10.1089/neu.1995.12.307; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; HERDEGEN T, 1993, J COMP NEUROL, V333, P271, DOI 10.1002/cne.903330212; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; HERRERA DG, 1990, NEUROSCIENCE, V35, P273, DOI 10.1016/0306-4522(90)90081-E; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Hogg S, 1998, J NEUROTRAUM, V15, P545, DOI 10.1089/neu.1998.15.545; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HUGHES P, 1993, NEUROSCIENCE, V57, P319, DOI 10.1016/0306-4522(93)90065-N; HUGHES P, 1995, PHARMACOL REV, V47, P133; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Killcross S, 1997, NATURE, V388, P377, DOI 10.1038/41097; LaBar KS, 1996, BEHAV NEUROSCI, V110, P991, DOI 10.1037/0735-7044.110.5.991; LORENZINI CA, 1991, PHYSIOL BEHAV, V49, P765, DOI 10.1016/0031-9384(91)90316-G; Maren S, 1996, BEHAV NEUROSCI, V110, P718, DOI 10.1037/0735-7044.110.4.718; Matsuoka N, 1996, J PHARMACOL EXP THER, V278, P891; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MICHAEL DB, 1995, J NEUROTRAUM, V12, P991; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN MA, 1993, NEUROSCI LETT, V163, P109, DOI 10.1016/0304-3940(93)90241-C; MORGAN MA, 1995, BEHAV NEUROSCI, V109, P681, DOI 10.1037/0735-7044.109.4.681; Muller J, 1997, BEHAV NEUROSCI, V111, P683, DOI 10.1037/0735-7044.111.4.683; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PHILLIPS RG, 1995, J NEUROSCI, V15, P5308; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Riedel G, 1997, NEUROREPORT, V8, P2477, DOI 10.1097/00001756-199707280-00013; SELDEN NRW, 1991, NEUROSCIENCE, V42, P335, DOI 10.1016/0306-4522(91)90379-3; Shin LM, 1997, ARCH GEN PSYCHIAT, V54, P233; Tang YP, 1997, J CEREBR BLOOD F MET, V17, P771; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	59	25	29	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 1	1999	826	2					181	192		10.1016/S0006-8993(99)01259-7			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	192BF	WOS:000080057100003	10224295				2022-02-06	
J	Barlow, KM; Minns, RA				Barlow, KM; Minns, RA			The relation between intracranial pressure and outcome in non-accidental head injury	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							NON-TRAUMATIC COMA; CHILDREN; SHAKEN	The aim of this retrospective study was to ascertain whether physiological derangement and potential secondary brain insult from raised intracranial pressure (ICP) or reduced cerebral perfusion pressure (CPP) in non-accidental head injury (NAHI) influences outcome. Any child who had a diagnosis of NARI and had ICP monitoring or measurements during the acute illness was entered in the study. Seventeen children with an average age 5.1 months (range 1 to 20 months) were identified. Details of the acute encephalopathy, lowest mean arterial blood pressure (MAP), mean of maximum ICP measured, lowest CPP, and neurodevelopmental outcome at follow up were obtained from the hospital case notes. Seshia's (1994) outcome classification scale was used. The lowest CPP was very significantly related to outcome (P=0.0047, tau=-0.544). Mean of maximum ICP did not correlate with outcome. The lowest MAP was significantly related to outcome (P=0.039). It was concluded that the degree of secondary brain insult from reduced CPP influences outcome.	Royal Hosp Sick Children, Dept Neurol, Edinburgh EH9 1LF, Midlothian, Scotland; Univ Edinburgh, Dept Child Life & Hlth, Edinburgh, Midlothian, Scotland		Minns, RA (corresponding author), Royal Hosp Sick Children, Dept Neurol, 9 Sciennes Rd, Edinburgh EH9 1LF, Midlothian, Scotland.		Barlow, Karen/C-1323-2014; Barlow, Karen/I-6492-2019	Barlow, Karen/0000-0003-2612-8507; Barlow, Karen/0000-0003-2612-8507			Barlow KM, 1998, SCOT MED J, V43, P112, DOI 10.1177/003693309804300407; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; FRANK Y, 1985, DEV MED CHILD NEUROL, V27, P312; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KALFF R, 1989, CHILD NERV SYST, V5, P156, DOI 10.1007/BF00272118; SESHIA SS, 1994, BAILLIERES CLIN PAED, V2, P173; SESHIA SS, 1983, DEV MED CHILD NEUROL, V25, P492; TASKER RC, 1988, ARCH DIS CHILD, V63, P895, DOI 10.1136/adc.63.8.895; TASKER RC, 1988, ARCH DIS CHILD, V63, P888, DOI 10.1136/adc.63.8.888	16	25	25	0	1	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	APR	1999	41	4					220	225		10.1017/S0012162299000481			6	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics	195ZJ	WOS:000080282800002	10355804				2022-02-06	
J	Kerrigan, DCC; Bang, MS; Burke, DT				Kerrigan, DCC; Bang, MS; Burke, DT			An algorithm to assess stiff-legged gait in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						rehabilitation; stiff-legged gait; traumatic brain injury	CONTRALATERAL SHOE-LIFT; CEREBRAL-PALSY; IMMOBILIZED KNEE; RELIABILITY; MANAGEMENT; WALKING	Spastic paretic stiff-legged gait Is a frequently encountered gait problem in patients with traumatic brain injury, as well as in many other patients with upper motor neuron disease. Formerly, spasticity of the quadriceps was considered to be the sole cause of stiff-legged gait. Quantitative gait analysis, however, may implicate hip flexor weakness or poor ankle mechanics as the cause of stiff-legged gait. We discuss the use of an algorithm to evaluate stiff-legged gait in traumatic brain injury using a quantitative gait analysis system such that the specific etiology of stiff-legged gait can be identified and can serve as the basis of a treatment plan.	Harvard Univ, Sch Med, Spaulding Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; Spaulding Rehabil Hosp, Ctr Rehabil Sci, Boston, MA USA; Seoul Natl Univ, Coll Med, Dept Rehabil Med, Seoul, South Korea		Kerrigan, DCC (corresponding author), Harvard Univ, Sch Med, Spaulding Hosp, Dept Phys Med & Rehabil, 125 Nashua St, Boston, MA 02114 USA.		Bang, Moon Suk/J-5501-2012				Abdulhadi HM, 1996, ARCH PHYS MED REHAB, V77, P670, DOI 10.1016/S0003-9993(96)90006-4; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Frigo C, 1998, MED BIOL ENG COMPUT, V36, P179, DOI 10.1007/BF02510740; GAGE JR, 1993, CLIN ORTHOP RELAT R, P126; Gage JR, 1989, SEMIN ORTHOP, V4, P72; HARRIS GF, 1994, ARCH PHYS MED REHAB, V75, P216; Kerrigan DC, 1998, GAIT POSTURE, V7, P117, DOI 10.1016/S0966-6362(97)00040-4; KERRIGAN DC, 1994, AM J PHYS MED REHAB, V73, P421, DOI 10.1097/00002060-199411000-00007; KERRIGAN DC, 1991, AM J PHYS MED REHAB, V70, P294; Kerrigan DC, 1997, ARCH PHYS MED REHAB, V78, P1085; KERRIGAN DC, 1998, REHABILITATION MED P; KOMAN LA, 1993, J PEDIATR ORTHOPED, V13, P489, DOI 10.1097/01241398-199307000-00013; KREBS DE, 1985, PHYS THER, V65, P1027, DOI 10.1093/ptj/65.7.1027; LAGE KJ, 1995, MED SCI SPORT EXER, V27, P8; MURRAY M P, 1984, Journal of Orthopaedic Research, V2, P272, DOI 10.1002/jor.1100020309; OLNEY SJ, 1991, ARCH PHYS MED REHAB, V72, P309; Perry J, 1992, GAIT ANAL NORMAL PAT; Piazza SJ, 1996, J BIOMECH, V29, P723, DOI 10.1016/0021-9290(95)00144-1; SAUNDERS JBDM, 1953, J BONE JOINT SURG AM, V35-A, P543, DOI 10.2106/00004623-195335030-00003; SUTHERLAND DH, 1990, J PEDIATR ORTHOPED, V10, P433; SUTHERLAND DH, 1978, DEV MED CHILD NEUROL, V20, P807; TREANOR WJ, 1969, CLIN ORTHOP RELAT R, P14; WATERS RL, 1979, J BONE JOINT SURG AM, V61, P927, DOI 10.2106/00004623-197961060-00022; Winter D.A., 1991, BIOMECHANICS MOTOR C; WINTER DA, 1995, BEHAV BRAIN RES, V67, P111, DOI 10.1016/0166-4328(94)00154-8	25	25	25	0	1	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1999	14	2					136	145		10.1097/00001199-199904000-00004			10	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	187DN	WOS:000079771800004	10191372				2022-02-06	
J	McHenry, MA				McHenry, MA			Aerodynamic, acoustic, and perceptual measures of nasality following traumatic brain injury	BRAIN INJURY			English	Article							LISTENER JUDGMENTS; HYPERNASALITY; FLOW	Data were obtained from 31 subjects who had incurred a traumatic brain injury (TBI). Two expert listeners judged nasality using direct magnitude estimation with a referent. They rated samples of the first sentence of the Rainbow Passage, played backwards, with all pauses removed. Sensitivity was good for nasalance, velopharyngeal airway resistance, and velopharyngeal orifice area, indicating that these measures would accurately identify an individual as nasal. Specificity was reduced, and was adequate only for nasalance. The reduced specificity was due to a high number of false positives, i.e. perceived nasality in the absence of objective corroboration. Analysis of the false positives revealed that a slow speaking rate could mislead a listener's perception of nasality. Overall, for individuals with dysarthria following TBI, the measure of nasalance may most accurately reflect listener perception of nasality.	Galveston Inst Human Commun, Transit Learning Community, Galveston, TX 77550 USA		McHenry, MA (corresponding author), Galveston Inst Human Commun, Transit Learning Community, 1528 PO St, Galveston, TX 77550 USA.						BARLOW S M, 1989, Journal of Voice, V3, P283, DOI 10.1016/S0892-1997(89)80050-5; BARLOW SM, 1991, J COMPUTER USERS SPE, V7, P211; BERRY RC, 1972, J SPEECH HEAR RES, V15, P185, DOI 10.1044/jshr.1501.185; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; Counihan D T, 1970, Cleft Palate J, V7, P261; DALSTON RM, 1991, CLEFT PALATE-CRAN J, V28, P184, DOI 10.1597/1545-1569(1991)028<0184:UONAAD>2.3.CO;2; DALSTON RM, 1986, CLEFT PALATE J, V23, P108; DELOREY RM, 1993, AM SPEECH LANG HEAR; Ebel RL., 1951, PSYCHOMETRIKA, V16, P407, DOI [10.1007/BF02288803, DOI 10.1007/BF02288803]; Fairbanks G., 1960, VOICE ARTICULATION D; FLETCHER SG, 1972, J SPEECH HEAR DISORD, V37, P329, DOI 10.1044/jshd.3703.329; FLETCHER SG, 1978, DIAGNOSING SPEECH DI; HARDIN MA, 1992, CLEFT PALATE-CRAN J, V29, P346, DOI 10.1597/1545-1569(1992)029<0346:CBNSAL>2.3.CO;2; KARNELL MP, 1995, CLEFT PALATE-CRAN J, V32, P145, DOI 10.1597/1545-1569(1995)032<0145:NDOHAT>2.3.CO;2; Kent R.D., 1992, ACOUSTIC ANAL SPEECH; McHenry M., 1997, AM J SPEECH-LANG PAT, V6, P55; McHenry MA, 1998, ARCH PHYS MED REHAB, V79, P545, DOI 10.1016/S0003-9993(98)90071-5; McHenry MA, 1996, DISORDERS MOTOR SPEE, P229; NELLIS JL, 1992, CLEFT PALATE-CRAN J, V29, P157, DOI 10.1597/1545-1569(1992)029<0157:CONALJ>2.3.CO;2; SCHIAVETTI N, 1981, J SPEECH HEAR RES, V24, P441, DOI 10.1044/jshr.2403.441; SEAVER EJ, 1991, J SPEECH HEAR RES, V34, P715, DOI 10.1044/jshr.3404.715; SNODGRAS JG, 1975, EXPT SENSORY PSYCHOL, P18; Southwood M., 1996, J MED SPEECH-LANG PA, V4, P13; *SPSS INC, 1994, SPSS WIND REL 6 1; THEODOROS D, 1993, BRAIN INJURY, V7, P59, DOI 10.3109/02699059309008157; Titze IR., 1994, PRINCIPLES VOICE PRO; WARREN D W, 1964, Cleft Palate J, V16, P52; Watterson Thomas, 1993, Journal of Communication Disorders, V26, P13, DOI 10.1016/0021-9924(93)90013-Z; Yorkston K., 1984, COMPUTERIZED ASSESSM; Zajac DJ, 1998, AM J SPEECH-LANG PAT, V7, P95, DOI 10.1044/1058-0360.0703.95; [No title captured]	31	25	26	1	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1999	13	4					281	290		10.1080/026990599121656			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	186RH	WOS:000079742400007	10230529				2022-02-06	
J	Hermann, DM; Mies, G; Hossmann, KA				Hermann, DM; Mies, G; Hossmann, KA			Biochemical changes and gene expression following traumatic brain injury: Role of spreading depression	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						neocortical trauma; cerebral metabolism; tissue acidosis; immediate-early gene; transient DC depolarization	PROTEIN-SYNTHESIS INHIBITORS; HSP70 MESSENGER-RNA; C-FOS; LACTATE; RATS; METABOLISM; DAMAGE; TRANSCRIPTION; ACTIVATION; ACIDS	The effects of spreading depression-like DC depolarizations on biochemical changes and gene expression were examined following traumatic neocortical lesions, as induced by transcranial cold injury. The surrounding of traumatic cold lesions was characterized by increased glucose and lactate contents, without major disturbances of protein synthesis or energy state. A transient pH decrease by 0.4 units was noticed 1 h post-injury, which shifted towards alkaline values by 3 h. These changes were similar in animals with spontaneous spreading depression-like DC shifts (n = 14) and those without spreading depressions (n = 7), but there was a marked difference in the gene response. In injured animals without SD, only a short-lasting response of c-fos, junB, c-jun and MKP-1 mRNAs as well as c-Fos protein was bilaterally found in the piriform cortex, and - with ipsilateral dominance - the dentate gyrus and hippocampal CA3/4 fields at 1 h after lesioning. In injured animals with spreading depressions, on the contrary, a strong elevation was seen in layers II-IV and VI of the injury-remote ipsilateral cerebral cortex, which persisted over as long as 6 h. The expression of c-Sos, junB and MKP-1 mRNAs was closely related to the time interval between the last spreading depression and the end of the experiments. Levels were highest shortly after transient DC shifts, and decreased thereafter monoexponentially with half-lives of 48, 75 and 58 min for c-fos, junB and MKP-1 mRNAs, respectively. Thus, spreading depression is a prominent factor influencing the trauma-related gene response, but - in contrast to focal ischemia - it does not aggravate the metabolic dysfunction.	Max Planck Inst Neurol Res, Dept Expt Neurol, D-50931 Cologne, Germany		Hermann, DM (corresponding author), Max Planck Inst Neurol Res, Dept Expt Neurol, Gleueler Str 50, D-50931 Cologne, Germany.	hermann@mpin-koeln.mpg.de	Hermann, Dirk M/AAP-5538-2020; Hermann, Dirk M./AAT-3652-2021	Hermann, Dirk M./0000-0003-0198-3152			Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Ginsberg MD, 1997, AM J PHYSIOL-HEART C, V272, pH2859, DOI 10.1152/ajpheart.1997.272.6.H2859; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; Hermann DM, 1998, NEUROREPORT, V9, P1249, DOI 10.1097/00001756-199804200-00053; HERMANN DM, 1998, IN PRESS NEUROSCIENC; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; KAMEZAWA T, 1994, ACTA NEUROCHIR, P499; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Marmarou A, 1993, Acta Neurochir Suppl (Wien), V57, P160; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MIES G, 1993, J NEUROCHEM, V60, P360, DOI 10.1111/j.1471-4159.1993.tb05860.x; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MIKAWA S, 1995, MOL BRAIN RES, V33, P288, DOI 10.1016/0169-328X(95)00146-J; NEUMANNHAEFELIN T, 1994, J CEREBR BLOOD F MET, V14, P206, DOI 10.1038/jcbfm.1994.27; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; Siesjo BK, 1996, ADV NEUROL, V71, P209; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WIESSNER C, 1995, NEUROSCIENCE, V64, P959, DOI 10.1016/0306-4522(94)00418-5; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; Yamashita K, 1996, BRAIN RES, V735, P285, DOI 10.1016/0006-8993(96)00578-1; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X	30	25	26	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		1999	14	2-3					103	108					6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	183XN	WOS:000079579700004					2022-02-06	
J	Kolakowsky-Hayner, SA; Kishore, R				Kolakowsky-Hayner, SA; Kishore, R			Caregiver functioning after traumatic injury	NEUROREHABILITATION			English	Article						caregiver functioning; traumatic brain injury; traumatic spinal cord injury; brief symptom inventory; family assessment device	FAMILY ASSESSMENT DEVICE; BRAIN INJURY; MCMASTER MODEL; HEAD-INJURY; FOLLOW-UP; DISTRESS; RELATIVES; SYMPTOMS; SAMPLE; IMPACT	Objectives: Investigate pervasiveness of unhealthy family functioning and psychological distress among primary caregivers of 28 adult outpatients with traumatic injuries. Describe caregiver functioning and psychological distress in caregivers of persons with traumatic brain injury and caregivers of persons with a traumatic spinal cord injury. Determine similarities and differences between the two populations. Study Design: Caregivers completed self-report measures including the Brief Symptom Inventory (BSI) and Family Assessment Device (FAD). Data were matched on respondent's gender, patient's age at injury, ethnicity, and marital status. Descriptive statistics were compiled for all variables. Independent samples t-tests and chi squares were computed to test for between group differences. Results: Similarities found between groups with regard to severity and mechanism of injury. Caregivers exhibited the highest levels of unhealthy functioning with regard to communication skills. Highest levels of healthy functioning were noted with regard to behavioral control. Almost 75% of caregivers reported elevated stress levels. Primary caregivers of persons with SCI report significantly (t(25) = 2.619, p = .015) more stress secondary to phobic anxiety than caregivers of persons with TBI. Conclusion: Previous research demonstrates that the BSI and FAD are valuable clinical tools. Current results suggest they are inappropriate for significantly distinguishing between SCI and TBI caregiver samples.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA		Kolakowsky-Hayner, SA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Box 980542, Richmond, VA 23298 USA.	sakolako@hsc.vcu.edu	Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909			Alfano D P, 1994, Appl Neuropsychol, V1, P57, DOI 10.1207/s15324826an0101&2_10; BEEBER BJ, 1992, REHABILITATION NURSI, V17, P332; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N, 1984, CLOSED HEAD INJURY P, P123; Canning RD, 1996, J PEDIATR PSYCHOL, V21, P735, DOI 10.1093/jpepsy/21.5.735; Derogatis L.R., 1975, BRIEF SYMPTOM INVENT; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EPSTEIN NB, 1978, J MARRIAGE FAM COUNS, V4, P19, DOI 10.1111/j.1752-0606.1978.tb00537.x; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Gervasio AH, 1997, J HEAD TRAUMA REHAB, V12, P14, DOI 10.1097/00001199-199706000-00003; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Kabacoff R.I., 1990, J FAM PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marshall J, 1998, FASEB J, V12, pA179; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Orsillo SM, 1993, J HEAD TRAUMA REHAB, V8, DOI [10.1097/00001199-199303000-00010, DOI 10.1097/00001199-199303000-00010]; Panting A, 1972, REHABILITATION, V38, P33; Pelletier P M, 1994, Appl Neuropsychol, V1, P38, DOI 10.1207/s15324826an0101&2_8; PETERS L C, 1992, Brain Injury, V6, P461, DOI 10.3109/02699059209008141; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; STEVENSONHINDE J, 1995, FAM PROCESS, V34, P337, DOI 10.1111/j.1545-5300.1995.00337.x; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Weitzenkamp DA, 1997, ARCH PHYS MED REHAB, V78, P822, DOI 10.1016/S0003-9993(97)90194-5; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31; [No title captured], DOI DOI 10.1097/00001199-198812000-00004	35	25	26	0	2	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		1999	13	1					27	33					7	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	244UT	WOS:000083069700005					2022-02-06	
J	Potter, DD; Barrett, K				Potter, DD; Barrett, K			Assessment of mild head injury with ERPs and neuropsychological tasks	JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						head injury; attention; memory; P3b; P3a; Nd; PASAT	EVENT-RELATED POTENTIALS; AUDITORY ODDBALL TASK; SEQUELAE; SYMPTOMS; CONCUSSION; ATTENTION; P300; DEFICITS; MEMORY	Mild head injury can result in the development of persistent symptoms including impairments of memory and: attention in a small but significant minority. The problem in assessing these difficulties in such cases is the likely interaction of psychogenic and organic causes. The aim of the present research:is to more,accurately characterize the nature of these cognitive deficits. Twelve asymptomatic volunteers, who;had experienced a mild head injury in the last 3.5 years, were compared to a matched control group. ERPs were recorded during the performance of the paced auditory serial addition task (PASAT) and a 3-stimulus auditory "oddball" task. Verbal paired associate, Trails A and B, Digit Symbol, Rey Figure Recall, NART, and Digit Span were also administered. The mild head injured group showed evidence of a mild impairment of episodic memory, slowing of attention shifting, but no changes in reaction time or error rates in either the "oddball" task or the PASAT. Although there was no-evidence of impairment of brain orienting responses in the 3-stimulus auditory oddball task there was evidence of reduced frontal negativity associated with changes in task demand in the PASAT This particular ERP feature appears similar to those associated with activation of selective attention mechanisms, thus suggesting that these asymptomatic individuals may be showing signs of a mild. impairment of allocation of attention resources.	Univ Dundee, Dept Psychol, Dundee DD1 4HN, Scotland; Haywood Hosp, Neurobehav Unit, Stoke On Trent, Staffs, England; Univ Keele, Dept Psychol, Keele ST5 5BG, Staffs, England		Potter, DD (corresponding author), Univ Dundee, Dept Psychol, Dundee DD1 4HN, Scotland.						BARIBEAU J, 1990, PSYCHOPHYSIOLOGICAL, P161; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; CAMPBELL KB, 1995, HDB NEUROPSYCHOLOGY, V10; CAMPBELL KB, 1990, NEW TRENDS ADV TECHN, P202; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; Coles, 1988, ADV PSYCHOPHYSIOLOGY, P69; CRAIK F, 1993, 34 ANN M PSYCH SOC W; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DAVIDOFF DA, 1988, COGNITIVE REHABILITA, V6, P8; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FISHER JM, 1994, SEMIN NEUROL, V14, P53, DOI 10.1055/s-2008-1041059; GENTILINI M, 1989, MILD HEAD INJURY, P163; GOODMAN JC, 1994, SEMIN NEUROL, V14, P19, DOI 10.1055/s-2008-1041054; GRONWALL D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Gronwall D, 1989, MILD HEAD INJURY, P153; HALL S, 1991, PERCEPT MOTOR SKILL, V72, P1295, DOI 10.2466/PMS.72.4.1295-1298; HAYES S, 1994, NEW STATESMAN SOC, V7, P14; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Miller E, 1970, Cortex, V6, P121; MILLER L, 1993, PSYCHOTHERAPY BRAIN; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; Nelson H.E., 1982, NATL ADULT READING T; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Osterrieth P., 1944, ARCH PSYCHOLOGIE, V30, P206; OTOOLE DM, 1987, PSYCHOPHYSIOLOGY, V24, P487, DOI 10.1111/j.1469-8986.1987.tb00325.x; PACKARD RC, 1994, SEMIN NEUROL, V14, P74, DOI 10.1055/s-2008-1041062; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Potter D, 1996, J PSYCHOPHYSIOL, V10, P79; POTTER DD, 1994, MAPP COGN TIM SPAC C; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; RUFF RM, 1986, SAN DIEGO NEUROPSYCH; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Rugg MD., 1994, COGNITIVE ELECTROPHY, P124, DOI 10.1007/978-1-4612-0283-7%5F5; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SCHOENHUBER R, 1989, MILD HEAD INJURY, P142; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Spreen O, 1991, COMPENDIUM NEUROPSYC; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANPETTEN C, 1991, J COGNITIVE NEUROSCI, V3, P129; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VERLEGER R, 1988, BEHAV BRAIN SCI, V11, P343, DOI 10.1017/S0140525X00058015; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 1981, WAIS R MANUAL; Woods DL., 1990, EVENT RELATED BRAIN, P178; YOUNG WB, 1994, SEMIN NEUROL, V14, P46, DOI 10.1055/s-2008-1041058	64	25	26	0	3	HOGREFE & HUBER PUBLISHERS	GOTTINGEN	ROHNSWEG 25, D-37085 GOTTINGEN, GERMANY	0269-8803			J PSYCHOPHYSIOL	J. Psychophysiol.		1999	13	3					173	189		10.1027//0269-8803.13.3.173			17	Psychology, Biological; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	236RA	WOS:000082611300005					2022-02-06	
J	Dritschel, BH; Kogan, L; Burton, A; Burton, E; Goddard, L				Dritschel, BH; Kogan, L; Burton, A; Burton, E; Goddard, L			Everyday planning difficulties following traumatic brain injury: a role for autobiographical memory	BRAIN INJURY			English	Article							DAMAGE	The present study examines the role of autobiographical memory in describing how to perform both open-ended and closed everyday activities in 12 patients suffering traumatic brain injury and 12 aged-matched controls. The frequency thigh versus low) of performing the activities was also manipulated. Patients seemed less well able to benefit from using specific autobiographical memories; they reported using significantly fewer specific autobiographical memories for describing how to perform low-frequency activities and significantly more such memories for high-frequency activities compared with controls. The quality of their descriptions was also significantly poorer for the open-ended activities. Finally, significant correlations were found between the quality of the descriptions and the retrieval of specific autobiographical memories for the controls only. The importance of the retrieval of specific autobiographical memories for everyday problem-solving is discussed.	Univ E London, Dept Psychol, Cognit Neuropsychol Res Unit, London E15 4LZ, England; Inst Psychotherapy Res, Princeton, NJ USA		Dritschel, BH (corresponding author), Univ E London, Dept Psychol, Cognit Neuropsychol Res Unit, Romford Rd, London E15 4LZ, England.		Goddard, Lorna/R-8635-2016; Burton, Mike/A-9491-2008	Goddard, Lorna/0000-0001-8884-3253; Burton, Mike/0000-0002-2035-2084; Dritschel, Barbara/0000-0002-0909-6323			BADDELEY AD, 1986, AUTOBIOGRAPHICAL MEM, P225; BADDELEY AD, 1997, HUMAN MEMORY, P85; BORRINI G, 1989, PSYCHOL MED, V19, P215, DOI 10.1017/S0033291700011181; CONWAY MA, 1996, BASIC APPL MEMORY TH, P295; DELLASALA S, 1993, NEUROPSYCHOLOGIA, V31, P823; DRITSCHEL B, 1991, EUR COGN SOC C CUOM; ELITHORN A, 1955, J NEUROL NEUROSUR PS, V18, P287, DOI 10.1136/jnnp.18.4.287; EVANS J, 1992, PSYCHOL MED, V22, P399, DOI 10.1017/S0033291700030348; Goddard L, 1996, J ABNORM PSYCHOL, V105, P609, DOI 10.1037/0021-843X.105.4.609; HAGEN C, 1979, AM SPEECH LANG HEAR; NEEDHAM DR, 1991, MEM COGNITION, V19, P543, DOI 10.3758/BF03197150; NELSON K, 1991, INT C MEM LANC UK; RYLANDER G, 1939, ACTA PSYCHIAT KBH S, V20, P3; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T, 1988, NEUROPSYCHOLOGY MENT, P328; WILLIAMS JMG, 1996, CONSTRUCTING OUR PAS, P244; Williams WH, 1998, NEUROPSYCHOL REHABIL, V8, P43, DOI 10.1080/713755551; Wilson BA, 1991, RIVERMEAD BEHAV MEMO	18	25	25	0	8	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1998	12	10					875	886					12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	121FR	WOS:000076003100006	9783085				2022-02-06	
J	Abu-Judeh, HH; Singh, M; Masdeu, JC; Abdel-Dayem, HM				Abu-Judeh, HH; Singh, M; Masdeu, JC; Abdel-Dayem, HM			Discordance between FDG uptake and technetium-99m-HMPAO brain perfusion in acute traumatic brain injury	JOURNAL OF NUCLEAR MEDICINE			English	Article						fluorine-18-fluorodeoxyglucose; technetium-99m-hexamethyl propyleneamine oxime; traumatic brain injury; coincidence imaging; SPECT brain perfusion	EMISSION COMPUTED-TOMOGRAPHY; HEAD-INJURY; PET; SPECT; METABOLISM; DEFICITS; DISEASE	A 28-yr-old woman who sustained a mild traumatic brain injury had an F-18-fluorodeoxyglucose (FDG) PET brain study using coincidence imaging performed on a dual-head gamma camera (MCD version; ADAC, Milpitas, CA) followed 24 hr later by Tc-99m-hexamethyl propyleneamine oxime SPECT brain perfusion imaging using a triple-head gamma camera (TRIONIX, Twinsburg, OH). The results of the SPECT brain perfusion study demonstrated decreased frontoparietal cortical brain perfusion, whereas F-18-FDG cerebral uptake was normal. Neuropsychological evaluation suggested frontal robe involvement. This case demonstrates the possibility of discordance between brain perfusion and glucose uptake in acute mild traumatic brain injury.	New York Med Coll, St Vincents Hosp & Med Ctr, Dept Radiol, Nucl Med Sect, New York, NY 10011 USA; New York Med Coll, St Vincents Hosp & Med Ctr, Dept Neurol, Nucl Med Sect, New York, NY 10011 USA		Abdel-Dayem, HM (corresponding author), New York Med Coll, St Vincents Hosp & Med Ctr, Dept Radiol, Nucl Med Sect, 53 W 11th St, New York, NY 10011 USA.		Masdeu, Joseph C/B-5052-2010				ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; Adams JH, 1975, HDB CLIN NEUROLOGY, V23, P35; Alavi A, 1989, J Neuropsychiatry Clin Neurosci, V1, pS45; ALAVI A, 1991, SEMIN NUCL MED, V21, P58, DOI 10.1016/S0001-2998(05)80079-0; Alavi A, 1996, J NUCL MED, V37, P1170; ALAVI A, 1990, J NUCL MED S, V31, pP741; ALAVI A, 1987, J CEREB BLOOD FLO S1, V7, pS646; BOECKER H, 1994, J COMPUT ASSIST TOMO, V18, P542, DOI 10.1097/00004728-199407000-00005; DAVIS PC, 1994, AM J ROENTGENOL, V162, P1267, DOI 10.2214/ajr.162.6.8191980; GEORGE J K, 1989, Journal of Nuclear Medicine, V30, P802; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; HENKIN R, 1996, NUCL MED ROLE POSITR, P1344; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LOESSNER A, 1995, J NUCL MED, V36, P1141; Masdeu J C, 1994, J Neuroimaging, V4, P177; MESSA C, 1994, J NUCL MED, V35, P210; MIELKE R, 1994, EUR J NUCL MED, V21, P1052; RAO N, 1984, ARCH PHYS MED REHAB, V65, P759; SABRI O, 1995, NUKLEARMED-NUCL MED, V34, P50; SOUDER E, 1990, Journal of Nuclear Medicine, V31, P876; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; STUSS DT, 1987, CLIN NEUROPSYCHOLOGI, V5, P139; Yamaki T, 1996, J NUCL MED, V37, P1166	25	25	25	0	0	SOC NUCLEAR MEDICINE INC	RESTON	1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA	0161-5505	1535-5667		J NUCL MED	J. Nucl. Med.	AUG	1998	39	8					1357	1359					3	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	108FG	WOS:000075254900012	9708506				2022-02-06	
J	Fitzpatrick, MO; Dewar, D; Teasdale, GM; Graham, DI				Fitzpatrick, MO; Dewar, D; Teasdale, GM; Graham, DI			The neuronal cytoskeleton in acute brain injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						cytoskeleton; head injury; microtubule; neurofilament	DIFFUSE AXONAL INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; TRANSIENT CEREBRAL-ISCHEMIA; HEAD-INJURY; RAT; IMMUNOREACTIVITY; HIPPOCAMPUS; GERBIL; VULNERABILITY; PERMEABILITY	The microtubules, neurofilaments and microfilaments of the neuronal cytoskeleton are essential for the normal functioning of the neurone. Recent studies have shown that disruption of the cytoskeleton may represent a final pathway in many types of neuronal cell injury with both the somato-dendritic and axonal cytoskeleton being affected. This review discusses the current evidence on the role of the neuronal cytoskeleton in the pathogenesis of traumatic brain damage.	So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland; So Gen Hosp, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Univ Glasgow, Wellcome Surg Inst, Glasgow, Lanark, Scotland		Fitzpatrick, MO (corresponding author), So Gen Hosp NHS Trust, Inst Neurol Sci, Dept Neurosurg, Glasgow, Lanark, Scotland.						Adams J. H., 1992, GREENFIELDS NEUROPAT; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; AOKI M, 1995, BRAIN RES, V669, P189, DOI 10.1016/0006-8993(94)01227-9; ARAKI T, 1989, ACTA NEUROL SCAND, V80, P548, DOI 10.1111/j.1600-0404.1989.tb03925.x; BRADY ST, 1992, NEUROREGENERATION, P7; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; DEWAR D, 1995, BRAIN RES, V684, P70, DOI 10.1016/0006-8993(95)00417-O; DEWAR D, 1993, ACTA NEUROPATHOL, V86, P623, DOI 10.1007/BF00294302; Dewar D, 1997, ACTA NEUROPATHOL, V93, P71, DOI 10.1007/s004010050584; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Fitzpatrick MO, 1996, BRIT J NEUROSURG, V10, P483, DOI 10.1080/02688699647122; GEDDES JW, 1994, J CEREBR BLOOD F MET, V14, P554, DOI 10.1038/jcbfm.1994.69; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; INUZUKA T, 1990, STROKE, V21, P917, DOI 10.1161/01.STR.21.6.917; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; OGATA N, 1989, J NEUROSURG, V70, P103, DOI 10.3171/jns.1989.70.1.0103; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POSTMANTUR R, 1994, J NEUROTRAUM, V11, P533; POSTMANTUR RM, 1996, J NEUROPATHOL EXP NE, V55, P68; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Vanicky I, 1995, NEUROREPORT, V7, P161, DOI 10.1097/00001756-199512000-00039; WHITSON JS, 1995, BRAIN RES, V694, P213, DOI 10.1016/0006-8993(95)00745-C; YAGHMAI A, 1992, J NEUROPATHOL EXP NE, V23, P63; YAMAMOTO K, 1986, BRAIN RES, V384, P1, DOI 10.1016/0006-8993(86)91212-6; YANAGIHARA T, 1990, ACTA NEUROPATHOL, V80, P499, DOI 10.1007/BF00294610; YOSHIMINE T, 1985, J NEUROSURG, V63, P922, DOI 10.3171/jns.1985.63.6.0922	37	25	26	1	3	CARFAX PUBL CO	ABINGDON	PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	AUG	1998	12	4					313	317					5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	115AC	WOS:000075640500003	10070422				2022-02-06	
J	Signorini, DF; Shad, A; Piper, IR; Statham, PFX				Signorini, DF; Shad, A; Piper, IR; Statham, PFX			A clinical evaluation of the Codman MicroSensor for intracranial pressure monitoring	BRITISH JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure; monitoring; traumatic brain injury		The strain-gauge Codman MicroSensor intracranial pressure (ICP) transducer has shown consistently good laboratory performance. To assess the practical performance of the system in patients following acute brain injury, 10 patients were fitted with a MicroSensor and a second ICP monitor. In five cases this was a fibre-optic transducer and in five cases an intraventricular fluid-filled device. Paired ICP values were recorded every 5 min. ICP values ranged from 0 to 31 mmHg. Altman-Bland plots showed that individual readings could differ by as much as 9 mmHg. Further analysis showed that much of this disagreement could be explained try a constant offset on each occasion. Comparison traces of ICP in individual patients show high agreement in timing and size of changes. The unexplained constant offset leads to uncertainty about the true ICP. Treatment decisions are often based upon absolute levels of ICP and patient care may therefore differ depending upon the monitor used.	Univ Edinburgh, Dept Clin Neurosci, Edinburgh, Midlothian, Scotland		Signorini, DF (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.						ALTMAN DG, 1983, J ROY STAT SOC D-STA, V32, P307, DOI 10.2307/2987937; BINGHAM K, 1997, J NEUROL NEUROSUR PS, V63, P130; Czosnyka M, 1996, NEUROSURGERY, V38, P219, DOI 10.1097/00006123-199601000-00053; GRAY WP, 1996, NEUROSURGERY, V39, P27; GUILLAUME J, 1951, REV NEUROL, V84, P131; LEGGATE JRS, 1988, INTRACRANIAL PRESSUR, V7, P31; Marmarou A.T., 1994, INTRACRANIAL PRESSUR, P15; MENDELOW AD, 1983, J NEUROSURG, V58, P45, DOI 10.3171/jns.1983.58.1.0045; PIPER IR, 1995, NEUROSURGERY, V36, P1142, DOI 10.1227/00006123-199506000-00012; PIPER IR, 1991, BR J INTENS CARE, V1, P73; Statham P, 1993, INTRACRANIAL PRESSUR, VVIII, P7	11	25	27	2	4	CARFAX PUBL CO	ABINGDON	PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.	JUN	1998	12	3					223	227					5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	ZY098	WOS:000074586400005	11013684				2022-02-06	
J	Ebmeyer, U; Safar, P; Radovsky, A; Obrist, W; Alexander, H; Pomeranz, S				Ebmeyer, U; Safar, P; Radovsky, A; Obrist, W; Alexander, H; Pomeranz, S			Moderate hypothermia for 48 hours after temporary epidural brain compression injury in a canine outcome model	JOURNAL OF NEUROTRAUMA			English	Article						brain death; cerebral resuscitation; epidural hematoma; hypothermia; intracranial hypertension; resuscitation; traumatic brain injury	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; CARDIAC-ARREST; MILD HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; INTRACRANIAL HYPERTENSION; GLOBAL-ISCHEMIA; TRAUMATIC COMA; DOGS; DAMAGE	In a previous study with this dog model, post-insult hypothermia of 31 degrees C for 5 h prevented secondary intraventricular pressure (IVP) rise, but during 35 degrees C or 38 degrees C, one-half of the dogs developed delayed IVP rise to brain death. We hypothesized that 31 degrees C extended to 48 h would prevent brain herniation. Using epidural balloon inflation, we increased contralateral IVP to 62 mm Hg for 90 min. Controlled ventilation was to 72 h and intensive care to 96 h. Group 1 dogs (n = 10) were normothermic controls (37.5 degrees C). Group 2 dogs (n = 10) were surface-cooled from 15 to 45 min of balloon inflation and maintained at moderate hypothermia (31 degrees C) to 48 h. Rewarming was from 48 to 72 h. Four additional dogs of hypothermia Group 2 had to be excluded from analysis for pneumonia and/or bleeding diathesis. After balloon deflation, IVP increased to 20 mm Hg or greater at 154 +/- 215 (range 15-720) min following the insult in Group 1 and at 1394 +/- 1191 (range 210-3420) min in Group 2 (p = 0.004), still during 31 degrees C but without further increase during hypothermia. Further IVP rise led to brain death in Group 1 in 6 of 10 dogs at 44 +/- 18 (range 21-72) h (all during controlled ventilation); and in Group 2, in 6 of 10 dogs at 87 +/- 11 (range 72-96) h (p = 0.001), all after rewarming, during spontaneous breathing. Survival to 96 h was achieved by 4 of 10 dogs in Group 1, and by 7 of 10 dogs in Group 2 (NS). Three of the six brain deaths in Group 2 occurred at 96 h. The macroscopically damaged brain volume was only numerically smaller in Group 2. The vermis downward shift was 6.8 +/- 3.5 mm in Group 1, versus 4.7 +/- 2.2 mm in Group 2 (p = 0.05). In an adjunctive study, in 4 additional normothermic dogs, hemispheric cerebral blood flow showed post-insult hypoperfusion bilaterally but no evidence of hyperemia preceding IVP rise to brain death. In conclusion, in this model, moderate hypothermia during and for 48 h after temporary epidural brain compression can maintain a low PVP during hypothermia but cannot prevent lethal brain swelling after rewarming and may cause coagulopathy and pulmonary complications.	Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Dept Anesthesiol Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA		Safar, P (corresponding author), Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318] Funding Source: Medline		ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; ASTRUP J, 1980, BRAIN RES, V199, P161, DOI 10.1016/0006-8993(80)90238-3; Baiping Lei, 1994, Stroke, V25, P147; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BIGELOW WG, 1950, ANN SURG, V132, P849, DOI 10.1097/00000658-195011000-00001; BORISMOLLER F, 1989, NEUROSCI RES COMMUN, V5, P87; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CHEN RYZ, 1978, AM J PHYSIOL, V235, pH136, DOI 10.1152/ajpheart.1978.235.2.H136; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Coimbra C, 1996, STROKE, V27, P1578, DOI 10.1161/01.STR.27.9.1578; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1995, J CEREBR BLOOD F MET, V15, P960, DOI 10.1038/jcbfm.1995.122; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DRIPPS RD, 1956, PHYSL INDUCED HYPOTH; EBMEYER U, 1993, CRIT CARE MED, V21, pS236; EBMEYER U, 1994, RESUSCITATION, V28, pS20; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GISVOLD SE, 1984, STROKE, V15, P803, DOI 10.1161/01.STR.15.5.803; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GREEN EJ, 1995, BRAIN RES, V702, P145, DOI 10.1016/0006-8993(95)01034-1; GRUBB RL, 1975, J NEUROSURG, V43, P385, DOI 10.3171/jns.1975.43.4.0385; HABASH AH, 1982, ACTA NEUROCHIR, V60, P7, DOI 10.1007/BF01401746; JENNETT B, 1975, LANCET, V1, P480; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KOCHANEK PM, 1997, CRITICAL CARE STATE, P119; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEONOV Y, 1990, STROKE, V21, P1600, DOI 10.1161/01.STR.21.11.1600; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marion DW, 1996, CRIT CARE MED, V24, pS81; MARMAROU A, 1996, BRAIN EDEMA 1996, P90; MICHENFELDER JD, 1970, ANESTHESIOLOGY, V33, P430, DOI 10.1097/00000542-197010000-00013; NARAYAN RK, 1995, J NEUROTRAUM, V12, P907, DOI 10.1089/neu.1995.12.907; NEMOTO EM, 1977, STROKE, V8, P558, DOI 10.1161/01.STR.8.5.558; NITTA M, 1990, ACTA NEUROCHIR, V104, P30, DOI 10.1007/BF01842890; OBRIST WD, 1990, CEREBROVAS BRAIN MET, V2, P283; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OUNG CM, 1993, J TRAUMA, V35, P251, DOI 10.1097/00005373-199308000-00013; PATT A, 1988, SURG CLIN N AM, V68, P775; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; POMERANZ S, 1996, P C NEUR SURG; RADOVSKY A, 1995, STROKE, V26, P2127, DOI 10.1161/01.STR.26.11.2127; ROSOMOFF HL, 1960, SURG GYNECOL OBSTET, V110, P27; ROSOMOFF HL, 1954, AM J PHYSIOL, V179, P85, DOI 10.1152/ajplegacy.1954.179.1.85; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; ROSOMOFF HL, 1959, ANN NY ACAD SCI, V80, P475, DOI 10.1111/j.1749-6632.1959.tb49225.x; ROSOMOFF HL, 1965, RESP THERAPY, P243; SAFAR P, 1988, CRIT CARE MED, V16, P923, DOI 10.1097/00003246-198810000-00003; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; SAFAR P, 1982, PROTECTION TISSUES H, P147; SAFAR P, 1996, TXT NEUROANESTHESIA, P557; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; SNYDER JV, 1975, STROKE, V6, P21, DOI 10.1161/01.STR.6.1.21; STEEN PA, 1980, ANESTHESIOLOGY, V52, P224, DOI 10.1097/00000542-198003000-00007; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; STONE HH, 1956, SURG GYNECOL OBSTET, V103, P313; TISHERMAN S, 1991, PREHOSP DISASTER MED, V6, P207; VAAGENES P, 1984, CRIT CARE MED, V12, P846, DOI 10.1097/00003246-198410000-00002; WEINRAUCH V, 1992, STROKE, V23, P1454, DOI 10.1161/01.STR.23.10.1454; Whalen M., 1996, Society for Neuroscience Abstracts, V22, P1904; Xiao F, 1998, AM J EMERG MED, V16, P17, DOI 10.1016/S0735-6757(98)90059-6; XIAO F, 1995, RESUSCITATION, V30, P51, DOI 10.1016/0300-9572(94)00858-D	76	25	26	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	1998	15	5					323	336		10.1089/neu.1998.15.323			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	ZL515	WOS:000073441300003	9605347				2022-02-06	
J	McKee, MD; Garay, ME; Schemitsch, EH; Kreder, HJ; Stephen, DJG				McKee, MD; Garay, ME; Schemitsch, EH; Kreder, HJ; Stephen, DJG			Irreducible fracture-dislocation of the hip: A severe injury with a poor prognosis	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						hip fracture-dislocation; irreducible; poor prognosis	TRAUMATIC POSTERIOR DISLOCATION	Objective: To determine the outcome of and prognostic factors associated with irreducible fracture-dislocations of the hip. Design: Retrospective review of a prospectively gathered trauma database. Methods: Using a prospectively gathered trauma database, we identified twenty-five patients with fracture-dislocations of the hip that were irreducible with closed means under a general anaesthetic. All were victims of high-energy trauma with severe injuries (mean Injury Severity Score = 25, range 9 to 54). Eighteen patients had multiple fractures, fifteen had associated systemic injury, and only four sustained the hip injury in an isolated fashion. There were seven associated sciatic nerve injuries (28 percent) and nine associated femoral head or neck fractures (36 percent). The mean time from injury to open reduction was 15.3 hours (range 3 to 58 hours). Results: Twenty-three patients (92 percent) were followed to definitive outcome. Despite accurate reduction, only six patients had satisfactory results (Thompson-Epstein = good or excellent). Poor results were associated with delay in reduction and an associated femoral head or neck fracture. Reasons for the poor results include avascular necrosis, posttraumatic arthritis or chondrolysis, persisting sciatic nerve injury, and heterotopic ossification. Conclusions: An irreducible fracture-dislocation of the hip is a severe injury with a poor prognosis and a high incidence of associated injuries. Outcome is best in patients who do not have an associated femoral head or neck fracture and those whose dislocation is promptly reduced.	St Michaels Hosp, Div Orthopaed, Toronto, ON M5B 1W8, Canada; Univ Toronto, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Div Orthopaed, Toronto, ON M4N 3M5, Canada		McKee, MD (corresponding author), 55 Queen St E,Suite 800, Toronto, ON M5C 1R6, Canada.		Schemitsch, Emil/G-5706-2017	Schemitsch, Emil/0000-0002-6435-9069			BOSSE MJ, 1988, J BONE JOINT SURG AM, V70A, P1231, DOI 10.2106/00004623-198870080-00016; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629, DOI 10.2106/00004623-197355080-00006; Brumback RJ, 1987, P HIP SOC, P181; BUTLER JE, 1981, J BONE JOINT SURG AM, V63, P1292, DOI 10.2106/00004623-198163080-00011; CANALE ST, 1979, J BONE JOINT SURG AM, V61, P7, DOI 10.2106/00004623-197961010-00003; CHAKRABORTI S, 1975, INJURY, V7, P134, DOI 10.1016/0020-1383(75)90011-X; DOWD GSE, 1979, J BONE JOINT SURG AM, V61, P1244, DOI 10.2106/00004623-197961080-00018; DREINHOFER KE, 1994, J BONE JOINT SURG BR, V76B, P6, DOI 10.1302/0301-620X.76B1.8300683; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, P116; EPSTEIN HC, 1985, CLIN ORTHOP RELAT R, P9; HEALY WL, 1995, J BONE JOINT SURG AM, V77A, P590, DOI 10.2106/00004623-199504000-00013; HOUGAARD K, 1986, ARCH ORTHOP TRAUM SU, V106, P32, DOI 10.1007/BF00435649; HOUGAARD K, 1988, J BONE JOINT SURG AM, V70A, P233, DOI 10.2106/00004623-198870020-00011; JEFFERY CC, 1957, J BONE JOINT SURG BR, V39, P310, DOI 10.1302/0301-620X.39B2.310; Kaempffe F A, 1991, J Orthop Trauma, V5, P439, DOI 10.1097/00005131-199112000-00009; KARPIK K, 1995, P ORTHOPAEDIC TRAUMA, P116; Levin P., 1992, SKELETAL TRAUMA, P1329; MARCHETTI ME, 1995, J ORTHOP TRAUMA, V10, P455; Matta JM, 1996, J BONE JOINT SURG AM, V78A, P1632, DOI 10.2106/00004623-199611000-00002; MOED B, 1989, ORTHOPEDIC T, V13, P759; PIPKIN G, 1957, J BONE JOINT SURG AM, V39, P1027, DOI 10.2106/00004623-195739050-00004; REILLY MC, 1996, P ORTHOPAEDIC TRAUMA, P115; SLATIS P, 1974, INJURY, V5, P188, DOI 10.1016/S0020-1383(74)80003-3; Swiontkowski M F, 1992, J Orthop Trauma, V6, P437, DOI 10.1097/00005131-199212000-00008; THOMPSON VP, 1951, J BONE JOINT SURG AM, V33-A, P746, DOI 10.2106/00004623-195133030-00023; Tornetta 3rd, 1997, J Am Acad Orthop Surg, V5, P27; UPADHYAY SS, 1981, J BONE JOINT SURG BR, V63, P548, DOI 10.1302/0301-620X.63B4.7298682; Yue JJ, 1996, J ORTHOP TRAUMA, V10, P447, DOI 10.1097/00005131-199610000-00001	28	25	25	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0890-5339			J ORTHOP TRAUMA	J. Orthop. Trauma	MAY	1998	12	4					223	229		10.1097/00005131-199805000-00001			7	Orthopedics; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Sport Sciences	ZM882	WOS:000073585800001	9619455				2022-02-06	
J	Ulus, IH; Ozyurt, G; Korfali, E				Ulus, IH; Ozyurt, G; Korfali, E			Decreased serum choline concentrations in humans after surgery, childbirth, and traumatic head injury	NEUROCHEMICAL RESEARCH			English	Article						choline; serum choline; surgical stress; pregnancy; childbirth stress; traumatic injury; head trauma	RAT CORPUS STRIATUM; TYROSINE-HYDROXYLASE; ACETYLCHOLINE-RELEASE; CONSCIOUS RATS; BETA-ENDORPHIN; BRAIN; STIMULATION; METABOLITES; DEFICIENCY; INDUCTION	The serum levels of choline decreased by approximately 50% in patients having a surgery under general as well as epidural anesthesia. The decrease is lasts for two days after surgery. Intravenous administration of succinylcholine, either by a single bolus injection or by a slow continuous infusion, increased the serum choline levels several folds during surgery. In these patients, a significant decrease in the serum choline levels was observed one and two days after surgery. In 16 pregnant women at the term, serum choline levels were higher than the value observed in 19 nonpregnant women. The serum choline levels decreased by about 40% or 60% after having a childbirth either by vaginal delivery or caesarean section, respectively. Serum choline levels in blood obtained from 9 patients with traumatic head injury were significantly lower than the observed levels in blood samples obtained from healthy volunteers. These observations show that serum choline levels increase during pregnancy and decrease during stressful situations in humans.	Uludag Univ, Fac Med, Dept Pharmacol & Clin Pharmacol, TR-16059 Bursa, Turkey; Uludag Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-16059 Bursa, Turkey; Uludag Univ, Fac Med, Dept Neurosurg, TR-16059 Bursa, Turkey		Ulus, IH (corresponding author), Uludag Univ, Fac Med, Dept Pharmacol & Clin Pharmacol, TR-16059 Bursa, Turkey.		Ulus, Ismail/D-5340-2015				ALTURA BM, 1978, P SOC EXP BIOL MED, V158, P77; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; BOUAZIZ H, 1995, ANESTH ANALG, V80, P1140, DOI 10.1097/00000539-199506000-00012; BUCHMAN AL, 1994, CLIN PHARMACOL THER, V55, P277, DOI 10.1038/clpt.1994.28; BURT ME, 1980, LANCET, V2, P638; BUYUKUYSAL RL, 1995, EUR J PHARMACOL, V281, P179, DOI 10.1016/0014-2999(95)00241-C; CONLAY LA, 1992, INT J SPORTS MED, V13, pS141, DOI 10.1055/s-2007-1024619; CONLAY LA, 1986, NEW ENGL J MED, V315, P892; Eisenach JC, 1996, ANESTH ANALG, V82, P621, DOI 10.1097/00000539-199603000-00034; FARBER SA, 1993, BRAIN RES, V607, P177, DOI 10.1016/0006-8993(93)91504-L; GARNER SC, 1995, J NUTR, V125, P2851; GROWDON JH, 1977, NEW ENGL J MED, V297, P524, DOI 10.1056/NEJM197709082971002; HELLER JH, 1953, SCIENCE, V118, P353, DOI 10.1126/science.118.3065.353; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; HolmesMcNary MQ, 1996, AM J CLIN NUTR, V64, P572, DOI 10.1093/ajcn/64.4.572; JOHNSON DA, 1992, LIFE SCI, V51, P1597, DOI 10.1016/0024-3205(92)90622-V; LINDAHL S, 1983, ACTA ANAESTH SCAND, V27, P50, DOI 10.1111/j.1399-6576.1983.tb01904.x; LOPEZ G, 1987, NEUROCHEM INT, V11, P293; LOPEZ G-COVIELLA I, 1992, Journal of Nutritional Biochemistry, V3, P313; LOPEZCOVIELLA I, 1995, J NEUROCHEM, V65, P889; LOY R, 1991, ADV EXP MED BIOL, V295, P373; MAIRE JCE, 1985, J PHYSIOL-PARIS, V80, P189; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; MILLINGTON WR, 1982, J NEUROCHEM, V38, P1748, DOI 10.1111/j.1471-4159.1982.tb06658.x; PANCHERI P, 1984, NEUROENDOCRINOL LETT, V6, P295; RENNICK B, 1976, KIDNEY INT, V10, P329, DOI 10.1038/ki.1976.116; ROHLFS EM, 1993, J NUTR, V123, P1762, DOI 10.1093/jn/123.10.1762; Savci V, 1996, BRAIN RES, V709, P97, DOI 10.1016/0006-8993(95)01308-3; Savci V, 1996, EUR J PHARMACOL, V309, P275, DOI 10.1016/0014-2999(96)00330-5; SAVCI V, 1995, J NEUROCHEM, V64, P378; SHEARD NF, 1986, AM J CLIN NUTR, V43, P219, DOI 10.1093/ajcn/43.2.219; SHEARD NF, 1994, J NUTR BIOCHEM, V5, P303, DOI 10.1016/0955-2863(94)90036-1; SLACK BE, 1989, FIDIA RES SERIES, V20, P233; STHAXHOLDT O, 1981, ACTA ANAESTH SCAND, V25, P434, DOI 10.1111/j.1399-6576.1981.tb01681.x; ULUS IH, 1989, BRAIN RES, V484, P217, DOI 10.1016/0006-8993(89)90364-8; ULUS IH, 1976, SCIENCE, V194, P1060, DOI 10.1126/science.10629; ULUS IH, 1978, J PHARMACOL EXP THER, V204, P676; ULUS IH, 1977, P NATL ACAD SCI USA, V74, P798, DOI 10.1073/pnas.74.2.798; ULUS IH, 1995, BRIT J PHARMACOL, V116, P1911, DOI 10.1111/j.1476-5381.1995.tb16682.x; WANG FL, 1975, ANAL BIOCHEM, V63, P195, DOI 10.1016/0003-2697(75)90204-3; WECKER L, 1980, BRAIN RES, V184, P234, DOI 10.1016/0006-8993(80)90605-8; WURTMAN RJ, 1992, TRENDS NEUROSCI, V15, P117, DOI 10.1016/0166-2236(92)90351-8; ZEISEL SH, 1995, J NUTR, V125, P3049; ZEISEL SH, 1991, FASEB J, V5, P2093, DOI 10.1096/fasebj.5.7.2010061; ZEISEL SH, 1990, J NUTR BIOCHEM, V1, P332, DOI 10.1016/0955-2863(90)90001-2	46	25	25	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAY	1998	23	5					727	732		10.1023/A:1022455325657			6	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	ZG369	WOS:000072994700020	9566612				2022-02-06	
J	Bednar, MM; Gross, CE; Howard, DB; Lynn, M				Bednar, MM; Gross, CE; Howard, DB; Lynn, M			Neutrophil activation in acute human central nervous system injury	NEUROLOGICAL RESEARCH			English	Article						stroke; trauma; subarachnoid hemorrhage; central nervous system injury; neutrophil; chemiluminescence	CEREBRAL-ARTERY OCCLUSION; ISCHEMIC CELL-DAMAGE; TRANSPORT INHIBITOR L-644,711; SECONDARY BRAIN INJURY; MONOCLONAL-ANTIBODY; RABBIT MODEL; POLYMORPHONUCLEAR LEUKOCYTES; THROMBOEMBOLIC STROKE; REPERFUSION INJURY; ADHESION MOLECULES	The hypothesis that neutrophil activation exacerbates brain injury in acute stroke is currently receiving wide acceptance. However, the temporal relationship of neutrophil activation to the ischemic event in clinical states is not clear. Therefore, this study was undertaken to examine human neutrophil activation by the technique of luminol-dependent chemiluminescence in both acute bland and hemorrhagic stroke. Patients (bland, n = 18; hemorrhagic, n = 16) were entered into this study within six hours of the ictus. These results were compared to other clinical central nervous system insults: subarachnoid hemorrhage (n = 11), spinal trauma (n = 9) and isolated closed head injury (n = 19). All subjects were sampled upon presentation to the emergency room and 0.5, 1, 2, 3, 4 and 5 days following the event Neutrophil activation, as determined by luminol-dependent chemiluminescence, was evident at day I following the ictus in the bland stroke group (p < 0.05), although this trend was not demonstrated for hemorrhagic stroke. Patients suffering a closed head injury demonstrated greater initial neutrophil activation with values being significantly lower than baseline at days 0.5 (p = 0.01) and 1 (p = 0.05). No significant change was demonstrated for the groups with spinal trauma or subarachnoid hemorrhage. These results support a role for neutrophil activation during various central nervous system insults and provide a temporal framework for considering drug therapy directed at transient suppression of neutrophil function.	Univ Vermont, Div Neurosurg, Burlington, VT 05405 USA; Univ Vermont, Gen Clin Res Ctr, Burlington, VT USA		Bednar, MM (corresponding author), Univ Vermont, Div Neurosurg, Given D319, Burlington, VT 05405 USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR109] Funding Source: Medline		BARONE FC, 1992, STROKE, V23, P1337, DOI 10.1161/01.STR.23.9.1337; Bednar, 1995, J Thromb Thrombolysis, V1, P179, DOI 10.1007/BF01062576; BEDNAR M, 1985, CIRC RES, V57, P131, DOI 10.1161/01.RES.57.1.131; BEDNAR M M, 1992, Neurological Research, V14, P53; BEDNAR MM, 1991, STROKE, V22, P44, DOI 10.1161/01.STR.22.1.44; Bednar MM, 1996, NEUROL RES, V18, P171; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; BOWES MP, 1995, NEUROLOGY, V45, P815, DOI 10.1212/WNL.45.4.815; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CLARK WM, 1994, STROKE, V25, P1411, DOI 10.1161/01.STR.25.7.1411; DELZOPPO GJ, 1991, STROKE, V22, P1276, DOI 10.1161/01.STR.22.10.1276; DUTKA AJ, 1989, STROKE, V20, P390, DOI 10.1161/01.STR.20.3.390; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FASSBENDER K, 1995, STROKE, V26, P1361, DOI 10.1161/01.STR.26.8.1361; GROGAARD B, 1989, J CEREBR BLOOD F MET, V9, P500, DOI 10.1038/jcbfm.1989.73; GROSS CE, 1993, STROKE, V24, P558, DOI 10.1161/01.STR.24.4.558; IKEDA Y, 1990, NEUROSURGERY, V27, P1; KOHUT JJ, 1992, STROKE, V23, P93, DOI 10.1161/01.STR.23.1.93; LESLIE JB, 1985, J NEUROSURG, V63, P659, DOI 10.3171/jns.1985.63.5.0659; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MATSUO Y, 1994, BRAIN RES, V656, P344, DOI 10.1016/0006-8993(94)91478-8; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; Penix Laroy, 1996, Stroke, V27, P177; SIMPSON PJ, 1990, CIRCULATION, V81, P226, DOI 10.1161/01.CIR.81.1.226; VERMES I, 1988, STROKE, V19, P631, DOI 10.1161/01.STR.19.5.631; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WILSON JT, 1995, J TRAUMA, V39, P473; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	34	25	26	0	0	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	DEC	1997	19	6					588	592					5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZC204	WOS:000072552000005	9427957				2022-02-06	
J	Parsons, LC; Crosby, LJ; Perlis, M; Britt, T; Jones, P				Parsons, LC; Crosby, LJ; Perlis, M; Britt, T; Jones, P			Longitudinal sleep EEG power spectral analysis studies in adolescents with minor head injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	13th Annual Houston Conference on Biomedical Engineering Research	FEB   09, 1996	HOUSTON, TX			electroencephalographic sleep readings; minor brain injury; Delta, Theta & Alpha-1 wave forms; acute and recovery phases; human traumatic brain injury	SEQUELAE; DENSITY	Power spectral analysis (PSA) was used to evaluate the longitudinal overnight electroencephalographic (EEG) sleep recordings of eight subjects, between the ages of 15 and 19 years, who had sustained a minor head injury (MHI). Recordings occurred within 72 h, 6 weeks, and 12 weeks following MHI. A conditioning night preceded the first study night during which EEG electrodes were in place and subjects slept at least 7.5 h with a mean sleep efficiency of 91%. PSA was performed on four channels of EEG data recorded from fronto-temporal (F3-T3, F4-T4), and temporal (T3-T5, T4-T6) electrodes. The three waveforms associated with sleep, Delta, Theta, and Alpha-1 were all significantly elevated within 72 h post-MHI. Over time all wave forms decreased in mean log power. Theta in rapid eye movement (REM) sleep Cycle 1 decreased significantly within 6 weeks postinjury. The greatest number of significant changes, over the 12-week period were recorded during the non-REM (NREM) sleep. Changes included (1) significant decreases in mean log power of Theta and Alpha-1 in Cycle 1 from fronto-temporal leads; (2) significant decreases in Delta, Theta, and Alpha-1 in Cycle 2 from fronto-temporal leads, and (3) significant decreases in Delta and Theta for consistency during Cycle 2 from temporal leads. The intrusion of Theta into the first REM cycle within 6 weeks and its subsequent decrease within 6 weeks suggested the initiation of recovery toward baseline values. This was followed by decreased levels of Theta power during NREM Cycles 1 and 2, and Delta power in Cycle 2, both of which approached their lowest levels within 12 wks. The decrease in Alpha-1 power occurred last. Alpha-1 remained elevated through both Cycles 1 and 2 of the 6th week and then showed a precipitous decrease between the sixth and twelfth week. These findings suggested that following MHI, the brain has a specific sequence of recovery as illustrated by Delta, Theta, and Alpha-1 powers requiring different time frames to reach their lowest levels.	UNIV ARIZONA,COLL MED,TUCSON,AZ 85721; VET AFFAIRS MED CTR,TUCSON,AZ; UNIV ROCHESTER,DEPT PSYCHIAT,ROCHESTER,NY; UNIV ARIZONA,CTR COMP INFORMAT TECHNOL,UNIVERSITY PK,PA; PENN STATE UNIV,UNIVERSITY PK,PA 16802		Parsons, LC (corresponding author), UNIV ARIZONA,COLL NURSING,TUCSON,AZ 85721, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS024169] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R0 1 NS24169] Funding Source: Medline		*AM SLEEP DIS ASS, 1990, INT CLASS SLEEP DIS; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BORBELY AA, 1981, ELECTROEN CLIN NEURO, V51, P483, DOI 10.1016/0013-4694(81)90225-X; COOLEY JW, 1965, MATH COMPUT, V19, P297, DOI 10.2307/2003354; DIJK DJ, 1990, SLEEP, V13, P430, DOI 10.1093/sleep/13.5.430; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; FEINBERG I, 1993, ENCY SLEEP DREAMING, P157; GOTTMAN J, 1990, CURRENT PRACTICE CLI, P51; HUBERTY CJ, 1989, PSYCHOL BULL, V105, P302, DOI 10.1037/0033-2909.105.2.302; JASPER H, 1948, ELECTROEN CLIN NEURO, V10, P371; Kowatch R A, 1989, Psychiatr Med, V7, P37; MACLEAN AW, 1995, SLEEP, V18, P565; MONROE LJ, 1967, J ABNORM PSYCHOL, V72, P255, DOI 10.1037/h0024563; Neter J, 1990, APPLIED LINEAR STATI, p[587, 761]; OHARA C, 1993, ANN C NAT AC NEUR PH; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARSONS LC, 1981, NEUROSCI LETT, V24, P199, DOI 10.1016/0304-3940(81)90248-2; PARSONS LC, 1982, NURS RES, V31, P260; PARSONS LC, 1968, THESIS U TEXAS MED B, V29, P1789; PARSONS LC, 1993, SLEEP RES, V21, P354; PARSONS LC, 1993, ENCY SLEEP DREAMING, P270; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Rechtschaffen A., 1968, MANUAL STANDARDIZED; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SAS, 1989, SAS STAT US GUID VER, V2, P846; TEASDALE G, 1974, LANCET, V2, P81; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; WILLIAMS RL, 1988, EEG HUMAN SLEEP CLIN	32	25	26	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1997	14	8					549	559		10.1089/neu.1997.14.549			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	XU894	WOS:A1997XU89400006	9300565				2022-02-06	
J	Phillips, LL; Lyeth, BG; Hamm, RJ; Jiang, JY; Povlishock, JT; Reeves, TM				Phillips, LL; Lyeth, BG; Hamm, RJ; Jiang, JY; Povlishock, JT; Reeves, TM			Effect of prior receptor antagonism on behavioral morbidity produced by combined fluid percussion injury and entorhinal cortical lesion	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						trauma; deafferentation; scopolamine; MK-801; cognitive function	TRAUMATIC BRAIN INJURY; COGNITIVE IMPAIRMENT; HIPPOCAMPAL FORMATION; NEUROTROPHIC FACTOR; CORTEX LESIONS; MESSENGER-RNA; TIME-COURSE; RAT; RECOVERY; NEURONS	We have used an animal model of traumatic brain injury (TBI) that incorporates both the neurotransmitter toxicity of fluid percussion TBI and deafferentation of bilateral entorhinal cortical (BEC) lesion to explore whether administration of muscarinic cholinergic or N-methyl-D-aspartate glutamatergic antagonists prior to injury ameliorates cognitive morbidity. Fifteen minutes prior to moderate central fluid percussion TBI, rats were given intraperitoneal injections of either scopolamine (1.0 mg/kg) or MK-801 (0.3 mg/kg) and 24 hr later underwent BEC lesion. Body weight was followed for 5 days postinjury, as was beam balance and beam walk performance to assure motor recovery prior to spatial memory testing. Each group was assessed for spatial memory deficits with the Morris water maze at short term (days 11-15) and long-term (60-64 days) postinjury intervals and then compared with untreated combined insult and sham-injured controls. Results showed that each drug significantly elevated body weight relative to untreated injured cases. Both scopolamine and MK-gOl reduced beam balance deficits, whereas neither drug had a significant effect on beam walk deficits. Interestingly, short-term cognitive deficits assessed on days 11-15 were differentially affected by the two drugs: MK-801 pretreatment enhanced the recovery of spatial memory performance, whereas scopolamine pretreatment did not. Long-term (days 60-64) deficits in spatial memory were not altered by pretreatment with either drug. Our results suggest that, unlike fluid percussion TBI alone, behavioral impairment may require more select intervention when deafferentation is part of the head trauma pathology. (C) 1997 Wiley-Liss, Inc.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,RICHMOND,VA 23298		Phillips, LL (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,POB 980693 MCV STN,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193, P01NS012587, P50NS012587, R01NS029995] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995, NS 12587, NS 20193] Funding Source: Medline		BLACKSTAD TW, 1956, J COMP NEUROL, V105, P417, DOI 10.1002/cne.901050305; Bullock R, 1994, INTRACRANIAL PRESSUR, P264; CASTREN E, 1993, EXP NEUROL, V122, P244, DOI 10.1006/exnr.1993.1124; DAI HL, 1995, BRAIN RES BULL, V36, P175, DOI 10.1016/0361-9230(94)00188-7; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; FASS B, 1983, BEHAV NEURAL BIOL, V37, P108, DOI 10.1016/S0163-1047(83)91117-2; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HUGHES P, 1993, NEUROREPORT, V4, P183, DOI 10.1097/00001756-199302000-00017; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; NITSCH R, 1991, BRAIN RES, V554, P304, DOI 10.1016/0006-8993(91)90205-A; NITSCH R, 1992, P NATL ACAD SCI USA, V89, P5197, DOI 10.1073/pnas.89.11.5197; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; Phillips L. L., 1995, Journal of Neurotrauma, V12, P419; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; PHILLIPS LL, 1995, J NEUROTRAUM, V12, P964; Povlishock John T., 1995, P504; REEVES TM, 1987, BEHAV NEUROSCI, V101, P179; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; SCHACTER GB, 1989, BRAIN RES, V494, P339, DOI 10.1016/0006-8993(89)90602-1; SCHEFF SW, 1977, BEHAV BIOL, V21, P286, DOI 10.1016/S0091-6773(77)90374-1; SCHEFF SW, 1977, BRAIN RES, V150, P45; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; STEWARD O, 1976, J COMP NEUROL, V167, P285, DOI 10.1002/cne.901670303; VARON S, 1989, PHARMACOPSYCHIATRY, V22, P120, DOI 10.1055/s-2007-1014631; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037	43	25	25	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	JUL 15	1997	49	2					197	206					10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XP112	WOS:A1997XP11200008	9272642				2022-02-06	
J	Giles, GM; Ridley, JE; Dill, A; Frye, S				Giles, GM; Ridley, JE; Dill, A; Frye, S			A consecutive series of adults with brain injury treated with a washing and dressing retraining program	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						activities of daily living; brain injuries; rehabilitation	HEAD-INJURY; TIME-DELAY; SKILLS; ENCEPHALITIS; STRATEGIES; BACKWARD; PATIENT	Objectives. Single-case reports indicate that behavioral method can assist persons with brain injury to redevelop self-care skills. However, the proportion of patients who could benefit from these interventions is unknown. The present study used a specific retraining protocol to treat all patients admitted to a single facility, over a 3-year period who were unable to wash and dress independently. Method. Four patients out of 48 met the study criteria and were treated with the washing and dressing protocol. Three had traumatic brain injury, and one had brain injury after cerebral bleed. The training program involved behavioral observation, task analysis, consistent practice, and cue fading. The Adaptive Behavior Scale was used to measure behavior change. Results. Three subjects achieved rapid independence in washing and dressing (20 days, 37 days, and 11 days of treatment), and one did not show significant clinical Improvement. Conclusion. All patients admitted to the facility during a 3-year period who required washing and dressing retraining were treated with the same protocol. The consecutive series design prevented researchers om selecting patients who they believed were good treatment candidates; therefore, the findings support the general applicability of the training program.	SAMUEL MERRITT COLL,OAKLAND,CA; TRANSIT BERKELEY,BERKELEY,CA; STANFORD SLEEP DISORDERS CTR,STANFORD,CA; GUARDIAN HLTH GRP INC,CORTE MADERA,CA; THERAPY RESOURCES INC,SONOMA,CA		Giles, GM (corresponding author), NEUROBEHAV PROGRAM HIGHVIEW,CLIN SERV,1301 E 31ST ST,OAKLAND,CA 94602, USA.						BLAKE KA, 1969, PSYCHOL REP, V25, P319, DOI 10.2466/pr0.1969.25.1.319; BURKE WH, 1988, INT J REHABIL RES, V11, P235, DOI 10.1097/00004356-198809000-00003; CERMAK LS, 1976, NEUROPSYCHOLOGIA, V14, P311, DOI 10.1016/0028-3932(76)90025-7; COHEN RE, 1986, ARCH PHYSICAL MED RE, V67, P833; EAMES P, 1985, J NEUROL NEUROSUR PS, V48, P613, DOI 10.1136/jnnp.48.7.613; Eames P, 1985, Int Rehabil Med, V7, P130; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; FOX RM, 1989, BEHAV THER, V20, P61; FUSSEY I, 1988, REHABILITATION SEVER; GILES GM, 1989, J CLIN EXP NEUROPSYC, V11, P311, DOI 10.1080/01688638908400891; GILES GM, 1989, ARCH PHYS MED REHAB, V70, P156; GILES GM, 1988, AM J OCCUP THER, V42, P658, DOI 10.5014/ajot.42.10.658; GILES GM, 1993, BRAIN INJURY REHABIL; Heacock L, 1989, Arch Phys Med Rehabil, V70, P720; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Jennett B, 1981, MANAGEMENT HEAD INJU; KATZMANN S, 1994, AM J OCCUP THER, V48, P259, DOI 10.5014/ajot.48.3.259; KAZDIN AE, 1994, BEHAVIOR MODIFICATIO; LEWIS FD, 1988, BEHAV THER, V19, P203, DOI 10.1016/S0005-7894(88)80043-1; MARTIN G, 1981, BEHAV RES SEVERE DEV, V2, P117; MCDONNELL J, 1987, J ASSOC PERS SEVERE, V12, P227, DOI 10.1177/154079698701200309; MCDONNELL J, 1989, EDUC TRAIN MENT RET, V24, P230; MCMILLAN T M, 1990, Brain Injury, V4, P399, DOI 10.3109/02699059009026193; NIHARA K, 1975, ADAPTIVE BEHAV SCALE; O'Reilly M. F., 1989, BEHAV RESIDENTIAL TR, V4, P359, DOI 10. 1002/bin. 2360040406; PULASKI KH, 1994, AM J OCCUP THER, V48, P263, DOI 10.5014/ajot.48.3.263; SPOONER F, 1984, EDUC TRAIN MENT RET, V19, P15; SPOONER F, 1981, DISS ABSTR INT A; TEASDALE G, 1974, LANCET, V2, P81; WALLS RT, 1981, BEHAV MODIF, V5, P61, DOI 10.1177/014544558151005; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WOLERY M, 1990, EDUC TRAIN MENT RET, V25, P243; [No title captured]; [No title captured]	34	25	25	0	1	AMER OCCUPATIONAL THERAPY ASSOC	ROCKVILLE	1383 PICCARD DRIVE PO BOX ROCKVILLE, MD 20850-4375	0272-9490			AM J OCCUP THER	Am. J. Occup. Ther.	APR	1997	51	4					256	266		10.5014/ajot.51.4.256			11	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	WN496	WOS:A1997WN49600003	9085724				2022-02-06	
J	McKindley, DS; Boucher, BA; Hess, MM; Rodman, JH; Feler, C; Fabian, TC				McKindley, DS; Boucher, BA; Hess, MM; Rodman, JH; Feler, C; Fabian, TC			Effect of acute phase response on phenytoin metabolism in neurotrauma patients	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article							TUMOR-NECROSIS-FACTOR; ADULT HUMAN HEPATOCYTES; C-REACTIVE PROTEIN; PROPHYLACTICALLY ADMINISTERED PHENYTOIN; POST-TRAUMATIC SEIZURES; HEPATIC DRUG-METABOLISM; SEVERE HEAD-INJURY; CYTOCHROME-P-450 ENZYMES; CLINICAL-PHARMACOLOGY; INTERLEUKIN-1 IL-1	The purpose of this prospective study was to correlate measures of the acute phase response, associated therapeutic interventions, and other clinical variables with the process of altered drug metabolism previously observed in patients with severe neurotrauma. Nine patients with severe head injury (Glasgow Coma Scale less than or equal to 8) requiring intravenous phenytoin were included in the study. A loading dose of phenytoin was followed by daily maintenance doses. Serial blood samples were taken after the loading dose and every even-numbered study day for 10 to 14 days for measurement of total and unbound concentrations of phenytoin, interleukin-1 beta, interleukin-6 (IL-6), tumor necrosis factor alpha, alpha(1)-acid-glycoprotein, C-reactive protein, and albumin. Time-invariant and time-variant Michaelis-Menten models were fit to the phenytoin concentration-time data. Protein intake was closely monitored. The mean (+/- SEM) unbound fraction of phenytoin increased from 0.17 +/- 0.02 on day 1 to 0.24 +/- 0.04 on day 10 (P < 0.05). The time-variant model was superior in describing the concentration-time data of unbound phenytoin in eight of nine patients. Mean (+/- SEM) pharmacokinetic parameter estimates for unbound phenytoin were: V-max(Delta) = 605 +/- 92 mg/day, V-max(B) = 149 +/- 26.3 mg/day, k(ind) = 0.013 +/- 0.004 hr(-1). Interleukin-6 was the only cytokine with significant concentration changes over time; it was inversely correlated with V-max,V-t. Peak concentrations of interleukin-6 also proved to be inversely correlated with V-max(B). The daily amount of protein administered was significantly correlated with V-max,V-t. Significant alterations in the metabolism of phenytoin occur after severe neurotrauma. The etiology of these changes is probably multifaceted. These results suggest that low initial phenytoin V-max may be explained by the presence of interleukin-6. An increase in oxidative metabolism that correlated with nutritional protein administration was observed later in these patients.	UNIV TENNESSEE, DEPT CLIN PHARM SURG & NEUROSURG, MEMPHIS, TN USA		McKindley, DS (corresponding author), UNIV RHODE ISL, DEPT PHARM PRACTICE, 144 FOGARTY HALL, KINGSTON, RI 02881 USA.						ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; ANDERSON KE, 1979, CLIN PHARMACOL THER, V26, P493, DOI 10.1002/cpt1979264493; AULITZKY WE, 1994, DRUGS, V48, P667, DOI 10.2165/00003495-199448050-00002; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BEAL SL, 1983, J PHARMACOKINET BIOP, V11, P641, DOI 10.1007/BF01059062; BOUCHER BA, 1988, CLIN PHARMACOL THER, V44, P675, DOI 10.1038/clpt.1988.211; BOUCHER BA, 1991, CLIN PHARMACOL THER, V50, P487, DOI 10.1038/clpt.1991.173; BOUCHER BA, 1987, CLIN PHARMACY, V6, P881; CALANDRA T, 1991, AM J MED, V91, P23, DOI 10.1016/0002-9343(91)90069-A; CASTELL JV, 1988, FEBS LETT, V232, P347, DOI 10.1016/0014-5793(88)80766-X; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; CHEN YL, 1992, BIOCHEM PHARMACOL, V44, P137, DOI 10.1016/0006-2952(92)90047-M; CHUICKSHANK AM, 1990, CLIN SCI, V79, P161; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; DARGENIO DZ, 1979, COMPUT PROG BIOMED, V9, P115, DOI 10.1016/0010-468X(79)90025-4; DELERS F, 1989, BIOCHEM BIOPH RES CO, V161, P81, DOI 10.1016/0006-291X(89)91563-5; DICKINSON RG, 1985, THER DRUG MONIT, V7, P283, DOI 10.1097/00007691-198507030-00008; FAGAN TC, 1987, CLIN PHARMACOL THER, V41, P402, DOI 10.1038/clpt.1987.48; GHEZZI P, 1986, INFECT IMMUN, V54, P837, DOI 10.1128/IAI.54.3.837-840.1986; GHEZZI P, 1986, BIOCHEM BIOPH RES CO, V136, P316, DOI 10.1016/0006-291X(86)90912-5; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GRIFFETH LK, 1983, DRUG METAB DISPOS, V11, P517; GRIFFETH LK, 1984, DRUG METAB DISPOS, V12, P588; GUO Y, 1990, CLIN IMMUNOL IMMUNOP, V54, P361, DOI 10.1016/0090-1229(90)90050-Z; JUAN D, 1986, CLIN PHARMACOL THER, V40, P187, DOI 10.1038/clpt.1986.162; KAPPAS A, 1976, CLIN PHARMACOL THER, V20, P643; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KRISHNASWAMY K, 1984, BRIT J CLIN PHARMACO, V17, P139, DOI 10.1111/j.1365-2125.1984.tb02328.x; LUDDEN TM, 1977, CLIN PHARMACOL THER, V21, P287; Markowsky SJ, 1996, ANN PHARMACOTHER, V30, P443, DOI 10.1177/106002809603000501; MARTIN E, 1977, J PHARMACOKINET BIOP, V5, P579, DOI 10.1007/BF01059685; MAWER GE, 1974, BRIT J CLIN PHARMACO, V1, P163, DOI 10.1111/j.1365-2125.1974.tb00226.x; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MOSHAGE HJ, 1988, BIOCHEM BIOPH RES CO, V155, P112, DOI 10.1016/S0006-291X(88)81056-8; OHZATO H, 1992, SURGERY, V111, P201; OTT L, 1987, JPEN-PARENTER ENTER, V11, P488, DOI 10.1177/0148607187011005488; POUS C, 1990, DRUG METAB DISPOS, V18, P467; RENTON KW, 1976, BIOCHEM BIOPH RES CO, V73, P343, DOI 10.1016/0006-291X(76)90713-0; Roberts P R, 1995, New Horiz, V3, P506; SCHLUTER B, 1991, J TRAUMA, V31, P1663, DOI 10.1097/00005373-199112000-00017; SHEDLOFSKY SI, 1987, LIFE SCI, V40, P2331, DOI 10.1016/0024-3205(87)90506-6; SLAUGHTER RL, 1995, ANN PHARMACOTHER, V29, P619, DOI 10.1177/106002809502900612; SUJITA K, 1990, BIOCHEM BIOPH RES CO, V168, P1217, DOI 10.1016/0006-291X(90)91158-O; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; THOMPSON PJ, 1983, BRIT J CLIN PHARMACO, V16, P267, DOI 10.1111/j.1365-2125.1983.tb02160.x; TOLER SM, 1993, DRUG METAB DISPOS, V21, P1064; VESELL ES, 1979, CLIN PHARMACOL THER, V26, P275; WERMELING DP, 1987, DRUG INTEL CLIN PHAR, V21, P459, DOI 10.1177/106002808702100517; YAMADA Y, 1990, ANN NY ACAD SCI, V587, P351, DOI 10.1111/j.1749-6632.1990.tb00176.x; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1985, NEUROSURGERY, V17, P784, DOI 10.1227/00006123-198511000-00010; YUEN GJ, 1983, RES COMMUN CHEM PATH, V42, P355	56	25	25	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0091-2700	1552-4604		J CLIN PHARMACOL	J. Clin. Pharmacol.	FEB	1997	37	2					129	139		10.1002/j.1552-4604.1997.tb04771.x			11	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	WK569	WOS:A1997WK56900007	9055139				2022-02-06	
J	Iwamoto, Y; Yamaki, T; Murakami, N; Umeda, M; Tanaka, C; Higuchi, T; Aoki, I; Naruse, S; Ueda, S				Iwamoto, Y; Yamaki, T; Murakami, N; Umeda, M; Tanaka, C; Higuchi, T; Aoki, I; Naruse, S; Ueda, S			Investigation of morphological change of lateral and midline fluid percussion injury in rats, using magnetic resonance imaging	NEUROSURGERY			English	Article						brain atrophy; cortical contusion; diffuse axonal injury; fluid percussion; magnetic resonance imaging; rat; traumatic brain injury	DIFFUSE AXONAL INJURY; CLOSED HEAD-INJURY; COMPUTED-TOMOGRAPHY; BRAIN INJURY; TRAUMA; INFARCTION; IMAGES	OBJECTIVE: Investigating the time course of morphological changes in experimental traumatic brain injury (TBI) in vivo helps to clarify the mechanism of TBI and develop new therapeutic modalities. We examined the morphological changes in experimental TBI, using magnetic resonance imaging (MRI) in a rat model. METHODS: We produced lateral fluid percussion injury (LFP) and midline fluid percussion injury (MFP) in rats, using the Yamaki fluid percussion device. The rats were divided into four groups: LFP, MFP, sham LFP, and sham MFP. MRI was performed with a 4.7-T magnetic resonance apparatus 2 days and 90 days after the induction of injury. T1-, T2-, and T2*-weighted images were obtained using a surface coil. RESULTS: Hemorrhage, contusion, and brain edema in LFP models were detected on the 2nd day after injury, and the necrotic tissue was absorbed and replaced by cerebrospinal fluid on the 90th day. In MFP animals, we detected a small hemorrhage in the corpus callosum with minimal brain edema around the hemorrhage on the 2nd day after injury, and on the 90th day, enlarged ventricles and cisterns were observed, indicating brain atrophy. CONCLUSION: MRI, therefore, is useful for plotting morphological changes in experimental TBI in vivo. We report the novel and clinically important finding of brain atrophy after experimental TBI.	KYOTO PREFECTURAL UNIV MED, DEPT NEUROSURG, KAMIGYO KU, KYOTO 602, JAPAN; MEIJI COLL ORIENTAL MED, DEPT NEUROSURG, KYOTO, JAPAN				Aoki, Ichio/G-2529-2011	Aoki, Ichio/0000-0002-4429-5053			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BUONANNO FS, 1983, STROKE, V14, P178, DOI 10.1161/01.STR.14.2.178; COHEN Y, 1991, MAGNET RESON MED, V17, P225, DOI 10.1002/mrm.1910170125; DUONG DH, 1992, J NEUROSURG, V77, P151, DOI 10.3171/jns.1992.77.1.0151; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HANSEN G, 1980, RADIOLOGY, V136, P695, DOI 10.1148/radiology.136.3.7403549; HAWKINS TD, 1976, CLIN RADIOL, V27, P279, DOI 10.1016/S0009-9260(76)80069-4; IWAMOTO Y, 1994, LIFE SCI, V55, P1651, DOI 10.1016/0024-3205(94)00332-7; IWAMOTO Y, 1993, ADV NEUROTRAUMA RES, V5, P6; KATO H, 1985, J CEREBR BLOOD F MET, V5, P267, DOI 10.1038/jcbfm.1985.34; LAUTERBUR PC, 1973, NATURE, V242, P190, DOI 10.1038/242190a0; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; MANO I, 1983, INVEST RADIOL, V18, P345, DOI 10.1097/00004424-198307000-00010; MURAKAMI N, 1992, ADV NEUROTRAUMA RES, V4, P7; MURAKAMI N, 1993, ADV NEUROTRAUMA RES, V5, P42; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; VANDONGEN KJ, 1980, NEUROSURGERY, V7, P14, DOI 10.1227/00006123-198007000-00003; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	27	25	27	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	1997	40	1					163	167		10.1097/00006123-199701000-00036			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	VY973	WOS:A1997VY97300082	8971838				2022-02-06	
J	Togher, L; Hand, L; Code, C				Togher, L; Hand, L; Code, C			A new perspective on the relationship between communication impairment and disempowerment following head injury in information exchanges	DISABILITY AND REHABILITATION			English	Article						traumatic brain injury; functional communication; empowerment	TRAUMATIC BRAIN INJURY; SOCIAL-INTERACTION; LANGUAGE; MEMORY	Communication disorders following closed head injury (CHI) have been described in terms of the impairments that affect the individual's ability to produce words, sentences and discourse. Rather than focusing on impairments, this paper examines the disability experienced by one CHI subject. Comparison is made between M. R., who has sustained a severe CHI, and his brother, S. R. during four telephone calls to their mother, a therapist, the police and the bus timetable information service, using exchange structure analysis. Results indicated that social distance between communication partners, and the nature of the interaction, affected the language choices made by both subjects. The communication partner was found to have a profound impact on the way each subject was able to negotiate each interaction. Results are discussed in terms of the ways in which therapists and society in general view disability and how this shapes social encounters, which in turn affects the outcomes which are made possible for people with CHI.	UNIV SYDNEY,SCH COMMUN DISORDERS,FAC HLTH SCI,LIDCOMBE,NSW,AUSTRALIA				Togher, Leanne/AAC-7083-2019; Code, Chris/F-4259-2010	Togher, Leanne/0000-0002-4518-6748			Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; BERRY M, 1981, STUDIES DISCOURSE AN, P120; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BURTON LA, 1993, J REHABILITATION OCT, P4; CONGER JA, 1988, ACAD MANAGE REV, V13, P471, DOI 10.2307/258093; CRISP R, 1991, AUSTR DISABILITY REV, V1, P37; FINE M, 1988, J SOC ISSUES, V44, P3, DOI 10.1111/j.1540-4560.1988.tb02045.x; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Foucault M., 2010, ARCHAEOLOGY KNOWLEDG; FULLAGER S, 1993, AUSTR DISABILITY REV, V4, P36; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; GOFFMAN E, 1963, BEHAVIOR PUBLIC PLAC; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; HAGEN C, 1982, COGNITIVE REHABILITA, P131; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HALLIDAY MAK, 1970, NEW HORIZON LINGUIST, P322; Halliday Michael Alexander Kirkwood, 1989, LANGUAGE CONTEXT TEX; HALPERN H, 1973, J SPEECH HEAR DISORD, V38, P162, DOI 10.1044/jshd.3802.162; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; Livingston M G, 1985, Int Rehabil Med, V7, P145; LIVINGSTON M G, 1990, Pediatrician, V17, P255; MALKMUS DD, 1989, TOP LANG DISORD, V9, P50, DOI 10.1097/00011363-198903000-00006; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; Martin J. R., 1992, ENGLISH TEXT SYSTEM; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Penn C, 1988, Brain Inj, V2, P3, DOI 10.3109/02699058809150928; Poynton C., 1985, LANGUAGE GENDER MAKI; Prigatano G. P., 1985, LANG SCI, V7, P217, DOI [10.1016/S0388-0001(85)80020-6, DOI 10.1016/S0388-0001(85)80020-6]; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; SOHLBERG MM, 1989, TOP LANG DISORD, V9, P15, DOI 10.1097/00011363-198903000-00004; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; VENTOLA E, 1987, STRUCTURE SOCIAL INT; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; Ylvisaker Mark, 1992, Seminars in Speech and Language, V13, P308, DOI 10.1055/s-2008-1064205; [No title captured]	42	25	28	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0963-8288			DISABIL REHABIL	Disabil. Rehabil.	NOV	1996	18	11					559	566		10.3109/09638289609166317			8	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	VX695	WOS:A1996VX69500004	9233853				2022-02-06	
J	Henley, CM; Muszynski, C; Cherian, L; Robertson, CS				Henley, CM; Muszynski, C; Cherian, L; Robertson, CS			Activation of ornithine decarboxylase and accumulation of putrescine after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; ornithine decarboxylase; polyamines; putrescine; trauma	REVERSIBLE CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; NMDA RECEPTOR; ALPHA-DIFLUOROMETHYLORNITHINE; POLYAMINE METABOLISM; VESTIBULAR NUCLEI; BARRIER BREAKDOWN; RAT; LABYRINTHECTOMY; STIMULATION	Activation of ornithine decarboxylase (ODC), the initial enzyme in polyamine synthesis, and accumulation of putrescine are thought to mediate pathological processes in the ischemic and traumatized brain. Past studies have separately investigated either ODC or polyamines after head injury. The purpose of the present study was to quantify both ODC activity and polyamines in the rat parietal cortex before and after controlled cortical impact injury. Adult, male rats underwent a right craniectomy and were subjected to a 5 m/sec, 2-mm deformation impact injury. Rats were sacrificed 1, 4, 8, and 24 h postimpact and tissues from the injured (right) and contralateral (left) hemisphere were analyzed for ODC and polyamines. ODC activity was determined by measuring the decarboxylation of [C-14]ornithine to putrescine. Putrescine, spermidine, and spermine were determined by high performance liquid chromatography. Cortical impact induced a 10- to 20-fold increase in ODC activity and a 4- to 5-fold increase in putrescine in the ipsilateral cortex. Spermidine and spermine did not significantly increase in the ipsilateral (right) cortex compared to controls (right cortex). In contrast, there was a slight increase in spermidine content in the contralateral (left) cortex after injury. The delayed increase in ODC activity and accumulation of putrescine may mediate pathophysiological changes observed after head injury.	BAYLOR COLL MED,BOBBY R ALFORD DEPT OTORHINOLARYNGOL COMMUNICAT S,DIV NEUROSCI,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROSURG,HOUSTON,TX 77030		Henley, CM (corresponding author), BAYLOR COLL MED,BOBBY R ALFORD DEPT OTORHINOLARYNGOL COMMUNICAT S,DEPT PHARMACOL,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27616] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS027616, P01NS027616] Funding Source: NIH RePORTER		ANDO M, 1984, J NEUROCHEM, V42, P94, DOI 10.1111/j.1471-4159.1984.tb09703.x; BACKOUS DD, 1994, OTOLARYNG HEAD NECK, V111, P377, DOI 10.1177/019459989411100401; Baskaya MFK, 1996, NEUROSURGERY, V38, P140; Baskaya MK, 1996, J NEUROTRAUM, V13, P85, DOI 10.1089/neu.1996.13.85; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; CARTER C, 1989, EUR J PHARMACOL, V164, P611, DOI 10.1016/0014-2999(89)90275-6; CARTER C, 1988, J PHARMACOL EXP THER, V247, P1222; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHOI DW, 1987, J NEUROSCI, V7, P369; COFFINO P, 1991, J CELL BIOCHEM, V45, P54, DOI 10.1002/jcb.240450112; DEMPSEY R J, 1988, Neurological Research, V10, P141; DEVERA N, 1991, J NEUROCHEM, V57, P1; DIENEL GA, 1984, J NEUROCHEM, V42, P1053, DOI 10.1111/j.1471-4159.1984.tb12710.x; DIENEL GA, 1985, J NEUROCHEM, V44, P600, DOI 10.1111/j.1471-4159.1985.tb05454.x; GILAD GM, 1992, BIOCHEM PHARMACOL, V44, P401, DOI 10.1016/0006-2952(92)90428-L; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; GOTTI B, 1990, BRAIN RES, V522, P290, DOI 10.1016/0006-8993(90)91473-T; HENLEY C, 1993, ACTA OTO-LARYNGOL, V113, P235, DOI 10.3109/00016489309135799; HENLEY CM, 1987, BRAIN RES BULL, V19, P695, DOI 10.1016/0361-9230(87)90056-6; HENLEY CM, 1994, OTOLARYNG HEAD NECK, V110, P103, DOI 10.1016/S0194-5998(94)70798-7; KOENIG H, 1983, NATURE, V305, P530, DOI 10.1038/305530a0; KOHSAKA S, 1981, DEV BRAIN RES, V1, P391, DOI 10.1016/0165-3806(81)90076-6; METCALF BW, 1978, J AM CHEM SOC, V100, P2551, DOI 10.1021/ja00476a050; MORRIS DR, 1991, J CELL BIOCHEM, V46, P102, DOI 10.1002/jcb.240460203; MUSZYNSKI CA, 1993, J CEREBR BLOOD F MET, V13, P1033, DOI 10.1038/jcbfm.1993.131; PASCHEN W, 1988, BRAIN RES, V453, P9, DOI 10.1016/0006-8993(88)90138-2; PASCHEN W, 1987, NEUROCHEM PATHOL, V7, P143, DOI 10.1007/BF02834214; PASCHEN W, 1992, CEREBROVAS BRAIN MET, V4, P59; PEGG AE, 1988, BIOCHEMISTRY-US, P11; PERONA BP, 1990, ANN PLAS SURG, V25, P26, DOI 10.1097/00000637-199007000-00006; PORCELLA A, 1991, EUR J PHARMACOL, V199, P267, DOI 10.1016/0014-2999(91)90469-7; REED LJ, 1990, J NEUROCHEM, V55, P780, DOI 10.1111/j.1471-4159.1990.tb04560.x; ROMANO C, 1994, NEUROPHARMAOCLOGY PO; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; RUSSELL DH, 1985, DRUG METAB REV, V16, P1, DOI 10.3109/03602538508991430; RUSSELL DH, 1974, J NEUROBIOL, V5, P349, DOI 10.1002/neu.480050406; SALZER TA, 1994, AM J OTOL, V15, P728; SCATTON B, 1993, FUND CLIN PHARMACOL, V7, P389, DOI 10.1111/j.1472-8206.1993.tb01036.x; SCHMITZ MP, 1993, NEUROSURGERY, V33, P882; SEILER N, 1981, MED BIOL, V59, P334; Seiler N, 1991, Prog Drug Res, V37, P107; Seiler N, 1988, Adv Exp Med Biol, V250, P127; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; TETZLAFF W, 1985, EXP NEUROL, V89, P679, DOI 10.1016/0014-4886(85)90016-0; TROUT JJ, 1986, LAB INVEST, V55, P622; WILLIAMS K, 1991, LIFE SCI, V48, P469, DOI 10.1016/0024-3205(91)90463-L	46	25	25	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1996	13	9					487	496		10.1089/neu.1996.13.487			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	VP266	WOS:A1996VP26600001	8913965				2022-02-06	
J	Shum, D; Sweeper, S; Murray, R				Shum, D; Sweeper, S; Murray, R			Performance on verbal implicit and explicit memory tasks following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						explicit memory; implicit memory; level of processing; traumatic brain injury	CLOSED-HEAD-INJURY; RETENTION; SURVIVORS	The study aimed to ascertain if implicit memory is preserved after traumatic brain injury (TBI). It used two explicit memory tasks (graphemic-cued recall and semantic-cued recall) and two implicit memory tasks (word-fragment completion and general knowledge) to compare the performance of 16 individuals with severe, long-term TBI, and 16 matched controls. In addition, it examined the effect of level of processing on memory-task performance. It was found that individuals with TBI performed significantly more poorly on the two explicit memory tasks but not the two implicit memory tasks. Moreover, it was found that these individuals did not benefit as much from deep processing of memory materials as the matched controls. Implications of these Endings for developing memory training programs are discussed.	GRIFFITH UNIV,SCH APPL PSYCHOL,NATHAN,QLD 4111,AUSTRALIA		Shum, D (corresponding author), GRIFFITH UNIV,NEUROPSYCHOL UNIT,NATHAN,QLD 4111,AUSTRALIA.		Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262			BLAXTON TA, 1992, MEM COGNITION, V20, P549, DOI 10.3758/BF03199587; BRANDT J, 1992, NEUROPSYCHOLOGY MEMO; CHALLIS BH, 1992, J EXP PSYCHOL LEARN, V18, P595, DOI 10.1037/0278-7393.18.3.595; CORKIN S, 1968, NEUROPSYCHOLOGIA, V6, P255, DOI 10.1016/0028-3932(68)90024-9; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; GARDINER JM, 1988, J EXP PSYCHOL LEARN, V14, P495, DOI 10.1037/0278-7393.14.3.495; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; GLISKY EL, 1989, HDB NEUROPSYCHOLOGY; GLISKY EL, 1992, J HEAD TRAUMA REHAB, V7, P1; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Levin H., 1989, HDB NEUROPSYCHOLOGY; MAPOU RL, 1992, HDB HEAD TRAUMA; MASSON MEJ, 1992, J EXP PSYCHOL GEN, V121, P145, DOI 10.1037/0096-3445.121.2.145; MUTTER SA, 1990, COGNITIVE NEUROPSYCH, V7, P329, DOI 10.1080/02643299008253447; Parkin A. J., 1993, NEUROPSYCHOLOGY AMNE; ROEDIGER HL, 1990, AM PSYCHOL, V45, P1043, DOI 10.1037/0003-066X.45.9.1043; SCHACTER DL, 1992, AM PSYCHOL, V47, P559, DOI 10.1037/0003-066X.47.4.559; Sholberg M. M., 1989, INTRO COGNITIVE REHA; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; WARRINGT.EK, 1970, NATURE, V228, P628, DOI 10.1038/228628a0; WARRINGTON EK, 1968, NATURE, V217, P972, DOI 10.1038/217972a0; WILSON BA, 1992, CLIN MANAGEMENT MEMO; WILSON BA, 1992, NEUROPSYCHOLOGY MEMO	25	25	25	2	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1996	11	2					43	53		10.1097/00001199-199604000-00005			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UD674	WOS:A1996UD67400005					2022-02-06	
J	Connolly, B; Emery, D; Armstrong, D				Connolly, B; Emery, D; Armstrong, D			The odontoid synchondrotic slip: An injury unique to young children	PEDIATRIC RADIOLOGY			English	Article							FRACTURES	We report seven children (three female, four male) diagnosed with traumatic synchondrotic slip of the odontoid. The clinical records, plain films, and CT scans were evaluated retrospectively. The patients ranged in age between 3 and 5 years. Their injuries resulted from a motor vehicle accident in four cases and from a fall from a height in three. The injury was isolated in five; it was associated with a closed head injury in one and with facial and brachial plexus trauma in another. Radiographs showed anterior angulation with or without displacement in all seven cases. Axial CT with sagittal reformation and 3D reconstructions were performed in six cases. This confirmed the synchondrotic slip and, in addition, identified a rotary component to the injury in three cases, with compromise of the canal in two. Other additional injuries were also noted. All cases were treated conservatively and the injuries healed. Only one child had a neurological deficit attributable to her head injury rather than to her cervical injury (MR of the cervical cord was normal). The presence of the synchondrosis between the dens and the body of C-2 makes this injury unique to children under 7 years of age; by the age of 7 the synchondrosis has fused.			Connolly, B (corresponding author), UNIV TORONTO,HOSP SICK CHILDREN,DEPT DIAGNOST IMAGING,555 UNIV AVE,TORONTO,ON MSG 1X8,CANADA.		Emery, Derek/V-4913-2019	Emery, Derek/0000-0003-2678-3077			ALP MS, 1990, BMJ-BRIT MED J, V300, P319, DOI 10.1136/bmj.300.6720.319; ANDERSON LD, 1974, J BONE JOINT SURG AM, VA 56, P1663, DOI 10.2106/00004623-197456080-00017; APPLE JS, 1987, PEDIATR RADIOL, V17, P45, DOI 10.1007/BF02386594; BAILEY DK, 1952, RADIOLOGY, V59, P712, DOI 10.1148/59.5.712; BLOCKEY NJ, 1956, J BONE JOINT SURG BR, V38, P794, DOI 10.1302/0301-620X.38B4.794; EWALD FC, 1971, J BONE JOINT SURG AM, VA 53, P1636, DOI 10.2106/00004623-197153080-00019; FLOMAN Y, 1991, J BONE JOINT SURG BR, V73, P640, DOI 10.1302/0301-620X.73B4.2071650; FREIBERGER RH, 1965, J BONE JOINT SURG AM, VA 47, P1231, DOI 10.2106/00004623-196547060-00013; FUJII E, 1988, SPINE, V13, P604; GRIFFITHS SC, 1972, J PEDIATR SURG, V7, P680, DOI 10.1016/0022-3468(72)90279-5; KELLER J, 1990, INJURY, V21, P191, DOI 10.1016/0020-1383(90)90098-F; LEVINE AM, 1986, ORTHOP CLIN N AM, V17, P31; MANDABACH M, 1993, PEDIATR NEUROSURG, V19, P225, DOI 10.1159/000120737; MCGRORY BJ, 1993, J BONE JOINT SURG AM, V75A, P988, DOI 10.2106/00004623-199307000-00004; OGDEN JA, 1984, SKELETAL RADIOL, V12, P169, DOI 10.1007/BF00361083; RIES MD, 1986, SPINE, V11, P1043, DOI 10.1097/00007632-198612000-00018; RUGE JR, 1988, J NEUROSURG, V68, P25, DOI 10.3171/jns.1988.68.1.0025; SEIMON LP, 1977, J BONE JOINT SURG AM, V59, P943, DOI 10.2106/00004623-197759070-00019; SHERK HH, 1978, J BONE JOINT SURG AM, V60, P921, DOI 10.2106/00004623-197860070-00008; VINING DJ, 1992, J NEUROSURG, V77, P795, DOI 10.3171/jns.1992.77.5.0795; Warwick R, 1973, GRAYS ANATOMY, V35th	21	25	25	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0301-0449			PEDIATR RADIOL	Pediatr. Radiol.	NOV	1995	25			1			S129	S133					5	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics; Radiology, Nuclear Medicine & Medical Imaging	TM948	WOS:A1995TM94800039	8577504				2022-02-06	
J	SMITH, GA; DIETRICH, AM; GARCIA, CT; SHIELDS, BJ				SMITH, GA; DIETRICH, AM; GARCIA, CT; SHIELDS, BJ			EPIDEMIOLOGY OF SHOPPING CART-RELATED INJURIES TO CHILDREN - AN ANALYSIS OF NATIONAL DATA FOR 1990 TO 1992	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							SAFETY	Objective: To describe the epidemiologic characteristics of shopping cart-related injuries among children in the United States. Design: A retrospective analysis of data from the National Electronic Injury Surveillance System of the US Consumer Product Safety Commission for 1990 to 1992. Results: An estimated 75 200 shopping cart-related injuries occurred in children younger than 15 years treated in US emergency departments during 1990 to 1992 (95% confidence interval, 57 500 to 92 900). Children younger than 5 years were at highest risk, accounting for 63 200 (84%) of the injuries. A 20% increase was observed in the number of injuries among 0- to 4-year-old children from 1990 to 1992. Fifty-three percent of injured children were male. The head and neck region was the most common anatomic site of injury, accounting for 74% of injuries among children younger than 15 years. An estimated 2000 children (2.7%) younger than 15 years required hospital admission (1.2% in 1990 compared with 3.5% in 1992). Children aged 0 to 4 years accounted for 93% of these hospital admissions. Among 0- to 14-year-old children, fractures accounted for 45% of hospital admissions, followed by internal injury (22%) and concussion (17%). Conclusions: Injuries related to shopping carts are an important cause of pediatric morbidity, especially among children younger than 5 years. These injuries can also result in death. Shopping carts should be redesigned to decrease the risk of injury to children, and transportation of children in shopping carts of current design should be prohibited.	OHIO STATE UNIV,COLL MED,DEPT PEDIAT,COLUMBUS,OH 43210								Baker SP, 1992, THE INJURY FACT BOOK, VSecond; CAMPBELL M, 1990, BRIT MED J, V301, P1370, DOI 10.1136/bmj.301.6765.1370; FERRARI JR, 1989, BEHAV MODIF, V13, P51, DOI 10.1177/01454455890131003; HARRELL WA, 1990, ACCIDENT ANAL PREV, V22, P531, DOI 10.1016/0001-4575(90)90025-G; ROBERTSON LS, 1983, INJURIES CAUSES CONT; SMITH GA, IN PRESS PEDIATRICS; TRINKOFF A, 1993, PUBLIC HEALTH REP, V108, P784; TULLY S, 1993, AM ACADEMY PEDIA JUN; 1986, US CONSUMER PRODUCT; 1992, MMWR-MORBID MORTAL W, V41, P271; 1993, EXPLANATION SHEET NE; 1991, AJDC, V145, P933	12	25	25	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	NOV	1995	149	11					1207	1210		10.1001/archpedi.1995.02170240025003			4	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	TD456	WOS:A1995TD45600003	7581750				2022-02-06	
J	KRAUS, JF; PEEK, C				KRAUS, JF; PEEK, C			THE IMPACT OF 2 RELATED PREVENTION STRATEGIES ON HEAD-INJURY REDUCTION AMONG NONFATALLY INJURED MOTOR CYCLE RIDERS, CALIFORNIA, 1991-1993	JOURNAL OF NEUROTRAUMA			English	Article						ACCIDENT PREVENTION; TRAFFIC ACCIDENTS; TRAUMA; LEGISLATION; EPIDEMIOLOGY	LAW; FATALITIES; HELMETS; COSTS	Although the traumatic injury death rate in the United States decreased during the last 20 years, the percent of all injury deaths attributable to brain injuries has remained steady. Head injuries are a leading cause of injury among motorcycle riders in crashes, and the helmet is an effective measure to reduce these injuries. To reduce the burden and cost of motorcycle injuries, many states have increased helmet use by introducing mandatory helmet legislation. This report presents evidence on the effects of the motorcycle helmet and helmet use legislation-two interrelated prevention strategies which decrease traumatic brain injury among motorcycle riders. Nonfatally injured motorcyclists were included if they crashed between January 1, 1991 and December 31, 1993 and were treated in one of 18 hospitals in 10 California counties. Medical records for all injured motorcyclists admitted to these 18 hospitals and those treated in the emergency department and released in eight of these hospitals were individually reviewed. Complete lists of injury diagnoses for each rider were coded according to the 1990 Abbreviated Injury Severity Scale by trained clinical staff. Before the universal helmet law was introduced (when only a third of injured riders wore helmets) 38.2% of riders sustained head injuries. When helmet use increased to over 85% of injured riders following the law, less than 25% of riders sustained head injuries. Both the severity and the number of head injuries per individual rider decreased after the mandatory helmet use law led to increased helmet use. Riders wearing helmets suffered fewer skull fractures, fewer intracranial injuries, had less frequent and shorter periods of loss of consciousness, more favorable GCS scores, and shorter hospital stays. Mandatory motorcycle helmet use laws are an effective mechanism to increase helmet use among riders and thus prevent head and brain injuries resulting from motorcycle crashes.			KRAUS, JF (corresponding author), UNIV CALIF LOS ANGELES,SCH PUBL HLTH,SO CALIF INJURY PREVENT RES CTR,10833 LECONTE AVE,LOS ANGELES,CA 90095, USA.						[Anonymous], 1990, ABBREVIATED INJURY S; CAIRNS H, 1941, BRIT MED J, V2, P465; Carey V, 1994, Aust J Public Health, V18, P25; DRYSDALE WF, 1975, J TRAUMA, V15, P99, DOI 10.1097/00005373-197502000-00003; EVANS L, 1991, ACCIDENT ANAL PREV, V23, P165, DOI 10.1016/0001-4575(91)90046-8; EVANS L, 1990, ACCIDENT ANAL PREV, V22, P167, DOI 10.1016/0001-4575(90)90067-U; FAYON A, 1976, P BIOMECHANICS INJUR; FLEMING NS, 1992, MED CARE, V30, P832, DOI 10.1097/00005650-199209000-00007; HURT HH, 1981, P AM ASS AUTOMOTIVE; KRANTZ KPG, 1985, INJURY, V16, P253; KRAUS JF, 1995, AM J PUBLIC HEALTH, V85, P96, DOI 10.2105/AJPH.85.1.96; KRAUS JF, 1975, AM J EPIDEMIOL, V102, P99, DOI 10.1093/oxfordjournals.aje.a112137; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; LOEB PD, 1993, ACCIDENT ANAL PREV, V25, P189, DOI 10.1016/0001-4575(93)90059-6; LUNA GK, 1981, WESTERN J MED, V135, P89; MCSWAIN NE, 1990, J TRAUMA, V30, P1189, DOI 10.1097/00005373-199010000-00002; MCSWAIN NE, 1984, DOTHS806760 NAT HIGH; MCSWAIN NE, 1984, DTN22782C05086; Mounce N, 1992, REINSTATED COMPREHEN; MUELLEMAN RL, 1992, ANN EMERG MED, V21, P266, DOI 10.1016/S0196-0644(05)80886-8; ROBERSTON L, 1992, INJURY EPIDEMIOLOGY; RUTLEDGE R, 1991, 35TH P ASS ADV AUT M; SARKAR S, 1995, J TRAUMA, V38, P242, DOI 10.1097/00005373-199502000-00017; SOSIN D, UNPUB; WAGENAAR AC, 1990, ACCIDENT ANAL PREV, V22, P253, DOI 10.1016/0001-4575(90)90017-F; WATSON GS, 1980, AM J PUBLIC HEALTH, V70, P579, DOI 10.2105/AJPH.70.6.579; ZADOR PL, 1993, AM J PUBLIC HEALTH, V83, P661, DOI 10.2105/AJPH.83.5.661; 1991, GAORCED91170; 1980, REPORT C EFFECT MOTO; 1994, TRAFFIC SAFETY FACTS; 1994, 1993 ANN REP FAT INJ; 1994, JAMA-J AM MED ASSOC, V272, P1535	32	25	25	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					873	881		10.1089/neu.1995.12.873			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600011	8594214				2022-02-06	
J	PAPERO, PH; PRANZATELLI, MR; MARGOLIS, LJ; TATE, E; WILSON, LA; GLASS, P				PAPERO, PH; PRANZATELLI, MR; MARGOLIS, LJ; TATE, E; WILSON, LA; GLASS, P			NEUROBEHAVIORAL AND PSYCHOSOCIAL FUNCTIONING OF CHILDREN WITH OPSOCLONUS-MYOCLONUS SYNDROME	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							CLOSED HEAD-INJURY; SYDENHAM CHOREA; NEURO-BLASTOMA; ADOLESCENTS; ENCEPHALOPATHY; CHILDHOOD; LEUKEMIA; OUTCOMES	Childhood opsoclonus-myoclonus syndrome (OMS) is a movement disorder which typically strikes children in the early preschool years, seriously affecting intellectual, social-emotional and general adaptive development. This series of 13 cases with well-documented neurological histories, aged 1.7 to 16.3 years, provides an initial systematic evaluation of these children's neuropsychological, psychosocial and adaptive status. As expected, children with OMS had significantly reduced intelligence and severe speech and motor output problems; however, most of them also demonstrated a range of preserved neurocognitive abilities and impressive goal-directedness and communicative effort. Psychosocial problems included mild behavioral impairment on the Achenbach Child Behavior Checklist, and severe adaptive limitations on the Vineland Adaptive Behavior Scales despite relatively strong social skills. Developmental factors and likelihood of subcortical localization are discussed, and practical guidelines are provided for behavioral and educational management of these children.	GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,DEPT NEUROL & PHARMACOL,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,DEPT PEDIAT,WASHINGTON,DC 20010; GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,CHILDRENS RES INST,NATL PEDIAT MYOCLONUS CTR,WASHINGTON,DC 20010		PAPERO, PH (corresponding author), GEORGE WASHINGTON UNIV,CHILDRENS NATL MED CTR,DEPT PSYCHIAT & BEHAV SCI,111 MICHIGAN AVE NW,WASHINGTON,DC 20010, USA.				FDA HHS [FD-R-000955, FD-R-000746] Funding Source: Medline		ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; Annett M.A., 1985, LEFT RIGHT HAND BRAI; BARON IS, 1993, NEUROPSYCHOL REHABIL, V3, P389, DOI 10.1080/09602019308401448; Bayley N., 1969, BAYLEY SCALES INFANT; BOLTSHAUSER E, 1979, HELV PAEDIATR ACTA, V34, P119; BROUWERS P, 1984, J CLIN NEUROPSYCHOL, V6, P325, DOI 10.1080/01688638408401222; Ciccetti D., 1984, VINELAND ADAPTIVE BE; DENNIS M, 1987, J CLIN EXP NEUROPSYC, V9, P593, DOI 10.1080/01688638708410771; Dennis M., 1988, CLIN NEUROPSYCHOLOGY, P89; DYKEN PR, 1986, CHILD NEUROPSYCHOLOG, V1, P175; FANTZ RL, 1979, CAN J PSYCHOL, V33, P277, DOI 10.1037/h0081726; FLETCHER JM, 1991, AM PSYCHOL, V46, P1267, DOI 10.1037/0003-066X.46.12.1267; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1984, EARLY BRAIN DAMAGE, V1, P189; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; GOLDMAN S, 1992, Neurology, V42, P320; HANSON CL, 1987, J CONSULT CLIN PSYCH, V55, P529, DOI 10.1037/0022-006X.55.4.529; HOLMESBERNSTEIN J, 1990, NEUROMETHODS, V17, P311, DOI DOI 10.1385/0896031330; HUBER SJ, 1990, SUBCORTICAL DEMENTIA, P73; Kaufman A., 1983, K ABC KAUFMAN ASSESS; KIENZLE GD, 1991, AM J NEURORADIOL, V12, P73; LEVIN HS, 1979, CHILD BRAIN, V5, P281; Luria A.R., 1973, WORKING BRAIN; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; OLEARY DS, 1984, EARLY BRAIN DAMAGE, V1, P215; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; PHILLIPS S, 1992, Neurology, V42, P288; PRANZATELLI MR, 1994, EXP NEUROL, V125, P142, DOI 10.1006/exnr.1994.1018; PRANZATELLI MR, 1992, CLIN NEUROPHARMACOL, V15, P186, DOI 10.1097/00002826-199206000-00002; ROURKE BP, 1983, NONVERBAL LEARNING D; Rourke BP., 1989, NONVERBAL LEARNING D; SENELICK RC, 1973, J PEDIATR SURG, V8, P623, DOI 10.1016/0022-3468(73)90400-4; SHAPIRO EG, 1992, J CLIN EXP NEUROPSYC, V14, P610, DOI 10.1080/01688639208402848; SOLLEE ND, 1987, J ABNORM CHILD PSYCH, V15, P479, DOI 10.1007/BF00917235; Strang J.D., 1983, CHILD NEUROPSYCHOLOG; SWEDO SE, 1993, PEDIATRICS, V91, P706; SWEDO SE, 1992, INT PEDIAT, V7, P136; TALON P, 1985, PEDIATRIE, V40, P441; TAYLOR HG, 1987, J PEDIATR PSYCHOL, V12, P395, DOI 10.1093/jpepsy/12.3.395; TELANDER RL, 1989, J PEDIATR SURG, V24, P11, DOI 10.1016/S0022-3468(89)80291-X; TUCHMAN RF, 1989, NEURORADIOLOGY, V31, P250, DOI 10.1007/BF00344353; WALLANDER JL, 1988, J PEDIATR PSYCHOL, V13, P197, DOI 10.1093/jpepsy/13.2.197; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D., 1989, WECHSLER PRESCHOOL P; Wechsler D., 1991, WISC 3 WECHSLER INTE	46	25	25	0	2	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	OCT	1995	37	10					915	932					18	Clinical Neurology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics	TH519	WOS:A1995TH51900008	7493725				2022-02-06	
J	BAVETTA, S; NIMMON, CC; WHITE, J; MCCABE, JM; HUNEIDI, AH; BOMANJI, J; BIRKENFELD, B; CHARLESWORTH, M; BRITTON, KE; GREENWOOD, RJ				BAVETTA, S; NIMMON, CC; WHITE, J; MCCABE, JM; HUNEIDI, AH; BOMANJI, J; BIRKENFELD, B; CHARLESWORTH, M; BRITTON, KE; GREENWOOD, RJ			A PROSPECTIVE-STUDY COMPARING SPET WITH MRI AND CT AS PROGNOSTIC INDICATORS FOLLOWING SEVERE CLOSED-HEAD INJURY	NUCLEAR MEDICINE COMMUNICATIONS			English	Article							CEREBRAL BLOOD-FLOW; COMPUTED-TOMOGRAPHY; TRAUMA; DISABILITY; SCALE	Ten patients were studied prospectively after severe closed head injury to determine the relationship between long-term clinical outcome and abnormalities detected by single photon emission tomography (Tc-99(m)-HMPAO SPET), CT and MRI obtained within 60 days of injury. The ability of SPET to detect abnormalities not visualized by CT or MRI after cerebral trauma is confirmed by the results of this study. Changes detected by SPET [global cerebral Mood flow (gCBF) and number of regional cerebral blood flow (rCBF) deficits] soon after trauma were shown to be more closely correlated with long-term outcome than changes detected by MRI or CT. Templates were used to classify lesions by site and a multivariate analysis was undertaken to establish the importance of defect position in predicting clinical outcome. The results suggest that lesions in the temporal lobes, frontal lobes and basal ganglia are related to poor prognosis, and that SPET yields more useful prognostic data than the other methods.	ST BARTHOLOMEWS HOSP,DEPT NEUROSURG,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT NUCL MED,LONDON,ENGLAND; ST BARTHOLOMEWS HOSP,DEPT NEURORADIOL,LONDON,ENGLAND; HOMERTON HOSP,REG REHABIL UNIT,LONDON,ENGLAND				Birkenfeld, Bozena/A-4796-2015	Birkenfeld, Bozena/0000-0003-1174-8199			ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; BRITTON KE, 1985, NUCL MED COMMUN, V6, P251, DOI 10.1097/00006231-198505000-00002; BULLOCK R, 1990, ACT NEUR S, V51, P286; CHOKSEY MS, 1991, J NEUROL NEUROSUR PS, V54, P6, DOI 10.1136/jnnp.54.1.6; ELL PJ, 1985, LANCET, V2, P50; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; HAYS WL, 1963, STATISTICS, P567; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; MAEDER P, 1991, ACTA RADIOL, V32, P271; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; NIMMON CC, 1989, NEUROIMAGING, V2, P43; ODOR W, 1991, INTENS CARE MED, V17, P149; PODREKA I, 1987, J NUCL MED, V28, P1657; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROPER SN, 1991, J NUCL MED, V32, P1684; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	24	25	25	0	0	CHAPMAN HALL LTD	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8HN	0143-3636			NUCL MED COMMUN	Nucl. Med. Commun.	DEC	1994	15	12					961	968		10.1097/00006231-199412000-00007			8	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	PU876	WOS:A1994PU87600007	7715895				2022-02-06	
J	JOHNSTON, MV; HALL, KM				JOHNSTON, MV; HALL, KM			OUTCOMES EVALUATION IN TBI REHABILITATION .1. OVERVIEW AND SYSTEM PRINCIPLES	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article								Questions of how to measure outcomes are commonly heard in rehabilitation today. In this supplement we review the current state of the art of outcomes measurement in traumatic brain injury rehabilitation, discuss key issues, and identify steps that need to be taken. The underlying question is not simply that of outcomes measurement but how to infer effective and cost-effective treatment. The validity of such inferences rests on multiple features of the entire clinical information system. Requirements for valid, feasible, outcome-oriented clinical data systems are described. Effectiveness is inferred from variations in outcomes experienced by similar persons who received differing interventions. Outcome data systems need large sample sizes and technically adequate severity adjusters. A nationwide TBI data system is needed to identify reasonably homogeneous subgroups in different programs whose outcomes can be meaningfully compared. In alliance with payors and persons with disabilities, rehabilitation professionals can create outcome data systems that will provide the knowledge necessary to improve the effectiveness and cost-effectiveness of rehabilitation programs.	SANTA CLARA VALLEY MED CTR,SAN JOSE,CA 95128		JOHNSTON, MV (corresponding author), KESSLER INST REHABIL INC,1199 PLEASANT VALLEY WAY,W ORANGE,NJ 07052, USA.							0	25	25	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1994	75	12			SI		SC2	SC9					8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	PY709	WOS:A1994PY70900002					2022-02-06	
J	STRAUSS, E; SPELLACY, F; HUNTER, M; BERRY, T				STRAUSS, E; SPELLACY, F; HUNTER, M; BERRY, T			ASSESSING BELIEVABLE DEFICITS ON MEASURES OF ATTENTION AND INFORMATION-PROCESSING CAPACITY	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							HEAD-INJURY; RECOVERY	The vulnerability of tests of sustained attention and speed of processing to faked deficits was evaluated by comparing the performances of normal controls, healthy subjects asked to simulate deficits, and patients with closed head injury on a simple auditory reaction-time task and on the PASAT. The results revealed that persons attempting to feign the effects of brain injury perform more poorly than non-malingerers on a simple reaction-time task and the PASAT. The reaction-time task, however, proved more effective than the PASAT at detecting dissimulation, accurately classifying about 76% of the subjects. This value reflects a respectable hit rate for three-group classification.			STRAUSS, E (corresponding author), UNIV VICTORIA,DEPT PSYCHOL,VICTORIA V8W 3P5,BC,CANADA.						ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1987, J CLIN EXP NEUROPSYC, V9, P167, DOI 10.1080/01688638708405357; BINDER LM, 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI DOI 10.1037/1040-3590.3.2.175; Bradley J. V., 1968, DISTRIBUTION FREE ST; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Kolb B., 1990, FUNDAMENTALS HUMAN N; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; PANKRATZ L, 1975, J CONSULT CLIN PSYCH, V43, P421, DOI 10.1037/h0076722; PANKRATZ L, 1979, J CONSULT CLIN PSYCH, V47, P409, DOI 10.1037/0022-006X.47.2.409; Rey A., 1964, EXAMEN CLIN PSYCHOL	16	25	25	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV-DEC	1994	9	6					483	490		10.1016/0887-6177(94)90039-6			8	Psychology, Clinical; Psychology	Social Science Citation Index (SSCI)	Psychology	PT254	WOS:A1994PT25400002	14590997				2022-02-06	
J	KAPLAN, CP; CORRIGAN, JD				KAPLAN, CP; CORRIGAN, JD			THE RELATIONSHIP BETWEEN COGNITION AND FUNCTIONAL INDEPENDENCE IN ADULTS WITH TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							MEDICAL REHABILITATION; ASSESSMENT SCALES; HEAD-INJURY; ORIENTATION; RECOVERY				KAPLAN, CP (corresponding author), OHIO STATE UNIV,DEPT PHYS MED & REHABIL,DIV REHABIL PSYCHOL,480 W 9TH AVE,COLUMBUS,OH 43210, USA.						BROOKS DN, 1990, REHABILITATION ADULT, P175; COHEN J, 1988, STATISTICAL POWE ANA, P414; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; CORRIGAN JD, 1985, ARCH PHYS MED REHAB, V66, P626; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DILLER L, 1987, NEUROBEHAVIORAL RECO, P150; GALBRAITH S, 1987, BRIT MED J, V294, P325, DOI 10.1136/bmj.294.6568.325; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1976, ARCH PHYS MED REHAB, V57, P103; GRANGER CV, 1992, AM J PHYS MED REHAB, V71, P108, DOI 10.1097/00002060-199204000-00009; GRANGER CV, 1984, FUNCTIONAL ASSESSMEN, P14; HAMILTON BB, 1987, ARCH PHYS MED REHAB, V68, P583; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; JACKSON RD, 1989, ARCH PHYS MED REHAB, V70, P33; JENNETT B, 1981, MANAGEMENT HEAD INJU, P295; Keith R., 1987, ADV CLIN REHABILITAT, V1, P10; KOTTKE FJ, 1982, KRUSENS HDB PHYSICAL, pR11; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; ROSE M, 1981, REHABILITATION MED M, P183; SANEDA D L, 1992, Brain Injury, V6, P167, DOI 10.3109/02699059209029655; SCHERZER BP, 1993, BRAIN INJURY, V7, P411, DOI 10.3109/02699059309029684; SILVERSTEIN B, 1991, ARCH PHYS MED REHAB, V72, P631; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; WILKERSON DL, 1992, ARCH PHYS MED REHAB, V73, P111; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456; 1980, WHO INT CLASSIFICATI, V14, P27; [No title captured]	30	25	25	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1994	75	6					643	647		10.1016/0003-9993(94)90186-4			5	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	NP636	WOS:A1994NP63600005	8002762				2022-02-06	
J	CHILDERS, MK; RUPRIGHT, J; SMITH, DW				CHILDERS, MK; RUPRIGHT, J; SMITH, DW			POSTTRAUMATIC HYPERTHERMIA IN ACUTE BRAIN INJURY REHABILITATION	BRAIN INJURY			English	Article							NEUROLEPTIC MALIGNANT SYNDROME; DANTROLENE; DOPAMINE; FEVER; MECHANISM	Fever frequently presents during recovery from traumatic brain injury (TBI). Elevated body temperature may result from ensuing infection, thrombophlebitis, drug reaction, or a defect in the central thermoregulatory system such as seen in post-traumatic hyperthermia (PTH). Typically, the diagnosis of PTH follows only after thorough investigation. Literature supports the theory that the febrile TBI patient, lacking a documented source, has central hyperthermia. The purpose of this study was to determine the incidence of PTH in the acute rehabilitation setting. We reviewed a consecutive series of 84 TBI patients participating in a rehabilitation programme. Four per cent of the patients in this study met our criteria for PTH. We describe a fever protocol that should aid the physician in diagnosis and treatment of the febrile TBI patient. Proposed mechanisms involved in thermoregulation are discussed.			CHILDERS, MK (corresponding author), UNIV HOSP & CLIN,DEPT PHYS MED & REHABIL,COLUMBIA,MO 65212, USA.			Childers, Martin/0000-0003-4754-0883			ACKERMAN D, 1980, J PHYSIOL-LONDON, V307, P59, DOI 10.1113/jphysiol.1980.sp013423; Adams RD, 1989, PRINCIPLES NEUROLOGY; BENEDEK G, 1987, CAN J NEUROL SCI, V14, P145; BONTKE CF, 1989, PHYSICAL MED REHABIL, V3, P55; Borison H L, 1967, Adv Pharmacol, V5, P129, DOI 10.1016/S1054-3589(08)60657-2; BULLARD DE, 1977, ANN NEUROL, V21, P138; COX B, 1978, J PHYSIOL-LONDON, V282, P471, DOI 10.1113/jphysiol.1978.sp012476; DAVIES JA, 1973, J PHARM PHARMACOL, V25, P705, DOI 10.1111/j.2042-7158.1973.tb10051.x; DINARELLO CA, 1988, REV INFECT DIS, V10, P168; FUXE K, 1972, J PHARM PHARMACOL, V24, P702, DOI 10.1111/j.2042-7158.1972.tb09093.x; GRANATO JE, 1983, ANN NEUROL, V14, P89, DOI 10.1002/ana.410140117; GRONERT GA, 1976, ANESTHESIOLOGY, V44, P488, DOI 10.1097/00000542-197606000-00005; GUZE BH, 1985, NEW ENGL J MED, V313, P163, DOI 10.1056/NEJM198507183130306; HARRISON GG, 1988, BRIT J ANAESTH, V60, P279, DOI 10.1093/bja/60.3.279; HENDERSON VW, 1981, NEUROLOGY, V31, P132, DOI 10.1212/WNL.31.2.132; HORN LJ, 1988, J HEAD TRAUMA REHAB, V3, P87; JACKSON R D, 1991, Brain Injury, V5, P93, DOI 10.3109/02699059108998518; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; LIPTON JM, 1986, ANNU REV PHYSIOL, V48, P613; MILTON AS, 1978, PHARM HYPOTHALAMUS, P113; MORGAN KG, 1977, J PHARMACOL EXP THER, V201, P138; Myers R D, 1984, Physiologist, V27, P41; PETERSDORF RG, 1983, HARRISONS PRINCIPLES, P57; QUINLAN JG, 1990, MUSCLE NERVE, V13, P904, DOI 10.1002/mus.880131003; Reid J L, 1975, Adv Neurol, V9, P73; RUDY TA, 1980, FEVER, P165; RUDY TA, J PHYSL, V272, P721; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SEGATORE M, 1992, J NEUROSCIENCE NURSI, V24, P105; STEWART CR, 1980, NEW ENGL J MED, V302, P1262; STITT JT, 1979, FED PROC, V38, P39; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; VANHILTEN JJ, 1991, CLIN NEUROL NEUROSUR, V93, P223, DOI 10.1016/S0303-8467(05)80007-1; YEHUDA S, 1972, NATURE, V240, P477, DOI 10.1038/240477a0	34	25	25	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1994	8	4					335	343		10.3109/02699059409150984			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	NP445	WOS:A1994NP44500004	8081348				2022-02-06	
J	TANDON, DA; THAKAR, A; MAHAPATRA, AK; GHOSH, P				TANDON, DA; THAKAR, A; MAHAPATRA, AK; GHOSH, P			TRANS-ETHMOIDAL OPTIC-NERVE DECOMPRESSION	CLINICAL OTOLARYNGOLOGY			English	Article						TRANS-ETHMOIDAL; OPTIC NERVE DECOMPRESSION; VISUAL EVOKED POTENTIAL	TRAUMA; FRACTURES; BLINDNESS	Blunt head injury frequently results in visual impairment, the optimal treatment of which is still debated. Over a 5-year-period (1987-1991) 111 patients with indirect optic nerve injury resulting from closed head trauma have been treated. In each case loss of vision was the only neurological deficit. In group A, 66 patients were initially treated with large doses of prednisolone (80 mg/day) for 3 weeks. Twenty-seven patients improved on steroids alone. In the remaining 39 patients in whom either unsatisfactory or no improvement occurred a transethmoidal optic nerve decompression was performed. Twenty-two patients in the latter group improved, thus yielding an overall improvement rate of 74.2% in group A. Group B (control), in which 45 patients were treated with prednisolone only (80 mg/day for 3 weeks), had an overall improvement rate of 51% (23 patients). The study reveals that while nearly half of such patients can improve on steroids alone, optic nerve decompression significantly improves recovery rates in patients where conservative treatment is unsatisfactory (P < 0.05). Total loss of vision not responding to steroids, absence of waveform on visual evoked response, and presence of-an optic canal fracture indicate a poor prognosis.	ALL INDIA INST MED SCI, DEPT NEUROSURG, NEW DELHI 110029, INDIA		TANDON, DA (corresponding author), ALL INDIA INST MED SCI, DEPT OTORHINOLARYNGOL & HEAD & NECK SURG, NEW DELHI 110029, INDIA.		Thakar, Alok/V-7701-2019				Aitken P., 1991, OPHTHALMOL CLIN N AM, V4, P479; ANDERSON RL, 1982, OPHTHALMOLOGY, V89, P445; BRIHAYE J, 1976, ACTA NEUROCHIR, V33, P319, DOI 10.1007/BF01886679; EDMUND J, 1963, ACTA OPHTHALMOL, V41, P693; FUJITANI T, 1986, JPN J OPHTHALMOL, V30, P125; Fukado Y, 1975, Mod Probl Ophthalmol, V14, P474; FUNK GF, 1989, HEAD NECK-J SCI SPEC, V11, P295, DOI 10.1002/hed.2880110403; HUGHES B, 1962, B JOHNS HOPKINS HOSP, V111, P98; KENNERDELL JS, 1976, ARCH OPHTHALMOL-CHIC, V94, P1040; LESSELL S, 1989, ARCH OPHTHALMOL-CHIC, V107, P382, DOI 10.1001/archopht.1989.01070010392031; Lillie WI, 1934, ARCH OPHTHALMOL-CHIC, V12, P500, DOI 10.1001/archopht.1934.00830170038005; MAHAPATRA AK, 1992, NEUROL INDIA, V40, P17; MANFREDI SJ, 1981, PLAST RECONSTR SURG, V68, P479, DOI 10.1097/00006534-198110000-00001; MANISCALCO JE, 1978, J NEUROSURG, V48, P402, DOI 10.3171/jns.1978.48.3.0402; NAU HE, 1987, ACTA NEUROCHIR, V89, P16, DOI 10.1007/BF01406662; NIHO S, 1961, AM J OPHTHALMOL, V51, P659, DOI 10.1016/0002-9394(61)91611-7; NIHO S, 1970, CAN J OPHTHALMOLOGY, V5, P22; OSGUTHORPE JD, 1985, OTOLARYNG CLIN N AM, V18, P125; RAMSAY JH, 1979, BRIT J OPHTHALMOL, V63, P607, DOI 10.1136/bjo.63.9.607; Rodger F C, 1943, Br J Ophthalmol, V27, P23, DOI 10.1136/bjo.27.1.23; SOFFERMAN RA, 1981, LARYNGOSCOPE, V91, P184	21	25	29	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1749-4478	1749-4486		CLIN OTOLARYNGOL	Clin. Otolaryngol.	APR	1994	19	2					98	104		10.1111/j.1365-2273.1994.tb01190.x			7	Otorhinolaryngology	Science Citation Index Expanded (SCI-EXPANDED)	Otorhinolaryngology	NH892	WOS:A1994NH89200003	8026103				2022-02-06	
J	WEISEND, MP; FEENEY, DM				WEISEND, MP; FEENEY, DM			THE RELATIONSHIP BETWEEN TRAUMATIC BRAIN INJURY-INDUCED CHANGES IN BRAIN TEMPERATURE AND BEHAVIORAL AND ANATOMICAL OUTCOME	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC BRAIN INJURY; HYPOTHERMIA; HYPERTHERMIA; NEUROPATHOLOGY; BEHAVIORAL RECOVERY	CEREBRAL BLOOD-FLOW; ISCHEMIC NEURONAL INJURY; EXPERIMENTAL HEAD-INJURY; MILD HYPOTHERMIA; MAGNETIC-RESONANCE; INTRACRANIAL-PRESSURE; MODERATE HYPOTHERMIA; FOREBRAIN ISCHEMIA; ENERGY-METABOLISM; ARTERY OCCLUSION	Alteration of brain temperature, experimentally induced or spontaneous, has been shown to affect the symptoms resulting from a variety of cerebral insults. This study examined the effect of traumatic brain injury (TBI) on brain and body temperature in rats and the relationship between TBI-induced temperature changes, neuropathology, and behavioral recovery. Anesthesia, surgery and TBI all caused changes in brain and body temperatures. The level of brain (but not body) temperature at the time of TBI was positively correlated with the severity of hippocampal and thalamic pathology. In contrast, the measured levels of both brain and body temperatures after TBI were not related to behavioral or neuroanatomical outcome. Interestingly, the increase in brain (but not body) temperature from the time of TBI to 5 to 10 minutes after termination of anesthesia was negatively correlated with behavioral and anatomical outcome. Simply stated, the more rapidly brain temperature returned toward normal, the better the rats' behavioral and anatomical outcome. This rate of return toward normal brain temperature is not interpreted as causally related to outcome but rather as an index of the severity of brain injury.	UNIV NEW MEXICO,DEPT PHYSIOL,ALBUQUERQUE,NM		WEISEND, MP (corresponding author), UNIV NEW MEXICO,DEPT PSYCHOL,LOGAN HALL,ROOM 278,ALBUQUERQUE,NM 87131, USA.						ABRAMS R. M., 1965, LIFE SCI, V4, P2399, DOI 10.1016/0024-3205(65)90295-X; AGARDH CD, 1992, ACTA NEUROPATHOL, V83, P379, DOI 10.1007/BF00713529; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; BAKER CJ, 1991, SURG NEUROL, V36, P175, DOI 10.1016/0090-3019(91)90109-M; BOYD R J, 1961, Surg Forum, V12, P408; BROWN AW, 1979, ANN NEUROL, V5, P127, DOI 10.1002/ana.410050206; BRUNNER EA, 1971, J NEUROCHEM, V18, P2301, DOI 10.1111/j.1471-4159.1971.tb00186.x; BUCHANAN TA, 1991, METABOLISM, V40, P330, DOI 10.1016/0026-0495(91)90118-G; BUSTO R, 1989, STROKE, V20, P1113, DOI 10.1161/01.STR.20.8.1113; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; CARLSSON C, 1976, ANESTHESIOLOGY, V44, P27, DOI 10.1097/00000542-197601000-00006; CHAN KH, 1992, NEUROSURGERY, V30, P697; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; DIETRICH WD, 1991, ACTA NEUROPATHOL, V81, P615, DOI 10.1007/BF00296371; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; DUHAIME AC, 1990, BRAIN RES, V512, P169, DOI 10.1016/0006-8993(90)91188-M; FAY T, 1945, RES PUBL ASS NERV ME, V24, P611; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1989, J NEUROTRAUM, V6, P209; FREUND TF, 1990, EXP NEUROL, V108, P251, DOI 10.1016/0014-4886(90)90131-B; GORDON CJ, 1990, PHYSIOL BEHAV, V47, P963, DOI 10.1016/0031-9384(90)90025-Y; GORDON CJ, 1991, AM J PHYSIOL, V260, pR120, DOI 10.1152/ajpregu.1991.260.1.R120; GORDON CJ, 1986, ANNU REV PHYSIOL, V48, P595, DOI 10.1146/annurev.ph.48.030186.003115; GORDON CJ, 1988, TOXICOLOGY, V53, P161, DOI 10.1016/0300-483X(88)90211-9; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; HAGERDAL M, 1978, ANESTHESIOLOGY, V49, P165, DOI 10.1097/00000542-197809000-00003; HANSEN TD, 1989, J CEREBR BLOOD F MET, V9, P323, DOI 10.1038/jcbfm.1989.50; HARALDSETH O, 1992, ACTA ANAESTH SCAND, V36, P393, DOI 10.1111/j.1399-6576.1992.tb03487.x; HAYWARD JN, 1969, BRAIN RES, V16, P417, DOI 10.1016/0006-8993(69)90236-4; HORN M, 1991, ACTA NEUROPATHOL, V81, P443, DOI 10.1007/BF00293466; Hynson J M, 1992, J Clin Anesth, V4, P194, DOI 10.1016/0952-8180(92)90064-8; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KONARSKA M, 1990, PSYCHOBIOLOGY, V18, P30; KURAMOTO T, 1979, ANESTHESIOLOGY, V51, P211, DOI 10.1097/00000542-197909000-00006; KUROIWA T, 1990, J CEREBR BLOOD F MET, V10, P550, DOI 10.1038/jcbfm.1990.97; LANDSBERG L, 1984, AM J PHYSIOL, V247, pE181, DOI 10.1152/ajpendo.1984.247.2.E181; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; LEONOV Y, 1990, J CEREBR BLOOD F MET, V10, P57, DOI 10.1038/jcbfm.1990.8; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LO EH, 1992, STROKE, V23, P889, DOI 10.1161/01.STR.23.6.889; LONG NC, 1990, PHYSIOL BEHAV, V47, P773, DOI 10.1016/0031-9384(90)90093-J; Maier NRF, 1935, J COMP NEUROL, V61, P395, DOI 10.1002/cne.900610209; MCARTHUR AJ, 1981, J THERM BIOL, V6, P43, DOI 10.1016/0306-4565(81)90042-5; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MICHENFELDER JD, 1984, CLIN NEUROSURG, V32, P105; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MINAMISAWA H, 1990, STROKE, V21, P758, DOI 10.1161/01.STR.21.5.758; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; NAGASAKA T, 1979, JPN J PHYSIOL, V29, P383; NATALE JE, 1989, STROKE, V20, P770, DOI 10.1161/01.STR.20.6.770; NEILL KH, 1990, J NEUROSCI METH, V33, P179, DOI 10.1016/0165-0270(90)90022-8; NEWMAN GC, 1992, BRAIN RES, V575, P159, DOI 10.1016/0006-8993(92)90438-F; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON B, 1977, J NEUROSURG, V47, P274, DOI 10.3171/jns.1977.47.2.0274; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Schmidt-Nielsen K., 1983, ANIMAL PHYSL ADAPTAT; SESSLER DI, 1987, ANESTHESIOLOGY, V67, P137, DOI 10.1097/00000542-198707000-00032; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; Shima K, 1991, J NEUROTRAUM, V8, P65; SIMPSON RE, 1991, NEUROSCI LETT, V124, P83, DOI 10.1016/0304-3940(91)90827-G; SUTTON R L, 1990, Society for Neuroscience Abstracts, V16, P777; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; TODD MM, 1984, ANESTHESIOLOGY, V60, P276, DOI 10.1097/00000542-198404000-00002; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VANDENPOL AN, 1990, J COMP NEUROL, V296, P654, DOI 10.1002/cne.902960410; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; WEISEND M P, 1989, Society for Neuroscience Abstracts, V15, P69; Weisend M. P., 1992, Society for Neuroscience Abstracts, V18, P179; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	90	25	25	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	JAN	1994	80	1					120	132		10.3171/jns.1994.80.1.0120			13	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	MQ154	WOS:A1994MQ15400017	8270998				2022-02-06	
J	WONG, CW				WONG, CW			THE CT CRITERIA FOR CONSERVATIVE TREATMENT - BUT UNDER CLOSE CLINICAL OBSERVATION - OF POSTERIOR-FOSSA EPIDURAL HEMATOMAS	ACTA NEUROCHIRURGICA			English	Article						HEAD INJURY; EPIDURAL HEMATOMA; POSTERIOR FOSSA; CONSERVATIVE TREATMENT	EXTRADURAL HEMATOMAS; COMPUTED-TOMOGRAPHY; CRANIAL FOSSA; MANAGEMENT; RESOLUTION; CHILDREN	In order to assess whether the indications for conservative treatment of supratentorial epidural haematomas are applicable also to posterior fossa epidural haematomas (PFEDH), the author reviewed the records of 25 patients. With a PFEDH volume of no more than 10 ml, a thickness of no more than 15 mm, a midline shift of no more than 5 mm, and in the absence of a significant intracranial haematoma elsewhere on computed tomography (CT) scans, the patients undergoing conservative treatment achieved the same excellent outcome as those undergoing early surgery. These CT criteria for conservative treatment of PFEDHs are similar to those of supratentorial epidural haematomas except the volume factor, namely, 10 ml in the former against 30 ml in the latter. That means a PFEDH of 10 ml or larger in the small posterior fossa may produce the same degree of midline shift and compression, and be as dangerous as an epidural haematoma of 30 ml or larger in the more capacious supratentorial compartment. But also for epidural haematomas of the posterior fossa, which initially are smaller than 10 ml, the general rule remains valid that they should be under close clinical supervision	CHANG GUNG MED COLL,CHANG GUNG MEM HOSP,DEPT SURG,DIV NEUROSURG,TAIPEI,TAIWAN								AMMIRATI M, 1984, NEUROSURGERY, V14, P541, DOI 10.1227/00006123-198405000-00002; AOKI N, 1988, J NEUROSURG, V68, P149, DOI 10.3171/jns.1988.68.1.0149; ASHKENAZI E, 1990, J TRAUMA, V30, P613, DOI 10.1097/00005373-199005000-00015; BOITEN J, 1989, J NEUROL NEUROSUR PS, V52, P914, DOI 10.1136/jnnp.52.7.914-a; BULLOCK R, 1985, NEUROSURGERY, V16, P602, DOI 10.1227/00006123-198505000-00003; CHEN TY, 1993, NEUROSURGERY, V32, P176, DOI 10.1227/00006123-199302000-00004; ERICSON K, 1981, ACTA RADIOL DIAGN, V22, P513, DOI 10.1177/028418518102200501; GARZAMERCADO R, 1983, J NEUROSURG, V59, P664, DOI 10.3171/jns.1983.59.4.0664; HOOPER RS, 1954, BRIT J SURG, V42, P19, DOI 10.1002/bjs.18004217103; ILLINGWORTH R, 1983, J NEUROL NEUROSUR PS, V46, P558, DOI 10.1136/jnnp.46.6.558; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; KUSHNER MJ, 1983, NEURORADIOLOGY, V24, P169; MEREDITH JM, 1961, AM J SURG, V102, P524, DOI 10.1016/0002-9610(61)90556-6; MORI K, 1983, CHILD BRAIN, V10, P130; MUNSLOW RA, 1951, J NEUROSURG, V8, P542, DOI 10.3171/jns.1951.8.5.0542; NEUBAUER UJ, 1987, ACTA NEUROCHIR, V87, P105, DOI 10.1007/BF01476060; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; PETERSEN OF, 1984, NEURORADIOLOGY, V26, P285; POZZATI E, 1986, NEUROSURGERY, V18, P696, DOI 10.1227/00006123-198606000-00003; POZZATI E, 1989, SURG NEUROL, V32, P300, DOI 10.1016/0090-3019(89)90234-6; RIVANO C, 1992, NEUROCHIRURGIA, V35, P43; SAKAI H, 1988, J NEUROSURG, V68, P566, DOI 10.3171/jns.1988.68.4.0566; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; STJOHN JN, 1986, SURG NEUROL, V25, P475; STONE JL, 1979, SURG NEUROL, V11, P419; TSAI FY, 1980, J COMPUT ASSIST TOMO, V4, P291, DOI 10.1097/00004728-198006000-00002; WEAVER D, 1981, J NEUROSURG, V54, P248, DOI 10.3171/jns.1981.54.2.0248; WONG C-W, 1991, Asian Journal of Surgery, V14, P64; WRIGHT RL, 1966, J NEUROSURG, V25, P402, DOI 10.3171/jns.1966.25.4.0402; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729; ZUCCARELLO M, 1981, NEUROSURGERY, V8, P434, DOI 10.1227/00006123-198104000-00005	31	25	25	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1994	126	2-4					124	127		10.1007/BF01476421			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	MY920	WOS:A1994MY92000012	8042543				2022-02-06	
J	FADEN, AI; TZENDZALIAN, PA				FADEN, AI; TZENDZALIAN, PA			PLATELET-ACTIVATING-FACTOR ANTAGONISTS LIMIT GLYCINE CHANGES AND BEHAVIORAL DEFICITS AFTER BRAIN TRAUMA	AMERICAN JOURNAL OF PHYSIOLOGY			English	Article						AMINO ACIDS; CATIONS; CEREBRAL EDEMA; PHOSPHOLIPIDS; RECEPTOR ANTAGONISTS	AMINO-ACIDS; EXTRACELLULAR LEVELS; NMDA-RECEPTORS; GERBIL BRAIN; BLOOD-FLOW; INJURY; RATS; ISCHEMIA; REPERFUSION	Tissue damage after traumatic brain injury (TBI) results in part from delayed biochemical changes initiated by the insult. Platelet-activating factor (PAF) is an alkylphospholipid that has been implicated in tissue damage after cerebral ischemia. PAF is toxic to certain neuronal cell lines in culture, reduces cerebral blood flow, alters the blood-brain barrier, and can enhance phospholipid hydrolysis. The recent development of receptor antagonists to PAF permits examination of its possible role in delayed tissue injury after neurotrauma. Treatment with the PAF receptor antagonists BN 52021 and WEB 2170 before injury significantly enhanced neurological recovery after fluid percussion-induced TBI in rats. Pretreatment with WEB 2170 also significantly limited alterations in tissue water content and tissue glycine levels after trauma, and reduced posttraumatic levels of extracellular glycine in ipsilateral hippocampus. These findings implicate PAF in the pathophysiology of TBI, through actions at PAF receptors. A possible role for glycine in this process is suggested.	GEORGETOWN UNIV,MED CTR,SCH MED,DEPT PHARMACOL,WASHINGTON,DC 20007		FADEN, AI (corresponding author), GEORGETOWN UNIV,MED CTR,SCH MED,DEPT NEUROL,OFF DEAN RES,MED DENT BLDG NW 101,3900 RESERVOIR RD,WASHINGTON,DC 20007, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027849] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5R01NS27849-02] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR903623] Funding Source: Medline		BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAQUET P, 1986, ADV INFLAMMAT RES, V12, P135; BUCHANAN DC, 1988, ANN NY ACAD SCI, P427; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEMEDIUK P, 1989, J NEUROCHEM, V52, P1529, DOI 10.1111/j.1471-4159.1989.tb09204.x; DOMINGO MT, 1988, BIOCHEM BIOPH RES CO, V151, P730, DOI 10.1016/S0006-291X(88)80341-3; FADEN A I, 1989, Society for Neuroscience Abstracts, V15, P1112; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P451; FAULER J, 1989, BIOCHIM BIOPHYS ACTA, V1013, P80, DOI 10.1016/0167-4889(89)90131-6; FRANCESCANGELI E, 1989, BIOCHEM BIOPH RES CO, V161, P107, DOI 10.1016/0006-291X(89)91567-2; FRERICHS KU, 1990, CEREBROVAS BRAIN MET, V2, P148; GLOBUS MYT, 1991, J NEUROCHEM, V57, P470, DOI 10.1111/j.1471-4159.1991.tb03775.x; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.biochem.55.1.483; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEUER HO, 1990, J PHARMACOL EXP THER, V255, P962; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; Kochanek P, 1991, J NEUROTRAUM, V8, P19, DOI 10.1089/neu.1991.8.19; KOCHANEK PM, 1988, J CEREBR BLOOD F MET, V8, P546, DOI 10.1038/jcbfm.1988.95; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KUMAR R, 1988, BIOCHIM BIOPHYS ACTA, V963, P375, DOI 10.1016/0005-2760(88)90304-9; LINDSBERG P J, 1989, Society for Neuroscience Abstracts, V15, P805; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PANETTA T, 1987, BIOCHEM BIOPH RES CO, V149, P580, DOI 10.1016/0006-291X(87)90407-4; TOKUMURA A, 1987, BIOCHEM BIOPH RES CO, V145, P415, DOI 10.1016/0006-291X(87)91338-6; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	30	25	29	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0002-9513			AM J PHYSIOL	Am. J. Physiol.	OCT	1992	263	4	2				R909	R914		10.1152/ajpregu.1992.263.4.R909			6	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	JU806	WOS:A1992JU80600073	1415805				2022-02-06	
J	GARCIALARREA, L; ARTRU, F; BERTRAND, O; PERNIER, J; MAUGUIERE, F				GARCIALARREA, L; ARTRU, F; BERTRAND, O; PERNIER, J; MAUGUIERE, F			THE COMBINED MONITORING OF BRAIN-STEM AUDITORY EVOKED-POTENTIALS AND INTRACRANIAL-PRESSURE IN COMA - A STUDY OF 57 PATIENTS	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							INTENSIVE-CARE UNIT; CLOSED HEAD-INJURY; EEG SPECTRA; RESPONSES; TRAUMA; DAMAGE; DEATH	Continuous monitoring of brainstem auditory evoked potentials (BAEPs) was carried out in 57 comatose patients for periods ranging from 5 hours to 13 days. In 53 cases intracranial pressure (ICP) was also simultaneously monitored. The study of relative changes of evoked potentials over time proved more relevant to prognosis than the mere consideration of "statistical normality" of waveforms; thus progressive degradation of the BAEPs was associated with a bad outcome even if the responses remained within normal limits. Contrary to previous reports, a normal BAEP obtained during the second week of coma did not necessarily indicate a good vital outcome; it could, however, do so in cases with a low probability of secondary insults. The simultaneous study of BAEPs and ICP showed that apparently significant (> 40 mm Hg) acute rises in ICP were not always followed by BAEP changes. The stability of BAEP's despite "significant" ICP rises was associated in our patients with a high probability of survival, while prolongation of central latency of BAEPs in response to ICP modifications was almost invariably followed by brain death. Continuous monitoring of brainstem responses provided a useful physiological counterpart to physical parameters such as ICP. Serial recording of cortical EPs should be added to BAEP monitoring to permit the early detection of rostrocaudal deterioration.	HOP NEUROL,DEPT ANAESTHESIOL,F-69394 LYON 3,FRANCE; INSERM,U280,F-69008 LYON,FRANCE		GARCIALARREA, L (corresponding author), HOP NEUROL,DEPT EEG,CERMEP,59 BVD PINEL,F-69394 LYON 3,FRANCE.		Bertrand, Olivier/B-6165-2008	Bertrand, Olivier/0000-0003-0733-7979; MAUGUIERE, Francois/0000-0003-4291-4727; Garcia-Larrea, Luis/0000-0002-9873-789X			BASTUJI H, 1988, ELECTROEN CLIN NEURO, V70, P9, DOI 10.1016/0013-4694(88)90189-7; BERTRAND O, 1987, ELECTROEN CLIN NEURO, V68, P433, DOI 10.1016/0168-5597(87)90055-4; BERTRAND O, 1985, THESIS LYON FRANCE; BOSTON J R, 1984, International Journal of Clinical Monitoring and Computing, V1, P13, DOI 10.1007/BF01726657; BREWER CC, 1984, EVOKED POTENTIAL, V2, P578; BUCHNER H, 1988, ELECTROEN CLIN NEURO, V69, P14, DOI 10.1016/0013-4694(88)90031-4; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CENZATO M, 1988, EVOKED POTENTIALS IC, P153; CHIAPPA KH, 1983, EVOKED POTENTIALS CL, P145; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; DEWEERD AW, 1985, ACTA NEUROL SCAND, V72, P489; FACCO E, 1985, ELECTROEN CLIN NEURO, V62, P332, DOI 10.1016/0168-5597(85)90041-3; FERBERT A, 1988, ELECTROEN CLIN NEURO, V69, P136, DOI 10.1016/0013-4694(88)90209-X; Fischer C, 1982, Adv Neurol, V32, P177; GARCIALARREA L, 1987, ELECTROEN CLIN NEURO, V68, P446, DOI 10.1016/0168-5597(87)90056-6; GARCIALARREA L, 1988, NEUROLOGY, V38, P1487, DOI 10.1212/WNL.38.9.1487; GARCIALARREA L, 1992, IN PRESS MANUAL CLIN; GREENBERG RP, 1977, J NEUROSURG, V47, P163, DOI 10.3171/jns.1977.47.2.0163; HACKE W, 1985, J NEUROL, V232, P125, DOI 10.1007/BF00313886; HASSLER O, 1967, NEUROLOGY, V17, P368, DOI 10.1212/WNL.17.4.368; JAVEL E, 1982, ARCH OTOLARYNGOL, V108, P71; JOHNSON RT, 1956, ACTA RADIOL, V46, P242, DOI 10.3109/00016925609170833; KAGA K, 1985, LARYNGOSCOPE, V95, P321; KARNAZE DS, 1985, NEUROLOGY, V35, P1122, DOI 10.1212/WNL.35.8.1122; KAWAHARA N, 1989, ACTA NEUROCHIR, V100, P142, DOI 10.1007/BF01403602; KLINTWORTH KG, 1968, AM J PATHOL, V53, P391; LITSCHER G, 1990, J CLIN MONITOR, V6, P10, DOI 10.1007/BF02832177; LUTSCHG J, 1983, AM J DIS CHILD, V137, P421; MARESCH H, 1983, ELECTROEN CLIN NEURO, V56, P531, DOI 10.1016/0013-4694(83)90239-0; MAUGUIERE F, 1988, EVOKED POTENTIALS IN, P153; MAYNARD DE, 1984, ANAESTHESIA, V39, P678, DOI 10.1111/j.1365-2044.1984.tb06477.x; PFURTSCHELLER G, 1987, J CLIN NEUROPHYSIOL, V4, P389, DOI 10.1097/00004691-198710000-00004; PFURTSCHELLER G, 1985, ELECTROEN CLIN NEURO, V61, pS27, DOI 10.1016/0013-4694(85)90138-5; Posner JB., 1980, DIAGNOSIS STUPOR COM, V3; Prior P, 1986, MONITORING CEREBRAL; ROSENBERG C, 1989, ADV EVOKED POTENTIAL, P223; ROUGEMONT JD, 1971, NEUROCHIRURGIE, V17, P579; SEALES DM, 1979, J TRAUMA, V19, P347, DOI 10.1097/00005373-197905000-00008; TSUBOKAWA T, 1980, J NEUROL NEUROSUR PS, V43, P1005, DOI 10.1136/jnnp.43.11.1005; Uziel A, 1982, Adv Neurol, V32, P195	41	25	26	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	1992	55	9					792	798		10.1136/jnnp.55.9.792			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	JN763	WOS:A1992JN76300010	1402970	Green Published, Bronze			2022-02-06	
J	VILKKI, J; HOLST, P; OHMAN, J; SERVO, A; HEISKANEN, O				VILKKI, J; HOLST, P; OHMAN, J; SERVO, A; HEISKANEN, O			COGNITIVE TEST PERFORMANCES RELATED TO EARLY AND LATE COMPUTED-TOMOGRAPHY FINDINGS AFTER CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							FRONTAL-LOBE; NEUROPSYCHOLOGICAL DEFICITS; LESIONS; RECOVERY; MEMORY	Computed tomography (CT) findings from early (less than 24 hours) and late scan (6 months) after closed-head injury (CHI) were compared to cognitive test scores obtained on an average of 4 months after injury in a consecutive series of 53 patients. The presence of parenchymal lesion was associated with poor test results, indicating cognitive inflexibility and disinhibition of routine response tendencies in novel tasks. These deficits have previously been found to be related in particular to frontal-lobe dysfunction, but the present study did not support the hypothesis that frontal lesion is the principal cause of this impairment in CHI. Parenchymal lesions in the right and left hemisphere were associated with spatial and verbal deficits, respectively. Ventricular enlargement in the late CT was related to cognitive inefficiency, both being strongly associated with age. The results suggest that parenchymal lesion in the early CT is an indicator of diffuse axonal injury, which results in cognitive inflexibility during recovery.			VILKKI, J (corresponding author), UNIV CENT HOSP HELSINKI,DEPT NEUROSURG,TOPELIUKSENKATU 5,SF-00260 HELSINKI,FINLAND.			Ohman, Juha/0000-0002-6592-1367			ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; Benton AL, 1963, REVISED VISUAL RETEN; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; FULD PA, 1980, CORTEX, V16, P255, DOI 10.1016/S0010-9452(80)80061-X; GENNARELLI TA, 1982, J NEUROSURG, V56, P25; Goldberg E., 1987, FRONTAL LOBES REVISI, P159; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Kolb B, 1980, FUNDAMENTALS HUMAN N; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Milner B., 1964, FRONTAL GRANULAR COR, P313; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1990, J CLIN EXP NEUROPSYC, V12, P34; TEASDALE G, 1984, CLOSED HEAD INJURY P, P5; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; VILKKI J, 1985, CORTEX, V21, P431, DOI 10.1016/S0010-9452(85)80007-1; VILKKI J, 1989, NEUROPSYCHOLOGIA, V27, P1101, DOI 10.1016/0028-3932(89)90189-9; VILKKI J, 1988, CORTEX, V24, P119, DOI 10.1016/S0010-9452(88)80020-0; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; WILSON J T L, 1990, Brain Injury, V4, P349; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Zimmerman RA, 1989, NEUROPSYCHOLOGY, V3, P191, DOI 10.1037/h0091791	33	25	26	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL	1992	14	4					518	532		10.1080/01688639208402841			15	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	JK552	WOS:A1992JK55200006	1400915				2022-02-06	
J	DEACON, D; CAMPBELL, KB				DEACON, D; CAMPBELL, KB			EFFECTS OF PERFORMANCE FEEDBACK ON P300 AND REACTION-TIME IN CLOSED HEAD-INJURED OUTPATIENTS	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article						REACTION TIME; P300 LATENCY; CLOSED HEAD INJURY; FEEDBACK	ACCURACY; SPEED; POTENTIALS; LATENCY	In an earlier study, we have demonstrated that the choice reaction times (RTs) of closed head-injured patients may be reduced significantly by instructions which emphasize speed, thus indicating that this portion of the RT delay was not due to a motor deficit. Despite the reduction in patient RTs, however, they remained significantly longer than those of controls. Furthermore, the RTs of patients were 56 msec longer than their P300 latencies, whereas those of controls occurred at about the same time as P300. The delay which remained in patient RTs was thus not entirely due to longer stimulus evaluation times. The goal of the present study was to further reduce patient RTs using feedback (FB) on response speed and time windows within which subjects were required to respond. When FB on speed and a 'narrow' time window were used, patient RTs occurred at about the same time as P300 latency (as was also the case with controls) indicating that the longer RTs of these patients in our earlier study, and in the other conditions of the present study, could not have been exaggerated beyond P300 latency due to a motor deficit. It was suggested that CHI patients may not be able to internally monitor their responses to the same degree as controls. The provision of external cues may have compensated for this deficit.	UNIV OTTAWA,OTTAWA K1N 6N5,ONTARIO,CANADA								Benson D.F., 1986, FRONTAL LOBES; BROOKHUIS KA, 1983, BIOL PSYCHOL, V17, P277, DOI 10.1016/0301-0511(83)90004-2; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROUWER WH, 1985, LIMITATION ATTENTION; Campbell K., 1986, ELECTROENCEPHALOGR S, V38, P486; CURRY SH, 1985, INT C ELECTROENCEPHA; DEACON D, UNPUB SPEED DECISION; DENCKER SJ, 1958, ACTA PSYCHIAT NEUROL, V33, P122; DUNCANJOHNSON CC, 1981, SCIENCE, V214, P938, DOI 10.1126/science.7302571; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; FITTS PM, 1966, J EXP PSYCHOL, V71, P849, DOI 10.1037/h0023232; GREEN DM, 1966, SIGNAL DETECTION THE; GREENHOUSE SW, 1959, PSYCHOMETRIKA, V24, P95, DOI 10.1007/BF02289823; Gronwall D, 1974, PSYCHOL EFFECTS CONC; KINSBOURNE M, 1977, AGING DEMENTIA, P217; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; LINK SW, 1971, PERCEPT PSYCHOPHYS, V9, P284, DOI 10.3758/BF03212649; Luria AR, 1973, PSYCHOPHYSIOLOGY FRO; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P169; MARTINIUS J, 1977, MONATSSCHR KINDERH, V125, P401; MCCARTHY G, 1981, SCIENCE, V211, P77, DOI 10.1126/science.7444452; Miller E, 1970, Cortex, V6, P121; MULDER G, 1984, PSYCHOL RES-PSYCH FO, V46, P15, DOI 10.1007/BF00308590; NORRMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236, DOI 10.1111/j.1600-0447.1961.tb07359.x; OMMAYA A, 1961, J NEUROSURG, V35, P236; Pachella R., 1974, HUMAN INFORMATION PR, P41; PFEFFERBAUM A, 1983, ELECTROEN CLIN NEURO, V55, P188, DOI 10.1016/0013-4694(83)90187-6; RABBITT P, 1979, BRIT J PSYCHOL, V70, P305, DOI 10.1111/j.2044-8295.1979.tb01687.x; RAGOT R, 1981, BIOL PSYCHOL, V13, P289, DOI 10.1016/0301-0511(81)90044-2; Ruchkin D.S., 1978, MULTIDISCIP PERSPECT, P175; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; SCHOUTEN JF, 1967, ACTA PSYCHOL, V27, P143, DOI 10.1016/0001-6918(67)90054-6; Stuss D. T, 1987, NEUROBEHAVIORAL RECO, V166; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Van Zomeren A. H., 1981, REACTION TIME ATTENT; VANZOMEREN AH, 1981, REACTION TIME ATTENT, P23; VANZOMEREN AH, 1981, REACTION TIME ATTENT, P50; VICKERS D, 1981, REACTION TIMES, P25; Welford A.T., 1980, REACTION TIMES; WINOGRON HSW, 1986, THESIS CARLETON U OT; WOOD CC, 1976, PERCEPT PSYCHOPHYS, V9, P93; [No title captured]	45	25	27	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.	FEB	1991	78	2					133	141		10.1016/0013-4694(91)90113-I			9	Engineering, Biomedical; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Engineering; Neurosciences & Neurology	EY029	WOS:A1991EY02900007	1704836				2022-02-06	
J	KOSTMIKUCKI, SA; OBLINGER, MM				KOSTMIKUCKI, SA; OBLINGER, MM			CHANGES IN GLIAL FIBRILLARY ACIDIC PROTEIN MESSENGER-RNA EXPRESSION AFTER CORTICOSPINAL AXOTOMY IN THE ADULT HAMSTER	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						AXONAL DEGENERATION; INTERMEDIATE FILAMENTS; INSITU HYBRIDIZATION; ASTROCYTES; NEURAL REGENERATION	CENTRAL NERVOUS-SYSTEM; INTERMEDIATE FILAMENTS; SPINAL-CORD; INSITU HYBRIDIZATION; REACTIVE GLIOSIS; RAT-BRAIN; ASTROCYTES; GFAP; INJURY; IMMUNOFLUORESCENCE	We examined changes in the expression of glial fibrillary acidic protein (GFAP) mRNA during Wallerian degeneration in the corticospinal system of the adult Golden hamster following axotomy. GFAP is the product of a type III intermediate filament (IF) gene that is expressed specifically in mature astrocytes. A well-studied component of a complex response termed reactive astrogliosis that occurs after various types of CNS injury is the increased production of astrocytic processes filled with GFAP-containing IFs. While increased expression of GFAP during reactive astrogliosis has been well established at the protein level, little is known about whether or not changes in GFAP mRNA levels occur after CNS injury. In the present study we used in situ hybridization methods to examine this issue. A S-35-labeled mouse GFAP cDNA probe was used for in situ hybridizations of sections of the brain stem obtained 2, 7, and 14 days after unilateral transections of the corticospinal tract in the caudal medulla. Film as well as emulsion autoradiography showed a dramatic increase in GFAP mRNA labeling associated with the degenerating corticospinal tract. GFAP mRNA levels were already dramatically increased in the injured corticospinal tract by 2 days post axotomy and remained elevated at 14 days. Interestingly, in addition to the robust increase in GFAP mRNA levels specifically associated with the degenerating tract, a diffuse increase in GFAP mRNA labeling was observed throughout the grey matter of the brain stem at 2 days post-axotomy, but not after this time. Immunoblotting and immunocytochemical experiments verified that the increased GFAP mRNA levels in the degenerating corticospinal system were accompanied by an increased expression of the protein. These results demonstrate that an increase in GFAP mRNA levels occurs during Wallerian degeneration in the CNS and suggest that increased expression of the GFAP gene is a major contributor to CNS scarring that results after direct traumatic injury.	CHICAGO MED SCH,DEPT CELL BIOL & ANAT,3333 GREEN BAY RD,N CHICAGO,IL 60064						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021571] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21571] Funding Source: Medline		AQUINO DA, 1988, J NEUROCHEM, V51, P1085, DOI 10.1111/j.1471-4159.1988.tb03072.x; AVOLA R, 1988, J NEUROSCI RES, V19, P230, DOI 10.1002/jnr.490190208; BIGNAMI A, 1973, BRAIN RES, V49, P393, DOI 10.1016/0006-8993(73)90430-7; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; CHIU FC, 1985, J NEUROIMMUNOL, V8, P283, DOI 10.1016/S0165-5728(85)80067-9; DAHL D, 1986, ASTROCYTES, V3, P1; EISENFELD AJ, 1984, INVEST OPHTH VIS SCI, V25, P1321; ENG LF, 1989, GLIA, V2, P308, DOI 10.1002/glia.440020504; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; FEDOROFF S, 1986, ASTROCYTES, V3, P35; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; GIULIAN D, 1988, J NEUROSCI, V8, P2485; JANECZKO K, 1988, BRAIN RES, V456, P280, DOI 10.1016/0006-8993(88)90229-6; KALIL K, 1982, J COMP NEUROL, V211, P265, DOI 10.1002/cne.902110305; LANDRY CF, 1990, J NEUROSCI RES, V25, P194, DOI 10.1002/jnr.490250207; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; LEWIS SA, 1985, J NEUROCHEM, V45, P913, DOI 10.1111/j.1471-4159.1985.tb04080.x; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; Marangos P. J., 1988, NEURONAL GLIAL PROTE, P339; MILLER RH, 1986, J NEUROSCI, V6, P22; MILLER RH, 1984, J NEUROSCI, V4, P585; MORRISON RS, 1985, J NEUROSCI RES, V14, P167, DOI 10.1002/jnr.490140202; Nathaniel EJ., 1981, ADV CELLULAR NEUROBI, P249, DOI [10.1016/B978-0-12-008302-2.50012-2, DOI 10.1016/B978-0-12-008302-2.50012-2]; NIETOSAMPEDRO M, 1988, CURRENT ISSUES NEURA, P301; OBLINGER M M, 1989, Journal of Cell Biology, V109, p71A; OBLINGER MM, 1987, J NEUROSCI, V7, P2510; PATEL AJ, 1985, BRAIN RES, V331, P1, DOI 10.1016/0006-8993(85)90708-5; PETERS A, 1976, FINE STRUCTURE NERVO, P231; POIRIER J, 1990, P NATL ACAD SCI USA, V87, P303, DOI 10.1073/pnas.87.1.303; PREDY R, 1989, BRAIN RES BULL, V22, P81, DOI 10.1016/0361-9230(89)90131-7; RAFF MC, 1983, J NEUROSCI, V3, P1290; RAJU TR, 1980, BRAIN RES, V200, P225, DOI 10.1016/0006-8993(80)91114-2; RATABOUL P, 1989, BRAIN RES BULL, V22, P155, DOI 10.1016/0361-9230(89)90140-8; RATABOUL P, 1988, J NEUROSCI RES, V20, P165, DOI 10.1002/jnr.490200204; REIER P J, 1989, P183; Schachner M., 1982, NEUROIMMUNOLOGY, P215; SELKOE DJ, 1982, BRAIN RES, V245, P117, DOI 10.1016/0006-8993(82)90344-4; SINGH DNP, 1989, ACTA ANAT, V134, P156; SKOFF RP, 1975, J COMP NEUROL, V161, P595, DOI 10.1002/cne.901610408; SMITH ME, 1983, BRAIN RES, V264, P241, DOI 10.1016/0006-8993(83)90822-3; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; TAKAMIYA M, 1988, J NEUROCHEM, V466, P201; TARDY M, 1989, J NEUROCHEM, V52, P162, DOI 10.1111/j.1471-4159.1989.tb10911.x; TETZLAFF W, 1988, GLIA, V1, P90, DOI 10.1002/glia.440010110; WONG J, 1987, METAB BRAIN DIS, V2, P291, DOI 10.1007/BF00999699	45	25	25	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC 605 THIRD AVE, NEW YORK, NY 10158-0012	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	FEB	1991	28	2					182	191		10.1002/jnr.490280205			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FA377	WOS:A1991FA37700004	2033647				2022-02-06	
J	MUTTER, SA; HOWARD, DV; HOWARD, JH; WIGGS, CL				MUTTER, SA; HOWARD, DV; HOWARD, JH; WIGGS, CL			PERFORMANCE ON DIRECT AND INDIRECT TESTS OF MEMORY AFTER MILD CLOSED HEAD-INJURY	COGNITIVE NEUROPSYCHOLOGY			English	Article									GEORGETOWN UNIV,WASHINGTON,DC 20057		MUTTER, SA (corresponding author), CATHOLIC UNIV AMER,HUMAN PERFORMANCE LAB,ROOM 100 OBOYLE,WASHINGTON,DC 20064, USA.						BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; BROOKS N, 1984, CLOSED HEAD INJURY P; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; DIKMAN S, 1986, NEUROBEHAVIOURAL REC; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; GRAF P, 1984, J EXP PSYCHOL LEARN, V10, P164, DOI 10.1037/0278-7393.10.1.164; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; JACOBY LL, 1983, J EXP PSYCHOL LEARN, V9, P21, DOI 10.1037/0278-7393.9.1.21; Kucera M., 1967, COMPUTATIONAL ANAL P; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; MILNER B, 1968, NEUROPSYCHOLOGIA, V6, P215, DOI 10.1016/0028-3932(68)90021-3; RICHARDSONKLAVE.A, 1988, ANN REV PSYCHOL, V39; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROEDIGER HL, 1987, MEMORY LEARNING EBBI; SCHACTER DL, 1986, J EXP PSYCHOL LEARN, V12, P432, DOI 10.1037/0278-7393.12.3.432; SCHACTER DL, 1989, J EXP PSYCHOL LEARN, V15, P3, DOI 10.1037/0278-7393.15.1.3; SCHACTER DL, 1986, J CLIN EXP NEUROPSYC, V8, P727, DOI 10.1080/01688638608405192; SCHACTER DL, 1987, J EXP PSYCHOL LEARN, V13, P501, DOI 10.1037/0278-7393.13.3.501; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SCHACTER DL, 1985, MEMORY SYSTEMS BRAIN; SHIMAMURA AP, 1989, J EXP PSYCHOL LEARN, V15, P721, DOI 10.1037/0278-7393.15.4.721; SHIMAMURA AP, 1986, Q J EXP PSYCHOL-A, V38, P619, DOI 10.1080/14640748608401617; SQUIRE LR, 1978, NEUROPSYCHOLOGIA, V16, P339, DOI 10.1016/0028-3932(78)90027-1; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TULVING E, 1982, J EXP PSYCHOL LEARN, V8, P336, DOI 10.1037/0278-7393.8.4.336; Tulving E., 1983, ELEMENTS EPISODIC ME; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; WARRINGTON EK, 1968, NATURE, V217, P972, DOI 10.1038/217972a0; WARRINGTON EK, 1970, NATURE, V228, P629; Winer BJ., 1971, STAT PRINCIPLES EXPT	34	25	25	0	0	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE, EAST SUSSEX, ENGLAND BN3 2FA	0264-3294			COGNITIVE NEUROPSYCH	Cogn. Neuropsychol.	AUG	1990	7	4					329	346		10.1080/02643299008253447			18	Psychology; Psychology, Experimental	Social Science Citation Index (SSCI)	Psychology	DU364	WOS:A1990DU36400004					2022-02-06	
J	OSHAUGHNESSY, EJ; FOWLER, RS; REID, V				OSHAUGHNESSY, EJ; FOWLER, RS; REID, V			SEQUELAE OF MILD CLOSED HEAD-INJURIES	JOURNAL OF FAMILY PRACTICE			English	Article											OSHAUGHNESSY, EJ (corresponding author), UNIV WASHINGTON,SCH MED,DEPT REHABIL MED,SEATTLE,WA 98195, USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; DILLER L, 1978, REHABILITATION INDIC; EDWARDS A, 1966, EDWARDS PERSONALITY; EVANS CD, 1976, INJURY, V8, P80, DOI 10.1016/0020-1383(76)90040-1; FLANIGAN C, 1981, THESIS U WASHINGTON; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Kraus J F, 1978, Adv Neurol, V19, P261; Lewin W, 1979, Acta Neurochir Suppl (Wien), V28, P128; LEWIN W, 1970, P ROY SOC MED, V63, P8; LUNDHOLM J, 1975, SCAND J REHABIL MED, V7, P97; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1965, LANCET, V1, P225; NAJENSEN T, 1975, SCAND J REHABIL MED, V8, P101; OVERGAARD J, 1973, LANCET, V2, P631; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SELZ M, 1979, J CONSULT CLIN PSYCH, V47, P258, DOI 10.1037/0022-006X.47.2.258; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Wechsler D., 1955, MANUAL WECHSLER ADUL; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	26	25	25	0	2	APPLETON & LANGE	E NORWALK	25 VAN ZANT ST, E NORWALK, CT 06855	0094-3509			J FAM PRACTICE	J. Fam. Pract.		1984	18	3					391	394					4	Primary Health Care; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	SF691	WOS:A1984SF69100005	6699578				2022-02-06	
J	BROWN, WJ; CANTY, T; VERITY, MA; YOSHIDA, N				BROWN, WJ; CANTY, T; VERITY, MA; YOSHIDA, N			EXPERIMENTAL CONCUSSION - ULTRASTRUCTURAL AND BIOCHEMICAL CORRELATES	AMERICAN JOURNAL OF PATHOLOGY			English	Article																	BODIAN D, 1964, B JOHNS HOPKINS HOSP, V114, P13; BOWSHER D, 1970, J ANAT, V106, P23; BOWSHER D, 1971, BRAIN RES, V28, P443, DOI 10.1016/0006-8993(71)90055-2; BRECKENRIDGE BM, 1962, J NEUROCHEM, V9, P383, DOI 10.1111/j.1471-4159.1962.tb09464.x; CHASON JL, 1958, J NEUROSURG, V15, P135, DOI 10.3171/jns.1958.15.2.0135; CHASON JL, 1957, J NEUROPATH EXP NEUR, V16, P102, DOI 10.1097/00005072-195701000-00012; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296, DOI 10.1152/physrev.1945.25.2.296; DOW RS, 1945, J NEUROPHYSIOL, V8, P161; DROCHMANS P, 1962, J ULTRA MOL STRUCT R, V6, P141, DOI 10.1016/S0022-5320(62)90050-3; EVANS JP, 1944, RES PUBL ASS NERV ME, V24, P254; FRIEDE R, 1958, BIOPHYSICS CONCUSS 2, P58; FRIEDE RL, 1960, J NEUROPATH EXP NEUR, V19, P266, DOI 10.1097/00005072-196004000-00007; FRIEDE RL, 1961, ARCH NEUROL-CHICAGO, V4, P449, DOI 10.1001/archneur.1961.00450100097012; Gray E G, 1966, Int Rev Cytol, V19, P111, DOI 10.1016/S0074-7696(08)60566-5; GRAY EG, 1961, J PHYSIOL-LONDON, V157, P581, DOI 10.1113/jphysiol.1961.sp006744; GRAY EG, 1959, J ANAT, V93, P420; GRILLO MA, 1966, PHARMACOL REV, V18, P387; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; Groat RA, 1944, AM J PHYSIOL, V141, P0117, DOI 10.1152/ajplegacy.1944.141.1.117; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; IBRAHIM MZM, 1970, AM J PATHOL, V60, P403; KARNOVSKY MJ, 1961, J BIOPHYS BIOCHEM CY, V11, P729, DOI 10.1083/jcb.11.3.729; Kerr SE, 1936, J BIOL CHEM, V116, P9; KIRKPATRICK JB, 1968, J COMP NEUROL, V132, P189, DOI 10.1002/cne.901320110; KLATZO I, 1961, J NEUROPATH EXP NEUR, V20, P459, DOI 10.1097/00005072-196120040-00001; KOENIG H, 1945, STAIN TECHNOL, V20, P13, DOI 10.3109/10520294509107124; Kuffler S. W., 1966, Ergebnisse der Physiologie, V57, P1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAXWELL DS, 1965, J CELL BIOL, V25, P141, DOI 10.1083/jcb.25.2.141; MCILWAIN H, 1952, BIOCHEM J, V52, P289, DOI 10.1042/bj0520289; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; REVEL JP, 1964, J HISTOCHEM CYTOCHEM, V12, P104, DOI 10.1177/12.2.104; RHINES R, 1946, AM J PHYSIOL, V146, P344, DOI 10.1152/ajplegacy.1946.146.3.344; ROLLESTON FS, 1967, BIOCHEM J, V104, P524, DOI 10.1042/bj1040524; SHIMIZU N, 1958, NATURE, V181, P781, DOI 10.1038/181781a0; SOTELO C, 1968, J CELL BIOL, V36, P151, DOI 10.1083/jcb.36.1.151; STRICH SJ, 1961, LANCET, V2, P443; TAKAGAKI G, 1968, J NEUROCHEM, V15, P903, DOI 10.1111/j.1471-4159.1968.tb11632.x; VENABLE JH, 1965, J CELL BIOL, V25, P407, DOI 10.1083/jcb.25.2.407; VERITY MA, 1969, BIOCHEM PHARMACOL, V18, P327, DOI 10.1016/0006-2952(69)90210-X; VERITY MA, 1963, J LAB CLIN MED, V62, P846; VESCO C, 1968, J NEUROCHEM, V15, P81, DOI 10.1111/j.1471-4159.1968.tb06177.x; WARD JW, 1948, J NEUROPHYSIOL, V11, P59, DOI 10.1152/jn.1948.11.2.59; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; WINDLE W. F., 1944, TRANS AMER NEUROL ASSOC, V70, P117; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1945, ANAT REC, V93, P201, DOI 10.1002/ar.1090930210; WOLFE LS, 1962, J NEUROCHEM, V9, P213, DOI 10.1111/j.1471-4159.1962.tb11862.x; WOOLLEY DE, 1963, P SOC EXP BIOL MED, V114, P571; YAMAMOTO T, 1963, J CELL BIOL, V16, P159, DOI 10.1083/jcb.16.1.159	54	25	25	1	1	AMER SOC INVESTIGATIVE PATHOLOGY, INC	BALTIMORE	428 EAST PRESTON ST, BALTIMORE, MD 21202-3993	0002-9440			AM J PATHOL	Am. J. Pathol.		1972	67	1					41	&					0	Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Pathology	M3066	WOS:A1972M306600003	5045878				2022-02-06	
J	DENCKER, SJ				DENCKER, SJ			CLOSED HEAD-INJURY IN TWINS - NEUROLOGIC, PSYCHOMETRIC, AND PSYCHIATRIC FOLLOW-UP-STUDY OF CONSECUTIVE CASES, USING CO-TWINS AS CONTROLS	ARCHIVES OF GENERAL PSYCHIATRY			English	Article																	ALEXANDER F, 1949, Public Health Rep, V64, P357, DOI 10.2307/4586894; DENCKER SJ, 1958, ACTA PSYCHIAT NEUR S, V122, P33; DENCKER SJ, 1958, ACTA PSYCHIAT NEUR S, V123, P33; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; ESSENMOLLER E, 1956, ACTA PSYCHIAT NEUR S, V100; PROBST H, 1949, Z Kinderpsychiatr, V15, P186; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; RUESCH J, 1945, RES PUBL ASS NERV ME, V24, P507; Wolff HG., 1948, HEADACHE OTHER HEAD; [No title captured]	10	25	25	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry		1960	2	5					569	575					7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	WF140	WOS:A1960WF14000012	13815890				2022-02-06	
J	Hadfield, G; Christie, RV				Hadfield, G; Christie, RV			A case of pulmonary concussion ("blast") due to high explosive	BRITISH MEDICAL JOURNAL			English	Article																		0	25	25	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN-JUN	1941	1941		1				77	78		10.1136/bmj.1.4176.77			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V07WL	WOS:000200531500081	20783485	Green Published			2022-02-06	
J	Cole, E; Weaver, A; Gall, L; West, A; Nevin, D; Tallach, R; O'Neill, B; Lahiri, S; Allard, S; Tai, N; Davenport, R; Green, L; Brohi, K				Cole, Elaine; Weaver, Anne; Gall, Lewis; West, Anita; Nevin, Daniel; Tallach, Rosel; O'Neill, Breda; Lahiri, Sumitra; Allard, Shubha; Tai, Nigel; Davenport, Ross; Green, Laura; Brohi, Karim			A Decade of Damage Control Resuscitation New Transfusion Practice, New Survivors, New Directions	ANNALS OF SURGERY			English	Article						damage control resuscitation; major hemorrhage; major hemorrhage; survivors; transfusion practice; trauma	TRAUMA-INDUCED COAGULOPATHY; BLOOD COMPONENT THERAPY; MASSIVE TRANSFUSION; PROTOCOL IMPROVES; TRANEXAMIC ACID; MORTALITY; HEMORRHAGE; MANAGEMENT; INJURY; DEATH	Objective: The aim of this study was to identify the effects of recent innovations in trauma major hemorrhage management on outcome and transfusion practice, and to determine the contemporary timings and patterns of death. Background: The last 10 years have seen a research-led change in hemorrhage management to damage control resuscitation (DCR), focused on the prevention and treatment of trauma-induced coagulopathy. Methods: A 10-year retrospective analysis of prospectively collected data of trauma patients who activated the Major Trauma Centre's major hemorrhage protocol (MHP) and received at least 1 unit of red blood cell transfusions (RBC). Results: A total of 1169 trauma patients activated the MHP and received at least 1 unit of RBC, with similar injury and admission physiology characteristics over the decade. Overall mortality declined from 45% in 2008 to 27% in 2017, whereas median RBC transfusion rates dropped from 12 to 4 units (massive transfusion rates from 68% to 24%). The proportion of deaths within 24 hours halved (33%-16%), principally with a fall in mortality between 3 and 24 hours (30%-6%). Survivors are now more likely to be discharged to their own home (57%-73%). Exsanguination is still the principal cause of early deaths, and the mortality associated with massive transfusion remains high (48%). Late deaths are now split between those due to traumatic brain injury (52%) and multiple organ dysfunction (45%). Conclusions: There have been remarkable reductions in mortality after major trauma hemorrhage in recent years. Mortality rates continue to be high and there remain important opportunities for further improvements in these patients.	[Cole, Elaine; Gall, Lewis; Davenport, Ross; Green, Laura; Brohi, Karim] Queen Mary Univ London, Blizard Inst, London, England; [Weaver, Anne; West, Anita; Nevin, Daniel; Tallach, Rosel; O'Neill, Breda; Lahiri, Sumitra; Allard, Shubha; Tai, Nigel; Davenport, Ross; Green, Laura; Brohi, Karim] Barts Hlth NHS Trust, London, England; [Tai, Nigel] Royal Ctr Def Med, Dept Mil Surg, Birmingham, W Midlands, England; [Tai, Nigel] Royal Ctr Def Med, Dept Trauma & Anaesthesia, Birmingham, W Midlands, England; [Green, Laura] NHS Blood & Transplant, London, England		Cole, E (corresponding author), Queen Mary Univ London, Blizard Inst, London, England.	e.cole@qmul.ac.uk		Cole, Elaine/0000-0002-3642-3537	National Institute for Health Research Programme Grant for Applied Research [RP-PG-0407-10036]; Centre for Trauma Sciences Barts Charity award [753/1722]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [F3-2013-602771]	This work was supported in part by a National Institute for Health Research Programme Grant for Applied Research (RP-PG-0407-10036), the Centre for Trauma Sciences Barts Charity award (753/1722), and the European Commission under the FP-7 HEALTH-Contract No. F3-2013-602771, entitled ``Targeted Action for Curing Trauma Induced Coagulopathy'' (TACTIC). TEM International GmbH (Munich, Germany) provided ROTEM reagents and equipment on an unrestricted basis.	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baksaas-Aasen K, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2224-9; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Cabrera CP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002352; Davenport R, 2011, CRIT CARE MED, V39, P2652, DOI 10.1097/CCM.0b013e3182281af5; Davenport R, 2011, J TRAUMA, V70, P90, DOI 10.1097/TA.0b013e318202e486; Drake SA, 2020, ANN SURG, V271, P375, DOI 10.1097/SLA.0000000000002999; Glen J, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i3051; Gonzalez E, 2016, ANN SURG, V263, P1051, DOI 10.1097/SLA.0000000000001608; Harvin JA, 2017, J TRAUMA ACUTE CARE, V83, P464, DOI 10.1097/TA.0000000000001619; Holcomb JB, 2007, J TRAUMA, V62, pS36, DOI 10.1097/TA.0b013e3180654134; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Hu Y, 2015, J SURG RES, V195, P284, DOI 10.1016/j.jss.2015.01.038; Hunt BJ, 2015, BRIT J HAEMATOL, V170, P788, DOI 10.1111/bjh.13580; Hwang K, 2018, WORLD J SURG, V42, P2067, DOI 10.1007/s00268-017-4441-5; Khan S, 2015, INTENS CARE MED, V41, P239, DOI 10.1007/s00134-014-3584-1; Khan S, 2013, INJURY, V44, P587, DOI 10.1016/j.injury.2012.09.029; Marsden M, 2018, J TRAUMA ACUTE CARE, V85, P620, DOI 10.1097/TA.0000000000001988; Moore EE, 2010, J TRAUMA, V69, P1600, DOI 10.1097/TA.0b013e318201124e; NICE, 2016, MAJ TRAUM ASS IN MAN; Nunn A, 2017, AM SURGEON, V83, P394; Pabinger I, 2017, WIEN KLIN WOCHENSCHR, V129, P303, DOI 10.1007/s00508-017-1194-y; Powell EK, 2016, J TRAUMA ACUTE CARE, V81, P458, DOI 10.1097/TA.0000000000001078; Rehn M, 2019, SHOCK, V51, P284, DOI 10.1097/SHK.0000000000001166; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shaz BH, 2011, J TRAUMA, V70, P1401, DOI 10.1097/TA.0b013e31821266e0; Shepherd JM, 2017, SHOCK, V47, P429, DOI 10.1097/SHK.0000000000000779; Spahn DR, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2347-3; Stainsby D, 2006, BRIT J HAEMATOL, V135, P634; Stanworth SJ, 2016, BRIT J SURG, V103, P357, DOI 10.1002/bjs.10052; Stanworth SJ, 2010, CRIT CARE, V14, DOI 10.1186/cc9394; Stein P, 2017, ANAESTHESIA, V72, P1317, DOI 10.1111/anae.13920; Tapia NM, 2013, J TRAUMA ACUTE CARE, V74, P378, DOI 10.1097/TA.0b013e31827e20e0; Teixeira PGR, 2007, J TRAUMA, V63, P1338, DOI 10.1097/TA.0b013e31815078ae; Tobin JM, 2014, J CRIT CARE, V29, DOI 10.1016/j.jcrc.2013.11.017; Vanzant EL, 2014, J TRAUMA ACUTE CARE, V76, P21, DOI 10.1097/TA.0b013e3182ab1ab5; Vondy A, 2011, EMERG MED J, V28, P250, DOI 10.1136/emj.2010.101022	38	24	24	8	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	JUN	2021	273	6					1215	1220		10.1097/SLA.0000000000003657			6	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	ST2UC	WOS:000662304000046	31651535	Green Submitted	Y	N	2022-02-06	
J	Liu, Y; Hsu, YH; Huang, APH; Hsu, SH				Liu, Yi; Hsu, Yi-Hua; Huang, Abel Po-Hao; Hsu, Shan-hui			Semi-Interpenetrating Polymer Network of Hyaluronan and Chitosan Self-Healing Hydrogels for Central Nervous System Repair	ACS APPLIED MATERIALS & INTERFACES			English	Article						self-healing hydrogel; semi-interpenetrating polymer network (SIPN); chitosan; hyaluronan (HA); central nervous system (CNS) repair	STEM-CELLS; INTRACEREBRAL HEMORRHAGE; FUNCTIONAL RECOVERY; IRON OVERLOAD; ACID; DELIVERY; SURVIVAL; TRANSPLANTATION; PROLIFERATION; BIOMATERIALS	The repair of the central nervous system (CNS) is a major challenge because of the difficulty for neurons or axons to regenerate after damages. Injectable hydrogels have been developed to deliver drugs or cells for neural repair, but these hydrogels usually require conditional stimuli or additional catalysts to control the gelling process. Self-healing hydrogels, which can be injected locally to fill tissue defects after stable gelation, are attractive candidates for CNS treatment. In the current study, the self-healing hydrogel with a semi-interpenetrating polymer network (SIPN) was prepared by incorporation of hyaluronan (HA) into the chitosan-based self-healing hydrogel. The addition of HA allowed the hydrogel to pass through a narrow needle much more easily. As the HA content increased, the hydrogel showed a more packed nanostructure and a more porous microstructure verified by coherent small-angle X-ray scattering and scanning electron microscopy. The unique structure of SIPN hydrogel enhanced the spreading, migration, proliferation, and differentiation of encapsulated neural stem cells in vitro. Compared to the pristine chitosan-based self-healing hydrogel, the SIPN hydrogel showed better biocompatibility, CNS injury repair, and functional recovery evaluated by the traumatic brain injury zebrafish model and intracerebral hemorrhage rat model. We proposed that the SIPN of HA and chitosan self-healing hydrogel allowed an adaptable environment for cell spreading and migration and had the potential as an injectable defect support for CNS repair.	[Liu, Yi; Huang, Abel Po-Hao; Hsu, Shan-hui] Natl Taiwan Univ, Inst Polymer Sci & Engn, Taipei 10617, Taiwan; [Hsu, Yi-Hua; Huang, Abel Po-Hao] Natl Taiwan Univ Hosp & Coll Med, Dept Surg, Taipei 10617, Taiwan; [Hsu, Shan-hui] Natl Hlth Res Inst, Inst Cellular & Syst Med, Miaoli 35053, Taiwan		Hsu, SH (corresponding author), Natl Taiwan Univ, Inst Polymer Sci & Engn, Taipei 10617, Taiwan.; Hsu, SH (corresponding author), Natl Hlth Res Inst, Inst Cellular & Syst Med, Miaoli 35053, Taiwan.	shhsu@ntu.edu.tw		HUANG, ABEL PO-HAO/0000-0002-5689-6761	National Taiwan UniversityNational Taiwan University [NTU-CC-109L891001]; National Health Research InstitutesNational Health Research Institutes, Japan [CS-109-PP-15]; Ministry of Science and Technology, Taiwan, R.O.C.Ministry of Science and Technology, Taiwan [MOST 108-2221-E-002-082-MY3]; National Synchrotron Radiation Research Center [2019-1-209]	This work was supported by the National Taiwan University (NTU-CC-109L891001), the National Health Research Institutes (CS-109-PP-15), and the Ministry of Science and Technology (MOST 108-2221-E-002-082-MY3), Taiwan, R.O.C. We thank the National Synchrotron Radiation Research Center (2019-1-209) and the staff of the TPS 25A, in particular, Dr. Yu-Shan Huang for providing the resources and technical support. We also thank the Taiwan Zebrafish Core Facility at National Taiwan University (NTU-ERP104R8600) for technical assistance.	Ballios BG, 2015, STEM CELL REP, V4, P1031, DOI 10.1016/j.stemcr.2015.04.008; Baumann MD, 2010, BIOMATERIALS, V31, P7631, DOI 10.1016/j.biomaterials.2010.07.004; Boehnke N, 2015, BIOMACROMOLECULES, V16, P2101, DOI 10.1021/acs.biomac.5b00519; Burdick JA, 2016, CELL STEM CELL, V18, P13, DOI 10.1016/j.stem.2015.12.004; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; Cheng KC, 2019, NPG ASIA MATER, V11, DOI 10.1038/s41427-019-0124-z; Cregg JM, 2014, EXP NEUROL, V253, P197, DOI 10.1016/j.expneurol.2013.12.024; da Silva LP, 2016, ACS APPL MATER INTER, V8, P33464, DOI 10.1021/acsami.6b11684; DelBigio MR, 1996, STROKE, V27, P2312, DOI 10.1161/01.STR.27.12.2312; Fernandez-Garcia L, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00296; Fernandez-Garcia L, 2016, ACTA BIOMATER, V45, P262, DOI 10.1016/j.actbio.2016.09.003; Gong YH, 2020, J CONTROL RELEASE, V320, P381, DOI 10.1016/j.jconrel.2020.01.029; Guo TW, 2019, INT J PHARMACEUT, V566, P46, DOI 10.1016/j.ijpharm.2019.05.050; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; He Y, 2019, ACS BIOMATER SCI ENG, V5, P1113, DOI 10.1021/acsbiomaterials.8b01609; Hoban DB, 2013, BIOMATERIALS, V34, P9420, DOI 10.1016/j.biomaterials.2013.08.073; Hsieh FY, 2018, BIOMATERIALS, V174, P31, DOI 10.1016/j.biomaterials.2018.05.014; Hsieh FY, 2017, NPG ASIA MATER, V9, DOI 10.1038/am.2017.23; Hsieh FY, 2015, NEURAL REGEN RES, V10, P1922, DOI 10.4103/1673-5374.169624; Hsieh FY, 2015, BIOMATERIALS, V71, P48, DOI 10.1016/j.biomaterials.2015.08.028; Hsu YC, 2009, DEV DYNAM, V238, P302, DOI 10.1002/dvdy.21753; Khaing ZZ, 2015, J MATER CHEM B, V3, P7850, DOI 10.1039/c5tb00974j; Kutty JK, 2007, BIOMATERIALS, V28, P4928, DOI 10.1016/j.biomaterials.2007.08.007; Lee HJ, 2017, ACTA BIOMATER, V64, P67, DOI 10.1016/j.actbio.2017.09.041; Lee HJ, 2015, ACTA BIOMATER, V14, P43, DOI 10.1016/j.actbio.2014.12.007; Li Y., 2017, JOVE-J VIS EXP, V127, P56253; Li YS, 2017, COLLOID SURFACE B, V149, P168, DOI 10.1016/j.colsurfb.2016.10.021; Liang Y, 2013, BIOMATERIALS, V34, P5521, DOI 10.1016/j.biomaterials.2013.03.095; Lim TC, 2020, TRANSL STROKE RES, V11, P412, DOI 10.1007/s12975-019-00721-y; Liu Y, 2020, NEURAL REGEN RES, V15, P1243, DOI 10.4103/1673-5374.272573; Liu Y, 2019, COLLOID SURFACE B, V174, P316, DOI 10.1016/j.colsurfb.2018.10.077; Liu Y, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00449; Luo PW, 2019, ADV BIOSYST, V3, DOI 10.1002/adbi.201800254; Luo TT, 2017, INT J PHARMACEUT, V534, P179, DOI 10.1016/j.ijpharm.2017.10.010; Matricardi P, 2013, ADV DRUG DELIVER REV, V65, P1172, DOI 10.1016/j.addr.2013.04.002; McLauchlan D, 2018, J NEUROL, V265, P984, DOI 10.1007/s00415-018-8818-7; Moshayedi P, 2016, BIOMATERIALS, V105, P145, DOI 10.1016/j.biomaterials.2016.07.028; Nicolle S, 2010, J BIOMECH, V43, P927, DOI 10.1016/j.jbiomech.2009.11.002; Nih LR, 2018, NAT MATER, V17, P642, DOI 10.1038/s41563-018-0083-8; Park J, 2017, NANOMED-NANOTECHNOL, V13, P1853, DOI 10.1016/j.nano.2017.04.001; Preston Marnie, 2011, Front Biosci (Schol Ed), V3, P1165; Sharp KG, 2012, EXP NEUROL, V235, P345, DOI 10.1016/j.expneurol.2012.02.016; Skaalure SC, 2014, ACTA BIOMATER, V10, P3409, DOI 10.1016/j.actbio.2014.04.013; Sun W, 2017, RSC ADV, V7, P15809, DOI 10.1039/c6ra23150k; Tseng TC, 2016, BIOMATERIALS, V102, P148, DOI 10.1016/j.biomaterials.2016.06.020; Tseng TC, 2015, ADV MATER, V27, P3518, DOI 10.1002/adma.201500762; Wang HY, 2015, ADV MATER, V27, P3717, DOI 10.1002/adma.201501558; Wu CD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108548; Xin XJ, 2004, J BIOMAT SCI-POLYM E, V15, P1223, DOI 10.1163/1568562041753025; Yang B, 2012, POLYM CHEM-UK, V3, P3235, DOI 10.1039/c2py20627g; Zhang K, 2018, J MATER CHEM B, V6, P2982, DOI 10.1039/c7tb03213g; Zhu Q, 2019, INT J PHARMACEUT, V566, P342, DOI 10.1016/j.ijpharm.2019.05.076; Zoratto Nicole, 2018, Adv Exp Med Biol, V1059, P155, DOI 10.1007/978-3-319-76735-2_7	53	24	24	22	96	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1944-8244	1944-8252		ACS APPL MATER INTER	ACS Appl. Mater. Interfaces	SEP 9	2020	12	36					40108	40120		10.1021/acsami.0c11433			13	Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics; Materials Science	NR3AC	WOS:000571433500016	32808527				2022-02-06	
J	Scotti, P; Seguin, C; Lo, BWY; de Guise, E; Troquet, JM; Marcoux, J				Scotti, Pasquale; Seguin, Chantal; Lo, Benjamin W. Y.; de Guise, Elaine; Troquet, Jean-Marc; Marcoux, Judith			Antithrombotic agents and traumatic brain injury in the elderly population: hemorrhage patterns and outcomes	JOURNAL OF NEUROSURGERY			English	Article						elderly population; antithrombotic agent; head injury; traumatic brain injury; intracranial hemorrhage	CHRONIC SUBDURAL HEMATOMAS; INTRACRANIAL HEMORRHAGE; PREINJURY WARFARIN; ANTIPLATELET AGENTS; HEAD-INJURY; ORAL ANTICOAGULATION; MORTALITY; THERAPY; REVERSAL; PATIENT	OBJECTIVE Among the elderly, use of antithrombotics (ATs), antiplatelets (APs; aspirin, clopidogrel), and/or anticoagulants (ACs; warfarin, direct oral ACs [DOACs; dabigatran, rivaroxaban, apixaban]) to prevent thromboembolic events must be carefully weighed against the risk of intracranial hemorrhage (ICH) with trauma. The goal of this study was to assess the risk of sustaining a traumatic brain injury (TBI), ICH, and poorer outcomes in relation to AT use among all patients 65 years or older presenting to a single institution with head trauma. METHODS Data were collected from all head trauma patients 65 years or older presenting to the authors' supraregional tertiary trauma center over a 24-month period and included age, sex, injury mechanism, medical history, international normalized ratio, Glasgow Coma Scale (GCS) score, ICH presence and type, hospital admission, reversal therapy, surgery, discharge destination, Extended Glasgow Outcome Scale (GOSE) score at discharge, and mortality. RESULTS A total of 1365 head trauma patients 65 years or older were included; 724 were on AT therapy (413 on APs, 151 on ACs, 59 on DOACs, 48 on 2 APs, 38 on AP+AC, and 15 on AP+DOAC) and 641 were not. Among all head trauma patients, the risk of sustaining a TBI was associated with AP use after adjusting for covariates. Of the 731 TBI patients, those using ATs had higher rates of ICH (p < 0.0001), functional dependency at discharge (GOSE score <= 4; p < 0.0001), and mortality (p < 0.0001). Elevated rates of ICH progression on follow-up CT scanning were observed in patients in the warfarin monotherapy (OR 5.30, p < 0.0001) and warfarin + AP (OR 6.15, p = 0.0011). Risk of mortality was not associated with single antiplatelet use but was notably high with 2 APs (OR 4.66, p = 0.0056), warfarin (OR 5.18, p = 0.0003), and DOAC use (OR 5.09, p = 0.0149). CONCLUSIONS Elderly trauma patients on ATs, especially combination therapy, are at elevated risk of ICH and poor outcomes compared with those not on AT therapy. While both AP and warfarin use alone and in combination were associated with significantly elevated odds of sustaining an ICH among TBI patients, only warfarin use was a predictor of hemorrhage progression on follow-up scans. The use of a single AP was not associated with mortality; however, the combination of both aspirin and clopidogrel was. Warfarin and DOAC users had comparable mortality rates; however, DOAC users had lower rates of ICH progression, and fewer survivors were functionally dependent at discharge than were warfarin users. DOACs are an overall safer alternative to warfarin for patients at high risk of falls.	[Scotti, Pasquale; Lo, Benjamin W. Y.; Marcoux, Judith] McGill Univ Hlth Ctr, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Seguin, Chantal] McGill Univ Hlth Ctr, Dept Hematol, Montreal, PQ, Canada; [Troquet, Jean-Marc] McGill Univ Hlth Ctr, Dept Emergency Med, Montreal, PQ, Canada; [de Guise, Elaine] Univ Montreal, Dept Psychol, Montreal, PQ, Canada		Marcoux, J (corresponding author), Montreal Gen Hosp, Montreal, PQ, Canada.	judith.marcoux@mcgill.ca					Andreotti F, 2015, EUR HEART J, V36, P3238, DOI 10.1093/eurheartj/ehv304; Asghar M, 2002, J ROY SOC MED, V95, P290, DOI 10.1258/jrsm.95.6.290; Balser D, 2015, J NEUROSURG, V123, P1209, DOI 10.3171/2014.9.JNS141550; Bavishi C, 2017, AM J MED, V130, DOI 10.1016/j.amjmed.2017.05.029; Bonville DJ, 2011, SURGERY, V150, P861, DOI 10.1016/j.surg.2011.07.070; Cull JD, 2015, AM SURGEON, V81, P128; Do MT, 2015, HEALTH PROMOT CHRON, V35, P99, DOI 10.24095/hpcdp.35.7.01; Dossett LA, 2011, ARCH SURG-CHICAGO, V146, P565, DOI 10.1001/archsurg.2010.313; Dunham CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109473; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P1180, DOI 10.1136/jnnp.2007.135178; Fitzmaurice DA, 2002, BMJ-BRIT MED J, V325, P828, DOI 10.1136/bmj.325.7368.828; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Fu TS, 2015, J TRAUMA ACUTE CARE, V79, P449, DOI 10.1097/TA.0000000000000733; Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Inohara T, 2018, JAMA-J AM MED ASSOC, V319, P463, DOI 10.1001/jama.2017.21917; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Johnston SC, 2018, NEW ENGL J MED, V379, P215, DOI 10.1056/NEJMoa1800410; Julien J, 2017, J CLIN NEUROSCI, V38, P122, DOI 10.1016/j.jocn.2016.12.032; Karni A, 2001, AM SURGEON, V67, P1098; Kobayashi L, 2017, J TRAUMA ACUTE CARE, V82, P827, DOI 10.1097/TA.0000000000001414; Le Roux P, 2014, J NEUROSURG, V121, P1, DOI 10.3171/2014.8.paradigm; Lowenstern A, 2018, ANN INTERN MED, V169, P774, DOI 10.7326/M18-1523; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Maung AA, 2016, J TRAUMA ACUTE CARE, V81, P652, DOI 10.1097/TA.0000000000001189; Melorose J, 2015, UN, V1, P587, DOI DOI 10.1017/CB09781107415324.004; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Narum S, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0094-1; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Pandya U, 2018, J CLIN NEUROSCI, V50, P88, DOI 10.1016/j.jocn.2018.01.073; Peck KA, 2014, J TRAUMA ACUTE CARE, V76, P431, DOI 10.1097/TA.0000000000000107; Pieracci FM, 2007, J TRAUMA, V63, P519, DOI 10.1097/TA.0b013e31812e519b; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Pollack CV, 2017, NEW ENGL J MED, V377, P431, DOI 10.1056/NEJMoa1707278; Pozzessere A, 2015, AM SURGEON, V81, P1039; Rust T, 2006, J CLIN NEUROSCI, V13, P823, DOI 10.1016/j.jocn.2004.12.013; Sandhaug M, 2015, BRAIN INJURY, V29, P1431, DOI 10.3109/02699052.2015.1063692; So CH, 2017, J THROMB THROMBOLYS, V43, P7, DOI 10.1007/s11239-016-1425-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1974, LANCET, V2, P81; Tollefsen MH, 2018, WORLD NEUROSURG, V114, pE209, DOI 10.1016/j.wneu.2018.02.167; Vandiver JW, 2018, J THROMB THROMBOLYS, V45, P423, DOI 10.1007/s11239-018-1635-0; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	45	24	24	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2020	133	2					486	495		10.3171/2019.4.JNS19252			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	OM5TQ	WOS:000586087300025	31277068				2022-02-06	
J	Vlaar, AP; Oczkowski, S; de Bruin, S; Wijnberge, M; Antonelli, M; Aubron, C; Aries, P; Duranteau, J; Juffermans, NP; Meier, J; Murphy, GJ; Abbasciano, R; Muller, M; Shah, A; Perner, A; Rygaard, S; Walsh, TS; Guyatt, G; Dionne, JC; Cecconi, M				Vlaar, Alexander P.; Oczkowski, Simon; de Bruin, Sanne; Wijnberge, Marije; Antonelli, Massimo; Aubron, Cecile; Aries, Philippe; Duranteau, Jacques; Juffermans, Nicole P.; Meier, Jens; Murphy, Gavin J.; Abbasciano, Riccardo; Muller, Marcella; Shah, Akshay; Perner, Anders; Rygaard, Sofie; Walsh, Timothy S.; Guyatt, Gordon; Dionne, J. C.; Cecconi, Maurizio			Transfusion strategies in non-bleeding critically ill adults: a clinical practice guideline from the European Society of Intensive Care Medicine	INTENSIVE CARE MEDICINE			English	Article						Transfusion; Coagulopathy; Critically ill; Guideline; Intensive care; Plasma; Platelets; Red blood cells; Point of care; EPO	RECOMBINANT-HUMAN-ERYTHROPOIETIN; FRESH-FROZEN PLASMA; BLOOD-CELL TRANSFUSION; EXTRACORPOREAL MEMBRANE-OXYGENATION; PREPROCEDURAL PLATELET TRANSFUSION; NEAR-INFRARED SPECTROSCOPY; PLACEBO-CONTROLLED TRIAL; TRAUMATIC BRAIN-INJURY; DOUBLE-BLIND; RESTRICTIVE TRANSFUSION	Objective To develop evidence-based clinical practice recommendations regarding transfusion practices in non-bleeding, critically ill adults. Design A task force involving 13 international experts and three methodologists used the GRADE approach for guideline development. Methods The task force identified four main topics: red blood cell transfusion thresholds, red blood cell transfusion avoidance strategies, platelet transfusion, and plasma transfusion. The panel developed structured guideline questions using population, intervention, comparison, and outcomes (PICO) format. Results The task force generated 16 clinical practice recommendations (3 strong recommendations, 13 conditional recommendations), and identified five PICOs with insufficient evidence to make any recommendation. Conclusions This clinical practice guideline provides evidence-based recommendations and identifies areas where further research is needed regarding transfusion practices and transfusion avoidance in non-bleeding, critically ill adults.	[Vlaar, Alexander P.; de Bruin, Sanne; Wijnberge, Marije; Juffermans, Nicole P.; Muller, Marcella] Amsterdam UMC, Dept Intens Care Med, Locat AMC, Amsterdam, Netherlands; [Oczkowski, Simon; Guyatt, Gordon; Dionne, J. C.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Oczkowski, Simon; Guyatt, Gordon; Dionne, J. C.] Guidelines Intens Care Dev & Evaluat GUIDE Grp, Hamilton, ON, Canada; [Oczkowski, Simon; Guyatt, Gordon; Dionne, J. C.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Wijnberge, Marije] Amsterdam UMC, Dept Anaesthesiol, Locat AMC, Amsterdam, Netherlands; [Antonelli, Massimo] Fdn Policlin Univ AGemelli IRCCS, Dept Anaesthesiol & Intens Care Med, Rome, Italy; [Antonelli, Massimo] Univ Cattolica Sacro Cuore, Ist Anaesthesiol & Rianimaz, Rome, Italy; [Aubron, Cecile; Aries, Philippe] Univ Bretagne Occidentale, Ctr Hosp Reg & Univ Brest, Dept Intens Care Med, Site La Cavale Blanche, Brest, France; [Duranteau, Jacques] HUPS, Dept Anaesthesia & Intens Care, Orsay, France; [Meier, Jens] Kepler Univ, Fac Med, Dept Anesthesiol & Crit Care Med, Linz, Austria; [Murphy, Gavin J.; Abbasciano, Riccardo] Univ Leicester, Coll Life Sci, NIHR Leicester Biomed Res Ctr, Cardiovasc,Dept Cardiovasc Sci, Leicester LE3 9QP, Leics, England; [Shah, Akshay] Univ Oxford, Radcliffe Dept Med, Oxford, England; [Shah, Akshay] John Radcliffe Hosp, Adult Intens Care Unit, Oxford, England; [Perner, Anders; Rygaard, Sofie] Univ Copenhagen, Rigshosp, Dept Intens Care, Copenhagen, Denmark; [Walsh, Timothy S.] Univ Edinburgh, Anaesthet Crit Care & Pain Med, Edinburgh, Midlothian, Scotland; [Cecconi, Maurizio] Humanitas Clin & Res Ctr IRCCS, Dept Anaesthesia & Intens Care Med, Milan, Italy; [Cecconi, Maurizio] Humanitas Univ, Via Rita Levi Montalcini, Milan, Italy; [Vlaar, Alexander P.] Univ Amsterdam, Dept Intens Care Med, Room C3-430,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands		Vlaar, AP (corresponding author), Amsterdam UMC, Dept Intens Care Med, Locat AMC, Amsterdam, Netherlands.; Vlaar, AP (corresponding author), Univ Amsterdam, Dept Intens Care Med, Room C3-430,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	a.p.vlaar@amsterdamumc.nl	Abbasciano, Riccardo/AAI-2375-2020; Dionne, Joanna Colleen/X-1720-2018; Cecconi, Maurizio/A-6241-2012	Abbasciano, Riccardo/0000-0001-6004-8741; Dionne, Joanna Colleen/0000-0002-9401-6868; Cecconi, Maurizio/0000-0002-4376-6538; ARIES, Philippe/0000-0003-3045-0734; Murphy, Gavin/0000-0003-0976-1482; Vlaar, Alexander/0000-0002-3453-7186	British Heart FoundationBritish Heart Foundation [RG/17/9/32812, RG/13/6/29947] Funding Source: Medline; Department of HealthEuropean Commission [DRF-2017-10-094] Funding Source: Medline		Adamczyk S, 2009, ANN FR ANESTH, V28, P522, DOI 10.1016/j.annfar.2009.03.013; Agerstrand CL, 2015, ANN THORAC SURG, V99, P590, DOI 10.1016/j.athoracsur.2014.08.039; Alonso-Coello P, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2016; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Bafeta A, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e813; Bergamin FS, 2017, CRIT CARE MED, V45, P766, DOI 10.1097/CCM.0000000000002283; BOLDT J, 1989, ANAESTHESIST, V38, P353; Bolton-Maggs PHB, 2016, TRANSFUSION MED, V26, P401, DOI 10.1111/tme.12380; Bracey AW, 1999, TRANSFUSION, V39, P1070, DOI 10.1046/j.1537-2995.1999.39101070.x; Cahill C, 2016, TRANSFUSION, V56, p32A; Carson JL, 2016, JAMA-J AM MED ASSOC, V316, P2025, DOI 10.1001/jama.2016.9185; Carson JL, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub4; Carson JL, 2013, AM HEART J, V165, P964, DOI 10.1016/j.ahj.2013.03.001; Chui BK, 2012, J TRAUMA ACUTE CARE, V73, P195, DOI 10.1097/TA.0b013e31824ba1da; Consten ECJ, 1996, J THORAC CARDIOV SUR, V112, P162, DOI 10.1016/S0022-5223(96)70192-7; Cooper HA, 2011, AM J CARDIOL, V108, P1108, DOI 10.1016/j.amjcard.2011.06.014; Cornell JE, 2014, ANN INTERN MED, V160, P267, DOI 10.7326/M13-2886; Corwin HL, 2002, JAMA-J AM MED ASSOC, V288, P2827, DOI 10.1001/jama.288.22.2827; Corwin HL, 2001, CRIT CARE MED, V29, pS201, DOI 10.1097/00003246-200109001-00011; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Curley A, 2019, NEW ENGL J MED, V380, P242, DOI 10.1056/NEJMoa1807320; Dara SI, 2005, CRIT CARE MED, V33, P2667, DOI [10.1097/01.CCM.0000186745.53059.F0, 10.1097/01.CCM.0000151062.00501.60]; de Almeida JP, 2015, ANESTHESIOLOGY, V122, P29, DOI 10.1097/ALN.0000000000000511; de Bruin S, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2591-6; DeZern AE, 2016, TRANSFUSION, V56, P1750, DOI 10.1111/trf.13658; Docherty AB, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i1351; Dolman HS, 2015, SURGERY, V158, P1083, DOI 10.1016/j.surg.2015.05.018; Elabbassi W, 2017, INDIAN HEART J, V69, P762, DOI 10.1016/j.ihj.2017.05.003; Estcourt LJ, 2017, BRIT J HAEMATOL, V176, P365, DOI 10.1111/bjh.14423; Fogagnolo A, 2017, INTENS CARE MED, V5, P41; Garrido-Martin P, 2012, INTERACT CARDIOV TH, V15, P1013, DOI 10.1093/icvts/ivs344; Georgopoulos D, 2005, CRIT CARE, V9, pR508, DOI 10.1186/cc3786; Gobatto ALN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-018-2273-9; Goldman M, 2005, TRANSFUS MED REV, V19, P2, DOI 10.1016/j.tmrv.2004.10.001; Guttendorf J, 2014, AM J CRIT CARE, V23, P365, DOI 10.4037/ajcc2014115; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012; Hajjar LA, 2010, JAMA-J AM MED ASSOC, V304, P1559, DOI 10.1001/jama.2010.1446; Harber CR, 2006, ANAESTH INTENS CARE, V34, P434, DOI 10.1177/0310057X0603400414; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439, DOI 10.1001/jama.273.18.1439; Hebert PC, 2001, CHEST, V119, P1850, DOI 10.1378/chest.119.6.1850; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Holst LB, 2014, NEW ENGL J MED, V371, P1381, DOI 10.1056/NEJMoa1406617; Jenq CC, 2018, ARTIF ORGANS, V42, P705, DOI 10.1111/aor.13123; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; Kasper SM, 2001, ANESTHESIOLOGY, V95, P81, DOI 10.1097/00000542-200107000-00017; Khamiees M, 2001, CHEST, V120, P1262, DOI 10.1378/chest.120.4.1262; Klein AA, 2016, ANAESTHESIA, V71, P829, DOI 10.1111/anae.13489; Laine A, 2018, J CARDIOTHOR VASC AN, V32, P132, DOI 10.1053/j.jvca.2017.08.039; LENZ C, 2007, TRANSFUS ALTERN TRAN, V9, P265, DOI DOI 10.1111/j.1778-428X.2007.00080.x; Litton E, 2016, INTENS CARE MED, V42, P1715, DOI 10.1007/s00134-016-4465-6; Liu F, 2018, NATL MED J INDIA, V31, P5, DOI 10.4103/0970-258X.243419; Loukas A, 2011, CRIT CARE S1, V15, pP425, DOI [10.1186/cc9845, DOI 10.1186/CC9845]; Luchette FA, 2012, AM J SURG, V203, P508, DOI 10.1016/j.amjsurg.2011.08.006; MacIsaac CM, 2003, ANAESTH INTENS CARE, V31, P653, DOI 10.1177/0310057X0303100607; MacLaren R, 2005, VALUE HEALTH, V8, P105, DOI 10.1111/j.1524-4733.2005.04006.x; Madi-Jebara SN, 2004, J CARDIOTHOR VASC AN, V18, P59, DOI 10.1053/j.jvca.2003.10.012; Mahdy Saad, 2009, Middle East Journal of Anesthesiology, V20, P219; MARTINOWITZ U, 1990, J THORAC CARDIOV SUR, V100, P92; Mazer CD, 2017, NEW ENGL J MED, V377, P2133, DOI 10.1056/NEJMoa1711818; Mazza Bruno Franco, 2015, Rev. bras. ter. intensiva, V27, P36, DOI 10.5935/0103-507X.20150007; McCredie VA, 2017, NEUROCRIT CARE, V26, P247, DOI 10.1007/s12028-016-0310-6; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Meier J, 2016, BRIT J ANAESTH, V116, P255, DOI 10.1093/bja/aev456; Moron NJE, 2003, REV ROL ENF, V26, P591; Muller MCA, 2015, J THROMB HAEMOST, V13, P989, DOI 10.1111/jth.12908; Muller MC, 2015, TRANSFUSION, V55, P26, DOI 10.1111/trf.12750; Muller MCA, 2017, TRANSFUS MED REV, V31, P223, DOI 10.1016/j.tmrv.2017.05.008; Mueller MM, 2019, JAMA-J AM MED ASSOC, V321, P983, DOI 10.1001/jama.2019.0554; Mung'ayi V, 2014, AFR J EMERG MED, V4, P66, DOI 10.1016/j.afjem.2013.06.004; Murphy GJ, 2015, NEW ENGL J MED, V372, P997, DOI 10.1056/NEJMoa1403612; Muthuchellappan R, 2018, TRANSFUSION MED, V28, P304, DOI 10.1111/tme.12504; Naidech AM, 2010, NEUROCRIT CARE, V13, P313, DOI 10.1007/s12028-010-9424-4; Napolitano LM, 2009, CRIT CARE MED, V37, P3124, DOI 10.1097/CCM.0b013e3181b39f1b; Navarro JL, 2015, INTENSIVE CARE MED E, V3, pA221, DOI [10.1186/2197-425X-3-S1-A221, DOI 10.1186/2197-425X-3-S1-A221]; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Orlov D, 2009, TRANSFUSION, V49, P682, DOI 10.1111/j.1537-2995.2008.02022.x; Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4; Padhi S, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h5832; Page C, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-14; Panholzer B, 2017, PERFUSION-UK, V32, P495, DOI 10.1177/0267659117693075; Parimi N, 2018, ANN CLIN LAB SCI, V48, P279; PERUZZI WT, 1993, CRIT CARE MED, V21, P501, DOI 10.1097/00003246-199304000-00007; Peterson J, 2011, NEWCASTLE OTTAWA SCA; Pieracci FM, 2014, CRIT CARE MED, V42, P2048, DOI 10.1097/CCM.0000000000000408; Pieracci FM, 2009, SURG INFECT, V10, P9, DOI 10.1089/sur.2008.043; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Powell M, 2012, APPALACH HERIT, V40, P12, DOI 10.1353/aph.2012.0002; Rasmussen Lone, 2010, Clin Epidemiol, V3, P1, DOI 10.2147/CLEP.S12885; Ratcliffe LEK, 2016, AM J KIDNEY DIS, V67, P548, DOI 10.1053/j.ajkd.2015.11.012; Rezende Ederlon, 2010, Rev. bras. ter. intensiva, V22, P5, DOI 10.1590/S0103-507X2010000100003; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rogers CA, 2017, BRIT J ANAESTH, V119, P384, DOI 10.1093/bja/aex182; Romers LHL, 2016, ANESTHESIOLOGY, V125, P124, DOI 10.1097/ALN.0000000000001156; Salman Salam S, 2007, J Intensive Care Med, V22, P105, DOI 10.1177/0885066606297969; Samarani G, 2015, AM J RESP CRIT CARE, V191; Sanchez-Giron F, 2008, ARCH PATHOL LAB MED, V132, P1916, DOI 10.1043/1543-2165-132.12.1916; Schmidt M, 2013, INTENS CARE MED, V39, P838, DOI 10.1007/s00134-012-2785-8; Schofield WN, 2003, MED J AUSTRALIA, V178, P117, DOI 10.5694/j.1326-5377.2003.tb05101.x; Segal JB, 2005, TRANSFUSION, V45, P1413, DOI 10.1111/j.1537-2995.2005.00546.x; Sehgal LR, 2001, TRANSFUSION, V41, P591, DOI 10.1046/j.1537-2995.2001.41050591.x; Shehata N, 2012, TRANSFUSION, V52, P91, DOI 10.1111/j.1537-2995.2011.03236.x; Shermock KM, 2005, CRIT CARE MED, V33, P497, DOI 10.1097/01.ccm.0000155988.78188.EE; Silver M, 2006, CRIT CARE MED, V34, P2310, DOI 10.1097/01.CCM.0000233873.17954.42; Simon GI, 2017, LANCET HAEMATOL, V4, pE465, DOI 10.1016/S2352-3026(17)30141-2; SMOLLER BR, 1989, AM J CLIN PATHOL, V91, P701, DOI 10.1093/ajcp/91.6.701; Stanworth SJ, 2013, NEW ENGL J MED, V368, P1771, DOI 10.1056/NEJMoa1212772; Stanworth SJ, 2011, CRIT CARE, V15, DOI 10.1186/cc10129; Stanworth SJ, 2011, TRANSFUSION, V51, P62, DOI 10.1111/j.1537-2995.2010.02798.x; Strauss R, 2002, CRIT CARE MED, V30, P1765, DOI 10.1097/00003246-200208000-00015; Surve RM, 2016, TRANSFUSION MED, V26, P343, DOI 10.1111/tme.12332; Swol J, 2018, PERFUSION-UK, V33, P546, DOI 10.1177/0267659118772457; Taha A, 2015, CRIT CARE, V19, P331, DOI [10.1186/cc14411, DOI 10.1186/CC14411]; Tinmouth A, 2013, TRANSFUSION, V53, P2222, DOI 10.1111/trf.12231; Torella F, 2002, SHOCK, V18, P440, DOI 10.1097/00024382-200211000-00009; TRIMBLE AS, 1964, J THORAC CARDIOV SUR, V48, P314, DOI 10.1016/S0022-5223(19)32798-9; Valentine SL, 2018, PEDIATR CRIT CARE ME, V19, P884, DOI 10.1097/PCC.0000000000001613; van Iperen CE, 2000, CRIT CARE MED, V28, P2773, DOI 10.1097/00003246-200008000-00015; Vanderschueren S, 2000, CRIT CARE MED, V28, P1871, DOI 10.1097/00003246-200006000-00031; Vavricka SR, 2003, ANN HEMATOL, V82, P570, DOI 10.1007/s00277-003-0707-0; Veelo DP, 2012, BLOOD TRANSFUS-ITALY, V10, P213, DOI 10.2450/2012.0086-11; Vincent JL, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2018-9; Vincent JL, 2006, CRIT CARE MED, V34, P1661, DOI 10.1097/01.CCM.0000217919.22155.85; Vincent JL, 2002, JAMA-J AM MED ASSOC, V288, P1499, DOI 10.1001/jama.288.12.1499; Vlaar APJ, 2013, LANCET, V382, P984, DOI 10.1016/S0140-6736(12)62197-7; Voelker MT, 2015, ARTIF ORGANS, V39, P374, DOI 10.1111/aor.12385; Walsh TS, 2013, CRIT CARE MED, V41, P2354, DOI 10.1097/CCM.0b013e318291cce4; Walsh TS, 2010, CRIT CARE MED, V38, P1939, DOI 10.1097/CCM.0b013e3181eb9d2b; Warner MA, 2019, ANESTH ANALG, V128, P288, DOI 10.1213/ANE.0000000000002794; Warner MA, 2017, TRANSFUSION, V57, P890, DOI 10.1111/trf.13996; Watson DM, 2011, TRANSFUSION MED, V21, P124, DOI 10.1111/j.1365-3148.2010.01049.x; Webert KE, 2008, TRANSFUSION, V48, P81, DOI 10.1111/j.1537-2995.2007.01485.x; Weingart C, 2015, ARTIF ORGANS, V39, P765, DOI 10.1111/aor.12464; Wilhelmi M, 2001, EUR J CARDIO-THORAC, V19, P657, DOI 10.1016/S1010-7940(01)00648-0; Woda RP, 1999, J CLIN MONITOR COMP, V15, P215, DOI 10.1023/A:1009936917049; Yang L, 2012, TRANSFUSION, V52, P1673, DOI 10.1111/j.1537-2995.2011.03515.x; Yoo YC, 2011, ANESTHESIOLOGY, V115, P929, DOI 10.1097/ALN.0b013e318232004b; Zeidler K, 2011, TRANSFUSION, V51, P2269, DOI 10.1111/j.1537-2995.2011.03147.x; Zogheib E, 2011, INTENS CARE MED, V37, pS155	143	24	25	1	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	APR	2020	46	4					673	696		10.1007/s00134-019-05884-8			24	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY5IV	WOS:000522601500012	31912207	Bronze, Green Published, Green Submitted			2022-02-06	
J	Hssayeni, MD; Croock, MS; Salman, AD; Al-khafaji, HF; Yahya, ZA; Ghoraani, B				Hssayeni, Murtadha D.; Croock, Muayad S.; Salman, Aymen D.; Al-khafaji, Hassan Falah; Yahya, Zakaria A.; Ghoraani, Behnaz			Intracranial Hemorrhage Segmentation Using a Deep Convolutional Model	DATA			English	Article; Data Paper						intracranial hemorrhage segmentation; ICH detection; fully convolutional network; U-Net; CT scans dataset	CT; TOMOGRAPHY; ALGORITHM	Traumatic brain injuries may cause intracranial hemorrhages (ICH). ICH could lead to disability or death if it is not accurately diagnosed and treated in a time-sensitive procedure. The current clinical protocol to diagnose ICH is examining Computerized Tomography (CT) scans by radiologists to detect ICH and localize its regions. However, this process relies heavily on the availability of an experienced radiologist. In this paper, we designed a study protocol to collect a dataset of 82 CT scans of subjects with a traumatic brain injury. Next, the ICH regions were manually delineated in each slice by a consensus decision of two radiologists. The dataset is publicly available online at the PhysioNet repository for future analysis and comparisons. In addition to publishing the dataset, which is the main purpose of this manuscript, we implemented a deep Fully Convolutional Networks (FCNs), known as U-Net, to segment the ICH regions from the CT scans in a fully-automated manner. The method as a proof of concept achieved a Dice coefficient of 0.31 for the ICH segmentation based on 5-fold cross-validation.	[Hssayeni, Murtadha D.; Ghoraani, Behnaz] Florida Atlantic Univ, Dept Comp & Elect Engn & Comp Sci, Boca Raton, FL 33431 USA; [Hssayeni, Murtadha D.; Croock, Muayad S.; Salman, Aymen D.] Univ Technol Baghdad, Comp Engn Dept, Baghdad 10001, Iraq; [Al-khafaji, Hassan Falah; Yahya, Zakaria A.] Babylon Hlth Directorate, Babil 51001, Iraq		Ghoraani, B (corresponding author), Florida Atlantic Univ, Dept Comp & Elect Engn & Comp Sci, Boca Raton, FL 33431 USA.	mhssayeni2017@fau.edu; muayadkrook@yahoo.com; aymasm_sw@yahoo.com; hassanradiology@gmail.com; jjojoirak123@gmail.com; bghoraani@fau.edu	Croock, Muayad Sadik/M-5624-2016; Salman, Aymen Dawood Salman/D-8107-2019	Croock, Muayad Sadik/0000-0001-5269-0697; Ghoraani, Behnaz/0000-0003-0075-7663; Hssayeni, Murtadha/0000-0002-8588-4639; Salman, Aymen Dawood Salman/0000-0002-1435-725X			Arbabshirani MR, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-017-0015-z; Bhadauria HS, 2014, SIGNAL IMAGE VIDEO P, V8, P357, DOI 10.1007/s11760-012-0298-0; Chan T, 2007, COMPUT MED IMAG GRAP, V31, P285, DOI 10.1016/j.compmedimag.2007.02.010; Chang PD, 2018, AM J NEURORADIOL, V39, P1609, DOI 10.3174/ajnr.A5742; Chi FL, 2014, WORLD J EMERG MED, V5, P203, DOI [10.5847/wjem.j.issn.1920-8642.2014.03.008, 10.5847/wjem.j.1920-8642.2014.03.008]; Chilamkurthy S., 2018, ARXIV180305854; Chilamkurthy S, 2018, LANCET, V392, P2388, DOI 10.1016/S0140-6736(18)31645-3; Cho J, 2019, J DIGIT IMAGING, V32, P450, DOI 10.1007/s10278-018-00172-1; Currie S, 2016, POSTGRAD MED J, V92, P41, DOI 10.1136/postgradmedj-2014-133211; Gautam A, 2019, ADV INTELL SYST, V748, P753, DOI 10.1007/978-981-13-0923-6_64; Goldberger AL, 2000, CIRCULATION, V101, pE215, DOI 10.1161/01.CIR.101.23.e215; Grewal M, 2018, I S BIOMED IMAGING, P281, DOI 10.1109/ISBI.2018.8363574; Hssayeni M.D., 2019, COMPUTED TOMOGRAPHY; Jnawali K, 2018, MED IMAGING 2018 COM; Kuang HL, 2019, IEEE ACCESS, V7, P39842, DOI 10.1109/ACCESS.2019.2906605; Kuo WC, 2018, LECT NOTES COMPUT SC, V11072, P715, DOI 10.1007/978-3-030-00931-1_82; Lee H, 2019, NAT BIOMED ENG, V3, P173, DOI 10.1038/s41551-018-0324-9; Li YH, 2012, INT J COMPUT ASS RAD, V7, P507, DOI 10.1007/s11548-011-0664-3; Li YH, 2012, J MED SYST, V36, P1259, DOI 10.1007/s10916-010-9587-8; Litjens G, 2017, MED IMAGE ANAL, V42, P60, DOI 10.1016/j.media.2017.07.005; Muschelli J, 2017, NEUROIMAGE-CLIN, V14, P379, DOI 10.1016/j.nicl.2017.02.007; Nag MK, 2019, INT J COMPUT ASS RAD, V14, P259, DOI 10.1007/s11548-018-1873-9; Prakash KNB, 2012, INT J COMPUT ASS RAD, V7, P785, DOI 10.1007/s11548-012-0670-0; Prevedello LM, 2017, RADIOLOGY, V285, P923, DOI 10.1148/radiol.2017162664; Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28; Shahangian B, 2016, BIOCYBERN BIOMED ENG, V36, P217, DOI 10.1016/j.bbe.2015.12.001; Strub WM, 2007, AM J NEURORADIOL, V28, P1679, DOI 10.3174/ajnr.A0653; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; Xue Zhiyun, 2012, AMIA Annu Symp Proc, V2012, P1023; Ye H, 2019, EUR RADIOL, V29, P6191, DOI 10.1007/s00330-019-06163-2; Yuh EL, 2008, J NEUROTRAUM, V25, P1163, DOI 10.1089/neu.2008.0590	32	24	24	0	2	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2306-5729		DATA	Data	MAR	2020	5	1							14	10.3390/data5010014			18	Computer Science, Information Systems; Multidisciplinary Sciences	Emerging Sources Citation Index (ESCI)	Computer Science; Science & Technology - Other Topics	LA1JX	WOS:000523712300006		gold, Green Submitted			2022-02-06	
J	Sen, T; Saha, P; Gupta, R; Foley, LM; Jiang, T; Abakumova, OS; Hitchens, TK; Sen, N				Sen, Tanusree; Saha, Pampa; Gupta, Rajaneesh; Foley, Lesley M.; Jiang, Tong; Abakumova, Olena S.; Hitchens, T. Kevin; Sen, Nilkantha			Aberrant ER Stress Induced Neuronal-IFN beta Elicits White Matter Injury Due to Microglial Activation and T-Cell Infiltration after TBI	JOURNAL OF NEUROSCIENCE			English	Article						IFN; microglia; neuroinflammation; traumatic brain injury; white matter injury	TRAUMATIC BRAIN-INJURY; ENDOPLASMIC-RETICULUM STRESS; INTRACEREBRAL INFLAMMATORY RESPONSE; CENTRAL-NERVOUS-SYSTEM; CONTROLLED CORTICAL IMPACT; ANXIETY-LIKE BEHAVIOR; DIFFUSION TENSOR; POLARIZATION DYNAMICS; MICE; DEGENERATION	Persistent endoplasmic reticulum (ER) stress in neurons is associated with activation of inflammatory cells and subsequent neuroinflammation following traumatic brain injury (TBI); however, the underlying mechanism remains elusive. We found that induction of neuronal-ER stress, which was mostly characterized by an increase in phosphorylation of a protein kinase R-like ER kinase (PERK) leads to release of excess interferon (IFN)beta due to atypical activation of the neuronal-STING signaling pathway. IFN beta enforced activation and polarization of the primary microglial cells to inflammatory M1 phenotype with the secretion of a proinflammatory chemokine CXCL10 due to activation of STAT1 signaling. The secreted CXCL10, in turn, stimulated the T-cell infiltration by serving as the ligand and chemoattractant for CXCR3(+)T-helper 1 (Th1) cells. The activation of microglial cells and infiltration of Th1 cells resulted in white matter injury, characterized by impaired myelin basic protein and neurofilament NF200, the reduced thickness of corpus callosum and external capsule, and decline of mature oligodendrocytes and oligodendrocyte precursor cells. Intranasal delivery of CXCL10 siRNA blocked Th1 infiltration but did not fully rescue microglial activation and white matter injury after TBI. However, impeding PERK-phosphorylation through the administration of GSK2656157 abrogated neuronal induction of IFN beta, switched microglial polarization to M2 phenotype, prevented Th1 infiltration, and increased Th2 and Treg levels. These events ultimately attenuated the white matter injury and improved anxiety and depressive-like behavior following TBI.	[Sen, Tanusree; Saha, Pampa; Gupta, Rajaneesh; Jiang, Tong; Abakumova, Olena S.; Sen, Nilkantha] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Foley, Lesley M.; Hitchens, T. Kevin] Univ Pittsburgh, Anim Imaging Ctr, Sch Med, Pittsburgh, PA 15044 USA		Sen, T; Sen, N (corresponding author), Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA.	tas215@pitt.edu; senn@pitt.edu	Gupta, Rajaneesh/AAD-5893-2019; Sen, Nilkantha/AAW-9788-2020	Gupta, Rajaneesh/0000-0003-0212-6478; Sen, Nilkantha/0000-0002-8383-8209	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS094516, R01EY025622]; University of PittsburghUniversity of Pittsburgh; Copeland Foundation	This work was partly supported by the National Institutes of Health (Grants R01NS094516 and R01EY025622 to N.S.), and the University of Pittsburgh and Copeland Foundation to T.S. and N.S.	Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Abdullah A, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1354-7; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Almeida-Suhett CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102627; Aroniadou-Anderjaska V, 2012, NEUROSCIENCE, V221, P157, DOI 10.1016/j.neuroscience.2012.07.006; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Baruch K, 2014, SCIENCE, V346, P89, DOI 10.1126/science.1252945; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Berl S, 2017, J NEUROSCI METH, V283, P15, DOI 10.1016/j.jneumeth.2017.03.015; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Bitko Vira, 2008, V442, P75, DOI 10.1007/978-1-59745-191-8_6; Booth V, 2002, BIOCHEMISTRY-US, V41, P10418, DOI 10.1021/bi026020q; Broussard JI, 2018, BRAIN INJURY, V32, P113, DOI 10.1080/02699052.2017.1380228; Cai X, 2014, MOL CELL, V54, P289, DOI 10.1016/j.molcel.2014.03.040; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CASH E, 1993, CELL IMMUNOL, V147, P129, DOI 10.1006/cimm.1993.1053; Cheeran MCJ, 2003, J VIROL, V77, P4502, DOI 10.1128/JVI.77.8.4502-4515.2003; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chen YX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08227-z; Chhatbar C, 2018, CELL REP, V25, P118, DOI 10.1016/j.celrep.2018.09.003; Cui YY, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00182; Dai PH, 2011, J VIROL, V85, P10814, DOI 10.1128/JVI.00104-11; Dash PK, 2015, J NEUROTRAUM, V32, P1608, DOI 10.1089/neu.2014.3772; Deczkowska A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00769-0; Dent KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121541; do Amaral JF, 2013, FUND CLIN PHARMACOL, V27, P471, DOI 10.1111/j.1472-8206.2012.01058.x; Donlin LT, 2014, J IMMUNOL, V193, P2373, DOI 10.4049/jimmunol.1400486; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Einat H, 2001, BEHAV BRAIN RES, V118, P77, DOI 10.1016/S0166-4328(00)00314-4; Ejlerskov P, 2015, CELL, V163, P324, DOI 10.1016/j.cell.2015.08.069; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Fenwick PS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128757; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fu HJ, 2019, NAT NEUROSCI, V22, P47, DOI 10.1038/s41593-018-0298-7; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Guida F, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00095; Harry GJ, 2013, PHARMACOL THERAPEUT, V139, P313, DOI 10.1016/j.pharmthera.2013.04.013; Hernandez-Rabaza V, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0420-7; Hilgenberg Lutz G W, 2007, J Vis Exp, P562, DOI 10.3791/562; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Hood KN, 2018, J NEUROSCI, V38, P2372, DOI 10.1523/JNEUROSCI.1756-17.2018; Jin XM, 2016, J BIOCHEM, V159, P491, DOI 10.1093/jb/mvw009; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jones KJ, 2015, J NEUROIMMUNE PHARM, V10, P587, DOI 10.1007/s11481-015-9625-x; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; Karve IP, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0128-15.2016; Lampron A, 2015, J EXP MED, V212, P481, DOI 10.1084/jem.20141656; Lian Hong, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1989; Liu SQ, 2015, SCIENCE, V347, P1217, DOI 10.1126/science.aaa2630; Liu YP, 2012, J IMMUNOL, V189, P4630, DOI 10.4049/jimmunol.1102737; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Long JA, 2015, J NEUROTRAUM, V32, P598, DOI 10.1089/neu.2014.3563; Lopez-Fabuel I, 2016, P NATL ACAD SCI USA, V113, P13063, DOI 10.1073/pnas.1613701113; Matveeva V, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113453; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Mckee CA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00556; Michlmayr D., 2014, INT J INTERF CYTOKIN, V6, P1, DOI [DOI 10.2147/IJICMR.S35953, 10.2147/IJICMR.S35953]; Mills CD, 2014, J INNATE IMMUN, V6, P716, DOI 10.1159/000364945; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moore SM, 2014, P NATL ACAD SCI USA, V111, P18061, DOI 10.1073/pnas.1411294111; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Narayana Ponnada A, 2017, Concussion, V2, pCNC35, DOI 10.2217/cnc-2016-0028; Ndode-Ekane XE, 2018, RESTOR NEUROL NEUROS, V36, P485, DOI 10.3233/RNN-170811; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Olah M, 2012, GLIA, V60, P306, DOI 10.1002/glia.21266; Petrasek J, 2013, P NATL ACAD SCI USA, V110, P16544, DOI 10.1073/pnas.1308331110; Pino Paula A, 2011, J Vis Exp, DOI 10.3791/2348; Pischiutta F, 2018, EXP NEUROL, V300, P167, DOI 10.1016/j.expneurol.2017.11.003; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Qin C, 2017, STROKE, V48, P3336, DOI 10.1161/STROKEAHA.117.018505; Qu WR, 2016, NEURAL REGEN RES, V11, P248, DOI 10.4103/1673-5374.177732; Rodgers KM, 2014, J NEUROTRAUM, V31, P487, DOI [10.1089/NEU.2013.3090, 10.1089/neu.2013.3090]; Rodriguez M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01819-9; Rojas-Rivera D, 2017, CELL DEATH DIFFER, V24, P1100, DOI 10.1038/cdd.2017.58; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Saha P, 2018, NEUROBIOL DIS, V118, P108, DOI 10.1016/j.nbd.2018.07.010; Schafer DP, 2016, ELIFE, V5, DOI 10.7554/eLife.15224; Sen T, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao6765; Sen T, 2017, J NEUROSCI, V37, P5900, DOI 10.1523/JNEUROSCI.2343-16.2017; Sen T, 2016, NEUROPHARMACOLOGY, V107, P79, DOI 10.1016/j.neuropharm.2016.03.009; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stirling DP, 2008, J NEUROSCI RES, V86, P1944, DOI 10.1002/jnr.21659; Tan HP, 2018, NEURAL REGEN RES, V13, P827, DOI 10.4103/1673-5374.232477; Tanaka Y, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002521; Taylor JM, 2014, NEUROBIOL AGING, V35, P1012, DOI 10.1016/j.neurobiolaging.2013.10.089; Wakade C, 2010, J NEUROSURG, V113, P1195, DOI 10.3171/2010.3.JNS091212; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang J, 2017, FREE RADICAL BIO MED, V113, P119, DOI 10.1016/j.freeradbiomed.2017.09.017; Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614; Wilson S, 2004, J NEUROTRAUM, V21, P239, DOI 10.1089/089771504322972031; Xia YG, 2018, P NATL ACAD SCI USA, V115, pE9230, DOI 10.1073/pnas.1810693115; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Xu ZH, 2015, J NEUROCHEM, V133, P233, DOI 10.1111/jnc.13064; Yi Y, 2018, MOL NEUROBIOL, V55, P2454, DOI 10.1007/s12035-017-0504-8; Yu F, 2015, NAT IMMUNOL, V16, P197, DOI 10.1038/ni.3053; Zhao XR, 2015, J NEUROSCI, V35, P11281, DOI 10.1523/JNEUROSCI.1685-15.2015; Zhu CY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12184-y; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	107	24	24	0	9	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JAN 8	2020	40	2					424	446		10.1523/JNEUROSCI.0718-19.2019			23	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	KB0QB	WOS:000506203800013	31694961	Bronze, Green Published			2022-02-06	
J	Eagle, SR; Kontos, AP; Pepping, GJ; Johnson, CD; Sinnott, A; Lagoy, A; Connaboy, C				Eagle, Shawn R.; Kontos, Anthony P.; Pepping, Gert-Jan; Johnson, Caleb D.; Sinnott, Aaron; Lagoy, Alice; Connaboy, Chris			Increased Risk of Musculoskeletal Injury Following Sport-Related Concussion: A Perception-Action Coupling Approach	SPORTS MEDICINE			English	Article							SUBSEQUENT INJURY; GAIT STABILITY; SCHEMA THEORY; ATTENTION; AFFORDANCES; CALIBRATION; INFORMATION; DISORDERS; CHILDREN; DEFICITS	Recent studies have concluded that athletes have increased risk of musculoskeletal injury following sport-related concussion. While an underlying explanation is still unknown, perceptual-motor control may be implicated in this increased risk. Some authors have purported that indirect perception (i.e., a "top-down" view of neuromuscular control) may be disrupted following sport-related concussion. Direct perception theory states that the athlete and environment are inextricably linked in a continuous perception-action coupling loop. That is, the athlete is able to directly perceive opportunities for action (e.g., "affordances") in the environment. Based on these notions, the aim of the current paper was to introduce a theoretical model that argues that sport-related concussion may dysregulate the direct perception process, potentially increasing behavioral risk of musculoskeletal injury during sport. Our model is integrated with a sport-related concussion clinical treatment model, which highlights individualized profiles that characterize the heterogeneous response to sport-related concussion. These profiles have a typical constellation of symptoms (e. g., anxiety, fatigue, ocular dysfunction, etc.), which themselves have been associated with disrupted perception-action coupling, independent of sport-related concussion. Therefore, we argue that athletes who have not re-established perception-action coupling loops following sport-related concussion may be at increased risk of subsequent musculoskeletal injury.	[Eagle, Shawn R.; Sinnott, Aaron; Lagoy, Alice; Connaboy, Chris] Univ Pittsburgh, Warrior Human Performance Res Ctr, Neuromuscular Res Lab, 3860 S Water St, Pittsburgh, PA 15203 USA; [Kontos, Anthony P.] Univ Pittsburgh, Dept Orthopaed Surg, UPMC Sports Med Concuss Program, Pittsburgh, PA USA; [Pepping, Gert-Jan] Australian Catholic Univ, Sch Behav & Hlth Sci, Brisbane, Qld, Australia; [Johnson, Caleb D.] Harvard Univ, Harvard Med Sch, Spaulding Natl Running Ctr, Cambridge, MA 02138 USA		Eagle, SR (corresponding author), Univ Pittsburgh, Warrior Human Performance Res Ctr, Neuromuscular Res Lab, 3860 S Water St, Pittsburgh, PA 15203 USA.	seagle@pitt.edu	Connaboy, Christopher/AAH-4514-2020; Eagle, Shawn/ABG-1388-2020; Pepping, Gert-Jan/B-2197-2010; Pepping, Gert-Jan/Y-8545-2019	Connaboy, Christopher/0000-0002-9031-2192; Eagle, Shawn/0000-0001-6767-1042; Pepping, Gert-Jan/0000-0002-5926-2000; Pepping, Gert-Jan/0000-0002-5926-2000; Sinnott, Aaron/0000-0002-8887-759X			Araujo D, 2019, INT REV SPORT EXER P, V12, P1, DOI 10.1080/1750984X.2017.1349826; Bernstein N.A., 1967, CONTROL REGULATION M; Bourrelly A, 2015, COGN PROCESS, V16, pS171, DOI 10.1007/s10339-015-0692-y; Brault S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037494; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Burman E, 2016, BMJ OPEN SPORT EXERC, V2, pe000092, DOI DOI 10.1136/BMJSEM-2015-000092; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Collins MW, 2016, NEUROSURGERY, V79, P912, DOI 10.1227/NEU.0000000000001447; Collins MW, 2014, KNEE SURG SPORT TR A, V22, P235, DOI 10.1007/s00167-013-2791-6; Connaboy C, 2019, AEROSP MED HUM PERF, V90, P77, DOI 10.3357/AMHP.5190.2019; Cordovil R, 2015, NEW IDEAS PSYCHOL, V36, P50, DOI 10.1016/j.newideapsych.2014.10.007; Craig CM, 2006, NATURWISSENSCHAFTEN, V93, P97, DOI 10.1007/s00114-005-0071-0; Cripps A, 2018, BRAIN INJURY, V32, P1566, DOI 10.1080/02699052.2018.1497812; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; Daviaux Y, 2016, PSYCHOL RES-PSYCH FO, V80, P224, DOI 10.1007/s00426-015-0653-1; Daviaux Y, 2014, EXP BRAIN RES, V232, P2243, DOI 10.1007/s00221-014-3915-z; Davids K, 2003, SPORTS MED, V33, P245, DOI 10.2165/00007256-200333040-00001; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; Eagle SR, 2019, CLIN J SPORT MED, DOI [10.1097/jsm0000000000000731, DOI 10.1097/JSM0000000000000731]; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Fait P, 2009, BRAIN INJURY, V23, P362, DOI 10.1080/02699050902788485; Fajen BR, 2005, J EXP PSYCHOL HUMAN, V31, P480, DOI 10.1037/0096-1523.31.3.480; Fajen BR, 2005, PERCEPTION, V34, P717, DOI 10.1068/p5405; Fajen BR, 2007, ECOL PSYCHOL, V19, P383, DOI 10.1080/10407410701557877; Fajen BR, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00085; Fajen BR, 2011, HUM MOVEMENT SCI, V30, P504, DOI 10.1016/j.humov.2010.07.016; Fajen BR, 2009, INT J SPORT PSYCHOL, V40, P79; Fernandez-Ruiz J, 2000, COGNITIVE BRAIN RES, V9, P223, DOI 10.1016/S0926-6410(99)00057-9; Franchak JM, 2019, J EXP CHILD PSYCHOL, V183, P100, DOI 10.1016/j.jecp.2019.01.016; Gibson J. J., 1979, ECOLOGICAL APPROACH, P127; Gibson JJ., 1966, SENSES CONSIDERED PE; Gilbert FC, 2016, SPORTS HEALTH, V8, P661, DOI 10.1177/1941738116666509; Grants L, 2017, INT J SPORTS PHYS TH, V12, P1011, DOI 10.26603/ijspt20171011; Graydon MM, 2012, COGNITION EMOTION, V26, P1301, DOI 10.1080/02699931.2012.667391; Harmon KG, 2019, BRIT J SPORT MED, V53, P213, DOI 10.1136/bjsports-2018-100338; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Hirsh JB, 2012, PSYCHOL REV, V119, P304, DOI 10.1037/a0026767; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2018, SPORTS MED, V48, P1097, DOI 10.1007/s40279-018-0871-y; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Kontos A. P., 2018, CONCUSSION CLIN PROF; Kontos AP, 2019, CURR SPORT MED REP, V18, P82, DOI 10.1249/JSR.0000000000000573; Kontos AP, 2017, J ATHL TRAINING, V52, P256, DOI 10.4085/1062-6050-51.11.05; Kontos AP, 2016, BRAIN IMAGING BEHAV, V10, P594, DOI 10.1007/s11682-015-9412-6; Leddy J, 2017, J ATHL TRAINING, V52, P299, DOI 10.4085/1062-6050-51.11.08; Lopez C, 2012, NEUROPSYCHOLOGIA, V50, P1830, DOI 10.1016/j.neuropsychologia.2012.04.008; Lopez C, 2011, BRAIN RES REV, V67, P119, DOI 10.1016/j.brainresrev.2010.12.002; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McGuckian TB, 2019, ECOL PSYCHOL, V31, P30, DOI 10.1080/10407413.2018.1495548; McGuckian TB, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02520; McGuckian TB, 2018, J SPORT SCI, V36, P861, DOI 10.1080/02640414.2017.1344780; McPherson AL, 2019, AM J SPORT MED, V47, P1754, DOI 10.1177/0363546518785901; Michaels C. F., 1981, DIRECT PERCEPTION; Moore DR, 2016, INT J PSYCHOPHYSIOL, V99, P85, DOI 10.1016/j.ijpsycho.2015.11.010; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Murdaugh DL, 2018, ARCH PHYS MED REHAB, V99, P960, DOI 10.1016/j.apmr.2018.01.005; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Nyberg G, 2015, CURR RES CONCUSSION, V2, P109; Palacios EM, 2017, J NEUROTRAUM, V34, P1546, DOI 10.1089/neu.2016.4752; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Pijpers JR, 2007, J SPORT SCI, V25, P97, DOI 10.1080/02640410600630894; Pijpers JR, 2006, ECOL PSYCHOL, V18, P131, DOI 10.1207/s15326969eco1803_1; PLUMERT JM, 1995, DEV PSYCHOL, V31, P866, DOI 10.1037/0012-1649.31.5.866; Poltavski D, 2017, OPTOMETRY VISION SCI, V94, P742, DOI 10.1097/OPX.0000000000001094; SCHMIDT RA, 1975, PSYCHOL REV, V82, P225, DOI 10.1037/h0076770; Schmidt RA, 2003, RES Q EXERCISE SPORT, V74, P366, DOI 10.1080/02701367.2003.10609106; Tkachenko N, 2016, PEDIATR NEUROL, V57, P46, DOI 10.1016/j.pediatrneurol.2015.12.019; van Andel S, 2017, HUM MOVEMENT SCI, V51, P59, DOI 10.1016/j.humov.2016.11.004; Watson G, 2011, HUM MOVEMENT SCI, V30, P942, DOI 10.1016/j.humov.2010.08.004; Withagen R, 2012, NEW IDEAS PSYCHOL, V30, P250, DOI 10.1016/j.newideapsych.2011.12.003	75	24	24	0	3	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	JAN	2020	50	1					15	23		10.1007/s40279-019-01144-3			9	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	KH7QB	WOS:000510843600002	31228023				2022-02-06	
J	Voormolen, DC; Haagsma, JA; Polinder, S; Maas, AIR; Steyerberg, EW; Vulekovic, P; Sewalt, CA; Gravesteijn, BY; Covic, A; Andelic, N; Plass, AM; von Steinbuechel, N				Voormolen, Daphne C.; Haagsma, Juanita A.; Polinder, Suzanne; Maas, Andrew I. R.; Steyerberg, Ewout W.; Vulekovic, Petar; Sewalt, Charlie A.; Gravesteijn, Benjamin Y.; Covic, Amra; Andelic, Nada; Plass, Anne Marie; von Steinbuechel, Nicole		CTR-TBI Participants Investigators	Post-Concussion Symptoms in Complicated vs. Uncomplicated Mild Traumatic Brain Injury Patients at Three and Six Months Post-Injury: Results from the CENTER-TBI Study	JOURNAL OF CLINICAL MEDICINE			English	Article						complicated mild traumatic brain injury; post-concussion symptoms; post-concussion syndrome; traumatic brain injury	POSTCONCUSSION SYNDROME; HEAD-INJURY; RISK-FACTORS; PREVALENCE; RATES; CARE	The aim of this study was to assess the occurrence of post-concussion symptoms and post-concussion syndrome (PCS) in a large cohort of patients after complicated and uncomplicated mild traumatic brain injury (mTBI) at three and six months post-injury. Patients were included through the prospective cohort study: Collaborative European NeuroTrauma Effectiveness Research (CENTER-TBI). Patients enrolled with mTBI (Glasgow Coma Scale 13-15) were further differentiated into complicated and uncomplicated mTBI based on the presence or absence of computed tomography abnormalities, respectively. The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) assessed post-concussion symptoms and PCS according to the mapped ICD-10 classification method. The occurrence of post-concussion symptoms and syndrome at both time points was calculated. Chi square tests were used to test for differences between and within groups. Logistic regression was performed to analyse the association between complicated versus uncomplicated mTBI and the prevalence of PCS. Patients after complicated mTBI reported slightly more post-concussion symptoms compared to those after uncomplicated mTBI. A higher percentage of patients after complicated mTBI were classified as having PCS at three (complicated: 46% vs. uncomplicated: 35%) and six months (complicated: 43% vs. uncomplicated 34%). After adjusting for baseline covariates, the effect of complicated versus uncomplicated mTBI at three months appeared minimal: odds ratio 1.25 (95% confidence interval: 0.95-1.66). Although patients after complicated mTBI report slightly more post-concussion symptoms and show higher PCS rates compared to those after uncomplicated mTBI at three and six months, complicated mTBI was only found a weak indicator for these problems.	[Voormolen, Daphne C.; Haagsma, Juanita A.; Polinder, Suzanne; Steyerberg, Ewout W.; Sewalt, Charlie A.; Gravesteijn, Benjamin Y.] Erasmus MC, Dept Publ Hlth, Univ Med Ctr Rotterdam, POB 2040, NL-3000 CA Rotterdam, Netherlands; [Haagsma, Juanita A.] Erasmus MC, Dept Emergency Med, Univ Med Ctr Rotterdam, NL-3000 CA Rotterdam, Netherlands; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, B-2650 Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Dept Neurosurg, B-2000 Edegem, Belgium; [Steyerberg, Ewout W.] Leiden Univ, Dept Med Stat & Bioinformat, Med Ctr, NL-2333 ZA Leiden, Netherlands; [Vulekovic, Petar] Clin Ctr Vojvodina, Clin Neurosurg, Novi Sad 21000, Serbia; [Covic, Amra; Plass, Anne Marie; von Steinbuechel, Nicole] UMG, Inst Med Psychol & Med Sociol, D-37075 Gottingen, Germany; [Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0372 Oslo, Norway; [Andelic, Nada] Univ Oslo, Fac Med, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Inst Hlth & Soc, N-0318 Oslo, Norway		Voormolen, DC (corresponding author), Erasmus MC, Dept Publ Hlth, Univ Med Ctr Rotterdam, POB 2040, NL-3000 CA Rotterdam, Netherlands.	d.voormolen@erasmusmc.nl; j.haagsma@erasmusmc.nl; s.polinder@erasmusmc.nl; Andrew.Maas@uza.be; e.steyerberg@erasmusmc.nl; pvulekovic@gmail.com; c.sewalt@erasmusmc.nl; b.gravesteijn@erasmusmc.nl; amra.covic@med.uni-goettingen.de; nandelic@online.no; annemarie.plass@med.uni-goettingen.de; nvsteinbuechel@med.uni-goettingen.de	Posti, Jussi P./Y-2908-2019; Gravesteijn, Benjamin/AAN-9524-2020; Maas, Andrew I.R./C-5584-2013	Posti, Jussi P./0000-0002-5925-5193; Gravesteijn, Benjamin/0000-0001-8096-5803; Plass, Anne Marie/0000-0002-7801-9655; Maas, Andrew I.R./0000-0003-1612-1264	Hannelore Kohl Stiftung (Germany); OneMind (USA); Integra LifeSciences Corporation (USA); Neurotrauma Sciences (USA); European Union 7th Framework program (EC) [602150]	CENTER-TBI was supported by the European Union 7th Framework program (EC grant 602150). Additional funding was obtained from the Hannelore Kohl Stiftung (Germany), from OneMind (USA), from Integra LifeSciences Corporation (USA) and from Neurotrauma Sciences (USA).	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Evans RW, 2010, HEADACHE, V50, P716, DOI 10.1111/j.1526-4610.2010.01645.x; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Iverson GL, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00489; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/415740; Katz Douglas I, 2015, Handb Clin Neurol, V127, P131, DOI 10.1016/B978-0-444-52892-6.00009-X; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; King NS, 2013, BRAIN IMPAIR, V14, P235, DOI 10.1017/BrImp.2013.17; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kondiles BR, 2015, HEALTH PSYCHOL BEHAV, V3, P1, DOI 10.1080/21642850.2014.966717; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Plass AM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210138; Polinder S, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01113; Rubin GJ, 1989, BIOMETRICAL J, V31, P131, DOI DOI 10.1002/BIMJ.4710310118; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Spinos P, 2010, J TRAUMA, V69, P789, DOI 10.1097/TA.0b013e3181edea67; Steyerberg EW, 2019, LANCET NEUROL, V18, P923, DOI 10.1016/S1474-4422(19)30232-7; Van Buuren S., 2012, FLEXIBLE IMPUTATION; van Buuren S, 2011, J STAT SOFTW, V45, P1; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Voormolen DC, 2018, J NEUROTRAUM, V35, P1233, DOI 10.1089/neu.2017.5257; Voormolen DC, 2019, BRAIN INJURY, V33, P1078, DOI 10.1080/02699052.2019.1607557; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organization, 1993, ICD 10 CLASS MENT BE	39	24	24	2	7	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		2077-0383		J CLIN MED	J. Clin. Med.	NOV	2019	8	11							1921	10.3390/jcm8111921			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	JV3VR	WOS:000502294400164	31717436	gold, Green Published			2022-02-06	
J	Gorgoraptis, N; Li, LM; Whittington, A; Zimmerman, KA; Maclean, LM; McLeod, C; Ross, E; Heslegrave, A; Zetterberg, H; Passchier, J; Matthews, PM; Gunn, RN; McMillan, TM; Sharp, DJ				Gorgoraptis, Nikos; Li, Lucia M.; Whittington, Alex; Zimmerman, Karl A.; Maclean, Linda M.; McLeod, Claire; Ross, Ewan; Heslegrave, Amanda; Zetterberg, Henrik; Passchier, Jan; Matthews, Paul M.; Gunn, Roger N.; McMillan, Tom M.; Sharp, David J.			In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury	SCIENCE TRANSLATIONAL MEDICINE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; AMYLOID-BETA ACCUMULATION; VOXEL-BASED MORPHOMETRY; ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; HEAD-INJURY; NEUROPATHOLOGICAL CRITERIA; COGNITIVE IMPAIRMENT; HYDROLASE L1; MOUSE MODEL	Traumatic brain injury (TBI) can trigger progressive neurodegeneration, with tau pathology seen years after a single moderate-severe TBI. Identifying this type of posttraumatic pathology in vivo might help to understand the role of tau pathology in TBI pathophysiology. We used flortaucipir positron emission tomography (PET) to investigate whether tau pathology is present many years after a single TBI in humans. We examined PET data in relation to markers of neurodegeneration in the cerebrospinal fluid (CSF), structural magnetic resonance imaging measures, and cognitive performance. Cerebral flortaucipir binding was variable, with many participants with TBI showing increases in cortical and white matter regions. At the group level, flortaucipir binding was increased in the right occipital cortex in TBI when compared to healthy controls. Flortaucipir binding was associated with increased total tau, phosphorylated tau, and ubiquitin carboxyl-terminal hydrolase L1 CSF concentrations, as well as with reduced fractional anisotropy and white matter tissue density in TBI. Apolipoprotein E (APOE) epsilon 4 genotype affected the relationship between flortaucipir binding and time since injury, CSF beta amyloid 1-42 (A beta 42) concentration, white matter tissue density, and longitudinal Mini-Mental State Examination scores in TBI. The results demonstrate that tau PET is a promising approach to investigating progressive neurodegeneration associated with tauopathy after TBI.	[Gorgoraptis, Nikos; Li, Lucia M.; Whittington, Alex; Zimmerman, Karl A.; Ross, Ewan; Matthews, Paul M.; Gunn, Roger N.; Sharp, David J.] Imperial Coll London, Dept Brain Sci, London W12 0NN, England; [Whittington, Alex; Passchier, Jan; Gunn, Roger N.] Invicro London, London W12 0NN, England; [Maclean, Linda M.; McLeod, Claire; McMillan, Tom M.] Univ Glasgow, Inst Hlth & Wellbeing, Glasgow G12 0XH, Lanark, Scotland; [Heslegrave, Amanda; Zetterberg, Henrik] UCL, UK Dementia Res Inst, London WC1N 3BG, England; [Heslegrave, Amanda; Zetterberg, Henrik] UCL Inst Neurol, Dept Neurodegenerat Dis, Queen Sq, London WC1N 3BG, England; [Zetterberg, Henrik] Sahlgrens Univ Hosp, Clin Neurochem Lab, S-43180 Molndal, Sweden; [Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, S-41345 Molndal, Sweden; [Matthews, Paul M.; Sharp, David J.] Imperial Coll London, UK Dementia Res Inst, London W12 0NN, England; [Sharp, David J.] Imperial Coll London, Royal British Leg Ctr Blast Injury Studies, London, England		Sharp, DJ (corresponding author), Imperial Coll London, Dept Brain Sci, London W12 0NN, England.; Sharp, DJ (corresponding author), Imperial Coll London, UK Dementia Res Inst, London W12 0NN, England.; Sharp, DJ (corresponding author), Imperial Coll London, Royal British Leg Ctr Blast Injury Studies, London, England.	david.sharp@imperial.ac.uk	Sharp, David J/A-2119-2013; Zimmerman, Karl/AAL-4988-2020	Zimmerman, Karl/0000-0003-1239-3414; Whittington, Alex/0000-0001-8768-3366; Heslegrave, Amanda/0000-0002-7290-6405; Gorgoraptis, Nikos/0000-0002-2588-9235; Ross, Ewan/0000-0002-5983-526X; Gunn, Roger/0000-0003-1181-5769	Medical Research Council (MRC) UKUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/L022141/1]; NIHR Research Professorship [NIHR-RP-011-048]; UK Dementia Research Institute; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [UKDRI-7006, UKDRI-1003, MR/L022141/1] Funding Source: UKRI	This project was funded by the Medical Research Council (MRC) UK grant number MR/L022141/1 (to D.J.S.). D.J.S. was supported by an NIHR Research Professorship (NIHR-RP-011-048). This work was supported by the UK Dementia Research Institute. Infrastructure was supported by the National Institute of Health Research (NIHR) Imperial Biomedical Research Centre.	Aerts MB, 2011, MOVEMENT DISORD, V26, P169, DOI 10.1002/mds.23341; Agdeppa ED, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0004.2001; Andreasen N, 2001, ARCH NEUROL-CHICAGO, V58, P373, DOI 10.1001/archneur.58.3.373; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Bilguvar K, 2013, P NATL ACAD SCI USA, V110, P3489, DOI 10.1073/pnas.1222732110; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Dickstein DL, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.175; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6; Harada R, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6010007; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Lee CM, 2018, J ALZHEIMERS DIS, V62, P1691, DOI 10.3233/JAD-170840; Li LZ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002028; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Makaretz SJ, 2018, J NEUROL NEUROSUR PS, V89, P1024, DOI 10.1136/jnnp-2017-316409; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Marquie M, 2017, ANN NEUROL, V81, P117, DOI 10.1002/ana.24844; Marquie M, 2015, ANN NEUROL, V78, P787, DOI 10.1002/ana.24517; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mechelli A, 2005, CURR MED IMAGING, V1, P105, DOI 10.2174/1573405054038726; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Noda K, 2006, NEUROPATHOLOGY, V26, P508, DOI 10.1111/j.1440-1789.2006.00722.x; Ohrfelt A, 2016, DEMENT GER COGN D EX, V6, P283, DOI 10.1159/000447239; Ossenkoppele R, 2016, BRAIN, V139, P1551, DOI 10.1093/brain/aww027; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Passamonti L, 2017, BRAIN, V140, P781, DOI 10.1093/brain/aww340; Pereira JMS, 2010, NEUROIMAGE, V49, P2205, DOI 10.1016/j.neuroimage.2009.10.068; Polymenidou M, 2012, J EXP MED, V209, P889, DOI 10.1084/jem.20120741; R Core Team, 2014, R LANG ENV STAT COMP; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ripolles P, 2012, NEUROIMAGE, V60, P1296, DOI 10.1016/j.neuroimage.2012.01.094; Sander K, 2016, ALZHEIMERS DEMENT, V12, P1116, DOI 10.1016/j.jalz.2016.01.003; Schwarz AJ, 2016, BRAIN, V139, P1539, DOI 10.1093/brain/aww023; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shi Y, 2017, NATURE, V549, P523, DOI 10.1038/nature24016; Smith DH, 2019, NAT REV NEUROL, V15, P179, DOI 10.1038/s41582-018-0114-8; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smith R, 2016, BRAIN, V139, P2372, DOI 10.1093/brain/aww163; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Spillantini MG, 2013, LANCET NEUROL, V12, P609, DOI 10.1016/S1474-4422(13)70090-5; Stern RA, 2019, NEW ENGL J MED, V380, P1716, DOI 10.1056/NEJMoa1900757; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Tosun D, 2017, BRAIN, V140, P1499, DOI 10.1093/brain/awx046; Tran HT, 2012, J NEUROPATH EXP NEUR, V71, P116, DOI 10.1097/NEN.0b013e3182456aed; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Tziortzi AC, 2011, NEUROIMAGE, V54, P264, DOI 10.1016/j.neuroimage.2010.06.044; Vermeiren C, 2018, MOVEMENT DISORD, V33, P273, DOI 10.1002/mds.27271; Wang L, 2016, JAMA NEUROL, V73, P1070, DOI 10.1001/jamaneurol.2016.2078; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Xia CJ, 2017, JAMA NEUROL, V74, P427, DOI 10.1001/jamaneurol.2016.5755; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zhang H, 2007, IEEE T MED IMAGING, V26, P1585, DOI 10.1109/TMI.2007.906784	82	24	24	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	SEP 4	2019	11	508							eaaw1993	10.1126/scitranslmed.aaw1993			14	Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine	IV6VQ	WOS:000484406300002	31484787	Green Accepted, Green Submitted			2022-02-06	
J	Desai, N; Wiebe, DJ; Corwin, DJ; Lockyer, JE; Grady, MF; Master, CL				Desai, Natasha; Wiebe, Douglas J.; Corwin, Daniel J.; Lockyer, Julia E.; Grady, Matthew F.; Master, Christina L.			Factors Affecting Recovery Trajectories in Pediatric Female Concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						pediatric concussion; sex differences; vestibular examination; vision examination; female concussion	SPORT; EPIDEMIOLOGY; SEVERITY; OUTCOMES	Objective: Up to one-third of children with concussion have persistent postconcussion symptoms lasting beyond 4 weeks. Females have been shown to have prolonged concussion recovery compared with males. This study examined characteristics in pediatric athletes with concussion to investigate the underlying factors that may contribute to this difference and their relation to recovery trajectories in females compared with males. Design: A retrospective cohort study of pediatric patients with sportsrelated concussion (SRC). Setting: A subspecialty pediatric concussion program. Subjects: One hundred ninety-two records were reviewed, 75 females and 117 males, ages 7 to 18 years old. Assessment of Risk Factors: Sex of patient, time to presentation to specialty care after injury, presence of vision, and vestibular deficits on initial clinical examination. Main Outcome Measures: The main outcome of interest was time to clinical recovery, defined by resolution of symptoms, recovery of physical examination deficits, including vision and vestibular examination, recovery of neurocognitive function, and return to school, exercise, and sport. Results: Pediatric females, on average, presented later to specialty care for evaluation after SRC than males. Females also took longer to recover on 5 markers of recovery: time to return to school without accommodations, time to return to noncontact exercise, time to return to full sport, time to recovery of neurocognitive function on computerized testing, and time to clinical recovery of vision and vestibular deficits on examination including smooth pursuits, saccades, gaze stability, near point of convergence, and balance. These sex-based differences in recovery disappeared when controlling for time to presentation to specialty care. Conclusions: In this cohort of pediatric patients, ages 7 to 18 years old with SRC, females took longer to recover than males. Our results indicate, however, that a modifiable extrinsic factor, time to presentation to specialty care, may contribute to this difference in recovery between the sexes.	[Desai, Natasha] Columbia Univ, Dept Orthoped, Div Sports Med, Med Ctr, New York, NY 10032 USA; [Wiebe, Douglas J.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Corwin, Daniel J.] Childrens Hosp Philadelphia, Div Emergency Med, Philadelphia, PA 19104 USA; [Lockyer, Julia E.; Grady, Matthew F.; Master, Christina L.] Childrens Hosp Philadelphia, Div Orthoped Surg & Sports Med, Philadelphia, PA 19104 USA; [Grady, Matthew F.; Master, Christina L.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA		Desai, N (corresponding author), Columbia Univ, Sch Med, 622 W 168th St,PH-11, New York, NY 10032 USA.	Nd2498@cumc.columbia.edu		Master, Christina/0000-0002-6717-4270			Babiss LA, 2009, J DEV BEHAV PEDIATR, V30, P376, DOI 10.1097/DBP.0b013e3181b33659; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Bock S, 2015, CHILD NERV SYST, V31, P2111, DOI 10.1007/s00381-015-2846-8; Brook EM, 2016, PHYSICIAN SPORTSMED, V44, P20, DOI 10.1080/00913847.2016.1142834; Bryan MA, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4635; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Davis-Hayes C, 2017, J AM ACAD ORTHOP SUR, V25, P818, DOI 10.5435/JAAOS-D-17-00276; Elbin RJ, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0910; Fehr SD, 2017, CLIN J SPORT MED; Haarbauer-Krupa J, 2018, J PEDIATR-US, V197, P241, DOI 10.1016/j.jpeds.2018.01.075; Iverson GL, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2017-097729; Kerr ZY, 2017, AM J PREV MED, V53, P914, DOI 10.1016/j.amepre.2017.05.017; Lavrich JB, 2010, CURR OPIN OPHTHALMOL, V21, P356, DOI 10.1097/ICU.0b013e32833cf03a; Leddy J, 2016, PM&R, V8, pS91, DOI 10.1016/j.pmrj.2015.10.017; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Master CL, 2018, CLIN J SPORT MED, V28, P139, DOI 10.1097/JSM.0000000000000507; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Miller JH, 2016, J NEUROSURG-PEDIATR, V17, P491, DOI 10.3171/2015.8.PEDS14332; Nazeer A, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00046; Oler M J, 1994, Arch Fam Med, V3, P781, DOI 10.1001/archfami.3.9.781; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Sufrinko AM, 2017, CLIN J SPORT MED, V27, P133, DOI 10.1097/JSM.0000000000000324; Tanveer S, 2017, PEDIATR NEUROL, V70, P44, DOI 10.1016/j.pediatrneurol.2017.02.001; Thiagarajan P, 2013, OPTOMETRY VISION SCI, V90, P57, DOI 10.1097/OPX.0b013e31827a233e; Wu JT, 2015, COMMITTEE EVALUATE S	31	24	24	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2019	29	5					361	367		10.1097/JSM.0000000000000646			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	KG1HH	WOS:000509692100003	31460948				2022-02-06	
J	Einarsen, CE; Moen, KG; Haberg, AK; Eikenes, L; Kvistad, KA; Xu, J; Moe, HK; Tollefsen, MH; Vik, A; Skandsen, T				Einarsen, Cathrine Elisabeth; Moen, Kent Goran; Haberg, Asta Kristine; Eikenes, Live; Kvistad, Kjell Arne; Xu, Jian; Moe, Hans Kristian; Tollefsen, Marie Hexeberg; Vik, Anne; Skandsen, Toril			Patients with Mild Traumatic Brain Injury Recruited from Both Hospital and Primary Care Settings: A Controlled Longitudinal Magnetic Resonance Imaging Study	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; MRI; PCS; prospective study; white matter hyperintensities	WHITE-MATTER HYPERINTENSITIES; POST-CONCUSSION SYMPTOMS; DIFFUSE AXONAL INJURY; SCANDINAVIAN GUIDELINES; OUTCOME PREDICTION; RANDOMIZED-TRIALS; CHRONIC PHASE; FOLLOW-UP; LESIONS; MRI	With an emphasis on traumatic axonal injury (TAI), frequency and evolution of traumatic intracranial lesions on 3T clinical magnetic resonance imaging (MRI) were assessed in a combined hospital and community-based study of patients with mild traumatic brain injury (mTBI). The findings were related to post-concussion symptoms (PCS) at 3 and 12 months. Prospectively, 194 patients (16-60 years of age) were recruited from the emergency departments at a level 1 trauma center and a municipal outpatient clinic into the Trondheim mTBI follow-up study. MRI was acquired within 72 h (n = 194) and at 3 (n = 165) and 12 months (n = 152) in patients and community controls (n = 78). The protocol included T2, diffusion weighted imaging, fluid attenuated inversion recovery (FLAIR), and susceptibility weighted imaging (SWI). PCS was assessed with British Columbia Post Concussion Symptom Inventory in patients and controls. Traumatic lesions were present in 12% on very early MRI, and in 5% when computed tomography (CT) was negative. TAI was found in 6% and persisted for 12 months on SWI, whereas TAI lesions on FLAIR disappeared or became less conspicuous on follow-up. PCS occurred in 33% of patients with lesions on MRI and in 19% in patients without lesions at 3 months (p = 0.12) and in 21% with lesions and 14% without lesions at 12 months (p = 0.49). Very early MRI depicted cases of TAI in patients with mTBI with microbleeds persisting for 12 months. Patients with traumatic lesions may have a more protracted recovery, but the study was underpowered to detect significant differences for PCS because of the low frequency of trauma-related MRI lesions.	[Einarsen, Cathrine Elisabeth; Moen, Kent Goran; Haberg, Asta Kristine; Moe, Hans Kristian; Tollefsen, Marie Hexeberg; Vik, Anne; Skandsen, Toril] Norwegian Univ Sci & Technol, Fac Med & Hlth Sci, Dept Neuromed & Movement Sci, Trondheim, Norway; [Eikenes, Live] Norwegian Univ Sci & Technol, Fac Med & Hlth Sci, Dept Circulat & Med Imaging, Trondheim, Norway; [Einarsen, Cathrine Elisabeth; Skandsen, Toril] Trondheim Reg & Univ Hosp, Dept Phys Med & Rehabil, St Olavs Hosp, Trondheim, Norway; [Haberg, Asta Kristine; Kvistad, Kjell Arne; Xu, Jian] Trondheim Reg & Univ Hosp, Dept Radiol & Nucl Med, St Olavs Hosp, Trondheim, Norway; [Vik, Anne] Trondheim Reg & Univ Hosp, Dept Neurosurg, St Olavs Hosp, Trondheim, Norway; [Moen, Kent Goran] Nord Trondelag Hosp Trust, Levanger Hosp, Dept Radiol, Levanger, Norway		Skandsen, T (corresponding author), Norwegian Univ Sci & Technol NTNU, Fac Med & Hlth Sci, Dept Neuromed & Movement Sci, N-7491 Trondheim, Norway.	toril.skandsen@ntnu.no		Moe, Hans Kristian/0000-0002-1699-6848	NTNU; Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital; National Norwegian Advisory Unit for functional MRI, St. Olavs Hospital, Trondheim University Hospital; Central Norway Regional Health Authority (RHA); Norwegian University of Science and Technology (NTNU); Liaison Committee	We thank the patients and controls. We also thank the staff of the Trondheim Municipal Emergency Department, the Department of Neurosurgery, the Department of Anesthesiology and Insensitive Care Medicine, and the Department of Radiology and Nuclear Medicine at St. Olavs Hospital, Trondheim University Hospital, for their cooperation during patient recruitment. We also thank the National Norwegian Advisory Unit for functional MRI for collaboration, for use of the MRI machine, and for flexibility in the MRI schedule. Finally, we also thank Stine Bjoralt for coordinating the data collection, and Ingeborg Nakken for her assistance with the MRI procedures. The study was funded by the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU). Cathrine E. Einarsen and Toril Skandsen received separate research grants from the same committee. Kent Goran Moen and Hans Kristian Moe also received a research grant from NTNU during the study period. In addition, the MRI images were funded by the National Norwegian Advisory Unit for functional MRI and Department of Radiology and Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital.	Ananthaharan A, 2018, BMC EMERG MED, V18, DOI 10.1186/s12873-018-0193-2; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chung SW, 2012, J KOREAN NEUROSURG S, V52, P377, DOI 10.3340/jkns.2012.52.4.377; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; Cnossen MC, 2018, J NEUROTRAUM, V35, P2691, DOI 10.1089/neu.2017.5486; Cnossen MC, 2017, J NEUROTRAUM, V34, P2396, DOI 10.1089/neu.2016.4819; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; de Haan S, 2017, NEURORADIOLOGY, V59, P963, DOI 10.1007/s00234-017-1898-8; De Simoni S, 2016, BRAIN, V139, P3137, DOI 10.1093/brain/aww241; Fewtrell MS, 2008, ARCH DIS CHILD, V93, P458, DOI 10.1136/adc.2007.127316; Geurts BHJ, 2012, BRAIN INJURY, V26, P1439, DOI 10.3109/02699052.2012.694563; Haberg AK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151080; Hopkins RO, 2006, J NEUROIMAGING, V16, P243, DOI 10.1111/j.1552-6569.2006.00047.x; Huang YL, 2015, NEUROLOGY, V84, P580, DOI 10.1212/WNL.0000000000001237; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hutchinson M, 2018, MAGN RESON IMAGING, V48, P138, DOI 10.1016/j.mri.2017.12.022; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Isokuortti H, 2018, J NEUROSURG, V129, P1588, DOI 10.3171/2017.7.JNS17615; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Iverson GL, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/415740; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lange RT, 2015, ARCH CLIN NEUROPSYCH, V30, P7, DOI 10.1093/arclin/acu060; Lasry O, 2017, NEUROLOGY, V89, P2198, DOI 10.1212/WNL.0000000000004671; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lydersen S, 2009, STAT MED, V28, P1159, DOI 10.1002/sim.3531; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; Metting Z, 2010, J NEUROTRAUM, V27, P2183, DOI 10.1089/neu.2010.1395; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Moe HK, 2018, J NEUROTRAUM, V35, P975, DOI 10.1089/neu.2017.5252; Moen KG, 2016, J NEUROSCI RES, V94, P623, DOI 10.1002/jnr.23728; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Muller K, 2009, NEUROSURGERY, V64, P698, DOI 10.1227/01.NEU.0000340978.42892.78; Nyquist PA, 2015, NEUROBIOL AGING, V36, P1653, DOI 10.1016/j.neurobiolaging.2015.01.005; Panenka WJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122746; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Schulz KF, 2002, LANCET, V359, P781, DOI 10.1016/S0140-6736(02)07882-0; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shetty T, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00836; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Skandsen T, 2018, SCAND J TRAUMA RESUS, V26, DOI 10.1186/s13049-018-0495-0; Spitz G, 2013, J NEUROTRAUM, V30, P2038, DOI 10.1089/neu.2013.3021; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Strand IH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-62; Suri AK, 2018, HAND CLINIC, V158, P205, DOI 10.1016/B978-0-444-63954-7.00021-5; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Trifan G, 2017, MAGN RESON IMAGING, V37, P243, DOI 10.1016/j.mri.2016.12.009; van den Heuvel DMJ, 2004, NEUROLOGY, V63, P1699, DOI 10.1212/01.WNL.0000143058.40388.44; van den Heuvel TLA, 2016, NEUROIMAGE-CLIN, V12, P241, DOI 10.1016/j.nicl.2016.07.002; van der Horn HJ, 2018, BRAIN IMAGING BEHAV, V12, P912, DOI 10.1007/s11682-017-9743-6; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; World Health Organization, 1993, ICD 10 CLASS MENT BE; Wu X, 2016, RADIOLOGY, V279, P693, DOI 10.1148/radiol.16142535; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	57	24	24	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2019	36	22					3172	3182		10.1089/neu.2018.6360		JUL 2019	11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	JI6MG	WOS:000479784000001	31280698	Green Published, hybrid, Green Submitted			2022-02-06	
J	Nitta, ME; Savitz, J; Nelson, LD; Teague, TK; Hoelzle, JB; McCrea, MA; Meier, TB				Nitta, Morgan E.; Savitz, Jonathan; Nelson, Lindsay D.; Teague, T. Kent; Hoelzle, James B.; McCrea, Michael A.; Meier, Timothy B.			Acute elevation of serum inflammatory markers predicts symptom recovery after concussion	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; C-REACTIVE PROTEIN; BLOOD; SPORT; IL-6; INTERLEUKIN-1-BETA; EXPRESSION; SEVERITY; CYTOKINE	Objective To test the hypothesis that acute elevations in serum inflammatory markers predict symptom recovery after sport-related concussion (SRC). Methods High school and collegiate football players (n = 857) were prospectively enrolled. Forty-one athletes with concussion and 43 matched control athletes met inclusion criteria. Serum levels of interleukin (IL)-6, IL-1 beta, IL-10, tumor necrosis factor, C-reactive protein, interferon-gamma, and IL-1 receptor antagonist and Sport Concussion Assessment Tool, 3rd edition (SCAT3) symptom severity scores were collected at a preinjury baseline, 6 and 24-48 hours postinjury, and approximately 8, 15, and 45 days following concussion. The number of days that athletes were symptomatic following SRC (i.e., duration of symptoms) was the primary outcome variable. Results IL-6 and IL-1RA were significantly elevated in athletes with concussion at 6 hours relative to preinjury and other postinjury visits, as well as compared to controls (ps <= 0.001). IL-6 and IL-1RA significantly discriminated concussed from control athletes at 6 hours postconcussion (IL-6 area under receiver operating characteristic curve 0.79 [95% confidence interval (CI) 0.65-0.92], IL-1RA AUC 0.79 [95% CI 0.67-0.90]). Further, IL-6 levels at 6 hours post-concussion were significantly associated with the duration of symptoms (hazard ratio for symptom recovery = 0.61 [95% CI 0.38-0.96], p = 0.031). Conclusions Results support the potential utility of IL-6 and IL-1RA as serum biomarkers of SRC and demonstrate the potential of these markers in identifying athletes at risk for prolonged recovery after SRC. Classification of evidence This study provides Class III evidence that serum levels of IL-6 and IL-1RA 6 hours postconcussion significantly discriminated concussed from control athletes.	[Nitta, Morgan E.; Nelson, Lindsay D.; McCrea, Michael A.; Meier, Timothy B.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Meier, Timothy B.] Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA; [Meier, Timothy B.] Med Coll Wisconsin, Dept Biomed Engn, Milwaukee, WI 53226 USA; [Nitta, Morgan E.; Hoelzle, James B.] Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA; [Savitz, Jonathan] Laureate Inst Brain Res, Tulsa, OK USA; [Savitz, Jonathan] Univ Tulsa, Oxley Coll Hlth Sci, Tulsa, OK 74104 USA; [Teague, T. Kent] Univ Oklahoma, Sch Community Med, Dept Surg, Norman, OK 73019 USA; [Teague, T. Kent] Univ Oklahoma, Sch Community Med, Dept Psychiat, Norman, OK 73019 USA; [Teague, T. Kent] Univ Oklahoma, Coll Pharm, Dept Pharmaceut Sci, Norman, OK 73019 USA; [Teague, T. Kent] Oklahoma State Univ, Dept Biochem & Microbiol, Ctr Hlth Sci, Tulsa, OK USA		Meier, TB (corresponding author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.; Meier, TB (corresponding author), Med Coll Wisconsin, Dept Cell Biol Neurobiol & Anat, Milwaukee, WI 53226 USA.; Meier, TB (corresponding author), Med Coll Wisconsin, Dept Biomed Engn, Milwaukee, WI 53226 USA.	tmeier@mcw.edu	Savitz, Jonathan/C-3088-2009; Teague, T. Kent/A-2527-2008	Savitz, Jonathan/0000-0001-8143-182X; Teague, T. Kent/0000-0002-4680-5440	Department of Defense Broad Agency Announcement for Extramural Medical Research [W81XWH-14-1-0561]; National Institute of Neurological Disorders and Stroke of the NIH [R21NS099789]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS102225]; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM121312]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH113871]; National Center for Advancing Translational Sciences, NIH [UL1TR001436]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM121312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH113871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS102225, R21NS099789] Funding Source: NIH RePORTER	Supported by the Department of Defense Broad Agency Announcement for Extramural Medical Research through award number W81XWH-14-1-0561, National Institute of Neurological Disorders and Stroke of the NIH under award number R21NS099789, and National Institute of Neurological Disorders and Stroke under award number R01NS102225. The National Institute of General Medical Sciences (P20GM121312) and the National Institute of Mental Health (R21MH113871) also provided support for this project. The REDCap electronic database and the Adult Translational Research Unit used for this project were supported by the National Center for Advancing Translational Sciences, NIH, award number UL1TR001436.	Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Di Battista AP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0500-3; Ellulu MS, 2017, ARCH MED SCI, V13, P851, DOI 10.5114/aoms.2016.58928; Gill J, 2017, BRAIN BEHAV IMMUN, V65, P90, DOI 10.1016/j.bbi.2017.02.015; Gill J, 2016, J HEAD TRAUMA REHAB, V31, P269, DOI 10.1097/HTR.0000000000000191; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kasapis C, 2005, J AM COLL CARDIOL, V45, P1563, DOI 10.1016/j.jacc.2004.12.077; Lagerstedt L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193278; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meier TB, 2017, J NEUROTRAUM, V34, P3134, DOI 10.1089/neu.2017.5046; Merchant-Borna K, 2016, J NEUROTRAUM, V33, P1576, DOI 10.1089/neu.2015.4191; Minambres E, 2003, CRIT CARE MED, V31, P933, DOI 10.1097/01.CCM.0000055370.66389.59; Palomo J, 2015, CYTOKINE, V76, P25, DOI 10.1016/j.cyto.2015.06.017; Raheja A, 2016, J NEUROSURG, V125, P631, DOI 10.3171/2015.6.JNS15674; Ritzel RM, 2018, J NEUROTRAUM, V35, P1419, DOI 10.1089/neu.2017.5399; Singh R, 2016, J NEUROL NEUROSUR PS, V87, P670, DOI 10.1136/jnnp-2015-311369; Su SH, 2014, BRAIN BEHAV IMMUN, V38, P111, DOI 10.1016/j.bbi.2014.01.009; Tasci A, 2003, NEUROL RES, V25, P871, DOI 10.1179/016164103771953998; Venetsanou K, 2007, EUR CYTOKINE NETW, V18, P206, DOI 10.1684/ecn.2007.0112; WechslerD, 2001, WECHSLER TEST ADULT; Weissberg I, 2014, JAMA NEUROL, V71, P1453, DOI 10.1001/jamaneurol.2014.2682; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Zeiler FA, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00331	34	24	24	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 30	2019	93	5					E497	E507		10.1212/WNL.0000000000007864			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IQ5LX	WOS:000480795200008	31270219	Green Published			2022-02-06	
J	Gratz, J; Guting, H; Thorn, S; Brazinova, A; Gorlinger, K; Schafer, N; Schochl, H; Stanworth, S; Maegele, M				Gratz, J.; Gueting, H.; Thorn, S.; Brazinova, A.; Goerlinger, K.; Schaefer, N.; Schoechl, H.; Stanworth, S.; Maegele, M.			Protocolised thromboelastometric-guided haemostatic management in patients with traumatic brain injury: a pilot study	ANAESTHESIA			English	Article						anaemia; coagulation; point-of-care testing; thromboelastometry; traumatic brain injury; management	COAGULOPATHY; TRANSFUSION; RESUSCITATION; SURGERY; CARE	Coagulopathy in patients with traumatic brain injury is associated with an increase in morbidity and mortality. Although timely and aggressive treatment of coagulopathy is of paramount importance, excessive transfusion of blood products has been linked with poor long-term outcomes in patients with traumatic brain injury. A point-of-care thromboelastometric-guided algorithm could assist in creating a more individually tailored approach to each patient. The aim of this study was to evaluate the feasibility of implementing a thromboelastometric-guided algorithm in centres that were formerly naive to thromboelastometry. Hence, we developed such an algorithm and provided training to four centres across Europe to direct the haemostatic management of patients with severe traumatic brain injury. The primary outcome was adherence to the algorithm and timing of the availability of relevant results. Thirty-two patients were included in the study. Complete adherence to the algorithm was observed in 20 out of 32 cases. The availability of thromboelastometric results after hospital admission was reported significantly earlier than conventional coagulation tests (median (IQR [range]) 33 (20-40 [14-250]) min vs. 71 (51-101 [32-290]) min; p = 0.037). Although only 5 out of 32 patients had abnormalities of conventional coagulation tests, 21 out of 32 patients had a coagulopathic baseline thromboelastometric trace. Implementing a thromboelastometric-guided algorithm for the haemostatic therapy of traumatic brain injury is feasible in centres formerly naive to this technology and may lead to more rapid and precise coagulation management. Further large-scale studies are warranted to confirm the results of this pilot trial and evaluate clinical outcomes.	[Gratz, J.] Med Univ Vienna, Dept Anaesthesia Crit Care & Pain Med, Vienna, Austria; [Gueting, H.; Schaefer, N.; Maegele, M.] Univ Witten Herdecke, Inst Res Operat Med, Cologne, Germany; [Thorn, S.] Monash Univ Melbourne, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Brazinova, A.] Comenius Univ, Fac Med, Inst Epidemiol, Bratislava, Slovakia; [Goerlinger, K.] Univ Hosp Essen, Dept Anaesthesia & Intens Care Med, Essen, Germany; [Goerlinger, K.] TEM Innovat GmbH, Munich, Germany; [Schoechl, H.] Paracelsus Med Univ Salzburg, Acad Teaching Hosp, AUVA Trauma Ctr Salzburg, Dept Anaesthesia & Intens Care Med, Salzburg, Austria; [Schoechl, H.] AUVA Trauma Res Ctr Vienna, Ludwig Boltzmann Inst Expt & Clin Traumatol, Vienna, Austria; [Stanworth, S.] Univ Oxford, Oxford Univ Hosp NHS Fdn Trust, Radcliffe Dept Med, Dept Haematol, Oxford, England; [Maegele, M.] Cologne Merheim Med Ctr, Dept Traumatol & Orthoped Surg, Cologne, Germany		Maegele, M (corresponding author), Univ Witten Herdecke, Inst Res Operat Med, Cologne, Germany.; Maegele, M (corresponding author), Cologne Merheim Med Ctr, Dept Traumatol & Orthoped Surg, Cologne, Germany.	marc.maegele@t-online.de	Gratz, Johannes/AAH-3566-2020; Brazinova, Alexandra/C-4265-2016	Brazinova, Alexandra/0000-0003-0625-256X; Gratz, Johannes/0000-0001-8717-0544	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [602150]; CSL Behring; Astra ZenecaAstraZeneca; BayerBayer AG; Biotest; IL Werfen/TEM International; LFB Biomedicaments	The authors thank all participating centres and staff for their commitment. The study was registered at the German Registry of Clinical Trials before the beginning of patient enrolment. This trial was conducted as an embedded sub-study within CENTER-TBI. As such it was supported by the European Commission 7th Framework Program (FP7/2007-2013) under grant agreement number 602150 (CENTER-TBI). The funder had no role in the design of the study; collection, analyses and interpretation of data; nor in writing the manuscript. JG has received support for congress travels and speaker fees from CSL Behring and Mitsubishi Tanabe Pharma. KG is Medical Director of Tem Innovations GmbH since 2012 and has received speaker fees and travel expenses reimbursement from CSL Behring and Octapharma. HS has received honoraria for participation in advisory board meetings for Bayer Healthcare, Bohringer Ingelheim, Werfen/TEM international and study grants from CSL Behring. Moreover, he has received speaker fees from CSL Behring, Cardinal Health, Roche, Haemonetics and Shire. MM has received support for congress travels, services to speaker bureaus and advisory boards and for research projects from Astra Zeneca, Bayer, Biotest, CSL Behring, IL Werfen/TEM International and LFB Biomedicaments. All other authors declare that they have no relevant competing interests.	Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; Baksaas-Aasen K, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2224-9; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Dunbar NM, 2009, TRANSFUSION, V49, P2652, DOI 10.1111/j.1537-2995.2009.02335.x; Epstein DS, 2016, J CLIN NEUROSCI, V29, P64, DOI 10.1016/j.jocn.2015.11.024; Girdauskas E, 2010, J THORAC CARDIOV SUR, V140, P1117, DOI 10.1016/j.jtcvs.2010.04.043; Gorlinger K, 2013, BRIT J ANAESTH, V110, P222, DOI 10.1093/bja/aes374; Gorlinger K, 2011, ANESTHESIOLOGY, V115, P1179, DOI 10.1097/ALN.0b013e31823497dd; Gonzalez E, 2017, CRIT CARE CLIN, V33, P119, DOI 10.1016/j.ccc.2016.09.002; Gorlinger K., 2006, HAMOSTASEOLOGIE S1, V26, P64; Greuters S, 2011, CRITICAL CARE, V15, P1; Haas T, 2015, BRIT J ANAESTH, V114, P217, DOI 10.1093/bja/aeu303; Hagemo JS, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0823-y; Inaba K, 2015, J TRAUMA ACUTE CARE, V78, P1220, DOI 10.1097/TA.0000000000000536; Khan S, 2014, J TRAUMA ACUTE CARE, V76, P561, DOI 10.1097/TA.0000000000000146; Leeper CM, 2018, J TRAUMA ACUTE CARE, V85, P12, DOI 10.1097/TA.0000000000001836; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maegele M, 2017, LANCET NEUROL, V16, P630, DOI 10.1016/S1474-4422(17)30197-7; Moore HB, 2014, J TRAUMA ACUTE CARE, V77, P811, DOI 10.1097/TA.0000000000000341; Rossaint R, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1265-x; Schafer N, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0147-6; Schenk B, 2019, ANAESTHESIA, V74, P348, DOI 10.1111/anae.14542; Schochl H, 2012, HAMOSTASEOLOGIE, V32, P22, DOI 10.5482/ha-1178; Schochl H, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-15; Schochl H, 2011, J NEUROTRAUM, V28, P2033, DOI 10.1089/neu.2010.1744; Stein P, 2017, ANAESTHESIA, V72, P1317, DOI 10.1111/anae.13920; Warner MA, 2010, J NEUROSURG, V113, P539, DOI 10.3171/2009.12.JNS091337; Wikkelso A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007871.pub3; Yuan Q, 2016, J NEUROTRAUM, V33, P1279, DOI 10.1089/neu.2015.4205; Zhang D., 2015, BIOMED RES INT, V2015, P1; Zhang JN, 2012, J NEUROTRAUM, V29, P2597, DOI 10.1089/neu.2012.2348	32	24	24	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	JUL	2019	74	7					883	890		10.1111/anae.14670			8	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	IC4LO	WOS:000470937400010	31032890				2022-02-06	
J	Leeper, CM; Yazer, MH; Cladis, FP; Saladino, R; Triulzi, DJ; Gaines, BA				Leeper, Christine M.; Yazer, Mark H.; Cladis, Franklyn P.; Saladino, Richard; Triulzi, Darrell J.; Gaines, Barbara A.			Cold-stored whole blood platelet function is preserved in injured children with hemorrhagic shock	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	32nd Annual Scientific Assembly of the Eastern-Association-for-Surgery-of-Trauma (EAST)	JAN 15-19, 2019	Austin, TX	Eastern Assoc Surg Trauma		Whole blood; transfusion; pediatric; coagulopathy; platelets	ACUTE TRAUMATIC COAGULOPATHY; MORTALITY; TRANSFUSION; FRESH; FEASIBILITY; 4-DEGREES-C; DEFINITION; ADMISSION	BACKGROUND Recent data demonstrate the safety of uncrossmatched cold-stored whole blood (WB) transfusion in pediatric trauma patients. The hemostatic capabilities of platelets within the cold-stored WB unit have been demonstrated via in vitro studies and animal models. However, platelet function has not been evaluated in pediatric recipients of cold-stored WB transfusions. METHODS Injured children, 2 years or older and 10 kg or greater with hemorrhagic shock received up to 30 mL/kg of cold-stored, low titer (<50) anti-A and -B, leukoreduced, group O- WB during their initial resuscitation. Patients were included if (1) they received WB and no conventional platelets, and (2) platelet count and thromboelastography maximum amplitude were measured both before and after transfusion. These data and relevant clinical outcomes (mortality, intensive care unit length of stay [LOS], hospital LOS and ventilator days) were compared to a historical cohort of pediatric trauma patients who received uncrossmatched red blood cells (RBC) and conventional room temperature platelets. RESULTS Twenty-two children were included in the study; 14 in the component cohort versus 8 in the WB cohort. Neither posttransfusion platelet count (129 x 109/L vs. 135 x 109/L) nor function (thromboelastography maximum amplitude, 59.5 mm vs. 60.2 mm) differed significantly between children receiving cold-stored platelets within the WB unit versus children who received conventional warm platelets. Median (interquartile range) weight-adjusted platelet transfusion volume in the historical cohort was 4.6 (2.5-7.7) mL/kg vs. 2.4 (1.3-4.0) mL/kg in the WB cohort (p = 0.03). There was no difference between groups in age, race, mechanism of injury, Injury Severity Score, vital signs, and severe traumatic brain injury (TBI). Outcomes, including mortality, intensive care unit LOS, hospital LOS, and ventilator days, were not significantly different between groups. CONCLUSION No difference was seen in posttransfusion platelet number or function in severely injured children receiving cold-stored WB platelets as compared to those receiving conventional room temperature-stored platelets. Larger cohorts are required to confirm these findings. Copyright (c) 2019 Wolters Kluwer Health, Inc. All rights reserved.	[Leeper, Christine M.; Gaines, Barbara A.] Univ Pittsburgh, Med Ctr, Dept Surg, Pittsburgh, PA USA; [Yazer, Mark H.; Triulzi, Darrell J.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA USA; [Leeper, Christine M.; Gaines, Barbara A.] Childrens Hosp Pittsburgh UPMC, Dept Surg, Pittsburgh, PA USA; [Saladino, Richard] Childrens Hosp Pittsburgh UPMC, Div Pediat Emergency Med, Pittsburgh, PA USA; [Cladis, Franklyn P.] Childrens Hosp Pittsburgh UPMC, Dept Anesthesiol & Perioperat Med, Pittsburgh, PA USA		Leeper, CM (corresponding author), 7th Floor,Fac Pavil,One Childrens Hosp Dr, Pittsburgh, PA 15224 USA.	leepercm@upmc.edu					Bassett Aaron K, 2016, J Spec Oper Med, V16, P5; BECKER GA, 1973, TRANSFUSION, V13, P61, DOI 10.1111/j.1537-2995.1973.tb05442.x; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Centers for Disease Control and Prevention, 2013, 10 LEAD CAUS DEATH A; Chiaretti A, 2001, PEDIATR NEUROSURG, V34, P131, DOI 10.1159/000056008; Christiaans SC, 2014, SHOCK, V41, P476, DOI 10.1097/SHK.0000000000000151; Cinat ME, 1999, ARCH SURG-CHICAGO, V134, P964, DOI 10.1001/archsurg.134.9.964; Cohen MJ, 2013, J TRAUMA ACUTE CARE, V75, pS40, DOI 10.1097/TA.0b013e31828fa43d; Daniel Y, 2017, J TRAUMA ACUTE CARE; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Hendrickson JE, 2012, J PEDIATR-US, V160, P204, DOI 10.1016/j.jpeds.2011.08.019; Hollingworth W, 2007, PEDIATR CRIT CARE ME, V8, P348, DOI 10.1097/01.PCC.0000270837.66217.3B; Jobes D, 2011, TRANSFUSION, V51, P43, DOI 10.1111/j.1537-2995.2010.02772.x; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Lao ZQ, 2012, INT J PREVENTIVE MED, V3, P303; Leeper CM, 2018, J TRAUMA ACUTE CARE, V85, P674, DOI 10.1097/TA.0000000000001823; Leeper CM, 2018, JAMA PEDIATR, V172, P491, DOI 10.1001/jamapediatrics.2017.5238; Leeper CM, 2017, J TRAUMA ACUTE CARE, V82, P27, DOI 10.1097/TA.0000000000001308; Leeper CM, 2016, J TRAUMA ACUTE CARE; Leeper CM, 2017, SURGERY; Liras IN, 2017, J AM COLL SURG; Maegele M, 2014, SHOCK, V41, P21, DOI 10.1097/SHK.0000000000000088; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; Nair PM, 2017, BRIT J HAEMATOL, V178, P119, DOI 10.1111/bjh.14751; Nair PM, 2014, J TRAUMA ACUTE CARE, V77, pS88, DOI 10.1097/TA.0000000000000327; Nessen SC, 2013, TRANSFUSION, V53, p107S, DOI 10.1111/trf.12044; Patregnani JT, 2012, PEDIATR CRIT CARE ME, V13, P273, DOI 10.1097/PCC.0b013e31822f1727; Peltan ID, 2015, CRIT CARE MED, V43, P1429, DOI 10.1097/CCM.0000000000000981; Pidcoke HF, 2013, TRANSFUSION, V53, p137S, DOI 10.1111/trf.12048; Reddoch KM, 2014, SHOCK, V41, P54, DOI 10.1097/SHK.0000000000000082; Remy KE, 2018, J TRAUMA ACUTE CARE, V84, pS104, DOI 10.1097/TA.0000000000001870; Seheult JN, 2017, TRANSFUSION MED, V27, P30, DOI 10.1111/tme.12372; Spinella PC, 2016, TRANSFUSION, V56, pS190, DOI 10.1111/trf.13491; Strandenes G, 2015, J TRAUMA ACUTE CARE, V78, pS31, DOI 10.1097/TA.0000000000000628; Torres IP, 2017, J THROMB HAEMOST, V15, P163, DOI 10.1111/jth.13556; Whittaker B, 2013, SHOCK, V39, P421, DOI 10.1097/SHK.0b013e31828e08cb; Wu XW, 2017, BRIT J HAEMATOL, V179, P802, DOI 10.1111/bjh.14999; Yazer MH, 2016, J TRAUMA ACUTE CARE, V81, P21, DOI 10.1097/TA.0000000000001100	38	24	24	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2019	87	1					49	53		10.1097/TA.0000000000002340			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	IH6VR	WOS:000474640900007	31033893				2022-02-06	
J	Younger, D; Murugan, M; Rao, KVR; Wu, LJ; Chandra, N				Younger, Daniel; Murugan, Madhuvika; Rao, Kakulavarapu V. Rama; Wu, Long-Jun; Chandra, Namas			Microglia Receptors in Animal Models of Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Microglia; Brain injury; Receptors	TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; METABOTROPIC GLUTAMATE RECEPTORS; TOLL-LIKE RECEPTORS; PPAR-GAMMA AGONIST; VASOACTIVE-INTESTINAL-PEPTIDE; IMPROVES FUNCTIONAL RECOVERY; CONTROLLED CORTICAL IMPACT; PROLIFERATOR-ACTIVATED RECEPTORS; OUTWARD POTASSIUM CURRENTS	Microglia have been implicated as a key mediator of chronic inflammation following traumatic brain injury (TBI). The animal models of TBI vary significantly based on the type of brain injury (focal versus diffuse). This has made it extremely difficult to assess the role of microglia and the window of microglia activation. Hence, the focus of this review is to summarize the time course ofmicroglia activation in various animal models of TBI. The review explores the repertoire of secondary injurymechanisms such as aberrant neurotransmitter release, oxidative stress, blood-brain barrier disruption, and production of pro-inflammatory cytokines that follow microglia activation. Since receptors act as sensors for activation, we highlight certain microglia receptors that have been implicated in TBI pathology, including fractalkine receptor (CX3CR1), purinergic receptor (P2Y12R), Toll-like receptor (TLR4), scavenger receptors, tumor necrosis factor receptor (TNF-1R), interleukin receptor (IL-1R), complement receptors, and peroxisome proliferator-activated receptor (PPAR). In addition to describing their downstream signaling pathways in TBI, we describe the functional consequences of their activation and the implication in behavioral outcomes. Taken together, this review will provide a holistic view of the role of microglia and its receptors in TBI based on animal studies.	[Younger, Daniel; Murugan, Madhuvika; Rao, Kakulavarapu V. Rama; Chandra, Namas] New Jersey Inst Technol, Dept Bioengn, 111 Lock St,Room105 CHEN Bldg, Newark, NJ 07102 USA; [Wu, Long-Jun] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA		Chandra, N (corresponding author), New Jersey Inst Technol, Dept Bioengn, 111 Lock St,Room105 CHEN Bldg, Newark, NJ 07102 USA.	namas.chandra@njit.edu	Wu, Long-Jun/AAK-7113-2020; Murugan, Madhuvika/AAZ-8533-2020	Wu, Long-Jun/0000-0001-8019-3380; Murugan, Madhuvika/0000-0002-0706-0730	US Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-15-1-0303]; New Jersey Commission for Brain Injury Research [CBIR17PIL020]; Rutgers Brain Health Institute [BHI-RUN-NJIT-2016]	This work was supported by funding from the US Army Medical Research and Material Command (W81XWH-15-1-0303), New Jersey Commission for Brain Injury Research (CBIR17PIL020), and Rutgers Brain Health Institute (BHI-RUN-NJIT-2016).	ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Abe N, 2018, GLIA; Andre R, 2005, J NEUROCHEM, V95, P324, DOI 10.1111/j.1471-4159.2005.03364.x; Avignone E, 2008, J NEUROSCI, V28, P9133, DOI 10.1523/JNEUROSCI.1820-08.2008; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bachstetter AD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-79; BADER MF, 1994, GLIA, V11, P336, DOI 10.1002/glia.440110406; Balcaitis S, 2003, NEUROREPORT, V14, P2373, DOI 10.1097/00001756-200312190-00017; Ballerini P, 2005, INT J IMMUNOPATH PH, V18, P255, DOI 10.1177/039463200501800208; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; Barger SW, 2001, J NEUROCHEM, V76, P846, DOI 10.1046/j.1471-4159.2001.00075.x; Basrai HS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153418; Basu A, 2002, J NEUROSCI, V22, P6071; Bate C, 2005, J NEUROIMMUNOL, V170, P62, DOI 10.1016/j.jneuroim.2005.08.021; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bernardino ALF, 2008, INFECT IMMUN, V76, P4385, DOI 10.1128/IAI.00394-08; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Biber K, 1999, J NEUROCHEM, V72, P1671, DOI 10.1046/j.1471-4159.1999.721671.x; Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011; Boddeke EWGH, 1999, EUR J PHARMACOL, V374, P309, DOI 10.1016/S0014-2999(99)00307-6; Boddeke EWGM, 1999, J NEUROIMMUNOL, V98, P176, DOI 10.1016/S0165-5728(99)00096-X; Boehme SA, 2000, J IMMUNOL, V165, P397, DOI 10.4049/jimmunol.165.1.397; Bollmann L, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00363; Bordey A, 2003, EUR J NEUROSCI, V18, P2893, DOI 10.1111/j.1460-9568.2003.03021.x; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bruttger J, 2015, IMMUNITY, V43, P92, DOI 10.1016/j.immuni.2015.06.012; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Bu W, 2016, FRONT NEUROSCI, V10, P17; Butchi NB, 2010, GLIA, V58, P650, DOI 10.1002/glia.20952; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Butovsky O, 2007, MOL CELL NEUROSCI, V35, P490, DOI 10.1016/j.mcn.2007.04.009; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Cabral GA, 2005, J LEUKOCYTE BIOL, V78, P1192, DOI 10.1189/jlb.0405216; Cao Q, 2008, GLIA, V56, P1224, DOI 10.1002/glia.20692; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Cavaliere F, 2005, NEUROSCIENCE, V136, P615, DOI 10.1016/j.neuroscience.2005.04.038; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Cervantes JL, 2012, CELL MOL IMMUNOL, V9, P434, DOI 10.1038/cmi.2012.38; Chang CZ, 2015, WORLD NEUROSURG, V84, P954, DOI 10.1016/j.wneu.2015.05.075; Chao CC, 1996, P NATL ACAD SCI USA, V93, P8051, DOI 10.1073/pnas.93.15.8051; Charles KJ, 2003, MOL CELL NEUROSCI, V24, P214, DOI 10.1016/S1044-7431(03)00162-3; Chattopadhyay N, 1999, J NEUROCHEM, V72, P1915, DOI 10.1046/j.1471-4159.1999.0721915.x; Chen GQ, 2002, SCIENCE, V296, P1634, DOI 10.1126/science.1071924; Chen KQ, 2006, J BIOL CHEM, V281, P3651, DOI 10.1074/jbc.M508125200; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Cho S, 2005, J NEUROSCI, V25, P2504, DOI 10.1523/JNEUROSCI.0035-05.2005; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi BY, 2012, BRAIN RES, V1481, P49, DOI 10.1016/j.brainres.2012.08.032; Christensen RN, 2006, J NEUROSCI RES, V84, P170, DOI 10.1002/jnr.20865; Clark AK, 2007, P NATL ACAD SCI USA, V104, P10655, DOI 10.1073/pnas.0610811104; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cowell RM, 2006, J NEUROIMMUNOL, V173, P155, DOI 10.1016/j.jneuroim.2006.01.005; Crehan H., 2012, INT J ALZHEIMERS DIS, V2012, DOI DOI 10.1155/2012/983640; Cruz CM, 2007, J BIOL CHEM, V282, P2871, DOI 10.1074/jbc.M608083200; Cui YH, 2002, J IMMUNOL, V168, P434, DOI 10.4049/jimmunol.168.1.434; CUNNINGHAM ET, 1993, IMMUNOL TODAY, V14, P171; Dalpke AH, 2002, J IMMUNOL, V168, P4854, DOI 10.4049/jimmunol.168.10.4854; De Simone R, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-4; del Puerto A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00197; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Delgado M, 2003, FASEB J, V17, P1922, DOI 10.1096/fj.02-1029fje; Delgado M, 2002, GLIA, V39, P148, DOI 10.1002/glia.10098; Deselms H, 2016, J NEUROSCI METH, V272, P69, DOI 10.1016/j.jneumeth.2016.02.002; DING AH, 1988, J IMMUNOL, V141, P2407; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOBRENIS K, 1995, BRAIN RES, V686, P239, DOI 10.1016/0006-8993(95)00452-V; Dong H, 2016, CELL MOL NEUROBIOL, V36, P639, DOI 10.1007/s10571-015-0244-0; Drouin-Ouellet J, 2011, GLIA, V59, P188, DOI 10.1002/glia.21086; Duncan JA, 2009, J IMMUNOL, V182, P6460, DOI 10.4049/jimmunol.0802696; Ebert S, 2005, J NEUROIMMUNOL, V159, P87, DOI 10.1016/j.jneuroim.2004.10.005; Ekmark-Lewen S, 2016, EUR J NEUROSCI, V43, P1016, DOI 10.1111/ejn.13190; El Khoury J, 1998, NEUROBIOL AGING, V19, pS81, DOI 10.1016/S0197-4580(98)00036-0; El Khoury JB, 2003, J EXP MED, V197, P1657, DOI 10.1084/jem.20021546; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Erturk A, 2016, J NEUROSCI, V36, P9962, DOI 10.1523/JNEUROSCI.1898-15.2016; Esen N, 2006, J IMMUNOL, V176, P6802, DOI 10.4049/jimmunol.176.11.6802; Eyo UB, 2015, J NEUROSCI, V35, P2417, DOI 10.1523/JNEUROSCI.3279-14.2015; Facchinetti F, 2003, GLIA, V41, P161, DOI 10.1002/glia.10177; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan KH, 2017, CHEM-BIOL INTERACT, V271, P15, DOI 10.1016/j.cbi.2017.04.021; Fang F, 2010, FASEB J, V24, P1043, DOI 10.1096/fj.09-139634; Farber K, 2005, MOL CELL NEUROSCI, V29, P128, DOI 10.1016/j.mcn.2005.01.003; Farez MF, 2009, NAT IMMUNOL, V10, P958, DOI 10.1038/ni.1775; Faul M, 2010, TRAUMATIC BRAIN INJU; Febinger HY, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0386-5; Feindt J, 1998, MOL BRAIN RES, V60, P228, DOI 10.1016/S0169-328X(98)00184-3; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Fiebich BL, 1996, GLIA, V18, P152, DOI 10.1002/(SICI)1098-1136(199610)18:2<152::AID-GLIA7>3.0.CO;2-2; Fujita H, 1998, NEUROSCI LETT, V242, P37, DOI 10.1016/S0304-3940(98)00003-2; Fujita R, 2008, J NEUROCHEM, V107, P152, DOI 10.1111/j.1471-4159.2008.05599.x; Fumagalli S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00081; Gao TL, 2012, J TRAUMA ACUTE CARE, V72, P643, DOI 10.1097/TA.0b013e31823c54a6; Gao WW, 2015, BRAIN RES, V1622, P230, DOI 10.1016/j.brainres.2015.04.035; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Garrett MC, 2009, BRAIN RES, V1298, P171, DOI 10.1016/j.brainres.2009.04.047; Gasque P, 1998, J IMMUNOL, V160, P3543; Gekker G, 2006, INT IMMUNOPHARMACOL, V6, P1029, DOI 10.1016/j.intimp.2005.12.005; Geurts JJG, 2003, BRAIN, V126, P1755, DOI 10.1093/brain/awg179; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gonzalez P, 2009, J NEUROPATH EXP NEUR, V68, P391, DOI 10.1097/NEN.0b013e31819dca30; Gonzalez-Rey E, 2008, BRAIN BEHAV IMMUN, V22, P35, DOI 10.1016/j.bbi.2007.07.004; Gottlieb M, 1997, J CEREBR BLOOD F MET, V17, P290, DOI 10.1097/00004647-199703000-00006; Grandbarbe L, 2007, GLIA, V55, P1519, DOI 10.1002/glia.20553; Gu N, 2016, BRAIN BEHAV IMMUN, V55, P82, DOI 10.1016/j.bbi.2015.11.007; Gyoneva S, 2015, J NEUROINFLAMM, V12, P12; Hagino Y, 2004, GLIA, V47, P68, DOI 10.1002/glia.20034; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hajishengallis G, 2007, J IMMUNOL, V179, P2359, DOI 10.4049/jimmunol.179.4.2359; Hall AA, 2009, GLIA, V57, P744, DOI 10.1002/glia.20802; Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636; Hammad A, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1066-z; Hammarberg C, 2003, J NEUROCHEM, V86, P1051, DOI 10.1046/j.1471-4159.2003.01919.x; Hanamsagar R, 2011, J NEUROCHEM, V119, P736, DOI 10.1111/j.1471-4159.2011.07481.x; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hanisch UK, 1997, J BIOL CHEM, V272, P28853, DOI 10.1074/jbc.272.46.28853; Hanisch UK, 2001, EUR J IMMUNOL, V31, P2104, DOI 10.1002/1521-4141(200107)31:7<2104::AID-IMMU2104>3.0.CO;2-3; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Harry GJ, 2008, J NEUROCHEM, V106, P281, DOI 10.1111/j.1471-4159.2008.05382.x; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Hausler KG, 2002, EUR J NEUROSCI, V16, P2113, DOI 10.1046/j.1460-9568.2002.02287.x; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Heese K, 1997, NEUROSCI LETT, V231, P83, DOI 10.1016/S0304-3940(97)00545-4; Hellewell SC, 2013, J NEUROINFLAMM, V10, P21; Hidetoshi T.-S., 2012, WIRES COMPUT STAT, V1, P493; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Horvath RJ, 2009, J NEUROSCI, V29, P998, DOI 10.1523/JNEUROSCI.4595-08.2009; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Hsieh CL, 2013, EUR J IMMUNOL, V43, P2010, DOI 10.1002/eji.201243084; Huang EYK, 2014, BEHAV BRAIN RES, V267, P156, DOI 10.1016/j.bbr.2014.03.033; Huang Z, 2007, NEUROSCI LETT, V417, P160, DOI 10.1016/j.neulet.2007.01.086; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Hunter RL, 2007, J NEUROCHEM, V100, P1375, DOI 10.1111/j.1471-4159.2006.04327.x; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Ichinohe T, 2009, J EXP MED, V206, P79, DOI 10.1084/jem.20081667; Ifuku M, 2007, J NEUROSCI, V27, P13065, DOI 10.1523/JNEUROSCI.3467-07.2007; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Ilschner S, 1996, NEUROSCIENCE, V73, P1109, DOI 10.1016/0306-4522(96)00107-8; Israel I, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0604-9; Jack CS, 2005, J IMMUNOL, V175, P4320, DOI 10.4049/jimmunol.175.7.4320; Jin XM, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0041892, 10.1371/journal.pone.0040637]; Kabadi SV, 2015, J CEREBR BLOOD F MET, V35, P2010, DOI 10.1038/jcbfm.2015.165; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kapadia R, 2008, FRONT BIOSCI-LANDMRK, V13, P1813, DOI 10.2741/2802; Kato G, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0004-16.2016; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kelso ML, 2014, CURR PHARM DESIGN, V20, P4284; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Kielian T, 2002, J NEUROIMMUNOL, V130, P86, DOI 10.1016/S0165-5728(02)00216-3; Kobayashi K, 2008, J NEUROSCI, V28, P2892, DOI 10.1523/JNEUROSCI.5589-07.2008; Kohl J, 2006, IMMUNOL RES, V34, P157, DOI 10.1385/IR:34:2:157; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Koizumi S, 2013, GLIA, V61, P47, DOI 10.1002/glia.22358; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kraft AD, 2009, NEUROTOXICOLOGY, V30, P785, DOI 10.1016/j.neuro.2009.07.001; Kuhn SA, 2004, MOL CELL NEUROSCI, V25, P312, DOI 10.1016/j.mcn.2003.10.023; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kuno R, 2005, J NEUROIMMUNOL, V162, P89, DOI 10.1016/j.jneuroim.2005.01.015; Kuriakose M, 2018, J NEUROTRAUMA; Kust BM, 1999, GLIA, V25, P120; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; Lafrenaye AD, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0405-6; Lai JP, 2000, NEUROSCIENCE, V101, P1137, DOI 10.1016/S0306-4522(00)00398-5; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lee SW, 2018, J NEUROTRAUM, V35, P1681, DOI 10.1089/neu.2017.5530; Lee YB, 2002, J NEUROSCI RES, V69, P94, DOI 10.1002/jnr.10253; Lehnardt S, 2002, J NEUROSCI, V22, P2478, DOI 10.1523/JNEUROSCI.22-07-02478.2002; Lehnardt S, 2006, J IMMUNOL, V177, P583, DOI 10.4049/jimmunol.177.1.583; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Light AR, 2006, NEURON GLIA BIOL, V2, P125, DOI 10.1017/S1740925X05000323; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Link VM, 2015, COLD SH Q B, V80, P213, DOI 10.1101/sqb.2015.80.027367; Liu C, 2014, ONCOL LETT, V8, P2747, DOI 10.3892/ol.2014.2575; Liu GJ, 2006, MOL PHARMACOL, V70, P851, DOI 10.1124/mol.105.021436; Liu GJ, 2009, EUR J NEUROSCI, V29, P1108, DOI 10.1111/j.1460-9568.2009.06659.x; Liu H, 2016, BIOCHEM BIOPH RES CO, V472, P648, DOI 10.1016/j.bbrc.2016.03.003; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu J, 2009, INVEST OPHTH VIS SCI, V50, P1408, DOI 10.1167/iovs.08-2398; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane D, 2014, NEUROTHERAPEUTICS, V11, P857, DOI 10.1007/s13311-014-0298-6; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, J BIOL CHEM, V284, P15629, DOI 10.1074/jbc.M806139200; Longhi L, 2008, ACTA NEUROCHIR SUPPL, V102, P409, DOI 10.1007/978-3-211-85578-2_80; Longhi L, 2013, J CEREBR BLOOD F MET, V33, P1182, DOI 10.1038/jcbfm.2013.65; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Lou NH, 2016, P NATL ACAD SCI USA, V113, P1074, DOI 10.1073/pnas.1520398113; Lue LF, 2001, EXP NEUROL, V171, P29, DOI 10.1006/exnr.2001.7732; Ma J, 2016, INFLAMMATION, V39, P2094, DOI 10.1007/s10753-016-0446-8; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Madry C, 2018, NEURON, V97, P299, DOI 10.1016/j.neuron.2017.12.002; Mao SS, 2012, J NEUROTRAUM, V29, P1941, DOI 10.1089/neu.2011.2244; Maresz K, 2005, J NEUROCHEM, V95, P437, DOI 10.1111/j.1471-4159.2005.03380.x; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Mastroeni D, 2009, NEUROBIOL AGING, V30, P1805, DOI 10.1016/j.neurobiolaging.2008.01.001; McIntosh TK, 1996, LAB INVEST, V74, P315; McLarnon JG, 1999, NEUROSCI LETT, V263, P9, DOI 10.1016/S0304-3940(99)00082-8; McMullan SM, 2012, ASN NEURO, V4, P323, DOI 10.1042/AN20120044; McNamee EN, 2010, EUR J PHARMACOL, V626, P219, DOI 10.1016/j.ejphar.2009.09.054; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Means TK, 2009, J EXP MED, V206, P637, DOI 10.1084/jem.20082109; Michalik L, 1999, CURR OPIN BIOTECH, V10, P564, DOI 10.1016/S0958-1669(99)00030-0; Michelucci A, 2009, J NEUROIMMUNOL, V210, P3, DOI 10.1016/j.jneuroim.2009.02.003; Mitrasinovic OM, 2003, NEUROBIOL AGING, V24, P807, DOI 10.1016/S0197-4580(02)00237-3; Mitrasinovic OM, 2003, NEUROSCI LETT, V344, P185, DOI 10.1016/S0304-3940(03)00474-9; Mitrasinovic OM, 2002, J BIOL CHEM, V277, P29889, DOI 10.1074/jbc.M200868200; Mittelbronn M, 2001, ACTA NEUROPATHOL, V101, P249; Miyoshi M, 2008, EUR J NEUROSCI, V27, P343, DOI 10.1111/j.1460-9568.2007.06014.x; Mizoguchi Y, 2009, J IMMUNOL, V183, P7778, DOI 10.4049/jimmunol.0901326; Moller T, 1997, NEUROREPORT, V8, P2127; Moller T, 2001, J BIOL CHEM, V276, P25946, DOI 10.1074/jbc.M102691200; Moller T, 1997, J NEUROSCI, V17, P615; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; Moore CS, 2015, NEUROL-NEUROIMMUNOL, V2, DOI 10.1212/NXI.0000000000000106; Moore KJ, 2002, J BIOL CHEM, V277, P47373, DOI 10.1074/jbc.M208788200; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Mori K, 2002, NEUROPHARMACOLOGY, V43, P1026, DOI 10.1016/S0028-3908(02)00211-3; Mori M, 1996, J NEUROSCI, V16, P3590; Morrison H, 2017, SCI REP, V7, P12; Murugan M, 2011, GLIA, V59, P521, DOI 10.1002/glia.21121; Nauseef WM, 2007, IMMUNOL REV, V219, P88, DOI 10.1111/j.1600-065X.2007.00550.x; Navone SE, 2018, OSTEOARTHR CARTILAGE, V26, P978, DOI 10.1016/j.joca.2018.04.013; Neher MD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-95; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Noda M, 2004, NEUROCHEM INT, V45, P437, DOI 10.1016/j.neuint.2003.07.007; Noda M, 2000, J NEUROSCI, V20, P251, DOI 10.1523/JNEUROSCI.20-01-00251.2000; Noda M, 2003, LIFE SCI, V72, P1573, DOI 10.1016/S0024-3205(02)02449-9; Noda M, 1999, NEUROSCIENCE, V92, P1465, DOI 10.1016/S0306-4522(99)00036-6; Noda M, 2007, J NEUROCHEM, V101, P397, DOI 10.1111/j.1471-4159.2006.04339.x; Nolte C, 1996, NEUROSCIENCE, V73, P1091, DOI 10.1016/0306-4522(96)00106-6; Ock J, 2007, J NEUROSCI RES, V85, P1989, DOI 10.1002/jnr.21322; Ferreira APO, 2013, NEUROCHEM INT, V63, P583, DOI 10.1016/j.neuint.2013.09.012; Olson JK, 2004, J IMMUNOL, V173, P3916, DOI 10.4049/jimmunol.173.6.3916; Osaka H, 1999, NEUROSCIENCE, V88, P1073, DOI 10.1016/S0306-4522(98)00372-8; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Petitto JN, 2003, J NEUROIMMUNOL, V134, P95, DOI 10.1016/S0165-5728(02)00422-8; Pilipovic K, 2015, PROG NEURO-PSYCHOPH, V59, P8, DOI 10.1016/j.pnpbp.2015.01.003; Pinteaux E, 2002, J NEUROCHEM, V83, P754, DOI 10.1046/j.1471-4159.2002.01184.x; Pinteaux-Jones F, 2008, J NEUROCHEM, V106, P442, DOI 10.1111/j.1471-4159.2008.05426.x; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Prinz M, 1999, J NEUROCHEM, V72, P2215, DOI 10.1046/j.1471-4159.1999.0722215.x; Prinz M, 1999, J NEUROPATH EXP NEUR, V58, P1078, DOI 10.1097/00005072-199910000-00006; Prinz M, 2008, IMMUNITY, V28, P675, DOI 10.1016/j.immuni.2008.03.011; Qian HH, 2017, MOL MED REP, V16, P3922, DOI 10.3892/mmr.2017.7079; Qin LY, 2005, GLIA, V52, P78, DOI 10.1002/glia.20225; Qu BG, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43059; Ramirez BG, 2005, J NEUROSCI, V25, P1904, DOI 10.1523/JNEUROSCI.4540-04.2005; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Ransohoff RM, 2011, NAT NEUROSCI, V14, P1098, DOI 10.1038/nn.2917; Rao KVR, J NEUROTRAUMA, V14; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Rappert A, 2002, J IMMUNOL, V168, P3221, DOI 10.4049/jimmunol.168.7.3221; Rasley A, 2002, GLIA, V37, P258, DOI 10.1002/glia.10034; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758; Robson MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150068; Rock RB, 2008, J NEUROIMMUNE PHARM, V3, P143, DOI 10.1007/s11481-007-9098-7; SAKAI N, 1995, J NEUROCHEM, V65, P895; Sankarapandi S, 1998, ARCH BIOCHEM BIOPHYS, V353, P312, DOI 10.1006/abbi.1998.0658; Sasaki Y, 2003, GLIA, V44, P242, DOI 10.1002/glia.10293; Sattayaprasert P, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-11; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; SAWADA M, 1995, J NEUROCHEM, V64, P1973; Schulz C, 2012, SCIENCE, V336, P86, DOI 10.1126/science.1219179; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Sheedy FJ, 2013, NAT IMMUNOL, V14, P812, DOI 10.1038/ni.2639; Shi FS, 2013, J NEUROIMMUNOL, V260, P121, DOI 10.1016/j.jneuroim.2013.04.016; Shimizu E, 2008, J IMMUNOL, V181, P6503, DOI 10.4049/jimmunol.181.9.6503; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shytle RD, 2004, J NEUROCHEM, V89, P337, DOI 10.1046/j.1471-4159.2004.02347.x; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sieger D, 2012, DEV CELL, V22, P1138, DOI 10.1016/j.devcel.2012.04.012; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Sipe GO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10905; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Stankovic ND, 2016, ACTA NEUROPATHOL, V131, P347, DOI 10.1007/s00401-015-1524-y; Stavridis S, 2005, HISTOCHEM CELL BIOL, V123, P377, DOI 10.1007/s00418-004-0743-4; Stewart CR, 2010, NAT IMMUNOL, V11, P155, DOI 10.1038/ni.1836; Stohwasser R, 2000, GLIA, V29, P355, DOI 10.1002/(SICI)1098-1136(20000215)29:4<355::AID-GLIA6>3.0.CO;2-4; Suuronen T, 2006, NEUROCHEM INT, V49, P610, DOI 10.1016/j.neuint.2006.05.001; Suzuki T, 2006, J NEUROSCI RES, V83, P1461, DOI 10.1002/jnr.20850; Swiatkowski P, 2016, NEUROSCIENCE, V318, P22, DOI 10.1016/j.neuroscience.2016.01.008; Syed MM, 2007, J NEUROCHEM, V103, P1461, DOI 10.1111/j.1471-4159.2007.04838.x; Tanaka J, 1997, GLIA, V20, P23, DOI 10.1002/(SICI)1098-1136(199705)20:1<23::AID-GLIA3>3.3.CO;2-U; Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Taylor DL, 2002, J NEUROCHEM, V82, P1179, DOI 10.1046/j.1471-4159.2002.01062.x; Taylor DL, 2005, J NEUROSCI, V25, P2952, DOI 10.1523/JNEUROSCI.4456-04.2005; Taylor DL, 2003, J NEUROSCI, V23, P2150; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Tiffany HL, 2001, J BIOL CHEM, V276, P23645, DOI 10.1074/jbc.M101031200; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Town T, 2006, J IMMUNOL, V176, P3804, DOI 10.4049/jimmunol.176.6.3804; Tozaki-Saitoh H, 2017, J NEUROCHEM, V141, P100, DOI 10.1111/jnc.13968; Trahanas DM, 2015, SHOCK, V43, P255, DOI 10.1097/SHK.0000000000000291; Truettner JS, 2017, J CEREBR BLOOD F MET, V37, P2952, DOI 10.1177/0271678X16680003; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; van Rossum D, 2008, GLIA, V56, P271, DOI 10.1002/glia.20611; Veerhuis R, 2011, MOL IMMUNOL, V48, P1592, DOI 10.1016/j.molimm.2011.04.003; Venneti S, 2007, EXP NEUROL, V207, P118, DOI 10.1016/j.expneurol.2007.06.003; Visentin S, 2006, Purinergic Signal, V2, P605, DOI 10.1007/s11302-006-9023-1; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang JW, 2013, BIOCHEM BIOPH RES CO, V430, P1016, DOI 10.1016/j.bbrc.2012.12.046; Wang JW, 2012, BRAIN RES, V1464, P73, DOI 10.1016/j.brainres.2012.05.014; Wang WY, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.49; Wang X, 1999, BRAIN RES, V842, P159, DOI 10.1016/S0006-8993(99)01849-1; Wang XJ, 2007, J NEUROIMMUNE PHARM, V2, P259, DOI 10.1007/s11481-007-9075-1; Warden A, 2016, SCI REP, V6, P15; Weber DJ, 2015, ANTIOXID REDOX SIGN, V23, P1316, DOI 10.1089/ars.2015.6299; Weber DJ, 2014, SCI TRANSL MED, V6, P252; Wen L, 2018, J NEUROTRAUM, V35, P2330, DOI 10.1089/neu.2017.5540; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wilkinson B, 2006, J BIOL CHEM, V281, P20842, DOI 10.1074/jbc.M600627200; Wilkinson K., 2012, INT J ALZHEIMERS DIS, V2012, DOI [10.1155/2012/489456, DOI 10.1155/2012/489456]; Woo MS, 2016, J BIOL CHEM, V291, P23654, DOI 10.1074/jbc.M116.750018; Wright GJ, 2003, J IMMUNOL, V171, P3034, DOI 10.4049/jimmunol.171.6.3034; Xiang ZH, 2005, GLIA, V52, P119, DOI 10.1002/glia.20227; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu LY, 2016, EXP NEUROL, V277, P268, DOI 10.1016/j.expneurol.2016.01.010; Xu PF, 2015, BRAIN BEHAV IMMUN, V50, P87, DOI 10.1016/j.bbi.2015.06.020; Yager PH, 2008, J CEREBR BLOOD F MET, V28, P1030, DOI 10.1038/sj.jcbfm.9600605; YAMASHITA K, 1994, J NEUROCHEM, V63, P1042; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; Yang SX, 2006, J CEREBR BLOOD F MET, V26, P1490, DOI 10.1038/sj.jcbfm.9600305; Yao XL, 2017, J NEUROIMMUNOL, V310, P38, DOI 10.1016/j.jneuroim.2017.06.006; Yehualaeshet T, 1999, AM J PATHOL, V155, P841, DOI 10.1016/S0002-9440(10)65183-8; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zanier ER, 2016, J NEUROTRAUM, V33, P1060, DOI 10.1089/neu.2015.4041; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014]; Zhang Z, 2006, CELL MOL LIFE SCI, V63, P2901, DOI 10.1007/s00018-006-6189-1; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771; Zhang ZY, 2007, ACTA NEUROPATHOL, V113, P675, DOI 10.1007/s00401-007-0195-8; Zhao X, 2018, DEV NEUROBIOY; Zhuang ZY, 2007, BRAIN BEHAV IMMUN, V21, P642, DOI 10.1016/j.bbi.2006.11.003; Ziebell JM, 2012, J NEUROINFLAMM, V9, P11; Zuiderwijk-Sick EA, 2007, GLIA, V55, P1589, DOI 10.1002/glia.20572	367	24	26	5	14	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUL	2019	56	7					5202	5228		10.1007/s12035-018-1428-7			27	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	IT8VJ	WOS:000483159700046	30554385				2022-02-06	
J	Romero-Martinez, A; Lila, M; Gracia, E; Moya-Albiol, L				Romero-Martinez, Angel; Lila, Marisol; Gracia, Enrique; Moya-Albiol, Luis			Improving empathy with motivational strategies in batterer intervention programmes: Results of a randomized controlled trial	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article						batterer interventions; cognitive flexibility; emotion-decoding abilities; intimate partner violence; neuropsychology	TRAUMATIC BRAIN-INJURY; DOMESTIC VIOLENCE; COGNITIVE FLEXIBILITY; PARTNER; PERPETRATORS; MECHANISMS; MIND; IMPAIRMENTS; VERSION; EYES	ObjectivesEmpathy (i.e., the ability to decode emotions, as well as cognitive and emotional empathy) is involved in moral reasoning, prosocial behaviour, social and emotional adequacy, mood and behaviour regulation. Hence, alterations in these functions could reduce behaviour control and the adoption of specific types of violence such as intimate partner violence (IPV). Although interventions for IPV perpetrators focus on reducing IPV risk factors and increasing protective factors to prevent this kind of violence, the study of the effectiveness of these programmes in promoting changes in empathy (cognitive and emotional) has been neglected. DesignHence, the main aim of this study was to compare the effectiveness of two different modalities of IPV intervention programmes (Standard Batterer Intervention Programs [SBIP] vs. SBIP+Individualized Motivational Plan [IMP]) in promoting empathic improvements after both interventions. MethodParticipants were randomly assigned to receive SBIP (n=40) or SBIP+IMP (n=53). The effectiveness of the intervention in the total sample and the group effects were evaluated with general linear model repeated-measures ANOVA. ResultsResults revealed that only the IPV perpetrators who received the SBIP+IMP were more accurate in decoding emotional facial signals and presented better cognitive empathy (perspective taking) after the intervention programme. ConclusionsOur study reinforces the view that different modalities of IPV intervention might lead to different cognitive outcomes after the intervention. Thus, these results may help professionals to develop specific intervention programmes focused on improving cognitive abilities in order to reduce IPV recidivism. Practitioner points Interventions for batterers' neglected empathic changes after these programmes. Not enough randomized controlled trials for these kinds of interventions. An improvement in the ability to decode emotions after the intervention programme. An improvement in cognitive empathy (perspective taking) after the intervention programme. Different modalities of IPV intervention might lead to different cognitive outcomes after the intervention.	[Romero-Martinez, Angel; Moya-Albiol, Luis] Univ Valencia, Dept Psychobiol, Ave Blasco Ibanez 21, Valencia 46010, Spain; [Lila, Marisol; Gracia, Enrique] Univ Valencia, Dept Social Psychol, Valencia, Spain		Romero-Martinez, A (corresponding author), Univ Valencia, Dept Psychobiol, Ave Blasco Ibanez 21, Valencia 46010, Spain.	Angel.Romero@uv.es	Lila, Marisol/G-8638-2011; Gracia, Enrique/B-7105-2008; ROMERO-MARTINEZ, ANGEL/L-7316-2018	Lila, Marisol/0000-0002-0522-7461; Gracia, Enrique/0000-0003-0514-2983; Romero-Martinez, Angel/0000-0002-5922-0265	Beca Leonardo a Investigadores y Creadores Culturales 2018 de la Fundacion BBVABBVA Foundation; 2018 Leonardo Grant for Researchers and Cultural Creators, BBVA FoundationBBVA Foundation	The implementation of this study has partly been made possible by funding from the Beca Leonardo a Investigadores y Creadores Culturales 2018 de la Fundacion BBVA. Project supported by a 2018 Leonardo Grant for Researchers and Cultural Creators, BBVA Foundation. The Foundation accepts no responsibility for the opinions, statements and contents included in the project and/or the results thereof, which are entirely the responsibility of the authors.	Arbach K, 2018, PSYCHOSOC INTERV, V27, P105, DOI 10.5093/pi2018a13; Arias Esther, 2013, Psychosocial Intervention, V22, P153, DOI 10.5093/in2013a18; Babcock JC, 2004, CLIN PSYCHOL REV, V23, P1023, DOI 10.1016/j.cpr.2002.07.001; Balconi M, 2016, COGNITION EMOTION, V30, P210, DOI 10.1080/02699931.2014.993306; Baldner C, 2014, MOTIV EMOTION, V38, P727, DOI 10.1007/s11031-014-9417-2; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1017/S0021963001006643; Batchelder L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169185; Bowen E., 2011, REHABILITATION PARTN; Burnett EJ, 2016, PROG NEURO-PSYCHOPH, V65, DOI 10.1016/j.pnpbp.2015.08.012; Cohen J., 2013, STAT POWER ANAL BEHA; Crane CA, 2013, J COUNS PSYCHOL, V60, P180, DOI 10.1037/a0032178; Cunha O, 2014, REV PSIQ CLIN-BRAZIL, V41, P40, DOI 10.1590/0101-60830000000008; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; DAVIS MH, 1983, J PERS SOC PSYCHOL, V44, P113, DOI 10.1037/0022-3514.44.1.113; De Obeso Orendain A. D. O., 2012, P 11 INT C COGN MOD, P49; Eckhardt C, 2008, VIOLENCE VICTIMS, V23, P446, DOI 10.1891/0886-6708.23.4.446; Eckhardt CI, 2013, PARTN ABUSE, V4, P196, DOI 10.1891/1946-6560.4.2.196; Feder L., 2005, J EXP CRIMINOL, V1, P239, DOI [DOI 10.1007/S11292-005-1179-0, https://doi.org/10.1007/s11292-005-1179-0]; Fernandez-Abascal EG, 2013, MOL AUTISM, V4, DOI 10.1186/2040-2392-4-33; Ferrer-Perez VA, 2016, PSYCHOSOC INTERV, V25, P159, DOI 10.1016/j.psi.2016.06.001; Gondolf EW, 2004, AGGRESS VIOLENT BEH, V9, P605, DOI 10.1016/j.avb.2003.06.001; Heinz AJ, 2011, NAT REV NEUROSCI, V12, P400, DOI 10.1038/nrn3042; Huelle JO, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00077; Ingram F, 1999, BRIT J CLIN PSYCHOL, V38, P209, DOI 10.1348/014466599162764; Lopez-Ossorio JJ, 2018, PSYCHOSOC INTERV, V27, P95, DOI 10.5093/pi2018a11; Kistenmacher BR, 2008, VIOLENCE VICTIMS, V23, P558, DOI 10.1891/0886-6708.23.5.558; Kurowski BG, 2014, JAMA PEDIATR, V168, P523, DOI 10.1001/jamapediatrics.2013.5070; Lawrence EJ, 2004, PSYCHOL MED, V34, P911, DOI 10.1017/S0033291703001624; Lila M, 2018, J CONSULT CLIN PSYCH, V86, P309, DOI 10.1037/ccp0000291; Lila M, 2013, EUR J PSYCHOL APPL L, V5, P147, DOI 10.5093/ejpalc2013a4; Lila M, 2012, REV LAT AM PSICOL, V44, P99; Maleki L., 2016, INT J SOCIAL BEHAV E, V9, P3654; Martin-Fernandez M, 2018, PSYCHOSOC INTERV, V27, P133, DOI 10.5093/pi2018a18; Martinez AM, 2017, CURR OPIN PSYCHOL, V17, P27, DOI 10.1016/j.copsyc.2017.06.009; Mestre-Escriva V, 2004, PSICOTHEMA, V16, P255; Murphy C. M., 2017, J INTERPERSONAL VIOL; Musser PH, 2008, VIOLENCE VICTIMS, V23, P539, DOI 10.1891/0886-6708.23.5.539; Nyhus E, 2009, BRAIN COGNITION, V71, P437, DOI 10.1016/j.bandc.2009.03.005; Pinto LA, 2010, AGGRESS VIOLENT BEH, V15, P387, DOI 10.1016/j.avb.2010.07.001; Ramsoy TZ, 2015, SOC NEUROSCI-UK, V10, P179, DOI 10.1080/17470919.2014.965341; Richardson JTE, 2011, EDUC RES REV-NETH, V6, P135, DOI 10.1016/j.edurev.2010.12.001; Romero-Martinez A, 2017, PSYCHOSOC INTERV, V26, P165, DOI 10.1016/j.psi.2017.06.002; Romero-Martinez A, 2016, EUR J PSYCHOL APPL L, V8, P57, DOI 10.1016/j.ejpal.2016.01.001; Romero-Martinez A, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13040394; Romero-Martinez A, 2013, REV NEUROLOGIA, V57, P515, DOI 10.33588/rn.5711.2013141; Romero-Martinez A, 2013, INT J ENV RES PUB HE, V10, P3753, DOI 10.3390/ijerph10083753; Romero-Martinez A, 2013, AGGRESSIVE BEHAV, V39, P355, DOI 10.1002/ab.21490; Santirso FA, 2018, INT J CLIN HLTH PSYC, V18, P152, DOI 10.1016/j.ijchp.2018.02.003; Sato W, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00151; Schipper M, 2013, SOC NEUROSCI-UK, V8, P101, DOI 10.1080/17470919.2012.761650; Stemme A, 2007, J COMPUT NEUROSCI, V23, P313, DOI 10.1007/s10827-007-0034-x; Sun S, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01059; Thye MD, 2018, NEUROSCIENCE, V374, P172, DOI 10.1016/j.neuroscience.2018.01.045; van Berkhout ET, 2016, J COUNS PSYCHOL, V63, P32, DOI 10.1037/cou0000093; Zaki J, 2014, PSYCHOL BULL, V140, P1608, DOI 10.1037/a0037679	55	24	24	3	24	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0144-6657	2044-8260		BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	JUN	2019	58	2					125	139		10.1111/bjc.12204			15	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	HX1WJ	WOS:000467183500001	30345574				2022-02-06	
J	Zahniser, E; Nelson, LD; Dikmen, SS; Machamer, JE; Stein, MB; Yuh, E; Manley, GT; Temkin, NR; Adeoye, O; Badjatia, N; Boase, K; Bodien, Y; Bullock, MR; Chesnut, R; Corrigan, JD; Crawford, K; Diaz-Arrastia, R; Duhaime, AC; Ellenbogen, R; Feeser, VR; Ferguson, A; Foreman, B; Gardner, R; Gaudette, E; Giacino, J; Gonzalez, L; Gopinath, S; Gullapalli, R; Hemphill, JC; Hotz, G; Jain, S; Korley, F; Kramer, J; Kreitzer, N; Levin, H; Lindsell, C; Madden, C; Martin, A; McAllister, T; McCrea, M; Merchant, R; Mukherjee, P; Noel, F; Okonkwo, D; Palacios, E; Perl, D; Puccio, A; Rabinowitz, M; Robertson, C; Rosand, J; Sander, A; Satris, G; Schnyer, D; Seabury, S; Sherer, M; Taylor, S; Toga, A; Valadka, A; Vassar, M; Vespa, P; Wang, K; Yue, J; Zafonte, R				Zahniser, Evan; Nelson, Lindsay D.; Dikmen, Sureyya S.; Machamer, Joan E.; Stein, Murray B.; Yuh, Esther; Manley, Geoffrey T.; Temkin, Nancy R.; Adeoye, Opeolu; Badjatia, Neeraj; Boase, Kim; Bodien, Yelena; Bullock, M. Ross; Chesnut, Randall; Corrigan, John D.; Crawford, Karen; Diaz-Arrastia, Ramon; Duhaime, Ann-Christine; Ellenbogen, Richard; Feeser, V. Ramana; Ferguson, Adam; Foreman, Brandon; Gardner, Raquel; Gaudette, Etienne; Giacino, Joseph; Gonzalez, Luis; Gopinath, Shankar; Gullapalli, Rao; Hemphill, J. Claude; Hotz, Gillian; Jain, Sonia; Korley, Frederick; Kramer, Joel; Kreitzer, Natalie; Levin, Harvey; Lindsell, Chris; Madden, Christopher; Martin, Alastair; McAllister, Thomas; McCrea, Michael; Merchant, Randall; Mukherjee, Pratik; Noel, Florence; Okonkwo, David; Palacios, Eva; Perl, Daniel; Puccio, Ava; Rabinowitz, Miri; Robertson, Claudia; Rosand, Jonathan; Sander, Angelle; Satris, Gabriella; Schnyer, David; Seabury, Seth; Sherer, Mark; Taylor, Sabrina; Toga, Arthur; Valadka, Alex; Vassar, Mary; Vespa, Paul; Wang, Kevin; Yue, John; Zafonte, Ross		TRACK-TBI Investigators	The Temporal Relationship of Mental Health Problems and Functional Limitations following mTBI: A TRACK-TBI and TED Study	JOURNAL OF NEUROTRAUMA			English	Article						brain injuries; mental health; patient outcome assessment; traumatic	TRAUMATIC BRAIN-INJURY; DEPRESSION; PREVALENCE	Mental health problems, such as depression and anxiety, are often associated with functional limitations after traumatic brain injury (TBI), prompting researchers to explore which of these TBI-related sequelae tends to precede the other. Past studies among patients with injuries ranging in severity have predominantly reported that functional impairments predict subsequent psychological concerns, rather than the other way around; however, it remains unclear whether this directionality holds for individuals with mild TBI (mTBI). The present study utilized a cross-lagged panel design within a structural equation modeling analytical framework to explore the longitudinal relationships of symptoms of depression and anxiety to functional status among 717 adult mTBI patients, with assessments occurring at 2 weeks and 3 months post-injury. Symptoms of both depression and anxiety significantly predicted subsequent functional limitations (lambda s = -0.21 and -0.25), whereas the reverse effects were nonsignificant (lambda s = -0.05 and -0.03); thus, psychological concerns appeared to function as a precursor to functional impairment. This pattern was particularly pronounced among patients with normal head computed tomography (CT) results; however, results were less clear cut among those subjects whose injuries were accompanied by intracranial abnormalities detected on CT imaging, suggesting the possibility of a more reciprocal relationship in the case of CT-positive mTBI. These results may serve to partially explain the incidence of persistent functional limitations observed among subsets of mTBI patients in past studies. Findings likewise highlight the importance of assessment and treatment for mental health problems after mTBI as an important factor to promote psychological well-being and functional recovery.	[Zahniser, Evan; Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, 325 Ninth Ave,Box 359924, Seattle, WA 98104 USA; [Dikmen, Sureyya S.; Machamer, Joan E.] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98104 USA; [Nelson, Lindsay D.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA; [Yuh, Esther] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Adeoye, Opeolu; Foreman, Brandon; Kreitzer, Natalie] Univ Cincinnati, Cincinnati, OH 45221 USA; [Badjatia, Neeraj; Gullapalli, Rao] Univ Maryland, College Pk, MD 20742 USA; [Boase, Kim; Chesnut, Randall; Ellenbogen, Richard] Univ Washington, Seattle, WA 98195 USA; [Bodien, Yelena; Rosand, Jonathan] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Bullock, M. Ross; Hotz, Gillian] Univ Miami, Coral Gables, FL 33124 USA; [Corrigan, John D.] Ohio State Univ, Columbus, OH 43210 USA; [Crawford, Karen; Gaudette, Etienne; Seabury, Seth; Toga, Arthur] Univ Southern Calif, Los Angeles, CA USA; [Diaz-Arrastia, Ramon] Univ Penn, Philadelphia, PA 19104 USA; [Duhaime, Ann-Christine] Mass Gen Hosp, Boston, MA USA; [Feeser, V. Ramana; Merchant, Randall; Valadka, Alex] Virginia Commonwealth Univ, Richmond, VA 23284 USA; [Ferguson, Adam; Gardner, Raquel; Hemphill, J. Claude; Kramer, Joel; Martin, Alastair; Mukherjee, Pratik; Palacios, Eva; Satris, Gabriella; Taylor, Sabrina; Vassar, Mary; Yue, John] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Giacino, Joseph] Spaulding Rehabil Hosp, Boston, MA USA; [Gonzalez, Luis; Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Gopinath, Shankar; Levin, Harvey; Noel, Florence; Robertson, Claudia; Sander, Angelle] Baylor Coll Med, Houston, TX 77030 USA; [Jain, Sonia] Univ San Diego, San Diego, CA 92110 USA; [Korley, Frederick] Univ Michigan, Ann Arbor, MI 48109 USA; [Lindsell, Chris] Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA; [Madden, Christopher] UT Southwestern, Dallas, TX USA; [McAllister, Thomas] Indiana Univ, Bloomington, IN 47405 USA; [McCrea, Michael] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Okonkwo, David; Puccio, Ava; Rabinowitz, Miri] Univ Pittsburgh, Pittsburgh, PA 15260 USA; [Perl, Daniel] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Schnyer, David] UT Austin, Austin, TX USA; [Vespa, Paul] Univ Calif Los Angeles, Los Angeles, CA USA; [Wang, Kevin] Univ Florida, Gainesville, FL 32611 USA; [Zafonte, Ross] Harvard Med Sch, Boston, MA 02115 USA		Temkin, NR (corresponding author), Univ Washington, Dept Neurol Surg, 325 Ninth Ave,Box 359924, Seattle, WA 98104 USA.	temkin@uw.edu	Schnyer, David/ABD-6372-2021; Badjatia, Neeraj/AAS-4855-2021; Giacino, Joseph/AAF-1952-2021; Hemphill, Claude/AAY-5630-2021; Yue, John K/P-1348-2015	Schnyer, David/0000-0002-7472-2853; Giacino, Joseph/0000-0002-7916-9698; Hemphill, Claude/0000-0003-4019-7525; Yue, John K/0000-0001-9694-7722; Bodien, Yelena/0000-0003-4858-2903; Ferguson, Adam/0000-0001-7102-1608	D.O.D. U.S. ArmyUnited States Department of Defense [W81XWH-14-2-0176]; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1U01NS086090]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090] Funding Source: NIH RePORTER	This study was supported by funding from the following grants: D.O.D. U.S. Army W81XWH-14-2-0176 and NIH/NINDS 1U01NS086090.	Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Cheung MWL, 2009, STRUCT EQU MODELING, V16, P267, DOI 10.1080/10705510902751291; Deb S, 1999, AM J PSYCHIAT, V156, P374; Derogatis L.R., 2000, BRIEF SYMPTOM INVENT; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Dikmen S.S., 1990, ARCH PHYS MED REHAB, V84, P1449; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Joreskog K. G., 1993, LISREL 8 STRUCTURAL; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; Kline R.B., 2005, PRINCIPLES PRACTICE, V2nd; Korley FK, 2017, J NEUROTRAUM, V34, P1531, DOI 10.1089/neu.2016.4723; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kwan JLY, 2011, BEHAV RES METHODS, V43, P730, DOI 10.3758/s13428-011-0088-6; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; PELZ DC, 1964, AM SOCIOL REV, V29, P836, DOI 10.2307/2090866; Perrin PB, 2017, AM J PHYS MED REHAB, V96, P374, DOI 10.1097/PHM.0000000000000644; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RINDSKOPF D, 1984, PSYCHOMETRIKA, V49, P37, DOI 10.1007/BF02294204; Ruff R.M., 2009, BRAIN INJURY, V10, P551; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Seabury SA, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0210; Sherer M, 2015, CLIN NEUROPSYCHOL, V29, P522, DOI 10.1080/13854046.2015.1052763; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; TEMKIN N, 2005, J NEUROTRAUM, V20, P229; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	31	24	24	1	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2019	36	11					1786	1793		10.1089/neu.2018.6172			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	IB1EQ	WOS:000470007600009	30543138	Green Published			2022-02-06	
J	Forrest, SL; Kril, JJ; Wagner, S; Honigschnabl, S; Reiner, A; Fischer, P; Kovacs, GG				Forrest, Shelley L.; Kril, Jillian J.; Wagner, Stephanie; Hoenigschnabl, Selma; Reiner, Angelika; Fischer, Peter; Kovacs, Gabor G.			Chronic Traumatic Encephalopathy (CTE) Is Absent From a European Community-Based Aging Cohort While Cortical Aging-Related Tau Astrogliopathy (ARTAG) Is Highly Prevalent	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Aging; Aging-related tau astrogliopathy; ARTAG; Chronic traumatic encephalopathy; Community-based study; CTE; Neuropathology	BRAIN-INJURY; PATHOLOGY; NEUROPATHOLOGY; DISEASE	This study determined the prevalence of chronic traumatic encephalopathy (CTE) and cortical aging-related tau astrogliopathy (ARTAG) in a European community-based population (n = 310). The frontal, parietal, and temporal cortices, representing initial stages of CTE were assessed. No case fulfilling CTE consensus criteria was found. However, isolated astroglial or neuronal tau pathologies were recognized in the depths of cortical sulci (<2%). A single case (female, 85 years) without a history of traumatic brain injury (TBI) showed combined tau-immunoreactive features confined to frontal sulci without perivascular accumulation. Another 24 cases had single tau pathologies in cortical sulci. ARTAG was identified in 117 cases (38%), with a similar regional prevalence. Gray matter ARTAG was the most common followed by subpial, white matter, and perivascular. The presence of any type of ARTAG was strongly associated with having another type of ARTAG in the same region (p < 0.05). In summary, although isolated tau pathologies in the depths of cortical sulci were identified, no case fulfilled diagnostic criteria of CTE. Cortical ARTAG in this population is common and contrasts the high prevalence of CTE in individuals with repeated mild TBI. ARTAG in isolation might not be indicative of CTE although commonalities in pathogenesis should be considered.	[Forrest, Shelley L.; Kril, Jillian J.] Univ Sydney, Charles Perkins Ctr, Fac Med & Hlth, Sydney, NSW, Australia; [Forrest, Shelley L.; Kril, Jillian J.] Univ Sydney, Discipline Pathol, Sydney, NSW, Australia; [Wagner, Stephanie; Kovacs, Gabor G.] Med Univ Vienna, Inst Neurol, AKH Wien 4J Wahringer Gurtel 18-20, A-1097 Vienna, Austria; [Hoenigschnabl, Selma; Reiner, Angelika] Danube Hosp, Dept Pathol, Vienna, Austria; [Fischer, Peter] Danube Hosp, Dept Psychiat, Vienna, Austria		Kovacs, GG (corresponding author), Med Univ Vienna, Inst Neurol, AKH Wien 4J Wahringer Gurtel 18-20, A-1097 Vienna, Austria.	gabor.kovacs@meduniwien.ac.at	Forrest, Shelley/ABG-2644-2020; Kovacs, Gabor G/A-7468-2013	Kovacs, Gabor G/0000-0003-3841-5511	Ludwig Boltzmann Institute of Ageing Research; NHMRC Project GrantNational Health and Medical Research Council of Australia [1132524]; Alzheimer's Australia Dementia Research Foundation via the Rosemary Foundation Travel Fellowship	The Vienna Trans-Danube Ageing (VITA) study was supported and organized by the Ludwig Boltzmann Institute of Ageing Research. In addition, this study was supported by NHMRC Project Grant (1132524). The Alzheimer's Australia Dementia Research Foundation via the Rosemary Foundation Travel Fellowship supports S.L.F. and J.J.K.	Asken BM, 2017, JAMA NEUROL, V74, P1255, DOI 10.1001/jamaneurol.2017.2396; Baskota SU, 2019, LAB INVEST, V99, P1068, DOI 10.1038/s41374-018-0166-9; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Forrest SL, 2018, BRAIN, V141, P521, DOI 10.1093/brain/awx328; Ghajari M, 2017, BRAIN, V140, P333, DOI 10.1093/brain/aww317; Goldfinger MH, 2018, ACTA NEUROPATHOL, V136, P973, DOI 10.1007/s00401-018-1926-8; Hsu ET, 2018, ACTA NEUROPATHOL, V136, P955, DOI 10.1007/s00401-018-1902-3; Koga S, 2016, J NEUROPATH EXP NEUR, V75, P963, DOI 10.1093/jnen/nlw073; Kovacs GG, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0552-y; Kovacs GG, 2017, J NEUROPATH EXP NEUR, V76, P605, DOI 10.1093/jnen/nlx041; Kovacs GG, 2017, J NEUROPATH EXP NEUR, V76, P270, DOI 10.1093/jnen/nlx007; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Kovacs GG, 2013, ACTA NEUROPATHOL, V126, P365, DOI 10.1007/s00401-013-1157-y; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Liu AKL, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0330-7; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Noy S, 2016, J NEUROPATH EXP NEUR, V75, P1145, DOI 10.1093/jnen/nlw092; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; Robinson JL, 2018, ACTA NEUROPATHOL, V136, P377, DOI 10.1007/s00401-018-1872-5; Saito Y, 2004, J NEUROPATH EXP NEUR, V63, P911, DOI 10.1093/jnen/63.9.911; Schultz C, 2004, NEUROBIOL AGING, V25, P397, DOI 10.1016/S0197-4580(03)00113-1; Shively SB, 2017, ACTA NEUROPATHOL, V133, P353, DOI 10.1007/s00401-016-1649-7; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f	32	24	24	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAY	2019	78	5					398	405		10.1093/jnen/nlz017			8	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	IF7KX	WOS:000473264100003	30939193	Bronze			2022-02-06	
J	Sugarman, MA; McKee, AC; Stein, TD; Tripodis, Y; Besser, LM; Martin, B; Palmisano, JN; Steinberg, EG; O'Connor, MK; Au, R; McClean, M; Killiany, R; Mez, J; Weiner, MW; Kowall, NW; Stern, RA; Alosco, ML				Sugarman, Michael A.; McKee, Ann C.; Stein, Thor D.; Tripodis, Yorghos; Besser, Lilah M.; Martin, Brett; Palmisano, Joseph N.; Steinberg, Eric G.; O'Connor, Maureen K.; Au, Rhoda; McClean, Michael; Killiany, Ronald; Mez, Jesse; Weiner, Michael W.; Kowall, Neil W.; Stern, Robert A.; Alosco, Michael L.			Failure to detect an association between self-reported traumatic brain injury and Alzheimer's disease neuropathology and dementia	ALZHEIMERS & DEMENTIA			English	Article						Alzheimer's disease; Traumatic brain injury; Cognitive decline; Neurodegenerative disease; NACC; Concussion	MILD COGNITIVE IMPAIRMENT; DATA SET UDS; AMYLOID ANGIOPATHY; CLINICAL-DIAGNOSIS; HEAD IMPACTS; HISTORY; ENCEPHALOPATHY; RISK; CONSCIOUSNESS; ASSESSMENTS	Introduction: Recent research with neuropathologic or biomarker evidence of Alzheimer's disease (AD) casts doubt on traumatic brain injury (TBI) as a risk factor for AD. We leveraged the National Alzheimer's Coordinating Center to examine the association between self-reported TBI with loss of consciousness and AD neuropathologic changes, and with baseline and longitudinal clinical status. Methods: The sample included 4761 autopsy participants (453 with remote TBI with loss of consciousness; 2822 with AD neuropathologic changes) from National Alzheimer's Coordinating Center. Results: Self-reported TBI did not predict AD neuropathologic changes (P >. 10). Reported TBI was not associated with baseline or change in dementia severity or cognitive function in participants with or without autopsy-confirmed AD. Discussion: Self-reported TBI with loss of consciousness may not be an independent risk factor for clinical or pathological AD. Research that evaluates number and severity of TBIs is needed to clarify the neuropathological links between TBI and dementia documented in other large clinical databases. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.	[Sugarman, Michael A.; McKee, Ann C.; Stein, Thor D.; Tripodis, Yorghos; Martin, Brett; Palmisano, Joseph N.; Steinberg, Eric G.; O'Connor, Maureen K.; Killiany, Ronald; Mez, Jesse; Kowall, Neil W.; Stern, Robert A.; Alosco, Michael L.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Sugarman, Michael A.; McKee, Ann C.; Stein, Thor D.; Tripodis, Yorghos; Martin, Brett; Palmisano, Joseph N.; Steinberg, Eric G.; O'Connor, Maureen K.; Killiany, Ronald; Mez, Jesse; Kowall, Neil W.; Stern, Robert A.; Alosco, Michael L.] Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA; [Sugarman, Michael A.; O'Connor, Maureen K.] Edith Nourse Rogers Mem Vet Hosp, Dept Neuropsychol, Bedford, MA USA; [McKee, Ann C.; Au, Rhoda; Mez, Jesse; Kowall, Neil W.; Stern, Robert A.; Alosco, Michael L.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [McKee, Ann C.; Stein, Thor D.; Kowall, Neil W.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [McKee, Ann C.; Stein, Thor D.] VA Boston Healthcare Syst, Boston, MA USA; [McKee, Ann C.; Stein, Thor D.] Dept Vet Affairs Med Ctr, Bedford, MA USA; [Tripodis, Yorghos] Boston Univ, Dept Biostat, Sch Publ Hlth, Boston, MA USA; [Besser, Lilah M.] Univ Washington, Natl Alzheimers Coordinating Ctr, Seattle, WA 98195 USA; [Martin, Brett; Palmisano, Joseph N.] Boston Univ, Sch Publ Hlth, Biostat & Epidemiol Data Analyt Centel, Boston, MA USA; [Au, Rhoda] NHLBI, Framingham Heart Study, Boston, MA USA; [Au, Rhoda] Boston Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA USA; [Au, Rhoda; Killiany, Ronald; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [McClean, Michael; Killiany, Ronald] Boston Univ, Dept Environm Hlth, Sch Publ Hlth, Boston, MA USA; [Killiany, Ronald] Boston Univ, Sch Med, Ctr Biomed Imaging, Boston, MA 02118 USA; [Weiner, Michael W.] Dept Vet Affairs Med Ctr, Ctr Imaging & Neurodegenerat Dis, San Francisco, CA USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA; [Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Kowall, Neil W.] VA Boston Healthcare Syst, Neurol Serv, Boston, MA USA; [Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA		Alosco, ML (corresponding author), Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA.; Alosco, ML (corresponding author), Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA.; Alosco, ML (corresponding author), Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.	malosco@bu.edu	Killiany, Ronald/Y-7251-2019; Besser, Lilah/AAD-3304-2020; , Bob/ABA-8507-2020	Killiany, Ronald/0000-0003-4740-2181; Tripodis, Yorghos/0000-0003-2190-7608; O'Connor, Maureen/0000-0002-2466-0367	NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161, P50 AG047366, P30 AG010129, P50 AG016573, P50 AG005131]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 AG13846, U01NS093334, U01NS086659-01, 1F32NS096803-01, K23NS102399, K23AG046377, RF1AG05416]; National Center for Advancing Translational Sciences, National Institutes of Health, through Boston University Clinical & Translational Science Institute (BU-CTSI) [1UL1TR001430]; NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG016976];  [P50 AG005142];  [P30 AG012300];  [P30 AG049638];  [P50 AG005136];  [P50 AG033514];  [P50 AG005681];  [P50 AG047270];  [P50 AG023501];  [P30 AG035982];  [P30 AG028383];  [P30 AG053760];  [P30 AG010124];  [P50 AG005133]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS093334, U01NS086659, K23NS102399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010129, P30AG019610, P50AG047266, P50AG025688, P50AG005133, P50AG005146, P30AG010161, P50AG047366, P30AG010133, P50AG016574, K23AG046377, P30AG062715, R01AG061028, P50AG005136, P30AG049638, RF1AG054156, P50AG016573, P50AG005138, P30AG035982, P50AG005681, R01AG062348, P50AG023501, P30AG013846, P50AG008702, P30AG008051, P30AG013854, P50AG047270, P30AG008017, U01AG016976, P50AG005131, P30AG053760, P50AG033514, P50AG005134] Funding Source: NIH RePORTER	The National Alzheimer's Coordinating Center (NACC) database is funded by NIA/NIH GrantU01AG016976. NACC data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PINeilKowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG005131 (PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), and P50 AG047270 (PI Stephen Strittmatter, MD, PhD). This work was supported by grants from the NIH (P30 AG13846; U01NS093334, U01NS086659-01; 1F32NS096803-01; K23NS102399; K23AG046377; RF1AG05416). This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Boston University Clinical & Translational Science Institute (BU-CTSI) Grant Number 1UL1TR001430. The content is solely the responsibility of the authors. There is no sponsor.	Adams JW, 2019, J NEUROPATHOL EXP NE; Alafuzoff I, 2008, BRAIN PATHOL, V18, P484, DOI 10.1111/j.1750-3639.2008.00147.x; Alafuzoff I, 2008, ACTA NEUROPATHOL, V115, P533, DOI 10.1007/s00401-008-0358-2; Alafuzoff I, 2006, J NEUROPATH EXP NEUR, V65, P740, DOI 10.1097/01.jnen.0000229986.17548.27; Alafuzoff I, 2009, ACTA NEUROPATHOL, V117, P309, DOI 10.1007/s00401-009-0485-4; Alosco ML, 2018, ANN NEUROL, V83, P886, DOI 10.1002/ana.25245; Alosco ML, 2017, J ALZHEIMERS DIS, V57, P953, DOI 10.3233/JAD-161205; [Anonymous], 2014, R LANG ENV STAT COMP; Barnes DE, 2018, JAMA NEUROL, V75, P1055, DOI 10.1001/jamaneurol.2018.0815; Beach TG, 2012, J NEUROPATH EXP NEUR, V71, P266, DOI 10.1097/NEN.0b013e31824b211b; Beekly DL, 2004, ALZ DIS ASSOC DIS, V18, P270; Besser LM, 2018, J NEUROPATH EXP NEUR, V77, P717, DOI 10.1093/jnen/nly049; Besser LM, 2016, J NEUROPATH EXP NEUR, V75, P955, DOI 10.1093/jnen/nlw072; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Chinn S, 2000, STAT MED, V19, P3127, DOI 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.3.CO;2-D; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Esopenko C, 2017, J NEUROL NEUROSUR PS, V88, P512, DOI 10.1136/jnnp-2016-315260; Fann JR, 2018, LANCET PSYCHIAT, V5, P424, DOI 10.1016/S2215-0366(18)30065-8; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2018, NEUROLOGY, V90, pE1771, DOI 10.1212/WNL.0000000000005522; Gardner Raquel C, 2015, Neurol Clin Pract, V5, P285; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hayes JP, 2017, BRAIN, V140, P813, DOI 10.1093/brain/aww344; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Jarrett M, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00011; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Koerte IK, 2017, J NEUROTRAUM, V34, P2389, DOI 10.1089/neu.2016.4960; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Levitch CF, 2018, J INT NEUROPSYCH SOC, V24, P147, DOI 10.1017/S1355617717000790; Ling HL, 2017, ACTA NEUROPATHOL, V133, P337, DOI 10.1007/s00401-017-1680-3; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; LoBue C, 2018, NEUROPSYCHOLOGY, V32, P401, DOI 10.1037/neu0000431; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mielke MM, 2014, NEUROLOGY, V82, P70, DOI 10.1212/01.wnl.0000438229.56094.54; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Montine TJ, 2016, ALZHEIMERS DEMENT, V12, P164, DOI 10.1016/j.jalz.2015.07.492; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; Nordstrom A, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002496; Olichney JM, 2000, ANN NY ACAD SCI, V903, P138, DOI 10.1111/j.1749-6632.2000.tb06360.x; Plassman Brenda L, 2015, Handb Clin Neurol, V128, P711, DOI 10.1016/B978-0-444-63521-1.00044-3; Ramos-Cejudo J, 2018, EBIOMEDICINE, V28, P21, DOI 10.1016/j.ebiom.2018.01.021; Schaffert J, 2018, NEUROPSYCHOLOGY, V32, P410, DOI 10.1037/neu0000423; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Sollmann N, 2018, NEUROIMAGE-CLIN, V17, P642, DOI 10.1016/j.nicl.2017.11.020; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Tripodis Y, 2017, J ALZHEIMERS DIS, V59, P251, DOI 10.3233/JAD-160585; VONSATTEL JPG, 1991, ANN NEUROL, V30, P637, DOI 10.1002/ana.410300503; Weiner Michael W, 2017, Alzheimers Dement (N Y), V3, P177, DOI 10.1016/j.trci.2017.02.005; Weintraub S, 2009, ALZ DIS ASSOC DIS, V23, P91, DOI 10.1097/WAD.0b013e318191c7dd; Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x	62	24	24	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	MAY	2019	15	5					686	698		10.1016/j.jalz.2018.12.015			13	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	HX2KN	WOS:000467220800009	30852157	Green Accepted			2022-02-06	
J	Belardo, C; Iannotta, M; Boccella, S; Rubino, RC; Ricciardi, F; Infantino, R; Pieretti, G; Stella, L; Paino, S; Marabese, I; Maisto, R; Luongo, L; Maione, S; Guida, F				Belardo, Carmela; Iannotta, Monica; Boccella, Serena; Rubino, Rosamaria Cristina; Ricciardi, Flavia; Infantino, Rosmara; Pieretti, Gorizio; Stella, Luigi; Paino, Salvatore; Marabese, Ida; Maisto, Rosa; Luongo, Livio; Maione, Sabatino; Guida, Francesca			Oral Cannabidiol Prevents Allodynia and Neurological Dysfunctions in a Mouse Model of Mild Traumatic Brain Injury	FRONTIERS IN PHARMACOLOGY			English	Article						cannabidiol; traumatic brain injury; pain; behavior; microdialysis	IN-VITRO; PAIN; NEUROPROTECTION; INHIBITION; MICE	Neurological dysfunctions are the most impactful and persistent consequences of traumatic brain injury (TBI). Indeed, previous reports suggest that an association between TBI and chronic pain syndromes, as well anxio-depressive behaviors, tends to be more common in patients with mild forms of TBI. At present, no effective treatment options are available for these symptoms. In the present study, we used a weight drop mild TBI mouse model to investigate the effect of a commercially available 10% Cannabidiol (CBD) oil on both the sensorial and neuropsychiatric dysfunctions associated with mild TBI through behavioral and biomolecular approaches. TBI mice developed chronic pain associated with anxious and aggressive behavior, followed by a late depressive-like behavior and impaired social interaction. Such behaviors were related with specific changes in neurotransmitters release at cortical levels. CBD oral treatment restored the behavioral alterations and partially normalized the cortical biochemical changes. In conclusion, our data show some of the brain modifications probably responsible for the behavioral phenotype associated with TBI and suggest the CBD as a pharmacological tool to improve neurological dysfunctions caused by the trauma.	[Belardo, Carmela; Iannotta, Monica; Boccella, Serena; Ricciardi, Flavia; Infantino, Rosmara; Paino, Salvatore; Marabese, Ida; Maisto, Rosa; Luongo, Livio; Maione, Sabatino; Guida, Francesca] Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy; [Rubino, Rosamaria Cristina] Enecta S l, Bologna, Italy; [Pieretti, Gorizio] Univ Campania Luigi Vanvitelli, Dept Plast Surg, Naples, Italy; [Stella, Luigi] Drug Addict Unit SerT, Naples, Italy		Maione, S; Guida, F (corresponding author), Univ Campania Luigi Vanvitelli, Dept Expt Med, Naples, Italy.	sabatino.maione@unicampania.it; franc.guida@gmail.com	Belardo, Carmela/AAA-9319-2022; pieretti, gorizio/AAJ-8216-2020	pieretti, gorizio/0000-0002-0326-8438; Infantino, Rosmara/0000-0003-1266-6881; Maione, Sabatino/0000-0003-3850-6704	Department of Experimental Medicine of Universisty of Campania	We thank Enecta Group for providing Cannabidiol. We also thank the Department of Experimental Medicine of Universisty of Campania for publication fees.	Apps R, 2015, NAT REV NEUROSCI, V16, P642, DOI 10.1038/nrn4028; Arciniegas DB, 2011, INT J PSYCHOPHYSIOL, V82, P41, DOI 10.1016/j.ijpsycho.2011.03.004; Aspide R, 1998, BEHAV BRAIN RES, V95, P123, DOI 10.1016/S0166-4328(97)00217-9; Boccella S, 2019, NEUROBIOL DIS, V121, P106, DOI 10.1016/j.nbd.2018.09.023; Carrier EJ, 2006, P NATL ACAD SCI USA, V103, P7895, DOI 10.1073/pnas.0511232103; Castillo A, 2010, NEUROBIOL DIS, V37, P434, DOI 10.1016/j.nbd.2009.10.023; D'Aniello A, 2017, NEUROSCI LETT, V651, P151, DOI 10.1016/j.neulet.2017.04.041; De Gregorio D, 2019, PAIN, V160, P136, DOI 10.1097/j.pain.0000000000001386; Feliciano DP, 2014, NEUROSCI LETT, V583, P55, DOI 10.1016/j.neulet.2014.09.030; Fernandez-Ruiz J, 2013, BRIT J CLIN PHARMACO, V75, P323, DOI 10.1111/j.1365-2125.2012.04341.x; Giordano C, 2012, CEREB CORTEX, V22, P2495, DOI 10.1093/cercor/bhr328; Guida F, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0139-5; Guida F, 2017, RECEPT SER, P15, DOI 10.1007/978-3-319-56170-7_2; Guida F, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00095; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hayakawa K, 2007, J NEUROCHEM, V102, P1488, DOI 10.1111/j.1471-4159.2007.04565.x; Hayakawa K, 2010, PHARMACEUTICALS, V3, P2197, DOI 10.3390/ph3072197; Lastres-Becker I, 2005, NEUROBIOL DIS, V19, P96, DOI 10.1016/j.nbd.2004.11.009; Lever C, 2006, REV NEUROSCIENCE, V17, P111; Liu JJ, 2019, NEUROIMMUNOMODULAT, V26, P102, DOI 10.1159/000495467; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Luongo L, 2013, NEUROPHARMACOLOGY, V66, P317, DOI 10.1016/j.neuropharm.2012.05.047; Mayeux J, 2017, J NEUROTRAUM, V34, P436, DOI 10.1089/neu.2016.4452; Palazzo E, 2015, PAIN, V156, P1060, DOI 10.1097/j.pain.0000000000000150; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Schonhofen P, 2018, CNS DRUGS, V32, P697, DOI 10.1007/s40263-018-0550-4; Schurman LD, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00069; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Vialou V, 2014, J NEUROSCI, V34, P3878, DOI 10.1523/JNEUROSCI.1787-13.2014; Vigano D, 2009, INT J NEUROPSYCHOPH, V12, P599, DOI 10.1017/S1461145708009371; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018	32	24	24	6	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-9812			FRONT PHARMACOL	Front. Pharmacol.	APR 16	2019	10								352	10.3389/fphar.2019.00352			11	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	HT5IQ	WOS:000464597500001	31040777	gold, Green Published			2022-02-06	
J	Yue, JK; Cnossen, MC; Winkler, EA; Deng, HS; Phelps, RRL; Coss, NA; Sharma, S; Robinson, CK; Suen, CG; Vassar, MJ; Schnyer, DM; Puccio, AM; Gardner, RC; Yuh, EL; Mukherjee, P; Valadka, AB; Okonkwo, DO; Lingsma, HF; Manley, GT; Cooper, SR; Dams-O'Connor, K; Gordon, WA; Hricik, AJ; Maas, AIR; Menon, DK; Morabito, DJ				Yue, John K.; Cnossen, Maryse C.; Winkler, Ethan A.; Deng, Hansen; Phelps, Ryan R. L.; Coss, Nathan A.; Sharma, Sourabh; Robinson, Caitlin K.; Suen, Catherine G.; Vassar, Mary J.; Schnyer, David M.; Puccio, Ave M.; Gardner, Raquel C.; Yuh, Esther L.; Mukherjee, Pratik; Valadka, Alex B.; Okonkwo, David O.; Lingsma, Hester F.; Manley, Geoffrey T.; Cooper, Shelly R.; Dams-O'Connor, Kristen; Gordon, Wayne A.; Hricik, Allison J.; Maas, Andrew I. R.; Menon, David K.; Morabito, Diane J.		TRACK-TBI Investigators	Pre-injury Comorbidities Are Associated With Functional Impairment and Post-concussive Symptoms at 3-and 6-Months After Mild Traumatic Brain Injury: A TRACK-TBI Study	FRONTIERS IN NEUROLOGY			English	Article						functional impairment; mild traumatic brain injury; post-concussive symptoms; pre-injury comorbidities; prognosis	COMMON DATA ELEMENTS; OUTCOME PREDICTION; UNITED-STATES; HEADACHE; RECOMMENDATIONS; VETERANS; HISTORY; DEATHS; TASK	Introduction: Over 70% of traumatic brain injuries (FBI) are classified as mild (mTBI), which present heterogeneously. Associations between pre-injury comorbidities and outcomes are not well-understood, and understanding their status as risk factors may improve mTBI management and prognostication. Methods: mTBI subjects (GCS 13-15) from TRACK-TBI Pilot completing 3- and 6-month functional [Glasgow Outcome Scale-Extended (GOSE)] and post-concussive outcomes [Acute Concussion Evaluation (ACE) physical/cognitive/sleep/emotional subdomains] were extracted. Pre-injury comorbidities >10% incidence were included in regressions for functional disability (GOSE <= 6) and post-concussive symptoms by subdomain. Odds ratios (OR) and mean differences (B) were reported. Significance was assessed at p < 0.0083 (Bonferroni correction). Results: In 260 subjects sustaining blunt mTBI, mean age was 44.0-years and 70.4% were male. Baseline comorbidities >10% incidence included psychiatric-30.0%, cardiac (hypertension)-23.8%, cardiac (structural/valvular/ischemic)-20.4%, gastrointestinal-15.8%, pulmonary-15.0%, and headache/migraine-11.5%. At 3- and 6-months separately, 30.8% had GOSE <= 6. At 3-months, psychiatric (GOSE <= 6: OR = 2.75, 95% CI [1.44-5.27]; ACE-physical: B = 1.06 [0.38-1.73]; ACE-cognitive: B = 0.72 [0.26-1.17]; ACE-sleep: B = 0.46 [0.17-0.75]; ACE-emotional: B = 0.64 [0.25-1.03]), headache/migraine (GOSE <= 6: OR = 4.10 [1.67-10.07]; ACE-sleep: B = 0.57 [0.15-1.00]; ACE-emotional: B = 0.92 [0.35-1.49]), and gastrointestinal history (ACE-physical: B = 1.25 [0.41-2.10]) were multivariable predictors of worse outcomes. At 6-months, psychiatric (GOSE <= 6: OR = 2.57 [1.38-4.77]; ACE-physical: B = 1.38 [0.68-2.09]; ACE-cognitive: B = 0.74 [0.28-1.20]; ACE-sleep: B = 0.51 [0.20-0.83]; ACE-emotional: B = 0.93 [0.53-1.33]), and headache/migraine history (ACE-physical: B = 1.81 [0.79-2.84]) predicted worse outcomes. Conclusions: Pre-injury psychiatric and pre-injury headache/migraine symptoms are risk factors for worse functional and post-concussive outcomes at 3- and 6-months post-mTBI. mTBI patients presenting to acute care should be evaluated for psychiatric and headache/migraine history, with lower thresholds for providing TBI education/resources, surveillance, and follow-up/referrals.	[Yue, John K.; Winkler, Ethan A.; Deng, Hansen; Phelps, Ryan R. L.; Coss, Nathan A.; Sharma, Sourabh; Robinson, Caitlin K.; Suen, Catherine G.; Vassar, Mary J.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94115 USA; [Yue, John K.; Winkler, Ethan A.; Deng, Hansen; Phelps, Ryan R. L.; Coss, Nathan A.; Sharma, Sourabh; Robinson, Caitlin K.; Suen, Catherine G.; Vassar, Mary J.; Yuh, Esther L.; Mukherjee, Pratik; Manley, Geoffrey T.] Zuckerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Cnossen, Maryse C.; Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Suen, Catherine G.] Univ Utah, Dept Neurol, Salt Lake City, UT USA; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Puccio, Ave M.; Okonkwo, David O.; Hricik, Allison J.] Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA USA; [Gardner, Raquel C.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Gardner, Raquel C.] Vet Affairs Med Ctr, Dept Neurol, San Francisco, CA 94121 USA; [Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; [Cooper, Shelly R.] Washington Univ, Dept Psychol, St Louis, MO 63130 USA; [Dams-O'Connor, Kristen; Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Maas, Andrew I. R.] Univ Hosp Antwerp, Dept Neurosurg, Edegem, Belgium; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Morabito, Diane J.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA		Yue, JK (corresponding author), Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94115 USA.; Yue, JK (corresponding author), Zuckerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA.	john.yue@ucst.edu; manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015; Schnyer, David/ABD-6372-2021	Yue, John K/0000-0001-9694-7722; Schnyer, David/0000-0002-7472-2853	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RC2NS069409-01, 3RC2NS069409-02S1, 5RC2NS069409-02, 1U01NS086090-01, 3U01NS086090-02S1, 3U01NS086090-02S2, 3U01NS086090-03S1, 5U01NS086090-02, 5U01NS086090-03]; US DODUnited States Department of Defense [W81XWH-14-2-0176, W81XWH-13-1-0441]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090] Funding Source: NIH RePORTER	This work was supported by the following grants: NINDS 1RC2NS069409-01, 3RC2NS069409-02S1, 5RC2NS069409-02, 1U01NS086090-01, 3U01NS086090-02S1, 3U01NS086090-02S2, 3U01NS086090-03S1, 5U01NS086090-02, 5U01NS086090-03; US DOD W81XWH-13-1-0441, US DOD W81XWH-14-2-0176 (to GM). Funders were not involved in writing of thismanuscript or submission for publication. No authors were paid to write this article by a pharmaceutical company or other agency. The authors had full access to all data in the study and had final responsibility for the decision to submit for publication.	Ahmadi N, 2015, BRAIN INJURY, V29, P1635, DOI 10.3109/02699052.2015.1075149; Amick MM, 2013, J INT NEUROPSYCH SOC, V19, P792, DOI 10.1017/S1355617713000544; Beri N, 2019, CLIN GENET, V95, P293, DOI 10.1111/cge.13474; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cnossen MC, 2017, J NEUROTRAUM, V34, P2396, DOI 10.1089/neu.2016.4819; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Davenport ND, 2016, BRAIN INJURY, V30, P1491, DOI 10.1080/02699052.2016.1219057; de Koning ME, 2017, BRAIN INJURY, V31, P1102, DOI 10.1080/02699052.2017.1296193; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Esterov D, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7080100; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; Giola G, 2006, ACUTE CONCUSSION EVA; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Heltemes KJ, 2011, MIL MED, V176, P147, DOI 10.7205/MILMED-D-10-00191; Hoffman JM, 2011, J NEUROTRAUM, V28, P1719, DOI 10.1089/neu.2011.1914; Isokuortti H, 2016, J NEUROTRAUM, V33, P232, DOI 10.1089/neu.2015.3888; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jagoda AS, 2009, J EMERG NURS, V35, pe5, DOI DOI 10.1016/J.JEN.2008.12.010; Jodoin M, 2017, INJURY, V48, P1927, DOI 10.1016/j.injury.2017.06.025; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lucas S, 2015, BRAIN NEUROTRAUMA MO, DOI [10.1201/b18126-16, DOI 10.1201/B18126-16]; Lucas S, 2016, HEADACHE, V56, P323, DOI 10.1111/head.12762; Lucas S, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0520-1; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Pirracchio R, 2018, STAT METHODS MED RES, V27, P286, DOI 10.1177/0962280215627335; Solomon S, 2001, MED CLIN N AM, V85, P987, DOI 10.1016/S0025-7125(05)70355-2; Spielberg JM, 2015, BIOL PSYCHIAT, V78, P210, DOI 10.1016/j.biopsych.2015.02.013; Stein MB, 2016, J NEUROTRAUM, V33, P2125, DOI 10.1089/neu.2015.4320; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Theadom A, 2016, BRIT J GEN PRACT, V66, pE16, DOI 10.3399/bjgp16X683161; van der Naalt J, 2017, LANCET NEUROL, V16, P532, DOI 10.1016/S1474-4422(17)30117-5; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Walker WC, 2015, BRAIN INJURY, V29, P1581, DOI 10.3109/02699052.2015.1075151; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	42	24	24	0	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	APR 9	2019	10								343	10.3389/fneur.2019.00343			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HS6AS	WOS:000463953300001	31024436	Green Published, gold			2022-02-06	
J	Posti, JP; Takala, RSK; Lagerstedt, L; Dickens, AM; Hossain, I; Mohammadian, M; Ala-Seppala, H; Frantzen, J; van Gils, M; Hutchinson, PJ; Katila, AJ; Maanpaa, HR; Menon, DK; Newcombe, VF; Tallus, J; Hrusovsky, K; Wilson, DH; Gill, J; Sanchez, JC; Tenovuo, O; Zetterberg, H; Blennow, K				Posti, Jussi P.; Takala, Riikka S. K.; Lagerstedt, Linnea; Dickens, Alex M.; Hossain, Iftakher; Mohammadian, Mehrbod; Ala-Seppaelae, Henna; Frantzen, Janek; van Gils, Mark; Hutchinson, Peter J.; Katila, Ari J.; Maanpaeae, Henna-Riikka; Menon, David K.; Newcombe, Virginia F.; Tallus, Jussi; Hrusovsky, Kevin; Wilson, David H.; Gill, Jessica; Sanchez, Jean-Charles; Tenovuo, Olli; Zetterberg, Henrik; Blennow, Kaj			Correlation of Blood Biomarkers and Biomarker Panels with Traumatic Findings on Computed Tomography after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; computed tomography; traumatic brain injury	FIBRILLARY ACIDIC PROTEIN; SERUM NEUROFILAMENT LIGHT; PLASMA-LEVELS; CT; S100-BETA; INCREASES; DIAGNOSIS; S100B; TAU	The aim of the study was to examine the ability of eight protein biomarkers and their combinations in discriminating computed tomography (CT)-negative and CT-positive patients with traumatic brain injury (TBI), utilizing highly sensitive immunoassays in a well-characterized cohort. Blood samples were obtained from 160 patients with acute TBI within 24 h of admission. Levels of beta-amyloid isoforms 1-40 (A beta 40) and 1-42 (A beta 42), glial fibrillary acidic protein (GFAP), heart fatty-acid binding protein (H-FABP), interleukin 10 (IL-10), neurofilament light (NF-L), S100 calcium-binding protein B (S100B), and tau were measured. Patients were divided into CT-negative (n = 65) and CT-positive (n = 95), and analyses were conducted separately for TBIs of all severities (Glasgow Coma Scale [GCS] score 3-15) and mild TBIs (mTBIs; GCS 13-15). NF-L, GFAP, and tau were the best in discriminating CT-negative and CT-positive patients, both in patients with mTBI and with all severities. In patients with all severities, area under the curve of the receiver operating characteristic (AUC) was 0.822, 0.817, and 0.781 for GFAP, NF-L, and tau, respectively. In patients with mTBI, AUC was 0.720, 0.689, and 0.676, for GFAP, tau, and NF-L, respectively. The best panel of three biomarkers for discriminating CT-negative and CT-positive patients in the group of all severities was a combination of GFAP+H-FABP+IL-10, with a sensitivity of 100% and specificity of 38.5%. In patients with mTBI, the best panel of three biomarkers was H-FABP+S100B+tau, with a sensitivity of 100% and specificity of 46.4%. Panels of biomarkers outperform individual biomarkers in separating CT-negative and CT-positive patients. Panels consisted mainly of different biomarkers than those that performed best as an individual biomarker.	[Posti, Jussi P.; Hossain, Iftakher; Frantzen, Janek; Maanpaeae, Henna-Riikka] Turku Univ Hosp, Dept Neurosurg, POB 52, FI-20521 Turku, Finland; [Posti, Jussi P.; Takala, Riikka S. K.; Hossain, Iftakher; Mohammadian, Mehrbod; Ala-Seppaelae, Henna; Katila, Ari J.; Maanpaeae, Henna-Riikka; Tallus, Jussi; Tenovuo, Olli] Turku Univ Hosp, Turku Brain Injury Ctr, Turku, Finland; [Tallus, Jussi] Turku Univ Hosp, Dept Radiol, Turku, Finland; [Posti, Jussi P.; Hossain, Iftakher; Mohammadian, Mehrbod; Ala-Seppaelae, Henna; Frantzen, Janek; Maanpaeae, Henna-Riikka; Tallus, Jussi; Tenovuo, Olli] Univ Turku, Dept Neurol, Turku, Finland; [Dickens, Alex M.; Sanchez, Jean-Charles] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Takala, Riikka S. K.] Turku Univ Hosp, Perioperat Serv Intens Care Med & Pain Management, Turku, Finland; [Lagerstedt, Linnea; Katila, Ari J.] Univ Geneva, Dept Special Internal Med, Geneva, Switzerland; [van Gils, Mark] VTT Tech Res Ctr Finland Ltd, Tampere, Finland; [Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge, England; [Menon, David K.; Newcombe, Virginia F.] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge, England; [Hrusovsky, Kevin; Wilson, David H.] Quanterix Corp, Lexington, MA USA; [Gill, Jessica] NINR, NIH, Bethesda, MD 20892 USA; [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat & Neurochem, Molndal, Sweden; [Zetterberg, Henrik; Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Zetterberg, Henrik] UCL, Dept Neurodegenerat Dis, London, England; [Zetterberg, Henrik] UCL, UK Dementia Res Inst UCL, London, England		Posti, JP (corresponding author), Turku Univ Hosp, Dept Neurosurg, POB 52, FI-20521 Turku, Finland.	jussi.posti@utu.fi	Mohammadian, Mehrbod/AAH-1018-2019; Gill, Gill M/Q-2020-2017; Posti, Jussi P./Y-2908-2019; Dickens, Alex/F-8566-2013	Mohammadian, Mehrbod/0000-0002-6851-7511; Posti, Jussi P./0000-0002-5925-5193; Hossain, Iftakher/0000-0003-4836-1158; van Gils, Mark/0000-0002-0029-1771; Hutchinson, Peter/0000-0002-2796-1835; Dickens, Alex/0000-0002-3178-8449; Ala-Seppala, Henna/0000-0002-1577-3028; Newcombe, Virginia/0000-0001-6044-9035	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [FP7-270259-TBIcare]; Emil Aaltonen Foundation; Finnish Brain Foundation; Integra EANS Research Grant; University of Turku Graduate School; NIHR Research Professorship; NIHR Cambridge BRC; NIHR Research UK; Academy of Medical Sciences/The Health Foundation Clinician Scientist Fellowship; Wallenberg Academy Fellowship; Swedish and European Research Councils; Torsten Soderberg Professorship in Medicine - Royal Swedish Academy of Sciences; Swedish Research CouncilSwedish Research CouncilEuropean Commission; Government's Special Financial Transfer tied to academic research in Health Sciences (Finland); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390, G0600986, G0601025, G1002277, G0502030] Funding Source: UKRI	This work was partially funded by the European Commission under the 7th Framework Programme (FP7-270259-TBIcare), Government's Special Financial Transfer tied to academic research in Health Sciences (Finland) (JPP), Emil Aaltonen Foundation (JPP), Finnish Brain Foundation (JPP), Integra EANS Research Grant (IH), University of Turku Graduate School funding (MM), NIHR Research Professorship and the NIHR Cambridge BRC (PJH), NIHR Research UK (through a Senior Investigator Award and the Cambridge Biomedical Research Centre) (DKM), Academy of Medical Sciences/The Health Foundation Clinician Scientist Fellowship (VFN); Wallenberg Academy Fellowship and grants from the Swedish and European Research Councils (HZ), Torsten Soderberg Professorship in Medicine, award by the Royal Swedish Academy of Sciences, grants from the Swedish Research Council (KB).	Ala-Seppala H., 2016, BRAIN INJURY, P30; Bazarian JJ, 2018, LANCET NEUROL, V17, P782, DOI 10.1016/S1474-4422(18)30231-X; Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Bogoslovsky T, 2017, J NEUROTRAUM, V34, P66, DOI 10.1089/neu.2015.4333; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Hainard A, 2013, TRANSLANT PROTEOMICS, V1, P57, DOI [10.1016/J.TRPROT.2013.04.003, DOI 10.1016/J.TRPROT.2013.04.003, 10.1016/j.trprot.2013.04.003]; Hasselblatt M, 2004, NEUROLOGY, V62, P1634, DOI 10.1212/01.WNL.0000123092.97047.B1; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; HODGKINSON S, 2014, BMJ-BRIT MED J, V348, DOI DOI 10.1136/BMJ.G104; Isokuortti H, 2014, INJURY, V45, P1340, DOI 10.1016/j.injury.2014.04.012; Kasper C.E., 2015, TRAUMATIC BRAIN INJU; Lagerstedt L, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193278; Lagerstedt L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175572; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Ljungqvist J, 2017, J NEUROTRAUM, V34, P1124, DOI 10.1089/neu.2016.4496; Luoto TM, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00652; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Missler U, 1999, CLIN CHEM, V45, P138; Ohrt-Nissen S, 2011, EMERG MED J, V28, P941, DOI 10.1136/emj.2010.091363; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Posti J.P., 2016, NEUROSURGERY, P79; Posti J.P., 2017, J NEUROTRAUM, P34; Rubenstein R, 2017, JAMA NEUROL, V74, P1063, DOI 10.1001/jamaneurol.2017.0655; Ruopp MD, 2008, BIOMETRICAL J, V50, P419, DOI 10.1002/bimj.200710415; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Smits M, 2007, RADIOLOGY, V245, P831, DOI 10.1148/radiol.2452061509; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sweeney T.E., 2015, WORLD J EMERG SURG, P10; Takala RSK, 2016, WORLD NEUROSURG, V87, P8, DOI 10.1016/j.wneu.2015.10.066; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Welch RD, 2017, J NEUROTRAUM, V34, P1957, DOI 10.1089/neu.2016.4772; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Wilson DH, 2016, JALA-J LAB AUTOM, V21, P533, DOI 10.1177/2211068215589580	40	24	25	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 15	2019	36	14					2178	2189		10.1089/neu.2018.6254		APR 2019	12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	IH1NO	WOS:000463593400001	30760178	Green Submitted, Green Published			2022-02-06	
J	Bar-Or, D; Rael, LT; Madayag, RM; Banton, KL; Tanner, A; Acuna, DL; Lieser, MJ; Marshall, GT; Mains, CW; Brody, E				Bar-Or, David; Rael, Leonard T.; Madayag, Robert M.; Banton, Kaysie L.; Tanner, Allen, II; Acuna, David L.; Lieser, Mark J.; Marshall, Gary T.; Mains, Charles W.; Brody, Edward			Stress Hyperglycemia in Critically Ill Patients: Insight Into Possible Molecular Pathways	FRONTIERS IN MEDICINE			English	Article						sepsis; Warburg effect; hyperglycemia; glycolysis; oxidative phosphorylation; dipeptidyl peptidase IV	INTENSIVE INSULIN THERAPY; CD26/DIPEPTIDYL PEPTIDASE IV; GLUCOSE-METABOLISM; LACTATE; MORTALITY; DYSFUNCTION; INHIBITION; GLYCOLYSIS; EXPRESSION; SUCCINATE	Severe sepsis, systemic inflammatory response syndrome (SIRS), and traumatic brain injury are frequently associated with hyperglycemia in non-diabetic patients. In patients suffering from any of these conditions, hyperglycemia at admission to an intensive care unit (ICU) is directly correlated with increased mortality or morbidity. Although there was initial enthusiasm for insulin treatment to blood glucose levels below 110 mg/dL in these patients, recent understanding suggests that the potential for hypoglycemic complications make this approach potentially dangerous. More moderate glucose control seems to be more beneficial than the aggressive glucose lowering initially suggested. An important publication has shown that hyperlactatemia accompanying hyperglycemia could be the real culprit in bad outcomes. This suggests that coupling moderate glucose lowering with therapeutic agents which might treat the underlying metabolic disturbances in these conditions may be a better strategy. The key metabolic disturbance in these three conditions seems to be persistent glycolysis as an energy source even in the presence of adequate tissue oxygenation (the Warburg Effect). We look at recent advances in understanding aerobic glycolysis and possibly the action of DPP4 on incretins resulting in insulin dysregulation and suggest key metabolic pathways involved in hyperglycemia regulation.	[Bar-Or, David; Rael, Leonard T.; Banton, Kaysie L.] Swedish Med Ctr, Trauma Res Lab, Englewood, CO 80110 USA; [Bar-Or, David; Madayag, Robert M.; Mains, Charles W.] St Anthony Hosp, Lakewood, CO 80228 USA; [Bar-Or, David; Tanner, Allen, II] Penrose Community Hosp, Colorado Springs, CO 80907 USA; [Bar-Or, David; Acuna, David L.] Wesley Med Ctr, Wichita, KS 67214 USA; [Bar-Or, David; Lieser, Mark J.] Res Med Ctr, Kansas City, MO 64132 USA; [Bar-Or, David; Marshall, Gary T.] Med City Plano Hosp, Plano, TX 75075 USA; [Brody, Edward] SomaLogic Inc, Boulder, CO USA		Bar-Or, D (corresponding author), Swedish Med Ctr, Trauma Res Lab, Englewood, CO 80110 USA.; Bar-Or, D (corresponding author), St Anthony Hosp, Lakewood, CO 80228 USA.; Bar-Or, D (corresponding author), Penrose Community Hosp, Colorado Springs, CO 80907 USA.; Bar-Or, D (corresponding author), Wesley Med Ctr, Wichita, KS 67214 USA.; Bar-Or, D (corresponding author), Res Med Ctr, Kansas City, MO 64132 USA.; Bar-Or, D (corresponding author), Med City Plano Hosp, Plano, TX 75075 USA.	davidbme49@gmail.com	Bar-Or, David/AAE-9328-2020				Abrahami D, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k872; Bar-Or D, 2018, J CRIT CARE, V43, P197, DOI 10.1016/j.jcrc.2017.09.012; Barth E, 2007, CRIT CARE MED, V35, pS508, DOI 10.1097/01.CCM.0000278047.06965.20; Bochicchio Grant V, 2008, Adv Surg, V42, P261, DOI 10.1016/j.yasu.2008.03.006; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Chen J, 2011, ONCOGENE, V30, P4297, DOI 10.1038/onc.2011.137; Choi CS, 2002, AM J PHYSIOL-ENDOC M, V283, pE233, DOI 10.1152/ajpendo.00557.2001; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Dienel GA, 2012, J CEREBR BLOOD F MET, V32, P1107, DOI 10.1038/jcbfm.2011.175; Douzinas EE, 1997, AM J RESP CRIT CARE, V155, P53, DOI 10.1164/ajrccm.155.1.9001289; Durinx C, 2000, EUR J BIOCHEM, V267, P5608, DOI 10.1046/j.1432-1327.2000.01634.x; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; FLENTKE GR, 1991, P NATL ACAD SCI USA, V88, P1556, DOI 10.1073/pnas.88.4.1556; Flierl MA, 2007, NATURE, V449, P721, DOI 10.1038/nature06185; Green JP, 2012, ACAD EMERG MED, V19, P1268, DOI 10.1111/acem.12015; Hatwal Amitabh, 2012, Indian J Endocrinol Metab, V16, pS239, DOI 10.4103/2230-8210.104049; Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68; Kim SC, 2015, ANN RHEUM DIS, V74, P1968, DOI 10.1136/annrheumdis-2014-205216; Koivunen P, 2007, J BIOL CHEM, V282, P4524, DOI 10.1074/jbc.M610415200; Koska Juraj, 2012, Cardiovascular & Hematological Agents in Medicinal Chemistry, V10, P295; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Levraut J, 2003, CRIT CARE MED, V31, P705, DOI 10.1097/01.CCM.0000045561.85810.45; Levy B, 2006, CURR OPIN CRIT CARE, V12, P315, DOI 10.1097/01.ccx.0000235208.77450.15; Lombardi AM, 1999, AM J PHYSIOL-ENDOC M, V276, pE922, DOI 10.1152/ajpendo.1999.276.5.E922; Nemoto E, 1999, INFECT IMMUN, V67, P6225; Osterbur K, 2014, J VET INTERN MED, V28, P1141, DOI 10.1111/jvim.12364; Revelly JP, 2005, CRIT CARE MED, V33, P2235, DOI 10.1097/01.CCM.0000181525.99295.8F; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Shestov AA, 2014, ELIFE, V3, DOI 10.7554/eLife.03342; Shi J, 2016, ONCOTARGET, V7, P71052, DOI 10.18632/oncotarget.11958; Simpson IA, 2007, J CEREBR BLOOD F MET, V27, P1766, DOI 10.1038/sj.jcbfm.9600521; Sperry JL, 2007, J TRAUMA, V63, P487, DOI 10.1097/TA.0b013e31812e51fc; Stapleton RD, 2018, GLYCEMIC CONTROL INT; Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; van Niekerk G, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1775-1; Whitcomb BW, 2005, CRIT CARE MED, V33, P2772, DOI 10.1097/01.CCM.0000189741.44071.25; Yang LC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5436	41	24	24	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		2296-858X		FRONT MED-LAUSANNE	Front. Med.	MAR 27	2019	6								54	10.3389/fmed.2019.00054			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HQ8DP	WOS:000462654500002	30972338	gold, Green Published			2022-02-06	
J	Chao, LL				Chao, Linda L.			Effects of Home Photobiomodulation Treatments on Cognitive and Behavioral Function, Cerebral Perfusion, and Resting-State Functional Connectivity in Patients with Dementia: A Pilot Trial	PHOTOBIOMODULATION PHOTOMEDICINE AND LASER SURGERY			English	Article						dementia; Alzheimer's disease; photobiomodulation; LED; neuroimaging	MILD ALZHEIMERS-DISEASE; TRAUMATIC BRAIN-INJURY; DEFAULT-MODE NETWORK; LEVEL LIGHT THERAPY; BLOOD-FLOW; QUANTITATIVE-ANALYSIS; DONEPEZIL; IMPAIRMENT; FMRI; INCREASE	Objective: To examine the effects of transcranial and intranasal photobiomodulation (PBM) therapy, administered at home, in patients with dementia. Background: This study sought to replicate and build upon a previously published case series report describing improved cognitive function in five patients with mild-to-moderate dementia after 12 weeks of transcranial and intranasal near-infrared (NIR) PBM therapy. Materials and methods: Eight participants (mean age: 79.8 +/- 5.8 years old) diagnosed with dementia by their physicians were randomized to 12 weeks of usual care (UC, n = 4) or home PBM treatments (n = 4). The NIR PBM treatments were administered by a study partner at home three times per week with the Vielight Neuro Gamma device. The participants were assessed with the Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog) subscale and the Neuropsychiatric Inventory (NPI) at baseline and 6 and 12 weeks, and with arterial spin-labeled perfusion magnetic resonance imaging ( MRI) and resting-state functional MRI at baseline and 12 weeks. Results: At baseline, the UC and PBM groups did not differ demographically or clinically. However, after 12 weeks, there were improvements in ADAS-cog (group x time interaction: F-1.6 = 16.35, p = 0.007) and NPI (group x time interaction: F-1.6 = 7.52, p = 0.03), increased cerebral perfusion (group x time interaction: F-1,F-6 = 8.46, p < 0.03), and increased connectivity between the posterior cingulate cortex and lateral parietal nodes within the default-mode network in the PBM group. Conclusions: Because PBM was well tolerated and associated with no adverse side effects, these results support the potential of PBM therapy as a viable home treatment for individuals with dementia.	[Chao, Linda L.] San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, 4150 Clement St 114M, San Francisco, CA 94121 USA; [Chao, Linda L.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA USA; [Chao, Linda L.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA		Chao, LL (corresponding author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis, 4150 Clement St 114M, San Francisco, CA 94121 USA.	linda.chao@ucsf.edu					Alsop DC, 2000, ANN NEUROL, V47, P93, DOI 10.1002/1531-8249(200001)47:1<93::AID-ANA15>3.3.CO;2-#; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Asllani I, 2008, J CEREBR BLOOD F MET, V28, P725, DOI 10.1038/sj.jcbfm.9600570; Bai F, 2009, BRAIN RES, V1302, P167, DOI 10.1016/j.brainres.2009.09.028; Birks JS, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001190.pub3; Blautzik J, 2016, EUR NEUROPSYCHOPHARM, V26, P602, DOI 10.1016/j.euroneuro.2015.12.006; Cassano P, 2016, NEUROPHOTONICS, V3, DOI 10.1117/1.NPh.3.3.031404; Chen NK, 2003, NEUROIMAGE, V19, P817, DOI 10.1016/S1053-8119(03)00091-0; Chetelat G, 2003, BRAIN, V126, P1955, DOI 10.1093/brain/awg196; Chirles TJ, 2017, J ALZHEIMERS DIS, V57, P845, DOI 10.3233/JAD-161151; Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S; Dai WY, 2009, RADIOLOGY, V250, P856, DOI 10.1148/radiol.2503080751; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Deardorff WJ, 2015, DRUG AGING, V32, P537, DOI 10.1007/s40266-015-0273-x; Dennis EL, 2014, NEUROPSYCHOL REV, V24, P49, DOI 10.1007/s11065-014-9249-6; Detre JA, 1999, EUR J RADIOL, V30, P115, DOI 10.1016/S0720-048X(99)00050-9; Ding B, 2014, CLIN INTERV AGING, V9, P493, DOI 10.2147/CIA.S58879; Farlow MR, 2013, CNS NEUROSCI THER, V19, P745, DOI 10.1111/cns.12158; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Goveas JS, 2011, J MAGN RESON IMAGING, V34, P764, DOI 10.1002/jmri.22662; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Grillo SL, 2013, J PHOTOCH PHOTOBIO B, V123, P13, DOI 10.1016/j.jphotobiol.2013.02.015; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hamblin MR, 2016, BBA CLIN, V6, P113, DOI 10.1016/j.bbacli.2016.09.002; Iaccarino HF, 2016, NATURE, V540, P230, DOI 10.1038/nature20587; Jagdeo JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047460; Johnson NA, 2005, RADIOLOGY, V234, P851, DOI 10.1148/radiol.2343040197; Karu TI, 2008, PHOTOCHEM PHOTOBIOL, V84, P1091, DOI 10.1111/j.1751-1097.2008.00394.x; Li WJ, 2012, NEUROIMAGE, V60, P1083, DOI 10.1016/j.neuroimage.2011.12.077; Lorenzi M, 2011, DRUG AGING, V28, P205, DOI 10.2165/11586440-000000000-00000; Lustig C, 2003, P NATL ACAD SCI USA, V100, P14504, DOI 10.1073/pnas.2235925100; Mangialasche F, 2010, LANCET NEUROL, V9, P702, DOI 10.1016/S1474-4422(10)70119-8; Mayeux R, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006239; Mazza M, 2011, J ALZHEIMERS DIS, V23, P375, DOI 10.3233/JAD-2010-090700; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Mevel Katell, 2011, Int J Alzheimers Dis, V2011, P535816, DOI 10.4061/2011/535816; Morries LD, 2015, NEUROPSYCH DIS TREAT, V11, P2159, DOI 10.2147/NDT.S65809; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Nawashiro H, 2012, PHOTOMED LASER SURG, V30, P231, DOI 10.1089/pho.2011.3044; Nobili F, 2002, CLIN NEUROPHYSIOL, V113, P1241, DOI 10.1016/S1388-2457(02)00110-4; Ojemann JG, 1997, NEUROIMAGE, V6, P156, DOI 10.1006/nimg.1997.0289; Perl DP, 2010, MT SINAI J MED, V77, P32, DOI 10.1002/msj.20157; Petrella JR, 2011, NEUROLOGY, V76, P511, DOI 10.1212/WNL.0b013e31820af94e; Purushothuman S, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt232; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Rojas JC, 2012, J ALZHEIMERS DIS, V32, P741, DOI 10.3233/JAD-2012-120817; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Saltmarche AE, 2017, PHOTOMED LASER SURG, V35, P432, DOI 10.1089/pho.2016.4227; SCHAPIRO MB, 1993, J NEUROL NEUROSUR PS, V56, P859, DOI 10.1136/jnnp.56.8.859; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Sole-Padulles C, 2013, J CLIN PSYCHOPHARM, V33, P199, DOI 10.1097/JCP.0b013e3182825bfd; Sommer AP, 2012, PHOTOMED LASER SURG, V30, P54, DOI 10.1089/pho.2011.3073; Sorg C, 2007, P NATL ACAD SCI USA, V104, P18760, DOI 10.1073/pnas.0708803104; Staff RT, 2000, NUCL MED COMMUN, V21, P37, DOI 10.1097/00006231-200001000-00007; Stefanova E, 2006, J NEURAL TRANSM, V113, P205, DOI 10.1007/s00702-005-0312-6; Suo C, 2016, MOL PSYCHIATR, V21, P1645, DOI 10.1038/mp.2016.57; Tedford CE, 2015, LASER SURG MED, V47, P312, DOI 10.1002/lsm.22343; Tian FH, 2016, LASER SURG MED, V48, P343, DOI 10.1002/lsm.22471; Uozumi Y, 2010, LASER SURG MED, V42, P566, DOI 10.1002/lsm.20938; Vemuri P, 2012, ALZHEIMERS RES THER, V4, DOI 10.1186/alzrt100; Venneri A, 2002, NEUROREPORT, V13, P83, DOI 10.1097/00001756-200201210-00020; Wang K, 2007, HUM BRAIN MAPP, V28, P967, DOI 10.1002/hbm.20324; Wells RE, 2013, J AM GERIATR SOC, V61, P642, DOI 10.1111/jgs.12179; Weyer G, 1997, Int Psychogeriatr, V9, P123, DOI 10.1017/S1041610297004298; Whitfield-Gabrieli S, 2012, BRAIN CONNECT, V2, P125, DOI 10.1089/brain.2012.0073; Wilcock G, 2003, DRUG AGING, V20, P777, DOI 10.2165/00002512-200320100-00006; Wilcock GK, 2000, BRIT MED J, V321, P1445, DOI 10.1136/bmj.321.7274.1445; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Yoshiura T, 2009, AM J NEURORADIOL, V30, P1388, DOI 10.3174/ajnr.A1562; Zhang HY, 2009, BEHAV BRAIN RES, V197, P103, DOI 10.1016/j.bbr.2008.08.012	73	24	24	4	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA		2578-5478		PHOTOBIOMODULATION P	Photobiomodulation Photomed. Laser Surg.	MAR	2019	37	3					133	141		10.1089/photob.2018.4555			9	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	JD0SZ	WOS:000489687900002	31050950				2022-02-06	
J	Corley, J; Lepard, J; Barthelemy, E; Ashby, JL; Park, KB				Corley, Jacquelyn; Lepard, Jacob; Barthelemy, Ernest; Ashby, Joanna L.; Park, Kee B.			Essential Neurosurgical Workforce Needed to Address Neurotrauma in Low- and Middle-Income Countries	WORLD NEUROSURGERY			English	Article						Global neurosurgery; Low-and middle-income countries; Neurotrauma; Traumatic brain injury; Traumatic spinal injury	SURGICAL CARE; EMERGENCY NEUROSURGERY; MODELING STRATEGY; GENERAL SURGEONS; ACCESS; HEALTH	BACKGROUND: Among all trauma-related injuries globally, traumatic brain injury (TBI) and traumatic spine injury (TSI) account for the largest proportion of cases. Where previously data was lacking, recent efforts have been initiated to better quantify the extent of neurotrauma in low-and middle-income countries (LMICs). This information is vital to understand the current neurosurgical deficit so that resources and efforts can be focused on where they are needed most. The purpose of this study is to determine the minimum number of neurosurgeons to address the neurotrauma demand in LMICs and evaluate current evidence to support facility needs so that policy-based recommendations can be made to prioritize development initiatives to scale up neurosurgical services. METHODS: Using existing data regarding the incidence of TBI and TSI in LMICs and current neurosurgical workforce and estimates of case load capacity, the minimum number of neurosurgeons needed to address neurotrauma per population was calculated. Evidence was gathered regarding necessary hospital facilities and disbursement patterns based on time needed to intervene effectively for neurotrauma. RESULTS: There are 4,897,139 total operative cases of TBI and TSI combined in LMICs annually. At minimum, there needs to be 1 neurosurgeon only performing neurotrauma cases per approximately 212,000 people. Evidence suggests that patients should be within 4 hours of a neurosurgical facility at the very least. CONCLUSIONS: The development of neurotrauma systems is essential to address the large burden of neurotrauma in LMICs. The minimum requirements for neurosurgical workforce is 1 neurotrauma surgeon per 212,000 people.	[Corley, Jacquelyn; Lepard, Jacob; Barthelemy, Ernest; Ashby, Joanna L.; Park, Kee B.] Harvard Med Sch, Global Neurosurg Initiat, Program Global Surg & Social Change, Boston, MA 02115 USA; [Corley, Jacquelyn] Duke Dept Neurosurg, Durham, NC 27704 USA; [Lepard, Jacob] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA; [Lepard, Jacob] Boston Childrens Hosp, Boston, MA USA; [Barthelemy, Ernest] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA; [Ashby, Joanna L.] Univ Glasgow, Med Sch, Glasgow, Lanark, Scotland		Corley, J (corresponding author), Harvard Med Sch, Global Neurosurg Initiat, Program Global Surg & Social Change, Boston, MA 02115 USA.; Corley, J (corresponding author), Duke Dept Neurosurg, Durham, NC 27704 USA.	jacorley21@gmail.com					Albutt K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195986; Alkire BC, 2015, LANCET GLOB HEALTH, V3, pE316, DOI 10.1016/S2214-109X(15)70115-4; Bagan M, 2010, WORLD NEUROSURG, V73, P289, DOI 10.1016/j.wneu.2010.03.007; Cairo SB, 2018, PEDIATR SURG INT, V34, P467, DOI 10.1007/s00383-018-4238-0; Chao TE, 2015, WORLD J SURG, V39, P2140, DOI 10.1007/s00268-014-2905-4; Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500; El Khamlichi Abdeslam, 2014, World Neurosurg, V81, P234, DOI 10.1016/j.wneu.2013.10.051; Esquivel MM, 2016, JAMA SURG, V151, P1064, DOI 10.1001/jamasurg.2016.2303; Haglund MM, 2011, WORLD J SURG, V35, P1175, DOI 10.1007/s00268-011-1080-0; Kanyi JK, 2018, WORLD J SURG, V42, P40, DOI 10.1007/s00268-017-4143-z; Kempthorne P, 2017, ANESTH ANALG, V125, P981, DOI 10.1213/ANE.0000000000002258; Kumar R, 2018, WORLD NEUROSURG, V113, pE345, DOI 10.1016/j.wneu.2018.02.033; Luck T, 2015, ANZ J SURG, V85, P610, DOI 10.1111/ans.13138; Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X; Muniz SA, 2017, J TRAUMA NURS, V24, P306, DOI 10.1097/JTN.0000000000000310; Rose J, 2015, LANCET GLOB HEALTH, V3, pS13, DOI 10.1016/S2214-109X(15)70087-2; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Santos MM, 2018, WORLD NEUROSURG, V113, P425, DOI 10.1016/j.wneu.2018.01.084; Treacy PJ, 2005, ANZ J SURG, V75, P852, DOI 10.1111/j.1445-2197.2005.03549.x; Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8; World Health Organization, 2008, TASK SHIFT GLOB REC	21	24	24	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAR	2019	123						295	299		10.1016/j.wneu.2018.12.042			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	HR2II	WOS:000462958400151	30579006				2022-02-06	
J	Mocelin, R; Marcon, M; D'ambros, S; Mattos, J; Sachett, A; Siebel, AM; Herrmann, AP; Piato, A				Mocelin, Ricieri; Marcon, Matheus; D'ambros, Simone; Mattos, Juliane; Sachett, Adrieli; Siebel, Anna M.; Herrmann, Ana P.; Piato, Angelo			N-Acetylcysteine Reverses Anxiety and Oxidative Damage Induced by Unpredictable Chronic Stress in Zebrafish	MOLECULAR NEUROBIOLOGY			English	Article						N-acetylcysteine; Unpredictable chronic stress; Behavior; Oxidative status; Zebrafish	MANGANESE SUPEROXIDE-DISMUTASE; NEURODEGENERATIVE DISEASES; NITRIC-OXIDE; BRAIN-INJURY; MILD STRESS; DISORDERS; BEHAVIOR; DEPRESSION; INFLAMMATION; MECHANISMS	There is accumulating evidence on the use of N-acetylcysteine (NAC) in the treatment of patients with neuropsychiatric disorders. As a multi-target drug and a glutathione precursor, NAC is a promising molecule in the management of stress-related disorders, for which there is an expanding field of research investigating novel therapies targeting oxidative pathways. The deleterious effects of chronic stress in the central nervous system are a result of glutamatergic hyperactivation, glutathione (GSH) depletion, oxidative stress, and increased inflammatory response, among others. The aim of this study was to investigate the effects of NAC in zebrafish submitted to unpredictable chronic stress (UCS). Animals were initially stressed or not for 7days, followed by treatment with NAC (1mg/L, 10min) or vehicle for 7days. UCS decreased the number of entries and time spent in the top area in the novel tank test, which indicate increased anxiety levels. It also increased reactive oxygen species (ROS) levels and lipid peroxidation (TBARS) while decreased non-protein thiols (NPSH) and superoxide dismutase (SOD) activity. NAC reversed the anxiety-like behavior and oxidative damage observed in stressed animals. Additional studies are needed to investigate the effects of this agent on glutamatergic modulation and inflammatory markers related to stress. Nevertheless, our study adds to the existing body of evidence supporting the clinical evaluation of NAC in mood disorders, anxiety, post-traumatic stress disorder, and other conditions associated with stress.	[Mocelin, Ricieri; Marcon, Matheus; D'ambros, Simone; Mattos, Juliane; Sachett, Adrieli; Piato, Angelo] Univ Fed Rio Grande do Sul, Programa Posgrad Neurociencias, ICBS, Rua Sarmento Leite 500-305, BR-90050170 Porto Alegre, RS, Brazil; [Herrmann, Ana P.] Univ Fed Rio Grande do Sul, Programa Posgrad Farmacol & Terapeut, Rua Sarmento Leite 500-305, BR-90050170 Porto Alegre, RS, Brazil; [Siebel, Anna M.] Univ Comunitaria Regiao Chapeco, Programa Posgrad Ciencias Ambientais, Ave Senador Atilio Fontana 591E, BR-89809000 Chapeco, SC, Brazil; [Piato, Angelo] ZNRC, 309 Palmer Court, Slidell, LA 70458 USA		Piato, A (corresponding author), Univ Fed Rio Grande do Sul, Programa Posgrad Neurociencias, ICBS, Rua Sarmento Leite 500-305, BR-90050170 Porto Alegre, RS, Brazil.; Piato, A (corresponding author), ZNRC, 309 Palmer Court, Slidell, LA 70458 USA.	angelopiato@ufrgs.br	Sachett, Adrieli/AAD-7020-2022; Siebel, Anna Maria/Y-7933-2019; Marcon, Matheus/L-1880-2018; Piato, Angelo/K-3444-2012; Herrmann, Ana Paula/F-3694-2011; Siebel, Anna M/D-1020-2013; Mocelin, Ricieri Naue/E-4814-2015	Siebel, Anna Maria/0000-0002-7896-1456; Marcon, Matheus/0000-0002-1486-688X; Piato, Angelo/0000-0001-5109-7306; Herrmann, Ana Paula/0000-0002-0330-0741; Siebel, Anna M/0000-0002-7896-1456; Mocelin, Ricieri Naue/0000-0001-7210-1247; Sachett, Adrieli/0000-0003-1058-6888; Mattos, Juliane/0000-0001-9520-8098	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [401162/2016-8, 302800/2017-4]; Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS)Fundacao de Amparo a Ciencia e Tecnologia do Estado do Rio Grande do Sul (FAPERGS) [17/2551-0000974-6]	This work was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, Brazil (CNPq, Proc. 401162/2016-8 and 302800/2017-4) and Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS, Proc. 17/2551-0000974-6).	Aschbacher K, 2013, PSYCHONEUROENDOCRINO, V38, P1698, DOI 10.1016/j.psyneuen.2013.02.004; Barnham KJ, 2004, NAT REV DRUG DISCOV, V3, P205, DOI 10.1038/nrd1330; Barreiro E, 2005, EUR RESPIR J, V26, P1032, DOI 10.1183/09031936.05.00003705; Bencan Z, 2009, PHARMACOL BIOCHEM BE, V94, P75, DOI 10.1016/j.pbb.2009.07.009; Berk M, 2014, J CLIN PSYCHIAT, V75, P628, DOI 10.4088/JCP.13m08454; Berk M, 2013, TRENDS PHARMACOL SCI, V34, P167, DOI 10.1016/j.tips.2013.01.001; Biala G, 2018, MOL NEUROBIOL, V55, P3270, DOI 10.1007/s12035-017-0585-4; Biala G, 2017, MOL NEUROBIOL, V54, P904, DOI 10.1007/s12035-016-9701-0; Cacciatore I, 2010, MOLECULES, V15, P1242, DOI 10.3390/molecules15031242; Chen S, 2014, NEUROPATH APPL NEURO, V40, P759, DOI 10.1111/nan.12103; Chen T, 2016, INFLAMMATION, V39, P483, DOI 10.1007/s10753-015-0272-4; Chrousos GP, 2009, NAT REV ENDOCRINOL, V5, P374, DOI 10.1038/nrendo.2009.106; Cummings JL, 2006, NAT REV DRUG DISCOV, V5, P64, DOI 10.1038/nrd1928; de Andrade KQ, 2015, INT J MOL SCI, V16, P30269, DOI 10.3390/ijms161226225; Dean O, 2011, J PSYCHIATR NEUROSCI, V36, P78, DOI 10.1503/jpn.100057; Deepmala, 2015, NEUROSCI BIOBEHAV R, V55, P294, DOI 10.1016/j.neubiorev.2015.04.015; Duman RS, 2016, NAT MED, V22, P238, DOI 10.1038/nm.4050; Fernandes BS, 2016, J CLIN PSYCHIAT, V77, pE457, DOI 10.4088/JCP.15r09984; Filipovic D, 2009, GEN PHYSIOL BIOPHYS, V28, P53; Ortiz GG, 2017, ADV PROTEIN CHEM STR, V108, P1, DOI 10.1016/bs.apcsb.2017.01.003; Gawali NB, 2017, BRAIN RES, V1663, P66, DOI 10.1016/j.brainres.2017.03.004; Gunther M, 2015, J CLIN NEUROSCI, V22, P1477, DOI 10.1016/j.jocn.2015.03.025; Herrmann AP, 2014, SCHIZOPHR RES, V155, P109, DOI 10.1016/j.schres.2014.03.012; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Kalueff A., 2017, RIGHTS WRONGS ZEBRAF, DOI [10.1007/978-3-319-33774-6_3, DOI 10.1007/978-3-319-33774-6_3]; Keller JN, 1998, J NEUROSCI, V18, P687; Kowalczyk-Pachel D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147238; Kumar B, 2011, PSYCHOPHARMACOLOGY, V214, P819, DOI 10.1007/s00213-010-2094-2; Kysil EV, 2017, ZEBRAFISH, V14, P197, DOI 10.1089/zeb.2016.1415; MacMillan-Crow LA, 1998, BIOCHEMISTRY-US, V37, P1613, DOI 10.1021/bi971894b; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P676, DOI 10.1016/j.pnpbp.2010.05.004; Mao GW, 2016, MOL BIOL REP, V43, P31, DOI 10.1007/s11033-015-3935-1; Marcon M, 2018, J EXP BIOL, V221, DOI 10.1242/jeb.176735; Marcon M, 2016, PSYCHOPHARMACOLOGY, V233, P3815, DOI 10.1007/s00213-016-4408-5; Miller AH, 2016, NAT REV IMMUNOL, V16, P22, DOI 10.1038/nri.2015.5; Minarini A, 2017, EXPERT OPIN DRUG MET, V13, P279, DOI 10.1080/17425255.2017.1251580; Mocelin R, 2018, NEUROCHEM RES, V43, P458, DOI 10.1007/s11064-017-2442-2; Mocelin R, 2015, PHARMACOL BIOCHEM BE, V139, P121, DOI 10.1016/j.pbb.2015.08.006; Muller TE, 2017, PROG NEURO-PSYCHOPH, V79, P105, DOI 10.1016/j.pnpbp.2017.05.026; Musazzi L, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/8389737; Nagata K, 2007, RESP MED, V101, P800, DOI 10.1016/j.rmed.2006.07.017; Niedzielska E, 2016, MOL NEUROBIOL, V53, P4094, DOI 10.1007/s12035-015-9337-5; Olivenza R, 2000, J NEUROCHEM, V74, P785, DOI 10.1046/j.1471-4159.2000.740785.x; Park CS, 2015, ELIFE, V4, DOI 10.7554/eLife.10829; Peterlik D, 2016, CURR NEUROPHARMACOL, V14, P514, DOI 10.2174/1570159X13666150515234920; Piato AL, 2011, PROG NEURO-PSYCHOPH, V35, P561, DOI 10.1016/j.pnpbp.2010.12.018; Pittman J., 2017, RIGHTS WRONGS ZEBRAF, P33, DOI [10.1007/978-3-319-33774-6_2, DOI 10.1007/978-3-319-33774-6_2]; Popoli M, 2012, NAT REV NEUROSCI, V13, P22, DOI 10.1038/nrn3138; Rambo CL, 2017, PHYSIOL BEHAV, V171, P50, DOI 10.1016/j.physbeh.2016.12.032; Sandi C, 2015, NAT REV NEUROSCI, V16, P290, DOI 10.1038/nrn3918; Santos P, 2017, BEHAV BRAIN RES, V317, P461, DOI 10.1016/j.bbr.2016.10.010; Schneider R, 2017, NEUROCHEM RES, V42, P2135, DOI 10.1007/s11064-017-2218-8; Schneider R, 2015, ALCOHOL, V49, P259, DOI 10.1016/j.alcohol.2015.01.009; Shahripour RB, 2014, BRAIN BEHAV, V4, P108, DOI 10.1002/brb3.208; SLOT JW, 1986, LAB INVEST, V55, P363; Song C, 2018, PROG NEURO-PSYCHOPH, V81, P384, DOI 10.1016/j.pnpbp.2017.08.021; Thakur T, 2017, INT IMMUNOPHARMACOL, V50, P236, DOI 10.1016/j.intimp.2017.07.002; Weydert CJ, 2010, NAT PROTOC, V5, P51, DOI 10.1038/nprot.2009.197; Yang YY, 2008, J HEPATOL, V49, P25, DOI 10.1016/j.jhep.2008.02.012	59	24	24	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	FEB	2019	56	2					1188	1195		10.1007/s12035-018-1165-y			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	HN8TY	WOS:000460470300029	29876880				2022-02-06	
J	Wang, HHE; Campbell-Sills, L; Kessler, RC; Sun, XY; Heeringa, SG; Nock, MK; Ursano, RJ; Jain, S; Stein, MB				Wang, Hohui E.; Campbell-Sills, Laura; Kessler, Ronald C.; Sun, Xiaoying; Heeringa, Steven G.; Nock, Matthew K.; Ursano, Robert J.; Jain, Sonia; Stein, Murray B.			Pre-deployment insomnia is associated with post-deployment post-traumatic stress disorder and suicidal ideation in US Army soldiers	SLEEP			English	Article						insomnia; sleep disturbance; suicide; PTSD; military personnel; deployment; stress	TRAUMATIC BRAIN-INJURY; SLEEP DISTURBANCES; ASSESS RISK; PSYCHIATRIC MORBIDITY; PTSD SYMPTOMS; MILITARY; RESILIENCE; NIGHTMARES; IMPACT; PREDICTORS	Study Objectives: Insomnia is prevalent among military personnel and may increase risk of mental disorders and suicidal ideation. This study examined associations of pre-deployment insomnia with post-deployment post-traumatic stress disorder (PTSD) and suicidal ideation among US Army soldiers. Methods: Soldiers from three Brigade Combat Teams completed surveys 1-2 months before deploying to Afghanistan in 2012 (T0), on return from deployment (T1), 3 months later (T2), and 9 months later (T3). Logistic regression was performed to estimate associations of pre-deployment (T0) insomnia with post-deployment (T2 or T3) PTSD and suicidal ideation among respondents who completed surveys at all waves (n = 4645). A hierarchy of models incorporated, increasing controls for pre-deployment risk factors and deployment experiences. Results: Pre-deployment insomnia was associated with increased risk of post-deployment PTSD (adjusted odds ratio [AOR] = 3.14, 95% confidence interval [CI] = 2.58% to 3.82%, p<.0005) and suicidal ideation (AOR = 2.78, 95% CI = 2.07% to 3.74%, p<.0005) in models adjusting for sociodemographic characteristics and prior deployment history. Adjustment for other pre-deployment risk factors and deployment experiences attenuated these associations; however, insomnia remained significantly associated with post-deployment PTSD (AOR = 1.50, 95% CI = 1.19% to 1.89%, p = .001) and suicidal ideation (AOR = 1.43, 95% CI = 1.04% to 1.95%, p = .027). Subgroup models showed that pre-deployment insomnia was associated with incident PTSD (AOR = 1.55, 95% CI = 1.17% to 2.07%, p = .003) and suicidal ideation (AOR = 1.67, 95% CI = 1.16% to 2.40%, p = .006) among soldiers with no pre-deployment history of these problems. Conclusions: Pre-deployment insomnia contributed to prediction of post-deployment PTSD and suicidal ideation in Army soldiers, suggesting that detection of insomnia could facilitate targeting of risk mitigation programs. Future studies should investigate whether treatment of insomnia helps prevent PTSD and suicidal ideation among deployed service members.	[Wang, Hohui E.; Campbell-Sills, Laura; Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Kessler, Ronald C.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA; [Sun, Xiaoying; Jain, Sonia; Stein, Murray B.] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA; [Heeringa, Steven G.] Univ Michigan, Inst Social Res, Ann Arbor, MI USA; [Nock, Matthew K.] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA; [Ursano, Robert J.] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Ctr Study Traumat Stress, Bethesda, MD 20814 USA; [Stein, Murray B.] VA San Diego Healthcare Syst, San Diego, CA USA		Wang, HHE (corresponding author), Univ Calif San Francisco, Dept Psychiat, Langley Porter Psychiat Hosp & Clin, 401 Parnassus Ave, San Francisco, CA 94143 USA.	Hohui.Wang@ucsf.edu	Nock, Matthew/AAE-8330-2019; Ursano, Robert/ABE-6533-2020; Wang, Hohui/AAF-5592-2020	Wang, Hohui E./0000-0001-9486-8473	Department of the Army; US Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH) [U01MH087981]; Department of Defense (USUHS grant)United States Department of Defense [HU0001-15-2-0004]	Army STARRS was sponsored by the Department of the Army and funded under cooperative agreement number U01MH087981 (2009-2015) with the US Department of Health and Human Services, National Institutes of Health, National Institute of Mental Health (NIH/NIMH). Subsequently, STARRS-LS was sponsored and funded by the Department of Defense (USUHS grant number HU0001-15-2-0004). The contents are solely the responsibility of the authors and do not necessarily represent the views of the Department of Health and Human Services, NIMH, the Department of the Army, the Department of Veterans Affairs, or the Department of Defense.	Association A.P, 2013, DIAGN STAT MAN MENT; Babson KA, 2010, J ANXIETY DISORD, V24, P1, DOI 10.1016/j.janxdis.2009.08.002; Bernert Rebecca A, 2007, Neuropsychiatr Dis Treat, V3, P735; Bernert RA, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0554-4; Bjorngaard JH, 2011, SLEEP, V34, P1155, DOI 10.5665/SLEEP.1228; Bramoweth AD, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0401-4; Breslau N, 2004, ARCH GEN PSYCHIAT, V61, P508, DOI 10.1001/archpsyc.61.5.508; Brown CA, 2013, SLEEP DISORD, V2013; Caldwell JA, 2017, J SLEEP RES, V26, P665, DOI 10.1111/jsr.12543; Campbell-Sills L, 2018, PSYCHOL MED, V48, P1624, DOI 10.1017/S0033291717003105; Cox RC, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0773-y; DeViva Jason C, 2004, Behav Sleep Med, V2, P162, DOI 10.1207/s15402010bsm0203_5; EATON WW, 1995, AM J PSYCHIAT, V152, P967; FAWCETT J, 1990, AM J PSYCHIAT, V147, P1189; Feusner J, 2001, PSYCHIAT RES, V104, P109, DOI 10.1016/S0165-1781(01)00296-7; Finan PH, 2013, SLEEP MED REV, V17, P173, DOI 10.1016/j.smrv.2012.03.003; Fisher K, 2017, ARCH SUICIDE RES, V21, P531, DOI 10.1080/13811118.2016.1193077; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Gehrman P, 2013, SLEEP, V36, P1009, DOI 10.5665/sleep.2798; Germain A, 2013, AM J PSYCHIAT, V170, P372, DOI 10.1176/appi.ajp.2012.12040432; Germain A, 2012, J PSYCHOSOM RES, V72, P89, DOI 10.1016/j.jpsychores.2011.11.010; Gilbert KS, 2015, CLIN PSYCHOL REV, V40, P195, DOI 10.1016/j.cpr.2015.05.008; Goldstein TR, 2008, J CONSULT CLIN PSYCH, V76, P84, DOI 10.1037/0022-006X.76.1.84; Hines LA, 2014, CAN J PSYCHIAT, V59, P468, DOI 10.1177/070674371405900903; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hom MA, 2016, J PSYCHIATR RES, V79, P108, DOI 10.1016/j.jpsychires.2016.05.008; Jones K, 2001, SLEEP MED REV, V5, P463, DOI 10.1053/smrv.2001.0203; Keilp JG, 2013, PSYCHOL MED, V43, P539, DOI 10.1017/S0033291712001419; Kessler RC, 2004, INT J METH PSYCH RES, V13, P93, DOI 10.1002/mpr.168; Kessler RC, 2013, INT J METH PSYCH RES, V22, P267, DOI 10.1002/mpr.1401; Kessler RC, 2013, INT J METH PSYCH RES, V22, P303, DOI 10.1002/mpr.1398; Kessler RC, 2013, INT J METH PSYCH RES, V22, P288, DOI 10.1002/mpr.1399; Kessler RC, 2010, SLEEP, V33, P1539, DOI 10.1093/sleep/33.11.1539; Kodaka M, 2014, SLEEP MED, V15, P430, DOI 10.1016/j.sleep.2013.11.789; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1111, DOI 10.1001/jama.2009.342; Lamarche LJ, 2007, J CLIN PSYCHIAT, V68, P1257, DOI 10.4088/JCP.v68n0813; Leger D, 2002, SLEEP, V25, P625; Levin-Rector A, 2018, J TRAUMA STRESS, V31, P568, DOI 10.1002/jts.22316; Li SX, 2010, J CLIN PSYCHIAT, V71, P1440, DOI 10.4088/JCP.09m05661gry; McCall WV, 2013, CURR PSYCHIAT REP, V15, DOI 10.1007/s11920-013-0389-9; McCall WV, 2013, J CLIN SLEEP MED, V9, P135, DOI 10.5664/jcsm.2408; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P1659; Mellman TA, 2007, J TRAUMA STRESS, V20, P893, DOI 10.1002/jts.20246; Morin CM, 2006, SLEEP MED, V7, P123, DOI 10.1016/j.sleep.2005.08.008; Nadorff MR, 2013, J GERONTOL B-PSYCHOL, V68, P145, DOI 10.1093/geronb/gbs061; Nadorff MR, 2011, SLEEP, V34, P93, DOI 10.1093/sleep/34.1.93; Neylan TC, 2010, BIOL PSYCHIAT, V68, P494, DOI 10.1016/j.biopsych.2010.04.035; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Pigeon Wilfred R, 2012, J Clin Psychiatry, V73, pe1160, DOI 10.4088/JCP.11r07586; Pigeon WR, 2012, AM J PUBLIC HEALTH, V102, pS93, DOI 10.2105/AJPH.2011.300470; Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704; Reist C, 2017, J TRAUMA STRESS, V30, P186, DOI 10.1002/jts.22168; Ressler KJ, 2014, PSYCHIATRY, V77, P120, DOI 10.1521/psyc.2014.77.2.120; Ribeiro JD, 2012, J AFFECT DISORDERS, V136, P743, DOI 10.1016/j.jad.2011.09.049; Richardson JD, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1372-5; Riemann D, 2003, J AFFECT DISORDERS, V76, P255, DOI 10.1016/S0165-0327(02)00072-1; Roth T, 2011, BIOL PSYCHIAT, V69, P592, DOI 10.1016/j.biopsych.2010.10.023; Sandman N, 2017, SCI REP-UK, V7, DOI 10.1038/srep44756; Sharafkhaneh A, 2005, SLEEP, V28, P1405, DOI 10.1093/sleep/28.11.1405; Sjostrom N, 2009, PSYCHIAT RES, V170, P208, DOI 10.1016/j.psychres.2008.09.006; Stein MB, 2015, AM J PSYCHIAT, V172, P1101, DOI 10.1176/appi.ajp.2015.14121572; Tanskanen A, 2001, SLEEP, V24, P844; Team RC. R Core Team R, 2016, R LANG ENV STAT COMP; Troxel Wendy M, 2015, Rand Health Q, V5, P19; Ursano RJ, 2014, PSYCHIATRY, V77, P107, DOI 10.1521/psyc.2014.77.2.107; van Liempt S, 2013, DEPRESS ANXIETY, V30, P469, DOI 10.1002/da.22054; Wells TS, 2011, INT REV PSYCHIATR, V23, P144, DOI 10.3109/09540261.2011.558833; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Woznica AA, 2015, SLEEP MED REV, V22, P37, DOI 10.1016/j.smrv.2014.10.004; Wright KM, 2011, J CLIN PSYCHOL, V67, P1240, DOI 10.1002/jclp.20845	72	24	25	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0161-8105	1550-9109		SLEEP	Sleep	FEB	2019	42	2							zsy229	10.1093/sleep/zsy229			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	HM3BE	WOS:000459346600020	30508139	Green Published, Bronze			2022-02-06	
J	Epstein, D; Goodman, LA				Epstein, Deborah; Goodman, Lisa A.			DISCOUNTING WOMEN: DOUBTING DOMESTIC VIOLENCE SURVIVORS' CREDIBILITY AND DISMISSING THEIR EXPERIENCES	UNIVERSITY OF PENNSYLVANIA LAW REVIEW			English	Article							INTIMATE PARTNER-VIOLENCE; TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; VICTIMS; LEGAL; BIAS; EYEWITNESS; IDENTITY; IMPACT; ABUSE	In recent months, we've seen an unprecedented wave of testimonials about the serious harms women all too frequently endure. The #MeToo moment, the #WhyIStayed campaign, and the Larry Nassar sentencing hearings have raised public awareness not only about workplace harassment, domestic violence, and sexual abuse, but also about how routinely women survivors face a Gaslight-style gauntlet of doubt, disbelief, and outright dismissal of their stories. This pattern is particularly disturbing in the justice system, where women face a legal twilight zone: laws meant to protect them and deter further abuse often fail to achieve their purpose, because women telling stories of abuse by their male partners are simply not believed. To fully grasp the nature of this new moment in gendered power relations-and to cement the significant gains won by these public campaigns-we need to take a full, considered look at when, how, and why the justice system and other key social institutions discount women's credibility. We use the lens of intimate partner violence to examine the ways in which women's credibility is discounted in a range of legal and social service system settings. First, judges and others improperly discount as implausible women's stories of abuse, based on a failure to understand both the symptoms arising from neurological and psychological trauma, and the practical constraints on survivors' lives. Second, gatekeepers unjustly discount women's personal trustworthiness, based on both inaccurate interpretations of survivors' courtroom demeanor and negative cultural stereotypes about women and their motivations for seeking assistance. Moreover, even when a woman manages to overcome all the initial modes of institutional skepticism that minimize her account of abuse, she often finds that the systems designed to furnish her with help and protection dismiss the importance of her experiences. Instead, all too often, the arbiters of justice and social welfare adopt and enforce legal and social policies and practices with little regard for how they perpetuate patterns of abuse. Two distinct harms arise from this pervasive pattern of credibility discounting and experiential dismissal. First, the discrediting of survivors constitutes its own psychic injury-an institutional betrayal that echoes the psychological abuse women suffer at the hands of individual perpetrators. Second, the pronounced, nearly instinctive penchant for devaluing women's testimony is so deeply embedded within survivors' experience that it becomes a potent, independent obstacle to their efforts to obtain safety and justice. The reflexive discounting of women's stories of domestic violence finds analogs among the kindred diminutions and dismissals that harm so many other women who resist the abusive exercise of male power, from survivors of workplace harassment to victims of sexual assault on and off campus. For these women, too, credibility discounts both deepen the harm they experience and create yet another impediment to healing and justice. Concrete, systematic reforms are needed to eradicate these unjust, gender-based credibility discounts and experiential dismissals, and to enable women subjected to male abuses of power at long last to trust the responsiveness of the justice system.	[Epstein, Deborah] Georgetown Univ, Ctr Law, Domest Violence Clin, Washington, DC 20057 USA; [Goodman, Lisa A.] Boston Coll, Lynch Sch Educ, Dept Counseling Dev & Educ Psychol, Chestnut Hill, MA 02167 USA		Epstein, D (corresponding author), Georgetown Univ, Ctr Law, Domest Violence Clin, Washington, DC 20057 USA.						Abbott HP, 2008, CAMBRIDGE INTRO LIT, P40; ACLU, 2015, SILENCED NUIS ORD PU, P22; ACLU, 2015, RESP FIELD SEX ASS D; Adams Betty, 2014, PRESS HERALD    0603; Adams TM, 2006, J BLACK STUD, V36, P938, DOI 10.1177/0021934704274072; AM. BAR ASS'N, CUST DEC CAS DOM VIO; AMSTERDAM AG, 2000, MINDING LAW, P110; [Anonymous], 2003, FINAL REPORT PENNSYL, P405; [Anonymous], 2017, COMMUNICATION; [Anonymous], 2012, WASH POST; [Anonymous], COMMUNICATION; [Anonymous], 2018, COMMUNICATION; [Anonymous], 2017, COMMUNICATION; [Anonymous], 2014, NATL PUB RADIO; [Anonymous], 2016, CIVIL VOICES    0630; [Anonymous], 2014, WHAT IS GASL; [Anonymous], 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; [Anonymous], 2017, COMMUNICATION; [Anonymous], 2018, COMMUNICATION; [Anonymous], YOUR GROUND BOY ASKS; [Anonymous], 2013, WSMV            0425; [Anonymous], 2014, COMMUNICATION; [Anonymous], 2018, COMMUNICATION; [Anonymous], 2018, COMMUNICATION; [Anonymous], 2018, COMMUNICATION; [Anonymous], 1944, GASLIGHT; [Anonymous], 2012, WBAL TV TELEVIS 0904; [Anonymous], 2017, COMMUNICATION; Bailey Alison, 2014, SOC EPISTEMOL, V3, P62; Balos Beverly, 2006, TEMP POL CIV RTS L R, V15, P557; Balos Beverly, 2006, TEMP POL CIV RTS L R, V15, P567; BANCROFT LUNDY, 2002, BATTERER PARENT, P15; Barasch Amy, 2015, SLATE; Beck JG, 2007, PROF PSYCHOL-RES PR, V38, P629, DOI 10.1037/0735-7028.38.6.629; BECKER FN, 2013, CRIME FREE LEGAL PRA, P1; Bennett L, 1999, J INTERPERS VIOLENCE, V14, P761, DOI 10.1177/088626099014007006; BERGMAN PAUL, 2013, TRIAL ADVOCACY NUTSH, P58; Berman GL, 1996, J APPL PSYCHOL, V81, P170, DOI 10.1037/0021-9010.81.2.170; BERMAN GL, 1995, LAW HUMAN BEHAV, V19, P79, DOI 10.1007/BF01499074; BLACK MICHELE C., 2010, NATL INTIMATE PARTNE, P2; Blow CM, 2014, NY TIMES; Bond CEW, 2014, BRIT J CRIMINOL, V54, P849, DOI 10.1093/bjc/azu034; Brea Jennifer, 2017, BOS GLOBE; Brewer N, 2004, J APPL SOC PSYCHOL, V34, P493, DOI 10.1111/j.1559-1816.2004.tb02558.x; Brewer N, 1999, APPL COGNITIVE PSYCH, V13, P297, DOI 10.1002/(SICI)1099-0720(199908)13:4<297::AID-ACP578>3.0.CO;2-S; Brewer N., 1999, PSYCHIAT PSYCHOL LAW, V6, P97, DOI [10.1080/13218719909524952, DOI 10.1080/13218719909524952]; Briggs Lakisha, 2015, GUARDIAN; Briquelet Kate, 2015, DAILY BEAST; Brownridge DA, 2006, AGGRESS VIOLENT BEH, V11, P514, DOI 10.1016/j.avb.2006.01.009; BUREAU OF JUSTICE STATISTICS U. S. DEP'T OF JUSTICE, 2005, FAM VIOL STAT INCL S, P2; Buzawa, 2009, VIOLENCE WOMEN FAMIL, P185; Campbell JC, 2018, J WOMENS HEALTH, V27, P761, DOI 10.1089/jwh.2016.6311; Campbell R, 2008, AM PSYCHOL, V63, P702, DOI 10.1037/0003-066X.63.8.702; CAMUS ALBERT, 1942, STRANGER, p[8, 20, 64]; CAMUS ALBERT, 1988, STRANGER, p[8, 20, 64]; Carlin A, 2016, UCLA LAW REV, V63, P450; Cattaneo LB, 2005, TRAUMA VIOLENCE ABUS, V6, P141, DOI 10.1177/1524838005275088; Chang, 2018, VANITY FAIR; CHAVKIN DAVID, 2002, CLIN LEGAL ED TXB LA, P93; Chemaly S., 2013, ROLE REBOOT     1119; Chen EH, 2008, ACAD EMERG MED, V15, P414, DOI 10.1111/j.1553-2712.2008.00100.x; CNN, 2010, CNN; Codrea-Rado A, 2017, NY TIMES; COKER AL, AM J PUB HLTH, V90, P553; Coker Donna, 2000, UC DAVIS L REV, V33, P1009; Coker Donna, 2000, UC DAVIS L REV, V33, P1021; Conner Dana Harrington, 2009, AM U J GENDER SOC PO, V17, P174; Conner Dana Harrington, 2009, AM U J GENDER SOC PO, V17, P163; Corrigan John D., 2003, American Journal of Obstetrics and Gynecology, V188, pS71, DOI 10.1067/mob.2003.404; Crocker Lizzie, 2014, DAILY BEAST; CRON LISA, 2012, WIRED STORY WRITERS, P185; David Lynch Found, 2017, YOUTUBE; Davis Kevin, 2012, ABA J, V98, p[37, 37]; Desmarais SL, 2009, LAW HUMAN BEHAV, V33, P470, DOI 10.1007/s10979-008-9165-5; Desmond M, 2013, AM SOCIOL REV, V78, P117, DOI 10.1177/0003122412470829; Desmond Matthew, 2012, AM SOCIOL REV, V78, P132; Devine PG, 2012, J EXP SOC PSYCHOL, V48, P1267, DOI 10.1016/j.jesp.2012.06.003; DONNA STIENSTRA ET AL. FED. JUDICIAL CTR., 2011, ASSISTANCE PROSE LIT, P21; Dotson K, 2011, HYPATIA, V26, P236, DOI 10.1111/j.1527-2001.2011.01177.x; Duncan Martha Grace, 2017, HARV J L GENDER 0919; Dutton M A, 1999, Violence Vict, V14, P89; Dutton Mary Ann, 1993, HOFSTRA LAW REV, V21, P1191; Dutton Mary Ann, 1993, HOFSTRA L REV, V21, P1221; Dutton Mary Ann, 1999, VIOLENCE VICTIMS, V14, P101; EDELMAN PETER, 2017, NOT CRIME BE POOR CR, P135; Ehlers A, 2004, MEMORY, V12, P403, DOI 10.1080/09658210444000025; Epstein D., 1999, YALE J LAW FEMINISM, V11, P3; Epstein D., 2003, AM U J GENDER SOC PO, V11, P465; Epstein Deborah, 2003, AM U J GENDER SOC PO, V11, P467; Epstein Deborah, 2018, NY TIMES; Fessler Pam, 2016, NATL PUBLIC RADIO; Flaherty M. P., 2014, WASH POST; Fleury R E, 1998, Violence Vict, V13, P333; Fleury Ruth E., 1998, VIOLENCE VICTIMS, V13, P342; Fleury-Steiner RE, 2006, J COMMUNITY PSYCHOL, V34, P327, DOI 10.1002/jcop.20102; Freud S, 1975, STANDARD EDITION COM; FREUD SIGMUND, 1963, AUTOBIOGRAPHICAL STU, P62; FREUD SIGMUND, 1925, AUTOBIOGRAPHICAL STU, P62; Fricker M., 2007, EPISTEMIC INJUSTICE, DOI [10.1093/acprof:oso/9780198237907.001.0001, DOI 10.1093/ACPROF:OSO/9780198237907.001.0001]; Fugere Patty Mullahy, 2014, HUFFINGTON POST 0221; Garay-Serratos Maria E., 2015, L A TIMES; Gilbert, 2018, ATLANTIC; Gilman, 2014, AM U J GENDER SOC PO, V22, P247; Gilman Michele Estrin, 2014, AM U J GENDER SOC PO, V22, P249; Glaser J, 2008, J EXP SOC PSYCHOL, V44, P164, DOI 10.1016/j.jesp.2007.01.002; GODSIL RACHEL D., 2016, 2 SCI EQUALITY EFFEC, P12; Golding JM, 1999, J FAM VIOLENCE, V14, P99, DOI 10.1023/A:1022079418229; Goodman LA, 2011, PSYCHOL VIOLENCE, V1, P79, DOI 10.1037/a0022977; GOODMAN LISA A., 2009, LISTENING BATTERED W, P107; GROSE CAROLYN, 2017, LAWYERS CLIENTS NARR, P15; Gutowski Ellen, 2018, INTIMATE PARTNER VIO; Haberman Clyde, 2014, NY TIMES; Haberman Maggie ., 2018, NY TIMES; Hanna C, 1996, HARVARD LAW REV, V109, P1849, DOI 10.2307/1342079; Hanna Cheryl, 1996, HARVARD LAW REV, V109, P1878; Hare SC, 2010, J FAM VIOLENCE, V25, P765, DOI 10.1007/s10896-010-9334-4; Herman JL, 2005, VIOLENCE AGAINST WOM, V11, P571, DOI 10.1177/1077801205274450; Herman Judith, 1984, NATION, P293; HERMAN JUDITH LEWIS, 1997, TRAUMA RECOVERY, P37; Holt S, 2008, CHILD ABUSE NEGLECT, V32, P797, DOI 10.1016/j.chiabu.2008.02.004; Hopper J., 2018, PSYCHOL TODAY; Howard Greg, 2014, DEADSPIN        0731; Hunnicutt G, 2017, J FAM VIOLENCE, V32, P471, DOI 10.1007/s10896-016-9854-7; Institute for Children and Poverty, 2002, HIDD MIGR WHY NEW YO; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; Jeltsen M., 2015, HUFFINGTON POST; Johnson, 2010, CARDOZO L REV, V32, P519; Johnson Margaret, 2009, UC DAVIS L REV, V42, P1107; Johnson Margaret, 2010, CARDOZO L REV, V32, P566; Johnson Margaret, 2010, CARDOZO L REV, V32, P536; Johnson Margaret E., 2009, UC DAVIS L REV, V42, P1143; Johnson MP, 2005, J FAM ISSUES, V26, P322, DOI 10.1177/0192513X04270345; Johnston JR, 2005, FAM COURT REV, V43, P283, DOI 10.1111/j.1744-1617.2005.00029.x; Johnston Janet R., 2005, FAM CT REV, V43, P290; Jones L., 2001, TRAUMA VIOLENCE ABUS, V2, P99, DOI [10.1177/1524838001002002001, DOI 10.1177/1524838001002002001]; Jones Loring, 2001, TRAUMA VIOLENCE ABUS, V2, P100; Kane John L., 2007, LITIG, V33, P31; Kane John L., 2007, LITIG, V33, P32; KEILITZ SUSAN L., 1997, CIVIL PROTECTION ORD, P12; King Donna J., 2017, DEPAUL J WOMEN GENDE, V6, P1; King Donna J., 2017, DEPAUL J WOMEN GENDE, V6, P29; Kirsch Thomas L., 2001, WM MARY J WOMEN L, V7, P387; KIRSCH TL, 2001, WM MARY J WOMEN L, V7, P383; Kitchener Caroline, 2018, ATLANTIC; Kohn L. S, 2003, J GENDER SOCIAL POLI, V11, P733; Kohn Laurie S., 2003, AM U J GENDER SOC PO, V11, P742; Kuennen T.L., 2010, BYU L REV, V2, P515; Kuennen Tamara L., 2010, BYU L REV, V2010, P585; Lancer Darlene, 2018, PSYCHOL TODAY; LEGAL SERVS. CORP, 2017, JUST GAP MEAS UNM CI, P52; Levin R., 2004, PATHWAYS HOMELESSNES; Levinson Justin, 2017, FLA LAW REV, V69, P63; Levinson Justin D., 2017, FLA L REV, V69, P104; Lewis Brigitte, 2016, ASIA PAC POL SO 0906; LOGAN TK, 2015, NATL DOMESTIC VIOLEN, P9; LYON ELEANOR, 2008, M SURV NEEDS MULT ST, piv; MacKinnon Catharine, 2018, NEW YORK TIMES 0204; Mahoney P., 2001, SOURCEBOOK VIOLENCE, P143; MARKS G, 1987, PSYCHOL BULL, V102, P72, DOI 10.1037/0033-2909.102.1.72; MASSON JEFFREY MOUSSAIEFF, 1984, ASSAULT TRUTH FREUDS, P107; Masson JM, 1984, ASSAULT TRUTH FREUDS; MAYER J, 1994, STRANGE JUSTICE SELL; MCCRAY R, 2017, SLATE; Mechanic MB, 2008, VIOLENCE AGAINST WOM, V14, P634, DOI 10.1177/1077801208319283; Medina J., 2017, ROUTLEDGE HDB EPISTE, P167; Meier JS, 2009, J CHILD CUSTODY, V6, P232, DOI 10.1080/15379410903084681; Meier Joan S., 1993, HOFSTRA L REV, V21, P1313; Meier Joan S., 2017, LAW INEQ, V35, P328; MEIER JS, 2017, LAW INEQ, V0035; Meier JS, 1993, HOFSTRA L REV, V21, P1295; Morabito Nate, 2016, WJHL            0911; Murphy Jane C., 1993, HOFSTRA L REV, V21, P1275; MURPHY JC, 1993, HOFSTRA L REV, V21, P1243; Nadasen Premilla, 2007, BLACK WOMEN GENDER F, V1, P66, DOI DOI 10.5406/BLACWOMEGENDFAMI.1.2.0052; Nagle JE, 2014, BEHAV SCI LAW, V32, P195, DOI 10.1002/bsl.2112; Nagle Jacklyn E., 2014, BEHAV SCI L, V32, P203; NAT'L CTR, 2017, INTIMATE PARTNER VIO; NAT'L INST. OF NEUROLOGICAL DISORDERS & STROKE, TRAUM BRAIN INJ HOP; National Quality Forum, 2013, PREP COURT PROC SURV, P1; Paquette D., 2017, WASH POST; Park Sandra S., 2016, MSNBC           0325; PARTNERS FOR PEACE, 2016, UND TRAUM INJ CONC S; Pico-Alfonso MA, 2005, NEUROSCI BIOBEHAV R, V29, P181, DOI 10.1016/j.neubiorev.2004.08.010; Pimpare S., 2017, WASH POST; Porter Eduardo, 2015, NY TIMES; POSTMUS JL, AFFILIA, V15, P244; Potter Rob, 1999, PSYCHIAT PSYCHOL LAW, V6, P101; Pressley Nelson, 2018, WASH POST; Przekop M., 2011, SEATTLE J SOCIAL JUS, V9, P1053; Przekop Mary, 2011, SEATTLE J SOC JUST, V9, P1078; Rachlinski JJ, 2009, NOTRE DAME LAW REV, V84, P1195; Rand Joseph W., 2000, CONN L REV, V33, P42; RAND JW, 2000, CONN L REV, V33, P1; Raphael J, 2004, VIOLENCE AGAINST WOM, V10, P1354, DOI 10.1177/1077801204269350; Raphael Jody, 2003, AM U J GENDER SOC PO, V11, P367; Raphael Jody, 2003, J GENDER SOC POLY L, V11, P369; Rhodes NR, 1998, AGGRESS VIOLENT BEH, V3, P391, DOI 10.1016/S1359-1789(97)00025-6; Riger S, 2002, J INTERPERS VIOLENCE, V17, P184, DOI 10.1177/0886260502017002005; Riger Stephanie, 2002, J INTERPERS VIOLENCE, V17, P198; Robbins M., 2014, CNN; ROSS L, 1977, J EXP SOC PSYCHOL, V13, P279, DOI 10.1016/0022-1031(77)90049-X; RYCROFT C, 1984, NEW YORK REV BOOKS, V31, P3; Salerno JM, 2015, LAW HUMAN BEHAV, V39, P581, DOI 10.1037/lhb0000147; Savion Leah, 2009, J SCHOLARSHIP TEACHI, V9, P81; Savion Leah, 2009, J SCHOLARSHIP TEACHI, V9, P87; Schafran Lynn Hecht, 1995, BEST AM BAR ASS SECT, V34, P40; Schafran Lynn Hecht, 1995, JUDGES J, P42; Schmelzer Elise, 2016, WASH POST; Sherin Jonathan E, 2011, Dialogues Clin Neurosci, V13, P263; Smith CP, 2014, AM PSYCHOL, V69, P575, DOI 10.1037/a0037564; SMITH Holly, 2016, U MASS L REV, V11, P64; Snyder R. L., 2015, NEW YORKER; Solan L, 2008, COLUMBIA LAW REV, V108, P1268; Solnit Rebecca, 2014, HARPERS MAGAZINE, P4; Stark Evan, 2012, REPRESENTING B UNPUB; STATE OF MD. ADMIN. OFFICE OF THE COURTS, 2017, DOM VIOL MONTHL SUMM; Steele CM, 1997, AM PSYCHOL, V52, P613, DOI 10.1037/0003-066X.52.6.613; Steele CM, 2002, ADV EXP SOC PSYCHOL, V34, P379, DOI 10.1016/S0065-2601(02)80009-0; Stoever JK, 2017, WASH LAW REV, V92, P861; STORR A, 1984, NEW YORK TIMES BK R, P3; Strack GB, 2001, J EMERG MED, V21, P303, DOI 10.1016/S0736-4679(01)00399-7; Swent Jeannette F., 1996, S CAL REV L WOMENS S, V6, P1; Swent Jeannette F., 1996, S CAL REV L WOMENS S, V6, P61; TJADEN PATRICIA, 2000, EXTENT NATURE AND CO, P52; Tolman RM, 2000, J SOC ISSUES, V56, P655, DOI 10.1111/0022-4537.00190; Tuerkheimer D, 2017, U PENN LAW REV, V166, P1; Tuerkheimer Deborah, 2017, U PENN LAW REV, V166, P3; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Valera E, 2017, BRAIN IMAGING BEHAV, V11, P1664, DOI 10.1007/s11682-016-9643-1; Valera EM, 2018, J WOMENS HEALTH, V27, P735, DOI 10.1089/jwh.2017.6838; VAN DER KOLK BESSEL, 2014, BODY KEEPS SCORE BRA, P182; Wash. Legal Clinic for the Homeless, 2017, PUBLIC; West Kanye, 2005, LATE REGISTRATION; Witt C.E., 2002, MIND ONES OWN FEMINI, P154; Women of Color Network, 2006, FACTS STATS DOM VIOL; World Health Organization, 2012, UNDERSTANDING ADDRES; Wright CV, 2012, J TRAUMA STRESS, V25, P675, DOI 10.1002/jts.21754; Yarbrough M., 2000, J GENDER RACE JUST, V3, P625; Yarbrough Marilyn, 2000, J GENDER RACE JUST, V3, P629; Young K, 2001, SUB-STANCE, P72; ZACHAREK S, 2017, TIME; 2017, HOUSING NEEDS VICTIM, P1; [No title captured]	243	24	24	2	14	UNIV PENN LAW SCH	PHILADELPHIA	3400 CHESTNUT ST, PHILADELPHIA, PA 19104-6204 USA	0041-9907			U PENN LAW REV	Univ. Pa. Law Rev.	JAN	2019	167	2					399	461					63	Law	Social Science Citation Index (SSCI)	Government & Law	HZ4TG	WOS:000468843200003					2022-02-06	
J	Johnson, RW; Ng, KWP; Dietz, AR; Hartman, ME; Baty, JD; Hasan, N; Zaidman, CM; Shoykhet, M				Johnson, Ryan W.; Ng, Kay W. P.; Dietz, Alexander R.; Hartman, Mary E.; Baty, Jack D.; Hasan, Nausheen; Zaidman, Craig M.; Shoykhet, Michael			Muscle atrophy in mechanically-ventilated critically ill children	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; ICU-ACQUIRED WEAKNESS; ELECTRICAL-IMPEDANCE MYOGRAPHY; RISK-FACTORS; METABOLIC-RESPONSE; POLYNEUROPATHY; DYSFUNCTION; ULTRASOUND; PARESIS; INJURY	Importance ICU-acquired muscle atrophy occurs commonly and worsens outcomes in adults. The incidence and severity of muscle atrophy in critically ill children are poorly characterized. Objective To determine incidence, severity and risk factors for muscle atrophy in critically ill children. Design, setting and participants A single-center, prospective cohort study of 34 children receiving invasive mechanical ventilation for >= 48 hours. Patients 1 week- 18 years old with respiratory failure and without preexisting neuromuscular disease or skeletal trauma were recruited from a tertiary Pediatric Intensive Care Unit (PICU) between June 2015 and May 2016. We used serial bedside ultrasound to assess thickness of the diaphragm, biceps brachii/brachialis, quadriceps femoris and tibialis anterior. Serial electrical impedance myography (EIM) was assessed in children >1 year old. Medical records were abstracted from an electronic database. Exposures Respiratory failure requiring endotracheal intubation for >= 48 hours. Main outcome and measures The primary outcome was percent change in muscle thickness. Secondary outcomes were changes in EIM-derived fat percentage and "quality". Results Of 34 enrolled patients, 30 completed >= 2 ultrasound assessments with a median interval of 6 (IQR 6-7) days. Mean age was 5.42 years, with 12 infants <1 year (40%) and 18 children >1 year old (60%). In the entire cohort, diaphragm thickness decreased 11.1% (95%CI, -19.7% to -2.52%) between the first two assessments or 2.2%/day. Quadriceps thickness decreased 8.62% (95%CI, -15.7% to -1.54%) or 1.5%/day. Biceps (-1.71%; 95%CI, -8.15% to 4.73%) and tibialis (0.52%; 95%CI, -5.81% to 3.40%) thicknesses did not change. Among the entire cohort, 47% (14/30) experienced diaphragm atrophy (defined a priorias >= 10% decrease in thickness). Eighty three percent of patients (25/30) experienced atrophy in >= 1 muscle group, and 47% (14/30)-in >= 2 muscle groups. On multivariate linear regression, increasing age and traumatic brain injury (TBI) were associated with greater muscle loss. EIM revealed increased fat percentage and decreased muscle "quality". Conclusions and relevance In children receiving invasive mechanical ventilation, diaphragm and other skeletal muscle atrophy is common and rapid. Increasing age and TBI may increase severity of limb muscle atrophy. Prospective studies are required to link muscle atrophy to functional outcomes in critically ill children.	[Johnson, Ryan W.; Hartman, Mary E.; Shoykhet, Michael] Washington Univ, Dept Pediat, Sch Med, St Louis, MO 63110 USA; [Ng, Kay W. P.; Dietz, Alexander R.; Zaidman, Craig M.] Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA; [Ng, Kay W. P.] Natl Univ, Dept Med, Singapore, Singapore; [Dietz, Alexander R.] Blue Sky Neurol, Englewood, CO USA; [Baty, Jack D.] Washington Univ, Div Biostat, Sch Med, St Louis, MO 63110 USA; [Hasan, Nausheen] St Louis Childrens Hosp, St Louis, MO 63178 USA; [Shoykhet, Michael] Childrens Natl Med Ctr, Childrens Res Inst, Washington, DC 20010 USA		Shoykhet, M (corresponding author), Washington Univ, Dept Pediat, Sch Med, St Louis, MO 63110 USA.; Shoykhet, M (corresponding author), Childrens Natl Med Ctr, Childrens Res Inst, Washington, DC 20010 USA.	mshoykhet@childrensnational.org		Shoykhet, Michael/0000-0001-5031-2377	Washington University [ICTS CTSA808]	This work was supported by MS (Washington University ICTS CTSA808). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banwell BL, 2003, NEUROLOGY, V61, P1779, DOI 10.1212/01.WNL.0000098886.90030.67; Charrueau C, 2009, J NEUROTRAUM, V26, P1911, DOI 10.1089/neu.2008.0737; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; Corpeno R, 2014, J PHYSIOL-LONDON, V592, P3859, DOI 10.1113/jphysiol.2014.277962; Curley MAQ, 2006, PEDIATR CRIT CARE ME, V7, P107, DOI 10.1097/01.PCC.0000200955.40962.38; De Jonghe B, 2004, INTENS CARE MED, V30, P1117, DOI 10.1007/s00134-004-2174-z; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; de Letter MACJ, 2001, CRIT CARE MED, V29, P2281, DOI 10.1097/00003246-200112000-00008; Dejonghe B, 2009, CERAMICS-ART PERCEPT, P37; Demoule A, 2013, AM J RESP CRIT CARE, V188, P213, DOI 10.1164/rccm.201209-1668OC; Fan E, 2014, CRIT CARE MED, V42, P849, DOI 10.1097/CCM.0000000000000040; Field-Ridley A, 2016, PEDIATR CRIT CARE ME, V17, P53, DOI 10.1097/PCC.0000000000000538; Fukunaga T, 2001, ACTA PHYSIOL SCAND, V172, P249, DOI 10.1046/j.1365-201x.2001.00867.x; Garnacho-Montero J, 2005, CRIT CARE MED, V33, P349, DOI 10.1097/01.CCM.0000153521.41848.7E; Gerovasili V, 2009, CRIT CARE, V13, DOI 10.1186/cc8123; Glau CL, 2018, PEDIATR CRIT CARE ME, V19, P406, DOI 10.1097/PCC.0000000000001485; Goligher EC, 2018, AM J RESP CRIT CARE, V197, P204, DOI 10.1164/rccm.201703-0536OC; Gruther W, 2008, J REHABIL MED, V40, P185, DOI 10.2340/16501977-0139; Hermans G, 2014, AM J RESP CRIT CARE, V190, P410, DOI 10.1164/rccm.201312-2257OC; Hirose T, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2013.02.010; Jaber S, 2011, AM J RESP CRIT CARE, V183, P364, DOI 10.1164/rccm.201004-0670OC; KANEHISA H, 1994, EUR J APPL PHYSIOL, V68, P148, DOI 10.1007/BF00244028; Khemani RG, 2017, CRIT CARE MED, V45, pE798, DOI 10.1097/CCM.0000000000002433; Koch S, 2011, J NEUROL NEUROSUR PS, V82, P287, DOI 10.1136/jnnp.2009.192997; Kress JP, 2014, NEW ENGL J MED, V370, P1626, DOI 10.1056/NEJMra1209390; LEIJTEN FSS, 1995, JAMA-J AM MED ASSOC, V274, P1221, DOI 10.1001/jama.274.15.1221; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Lu ZH, 2016, RESP CARE, V61, P1316, DOI 10.4187/respcare.04746; Mtaweh H, 2014, PEDIATR CRIT CARE ME, V15, P242, DOI 10.1097/PCC.0000000000000041; Ng KW, 2018, MUSCLE NERVE; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Rodriguez PO, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2011.04.010; Sanchez B, 2017, NEUROTHERAPEUTICS, V14, P107, DOI 10.1007/s13311-016-0491-x; Shahidi B, 2018, J NEUROTRAUM, V35, P398, DOI 10.1089/neu.2017.5172; Sharshar T, 2009, CRIT CARE MED, V37, P3047, DOI 10.1097/CCM.0b013e3181b027e9; Tarulli A, 2005, NEUROLOGY, V65, P451, DOI 10.1212/01.wnl.0000172338.95064.cb; Valla FV, 2017, PEDIATR CRIT CARE ME, V18, pE339, DOI 10.1097/PCC.0000000000001235; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wieske L, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0937-2; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Zaidman CM, 2015, MUSCLE NERVE, V52, P592, DOI 10.1002/mus.24611; Zaidman CM, 2014, MUSCLE NERVE, V50, P124, DOI 10.1002/mus.24117	44	24	26	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 19	2018	13	12							e0207720	10.1371/journal.pone.0207720			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	HE9NT	WOS:000453779300015	30566470	Green Published, Green Submitted, gold			2022-02-06	
J	Papa, L; Slobounov, SM; Breiter, HC; Walter, A; Bream, T; Seidenberg, P; Bailes, JE; Bravo, S; Johnson, B; Kaufman, D; Molfese, DL; Talavage, TM; Zhu, DC; Knollmann-Ritschel, B; Bhomia, M				Papa, Linda; Slobounov, Semyon M.; Breiter, Hans C.; Walter, Alexa; Bream, Tim; Seidenberg, Peter; Bailes, Julian E.; Bravo, Stephen; Johnson, Brian; Kaufman, David; Molfese, Dennis L.; Talavage, Thomas M.; Zhu, David C.; Knollmann-Ritschel, Barbara; Bhomia, Manish		Concussion Neuroimaging Consortium	Elevations in MicroRNA Biomarkers in Serum Are Associated with Measures of Concussion, Neurocognitive Function, and Subconcussive Trauma over a Single National Collegiate Athletic Association Division I Season in Collegiate Football Players	JOURNAL OF NEUROTRAUMA			English	Article						athletes; biomarkers; cognition, diagnosis; collegiate; concussion; football; mild traumatic brain injury; miRNA; prognosis sports; subconcussive impacts	DEFAULT MODE NETWORK; HEAD IMPACT EXPOSURE; BRAIN-INJURY; YOUTH; DIAGNOSIS	This prospective controlled observational cohort study assessed the performance of a novel panel of serum microRNA (miRNA) biomarkers on indicators of concussion, subconcussive impacts, and neurocognitive function in collegiate football players over the playing season. Male collegiate student football athletes participating in a Division I Football Bowl Subdivision of the National Collegiate Athletic Association (NCAA) were enrolled. There were a total of 53 participants included in the study, 30 non-athlete control subjects and 23 male collegiate student football athletes. Neurocognitive assessments and blood samples were taken within the week before the athletic season began and within the week after the last game of the season and measured for a panel of pre-selected miRNA biomarkers. All the athletes had elevated levels of circulating miRNAs at the beginning of the season compared with control subjects (p < 0.001). Athletes with the lowest standard assessment of concussion (SAC) scores at the beginning of the season had the highest levels of miRNAs. The area under the curve (AUC) for predicting pre-season SAC scores were miR-195 (0.90), miR-20a (0.89), miR-151-5p (0.86), miR-505* (0.85), miR-9-3p (0.77), and miR-362-3p (0.76). In athletes with declining neurocognitive function over the season, concentrations of miRNAs increased over same period. There were significant negative correlations with miR-505* (p = 0.011), miR-30d (p = 0.007), miR-92 (p = 0.033), and (p = 0.008). The miRNAs correlating with balance problems were miR-505* (p = 0.007), miR-30d (p = 0.028), and miR-151-5p (p = 0.023). Those correlating with poor reaction times were miR-20a (0.043), miR-505* (p = 0.049), miR-30d (p = 0.031), miR-92 (p = 0.015), and miR-151-5p (p = 0.044). Select miRNAs were associated with baseline concussion assessments at the beginning of the season and with neurocognitive changes from pre to post-season in collegiate football players. Should these findings be replicated in a larger cohort of athletes, these markers could potentially serve as measures of neurocognitive status in athletes at risk for concussion and subconcussive injuries.	[Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, 86 W Underwood,S-200, Orlando, FL 32806 USA; [Papa, Linda] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ, Canada; [Slobounov, Semyon M.; Walter, Alexa; Johnson, Brian] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Bream, Tim] Penn State Univ, Athlet Dept, University Pk, PA 16802 USA; [Breiter, Hans C.] Northwestern Univ, Dept Psychiat & Behav Sci, Warren Wright Adolescent Ctr, Chicago, IL 60611 USA; [Seidenberg, Peter] Penn State Coll Med, Dept Orthopaed & Rehabil, University Pk, PA USA; [Seidenberg, Peter] Penn State Coll Med, Dept Family & Community Med, University Pk, PA USA; [Bailes, Julian E.] Univ Chicago, Dept Neurosurg, Northshore Univ Hlth Syst, Pritzker Sch Med, Chicago, IL 60637 USA; [Bravo, Stephen] Sandlake Imaging, Orlando, FL USA; [Kaufman, David] Michigan State Univ, Dept Neurol & Ophthalmol, E Lansing, MI 48824 USA; [Zhu, David C.] Michigan State Univ, Dept Radiol & Psychol, E Lansing, MI 48824 USA; [Molfese, Dennis L.] Univ Nebraska, Dept Psychol, Lincoln, NE 68588 USA; [Talavage, Thomas M.] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Knollmann-Ritschel, Barbara; Bhomia, Manish] Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA		Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, 86 W Underwood,S-200, Orlando, FL 32806 USA.; Bhomia, M (corresponding author), Uniformed Serv Univ Hlth Sci, Henry M Jackson Fdn HJF, Bldg B,3082,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	lpstat@aol.com; manish.bhomia.ctr@usuhs.edu		Talavage, Thomas/0000-0003-4977-6398	DMRDP [D10_I_AR_J6_855]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER	The authors thank Dr. Zhao Zhang Li, Bio-Instrumentation Center (BIC), UHUHS, for her help with digital microRNA PCR experiments. The microRNA analysis was funded by DMRDP grant D10_I_AR_J6_855.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Bahrami N, 2016, RADIOLOGY, V281, P919, DOI 10.1148/radiol.2016160564; Bailes JE, 2014, PROG NEUROL SURG, V28, P50, DOI 10.1159/000358765; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Bhomia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28148; Campolettano ET, 2017, J NEUROSURG-PEDIATR, V20, P604, DOI 10.3171/2017.5.PEDS17185; Centers for Disease Control and Prevention, 2017, HEADS HLTH CAR PROV; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Fehlmann T, 2016, RNA BIOL, V13, P1084, DOI 10.1080/15476286.2016.1234658; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Hicks SD, 2018, J NEUROTRAUM, V35, P64, DOI 10.1089/neu.2017.5111; Jin XF, 2013, CELL MOL NEUROBIOL, V33, P601, DOI 10.1007/s10571-013-9940-9; Johnson B, 2014, J NEUROTRAUM, V31, P1907, DOI 10.1089/neu.2014.3415; Johnson JJ, 2018, JAMA PEDIATR, V172, P65, DOI 10.1001/jamapediatrics.2017.3884; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; Mitra B, 2017, J CLIN NEUROSCI, V38, P37, DOI 10.1016/j.jocn.2016.12.009; NCAA, 2018, EST PROB COMP COLL A; Papa L, 2018, J NEUROTRAUM, V35, P32, DOI 10.1089/neu.2017.4994; Papa L, 2016, SPORTS MED ARTHROSC, V24, P108, DOI 10.1097/JSA.0000000000000117; Papa L, 2016, J NEUROTRAUM, V33, P58, DOI 10.1089/neu.2015.3869; Papa L, 2015, ACAD EMERG MED, V22, P1274, DOI 10.1111/acem.12795; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Reynolds BB., 2017, BRAIN IMAGING BEHAV; Slobounov SM, 2017, NEUROIMAGE-CLIN, V14, P708, DOI 10.1016/j.nicl.2017.03.006; Teel E, 2016, NEUROPSYCHOLOGY, V30, P474, DOI 10.1037/neu0000261; Teel EF, 2015, CLIN J SPORT MED, V25, P144, DOI 10.1097/JSM.0000000000000109; Tsushima WT, 2018, APPL NEUROPSYCH-CHIL, V7, P14, DOI 10.1080/21622965.2016.1220860	29	24	25	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2019	36	8					1343	1351		10.1089/neu.2018.6072		DEC 2018	9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HS4DK	WOS:000452128200001	30343622	Green Published			2022-02-06	
J	Almeida, VM; Paiva, AE; Sena, IFG; Mintz, A; Magno, LAV; Birbrair, A				Almeida, Viviani M.; Paiva, Ana E.; Sena, Isadora F. G.; Mintz, Akiva; Magno, Luiz Alexandre V.; Birbrair, Alexander			Pericytes Make Spinal Cord Breathless after Injury	NEUROSCIENTIST			English	Article						pericytes; spinal cord injury; blood flow; microenvironment; scar	SKELETAL-MUSCLE; CAPILLARY PERICYTES; BLOOD-FLOW; MICROVASCULAR PERICYTES; VASCULAR MORPHOGENESIS; PERIVASCULAR CELLS; BONE-MARROW; BRAIN; TISSUE; REGENERATION	Traumatic spinal cord injury is a devastating condition that leads to significant neurological deficits and reduced quality of life. Therapeutic interventions after spinal cord lesions are designed to address multiple aspects of the secondary damage. However, the lack of detailed knowledge about the cellular and molecular changes that occur after spinal cord injury restricts the design of effective treatments. Li and colleagues using a rat model of spinal cord injury and in vivo microscopy reveal that pericytes play a key role in the regulation of capillary tone and blood flow in the spinal cord below the site of the lesion. Strikingly, inhibition of specific proteins expressed by pericytes after spinal cord injury diminished hypoxia and improved motor function and locomotion of the injured rats. This work highlights a novel central cellular population that might be pharmacologically targeted in patients with spinal cord trauma. The emerging knowledge from this research may provide new approaches for the treatment of spinal cord injury.	[Almeida, Viviani M.; Paiva, Ana E.; Sena, Isadora F. G.; Birbrair, Alexander] Univ Fed Minas Gerais, Dept Pathol, Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil; [Mintz, Akiva] Columbia Univ, Med Ctr, Dept Radiol, New York, NY USA; [Magno, Luiz Alexandre V.] Univ Fed Minas Gerais, Dept Mental Hlth, Belo Horizonte, MG, Brazil; [Birbrair, Alexander] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10467 USA; [Birbrair, Alexander] Albert Einstein Coll Med, Ruth L & David S Gottesman Inst Stem Cell & Regen, Bronx, NY 10467 USA		Birbrair, A (corresponding author), Univ Fed Minas Gerais, Dept Pathol, Antonio Carlos 6627, BR-31270901 Belo Horizonte, MG, Brazil.	birbrair@icb.ufmg.br	Magno, Luiz Alexandre V./AAJ-9839-2021; Birbrair, Alexander/H-2497-2012; Magno, Alexandre/B-1552-2010; Sena, Isadora/E-5373-2018	Magno, Luiz Alexandre V./0000-0003-3693-1897; Birbrair, Alexander/0000-0003-1015-2561; Magno, Alexandre/0000-0003-3693-1897; Fernandes Gilson Sena, Isadora/0000-0002-4304-9707; Mendes de Almeida, Viviani/0000-0001-6061-8038	Pro-reitoria de Pesquisa/Universidade Federal de Minas Gerais (PRPq/UFMG); National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01CA179072-01A1]; American Cancer Society Mentored Research Scholar GrantAmerican Cancer Society [124443-MRSG-13-121-01-CDD]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA179072] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Alexander Birbrair is supported by a grant from Pro-reitoria de Pesquisa/Universidade Federal de Minas Gerais (PRPq/UFMG) (Edital 05/2016); Akiva Mintz is supported by the National Institute of Health (1R01CA179072-01A1) and by the American Cancer Society Mentored Research Scholar Grant (124443-MRSG-13-121-01-CDD).	Ahn SK, 2010, BRAIN RES, V1346, P92, DOI 10.1016/j.brainres.2010.05.057; ALLSOPP G, 1979, J ANAT, V128, P155; Andreotti JP, 2017, CELL STEM CELL, V21, P293, DOI 10.1016/j.stem.2017.08.005; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Asada N, 2017, NAT CELL BIOL, V19, P214, DOI 10.1038/ncb3475; Azevedo PO, NEUROSCIENCE; Bechmann I, 2001, EUR J NEUROSCI, V14, P1651, DOI 10.1046/j.0953-816x.2001.01793.x; Bell RD, 2010, NEURON, V68, P409, DOI 10.1016/j.neuron.2010.09.043; Biesecker KR, 2016, J NEUROSCI, V36, P9435, DOI 10.1523/JNEUROSCI.1782-16.2016; Birbrair A, 2017, STEM CELLS DEV, V26, P1013, DOI 10.1089/scd.2017.0044; Birbrair A, 2017, STEM CELL TRANSL MED, V6, P471, DOI 10.5966/sctm.2016-0007; Birbrair A, 2016, ANN NY ACAD SCI, V1370, P82, DOI 10.1111/nyas.13016; Birbrair A, 2015, STEM CELL REV REP, V11, P547, DOI 10.1007/s12015-015-9588-6; Birbrair A, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt512; Birbrair A, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00245; Birbrair A, 2015, CLIN SCI, V128, P81, DOI 10.1042/CS20140278; Birbrair A, 2014, AM J PHYSIOL-CELL PH, V307, pC25, DOI 10.1152/ajpcell.00084.2014; Birbrair A, 2013, AM J PHYSIOL-CELL PH, V305, pC1098, DOI 10.1152/ajpcell.00171.2013; Birbrair A, 2013, STEM CELLS DEV, V22, P2298, DOI 10.1089/scd.2012.0647; Birbrair A, 2013, STEM CELL RES, V10, P67, DOI 10.1016/j.scr.2012.09.003; Birbrair A, 2013, EXP CELL RES, V319, P45, DOI 10.1016/j.yexcr.2012.09.008; Birbrair A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016816; Bondjers C, 2006, FASEB J, V20, P1703, DOI 10.1096/fj.05-4944fje; Borges I, 2017, STEM CELL REV REP, V13, P567, DOI 10.1007/s12015-017-9747-z; Castejon OJ, 2011, FOLIA NEUROPATHOL, V49, P162; Coatti GC, 2017, STEM CELL REV REP, V13, P686, DOI 10.1007/s12015-017-9752-2; Crisan M, 2012, J CELL MOL MED, V16, P2851, DOI 10.1111/j.1582-4934.2012.01617.x; Prazeres PHDM, 2017, DEV BIOL, V427, P6, DOI 10.1016/j.ydbio.2017.05.001; DIAZFLORES L, 1991, HISTOL HISTOPATHOL, V6, P269; Domingo A, 2012, J NEUROTRAUM, V29, P865, DOI 10.1089/neu.2011.2052; Enge M, 2002, EMBO J, V21, P4307, DOI 10.1093/emboj/cdf418; Fisher M, 2009, STROKE, V40, pS13, DOI 10.1161/STROKEAHA.108.533117; Gaskill PJ, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-203; Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165; Guillemin GJ, 2004, J LEUKOCYTE BIOL, V75, P388, DOI 10.1189/jlb.0303114; Hall CN, 2014, NATURE, V508, P55, DOI 10.1038/nature13165; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6; Idzko M, 2004, J IMMUNOL, V172, P6011, DOI 10.4049/jimmunol.172.10.6011; Khan JA, 2016, SCIENCE, V351, P176, DOI 10.1126/science.aad0084; Kim JA, 2006, J CEREBR BLOOD F MET, V26, P209, DOI 10.1038/sj.jcbfm.9600181; Kunisaki Y, 2013, NATURE, V502, P637, DOI 10.1038/nature12612; KUNZ J, 1994, J NEUROCHEM, V62, P2375; LI XM, 1992, J NEUROCHEM, V59, P1172, DOI 10.1111/j.1471-4159.1992.tb08363.x; Li YQ, 2017, NAT MED, V23, P733, DOI 10.1038/nm.4331; Licona-Limon I, 2015, J LEUKOCYTE BIOL, V98, P85, DOI 10.1189/jlb.2A0914-458R; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Lousado L, CELL DEATH DIS; Massot O, 1999, NEUROPSYCHOPHARMACOL, V21, P530, DOI 10.1016/S0893-133X(99)00042-1; Metz GAS, 2000, J NEUROTRAUM, V17, P1, DOI 10.1089/neu.2000.17.1; Mishra A, 2016, NAT NEUROSCI, V19, P1619, DOI 10.1038/nn.4428; Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6; Myers J, 2007, AM J PHYS MED REHAB, V86, P142, DOI 10.1097/PHM.0b013e31802f0247; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; NEHLS V, 1991, J CELL BIOL, V113, P147, DOI 10.1083/jcb.113.1.147; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; Paiva AE, NEOPLASIA; Peppiatt CM, 2006, NATURE, V443, P700, DOI 10.1038/nature05193; Phillips AA, 2016, J CEREBR BLOOD F MET, V36, P647, DOI 10.1177/0271678X15617954; Phillips AA, 2013, BRAIN SCI, V3, P781, DOI 10.3390/brainsci3020781; Phillips AA, 2014, J CEREBR BLOOD F MET, V34, P794, DOI 10.1038/jcbfm.2014.3; Prazeres PHDM, CELL MOL NEUROBIOL; Razzaque Z, 2002, BRIT J CLIN PHARMACO, V53, P266, DOI 10.1046/j.0306-5251.2001.01536.x; Rossignol S, 2007, J NEUROSCI, V27, P11782, DOI 10.1523/JNEUROSCI.3444-07.2007; Rouget C., 1873, ARCH PHYSL NORM PATH, V5, P603; Santos GSP, EYE; Sena IFG, CELL CYCLE; Sena IFG, 2017, EXP HEMATOL, V54, P12, DOI 10.1016/j.exphem.2017.06.349; SHEPRO D, 1993, FASEB J, V7, P1031, DOI 10.1096/fasebj.7.11.8370472; Sims DE, 2000, CLIN EXP PHARMACOL P, V27, P842, DOI 10.1046/j.1440-1681.2000.03343.x; Soderblom C, 2013, J NEUROSCI, V33, P13882, DOI 10.1523/JNEUROSCI.2524-13.2013; Stark K, 2013, NAT IMMUNOL, V14, P41, DOI 10.1038/ni.2477; Tu ZD, 2011, INVEST OPHTH VIS SCI, V52, P9005, DOI 10.1167/iovs.11-8008; Uhlirova H, 2016, ELIFE, V5, DOI [10.7554/elife.14315, 10.7554/eLife.14315]; Wanjare M, 2013, BIOTECHNOL J, V8, P434, DOI 10.1002/biot.201200199; WAXMAN SG, 1992, J NEUROTRAUM, V9, pS105; Winkler EA, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-32; Yotsumoto F, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.1001204; Zimmermann KW, 1923, Z ANAT ENTWICKL GESC, V68, P29	79	24	24	1	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	OCT	2018	24	5					440	447		10.1177/1073858417731522			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GS2HP	WOS:000443368300004	29283016	Green Accepted			2022-02-06	
J	Bianchi, F; Malboubi, M; Li, YC; George, JH; Jerusalem, A; Szele, F; Thompson, MS; Ye, H				Bianchi, Fabio; Malboubi, Majid; Li, Yichen; George, Julian H.; Jerusalem, Antoine; Szele, Francis; Thompson, Mark S.; Ye, Hua			Rapid and efficient differentiation of functional motor neurons from human iPSC for neural injury modelling	STEM CELL RESEARCH			English	Article						Induced pluripotent stem cells (iPSC); Motor neuron differentiation; Electrophysiology; Neural injury	PLURIPOTENT STEM-CELLS; TRAUMATIC BRAIN-INJURY; NETWORK ACTIVITY; DIRECTED DIFFERENTIATION; PERIPHERAL-NERVES; HUMAN FIBROBLASTS; CORTICAL-NEURONS; ANIMAL-MODELS; ACUTE STRETCH; SPINAL-CORD	Primary rodent neurons and immortalised cell lines have overwhelmingly been used for in vitro studies of traumatic injury to peripheral and central neurons, but have some limitations of physiological accuracy. Motor neurons (MN) derived from human induced pluripotent stem cells (iPSCs) enable the generation of cell models with features relevant to human physiology. To facilitate this, it is desirable that MN protocols both rapidly and efficiently differentiate human iPSCs into electrophysiologically active MNs. In this study, we present a simple, rapid protocol for differentiation of human iPSCs into functional spinal (lower) MNs, involving only adherent culture and use of small molecules for directed differentiation, with the ultimate aim of rapid production of electrophysiologically functional cells for short-term neural injury experiments. We show successful differentiation in two unrelated iPSC lines, by quantifying neural-specific marker expression, and by evaluating cell functionality at different maturation stages by calcium imaging and patch clamping. Differentiated neurons were shown to be electrophysiologically altered by uniaxial mechanical deformation. Spontaneous network activity decreased with applied stretch, indicating aberrant network connectivity. These results demonstrate the feasibility of this rapid, simple protocol for differentiating iPSC-derived MNs, suitable for in vitro neural injury studies focussing on electrophysiological alterations caused by mechanical deformation or trauma.	[Bianchi, Fabio; Malboubi, Majid; George, Julian H.; Thompson, Mark S.; Ye, Hua] Univ Oxford, Dept Engn Sci, Inst Biomed Engn, Oxford OX3 7DQ, England; [Jerusalem, Antoine] Univ Oxford, Dept Engn Sci, Oxford OX1 3PJ, England; [Li, Yichen; Szele, Francis] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3QX, England		Ye, H (corresponding author), Univ Oxford, Dept Engn Sci, Inst Biomed Engn, Oxford OX3 7DQ, England.	hua.ye@eng.ox.ac.uk	Ye, Hua/L-5408-2019	Ye, Hua/0000-0001-7613-6041; George, Julian/0000-0002-0701-5040	China Regenerative Medicine Limited (CRMI); EPSRC DTPUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [1514540]; European Union's Seventh Framework Programme (FP7 2007-2013) ERC Grant [306587]	The authors would like to acknowledge Dr. Zameel Cader and Dr. Satyan Chintawar for kindly providing SB-AD3-1 cells through StemBANCC. Authors acknowledge China Regenerative Medicine Limited (CRMI) for funding and the EPSRC DTP award number 1514540 for F.B. funding. M.B. and A.J. acknowledge funding from the European Union's Seventh Framework Programme (FP7 2007-2013) ERC Grant Agreement No. 306587.	Abid A, 2016, ORTHOP TRAUMATOL-SUR, V102, pS125, DOI 10.1016/j.otsr.2015.05.008; Amoroso MW, 2013, J NEUROSCI, V33, P574, DOI 10.1523/JNEUROSCI.0906-12.2013; Bar-Kochba E, 2016, SCI REP-UK, V6, DOI 10.1038/srep30550; Biffi E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083899; Bueno FR, 2008, TISSUE ENG PART B-RE, V14, P219, DOI 10.1089/ten.teb.2008.0020; Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529; Clark AJ, 2017, BRAIN, V140, P898, DOI 10.1093/brain/awx012; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Du ZW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7626; Faravelli I, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt476; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Grienberger C, 2012, NEURON, V73, P862, DOI 10.1016/j.neuron.2012.02.011; Hu BY, 2010, METHODS MOL BIOL, V636, P123, DOI 10.1007/978-1-60761-691-7_8; Hu BY, 2010, P NATL ACAD SCI USA, V107, P4335, DOI 10.1073/pnas.0910012107; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Kang WH, 2015, J NEUROTRAUM, V32, P1011, DOI 10.1089/neu.2014.3667; Karumbayaram S, 2009, STEM CELLS, V27, P806, DOI 10.1002/stem.31; Kim DS, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00109; Kobold S, 2015, STEM CELL REP, V4, P914, DOI 10.1016/j.stemcr.2015.03.002; Kurtoglu E., 2017, JBSE, V12; Li WL, 2011, P NATL ACAD SCI USA, V108, P8299, DOI 10.1073/pnas.1014041108; Magou GC, 2015, BRAIN RES, V1624, P525, DOI 10.1016/j.brainres.2015.07.056; Mann K, 2017, CURR BIOL, V27, P2389, DOI 10.1016/j.cub.2017.06.076; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Maury Y, 2015, NAT BIOTECHNOL, V33, P89, DOI 10.1038/nbt.3049; Mazzara PG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14088; MILLER RG, 1987, MUSCLE NERVE, V10, P698, DOI 10.1002/mus.880100805; Muhr J, 1999, NEURON, V23, P689, DOI 10.1016/S0896-6273(01)80028-3; Neely MD, 2012, ACS CHEM NEUROSCI, V3, P482, DOI 10.1021/cn300029t; OGATA K, 1986, J HAND SURG-BRIT EUR, V11B, P10, DOI 10.1016/0266-7681(86)90003-3; Patani R, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1216; Pfister BJ, 2003, ANN BIOMED ENG, V31, P589, DOI 10.1114/1.1566445; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Rickett T, 2011, J MED SYST, V35, P787, DOI 10.1007/s10916-010-9468-1; Robinson LR, 2000, MUSCLE NERVE, V23, P863, DOI 10.1002/(SICI)1097-4598(200006)23:6<863::AID-MUS4>3.0.CO;2-0; Rostock C, 2018, NEUROSCIENCE, V387, P13, DOI 10.1016/j.neuroscience.2017.11.047; Salimi A, 2014, MOL BIOL REP, V41, P1713, DOI 10.1007/s11033-014-3020-1; Sances S, 2016, NAT NEUROSCI, V19, P542, DOI 10.1038/nn.4273; Sherman SA, 2016, SCI REP-UK, V6, DOI 10.1038/srep34097; Shimojo D, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0172-4; Skotak M, 2012, J NEUROSCI METH, V205, P159, DOI 10.1016/j.jneumeth.2012.01.001; Sun AX, 2016, CELL REP, V16, P1942, DOI 10.1016/j.celrep.2016.07.035; Sun WJ, 2012, J NEUROTRAUM, V29, P611, DOI 10.1089/neu.2011.2086; Surmacz B, 2012, STEM CELLS, V30, P1875, DOI 10.1002/stem.1166; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tao YL, 2016, CELL STEM CELL, V19, P573, DOI 10.1016/j.stem.2016.10.015; Topp KS, 2006, PHYS THER, V86, P92, DOI 10.1093/ptj/86.1.92; Wang XS, 1997, BRAIN RES, V767, P239, DOI 10.1016/S0006-8993(97)00585-4; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zeng H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011853; Zhang PB, 2014, JOVE-J VIS EXP, DOI 10.3791/51737; Zhou JX, 2010, STEM CELLS, V28, P1741, DOI 10.1002/stem.504	54	24	24	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1873-5061	1876-7753		STEM CELL RES	Stem Cell Res.	OCT	2018	32						126	134		10.1016/j.scr.2018.09.006			9	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology	GW9JI	WOS:000447301200019	30278374	gold, Green Published			2022-02-06	
J	Hsu, WC; Sugiarto, T; Lin, YJ; Yang, FC; Lin, ZY; Sun, CT; Hsu, CL; Chou, KN				Hsu, Wei-Chun; Sugiarto, Tommy; Lin, Yi-Jia; Yang, Fu-Chi; Lin, Zheng-Yi; Sun, Chi-Tien; Hsu, Chun-Lung; Chou, Kuan-Nien			Multiple-Wearable-Sensor-Based Gait Classification and Analysis in Patients with Neurological Disorders	SENSORS			English	Article						wearable device; gait analysis; IMU sensors; gait classification; stroke patients; neurological disorders	PHYSICAL-ACTIVITY; TRIAXIAL ACCELEROMETER; AMBULATORY SYSTEM; INERTIAL SENSORS; PARAMETERS; STABILITY; SUPPORT; HARMONY; EVENTS	The aim of this study was to conduct a comprehensive analysis of the placement of multiple wearable sensors for the purpose of analyzing and classifying the gaits of patients with neurological disorders. Seven inertial measurement unit (IMU) sensors were placed at seven locations: the lower back (L5) and both sides of the thigh, distal tibia (shank), and foot. The 20 subjects selected to participate in this study were separated into two groups: stroke patients (11) and patients with neurological disorders other than stroke (brain concussion, spinal injury, or brain hemorrhage) (9). The temporal parameters of gait were calculated using a wearable device, and various features and sensor configurations were examined to establish the ideal accuracy for classifying different groups. A comparison of the various methods and features for classifying the three groups revealed that a combination of time domain and gait temporal feature-based classification with the Multilayer Perceptron (MLP) algorithm outperformed the other methods of feature-based classification. The classification results of different sensor placements revealed that the sensor placed on the shank achieved higher accuracy than the other sensor placements (L5, foot, and thigh). The placement-based classification of the shank sensor achieved 89.13% testing accuracy with the Decision Tree (DT) classifier algorithm. The results of this study indicate that the wearable IMU device is capable of differentiating between the gait patterns of healthy patients, patients with stroke, and patients with other neurological disorders. Moreover, the most favorable results were reported for the classification that used the combination of time domain and gait temporal features as the model input and the shank location for sensor placement.	[Hsu, Wei-Chun; Sugiarto, Tommy; Lin, Yi-Jia] Natl Taiwan Univ Sci & Technol, Grad Inst Biomed Engn, Taipei 10607, Taiwan; [Hsu, Wei-Chun; Sugiarto, Tommy] Natl Taiwan Univ Sci & Technol, Grad Inst Appl Sci & Technol, Taipei 10607, Taiwan; [Hsu, Wei-Chun] Natl Def Med Ctr, Dept Biomed Engn, Taipei 11490, Taiwan; [Sun, Chi-Tien; Hsu, Chun-Lung] Ind Technol Res Inst, Div Embedded Syst & SoC Technol, Syst Integrat & Applicat Dept, Informat & Commun Res Lab, Hsinchu 31057, Taiwan; [Yang, Fu-Chi] Triserv Gen Hosp, Dept Neurol, Natl Def Med Ctr, Taipei 11490, Taiwan; [Lin, Zheng-Yi] Taipei City Hosp, Dept Phys Med & Rehabil, Zhongxing Branch, Taipei 10341, Taiwan; [Chou, Kuan-Nien] Triserv Gen Hosp, Neurosurg Dept, Taipei 11490, Taiwan		Hsu, WC (corresponding author), Natl Taiwan Univ Sci & Technol, Grad Inst Biomed Engn, Taipei 10607, Taiwan.; Hsu, WC (corresponding author), Natl Taiwan Univ Sci & Technol, Grad Inst Appl Sci & Technol, Taipei 10607, Taiwan.; Hsu, WC (corresponding author), Natl Def Med Ctr, Dept Biomed Engn, Taipei 11490, Taiwan.; Chou, KN (corresponding author), Triserv Gen Hosp, Neurosurg Dept, Taipei 11490, Taiwan.	wchsu@mail.ntust.edu.tw; d10622817@mail.ntust.edu.tw; jiajia527@gmail.com; Fuji-yang@yahoo.com.tw; DAP52@tpech.gov.tw; ctsun@itri.org.tw; clh@itri.org.tw; choukuannien@gmail.com	Sugiarto, Tommy/W-8465-2019	Sugiarto, Tommy/0000-0002-8814-1275; Yang, Fu-Chi/0000-0001-6831-3634; Lin, C. Delmar/0000-0003-0720-7584	Ministry of Science and Technology, TaiwanMinistry of Science and Technology, Taiwan [MOST104-2628-E-011-006-MY3]; National Taiwan University of Science and Technology [TSGH-NTUST-104-05]; Tri-Service General Hospital [TSGH-NTUST-107-04]; Industrial Technology Research Institute [107A02104]	The authors gratefully acknowledge financial support from the grant from the Ministry of Science and Technology, Taiwan (MOST104-2628-E-011-006-MY3 to W.-C.H., the corresponding author Wei-Chun Hsu), the National Taiwan University of Science and Technology (TSGH-NTUST-104-05), the Tri-Service General Hospital (TSGH-NTUST-107-04), and Industrial Technology Research Institute (107A02104).	Aminian K, 2002, J BIOMECH, V35, P689, DOI 10.1016/S0021-9290(02)00008-8; Anwary AR, 2018, IEEE SENS J, V18, P2555, DOI 10.1109/JSEN.2017.2786587; Begg RK, 2005, IEEE T BIO-MED ENG, V52, P828, DOI 10.1109/TBME.2005.845241; Bishop C. M., 1995, NEURAL NETWORKS PATT; Carcreff L, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18020394; Coley B, 2005, GAIT POSTURE, V22, P287, DOI 10.1016/j.gaitpost.2004.08.008; Daliri MR, 2012, MEASUREMENT, V45, P1729, DOI 10.1016/j.measurement.2012.04.013; De Vroey H, 2018, CLIN BIOMECH, V54, P22, DOI 10.1016/j.clinbiomech.2018.03.002; Del Din S, 2016, IEEE J BIOMED HEALTH, V20, P838, DOI 10.1109/JBHI.2015.2419317; Freund Y, 1997, J COMPUT SYST SCI, V55, P119, DOI 10.1006/jcss.1997.1504; Godfrey A, 2014, IEEE ENG MED BIO, P5892, DOI 10.1109/EMBC.2014.6944969; Iosa M, 2016, J MED BIOL ENG, V36, P635, DOI 10.1007/s40846-016-0178-0; Iosa M, 2016, EXPERT REV MED DEVIC, V13, P641, DOI 10.1080/17434440.2016.1198694; Iosa M, 2014, J REHABIL RES DEV, V51, P623, DOI 10.1682/JRRD.2013.07.0162; Iosa M, 2012, RES DEV DISABIL, V33, P129, DOI 10.1016/j.ridd.2011.08.031; Jasiewicz JM, 2006, GAIT POSTURE, V24, P502, DOI 10.1016/j.gaitpost.2005.12.017; Kavanagh JJ, 2006, J BIOMECH, V39, P2863, DOI 10.1016/j.jbiomech.2005.09.012; Khandelwal S, 2018, GAIT POSTURE, V59, P278, DOI 10.1016/j.gaitpost.2017.07.030; Long X, 2009, IEEE ENG MED BIO, P6107, DOI 10.1109/IEMBS.2009.5334925; Mannini A, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16010134; Mannini A, 2010, SENSORS-BASEL, V10, P1154, DOI 10.3390/s100201154; Patterson KK, 2010, GAIT POSTURE, V31, P241, DOI 10.1016/j.gaitpost.2009.10.014; Plasqui G, 2007, OBESITY, V15, P2371, DOI 10.1038/oby.2007.281; Pogorelc B, 2012, MULTIMED TOOLS APPL, V58, P333, DOI 10.1007/s11042-011-0786-1; Rowlands AV, 2004, MED SCI SPORT EXER, V36, P518, DOI 10.1249/01.MSS.0000117158.14542.E7; Salarian A, 2004, IEEE T BIO-MED ENG, V51, P1434, DOI 10.1109/TBME.2004.827933; Salarian A, 2013, IEEE T BIO-MED ENG, V60, P72, DOI 10.1109/TBME.2012.2223465; Salatino G., 2016, GAIT POSTURE, V49, pS16, DOI [10.1016/j.gaitpost.2016.07.046, DOI 10.1016/J.GAITPOST.2016.07.046]; Sejdic E, 2014, IEEE T NEUR SYS REH, V22, P603, DOI 10.1109/TNSRE.2013.2265887; Sinclair J, 2013, J APPL BIOMECH, V29, P118, DOI 10.1123/jab.29.1.118; Steele BG, 2000, CHEST, V117, P1359, DOI 10.1378/chest.117.5.1359; Taraldsen K, 2012, MATURITAS, V71, P13, DOI 10.1016/j.maturitas.2011.11.003; Trojaniello D, 2014, GAIT POSTURE, V40, P487, DOI 10.1016/j.gaitpost.2014.07.007; Vienne A, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00817; Weiss A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096675; ZHANG H, 2004, FLAIRS2004 C; Zhang J, 2014, ANN BIOMED ENG, V42, P600, DOI 10.1007/s10439-013-0917-0; Zheng HR, 2009, STUD COMPUT INTELL, V189, P57	38	24	25	2	10	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1424-8220			SENSORS-BASEL	Sensors	OCT	2018	18	10							3397	10.3390/s18103397			17	Chemistry, Analytical; Engineering, Electrical & Electronic; Instruments & Instrumentation	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Engineering; Instruments & Instrumentation	GY5YX	WOS:000448661500225	30314269	Green Submitted, Green Published, gold			2022-02-06	
J	Mouzon, B; Bachmeier, C; Ojo, J; Acker, C; Ferguson, S; Crynen, G; Davies, P; Mullan, M; Stewart, W; Crawford, F				Mouzon, Benoit; Bachmeier, Corbin; Ojo, Joseph; Acker, Christopher; Ferguson, Scott; Crynen, Gogce; Davies, Peter; Mullan, Michael; Stewart, William; Crawford, Fiona			Chronic White Matter Degeneration, But No Tau Pathology at One-Year Post-Repetitive Mild Traumatic Brain Injury in a Tau Transgenic Model	JOURNAL OF NEUROTRAUMA			English	Article						adult head injury; age; animal studies; axonal injury; behavior	MOUSE MODEL; NEURONAL PLASTICITY; AXONAL INJURY; HEAD-INJURY; PHOSPHORYLATION; ANESTHESIA; TAUOPATHY; PROTEIN; HYPERPHOSPHORYLATION; ACCUMULATION	Tau pathology associated with chronic traumatic encephalopathy has been documented in the brains of individuals with a history of repetitive mild traumatic brain injury (r-mTBI). At this stage, the pathobiological role of tau in r-mTBI has not been extensively explored in appropriate pre-clinical models. Here, we describe the acute and chronic behavioral and histopathological effects of single and repetitive mild TBI (five injuries given at 48h intervals) in young adult (3 months old) hTau mice that express all six isoforms of hTau on a null murine tau background. Animals exposed to r-mTBI showed impaired visuospatial learning in the Barnes maze test that progressively worsened from two weeks to 12 months post-injury, which was also accompanied by significant deficits in visuospatial memory consolidation at 12 months post-injury. In contrast, only marginal changes were observed in visuospatial learning at six and 12 months after single mTBI. Histopathological analyses revealed that hTau mice developed axonal injury, thinning of the corpus callosum, microgliosis and astrogliosis in the white matter at acute and chronic time points after injury. Tau immunohistochemistry and enzyme-linked immunosorbent assay data suggest, however, only transient, injury-dependent increases in phosphorylated tau in the cerebral cortex beneath the impact site and in the CA1/CA3 subregion of the hippocampus after single or r-mTBI. This study implicates white matter degeneration as a prominent feature of survival from mTBI, while the role of tau pathology in the neuropathological sequelae of TBI remains elusive.	[Mouzon, Benoit; Bachmeier, Corbin; Ojo, Joseph; Ferguson, Scott; Crynen, Gogce; Mullan, Michael; Crawford, Fiona] Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA; [Acker, Christopher; Davies, Peter] Feinstein Inst Med Res, Manhasset, NY USA; [Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, Lab Med Bldg, Glasgow, Lanark, Scotland		Mouzon, B (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	bmouzon@roskampinstitute.org	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Stewart, William/0000-0003-2199-2582	Department of Defense awardUnited States Department of Defense [W81XWH-10-1-0759]; Roskamp Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS038104, R01NS094]; DODUnited States Department of Defense; NHS Research Scotland Career Research Fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104] Funding Source: NIH RePORTER	This research was funded by a Department of Defense award (W81XWH-10-1-0759) to Dr. Fiona Crawford, and by the Roskamp Foundation. Dr. Crawford is a VA Research Career Scientist. Dr. Stewart is supported by NIH grants R01NS038104 & R01NS094, DOD and an NHS Research Scotland Career Research Fellowship. Any opinions, findings, conclusions or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the views of the U.S. Government, or the U.S. Department of Veterans Affairs, and no official endorsement should be inferred.'	Andorfer C, 2003, J NEUROCHEM, V86, P582, DOI 10.1046/j.1471-4159.2003.01879.x; Arendt T, 2003, J NEUROSCI, V23, P6972, DOI 10.1523/JNEUROSCI.23-18-06972.2003; Arendt T, 2013, AM J PHYSIOL-REG I, V305, pR478, DOI 10.1152/ajpregu.00117.2013; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Dave KR, 2012, COMP BIOCHEM PHYS B, V162, P1, DOI 10.1016/j.cbpb.2012.01.008; Duff K, 2000, NEUROBIOL DIS, V7, P87, DOI 10.1006/nbdi.1999.0279; Ferguson S, 2017, J NEUROTRAUM, V34, P1676, DOI 10.1089/neu.2016.4636; Ferguson SA, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00416; Hawkins BE, 2013, J BIOL CHEM, V288, P17042, DOI 10.1074/jbc.M113.472746; Jicha GA, 1999, J NEUROCHEM, V72, P214, DOI 10.1046/j.1471-4159.1999.0720214.x; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Mouzon BC, 2018, ANN CLIN TRANSL NEUR, V5, P64, DOI 10.1002/acn3.510; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Ojo JO, 2016, J NEUROPATH EXP NEUR, V75, P636, DOI 10.1093/jnen/nlw035; Ojo JO, 2016, EXP NEUROL, V275, P389, DOI 10.1016/j.expneurol.2015.06.003; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Planel E, 2007, J NEUROSCI, V27, P3090, DOI 10.1523/JNEUROSCI.4854-06.2007; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Run XQ, 2009, J ALZHEIMERS DIS, V16, P619, DOI 10.3233/JAD-2009-1003; Schneider A, 1999, BIOCHEMISTRY-US, V38, P3549, DOI 10.1021/bi981874p; Schraen-Maschke S, 2008, BIOMARK MED, V2, P363, DOI 10.2217/17520363.2.4.363; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Tran HT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025475; Tran HT, 2011, J NEUROSCI, V31, P9513, DOI 10.1523/JNEUROSCI.0858-11.2011; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Whittington RA, 2013, PROG NEURO-PSYCHOPH, V47, P147, DOI 10.1016/j.pnpbp.2013.03.004; Winston CN, 2016, AM J PATHOL, V186, P552, DOI 10.1016/j.ajpath.2015.11.006; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zhong Q, 2012, J BIOL CHEM, V287, P20711, DOI 10.1074/jbc.M112.364067	45	24	24	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2019	36	4					576	588		10.1089/neu.2018.5720		SEP 2018	13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	HM4MQ	WOS:000444036000001	29993324	Green Accepted, Green Published			2022-02-06	
J	Erdodi, LA; Hurtubise, JL; Charron, C; Dunn, A; Enache, A; McDermott, A; Hirst, RB				Erdodi, Laszlo A.; Hurtubise, Jessica L.; Charron, Carly; Dunn, Alexa; Enache, Anca; McDermott, Abigail; Hirst, Rayna B.			The D-KEFS Trails as Performance Validity Tests	PSYCHOLOGICAL ASSESSMENT			English	Article						performance validity; embedded validity indicators; Erdodi Index; trail making test; D-KEFS	TRAUMATIC BRAIN-INJURY; FORCED-CHOICE RECOGNITION; ADULT INTELLIGENCE SCALE; COMPLEX IDEATIONAL MATERIAL; FALSE-POSITIVE RATES; VERBAL-LEARNING TEST; RESPONSE BIAS; CLASSIFICATION ACCURACY; NEUROPSYCHOLOGICAL ASSESSMENT; MULTIPLE PERFORMANCE	This study was designed to examine the potential of the Delis-Kaplan Executive System (D-KEFS) version of the Trail Making Test (TMT) as a performance validity test (PVT). Data were collected from a mixed clinical sample of 157 consecutively referred outpatients (49% male, M-Age = 47.1, M-Education = 13.6) undergoing neuropsychological assessment at an academic medical center in the northeastern United States. Sensitivity and specificity of the D-KEFS Trails to psychometrically defined invalid responding was calculated across various cutoffs and criterion PVTs. The D-KEFS Trails produced classification accuracy comparable to the original version of the TMT, hovering around the "Larrabee limit" (.50 sensitivity at.90 specificity). Different cutoffs (age-corrected scaled score = 5 on Trails 1-3, <= 4 on Trails 4 and <= 8 on Trails 5) were needed to achieve the same classification accuracy across the five trials. Combining multiple cutoffs improved the signal detection performance. The study provides preliminary evidence of the utility of D-KEFS Trails as a PVT. Embedded PVTs are valuable, because they make a multivariate approach to validity assessment feasible. Combining validity indicators is superior to relying on single cutoffs. Public Significance Statement Unusually low performance on visuomotor processing speed test is more likely to reflect noncredible performance than genuine impairment. Public Significance Statement Unusually low performance on visuomotor processing speed test is more likely to reflect noncredible performance than genuine impairment.	[Erdodi, Laszlo A.; Hurtubise, Jessica L.; Charron, Carly; Dunn, Alexa; Enache, Anca; McDermott, Abigail] Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Hirst, Rayna B.] Palo Alto Univ, Neuropsychol Program, Palo Alto, CA USA		Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.co		Charron, Carly/0000-0001-5647-6903			An KY, 2017, CLIN NEUROPSYCHOL, V31, P193, DOI 10.1080/13854046.2016.1217046; An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Ashendorf L, 2017, CLIN NEUROPSYCHOL, V31, P857, DOI 10.1080/13854046.2017.1285961; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Barhon LI, 2015, APPL NEUROPSYCH-ADUL, V22, P114, DOI 10.1080/23279095.2013.863775; Berthelson L, 2013, BRAIN INJURY, V27, P909, DOI 10.3109/02699052.2013.793400; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Bilder RM, 2014, CLIN NEUROPSYCHOL, V28, P1212, DOI 10.1080/13854046.2014.969774; Boone K., 2013, CLINICAL PRACTICE OF; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Bush SS, 2014, PSYCHOL INJ LAW, V7, P197, DOI 10.1007/s12207-014-9198-7; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Busse M, 2012, CLIN NEUROPSYCHOL, V26, P675, DOI 10.1080/13854046.2012.679623; Chafetz MD, 2015, CLIN NEUROPSYCHOL, V29, P723, DOI 10.1080/13854046.2015.1099738; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P199, DOI 10.1080/13854046.2014.884633; Delis DC., 2001, DELIS KAPLAN EXECUTI; Delis DC., 1994, CALIFORNIA VERBAL LE; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Erdodi L.A., 2017, PSYCHOL NEUROSCIENCE, V10, P325, DOI [10.1037/pne0000103, DOI 10.1037/PNE0000103, https://doi.org//10.1037/pne0000103, DOI https://doi.org/10.1037/pne0000103]; Erdodi L. A., 2017, ARCH CLIN NEUROPSYCH, DOI [10. 1093/arclin/acx110, DOI 10.1093/ARCLIN/ACX110]; Erdodi L, 2017, APPL NEUROPSYCH-ADUL, V24, P264, DOI 10.1080/23279095.2016.1154856; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P327, DOI 10.1080/23279095.2017.1298600; Erdodi LA, 2017, BRAIN INJURY, V31, P1362, DOI 10.1080/02699052.2017.1332386; Erdodi LA, 2018, APPL NEUROPSYCH-ADUL, V25, P19, DOI 10.1080/23279095.2016.1232262; Erdodi LA, 2017, J CLIN EXP NEUROPSYC, V39, P369, DOI 10.1080/13803395.2016.1230181; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2017, CLIN NEUROPSYCHOL, V31, P168, DOI 10.1080/13854046.2016.1224392; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; GOEBEL RA, 1983, J CLIN PSYCHOL, V39, P731, DOI 10.1002/1097-4679(198309)39:5<731::AID-JCLP2270390515>3.0.CO;2-T; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Halasz I, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00136; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Iverson GL, 2002, CLIN NEUROPSYCHOL, V16, P398, DOI 10.1076/clin.16.3.398.13861; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Johnson DE, 2001, ARCH CLIN NEUROPSYCH, V16, P587; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Larrabee G. J., 2012, FORENSIC NEUROPSYCHO, P117; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Larrabee GJ, 2014, CLIN NEUROPSYCHOL, V28, P1230, DOI 10.1080/13854046.2014.988754; Larrabee GJ, 2014, ARCH CLIN NEUROPSYCH, V29, P364, DOI 10.1093/arclin/acu019; Leighton A, 2014, J INT NEUROPSYCH SOC, V20, P873, DOI 10.1017/S135561771400085X; Lezak MD, 2012, NEUROPSYCHOLOGICAL A; Lichtenstein JD, 2018, CHILD NEUROPSYCHOL, V24, P247, DOI 10.1080/09297049.2016.1259402; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Miele AS, 2012, ARCH CLIN NEUROPSYCH, V27, P10, DOI 10.1093/arclin/acr084; Millis SR, 1998, J CLIN EXP NEUROPSYC, V20, P167, DOI 10.1076/jcen.20.2.167.1171; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Neipert L, 2014, BRAIN INJURY, V28, P1667, DOI 10.3109/02699052.2014.947623; Odland AP, 2015, PSYCHOL INJ LAW, V8, P46, DOI 10.1007/s12207-015-9216-4; Pearson, 2009, ADV CLIN SOL WAIS 4; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A., 1964, EXAMEN CLIN PSYCHOL; Root JC, 2006, J INT NEUROPSYCH SOC, V12, P688, DOI 10.1017/S1355617706060838; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Schwartz ES, 2016, J INT NEUROPSYCH SOC, V22, P851, DOI 10.1017/S1355617716000746; Shura RD, 2016, APPL NEUROPSYCH-ADUL, V23, P94, DOI 10.1080/23279095.2015.1014556; Silk-Eglit GM, 2015, APPL NEUROPSYCH-ADUL, V22, P335, DOI 10.1080/23279095.2014.938809; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Whiteside DM, 2015, J CLIN EXP NEUROPSYC, V37, P220, DOI 10.1080/13803395.2014.1002758	72	24	24	2	4	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	1040-3590	1939-134X		PSYCHOL ASSESSMENT	Psychol. Assess.	AUG	2018	30	8					1082	1095		10.1037/pas0000561			14	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	GP1HU	WOS:000440566800009	29952596				2022-02-06	
J	Rodriguez-Grande, B; Obenaus, A; Ichkova, A; Aussudre, J; Bessy, T; Barse, E; Hiba, B; Catheline, G; Barriere, G; Badaut, J				Rodriguez-Grande, Beatriz; Obenaus, Andre; Ichkova, Aleksandra; Aussudre, Justine; Bessy, Thomas; Barse, Elodie; Hiba, Bassem; Catheline, Gwenaelle; Barriere, Gregory; Badaut, Jerome			Gliovascular changes precede white matter damage and long-term disorders in juvenile mild closed head injury	GLIA			English	Article						AQP4; astrocyte; mild traumatic brain injury; MRI; pediatric; white matter	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; MYELIN BASIC-PROTEIN; CORPUS-CALLOSUM; CORTICAL CONTUSION; RNA INTERFERENCE; AQUAPORIN 4; MICE; CHILDREN; IMPACT	Traumatic brain injury (TBI) is a leading cause of hospital visits in pediatric patients and often leads to long-term disorders even in cases of mild severity. White matter (WM) alterations are commonly observed in patients months or years after the injury assessed by magnetic resonance imaging (MRI), but little is known about WM pathophysiology early after mild pediatric TBI. To evaluate the status of the gliovascular unit in this context, mild TBI was induced in postnatal-day 17 mice using a closed head injury model with two grades of severity (G1, G2). G2 resulted in significant WM edema (increased T2-signal) and BBB damage (IgG-extravasation immunostaining) whereas decreased T2 and the increased levels of astrocytic water-channel AQP4 were observed in G1 mice 1 day post-injury. Both severities induced astrogliosis (GFAP immunolabeling). No changes in myelin and neurofilament were detected at this acute time point. One month after injury G2 mice exhibited diffusion tensor imaging MRI alterations (decreased fractional anisotropy) accompanied by decreased neurofilament staining in the WM. Both severities induced behavioral impairments at this time point. In conclusion, long-term deficits and WM changes similar to those found after clinical TBI are preceded by distinct early gliovascular phenotype alterations after juvenile mild TBI, revealing AQP4 as a potential candidate for severity-based treatments.	[Rodriguez-Grande, Beatriz; Obenaus, Andre; Ichkova, Aleksandra; Aussudre, Justine; Bessy, Thomas; Barse, Elodie; Hiba, Bassem; Catheline, Gwenaelle; Barriere, Gregory; Badaut, Jerome] Univ Bordeaux, CNRS UMR5287, Inst Neurosci Cognit & Integrat Aquitaine, Bordeaux, France; [Obenaus, Andre] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA USA; [Obenaus, Andre; Badaut, Jerome] Loma Linda Univ, Sch Med, Dept Basic Sci, Loma Linda, CA USA; [Obenaus, Andre] UC Riverside, Div Biomed Sci, Ctr Glial Neuronal Interact, Riverside, CA USA; [Obenaus, Andre] Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA; [Barse, Elodie; Catheline, Gwenaelle] EPHE, PSL, Bordeaux, France		Badaut, J (corresponding author), Bordeaux Univ, UMR CNRS 5287, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	jerome.badaut@u-bordeaux.fr	Rodriguez-Grande, Beatriz/I-5397-2015	Rodriguez-Grande, Beatriz/0000-0002-4638-7576; , Andre/0000-0003-0081-6950; catheline, gwenaelle/0000-0003-1949-8913; Bessy, Thomas/0000-0001-9911-4400; Barriere, Gregory/0000-0002-0704-508X	Eranet Neuron CNS-aflame; Idex Funding Bordeaux [ANR-10-IDEX-03-02]; BIS-Idex; TRAIL-Laboratory of Excellence TRAIL [ANR-10-LABX-57]	Eranet Neuron CNS-aflame; Idex Funding Bordeaux (ANR-10-IDEX-03-02 to AO & JB); BIS-Idex; TRAIL-Laboratory of Excellence TRAIL (ANR-10-LABX-57 to JB)	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Alvarez JI, 2013, GLIA, V61, P1939, DOI 10.1002/glia.22575; Arenth PM, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318289ede5; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Babikian T, 2015, J NEUROTRAUM, V32, P1849, DOI 10.1089/neu.2015.3971; Badaut J, 2014, BBA-GEN SUBJECTS, V1840, P1554, DOI 10.1016/j.bbagen.2013.10.032; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Bajwa NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146886; Baldwin SA, 1996, GLIA, V16, P266; Ballachey EL, 1932, U CALIFORNIA PUBLICA, V6, P1; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Bartnik-Olson BL, 2014, J NEUROTRAUM, V31, P1497, DOI 10.1089/neu.2013.3213; BERACOCHEA D, 1987, BEHAV BRAIN RES, V25, P63, DOI 10.1016/0166-4328(87)90045-3; Blanchard DC, 2001, NEUROSCI BIOBEHAV R, V25, P205, DOI 10.1016/S0149-7634(01)00009-4; BODHIREDDY SR, 1994, J NEUROPATH EXP NEUR, V53, P144, DOI 10.1097/00005072-199403000-00005; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Cho M, 2009, NAT NEUROSCI, V12, P1085, DOI 10.1038/nn0909-1085; Choy M, 2014, J NEUROSCI, V34, P8672, DOI 10.1523/JNEUROSCI.4806-13.2014; DEAN PJA, 2013, FRONT HUM NEUROSCI, V0007; Dennis EL, 2015, J NEUROSCI, V35, P10202, DOI 10.1523/JNEUROSCI.1595-15.2015; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Deoni SCL, 2011, J NEUROSCI, V31, P784, DOI 10.1523/JNEUROSCI.2106-10.2011; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Dubois J, 2014, NEUROSCIENCE, V276, P48, DOI 10.1016/j.neuroscience.2013.12.044; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Filosa JA, 2016, NEUROSCIENCE, V323, P96, DOI 10.1016/j.neuroscience.2015.03.064; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Girard N, 2007, J NEURORADIOLOGY, V34, P290, DOI 10.1016/j.neurad.2007.07.007; Hanell A, 2015, ACTA NEUROPATHOL, V129, P317, DOI 10.1007/s00401-014-1376-x; Harris NG, 2016, NEUROIMAGE, V133, P129, DOI 10.1016/j.neuroimage.2016.03.012; Hernandez A, 2016, J NEUROCHEM, V136, P18, DOI 10.1111/jnc.13402; Hirt L, 2009, J CEREBR BLOOD F MET, V29, P423, DOI 10.1038/jcbfm.2008.133; Howarth C, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00103; Iannotti CA, 2011, EXP NEUROL, V230, P3, DOI 10.1016/j.expneurol.2010.03.010; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jullienne A, 2016, J NEUROSCI RES, V94, P609, DOI 10.1002/jnr.23732; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Kenney K, 2016, EXP NEUROL, V275, P353, DOI 10.1016/j.expneurol.2015.05.019; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Laitinen T, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3389/fnins.7015.00128, 10.3389/fnins.2015.00128]; Liang FY, 2015, NEUROSCI LETT, V598, P29, DOI 10.1016/j.neulet.2015.05.006; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Lumba-Brown A, 2016, REPORT PEDIAT MILD T; Mallya S, 2015, J NEUROTRAUM, V32, P411, DOI 10.1089/neu.2014.3504; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McAuliffe M. J., 2001, P 14 IEEE S COMP BAS; Nguyen R, 2016, CAN J NEUROL SCI, V43, P774, DOI 10.1017/cjn.2016.290; Petraglia Anthony L, 2014, Neurosurgery, V75 Suppl 4, pS34, DOI 10.1227/NEU.0000000000000472; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Ribeiro MD, 2006, J NEUROSCI RES, V83, P1231, DOI 10.1002/jnr.20819; Roberts RM, 2014, DEV NEUROPSYCHOL, V39, P600, DOI 10.1080/87565641.2014.973958; Rodriguez-Grande B, 2017, BRAIN EDEMA: FROM MOLECULAR MECHANISMS TO CLINICAL PRACTICE, P163, DOI 10.1016/B978-0-12-803196-4.00009-6; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rowe RK, 2016, METHODS MOL BIOL, V1462, P211, DOI 10.1007/978-1-4939-3816-2_13; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Spitz G, 2017, J NEUROTRAUM, V34, P807, DOI 10.1089/neu.2016.4527; Stokum JA, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0239-6; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; WALSH RN, 1976, PSYCHOL BULL, V83, P482, DOI 10.1037/0033-2909.83.3.482; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Yao XM, 2015, J NEUROTRAUM, V32, P1458, DOI 10.1089/neu.2014.3675	73	24	24	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	AUG	2018	66	8					1663	1677		10.1002/glia.23336			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	GN1BV	WOS:000438719700009	29665077				2022-02-06	
J	Jha, KA; Pentecost, M; Lenin, R; Klaic, L; Elshaer, SL; Gentry, J; Russell, JM; Beland, A; Reiner, A; Jotterand, V; Sohl, N; Gangaraju, R				Jha, Kumar Abhiram; Pentecost, Mickey; Lenin, Raji; Klaic, Lada; Elshaer, Sally L.; Gentry, Jordy; Russell, John M.; Beland, Alex; Reiner, Anton; Jotterand, Veronique; Sohl, Nicolas; Gangaraju, Rajashekhar			Concentrated Conditioned Media from Adipose Tissue Derived Mesenchymal Stem Cells Mitigates Visual Deficits and Retinal Inflammation Following Mild Traumatic Brain Injury	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						TBI; adult stem cells; TSG6; retinal ganglion cells; oxidative stress; TIMP1; microglia; trans-endothelial electrical resistance	STROMAL CELLS; GANGLION-CELLS; LUNG INJURY; MOUSE MODEL; INTRAVITREAL INJECTION; IFATS COLLECTION; RODENT MODEL; SPINAL-CORD; VISION LOSS; BLAST	Blast concussions are a common injury sustained in military combat today. Inflammation due to microglial polarization can drive the development of visual defects following blast injuries. In this study, we assessed whether anti-inflammatory factors released by the mesenchymal stem cells derived from adipose tissue (adipose stem cells, ASC) can limit retinal tissue damage and improve visual function in a mouse model of visual deficits following mild traumatic brain injury. We show that intravitreal injection of 1 mu L of ASC concentrated conditioned medium from cells pre-stimulated with inflammatory cytokines (ASC-CCM) mitigates loss of visual acuity and contrast sensitivity four weeks post blast injury. Moreover, blast mice showed increased retinal expression of genes associated with microglial activation and inflammation by molecular analyses, retinal glial fibrillary acidic protein (GFAP) immunoreactivity, and increased loss of ganglion cells. Interestingly, blast mice that received ASC-CCM improved in all parameters above. In vitro, ASC-CCM not only suppressed microglial activation but also protected against Tumor necrosis alpha (TNF alpha) induced endothelial permeability as measured by transendothelial electrical resistance. Biochemical and molecular analyses demonstrate TSG-6 is highly expressed in ASC-CCM from cells pre-stimulated with TNF alpha and IFN gamma but not from unstimulated cells. Our findings suggest that ASC-CCM mitigates visual deficits of the blast injury through their anti-inflammatory properties on activated pro-inflammatory microglia and endothelial cells. A regenerative therapy for immediate delivery at the time of injury may provide a practical and cost-effective solution against the traumatic effects of blast injuries to the retina.	[Jha, Kumar Abhiram; Lenin, Raji; Elshaer, Sally L.; Gentry, Jordy; Russell, John M.; Reiner, Anton; Gangaraju, Rajashekhar] Univ Tennessee, Dept Ophthalmol, Coll Med, Hlth Sci Ctr, Memphis, TN 38163 USA; [Pentecost, Mickey; Klaic, Lada; Beland, Alex; Jotterand, Veronique; Sohl, Nicolas] Cell Care Therapeut Inc, Monrovia, CA 91016 USA; [Reiner, Anton; Gangaraju, Rajashekhar] Univ Tennessee, Dept Anat & Neurobiol, Coll Med, Hlth Sci Ctr, Memphis, TN 38163 USA		Gangaraju, R (corresponding author), Univ Tennessee, Dept Ophthalmol, Coll Med, Hlth Sci Ctr, Memphis, TN 38163 USA.; Gangaraju, R (corresponding author), Univ Tennessee, Dept Anat & Neurobiol, Coll Med, Hlth Sci Ctr, Memphis, TN 38163 USA.	kjha@uthsc.edu; mickey.pentecost@gmail.com; rrajeshl@uthsc.edu; lklaic@cell-care.com; slelshaer@gmail.com; jgentr21@uthsc.edu; jrusse74@uthsc.edu; abeland16@students.kgi.edu; areiner@uthsc.edu; vjotterand@cell-care.com; nsohl@cell-care.com; sgangara@uthsc.edu	Reiner, Anton/AAG-8860-2020; Gangaraju, Rajashekhar/I-7852-2019	Reiner, Anton/0000-0002-2146-5232; Gangaraju, Rajashekhar/0000-0002-6664-8286	Department of DefenseUnited States Department of Defense [W81XWH-16-1-0761, W81XWH-16-1-0076]; National Eye InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY023427]; Research to Prevent BlindnessResearch to Prevent Blindness (RPB); Neuroscience Institute, UTHSC; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY023427] Funding Source: NIH RePORTER	This study was funded by grants from the Department of Defense (W81XWH-16-1-0761), National Eye Institute (EY023427), and unrestricted funds from Research to Prevent Blindness to R.G. and Department of Defense (W81XWH-16-1-0076) to A.R. K.A.J. is a recipient of postdoc fellowship award from Neuroscience Institute, UTHSC. The funders played no role in the conduct of the study, collection of data, management of the study, analysis of data, interpretation of data, or preparation of the manuscript.	Adutler-Lieber S, 2013, J CARDIOVASC PHARM T, V18, P78, DOI 10.1177/1074248412453875; Andreeva ER, 2018, J CELL PHYSIOL, V233, P1535, DOI 10.1002/jcp.26046; Bhattacharya Sujoy, 2017, Curr Mol Biol Rep, V3, P172, DOI 10.1007/s40610-017-0069-3; Block GJ, 2009, STEM CELLS, V27, P670, DOI [10.1634/stemcells.stemcells.2008-0742, 10.1002/stem.20080742]; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Bricker-Anthony C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131921; Bricker-Anthony C, 2014, INVEST OPHTH VIS SCI, V55, P4853, DOI 10.1167/iovs.14-14353; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Chan TM, 2014, CELL TRANSPLANT, V23, P549, DOI 10.3727/096368914X678445; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Chung JY, 2012, J NEUROL SCI, V317, P40, DOI 10.1016/j.jns.2012.02.035; Dantuma E, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt37; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Douglas RM, 2005, VISUAL NEUROSCI, V22, P677, DOI 10.1017/S0952523805225166; Duan L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073768; Guley NH, 2016, J NEUROTRAUM, V33, P403, DOI 10.1089/neu.2015.3886; Harting MT, 2018, STEM CELLS, V36, P79, DOI 10.1002/stem.2730; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Hines-Beard J, 2012, EXP EYE RES, V99, P63, DOI 10.1016/j.exer.2012.03.013; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Iandiev I, 2008, INVEST OPHTH VIS SCI, V49, P3559, DOI 10.1167/iovs.08-1723; Ionescu L, 2012, AM J PHYSIOL-LUNG C, V303, pL967, DOI 10.1152/ajplung.00144.2011; Jha KA, 2015, NEUROCHEM RES, V40, P2153, DOI 10.1007/s11064-015-1698-7; Jiang DS, 2013, BIOMATERIALS, V34, P2501, DOI 10.1016/j.biomaterials.2012.12.014; Johnson TV, 2010, INVEST OPHTH VIS SCI, V51, P2051, DOI 10.1167/iovs.09-4509; Kabu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127971; Karussis D, 2008, J NEUROL SCI, V265, P131, DOI 10.1016/j.jns.2007.05.005; Kim J, 2009, EXP HEMATOL, V37, P1445, DOI 10.1016/j.exphem.2009.09.004; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583; Landiev I, 2006, EXP EYE RES, V82, P449, DOI 10.1016/j.exer.2005.07.018; Lee MJ, 2010, J PROTEOME RES, V9, P1754, DOI 10.1021/pr900898n; Li W, 2013, STEM CELL RES, V10, P405, DOI 10.1016/j.scr.2013.01.005; Liu Y, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-135; Lu HY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0422-3; Mammadova N, 2017, AM J PATHOL, V187, P1459, DOI 10.1016/j.ajpath.2017.03.005; Marks PW, 2017, NEW ENGL J MED, V376, P1007, DOI 10.1056/NEJMp1613723; McGuckin CP, 2013, ARCH BIOCHEM BIOPHYS, V534, P88, DOI 10.1016/j.abb.2013.02.005; Mead B, 2016, CYTOTHERAPY, V18, P487, DOI 10.1016/j.jcyt.2015.12.002; Mead B, 2013, INVEST OPHTH VIS SCI, V54, P7544, DOI 10.1167/iovs.13-13045; Nakajima H, 2012, J NEUROTRAUM, V29, P1614, DOI 10.1089/neu.2011.2109; Newell KA, 2011, SEMIN IMMUNOPATHOL, V33, P91, DOI 10.1007/s00281-011-0255-y; Ostanin AA, 2011, B EXP BIOL MED+, V151, P133, DOI 10.1007/s10517-011-1275-2; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Potter DR, 2018, J TRAUMA ACUTE CARE, V84, P245, DOI 10.1097/TA.0000000000001744; Presley C, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.159; Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541; Rajashekhar G, 2008, STEM CELLS, V26, P2674, DOI 10.1634/stemcells.2008-0277; Rajashekhar G, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00059; Rajashekhar G, 2014, EXP EYE RES, V122, P77, DOI 10.1016/j.exer.2014.03.004; Rajashekhar G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084671; Redell JB, 2007, NEUROSCI LETT, V413, P36, DOI 10.1016/j.neulet.2006.11.060; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Rodriguez TM, 2015, STEM CELL TRANSL MED, V4, P894, DOI 10.5966/sctm.2015-0012; Sahler CS, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/659652; Sala E, 2015, GASTROENTEROLOGY, V149, P163, DOI 10.1053/j.gastro.2015.03.013; Saraf SS, 2017, OSLI RETINA, V48, P772, DOI 10.3928/23258160-20170829-16; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Shang QW, 2015, STEM CELLS DEV, V24, P2052, DOI 10.1089/scd.2014.0557; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Sugitani S, 2013, EXP EYE RES, V116, P254, DOI 10.1016/j.exer.2013.09.013; Tobita M, 2011, DISCOV MED, V11, P160; Traktuev DO, 2008, CIRC RES, V102, P77, DOI 10.1161/CIRCRESAHA.107.159475; Tzameret A, 2014, EXP EYE RES, V118, P135, DOI 10.1016/j.exer.2013.10.023; Vien L, 2017, OPTOMETRY VISION SCI, V94, P125, DOI 10.1097/OPX.0000000000000899; Volkman R, 2017, STEM CELLS, V35, P1867, DOI 10.1002/stem.2651; Wei X, 2009, NEUROSCI LETT, V462, P76, DOI 10.1016/j.neulet.2009.06.054; Wei X, 2009, STEM CELLS, V27, P478, DOI 10.1634/stemcells.2008-0333; Weichel ED, 2008, OPHTHALMOLOGY, V115, P2235, DOI 10.1016/j.ophtha.2008.08.033; Xie J, 2015, STEM CELLS, V33, P468, DOI 10.1002/stem.1851; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0257-0; Zanier ER, 2014, NEUROTHERAPEUTICS, V11, P679, DOI 10.1007/s13311-014-0277-y; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106	76	24	25	2	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	JUL	2018	19	7							2016	10.3390/ijms19072016			22	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Chemistry	GR6UX	WOS:000442807400195	29997321	Green Published, gold, Green Submitted			2022-02-06	
J	Piccirillo, S; Castaldo, P; Macri, ML; Amoroso, S; Magi, S				Piccirillo, Silvia; Castaldo, Pasqualina; Macri, Maria Loredana; Amoroso, Salvatore; Magi, Simona			Glutamate as a potential "survival factor" in an in vitro model of neuronal hypoxia/reoxygenation injury: leading role of the Na+/Ca2+ exchanger	CELL DEATH & DISEASE			English	Article							AMINO-ACID TRANSPORTERS; SODIUM-CALCIUM EXCHANGE; NEUROBLASTOMA SH-SY5Y CELLS; OXYGEN-GLUCOSE DEPRIVATION; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; NA+-CA2+ EXCHANGER; ADULT-RAT; EAAC1; DEATH	In brain ischemia, reduction in oxygen and substrates affects mitochondrial respiratory chain and aerobic metabolism, culminating in ATP production impairment, ionic imbalance, and cell death. The restoration of blood flow and reoxygenation are frequently associated with exacerbation of tissue injury, giving rise to ischemia/reperfusion (I/R) injury. In this setting, the imbalance of brain bioenergetics induces important metabolic adaptations, including utilization of alternative energy sources, such as glutamate. Although glutamate has long been considered as a neurotoxin, it can also be used as intermediary metabolite for ATP synthesis, and both the Na/+Ca2+ exchanger (NCX) and the Na+-dependent excitatory amino-acid transporters (EAATs) are essential in this pathway. Here we analyzed the role of NCX in the potential of glutamate to improve metabolism and survival of neuronal cells subjected to hypoxia/reoxygenation (H/R). In SH-SY5Y neuroblastoma cells differentiated into a neuron-like state, H/R produced a significant cell damage, a decrease in ATP cellular content, and intracellular Ca2+ alterations. Exposure to glutamate at the onset of the reoxygenation phase attenuated H/R-induced cell damage and evoked a significant raise in intracellular ATP levels. Furthermore, we found that in H/R cells NCX reverse-mode activity was reduced, and that glutamate limited such reduction. All the effects induced by glutamate supplementation were lost when cells were transfected with small interfering RNA against NCX1 and EAAT3, suggesting the need of a specific functional interplay between these proteins for glutamate-induced protection. Collectively, our results revealed the potential beneficial effect of glutamate in an in vitro model of H/R injury and focused on the essential role exerted by NCX1. Although preliminary, these findings could be a starting point to further investigate in in vivo systems such protective effect in ischemic settings, shedding a new light on the classical view of glutamate as detrimental factor.	[Piccirillo, Silvia; Castaldo, Pasqualina; Macri, Maria Loredana; Amoroso, Salvatore; Magi, Simona] Univ Politecn Marche, Sch Med, Dept Biomed Sci & Publ Hlth, Via Tronto 10-A, I-60126 Ancona, Italy		Magi, S (corresponding author), Univ Politecn Marche, Sch Med, Dept Biomed Sci & Publ Hlth, Via Tronto 10-A, I-60126 Ancona, Italy.	s.magi@univpm.it	MAGI, Simona/O-4651-2019	MAGI, Simona/0000-0002-8115-8226	"Ricerca Scientifica di Ateneo" (RSA) Grants from University "Politecnica delle Marche"	We are grateful to Gerardo Galeazzi, Franco Pettinari, and Carlo Alfredo Violet for their excellent technical assistance. This work was supported by "Ricerca Scientifica di Ateneo" (RSA) Grants (2015-2017) from University "Politecnica delle Marche".	Albrecht J, 2010, NEURON GLIA BIOL, V6, P263, DOI 10.1017/S1740925X11000093; Amoroso S, 1997, BRIT J PHARMACOL, V121, P303, DOI 10.1038/sj.bjp.0701092; Aoyama K, 2006, NAT NEUROSCI, V9, P119, DOI 10.1038/nn1609; Berman AE, 2011, ANN NEUROL, V69, P509, DOI 10.1002/ana.22162; BIEDLER JL, 1978, CANCER RES, V38, P3751; Bjorn-Yoshimoto WE, 2016, NEUROCHEM INT, V98, P4, DOI 10.1016/j.neuint.2016.05.007; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; Bonde C, 2005, NEUROSCIENCE, V136, P779, DOI 10.1016/j.neuroscience.2005.07.020; Canzoniero LMT, 2006, J NEUROSCI RES, V84, P692, DOI 10.1002/jnr.20971; Castaldo P, 2007, NEUROPHARMACOLOGY, V53, P369, DOI 10.1016/j.neuropharm.2007.05.019; Castaldo P, 2017, EUR J PHARMACOL, V794, P246, DOI 10.1016/j.ejphar.2016.11.045; Chen YM, 2003, J NEUROCHEM, V84, P1332, DOI 10.1046/j.1471-4159.2003.01630.x; Choi BY, 2014, INT J MOL SCI, V15, P19444, DOI 10.3390/ijms151119444; Cross JL, 2012, NEUROSCI RES, V73, P191, DOI 10.1016/j.neures.2012.04.007; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Denton RM, 2009, BBA-BIOENERGETICS, V1787, P1309, DOI 10.1016/j.bbabio.2009.01.005; Dirnagl U, 2008, NEUROPHARMACOLOGY, V55, P334, DOI 10.1016/j.neuropharm.2008.02.017; Divito CB, 2014, NEUROCHEM INT, V73, P172, DOI 10.1016/j.neuint.2013.12.008; Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Filograna R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136769; Gobbi P, 2007, PHARMACOL RES, V56, P556, DOI 10.1016/j.phrs.2007.10.005; Gottlieb M, 2000, J CEREBR BLOOD F MET, V20, P678, DOI 10.1097/00004647-200004000-00005; Hilgemann DW, 2018, J GEN PHYSIOL, V150, P211, DOI 10.1085/jgp.201711875; Husson A, 2003, EUR J BIOCHEM, V270, P1887, DOI 10.1046/j.1432-1033.2003.03559.x; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Iwamoto T, 2004, MOL PHARMACOL, V66, P45, DOI 10.1124/mol.66.1.45; KATSURA K, 1994, BIOCHEM SOC T, V22, P991, DOI 10.1042/bst0220991; Kim AY, 2017, NEUROSCIENCE, V340, P487, DOI 10.1016/j.neuroscience.2016.11.007; Lariccia V, 2011, J GEN PHYSIOL, V137, P111, DOI 10.1085/jgp.201010468; Li LL, 2011, J CEREBR BLOOD F MET, V31, P1283, DOI 10.1038/jcbfm.2010.222; Magi S, 2005, J PHARMACOL EXP THER, V315, P291, DOI 10.1124/jpet.105.088948; Magi S, 2015, EUR J PHARMACOL, V746, P31, DOI 10.1016/j.ejphar.2014.10.054; Magi S, 2013, MOL PHARMACOL, V84, P603, DOI 10.1124/mol.113.087775; Magi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034015; Maiolino M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13478-x; Matsuda T, 2001, J PHARMACOL EXP THER, V298, P249; McKenna MC, 2007, J NEUROSCI RES, V85, P3347, DOI 10.1002/jnr.21444; Miglio G, 2004, EUR J PHARMACOL, V489, P157, DOI 10.1016/j.ejphar.2004.03.006; Minelli A, 2007, CELL CALCIUM, V41, P221, DOI 10.1016/j.ceca.2006.06.004; NAARALA J, 1993, FEBS LETT, V330, P222, DOI 10.1016/0014-5793(93)80278-3; Nelson RM, 2003, BRAIN RES, V964, P1, DOI 10.1016/S0006-8993(02)03691-0; Olianas MC, 2017, EUR J PHARMACOL, V794, P135, DOI 10.1016/j.ejphar.2016.11.030; Pascual JM, 1998, STROKE, V29, P1048, DOI 10.1161/01.STR.29.5.1048; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; Pignataro G, 2004, STROKE, V35, P2566, DOI 10.1161/01.STR.0000143730.29964.93; Quednau BD, 1997, AM J PHYSIOL-CELL PH, V272, pC1250, DOI 10.1152/ajpcell.1997.272.4.C1250; Reeves JP, 2003, J GEN PHYSIOL, V122, P621, DOI 10.1085/jgp.200308915; Rink C, 2017, FASEB J, V31, P1709, DOI 10.1096/fj.201601033R; Rink C, 2011, ANTIOXID REDOX SIGN, V14, P1777, DOI 10.1089/ars.2011.3930; Ronsisvalle N, 2014, CURR ALZHEIMER RES, V11, P714, DOI 10.2174/1567205011666140618104430; Scorziello A, 2004, J NEUROSCI RES, V76, P812, DOI 10.1002/jnr.20096; Seal RP, 1999, ANNU REV PHARMACOL, V39, P431, DOI 10.1146/annurev.pharmtox.39.1.431; Shenoda B, 2015, TRANSL STROKE RES, V6, P181, DOI 10.1007/s12975-015-0395-9; Shimamoto K, 1998, MOL PHARMACOL, V53, P195, DOI 10.1124/mol.53.2.195; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Sisalli MJ, 2014, CELL DEATH DIFFER, V21, P1142, DOI 10.1038/cdd.2014.32; Sonnewald U, 2002, NEUROCHEM RES, V27, P43, DOI 10.1023/A:1014846404492; Staiano RL, 2009, EUR J IMMUNOL, V39, P1405, DOI 10.1002/eji.200838792; Sun DD, 1998, AM J PHYSIOL-CELL PH, V275, pC772, DOI 10.1152/ajpcell.1998.275.3.C772; Sun ZW, 2010, NEUROSCI BULL, V26, P8, DOI 10.1007/s12264-010-0813-7; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699	63	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-4889			CELL DEATH DIS	Cell Death Dis.	JUN 28	2018	9								731	10.1038/s41419-018-0784-6			14	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	GK9OQ	WOS:000436581500003	29955038	Green Published, gold			2022-02-06	
J	Ezaz, G; Murphy, SL; Mellinger, J; Tapper, EB				Ezaz, Ghideon; Murphy, Susan L.; Mellinger, Jessica; Tapper, Elliot B.			Increased Morbidity and Mortality Associated with Falls Among Patients with Cirrhosis	AMERICAN JOURNAL OF MEDICINE			English	Article						Emergency medicine; Hepatic encephalopathy; Intracranial hemorrhage; Liver disease	HOSPITALIZED-PATIENTS; VITAMIN-D; RISK; INJURIES; PREDICTORS	BACKGROUND: Injuries are more morbid and complicated to manage in patients with cirrhosis. However, data are limited regarding the relative risk of injury and severity of injury from falls in patients with cirrhosis compared with those without cirrhosis. METHODS: We examined the nationally representative National Emergency Department Sample, an all-payer database including all patients presenting with falls, 2009-2012. We determined the relative risks for and clinical associations with severe injuries. Outcomes included hospitalization, length of stay, costs, and in-hospital death. Outcomes were compared with those of patients with congestive heart failure. RESULTS: We identified 102,977 visits involving patients with cirrhosis and 26,996,120 involving patients without cirrhosis who presented with a fall. Overall and compared with patients with congestive heart failure, the adjusted risk of severe injury was higher for patients with cirrhosis. These included intracranial hemorrhage (2.33; 95% confidence interval [CI], 2.02-2.68), skull fracture (1.75; 95% CI, 1.53-2.00), and pelvic fracture (1.71; 95% CI, 1.56-1.88). Risk was lower for less-severe injuries, such as concussion (0.95; 95% CI, 0.86-1.06) and lower-leg fracture (0.86; 95% CI, 0.80-0.91). Risk factors significantly positively associated with severe injury on multivariate analysis were hepatic encephalopathy, alcohol abuse, and infection. Cirrhosis was associated with increased risk of in-hospital death, longer length of stay, and higher costs after a fall. All outcomes were worse compared with those for patients with congestive heart failure CONCLUSION: Falls are common in patients with cirrhosis, and they are more likely to incur severe injuries, with increased hospital costs and risk of death. Poor outcomes are most associated with ascites, hepatic encephalopathy, alcohol abuse, and infection, highlighting the subgroups at highest risk and most likely to benefit from preventative interventions. (C) 2018 Elsevier Inc. All rights reserved.	[Ezaz, Ghideon] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Gastroenterol & Hepatol, Boston, MA USA; [Murphy, Susan L.; Tapper, Elliot B.] Vet Affairs Hosp, Ann Arbor, MI USA; [Murphy, Susan L.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Mellinger, Jessica; Tapper, Elliot B.] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA; [Mellinger, Jessica; Tapper, Elliot B.] Inst Healthcare Policy & Innovat, Ann Arbor, MI USA		Tapper, EB (corresponding author), Univ Michigan, Sch Med, Dept Med, Div Gastroenterol & Hepatol, 3912 Taubman,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	etapper@umich.edu		Murphy, Susan/0000-0001-7924-0012			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BATES DW, 1995, AM J MED, V99, P137, DOI 10.1016/S0002-9343(99)80133-8; Beste LA, 2015, GASTROENTEROLOGY, V149, P1471, DOI 10.1053/j.gastro.2015.07.056; Bischoff-Ferrari HA, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3692; Cohen SM, 2005, J ARTHROPLASTY, V20, P460, DOI 10.1016/j.arth.2004.05.004; Cook WL, 2006, CLIN J AM SOC NEPHRO, V1, P1197, DOI 10.2215/CJN.01650506; Horan JM, 2003, EPIDEMIOL REV, V25, P24, DOI 10.1093/epirev/mxg010; Inouye SK, 2007, J AM GERIATR SOC, V55, P780, DOI 10.1111/j.1532-5415.2007.01156.x; Janssen HCJP, 2002, AM J CLIN NUTR, V75, P611, DOI 10.1093/ajcn/75.4.611; Mathur AK, 2017, WORLD J GASTROENTERO, V23, P1857, DOI 10.3748/wjg.v23.i10.1857; Nehra MS, 2013, J CLIN GASTROENTEROL, V47, pE50, DOI 10.1097/MCG.0b013e3182688d2f; Palmer CS, 2016, INJURY, V47, P109, DOI 10.1016/j.injury.2015.07.003; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Roman E, 2011, AM J GASTROENTEROL, V106, P476, DOI 10.1038/ajg.2010.413; Schwartz AV, 2002, DIABETES CARE, V25, P1749, DOI 10.2337/diacare.25.10.1749; Soriano G, 2012, HEPATOLOGY, V55, P1922, DOI 10.1002/hep.25554; Stepanova M, 2017, CLIN GASTROENTEROL H, V15, P759, DOI 10.1016/j.cgh.2016.07.020; Tapper EB, 2015, CLIN GASTROENTEROL H, V13, P1670, DOI 10.1016/j.cgh.2015.03.019; Tapper EB, 2015, HEPATOLOGY, V62, P584, DOI 10.1002/hep.27830; Tapper EB, 2015, MAYO CLIN PROC, V90, P646, DOI 10.1016/j.mayocp.2015.03.003; Teh SH, 2007, GASTROENTEROLOGY, V132, P1261, DOI 10.1053/j.gastro.2007.01.040; Tromp AM, 2001, J CLIN EPIDEMIOL, V54, P837, DOI 10.1016/S0895-4356(01)00349-3	22	24	25	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9343	1555-7162		AM J MED	Am. J. Med.	JUN	2018	131	6					645	+		10.1016/j.amjmed.2018.01.026			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	GG7JS	WOS:000432874900040	29453941				2022-02-06	
